Word	Tag	Begin-End
Tricuspid	B	0-9
valve	I	10-15
regurgitation	I	16-29
and	O	30-33
lithium	O	34-41
carbonate	O	42-51
toxicity	B	52-60
in	O	61-63
a	O	64-65
newborn	O	66-73
infant	O	74-80
.	O	80-81

A	O	82-83
newborn	O	84-91
with	O	92-96
massive	O	97-104
tricuspid	B	105-114
regurgitation	I	115-128
,	O	128-129
atrial	B	130-136
flutter	I	137-144
,	O	144-145
congestive	B	146-156
heart	I	157-162
failure	I	163-170
,	O	170-171
and	O	172-175
a	O	176-177
high	O	178-182
serum	O	183-188
lithium	O	189-196
level	O	197-202
is	O	203-205
described	O	206-215
.	O	215-216

This	O	217-221
is	O	222-224
the	O	225-228
first	O	229-234
patient	O	235-242
to	O	243-245
initially	O	246-255
manifest	O	256-264
tricuspid	B	265-274
regurgitation	I	275-288
and	O	289-292
atrial	B	293-299
flutter	I	300-307
,	O	307-308
and	O	309-312
the	O	313-316
11th	O	317-321
described	O	322-331
patient	O	332-339
with	O	340-344
cardiac	B	345-352
disease	I	353-360
among	O	361-366
infants	O	367-374
exposed	O	375-382
to	O	383-385
lithium	O	386-393
compounds	O	394-403
in	O	404-406
the	O	407-410
first	O	411-416
trimester	O	417-426
of	O	427-429
pregnancy	O	430-439
.	O	439-440

Sixty	O	441-446
-	O	446-447
three	O	447-452
percent	O	453-460
of	O	461-463
these	O	464-469
infants	O	470-477
had	O	478-481
tricuspid	O	482-491
valve	O	492-497
involvement	O	498-509
.	O	509-510

Lithium	O	511-518
carbonate	O	519-528
may	O	529-532
be	O	533-535
a	O	536-537
factor	O	538-544
in	O	545-547
the	O	548-551
increasing	O	552-562
incidence	O	563-572
of	O	573-575
congenital	B	576-586
heart	I	587-592
disease	I	593-600
when	O	601-605
taken	O	606-611
during	O	612-618
early	O	619-624
pregnancy	O	625-634
.	O	634-635

It	O	636-638
also	O	639-643
causes	O	644-650
neurologic	B	651-661
depression	I	662-672
,	O	672-673
cyanosis	B	674-682
,	O	682-683
and	O	684-687
cardiac	B	688-695
arrhythmia	I	696-706
when	O	707-711
consumed	O	712-720
prior	O	721-726
to	O	727-729
delivery	O	730-738
.	O	738-739

Phenobarbital	O	0-13
-	O	13-14
induced	O	14-21
dyskinesia	B	22-32
in	O	33-35
a	O	36-37
neurologically	B	38-52
-	I	52-53
impaired	I	53-61
child	O	62-67
.	O	67-68

A	O	69-70
2	O	71-72
-	O	72-73
year	O	73-77
-	O	72-73
old	O	78-81
child	O	82-87
with	O	88-92
known	O	93-98
neurologic	B	99-109
impairment	I	110-120
developed	O	121-130
a	O	131-132
dyskinesia	B	133-143
soon	O	144-148
after	O	149-154
starting	O	155-163
phenobarbital	O	164-177
therapy	O	178-185
for	O	186-189
seizures	B	190-198
.	O	198-199

Known	O	200-205
causes	O	206-212
of	O	213-215
movement	B	216-224
disorders	I	225-234
were	O	235-239
eliminated	O	240-250
after	O	251-256
evaluation	O	257-267
.	O	267-268

On	O	269-271
repeat	O	272-278
challenge	O	279-288
with	O	289-293
phenobarbital	O	294-307
,	O	307-308
the	O	309-312
dyskinesia	B	313-323
recurred	O	324-332
.	O	332-333

Phenobarbital	O	334-347
should	O	348-354
be	O	355-357
added	O	358-363
to	O	364-366
the	O	367-370
list	O	371-375
of	O	376-378
anticonvulsant	O	379-393
drugs	O	394-399
that	O	400-404
can	O	405-408
cause	O	409-414
movement	B	415-423
disorders	I	424-433
.	O	433-434

Acute	O	0-5
changes	O	6-13
of	O	14-16
blood	O	17-22
ammonia	O	23-30
may	O	31-34
predict	O	35-42
short	O	43-48
-	O	48-49
term	O	49-53
adverse	O	54-61
effects	O	62-69
of	O	70-72
valproic	O	73-81
acid	O	82-86
.	O	86-87

Valproic	O	88-96
acid	O	97-101
(	O	102-103
VPA	O	103-106
)	O	106-107
was	O	108-111
given	O	112-117
to	O	118-120
24	O	121-123
epileptic	B	124-133
patients	O	134-142
who	O	143-146
were	O	147-151
already	O	152-159
being	O	160-165
treated	O	166-173
with	O	174-178
other	O	179-184
antiepileptic	O	185-198
drugs	O	199-204
.	O	204-205

A	O	206-207
standardized	O	208-220
loading	O	221-228
dose	O	229-233
of	O	234-236
VPA	O	237-240
was	O	241-244
administered	O	245-257
,	O	257-258
and	O	259-262
venous	O	263-269
blood	O	270-275
was	O	276-279
sampled	O	280-287
at	O	288-290
0	O	291-292
,	O	292-293
1	O	294-295
,	O	295-296
2	O	297-298
,	O	298-299
3	O	300-301
,	O	301-302
and	O	303-306
4	O	307-308
hours	O	309-314
.	O	314-315

Ammonia	O	316-323
(	O	324-325
NH3	O	325-328
)	O	328-329
was	O	330-333
higher	O	334-340
in	O	341-343
patients	O	344-352
who	O	353-356
,	O	356-357
during	O	358-364
continuous	O	365-375
therapy	O	376-383
,	O	383-384
complained	O	385-395
of	O	396-398
drowsiness	B	399-409
(	O	410-411
7	O	411-412
patients	O	413-421
)	O	421-422
than	O	423-427
in	O	428-430
those	O	431-436
who	O	437-440
were	O	441-445
symptom	O	446-453
-	O	453-454
free	O	454-458
(	O	459-460
17	O	460-462
patients	O	463-471
)	O	471-472
,	O	472-473
although	O	474-482
VPA	O	483-486
plasma	O	487-493
levels	O	494-500
were	O	501-505
similar	O	506-513
in	O	514-516
both	O	517-521
groups	O	522-528
.	O	528-529

By	O	530-532
measuring	O	533-542
VPA	O	543-546
-	O	546-547
induced	O	547-554
changes	O	555-562
of	O	563-565
blood	O	566-571
NH3	O	572-575
content	O	576-583
,	O	583-584
it	O	585-587
may	O	588-591
be	O	592-594
possible	O	595-603
to	O	604-606
identify	O	607-615
patients	O	616-624
at	O	625-627
higher	O	628-634
risk	O	635-639
of	O	640-642
obtundation	O	643-654
when	O	655-659
VPA	O	660-663
is	O	664-666
given	O	667-672
chronically	O	673-684
.	O	684-685

Effects	O	0-7
of	O	8-10
calcitonin	O	11-21
on	O	22-24
rat	O	25-28
extrapyramidal	O	29-43
motor	O	44-49
system	O	50-56
:	O	56-57
behavioral	O	58-68
and	O	69-72
biochemical	O	73-84
data	O	85-89
.	O	89-90

The	O	91-94
effects	O	95-102
of	O	103-105
i	O	106-107
.	O	107-108
v	O	108-109
.	O	107-108
c	O	110-111
.	O	107-108

injection	O	113-122
of	O	123-125
human	O	126-131
and	O	132-135
salmon	O	136-142
calcitonin	O	143-153
on	O	154-156
biochemical	O	157-168
and	O	169-172
behavioral	O	173-183
parameters	O	184-194
related	O	195-202
to	O	203-205
the	O	206-209
extrapyramidal	O	210-224
motor	O	225-230
system	O	231-237
,	O	237-238
were	O	239-243
investigated	O	244-256
in	O	257-259
male	O	260-264
rats	O	265-269
.	O	269-270

Calcitonin	O	271-281
injection	O	282-291
resulted	O	292-300
in	O	301-303
a	O	304-305
potentiation	O	306-318
of	O	319-321
haloperidol	O	322-333
-	O	333-334
induced	O	334-341
catalepsy	B	342-351
and	O	352-355
a	O	356-357
partial	O	358-365
prevention	O	366-376
of	O	377-379
apomorphine	O	380-391
-	O	391-392
induced	O	392-399
hyperactivity	B	400-413
.	O	413-414

Moreover	O	415-423
calcitonin	O	424-434
induced	O	435-442
a	O	443-444
significant	O	445-456
decrease	O	457-465
in	O	466-468
nigral	O	469-475
GAD	O	476-479
activity	O	480-488
but	O	489-492
no	O	493-495
change	O	496-502
in	O	503-505
striatal	O	506-514
DA	O	515-517
and	O	518-521
DOPAC	O	522-527
concentration	O	528-541
or	O	542-544
GAD	O	545-548
activity	O	549-557
.	O	557-558

The	O	559-562
results	O	563-570
are	O	571-574
discussed	O	575-584
in	O	585-587
view	O	588-592
of	O	593-595
a	O	596-597
primary	O	598-605
action	O	606-612
of	O	613-615
calcitonin	O	616-626
on	O	627-629
the	O	630-633
striatonigral	O	634-647
GABAergic	O	648-657
pathway	O	658-665
mediating	O	666-675
the	O	676-679
DA	O	680-682
-	O	682-683
related	O	683-690
behavioral	O	691-701
messages	O	702-710
of	O	711-713
striatal	O	714-722
origin	O	723-729
.	O	729-730

Development	O	0-11
of	O	12-14
isoproterenol	O	15-28
-	O	28-29
induced	O	29-36
cardiac	B	37-44
hypertrophy	I	45-56
.	O	56-57

The	O	58-61
development	O	62-73
of	O	74-76
cardiac	B	77-84
hypertrophy	I	85-96
was	O	97-100
studied	O	101-108
in	O	109-111
adult	O	112-117
female	O	118-124
Wistar	O	125-131
rats	O	132-136
following	O	137-146
daily	O	147-152
subcutaneous	O	153-165
injections	O	166-176
of	O	177-179
isoproterenol	O	180-193
(	O	194-195
ISO	O	195-198
)	O	198-199
(	O	200-201
0	O	201-202
.	O	202-203
3	O	203-204
mg	O	205-207
/	O	207-208
kg	O	208-210
body	O	211-215
weight	O	216-222
)	O	222-223
.	O	223-224

A	O	225-226
time	O	227-231
course	O	232-238
was	O	239-242
established	O	243-254
for	O	255-258
the	O	259-262
change	O	263-269
in	O	270-272
tissue	O	273-279
mass	O	280-284
,	O	284-285
RNA	O	286-289
and	O	290-293
DNA	O	294-297
content	O	298-305
,	O	305-306
as	O	307-309
well	O	310-314
as	O	315-317
hydroxyproline	O	318-332
content	O	333-340
.	O	340-341

Heart	O	342-347
weight	O	348-354
increased	O	355-364
44	O	365-367
%	O	367-368
after	O	369-374
8	O	375-376
days	O	377-381
of	O	382-384
treatment	O	385-394
with	O	395-399
a	O	400-401
half	O	402-406
time	O	407-411
of	O	412-414
3	O	415-416
.	O	416-417
4	O	417-418
days	O	419-423
.	O	423-424

Ventricular	O	425-436
RNA	O	437-440
content	O	441-448
was	O	449-452
elevated	O	453-461
26	O	462-464
%	O	464-465
after	O	466-471
24	O	472-474
h	O	475-476
of	O	477-479
a	O	480-481
single	O	482-488
injection	O	489-498
and	O	499-502
reached	O	503-510
a	O	511-512
maximal	O	513-520
level	O	521-526
following	O	527-536
8	O	537-538
days	O	539-543
of	O	544-546
therapy	O	547-554
.	O	554-555

The	O	556-559
half	O	560-564
time	O	565-569
for	O	570-573
RNA	O	574-577
accumulation	O	578-590
was	O	591-594
2	O	595-596
.	O	596-597
0	O	597-598
days	O	599-603
.	O	603-604

The	O	605-608
total	O	609-614
content	O	615-622
of	O	623-625
hydroxyproline	O	626-640
remained	O	641-649
stable	O	650-656
during	O	657-663
the	O	664-667
first	O	668-673
2	O	674-675
days	O	676-680
of	O	681-683
treatment	O	684-693
but	O	694-697
increased	O	698-707
46	O	708-710
%	O	710-711
after	O	712-717
4	O	718-719
days	O	720-724
of	O	725-727
therapy	O	728-735
.	O	735-736

Ventricular	O	737-748
DNA	O	749-752
content	O	753-760
was	O	761-764
unchanged	O	765-774
during	O	775-781
the	O	782-785
early	O	786-791
stage	O	792-797
(	O	798-799
1	O	799-800
-	O	800-801
4	O	801-802
days	O	803-807
)	O	807-808
of	O	809-811
hypertrophic	B	812-824
growth	O	825-831
but	O	832-835
increased	O	836-845
to	O	846-848
a	O	849-850
new	O	851-854
steady	O	855-861
-	O	861-862
state	O	862-867
level	O	868-873
19	O	874-876
%	O	876-877
above	O	878-883
the	O	884-887
controls	O	888-896
after	O	897-902
8	O	903-904
days	O	905-909
of	O	910-912
treatment	O	913-922
.	O	922-923

Intraventricular	O	924-940
pressures	O	941-950
and	O	951-954
coronary	O	955-963
flow	O	964-968
measures	O	969-977
were	O	978-982
similar	O	983-990
for	O	991-994
control	O	995-1002
and	O	1003-1006
experimental	O	1007-1019
animals	O	1020-1027
following	O	1028-1037
4	O	1038-1039
days	O	1040-1044
of	O	1045-1047
developed	O	1048-1057
hypertrophy	B	1058-1069
.	O	1069-1070

However	O	1071-1078
,	O	1078-1079
dP	O	1080-1082
/	O	1082-1083
dt	O	1083-1085
in	O	1086-1088
the	O	1089-1092
ISO	O	1093-1096
-	O	1096-1097
treated	O	1097-1104
hearts	O	1105-1111
was	O	1112-1115
slightly	O	1116-1124
but	O	1125-1128
significantly	O	1129-1142
(	O	1143-1144
P	O	1144-1145
less	O	1146-1150
than	O	1151-1155
0	O	1156-1157
.	O	1157-1158
05	O	1158-1160
)	O	1160-1161
elevated	O	1162-1170
.	O	1170-1171

These	O	1172-1177
data	O	1178-1182
indicate	O	1183-1191
that	O	1192-1196
the	O	1197-1200
adaptive	O	1201-1209
response	O	1210-1218
to	O	1219-1221
ISO	O	1222-1225
shows	O	1226-1231
an	O	1232-1234
early	O	1235-1240
hypertrophic	B	1241-1253
phase	O	1254-1259
(	O	1260-1261
1	O	1261-1262
-	O	1262-1263
4	O	1263-1264
days	O	1265-1269
)	O	1269-1270
characterized	O	1271-1284
by	O	1285-1287
a	O	1288-1289
substantial	O	1290-1301
increase	O	1302-1310
in	O	1311-1313
RNA	O	1314-1317
content	O	1318-1325
and	O	1326-1329
cardiac	O	1330-1337
mass	O	1338-1342
in	O	1343-1345
the	O	1346-1349
absence	O	1350-1357
of	O	1358-1360
changes	O	1361-1368
in	O	1369-1371
DNA	O	1372-1375
.	O	1375-1376

However	O	1377-1384
,	O	1384-1385
prolonged	O	1386-1395
stimulation	O	1396-1407
(	O	1408-1409
8	O	1409-1410
-	O	1410-1411
12	O	1411-1413
days	O	1414-1418
)	O	1418-1419
appears	O	1420-1427
to	O	1428-1430
represent	O	1431-1440
a	O	1441-1442
complex	O	1443-1450
integration	O	1451-1462
of	O	1463-1465
both	O	1466-1470
cellular	O	1471-1479
hypertrophy	B	1480-1491
and	O	1492-1495
hyperplasia	B	1496-1507
within	O	1508-1514
the	O	1515-1518
heart	O	1519-1524
.	O	1524-1525

Co	O	0-2
-	O	2-3
carcinogenic	B	3-15
effect	O	16-22
of	O	23-25
retinyl	O	26-33
acetate	O	34-41
on	O	42-44
forestomach	B	45-56
carcinogenesis	I	57-71
of	O	72-74
male	O	75-79
F344	O	80-84
rats	O	85-89
induced	O	90-97
with	O	98-102
butylated	O	103-112
hydroxyanisole	O	113-127
.	O	127-128

The	O	129-132
potential	O	133-142
modifying	O	143-152
effect	O	153-159
of	O	160-162
retinyl	O	163-170
acetate	O	171-178
(	O	179-180
RA	O	180-182
)	O	182-183
on	O	184-186
butylated	O	187-196
hydroxyanisole	O	197-211
(	O	212-213
BHA	O	213-216
)	O	216-217
-	O	217-218
induced	O	218-225
rat	O	226-229
forestomach	B	230-241
tumorigenesis	I	242-255
was	O	256-259
examined	O	260-268
.	O	268-269

Male	O	270-274
F344	O	275-279
rats	O	280-284
,	O	284-285
5	O	286-287
weeks	O	288-293
of	O	294-296
age	O	297-300
,	O	300-301
were	O	302-306
maintained	O	307-317
on	O	318-320
diet	O	321-325
containing	O	326-336
1	O	337-338
%	O	338-339
or	O	340-342
2	O	343-344
%	O	344-345
BHA	O	346-349
by	O	350-352
weight	O	353-359
and	O	360-363
simultaneously	O	364-378
on	O	379-381
drinking	O	382-390
water	O	391-396
supplemented	O	397-409
with	O	410-414
RA	O	415-417
at	O	418-420
various	O	421-428
concentrations	O	429-443
(	O	444-445
w	O	445-446
/	O	446-447
v	O	447-448
)	O	448-449
for	O	450-453
52	O	454-456
weeks	O	457-462
.	O	462-463

In	O	464-466
groups	O	467-473
given	O	474-479
2	O	480-481
%	O	481-482
BHA	O	483-486
,	O	486-487
although	O	488-496
marked	O	497-503
hyperplastic	O	504-516
changes	O	517-524
of	O	525-527
the	O	528-531
forestomach	O	532-543
epithelium	O	544-554
were	O	555-559
observed	O	560-568
in	O	569-571
all	O	572-575
animals	O	576-583
,	O	583-584
co	O	585-587
-	O	587-588
administration	O	588-602
of	O	603-605
0	O	606-607
.	O	607-608
25	O	608-610
%	O	610-611
RA	O	612-614
significantly	O	615-628
(	O	629-630
P	O	630-631
less	O	632-636
than	O	637-641
0	O	642-643
.	O	643-644
05	O	644-646
)	O	646-647
increased	O	648-657
the	O	658-661
incidence	O	662-671
of	O	672-674
forestomach	B	675-686
tumors	I	687-693
(	O	694-695
squamous	B	695-703
cell	I	704-708
papilloma	I	709-718
and	O	719-722
carcinoma	B	723-732
)	O	732-733
to	O	734-736
60	O	737-739
%	O	739-740
(	O	741-742
9	O	742-743
/	O	743-744
15	O	744-746
,	O	746-747
2	O	748-749
rats	O	750-754
with	O	755-759
carcinoma	B	760-769
)	O	769-770
from	O	771-775
15	O	776-778
%	O	778-779
(	O	780-781
3	O	781-782
/	O	782-783
20	O	783-785
,	O	785-786
one	O	787-790
rat	O	791-794
with	O	795-799
carcinoma	B	800-809
)	O	809-810
in	O	811-813
the	O	814-817
group	O	818-823
given	O	824-829
RA	O	830-832
-	O	832-833
free	O	833-837
water	O	838-843
.	O	843-844

In	O	845-847
rats	O	848-852
given	O	853-858
1	O	859-860
%	O	860-861
BHA	O	862-865
,	O	865-866
RA	O	867-869
co	O	870-872
-	O	872-873
administered	O	873-885
at	O	886-888
a	O	889-890
dose	O	891-895
of	O	896-898
0	O	899-900
.	O	900-901
05	O	901-903
,	O	903-904
0	O	905-906
.	O	906-907
1	O	907-908
,	O	908-909
0	O	910-911
.	O	911-912
2	O	912-913
or	O	914-916
0	O	917-918
.	O	918-919
25	O	919-921
%	O	921-922
showed	O	923-929
a	O	930-931
dose	O	932-936
-	O	936-937
dependent	O	937-946
enhancing	O	947-956
effect	O	957-963
on	O	964-966
the	O	967-970
development	O	971-982
of	O	983-985
the	O	986-989
BHA	O	990-993
-	O	993-994
induced	O	994-1001
epithelial	B	1002-1012
hyperplasia	I	1013-1024
.	O	1024-1025

Tumors	B	1026-1032
,	O	1032-1033
all	O	1034-1037
papillomas	B	1038-1048
,	O	1048-1049
were	O	1050-1054
induced	O	1055-1062
in	O	1063-1065
3	O	1066-1067
rats	O	1068-1072
(	O	1073-1074
17	O	1074-1076
%	O	1076-1077
)	O	1077-1078
with	O	1079-1083
0	O	1084-1085
.	O	1085-1086
25	O	1086-1088
%	O	1088-1089
RA	O	1090-1092
and	O	1093-1096
in	O	1097-1099
one	O	1100-1103
rat	O	1104-1107
(	O	1108-1109
10	O	1109-1111
%	O	1111-1112
)	O	1112-1113
with	O	1114-1118
0	O	1119-1120
.	O	1120-1121
05	O	1121-1123
%	O	1123-1124
RA	O	1125-1127
co	O	1128-1130
-	O	1130-1131
administration	O	1131-1145
.	O	1145-1146

RA	O	1147-1149
alone	O	1150-1155
did	O	1156-1159
not	O	1160-1163
induce	O	1164-1170
hyperplastic	O	1171-1183
changes	O	1184-1191
in	O	1192-1194
the	O	1195-1198
forestomach	O	1199-1210
.	O	1210-1211

These	O	1212-1217
findings	O	1218-1226
indicate	O	1227-1235
that	O	1236-1240
RA	O	1241-1243
acted	O	1244-1249
as	O	1250-1252
a	O	1253-1254
co	O	1255-1257
-	O	1257-1258
carcinogen	O	1258-1268
in	O	1269-1271
the	O	1272-1275
BHA	O	1276-1279
forestomach	B	1280-1291
carcinogenesis	I	1292-1306
of	O	1307-1309
the	O	1310-1313
rat	O	1314-1317
.	O	1317-1318

Ketanserin	O	0-10
pretreatment	O	11-23
reverses	O	24-32
alfentanil	O	33-43
-	O	43-44
induced	O	44-51
muscle	B	52-58
rigidity	I	59-67
.	O	67-68

Systemic	O	69-77
pretreatment	O	78-90
with	O	91-95
ketanserin	O	96-106
,	O	106-107
a	O	108-109
relatively	O	110-120
specific	O	121-129
type	O	130-134
-	O	134-135
2	O	135-136
serotonin	O	137-146
receptor	O	147-155
antagonist	O	156-166
,	O	166-167
significantly	O	168-181
attenuated	O	182-192
the	O	193-196
muscle	B	197-203
rigidity	I	204-212
produced	O	213-221
in	O	222-224
rats	O	225-229
by	O	230-232
the	O	233-236
potent	O	237-243
short	O	244-249
-	O	249-250
acting	O	250-256
opiate	O	257-263
agonist	O	264-271
alfentanil	O	272-282
.	O	282-283

Following	O	284-293
placement	O	294-303
of	O	304-306
subcutaneous	O	307-319
electrodes	O	320-330
in	O	331-333
each	O	334-338
animal	O	339-345
'	O	345-346
s	O	346-347
left	O	348-352
gastrocnemius	O	353-366
muscle	O	367-373
,	O	373-374
rigidity	B	375-383
was	O	384-387
assessed	O	388-396
by	O	397-399
analyzing	O	400-409
root	O	410-414
-	O	414-415
mean	O	415-419
-	O	414-415
square	O	420-426
electromyographic	O	427-444
activity	O	445-453
.	O	453-454

Intraperitoneal	O	455-470
ketanserin	O	471-481
administration	O	482-496
at	O	497-499
doses	O	500-505
of	O	506-508
0	O	509-510
.	O	510-511
63	O	511-513
and	O	514-517
2	O	518-519
.	O	519-520
5	O	520-521
mg	O	522-524
/	O	524-525
kg	O	525-527
prevented	O	528-537
the	O	538-541
alfentanil	O	542-552
-	O	552-553
induced	O	553-560
increase	O	561-569
in	O	570-572
electromyographic	O	573-590
activity	O	591-599
compared	O	600-608
with	O	609-613
animals	O	614-621
pretreated	O	622-632
with	O	633-637
saline	O	638-644
.	O	644-645

Chlordiazepoxide	O	646-662
at	O	663-665
doses	O	666-671
up	O	672-674
to	O	675-677
10	O	678-680
mg	O	681-683
/	O	683-684
kg	O	684-686
failed	O	687-693
to	O	694-696
significantly	O	697-710
influence	O	711-720
the	O	721-724
rigidity	B	725-733
produced	O	734-742
by	O	743-745
alfentanil	O	746-756
.	O	756-757

Despite	O	758-765
the	O	766-769
absence	O	770-777
of	O	778-780
rigidity	B	781-789
,	O	789-790
animals	O	791-798
that	O	799-803
received	O	804-812
ketanserin	O	813-823
(	O	824-825
greater	O	825-832
than	O	833-837
0	O	838-839
.	O	839-840
31	O	840-842
mg	O	843-845
/	O	845-846
kg	O	846-848
i	O	849-850
.	O	850-851
p	O	851-852
.	O	850-851
)	O	853-854
followed	O	855-863
by	O	864-866
alfentanil	O	867-877
were	O	878-882
motionless	O	883-893
,	O	893-894
flaccid	O	895-902
,	O	902-903
and	O	904-907
less	O	908-912
responsive	O	913-923
to	O	924-926
external	O	927-935
stimuli	O	936-943
than	O	944-948
were	O	949-953
animals	O	954-961
receiving	O	962-971
alfentanil	O	972-982
alone	O	983-988
.	O	988-989

Rats	O	990-994
that	O	995-999
received	O	1000-1008
ketanserin	O	1009-1019
and	O	1020-1023
alfentanil	O	1024-1034
exhibited	O	1035-1044
less	O	1045-1049
rearing	O	1050-1057
and	O	1058-1061
exploratory	O	1062-1073
behavior	O	1074-1082
at	O	1083-1085
the	O	1086-1089
end	O	1090-1093
of	O	1094-1096
the	O	1097-1100
60	O	1101-1103
-	O	1103-1104
min	O	1104-1107
recording	O	1108-1117
period	O	1118-1124
than	O	1125-1129
did	O	1130-1133
animals	O	1134-1141
that	O	1142-1146
received	O	1147-1155
ketanserin	O	1156-1166
alone	O	1167-1172
.	O	1172-1173

These	O	1174-1179
results	O	1180-1187
,	O	1187-1188
in	O	1189-1191
combination	O	1192-1203
with	O	1204-1208
previous	O	1209-1217
work	O	1218-1222
,	O	1222-1223
suggest	O	1224-1231
that	O	1232-1236
muscle	B	1237-1243
rigidity	I	1244-1252
,	O	1252-1253
a	O	1254-1255
clinically	O	1256-1266
relevant	O	1267-1275
side	O	1276-1280
-	O	1280-1281
effect	O	1281-1287
of	O	1288-1290
parenteral	O	1291-1301
narcotic	O	1302-1310
administration	O	1311-1325
,	O	1325-1326
may	O	1327-1330
be	O	1331-1333
partly	O	1334-1340
mediated	O	1341-1349
via	O	1350-1353
serotonergic	O	1354-1366
pathways	O	1367-1375
.	O	1375-1376

Pretreatment	O	1377-1389
with	O	1390-1394
type	O	1395-1399
-	O	1399-1400
2	O	1400-1401
serotonin	O	1402-1411
antagonists	O	1412-1423
may	O	1424-1427
be	O	1428-1430
clinically	O	1431-1441
useful	O	1442-1448
in	O	1449-1451
attenuating	O	1452-1463
opiate	O	1464-1470
-	O	1470-1471
induced	O	1471-1478
rigidity	B	1479-1487
,	O	1487-1488
although	O	1489-1497
further	O	1498-1505
studies	O	1506-1513
will	O	1514-1518
be	O	1519-1521
necessary	O	1522-1531
to	O	1532-1534
assess	O	1535-1541
the	O	1542-1545
interaction	O	1546-1557
of	O	1558-1560
possibly	O	1561-1569
enhanced	O	1570-1578
CNS	O	1579-1582
,	O	1582-1583
cardiovascular	B	1584-1598
,	I	1598-1599
and	I	1600-1603
respiratory	I	1604-1615
depression	I	1616-1626
.	O	1626-1627

Glycopyrronium	O	0-14
requirements	O	15-27
for	O	28-31
antagonism	O	32-42
of	O	43-45
the	O	46-49
muscarinic	O	50-60
side	O	61-65
effects	O	66-73
of	O	74-76
edrophonium	O	77-88
.	O	88-89

We	O	90-92
have	O	93-97
compared	O	98-106
,	O	106-107
in	O	108-110
60	O	111-113
adult	O	114-119
patients	O	120-128
,	O	128-129
the	O	130-133
cardiovascular	O	134-148
effects	O	149-156
of	O	157-159
glycopyrronium	O	160-174
5	O	175-176
micrograms	O	177-187
kg	O	188-190
-	O	190-191
1	O	191-192
and	O	193-196
10	O	197-199
micrograms	O	200-210
kg	O	211-213
-	O	213-214
1	O	214-215
given	O	216-221
either	O	222-228
simultaneously	O	229-243
or	O	244-246
1	O	247-248
min	O	249-252
before	O	253-259
edrophonium	O	260-271
1	O	272-273
mg	O	274-276
kg	O	277-279
-	O	279-280
1	O	280-281
.	O	281-282

Significant	O	283-294
differences	O	295-306
between	O	307-314
the	O	315-318
four	O	319-323
groups	O	324-330
were	O	331-335
detected	O	336-344
(	O	345-346
P	O	346-347
less	O	348-352
than	O	353-357
0	O	358-359
.	O	359-360
001	O	360-363
)	O	363-364
.	O	359-360

Both	O	366-370
groups	O	371-377
receiving	O	378-387
10	O	388-390
micrograms	O	391-401
kg	O	402-404
-	O	404-405
1	O	405-406
showed	O	407-413
increases	O	414-423
in	O	424-426
heart	O	427-432
rate	O	433-437
of	O	438-440
up	O	441-443
to	O	444-446
30	O	447-449
beat	O	450-454
min	O	455-458
-	O	458-459
1	O	459-460
(	O	461-462
95	O	462-464
%	O	464-465
confidence	O	466-476
limits	O	477-483
28	O	484-486
-	O	486-487
32	O	487-489
beat	O	490-494
min	O	495-498
-	O	498-499
1	O	499-500
)	O	500-501
.	O	501-502

Use	O	503-506
of	O	507-509
glycopyrronium	O	510-524
5	O	525-526
micrograms	O	527-537
kg	O	538-540
-	O	540-541
1	O	541-542
provided	O	543-551
greater	O	552-559
cardiovascular	O	560-574
stability	O	575-584
and	O	585-588
,	O	588-589
given	O	590-595
1	O	596-597
min	O	598-601
before	O	602-608
the	O	609-612
edrophonium	O	613-624
,	O	624-625
was	O	626-629
sufficient	O	630-640
to	O	641-643
minimize	O	644-652
early	O	653-658
,	O	658-659
edrophonium	O	660-671
-	O	671-672
induced	O	672-679
bradycardias	B	680-692
.	O	692-693

This	O	694-698
low	O	699-702
dose	O	703-707
of	O	708-710
glycopyrronium	O	711-725
provided	O	726-734
good	O	735-739
control	O	740-747
of	O	748-750
oropharyngeal	O	751-764
secretions	O	765-775
.	O	775-776

Involvement	O	0-11
of	O	12-14
locus	O	15-20
coeruleus	O	21-30
and	O	31-34
noradrenergic	O	35-48
neurotransmission	O	49-66
in	O	67-69
fentanyl	O	70-78
-	O	78-79
induced	O	79-86
muscular	B	87-95
rigidity	I	96-104
in	O	105-107
the	O	108-111
rat	O	112-115
.	O	115-116

Whereas	O	117-124
muscular	B	125-133
rigidity	I	134-142
is	O	143-145
a	O	146-147
well	O	148-152
-	O	152-153
known	O	153-158
side	O	159-163
effect	O	164-170
that	O	171-175
is	O	176-178
associated	O	179-189
with	O	190-194
high	O	195-199
-	O	199-200
dose	O	200-204
fentanyl	O	205-213
anesthesia	O	214-224
,	O	224-225
a	O	226-227
paucity	O	228-235
of	O	236-238
information	O	239-250
exists	O	251-257
with	O	258-262
regard	O	263-269
to	O	270-272
its	O	273-276
underlying	O	277-287
mechanism	O	288-297
(	O	297-298
s	O	295-296
)	O	299-300
.	O	300-301

We	O	302-304
investigated	O	305-317
in	O	318-320
this	O	321-325
study	O	326-331
the	O	332-335
possible	O	336-344
engagement	O	345-355
of	O	356-358
locus	O	359-364
coeruleus	O	365-374
of	O	375-377
the	O	378-381
pons	O	382-386
in	O	387-389
this	O	390-394
phenomenon	O	395-405
,	O	405-406
using	O	407-412
male	O	413-417
Sprague	O	418-425
-	O	425-426
Dawley	O	426-432
rats	O	433-437
anesthetized	O	438-450
with	O	451-455
ketamine	O	456-464
.	O	464-465

Under	O	466-471
proper	O	472-478
control	O	479-486
of	O	487-489
respiration	O	490-501
,	O	501-502
body	O	503-507
temperature	O	508-519
and	O	520-523
end	O	524-527
-	O	527-528
tidal	O	528-533
CO2	O	534-537
,	O	537-538
intravenous	O	539-550
administration	O	551-565
of	O	566-568
fentanyl	O	569-577
(	O	578-579
50	O	579-581
or	O	582-584
100	O	585-588
micrograms	O	589-599
/	O	599-600
kg	O	600-602
)	O	602-603
consistently	O	604-616
promoted	O	617-625
an	O	626-628
increase	O	629-637
in	O	638-640
electromyographic	O	641-658
activity	O	659-667
recorded	O	668-676
from	O	677-681
the	O	682-685
gastrocnemius	O	686-699
and	O	700-703
abdominal	O	704-713
rectus	O	714-720
muscles	O	721-728
.	O	728-729

Such	O	730-734
an	O	735-737
induced	O	738-745
muscular	B	746-754
rigidity	I	755-763
by	O	764-766
the	O	767-770
narcotic	O	771-779
agent	O	780-785
was	O	786-789
significantly	O	790-803
antagonized	O	804-815
or	O	816-818
even	O	819-823
reduced	O	824-831
by	O	832-834
prior	O	835-840
electrolytic	O	841-853
lesions	O	854-861
of	O	862-864
the	O	865-868
locus	O	869-874
coeruleus	O	875-884
or	O	885-887
pretreatment	O	888-900
with	O	901-905
the	O	906-909
alpha	O	910-915
-	O	915-916
adrenoceptor	O	916-928
blocker	O	929-936
,	O	936-937
prazosin	O	938-946
.	O	946-947

Microinjection	O	948-962
of	O	963-965
fentanyl	O	966-974
(	O	975-976
2	O	976-977
.	O	977-978
5	O	978-979
micrograms	O	980-990
/	O	990-991
50	O	991-993
nl	O	994-996
)	O	996-997
directly	O	998-1006
into	O	1007-1011
this	O	1012-1016
pontine	O	1017-1024
nucleus	O	1025-1032
,	O	1032-1033
on	O	1034-1036
the	O	1037-1040
other	O	1041-1046
hand	O	1047-1051
,	O	1051-1052
elicited	O	1053-1061
discernible	O	1062-1073
electromyographic	O	1074-1091
excitation	O	1092-1102
.	O	1102-1103

It	O	1104-1106
is	O	1107-1109
speculated	O	1110-1120
that	O	1121-1125
the	O	1126-1129
induction	O	1130-1139
of	O	1140-1142
muscular	B	1143-1151
rigidity	I	1152-1160
by	O	1161-1163
fentanyl	O	1164-1172
may	O	1173-1176
involve	O	1177-1184
the	O	1185-1188
coerulospinal	O	1189-1202
noradrenergic	O	1203-1216
fibers	O	1217-1223
to	O	1224-1226
the	O	1227-1230
spinal	O	1231-1237
motoneurons	O	1238-1249
.	O	1249-1250

Cerebral	B	0-8
sinus	I	9-14
thrombosis	I	15-25
as	O	26-28
a	O	29-30
potential	O	31-40
hazard	O	41-47
of	O	48-50
antifibrinolytic	O	51-67
treatment	O	68-77
in	O	78-80
menorrhagia	B	81-92
.	O	92-93

We	O	94-96
describe	O	97-105
a	O	106-107
42	O	108-110
-	O	110-111
year	O	111-115
-	O	110-111
old	O	116-119
woman	O	120-125
who	O	126-129
developed	O	130-139
superior	O	140-148
sagittal	B	149-157
and	I	158-161
left	I	162-166
transverse	I	167-177
sinus	I	178-183
thrombosis	I	184-194
associated	O	195-205
with	O	206-210
prolonged	O	211-220
epsilon	O	221-228
-	O	228-229
aminocaproic	O	229-241
acid	O	242-246
therapy	O	247-254
for	O	255-258
menorrhagia	B	259-270
.	O	270-271

This	O	272-276
antifibrinolytic	O	277-293
agent	O	294-299
has	O	300-303
been	O	304-308
used	O	309-313
in	O	314-316
women	O	317-322
with	O	323-327
menorrhagia	B	328-339
to	O	340-342
promote	O	343-350
clotting	O	351-359
and	O	360-363
reduce	O	364-370
blood	B	371-376
loss	I	377-381
.	O	381-382

Although	O	383-391
increased	O	392-401
risk	O	402-406
of	O	407-409
thromboembolic	B	410-424
disease	I	425-432
has	O	433-436
been	O	437-441
reported	O	442-450
during	O	451-457
treatment	O	458-467
with	O	468-472
epsilon	O	473-480
-	O	480-481
aminocaproic	O	481-493
acid	O	494-498
,	O	498-499
cerebral	B	500-508
sinus	I	509-514
thrombosis	I	515-525
has	O	526-529
not	O	530-533
been	O	534-538
previously	O	539-549
described	O	550-559
.	O	559-560

Careful	O	561-568
use	O	569-572
of	O	573-575
epsilon	O	576-583
-	O	583-584
aminocaproic	O	584-596
acid	O	597-601
therapy	O	602-609
is	O	610-612
recommended	O	613-624
.	O	624-625

Hemorrhagic	B	0-11
cystitis	I	12-20
complicating	O	21-33
bone	O	34-38
marrow	O	39-45
transplantation	O	46-61
.	O	61-62

Hemorrhagic	B	63-74
cystitis	I	75-83
is	O	84-86
a	O	87-88
potentially	O	89-100
serious	O	101-108
complication	O	109-121
of	O	122-124
high	O	125-129
-	O	129-130
dose	O	130-134
cyclophosphamide	O	135-151
therapy	O	152-159
administered	O	160-172
before	O	173-179
bone	O	180-184
marrow	O	185-191
transplantation	O	192-207
.	O	207-208

As	O	209-211
standard	O	212-220
practice	O	221-229
at	O	230-232
our	O	233-236
institution	O	237-248
,	O	248-249
patients	O	250-258
who	O	259-262
are	O	263-266
scheduled	O	267-276
to	O	277-279
receive	O	280-287
a	O	288-289
bone	O	290-294
marrow	O	295-301
transplant	O	302-312
are	O	313-316
treated	O	317-324
prophylactically	O	325-341
with	O	342-346
forced	O	347-353
hydration	O	354-363
and	O	364-367
bladder	O	368-375
irrigation	O	376-386
.	O	386-387

In	O	388-390
an	O	391-393
attempt	O	394-401
to	O	402-404
obviate	O	405-412
the	O	413-416
inconvenience	O	417-430
of	O	431-433
bladder	O	434-441
irrigation	O	442-452
,	O	452-453
we	O	454-456
conducted	O	457-466
a	O	467-468
feasibility	O	469-480
trial	O	481-486
of	O	487-489
uroprophylaxis	O	490-504
with	O	505-509
mesna	O	510-515
,	O	515-516
which	O	517-522
neutralizes	O	523-534
the	O	535-538
hepatic	O	539-546
metabolite	O	547-557
of	O	558-560
cyclophosphamide	O	561-577
that	O	578-582
causes	O	583-589
hemorrhagic	B	590-601
cystitis	I	602-610
.	O	610-611

Of	O	612-614
97	O	615-617
patients	O	618-626
who	O	627-630
received	O	631-639
standard	O	640-648
prophylaxis	O	649-660
,	O	660-661
4	O	662-663
had	O	664-667
symptomatic	O	668-679
hemorrhagic	B	680-691
cystitis	I	692-700
.	O	700-701

In	O	702-704
contrast	O	705-713
,	O	713-714
two	O	715-718
of	O	719-721
four	O	722-726
consecutive	O	727-738
patients	O	739-747
who	O	748-751
received	O	752-760
mesna	O	761-766
uroprophylaxis	O	767-781
before	O	782-788
allogeneic	O	789-799
bone	O	800-804
marrow	O	805-811
transplantation	O	812-827
had	O	828-831
severe	O	832-838
hemorrhagic	B	839-850
cystitis	I	851-859
for	O	860-863
at	O	864-866
least	O	867-872
2	O	873-874
weeks	O	875-880
.	O	880-881

Because	O	882-889
of	O	890-892
this	O	893-897
suboptimal	O	898-908
result	O	909-915
,	O	915-916
we	O	917-919
resumed	O	920-927
the	O	928-931
use	O	932-935
of	O	936-938
bladder	O	939-946
irrigation	O	947-957
and	O	958-961
forced	O	962-968
hydration	O	969-978
to	O	979-981
minimize	O	982-990
the	O	991-994
risk	O	995-999
of	O	1000-1002
hemorrhagic	B	1003-1014
cystitis	I	1015-1023
.	O	1023-1024

Reversal	O	0-8
of	O	9-11
central	O	12-19
benzodiazepine	O	20-34
effects	O	35-42
by	O	43-45
flumazenil	O	46-56
after	O	57-62
intravenous	O	63-74
conscious	O	75-84
sedation	O	85-93
with	O	94-98
diazepam	O	99-107
and	O	108-111
opioids	O	112-119
:	O	119-120
report	O	121-127
of	O	128-130
a	O	131-132
double	O	133-139
-	O	139-140
blind	O	140-145
multicenter	O	146-157
study	O	158-163
.	O	163-164

The	O	165-168
Flumazenil	O	169-179
in	O	180-182
Intravenous	O	183-194
Conscious	O	195-204
Sedation	O	205-213
with	O	214-218
Diazepam	O	219-227
Multicenter	O	228-239
Study	O	240-245
Group	O	246-251
II	O	252-254
.	O	254-255

The	O	256-259
efficacy	O	260-268
and	O	269-272
safety	O	273-279
of	O	280-282
a	O	283-284
new	O	285-288
benzodiazepine	O	289-303
antagonist	O	304-314
,	O	314-315
flumazenil	O	316-326
,	O	326-327
were	O	328-332
assessed	O	333-341
in	O	342-344
a	O	345-346
double	O	347-353
-	O	353-354
blind	O	354-359
multicenter	O	360-371
study	O	372-377
.	O	377-378

Flumazenil	O	379-389
(	O	390-391
mean	O	391-395
dose	O	396-400
,	O	400-401
0	O	402-403
.	O	403-404
76	O	404-406
mg	O	407-409
)	O	409-410
or	O	411-413
placebo	O	414-421
(	O	422-423
mean	O	423-427
dose	O	428-432
,	O	432-433
8	O	434-435
.	O	435-436
9	O	436-437
ml	O	438-440
)	O	440-441
was	O	442-445
administered	O	446-458
intravenously	O	459-472
to	O	473-475
130	O	476-479
and	O	480-483
67	O	484-486
patients	O	487-495
,	O	495-496
respectively	O	497-509
,	O	509-510
who	O	511-514
had	O	515-518
been	O	519-523
given	O	524-529
diazepam	O	530-538
in	O	539-541
conjunction	O	542-553
with	O	554-558
an	O	559-561
opioid	O	562-568
(	O	569-570
fentanyl	O	570-578
,	O	578-579
meperidine	O	580-590
,	O	590-591
or	O	592-594
morphine	O	595-603
)	O	603-604
for	O	605-608
the	O	609-612
induction	O	613-622
and	O	623-626
maintenance	O	627-638
of	O	639-641
intravenous	O	642-653
conscious	O	654-663
sedation	O	664-672
for	O	673-676
diagnostic	O	677-687
or	O	688-690
therapeutic	O	691-702
surgical	O	703-711
procedures	O	712-722
.	O	722-723

The	O	724-727
group	O	728-733
assessable	O	734-744
for	O	745-748
efficacy	O	749-757
comprised	O	758-767
122	O	768-771
patients	O	772-780
treated	O	781-788
with	O	789-793
flumazenil	O	794-804
and	O	805-808
64	O	809-811
patients	O	812-820
given	O	821-826
placebo	O	827-834
.	O	834-835

After	O	836-841
5	O	842-843
minutes	O	844-851
,	O	851-852
80	O	853-855
/	O	855-856
115	O	856-859
(	O	860-861
70	O	861-863
%	O	863-864
)	O	864-865
flumazenil	O	866-876
-	O	876-877
treated	O	877-884
patients	O	885-893
,	O	893-894
compared	O	895-903
with	O	904-908
21	O	909-911
/	O	911-912
63	O	912-914
(	O	915-916
33	O	916-918
%	O	918-919
)	O	919-920
placebo	O	921-928
-	O	928-929
treated	O	929-936
patients	O	937-945
,	O	945-946
were	O	947-951
completely	O	952-962
awake	O	963-968
and	O	969-972
alert	O	973-978
,	O	978-979
as	O	980-982
indicated	O	983-992
by	O	993-995
a	O	996-997
score	O	998-1003
of	O	1004-1006
5	O	1007-1008
on	O	1009-1011
the	O	1012-1015
Observer	O	1016-1024
'	O	1024-1025
s	O	1018-1019
Assessment	O	1027-1037
of	O	1038-1040
Alertness	O	1041-1050
/	O	1050-1051
Sedation	O	1051-1059
Scale	O	1060-1065
.	O	1065-1066

Ninety	O	1067-1073
-	O	1073-1074
five	O	1074-1078
percent	O	1079-1086
of	O	1087-1089
patients	O	1090-1098
in	O	1099-1101
each	O	1102-1106
group	O	1107-1112
who	O	1113-1116
attained	O	1117-1125
a	O	1126-1127
score	O	1128-1133
of	O	1134-1136
5	O	1137-1138
at	O	1139-1141
the	O	1142-1145
5	O	1146-1147
-	O	1147-1148
minute	O	1148-1154
assessment	O	1155-1165
showed	O	1166-1172
no	O	1173-1175
loss	O	1176-1180
of	O	1181-1183
alertness	O	1184-1193
throughout	O	1194-1204
the	O	1205-1208
180	O	1209-1212
-	O	1212-1213
minute	O	1213-1219
assessment	O	1220-1230
period	O	1231-1237
.	O	1237-1238

Flumazenil	O	1239-1249
-	O	1249-1250
treated	O	1250-1257
patients	O	1258-1266
also	O	1267-1271
performed	O	1272-1281
significantly	O	1282-1295
better	O	1296-1302
on	O	1303-1305
the	O	1306-1309
Finger	O	1310-1316
-	O	1316-1317
to	O	1317-1319
-	O	1316-1317
Nose	O	1320-1324
Test	O	1325-1329
and	O	1330-1333
the	O	1334-1337
recall	O	1338-1344
of	O	1345-1347
pictures	O	1348-1356
shown	O	1357-1362
at	O	1363-1365
the	O	1366-1369
5	O	1370-1371
-	O	1371-1372
minute	O	1372-1378
assessment	O	1379-1389
.	O	1389-1390

Flumazenil	O	1391-1401
was	O	1402-1405
well	O	1406-1410
tolerated	O	1411-1420
,	O	1420-1421
with	O	1422-1426
no	O	1427-1429
serious	O	1430-1437
adverse	O	1438-1445
effects	O	1446-1453
reported	O	1454-1462
.	O	1462-1463

Thirty	O	1464-1470
-	O	1470-1471
nine	O	1471-1475
(	O	1476-1477
30	O	1477-1479
%	O	1479-1480
)	O	1480-1481
of	O	1482-1484
flumazenil	O	1485-1495
-	O	1495-1496
treated	O	1496-1503
patients	O	1504-1512
,	O	1512-1513
compared	O	1514-1522
with	O	1523-1527
17	O	1528-1530
(	O	1531-1532
25	O	1532-1534
%	O	1534-1535
)	O	1535-1536
of	O	1537-1539
placebo	O	1540-1547
-	O	1547-1548
treated	O	1548-1555
patients	O	1556-1564
had	O	1565-1568
one	O	1569-1572
or	O	1573-1575
more	O	1576-1580
drug	O	1581-1585
-	O	1585-1586
related	O	1586-1593
adverse	O	1594-1601
experiences	O	1602-1613
.	O	1613-1614

The	O	1615-1618
most	O	1619-1623
common	O	1624-1630
adverse	O	1631-1638
effects	O	1639-1646
were	O	1647-1651
nausea	B	1652-1658
and	O	1659-1662
vomiting	B	1663-1671
in	O	1672-1674
the	O	1675-1678
flumazenil	O	1679-1689
group	O	1690-1695
and	O	1696-1699
nausea	B	1700-1706
and	O	1707-1710
injection	O	1711-1720
-	O	1720-1721
site	O	1721-1725
pain	B	1726-1730
in	O	1731-1733
the	O	1734-1737
placebo	O	1738-1745
group	O	1746-1751
.	O	1751-1752

Flumazenil	O	1753-1763
was	O	1764-1767
found	O	1768-1773
to	O	1774-1776
promptly	O	1777-1785
reverse	O	1786-1793
sedation	O	1794-1802
induced	O	1803-1810
by	O	1811-1813
diazepam	O	1814-1822
in	O	1823-1825
the	O	1826-1829
presence	O	1830-1838
of	O	1839-1841
opioids	O	1842-1849
.	O	1849-1850

Hepatic	O	0-7
adenomas	B	8-16
and	O	17-20
focal	B	21-26
nodular	I	27-34
hyperplasia	I	35-46
of	O	47-49
the	O	50-53
liver	O	54-59
in	O	60-62
young	O	63-68
women	O	69-74
on	O	75-77
oral	O	78-82
contraceptives	O	83-97
:	O	97-98
case	O	99-103
reports	O	104-111
.	O	111-112

Two	O	113-116
cases	O	117-122
of	O	123-125
hepatic	O	126-133
adenoma	B	134-141
and	O	142-145
one	O	146-149
of	O	150-152
focal	B	153-158
nodular	I	159-166
hyperplasia	I	167-178
presumably	O	179-189
associated	O	190-200
with	O	201-205
the	O	206-209
use	O	210-213
of	O	214-216
oral	O	217-221
contraceptives	O	222-236
,	O	236-237
are	O	238-241
reported	O	242-250
.	O	250-251

Special	O	252-259
reference	O	260-269
is	O	270-272
made	O	273-277
to	O	278-280
their	O	281-286
clinical	O	287-295
presentation	O	296-308
,	O	308-309
which	O	310-315
may	O	316-319
be	O	320-322
totally	O	323-330
asymptomatic	O	331-343
.	O	343-344

Liver	O	345-350
-	O	350-351
function	O	351-359
tests	O	360-365
are	O	366-369
of	O	370-372
little	O	373-379
diagnostic	O	380-390
value	O	391-396
,	O	396-397
but	O	398-401
valuable	O	402-410
information	O	411-422
may	O	423-426
be	O	427-429
obtained	O	430-438
from	O	439-443
both	O	444-448
liver	O	449-454
scanning	O	455-463
and	O	464-467
hepatic	O	468-475
angiography	O	476-487
.	O	487-488

Histologic	O	489-499
differences	O	500-511
and	O	512-515
clinical	O	516-524
similarities	O	525-537
between	O	538-545
hepatic	O	546-553
adenoma	B	554-561
and	O	562-565
focal	B	566-571
nodular	I	572-579
hyperplasia	I	580-591
of	O	592-594
the	O	595-598
liver	O	599-604
are	O	605-608
discussed	O	609-618
.	O	618-619

Arterial	O	0-8
thromboembolism	B	9-24
in	O	25-27
patients	O	28-36
receiving	O	37-46
systemic	O	47-55
heparin	O	56-63
therapy	O	64-71
:	O	71-72
a	O	73-74
complication	O	75-87
associated	O	88-98
with	O	99-103
heparin	O	104-111
-	O	111-112
induced	O	112-119
thrombocytopenia	B	120-136
.	O	136-137

Arterial	O	138-146
thromboembolism	B	147-162
is	O	163-165
a	O	166-167
recognized	O	168-178
complication	O	179-191
of	O	192-194
systemic	O	195-203
heparin	O	204-211
therapy	O	212-219
.	O	219-220

Characteristic	O	221-235
of	O	236-238
the	O	239-242
entity	O	243-249
is	O	250-252
arterial	B	253-261
occlusion	I	262-271
by	O	272-274
platelet	O	275-283
-	O	283-284
fibrin	O	284-290
thrombi	B	291-298
with	O	299-303
distal	O	304-310
ischemia	B	311-319
occurring	O	320-329
four	O	330-334
to	O	335-337
twenty	O	338-344
days	O	345-349
after	O	350-355
the	O	356-359
initiation	O	360-370
of	O	371-373
heparin	O	374-381
therapy	O	382-389
,	O	389-390
preceded	O	391-399
by	O	400-402
profound	O	403-411
thrombocytopenia	B	412-428
with	O	429-433
platelet	O	434-442
counts	O	443-449
in	O	450-452
the	O	453-456
range	O	457-462
of	O	463-465
30	O	466-468
,	O	468-469
000	O	469-472
to	O	473-475
40	O	476-478
,	O	478-479
000	O	479-482
per	O	483-486
cubic	O	487-492
millimeter	O	493-503
.	O	503-504

The	O	505-508
clinically	O	509-519
apparent	O	520-528
occlusion	O	529-538
may	O	539-542
be	O	543-545
preceded	O	546-554
by	O	555-557
gastrointestinal	B	558-574
and	I	575-578
musculoskeletal	I	579-594
symptoms	I	595-603
that	O	604-608
appear	O	609-615
to	O	616-618
be	O	619-621
ischemic	B	622-630
in	O	631-633
origin	O	634-640
,	O	640-641
and	O	642-645
might	O	646-651
serve	O	652-657
to	O	658-660
warn	O	661-665
the	O	666-669
clinician	O	670-679
of	O	680-682
these	O	683-688
complications	O	689-702
.	O	702-703

Previous	O	704-712
reports	O	713-720
of	O	721-723
these	O	724-729
phenomena	O	730-739
as	O	740-742
well	O	743-747
as	O	748-750
recent	O	751-757
studies	O	758-765
of	O	766-768
the	O	769-772
effect	O	773-779
of	O	780-782
heparin	O	783-790
are	O	791-794
reviewed	O	795-803
.	O	803-804

The	O	805-808
common	O	809-815
factor	O	816-822
relating	O	823-831
thromboembolism	B	832-847
and	O	848-851
thrombocytopenia	B	852-868
is	O	869-871
heparin	O	872-879
-	O	879-880
induced	O	880-887
platelet	B	888-896
aggregation	I	897-908
.	O	908-909

Appropriate	O	910-921
treatment	O	922-931
consists	O	932-940
of	O	941-943
discontinuation	O	944-959
of	O	960-962
heparin	O	963-970
,	O	970-971
and	O	972-975
anticoagulation	O	976-991
with	O	992-996
sodium	O	997-1003
warfarin	O	1004-1012
if	O	1013-1015
necessary	O	1016-1025
.	O	1025-1026

Vascular	O	1027-1035
procedures	O	1036-1046
are	O	1047-1050
performed	O	1051-1060
as	O	1061-1063
indicated	O	1064-1073
.	O	1073-1074

Long	O	0-4
-	O	4-5
term	O	5-9
prognosis	O	10-19
for	O	20-23
transplant	O	24-34
-	O	34-35
free	O	35-39
survivors	O	40-49
of	O	50-52
paracetamol	O	53-64
-	O	64-65
induced	O	65-72
acute	B	73-78
liver	I	79-84
failure	I	85-92
.	O	92-93

BACKGROUND	O	94-104
:	O	104-105
The	O	106-109
prognosis	O	110-119
for	O	120-123
transplant	O	124-134
-	O	134-135
free	O	135-139
survivors	O	140-149
of	O	150-152
paracetamol	O	153-164
-	O	164-165
induced	O	165-172
acute	B	173-178
liver	I	179-184
failure	I	185-192
remains	O	193-200
unknown	O	201-208
.	O	208-209

AIM	O	210-213
:	O	213-214
To	O	215-217
examine	O	218-225
whether	O	226-233
paracetamol	O	234-245
-	O	245-246
induced	O	246-253
acute	B	254-259
liver	I	260-265
failure	I	266-273
increases	O	274-283
long	O	284-288
-	O	288-289
term	O	289-293
mortality	O	294-303
.	O	303-304

METHODS	O	305-312
:	O	312-313
We	O	314-316
followed	O	317-325
up	O	326-328
all	O	329-332
transplant	O	333-343
-	O	343-344
free	O	344-348
survivors	O	349-358
of	O	359-361
paracetamol	O	362-373
-	O	373-374
induced	O	374-381
acute	B	382-387
liver	I	388-393
injury	I	394-400
,	O	400-401
hospitalized	O	402-414
in	O	415-417
a	O	418-419
Danish	O	420-426
national	O	427-435
referral	O	436-444
centre	O	445-451
during	O	452-458
1984	O	459-463
-	O	463-464
2004	O	464-468
.	O	468-469

We	O	470-472
compared	O	473-481
age	O	482-485
-	O	485-486
specific	O	486-494
mortality	O	495-504
rates	O	505-510
from	O	511-515
1	O	516-517
year	O	518-522
post	O	523-527
-	O	527-528
discharge	O	528-537
through	O	538-545
2008	O	546-550
between	O	551-558
those	O	559-564
in	O	565-567
whom	O	568-572
the	O	573-576
liver	B	577-582
injury	I	583-589
led	O	590-593
to	O	594-596
an	O	597-599
acute	B	600-605
liver	I	606-611
failure	I	612-619
and	O	620-623
those	O	624-629
in	O	630-632
whom	O	633-637
it	O	638-640
did	O	641-644
not	O	645-648
.	O	648-649

RESULTS	O	650-657
:	O	657-658
We	O	659-661
included	O	662-670
641	O	671-674
patients	O	675-683
.	O	683-684

On	O	685-687
average	O	688-695
,	O	695-696
age	O	697-700
-	O	700-701
specific	O	701-709
mortality	O	710-719
rates	O	720-725
were	O	726-730
slightly	O	731-739
higher	O	740-746
for	O	747-750
the	O	751-754
101	O	755-758
patients	O	759-767
whose	O	768-773
paracetamol	O	774-785
-	O	785-786
induced	O	786-793
liver	B	794-799
injury	I	800-806
had	O	807-810
caused	O	811-817
an	O	818-820
acute	B	821-826
liver	I	827-832
failure	I	833-840
(	O	841-842
adjusted	O	842-850
mortality	O	851-860
rate	O	861-865
ratio	O	866-871
=	O	872-873
1	O	874-875
.	O	875-876
70	O	876-878
,	O	878-879
95	O	880-882
%	O	882-883
CI	O	884-886
1	O	887-888
.	O	888-889
02	O	889-891
-	O	891-892
2	O	890-891
.	O	888-889
85	O	894-896
)	O	896-897
,	O	897-898

but	O	899-902
the	O	903-906
association	O	907-918
was	O	919-922
age	O	923-926
-	O	926-927
dependent	O	927-936
,	O	936-937
and	O	938-941
no	O	942-944
survivors	O	945-954
of	O	955-957
acute	B	958-963
liver	I	964-969
failure	I	970-977
died	O	978-982
of	O	983-985
liver	B	986-991
disease	I	992-999
,	O	999-1000
whereas	O	1001-1008
suicides	O	1009-1017
were	O	1018-1022
frequent	O	1023-1031
in	O	1032-1034
both	O	1035-1039
groups	O	1040-1046
.	O	1046-1047

These	O	1048-1053
observations	O	1054-1066
speak	O	1067-1072
against	O	1073-1080
long	O	1081-1085
-	O	1085-1086
term	O	1086-1090
effects	O	1091-1098
of	O	1099-1101
acute	B	1102-1107
liver	I	1108-1113
failure	I	1114-1121
.	O	1121-1122

More	O	1123-1127
likely	O	1128-1134
,	O	1134-1135
the	O	1136-1139
elevated	O	1140-1148
mortality	O	1149-1158
rate	O	1159-1163
ratio	O	1164-1169
resulted	O	1170-1178
from	O	1179-1183
incomplete	O	1184-1194
adjustment	O	1195-1205
for	O	1206-1209
the	O	1210-1213
greater	O	1214-1221
prevalence	O	1222-1232
of	O	1233-1235
substance	B	1236-1245
abuse	I	1246-1251
among	O	1252-1257
survivors	O	1258-1267
of	O	1268-1270
acute	B	1271-1276
liver	I	1277-1282
failure	I	1283-1290
.	O	1290-1291

CONCLUSIONS	O	1292-1303
:	O	1303-1304
Paracetamol	O	1305-1316
-	O	1316-1317
induced	O	1317-1324
acute	B	1325-1330
liver	I	1331-1336
failure	I	1337-1344
did	O	1345-1348
not	O	1349-1352
affect	O	1353-1359
long	O	1360-1364
-	O	1364-1365
term	O	1365-1369
mortality	O	1370-1379
.	O	1379-1380

Clinical	O	1381-1389
follow	O	1390-1396
-	O	1396-1397
up	O	1397-1399
may	O	1400-1403
be	O	1404-1406
justified	O	1407-1416
by	O	1417-1419
the	O	1420-1423
cause	O	1424-1429
of	O	1430-1432
the	O	1433-1436
liver	B	1437-1442
failure	I	1443-1450
,	O	1450-1451
but	O	1452-1455
not	O	1456-1459
by	O	1460-1462
the	O	1463-1466
liver	B	1467-1472
failure	I	1473-1480
itself	O	1481-1487
.	O	1487-1488

Serotonin	O	0-9
6	O	10-11
receptor	O	12-20
gene	O	21-25
is	O	26-28
associated	O	29-39
with	O	40-44
methamphetamine	O	45-60
-	O	60-61
induced	O	61-68
psychosis	B	69-78
in	O	79-81
a	O	82-83
Japanese	O	84-92
population	O	93-103
.	O	103-104

BACKGROUND	O	105-115
:	O	115-116
Altered	O	117-124
serotonergic	O	125-137
neural	O	138-144
transmission	O	145-157
is	O	158-160
hypothesized	O	161-173
to	O	174-176
be	O	177-179
a	O	180-181
susceptibility	O	182-196
factor	O	197-203
for	O	204-207
psychotic	B	208-217
disorders	I	218-227
such	O	228-232
as	O	233-235
schizophrenia	B	236-249
.	O	249-250

The	O	251-254
serotonin	O	255-264
6	O	265-266
(	O	267-268
5	O	268-269
-	O	269-270
HT6	O	270-273
)	O	273-274
receptor	O	275-283
is	O	284-286
therapeutically	O	287-302
targeted	O	303-311
by	O	312-314
several	O	315-322
second	O	323-329
generation	O	330-340
antipsychotics	O	341-355
,	O	355-356
such	O	357-361
as	O	362-364
clozapine	O	365-374
and	O	375-378
olanzapine	O	379-389
,	O	389-390
and	O	391-394
d	O	395-396
-	O	396-397
amphetamine	O	397-408
-	O	396-397
induced	O	409-416
hyperactivity	B	417-430
in	O	431-433
rats	O	434-438
is	O	439-441
corrected	O	442-451
with	O	452-456
the	O	457-460
use	O	461-464
of	O	465-467
a	O	468-469
selective	O	470-479
5	O	480-481
-	O	481-482
HT6	O	482-485
receptor	O	486-494
antagonist	O	495-505
.	O	505-506

In	O	507-509
addition	O	510-518
,	O	518-519
the	O	520-523
disrupted	O	524-533
prepulse	O	534-542
inhibition	O	543-553
induced	O	554-561
by	O	562-564
d	O	565-566
-	O	566-567
amphetamine	O	567-578
or	O	579-581
phencyclidine	O	582-595
was	O	596-599
restored	O	600-608
by	O	609-611
5	O	612-613
-	O	613-614
HT6	O	614-617
receptor	O	618-626
antagonist	O	627-637
in	O	638-640
an	O	641-643
animal	O	644-650
study	O	651-656
using	O	657-662
rats	O	663-667
.	O	667-668

These	O	669-674
animal	O	675-681
models	O	682-688
were	O	689-693
considered	O	694-704
to	O	705-707
reflect	O	708-715
the	O	716-719
positive	O	720-728
symptoms	O	729-737
of	O	738-740
schizophrenia	B	741-754
,	O	754-755
and	O	756-759
the	O	760-763
above	O	764-769
evidence	O	770-778
suggests	O	779-787
that	O	788-792
altered	O	793-800
5	O	801-802
-	O	802-803
HT6	O	803-806
receptors	O	807-816
are	O	817-820
involved	O	821-829
in	O	830-832
the	O	833-836
pathophysiology	O	837-852
of	O	853-855
psychotic	B	856-865
disorders	I	866-875
.	O	875-876

The	O	877-880
symptoms	O	881-889
of	O	890-892
methamphetamine	O	893-908
(	O	909-910
METH	O	910-914
)	O	914-915
-	O	915-916
induced	O	916-923
psychosis	B	924-933
are	O	934-937
similar	O	938-945
to	O	946-948
those	O	949-954
of	O	955-957
paranoid	B	958-966
type	I	967-971
schizophrenia	I	972-985
.	O	985-986

Therefore	O	987-996
,	O	996-997
we	O	998-1000
conducted	O	1001-1010
an	O	1011-1013
analysis	O	1014-1022
of	O	1023-1025
the	O	1026-1029
association	O	1030-1041
of	O	1042-1044
the	O	1045-1048
5	O	1049-1050
-	O	1050-1051
HT6	O	1051-1054
gene	O	1055-1059
(	O	1060-1061
HTR6	O	1061-1065
)	O	1065-1066
with	O	1067-1071
METH	O	1072-1076
-	O	1076-1077
induced	O	1077-1084
psychosis	B	1085-1094
.	O	1094-1095

METHOD	O	1096-1102
:	O	1102-1103
Using	O	1104-1109
five	O	1110-1114
tagging	O	1115-1122
SNPs	O	1123-1127
(	O	1128-1129
rs6693503	O	1129-1138
,	O	1138-1139
rs1805054	O	1140-1149
,	O	1149-1150
rs4912138	O	1151-1160
,	O	1160-1161
rs3790757	O	1162-1171
and	O	1172-1175
rs9659997	O	1176-1185
)	O	1185-1186
,	O	1186-1187
we	O	1188-1190
conducted	O	1191-1200
a	O	1201-1202
genetic	O	1203-1210
association	O	1211-1222
analysis	O	1223-1231
of	O	1232-1234
case	O	1235-1239
-	O	1239-1240
control	O	1240-1247
samples	O	1248-1255
(	O	1256-1257
197	O	1257-1260
METH	O	1261-1265
-	O	1265-1266
induced	O	1266-1273
psychosis	B	1274-1283
patients	O	1284-1292
and	O	1293-1296
337	O	1297-1300
controls	O	1301-1309
)	O	1309-1310
in	O	1311-1313
the	O	1314-1317
Japanese	O	1318-1326
population	O	1327-1337
.	O	1337-1338

The	O	1339-1342
age	O	1343-1346
and	O	1347-1350
sex	O	1351-1354
of	O	1355-1357
the	O	1358-1361
control	O	1362-1369
subjects	O	1370-1378
did	O	1379-1382
not	O	1383-1386
differ	O	1387-1393
from	O	1394-1398
those	O	1399-1404
of	O	1405-1407
the	O	1408-1411
methamphetamine	O	1412-1427
dependence	O	1428-1438
patients	O	1439-1447
.	O	1447-1448

RESULTS	O	1449-1456
:	O	1456-1457
rs6693503	O	1458-1467
was	O	1468-1471
associated	O	1472-1482
with	O	1483-1487
METH	O	1488-1492
-	O	1492-1493
induced	O	1493-1500
psychosis	B	1501-1510
patients	O	1511-1519
in	O	1520-1522
the	O	1523-1526
allele	O	1527-1533
/	O	1533-1534
genotype	O	1534-1542
-	O	1542-1543
wise	O	1543-1547
analysis	O	1548-1556
.	O	1556-1557

Moreover	O	1558-1566
,	O	1566-1567
this	O	1568-1572
association	O	1573-1584
remained	O	1585-1593
significant	O	1594-1605
after	O	1606-1611
Bonferroni	O	1612-1622
correction	O	1623-1633
.	O	1633-1634

In	O	1635-1637
the	O	1638-1641
haplotype	O	1642-1651
-	O	1651-1652
wise	O	1652-1656
analysis	O	1657-1665
,	O	1665-1666
we	O	1667-1669
detected	O	1670-1678
an	O	1679-1681
association	O	1682-1693
between	O	1694-1701
two	O	1702-1705
markers	O	1706-1713
(	O	1714-1715
rs6693503	O	1715-1724
and	O	1725-1728
rs1805054	O	1729-1738
)	O	1738-1739
and	O	1740-1743
three	O	1744-1749
markers	O	1750-1757
(	O	1758-1759
rs6693503	O	1759-1768
,	O	1768-1769
rs1805054	O	1770-1779
and	O	1780-1783
rs4912138	O	1784-1793
)	O	1793-1794
in	O	1795-1797
HTR6	O	1798-1802
and	O	1803-1806
METH	O	1807-1811
-	O	1811-1812
induced	O	1812-1819
psychosis	B	1820-1829
patients	O	1830-1838
,	O	1838-1839
respectively	O	1840-1852
.	O	1852-1853

CONCLUSION	O	1854-1864
:	O	1864-1865
HTR6	O	1866-1870
may	O	1871-1874
play	O	1875-1879
an	O	1880-1882
important	O	1883-1892
role	O	1893-1897
in	O	1898-1900
the	O	1901-1904
pathophysiology	O	1905-1920
of	O	1921-1923
METH	O	1924-1928
-	O	1928-1929
induced	O	1929-1936
psychosis	B	1937-1946
in	O	1947-1949
the	O	1950-1953
Japanese	O	1954-1962
population	O	1963-1973
.	O	1973-1974

Effect	O	0-6
of	O	7-9
increasing	O	10-20
intraperitoneal	O	21-36
infusion	O	37-45
rates	O	46-51
on	O	52-54
bupropion	O	55-64
hydrochloride	O	65-78
-	O	78-79
induced	O	79-86
seizures	B	87-95
in	O	96-98
mice	O	99-103
.	O	103-104

BACKGROUND	O	105-115
:	O	115-116
It	O	117-119
is	O	120-122
not	O	123-126
known	O	127-132
if	O	133-135
there	O	136-141
is	O	142-144
a	O	145-146
relationship	O	147-159
between	O	160-167
input	O	168-173
rate	O	174-178
and	O	179-182
incidence	O	183-192
of	O	193-195
bupropion	O	196-205
-	O	205-206
induced	O	206-213
seizures	B	214-222
.	O	222-223

This	O	224-228
is	O	229-231
important	O	232-241
,	O	241-242
since	O	243-248
different	O	249-258
controlled	O	259-269
release	O	270-277
formulations	O	278-290
of	O	291-293
bupropion	O	294-303
release	O	304-311
the	O	312-315
active	O	316-322
drug	O	323-327
at	O	328-330
different	O	331-340
rates	O	341-346
.	O	346-347

METHODS	O	348-355
:	O	355-356
We	O	357-359
investigated	O	360-372
the	O	373-376
effect	O	377-383
of	O	384-386
varying	O	387-394
the	O	395-398
intraperitoneal	O	399-414
infusion	O	415-423
rates	O	424-429
of	O	430-432
bupropion	O	433-442
HCl	O	443-446
120	O	447-450
mg	O	451-453
/	O	453-454
kg	O	454-456
,	O	456-457
a	O	458-459
known	O	460-465
convulsive	B	466-476
dose	O	477-481
50	O	482-484
(	O	485-486
CD50	O	486-490
)	O	490-491
,	O	491-492
on	O	493-495
the	O	496-499
incidence	O	500-509
and	O	510-513
severity	O	514-522
of	O	523-525
bupropion	O	526-535
-	O	535-536
induced	O	536-543
convulsions	B	544-555
in	O	556-558
the	O	559-562
Swiss	O	563-568
albino	O	569-575
mice	O	576-580
.	O	580-581

A	O	582-583
total	O	584-589
of	O	590-592
69	O	593-595
mice	O	596-600
,	O	600-601
approximately	O	602-615
7	O	616-617
weeks	O	618-623
of	O	624-626
age	O	627-630
,	O	630-631
and	O	632-635
weighing	O	636-644
21	O	645-647
.	O	647-648
0	O	648-649
to	O	650-652
29	O	653-655
.	O	655-656
1	O	656-657
g	O	658-659
were	O	660-664
randomly	O	665-673
assigned	O	674-682
to	O	683-685
bupropion	O	686-695
HCl	O	696-699
120	O	700-703
mg	O	704-706
/	O	706-707
kg	O	707-709
treatment	O	710-719
by	O	720-722
intraperitoneal	O	723-738
(	O	739-740
IP	O	740-742
)	O	742-743
administration	O	744-758
in	O	759-761
7	O	762-763
groups	O	764-770
(	O	771-772
9	O	772-773
to	O	774-776
10	O	777-779
animals	O	780-787
per	O	788-791
group	O	792-797
)	O	797-798
.	O	798-799

Bupropion	O	800-809
HCl	O	810-813
was	O	814-817
infused	O	818-825
through	O	826-833
a	O	834-835
surgically	O	836-846
implanted	O	847-856
IP	O	857-859
dosing	O	860-866
catheter	O	867-875
with	O	876-880
infusions	O	881-890
in	O	891-893
each	O	894-898
group	O	899-904
of	O	905-907
0	O	908-909
min	O	910-913
,	O	913-914
15	O	915-917
min	O	918-921
,	O	921-922
30	O	923-925
min	O	926-929
,	O	929-930
60	O	931-933
min	O	934-937
,	O	937-938
90	O	939-941
min	O	942-945
,	O	945-946
120	O	947-950
min	O	951-954
,	O	954-955
and	O	956-959
240	O	960-963
min	O	964-967
.	O	967-968

The	O	969-972
number	O	973-979
,	O	979-980
time	O	981-985
of	O	986-988
onset	O	989-994
,	O	994-995
duration	O	996-1004
and	O	1005-1008
the	O	1009-1012
intensity	O	1013-1022
of	O	1023-1025
the	O	1026-1029
convulsions	B	1030-1041
or	O	1042-1044
absence	O	1045-1052
of	O	1053-1055
convulsions	B	1056-1067
were	O	1068-1072
recorded	O	1073-1081
.	O	1081-1082

RESULTS	O	1083-1090
:	O	1090-1091
The	O	1092-1095
results	O	1096-1103
showed	O	1104-1110
that	O	1111-1115
IP	O	1116-1118
administration	O	1119-1133
of	O	1134-1136
bupropion	O	1137-1146
HCl	O	1147-1150
120	O	1151-1154
mg	O	1155-1157
/	O	1157-1158
kg	O	1158-1160
by	O	1161-1163
bolus	O	1164-1169
injection	O	1170-1179
induced	O	1180-1187
convulsions	B	1188-1199
in	O	1200-1202
6	O	1203-1204
out	O	1205-1208
of	O	1209-1211
10	O	1212-1214
mice	O	1215-1219
(	O	1220-1221
60	O	1221-1223
%	O	1223-1224
of	O	1225-1227
convulsing	O	1228-1238
mice	O	1239-1243
)	O	1243-1244
in	O	1245-1247
group	O	1248-1253
1	O	1254-1255
.	O	1255-1256
Logistic	O	1257-1265
regression	O	1266-1276
analysis	O	1277-1285
revealed	O	1286-1294
that	O	1295-1299
infusion	O	1300-1308
time	O	1309-1313
was	O	1314-1317
significant	O	1318-1329
(	O	1330-1331
p	O	1331-1332
=	O	1333-1334
0	O	1335-1336
.	O	1336-1337
0004	O	1337-1341
;	O	1341-1342
odds	O	1343-1347
ratio	O	1348-1353
=	O	1354-1355
0	O	1356-1357
.	O	1357-1358
974	O	1358-1361
)	O	1361-1362
and	O	1363-1366
increasing	O	1367-1377
the	O	1378-1381
IP	O	1382-1384
infusion	O	1385-1393
time	O	1394-1398
of	O	1399-1401
bupropion	O	1402-1411
HCl	O	1412-1415
120	O	1416-1419
mg	O	1420-1422
/	O	1422-1423
kg	O	1423-1425
was	O	1426-1429
associated	O	1430-1440
with	O	1441-1445
a	O	1446-1447
91	O	1448-1450
%	O	1450-1451
reduced	O	1452-1459
odds	O	1460-1464
of	O	1465-1467
convulsions	B	1468-1479
at	O	1480-1482
infusion	O	1483-1491
times	O	1492-1497
of	O	1498-1500
15	O	1501-1503
to	O	1504-1506
90	O	1507-1509
min	O	1510-1513
compared	O	1514-1522
to	O	1523-1525
bolus	O	1526-1531
injection	O	1532-1541
.	O	1541-1542

Further	O	1543-1550
increase	O	1551-1559
in	O	1560-1562
infusion	O	1563-1571
time	O	1572-1576
resulted	O	1577-1585
in	O	1586-1588
further	O	1589-1596
reduction	O	1597-1606
in	O	1607-1609
the	O	1610-1613
odds	O	1614-1618
of	O	1619-1621
convulsions	B	1622-1633
to	O	1634-1636
99	O	1637-1639
.	O	1639-1640
8	O	1640-1641
%	O	1641-1642
reduction	O	1643-1652
at	O	1653-1655
240	O	1656-1659
min	O	1660-1663
.	O	1663-1664

CONCLUSION	O	1665-1675
:	O	1675-1676
In	O	1677-1679
conclusion	O	1680-1690
,	O	1690-1691
the	O	1692-1695
demonstration	O	1696-1709
of	O	1710-1712
an	O	1713-1715
inverse	O	1716-1723
relationship	O	1724-1736
between	O	1737-1744
infusion	O	1745-1753
time	O	1754-1758
of	O	1759-1761
a	O	1762-1763
fixed	O	1764-1769
and	O	1770-1773
convulsive	B	1774-1784
dose	O	1785-1789
of	O	1790-1792
bupropion	O	1793-1802
and	O	1803-1806
the	O	1807-1810
risk	O	1811-1815
of	O	1816-1818
convulsions	B	1819-1830
in	O	1831-1833
a	O	1834-1835
prospective	O	1836-1847
study	O	1848-1853
is	O	1854-1856
novel	O	1857-1862
.	O	1862-1863

Detailed	O	0-8
spectral	O	9-17
profile	O	18-25
analysis	O	26-34
of	O	35-37
penicillin	O	38-48
-	O	48-49
induced	O	49-56
epileptiform	B	57-69
activity	I	70-78
in	O	79-81
anesthetized	O	82-94
rats	O	95-99
.	O	99-100

Penicillin	O	101-111
model	O	112-117
is	O	118-120
a	O	121-122
widely	O	123-129
used	O	130-134
experimental	O	135-147
model	O	148-153
for	O	154-157
epilepsy	B	158-166
research	O	167-175
.	O	175-176

In	O	177-179
the	O	180-183
present	O	184-191
study	O	192-197
we	O	198-200
aimed	O	201-206
to	O	207-209
portray	O	210-217
a	O	218-219
detailed	O	220-228
spectral	O	229-237
analysis	O	238-246
of	O	247-249
penicillin	O	250-260
-	O	260-261
induced	O	261-268
epileptiform	B	269-281
activity	I	282-290
in	O	291-293
comparison	O	294-304
with	O	305-309
basal	O	310-315
brain	O	316-321
activity	O	322-330
in	O	331-333
anesthetized	O	334-346
Wistar	O	347-353
rats	O	354-358
.	O	358-359

Male	O	360-364
Wistar	O	365-371
rats	O	372-376
were	O	377-381
anesthetized	O	382-394
with	O	395-399
i	O	400-401
.	O	401-402
p	O	402-403
.	O	401-402
urethane	O	405-413
and	O	414-417
connected	O	418-427
to	O	428-430
an	O	431-433
electrocorticogram	O	434-452
setup	O	453-458
.	O	458-459

After	O	460-465
a	O	466-467
short	O	468-473
period	O	474-480
of	O	481-483
basal	O	484-489
activity	O	490-498
recording	O	499-508
,	O	508-509
epileptic	B	510-519
focus	O	520-525
was	O	526-529
induced	O	530-537
by	O	538-540
injecting	O	541-550
400IU	O	551-556
/	O	556-557
2	O	557-558
microl	O	559-565
penicillin	O	566-576
-	O	576-577
G	O	577-578
potassium	O	579-588
into	O	589-593
the	O	594-597
left	O	598-602
lateral	O	603-610
ventricle	O	611-620
while	O	621-626
the	O	627-630
cortical	O	631-639
activity	O	640-648
was	O	649-652
continuously	O	653-665
recorded	O	666-674
.	O	674-675

Basal	O	676-681
activity	O	682-690
,	O	690-691
latent	O	692-698
period	O	699-705
and	O	706-709
the	O	710-713
penicillin	O	714-724
-	O	724-725
induced	O	725-732
epileptiform	B	733-745
activity	I	746-754
periods	O	755-762
were	O	763-767
then	O	768-772
analyzed	O	773-781
using	O	782-787
both	O	788-792
conventional	O	793-805
methods	O	806-813
and	O	814-817
spectral	O	818-826
analysis	O	827-835
.	O	835-836

Spectral	O	837-845
analyses	O	846-854
were	O	855-859
conducted	O	860-869
by	O	870-872
dividing	O	873-881
the	O	882-885
whole	O	886-891
spectrum	O	892-900
into	O	901-905
different	O	906-915
frequency	O	916-925
bands	O	926-931
including	O	932-941
delta	O	942-947
,	O	947-948
theta	O	949-954
(	O	955-956
slow	O	956-960
and	O	961-964
fast	O	965-969
)	O	969-970
,	O	970-971
alpha	O	972-977
-	O	977-978
sigma	O	978-983
,	O	983-984
beta	O	985-989
(	O	990-991
1	O	991-992
and	O	993-996
2	O	997-998
)	O	998-999
and	O	1000-1003
gamma	O	1004-1009
(	O	1010-1011
1	O	1011-1012
and	O	1013-1016
2	O	1017-1018
)	O	1018-1019
bands	O	1020-1025
.	O	1025-1026

Our	O	1027-1030
results	O	1031-1038
show	O	1039-1043
that	O	1044-1048
the	O	1049-1052
most	O	1053-1057
affected	O	1058-1066
frequency	O	1067-1076
bands	O	1077-1082
were	O	1083-1087
delta	O	1088-1093
,	O	1093-1094
theta	O	1095-1100
,	O	1100-1101
beta	O	1102-1106
-	O	1106-1107
2	O	1107-1108
and	O	1109-1112
gamma	O	1113-1118
-	O	1118-1119
2	O	1119-1120
bands	O	1121-1126
during	O	1127-1133
the	O	1134-1137
epileptiform	B	1138-1150
activity	I	1151-1159
and	O	1160-1163
there	O	1164-1169
were	O	1170-1174
marked	O	1175-1181
differences	O	1182-1193
in	O	1194-1196
terms	O	1197-1202
of	O	1203-1205
spectral	O	1206-1214
densities	O	1215-1224
between	O	1225-1232
three	O	1233-1238
investigated	O	1239-1251
episodes	O	1252-1260
(	O	1261-1262
basal	O	1262-1267
activity	O	1268-1276
,	O	1276-1277
latent	O	1278-1284
period	O	1285-1291
and	O	1292-1295
epileptiform	B	1296-1308
activity	I	1309-1317
)	O	1317-1318
.	O	1318-1319

Our	O	1320-1323
results	O	1324-1331
may	O	1332-1335
help	O	1336-1340
to	O	1341-1343
analyze	O	1344-1351
novel	O	1352-1357
data	O	1358-1362
obtained	O	1363-1371
using	O	1372-1377
similar	O	1378-1385
experimental	O	1386-1398
models	O	1399-1405
and	O	1406-1409
the	O	1410-1413
simple	O	1414-1420
analysis	O	1421-1429
method	O	1430-1436
described	O	1437-1446
here	O	1447-1451
can	O	1452-1455
be	O	1456-1458
used	O	1459-1463
in	O	1464-1466
similar	O	1467-1474
studies	O	1475-1482
to	O	1483-1485
investigate	O	1486-1497
the	O	1498-1501
basic	O	1502-1507
neuronal	O	1508-1516
mechanism	O	1517-1526
of	O	1527-1529
this	O	1530-1534
or	O	1535-1537
other	O	1538-1543
types	O	1544-1549
of	O	1550-1552
experimental	O	1553-1565
epilepsies	B	1566-1576
.	O	1576-1577

High	O	0-4
dose	O	5-9
dexmedetomidine	O	10-25
as	O	26-28
the	O	29-32
sole	O	33-37
sedative	O	38-46
for	O	47-50
pediatric	O	51-60
MRI	O	61-64
.	O	64-65

OBJECTIVE	O	66-75
:	O	75-76
This	O	77-81
large	O	82-87
-	O	87-88
scale	O	88-93
retrospective	O	94-107
review	O	108-114
evaluates	O	115-124
the	O	125-128
sedation	O	129-137
profile	O	138-145
of	O	146-148
dexmedetomidine	O	149-164
.	O	164-165

AIM	O	166-169
:	O	169-170
To	O	171-173
determine	O	174-183
the	O	184-187
hemodynamic	O	188-199
responses	O	200-209
,	O	209-210
efficacy	O	211-219
and	O	220-223
adverse	O	224-231
events	O	232-238
associated	O	239-249
with	O	250-254
the	O	255-258
use	O	259-262
of	O	263-265
high	O	266-270
dose	O	271-275
dexmedetomidine	O	276-291
as	O	292-294
the	O	295-298
sole	O	299-303
sedative	O	304-312
for	O	313-316
magnetic	O	317-325
resonance	O	326-335
imaging	O	336-343
(	O	344-345
MRI	O	345-348
)	O	348-349
studies	O	350-357
.	O	357-358

BACKGROUND	O	359-369
:	O	369-370
Dexmedetomidine	O	371-386
has	O	387-390
been	O	391-395
used	O	396-400
at	O	401-403
our	O	404-407
institution	O	408-419
since	O	420-425
2005	O	426-430
to	O	431-433
provide	O	434-441
sedation	O	442-450
for	O	451-454
pediatric	O	455-464
radiological	O	465-477
imaging	O	478-485
studies	O	486-493
.	O	493-494

Over	O	495-499
time	O	500-504
,	O	504-505
an	O	506-508
effective	O	509-518
protocol	O	519-527
utilizing	O	528-537
high	O	538-542
dose	O	543-547
dexmedetomidine	O	548-563
as	O	564-566
the	O	567-570
sole	O	571-575
sedative	O	576-584
agent	O	585-590
has	O	591-594
evolved	O	595-602
.	O	602-603

METHODS	O	604-611
/	O	611-612
MATERIALS	O	612-621
:	O	621-622
As	O	623-625
part	O	626-630
of	O	631-633
the	O	634-637
ongoing	O	638-645
Quality	O	646-653
Assurance	O	654-663
process	O	664-671
,	O	671-672
data	O	673-677
on	O	678-680
all	O	681-684
sedations	O	685-694
are	O	695-698
reviewed	O	699-707
monthly	O	708-715
and	O	716-719
protocols	O	720-729
modified	O	730-738
as	O	739-741
needed	O	742-748
.	O	748-749

Data	O	750-754
were	O	755-759
analyzed	O	760-768
from	O	769-773
all	O	774-777
747	O	778-781
consecutive	O	782-793
patients	O	794-802
who	O	803-806
received	O	807-815
dexmedetomidine	O	816-831
for	O	832-835
MRI	O	836-839
sedation	O	840-848
from	O	849-853
April	O	854-859
2005	O	860-864
to	O	865-867
April	O	868-873
2007	O	874-878
.	O	878-879

RESULTS	O	880-887
:	O	887-888
Since	O	889-894
2005	O	895-899
,	O	899-900
the	O	901-904
10	O	905-907
-	O	907-908
min	O	908-911
loading	O	912-919
dose	O	920-924
of	O	925-927
our	O	928-931
dexmedetomidine	O	932-947
protocol	O	948-956
increased	O	957-966
from	O	967-971
2	O	972-973
to	O	974-976
3	O	977-978
microg	O	979-985
.	O	985-986
kg	O	986-988
(	O	988-989
-	O	989-990
1	O	990-991
)	O	991-992
,	O	992-993

and	O	994-997
the	O	998-1001
infusion	O	1002-1010
rate	O	1011-1015
increased	O	1016-1025
from	O	1026-1030
1	O	1031-1032
to	O	1033-1035
1	O	1036-1037
.	O	1037-1038
5	O	1038-1039
to	O	1040-1042
2	O	1043-1044
microg	O	1045-1051
.	O	1051-1052
kg	O	1052-1054
(	O	1054-1055
-	O	1055-1056
1	O	1056-1057
)	O	1057-1058
.	O	1051-1052
h	O	1059-1060
(	O	1054-1055
-	O	1055-1056
1	O	1056-1057
)	O	1057-1058
.	O	1051-1052

The	O	1066-1069
current	O	1070-1077
sedation	O	1078-1086
protocol	O	1087-1095
progressively	O	1096-1109
increased	O	1110-1119
the	O	1120-1123
rate	O	1124-1128
of	O	1129-1131
successful	O	1132-1142
sedation	O	1143-1151
(	O	1152-1153
able	O	1153-1157
to	O	1158-1160
complete	O	1161-1169
the	O	1170-1173
imaging	O	1174-1181
study	O	1182-1187
)	O	1187-1188
when	O	1189-1193
using	O	1194-1199
dexmedetomidine	O	1200-1215
alone	O	1216-1221
from	O	1222-1226
91	O	1227-1229
.	O	1229-1230
8	O	1230-1231
%	O	1231-1232
to	O	1233-1235
97	O	1236-1238
.	O	1238-1239
6	O	1239-1240
%	O	1240-1241
(	O	1242-1243
P	O	1243-1244
=	O	1245-1246
0	O	1247-1248
.	O	1248-1249
009	O	1249-1252
)	O	1252-1253
,	O	1253-1254
reducing	O	1255-1263
the	O	1264-1267
requirement	O	1268-1279
for	O	1280-1283
adjuvant	O	1284-1292
pentobarbital	O	1293-1306
in	O	1307-1309
the	O	1310-1313
event	O	1314-1319
of	O	1320-1322
sedation	O	1323-1331
failure	O	1332-1339
with	O	1340-1344
dexmedetomidine	O	1345-1360
alone	O	1361-1366
and	O	1367-1370
decreased	O	1371-1380
the	O	1381-1384
mean	O	1385-1389
recovery	O	1390-1398
time	O	1399-1403
by	O	1404-1406
10	O	1407-1409
min	O	1410-1413
(	O	1414-1415
P	O	1415-1416
<	O	1417-1418
0	O	1419-1420
.	O	1420-1421
001	O	1421-1424
)	O	1424-1425
.	O	1420-1421

Although	O	1427-1435
dexmedetomidine	O	1436-1451
sedation	O	1452-1460
was	O	1461-1464
associated	O	1465-1475
with	O	1476-1480
a	O	1481-1482
16	O	1483-1485
%	O	1485-1486
incidence	O	1487-1496
of	O	1497-1499
bradycardia	B	1500-1511
,	O	1511-1512
all	O	1513-1516
concomitant	O	1517-1528
mean	O	1529-1533
arterial	O	1534-1542
blood	O	1543-1548
pressures	O	1549-1558
were	O	1559-1563
within	O	1564-1570
20	O	1571-1573
%	O	1573-1574
of	O	1575-1577
age	O	1578-1581
-	O	1581-1582
adjusted	O	1582-1590
normal	O	1591-1597
range	O	1598-1603
and	O	1604-1607
oxygen	O	1608-1614
saturations	O	1615-1626
were	O	1627-1631
95	O	1632-1634
%	O	1634-1635
or	O	1636-1638
higher	O	1639-1645
.	O	1645-1646

CONCLUSION	O	1647-1657
:	O	1657-1658
Dexmedetomidine	O	1659-1674
in	O	1675-1677
high	O	1678-1682
doses	O	1683-1688
provides	O	1689-1697
adequate	O	1698-1706
sedation	O	1707-1715
for	O	1716-1719
pediatric	O	1720-1729
MRI	O	1730-1733
studies	O	1734-1741
.	O	1741-1742

While	O	1743-1748
use	O	1749-1752
of	O	1753-1755
high	O	1756-1760
dose	O	1761-1765
dexmedetomidine	O	1766-1781
is	O	1782-1784
associated	O	1785-1795
with	O	1796-1800
decreases	O	1801-1810
in	O	1811-1813
heart	O	1814-1819
rate	O	1820-1824
and	O	1825-1828
blood	O	1829-1834
pressure	O	1835-1843
outside	O	1844-1851
the	O	1852-1855
established	O	1856-1867
'	O	1868-1869
awake	O	1869-1874
'	O	1868-1869
norms	O	1876-1881
,	O	1881-1882
this	O	1883-1887
deviation	O	1888-1897
is	O	1898-1900
generally	O	1901-1910
within	O	1911-1917
20	O	1918-1920
%	O	1920-1921
of	O	1922-1924
norms	O	1925-1930
,	O	1930-1931
and	O	1932-1935
is	O	1936-1938
not	O	1939-1942
associated	O	1943-1953
with	O	1954-1958
adverse	O	1959-1966
sequelae	O	1967-1975
.	O	1975-1976

Dexmedetomidine	O	1977-1992
is	O	1993-1995
useful	O	1996-2002
as	O	2003-2005
the	O	2006-2009
sole	O	2010-2014
sedative	O	2015-2023
for	O	2024-2027
pediatric	O	2028-2037
MRI	O	2038-2041
.	O	2041-2042

Methamphetamine	O	0-15
causes	O	16-22
alterations	O	23-34
in	O	35-37
the	O	38-41
MAP	O	42-45
kinase	O	46-52
-	O	52-53
related	O	53-60
pathways	O	61-69
in	O	70-72
the	O	73-76
brains	O	77-83
of	O	84-86
mice	O	87-91
that	O	92-96
display	O	97-104
increased	O	105-114
aggressiveness	B	115-129
.	O	129-130

Aggressive	B	131-141
behaviors	I	142-151
have	O	152-156
been	O	157-161
reported	O	162-170
in	O	171-173
patients	O	174-182
who	O	183-186
suffer	O	187-193
from	O	194-198
some	O	199-203
psychiatric	B	204-215
disorders	I	216-225
,	O	225-226
and	O	227-230
are	O	231-234
common	O	235-241
in	O	242-244
methamphetamine	O	245-260
(	O	261-262
METH	O	262-266
)	O	266-267
abusers	O	268-275
.	O	275-276

Herein	O	277-283
,	O	283-284
we	O	285-287
report	O	288-294
that	O	295-299
multiple	O	300-308
(	O	309-310
but	O	310-313
not	O	314-317
single	O	318-324
)	O	324-325
injections	O	326-336
of	O	337-339
METH	O	340-344
significantly	O	345-358
increased	O	359-368
aggressiveness	B	369-383
in	O	384-386
male	O	387-391
CD	O	392-394
-	O	394-395
1	O	395-396
mice	O	397-401
.	O	401-402

This	O	403-407
increase	O	408-416
in	O	417-419
aggressiveness	B	420-434
was	O	435-438
not	O	439-442
secondary	O	443-452
to	O	453-455
METH	O	456-460
-	O	460-461
induced	O	461-468
hyperactivity	B	469-482
.	O	482-483

Analysis	O	484-492
of	O	493-495
protein	O	496-503
expression	O	504-514
using	O	515-520
antibody	O	521-529
microarrays	O	530-541
and	O	542-545
Western	O	546-553
blotting	O	554-562
revealed	O	563-571
differential	O	572-584
changes	O	585-592
in	O	593-595
MAP	O	596-599
kinase	O	600-606
-	O	606-607
related	O	607-614
pathways	O	615-623
after	O	624-629
multiple	O	630-638
and	O	639-642
single	O	643-649
METH	O	650-654
injections	O	655-665
.	O	665-666

There	O	667-672
were	O	673-677
statistically	O	678-691
significant	O	692-703
(	O	704-705
p	O	705-706
<	O	706-707
0	O	707-708
.	O	708-709
05	O	709-711
)	O	711-712

decreases	O	713-722
in	O	723-725
MEK1	O	726-730
,	O	730-731
Erk2p	O	732-737
,	O	737-738
GSK3alpha	O	739-748
,	O	748-749
14	O	750-752
-	O	752-753
3	O	753-754
-	O	752-753
3e	O	755-757
,	O	757-758
and	O	759-762
MEK7	O	763-767
in	O	768-770
the	O	771-774
striata	O	775-782
of	O	783-785
mice	O	786-790
after	O	791-796
multiple	O	797-805
injections	O	806-816
of	O	817-819
METH	O	820-824
.	O	824-825

MEK1	O	826-830
was	O	831-834
significantly	O	835-848
decreased	O	849-858
also	O	859-863
after	O	864-869
a	O	870-871
single	O	872-878
injection	O	879-888
of	O	889-891
METH	O	892-896
,	O	896-897
but	O	898-901
to	O	902-904
a	O	905-906
much	O	907-911
lesser	O	912-918
degree	O	919-925
than	O	926-930
after	O	931-936
multiple	O	937-945
injections	O	946-956
of	O	957-959
METH	O	960-964
.	O	964-965

In	O	966-968
the	O	969-972
frontal	O	973-980
cortex	O	981-987
,	O	987-988
there	O	989-994
was	O	995-998
a	O	999-1000
statistically	O	1001-1014
significant	O	1015-1026
decrease	O	1027-1035
in	O	1036-1038
GSK3alpha	O	1039-1048
after	O	1049-1054
multiple	O	1055-1063
(	O	1064-1065
but	O	1065-1068
not	O	1069-1072
single	O	1073-1079
)	O	1079-1080
injections	O	1081-1091
of	O	1092-1094
METH	O	1095-1099
.	O	1099-1100

These	O	1101-1106
findings	O	1107-1115
suggest	O	1116-1123
that	O	1124-1128
alterations	O	1129-1140
in	O	1141-1143
MAP	O	1144-1147
kinase	O	1148-1154
-	O	1154-1155
related	O	1155-1162
pathways	O	1163-1171
in	O	1172-1174
the	O	1175-1178
prefronto	O	1179-1188
-	O	1188-1189
striatal	O	1189-1197
circuitries	O	1198-1209
might	O	1210-1215
be	O	1216-1218
involved	O	1219-1227
in	O	1228-1230
the	O	1231-1234
manifestation	O	1235-1248
of	O	1249-1251
aggressive	B	1252-1262
behaviors	I	1263-1272
in	O	1273-1275
mice	O	1276-1280
.	O	1280-1281

Lamotrigine	O	0-11
associated	O	12-22
with	O	23-27
exacerbation	O	28-40
or	O	41-43
de	O	44-46
novo	O	47-51
myoclonus	B	52-61
in	O	62-64
idiopathic	B	65-75
generalized	I	76-87
epilepsies	I	88-98
.	O	98-99

Five	O	100-104
patients	O	105-113
with	O	114-118
idiopathic	B	119-129
generalized	I	130-141
epilepsies	I	142-152
(	O	153-154
IGE	B	154-157
)	O	157-158
treated	O	159-166
with	O	167-171
lamotrigine	O	172-183
(	O	184-185
LTG	O	185-188
)	O	188-189
experienced	O	190-201
exacerbation	O	202-214
or	O	215-217
de	O	218-220
novo	O	221-225
appearance	O	226-236
of	O	237-239
myoclonic	B	240-249
jerks	I	250-255
(	O	256-257
MJ	B	257-259
)	O	259-260
.	O	260-261

In	O	262-264
three	O	265-270
patients	O	271-279
,	O	279-280
LTG	O	281-284
exacerbated	O	285-296
MJ	B	297-299
in	O	300-302
a	O	303-304
dose	O	305-309
-	O	309-310
dependent	O	310-319
manner	O	320-326
with	O	327-331
early	O	332-337
aggravation	O	338-349
during	O	350-356
titration	O	357-366
.	O	366-367

MJ	B	368-370
disappeared	O	371-382
when	O	383-387
LTG	O	388-391
dose	O	392-396
was	O	397-400
decreased	O	401-410
by	O	411-413
25	O	414-416
to	O	417-419
50	O	420-422
%	O	422-423
.	O	423-424

In	O	425-427
two	O	428-431
patients	O	432-440
,	O	440-441
LTG	O	442-445
exacerbated	O	446-457
MJ	B	458-460
in	O	461-463
a	O	464-465
delayed	O	466-473
but	O	474-477
more	O	478-482
severe	O	483-489
manner	O	490-496
,	O	496-497
with	O	498-502
myoclonic	B	503-512
status	I	513-519
that	O	520-524
only	O	525-529
ceased	O	530-536
after	O	537-542
LTG	O	543-546
withdrawal	O	547-557
.	O	557-558

rTMS	O	0-4
of	O	5-7
supplementary	O	8-21
motor	O	22-27
area	O	28-32
modulates	O	33-42
therapy	O	43-50
-	O	50-51
induced	O	51-58
dyskinesias	B	59-70
in	O	71-73
Parkinson	B	74-83
disease	I	84-91
.	O	91-92

The	O	93-96
neural	O	97-103
mechanisms	O	104-114
and	O	115-118
circuitry	O	119-128
involved	O	129-137
in	O	138-140
levodopa	O	141-149
-	O	149-150
induced	O	150-157
dyskinesia	B	158-168
are	O	169-172
unclear	O	173-180
.	O	180-181

Using	O	182-187
repetitive	O	188-198
transcranial	O	199-211
magnetic	O	212-220
stimulation	O	221-232
(	O	233-234
rTMS	O	234-238
)	O	238-239
over	O	240-244
the	O	245-248
supplementary	O	249-262
motor	O	263-268
area	O	269-273
(	O	274-275
SMA	O	275-278
)	O	278-279
in	O	280-282
a	O	283-284
group	O	285-290
of	O	291-293
patients	O	294-302
with	O	303-307
advanced	O	308-316
Parkinson	B	317-326
disease	I	327-334
,	O	334-335
the	O	336-339
authors	O	340-347
investigated	O	348-360
whether	O	361-368
modulation	O	369-379
of	O	380-382
SMA	O	383-386
excitability	O	387-399
may	O	400-403
result	O	404-410
in	O	411-413
a	O	414-415
modification	O	416-428
of	O	429-431
a	O	432-433
dyskinetic	B	434-444
state	O	445-450
induced	O	451-458
by	O	459-461
continuous	O	462-472
apomorphine	O	473-484
infusion	O	485-493
.	O	493-494

rTMS	O	495-499
at	O	500-502
1	O	503-504
Hz	O	505-507
was	O	508-511
observed	O	512-520
to	O	521-523
markedly	O	524-532
reduce	O	533-539
drug	B	540-544
-	I	544-545
induced	I	545-552
dyskinesias	I	553-564
,	O	564-565
whereas	O	566-573
5	O	574-575
-	O	575-576
Hz	O	576-578
rTMS	O	579-583
induced	O	584-591
a	O	592-593
slight	O	594-600
but	O	601-604
not	O	605-608
significant	O	609-620
increase	O	621-629
.	O	629-630

Assessment	O	0-10
of	O	11-13
the	O	14-17
onset	O	18-23
and	O	24-27
persistence	O	28-39
of	O	40-42
amnesia	B	43-50
during	O	51-57
procedural	O	58-68
sedation	O	69-77
with	O	78-82
propofol	O	83-91
.	O	91-92

OBJECTIVES	O	93-103
:	O	103-104
To	O	105-107
assess	O	108-114
patients	O	115-123
'	O	123-124
ability	O	125-132
to	O	133-135
repeat	O	136-142
and	O	143-146
recall	O	147-153
words	O	154-159
presented	O	160-169
to	O	170-172
them	O	173-177
while	O	178-183
undergoing	O	184-194
procedural	O	195-205
sedation	O	206-214
with	O	215-219
propofol	O	220-228
,	O	228-229
and	O	230-233
correlate	O	234-243
their	O	244-249
recall	O	250-256
with	O	257-261
their	O	262-267
level	O	268-273
of	O	274-276
awareness	O	277-286
as	O	287-289
measured	O	290-298
by	O	299-301
bispectral	O	302-312
index	O	313-318
(	O	319-320
BIS	O	320-323
)	O	323-324
monitoring	O	325-335
.	O	335-336

METHODS	O	337-344
:	O	344-345
This	O	346-350
was	O	351-354
a	O	355-356
prospective	O	357-368
,	O	368-369
single	O	370-376
-	O	376-377
intervention	O	377-389
study	O	390-395
of	O	396-398
consenting	O	399-409
adult	O	410-415
patients	O	416-424
undergoing	O	425-435
procedural	O	436-446
sedation	O	447-455
with	O	456-460
propofol	O	461-469
between	O	470-477
December	O	478-486
28	O	487-489
,	O	489-490
2002	O	491-495
,	O	495-496
and	O	497-500
October	O	501-508
31	O	509-511
,	O	511-512
2003	O	513-517
.	O	517-518

BIS	O	519-522
monitoring	O	523-533
was	O	534-537
initiated	O	538-547
starting	O	548-556
3	O	557-558
minutes	O	559-566
before	O	567-573
the	O	574-577
procedure	O	578-587
and	O	588-591
continuing	O	592-602
until	O	603-608
the	O	609-612
patient	O	613-620
had	O	621-624
regained	O	625-633
baseline	O	634-642
mental	O	643-649
status	O	650-656
.	O	656-657

At	O	658-660
1	O	661-662
-	O	662-663
minute	O	663-669
intervals	O	670-679
during	O	680-686
the	O	687-690
procedural	O	691-701
sedation	O	702-710
,	O	710-711
until	O	712-717
the	O	718-721
patient	O	722-729
regained	O	730-738
baseline	O	739-747
mental	O	748-754
status	O	755-761
at	O	762-764
the	O	765-768
end	O	769-772
of	O	773-775
the	O	776-779
procedure	O	780-789
,	O	789-790
a	O	791-792
word	O	793-797
from	O	798-802
a	O	803-804
standardized	O	805-817
list	O	818-822
was	O	823-826
read	O	827-831
aloud	O	832-837
,	O	837-838
and	O	839-842
the	O	843-846
patient	O	847-854
was	O	855-858
asked	O	859-864
to	O	865-867
immediately	O	868-879
repeat	O	880-886
the	O	887-890
word	O	891-895
to	O	896-898
the	O	899-902
investigator	O	903-915
.	O	915-916

The	O	917-920
BIS	O	921-924
score	O	925-930
at	O	931-933
the	O	934-937
time	O	938-942
the	O	943-946
word	O	947-951
was	O	952-955
read	O	956-960
and	O	961-964
the	O	965-968
patient	O	969-976
'	O	976-977
s	O	977-978
ability	O	979-986
to	O	987-989
repeat	O	990-996
the	O	997-1000
word	O	1001-1005
were	O	1006-1010
recorded	O	1011-1019
.	O	1019-1020

After	O	1021-1026
the	O	1027-1030
procedure	O	1031-1040
,	O	1040-1041
the	O	1042-1045
patient	O	1046-1053
was	O	1054-1057
asked	O	1058-1063
to	O	1064-1066
state	O	1067-1072
all	O	1073-1076
of	O	1077-1079
the	O	1080-1083
words	O	1084-1089
from	O	1090-1094
the	O	1095-1098
list	O	1099-1103
that	O	1104-1108
he	O	1109-1111
or	O	1112-1114
she	O	1115-1118
could	O	1119-1124
recall	O	1125-1131
,	O	1131-1132
and	O	1133-1136
to	O	1137-1139
identify	O	1140-1148
the	O	1149-1152
last	O	1153-1157
word	O	1158-1162
recalled	O	1163-1171
from	O	1172-1176
prior	O	1177-1182
to	O	1183-1185
the	O	1186-1189
start	O	1190-1195
of	O	1196-1198
the	O	1199-1202
procedure	O	1203-1212
and	O	1213-1216
the	O	1217-1220
first	O	1221-1226
word	O	1227-1231
recalled	O	1232-1240
from	O	1241-1245
after	O	1246-1251
the	O	1252-1255
procedure	O	1256-1265
was	O	1266-1269
completed	O	1270-1279
.	O	1279-1280

RESULTS	O	1281-1288
:	O	1288-1289
Seventy	O	1290-1297
-	O	1297-1298
five	O	1298-1302
consenting	O	1303-1313
patients	O	1314-1322
were	O	1323-1327
enrolled	O	1328-1336
;	O	1336-1337
one	O	1338-1341
patient	O	1342-1349
was	O	1350-1353
excluded	O	1354-1362
from	O	1363-1367
data	O	1368-1372
analysis	O	1373-1381
for	O	1382-1385
a	O	1386-1387
protocol	O	1388-1396
violation	O	1397-1406
.	O	1406-1407

No	O	1408-1410
serious	O	1411-1418
adverse	O	1419-1426
events	O	1427-1433
were	O	1434-1438
noted	O	1439-1444
during	O	1445-1451
the	O	1452-1455
procedural	O	1456-1466
sedations	O	1467-1476
.	O	1476-1477

The	O	1478-1481
mean	O	1482-1486
(	O	1487-1488
+	O	1488-1489
/	O	1489-1490
-	O	1490-1491
standard	O	1491-1499
deviation	O	1500-1509
)	O	1509-1510
time	O	1511-1515
of	O	1516-1518
data	O	1519-1523
collection	O	1524-1534
was	O	1535-1538
16	O	1539-1541
.	O	1541-1542
4	O	1542-1543
minutes	O	1544-1551
(	O	1552-1553
+	O	1553-1554
/	O	1554-1555
-	O	1555-1556
7	O	1556-1557
.	O	1557-1558
1	O	1558-1559
;	O	1559-1560

range	O	1561-1566
5	O	1567-1568
to	O	1569-1571
34	O	1572-1574
minutes	O	1575-1582
)	O	1582-1583
.	O	1583-1584

The	O	1585-1588
mean	O	1589-1593
initial	O	1594-1601
(	O	1602-1603
preprocedure	O	1603-1615
)	O	1615-1616
BIS	O	1617-1620
score	O	1621-1626
was	O	1627-1630
97	O	1631-1633
.	O	1633-1634
1	O	1634-1635
(	O	1636-1637
+	O	1637-1638
/	O	1638-1639
-	O	1639-1640
2	O	1640-1641
.	O	1641-1642
3	O	1642-1643
;	O	1643-1644

range	O	1645-1650
92	O	1651-1653
to	O	1654-1656
99	O	1657-1659
)	O	1659-1660
.	O	1660-1661

The	O	1662-1665
mean	O	1666-1670
lowest	O	1671-1677
BIS	O	1678-1681
score	O	1682-1687
occurring	O	1688-1697
during	O	1698-1704
these	O	1705-1710
procedural	O	1711-1721
sedations	O	1722-1731
was	O	1732-1735
66	O	1736-1738
.	O	1738-1739
9	O	1739-1740
(	O	1741-1742
+	O	1742-1743
/	O	1743-1744
-	O	1744-1745
14	O	1745-1747
.	O	1747-1748
4	O	1746-1747
;	O	1749-1750

range	O	1751-1756
33	O	1757-1759
to	O	1760-1762
91	O	1763-1765
)	O	1765-1766
.	O	1766-1767

The	O	1768-1771
mean	O	1772-1776
lowest	O	1777-1783
BIS	O	1784-1787
score	O	1788-1793
corresponding	O	1794-1807
to	O	1808-1810
the	O	1811-1814
ability	O	1815-1822
of	O	1823-1825
the	O	1826-1829
patient	O	1830-1837
to	O	1838-1840
immediately	O	1841-1852
repeat	O	1853-1859
words	O	1860-1865
read	O	1866-1870
from	O	1871-1875
the	O	1876-1879
list	O	1880-1884
was	O	1885-1888
77	O	1889-1891
.	O	1891-1892
1	O	1892-1893
(	O	1894-1895
95	O	1895-1897
%	O	1897-1898
CI	O	1899-1901
=	O	1902-1903
74	O	1904-1906
.	O	1906-1907
3	O	1907-1908
to	O	1909-1911
80	O	1912-1914
.	O	1914-1915
0	O	1913-1914
)	O	1916-1917
.	O	1914-1915

The	O	1919-1922
mean	O	1923-1927
highest	O	1928-1935
BIS	O	1936-1939
score	O	1940-1945
corresponding	O	1946-1959
to	O	1960-1962
the	O	1963-1966
inability	B	1967-1976
to	I	1977-1979
repeat	I	1980-1986
words	I	1987-1992
was	O	1993-1996
81	O	1997-1999
.	O	1999-2000
5	O	2000-2001
(	O	2002-2003
95	O	2003-2005
%	O	2005-2006
CI	O	2007-2009
=	O	2010-2011
78	O	2012-2014
.	O	2014-2015
1	O	2015-2016
to	O	2017-2019
84	O	2020-2022
.	O	2022-2023
8	O	2020-2021
)	O	2024-2025
.	O	2022-2023

The	O	2027-2030
mean	O	2031-2035
BIS	O	2036-2039
score	O	2040-2045
corresponding	O	2046-2059
to	O	2060-2062
the	O	2063-2066
last	O	2067-2071
word	O	2072-2076
recalled	O	2077-2085
from	O	2086-2090
prior	O	2091-2096
to	O	2097-2099
the	O	2100-2103
initiation	O	2104-2114
of	O	2115-2117
the	O	2118-2121
sedation	O	2122-2130
was	O	2131-2134
96	O	2135-2137
.	O	2137-2138
7	O	2138-2139
(	O	2140-2141
+	O	2141-2142
/	O	2142-2143
-	O	2143-2144
2	O	2144-2145
.	O	2145-2146
4	O	2146-2147
;	O	2147-2148

range	O	2149-2154
84	O	2155-2157
to	O	2158-2160
98	O	2161-2163
)	O	2163-2164
.	O	2164-2165

The	O	2166-2169
mean	O	2170-2174
BIS	O	2175-2178
score	O	2179-2184
corresponding	O	2185-2198
to	O	2199-2201
the	O	2202-2205
first	O	2206-2211
word	O	2212-2216
recalled	O	2217-2225
after	O	2226-2231
the	O	2232-2235
procedure	O	2236-2245
was	O	2246-2249
completed	O	2250-2259
was	O	2260-2263
91	O	2264-2266
.	O	2266-2267
2	O	2267-2268
(	O	2269-2270
95	O	2270-2272
%	O	2272-2273
CI	O	2274-2276
=	O	2277-2278
88	O	2279-2281
.	O	2281-2282
1	O	2282-2283
to	O	2284-2286
94	O	2287-2289
.	O	2289-2290
3	O	2290-2291
)	O	2291-2292
.	O	2289-2290

All	O	2294-2297
patients	O	2298-2306
recalled	O	2307-2315
at	O	2316-2318
least	O	2319-2324
one	O	2325-2328
word	O	2329-2333
that	O	2334-2338
had	O	2339-2342
been	O	2343-2347
read	O	2348-2352
to	O	2353-2355
them	O	2356-2360
during	O	2361-2367
the	O	2368-2371
protocol	O	2372-2380
.	O	2380-2381

The	O	2382-2385
mean	O	2386-2390
lowest	O	2391-2397
BIS	O	2398-2401
score	O	2402-2407
for	O	2408-2411
any	O	2412-2415
recalled	O	2416-2424
word	O	2425-2429
was	O	2430-2433
91	O	2434-2436
.	O	2436-2437
5	O	2437-2438
(	O	2439-2440
+	O	2440-2441
/	O	2441-2442
-	O	2442-2443
11	O	2443-2445
.	O	2445-2446
1	O	2443-2444
;	O	2447-2448

range	O	2449-2454
79	O	2455-2457
to	O	2458-2460
98	O	2461-2463
)	O	2463-2464
,	O	2464-2465
and	O	2466-2469
no	O	2470-2472
words	O	2473-2478
were	O	2479-2483
recalled	O	2484-2492
when	O	2493-2497
the	O	2498-2501
corresponding	O	2502-2515
BIS	O	2516-2519
score	O	2520-2525
was	O	2526-2529
less	O	2530-2534
than	O	2535-2539
90	O	2540-2542
.	O	2542-2543

CONCLUSIONS	O	2544-2555
:	O	2555-2556
There	O	2557-2562
is	O	2563-2565
a	O	2566-2567
range	O	2568-2573
of	O	2574-2576
BIS	O	2577-2580
scores	O	2581-2587
during	O	2588-2594
which	O	2595-2600
sedated	O	2601-2608
patients	O	2609-2617
are	O	2618-2621
able	O	2622-2626
to	O	2627-2629
repeat	O	2630-2636
words	O	2637-2642
read	O	2643-2647
to	O	2648-2650
them	O	2651-2655
but	O	2656-2659
are	O	2660-2663
not	O	2664-2667
able	O	2668-2672
to	O	2673-2675
subsequently	O	2676-2688
recall	O	2689-2695
these	O	2696-2701
words	O	2702-2707
.	O	2707-2708

Furthermore	O	2709-2720
,	O	2720-2721
patients	O	2722-2730
had	O	2731-2734
no	O	2735-2737
recall	O	2738-2744
of	O	2745-2747
words	O	2748-2753
repeated	O	2754-2762
prior	O	2763-2768
to	O	2769-2771
procedural	O	2772-2782
sedation	O	2783-2791
in	O	2792-2794
BIS	O	2795-2798
ranges	O	2799-2805
associated	O	2806-2816
with	O	2817-2821
recall	O	2822-2828
after	O	2829-2834
procedural	O	2835-2845
sedation	O	2846-2854
,	O	2854-2855
suggestive	O	2856-2866
of	O	2867-2869
retrograde	B	2870-2880
amnesia	I	2881-2888
.	O	2888-2889

Assessment	O	0-10
of	O	11-13
perinatal	O	14-23
hepatitis	B	24-33
B	I	34-35
and	O	36-39
rubella	B	40-47
prevention	O	48-58
in	O	59-61
New	O	62-65
Hampshire	O	66-75
delivery	O	76-84
hospitals	O	85-94
.	O	94-95

OBJECTIVE	O	96-105
:	O	105-106
To	O	107-109
evaluate	O	110-118
current	O	119-126
performance	O	127-138
on	O	139-141
recommended	O	142-153
perinatal	O	154-163
hepatitis	B	164-173
B	I	174-175
and	O	176-179
rubella	B	180-187
prevention	O	188-198
practices	O	199-208
in	O	209-211
New	O	212-215
Hampshire	O	216-225
.	O	225-226

METHODS	O	227-234
:	O	234-235
Data	O	236-240
were	O	241-245
extracted	O	246-255
from	O	256-260
2021	O	261-265
paired	O	266-272
mother	O	273-279
-	O	279-280
infant	O	280-286
records	O	287-294
for	O	295-298
the	O	299-302
year	O	303-307
2000	O	308-312
birth	O	313-318
cohort	O	319-325
in	O	326-328
New	O	329-332
Hampshire	O	333-342
'	O	342-343
s	O	337-338
25	O	345-347
delivery	O	348-356
hospitals	O	357-366
.	O	366-367

Assessment	O	368-378
was	O	379-382
done	O	383-387
on	O	388-390
the	O	391-394
following	O	395-404
:	O	404-405
prenatal	O	406-414
screening	O	415-424
for	O	425-428
hepatitis	B	429-438
B	I	439-440
and	O	441-444
rubella	B	445-452
,	O	452-453
administration	O	454-468
of	O	469-471
the	O	472-475
hepatitis	B	476-485
B	I	486-487
vaccine	O	488-495
birth	O	496-501
dose	O	502-506
to	O	507-509
all	O	510-513
infants	O	514-521
,	O	521-522
administration	O	523-537
of	O	538-540
hepatitis	B	541-550
B	I	551-552
immune	O	553-559
globulin	O	560-568
to	O	569-571
infants	O	572-579
who	O	580-583
were	O	584-588
born	O	589-593
to	O	594-596
hepatitis	O	597-606
B	O	607-608
surface	O	609-616
antigen	O	617-624
-	O	624-625
positive	O	625-633
mothers	O	634-641
,	O	641-642
rubella	B	643-650
immunity	O	651-659
,	O	659-660
and	O	661-664
administration	O	665-679
of	O	680-682
in	O	683-685
-	O	685-686
hospital	O	686-694
postpartum	O	695-705
rubella	B	706-713
vaccine	O	714-721
to	O	722-724
rubella	B	725-732
nonimmune	O	733-742
women	O	743-748
.	O	748-749

RESULTS	O	750-757
:	O	757-758
Prenatal	O	759-767
screening	O	768-777
rates	O	778-783
for	O	784-787
hepatitis	B	788-797
B	I	798-799
(	O	800-801
98	O	801-803
.	O	803-804
8	O	802-803
%	O	805-806
)	O	806-807
and	O	808-811
rubella	B	812-819
(	O	820-821
99	O	821-823
.	O	823-824
4	O	824-825
%	O	825-826
)	O	826-827
were	O	828-832
high	O	833-837
.	O	837-838

Hepatitis	B	839-848
B	I	849-850
vaccine	O	851-858
birth	O	859-864
dose	O	865-869
was	O	870-873
administered	O	874-886
to	O	887-889
76	O	890-892
.	O	892-893
2	O	893-894
%	O	894-895
of	O	896-898
all	O	899-902
infants	O	903-910
.	O	910-911

All	O	912-915
infants	O	916-923
who	O	924-927
were	O	928-932
born	O	933-937
to	O	938-940
hepatitis	O	941-950
B	O	951-952
surface	O	953-960
antigen	O	961-968
-	O	968-969
positive	O	969-977
mothers	O	978-985
also	O	986-990
received	O	991-999
hepatitis	B	1000-1009
B	I	1010-1011
immune	O	1012-1018
globulin	O	1019-1027
.	O	1027-1028

Multivariate	O	1029-1041
logistic	O	1042-1050
regression	O	1051-1061
showed	O	1062-1068
that	O	1069-1073
the	O	1074-1077
month	O	1078-1083
of	O	1084-1086
delivery	O	1087-1095
and	O	1096-1099
infant	O	1100-1106
birth	O	1107-1112
weight	O	1113-1119
were	O	1120-1124
independent	O	1125-1136
predictors	O	1137-1147
of	O	1148-1150
hepatitis	B	1151-1160
B	I	1161-1162
vaccination	O	1163-1174
.	O	1174-1175

The	O	1176-1179
proportion	O	1180-1190
of	O	1191-1193
infants	O	1194-1201
who	O	1202-1205
were	O	1206-1210
vaccinated	O	1211-1221
in	O	1222-1224
January	O	1225-1232
and	O	1233-1236
February	O	1237-1245
2000	O	1246-1250
(	O	1251-1252
48	O	1252-1254
.	O	1254-1255
5	O	1255-1256
%	O	1256-1257
and	O	1258-1261
67	O	1262-1264
.	O	1264-1265
5	O	1265-1266
%	O	1266-1267
,	O	1267-1268
respectively	O	1269-1281
)	O	1281-1282
was	O	1283-1286
less	O	1287-1291
than	O	1292-1296
any	O	1297-1300
other	O	1301-1306
months	O	1307-1313
,	O	1313-1314
whereas	O	1315-1322
the	O	1323-1326
proportion	O	1327-1337
who	O	1338-1341
were	O	1342-1346
vaccinated	O	1347-1357
in	O	1358-1360
December	O	1361-1369
2000	O	1370-1374
(	O	1375-1376
88	O	1376-1378
.	O	1378-1379
2	O	1379-1380
%	O	1380-1381
)	O	1381-1382
was	O	1383-1386
the	O	1387-1390
highest	O	1391-1398
.	O	1398-1399

Women	O	1400-1405
who	O	1406-1409
were	O	1410-1414
born	O	1415-1419
between	O	1420-1427
1971	O	1428-1432
and	O	1433-1436
1975	O	1437-1441
had	O	1442-1445
the	O	1446-1449
highest	O	1450-1457
rate	O	1458-1462
of	O	1463-1465
rubella	B	1466-1473
nonimmunity	O	1474-1485
(	O	1486-1487
9	O	1487-1488
.	O	1488-1489
5	O	1489-1490
%	O	1490-1491
)	O	1491-1492
.	O	1488-1489

In	O	1494-1496
-	O	1496-1497
hospital	O	1497-1505
postpartum	O	1506-1516
rubella	B	1517-1524
vaccine	O	1525-1532
administration	O	1533-1547
was	O	1548-1551
documented	O	1552-1562
for	O	1563-1566
75	O	1567-1569
.	O	1569-1570
6	O	1570-1571
%	O	1571-1572
of	O	1573-1575
nonimmune	O	1576-1585
women	O	1586-1591
.	O	1591-1592

CONCLUSION	O	1593-1603
:	O	1603-1604
This	O	1605-1609
study	O	1610-1615
documents	O	1616-1625
good	O	1626-1630
compliance	O	1631-1641
in	O	1642-1644
New	O	1645-1648
Hampshire	O	1649-1658
'	O	1658-1659
s	O	1653-1654
birthing	O	1661-1669
hospitals	O	1670-1679
with	O	1680-1684
national	O	1685-1693
guidelines	O	1694-1704
for	O	1705-1708
perinatal	O	1709-1718
hepatitis	B	1719-1728
B	I	1729-1730
and	O	1731-1734
rubella	B	1735-1742
prevention	O	1743-1753
and	O	1754-1757
highlights	O	1758-1768
potential	O	1769-1778
areas	O	1779-1784
for	O	1785-1788
improvement	O	1789-1800
.	O	1800-1801

Expression	O	0-10
of	O	11-13
p300	O	14-18
protects	O	19-27
cardiac	O	28-35
myocytes	O	36-44
from	O	45-49
apoptosis	O	50-59
in	O	60-62
vivo	O	63-67
.	O	67-68

Doxorubicin	O	69-80
is	O	81-83
an	O	84-86
anti	O	87-91
-	O	91-92
tumor	B	92-97
agent	O	98-103
that	O	104-108
represses	O	109-118
cardiac	O	119-126
-	O	126-127
specific	O	127-135
gene	O	136-140
expression	O	141-151
and	O	152-155
induces	O	156-163
myocardial	O	164-174
cell	O	175-179
apoptosis	O	180-189
.	O	189-190

Doxorubicin	O	191-202
depletes	O	203-211
cardiac	O	212-219
p300	O	220-224
,	O	224-225
a	O	226-227
transcriptional	O	228-243
coactivator	O	244-255
that	O	256-260
is	O	261-263
required	O	264-272
for	O	273-276
the	O	277-280
maintenance	O	281-292
of	O	293-295
the	O	296-299
differentiated	O	300-314
phenotype	O	315-324
of	O	325-327
cardiac	O	328-335
myocytes	O	336-344
.	O	344-345

However	O	346-353
,	O	353-354
the	O	355-358
role	O	359-363
of	O	364-366
p300	O	367-371
in	O	372-374
protection	O	375-385
against	O	386-393
doxorubicin	O	394-405
-	O	405-406
induced	O	406-413
apoptosis	O	414-423
is	O	424-426
unknown	O	427-434
.	O	434-435

Transgenic	O	436-446
mice	O	447-451
overexpressing	O	452-466
p300	O	467-471
in	O	472-474
the	O	475-478
heart	O	479-484
and	O	485-488
wild	O	489-493
-	O	493-494
type	O	494-498
mice	O	499-503
were	O	504-508
subjected	O	509-518
to	O	519-521
doxorubicin	O	522-533
treatment	O	534-543
.	O	543-544

Compared	O	545-553
with	O	554-558
wild	O	559-563
-	O	563-564
type	O	564-568
mice	O	569-573
,	O	573-574
transgenic	O	575-585
mice	O	586-590
exhibited	O	591-600
higher	O	601-607
survival	O	608-616
rate	O	617-621
as	O	622-624
well	O	625-629
as	O	630-632
more	O	633-637
preserved	O	638-647
left	O	648-652
ventricular	O	653-664
function	O	665-673
and	O	674-677
cardiac	O	678-685
expression	O	686-696
of	O	697-699
alpha	O	700-705
-	O	705-706
sarcomeric	O	706-716
actin	O	717-722
.	O	722-723

Doxorubicin	O	724-735
induced	O	736-743
myocardial	O	744-754
cell	O	755-759
apoptosis	O	760-769
in	O	770-772
wild	O	773-777
-	O	777-778
type	O	778-782
mice	O	783-787
but	O	788-791
not	O	792-795
in	O	796-798
transgenic	O	799-809
mice	O	810-814
.	O	814-815

Expression	O	816-826
of	O	827-829
p300	O	830-834
increased	O	835-844
the	O	845-848
cardiac	O	849-856
level	O	857-862
of	O	863-865
bcl	O	866-869
-	O	869-870
2	O	870-871
and	O	872-875
mdm	O	876-879
-	O	879-880
2	O	880-881
,	O	881-882
but	O	883-886
not	O	887-890
that	O	891-895
of	O	896-898
p53	O	899-902
or	O	903-905
other	O	906-911
members	O	912-919
of	O	920-922
the	O	923-926
bcl	O	927-930
-	O	930-931
2	O	931-932
family	O	933-939
.	O	939-940

These	O	941-946
findings	O	947-955
demonstrate	O	956-967
that	O	968-972
overexpression	O	973-987
of	O	988-990
p300	O	991-995
protects	O	996-1004
cardiac	O	1005-1012
myocytes	O	1013-1021
from	O	1022-1026
doxorubicin	O	1027-1038
-	O	1038-1039
induced	O	1039-1046
apoptosis	O	1047-1056
and	O	1057-1060
reduces	O	1061-1068
the	O	1069-1072
extent	O	1073-1079
of	O	1080-1082
acute	O	1083-1088
heart	B	1089-1094
failure	I	1095-1102
in	O	1103-1105
adult	O	1106-1111
mice	O	1112-1116
in	O	1117-1119
vivo	O	1120-1124
.	O	1124-1125

Mitochondrial	O	0-13
DNA	O	14-17
and	O	18-21
its	O	22-25
respiratory	O	26-37
chain	O	38-43
products	O	44-52
are	O	53-56
defective	O	57-66
in	O	67-69
doxorubicin	O	70-81
nephrosis	B	82-91
.	O	91-92

BACKGROUND	O	93-103
:	O	103-104
Doxorubicin	O	105-116
induces	O	117-124
a	O	125-126
self	O	127-131
-	O	131-132
perpetuating	O	132-144
nephropathy	B	145-156
characterized	O	157-170
by	O	171-173
early	O	174-179
glomerular	B	180-190
and	I	191-194
late	I	195-199
-	I	199-200
onset	I	200-205
tubular	I	206-213
lesions	I	214-221
in	O	222-224
rats	O	225-229
.	O	229-230

We	O	231-233
investigated	O	234-246
the	O	247-250
potential	O	251-260
role	O	261-265
of	O	266-268
mitochondrial	B	269-282
injury	I	283-289
in	O	290-292
the	O	293-296
onset	O	297-302
of	O	303-305
these	O	306-311
lesions	O	312-319
.	O	319-320

METHODS	O	321-328
:	O	328-329
Rats	O	330-334
were	O	335-339
treated	O	340-347
with	O	348-352
intravenous	O	353-364
doxorubicin	O	365-376
(	O	377-378
1	O	378-379
mg	O	380-382
kg	O	383-385
(	O	385-386
-	O	386-387
1	O	387-388
)	O	388-389
week	O	390-394
(	O	394-395
-	O	395-396
1	O	396-397
)	O	397-398
)	O	397-398
for	O	400-403
7	O	404-405
weeks	O	406-411
and	O	412-415
were	O	416-420
sacrificed	O	421-431
either	O	432-438
1	O	439-440
week	O	441-445
(	O	446-447
'	O	447-448
short	O	448-453
-	O	453-454
term	O	454-458
'	O	447-448
)	O	459-460
or	O	461-463
30	O	464-466
weeks	O	467-472
(	O	473-474
'	O	474-475
long	O	475-479
-	O	479-480
term	O	480-484
'	O	474-475
)	O	485-486
following	O	487-496
the	O	497-500
last	O	501-505
dose	O	506-510
.	O	510-511

Additional	O	512-522
rats	O	523-527
received	O	528-536
a	O	537-538
single	O	539-545
dose	O	546-550
either	O	551-557
6	O	558-559
days	O	560-564
or	O	565-567
2	O	568-569
h	O	570-571
prior	O	572-577
to	O	578-580
euthanasia	O	581-591
.	O	591-592

All	O	593-596
rats	O	597-601
were	O	602-606
killed	O	607-613
at	O	614-616
48	O	617-619
weeks	O	620-625
of	O	626-628
age	O	629-632
.	O	632-633

Glomerular	B	634-644
and	I	645-648
tubular	I	649-656
injury	I	657-663
was	O	664-667
monitored	O	668-677
and	O	678-681
correlated	O	682-692
to	O	693-695
the	O	696-699
activity	O	700-708
or	O	709-711
expression	O	712-722
of	O	723-725
respiratory	O	726-737
chain	O	738-743
components	O	744-754
.	O	754-755

Finally	O	756-763
,	O	763-764
we	O	765-767
quantified	O	768-778
both	O	779-783
nuclear	O	784-791
and	O	792-795
mitochondrial	O	796-809
DNA	O	810-813
(	O	814-815
mtDNA	O	815-820
)	O	820-821
as	O	822-824
well	O	825-829
as	O	830-832
superoxide	O	833-843
production	O	844-854
and	O	855-858
the	O	859-862
4834	O	863-867
base	O	868-872
pair	O	873-877
'	O	878-879
common	O	879-885
'	O	878-879
mtDNA	O	887-892
deletion	O	893-901
.	O	901-902

RESULTS	O	903-910
:	O	910-911
The	O	912-915
'	O	916-917
long	O	917-921
-	O	921-922
term	O	922-926
'	O	916-917
group	O	928-933
had	O	934-937
significant	O	938-949
glomerular	B	950-960
and	I	961-964
tubular	I	965-972
lesions	I	973-980
,	O	980-981
depressed	O	982-991
activities	O	992-1002
of	O	1003-1005
mtDNA	O	1006-1011
-	O	1011-1012
encoded	O	1012-1019
NADH	O	1020-1024
dehydrogenase	O	1025-1038
and	O	1039-1042
cytochrome	O	1043-1053
-	O	1053-1054
c	O	1043-1044
oxidase	O	1056-1063
(	O	1064-1065
COX	O	1065-1068
)	O	1068-1069
and	O	1070-1073
increased	O	1074-1083
citrate	O	1084-1091
synthase	O	1092-1100
activity	O	1101-1109
.	O	1109-1110

In	O	1111-1113
addition	O	1114-1122
,	O	1122-1123
expression	O	1124-1134
of	O	1135-1137
the	O	1138-1141
mtDNA	O	1142-1147
-	O	1147-1148
encoded	O	1148-1155
COX	O	1156-1159
subunit	O	1160-1167
I	O	1168-1169
was	O	1170-1173
reduced	O	1174-1181
and	O	1182-1185
mtDNA	O	1186-1191
levels	O	1192-1198
were	O	1199-1203
decreased	O	1204-1213
.	O	1213-1214

In	O	1215-1217
'	O	1218-1219
short	O	1219-1224
-	O	1224-1225
term	O	1225-1229
'	O	1218-1219
rats	O	1231-1235
,	O	1235-1236
there	O	1237-1242
were	O	1243-1247
fewer	O	1248-1253
tubular	B	1254-1261
lesions	I	1262-1269
,	O	1269-1270
but	O	1271-1274
similar	O	1275-1282
numbers	O	1283-1290
of	O	1291-1293
glomerular	B	1294-1304
lesions	I	1305-1312
activity	O	1313-1321
.	O	1321-1322

Among	O	1323-1328
all	O	1329-1332
animals	O	1333-1340
,	O	1340-1341
glomerular	B	1342-1352
and	I	1353-1356
tubular	I	1357-1364
injury	I	1365-1371
were	O	1372-1376
inversely	O	1377-1386
correlated	O	1387-1397
with	O	1398-1402
mtDNA	O	1403-1408
levels	O	1409-1415
,	O	1415-1416
mtDNA	O	1417-1422
-	O	1422-1423
encoded	O	1423-1430
respiratory	O	1431-1442
chain	O	1443-1448
activities	O	1449-1459
and	O	1460-1463
with	O	1464-1468
the	O	1469-1472
expression	O	1473-1483
of	O	1484-1486
the	O	1487-1490
mtDNA	O	1491-1496
-	O	1496-1497
encoded	O	1497-1504
respiratory	O	1505-1516
chain	O	1517-1522
subunit	O	1523-1530
COX	O	1531-1534
-	O	1534-1535
I	O	1535-1536
.	O	1536-1537

Injury	O	1538-1544
was	O	1545-1548
positively	O	1549-1559
correlated	O	1560-1570
with	O	1571-1575
superoxide	O	1576-1586
production	O	1587-1597
and	O	1598-1601
the	O	1602-1605
activities	O	1606-1616
of	O	1617-1619
nucleus	O	1620-1627
-	O	1627-1628
encoded	O	1628-1635
mitochondrial	O	1636-1649
or	O	1650-1652
cytoplasmic	O	1653-1664
enzymes	O	1665-1672
.	O	1672-1673

Kidneys	O	1674-1681
from	O	1682-1686
the	O	1687-1690
'	O	1691-1692
long	O	1692-1696
-	O	1696-1697
term	O	1697-1701
'	O	1691-1692
group	O	1703-1708
showed	O	1709-1715
more	O	1716-1720
mtDNA	O	1721-1726
deletions	O	1727-1736
than	O	1737-1741
in	O	1742-1744
'	O	1745-1746
short	O	1746-1751
-	O	1751-1752
term	O	1752-1756
'	O	1745-1746
animals	O	1758-1765
and	O	1766-1769
these	O	1770-1775
were	O	1776-1780
not	O	1781-1784
observed	O	1785-1793
in	O	1794-1796
the	O	1797-1800
other	O	1801-1806
groups	O	1807-1813
.	O	1813-1814

CONCLUSIONS	O	1815-1826
:	O	1826-1827
These	O	1828-1833
results	O	1834-1841
suggest	O	1842-1849
an	O	1850-1852
important	O	1853-1862
role	O	1863-1867
for	O	1868-1871
quantitative	O	1872-1884
and	O	1885-1888
qualitative	O	1889-1900
mtDNA	O	1901-1906
alterations	O	1907-1918
through	O	1919-1926
the	O	1927-1930
reduction	O	1931-1940
of	O	1941-1943
mtDNA	O	1944-1949
-	O	1949-1950
encoded	O	1950-1957
respiratory	O	1958-1969
chain	O	1970-1975
function	O	1976-1984
and	O	1985-1988
induction	O	1989-1998
of	O	1999-2001
superoxide	O	2002-2012
in	O	2013-2015
doxorubicin	O	2016-2027
-	O	2027-2028
induced	O	2028-2035
renal	B	2036-2041
lesions	I	2042-2049
.	O	2049-2050

Amphotericin	O	0-12
B	O	13-14
-	O	14-15
induced	O	15-22
seizures	B	23-31
in	O	32-34
a	O	35-36
patient	O	37-44
with	O	45-49
AIDS	B	50-54
.	O	54-55

OBJECTIVE	O	56-65
:	O	65-66
To	O	67-69
report	O	70-76
a	O	77-78
case	O	79-83
of	O	84-86
multiple	O	87-95
episodes	O	96-104
of	O	105-107
seizure	B	108-115
activity	O	116-124
in	O	125-127
an	O	128-130
AIDS	B	131-135
patent	O	136-142
following	O	143-152
amphotericin	O	153-165
B	O	166-167
infusion	O	168-176
.	O	176-177

CASE	O	178-182
SUMMARY	O	183-190
:	O	190-191
A	O	192-193
46	O	194-196
-	O	196-197
year	O	197-201
-	O	196-197
old	O	202-205
African	O	206-213
-	O	213-214
American	O	214-222
man	O	223-226
experienced	O	227-238
recurrent	O	239-248
grand	B	249-254
mal	I	255-258
seizures	I	259-267
during	O	268-274
intravenous	O	275-286
infusion	O	287-295
of	O	296-298
amphotericin	O	299-311
B	O	312-313
,	O	313-314
then	O	315-319
petit	O	320-325
mal	O	326-329
seizures	B	330-338
as	O	339-341
the	O	342-345
infusion	O	346-354
was	O	355-358
stopped	O	359-366
and	O	367-370
the	O	371-374
drug	O	375-379
concentrations	O	380-394
decreased	O	395-404
with	O	405-409
time	O	410-414
.	O	414-415

The	O	416-419
patients	O	420-428
concurrent	O	429-439
medications	O	440-451
included	O	452-460
didanosine	O	461-471
,	O	471-472
hydroxyzine	O	473-484
,	O	484-485
promethazine	O	486-498
,	O	498-499
hydrocortisone	O	500-514
,	O	514-515
and	O	516-519
prochlorperazine	O	520-536
.	O	536-537

Despite	O	538-545
administration	O	546-560
of	O	561-563
phenytoin	O	564-573
and	O	574-577
lorazepam	O	578-587
,	O	587-588
the	O	589-592
seizures	B	593-601
persisted	O	602-611
and	O	612-615
occurred	O	616-624
only	O	625-629
during	O	630-636
amphotercin	O	637-648
B	O	649-650
administration	O	651-665
.	O	665-666

DISCUSSION	O	667-677
:	O	677-678
AIDS	B	679-683
and	O	684-687
cryptococcal	B	688-700
meningitis	I	701-711
,	O	711-712
both	O	713-717
of	O	718-720
which	O	721-726
the	O	727-730
patient	O	731-738
had	O	739-742
,	O	742-743
can	O	744-747
potentially	O	748-759
cause	O	760-765
seizures	B	766-774
.	O	774-775

The	O	776-779
patient	O	780-787
had	O	788-791
a	O	792-793
history	O	794-801
of	O	802-804
alcohol	B	805-812
abuse	I	813-818
;	O	818-819
alcohol	O	820-827
intake	O	828-834
as	O	835-837
well	O	838-842
as	O	843-845
withdrawal	O	846-856
can	O	857-860
also	O	861-865
cause	O	866-871
seizures	B	872-880
.	O	880-881

Didanosine	O	882-892
also	O	893-897
has	O	898-901
a	O	902-903
potential	O	904-913
for	O	914-917
inducing	O	918-926
seizures	B	927-935
.	O	935-936

However	O	937-944
,	O	944-945
these	O	946-951
other	O	952-957
potential	O	958-967
causes	O	968-974
of	O	975-977
seizure	B	978-985
were	O	986-990
ruled	O	991-996
out	O	997-1000
.	O	1000-1001

The	O	1002-1005
time	O	1006-1010
course	O	1011-1017
of	O	1018-1020
events	O	1021-1027
suggested	O	1028-1037
that	O	1038-1042
amphotericin	O	1043-1055
B	O	1056-1057
was	O	1058-1061
the	O	1062-1065
cause	O	1066-1071
of	O	1072-1074
the	O	1075-1078
seizures	B	1079-1087
in	O	1088-1090
this	O	1091-1095
AIDS	B	1096-1100
patient	O	1101-1108
.	O	1108-1109

CONCLUSIONS	O	1110-1121
:	O	1121-1122
Amphotericin	O	1123-1135
B	O	1136-1137
seems	O	1138-1143
to	O	1144-1146
be	O	1147-1149
the	O	1150-1153
probable	O	1154-1162
cause	O	1163-1168
of	O	1169-1171
the	O	1172-1175
seizures	B	1176-1184
.	O	1184-1185

To	O	1186-1188
date	O	1189-1193
,	O	1193-1194
only	O	1195-1199
three	O	1200-1205
cases	O	1206-1211
of	O	1212-1214
seizures	B	1215-1223
associated	O	1224-1234
with	O	1235-1239
amphotericin	O	1240-1252
B	O	1253-1254
have	O	1255-1259
been	O	1260-1264
reported	O	1265-1273
in	O	1274-1276
the	O	1277-1280
literature	O	1281-1291
,	O	1291-1292
but	O	1293-1296
healthcare	O	1297-1307
providers	O	1308-1317
should	O	1318-1324
be	O	1325-1327
aware	O	1328-1333
of	O	1334-1336
the	O	1337-1340
potential	O	1341-1350
for	O	1351-1354
this	O	1355-1359
rare	O	1360-1364
adverse	O	1365-1372
effect	O	1373-1379
.	O	1379-1380

Therapeutic	O	0-11
drug	O	12-16
monitoring	O	17-27
of	O	28-30
tobramycin	O	31-41
:	O	41-42
once	O	43-47
-	O	47-48
daily	O	48-53
versus	O	54-60
twice	O	61-66
-	O	66-67
daily	O	67-72
dosage	O	73-79
schedules	O	80-89
.	O	89-90

OBJECTIVE	O	91-100
:	O	100-101
To	O	102-104
evaluate	O	105-113
the	O	114-117
effect	O	118-124
of	O	125-127
dosage	O	128-134
regimen	O	135-142
(	O	143-144
once	O	144-148
-	O	148-149
daily	O	149-154
vs	O	155-157
.	O	157-158
twice	O	159-164
-	O	164-165
daily	O	165-170
)	O	170-171
of	O	172-174
tobramicyn	O	175-185
on	O	186-188
steady	O	189-195
-	O	195-196
state	O	196-201
serum	O	202-207
concentrations	O	208-222
and	O	223-226
toxicity	B	227-235
.	O	235-236

MATERIALS	O	237-246
AND	O	247-250
METHODS	O	251-258
:	O	258-259
Patients	O	260-268
undergoing	O	269-279
treatment	O	280-289
with	O	290-294
i	O	295-296
.	O	296-297
v	O	297-298
.	O	296-297

tobramycin	O	300-310
(	O	311-312
4	O	312-313
mg	O	314-316
/	O	316-317
kg	O	317-319
/	O	316-317
day	O	320-323
)	O	323-324
were	O	325-329
randomised	O	330-340
to	O	341-343
two	O	344-347
groups	O	348-354
.	O	354-355

Group	O	356-361
OD	O	362-364
(	O	365-366
n	O	366-367
=	O	368-369
22	O	370-372
)	O	372-373
received	O	374-382
a	O	383-384
once	O	385-389
-	O	389-390
daily	O	390-395
dose	O	396-400
of	O	401-403
tobramycin	O	404-414
and	O	415-418
group	O	419-424
TD	O	425-427
(	O	428-429
n	O	429-430
=	O	431-432
21	O	433-435
)	O	435-436
received	O	437-445
the	O	446-449
same	O	450-454
dose	O	455-459
divided	O	460-467
into	O	468-472
two	O	473-476
doses	O	477-482
daily	O	483-488
.	O	488-489

Tobramycin	O	490-500
serum	O	501-506
concentrations	O	507-521
(	O	522-523
peak	O	523-527
and	O	528-531
trough	O	532-538
)	O	538-539
were	O	540-544
measured	O	545-553
by	O	554-556
enzyme	O	557-563
multiplied	O	564-574
immunoassay	O	575-586
.	O	586-587

The	O	588-591
renal	O	592-597
and	O	598-601
auditory	O	602-610
functions	O	611-620
of	O	621-623
the	O	624-627
patients	O	628-636
were	O	637-641
monitored	O	642-651
before	O	652-658
,	O	658-659
during	O	660-666
and	O	667-670
immediately	O	671-682
after	O	683-688
treatment	O	689-698
.	O	698-699

RESULTS	O	700-707
:	O	707-708
The	O	709-712
two	O	713-716
groups	O	717-723
were	O	724-728
comparable	O	729-739
with	O	740-744
respect	O	745-752
to	O	753-755
sex	O	756-759
,	O	759-760
age	O	761-764
,	O	764-765
body	O	766-770
weight	O	771-777
and	O	778-781
renal	O	782-787
function	O	788-796
.	O	796-797

No	O	798-800
statistically	O	801-814
significant	O	815-826
differences	O	827-838
were	O	839-843
found	O	844-849
in	O	850-852
mean	O	853-857
daily	O	858-863
dose	O	864-868
,	O	868-869
duration	O	870-878
of	O	879-881
treatment	O	882-891
,	O	891-892
or	O	893-895
cumulative	O	896-906
dose	O	907-911
.	O	911-912

Trough	O	913-919
concentrations	O	920-934
were	O	935-939
<	O	940-941
2	O	942-943
g	O	944-945
/	O	945-946
ml	O	946-948
in	O	949-951
the	O	952-955
two	O	956-959
groups	O	960-966
(	O	967-968
100	O	968-971
%	O	971-972
)	O	972-973
.	O	973-974

Peak	O	975-979
concentrations	O	980-994
were	O	995-999
>	O	1000-1001
6	O	1002-1003
microg	O	1004-1010
/	O	1010-1011
ml	O	1011-1013
in	O	1014-1016
100	O	1017-1020
%	O	1020-1021
of	O	1022-1024
the	O	1025-1028
OD	O	1029-1031
group	O	1032-1037
and	O	1038-1041
in	O	1042-1044
67	O	1045-1047
%	O	1047-1048
of	O	1049-1051
the	O	1052-1055
TD	O	1056-1058
group	O	1059-1064
(	O	1065-1066
P	O	1066-1067
<	O	1067-1068
0	O	1069-1070
.	O	1070-1071
01	O	1071-1073
)	O	1073-1074
.	O	1070-1071

Mean	O	1076-1080
peak	O	1081-1085
concentrations	O	1086-1100
were	O	1101-1105
markedly	O	1106-1114
different	O	1115-1124
:	O	1124-1125
11	O	1126-1128
.	O	1128-1129
00	O	1129-1131
+	O	1131-1132
/	O	1132-1133
-	O	1133-1134
2	O	1134-1135
.	O	1128-1129
89	O	1136-1138

microg	O	1139-1145
/	O	1145-1146
ml	O	1146-1148
in	O	1149-1151
OD	O	1152-1154
vs	O	1155-1157
.	O	1157-1158
6	O	1159-1160
.	O	1160-1161
53	O	1161-1163
+	O	1163-1164
/	O	1164-1165
-	O	1165-1166
1	O	1166-1167
.	O	1160-1161
45	O	1168-1170

microg	O	1171-1177
/	O	1177-1178
ml	O	1178-1180
in	O	1181-1183
TD	O	1184-1186
(	O	1187-1188
P	O	1188-1189
<	O	1189-1190
0	O	1191-1192
.	O	1192-1193
01	O	1193-1195
)	O	1195-1196
.	O	1192-1193

The	O	1198-1201
pharmacokinetics	O	1202-1218
parameters	O	1219-1229
were	O	1230-1234
:	O	1234-1235
Ke	O	1236-1238
,	O	1238-1239
(	O	1240-1241
0	O	1241-1242
.	O	1242-1243
15	O	1243-1245
+	O	1245-1246
/	O	1246-1247
-	O	1247-1248
0	O	1241-1242
.	O	1242-1243
03	O	1250-1252
/	O	1246-1247
h	O	1253-1254
in	O	1255-1257
OD	O	1258-1260
vs	O	1261-1263
.	O	1263-1264
0	O	1265-1266
.	O	1266-1267
24	O	1267-1269
+	O	1269-1270
/	O	1270-1271
-	O	1271-1272
0	O	1265-1266
.	O	1266-1267
06	O	1274-1276
/	O	1270-1271
h	O	1277-1278
in	O	1279-1281
TD	O	1282-1284
)	O	1284-1285
,	O	1285-1286
t1	O	1287-1289
/	O	1289-1290
2	O	1290-1291
,	O	1291-1292
(	O	1293-1294
4	O	1294-1295
.	O	1295-1296
95	O	1296-1298
+	O	1298-1299
/	O	1299-1300
-	O	1300-1301
1	O	1301-1302
.	O	1295-1296
41	O	1303-1305

h	O	1306-1307
in	O	1308-1310
OD	O	1311-1313
vs	O	1314-1316
.	O	1316-1317
3	O	1318-1319
.	O	1319-1320
07	O	1320-1322
+	O	1322-1323
/	O	1323-1324
-	O	1324-1325
0	O	1320-1321
.	O	1319-1320
71	O	1327-1329

h	O	1330-1331
in	O	1332-1334
TD	O	1335-1337
)	O	1337-1338
,	O	1338-1339
Vd	O	1340-1342
(	O	1343-1344
0	O	1344-1345
.	O	1345-1346
35	O	1346-1348
+	O	1348-1349
/	O	1349-1350
-	O	1350-1351
0	O	1344-1345
.	O	1345-1346
11	O	1353-1355
l	O	1356-1357
/	O	1357-1358
kg	O	1358-1360
in	O	1361-1363
OD	O	1364-1366
vs	O	1367-1369
.	O	1369-1370
0	O	1371-1372
.	O	1372-1373
33	O	1373-1375
+	O	1375-1376
/	O	1376-1377
-	O	1377-1378
0	O	1371-1372
.	O	1372-1373
09	O	1380-1382

l	O	1383-1384
/	O	1384-1385
kg	O	1385-1387
in	O	1388-1390
TD	O	1391-1393
)	O	1393-1394
,	O	1394-1395
Cl	O	1396-1398
(	O	1399-1400
0	O	1400-1401
.	O	1401-1402
86	O	1402-1404
+	O	1404-1405
/	O	1405-1406
-	O	1406-1407
0	O	1400-1401
.	O	1401-1402
29	O	1409-1411
ml	O	1412-1414
/	O	1414-1415
min	O	1415-1418
/	O	1414-1415
kg	O	1419-1421
in	O	1422-1424
OD	O	1425-1427
vs	O	1428-1430
.	O	1430-1431
1	O	1432-1433
.	O	1433-1434
28	O	1434-1436
+	O	1436-1437
/	O	1437-1438
-	O	1438-1439
0	O	1439-1440
.	O	1433-1434
33	O	1441-1443

ml	O	1444-1446
/	O	1446-1447
min	O	1447-1450
/	O	1446-1447
kg	O	1451-1453
in	O	1454-1456
TD	O	1457-1459
)	O	1459-1460
.	O	1460-1461

Increased	O	1462-1471
serum	O	1472-1477
creatinine	O	1478-1488
was	O	1489-1492
observed	O	1493-1501
in	O	1502-1504
73	O	1505-1507
%	O	1507-1508
of	O	1509-1511
patients	O	1512-1520
in	O	1521-1523
OD	O	1524-1526
versus	O	1527-1533
57	O	1534-1536
%	O	1536-1537
of	O	1538-1540
patients	O	1541-1549
in	O	1550-1552
TD	O	1553-1555
,	O	1555-1556
without	O	1557-1564
evidence	O	1565-1573
of	O	1574-1576
nephrotoxicity	B	1577-1591
.	O	1591-1592

In	O	1593-1595
TD	O	1596-1598
group	O	1599-1604
,	O	1604-1605
three	O	1606-1611
patients	O	1612-1620
developed	O	1621-1630
decreased	B	1631-1640
auditory	I	1641-1649
function	I	1650-1658
,	O	1658-1659
of	O	1660-1662
which	O	1663-1668
one	O	1669-1672
presented	O	1673-1682
with	O	1683-1687
an	O	1688-1690
auditory	B	1691-1699
loss	I	1700-1704
of	O	1705-1707
-	O	1708-1709
30	O	1709-1711
dB	O	1712-1714
,	O	1714-1715
whereas	O	1716-1723
in	O	1724-1726
the	O	1727-1730
OD	O	1731-1733
group	O	1734-1739
only	O	1740-1744
one	O	1745-1748
patient	O	1749-1756
presented	O	1757-1766
decreased	B	1767-1776
auditory	I	1777-1785
function	I	1786-1794
.	O	1794-1795

CONCLUSION	O	1796-1806
:	O	1806-1807
This	O	1808-1812
small	O	1813-1818
study	O	1819-1824
suggests	O	1825-1833
that	O	1834-1838
a	O	1839-1840
once	O	1841-1845
-	O	1845-1846
daily	O	1846-1851
dosing	O	1852-1858
regimen	O	1859-1866
of	O	1867-1869
tobramycin	O	1870-1880
is	O	1881-1883
at	O	1884-1886
least	O	1887-1892
as	O	1893-1895
effective	O	1896-1905
as	O	1906-1908
and	O	1909-1912
is	O	1913-1915
no	O	1916-1918
more	O	1919-1923
and	O	1924-1927
possibly	O	1928-1936
less	O	1937-1941
toxic	O	1942-1947
than	O	1948-1952
the	O	1953-1956
twice	O	1957-1962
-	O	1962-1963
daily	O	1963-1968
regimen	O	1969-1976
.	O	1976-1977

Using	O	1978-1983
a	O	1984-1985
single	O	1986-1992
-	O	1992-1993
dose	O	1993-1997
therapy	O	1998-2005
,	O	2005-2006
peak	O	2007-2011
concentration	O	2012-2025
determination	O	2026-2039
is	O	2040-2042
not	O	2043-2046
necessary	O	2047-2056
,	O	2056-2057
only	O	2058-2062
trough	O	2063-2069
samples	O	2070-2077
should	O	2078-2084
be	O	2085-2087
monitored	O	2088-2097
to	O	2098-2100
ensure	O	2101-2107
levels	O	2108-2114
below	O	2115-2120
2	O	2121-2122
microg	O	2123-2129
/	O	2129-2130
ml	O	2130-2132
.	O	2132-2133

Chronic	O	0-7
effects	O	8-15
of	O	16-18
a	O	19-20
novel	O	21-26
synthetic	O	27-36
anthracycline	O	37-50
derivative	O	51-61
(	O	62-63
SM	O	63-65
-	O	65-66
5887	O	66-70
)	O	70-71
on	O	72-74
normal	O	75-81
heart	O	82-87
and	O	88-91
doxorubicin	O	92-103
-	O	103-104
induced	O	104-111
cardiomyopathy	B	112-126
in	O	127-129
beagle	O	130-136
dogs	O	137-141
.	O	141-142

This	O	143-147
study	O	148-153
was	O	154-157
designed	O	158-166
to	O	167-169
investigate	O	170-181
the	O	182-185
chronic	O	186-193
cardiotoxic	B	194-205
potential	O	206-215
of	O	216-218
SM	O	219-221
-	O	221-222
5887	O	222-226
and	O	227-230
a	O	231-232
possible	O	233-241
deteriorating	O	242-255
effect	O	256-262
of	O	263-265
SM	O	266-268
-	O	268-269
5887	O	269-273
on	O	274-276
low	O	277-280
-	O	280-281
grade	O	281-286
cardiotoxicity	B	287-301
pre	O	302-305
-	O	305-306
induced	O	306-313
by	O	314-316
doxorubicin	O	317-328
in	O	329-331
beagle	O	332-338
dogs	O	339-343
.	O	343-344

In	O	345-347
the	O	348-351
chronic	O	352-359
treatment	O	360-369
,	O	369-370
beagle	O	371-377
dogs	O	378-382
of	O	383-385
each	O	386-390
sex	O	391-394
were	O	395-399
given	O	400-405
intravenously	O	406-419
once	O	420-424
every	O	425-430
3	O	431-432
weeks	O	433-438
,	O	438-439
either	O	440-446
a	O	447-448
sublethal	O	449-458
dose	O	459-463
of	O	464-466
doxorubicin	O	467-478
(	O	479-480
1	O	480-481
.	O	481-482
5	O	482-483
mg	O	484-486
/	O	486-487
kg	O	487-489
)	O	489-490
or	O	491-493
SM	O	494-496
-	O	496-497
5887	O	497-501
(	O	502-503
2	O	503-504
.	O	504-505
5	O	505-506
mg	O	507-509
/	O	509-510
kg	O	510-512
)	O	512-513
.	O	513-514

The	O	515-518
experiment	O	519-529
was	O	530-533
terminated	O	534-544
3	O	545-546
weeks	O	547-552
after	O	553-558
the	O	559-562
ninth	O	563-568
dosing	O	569-575
.	O	575-576

Animals	O	577-584
which	O	585-590
received	O	591-599
over	O	600-604
six	O	605-608
courses	O	609-616
of	O	617-619
doxorubicin	O	620-631
demonstrated	O	632-644
the	O	645-648
electrocardiogram	O	649-666
(	O	667-668
ECG	O	668-671
)	O	671-672
changes	O	673-680
,	O	680-681
decrease	O	682-690
of	O	691-693
blood	O	694-699
pressure	O	700-708
and	O	709-712
high	O	713-717
-	O	717-718
grade	O	718-723
histopathological	O	724-741
cardiomyopathy	B	742-756
,	O	756-757
while	O	758-763
animals	O	764-771
which	O	772-777
were	O	778-782
terminally	O	783-793
sacrificed	O	794-804
after	O	805-810
the	O	811-814
SM	O	815-817
-	O	817-818
5887	O	818-822
administration	O	823-837
did	O	838-841
not	O	842-845
show	O	846-850
any	O	851-854
changes	O	855-862
in	O	863-865
ECG	O	866-869
,	O	869-870
blood	O	871-876
pressure	O	877-885
and	O	886-889
histopathological	O	890-907
examinations	O	908-920
.	O	920-921

To	O	922-924
examine	O	925-932
a	O	933-934
possibly	O	935-943
deteriorating	O	944-957
cardiotoxic	B	958-969
effect	O	970-976
of	O	977-979
SM	O	980-982
-	O	982-983
5887	O	983-987
,	O	987-988
low	O	989-992
-	O	992-993
grade	O	993-998
cardiomyopathy	B	999-1013
was	O	1014-1017
induced	O	1018-1025
in	O	1026-1028
dogs	O	1029-1033
by	O	1034-1036
four	O	1037-1041
courses	O	1042-1049
of	O	1050-1052
doxorubicin	O	1053-1064
(	O	1065-1066
1	O	1066-1067
.	O	1067-1068
5	O	1068-1069
mg	O	1070-1072
/	O	1072-1073
kg	O	1073-1075
)	O	1075-1076
.	O	1076-1077

Nine	O	1078-1082
weeks	O	1083-1088
after	O	1089-1094
pre	O	1095-1098
-	O	1098-1099
treatment	O	1099-1108
,	O	1108-1109
dogs	O	1110-1114
were	O	1115-1119
given	O	1120-1125
four	O	1126-1130
courses	O	1131-1138
of	O	1139-1141
either	O	1142-1148
doxorubicin	O	1149-1160
(	O	1161-1162
1	O	1162-1163
.	O	1163-1164
5	O	1164-1165
mg	O	1166-1168
/	O	1168-1169
kg	O	1169-1171
)	O	1171-1172
or	O	1173-1175
SM	O	1176-1178
-	O	1178-1179
5887	O	1179-1183
(	O	1184-1185
2	O	1185-1186
.	O	1186-1187
5	O	1187-1188
mg	O	1189-1191
/	O	1191-1192
kg	O	1192-1194
)	O	1194-1195
once	O	1196-1200
every	O	1201-1206
3	O	1207-1208
weeks	O	1209-1214
.	O	1214-1215

The	O	1216-1219
low	O	1220-1223
-	O	1223-1224
grade	O	1224-1229
cardiotoxic	B	1230-1241
changes	O	1242-1249
were	O	1250-1254
enhanced	O	1255-1263
by	O	1264-1266
the	O	1267-1270
additional	O	1271-1281
doxorubicin	O	1282-1293
treatment	O	1294-1303
.	O	1303-1304

On	O	1305-1307
the	O	1308-1311
contrary	O	1312-1320
,	O	1320-1321
the	O	1322-1325
SM	O	1326-1328
-	O	1328-1329
5887	O	1329-1333
treatment	O	1334-1343
did	O	1344-1347
not	O	1348-1351
progress	O	1352-1360
the	O	1361-1364
grade	O	1365-1370
of	O	1371-1373
cardiomyopathy	B	1374-1388
.	O	1388-1389

In	O	1390-1392
conclusion	O	1393-1403
,	O	1403-1404
SM	O	1405-1407
-	O	1407-1408
5887	O	1408-1412
does	O	1413-1417
not	O	1418-1421
have	O	1422-1426
any	O	1427-1430
potential	O	1431-1440
of	O	1441-1443
chronic	O	1444-1451
cardiotoxicity	B	1452-1466
and	O	1467-1470
deteriorating	O	1471-1484
effect	O	1485-1491
on	O	1492-1494
doxorubicin	O	1495-1506
-	O	1506-1507
induced	O	1507-1514
cardiotoxicity	B	1515-1529
in	O	1530-1532
dogs	O	1533-1537
.	O	1537-1538

Posteroventral	O	0-14
medial	O	15-21
pallidotomy	O	22-33
in	O	34-36
advanced	O	37-45
Parkinson	B	46-55
'	I	55-56
s	I	52-53
disease	I	58-65
.	O	65-66

BACKGROUND	O	67-77
:	O	77-78
Posteroventral	O	79-93
medial	O	94-100
pallidotomy	O	101-112
sometimes	O	113-122
produces	O	123-131
striking	O	132-140
improvement	O	141-152
in	O	153-155
patients	O	156-164
with	O	165-169
advanced	O	170-178
Parkinson	B	179-188
'	I	188-189
s	I	185-186
disease	I	191-198
,	O	198-199
but	O	200-203
the	O	204-207
studies	O	208-215
to	O	216-218
date	O	219-223
have	O	224-228
involved	O	229-237
small	O	238-243
numbers	O	244-251
of	O	252-254
patients	O	255-263
and	O	264-267
short	O	268-273
-	O	273-274
term	O	274-278
follow	O	279-285
-	O	285-286
up	O	286-288
.	O	288-289

METHODS	O	290-297
:	O	297-298
Forty	O	299-304
patients	O	305-313
with	O	314-318
Parkinson	B	319-328
'	I	328-329
s	I	325-326
disease	I	331-338
underwent	O	339-348
serial	O	349-355
,	O	355-356
detailed	O	357-365
assessments	O	366-377
both	O	378-382
after	O	383-388
drug	O	389-393
withdrawal	O	394-404
(	O	405-406
"	O	406-407
off	O	407-410
"	O	406-407
period	O	412-418
)	O	418-419
and	O	420-423
while	O	424-429
taking	O	430-436
their	O	437-442
optimal	O	443-450
medical	O	451-458
regimens	O	459-467
(	O	468-469
"	O	469-470
on	O	470-472
"	O	469-470
period	O	474-480
)	O	480-481
.	O	481-482

All	O	483-486
patients	O	487-495
were	O	496-500
examined	O	501-509
preoperatively	O	510-524
and	O	525-528
39	O	529-531
were	O	532-536
examined	O	537-545
at	O	546-548
six	O	549-552
months	O	553-559
;	O	559-560
27	O	561-563
of	O	564-566
the	O	567-570
patients	O	571-579
were	O	580-584
also	O	585-589
examined	O	590-598
at	O	599-601
one	O	602-605
year	O	606-610
,	O	610-611
and	O	612-615
11	O	616-618
at	O	619-621
two	O	622-625
years	O	626-631
.	O	631-632

RESULTS	O	633-640
:	O	640-641
The	O	642-645
percent	O	646-653
improvements	O	654-666
at	O	667-669
six	O	670-673
months	O	674-680
were	O	681-685
as	O	686-688
follows	O	689-696
:	O	696-697
off	O	698-701
-	O	701-702
period	O	702-708
score	O	709-714
for	O	715-718
overall	O	719-726
motor	O	727-732
function	O	733-741
,	O	741-742
28	O	743-745
percent	O	746-753
(	O	754-755
95	O	755-757
percent	O	758-765
confidence	O	766-776
interval	O	777-785
,	O	785-786
19	O	787-789
to	O	790-792
38	O	793-795
percent	O	796-803
)	O	803-804
,	O	804-805
with	O	806-810
most	O	811-815
of	O	816-818
the	O	819-822
improvement	O	823-834
in	O	835-837
the	O	838-841
contralateral	O	842-855
limbs	O	856-861
;	O	861-862
off	O	863-866
-	O	866-867
period	O	867-873
score	O	874-879
for	O	880-883
activities	O	884-894
of	O	895-897
daily	O	898-903
living	O	904-910
,	O	910-911
29	O	912-914
percent	O	915-922
(	O	923-924
95	O	924-926
percent	O	927-934
confidence	O	935-945
interval	O	946-954
,	O	954-955
19	O	956-958
to	O	959-961
39	O	962-964
percent	O	965-972
)	O	972-973
;	O	973-974
on	O	975-977
-	O	977-978
period	O	978-984
score	O	985-990
for	O	991-994
contralateral	O	995-1008
dyskinesias	B	1009-1020
,	O	1020-1021
82	O	1022-1024
percent	O	1025-1032
(	O	1033-1034
95	O	1034-1036
percent	O	1037-1044
confidence	O	1045-1055
interval	O	1056-1064
,	O	1064-1065
72	O	1066-1068
to	O	1069-1071
91	O	1072-1074
percent	O	1075-1082
)	O	1082-1083
;	O	1083-1084
and	O	1085-1088
on	O	1089-1091
-	O	1091-1092
period	O	1092-1098
score	O	1099-1104
for	O	1105-1108
ipsilateral	O	1109-1120
dyskinesias	B	1121-1132
,	O	1132-1133
44	O	1134-1136
percent	O	1137-1144
(	O	1145-1146
95	O	1146-1148
percent	O	1149-1156
confidence	O	1157-1167
interval	O	1168-1176
,	O	1176-1177
29	O	1178-1180
to	O	1181-1183
59	O	1184-1186
percent	O	1187-1194
)	O	1194-1195
.	O	1195-1196

The	O	1197-1200
improvements	O	1201-1213
in	O	1214-1216
dyskinesias	B	1217-1228
and	O	1229-1232
the	O	1233-1236
total	O	1237-1242
scores	O	1243-1249
for	O	1250-1253
off	O	1254-1257
-	O	1257-1258
period	O	1258-1264
parkinsonism	B	1265-1277
,	O	1277-1278
contralateral	O	1279-1292
bradykinesia	B	1293-1305
,	O	1305-1306
and	O	1307-1310
rigidity	B	1311-1319
were	O	1320-1324
sustained	O	1325-1334
in	O	1335-1337
the	O	1338-1341
11	O	1342-1344
patients	O	1345-1353
examined	O	1354-1362
at	O	1363-1365
two	O	1366-1369
years	O	1370-1375
.	O	1375-1376

The	O	1377-1380
improvement	O	1381-1392
in	O	1393-1395
ipsilateral	O	1396-1407
dyskinesias	B	1408-1419
was	O	1420-1423
lost	O	1424-1428
after	O	1429-1434
one	O	1435-1438
year	O	1439-1443
,	O	1443-1444
and	O	1445-1448
the	O	1449-1452
improvements	O	1453-1465
in	O	1466-1468
postural	O	1469-1477
stability	O	1478-1487
and	O	1488-1491
gait	O	1492-1496
lasted	O	1497-1503
only	O	1504-1508
three	O	1509-1514
to	O	1515-1517
six	O	1518-1521
months	O	1522-1528
.	O	1528-1529

Approximately	O	1530-1543
half	O	1544-1548
the	O	1549-1552
patients	O	1553-1561
who	O	1562-1565
had	O	1566-1569
been	O	1570-1574
dependent	O	1575-1584
on	O	1585-1587
assistance	O	1588-1598
in	O	1599-1601
activities	O	1602-1612
of	O	1613-1615
daily	O	1616-1621
living	O	1622-1628
in	O	1629-1631
the	O	1632-1635
off	O	1636-1639
period	O	1640-1646
before	O	1647-1653
surgery	O	1654-1661
became	O	1662-1668
independent	O	1669-1680
after	O	1681-1686
surgery	O	1687-1694
.	O	1694-1695

The	O	1696-1699
complications	O	1700-1713
of	O	1714-1716
surgery	O	1717-1724
were	O	1725-1729
generally	O	1730-1739
well	O	1740-1744
tolerated	O	1745-1754
,	O	1754-1755
and	O	1756-1759
there	O	1760-1765
were	O	1766-1770
no	O	1771-1773
significant	O	1774-1785
changes	O	1786-1793
in	O	1794-1796
the	O	1797-1800
use	O	1801-1804
of	O	1805-1807
medication	O	1808-1818
.	O	1818-1819

CONCLUSIONS	O	1820-1831
:	O	1831-1832
In	O	1833-1835
late	O	1836-1840
-	O	1840-1841
stage	O	1841-1846
Parkinson	B	1847-1856
'	I	1856-1857
s	I	1853-1854
disease	I	1859-1866
,	O	1866-1867
pallidotomy	O	1868-1879
significantly	O	1880-1893
reduces	O	1894-1901
levodopa	O	1902-1910
-	O	1910-1911
induced	O	1911-1918
dyskinesias	B	1919-1930
and	O	1931-1934
off	O	1935-1938
-	O	1938-1939
period	O	1939-1945
disability	O	1946-1956
.	O	1956-1957

Much	O	1958-1962
of	O	1963-1965
the	O	1966-1969
benefit	O	1970-1977
is	O	1978-1980
sustained	O	1981-1990
at	O	1991-1993
two	O	1994-1997
years	O	1998-2003
,	O	2003-2004
although	O	2005-2013
some	O	2014-2018
improvements	O	2019-2031
,	O	2031-2032
such	O	2033-2037
as	O	2038-2040
those	O	2041-2046
on	O	2047-2049
the	O	2050-2053
ipsilateral	O	2054-2065
side	O	2066-2070
and	O	2071-2074
in	O	2075-2077
axial	O	2078-2083
symptoms	O	2084-2092
,	O	2092-2093
wane	O	2094-2098
within	O	2099-2105
the	O	2106-2109
first	O	2110-2115
year	O	2116-2120
.	O	2120-2121

The	O	2122-2125
on	O	2126-2128
-	O	2128-2129
period	O	2129-2135
symptoms	O	2136-2144
that	O	2145-2149
are	O	2150-2153
resistant	O	2154-2163
to	O	2164-2166
dopaminergic	O	2167-2179
therapy	O	2180-2187
do	O	2188-2190
not	O	2191-2194
respond	O	2195-2202
to	O	2203-2205
pallidotomy	O	2206-2217
.	O	2217-2218

Neuropeptide	O	0-12
-	O	12-13
Y	O	13-14
immunoreactivity	O	15-31
in	O	32-34
the	O	35-38
pilocarpine	O	39-50
model	O	51-56
of	O	57-59
temporal	B	60-68
lobe	I	69-73
epilepsy	I	74-82
.	O	82-83

Neuropeptide	O	84-96
-	O	96-97
Y	O	97-98
(	O	99-100
NPY	O	100-103
)	O	103-104
is	O	105-107
expressed	O	108-117
by	O	118-120
granule	O	121-128
cells	O	129-134
and	O	135-138
mossy	O	139-144
fibres	O	145-151
of	O	152-154
the	O	155-158
hippocampal	O	159-170
dentate	O	171-178
gyrus	O	179-184
during	O	185-191
experimental	O	192-204
temporal	B	205-213
lobe	I	214-218
epilepsy	I	219-227
(	O	228-229
TLE	B	229-232
)	O	232-233
.	O	233-234

This	O	235-239
expression	O	240-250
may	O	251-254
represent	O	255-264
an	O	265-267
endogenous	O	268-278
damping	O	279-286
mechanism	O	287-296
since	O	297-302
NPY	O	303-306
has	O	307-310
been	O	311-315
shown	O	316-321
to	O	322-324
block	O	325-330
seizure	B	331-338
-	O	338-339
like	O	339-343
events	O	344-350
following	O	351-360
high	O	361-365
-	O	365-366
frequency	O	366-375
stimulation	O	376-387
in	O	388-390
hippocampal	O	391-402
slices	O	403-409
.	O	409-410

The	O	411-414
pilocarpine	O	415-426
(	O	427-428
PILO	O	428-432
)	O	432-433
model	O	434-439
of	O	440-442
epilepsy	B	443-451
is	O	452-454
characterized	O	455-468
by	O	469-471
an	O	472-474
acute	O	475-480
period	O	481-487
of	O	488-490
status	B	491-497
epilepticus	I	498-509
followed	O	510-518
by	O	519-521
spontaneous	O	522-533
recurrent	O	534-543
seizures	B	544-552
and	O	553-556
related	O	557-564
brain	B	565-570
damage	I	571-577
.	O	577-578

We	O	579-581
report	O	582-588
peroxidase	O	589-599
-	O	599-600
antiperoxidase	O	600-614
immunostaining	O	615-629
for	O	630-633
NPY	O	634-637
in	O	638-640
several	O	641-648
brain	O	649-654
regions	O	655-662
in	O	663-665
this	O	666-670
model	O	671-676
.	O	676-677

PILO	O	678-682
-	O	682-683
injected	O	683-691
animals	O	692-699
exhibited	O	700-709
NPY	O	710-713
immunoreactivity	O	714-730
in	O	731-733
the	O	734-737
region	O	738-744
of	O	745-747
the	O	748-751
mossy	O	752-757
fibre	O	758-763
terminals	O	764-773
,	O	773-774
in	O	775-777
the	O	778-781
dentate	O	782-789
gyrus	O	790-795
inner	O	796-801
molecular	O	802-811
layer	O	812-817
and	O	818-821
,	O	821-822
in	O	823-825
a	O	826-827
few	O	828-831
cases	O	832-837
,	O	837-838
within	O	839-845
presumed	O	846-854
granule	O	855-862
cells	O	863-868
.	O	868-869

NPY	O	870-873
immunoreactivity	O	874-890
was	O	891-894
also	O	895-899
dramatically	O	900-912
changed	O	913-920
in	O	921-923
the	O	924-927
entorhinal	O	928-938
cortex	O	939-945
,	O	945-946
amygdala	O	947-955
and	O	956-959
sensorimotor	O	960-972
areas	O	973-978
.	O	978-979

In	O	980-982
addition	O	983-991
,	O	991-992
PILO	O	993-997
injected	O	998-1006
animals	O	1007-1014
exhibited	O	1015-1024
a	O	1025-1026
reduction	O	1027-1036
in	O	1037-1039
the	O	1040-1043
number	O	1044-1050
of	O	1051-1053
NPY	O	1054-1057
-	O	1057-1058
immunoreactive	O	1058-1072
interneurons	O	1073-1085
compared	O	1086-1094
with	O	1095-1099
controls	O	1100-1108
.	O	1108-1109

The	O	1110-1113
results	O	1114-1121
demonstrate	O	1122-1133
that	O	1134-1138
changes	O	1139-1146
in	O	1147-1149
NPY	O	1150-1153
expression	O	1154-1164
,	O	1164-1165
including	O	1166-1175
expression	O	1176-1186
in	O	1187-1189
the	O	1190-1193
granule	O	1194-1201
cells	O	1202-1207
and	O	1208-1211
mossy	O	1212-1217
fibres	O	1218-1224
and	O	1225-1228
the	O	1229-1232
loss	O	1233-1237
of	O	1238-1240
vulnerable	O	1241-1251
NPY	O	1252-1255
neurons	O	1256-1263
,	O	1263-1264
are	O	1265-1268
present	O	1269-1276
in	O	1277-1279
the	O	1280-1283
PILO	O	1284-1288
model	O	1289-1294
of	O	1295-1297
TLE	B	1298-1301
.	O	1301-1302

However	O	1303-1310
,	O	1310-1311
the	O	1312-1315
significance	O	1316-1328
of	O	1329-1331
this	O	1332-1336
changed	O	1337-1344
synthesis	O	1345-1354
of	O	1355-1357
NPY	O	1358-1361
remains	O	1362-1369
to	O	1370-1372
be	O	1373-1375
determined	O	1376-1386
.	O	1386-1387

Effect	O	0-6
of	O	7-9
myopic	O	10-16
excimer	O	17-24
laser	O	25-30
photorefractive	O	31-46
keratectomy	O	47-58
on	O	59-61
the	O	62-65
electrophysiologic	O	66-84
function	O	85-93
of	O	94-96
the	O	97-100
retina	O	101-107
and	O	108-111
optic	O	112-117
nerve	O	118-123
.	O	123-124

PURPOSE	O	125-132
:	O	132-133
To	O	134-136
assess	O	137-143
by	O	144-146
electrophysiologic	O	147-165
testing	O	166-173
the	O	174-177
effect	O	178-184
of	O	185-187
photorefractive	O	188-203
keratectomy	O	204-215
(	O	216-217
PRK	O	217-220
)	O	220-221
on	O	222-224
the	O	225-228
retina	O	229-235
and	O	236-239
optic	O	240-245
nerve	O	246-251
.	O	251-252

SETTING	O	253-260
:	O	260-261
Eye	O	262-265
Clinic	O	266-272
,	O	272-273
S	O	274-275
.	O	275-276
Salvatore	O	277-286
Hospital	O	287-295
,	O	295-296
L	O	297-298
'	O	298-299
Aquila	O	299-305
University	O	306-316
,	O	316-317
Italy	O	318-323
.	O	323-324

METHODS	O	325-332
:	O	332-333
Standard	O	334-342
pattern	O	343-350
electroretinograms	O	351-369
(	O	370-371
P	O	371-372
-	O	372-373
ERGs	O	373-377
)	O	377-378
and	O	379-382
standard	O	383-391
pattern	O	392-399
visual	O	400-406
evoked	O	407-413
potentials	O	414-424
(	O	425-426
P	O	426-427
-	O	427-428
VEPs	O	428-432
)	O	432-433
were	O	434-438
done	O	439-443
in	O	444-446
25	O	447-449
eyes	O	450-454
of	O	455-457
25	O	458-460
patients	O	461-469
who	O	470-473
had	O	474-477
myopic	O	478-484
PRK	O	485-488
for	O	489-492
an	O	493-495
attempted	O	496-505
correction	O	506-516
between	O	517-524
5	O	525-526
.	O	526-527
00	O	527-529
and	O	530-533
15	O	534-536
.	O	536-537
00	O	537-539
diopters	O	540-548
(	O	549-550
D	O	550-551
)	O	551-552
(	O	553-554
mean	O	554-558
8	O	559-560
.	O	560-561
00	O	561-563
D	O	564-565
)	O	565-566
.	O	566-567

Testing	O	568-575
was	O	576-579
done	O	580-584
preoperatively	O	585-599
and	O	600-603
3	O	604-605
,	O	605-606
6	O	607-608
,	O	608-609
12	O	610-612
,	O	612-613
and	O	614-617
18	O	618-620
months	O	621-627
postoperatively	O	628-643
.	O	643-644

The	O	645-648
contralateral	O	649-662
eyes	O	663-667
served	O	668-674
as	O	675-677
controls	O	678-686
.	O	686-687

During	O	688-694
the	O	695-698
follow	O	699-705
-	O	705-706
up	O	706-708
,	O	708-709
3	O	710-711
patients	O	712-720
(	O	721-722
12	O	722-724
%	O	724-725
)	O	725-726
developed	O	727-736
steroid	O	737-744
-	O	744-745
induced	O	745-752
elevated	B	753-761
intraocular	I	762-773
pressure	I	774-782
(	O	783-784
IOP	O	784-787
)	O	787-788
that	O	789-793
resolved	O	794-802
after	O	803-808
corticosteroid	O	809-823
therapy	O	824-831
was	O	832-835
discontinued	O	836-848
.	O	848-849

RESULTS	O	850-857
:	O	857-858
No	O	859-861
statistically	O	862-875
significant	O	876-887
differences	O	888-899
were	O	900-904
seen	O	905-909
between	O	910-917
treated	O	918-925
and	O	926-929
control	O	930-937
eyes	O	938-942
nor	O	943-946
between	O	947-954
treated	O	955-962
eyes	O	963-967
preoperatively	O	968-982
and	O	983-986
postoperatively	O	987-1002
.	O	1002-1003

CONCLUSION	O	1004-1014
:	O	1014-1015
Myopic	O	1016-1022
excimer	O	1023-1030
laser	O	1031-1036
PRK	O	1037-1040
did	O	1041-1044
not	O	1045-1048
seem	O	1049-1053
to	O	1054-1056
affect	O	1057-1063
the	O	1064-1067
posterior	O	1068-1077
segment	O	1078-1085
.	O	1085-1086

The	O	1087-1090
transient	O	1091-1100
steroid	O	1101-1108
-	O	1108-1109
induced	O	1109-1116
IOP	B	1117-1120
rise	I	1121-1125
did	O	1126-1129
not	O	1130-1133
seem	O	1134-1138
to	O	1139-1141
cause	O	1142-1147
functional	O	1148-1158
impairment	O	1159-1169
.	O	1169-1170

Liposomal	O	0-9
daunorubicin	O	10-22
in	O	23-25
advanced	O	26-34
Kaposi	B	35-41
'	I	41-42
s	I	39-40
sarcoma	I	44-51
:	O	51-52
a	O	53-54
phase	O	55-60
II	O	61-63
study	O	64-69
.	O	69-70

We	O	71-73
report	O	74-80
a	O	81-82
non	O	83-86
-	O	86-87
randomized	O	87-97
Phase	O	98-103
II	O	104-106
clinical	O	107-115
trial	O	116-121
to	O	122-124
assess	O	125-131
the	O	132-135
efficacy	O	136-144
and	O	145-148
safety	O	149-155
of	O	156-158
liposomal	O	159-168
daunorubicin	O	169-181
(	O	182-183
DaunoXome	O	183-192
)	O	192-193
in	O	194-196
the	O	197-200
treatment	O	201-210
of	O	211-213
AIDS	B	214-218
related	O	219-226
Kaposi	B	227-233
'	I	233-234
s	I	231-232
sarcoma	I	236-243
.	O	243-244

Eleven	O	245-251
homosexual	O	252-262
men	O	263-266
with	O	267-271
advanced	O	272-280
Kaposi	B	281-287
'	I	287-288
s	I	285-286
sarcoma	I	290-297
were	O	298-302
entered	O	303-310
in	O	311-313
the	O	314-317
trial	O	318-323
.	O	323-324

Changes	O	325-332
in	O	333-335
size	O	336-340
,	O	340-341
colour	O	342-348
and	O	349-352
associated	O	353-363
oedema	B	364-370
of	O	371-373
selected	O	374-382
'	O	383-384
target	O	384-390
'	O	383-384
lesions	O	392-399
were	O	400-404
measured	O	405-413
.	O	413-414

Clinical	O	415-423
,	O	423-424
biochemical	O	425-436
and	O	437-440
haematological	O	441-455
toxicities	B	456-466
were	O	467-471
assessed	O	472-480
.	O	480-481

Ten	O	482-485
subjects	O	486-494
were	O	495-499
evaluated	O	500-509
.	O	509-510

A	O	511-512
partial	O	513-520
response	O	521-529
was	O	530-533
achieved	O	534-542
in	O	543-545
four	O	546-550
,	O	550-551
of	O	552-554
whom	O	555-559
two	O	560-563
subsequently	O	564-576
relapsed	O	577-585
.	O	585-586

Stabilization	O	587-600
of	O	601-603
Kaposi	B	604-610
'	I	610-611
s	I	608-609
sarcoma	I	613-620
occurred	O	621-629
in	O	630-632
the	O	633-636
remaining	O	637-646
six	O	647-650
,	O	650-651
maintained	O	652-662
until	O	663-668
the	O	669-672
end	O	673-676
of	O	677-679
the	O	680-683
trial	O	684-689
period	O	690-696
in	O	697-699
four	O	700-704
.	O	704-705

The	O	706-709
drug	O	710-714
was	O	715-718
generally	O	719-728
well	O	729-733
tolerated	O	734-743
,	O	743-744
with	O	745-749
few	O	750-753
mild	O	754-758
symptoms	O	759-767
of	O	768-770
toxicity	B	771-779
.	O	779-780

The	O	781-784
main	O	785-789
problem	O	790-797
encountered	O	798-809
was	O	810-813
haematological	O	814-828
toxicity	B	829-837
,	O	837-838
with	O	839-843
three	O	844-849
subjects	O	850-858
experiencing	O	859-871
severe	O	872-878
neutropenia	B	879-890
(	O	891-892
neutrophil	O	892-902
count	O	903-908
<	O	909-910
0	O	911-912
.	O	912-913
5	O	913-914
x	O	915-916
10	O	917-919
(	O	919-920
9	O	920-921
)	O	921-922
/	O	922-923
l	O	923-924
)	O	921-922
.	O	925-926

There	O	927-932
was	O	933-936
no	O	937-939
evidence	O	940-948
of	O	949-951
cardiotoxicity	B	952-966
.	O	966-967

In	O	968-970
this	O	971-975
small	O	976-981
patient	O	982-989
sample	O	990-996
,	O	996-997
liposomal	O	998-1007
daunorubicin	O	1008-1020
was	O	1021-1024
an	O	1025-1027
effective	O	1028-1037
and	O	1038-1041
well	O	1042-1046
tolerated	O	1047-1056
agent	O	1057-1062
in	O	1063-1065
the	O	1066-1069
treatment	O	1070-1079
of	O	1080-1082
Kaposi	B	1083-1089
'	I	1089-1090
s	I	1087-1088
sarcoma	I	1092-1099
.	O	1099-1100

Failure	O	0-7
of	O	8-10
ancrod	O	11-17
in	O	18-20
the	O	21-24
treatment	O	25-34
of	O	35-37
heparin	O	38-45
-	O	45-46
induced	O	46-53
arterial	O	54-62
thrombosis	B	63-73
.	O	73-74

The	O	75-78
morbidity	O	79-88
and	O	89-92
mortality	O	93-102
associated	O	103-113
with	O	114-118
heparin	O	119-126
-	O	126-127
induced	O	127-134
thrombosis	B	135-145
remain	O	146-152
high	O	153-157
despite	O	158-165
numerous	O	166-174
empirical	O	175-184
therapies	O	185-194
.	O	194-195

Ancrod	O	196-202
has	O	203-206
been	O	207-211
used	O	212-216
successfully	O	217-229
for	O	230-233
prophylaxis	O	234-245
against	O	246-253
development	O	254-265
of	O	266-268
thrombosis	B	269-279
in	O	280-282
patients	O	283-291
with	O	292-296
heparin	O	297-304
induced	O	305-312
platelet	B	313-321
aggregation	I	322-333
who	O	334-337
require	O	338-345
brief	O	346-351
reexposure	O	352-362
to	O	363-365
heparin	O	366-373
,	O	373-374
but	O	375-378
its	O	379-382
success	O	383-390
in	O	391-393
patients	O	394-402
who	O	403-406
have	O	407-411
developed	O	412-421
the	O	422-425
thrombosis	B	426-436
syndrome	O	437-445
is	O	446-448
not	O	449-452
well	O	453-457
defined	O	458-465
.	O	465-466

The	O	467-470
authors	O	471-478
present	O	479-486
a	O	487-488
case	O	489-493
of	O	494-496
failure	O	497-504
of	O	505-507
ancrod	O	508-514
treatment	O	515-524
in	O	525-527
a	O	528-529
patient	O	530-537
with	O	538-542
heparin	O	543-550
-	O	550-551
induced	O	551-558
thrombosis	B	559-569
.	O	569-570

Seizure	B	0-7
after	O	8-13
flumazenil	O	14-24
administration	O	25-39
in	O	40-42
a	O	43-44
pediatric	O	45-54
patient	O	55-62
.	O	62-63

Flumazenil	O	64-74
is	O	75-77
a	O	78-79
benzodiazepine	O	80-94
receptor	O	95-103
antagonist	O	104-114
used	O	115-119
to	O	120-122
reverse	O	123-130
sedation	O	131-139
and	O	140-143
respiratory	B	144-155
depression	I	156-166
induced	O	167-174
by	O	175-177
benzodiazepines	O	178-193
.	O	193-194

Seizures	B	195-203
and	O	204-207
cardiac	B	208-215
arrhythmias	I	216-227
have	O	228-232
complicated	O	233-244
its	O	245-248
use	O	249-252
in	O	253-255
adult	O	256-261
patients	O	262-270
.	O	270-271

Overdose	B	272-280
patients	O	281-289
who	O	290-293
have	O	294-298
coingested	O	299-309
tricyclic	O	310-319
antidepressants	O	320-335
have	O	336-340
a	O	341-342
higher	O	343-349
risk	O	350-354
of	O	355-357
these	O	358-363
complications	O	364-377
.	O	377-378

Little	O	379-385
information	O	386-397
exists	O	398-404
concerning	O	405-415
adverse	O	416-423
effects	O	424-431
of	O	432-434
flumazenil	O	435-445
in	O	446-448
children	O	449-457
.	O	457-458

We	O	459-461
report	O	462-468
the	O	469-472
occurrence	O	473-483
of	O	484-486
a	O	487-488
generalized	O	489-500
tonic	B	501-506
-	I	506-507
clonic	I	507-513
seizure	I	514-521
in	O	522-524
a	O	525-526
pediatric	O	527-536
patient	O	537-544
following	O	545-554
the	O	555-558
administration	O	559-573
of	O	574-576
flumazenil	O	577-587
.	O	587-588

Remodelling	O	0-11
of	O	12-14
nerve	O	15-20
structure	O	21-30
in	O	31-33
experimental	O	34-46
isoniazid	O	47-56
neuropathy	B	57-67
in	O	68-70
the	O	71-74
rat	O	75-78
.	O	78-79

The	O	80-83
neuropathy	B	84-94
caused	O	95-101
by	O	102-104
a	O	105-106
single	O	107-113
dose	O	114-118
of	O	119-121
isoniazid	O	122-131
in	O	132-134
rats	O	135-139
was	O	140-143
studied	O	144-151
with	O	152-156
a	O	157-158
computer	O	159-167
-	O	167-168
assisted	O	168-176
morphometric	O	177-189
method	O	190-196
.	O	196-197

Scatter	O	198-205
diagrams	O	206-214
of	O	215-217
the	O	218-221
g	O	222-223
ratio	O	224-229
(	O	230-231
quotient	O	231-239
fibre	O	240-245
diameter	O	246-254
/	O	254-255
axon	O	255-259
diameter	O	260-268
)	O	268-269
define	O	270-276
regenerating	O	277-289
fibres	O	290-296
as	O	297-299
a	O	300-301
distinct	O	302-310
population	O	311-321
,	O	321-322
distinguishable	O	323-338
from	O	339-343
the	O	344-347
surviving	O	348-357
fibres	O	358-364
by	O	365-367
reduced	O	368-375
sheath	O	376-382
thickness	O	383-392
and	O	393-396
reduced	O	397-404
axon	O	405-409
calibre	O	410-417
.	O	417-418

There	O	419-424
was	O	425-428
also	O	429-433
evidence	O	434-442
of	O	443-445
a	O	446-447
subtle	O	448-454
direct	O	455-461
toxic	O	462-467
effect	O	468-474
on	O	475-477
the	O	478-481
entire	O	482-488
fibre	O	489-494
population	O	495-505
,	O	505-506
causing	O	507-514
axon	O	515-519
shrinkage	O	520-529
masked	O	530-536
by	O	537-539
readjustment	O	540-552
of	O	553-555
the	O	556-559
myelin	O	560-566
sheath	O	567-573
.	O	573-574

Selective	O	0-9
injection	O	10-19
of	O	20-22
iopentol	O	23-31
,	O	31-32
iohexol	O	33-40
and	O	41-44
metrizoate	O	45-55
into	O	56-60
the	O	61-64
left	O	65-69
coronary	O	70-78
artery	O	79-85
of	O	86-88
the	O	89-92
dog	O	93-96
.	O	96-97

Induction	O	98-107
of	O	108-110
ventricular	B	111-122
fibrillation	I	123-135
and	O	136-139
decrease	O	140-148
of	O	149-151
aortic	O	152-158
pressure	O	159-167
.	O	167-168

In	O	169-171
twenty	O	172-178
beagle	O	179-185
dogs	O	186-190
selective	O	191-200
injections	O	201-211
were	O	212-216
made	O	217-221
into	O	222-226
the	O	227-230
left	O	231-235
coronary	O	236-244
artery	O	245-251
with	O	252-256
iopentol	O	257-265
,	O	265-266
iohexol	O	267-274
and	O	275-278
metrizoate	O	279-289
in	O	290-292
doses	O	293-298
of	O	299-301
4	O	302-303
ml	O	304-306
,	O	306-307
8	O	308-309
ml	O	310-312
and	O	313-316
16	O	317-319
ml	O	320-322
.	O	322-323

Thirty	O	324-330
-	O	330-331
six	O	331-334
iopentol	O	335-343
injections	O	344-354
,	O	354-355
35	O	356-358
iohexol	O	359-366
injections	O	367-377
and	O	378-381
37	O	382-384
metrizoate	O	385-395
injections	O	396-406
were	O	407-411
made	O	412-416
.	O	416-417

Frequencies	O	418-429
of	O	430-432
ventricular	B	433-444
fibrillation	I	445-457
were	O	458-462
significantly	O	463-476
lower	O	477-482
(	O	483-484
p	O	484-485
less	O	486-490
than	O	491-495
0	O	496-497
.	O	497-498
05	O	498-500
)	O	500-501
after	O	502-507
iopentol	O	508-516
(	O	517-518
0	O	518-519
%	O	519-520
)	O	520-521
and	O	522-525
iohexol	O	526-533
(	O	534-535
3	O	535-536
%	O	536-537
)	O	537-538
than	O	539-543
after	O	544-549
metrizoate	O	550-560
(	O	561-562
22	O	562-564
%	O	564-565
)	O	565-566
.	O	566-567

Iopentol	O	568-576
and	O	577-580
iohexol	O	581-588
also	O	589-593
produced	O	594-602
significantly	O	603-616
less	O	617-621
decrease	O	622-630
in	O	631-633
aortic	O	634-640
blood	O	641-646
pressure	O	647-655
than	O	656-660
metrizoate	O	661-671
at	O	672-674
the	O	675-678
different	O	679-688
doses	O	689-694
.	O	694-695

Magnetic	O	0-8
resonance	O	9-18
imaging	O	19-26
of	O	27-29
cerebral	O	30-38
venous	B	39-45
thrombosis	I	46-56
secondary	O	57-66
to	O	67-69
"	O	70-71
low	O	71-74
-	O	74-75
dose	O	75-79
"	O	70-71
birth	O	81-86
control	O	87-94
pills	O	95-100
.	O	100-101

The	O	102-105
clinical	O	106-114
and	O	115-118
radiographic	O	119-131
features	O	132-140
of	O	141-143
cerebral	O	144-152
deep	B	153-157
venous	I	158-164
thrombosis	I	165-175
in	O	176-178
a	O	179-180
21	O	181-183
-	O	183-184
year	O	184-188
-	O	183-184
old	O	189-192
white	O	193-198
woman	O	199-204
are	O	205-208
presented	O	209-218
.	O	218-219

This	O	220-224
nulliparous	O	225-236
patient	O	237-244
presented	O	245-254
with	O	255-259
relatively	O	260-270
mild	O	271-275
clinical	O	276-284
symptoms	O	285-293
and	O	294-297
progressing	O	298-309
mental	O	310-316
status	O	317-323
changes	O	324-331
.	O	331-332

The	O	333-336
only	O	337-341
known	O	342-347
risk	O	348-352
factor	O	353-359
was	O	360-363
"	O	364-365
low	O	365-368
-	O	368-369
dose	O	369-373
"	O	364-365
oral	O	375-379
contraceptive	O	380-393
pills	O	394-399
.	O	399-400

The	O	401-404
magnetic	O	405-413
resonance	O	414-423
image	O	424-429
(	O	430-431
MRI	O	431-434
)	O	434-435
showed	O	436-442
increased	O	443-452
signal	O	453-459
intensity	O	460-469
from	O	470-474
the	O	475-478
internal	O	479-487
cerebral	O	488-496
veins	O	497-502
,	O	502-503
vein	O	504-508
of	O	509-511
Galen	O	512-517
,	O	517-518
and	O	519-522
straight	O	523-531
sinus	O	532-537
.	O	537-538

The	O	539-542
diagnosis	O	543-552
was	O	553-556
confirmed	O	557-566
by	O	567-569
arterial	O	570-578
angiography	O	579-590
.	O	590-591

Relation	O	0-8
of	O	9-11
perfusion	O	12-21
defects	O	22-29
observed	O	30-38
with	O	39-43
myocardial	O	44-54
contrast	O	55-63
echocardiography	O	64-80
to	O	81-83
the	O	84-87
severity	O	88-96
of	O	97-99
coronary	B	100-108
stenosis	I	109-117
:	O	117-118
correlation	O	119-130
with	O	131-135
thallium	O	136-144
-	O	144-145
201	O	145-148
single	O	149-155
-	O	155-156
photon	O	156-162
emission	O	163-171
tomography	O	172-182
.	O	182-183

It	O	184-186
has	O	187-190
been	O	191-195
previously	O	196-206
shown	O	207-212
that	O	213-217
myocardial	O	218-228
contrast	O	229-237
echocardiography	O	238-254
is	O	255-257
a	O	258-259
valuable	O	260-268
technique	O	269-278
for	O	279-282
delineating	O	283-294
regions	O	295-302
of	O	303-305
myocardial	O	306-316
underperfusion	O	317-331
secondary	O	332-341
to	O	342-344
coronary	B	345-353
occlusion	I	354-363
and	O	364-367
to	O	368-370
critical	O	371-379
coronary	B	380-388
stenoses	I	389-397
in	O	398-400
the	O	401-404
presence	O	405-413
of	O	414-416
hyperemic	B	417-426
stimulation	O	427-438
.	O	438-439

The	O	440-443
aim	O	444-447
of	O	448-450
this	O	451-455
study	O	456-461
was	O	462-465
to	O	466-468
determine	O	469-478
whether	O	479-486
myocardial	O	487-497
contrast	O	498-506
echocardiography	O	507-523
performed	O	524-533
with	O	534-538
a	O	539-540
stable	O	541-547
solution	O	548-556
of	O	557-559
sonicated	O	560-569
albumin	O	570-577
could	O	578-583
detect	O	584-590
regions	O	591-598
of	O	599-601
myocardial	O	602-612
underperfusion	O	613-627
resulting	O	628-637
from	O	638-642
various	O	643-650
degrees	O	651-658
of	O	659-661
coronary	B	662-670
stenosis	I	671-679
.	O	679-680

The	O	681-684
perfusion	O	685-694
defect	O	695-701
produced	O	702-710
in	O	711-713
16	O	714-716
open	O	717-721
chest	O	722-727
dogs	O	728-732
was	O	733-736
compared	O	737-745
with	O	746-750
the	O	751-754
anatomic	O	755-763
area	O	764-768
at	O	769-771
risk	O	772-776
measured	O	777-785
by	O	786-788
the	O	789-792
postmortem	O	793-803
dual	O	804-808
-	O	808-809
perfusion	O	809-818
technique	O	819-828
and	O	829-832
with	O	833-837
thallium	O	838-846
-	O	846-847
201	O	847-850
single	O	851-857
-	O	857-858
photon	O	858-864
emission	O	865-873
tomography	O	874-884
(	O	885-886
SPECT	O	886-891
)	O	891-892
.	O	892-893

During	O	894-900
a	O	901-902
transient	O	903-912
(	O	913-914
20	O	914-916
-	O	916-917
s	O	917-918
)	O	918-919
coronary	B	920-928
occlusion	I	929-938
,	O	938-939
a	O	940-941
perfusion	O	942-951
defect	O	952-958
was	O	959-962
observed	O	963-971
with	O	972-976
contrast	O	977-985
echocardiography	O	986-1002
in	O	1003-1005
14	O	1006-1008
of	O	1009-1011
the	O	1012-1015
15	O	1016-1018
dogs	O	1019-1023
in	O	1024-1026
which	O	1027-1032
the	O	1033-1036
occlusion	O	1037-1046
was	O	1047-1050
produced	O	1051-1059
.	O	1059-1060

The	O	1061-1064
perfusion	O	1065-1074
defect	O	1075-1081
correlated	O	1082-1092
significantly	O	1093-1106
with	O	1107-1111
the	O	1112-1115
anatomic	O	1116-1124
area	O	1125-1129
at	O	1130-1132
risk	O	1133-1137
(	O	1138-1139
r	O	1139-1140
=	O	1141-1142
0	O	1143-1144
.	O	1144-1145
74	O	1145-1147
;	O	1147-1148
p	O	1149-1150
less	O	1151-1155
than	O	1156-1160
0	O	1161-1162
.	O	1162-1163
002	O	1163-1166
)	O	1166-1167
.	O	1162-1163

During	O	1169-1175
dipyridamole	O	1176-1188
-	O	1188-1189
induced	O	1189-1196
hyperemia	B	1197-1206
,	O	1206-1207
12	O	1208-1210
of	O	1211-1213
the	O	1214-1217
16	O	1218-1220
dogs	O	1221-1225
with	O	1226-1230
a	O	1231-1232
partial	O	1233-1240
coronary	B	1241-1249
stenosis	I	1250-1258
had	O	1259-1262
a	O	1263-1264
visible	O	1265-1272
area	O	1273-1277
of	O	1278-1280
hypoperfusion	O	1281-1294
by	O	1295-1297
contrast	O	1298-1306
echocardiography	O	1307-1323
.	O	1323-1324

The	O	1325-1328
four	O	1329-1333
dogs	O	1334-1338
without	O	1339-1346
a	O	1347-1348
perfusion	O	1349-1358
defect	O	1359-1365
had	O	1366-1369
a	O	1370-1371
stenosis	O	1372-1380
that	O	1381-1385
resulted	O	1386-1394
in	O	1395-1397
a	O	1398-1399
mild	O	1400-1404
(	O	1405-1406
0	O	1406-1407
%	O	1407-1408
to	O	1409-1411
50	O	1412-1414
%	O	1414-1415
)	O	1415-1416
reduction	O	1417-1426
in	O	1427-1429
dipyridamole	O	1430-1442
-	O	1442-1443
induced	O	1443-1450
hyperemia	B	1451-1460
.	O	1460-1461

The	O	1462-1465
size	O	1466-1470
of	O	1471-1473
the	O	1474-1477
perfusion	O	1478-1487
defect	O	1488-1494
during	O	1495-1501
stenosis	O	1502-1510
correlated	O	1511-1521
significantly	O	1522-1535
with	O	1536-1540
the	O	1541-1544
anatomic	O	1545-1553
area	O	1554-1558
at	O	1559-1561
risk	O	1562-1566
(	O	1567-1568
r	O	1568-1569
=	O	1570-1571
0	O	1572-1573
.	O	1573-1574
61	O	1574-1576
;	O	1576-1577
p	O	1578-1579
=	O	1580-1581
0	O	1582-1583
.	O	1583-1584
02	O	1584-1586
)	O	1586-1587
.	O	1583-1584

Thallium	O	1589-1597
-	O	1597-1598
201	O	1598-1601
SPECT	O	1602-1607
demonstrated	O	1608-1620
a	O	1621-1622
perfusion	O	1623-1632
defect	O	1633-1639
in	O	1640-1642
all	O	1643-1646
14	O	1647-1649
dogs	O	1650-1654
analyzed	O	1655-1663
during	O	1664-1670
dipyridamole	O	1671-1683
-	O	1683-1684
induced	O	1684-1691
hyperemia	B	1692-1701
;	O	1701-1702
the	O	1703-1706
size	O	1707-1711
of	O	1712-1714
the	O	1715-1718
perfusion	O	1719-1728
defect	O	1729-1735
correlated	O	1736-1746
with	O	1747-1751
the	O	1752-1755
anatomic	O	1756-1764
area	O	1765-1769
at	O	1770-1772
risk	O	1773-1777
(	O	1778-1779
r	O	1779-1780
=	O	1781-1782
0	O	1783-1784
.	O	1784-1785
58	O	1785-1787
;	O	1787-1788
p	O	1789-1790
less	O	1791-1795
than	O	1796-1800
0	O	1801-1802
.	O	1802-1803
03	O	1803-1805
)	O	1805-1806
and	O	1807-1810
with	O	1811-1815
the	O	1816-1819
perfusion	O	1820-1829
defect	O	1830-1836
by	O	1837-1839
contrast	O	1840-1848
echocardiography	O	1849-1865
(	O	1866-1867
r	O	1867-1868
=	O	1869-1870
0	O	1871-1872
.	O	1872-1873
58	O	1873-1875
;	O	1875-1876
p	O	1877-1878
less	O	1879-1883
than	O	1884-1888
0	O	1889-1890
.	O	1890-1891
03	O	1891-1893
)	O	1893-1894
.	O	1890-1891

Thus	O	1896-1900
,	O	1900-1901
myocardial	O	1902-1912
contrast	O	1913-1921
echocardiography	O	1922-1938
can	O	1939-1942
be	O	1943-1945
used	O	1946-1950
to	O	1951-1953
visualize	O	1954-1963
and	O	1964-1967
quantitate	O	1968-1978
the	O	1979-1982
amount	O	1983-1989
of	O	1990-1992
jeopardized	O	1993-2004
myocardium	O	2005-2015
during	O	2016-2022
moderate	O	2023-2031
to	O	2032-2034
severe	O	2035-2041
degrees	O	2042-2049
of	O	2050-2052
coronary	B	2053-2061
stenosis	I	2062-2070
.	O	2070-2071

The	O	2072-2075
results	O	2076-2083
obtained	O	2084-2092
show	O	2093-2097
a	O	2098-2099
correlation	O	2100-2111
with	O	2112-2116
the	O	2117-2120
anatomic	O	2121-2129
area	O	2130-2134
at	O	2135-2137
risk	O	2138-2142
similar	O	2143-2150
to	O	2151-2153
that	O	2154-2158
obtained	O	2159-2167
with	O	2168-2172
thallium	O	2173-2181
-	O	2181-2182
201	O	2182-2185
SPECT	O	2186-2191
.	O	2191-2192

Potential	O	0-9
deleterious	O	10-21
effect	O	22-28
of	O	29-31
furosemide	O	32-42
in	O	43-45
radiocontrast	O	46-59
nephropathy	B	60-71
.	O	71-72

The	O	73-76
purpose	O	77-84
of	O	85-87
the	O	88-91
study	O	92-97
was	O	98-101
to	O	102-104
determine	O	105-114
the	O	115-118
efficacy	O	119-127
of	O	128-130
furosemide	O	131-141
in	O	142-144
addition	O	145-153
to	O	154-156
intravenous	O	157-168
fluids	O	169-175
in	O	176-178
the	O	179-182
prevention	O	183-193
of	O	194-196
radiocontrast	O	197-210
nephropathy	B	211-222
.	O	222-223

18	O	224-226
patients	O	227-235
,	O	235-236
referred	O	237-245
to	O	246-248
a	O	249-250
radiocontrast	O	251-264
study	O	265-270
,	O	270-271
considered	O	272-282
at	O	283-285
risk	O	286-290
because	O	291-298
of	O	299-301
preexisting	O	302-313
renal	B	314-319
insufficiency	I	320-333
,	O	333-334
were	O	335-339
enrolled	O	340-348
in	O	349-351
a	O	352-353
prospective	O	354-365
,	O	365-366
randomized	O	367-377
,	O	377-378
controlled	O	379-389
trial	O	390-395
,	O	395-396
performed	O	397-406
at	O	407-409
the	O	410-413
secondary	O	414-423
care	O	424-428
center	O	429-435
of	O	436-438
a	O	439-440
1	O	441-442
,	O	442-443
100	O	443-446
-	O	446-447
bed	O	447-450
private	O	451-458
university	O	459-469
hospital	O	470-478
.	O	478-479

In	O	480-482
addition	O	483-491
to	O	492-494
fluids	O	495-501
,	O	501-502
the	O	503-506
treatment	O	507-516
group	O	517-522
received	O	523-531
furosemide	O	532-542
(	O	543-544
mean	O	544-548
dose	O	549-553
110	O	554-557
mg	O	558-560
)	O	560-561
intravenously	O	562-575
30	O	576-578
min	O	579-582
prior	O	583-588
to	O	589-591
the	O	592-595
injection	O	596-605
of	O	606-608
contrast	O	609-617
material	O	618-626
.	O	626-627

The	O	628-631
control	O	632-639
group	O	640-645
received	O	646-654
fluids	O	655-661
(	O	662-663
mean	O	663-667
3	O	668-669
liters	O	670-676
)	O	676-677
.	O	677-678

Radiological	O	679-691
studies	O	692-699
were	O	700-704
mostly	O	705-711
angiographies	O	712-725
performed	O	726-735
with	O	736-740
both	O	741-745
ionic	O	746-751
and	O	752-755
non	O	756-759
-	O	759-760
ionic	O	760-765
contrast	O	766-774
material	O	775-783
,	O	783-784
at	O	785-787
an	O	788-790
average	O	791-798
dose	O	799-803
of	O	804-806
245	O	807-810
ml	O	811-813
.	O	813-814

Renal	B	815-820
function	I	821-829
significantly	I	830-843
deteriorated	I	844-856
in	O	857-859
the	O	860-863
group	O	864-869
pretreated	O	870-880
with	O	881-885
furosemide	O	886-896
(	O	897-898
p	O	898-899
<	O	900-901
0	O	902-903
.	O	903-904
005	O	904-907
by	O	908-910
ANOVA	O	911-916
)	O	916-917
,	O	917-918
with	O	919-923
a	O	924-925
rise	O	926-930
in	O	931-933
serum	O	934-939
creatinine	O	940-950
from	O	951-955
145	O	956-959
+	O	960-961
/	O	961-962
-	O	962-963
13	O	964-966
to	O	967-969
182	O	970-973
+	O	974-975
/	O	975-976
-	O	976-977
16	O	978-980
mumol	O	981-986
/	O	986-987
l	O	985-986
at	O	989-991
24	O	992-994
h	O	995-996
,	O	996-997
while	O	998-1003
no	O	1004-1006
change	O	1007-1013
occurred	O	1014-1022
in	O	1023-1025
the	O	1026-1029
control	O	1030-1037
group	O	1038-1043
(	O	1044-1045
from	O	1045-1049
141	O	1050-1053
+	O	1054-1055
/	O	1055-1056
-	O	1056-1057
6	O	1058-1059
to	O	1060-1062
142	O	1063-1066
+	O	1067-1068
/	O	1068-1069
-	O	1069-1070
7	O	1071-1072
mumol	O	1073-1078
/	O	1078-1079
l	O	1077-1078
)	O	1080-1081
.	O	1081-1082

Renal	B	1083-1088
failure	I	1089-1096
was	O	1097-1100
associated	O	1101-1111
with	O	1112-1116
weight	B	1117-1123
loss	I	1124-1128
in	O	1129-1131
the	O	1132-1135
furosemide	O	1136-1146
-	O	1146-1147
treated	O	1147-1154
group	O	1155-1160
.	O	1160-1161

Furosemide	O	1162-1172
may	O	1173-1176
be	O	1177-1179
deleterious	O	1180-1191
in	O	1192-1194
the	O	1195-1198
prevention	O	1199-1209
of	O	1210-1212
radiocontrast	O	1213-1226
nephropathy	B	1227-1238
.	O	1238-1239

The	O	0-3
renal	O	4-9
pathology	O	10-19
in	O	20-22
a	O	23-24
case	O	25-29
of	O	30-32
lithium	O	33-40
-	O	40-41
induced	O	41-48
diabetes	B	49-57
insipidus	I	58-67
.	O	67-68

A	O	69-70
case	O	71-75
of	O	76-78
lithium	O	79-86
-	O	86-87
induced	O	87-94
diabetes	B	95-103
insipidus	I	104-113
is	O	114-116
reported	O	117-125
.	O	125-126

At	O	127-129
necropsy	O	130-138
microscopy	O	139-149
shoed	O	150-155
unique	O	156-162
and	O	163-166
extensive	O	167-176
damage	O	177-183
to	O	184-186
cells	O	187-192
lining	O	193-199
the	O	200-203
distal	O	204-210
nephron	O	211-218
.	O	218-219

It	O	220-222
is	O	223-225
suggested	O	226-235
that	O	236-240
these	O	241-246
changes	O	247-254
represent	O	255-264
a	O	265-266
specific	O	267-275
toxic	O	276-281
effect	O	282-288
of	O	289-291
lithium	O	292-299
,	O	299-300
reported	O	301-309
here	O	310-314
for	O	315-318
the	O	319-322
first	O	323-328
time	O	329-333
in	O	334-336
man	O	337-340
.	O	340-341

Etiologic	O	0-9
factors	O	10-17
in	O	18-20
the	O	21-24
pathogenesis	O	25-37
of	O	38-40
liver	B	41-46
tumors	I	47-53
associated	O	54-64
with	O	65-69
oral	O	70-74
contraceptives	O	75-89
.	O	89-90

Within	O	91-97
the	O	98-101
last	O	102-106
several	O	107-114
years	O	115-120
,	O	120-121
previously	O	122-132
rare	O	133-137
liver	B	138-143
tumors	I	144-150
have	O	151-155
been	O	156-160
seen	O	161-165
in	O	166-168
young	O	169-174
women	O	175-180
using	O	181-186
oral	O	187-191
contraceptive	O	192-205
steroids	O	206-214
.	O	214-215

The	O	216-219
Registry	O	220-228
for	O	229-232
Liver	B	233-238
Tumors	I	239-245
Associated	O	246-256
with	O	257-261
Oral	O	262-266
Contraceptives	O	267-281
at	O	282-284
the	O	285-288
University	O	289-299
of	O	300-302
California	O	303-313
,	O	313-314
Irvine	O	315-321
,	O	321-322
has	O	323-326
clearly	O	327-334
identified	O	335-345
27	O	346-348
cases	O	349-354
.	O	354-355

The	O	356-359
recent	O	360-366
literature	O	367-377
contains	O	378-386
44	O	387-389
case	O	390-394
reports	O	395-402
.	O	402-403

Common	O	404-410
to	O	411-413
these	O	414-419
71	O	420-422
cases	O	423-428
has	O	429-432
been	O	433-437
a	O	438-439
histopathologic	O	440-455
diagnosis	O	456-465
of	O	466-468
focal	B	469-474
nodular	I	475-482
hyperplasia	I	483-494
,	O	494-495
adenoma	B	496-503
,	O	503-504
hamartoma	B	505-514
,	O	514-515
and	O	516-519
hepatoma	B	520-528
.	O	528-529

Significant	O	530-541
statistical	O	542-553
etiologic	O	554-563
factors	O	564-571
include	O	572-579
prolonged	O	580-589
uninterrupted	O	590-603
usage	O	604-609
of	O	610-612
oral	O	613-617
contraceptive	O	618-631
steroids	O	632-640
.	O	640-641

Eight	O	642-647
deaths	O	648-654
and	O	655-658
liver	O	659-664
rupture	B	665-672
in	O	673-675
18	O	676-678
patients	O	679-687
attest	O	688-694
to	O	695-697
the	O	698-701
seriousness	O	702-713
of	O	714-716
this	O	717-721
new	O	722-725
potentially	O	726-737
lethal	O	738-744
adverse	O	745-752
phenomenon	O	753-763
.	O	763-764

Graft	B	0-5
-	I	5-6
versus	I	6-12
-	I	5-6
host	I	13-17
disease	I	18-25
prophylaxis	O	26-37
with	O	38-42
everolimus	O	43-53
and	O	54-57
tacrolimus	O	58-68
is	O	69-71
associated	O	72-82
with	O	83-87
a	O	88-89
high	O	90-94
incidence	O	95-104
of	O	105-107
sinusoidal	B	108-118
obstruction	I	119-130
syndrome	I	131-139
and	O	140-143
microangiopathy	B	144-159
:	O	159-160
results	O	161-168
of	O	169-171
the	O	172-175
EVTAC	O	176-181
trial	O	182-187
.	O	187-188

A	O	189-190
calcineurin	O	191-202
inhibitor	O	203-212
combined	O	213-221
with	O	222-226
methotrexate	O	227-239
is	O	240-242
the	O	243-246
standard	O	247-255
prophylaxis	O	256-267
for	O	268-271
graft	B	272-277
-	I	277-278
versus	I	278-284
-	I	277-278
host	I	285-289
disease	I	290-297
(	O	298-299
GVHD	B	299-303
)	O	303-304
after	O	305-310
allogeneic	O	311-321
hematopoietic	O	322-335
stem	O	336-340
cell	O	341-345
transplantation	O	346-361
(	O	362-363
HSCT	O	363-367
)	O	367-368
.	O	368-369

Everolimus	O	370-380
,	O	380-381
a	O	382-383
derivative	O	384-394
of	O	395-397
sirolimus	O	398-407
,	O	407-408
seems	O	409-414
to	O	415-417
mediate	O	418-425
antileukemia	O	426-438
effects	O	439-446
.	O	446-447

We	O	448-450
report	O	451-457
on	O	458-460
a	O	461-462
combination	O	463-474
of	O	475-477
everolimus	O	478-488
and	O	489-492
tacrolimus	O	493-503
in	O	504-506
24	O	507-509
patients	O	510-518
(	O	519-520
median	O	520-526
age	O	527-530
,	O	530-531
62	O	532-534
years	O	535-540
)	O	540-541
with	O	542-546
either	O	547-553
myelodysplastic	B	554-569
syndrome	I	570-578
(	O	579-580
MDS	B	580-583
;	O	583-584
n	O	585-586
=	O	587-588
17	O	589-591
)	O	591-592
or	O	593-595
acute	B	596-601
myeloid	I	602-609
leukemia	I	610-618
(	O	619-620
AML	B	620-623
;	O	623-624
n	O	625-626
=	O	627-628
7	O	629-630
)	O	630-631
undergoing	O	632-642
intensive	O	643-652
conditioning	O	653-665
followed	O	666-674
by	O	675-677
HSCT	O	678-682
from	O	683-687
related	O	688-695
(	O	696-697
n	O	697-698
=	O	699-700
4	O	701-702
)	O	702-703
or	O	704-706
unrelated	O	707-716
(	O	717-718
n	O	718-719
=	O	720-721
20	O	722-724
)	O	724-725
donors	O	726-732
.	O	732-733

All	O	734-737
patients	O	738-746
engrafted	O	747-756
,	O	756-757
and	O	758-761
only	O	762-766
1	O	767-768
patient	O	769-776
experienced	O	777-788
grade	O	789-794
IV	O	795-797
mucositis	B	798-807
.	O	807-808

Nine	O	809-813
patients	O	814-822
(	O	823-824
37	O	824-826
%	O	826-827
)	O	827-828
developed	O	829-838
acute	O	839-844
grade	O	845-850
II	O	851-853
-	O	853-854
IV	O	854-856
GVHD	B	857-861
,	O	861-862
and	O	863-866
11	O	867-869
of	O	870-872
17	O	873-875
evaluable	O	876-885
patients	O	886-894
(	O	895-896
64	O	896-898
%	O	898-899
)	O	899-900
developed	O	901-910
chronic	O	911-918
extensive	O	919-928
GVHD	B	929-933
.	O	933-934

Transplantation	B	935-950
-	I	950-951
associated	I	951-961
microangiopathy	I	962-977
(	O	978-979
TMA	B	979-982
)	O	982-983
occurred	O	984-992
in	O	993-995
7	O	996-997
patients	O	998-1006
(	O	1007-1008
29	O	1008-1010
%	O	1010-1011
)	O	1011-1012
,	O	1012-1013
with	O	1014-1018
2	O	1019-1020
cases	O	1021-1026
of	O	1027-1029
acute	B	1030-1035
renal	I	1036-1041
failure	I	1042-1049
.	O	1049-1050

The	O	1051-1054
study	O	1055-1060
was	O	1061-1064
terminated	O	1065-1075
prematurely	O	1076-1087
because	O	1088-1095
an	O	1096-1098
additional	O	1099-1109
6	O	1110-1111
patients	O	1112-1120
(	O	1121-1122
25	O	1122-1124
%	O	1124-1125
)	O	1125-1126
developed	O	1127-1136
sinusoidal	B	1137-1147
obstruction	I	1148-1159
syndrome	I	1160-1168
(	O	1169-1170
SOS	B	1170-1173
)	O	1173-1174
,	O	1174-1175
which	O	1176-1181
was	O	1182-1185
fatal	O	1186-1191
in	O	1192-1194
2	O	1195-1196
cases	O	1197-1202
.	O	1202-1203

With	O	1204-1208
a	O	1209-1210
median	O	1211-1217
follow	O	1218-1224
-	O	1224-1225
up	O	1225-1227
of	O	1228-1230
26	O	1231-1233
months	O	1234-1240
,	O	1240-1241
the	O	1242-1245
2	O	1246-1247
-	O	1247-1248
year	O	1248-1252
overall	O	1253-1260
survival	O	1261-1269
rate	O	1270-1274
was	O	1275-1278
47	O	1279-1281
%	O	1281-1282
.	O	1282-1283

Although	O	1284-1292
this	O	1293-1297
new	O	1298-1301
combination	O	1302-1313
appears	O	1314-1321
to	O	1322-1324
be	O	1325-1327
effective	O	1328-1337
as	O	1338-1340
a	O	1341-1342
prophylactic	O	1343-1355
regimen	O	1356-1363
for	O	1364-1367
acute	O	1368-1373
GVHD	B	1374-1378
,	O	1378-1379
the	O	1380-1383
incidence	O	1384-1393
of	O	1394-1396
TMA	B	1397-1400
and	O	1401-1404
SOS	B	1405-1408
is	O	1409-1411
considerably	O	1412-1424
higher	O	1425-1431
than	O	1432-1436
seen	O	1437-1441
with	O	1442-1446
other	O	1447-1452
regimens	O	1453-1461
.	O	1461-1462

Effect	O	0-6
of	O	7-9
some	O	10-14
convulsants	O	15-26
on	O	27-29
the	O	30-33
protective	O	34-44
activity	O	45-53
of	O	54-56
loreclezole	O	57-68
and	O	69-72
its	O	73-76
combinations	O	77-89
with	O	90-94
valproate	O	95-104
or	O	105-107
clonazepam	O	108-118
in	O	119-121
amygdala	O	122-130
-	O	130-131
kindled	O	131-138
rats	O	139-143
.	O	143-144

Loreclezole	O	145-156
(	O	157-158
5	O	158-159
mg	O	160-162
/	O	162-163
kg	O	163-165
)	O	165-166
exerted	O	167-174
a	O	175-176
significant	O	177-188
protective	O	189-199
action	O	200-206
in	O	207-209
amygdala	O	210-218
-	O	218-219
kindled	O	219-226
rats	O	227-231
,	O	231-232
reducing	O	233-241
both	O	242-246
seizure	B	247-254
and	O	255-258
afterdischarge	O	259-273
durations	O	274-283
.	O	283-284

The	O	285-288
combinations	O	289-301
of	O	302-304
loreclezole	O	305-316
(	O	317-318
2	O	318-319
.	O	319-320
5	O	320-321
mg	O	322-324
/	O	324-325
kg	O	325-327
)	O	327-328
with	O	329-333
valproate	O	334-343
,	O	343-344
clonazepam	O	345-355
,	O	355-356
or	O	357-359
carbamazepine	O	360-373
(	O	374-375
applied	O	375-382
at	O	383-385
their	O	386-391
subprotective	O	392-405
doses	O	406-411
)	O	411-412
also	O	413-417
exhibited	O	418-427
antiseizure	O	428-439
effect	O	440-446
in	O	447-449
this	O	450-454
test	O	455-459
.	O	459-460

However	O	461-468
,	O	468-469
only	O	470-474
two	O	475-478
first	O	479-484
combinations	O	485-497
occurred	O	498-506
to	O	507-509
be	O	510-512
of	O	513-515
pharmacodynamic	O	516-531
nature	O	532-538
.	O	538-539

Among	O	540-545
several	O	546-553
chemoconvulsants	O	554-570
,	O	570-571
bicuculline	O	572-583
,	O	583-584
N	O	585-586
-	O	586-587
methyl	O	587-593
-	O	586-587
D	O	594-595
-	O	586-587
aspartic	O	596-604
acid	O	605-609
and	O	610-613
BAY	O	614-617
k	O	618-619
-	O	619-620
8644	O	620-624
(	O	625-626
the	O	626-629
opener	O	630-636
of	O	637-639
L	O	640-641
-	O	641-642
type	O	642-646
calcium	O	647-654
channels	O	655-663
)	O	663-664
reversed	O	665-673
the	O	674-677
protective	O	678-688
activity	O	689-697
of	O	698-700
loreclezole	O	701-712
alone	O	713-718
and	O	719-722
its	O	723-726
combination	O	727-738
with	O	739-743
valproate	O	744-753
.	O	753-754

On	O	755-757
the	O	758-761
other	O	762-767
hand	O	768-772
,	O	772-773
bicuculline	O	774-785
,	O	785-786
aminophylline	O	787-800
and	O	801-804
BAY	O	805-808
k	O	809-810
-	O	810-811
8644	O	811-815
inhibited	O	816-825
the	O	826-829
anticonvulsive	O	830-844
action	O	845-851
of	O	852-854
loreclezole	O	855-866
combined	O	867-875
with	O	876-880
clonazepam	O	881-891
.	O	891-892

The	O	893-896
results	O	897-904
support	O	905-912
the	O	913-916
hypothesis	O	917-927
that	O	928-932
the	O	933-936
protective	O	937-947
activity	O	948-956
of	O	957-959
loreclezole	O	960-971
and	O	972-975
its	O	976-979
combinations	O	980-992
with	O	993-997
other	O	998-1003
antiepileptics	O	1004-1018
may	O	1019-1022
involve	O	1023-1030
potentiation	O	1031-1043
of	O	1044-1046
GABAergic	O	1047-1056
neurotransmission	O	1057-1074
and	O	1075-1078
blockade	O	1079-1087
of	O	1088-1090
L	O	1091-1092
-	O	1092-1093
type	O	1093-1097
of	O	1098-1100
calcium	O	1101-1108
channels	O	1109-1117
.	O	1117-1118

Acute	B	0-5
liver	I	6-11
failure	I	12-19
with	O	20-24
concurrent	O	25-35
bupropion	O	36-45
and	O	46-49
carbimazole	O	50-61
therapy	O	62-69
.	O	69-70

OBJECTIVE	O	71-80
:	O	80-81
To	O	82-84
report	O	85-91
a	O	92-93
case	O	94-98
of	O	99-101
fatal	O	102-107
liver	B	108-113
failure	I	114-121
possibly	O	122-130
associated	O	131-141
with	O	142-146
concurrent	O	147-157
use	O	158-161
of	O	162-164
bupropion	O	165-174
and	O	175-178
carbimazole	O	179-190
.	O	190-191

CASE	O	192-196
SUMMARY	O	197-204
:	O	204-205
A	O	206-207
41	O	208-210
-	O	210-211
year	O	211-215
-	O	210-211
old	O	216-219
Chinese	O	220-227
man	O	228-231
with	O	232-236
a	O	237-238
history	O	239-246
of	O	247-249
hyperthyroidism	B	250-265
had	O	266-269
been	O	270-274
treated	O	275-282
with	O	283-287
carbimazole	O	288-299
and	O	300-303
propranolol	O	304-315
for	O	316-319
the	O	320-323
past	O	324-328
5	O	329-330
years	O	331-336
.	O	336-337

He	O	338-340
received	O	341-349
a	O	350-351
10	O	352-354
-	O	354-355
day	O	355-358
course	O	359-365
of	O	366-368
bupropion	O	369-378
as	O	379-381
an	O	382-384
aid	O	385-388
for	O	389-392
smoking	O	393-400
cessation	O	401-410
10	O	411-413
weeks	O	414-419
prior	O	420-425
to	O	426-428
presentation	O	429-441
.	O	441-442

He	O	443-445
developed	O	446-455
acute	B	456-461
liver	I	462-467
failure	I	468-475
with	O	476-480
rapid	O	481-486
deterioration	O	487-500
of	O	501-503
renal	O	504-509
function	O	510-518
.	O	518-519

Liver	O	520-525
biopsy	O	526-532
showed	O	533-539
evidence	O	540-548
of	O	549-551
nonspecific	O	552-563
drug	B	564-568
-	I	568-569
induced	I	569-576
acute	I	577-582
liver	I	583-588
injury	I	589-595
.	O	595-596

His	O	597-600
condition	O	601-610
was	O	611-614
further	O	615-622
complicated	O	623-634
by	O	635-637
sepsis	B	638-644
and	O	645-648
coagulopathy	B	649-661
.	O	661-662

Death	O	663-668
resulted	O	669-677
19	O	678-680
days	O	681-685
after	O	686-691
the	O	692-695
onset	O	696-701
of	O	702-704
symptoms	O	705-713
.	O	713-714

The	O	715-718
likelihood	O	719-729
that	O	730-734
bupropion	O	735-744
induced	O	745-752
hepatotoxicity	B	753-767
in	O	768-770
our	O	771-774
patient	O	775-782
was	O	783-786
possible	O	787-795
,	O	795-796
based	O	797-802
on	O	803-805
the	O	806-809
Naranjo	O	810-817
probability	O	818-829
scale	O	830-835
.	O	835-836

DISCUSSION	O	837-847
:	O	847-848
Although	O	849-857
there	O	858-863
is	O	864-866
increasing	O	867-877
evidence	O	878-886
of	O	887-889
hepatotoxicity	B	890-904
induced	O	905-912
by	O	913-915
bupropion	O	916-925
,	O	925-926
this	O	927-931
is	O	932-934
the	O	935-938
first	O	939-944
case	O	945-949
of	O	950-952
fatality	O	953-961
that	O	962-966
could	O	967-972
have	O	973-977
resulted	O	978-986
from	O	987-991
acute	B	992-997
liver	I	998-1003
failure	I	1004-1011
in	O	1012-1014
a	O	1015-1016
patient	O	1017-1024
receiving	O	1025-1034
bupropion	O	1035-1044
while	O	1045-1050
on	O	1051-1053
concomitant	O	1054-1065
treatment	O	1066-1075
with	O	1076-1080
carbimazole	O	1081-1092
.	O	1092-1093

CONCLUSIONS	O	1094-1105
:	O	1105-1106
Clinicians	O	1107-1117
should	O	1118-1124
be	O	1125-1127
aware	O	1128-1133
of	O	1134-1136
the	O	1137-1140
possibility	O	1141-1152
of	O	1153-1155
acute	B	1156-1161
liver	I	1162-1167
insult	I	1168-1174
induced	O	1175-1182
by	O	1183-1185
bupropion	O	1186-1195
given	O	1196-1201
concurrently	O	1202-1214
with	O	1215-1219
other	O	1220-1225
hepatotoxic	B	1226-1237
drugs	O	1238-1243
.	O	1243-1244

Long	O	0-4
term	O	5-9
hormone	O	10-17
therapy	O	18-25
for	O	26-29
perimenopausal	O	30-44
and	O	45-48
postmenopausal	O	49-63
women	O	64-69
.	O	69-70

BACKGROUND	O	71-81
:	O	81-82
Hormone	O	83-90
therapy	O	91-98
(	O	99-100
HT	O	100-102
)	O	102-103
is	O	104-106
widely	O	107-113
used	O	114-118
for	O	119-122
controlling	O	123-134
menopausal	O	135-145
symptoms	O	146-154
and	O	155-158
has	O	159-162
also	O	163-167
been	O	168-172
used	O	173-177
for	O	178-181
the	O	182-185
management	O	186-196
and	O	197-200
prevention	O	201-211
of	O	212-214
cardiovascular	B	215-229
disease	I	230-237
,	O	237-238
osteoporosis	B	239-251
and	O	252-255
dementia	B	256-264
in	O	265-267
older	O	268-273
women	O	274-279
.	O	279-280

This	O	281-285
is	O	286-288
an	O	289-291
updated	O	292-299
version	O	300-307
of	O	308-310
the	O	311-314
original	O	315-323
Cochrane	O	324-332
review	O	333-339
first	O	340-345
published	O	346-355
in	O	356-358
2005	O	359-363
.	O	363-364

OBJECTIVES	O	365-375
:	O	375-376
To	O	377-379
assess	O	380-386
the	O	387-390
effect	O	391-397
of	O	398-400
long	O	401-405
-	O	405-406
term	O	406-410
HT	O	411-413
on	O	414-416
mortality	O	417-426
,	O	426-427
cardiovascular	O	428-442
outcomes	O	443-451
,	O	451-452
cancer	B	453-459
,	O	459-460
gallbladder	B	461-472
disease	I	473-480
,	O	480-481
cognition	O	482-491
,	O	491-492
fractures	B	493-502
and	O	503-506
quality	O	507-514
of	O	515-517
life	O	518-522
.	O	522-523

SEARCH	O	524-530
STRATEGY	O	531-539
:	O	539-540
We	O	541-543
searched	O	544-552
the	O	553-556
following	O	557-566
databases	O	567-576
to	O	577-579
November	O	580-588
2007	O	589-593
:	O	593-594
Trials	O	595-601
Register	O	602-610
of	O	611-613
the	O	614-617
Cochrane	O	618-626
Menstrual	B	627-636
Disorders	I	637-646
and	O	647-650
Subfertility	O	651-663
Group	O	664-669
,	O	669-670
Cochrane	O	671-679
Central	O	680-687
Register	O	688-696
of	O	697-699
Controlled	O	700-710
Trials	O	711-717
,	O	717-718
MEDLINE	O	719-726
,	O	726-727
EMBASE	O	728-734
,	O	734-735
Biological	O	736-746
Abstracts	O	747-756
.	O	756-757

Also	O	758-762
relevant	O	763-771
non	O	772-775
-	O	775-776
indexed	O	776-783
journals	O	784-792
and	O	793-796
conference	O	797-807
abstracts	O	808-817
.	O	817-818

SELECTION	O	819-828
CRITERIA	O	829-837
:	O	837-838
Randomised	O	839-849
double	O	850-856
-	O	856-857
blind	O	857-862
trials	O	863-869
of	O	870-872
HT	O	873-875
versus	O	876-882
placebo	O	883-890
,	O	890-891
taken	O	892-897
for	O	898-901
at	O	902-904
least	O	905-910
one	O	911-914
year	O	915-919
by	O	920-922
perimenopausal	O	923-937
or	O	938-940
postmenopausal	O	941-955
women	O	956-961
.	O	961-962

HT	O	963-965
included	O	966-974
oestrogens	O	975-985
,	O	985-986
with	O	987-991
or	O	992-994
without	O	995-1002
progestogens	O	1003-1015
,	O	1015-1016
via	O	1017-1020
oral	O	1021-1025
,	O	1025-1026
transdermal	O	1027-1038
,	O	1038-1039
subcutaneous	O	1040-1052
or	O	1053-1055
transnasal	O	1056-1066
routes	O	1067-1073
.	O	1073-1074

DATA	O	1075-1079
COLLECTION	O	1080-1090
AND	O	1091-1094
ANALYSIS	O	1095-1103
:	O	1103-1104
Two	O	1105-1108
authors	O	1109-1116
independently	O	1117-1130
assessed	O	1131-1139
trial	O	1140-1145
quality	O	1146-1153
and	O	1154-1157
extracted	O	1158-1167
data	O	1168-1172
.	O	1172-1173

MAIN	O	1174-1178
RESULTS	O	1179-1186
:	O	1186-1187
Nineteen	O	1188-1196
trials	O	1197-1203
involving	O	1204-1213
41	O	1214-1216
,	O	1216-1217
904	O	1217-1220
women	O	1221-1226
were	O	1227-1231
included	O	1232-1240
.	O	1240-1241

In	O	1242-1244
relatively	O	1245-1255
healthy	O	1256-1263
women	O	1264-1269
,	O	1269-1270
combined	O	1271-1279
continuous	O	1280-1290
HT	O	1291-1293
significantly	O	1294-1307
increased	O	1308-1317
the	O	1318-1321
risk	O	1322-1326
of	O	1327-1329
venous	B	1330-1336
thrombo	I	1337-1344
-	I	1344-1345
embolism	I	1345-1353
or	O	1354-1356
coronary	O	1357-1365
event	O	1366-1371
(	O	1372-1373
after	O	1373-1378
one	O	1379-1382
year	O	1383-1387
'	O	1387-1388
s	O	1388-1389
use	O	1390-1393
)	O	1393-1394
,	O	1394-1395
stroke	B	1396-1402
(	O	1403-1404
after	O	1404-1409
three	O	1410-1415
years	O	1416-1421
)	O	1421-1422
,	O	1422-1423
breast	B	1424-1430
cancer	I	1431-1437
and	O	1438-1441
gallbladder	B	1442-1453
disease	I	1454-1461
.	O	1461-1462

Long	O	1463-1467
-	O	1467-1468
term	O	1468-1472
oestrogen	O	1473-1482
-	O	1482-1483
only	O	1483-1487
HT	O	1488-1490
significantly	O	1491-1504
increased	O	1505-1514
the	O	1515-1518
risk	O	1519-1523
of	O	1524-1526
venous	B	1527-1533
thrombo	I	1534-1541
-	I	1541-1542
embolism	I	1542-1550
,	O	1550-1551
stroke	B	1552-1558
and	O	1559-1562
gallbladder	B	1563-1574
disease	I	1575-1582
(	O	1583-1584
after	O	1584-1589
one	O	1590-1593
to	O	1594-1596
two	O	1597-1600
years	O	1601-1606
,	O	1606-1607
three	O	1608-1613
years	O	1614-1619
and	O	1620-1623
seven	O	1624-1629
years	O	1630-1635
'	O	1635-1636
use	O	1637-1640
respectively	O	1641-1653
)	O	1653-1654
,	O	1654-1655
but	O	1656-1659
did	O	1660-1663
not	O	1664-1667
significantly	O	1668-1681
increase	O	1682-1690
the	O	1691-1694
risk	O	1695-1699
of	O	1700-1702
breast	B	1703-1709
cancer	I	1710-1716
.	O	1716-1717

The	O	1718-1721
only	O	1722-1726
statistically	O	1727-1740
significant	O	1741-1752
benefits	O	1753-1761
of	O	1762-1764
HT	O	1765-1767
were	O	1768-1772
a	O	1773-1774
decreased	O	1775-1784
incidence	O	1785-1794
of	O	1795-1797
fractures	B	1798-1807
and	O	1808-1811
(	O	1812-1813
for	O	1813-1816
combined	O	1817-1825
HT	O	1826-1828
)	O	1828-1829
colon	B	1830-1835
cancer	I	1836-1842
,	O	1842-1843
with	O	1844-1848
long	O	1849-1853
-	O	1853-1854
term	O	1854-1858
use	O	1859-1862
.	O	1862-1863

Among	O	1864-1869
women	O	1870-1875
aged	O	1876-1880
over	O	1881-1885
65	O	1886-1888
who	O	1889-1892
were	O	1893-1897
relatively	O	1898-1908
healthy	O	1909-1916
(	O	1917-1918
i	O	1918-1919
.	O	1919-1920
e	O	1920-1921
.	O	1919-1920

generally	O	1923-1932
fit	O	1933-1936
,	O	1936-1937
without	O	1938-1945
overt	O	1946-1951
disease	O	1952-1959
)	O	1959-1960
and	O	1961-1964
taking	O	1965-1971
continuous	O	1972-1982
combined	O	1983-1991
HT	O	1992-1994
,	O	1994-1995
there	O	1996-2001
was	O	2002-2005
a	O	2006-2007
statistically	O	2008-2021
significant	O	2022-2033
increase	O	2034-2042
in	O	2043-2045
the	O	2046-2049
incidence	O	2050-2059
of	O	2060-2062
dementia	B	2063-2071
.	O	2071-2072

Among	O	2073-2078
women	O	2079-2084
with	O	2085-2089
cardiovascular	B	2090-2104
disease	I	2105-2112
,	O	2112-2113
long	O	2114-2118
-	O	2118-2119
term	O	2119-2123
use	O	2124-2127
of	O	2128-2130
combined	O	2131-2139
continuous	O	2140-2150
HT	O	2151-2153
significantly	O	2154-2167
increased	O	2168-2177
the	O	2178-2181
risk	O	2182-2186
of	O	2187-2189
venous	B	2190-2196
thrombo	I	2197-2204
-	I	2204-2205
embolism	I	2205-2213
.	O	2213-2214
One	O	2214-2217
trial	O	2218-2223
analysed	O	2224-2232
subgroups	O	2233-2242
of	O	2243-2245
2839	O	2246-2250
relatively	O	2251-2261
healthy	O	2262-2269
50	O	2270-2272
to	O	2273-2275
59	O	2276-2278
year	O	2279-2283
old	O	2284-2287
women	O	2288-2293
taking	O	2294-2300
combined	O	2301-2309
continuous	O	2310-2320
HT	O	2321-2323
and	O	2324-2327
1637	O	2328-2332
taking	O	2333-2339
oestrogen	O	2340-2349
-	O	2349-2350
only	O	2350-2354
HT	O	2355-2357
,	O	2357-2358
versus	O	2359-2365
similar	O	2366-2373
-	O	2373-2374
sized	O	2374-2379
placebo	O	2380-2387
groups	O	2388-2394
.	O	2394-2395

The	O	2396-2399
only	O	2400-2404
significantly	O	2405-2418
increased	O	2419-2428
risk	O	2429-2433
reported	O	2434-2442
was	O	2443-2446
for	O	2447-2450
venous	B	2451-2457
thrombo	I	2458-2465
-	I	2465-2466
embolism	I	2466-2474
in	O	2475-2477
women	O	2478-2483
taking	O	2484-2490
combined	O	2491-2499
continuous	O	2500-2510
HT	O	2511-2513
:	O	2513-2514
their	O	2515-2520
absolute	O	2521-2529
risk	O	2530-2534
remained	O	2535-2543
low	O	2544-2547
,	O	2547-2548
at	O	2549-2551
less	O	2552-2556
than	O	2557-2561
1	O	2562-2563
/	O	2563-2564
500	O	2564-2567
.	O	2567-2568

However	O	2569-2576
,	O	2576-2577
this	O	2578-2582
study	O	2583-2588
was	O	2589-2592
not	O	2593-2596
powered	O	2597-2604
to	O	2605-2607
detect	O	2608-2614
differences	O	2615-2626
between	O	2627-2634
groups	O	2635-2641
of	O	2642-2644
younger	O	2645-2652
women	O	2653-2658
.	O	2658-2659

AUTHORS	O	2660-2667
'	O	2667-2668
CONCLUSIONS	O	2669-2680
:	O	2680-2681
HT	O	2682-2684
is	O	2685-2687
not	O	2688-2691
indicated	O	2692-2701
for	O	2702-2705
the	O	2706-2709
routine	O	2710-2717
management	O	2718-2728
of	O	2729-2731
chronic	O	2732-2739
disease	O	2740-2747
.	O	2747-2748

We	O	2749-2751
need	O	2752-2756
more	O	2757-2761
evidence	O	2762-2770
on	O	2771-2773
the	O	2774-2777
safety	O	2778-2784
of	O	2785-2787
HT	O	2788-2790
for	O	2791-2794
menopausal	O	2795-2805
symptom	O	2806-2813
control	O	2814-2821
,	O	2821-2822
though	O	2823-2829
short	O	2830-2835
-	O	2835-2836
term	O	2836-2840
use	O	2841-2844
appears	O	2845-2852
to	O	2853-2855
be	O	2856-2858
relatively	O	2859-2869
safe	O	2870-2874
for	O	2875-2878
healthy	O	2879-2886
younger	O	2887-2894
women	O	2895-2900
.	O	2900-2901

Passage	O	0-7
of	O	8-10
mannitol	O	11-19
into	O	20-24
the	O	25-28
brain	O	29-34
around	O	35-41
gliomas	B	42-49
:	O	49-50
a	O	51-52
potential	O	53-62
cause	O	63-68
of	O	69-71
rebound	O	72-79
phenomenon	O	80-90
.	O	90-91

A	O	92-93
study	O	94-99
on	O	100-102
21	O	103-105
patients	O	106-114
.	O	114-115

AIM	O	116-119
:	O	119-120
Widespread	O	121-131
use	O	132-135
of	O	136-138
mannitol	O	139-147
to	O	148-150
reduce	O	151-157
brain	B	158-163
edema	I	164-169
and	O	170-173
lower	O	174-179
elevated	B	180-188
ICP	I	189-192
in	O	193-195
brain	B	196-201
tumor	I	202-207
patients	O	208-216
continues	O	217-226
to	O	227-229
be	O	230-232
afflicted	O	233-242
by	O	243-245
the	O	246-249
so	O	250-252
-	O	252-253
called	O	253-259
rebound	O	260-267
phenomenon	O	268-278
.	O	278-279

Leakage	O	280-287
of	O	288-290
mannitol	O	291-299
into	O	300-304
the	O	305-308
brain	O	309-314
parenchyma	O	315-325
through	O	326-333
an	O	334-336
altered	O	337-344
BBB	O	345-348
and	O	349-352
secondary	O	353-362
reversal	O	363-371
of	O	372-374
osmotic	O	375-382
gradient	O	383-391
is	O	392-394
considered	O	395-405
the	O	406-409
major	O	410-415
cause	O	416-421
of	O	422-424
rebound	O	425-432
.	O	433-434

This	O	435-439
has	O	440-443
only	O	444-448
been	O	449-453
demonstrated	O	454-466
experimentally	O	467-481
in	O	482-484
animals	O	485-492
.	O	492-493

As	O	494-496
a	O	497-498
contribution	O	499-511
to	O	512-514
this	O	515-519
issue	O	520-525
we	O	526-528
decided	O	529-536
to	O	537-539
research	O	540-548
the	O	549-552
possible	O	553-561
passage	O	562-569
of	O	570-572
mannitol	O	573-581
into	O	582-586
the	O	587-590
brain	O	591-596
after	O	597-602
administration	O	603-617
to	O	618-620
21	O	621-623
brain	B	624-629
tumor	I	630-635
patients	O	636-644
.	O	644-645

METHODS	O	646-653
:	O	653-654
Mannitol	O	655-663
(	O	664-665
18	O	665-667
%	O	667-668
solution	O	669-677
;	O	677-678
1	O	679-680
g	O	681-682
/	O	682-683
kg	O	683-685
)	O	685-686
was	O	687-690
administered	O	691-703
as	O	704-706
a	O	707-708
bolus	O	709-714
to	O	715-717
patients	O	718-726
(	O	727-728
ten	O	728-731
had	O	732-735
malignant	B	736-745
glioma	I	746-752
,	O	752-753
seven	O	754-759
brain	O	760-765
metastases	B	766-776
and	O	777-780
four	O	781-785
meningioma	B	786-796
)	O	796-797
about	O	798-803
30	O	804-806
minutes	O	807-814
before	O	815-821
craniotomy	O	822-832
.	O	832-833

During	O	834-840
resection	O	841-850
,	O	850-851
a	O	852-853
sample	O	854-860
of	O	861-863
the	O	864-867
surrounding	O	868-879
edematous	B	880-889
white	O	890-895
matter	O	896-902
was	O	903-906
taken	O	907-912
at	O	913-915
the	O	916-919
same	O	920-924
time	O	925-929
as	O	930-932
a	O	933-934
10	O	935-937
ml	O	938-940
venous	O	941-947
blood	O	948-953
sample	O	954-960
.	O	960-961

Mannitol	O	962-970
concentrations	O	971-985
were	O	986-990
measured	O	991-999
in	O	1000-1002
plasma	O	1003-1009
and	O	1010-1013
white	O	1014-1019
matter	O	1020-1026
by	O	1027-1029
a	O	1030-1031
modified	O	1032-1040
version	O	1041-1048
of	O	1049-1051
the	O	1052-1055
enzyme	O	1056-1062
assay	O	1063-1068
of	O	1069-1071
Blonquist	O	1072-1081
et	O	1082-1084
al	O	1085-1087
.	O	1087-1088

RESULTS	O	1089-1096
:	O	1096-1097
In	O	1098-1100
most	O	1101-1105
glioma	B	1106-1112
patients	O	1113-1121
,	O	1121-1122
mannitol	O	1123-1131
concentrations	O	1132-1146
in	O	1147-1149
white	O	1150-1155
matter	O	1156-1162
were	O	1163-1167
2	O	1168-1169
to	O	1170-1172
6	O	1173-1174
times	O	1175-1180
higher	O	1181-1187
than	O	1188-1192
in	O	1193-1195
plasma	O	1196-1202
(	O	1203-1204
mean	O	1204-1208
3	O	1209-1210
.	O	1210-1211
5	O	1211-1212
times	O	1213-1218
)	O	1218-1219
.	O	1219-1220

In	O	1221-1223
meningioma	B	1224-1234
and	O	1235-1238
metastases	B	1239-1249
patients	O	1250-1258
plasma	O	1259-1265
concentrations	O	1266-1280
of	O	1281-1283
mannitol	O	1284-1292
were	O	1293-1297
higher	O	1298-1304
than	O	1305-1309
white	O	1310-1315
matter	O	1316-1322
concentrations	O	1323-1337
except	O	1338-1344
in	O	1345-1347
three	O	1348-1353
cases	O	1354-1359
with	O	1360-1364
infiltration	O	1365-1377
by	O	1378-1380
neoplastic	O	1381-1391
cells	O	1392-1397
.	O	1397-1398

CONCLUSIONS	O	1399-1410
:	O	1410-1411
The	O	1412-1415
results	O	1416-1423
of	O	1424-1426
our	O	1427-1430
study	O	1431-1436
show	O	1437-1441
that	O	1442-1446
even	O	1447-1451
after	O	1452-1457
a	O	1458-1459
single	O	1460-1466
bolus	O	1467-1472
,	O	1472-1473
mannitol	O	1474-1482
may	O	1483-1486
leak	O	1487-1491
through	O	1492-1499
the	O	1500-1503
altered	O	1504-1511
BBB	O	1512-1515
near	O	1516-1520
gliomas	B	1521-1528
,	O	1528-1529
reversing	O	1530-1539
the	O	1540-1543
initial	O	1544-1551
plasma	O	1552-1558
-	O	1558-1559
to	O	1559-1561
-	O	1558-1559
blood	O	1562-1567
osmotic	O	1568-1575
gradient	O	1576-1584
,	O	1584-1585
aggravating	O	1586-1597
peritumoral	O	1598-1609
edema	B	1610-1615
and	O	1616-1619
promoting	O	1620-1629
rebound	O	1630-1637
of	O	1638-1640
ICP	O	1641-1644
.	O	1644-1645

Can	O	0-3
lidocaine	O	4-13
reduce	O	14-20
succinylcholine	O	21-36
induced	O	37-44
postoperative	B	45-58
myalgia	I	59-66
?	O	66-67

This	O	68-72
study	O	73-78
was	O	79-82
undertaken	O	83-93
to	O	94-96
determine	O	97-106
the	O	107-110
effect	O	111-117
of	O	118-120
lidocaine	O	121-130
pretreatment	O	131-143
on	O	144-146
reduction	O	147-156
of	O	157-159
succinylcholine	O	160-175
-	O	175-176
induced	O	176-183
myalgia	B	184-191
in	O	192-194
patients	O	195-203
undergoing	O	204-214
general	O	215-222
anesthesia	O	223-233
for	O	234-237
gynecological	O	238-251
surgery	O	252-259
.	O	259-260

One	O	261-264
hundred	O	265-272
and	O	273-276
thirty	O	277-283
-	O	283-284
five	O	284-288
patients	O	289-297
were	O	298-302
assigned	O	303-311
to	O	312-314
one	O	315-318
of	O	319-321
three	O	322-327
groups	O	328-334
in	O	335-337
a	O	338-339
prospective	O	340-351
,	O	351-352
double	O	353-359
blind	O	360-365
,	O	365-366
randomized	O	367-377
manner	O	378-384
.	O	384-385

Group	O	386-391
PS	O	392-394
,	O	394-395
the	O	396-399
control	O	400-407
group	O	408-413
,	O	413-414
received	O	415-423
normal	O	424-430
saline	O	431-437
and	O	438-441
succinylcholine	O	442-457
1	O	458-459
.	O	459-460
5	O	460-461
mg	O	462-464
x	O	465-466
kg	O	467-469
(	O	469-470
-	O	470-471
1	O	471-472
)	O	472-473
;	O	473-474
Group	O	475-480
LS	O	481-483
,	O	483-484
lidocaine	O	485-494
1	O	495-496
.	O	496-497
5	O	497-498
mg	O	499-501
x	O	502-503
kg	O	504-506
(	O	506-507
-	O	507-508
1	O	508-509
)	O	509-510
and	O	511-514
succinylcholine	O	515-530
1	O	531-532
.	O	532-533
5	O	533-534
mg	O	535-537
x	O	538-539
kg	O	540-542
(	O	542-543
-	O	543-544
1	O	544-545
)	O	545-546
;	O	546-547
Group	O	548-553
PR	O	554-556
,	O	556-557
normal	O	558-564
saline	O	565-571
and	O	572-575
rocuronium	O	576-586
0	O	587-588
.	O	588-589
6	O	589-590
mg	O	591-593
x	O	594-595
kg	O	596-598
(	O	598-599
-	O	599-600
1	O	600-601
)	O	601-602
.	O	602-603

Morphine	O	604-612
0	O	613-614
.	O	614-615
1	O	615-616
mg	O	617-619
x	O	620-621
kg	O	622-624
(	O	624-625
-	O	625-626
1	O	626-627
)	O	627-628
iv	O	629-631
was	O	632-635
given	O	636-641
for	O	642-645
premedication	O	646-659
and	O	660-663
all	O	664-667
patients	O	668-676
were	O	677-681
monitored	O	682-691
with	O	692-696
a	O	697-698
noninvasive	O	699-710
blood	O	711-716
pressure	O	717-725
monitor	O	726-733
,	O	733-734
ECG	O	735-738
and	O	739-742
pulse	O	743-748
oximetry	O	749-757
.	O	757-758

Anesthesia	O	759-769
was	O	770-773
induced	O	774-781
with	O	782-786
5	O	787-788
mg	O	789-791
.	O	791-792
kg	O	792-794
(	O	794-795
-	O	795-796
1	O	796-797
)	O	797-798
thiopental	O	799-809
iv	O	810-812
.	O	812-813

followed	O	814-822
by	O	823-825
succinylcholine	O	826-841
(	O	842-843
Group	O	843-848
PS	O	849-851
,	O	851-852
LS	O	853-855
)	O	855-856
or	O	857-859
rocuronium	O	860-870
(	O	871-872
Group	O	872-877
PR	O	878-880
)	O	880-881
for	O	882-885
tracheal	O	886-894
intubation	O	895-905
.	O	905-906

Following	O	907-916
administration	O	917-931
of	O	932-934
these	O	935-940
agents	O	941-947
,	O	947-948
the	O	949-952
presence	O	953-961
,	O	961-962
and	O	963-966
degree	O	967-973
of	O	974-976
fasciculation	B	977-990
were	O	991-995
assessed	O	996-1004
visually	O	1005-1013
on	O	1014-1016
a	O	1017-1018
four	O	1019-1023
point	O	1024-1029
scale	O	1030-1035
by	O	1036-1038
one	O	1039-1042
investigator	O	1043-1055
who	O	1056-1059
was	O	1060-1063
blinded	O	1064-1071
to	O	1072-1074
the	O	1075-1078
drug	O	1079-1083
administered	O	1084-1096
.	O	1096-1097

The	O	1098-1101
blood	O	1102-1107
pressure	O	1108-1116
and	O	1117-1120
heart	O	1121-1126
rate	O	1127-1131
of	O	1132-1134
each	O	1135-1139
patient	O	1140-1147
were	O	1148-1152
monitored	O	1153-1162
on	O	1163-1165
nine	O	1166-1170
occasions	O	1171-1180
.	O	1180-1181

Twenty	O	1182-1188
-	O	1188-1189
four	O	1189-1193
hours	O	1194-1199
later	O	1200-1205
,	O	1205-1206
any	O	1207-1210
myalgia	B	1211-1218
experienced	O	1219-1230
was	O	1231-1234
assessed	O	1235-1243
according	O	1244-1253
to	O	1254-1256
a	O	1257-1258
structured	O	1259-1269
questionaire	O	1270-1282
and	O	1283-1286
graded	O	1287-1293
by	O	1294-1296
a	O	1297-1298
four	O	1299-1303
point	O	1304-1309
scale	O	1310-1315
by	O	1316-1318
one	O	1319-1322
investigator	O	1323-1335
blinded	O	1336-1343
to	O	1344-1346
the	O	1347-1350
intraoperative	O	1351-1365
management	O	1366-1376
.	O	1376-1377

The	O	1378-1381
results	O	1382-1389
indicate	O	1390-1398
that	O	1399-1403
muscle	B	1404-1410
fasciculation	I	1411-1424
was	O	1425-1428
not	O	1429-1432
found	O	1433-1438
in	O	1439-1441
Group	O	1442-1447
PR	O	1448-1450
while	O	1451-1456
the	O	1457-1460
patients	O	1461-1469
in	O	1470-1472
Group	O	1473-1478
LS	O	1479-1481
had	O	1482-1485
a	O	1486-1487
lower	O	1488-1493
incidence	O	1494-1503
of	O	1504-1506
muscle	B	1507-1513
fasciculation	I	1514-1527
than	O	1528-1532
those	O	1533-1538
in	O	1539-1541
Group	O	1542-1547
PS	O	1548-1550
(	O	1551-1552
p	O	1552-1553
<	O	1554-1555
0	O	1556-1557
.	O	1557-1558
001	O	1558-1561
)	O	1561-1562
.	O	1557-1558

At	O	1564-1566
24	O	1567-1569
h	O	1570-1571
,	O	1571-1572
the	O	1573-1576
incidence	O	1577-1586
of	O	1587-1589
myalgia	B	1590-1597
was	O	1598-1601
higher	O	1602-1608
in	O	1609-1611
Group	O	1612-1617
PS	O	1618-1620
than	O	1621-1625
in	O	1626-1628
Group	O	1629-1634
LS	O	1635-1637
and	O	1638-1641
PR	O	1642-1644
(	O	1645-1646
p	O	1646-1647
<	O	1648-1649
0	O	1650-1651
.	O	1651-1652
05	O	1652-1654
)	O	1654-1655
.	O	1651-1652

A	O	1657-1658
correlation	O	1659-1670
was	O	1671-1674
not	O	1675-1678
found	O	1679-1684
between	O	1685-1692
the	O	1693-1696
incidence	O	1697-1706
of	O	1707-1709
myalgia	B	1710-1717
and	O	1718-1721
the	O	1722-1725
occurrence	O	1726-1736
of	O	1737-1739
muscle	B	1740-1746
fasciculation	I	1747-1760
.	O	1760-1761

The	O	1762-1765
changes	O	1766-1773
in	O	1774-1776
systolic	O	1777-1785
and	O	1786-1789
diastolic	O	1790-1799
blood	O	1800-1805
pressure	O	1806-1814
and	O	1815-1818
heart	O	1819-1824
rate	O	1825-1829
were	O	1830-1834
not	O	1835-1838
significant	O	1839-1850
among	O	1851-1856
the	O	1857-1860
three	O	1861-1866
groups	O	1867-1873
.	O	1873-1874

In	O	1875-1877
conclusion	O	1878-1888
,	O	1888-1889
where	O	1890-1895
succinylcholine	O	1896-1911
is	O	1912-1914
used	O	1915-1919
,	O	1919-1920
lidocaine	O	1921-1930
is	O	1931-1933
proven	O	1934-1940
to	O	1941-1943
be	O	1944-1946
the	O	1947-1950
useful	O	1951-1957
pretreatment	O	1958-1970
agent	O	1971-1976
for	O	1977-1980
the	O	1981-1984
reduction	O	1985-1994
of	O	1995-1997
postoperative	B	1998-2011
myalgia	I	2012-2019
.	O	2019-2020

Open	O	0-4
-	O	4-5
label	O	5-10
assessment	O	11-21
of	O	22-24
levofloxacin	O	25-37
for	O	38-41
the	O	42-45
treatment	O	46-55
of	O	56-58
acute	O	59-64
bacterial	O	65-74
sinusitis	B	75-84
in	O	85-87
adults	O	88-94
.	O	94-95

PURPOSE	O	96-103
:	O	103-104
To	O	105-107
evaluate	O	108-116
the	O	117-120
efficacy	O	121-129
and	O	130-133
safety	O	134-140
of	O	141-143
levofloxacin	O	144-156
(	O	157-158
500	O	158-161
mg	O	162-164
orally	O	165-171
once	O	172-176
daily	O	177-182
for	O	183-186
10	O	187-189
to	O	190-192
14	O	193-195
days	O	196-200
)	O	200-201
in	O	202-204
treating	O	205-213
adult	O	214-219
outpatients	O	220-231
with	O	232-236
acute	O	237-242
bacterial	O	243-252
sinusitis	B	253-262
.	O	262-263

PATIENTS	O	264-272
AND	O	273-276
METHODS	O	277-284
:	O	284-285
A	O	286-287
total	O	288-293
of	O	294-296
329	O	297-300
patients	O	301-309
enrolled	O	310-318
in	O	319-321
the	O	322-325
study	O	326-331
at	O	332-334
24	O	335-337
centers	O	338-345
.	O	345-346

All	O	347-350
patients	O	351-359
had	O	360-363
a	O	364-365
pre	O	366-369
-	O	369-370
therapy	O	370-377
Gram	O	378-382
'	O	382-383
s	O	383-384
stain	O	385-390
and	O	391-394
culture	O	395-402
of	O	403-405
sinus	O	406-411
exudate	O	412-419
obtained	O	420-428
by	O	429-431
antral	O	432-438
puncture	O	439-447
or	O	448-450
nasal	O	451-456
endoscopy	O	457-466
.	O	466-467

Clinical	O	468-476
response	O	477-485
was	O	486-489
assessed	O	490-498
on	O	499-501
the	O	502-505
basis	O	506-511
of	O	512-514
signs	O	515-520
and	O	521-524
symptoms	O	525-533
and	O	534-537
sinus	O	538-543
radiograph	O	544-554
or	O	555-557
computed	O	558-566
tomography	O	567-577
results	O	578-585
.	O	585-586

Microbiologic	O	587-600
cure	O	601-605
rates	O	606-611
were	O	612-616
determined	O	617-627
on	O	628-630
the	O	631-634
basis	O	635-640
of	O	641-643
presumed	O	644-652
plus	O	653-657
documented	O	658-668
eradication	O	669-680
of	O	681-683
the	O	684-687
pre	O	688-691
-	O	691-692
therapy	O	692-699
pathogen	O	700-708
(	O	708-709
s	O	709-710
)	O	710-711
.	O	711-712

RESULTS	O	713-720
:	O	720-721
The	O	722-725
most	O	726-730
common	O	731-737
pathogens	O	738-747
were	O	748-752
Haemophilus	O	753-764
influenzae	O	765-775
,	O	775-776
Streptococcus	O	777-790
pneumoniae	O	791-801
,	O	801-802
Staphylococcus	O	803-817
aureus	O	818-824
,	O	824-825
and	O	826-829
Moraxella	O	830-839
catarrhalis	O	840-851
.	O	851-852

Of	O	853-855
300	O	856-859
clinically	O	860-870
evaluable	O	871-880
patients	O	881-889
,	O	889-890
175	O	891-894
(	O	895-896
58	O	896-898
%	O	898-899
)	O	899-900
were	O	901-905
cured	O	906-911
and	O	912-915
90	O	916-918
(	O	919-920
30	O	920-922
%	O	922-923
)	O	923-924
were	O	925-929
improved	O	930-938
at	O	939-941
the	O	942-945
post	O	946-950
-	O	950-951
therapy	O	951-958
evaluation	O	959-969
,	O	969-970
resulting	O	971-980
in	O	981-983
a	O	984-985
clinical	O	986-994
success	O	995-1002
rate	O	1003-1007
of	O	1008-1010
88	O	1011-1013
%	O	1013-1014
.	O	1014-1015

Thirty	O	1016-1022
-	O	1022-1023
five	O	1023-1027
patients	O	1028-1036
(	O	1037-1038
12	O	1038-1040
%	O	1040-1041
)	O	1041-1042
clinically	O	1043-1053
failed	O	1054-1060
treatment	O	1061-1070
.	O	1070-1071

The	O	1072-1075
microbiologic	O	1076-1089
eradication	O	1090-1101
rate	O	1102-1106
(	O	1107-1108
presumed	O	1108-1116
plus	O	1117-1121
documented	O	1122-1132
)	O	1132-1133
among	O	1134-1139
138	O	1140-1143
microbiologically	O	1144-1161
evaluable	O	1162-1171
patients	O	1172-1180
was	O	1181-1184
92	O	1185-1187
%	O	1187-1188
.	O	1188-1189

Microbiologic	O	1190-1203
eradication	O	1204-1215
rates	O	1216-1221
(	O	1222-1223
presumed	O	1223-1231
plus	O	1232-1236
documented	O	1237-1247
)	O	1247-1248
of	O	1249-1251
the	O	1252-1255
most	O	1256-1260
common	O	1261-1267
pathogens	O	1268-1277
ranged	O	1278-1284
from	O	1285-1289
93	O	1290-1292
%	O	1292-1293
(	O	1294-1295
M	O	1295-1296
.	O	1296-1297

catarrhalis	O	1298-1309
)	O	1309-1310
to	O	1311-1313
100	O	1314-1317
%	O	1317-1318
(	O	1319-1320
S	O	1320-1321
.	O	1321-1322
pneumoniae	O	1323-1333
)	O	1333-1334
at	O	1335-1337
the	O	1338-1341
post	O	1342-1346
-	O	1346-1347
therapy	O	1347-1354
visit	O	1355-1360
.	O	1360-1361

All	O	1362-1365
but	O	1366-1369
one	O	1370-1373
of	O	1374-1376
the	O	1377-1380
265	O	1381-1384
patients	O	1385-1393
who	O	1394-1397
were	O	1398-1402
cured	O	1403-1408
or	O	1409-1411
improved	O	1412-1420
at	O	1421-1423
post	O	1424-1428
-	O	1428-1429
therapy	O	1429-1436
returned	O	1437-1445
for	O	1446-1449
a	O	1450-1451
long	O	1452-1456
-	O	1456-1457
term	O	1457-1461
follow	O	1462-1468
-	O	1468-1469
up	O	1469-1471
visit	O	1472-1477
;	O	1477-1478
243	O	1479-1482
(	O	1483-1484
92	O	1484-1486
%	O	1486-1487
)	O	1487-1488
remained	O	1489-1497
well	O	1498-1502
4	O	1503-1504
to	O	1505-1507
6	O	1508-1509
weeks	O	1510-1515
after	O	1516-1521
therapy	O	1522-1529
;	O	1529-1530
and	O	1531-1534
21	O	1535-1537
(	O	1538-1539
8	O	1539-1540
%	O	1540-1541
)	O	1541-1542
had	O	1543-1546
a	O	1547-1548
relapse	O	1549-1556
of	O	1557-1559
symptoms	O	1560-1568
.	O	1568-1569

Adverse	O	1570-1577
events	O	1578-1584
considered	O	1585-1595
to	O	1596-1598
be	O	1599-1601
related	O	1602-1609
to	O	1610-1612
levofloxacin	O	1613-1625
administration	O	1626-1640
were	O	1641-1645
reported	O	1646-1654
by	O	1655-1657
29	O	1658-1660
patients	O	1661-1669
(	O	1670-1671
9	O	1671-1672
%	O	1672-1673
)	O	1673-1674
.	O	1674-1675

The	O	1676-1679
most	O	1680-1684
common	O	1685-1691
drug	O	1692-1696
-	O	1696-1697
related	O	1697-1704
adverse	O	1705-1712
events	O	1713-1719
were	O	1720-1724
diarrhea	B	1725-1733
,	O	1733-1734
flatulence	B	1735-1745
,	O	1745-1746
and	O	1747-1750
nausea	B	1751-1757
;	O	1757-1758
most	O	1759-1763
adverse	O	1764-1771
events	O	1772-1778
were	O	1779-1783
mild	O	1784-1788
to	O	1789-1791
moderate	O	1792-1800
in	O	1801-1803
severity	O	1804-1812
.	O	1812-1813

CONCLUSION	O	1814-1824
:	O	1824-1825
The	O	1826-1829
results	O	1830-1837
of	O	1838-1840
this	O	1841-1845
study	O	1846-1851
indicate	O	1852-1860
that	O	1861-1865
levofloxacin	O	1866-1878
500	O	1879-1882
mg	O	1883-1885
once	O	1886-1890
daily	O	1891-1896
is	O	1897-1899
an	O	1900-1902
effective	O	1903-1912
and	O	1913-1916
safe	O	1917-1921
treatment	O	1922-1931
for	O	1932-1935
acute	O	1936-1941
bacterial	O	1942-1951
sinusitis	B	1952-1961
.	O	1961-1962

Clinical	O	0-8
evaluation	O	9-19
on	O	20-22
combined	O	23-31
administration	O	32-46
of	O	47-49
oral	O	50-54
prostacyclin	O	55-67
analogue	O	68-76
beraprost	O	77-86
and	O	87-90
phosphodiesterase	O	91-108
inhibitor	O	109-118
cilostazol	O	119-129
.	O	129-130

Among	O	131-136
various	O	137-144
oral	O	145-149
antiplatelets	O	150-163
,	O	163-164
a	O	165-166
combination	O	167-178
of	O	179-181
a	O	182-183
novel	O	184-189
prostacyclin	O	190-202
analogue	O	203-211
beraprost	O	212-221
(	O	222-223
BPT	O	223-226
)	O	226-227
and	O	228-231
a	O	232-233
potent	O	234-240
phosphodiesterase	O	241-258
inhibitor	O	259-268
cilostazol	O	269-279
(	O	280-281
CLZ	O	281-284
)	O	284-285
may	O	286-289
result	O	290-296
in	O	297-299
untoward	O	300-308
clinical	O	309-317
effects	O	318-325
due	O	326-329
to	O	330-332
possible	O	333-341
synergistic	O	342-353
elevation	O	354-363
of	O	364-366
intracellular	O	367-380
cAMP	O	381-385
(	O	386-387
cyclic	O	387-393
adenosine	O	394-403
3	O	404-405
'	O	405-406
,	O	406-407
5	O	407-408
'	O	405-406
-	O	409-410
monophosphate	O	410-423
)	O	423-424
.	O	424-425
Thereby	O	426-433
,	O	433-434
a	O	435-436
clinical	O	437-445
study	O	446-451
of	O	452-454
the	O	455-458
combined	O	459-467
administration	O	468-482
of	O	483-485
the	O	486-489
two	O	490-493
agents	O	494-500
was	O	501-504
attempted	O	505-514
.	O	514-515

Twelve	O	516-522
healthy	O	523-530
volunteers	O	531-541
were	O	542-546
assigned	O	547-555
to	O	556-558
take	O	559-563
BPT	O	564-567
/	O	567-568
CLZ	O	568-571
in	O	572-574
the	O	575-578
following	O	579-588
schedule	O	589-597
;	O	597-598
BPT	O	599-602
:	O	602-603
40	O	604-606
micrograms	O	607-617
at	O	618-620
day	O	621-624
1	O	625-626
and	O	627-630
120	O	631-634
micrograms	O	635-645
t	O	646-647
.	O	647-648
i	O	648-649
.	O	647-648
d	O	650-651
.	O	647-648

from	O	653-657
day	O	658-661
7	O	662-663
to	O	664-666
14	O	667-669
,	O	669-670
CLZ	O	671-674
:	O	674-675
200	O	676-679
mg	O	680-682
t	O	683-684
.	O	684-685
i	O	685-686
.	O	684-685
d	O	687-688
.	O	684-685

from	O	690-694
day	O	695-698
3	O	699-700
to	O	701-703
14	O	704-706
.	O	706-707

At	O	708-710
various	O	711-718
time	O	719-723
intervals	O	724-733
,	O	733-734
physical	O	735-743
examination	O	744-755
and	O	756-759
blood	O	760-765
collection	O	766-776
for	O	777-780
ex	O	781-783
vivo	O	784-788
platelet	B	789-797
aggregation	I	798-809
and	O	810-813
determination	O	814-827
of	O	828-830
intraplatelet	O	831-844
cAMP	O	845-849
were	O	850-854
performed	O	855-864
.	O	864-865

Throughout	O	866-876
the	O	877-880
observation	O	881-892
period	O	893-899
,	O	899-900
no	O	901-903
significant	O	904-915
alteration	O	916-926
in	O	927-929
vital	O	930-935
signs	O	936-941
was	O	942-945
observed	O	946-954
.	O	954-955

Seven	O	956-961
out	O	962-965
of	O	966-968
12	O	969-971
subjects	O	972-980
experienced	O	981-992
headache	B	993-1001
of	O	1002-1004
a	O	1005-1006
short	O	1007-1012
duration	O	1013-1021
accompanying	O	1022-1034
facial	B	1035-1041
flush	I	1042-1047
in	O	1048-1050
one	O	1051-1054
and	O	1055-1058
nausea	B	1059-1065
in	O	1066-1068
one	O	1069-1072
,	O	1072-1073
especially	O	1074-1084
after	O	1085-1090
ingestion	O	1091-1100
of	O	1101-1103
CLZ	O	1104-1107
.	O	1107-1108

All	O	1109-1112
of	O	1113-1115
these	O	1116-1121
symptoms	O	1122-1130
,	O	1130-1131
probably	O	1132-1140
caused	O	1141-1147
by	O	1148-1150
the	O	1151-1154
vasodilating	O	1155-1167
effect	O	1168-1174
of	O	1175-1177
the	O	1178-1181
two	O	1182-1185
agents	O	1186-1192
,	O	1192-1193
were	O	1194-1198
of	O	1199-1201
mild	O	1202-1206
degree	O	1207-1213
and	O	1214-1217
no	O	1218-1220
special	O	1221-1228
treatment	O	1229-1238
was	O	1239-1242
required	O	1243-1251
.	O	1251-1252

Intraplatelet	O	1253-1266
cAMP	O	1267-1271
content	O	1272-1279
was	O	1280-1283
gradually	O	1284-1293
but	O	1294-1297
significantly	O	1298-1311
increased	O	1312-1321
to	O	1322-1324
9	O	1325-1326
.	O	1326-1327
84	O	1327-1329
+	O	1330-1331
/	O	1331-1332
-	O	1332-1333
4	O	1334-1335
.	O	1335-1336
59	O	1336-1338
pmol	O	1339-1343
per	O	1344-1347
10	O	1348-1350
(	O	1350-1351
9	O	1351-1352
)	O	1352-1353
platelets	O	1354-1363
at	O	1364-1366
day	O	1367-1370
14	O	1371-1373
in	O	1374-1376
comparison	O	1377-1387
with	O	1388-1392
the	O	1393-1396
initial	O	1397-1404
value	O	1405-1410
(	O	1411-1412
6	O	1412-1413
.	O	1413-1414
87	O	1414-1416
+	O	1417-1418
/	O	1418-1419
-	O	1419-1420
2	O	1421-1422
.	O	1422-1423
25	O	1423-1425
pmol	O	1426-1430
)	O	1430-1431
.	O	1431-1432

The	O	1433-1436
platelet	O	1437-1445
aggregability	O	1446-1459
was	O	1460-1463
significantly	O	1464-1477
suppressed	O	1478-1488
at	O	1489-1491
various	O	1492-1499
time	O	1500-1504
intervals	O	1505-1514
but	O	1515-1518
no	O	1519-1521
additive	O	1522-1530
or	O	1531-1533
synergistic	O	1534-1545
inhibitory	O	1546-1556
effect	O	1557-1563
by	O	1564-1566
the	O	1567-1570
combined	O	1571-1579
administration	O	1580-1594
was	O	1595-1598
noted	O	1599-1604
.	O	1604-1605

In	O	1606-1608
conclusion	O	1609-1619
,	O	1619-1620
the	O	1621-1624
combined	O	1625-1633
administration	O	1634-1648
of	O	1649-1651
BPT	O	1652-1655
/	O	1655-1656
CLZ	O	1656-1659
is	O	1660-1662
safe	O	1663-1667
at	O	1668-1670
doses	O	1671-1676
used	O	1677-1681
in	O	1682-1684
the	O	1685-1688
study	O	1689-1694
,	O	1694-1695
though	O	1696-1702
the	O	1703-1706
beneficial	O	1707-1717
clinical	O	1718-1726
effect	O	1727-1733
of	O	1734-1736
the	O	1737-1740
combined	O	1741-1749
administration	O	1750-1764
has	O	1765-1768
yet	O	1769-1772
to	O	1773-1775
be	O	1776-1778
elucidated	O	1779-1789
.	O	1789-1790

Gastrointestinal	O	0-16
tolerability	O	17-29
of	O	30-32
etoricoxib	O	33-43
in	O	44-46
rheumatoid	B	47-57
arthritis	I	58-67
patients	O	68-76
:	O	76-77
results	O	78-85
of	O	86-88
the	O	89-92
etoricoxib	O	93-103
vs	O	104-106
diclofenac	O	107-117
sodium	O	118-124
gastrointestinal	O	125-141
tolerability	O	142-154
and	O	155-158
effectiveness	O	159-172
trial	O	173-178
(	O	179-180
EDGE	O	180-184
-	O	184-185
II	O	185-187
)	O	187-188
.	O	188-189

OBJECTIVE	O	190-199
:	O	199-200
A	O	201-202
randomised	O	203-213
,	O	213-214
double	O	215-221
-	O	221-222
blind	O	222-227
study	O	228-233
to	O	234-236
compare	O	237-244
the	O	245-248
gastrointestinal	O	249-265
(	O	266-267
GI	O	267-269
)	O	269-270
tolerability	O	271-283
,	O	283-284
safety	O	285-291
and	O	292-295
efficacy	O	296-304
of	O	305-307
etoricoxib	O	308-318
and	O	319-322
diclofenac	O	323-333
in	O	334-336
patients	O	337-345
with	O	346-350
rheumatoid	B	351-361
arthritis	I	362-371
(	O	372-373
RA	B	373-375
)	O	375-376
.	O	376-377

PATIENTS	O	378-386
AND	O	387-390
METHODS	O	391-398
:	O	398-399
A	O	400-401
total	O	402-407
of	O	408-410
4086	O	411-415
patients	O	416-424
(	O	425-426
mean	O	426-430
age	O	431-434
60	O	435-437
.	O	437-438
8	O	438-439
years	O	440-445
)	O	445-446
diagnosed	O	447-456
with	O	457-461
RA	B	462-464
were	O	465-469
enrolled	O	470-478
and	O	479-482
received	O	483-491
etoricoxib	O	492-502
90	O	503-505
mg	O	506-508
daily	O	509-514
(	O	515-516
n	O	516-517
=	O	518-519
2032	O	520-524
)	O	524-525
or	O	526-528
diclofenac	O	529-539
75	O	540-542
mg	O	543-545
twice	O	546-551
daily	O	552-557
(	O	558-559
n	O	559-560
=	O	561-562
2054	O	563-567
)	O	567-568
.	O	568-569

Use	O	570-573
of	O	574-576
gastroprotective	O	577-593
agents	O	594-600
and	O	601-604
low	O	605-608
-	O	608-609
dose	O	609-613
aspirin	O	614-621
was	O	622-625
allowed	O	626-633
.	O	633-634

The	O	635-638
prespecified	O	639-651
primary	O	652-659
end	O	660-663
point	O	664-669
consisted	O	670-679
of	O	680-682
the	O	683-686
cumulative	O	687-697
rate	O	698-702
of	O	703-705
patient	O	706-713
discontinuations	O	714-730
due	O	731-734
to	O	735-737
clinical	O	738-746
and	O	747-750
laboratory	O	751-761
GI	O	762-764
adverse	O	765-772
experiences	O	773-784
(	O	785-786
AEs	O	786-789
)	O	789-790
.	O	790-791

General	O	792-799
safety	O	800-806
was	O	807-810
also	O	811-815
assessed	O	816-824
,	O	824-825
including	O	826-835
adjudicated	O	836-847
thrombotic	B	848-858
cardiovascular	I	859-873
event	O	874-879
data	O	880-884
.	O	884-885

Efficacy	O	886-894
was	O	895-898
evaluated	O	899-908
using	O	909-914
the	O	915-918
Patient	O	919-926
Global	O	927-933
Assessment	O	934-944
of	O	945-947
Disease	O	948-955
Status	O	956-962
(	O	963-964
PGADS	O	964-969
;	O	969-970
0	O	971-972
-	O	972-973
4	O	973-974
point	O	975-980
scale	O	981-986
)	O	986-987
.	O	987-988

RESULTS	O	989-996
:	O	996-997
Mean	O	998-1002
(	O	1003-1004
SD	O	1004-1006
;	O	1006-1007
maximum	O	1008-1015
)	O	1015-1016
duration	O	1017-1025
of	O	1026-1028
treatment	O	1029-1038
was	O	1039-1042
19	O	1043-1045
.	O	1045-1046
3	O	1046-1047
(	O	1048-1049
10	O	1049-1051
.	O	1051-1052
3	O	1052-1053
;	O	1053-1054
32	O	1055-1057
.	O	1057-1058
9	O	1058-1059
)	O	1059-1060
and	O	1061-1064
19	O	1065-1067
.	O	1067-1068
1	O	1065-1066
(	O	1070-1071
10	O	1071-1073
.	O	1073-1074
4	O	1074-1075
;	O	1075-1076
33	O	1077-1079
.	O	1079-1080
1	O	1080-1081
)	O	1081-1082
months	O	1083-1089
in	O	1090-1092
the	O	1093-1096
etoricoxib	O	1097-1107
and	O	1108-1111
diclofenac	O	1112-1122
groups	O	1123-1129
,	O	1129-1130
respectively	O	1131-1143
.	O	1143-1144

The	O	1145-1148
cumulative	O	1149-1159
discontinuation	O	1160-1175
rate	O	1176-1180
due	O	1181-1184
to	O	1185-1187
GI	B	1188-1190
AEs	I	1191-1194
was	O	1195-1198
significantly	O	1199-1212
lower	O	1213-1218
with	O	1219-1223
etoricoxib	O	1224-1234
than	O	1235-1239
diclofenac	O	1240-1250
(	O	1251-1252
5	O	1252-1253
.	O	1253-1254
2	O	1254-1255
vs	O	1256-1258
8	O	1259-1260
.	O	1260-1261
5	O	1261-1262
events	O	1263-1269
per	O	1270-1273
100	O	1274-1277
patient	O	1278-1285
-	O	1285-1286
years	O	1286-1291
,	O	1291-1292
respectively	O	1293-1305
;	O	1305-1306
hazard	O	1307-1313
ratio	O	1314-1319
0	O	1320-1321
.	O	1321-1322
62	O	1322-1324
(	O	1325-1326
95	O	1326-1328
%	O	1328-1329
CI	O	1330-1332
:	O	1332-1333
0	O	1334-1335
.	O	1335-1336
47	O	1336-1338
,	O	1338-1339
0	O	1340-1341
.	O	1341-1342
81	O	1342-1344
;	O	1344-1345
p	O	1346-1347
<	O	1347-1348
or	O	1348-1350
=	O	1350-1351
0	O	1351-1352
.	O	1352-1353
001	O	1353-1356
)	O	1356-1357
)	O	1356-1357
.	O	1352-1353

The	O	1360-1363
incidence	O	1364-1373
of	O	1374-1376
discontinuations	O	1377-1393
for	O	1394-1397
hypertension	B	1398-1410
-	O	1410-1411
related	O	1411-1418
and	O	1419-1422
oedema	B	1423-1429
-	O	1429-1430
related	O	1430-1437
AEs	O	1438-1441
were	O	1442-1446
significantly	O	1447-1460
higher	O	1461-1467
with	O	1468-1472
etoricoxib	O	1473-1483
(	O	1484-1485
2	O	1485-1486
.	O	1486-1487
5	O	1487-1488
%	O	1488-1489
and	O	1490-1493
1	O	1494-1495
.	O	1495-1496
1	O	1494-1495
%	O	1497-1498
respectively	O	1499-1511
)	O	1511-1512
compared	O	1513-1521
with	O	1522-1526
diclofenac	O	1527-1537
(	O	1538-1539
1	O	1539-1540
.	O	1540-1541
5	O	1541-1542
%	O	1542-1543
and	O	1544-1547
0	O	1548-1549
.	O	1549-1550
4	O	1550-1551
%	O	1551-1552
respectively	O	1553-1565
;	O	1565-1566
p	O	1567-1568
<	O	1568-1569
0	O	1569-1570
.	O	1570-1571
001	O	1571-1574
for	O	1575-1578
hypertension	B	1579-1591
and	O	1592-1595
p	O	1596-1597
<	O	1597-1598
0	O	1598-1599
.	O	1599-1600
01	O	1600-1602
for	O	1603-1606
oedema	B	1607-1613
)	O	1613-1614
.	O	1614-1615

Etoricoxib	O	1616-1626
and	O	1627-1630
diclofenac	O	1631-1641
treatment	O	1642-1651
resulted	O	1652-1660
in	O	1661-1663
similar	O	1664-1671
efficacy	O	1672-1680
(	O	1681-1682
PGADS	O	1682-1687
mean	O	1688-1692
changes	O	1693-1700
from	O	1701-1705
baseline	O	1706-1714
-	O	1715-1716
0	O	1716-1717
.	O	1717-1718
62	O	1718-1720
vs	O	1721-1723
-	O	1724-1725
0	O	1725-1726
.	O	1726-1727
58	O	1727-1729
,	O	1729-1730
respectively	O	1731-1743
)	O	1743-1744
.	O	1744-1745

CONCLUSIONS	O	1746-1757
:	O	1757-1758
Etoricoxib	O	1759-1769
90	O	1770-1772
mg	O	1773-1775
demonstrated	O	1776-1788
a	O	1789-1790
significantly	O	1791-1804
lower	O	1805-1810
risk	O	1811-1815
for	O	1816-1819
discontinuing	O	1820-1833
treatment	O	1834-1843
due	O	1844-1847
to	O	1848-1850
GI	B	1851-1853
AEs	I	1854-1857
compared	O	1858-1866
with	O	1867-1871
diclofenac	O	1872-1882
150	O	1883-1886
mg	O	1887-1889
.	O	1889-1890

Discontinuations	O	1891-1907
from	O	1908-1912
renovascular	O	1913-1925
AEs	O	1926-1929
,	O	1929-1930
although	O	1931-1939
less	O	1940-1944
common	O	1945-1951
than	O	1952-1956
discontinuations	O	1957-1973
from	O	1974-1978
GI	B	1979-1981
AEs	I	1982-1985
,	O	1985-1986
were	O	1987-1991
significantly	O	1992-2005
higher	O	2006-2012
with	O	2013-2017
etoricoxib	O	2018-2028
.	O	2028-2029

Placebo	O	0-7
-	O	7-8
level	O	8-13
incidence	O	14-23
of	O	24-26
extrapyramidal	B	27-41
symptoms	I	42-50
(	O	51-52
EPS	B	52-55
)	O	55-56
with	O	57-61
quetiapine	O	62-72
in	O	73-75
controlled	O	76-86
studies	O	87-94
of	O	95-97
patients	O	98-106
with	O	107-111
bipolar	B	112-119
mania	I	120-125
.	O	125-126

OBJECTIVES	O	127-137
:	O	137-138
To	O	139-141
evaluate	O	142-150
extrapyramidal	B	151-165
symptoms	I	166-174
(	O	175-176
EPS	B	176-179
)	O	179-180
,	O	180-181
including	O	182-191
akathisia	B	192-201
,	O	201-202
with	O	203-207
quetiapine	O	208-218
in	O	219-221
patients	O	222-230
with	O	231-235
bipolar	B	236-243
mania	I	244-249
.	O	249-250

METHODS	O	251-258
:	O	258-259
Data	O	260-264
were	O	265-269
analyzed	O	270-278
from	O	279-283
four	O	284-288
similarly	O	289-298
designed	O	299-307
,	O	307-308
randomized	O	309-319
,	O	319-320
double	O	321-327
-	O	327-328
blind	O	328-333
,	O	333-334
3	O	335-336
-	O	336-337
to	O	338-340
12	O	341-343
-	O	343-344
week	O	344-348
studies	O	349-356
.	O	356-357

Two	O	358-361
studies	O	362-369
evaluated	O	370-379
quetiapine	O	380-390
monotherapy	O	391-402
(	O	403-404
up	O	404-406
to	O	407-409
800	O	410-413
mg	O	414-416
/	O	416-417
day	O	417-420
)	O	420-421
(	O	422-423
n	O	423-424
=	O	425-426
209	O	427-430
)	O	430-431
versus	O	432-438
placebo	O	439-446
(	O	447-448
n	O	448-449
=	O	450-451
198	O	452-455
)	O	455-456
,	O	456-457
with	O	458-462
lithium	O	463-470
or	O	471-473
haloperidol	O	474-485
monotherapy	O	486-497
as	O	498-500
respective	O	501-511
active	O	512-518
controls	O	519-527
.	O	527-528

Two	O	529-532
studies	O	533-540
evaluated	O	541-550
quetiapine	O	551-561
(	O	562-563
up	O	563-565
to	O	566-568
800	O	569-572
mg	O	573-575
/	O	575-576
day	O	576-579
)	O	579-580
in	O	581-583
combination	O	584-595
with	O	596-600
a	O	601-602
mood	O	603-607
stabilizer	O	608-618
(	O	619-620
lithium	O	620-627
or	O	628-630
divalproex	O	631-641
,	O	641-642
QTP	O	643-646
+	O	647-648
Li	O	649-651
/	O	651-652
DVP	O	652-655
)	O	655-656
(	O	657-658
n	O	658-659
=	O	660-661
196	O	662-665
)	O	665-666
compared	O	667-675
to	O	676-678
placebo	O	679-686
and	O	687-690
mood	O	691-695
stabilizer	O	696-706
(	O	707-708
PBO	O	708-711
+	O	712-713
Li	O	714-716
/	O	716-717
DVP	O	717-720
)	O	720-721
(	O	722-723
n	O	723-724
=	O	725-726
203	O	727-730
)	O	730-731
.	O	731-732

Extrapyramidal	B	733-747
symptoms	I	748-756
were	O	757-761
evaluated	O	762-771
using	O	772-777
the	O	778-781
Simpson	O	782-789
-	O	789-790
Angus	O	790-795
Scale	O	796-801
(	O	802-803
SAS	O	803-806
)	O	806-807
,	O	807-808
the	O	809-812
Barnes	O	813-819
Akathisia	O	820-829
Rating	O	830-836
Scale	O	837-842
(	O	843-844
BARS	O	844-848
)	O	848-849
,	O	849-850
adverse	O	851-858
event	O	859-864
reports	O	865-872
and	O	873-876
anticholinergic	O	877-892
drug	O	893-897
usage	O	898-903
.	O	903-904

RESULTS	O	905-912
:	O	912-913
The	O	914-917
incidence	O	918-927
of	O	928-930
EPS	B	931-934
-	O	934-935
related	O	935-942
adverse	O	943-950
events	O	951-957
,	O	957-958
including	O	959-968
akathisia	B	969-978
,	O	978-979
was	O	980-983
no	O	984-986
different	O	987-996
with	O	997-1001
quetiapine	O	1002-1012
monotherapy	O	1013-1024
(	O	1025-1026
12	O	1026-1028
.	O	1028-1029
9	O	1029-1030
%	O	1030-1031
)	O	1031-1032
than	O	1033-1037
with	O	1038-1042
placebo	O	1043-1050
(	O	1051-1052
13	O	1052-1054
.	O	1054-1055
1	O	1052-1053
%	O	1056-1057
)	O	1057-1058
.	O	1054-1055

Similarly	O	1060-1069
,	O	1069-1070
EPS	B	1071-1074
-	O	1074-1075
related	O	1075-1082
adverse	O	1083-1090
events	O	1091-1097
with	O	1098-1102
QTP	O	1103-1106
+	O	1107-1108
Li	O	1109-1111
/	O	1111-1112
DVP	O	1112-1115
(	O	1116-1117
21	O	1117-1119
.	O	1119-1120
4	O	1120-1121
%	O	1121-1122
)	O	1122-1123
were	O	1124-1128
no	O	1129-1131
different	O	1132-1141
than	O	1142-1146
with	O	1147-1151
PBO	O	1152-1155
+	O	1156-1157
Li	O	1158-1160
/	O	1160-1161
DVP	O	1161-1164
(	O	1165-1166
19	O	1166-1168
.	O	1168-1169
2	O	1169-1170
%	O	1170-1171
)	O	1171-1172
.	O	1168-1169

Adverse	O	1174-1181
events	O	1182-1188
related	O	1189-1196
to	O	1197-1199
EPS	B	1200-1203
occurred	O	1204-1212
in	O	1213-1215
59	O	1216-1218
.	O	1218-1219
6	O	1219-1220
%	O	1220-1221
of	O	1222-1224
patients	O	1225-1233
treated	O	1234-1241
with	O	1242-1246
haloperidol	O	1247-1258
(	O	1259-1260
n	O	1260-1261
=	O	1262-1263
99	O	1264-1266
)	O	1266-1267
monotherapy	O	1268-1279
,	O	1279-1280
whereas	O	1281-1288
26	O	1289-1291
.	O	1291-1292
5	O	1292-1293
%	O	1293-1294
of	O	1295-1297
patients	O	1298-1306
treated	O	1307-1314
with	O	1315-1319
lithium	O	1320-1327
(	O	1328-1329
n	O	1329-1330
=	O	1331-1332
98	O	1333-1335
)	O	1335-1336
monotherapy	O	1337-1348
experienced	O	1349-1360
adverse	O	1361-1368
events	O	1369-1375
related	O	1376-1383
to	O	1384-1386
EPS	B	1387-1390
.	O	1390-1391

The	O	1392-1395
incidence	O	1396-1405
of	O	1406-1408
akathisia	B	1409-1418
was	O	1419-1422
low	O	1423-1426
and	O	1427-1430
similar	O	1431-1438
with	O	1439-1443
quetiapine	O	1444-1454
monotherapy	O	1455-1466
(	O	1467-1468
3	O	1468-1469
.	O	1469-1470
3	O	1468-1469
%	O	1471-1472
)	O	1472-1473
and	O	1474-1477
placebo	O	1478-1485
(	O	1486-1487
6	O	1487-1488
.	O	1488-1489
1	O	1489-1490
%	O	1490-1491
)	O	1491-1492
,	O	1492-1493
and	O	1494-1497
with	O	1498-1502
QTP	O	1503-1506
+	O	1507-1508
Li	O	1509-1511
/	O	1511-1512
DVP	O	1512-1515
(	O	1516-1517
3	O	1517-1518
.	O	1518-1519
6	O	1519-1520
%	O	1520-1521
)	O	1521-1522
and	O	1523-1526
PBO	O	1527-1530
+	O	1531-1532
Li	O	1533-1535
/	O	1535-1536
DVP	O	1536-1539
(	O	1540-1541
4	O	1541-1542
.	O	1542-1543
9	O	1543-1544
%	O	1544-1545
)	O	1545-1546
.	O	1542-1543

Lithium	O	1548-1555
was	O	1556-1559
associated	O	1560-1570
with	O	1571-1575
a	O	1576-1577
significantly	O	1578-1591
higher	O	1592-1598
incidence	O	1599-1608
(	O	1609-1610
p	O	1610-1611
<	O	1612-1613
0	O	1614-1615
.	O	1615-1616
05	O	1616-1618
)	O	1618-1619
of	O	1620-1622
tremor	B	1623-1629
(	O	1630-1631
18	O	1631-1633
.	O	1633-1634
4	O	1634-1635
%	O	1635-1636
)	O	1636-1637
than	O	1638-1642
quetiapine	O	1643-1653
(	O	1654-1655
5	O	1655-1656
.	O	1656-1657
6	O	1657-1658
%	O	1658-1659
)	O	1659-1660
;	O	1660-1661
cerebellar	O	1662-1672
tremor	B	1673-1679
,	O	1679-1680
which	O	1681-1686
is	O	1687-1689
a	O	1690-1691
known	O	1692-1697
adverse	O	1698-1705
effect	O	1706-1712
of	O	1713-1715
lithium	O	1716-1723
,	O	1723-1724
may	O	1725-1728
have	O	1729-1733
contributed	O	1734-1745
to	O	1746-1748
the	O	1749-1752
elevated	O	1753-1761
rate	O	1762-1766
of	O	1767-1769
tremor	B	1770-1776
in	O	1777-1779
patients	O	1780-1788
receiving	O	1789-1798
lithium	O	1799-1806
therapy	O	1807-1814
.	O	1814-1815

Haloperidol	O	1816-1827
induced	O	1828-1835
a	O	1836-1837
significantly	O	1838-1851
higher	O	1852-1858
incidence	O	1859-1868
(	O	1869-1870
p	O	1870-1871
<	O	1872-1873
0	O	1874-1875
.	O	1875-1876
001	O	1876-1879
)	O	1879-1880
of	O	1881-1883
akathisia	B	1884-1893
(	O	1894-1895
33	O	1895-1897
.	O	1897-1898
3	O	1895-1896
%	O	1899-1900
versus	O	1901-1907
5	O	1908-1909
.	O	1909-1910
9	O	1910-1911
%	O	1911-1912
)	O	1912-1913
,	O	1913-1914
tremor	B	1915-1921
(	O	1922-1923
30	O	1923-1925
.	O	1925-1926
3	O	1923-1924
%	O	1927-1928
versus	O	1929-1935
7	O	1936-1937
.	O	1937-1938
8	O	1938-1939
%	O	1939-1940
)	O	1940-1941
,	O	1941-1942
and	O	1943-1946
extrapyramidal	B	1947-1961
syndrome	I	1962-1970
(	O	1971-1972
35	O	1972-1974
.	O	1974-1975
4	O	1975-1976
%	O	1976-1977
versus	O	1978-1984
5	O	1985-1986
.	O	1986-1987
9	O	1987-1988
%	O	1988-1989
)	O	1989-1990
than	O	1991-1995
quetiapine	O	1996-2006
.	O	2006-2007

No	O	2008-2010
significant	O	2011-2022
differences	O	2023-2034
were	O	2035-2039
observed	O	2040-2048
between	O	2049-2056
quetiapine	O	2057-2067
and	O	2068-2071
placebo	O	2072-2079
on	O	2080-2082
SAS	O	2083-2086
and	O	2087-2090
BARS	O	2091-2095
scores	O	2096-2102
.	O	2102-2103

Anticholinergic	O	2104-2119
use	O	2120-2123
was	O	2124-2127
low	O	2128-2131
and	O	2132-2135
similar	O	2136-2143
with	O	2144-2148
quetiapine	O	2149-2159
or	O	2160-2162
placebo	O	2163-2170
.	O	2170-2171

CONCLUSIONS	O	2172-2183
:	O	2183-2184
In	O	2185-2187
bipolar	B	2188-2195
mania	I	2196-2201
,	O	2201-2202
the	O	2203-2206
incidence	O	2207-2216
of	O	2217-2219
EPS	B	2220-2223
,	O	2223-2224
including	O	2225-2234
akathisia	B	2235-2244
,	O	2244-2245
with	O	2246-2250
quetiapine	O	2251-2261
therapy	O	2262-2269
is	O	2270-2272
similar	O	2273-2280
to	O	2281-2283
that	O	2284-2288
with	O	2289-2293
placebo	O	2294-2301
.	O	2301-2302

Contribution	O	0-12
of	O	13-15
the	O	16-19
sympathetic	O	20-31
nervous	O	32-39
system	O	40-46
to	O	47-49
salt	O	50-54
-	O	54-55
sensitivity	O	55-66
in	O	67-69
lifetime	O	70-78
captopril	O	79-88
-	O	88-89
treated	O	89-96
spontaneously	O	97-110
hypertensive	B	111-123
rats	O	124-128
.	O	128-129

OBJECTIVE	O	130-139
:	O	139-140
To	O	141-143
test	O	144-148
the	O	149-152
hypothesis	O	153-163
that	O	164-168
,	O	168-169
in	O	170-172
lifetime	O	173-181
captopril	O	182-191
-	O	191-192
treated	O	192-199
spontaneously	O	200-213
hypertensive	B	214-226
rats	O	227-231
(	O	232-233
SHR	O	233-236
)	O	236-237
,	O	237-238
the	O	239-242
sympathetic	O	243-254
nervous	O	255-262
system	O	263-269
contributes	O	270-281
importantly	O	282-293
to	O	294-296
the	O	297-300
hypertensive	B	301-313
effect	O	314-320
of	O	321-323
dietary	O	324-331
sodium	O	332-338
chloride	O	339-347
supplementation	O	348-363
.	O	363-364

METHODS	O	365-372
:	O	372-373
Male	O	374-378
SHR	O	379-382
(	O	383-384
aged	O	384-388
6	O	389-390
weeks	O	391-396
)	O	396-397
that	O	398-402
had	O	403-406
been	O	407-411
treated	O	412-419
from	O	420-424
conception	O	425-435
onward	O	436-442
with	O	443-447
either	O	448-454
captopril	O	455-464
or	O	465-467
vehicle	O	468-475
remained	O	476-484
on	O	485-487
a	O	488-489
basal	O	490-495
sodium	O	496-502
chloride	O	503-511
diet	O	512-516
or	O	517-519
were	O	520-524
fed	O	525-528
a	O	529-530
high	O	531-535
sodium	O	536-542
chloride	O	543-551
diet	O	552-556
.	O	556-557

After	O	558-563
2	O	564-565
weeks	O	566-571
,	O	571-572
the	O	573-576
rats	O	577-581
were	O	582-586
subjected	O	587-596
to	O	597-599
ganglionic	O	600-610
blockade	O	611-619
and	O	620-623
2	O	624-625
days	O	626-630
later	O	631-636
,	O	636-637
an	O	638-640
infusion	O	641-649
of	O	650-652
clonidine	O	653-662
.	O	662-663

RESULTS	O	664-671
:	O	671-672
Lifetime	O	673-681
captopril	O	682-691
treatment	O	692-701
significantly	O	702-715
lowered	O	716-723
mean	O	724-728
arterial	O	729-737
pressure	O	738-746
in	O	747-749
both	O	750-754
groups	O	755-761
.	O	761-762

Intravenous	O	763-774
infusion	O	775-783
of	O	784-786
the	O	787-790
ganglionic	O	791-801
blocker	O	802-809
hexamethonium	O	810-823
resulted	O	824-832
in	O	833-835
a	O	836-837
rapid	O	838-843
decline	O	844-851
in	O	852-854
MAP	O	855-858
that	O	859-863
eliminated	O	864-874
the	O	875-878
dietary	O	879-886
sodium	O	887-893
chloride	O	894-902
-	O	902-903
induced	O	903-910
increase	B	911-919
in	I	920-922
MAP	I	923-926
in	O	927-929
both	O	930-934
groups	O	935-941
.	O	941-942

Infusion	O	943-951
of	O	952-954
the	O	955-958
central	O	959-966
nervous	O	967-974
system	O	975-981
alpha2	O	982-988
-	O	988-989
adrenergic	O	989-999
receptor	O	1000-1008
agonist	O	1009-1016
clonidine	O	1017-1026
also	O	1027-1031
resulted	O	1032-1040
in	O	1041-1043
a	O	1044-1045
greater	O	1046-1053
reduction	O	1054-1063
in	O	1064-1066
MAP	O	1067-1070
in	O	1071-1073
both	O	1074-1078
groups	O	1079-1085
of	O	1086-1088
SHR	O	1089-1092
that	O	1093-1097
were	O	1098-1102
fed	O	1103-1106
the	O	1107-1110
high	O	1111-1115
(	O	1116-1117
compared	O	1117-1125
with	O	1126-1130
the	O	1131-1134
basal	O	1135-1140
)	O	1140-1141
sodium	O	1142-1148
chloride	O	1149-1157
diet	O	1158-1162
.	O	1162-1163

CONCLUSIONS	O	1164-1175
:	O	1175-1176
In	O	1177-1179
both	O	1180-1184
lifetime	O	1185-1193
captopril	O	1194-1203
-	O	1203-1204
treated	O	1204-1211
and	O	1212-1215
control	O	1216-1223
SHR	O	1224-1227
,	O	1227-1228
the	O	1229-1232
sympathetic	O	1233-1244
nervous	O	1245-1252
system	O	1253-1259
contributes	O	1260-1271
to	O	1272-1274
the	O	1275-1278
pressor	O	1279-1286
effects	O	1287-1294
of	O	1295-1297
a	O	1298-1299
high	O	1300-1304
sodium	O	1305-1311
chloride	O	1312-1320
diet	O	1321-1325
.	O	1325-1326

Dose	O	0-4
-	O	4-5
related	O	5-12
beneficial	O	13-23
and	O	24-27
adverse	O	28-35
effects	O	36-43
of	O	44-46
dietary	O	47-54
corticosterone	O	55-69
on	O	70-72
organophosphorus	O	73-89
-	O	89-90
induced	O	90-97
delayed	O	98-105
neuropathy	B	106-116
in	O	117-119
chickens	O	120-128
.	O	128-129

Tri	O	130-133
-	O	133-134
ortho	O	134-139
-	O	133-134
tolyl	O	140-145
phosphate	O	146-155
(	O	156-157
TOTP	O	157-161
)	O	161-162
,	O	162-163
360	O	164-167
mg	O	168-170
/	O	170-171
kg	O	171-173
,	O	173-174
po	O	175-177
,	O	177-178
and	O	179-182
0	O	183-184
,	O	184-185
0	O	183-184
'	O	186-187
-	O	187-188
diisopropyl	O	188-199
phosphorofluoridate	O	200-219
(	O	220-221
DFP	O	221-224
)	O	224-225
,	O	225-226
1	O	227-228
mg	O	229-231
/	O	231-232
kg	O	232-234
sc	O	235-237
,	O	237-238
were	O	239-243
administered	O	244-256
to	O	257-259
adult	O	260-265
White	O	266-271
Leghorn	O	272-279
chickens	O	280-288
24	O	289-291
hr	O	292-294
after	O	295-300
they	O	301-305
were	O	306-310
placed	O	311-317
on	O	318-320
diets	O	321-326
containing	O	327-337
0	O	338-339
to	O	340-342
300	O	343-346
ppm	O	347-350
corticosterone	O	351-365
.	O	365-366

Supplemented	O	367-379
diets	O	380-385
were	O	386-390
continued	O	391-400
until	O	401-406
clinical	O	407-415
signs	O	416-421
and	O	422-425
lesions	O	426-433
of	O	434-436
delayed	O	437-444
neuropathy	B	445-455
appeared	O	456-464
.	O	464-465

Although	O	466-474
low	O	475-478
concentrations	O	479-493
(	O	494-495
less	O	495-499
than	O	500-504
or	O	505-507
equal	O	508-513
to	O	514-516
50	O	517-519
ppm	O	520-523
)	O	523-524
of	O	525-527
corticosterone	O	528-542
had	O	543-546
beneficial	O	547-557
effects	O	558-565
on	O	566-568
TOTP	O	569-573
-	O	573-574
induced	O	574-581
neuropathy	B	582-592
,	O	592-593
greater	O	594-601
than	O	602-606
or	O	607-609
equal	O	610-615
to	O	616-618
200	O	619-622
ppm	O	623-626
exacerbated	O	627-638
clinical	O	639-647
signs	O	648-653
in	O	654-656
chickens	O	657-665
given	O	666-671
either	O	672-678
TOTP	O	679-683
or	O	684-686
DFP	O	687-690
.	O	690-691

Neurotoxic	B	692-702
esterase	O	703-711
activities	O	712-722
24	O	723-725
hr	O	726-728
after	O	729-734
TOTP	O	735-739
or	O	740-742
DFP	O	743-746
were	O	747-751
less	O	752-756
than	O	757-761
20	O	762-764
%	O	764-765
of	O	766-768
values	O	769-775
measured	O	776-784
in	O	785-787
chickens	O	788-796
not	O	797-800
given	O	801-806
organophosphorous	O	807-824
compounds	O	825-834
.	O	834-835

Chickens	O	836-844
given	O	845-850
200	O	851-854
ppm	O	855-858
corticosterone	O	859-873
without	O	874-881
TOTP	O	882-886
or	O	887-889
DFP	O	890-893
had	O	894-897
significantly	O	898-911
elevated	O	912-920
activity	O	921-929
of	O	930-932
plasma	O	933-939
cholinesterase	O	940-954
and	O	955-958
significantly	O	959-972
inhibited	O	973-982
activity	O	983-991
of	O	992-994
liver	O	995-1000
carboxylesterase	O	1001-1017
.	O	1017-1018

Degenerating	B	1019-1031
myelinated	I	1032-1042
fibers	I	1043-1049
were	O	1050-1054
also	O	1055-1059
evident	O	1060-1067
in	O	1068-1070
distal	O	1071-1077
levels	O	1078-1084
of	O	1085-1087
the	O	1088-1091
peripheral	O	1092-1102
nerves	O	1103-1109
of	O	1110-1112
chickens	O	1113-1121
given	O	1122-1127
TOTP	O	1128-1132
or	O	1133-1135
DFP	O	1136-1139
.	O	1139-1140

In	O	0-2
vivo	O	3-7
characterization	O	8-24
of	O	25-27
a	O	28-29
dual	O	30-34
adenosine	O	35-44
A2A	O	45-48
/	O	48-49
A1	O	49-51
receptor	O	52-60
antagonist	O	61-71
in	O	72-74
animal	O	75-81
models	O	82-88
of	O	89-91
Parkinson	B	92-101
'	I	101-102
s	I	98-99
disease	I	104-111
.	O	111-112

The	O	113-116
in	O	117-119
vivo	O	120-124
characterization	O	125-141
of	O	142-144
a	O	145-146
dual	O	147-151
adenosine	O	152-161
A	O	162-163
(	O	163-164
2A	O	164-166
)	O	166-167
/	O	167-168
A	O	162-163
(	O	163-164
1	O	170-171
)	O	166-167
receptor	O	173-181
antagonist	O	182-192
in	O	193-195
several	O	196-203
animal	O	204-210
models	O	211-217
of	O	218-220
Parkinson	B	221-230
'	I	230-231
s	I	227-228
disease	I	233-240
is	O	241-243
described	O	244-253
.	O	253-254

Discovery	O	255-264
and	O	265-268
scale	O	269-274
-	O	274-275
up	O	275-277
syntheses	O	278-287
of	O	288-290
compound	O	291-299
1	O	300-301
are	O	302-305
described	O	306-315
in	O	316-318
detail	O	319-325
,	O	325-326
highlighting	O	327-339
optimization	O	340-352
steps	O	353-358
that	O	359-363
increased	O	364-373
the	O	374-377
overall	O	378-385
yield	O	386-391
of	O	392-394
1	O	395-396
from	O	397-401
10	O	402-404
.	O	404-405
0	O	403-404
%	O	406-407
to	O	408-410
30	O	411-413
.	O	413-414
5	O	414-415
%	O	415-416
.	O	413-414

Compound	O	418-426
1	O	427-428
is	O	429-431
a	O	432-433
potent	O	434-440
A	O	441-442
(	O	442-443
2A	O	443-445
)	O	445-446
/	O	446-447
A	O	441-442
(	O	442-443
1	O	449-450
)	O	445-446
receptor	O	452-460
antagonist	O	461-471
in	O	472-474
vitro	O	475-480
(	O	481-482
A	O	482-483
(	O	481-482
2A	O	484-486
)	O	486-487
K	O	488-489
(	O	489-490
i	O	490-491
)	O	491-492
=	O	493-494
4	O	495-496
.	O	496-497
1	O	497-498
nM	O	499-501
;	O	501-502
A	O	503-504
(	O	504-505
1	O	505-506
)	O	506-507
K	O	508-509
(	O	509-510
i	O	510-511
)	O	511-512
=	O	513-514
17	O	515-517
.	O	517-518
0	O	518-519
nM	O	520-522
)	O	522-523
that	O	524-528
has	O	529-532
excellent	O	533-542
activity	O	543-551
,	O	551-552
after	O	553-558
oral	O	559-563
administration	O	564-578
,	O	578-579
across	O	580-586
a	O	587-588
number	O	589-595
of	O	596-598
animal	O	599-605
models	O	606-612
of	O	613-615
Parkinson	B	616-625
'	I	625-626
s	I	622-623
disease	I	628-635
including	O	636-645
mouse	O	646-651
and	O	652-655
rat	O	656-659
models	O	660-666
of	O	667-669
haloperidol	O	670-681
-	O	681-682
induced	O	682-689
catalepsy	B	690-699
,	O	699-700
mouse	O	701-706
model	O	707-712
of	O	713-715
reserpine	O	716-725
-	O	725-726
induced	O	726-733
akinesia	B	734-742
,	O	742-743
rat	O	744-747
6	O	748-749
-	O	749-750
hydroxydopamine	O	750-765
(	O	766-767
6	O	767-768
-	O	768-769
OHDA	O	769-773
)	O	773-774
lesion	O	775-781
model	O	782-787
of	O	788-790
drug	O	791-795
-	O	795-796
induced	O	796-803
rotation	O	804-812
,	O	812-813
and	O	814-817
MPTP	O	818-822
-	O	822-823
treated	O	823-830
non	O	831-834
-	O	834-835
human	O	835-840
primate	O	841-848
model	O	849-854
.	O	854-855

An	O	0-2
extremely	O	3-12
rare	O	13-17
case	O	18-22
of	O	23-25
delusional	B	26-36
parasitosis	I	37-48
in	O	49-51
a	O	52-53
chronic	B	54-61
hepatitis	I	62-71
C	I	72-73
patient	O	74-81
during	O	82-88
pegylated	O	89-98
interferon	O	99-109
alpha	O	110-115
-	O	115-116
2b	O	116-118
and	O	119-122
ribavirin	O	123-132
treatment	O	133-142
.	O	142-143

During	O	144-150
treatment	O	151-160
of	O	161-163
chronic	B	164-171
hepatitis	I	172-181
C	I	182-183
patients	O	184-192
with	O	193-197
interferon	O	198-208
and	O	209-212
ribavirin	O	213-222
,	O	222-223
a	O	224-225
lot	O	226-229
of	O	230-232
side	O	233-237
effects	O	238-245
are	O	246-249
described	O	250-259
.	O	259-260

Twenty	O	261-267
-	O	267-268
three	O	268-273
percent	O	274-281
to	O	282-284
44	O	285-287
%	O	287-288
of	O	289-291
patients	O	292-300
develop	O	301-308
depression	B	309-319
.	O	319-320

A	O	321-322
minority	O	323-331
of	O	332-334
patients	O	335-343
evolve	O	344-350
to	O	351-353
psychosis	B	354-363
.	O	363-364

To	O	365-367
the	O	368-371
best	O	372-376
of	O	377-379
our	O	380-383
knowledge	O	384-393
,	O	393-394
no	O	395-397
cases	O	398-403
of	O	404-406
psychogenic	B	407-418
parasitosis	I	419-430
occurring	O	431-440
during	O	441-447
interferon	O	448-458
therapy	O	459-466
have	O	467-471
been	O	472-476
described	O	477-486
in	O	487-489
the	O	490-493
literature	O	494-504
.	O	504-505

We	O	506-508
present	O	509-516
a	O	517-518
49	O	519-521
-	O	521-522
year	O	522-526
-	O	521-522
old	O	527-530
woman	O	531-536
who	O	537-540
developed	O	541-550
a	O	551-552
delusional	B	553-563
parasitosis	I	564-575
during	O	576-582
treatment	O	583-592
with	O	593-597
pegylated	O	598-607
interferon	O	608-618
alpha	O	619-624
-	O	624-625
2b	O	625-627
weekly	O	628-634
and	O	635-638
ribavirin	O	639-648
.	O	648-649

She	O	650-653
complained	O	654-664
of	O	665-667
seeing	O	668-674
parasites	O	675-684
and	O	685-688
the	O	689-692
larvae	O	693-699
of	O	700-702
fleas	O	703-708
in	O	709-711
her	O	712-715
stools	O	716-722
.	O	722-723

This	O	724-728
could	O	729-734
not	O	735-738
be	O	739-741
confirmed	O	742-751
by	O	752-754
any	O	755-758
technical	O	759-768
examination	O	769-780
.	O	780-781

All	O	782-785
the	O	786-789
complaints	O	790-800
disappeared	O	801-812
after	O	813-818
stopping	O	819-827
pegylated	O	828-837
interferon	O	838-848
alpha	O	849-854
-	O	854-855
2b	O	855-857
and	O	858-861
reappeared	O	862-872
after	O	873-878
restarting	O	879-889
it	O	890-892
.	O	892-893

She	O	894-897
had	O	898-901
a	O	902-903
complete	O	904-912
sustained	O	913-922
viral	O	923-928
response	O	929-937
.	O	937-938

Possible	O	0-8
neuroleptic	B	9-20
malignant	I	21-30
syndrome	I	31-39
related	O	40-47
to	O	48-50
concomitant	O	51-62
treatment	O	63-72
with	O	73-77
paroxetine	O	78-88
and	O	89-92
alprazolam	O	93-103
.	O	103-104

A	O	105-106
74	O	107-109
-	O	109-110
year	O	110-114
-	O	109-110
old	O	115-118
man	O	119-122
with	O	123-127
depressive	B	128-138
symptoms	I	139-147
was	O	148-151
admitted	O	152-160
to	O	161-163
a	O	164-165
psychiatric	B	166-177
hospital	O	178-186
due	O	187-190
to	O	191-193
insomnia	B	194-202
,	O	202-203
loss	B	204-208
of	I	209-211
appetite	I	212-220
,	O	220-221
exhaustion	O	222-232
,	O	232-233
and	O	234-237
agitation	B	238-247
.	O	247-248

Medical	O	249-256
treatment	O	257-266
was	O	267-270
initiated	O	271-280
at	O	281-283
a	O	284-285
daily	O	286-291
dose	O	292-296
of	O	297-299
20	O	300-302
mg	O	303-305
paroxetine	O	306-316
and	O	317-320
1	O	321-322
.	O	322-323
2	O	323-324
mg	O	325-327
alprazolam	O	328-338
.	O	338-339

On	O	340-342
the	O	343-346
10th	O	347-351
day	O	352-355
of	O	356-358
paroxetine	O	359-369
and	O	370-373
alprazolam	O	374-384
treatment	O	385-394
,	O	394-395
the	O	396-399
patient	O	400-407
exhibited	O	408-417
marked	O	418-424
psychomotor	B	425-436
retardation	I	437-448
,	O	448-449
disorientation	O	450-464
,	O	464-465
and	O	466-469
severe	O	470-476
muscle	B	477-483
rigidity	I	484-492
with	O	493-497
tremors	B	498-505
.	O	505-506

The	O	507-510
patient	O	511-518
had	O	519-522
a	O	523-524
fever	B	525-530
(	O	531-532
38	O	532-534
.	O	534-535
2	O	535-536
degrees	O	537-544
C	O	545-546
)	O	546-547
,	O	547-548
fluctuating	O	549-560
blood	O	561-566
pressure	O	567-575
(	O	576-577
between	O	577-584
165	O	585-588
/	O	588-589
90	O	589-591
and	O	592-595
130	O	596-599
/	O	599-600
70	O	600-602
mg	O	603-605
mm	O	606-608
Hg	O	609-611
)	O	611-612
,	O	612-613
and	O	614-617
severe	O	618-624
extrapyramidal	B	625-639
symptoms	I	640-648
.	O	648-649

Laboratory	O	650-660
tests	O	661-666
showed	O	667-673
an	O	674-676
elevation	O	677-686
of	O	687-689
creatine	O	690-698
phosphokinase	O	699-712
(	O	713-714
2218	O	714-718
IU	O	719-721
/	O	721-722
L	O	722-723
)	O	723-724
,	O	724-725
aspartate	O	726-735
aminotransferase	O	736-752
(	O	753-754
134	O	754-757
IU	O	758-760
/	O	760-761
L	O	761-762
)	O	762-763
,	O	763-764
alanine	O	765-772
aminotransferase	O	773-789
(	O	790-791
78	O	791-793
IU	O	794-796
/	O	796-797
L	O	797-798
)	O	798-799
,	O	799-800
and	O	801-804
BUN	O	805-808
(	O	809-810
27	O	810-812
.	O	812-813
9	O	813-814
mg	O	815-817
/	O	817-818
ml	O	818-820
)	O	820-821
levels	O	822-828
.	O	828-829

The	O	830-833
patient	O	834-841
received	O	842-850
bromocriptine	O	851-864
and	O	865-868
diazepam	O	869-877
to	O	878-880
treat	O	881-886
his	O	887-890
symptoms	O	891-899
.	O	899-900

7	O	901-902
days	O	903-907
later	O	908-913
,	O	913-914
the	O	915-918
fever	B	919-924
disappeared	O	925-936
and	O	937-940
the	O	941-944
patient	O	945-952
'	O	952-953
s	O	953-954
serum	O	955-960
CPK	O	961-964
levels	O	965-971
were	O	972-976
normalized	O	977-987
(	O	988-989
175	O	989-992
IU	O	993-995
/	O	995-996
L	O	996-997
)	O	997-998
.	O	998-999

This	O	1000-1004
patient	O	1005-1012
presented	O	1013-1022
with	O	1023-1027
symptoms	O	1028-1036
of	O	1037-1039
neuroleptic	B	1040-1051
malignant	I	1052-1061
syndrome	I	1062-1070
(	O	1071-1072
NMS	B	1072-1075
)	O	1075-1076
,	O	1076-1077
thus	O	1078-1082
demonstrating	O	1083-1096
that	O	1097-1101
NMS	B	1102-1105
-	O	1105-1106
like	O	1106-1110
symptoms	O	1111-1119
can	O	1120-1123
occur	O	1124-1129
after	O	1130-1135
combined	O	1136-1144
paroxetine	O	1145-1155
and	O	1156-1159
alprazolam	O	1160-1170
treatment	O	1171-1180
.	O	1180-1181

The	O	1182-1185
adverse	O	1186-1193
drug	O	1194-1198
reaction	O	1199-1207
score	O	1208-1213
obtained	O	1214-1222
by	O	1223-1225
the	O	1226-1229
Naranjo	O	1230-1237
algorithm	O	1238-1247
was	O	1248-1251
6	O	1252-1253
in	O	1254-1256
our	O	1257-1260
case	O	1261-1265
,	O	1265-1266
indicating	O	1267-1277
a	O	1278-1279
probable	O	1280-1288
relationship	O	1289-1301
between	O	1302-1309
the	O	1310-1313
patient	O	1314-1321
'	O	1321-1322
s	O	1322-1323
NMS	B	1324-1327
-	O	1327-1328
like	O	1328-1332
adverse	O	1333-1340
symptoms	O	1341-1349
and	O	1350-1353
the	O	1354-1357
combined	O	1358-1366
treatment	O	1367-1376
used	O	1377-1381
in	O	1382-1384
this	O	1385-1389
case	O	1390-1394
.	O	1394-1395

The	O	1396-1399
involvement	O	1400-1411
of	O	1412-1414
physiologic	O	1415-1426
and	O	1427-1430
environmental	O	1431-1444
aspects	O	1445-1452
specific	O	1453-1461
to	O	1462-1464
this	O	1465-1469
patient	O	1470-1477
was	O	1478-1481
suspected	O	1482-1491
.	O	1491-1492

Several	O	1493-1500
risk	O	1501-1505
factors	O	1506-1513
for	O	1514-1517
NMS	B	1518-1521
should	O	1522-1528
be	O	1529-1531
noted	O	1532-1537
in	O	1538-1540
elderly	O	1541-1548
depressive	B	1549-1559
patients	O	1560-1568
whose	O	1569-1574
symptoms	O	1575-1583
often	O	1584-1589
include	O	1590-1597
dehydration	B	1598-1609
,	O	1609-1610
agitation	B	1611-1620
,	O	1620-1621
malnutrition	B	1622-1634
,	O	1634-1635
and	O	1636-1639
exhaustion	O	1640-1650
.	O	1650-1651

Careful	O	1652-1659
therapeutic	O	1660-1671
intervention	O	1672-1684
is	O	1685-1687
necessary	O	1688-1697
in	O	1698-1700
cases	O	1701-1706
involving	O	1707-1716
elderly	O	1717-1724
patients	O	1725-1733
who	O	1734-1737
suffer	O	1738-1744
from	O	1745-1749
depression	B	1750-1760
.	O	1760-1761

Pilocarpine	O	0-11
seizures	B	12-20
cause	O	21-26
age	O	27-30
-	O	30-31
dependent	O	31-40
impairment	B	41-51
in	I	52-54
auditory	I	55-63
location	I	64-72
discrimination	I	73-87
.	O	87-88

Children	O	89-97
who	O	98-101
have	O	102-106
status	B	107-113
epilepticus	I	114-125
have	O	126-130
continuous	O	131-141
or	O	142-144
rapidly	O	145-152
repeating	O	153-162
seizures	B	163-171
that	O	172-176
may	O	177-180
be	O	181-183
life	O	184-188
-	O	188-189
threatening	O	189-200
and	O	201-204
may	O	205-208
cause	O	209-214
life	O	215-219
-	O	219-220
long	O	220-224
changes	O	225-232
in	O	233-235
brain	O	236-241
and	O	242-245
behavior	O	246-254
.	O	254-255

The	O	256-259
extent	O	260-266
to	O	267-269
which	O	270-275
status	B	276-282
epilepticus	I	283-294
causes	O	295-301
deficits	B	302-310
in	I	311-313
auditory	I	314-322
discrimination	I	323-337
is	O	338-340
unknown	O	341-348
.	O	348-349

A	O	350-351
naturalistic	O	352-364
auditory	O	365-373
location	O	374-382
discrimination	O	383-397
method	O	398-404
was	O	405-408
used	O	409-413
to	O	414-416
evaluate	O	417-425
this	O	426-430
question	O	431-439
using	O	440-445
an	O	446-448
animal	O	449-455
model	O	456-461
of	O	462-464
status	B	465-471
epilepticus	I	472-483
.	O	483-484

Male	O	485-489
Sprague	O	490-497
-	O	497-498
Dawley	O	498-504
rats	O	505-509
were	O	510-514
injected	O	515-523
with	O	524-528
saline	O	529-535
on	O	536-538
postnatal	O	539-548
day	O	549-552
(	O	553-554
P	O	554-555
)	O	555-556
20	O	557-559
,	O	559-560
or	O	561-563
a	O	564-565
convulsant	O	566-576
dose	O	577-581
of	O	582-584
pilocarpine	O	585-596
on	O	597-599
P20	O	600-603
or	O	604-606
P45	O	607-610
.	O	610-611

Pilocarpine	O	612-623
on	O	624-626
either	O	627-633
day	O	634-637
induced	O	638-645
status	B	646-652
epilepticus	I	653-664
;	O	664-665
status	B	666-672
epilepticus	I	673-684
at	O	685-687
P45	O	688-691
resulted	O	692-700
in	O	701-703
CA3	O	704-707
cell	O	708-712
loss	O	713-717
and	O	718-721
spontaneous	O	722-733
seizures	B	734-742
,	O	742-743
whereas	O	744-751
P20	O	752-755
rats	O	756-760
had	O	761-764
no	O	765-767
cell	O	768-772
loss	O	773-777
or	O	778-780
spontaneous	O	781-792
seizures	B	793-801
.	O	801-802

Mature	O	803-809
rats	O	810-814
were	O	815-819
trained	O	820-827
with	O	828-832
sound	O	833-838
-	O	838-839
source	O	839-845
location	O	846-854
and	O	855-858
sound	O	859-864
-	O	864-865
silence	O	865-872
discriminations	O	873-888
.	O	888-889

Control	O	890-897
(	O	898-899
saline	O	899-905
P20	O	906-909
)	O	909-910
rats	O	911-915
acquired	O	916-924
both	O	925-929
discriminations	O	930-945
immediately	O	946-957
.	O	957-958

In	O	959-961
status	B	962-968
epilepticus	I	969-980
(	O	981-982
P20	O	982-985
)	O	985-986
rats	O	987-991
,	O	991-992
acquisition	O	993-1004
of	O	1005-1007
the	O	1008-1011
sound	O	1012-1017
-	O	1017-1018
source	O	1018-1024
location	O	1025-1033
discrimination	O	1034-1048
was	O	1049-1052
moderately	O	1053-1063
impaired	O	1064-1072
.	O	1072-1073

Status	B	1074-1080
epilepticus	I	1081-1092
(	O	1093-1094
P45	O	1094-1097
)	O	1097-1098
rats	O	1099-1103
failed	O	1104-1110
to	O	1111-1113
acquire	O	1114-1121
either	O	1122-1128
sound	O	1129-1134
-	O	1134-1135
source	O	1135-1141
location	O	1142-1150
or	O	1151-1153
sound	O	1154-1159
-	O	1159-1160
silence	O	1160-1167
discriminations	O	1168-1183
.	O	1183-1184

Status	B	1185-1191
epilepticus	I	1192-1203
in	O	1204-1206
rat	O	1207-1210
causes	O	1211-1217
an	O	1218-1220
age	O	1221-1224
-	O	1224-1225
dependent	O	1225-1234
,	O	1234-1235
long	O	1236-1240
-	O	1240-1241
term	O	1241-1245
impairment	B	1246-1256
in	I	1257-1259
auditory	I	1260-1268
discrimination	I	1269-1283
.	O	1283-1284

This	O	1285-1289
impairment	O	1290-1300
may	O	1301-1304
explain	O	1305-1312
one	O	1313-1316
cause	O	1317-1322
of	O	1323-1325
impaired	B	1326-1334
auditory	I	1335-1343
location	I	1344-1352
discrimination	I	1353-1367
in	O	1368-1370
humans	O	1371-1377
.	O	1377-1378

Cardiovascular	O	0-14
risk	O	15-19
with	O	20-24
cyclooxygenase	O	25-39
inhibitors	O	40-50
:	O	50-51
general	O	52-59
problem	O	60-67
with	O	68-72
substance	O	73-82
specific	O	83-91
differences	O	92-103
?	O	103-104

Randomised	O	105-115
clinical	O	116-124
trials	O	125-131
and	O	132-135
observational	O	136-149
studies	O	150-157
have	O	158-162
shown	O	163-168
an	O	169-171
increased	O	172-181
risk	O	182-186
of	O	187-189
myocardial	B	190-200
infarction	I	201-211
,	O	211-212
stroke	B	213-219
,	O	219-220
hypertension	B	221-233
and	O	234-237
heart	B	238-243
failure	I	244-251
during	O	252-258
treatment	O	259-268
with	O	269-273
cyclooxygenase	O	274-288
inhibitors	O	289-299
.	O	299-300

Adverse	O	301-308
cardiovascular	O	309-323
effects	O	324-331
occurred	O	332-340
mainly	O	341-347
,	O	347-348
but	O	349-352
not	O	353-356
exclusively	O	357-368
,	O	368-369
in	O	370-372
patients	O	373-381
with	O	382-386
concomitant	O	387-398
risk	O	399-403
factors	O	404-411
.	O	411-412

Cyclooxygenase	O	413-427
inhibitors	O	428-438
cause	O	439-444
complex	O	445-452
changes	O	453-460
in	O	461-463
renal	O	464-469
,	O	469-470
vascular	O	471-479
and	O	480-483
cardiac	O	484-491
prostanoid	O	492-502
profiles	O	503-511
thereby	O	512-519
increasing	O	520-530
vascular	O	531-539
resistance	O	540-550
and	O	551-554
fluid	O	555-560
retention	O	561-570
.	O	570-571

The	O	572-575
incidence	O	576-585
of	O	586-588
cardiovascular	O	589-603
adverse	O	604-611
events	O	612-618
tends	O	619-624
to	O	625-627
increase	O	628-636
with	O	637-641
the	O	642-645
daily	O	646-651
dose	O	652-656
and	O	657-660
total	O	661-666
exposure	O	667-675
time	O	676-680
.	O	680-681

A	O	682-683
comparison	O	684-694
of	O	695-697
individual	O	698-708
selective	O	709-718
and	O	719-722
unselective	O	723-734
cyclooxygenase	O	735-749
inhibitors	O	750-760
suggests	O	761-769
substance	O	770-779
-	O	779-780
specific	O	780-788
differences	O	789-800
,	O	800-801
which	O	802-807
may	O	808-811
depend	O	812-818
on	O	819-821
differences	O	822-833
in	O	834-836
pharmacokinetic	O	837-852
parameters	O	853-863
or	O	864-866
inhibitory	O	867-877
potency	O	878-885
and	O	886-889
may	O	890-893
be	O	894-896
contributed	O	897-908
by	O	909-911
prostaglandin	O	912-925
-	O	925-926
independent	O	926-937
effects	O	938-945
.	O	945-946

Diagnostic	O	947-957
markers	O	958-965
such	O	966-970
as	O	971-973
N	O	974-975
-	O	975-976
terminal	O	976-984
pro	O	985-988
brain	O	989-994
natriuretic	O	995-1006
peptide	O	1007-1014
(	O	1015-1016
NT	O	1016-1018
-	O	1018-1019
proBNP	O	1019-1025
)	O	1025-1026
or	O	1027-1029
high	O	1030-1034
-	O	1034-1035
sensitive	O	1035-1044
C	O	1045-1046
-	O	1046-1047
reactive	O	1047-1055
protein	O	1056-1063
might	O	1064-1069
help	O	1070-1074
in	O	1075-1077
the	O	1078-1081
early	O	1082-1087
identification	O	1088-1102
of	O	1103-1105
patients	O	1106-1114
at	O	1115-1117
risk	O	1118-1122
,	O	1122-1123
thus	O	1124-1128
avoiding	O	1129-1137
the	O	1138-1141
occurrence	O	1142-1152
of	O	1153-1155
serious	O	1156-1163
cardiovascular	B	1164-1178
toxicity	I	1179-1187
.	O	1187-1188

Predictors	O	0-10
of	O	11-13
decreased	B	14-23
renal	I	24-29
function	I	30-38
in	O	39-41
patients	O	42-50
with	O	51-55
heart	B	56-61
failure	I	62-69
during	O	70-76
angiotensin	O	77-88
-	O	88-89
converting	O	89-99
enzyme	O	100-106
inhibitor	O	107-116
therapy	O	117-124
:	O	124-125
results	O	126-133
from	O	134-138
the	O	139-142
studies	O	143-150
of	O	151-153
left	B	154-158
ventricular	I	159-170
dysfunction	I	171-182
(	O	183-184
SOLVD	O	184-189
)	O	189-190
BACKGROUND	O	191-201
:	O	201-202
Although	O	203-211
angiotensin	O	212-223
-	O	223-224
converting	O	224-234
enzyme	O	235-241
inhibitor	O	242-251
therapy	O	252-259
reduces	O	260-267
mortality	O	268-277
rates	O	278-283
in	O	284-286
patients	O	287-295
with	O	296-300
congestive	B	301-311
heart	I	312-317
failure	I	318-325
(	O	326-327
CHF	B	327-330
)	O	330-331
,	O	331-332
it	O	333-335
may	O	336-339
also	O	340-344
cause	O	345-350
decreased	B	351-360
renal	I	361-366
function	I	367-375
.	O	375-376

Little	O	377-383
information	O	384-395
is	O	396-398
available	O	399-408
to	O	409-411
predict	O	412-419
which	O	420-425
patients	O	426-434
are	O	435-438
at	O	439-441
highest	O	442-449
risk	O	450-454
for	O	455-458
this	O	459-463
complication	O	464-476
.	O	476-477

OBJECTIVE	O	478-487
:	O	487-488
To	O	489-491
quantify	O	492-500
specific	O	501-509
clinical	O	510-518
predictors	O	519-529
of	O	530-532
reduction	B	533-542
in	I	543-545
renal	I	546-551
function	I	552-560
in	O	561-563
patients	O	564-572
with	O	573-577
CHF	B	578-581
who	O	582-585
are	O	586-589
prescribed	O	590-600
angiotensin	O	601-612
-	O	612-613
converting	O	613-623
enzyme	O	624-630
inhibitor	O	631-640
therapy	O	641-648
.	O	648-649

METHOD	O	650-656
:	O	656-657
We	O	658-660
analyzed	O	661-669
data	O	670-674
from	O	675-679
the	O	680-683
Studies	O	684-691
of	O	692-694
Left	B	695-699
Ventricular	I	700-711
Dysfunction	I	712-723
(	O	724-725
SOLVD	O	725-730
)	O	730-731
,	O	731-732
a	O	733-734
randomized	O	735-745
,	O	745-746
double	O	747-753
-	O	753-754
blind	O	754-759
,	O	759-760
placebo	O	761-768
-	O	768-769
controlled	O	769-779
trial	O	780-785
of	O	786-788
enalapril	O	789-798
for	O	799-802
the	O	803-806
treatment	O	807-816
of	O	817-819
CHF	B	820-823
.	O	823-824

There	O	825-830
were	O	831-835
3379	O	836-840
patients	O	841-849
randomly	O	850-858
assigned	O	859-867
to	O	868-870
enalapril	O	871-880
with	O	881-885
a	O	886-887
median	O	888-894
follow	O	895-901
-	O	901-902
up	O	902-904
of	O	905-907
974	O	908-911
days	O	912-916
and	O	917-920
3379	O	921-925
patients	O	926-934
randomly	O	935-943
assigned	O	944-952
to	O	953-955
placebo	O	956-963
with	O	964-968
a	O	969-970
mean	O	971-975
follow	O	976-982
-	O	982-983
up	O	983-985
of	O	986-988
967	O	989-992
days	O	993-997
.	O	997-998

Decreased	B	999-1008
renal	I	1009-1014
function	I	1015-1023
was	O	1024-1027
defined	O	1028-1035
as	O	1036-1038
a	O	1039-1040
rise	O	1041-1045
in	O	1046-1048
serum	O	1049-1054
creatinine	O	1055-1065
>	O	1066-1067
/	O	1067-1068
=	O	1068-1069
0	O	1069-1070
.	O	1070-1071
5	O	1071-1072
mg	O	1073-1075
/	O	1075-1076
dL	O	1076-1078
(	O	1079-1080
44	O	1080-1082
micromol	O	1083-1091
/	O	1091-1092
L	O	1092-1093
)	O	1093-1094
from	O	1095-1099
baseline	O	1100-1108
.	O	1108-1109

We	O	1110-1112
used	O	1113-1117
time	O	1118-1122
-	O	1122-1123
to	O	1123-1125
-	O	1122-1123
event	O	1126-1131
analysis	O	1132-1140
to	O	1141-1143
identify	O	1144-1152
potential	O	1153-1162
predictors	O	1163-1173
of	O	1174-1176
decrease	O	1177-1185
in	O	1186-1188
renal	O	1189-1194
function	O	1195-1203
including	O	1204-1213
age	O	1214-1217
,	O	1217-1218
baseline	O	1219-1227
ejection	O	1228-1236
fraction	O	1237-1245
,	O	1245-1246
baseline	O	1247-1255
creatinine	O	1256-1266
,	O	1266-1267
low	O	1268-1271
systolic	O	1272-1280
blood	O	1281-1286
pressure	O	1287-1295
(	O	1296-1297
<	O	1297-1298
100	O	1298-1301
mm	O	1302-1304
Hg	O	1305-1307
)	O	1307-1308
,	O	1308-1309
history	O	1310-1317
of	O	1318-1320
hypertension	B	1321-1333
,	O	1333-1334
diabetes	B	1335-1343
,	O	1343-1344
and	O	1345-1348
use	O	1349-1352
of	O	1353-1355
antiplatelet	O	1356-1368
,	O	1368-1369
diuretic	O	1370-1378
,	O	1378-1379
and	O	1380-1383
beta	O	1384-1388
-	O	1388-1389
blocker	O	1389-1396
therapy	O	1397-1404
.	O	1404-1405

RESULTS	O	1406-1413
:	O	1413-1414
Patients	O	1415-1423
randomly	O	1424-1432
assigned	O	1433-1441
to	O	1442-1444
enalapril	O	1445-1454
had	O	1455-1458
a	O	1459-1460
33	O	1461-1463
%	O	1463-1464
greater	O	1465-1472
likelihood	O	1473-1483
of	O	1484-1486
decreased	B	1487-1496
renal	I	1497-1502
function	I	1503-1511
than	O	1512-1516
controls	O	1517-1525
(	O	1526-1527
P	O	1527-1528
=	O	1529-1530
.	O	1530-1531
003	O	1531-1534
)	O	1534-1535
.	O	1530-1531

By	O	1537-1539
multivariate	O	1540-1552
analysis	O	1553-1561
,	O	1561-1562
in	O	1563-1565
both	O	1566-1570
the	O	1571-1574
placebo	O	1575-1582
and	O	1583-1586
enalapril	O	1587-1596
groups	O	1597-1603
older	O	1604-1609
age	O	1610-1613
,	O	1613-1614
diuretic	O	1615-1623
therapy	O	1624-1631
,	O	1631-1632
and	O	1633-1636
diabetes	B	1637-1645
were	O	1646-1650
associated	O	1651-1661
with	O	1662-1666
decreased	B	1667-1676
renal	I	1677-1682
function	I	1683-1691
,	O	1691-1692
whereas	O	1693-1700
beta	O	1701-1705
-	O	1705-1706
blocker	O	1706-1713
therapy	O	1714-1721
and	O	1722-1725
higher	O	1726-1732
ejection	O	1733-1741
fraction	O	1742-1750
were	O	1751-1755
renoprotective	O	1756-1770
.	O	1770-1771

Older	O	1772-1777
age	O	1778-1781
was	O	1782-1785
associated	O	1786-1796
with	O	1797-1801
a	O	1802-1803
greater	O	1804-1811
risk	O	1812-1816
of	O	1817-1819
developing	O	1820-1830
decreased	B	1831-1840
renal	I	1841-1846
function	I	1847-1855
in	O	1856-1858
both	O	1859-1863
groups	O	1864-1870
,	O	1870-1871
but	O	1872-1875
significantly	O	1876-1889
more	O	1890-1894
so	O	1895-1897
in	O	1898-1900
the	O	1901-1904
enalapril	O	1905-1914
group	O	1915-1920
(	O	1921-1922
enalapril	O	1922-1931
:	O	1931-1932
risk	O	1933-1937
ratio	O	1938-1943
[	O	1944-1945
RR	O	1945-1947
]	O	1947-1948
1	O	1949-1950
.	O	1950-1951
42	O	1951-1953
per	O	1954-1957
10	O	1958-1960
years	O	1961-1966
,	O	1966-1967
95	O	1968-1970
%	O	1970-1971
confidence	O	1972-1982
interval	O	1983-1991
[	O	1992-1993
CI	O	1993-1995
]	O	1995-1996
1	O	1997-1998
.	O	1998-1999
32	O	1999-2001
-	O	2001-2002
1	O	1997-1998
.	O	1998-1999
52	O	2004-2006
with	O	2007-2011
enalapril	O	2012-2021
;	O	2021-2022
placebo	O	2023-2030
:	O	2030-2031
RR	O	2032-2034
1	O	2035-2036
.	O	2036-2037
18	O	2037-2039
,	O	2039-2040
95	O	2041-2043
%	O	2043-2044
CI	O	2045-2047
1	O	2048-2049
.	O	2049-2050
12	O	2050-2052
-	O	2052-2053
1	O	2048-2049
.	O	2049-2050
25	O	2055-2057
)	O	2057-2058
.	O	2049-2050

Diuretic	O	2060-2068
therapy	O	2069-2076
was	O	2077-2080
likewise	O	2081-2089
associated	O	2090-2100
with	O	2101-2105
a	O	2106-2107
greater	O	2108-2115
risk	O	2116-2120
of	O	2121-2123
decreased	B	2124-2133
renal	I	2134-2139
function	I	2140-2148
in	O	2149-2151
the	O	2152-2155
enalapril	O	2156-2165
group	O	2166-2171
(	O	2172-2173
RR	O	2173-2175
1	O	2176-2177
.	O	2177-2178
89	O	2178-2180
,	O	2180-2181
95	O	2182-2184
%	O	2184-2185
CI	O	2186-2188
1	O	2189-2190
.	O	2190-2191
70	O	2191-2193
-	O	2193-2194
2	O	2194-2195
.	O	2190-2191
08	O	2196-2198
)	O	2198-2199

than	O	2200-2204
in	O	2205-2207
the	O	2208-2211
placebo	O	2212-2219
group	O	2220-2225
(	O	2226-2227
RR	O	2227-2229
1	O	2230-2231
.	O	2231-2232
35	O	2232-2234
,	O	2234-2235
95	O	2236-2238
%	O	2238-2239
CI	O	2240-2242
1	O	2243-2244
.	O	2244-2245
09	O	2245-2247
-	O	2247-2248
1	O	2243-2244
.	O	2244-2245
66	O	2250-2252
)	O	2252-2253
.	O	2244-2245

Conversely	O	2255-2265
,	O	2265-2266
enalapril	O	2267-2276
had	O	2277-2280
a	O	2281-2282
relative	O	2283-2291
renoprotective	O	2292-2306
effect	O	2307-2313
(	O	2314-2315
RR	O	2315-2317
1	O	2318-2319
.	O	2319-2320
33	O	2320-2322
,	O	2322-2323
95	O	2324-2326
%	O	2326-2327
CI	O	2328-2330
1	O	2331-2332
.	O	2332-2333
13	O	2333-2335
-	O	2335-2336
1	O	2331-2332
.	O	2332-2333
53	O	2338-2340
)	O	2340-2341

compared	O	2342-2350
with	O	2351-2355
placebo	O	2356-2363
(	O	2364-2365
RR	O	2365-2367
1	O	2368-2369
.	O	2369-2370
96	O	2370-2372
,	O	2372-2373
95	O	2374-2376
%	O	2376-2377
CI	O	2378-2380
1	O	2381-2382
.	O	2382-2383
57	O	2383-2385
-	O	2385-2386
2	O	2386-2387
.	O	2382-2383
44	O	2388-2390
)	O	2390-2391
in	O	2392-2394
patients	O	2395-2403
with	O	2404-2408
diabetes	B	2409-2417
.	O	2417-2418

A	O	2419-2420
lower	O	2421-2426
risk	O	2427-2431
of	O	2432-2434
renal	B	2435-2440
impairment	I	2441-2451
was	O	2452-2455
seen	O	2456-2460
in	O	2461-2463
both	O	2464-2468
groups	O	2469-2475
with	O	2476-2480
beta	O	2481-2485
-	O	2485-2486
blocker	O	2486-2493
therapy	O	2494-2501
(	O	2502-2503
RR	O	2503-2505
0	O	2506-2507
.	O	2507-2508
70	O	2508-2510
,	O	2510-2511
95	O	2512-2514
%	O	2514-2515
CI	O	2516-2518
0	O	2519-2520
.	O	2520-2521
57	O	2521-2523
-	O	2523-2524
0	O	2519-2520
.	O	2520-2521
85	O	2526-2528
)	O	2528-2529

and	O	2530-2533
higher	O	2534-2540
baseline	O	2541-2549
ejection	O	2550-2558
fraction	O	2559-2567
(	O	2568-2569
RR	O	2569-2571
0	O	2572-2573
.	O	2573-2574
93	O	2574-2576
per	O	2577-2580
5	O	2581-2582
%	O	2582-2583
increment	O	2584-2593
,	O	2593-2594
95	O	2595-2597
%	O	2597-2598
CI	O	2599-2601
0	O	2602-2603
.	O	2603-2604
91	O	2604-2606
-	O	2606-2607
0	O	2602-2603
.	O	2603-2604

96	O	2610-2612
)	O	2612-2613
.	O	2613-2614

CONCLUSIONS	O	2615-2626
:	O	2626-2627
Enalapril	O	2628-2637
use	O	2638-2641
caused	O	2642-2648
a	O	2649-2650
33	O	2651-2653
%	O	2653-2654
increase	O	2655-2663
in	O	2664-2666
the	O	2667-2670
risk	O	2671-2675
of	O	2676-2678
decreased	B	2679-2688
renal	I	2689-2694
function	I	2695-2703
in	O	2704-2706
patients	O	2707-2715
with	O	2716-2720
CHF	B	2721-2724
.	O	2724-2725

Diuretic	O	2726-2734
use	O	2735-2738
and	O	2739-2742
advanced	O	2743-2751
age	O	2752-2755
increased	O	2756-2765
this	O	2766-2770
risk	O	2771-2775
.	O	2775-2776

Diabetes	B	2777-2785
was	O	2786-2789
associated	O	2790-2800
with	O	2801-2805
an	O	2806-2808
increased	O	2809-2818
risk	O	2819-2823
of	O	2824-2826
renal	B	2827-2832
impairment	I	2833-2843
in	O	2844-2846
all	O	2847-2850
patients	O	2851-2859
with	O	2860-2864
CHF	B	2865-2868
,	O	2868-2869
but	O	2870-2873
this	O	2874-2878
risk	O	2879-2883
was	O	2884-2887
reduced	O	2888-2895
in	O	2896-2898
the	O	2899-2902
enalapril	O	2903-2912
group	O	2913-2918
compared	O	2919-2927
with	O	2928-2932
the	O	2933-2936
placebo	O	2937-2944
group	O	2945-2950
.	O	2950-2951

beta	O	2952-2956
-	O	2956-2957
Blocker	O	2957-2964
therapy	O	2965-2972
and	O	2973-2976
higher	O	2977-2983
ejection	O	2984-2992
fraction	O	2993-3001
were	O	3002-3006
renoprotective	O	3007-3021
in	O	3022-3024
all	O	3025-3028
patients	O	3029-3037
regardless	O	3038-3048
of	O	3049-3051
therapy	O	3052-3059
.	O	3059-3060

Pemoline	O	0-8
induced	O	9-16
acute	O	17-22
choreoathetosis	B	23-38
:	O	38-39
case	O	40-44
report	O	45-51
and	O	52-55
review	O	56-62
of	O	63-65
the	O	66-69
literature	O	70-80
.	O	80-81

BACKGROUND	O	82-92
:	O	92-93
Pemoline	O	94-102
is	O	103-105
an	O	106-108
oxazolidine	O	109-120
derivative	O	121-131
that	O	132-136
is	O	137-139
structurally	O	140-152
different	O	153-162
from	O	163-167
amphetamines	O	168-180
and	O	181-184
used	O	185-189
in	O	190-192
the	O	193-196
treatment	O	197-206
of	O	207-209
attention	B	210-219
deficit	I	220-227
disorder	I	228-236
.	O	236-237

Pemoline	O	238-246
has	O	247-250
not	O	251-254
been	O	255-259
commonly	O	260-268
associated	O	269-279
in	O	280-282
the	O	283-286
literature	O	287-297
as	O	298-300
a	O	301-302
cause	O	303-308
of	O	309-311
acute	O	312-317
movement	B	318-326
disorders	I	327-336
.	O	336-337

The	O	338-341
following	O	342-351
case	O	352-356
describes	O	357-366
two	O	367-370
children	O	371-379
acutely	O	380-387
poisoned	O	388-396
with	O	397-401
pemoline	O	402-410
who	O	411-414
experienced	O	415-426
profound	O	427-435
choreoathetosis	B	436-451
.	O	451-452

CASE	O	453-457
REPORT	O	458-464
:	O	464-465
Two	O	466-469
,	O	469-470
3	O	471-472
-	O	472-473
year	O	473-477
-	O	472-473
old	O	478-481
male	O	482-486
,	O	486-487
identical	O	488-497
twin	O	498-502
siblings	O	503-511
presented	O	512-521
to	O	522-524
the	O	525-528
emergency	O	529-538
department	O	539-549
after	O	550-555
found	O	556-561
playing	O	562-569
with	O	570-574
a	O	575-576
an	O	577-579
empty	O	580-585
bottle	O	586-592
of	O	593-595
pemoline	O	596-604
originally	O	605-615
containing	O	616-626
59	O	627-629
tablets	O	630-637
.	O	637-638

The	O	639-642
children	O	643-651
had	O	652-655
a	O	656-657
medical	O	658-665
history	O	666-673
significant	O	674-685
for	O	686-689
attention	B	690-699
deficit	I	700-707
disorder	I	708-716
previously	O	717-727
treated	O	728-735
with	O	736-740
methylphenidate	O	741-756
without	O	757-764
success	O	765-772
.	O	772-773

This	O	774-778
was	O	779-782
their	O	783-788
first	O	789-794
day	O	795-798
of	O	799-801
pemoline	O	802-810
therapy	O	811-818
.	O	818-819

The	O	820-823
choreoathetoid	B	824-838
movements	O	839-848
began	O	849-854
45	O	855-857
min	O	858-861
to	O	862-864
1	O	865-866
h	O	867-868
after	O	869-874
ingestion	O	875-884
.	O	884-885

The	O	886-889
children	O	890-898
gave	O	899-903
no	O	904-906
history	O	907-914
of	O	915-917
prior	O	918-923
movement	B	924-932
disorders	I	933-942
and	O	943-946
there	O	947-952
was	O	953-956
no	O	957-959
family	O	960-966
history	O	967-974
of	O	975-977
movement	B	978-986
disorders	I	987-996
.	O	996-997

The	O	998-1001
children	O	1002-1010
received	O	1011-1019
gastrointestinal	O	1020-1036
decontamination	O	1037-1052
and	O	1053-1056
high	O	1057-1061
doses	O	1062-1067
of	O	1068-1070
intravenous	O	1071-1082
benzodiazepines	O	1083-1098
in	O	1099-1101
an	O	1102-1104
attempt	O	1105-1112
to	O	1113-1115
control	O	1116-1123
the	O	1124-1127
choreoathetoid	B	1128-1142
movements	O	1143-1152
.	O	1152-1153

Despite	O	1154-1161
treatment	O	1162-1171
,	O	1171-1172
the	O	1173-1176
children	O	1177-1185
continued	O	1186-1195
to	O	1196-1198
have	O	1199-1203
choreoathetosis	B	1204-1219
for	O	1220-1223
approximately	O	1224-1237
24	O	1238-1240
hours	O	1241-1246
.	O	1246-1247

Forty	O	1248-1253
-	O	1253-1254
eight	O	1254-1259
hours	O	1260-1265
after	O	1266-1271
admission	O	1272-1281
,	O	1281-1282
the	O	1283-1286
children	O	1287-1295
appeared	O	1296-1304
to	O	1305-1307
be	O	1308-1310
at	O	1311-1313
their	O	1314-1319
baseline	O	1320-1328
and	O	1329-1332
were	O	1333-1337
discharged	O	1338-1348
home	O	1349-1353
.	O	1353-1354

CONCLUSION	O	1355-1365
:	O	1365-1366
Pemoline	O	1367-1375
associated	O	1376-1386
movement	B	1387-1395
disorder	I	1396-1404
has	O	1405-1408
been	O	1409-1413
rarely	O	1414-1420
reported	O	1421-1429
in	O	1430-1432
the	O	1433-1436
acute	O	1437-1442
toxicology	O	1443-1453
literature	O	1454-1464
.	O	1464-1465

The	O	1466-1469
possibility	O	1470-1481
of	O	1482-1484
choreoathetoid	B	1485-1499
movements	O	1500-1509
should	O	1510-1516
be	O	1517-1519
considered	O	1520-1530
in	O	1531-1533
patients	O	1534-1542
presenting	O	1543-1553
after	O	1554-1559
pemoline	O	1560-1568
overdose	B	1569-1577
.	O	1577-1578

Continuous	O	0-10
subcutaneous	O	11-23
administration	O	24-38
of	O	39-41
mesna	O	42-47
to	O	48-50
prevent	O	51-58
ifosfamide	O	59-69
-	O	69-70
induced	O	70-77
hemorrhagic	B	78-89
cystitis	I	90-98
.	O	98-99

Hemorrhagic	B	100-111
cystitis	I	112-120
is	O	121-123
a	O	124-125
major	O	126-131
potential	O	132-141
toxicity	B	142-150
of	O	151-153
ifosfamide	O	154-164
that	O	165-169
can	O	170-173
be	O	174-176
prevented	O	177-186
by	O	187-189
administering	O	190-203
mesna	O	204-209
along	O	210-215
with	O	216-220
the	O	221-224
cytotoxic	O	225-234
agent	O	235-240
.	O	240-241

Mesna	O	242-247
is	O	248-250
generally	O	251-260
administered	O	261-273
by	O	274-276
the	O	277-280
intravenous	O	281-292
route	O	293-298
,	O	298-299
although	O	300-308
experience	O	309-319
with	O	320-324
oral	O	325-329
delivery	O	330-338
of	O	339-341
the	O	342-345
drug	O	346-350
has	O	351-354
increased	O	355-364
.	O	364-365

The	O	366-369
continuous	O	370-380
subcutaneous	O	381-393
administration	O	394-408
of	O	409-411
mesna	O	412-417
has	O	418-421
the	O	422-425
advantage	O	426-435
of	O	436-438
not	O	439-442
requiring	O	443-452
intravenous	O	453-464
access	O	465-471
.	O	471-472

In	O	473-475
addition	O	476-484
,	O	484-485
subcutaneous	O	486-498
delivery	O	499-507
of	O	508-510
the	O	511-514
neutralizing	O	515-527
agent	O	528-533
will	O	534-538
not	O	539-542
be	O	543-545
associated	O	546-556
with	O	557-561
the	O	562-565
risk	O	566-570
of	O	571-573
inadequate	O	574-584
urinary	O	585-592
mesna	O	593-598
concentrations	O	599-613
,	O	613-614
such	O	615-619
as	O	620-622
in	O	623-625
a	O	626-627
patient	O	628-635
taking	O	636-642
oral	O	643-647
mesna	O	648-653
who	O	654-657
experiences	O	658-669
severe	O	670-676
ifosfamide	O	677-687
-	O	687-688
induced	O	688-695
emesis	B	696-702
and	O	703-706
is	O	707-709
unable	O	710-716
to	O	717-719
absorb	O	720-726
the	O	727-730
drug	O	731-735
.	O	735-736

Limited	O	737-744
clinical	O	745-753
experience	O	754-764
with	O	765-769
continuous	O	770-780
subcutaneous	O	781-793
mesna	O	794-799
administration	O	800-814
suggests	O	815-823
it	O	824-826
is	O	827-829
a	O	830-831
safe	O	832-836
,	O	836-837
practical	O	838-847
,	O	847-848
and	O	849-852
economic	O	853-861
method	O	862-868
of	O	869-871
drug	O	872-876
delivery	O	877-885
that	O	886-890
permits	O	891-898
ifosfamide	O	899-909
to	O	910-912
be	O	913-915
administered	O	916-928
successfully	O	929-941
in	O	942-944
the	O	945-948
outpatient	O	949-959
setting	O	960-967
.	O	967-968

Modification	O	0-12
of	O	13-15
drug	O	16-20
action	O	21-27
by	O	28-30
hyperammonemia	B	31-45
.	O	45-46

Pretreatment	O	47-59
with	O	60-64
ammonium	O	65-73
acetate	O	74-81
(	O	82-83
NH4Ac	O	83-88
)	O	88-89
(	O	90-91
6	O	91-92
mmol	O	93-97
/	O	97-98
kg	O	98-100
s	O	101-102
.	O	102-103
c	O	103-104
.	O	102-103
)	O	105-106
approximately	O	107-120
doubled	O	121-128
the	O	129-132
time	O	133-137
morphine	O	138-146
-	O	146-147
treated	O	147-154
mice	O	155-159
remained	O	160-168
on	O	169-171
a	O	172-173
hot	O	174-177
surface	O	178-185
and	O	186-189
similarly	O	190-199
increased	O	200-209
muscular	O	210-218
incoordination	B	219-233
by	O	234-236
diazepam	O	237-245
,	O	245-246
but	O	247-250
NH4Ac	O	251-256
treatment	O	257-266
alone	O	267-272
had	O	273-276
no	O	277-279
effect	O	280-286
.	O	286-287

Thus	O	288-292
,	O	292-293
hyperammonemia	B	294-308
is	O	309-311
capable	O	312-319
of	O	320-322
altering	O	323-331
drug	O	332-336
action	O	337-343
and	O	344-347
must	O	348-352
be	O	353-355
considered	O	356-366
along	O	367-372
with	O	373-377
impaired	O	378-386
drug	O	387-391
metabolism	O	392-402
in	O	403-405
enhanced	O	406-414
drug	O	415-419
responses	O	420-429
associated	O	430-440
with	O	441-445
liver	B	446-451
disease	I	452-459
.	O	459-460

Experiments	O	461-472
in	O	473-475
vitro	O	476-481
showed	O	482-488
that	O	489-493
acetylcholine	O	494-507
-	O	507-508
induced	O	508-515
catecholamine	O	516-529
release	O	530-537
from	O	538-542
bovine	O	543-549
adrenal	O	550-557
medulla	O	558-565
is	O	566-568
depressed	O	569-578
as	O	579-581
much	O	582-586
as	O	587-589
50	O	590-592
%	O	592-593
by	O	594-596
0	O	597-598
.	O	598-599
3	O	599-600
mM	O	601-603
NH4Ac	O	604-609
and	O	610-613
KCl	O	614-617
-	O	617-618
induced	O	618-625
contractions	O	626-638
of	O	639-641
guinea	O	642-648
-	O	648-649
pig	O	649-652
ileum	O	653-658
were	O	659-663
inhibited	O	664-673
20	O	674-676
%	O	676-677
by	O	678-680
5	O	681-682
mM	O	683-685
NH4Ac	O	686-691
.	O	691-692

Addition	O	693-701
of	O	702-704
excess	O	705-711
calcium	O	712-719
reversed	O	720-728
the	O	729-732
depression	B	733-743
in	O	744-746
both	O	747-751
tissues	O	752-759
,	O	759-760
but	O	761-764
calcium	O	765-772
-	O	772-773
independent	O	773-784
catecholamine	O	785-798
release	O	799-806
by	O	807-809
acetaldehyde	O	810-822
was	O	823-826
not	O	827-830
blocked	O	831-838
by	O	839-841
NH4Ac	O	842-847
.	O	847-848

These	O	849-854
results	O	855-862
suggested	O	863-872
that	O	873-877
ammonia	O	878-885
blocks	O	886-892
calcium	O	893-900
channels	O	901-909
.	O	909-910

Parallels	O	911-920
in	O	921-923
the	O	924-927
actions	O	928-935
of	O	936-938
NH4Ac	O	939-944
and	O	945-948
the	O	949-952
calcium	O	953-960
channel	O	961-968
blocker	O	969-976
verapamil	O	977-986
support	O	987-994
this	O	995-999
concept	O	1000-1007
.	O	1007-1008

Both	O	1009-1013
verapamil	O	1014-1023
(	O	1024-1025
10	O	1025-1027
mg	O	1028-1030
/	O	1030-1031
kg	O	1031-1033
i	O	1034-1035
.	O	1035-1036
p	O	1036-1037
.	O	1035-1036
)	O	1038-1039
and	O	1040-1043
NH4Ac	O	1044-1049
pretreatment	O	1050-1062
enhanced	O	1063-1071
morphine	O	1072-1080
analgesia	B	1081-1090
-	O	1090-1091
and	O	1092-1095
diazepam	O	1096-1104
-	O	1104-1105
induced	O	1105-1112
muscular	O	1113-1121
incoordination	B	1122-1136
and	O	1137-1140
antagonized	O	1141-1152
amphetamine	O	1153-1164
-	O	1164-1165
induced	O	1165-1172
motor	O	1173-1178
activity	O	1179-1187
,	O	1187-1188
and	O	1189-1192
neither	O	1193-1200
verapamil	O	1201-1210
nor	O	1211-1214
NH4Ac	O	1215-1220
affected	O	1221-1229
the	O	1230-1233
convulsant	O	1234-1244
action	O	1245-1251
of	O	1252-1254
metrazol	O	1255-1263
.	O	1263-1264

The	O	1265-1268
data	O	1269-1273
suggest	O	1274-1281
that	O	1282-1286
hyperammonemia	B	1287-1301
exerts	O	1302-1308
a	O	1309-1310
calcium	O	1311-1318
channel	O	1319-1326
blocking	O	1327-1335
action	O	1336-1342
which	O	1343-1348
enhances	O	1349-1357
the	O	1358-1361
effects	O	1362-1369
of	O	1370-1372
central	O	1373-1380
nervous	O	1381-1388
system	O	1389-1395
depressants	O	1396-1407
and	O	1408-1411
certain	O	1412-1419
opioid	O	1420-1426
analgesics	O	1427-1437
.	O	1437-1438

Risk	O	0-4
of	O	5-7
nephropathy	B	8-19
after	O	20-25
consumption	O	26-37
of	O	38-40
nonionic	O	41-49
contrast	O	50-58
media	O	59-64
by	O	65-67
children	O	68-76
undergoing	O	77-87
cardiac	O	88-95
angiography	O	96-107
:	O	107-108
a	O	109-110
prospective	O	111-122
study	O	123-128
.	O	128-129

Despite	O	130-137
increasing	O	138-148
reports	O	149-156
on	O	157-159
nonionic	O	160-168
contrast	O	169-177
media	O	178-183
-	O	183-184
induced	O	184-191
nephropathy	B	192-203
(	O	204-205
CIN	B	205-208
)	O	208-209
in	O	210-212
hospitalized	O	213-225
adult	O	226-231
patients	O	232-240
during	O	241-247
cardiac	O	248-255
procedures	O	256-266
,	O	266-267
the	O	268-271
studies	O	272-279
in	O	280-282
pediatrics	O	283-293
are	O	294-297
limited	O	298-305
,	O	305-306
with	O	307-311
even	O	312-316
less	O	317-321
focus	O	322-327
on	O	328-330
possible	O	331-339
predisposing	O	340-352
factors	O	353-360
and	O	361-364
preventive	O	365-375
measures	O	376-384
for	O	385-388
patients	O	389-397
undergoing	O	398-408
cardiac	O	409-416
angiography	O	417-428
.	O	428-429

This	O	430-434
prospective	O	435-446
study	O	447-452
determined	O	453-463
the	O	464-467
incidence	O	468-477
of	O	478-480
CIN	B	481-484
for	O	485-488
two	O	489-492
nonionic	O	493-501
contrast	O	502-510
media	O	511-516
(	O	517-518
CM	O	518-520
)	O	520-521
,	O	521-522
iopromide	O	523-532
and	O	533-536
iohexol	O	537-544
,	O	544-545
among	O	546-551
80	O	552-554
patients	O	555-563
younger	O	564-571
than	O	572-576
18	O	577-579
years	O	580-585
and	O	586-589
compared	O	590-598
the	O	599-602
rates	O	603-608
for	O	609-612
this	O	613-617
complication	O	618-630
in	O	631-633
relation	O	634-642
to	O	643-645
the	O	646-649
type	O	650-654
and	O	655-658
dosage	O	659-665
of	O	666-668
CM	O	669-671
and	O	672-675
the	O	676-679
presence	O	680-688
of	O	689-691
cyanosis	B	692-700
.	O	700-701

The	O	702-705
80	O	706-708
patients	O	709-717
in	O	718-720
the	O	721-724
study	O	725-730
consecutively	O	731-744
received	O	745-753
either	O	754-760
iopromide	O	761-770
(	O	771-772
group	O	772-777
A	O	778-779
,	O	779-780
n	O	781-782
=	O	783-784
40	O	785-787
)	O	787-788
or	O	789-791
iohexol	O	792-799
(	O	800-801
group	O	801-806
B	O	807-808
,	O	808-809
n	O	810-811
=	O	812-813
40	O	814-816
)	O	816-817
.	O	817-818

Serum	O	819-824
sodium	O	825-831
(	O	832-833
Na	O	833-835
)	O	835-836
,	O	836-837
potassium	O	838-847
(	O	848-849
K	O	849-850
)	O	850-851
,	O	851-852
and	O	853-856
creatinine	O	857-867
(	O	868-869
Cr	O	869-871
)	O	871-872
were	O	873-877
measured	O	878-886
24	O	887-889
h	O	890-891
before	O	892-898
angiography	O	899-910
as	O	911-913
baseline	O	914-922
values	O	923-929
,	O	929-930
then	O	931-935
measured	O	936-944
again	O	945-950
at	O	951-953
12	O	954-956
-	O	956-957
,	O	957-958
24	O	959-961
-	O	961-962
,	O	962-963
and	O	964-967
48	O	968-970
-	O	970-971
h	O	971-972
intervals	O	973-982
after	O	983-988
CM	O	989-991
use	O	992-995
.	O	995-996

Urine	O	997-1002
samples	O	1003-1010
for	O	1011-1014
Na	O	1015-1017
and	O	1018-1021
Cr	O	1022-1024
also	O	1025-1029
were	O	1030-1034
checked	O	1035-1042
at	O	1043-1045
the	O	1046-1049
same	O	1050-1054
intervals	O	1055-1064
.	O	1064-1065

Risk	O	1066-1070
of	O	1071-1073
renal	B	1074-1079
failure	I	1080-1087
,	O	1087-1088
Injury	B	1089-1095
to	I	1096-1098
the	I	1099-1102
kidney	I	1103-1109
,	O	1109-1110
Failure	B	1111-1118
of	I	1119-1121
kidney	I	1122-1128
function	I	1129-1137
,	O	1137-1138
Loss	B	1139-1143
of	I	1144-1146
kidney	I	1147-1153
function	I	1154-1162
,	O	1162-1163
and	O	1164-1167
End	O	1168-1171
-	O	1171-1172
stage	O	1172-1177
renal	B	1178-1183
damage	I	1184-1190
(	O	1191-1192
RIFLE	O	1192-1197
criteria	O	1198-1206
)	O	1206-1207
were	O	1208-1212
used	O	1213-1217
to	O	1218-1220
define	O	1221-1227
CIN	B	1228-1231
and	O	1232-1235
its	O	1236-1239
incidence	O	1240-1249
in	O	1250-1252
the	O	1253-1256
study	O	1257-1262
population	O	1263-1273
.	O	1273-1274

Accordingly	O	1275-1286
,	O	1286-1287
among	O	1288-1293
the	O	1294-1297
15	O	1298-1300
CIN	B	1301-1304
patients	O	1305-1313
(	O	1314-1315
18	O	1315-1317
.	O	1317-1318
75	O	1318-1320
%	O	1320-1321
)	O	1321-1322
,	O	1322-1323
7	O	1324-1325
.	O	1325-1326
5	O	1326-1327
%	O	1327-1328
of	O	1329-1331
the	O	1332-1335
patients	O	1336-1344
in	O	1345-1347
group	O	1348-1353
A	O	1354-1355
had	O	1356-1359
increased	O	1360-1369
risk	O	1370-1374
and	O	1375-1378
3	O	1379-1380
.	O	1380-1381
75	O	1381-1383
%	O	1383-1384
had	O	1385-1388
renal	B	1389-1394
injury	I	1395-1401
,	O	1401-1402
whereas	O	1403-1410
5	O	1411-1412
%	O	1412-1413
of	O	1414-1416
group	O	1417-1422
B	O	1423-1424
had	O	1425-1428
increased	O	1429-1438
risk	O	1439-1443
and	O	1444-1447
2	O	1448-1449
.	O	1449-1450
5	O	1450-1451
%	O	1451-1452
had	O	1453-1456
renal	B	1457-1462
injury	I	1463-1469
.	O	1469-1470

Whereas	O	1471-1478
33	O	1479-1481
.	O	1481-1482
3	O	1479-1480
%	O	1483-1484
of	O	1485-1487
the	O	1488-1491
patients	O	1492-1500
with	O	1501-1505
CIN	B	1506-1509
were	O	1510-1514
among	O	1515-1520
those	O	1521-1526
who	O	1527-1530
received	O	1531-1539
the	O	1540-1543
proper	O	1544-1550
dosage	O	1551-1557
of	O	1558-1560
CM	O	1561-1563
,	O	1563-1564
the	O	1565-1568
percentage	O	1569-1579
increased	O	1580-1589
to	O	1590-1592
66	O	1593-1595
.	O	1595-1596
6	O	1593-1594
%	O	1597-1598
among	O	1599-1604
those	O	1605-1610
who	O	1611-1614
received	O	1615-1623
larger	O	1624-1630
doses	O	1631-1636
,	O	1636-1637
with	O	1638-1642
a	O	1643-1644
significant	O	1645-1656
difference	O	1657-1667
in	O	1668-1670
the	O	1671-1674
incidence	O	1675-1684
of	O	1685-1687
CIN	B	1688-1691
related	O	1692-1699
to	O	1700-1702
the	O	1703-1706
different	O	1707-1716
dosages	O	1717-1724
of	O	1725-1727
CM	O	1728-1730
(	O	1731-1732
p	O	1732-1733
=	O	1734-1735
0	O	1736-1737
.	O	1737-1738
014	O	1738-1741
)	O	1741-1742
.	O	1737-1738

Among	O	1744-1749
the	O	1750-1753
15	O	1754-1756
patients	O	1757-1765
with	O	1766-1770
CIN	B	1771-1774
,	O	1774-1775
6	O	1776-1777
had	O	1778-1781
cyanotic	O	1782-1790
congenital	B	1791-1801
heart	I	1802-1807
diseases	I	1808-1816
,	O	1816-1817
but	O	1818-1821
the	O	1822-1825
incidence	O	1826-1835
did	O	1836-1839
not	O	1840-1843
differ	O	1844-1850
significantly	O	1851-1864
from	O	1865-1869
that	O	1870-1874
for	O	1875-1878
the	O	1879-1882
noncyanotic	O	1883-1894
patients	O	1895-1903
(	O	1904-1905
p	O	1905-1906
=	O	1907-1908
0	O	1909-1910
.	O	1910-1911
243	O	1911-1914
)	O	1914-1915
.	O	1910-1911

Although	O	1917-1925
clinically	O	1926-1936
silent	O	1937-1943
,	O	1943-1944
CIN	B	1945-1948
is	O	1949-1951
not	O	1952-1955
rare	O	1956-1960
in	O	1961-1963
pediatrics	O	1964-1974
.	O	1974-1975

The	O	1976-1979
incidence	O	1980-1989
depends	O	1990-1997
on	O	1998-2000
dosage	O	2001-2007
but	O	2008-2011
not	O	2012-2015
on	O	2016-2018
the	O	2019-2022
type	O	2023-2027
of	O	2028-2030
consumed	O	2031-2039
nonionic	O	2040-2048
CM	O	2049-2051
,	O	2051-2052
nor	O	2053-2056
on	O	2057-2059
the	O	2060-2063
presence	O	2064-2072
of	O	2073-2075
cyanosis	B	2076-2084
,	O	2084-2085
and	O	2086-2089
although	O	2090-2098
CIN	B	2099-2102
usually	O	2103-2110
is	O	2111-2113
reversible	O	2114-2124
,	O	2124-2125
more	O	2126-2130
concern	O	2131-2138
is	O	2139-2141
needed	O	2142-2148
for	O	2149-2152
the	O	2153-2156
prevention	O	2157-2167
of	O	2168-2170
such	O	2171-2175
a	O	2176-2177
complication	O	2178-2190
in	O	2191-2193
children	O	2194-2202
.	O	2202-2203

A	O	0-1
case	O	2-6
of	O	7-9
ventricular	B	10-21
tachycardia	I	22-33
related	O	34-41
to	O	42-44
caffeine	O	45-53
pretreatment	O	54-66
.	O	66-67

Suboptimal	O	68-78
seizure	B	79-86
duration	O	87-95
is	O	96-98
commonly	O	99-107
encountered	O	108-119
in	O	120-122
electroconvulsive	O	123-140
therapy	O	141-148
practice	O	149-157
,	O	157-158
especially	O	159-169
in	O	170-172
older	O	173-178
patients	O	179-187
with	O	188-192
higher	O	193-199
seizure	B	200-207
thresholds	O	208-218
.	O	218-219

Intravenous	O	220-231
caffeine	O	232-240
is	O	241-243
commonly	O	244-252
used	O	253-257
to	O	258-260
improve	O	261-268
seizure	B	269-276
duration	O	277-285
and	O	286-289
quality	O	290-297
in	O	298-300
such	O	301-305
patients	O	306-314
and	O	315-318
is	O	319-321
generally	O	322-331
well	O	332-336
tolerated	O	337-346
aside	O	347-352
from	O	353-357
occasional	O	358-368
reports	O	369-376
of	O	377-379
relatively	O	380-390
benign	O	391-397
ventricular	B	398-409
ectopy	I	410-416
.	O	416-417

We	O	418-420
describe	O	421-429
a	O	430-431
patient	O	432-439
with	O	440-444
no	O	445-447
previous	O	448-456
history	O	457-464
of	O	465-467
cardiac	B	468-475
disease	I	476-483
or	O	484-486
arrhythmia	B	487-497
who	O	498-501
developed	O	502-511
sustained	O	512-521
bigeminy	O	522-530
and	O	531-534
2	O	535-536
brief	O	537-542
runs	O	543-547
of	O	548-550
ventricular	B	551-562
tachycardia	I	563-574
after	O	575-580
caffeine	O	581-589
administration	O	590-604
.	O	604-605

Although	O	606-614
intravenous	O	615-626
caffeine	O	627-635
is	O	636-638
generally	O	639-648
well	O	649-653
tolerated	O	654-663
,	O	663-664
the	O	665-668
clinician	O	669-678
should	O	679-685
be	O	686-688
aware	O	689-694
of	O	695-697
the	O	698-701
potential	O	702-711
for	O	712-715
unpredictable	O	716-729
and	O	730-733
serious	O	734-741
ventricular	B	742-753
arrhythmias	I	754-765
.	O	765-766

Optical	O	0-7
coherence	O	8-17
tomography	O	18-28
can	O	29-32
measure	O	33-40
axonal	O	41-47
loss	O	48-52
in	O	53-55
patients	O	56-64
with	O	65-69
ethambutol	O	70-80
-	O	80-81
induced	O	81-88
optic	B	89-94
neuropathy	I	95-105
.	O	105-106

PURPOSE	O	107-114
:	O	114-115
To	O	116-118
map	O	119-122
and	O	123-126
identify	O	127-135
the	O	136-139
pattern	O	140-147
,	O	147-148
in	O	149-151
vivo	O	152-156
,	O	156-157
of	O	158-160
axonal	B	161-167
degeneration	I	168-180
in	O	181-183
ethambutol	O	184-194
-	O	194-195
induced	O	195-202
optic	B	203-208
neuropathy	I	209-219
using	O	220-225
optical	O	226-233
coherence	O	234-243
tomography	O	244-254
(	O	255-256
OCT	O	256-259
)	O	259-260
.	O	260-261

Ethambutol	O	262-272
is	O	273-275
an	O	276-278
antimycobacterial	O	279-296
agent	O	297-302
often	O	303-308
used	O	309-313
to	O	314-316
treat	O	317-322
tuberculosis	B	323-335
.	O	335-336

A	O	337-338
serious	O	339-346
complication	O	347-359
of	O	360-362
ethambutol	O	363-373
is	O	374-376
an	O	377-379
optic	B	380-385
neuropathy	I	386-396
that	O	397-401
impairs	O	402-409
visual	O	410-416
acuity	O	417-423
,	O	423-424
contrast	O	425-433
sensitivity	O	434-445
,	O	445-446
and	O	447-450
color	O	451-456
vision	O	457-463
.	O	463-464

However	O	465-472
,	O	472-473
early	O	474-479
on	O	480-482
,	O	482-483
when	O	484-488
the	O	489-492
toxic	O	493-498
optic	B	499-504
neuropathy	I	505-515
is	O	516-518
mild	O	519-523
and	O	524-527
partly	O	528-534
reversible	O	535-545
,	O	545-546
the	O	547-550
funduscopic	O	551-562
findings	O	563-571
are	O	572-575
often	O	576-581
subtle	O	582-588
and	O	589-592
easy	O	593-597
to	O	598-600
miss	O	601-605
.	O	605-606

METHODS	O	607-614
:	O	614-615
Three	O	616-621
subjects	O	622-630
with	O	631-635
a	O	636-637
history	O	638-645
of	O	646-648
ethambutol	O	649-659
(	O	660-661
EMB	O	661-664
)	O	664-665
-	O	665-666
induced	O	666-673
optic	B	674-679
neuropathy	I	680-690
of	O	691-693
short	O	694-699
-	O	699-700
,	O	700-701
intermediate	O	702-714
-	O	714-715
,	O	715-716
and	O	717-720
long	O	721-725
-	O	725-726
term	O	726-730
visual	B	731-737
deficits	I	738-746
were	O	747-751
administered	O	752-764
a	O	765-766
full	O	767-771
neuro	O	772-777
-	O	777-778
ophthalmologic	O	778-792
examination	O	793-804
including	O	805-814
visual	O	815-821
acuity	O	822-828
,	O	828-829
color	O	830-835
vision	O	836-842
,	O	842-843
contrast	O	844-852
sensitivity	O	853-864
,	O	864-865
and	O	866-869
fundus	O	870-876
examination	O	877-888
.	O	888-889

In	O	890-892
addition	O	893-901
,	O	901-902
OCT	O	903-906
(	O	907-908
OCT	O	908-911
3000	O	912-916
,	O	916-917
Humphrey	O	918-926
-	O	926-927
Zeiss	O	927-932
,	O	932-933
Dublin	O	934-940
,	O	940-941
CA	O	942-944
)	O	944-945
was	O	946-949
performed	O	950-959
on	O	960-962
both	O	963-967
eyes	O	968-972
of	O	973-975
each	O	976-980
subject	O	981-988
using	O	989-994
the	O	995-998
retinal	O	999-1006
nerve	O	1007-1012
fiber	O	1013-1018
layer	O	1019-1024
(	O	1025-1026
RNFL	O	1026-1030
)	O	1030-1031
analysis	O	1032-1040
protocol	O	1041-1049
.	O	1049-1050

OCT	O	1051-1054
interpolates	O	1055-1067
data	O	1068-1072
from	O	1073-1077
100	O	1078-1081
points	O	1082-1088
around	O	1089-1095
the	O	1096-1099
optic	O	1100-1105
nerve	O	1106-1111
to	O	1112-1114
effectively	O	1115-1126
map	O	1127-1130
out	O	1131-1134
the	O	1135-1138
RNFL	O	1139-1143
.	O	1143-1144

RESULTS	O	1145-1152
:	O	1152-1153
The	O	1154-1157
results	O	1158-1165
were	O	1166-1170
compared	O	1171-1179
to	O	1180-1182
the	O	1183-1186
calculated	O	1187-1197
average	O	1198-1205
RNFL	O	1206-1210
of	O	1211-1213
normal	O	1214-1220
eyes	O	1221-1225
accumulated	O	1226-1237
from	O	1238-1242
four	O	1243-1247
prior	O	1248-1253
studies	O	1254-1261
using	O	1262-1267
OCT	O	1268-1271
,	O	1271-1272
n	O	1273-1274
=	O	1274-1275
661	O	1275-1278
.	O	1278-1279

In	O	1280-1282
all	O	1283-1286
subjects	O	1287-1295
with	O	1296-1300
history	O	1301-1308
of	O	1309-1311
EMB	O	1312-1315
-	O	1315-1316
induced	O	1316-1323
optic	B	1324-1329
neuropathy	I	1330-1340
,	O	1340-1341
there	O	1342-1347
was	O	1348-1351
a	O	1352-1353
mean	O	1354-1358
loss	O	1359-1363
of	O	1364-1366
72	O	1367-1369
%	O	1369-1370
nerve	O	1371-1376
fiber	O	1377-1382
layer	O	1383-1388
thickness	O	1389-1398
in	O	1399-1401
the	O	1402-1405
temporal	O	1406-1414
quadrant	O	1415-1423
(	O	1424-1425
patient	O	1425-1432
A	O	1433-1434
,	O	1434-1435
with	O	1436-1440
eventual	O	1441-1449
recovery	O	1450-1458
of	O	1459-1461
visual	O	1462-1468
acuity	O	1469-1475
and	O	1476-1479
fields	O	1480-1486
,	O	1486-1487
58	O	1488-1490
%	O	1490-1491
loss	O	1492-1496
;	O	1496-1497
patient	O	1498-1505
B	O	1506-1507
,	O	1507-1508
with	O	1509-1513
intermediate	O	1514-1526
visual	B	1527-1533
deficits	I	1534-1542
,	O	1542-1543
68	O	1544-1546
%	O	1546-1547
loss	O	1548-1552
;	O	1552-1553
patient	O	1554-1561
C	O	1562-1563
,	O	1563-1564
with	O	1565-1569
chronic	O	1570-1577
visual	B	1578-1584
deficits	I	1585-1593
,	O	1593-1594
90	O	1595-1597
%	O	1597-1598
loss	O	1599-1603
)	O	1603-1604
,	O	1604-1605
with	O	1606-1610
an	O	1611-1613
average	O	1614-1621
mean	O	1622-1626
optic	O	1627-1632
nerve	O	1633-1638
thickness	O	1639-1648
of	O	1649-1651
26	O	1652-1654
+	O	1654-1655
/	O	1655-1656
-	O	1656-1657
16	O	1657-1659
microm	O	1660-1666
.	O	1666-1667

There	O	1668-1673
was	O	1674-1677
a	O	1678-1679
combined	O	1680-1688
mean	O	1689-1693
loss	O	1694-1698
of	O	1699-1701
46	O	1702-1704
%	O	1704-1705
of	O	1706-1708
fibers	O	1709-1715
from	O	1716-1720
the	O	1721-1724
superior	O	1725-1733
,	O	1733-1734
inferior	O	1735-1743
,	O	1743-1744
and	O	1745-1748
nasal	O	1749-1754
quadrants	O	1755-1764
in	O	1765-1767
the	O	1768-1771
(	O	1772-1773
six	O	1773-1776
)	O	1776-1777
eyes	O	1778-1782
of	O	1783-1785
all	O	1786-1789
three	O	1790-1795
subjects	O	1796-1804
(	O	1805-1806
mean	O	1806-1810
average	O	1811-1818
thickness	O	1819-1828
of	O	1829-1831
55	O	1832-1834
+	O	1834-1835
/	O	1835-1836
-	O	1836-1837
29	O	1837-1839
microm	O	1840-1846
)	O	1846-1847
.	O	1847-1848

In	O	1849-1851
both	O	1852-1856
sets	O	1857-1861
(	O	1862-1863
four	O	1863-1867
)	O	1867-1868
of	O	1869-1871
eyes	O	1872-1876
of	O	1877-1879
the	O	1880-1883
subjects	O	1884-1892
with	O	1893-1897
persistent	O	1898-1908
visual	B	1909-1915
deficits	I	1916-1924
(	O	1925-1926
patients	O	1926-1934
B	O	1935-1936
and	O	1937-1940
C	O	1941-1942
)	O	1942-1943
,	O	1943-1944
there	O	1945-1950
was	O	1951-1954
an	O	1955-1957
average	O	1958-1965
loss	O	1966-1970
of	O	1971-1973
79	O	1974-1976
%	O	1976-1977
of	O	1978-1980
nerve	O	1981-1986
fiber	O	1987-1992
thickness	O	1993-2002
in	O	2003-2005
the	O	2006-2009
temporal	O	2010-2018
quadrant	O	2019-2027
.	O	2027-2028

CONCLUSIONS	O	2029-2040
:	O	2040-2041
The	O	2042-2045
OCT	O	2046-2049
results	O	2050-2057
in	O	2058-2060
these	O	2061-2066
patients	O	2067-2075
with	O	2076-2080
EMB	O	2081-2084
-	O	2084-2085
induced	O	2085-2092
optic	B	2093-2098
neuropathy	I	2099-2109
show	O	2110-2114
considerable	O	2115-2127
loss	O	2128-2132
especially	O	2133-2143
of	O	2144-2146
the	O	2147-2150
temporal	O	2151-2159
fibers	O	2160-2166
.	O	2166-2167

This	O	2168-2172
is	O	2173-2175
consistent	O	2176-2186
with	O	2187-2191
prior	O	2192-2197
histopathological	O	2198-2215
studies	O	2216-2223
that	O	2224-2228
show	O	2229-2233
predominant	O	2234-2245
loss	O	2246-2250
of	O	2251-2253
parvo	O	2254-2259
-	O	2259-2260
cellular	O	2260-2268
axons	O	2269-2274
(	O	2275-2276
or	O	2276-2278
small	O	2279-2284
-	O	2284-2285
caliber	O	2285-2292
axons	O	2293-2298
)	O	2298-2299
within	O	2300-2306
the	O	2307-2310
papillo	O	2311-2318
-	O	2318-2319
macular	O	2319-2326
bundle	O	2327-2333
in	O	2334-2336
toxic	O	2337-2342
or	O	2343-2345
hereditary	O	2346-2356
optic	B	2357-2362
neuropathies	I	2363-2375
.	O	2375-2376

OCT	O	2377-2380
can	O	2381-2384
be	O	2385-2387
a	O	2388-2389
valuable	O	2390-2398
tool	O	2399-2403
in	O	2404-2406
the	O	2407-2410
quantitative	O	2411-2423
analysis	O	2424-2432
of	O	2433-2435
optic	B	2436-2441
neuropathies	I	2442-2454
.	O	2454-2455

Additionally	O	2456-2468
,	O	2468-2469
in	O	2470-2472
terms	O	2473-2478
of	O	2479-2481
management	O	2482-2492
of	O	2493-2495
EMB	O	2496-2499
-	O	2499-2500
induced	O	2500-2507
optic	B	2508-2513
neuropathy	I	2514-2524
,	O	2524-2525
it	O	2526-2528
is	O	2529-2531
important	O	2532-2541
to	O	2542-2544
properly	O	2545-2553
manage	O	2554-2560
ethambutol	O	2561-2571
dosing	O	2572-2578
in	O	2579-2581
patients	O	2582-2590
with	O	2591-2595
renal	B	2596-2601
impairment	I	2602-2612
and	O	2613-2616
to	O	2617-2619
achieve	O	2620-2627
proper	O	2628-2634
transition	O	2635-2645
to	O	2646-2648
a	O	2649-2650
maintenance	O	2651-2662
dose	O	2663-2667
once	O	2668-2672
an	O	2673-2675
appropriate	O	2676-2687
loading	O	2688-2695
dose	O	2696-2700
has	O	2701-2704
been	O	2705-2709
reached	O	2710-2717
.	O	2717-2718

Effects	O	0-7
of	O	8-10
the	O	11-14
cyclooxygenase	O	15-29
-	O	29-30
2	O	30-31
specific	O	32-40
inhibitor	O	41-50
valdecoxib	O	51-61
versus	O	62-68
nonsteroidal	O	69-81
antiinflammatory	O	82-98
agents	O	99-105
and	O	106-109
placebo	O	110-117
on	O	118-120
cardiovascular	O	121-135
thrombotic	B	136-146
events	O	147-153
in	O	154-156
patients	O	157-165
with	O	166-170
arthritis	B	171-180
.	O	180-181

There	O	182-187
have	O	188-192
been	O	193-197
concerns	O	198-206
that	O	207-211
the	O	212-215
risk	O	216-220
of	O	221-223
cardiovascular	O	224-238
thrombotic	B	239-249
events	O	250-256
may	O	257-260
be	O	261-263
higher	O	264-270
with	O	271-275
cyclooxygenase	O	276-290
(	O	291-292
COX	O	292-295
)	O	295-296
-	O	296-297
2	O	297-298
-	O	296-297
specific	O	299-307
inhibitors	O	308-318
than	O	319-323
nonselective	O	324-336
nonsteroidal	O	337-349
antiinflammatory	O	350-366
drugs	O	367-372
(	O	373-374
NSAIDs	O	374-380
)	O	380-381
.	O	381-382

We	O	383-385
evaluated	O	386-395
cardiovascular	O	396-410
event	O	411-416
data	O	417-421
for	O	422-425
valdecoxib	O	426-436
,	O	436-437
a	O	438-439
new	O	440-443
COX	O	444-447
-	O	447-448
2	O	448-449
-	O	447-448
specific	O	450-458
inhibitor	O	459-468
in	O	469-471
approximately	O	472-485
8000	O	486-490
patients	O	491-499
with	O	500-504
osteoarthritis	B	505-519
and	O	520-523
rheumatoid	B	524-534
arthritis	I	535-544
treated	O	545-552
with	O	553-557
this	O	558-562
agent	O	563-568
in	O	569-571
randomized	O	572-582
clinical	O	583-591
trials	O	592-598
.	O	598-599

The	O	600-603
incidence	O	604-613
of	O	614-616
cardiovascular	O	617-631
thrombotic	B	632-642
events	O	643-649
(	O	650-651
cardiac	O	651-658
,	O	658-659
cerebrovascular	O	660-675
and	O	676-679
peripheral	O	680-690
vascular	O	691-699
,	O	699-700
or	O	701-703
arterial	O	704-712
thrombotic	B	713-723
)	O	723-724
was	O	725-728
determined	O	729-739
by	O	740-742
analyzing	O	743-752
pooled	O	753-759
valdecoxib	O	760-770
(	O	771-772
10	O	772-774
-	O	774-775
80	O	775-777
mg	O	778-780
daily	O	781-786
)	O	786-787
,	O	787-788
nonselective	O	789-801
NSAID	O	802-807
(	O	808-809
diclofenac	O	809-819
75	O	820-822
mg	O	823-825
bid	O	826-829
,	O	829-830
ibuprofen	O	831-840
800	O	841-844
mg	O	845-847
tid	O	848-851
,	O	851-852
or	O	853-855
naproxen	O	856-864
500	O	865-868
mg	O	869-871
bid	O	872-875
)	O	875-876
and	O	877-880
placebo	O	881-888
data	O	889-893
from	O	894-898
10	O	899-901
randomized	O	902-912
osteoarthritis	B	913-927
and	O	928-931
rheumatoid	B	932-942
arthritis	I	943-952
trials	O	953-959
that	O	960-964
were	O	965-969
6	O	970-971
-	O	971-972
52	O	972-974
weeks	O	975-980
in	O	981-983
duration	O	984-992
.	O	992-993

The	O	994-997
incidence	O	998-1007
rates	O	1008-1013
of	O	1014-1016
events	O	1017-1023
were	O	1024-1028
determined	O	1029-1039
in	O	1040-1042
all	O	1043-1046
patients	O	1047-1055
(	O	1056-1057
n	O	1057-1058
=	O	1059-1060
7934	O	1061-1065
)	O	1065-1066
and	O	1067-1070
in	O	1071-1073
users	O	1074-1079
of	O	1080-1082
low	O	1083-1086
-	O	1086-1087
dose	O	1087-1091
(	O	1092-1093
<	O	1093-1094
or	O	1095-1097
=	O	1098-1099
325	O	1099-1102
mg	O	1103-1105
daily	O	1106-1111
)	O	1111-1112
aspirin	O	1113-1120
(	O	1121-1122
n	O	1122-1123
=	O	1124-1125
1051	O	1126-1130
)	O	1130-1131
and	O	1132-1135
nonusers	O	1136-1144
of	O	1145-1147
aspirin	O	1148-1155
(	O	1156-1157
n	O	1157-1158
=	O	1159-1160
6883	O	1161-1165
)	O	1165-1166
.	O	1166-1167

Crude	O	1168-1173
and	O	1174-1177
exposure	O	1178-1186
-	O	1186-1187
adjusted	O	1187-1195
incidences	O	1196-1206
of	O	1207-1209
thrombotic	B	1210-1220
events	O	1221-1227
were	O	1228-1232
similar	O	1233-1240
for	O	1241-1244
valdecoxib	O	1245-1255
,	O	1255-1256
NSAIDs	O	1257-1263
,	O	1263-1264
and	O	1265-1268
placebo	O	1269-1276
.	O	1276-1277

The	O	1278-1281
risk	O	1282-1286
of	O	1287-1289
serious	O	1290-1297
thrombotic	B	1298-1308
events	O	1309-1315
was	O	1316-1319
also	O	1320-1324
similar	O	1325-1332
for	O	1333-1336
each	O	1337-1341
valdecoxib	O	1342-1352
dose	O	1353-1357
.	O	1357-1358

Thrombotic	B	1359-1369
risk	O	1370-1374
was	O	1375-1378
consistently	O	1379-1391
higher	O	1392-1398
for	O	1399-1402
users	O	1403-1408
of	O	1409-1411
aspirin	O	1412-1419
users	O	1420-1425
than	O	1426-1430
nonusers	O	1431-1439
of	O	1440-1442
aspirin	O	1443-1450
(	O	1451-1452
placebo	O	1452-1459
,	O	1459-1460
1	O	1461-1462
.	O	1462-1463
4	O	1463-1464
%	O	1464-1465
vs	O	1466-1468
.	O	1468-1469
0	O	1470-1471
%	O	1471-1472
;	O	1472-1473
valdecoxib	O	1474-1484
,	O	1484-1485
1	O	1486-1487
.	O	1487-1488
7	O	1488-1489
%	O	1489-1490
vs	O	1491-1493
.	O	1493-1494
0	O	1495-1496
.	O	1496-1497
2	O	1497-1498
%	O	1498-1499
;	O	1499-1500
NSAIDs	O	1501-1507
,	O	1507-1508
1	O	1509-1510
.	O	1510-1511
9	O	1511-1512
%	O	1512-1513
vs	O	1514-1516
.	O	1516-1517
0	O	1518-1519
.	O	1519-1520
5	O	1520-1521
%	O	1521-1522
)	O	1522-1523
.	O	1519-1520

The	O	1525-1528
rates	O	1529-1534
of	O	1535-1537
events	O	1538-1544
in	O	1545-1547
users	O	1548-1553
of	O	1554-1556
aspirin	O	1557-1564
were	O	1565-1569
similar	O	1570-1577
for	O	1578-1581
all	O	1582-1585
3	O	1586-1587
treatment	O	1588-1597
groups	O	1598-1604
and	O	1605-1608
across	O	1609-1615
valdecoxib	O	1616-1626
doses	O	1627-1632
.	O	1632-1633

Short	O	1634-1639
-	O	1639-1640
and	O	1641-1644
intermediate	O	1645-1657
-	O	1657-1658
term	O	1647-1651
treatment	O	1663-1672
with	O	1673-1677
therapeutic	O	1678-1689
(	O	1690-1691
10	O	1691-1693
or	O	1694-1696
20	O	1697-1699
mg	O	1700-1702
daily	O	1703-1708
)	O	1708-1709
and	O	1710-1713
supratherapeutic	O	1714-1730
(	O	1731-1732
40	O	1732-1734
or	O	1735-1737
80	O	1738-1740
mg	O	1741-1743
daily	O	1744-1749
)	O	1749-1750
valdecoxib	O	1751-1761
doses	O	1762-1767
was	O	1768-1771
not	O	1772-1775
associated	O	1776-1786
with	O	1787-1791
an	O	1792-1794
increased	O	1795-1804
incidence	O	1805-1814
of	O	1815-1817
thrombotic	B	1818-1828
events	O	1829-1835
relative	O	1836-1844
to	O	1845-1847
nonselective	O	1848-1860
NSAIDs	O	1861-1867
or	O	1868-1870
placebo	O	1871-1878
in	O	1879-1881
osteoarthritis	B	1882-1896
and	O	1897-1900
rheumatoid	B	1901-1911
arthritis	I	1912-1921
patients	O	1922-1930
in	O	1931-1933
controlled	O	1934-1944
clinical	O	1945-1953
trials	O	1954-1960
.	O	1960-1961

A	O	0-1
randomized	O	2-12
,	O	12-13
placebo	O	14-21
-	O	21-22
controlled	O	22-32
,	O	32-33
crossover	O	34-43
study	O	44-49
of	O	50-52
ephedrine	O	53-62
for	O	63-66
SSRI	O	67-71
-	O	71-72
induced	O	72-79
female	O	80-86
sexual	B	87-93
dysfunction	I	94-105
.	O	105-106

The	O	107-110
objective	O	111-120
of	O	121-123
this	O	124-128
study	O	129-134
was	O	135-138
to	O	139-141
determine	O	142-151
whether	O	152-159
ephedrine	O	160-169
,	O	169-170
an	O	171-173
alpha	O	174-179
-	O	179-180
and	O	181-184
beta	O	185-189
-	O	189-190
adrenergic	O	190-200
agonist	O	201-208
previously	O	209-219
shown	O	220-225
to	O	226-228
enhance	O	229-236
genital	O	237-244
blood	O	245-250
flow	O	251-255
in	O	256-258
women	O	259-264
,	O	264-265
has	O	266-269
beneficial	O	270-280
effects	O	281-288
in	O	289-291
reversing	O	292-301
antidepressant	O	302-316
-	O	316-317
induced	O	317-324
sexual	B	325-331
dysfunction	I	332-343
.	O	343-344

Nineteen	O	345-353
sexually	B	354-362
dysfunctional	I	363-376
women	O	377-382
receiving	O	383-392
either	O	393-399
fluoxetine	O	400-410
,	O	410-411
sertraline	O	412-422
,	O	422-423
or	O	424-426
paroxetine	O	427-437
participated	O	438-450
in	O	451-453
an	O	454-456
eight	O	457-462
-	O	462-463
week	O	463-467
,	O	467-468
double	O	469-475
-	O	475-476
blind	O	476-481
,	O	481-482
placebo	O	483-490
-	O	490-491
controlled	O	491-501
,	O	501-502
cross	O	503-508
-	O	508-509
over	O	509-513
study	O	514-519
of	O	520-522
the	O	523-526
effects	O	527-534
of	O	535-537
ephedrine	O	538-547
(	O	548-549
50	O	549-551
mg	O	552-554
)	O	554-555
on	O	556-558
self	O	559-563
-	O	563-564
report	O	564-570
measures	O	571-579
of	O	580-582
sexual	O	583-589
desire	O	590-596
,	O	596-597
arousal	O	598-605
,	O	605-606
orgasm	O	607-613
,	O	613-614
and	O	615-618
sexual	O	619-625
satisfaction	O	626-638
.	O	638-639

Although	O	640-648
there	O	649-654
were	O	655-659
significant	O	660-671
improvements	O	672-684
relative	O	685-693
to	O	694-696
baseline	O	697-705
in	O	706-708
sexual	O	709-715
desire	O	716-722
and	O	723-726
orgasm	O	727-733
intensity	O	734-743
/	O	743-744
pleasure	O	744-752
on	O	753-755
50	O	756-758
mg	O	759-761
ephedrine	O	762-771
1	O	772-773
-	O	773-774
hr	O	774-776
prior	O	777-782
to	O	783-785
sexual	O	786-792
activity	O	793-801
,	O	801-802
significant	O	803-814
improvements	O	815-827
in	O	828-830
these	O	831-836
measures	O	837-845
,	O	845-846
as	O	847-849
well	O	850-854
as	O	855-857
in	O	858-860
sexual	O	861-867
arousal	O	868-875
and	O	876-879
orgasmic	O	880-888
ability	O	889-896
also	O	897-901
were	O	902-906
noted	O	907-912
with	O	913-917
placebo	O	918-925
.	O	925-926

These	O	927-932
findings	O	933-941
highlight	O	942-951
the	O	952-955
importance	O	956-966
of	O	967-969
conducting	O	970-980
placebo	O	981-988
-	O	988-989
controlled	O	989-999
trials	O	1000-1006
for	O	1007-1010
this	O	1011-1015
condition	O	1016-1025
.	O	1025-1026

Erectile	B	0-8
dysfunction	I	9-20
occurs	O	21-27
following	O	28-37
substantia	O	38-48
nigra	O	49-54
lesions	O	55-62
in	O	63-65
the	O	66-69
rat	O	70-73
.	O	73-74

Erectile	O	75-83
function	O	84-92
was	O	93-96
assessed	O	97-105
6	O	106-107
weeks	O	108-113
following	O	114-123
uni	O	124-127
-	O	127-128
and	O	129-132
bilateral	O	133-142
injections	O	143-153
of	O	154-156
6	O	157-158
-	O	158-159
hydroxydopamine	O	159-174
in	O	175-177
the	O	178-181
substantia	O	182-192
nigra	O	193-198
nucleus	O	199-206
of	O	207-209
the	O	210-213
brain	O	214-219
.	O	219-220

Behavioral	O	221-231
apomorphine	O	232-243
-	O	243-244
induced	O	244-251
penile	O	252-258
erections	O	259-268
were	O	269-273
reduced	O	274-281
(	O	282-283
5	O	283-284
/	O	284-285
8	O	285-286
)	O	286-287
and	O	288-291
increased	O	292-301
(	O	302-303
3	O	303-304
/	O	304-305
8	O	305-306
)	O	306-307
in	O	308-310
uni	O	311-314
-	O	314-315
and	O	316-319
bilateral	O	320-329
lesioned	O	330-338
animals	O	339-346
.	O	346-347

Intracavernous	O	348-362
pressures	O	363-372
,	O	372-373
following	O	374-383
electrical	O	384-394
stimulation	O	395-406
of	O	407-409
the	O	410-413
cavernous	O	414-423
nerve	O	424-429
,	O	429-430
decreased	O	431-440
in	O	441-443
lesioned	O	444-452
animals	O	453-460
.	O	460-461

Lesions	O	462-469
of	O	470-472
the	O	473-476
substantia	O	477-487
nigra	O	488-493
were	O	494-498
confirmed	O	499-508
by	O	509-511
histology	O	512-521
.	O	521-522

Concentration	O	523-536
of	O	537-539
dopamine	O	540-548
and	O	549-552
its	O	553-556
metabolites	O	557-568
were	O	569-573
decreased	O	574-583
in	O	584-586
the	O	587-590
striatum	O	591-599
of	O	600-602
substantia	O	603-613
nigra	O	614-619
lesioned	O	620-628
rats	O	629-633
.	O	633-634

Lesions	O	635-642
of	O	643-645
the	O	646-649
substantia	O	650-660
nigra	O	661-666
are	O	667-670
therefore	O	671-680
associated	O	681-691
with	O	692-696
erectile	B	697-705
dysfunction	I	706-717
in	O	718-720
rats	O	721-725
and	O	726-729
may	O	730-733
serve	O	734-739
as	O	740-742
a	O	743-744
model	O	745-750
to	O	751-753
study	O	754-759
erectile	B	760-768
dysfunction	I	769-780
in	O	781-783
Parkinson	B	784-793
'	I	793-794
s	I	790-791
disease	I	796-803
.	O	803-804

Potential	O	0-9
therapeutic	O	10-21
use	O	22-25
of	O	26-28
the	O	29-32
selective	O	33-42
dopamine	O	43-51
D1	O	52-54
receptor	O	55-63
agonist	O	64-71
,	O	71-72
A	O	73-74
-	O	74-75
86929	O	75-80
:	O	80-81
an	O	82-84
acute	O	85-90
study	O	91-96
in	O	97-99
parkinsonian	B	100-112
levodopa	O	113-121
-	O	121-122
primed	O	122-128
monkeys	O	129-136
.	O	136-137

The	O	138-141
clinical	O	142-150
utility	O	151-158
of	O	159-161
dopamine	O	162-170
(	O	171-172
DA	O	172-174
)	O	174-175
D1	O	176-178
receptor	O	179-187
agonists	O	188-196
in	O	197-199
the	O	200-203
treatment	O	204-213
of	O	214-216
Parkinson	B	217-226
'	I	226-227
s	I	223-224
disease	I	229-236
(	O	237-238
PD	B	238-240
)	O	240-241
is	O	242-244
still	O	245-250
unclear	O	251-258
.	O	258-259

The	O	260-263
therapeutic	O	264-275
use	O	276-279
of	O	280-282
selective	O	283-292
DA	O	293-295
D1	O	296-298
receptor	O	299-307
agonists	O	308-316
such	O	317-321
as	O	322-324
SKF	O	325-328
-	O	328-329
82958	O	329-334
(	O	335-336
6	O	336-337
-	O	337-338
chloro	O	338-344
-	O	337-338
7	O	345-346
,	O	346-347
8	O	347-348
-	O	337-338
dihydroxy	O	349-358
-	O	337-338
3	O	359-360
-	O	337-338
allyl	O	361-366
-	O	337-338
1	O	367-368
-	O	337-338
phenyl	O	369-375
-	O	337-338
2	O	376-377
,	O	346-347
3	O	359-360
,	O	346-347
4	O	380-381
,	O	346-347
5	O	382-383
-	O	337-338
tetrahydro	O	384-394
-	O	337-338
1H	O	395-397
-	O	337-338
3	O	359-360
-	O	337-338
benzaze	O	400-407
pine	O	408-412
hydrobromide	O	413-425
)	O	425-426
and	O	427-430
A	O	431-432
-	O	432-433
77636	O	433-438
(	O	439-440
[	O	440-441
1R	O	441-443
,	O	443-444
3S	O	445-447
]	O	447-448
3	O	449-450
-	O	450-451
[	O	451-452
1	O	452-453
'	O	453-454
-	O	450-451
admantyl	O	455-463
]	O	463-464
-	O	450-451
1	O	452-453
-	O	450-451
aminomethyl	O	467-478
-	O	450-451
3	O	449-450
,	O	480-481
4	O	481-482
-	O	450-451
dihydro	O	483-490
-	O	450-451
5	O	491-492
,	O	480-481
6	O	493-494
-	O	450-451
dihydroxy	O	495-504
-	O	450-451
1H	O	505-507
-	O	450-451
2	O	508-509
-	O	450-451
benzo	O	510-515
pyran	O	516-521
hydrochloride	O	522-535
)	O	535-536
seems	O	537-542
limited	O	543-550
because	O	551-558
of	O	559-561
their	O	562-567
duration	O	568-576
of	O	577-579
action	O	580-586
,	O	586-587
which	O	588-593
is	O	594-596
too	O	597-600
short	O	601-606
for	O	607-610
SKF	O	611-614
-	O	614-615
82958	O	615-620
(	O	621-622
<	O	622-623
1	O	624-625
hr	O	626-628
)	O	628-629
and	O	630-633
too	O	634-637
long	O	638-642
for	O	643-646
A	O	647-648
-	O	648-649
77636	O	649-654
(	O	655-656
>	O	656-657
20	O	658-660
hr	O	661-663
,	O	663-664
leading	O	665-672
to	O	673-675
behavioral	O	676-686
tolerance	O	687-696
)	O	696-697
.	O	697-698

We	O	699-701
therefore	O	702-711
conducted	O	712-721
the	O	722-725
present	O	726-733
acute	O	734-739
dose	O	740-744
-	O	744-745
response	O	745-753
study	O	754-759
in	O	760-762
four	O	763-767
1	O	768-769
-	O	769-770
methyl	O	770-776
-	O	769-770
4	O	777-778
-	O	769-770
phenyl	O	779-785
-	O	769-770
1	O	768-769
,	O	787-788
2	O	788-789
,	O	787-788
3	O	790-791
,	O	787-788
6	O	792-793
-	O	769-770
tetrahydropyridine	O	794-812
(	O	813-814
MPTP	O	814-818
)	O	818-819
-	O	819-820
exposed	O	820-827
cynomolgus	O	828-838
monkeys	O	839-846
primed	O	847-853
to	O	854-856
exhibit	O	857-864
levodopa	O	865-873
-	O	873-874
induced	O	874-881
dyskinesias	B	882-893
to	O	894-896
evaluate	O	897-905
the	O	906-909
locomotor	O	910-919
and	O	920-923
dyskinetic	B	924-934
effects	O	935-942
on	O	943-945
challenge	O	946-955
with	O	956-960
four	O	961-965
doses	O	966-971
(	O	972-973
from	O	973-977
0	O	978-979
.	O	979-980
03	O	980-982
to	O	983-985
1	O	986-987
.	O	987-988
0	O	988-989
mg	O	990-992
/	O	992-993
kg	O	993-995
)	O	995-996
of	O	997-999
A	O	1000-1001
-	O	1001-1002
86929	O	1002-1007
(	O	1008-1009
[	O	1009-1010
-	O	1010-1011
]	O	1011-1012
-	O	1010-1011
[	O	1009-1010
5aR	O	1014-1017
,	O	1017-1018
11bS	O	1018-1022
]	O	1011-1012
-	O	1010-1011
4	O	1024-1025
,	O	1017-1018
5	O	1014-1015
,	O	1017-1018
5a	O	1014-1016
,	O	1017-1018
6	O	1031-1032
,	O	1017-1018
7	O	1033-1034
,	O	1017-1018
11b	O	1018-1021
-	O	1010-1011
hexahydro	O	1039-1048
-	O	1010-1011
2	O	1049-1050
-	O	1010-1011
propyl	O	1051-1057
-	O	1010-1011
3	O	1058-1059
-	O	1010-1011
thia	O	1060-1064
-	O	1010-1011
5	O	1014-1015
-	O	1010-1011
+	O	1067-1068
+	O	1069-1070
+	O	1069-1070
azacyclopent	O	1071-1083
-	O	1083-1084
1	O	1084-1085
-	O	1083-1084
ena	O	1087-1090
[	O	1090-1091
c	O	1091-1092
]	O	1092-1093
phenathrene	O	1093-1104
-	O	1104-1105
9	O	1105-1106
-	O	1104-1105
10	O	1107-1109
-	O	1104-1105
diol	O	1110-1114
)	O	1114-1115
,	O	1115-1116
a	O	1117-1118
selective	O	1119-1128
and	O	1129-1132
full	O	1133-1137
DA	O	1138-1140
D1	O	1141-1143
-	O	1143-1144
like	O	1144-1148
receptor	O	1149-1157
agonist	O	1158-1165
with	O	1166-1170
an	O	1171-1173
intermediate	O	1174-1186
duration	O	1187-1195
of	O	1196-1198
action	O	1199-1205
.	O	1205-1206

Levodopa	O	1207-1215
and	O	1216-1219
the	O	1220-1223
DA	O	1224-1226
D2	O	1227-1229
-	O	1229-1230
like	O	1230-1234
receptor	O	1235-1243
agonist	O	1244-1251
,	O	1251-1252
LY	O	1253-1255
-	O	1255-1256
171555	O	1256-1262
(	O	1263-1264
[	O	1264-1265
4aR	O	1265-1268
-	O	1268-1269
trans	O	1269-1274
]	O	1274-1275
-	O	1268-1269
4	O	1265-1266
,	O	1277-1278
4a	O	1265-1267
,	O	1277-1278
5	O	1281-1282
,	O	1277-1278
6	O	1283-1284
,	O	1277-1278
7	O	1285-1286
,	O	1277-1278
8	O	1287-1288
,	O	1277-1278
8a	O	1289-1291
,	O	1277-1278
9	O	1292-1293
-	O	1268-1269
o	O	1294-1295
-	O	1268-1269
dihydro	O	1296-1303
-	O	1268-1269
5n	O	1304-1306
-	O	1268-1269
propyl	O	1307-1313
-	O	1268-1269
2H	O	1314-1316
-	O	1268-1269
pyrazo	O	1317-1323
lo	O	1324-1326
-	O	1326-1327
3	O	1327-1328
-	O	1326-1327
4	O	1329-1330
-	O	1326-1327
quinoline	O	1331-1340
hydrochloride	O	1341-1354
)	O	1354-1355
were	O	1356-1360
also	O	1361-1365
used	O	1366-1370
for	O	1371-1374
comparison	O	1375-1385
.	O	1385-1386

Acute	O	1387-1392
administration	O	1393-1407
of	O	1408-1410
A	O	1411-1412
-	O	1412-1413
86929	O	1413-1418
was	O	1419-1422
as	O	1423-1425
efficacious	O	1426-1437
in	O	1438-1440
alleviating	O	1441-1452
MPTP	O	1453-1457
-	O	1457-1458
induced	O	1458-1465
parkinsonism	B	1466-1478
as	O	1479-1481
levodopa	O	1482-1490
and	O	1491-1494
LY	O	1495-1497
-	O	1497-1498
171555	O	1498-1504
,	O	1504-1505
but	O	1506-1509
was	O	1510-1513
less	O	1514-1518
likely	O	1519-1525
to	O	1526-1528
reproduce	O	1529-1538
the	O	1539-1542
levodopa	O	1543-1551
-	O	1551-1552
induced	O	1552-1559
dyskinesias	B	1560-1571
in	O	1572-1574
these	O	1575-1580
animals	O	1581-1588
than	O	1589-1593
with	O	1594-1598
either	O	1599-1605
LY	O	1606-1608
-	O	1608-1609
171555	O	1609-1615
or	O	1616-1618
subsequent	O	1619-1629
challenge	O	1630-1639
of	O	1640-1642
levodopa	O	1643-1651
.	O	1651-1652

Selective	O	1653-1662
stimulation	O	1663-1674
of	O	1675-1677
the	O	1678-1681
DA	O	1682-1684
D1	O	1685-1687
receptor	O	1688-1696
may	O	1697-1700
provide	O	1701-1708
better	O	1709-1715
integration	O	1716-1727
of	O	1728-1730
neural	O	1731-1737
inputs	O	1738-1744
transmitted	O	1745-1756
to	O	1757-1759
the	O	1760-1763
internal	O	1764-1772
segment	O	1773-1780
of	O	1781-1783
the	O	1784-1787
globus	O	1788-1794
pallidus	O	1795-1803
(	O	1804-1805
referred	O	1805-1813
to	O	1814-1816
as	O	1817-1819
the	O	1820-1823
basal	O	1824-1829
ganglia	O	1830-1837
output	O	1838-1844
)	O	1844-1845
compared	O	1846-1854
with	O	1855-1859
levodopa	O	1860-1868
and	O	1869-1872
selective	O	1873-1882
DA	O	1883-1885
D2	O	1886-1888
receptor	O	1889-1897
agonist	O	1898-1905
.	O	1905-1906

Potent	O	1907-1913
DA	O	1914-1916
D1	O	1917-1919
receptor	O	1920-1928
agents	O	1929-1935
with	O	1936-1940
an	O	1941-1943
intermediate	O	1944-1956
duration	O	1957-1965
of	O	1966-1968
efficacy	O	1969-1977
such	O	1978-1982
as	O	1983-1985
A	O	1986-1987
-	O	1987-1988
86929	O	1988-1993
(	O	1994-1995
approximately	O	1995-2008
4	O	2009-2010
hr	O	2011-2013
at	O	2014-2016
higher	O	2017-2023
doses	O	2024-2029
tested	O	2030-2036
)	O	2036-2037
are	O	2038-2041
potential	O	2042-2051
therapeutic	O	2052-2063
tools	O	2064-2069
in	O	2070-2072
PD	B	2073-2075
and	O	2076-2079
merit	O	2080-2085
further	O	2086-2093
attention	O	2094-2103
.	O	2103-2104

Deaths	O	0-6
from	O	7-11
local	O	12-17
anesthetic	O	18-28
-	O	28-29
induced	O	29-36
convulsions	B	37-48
in	O	49-51
mice	O	52-56
.	O	56-57

Median	O	58-64
convulsant	O	65-75
(	O	76-77
CD50	O	77-81
)	O	81-82
and	O	83-86
median	O	87-93
lethal	O	94-100
(	O	101-102
LD50	O	102-106
)	O	106-107
doses	O	108-113
of	O	114-116
three	O	117-122
representative	O	123-137
local	O	138-143
anesthetics	O	144-155
were	O	156-160
determined	O	161-171
in	O	172-174
adult	O	175-180
mice	O	181-185
to	O	186-188
evaluate	O	189-197
the	O	198-201
threat	O	202-208
to	O	209-211
life	O	212-216
of	O	217-219
local	O	220-225
anesthetic	O	226-236
-	O	236-237
induced	O	237-244
convulsions	B	245-256
.	O	256-257

The	O	258-261
CD50	O	262-266
and	O	267-270
LD50	O	271-275
,	O	275-276
respectively	O	277-289
,	O	289-290
were	O	291-295
57	O	296-298
.	O	298-299
7	O	297-298
and	O	301-304
58	O	305-307
.	O	307-308
7	O	308-309
mg	O	310-312
/	O	312-313
kg	O	313-315
for	O	316-319
bupivacaine	O	320-331
,	O	331-332
111	O	333-336
.	O	336-337
0	O	337-338
and	O	339-342
133	O	343-346
.	O	346-347
1	O	343-344
mg	O	349-351
/	O	351-352
kg	O	352-354
for	O	355-358
lidocaine	O	359-368
,	O	368-369
and	O	370-373
243	O	374-377
.	O	377-378
4	O	375-376
and	O	380-383
266	O	384-387
.	O	387-388
5	O	388-389
mg	O	390-392
/	O	392-393
kg	O	393-395
for	O	396-399
chloroprocaine	O	400-414
.	O	414-415

When	O	416-420
given	O	421-426
intraperitoneally	O	427-444
,	O	444-445
bupivacaine	O	446-457
thus	O	458-462
was	O	463-466
only	O	467-471
about	O	472-477
twice	O	478-483
as	O	484-486
toxic	O	487-492
as	O	493-495
lidocaine	O	496-505
and	O	506-509
four	O	510-514
times	O	515-520
as	O	521-523
toxic	O	524-529
as	O	530-532
chloroprocaine	O	533-547
.	O	547-548

Convulsions	B	549-560
always	O	561-567
preceded	O	568-576
death	O	577-582
,	O	582-583
except	O	584-590
after	O	591-596
precipitous	O	597-608
cardiopulmonary	B	609-624
arrest	I	625-631
from	O	632-636
extreme	O	637-644
doses	O	645-650
.	O	650-651

A	O	652-653
CD50	O	654-658
dose	O	659-663
of	O	664-666
local	O	667-672
anesthetic	O	673-683
(	O	684-685
causing	O	685-692
convulsions	B	693-704
in	O	705-707
50	O	708-710
%	O	710-711
of	O	712-714
mice	O	715-719
)	O	719-720
was	O	721-724
fatal	O	725-730
in	O	731-733
90	O	734-736
%	O	736-737
of	O	738-740
bupivacaine	O	741-752
-	O	752-753
induced	O	753-760
seizures	B	761-769
,	O	769-770
in	O	771-773
57	O	774-776
%	O	776-777
of	O	778-780
the	O	781-784
chloroprocaine	O	785-799
group	O	800-805
,	O	805-806
and	O	807-810
in	O	811-813
6	O	814-815
%	O	815-816
of	O	817-819
the	O	820-823
lidocaine	O	824-833
group	O	834-839
.	O	839-840

The	O	841-844
narrow	O	845-851
gap	O	852-855
between	O	856-863
convulsant	O	864-874
and	O	875-878
lethal	O	879-885
doses	O	886-891
of	O	892-894
local	O	895-900
anesthetics	O	901-912
indicates	O	913-922
that	O	923-927
untreated	O	928-937
convulsions	B	938-949
present	O	950-957
much	O	958-962
more	O	963-967
of	O	968-970
a	O	971-972
threat	O	973-979
to	O	980-982
life	O	983-987
than	O	988-992
heretofore	O	993-1003
appreciated	O	1004-1015
.	O	1015-1016

Myoclonic	B	0-9
,	I	9-10
atonic	I	11-17
,	I	17-18
and	I	19-22
absence	I	23-30
seizures	I	31-39
following	O	40-49
institution	O	50-61
of	O	62-64
carbamazepine	O	65-78
therapy	O	79-86
in	O	87-89
children	O	90-98
.	O	98-99

Five	O	100-104
children	O	105-113
,	O	113-114
aged	O	115-119
3	O	120-121
to	O	122-124
11	O	125-127
years	O	128-133
,	O	133-134
treated	O	135-142
with	O	143-147
carbamazepine	O	148-161
for	O	162-165
epilepsy	B	166-174
,	O	174-175
had	O	176-179
an	O	180-182
acute	O	183-188
aberrant	O	189-197
reaction	O	198-206
characterized	O	207-220
by	O	221-223
the	O	224-227
onset	O	228-233
of	O	234-236
myoclonic	B	237-246
,	I	246-247
atypical	I	248-256
absence	I	257-264
and	I	265-268
/	I	268-269
or	I	269-271
atonic	I	272-278
(	I	279-280
minor	I	280-285
motor	I	286-291
)	I	291-292
seizures	I	293-301
within	O	302-308
a	O	309-310
few	O	311-314
days	O	315-319
.	O	319-320

When	O	321-325
the	O	326-329
carbamazepine	O	330-343
was	O	344-347
discontinued	O	348-360
,	O	360-361
two	O	362-365
of	O	366-368
the	O	369-372
children	O	373-381
returned	O	382-390
to	O	391-393
their	O	394-399
former	O	400-406
state	O	407-412
very	O	413-417
quickly	O	418-425
,	O	425-426
two	O	427-430
had	O	431-434
the	O	435-438
minor	O	439-444
motor	O	445-450
seizures	B	451-459
resolve	O	460-467
in	O	468-470
3	O	471-472
and	O	473-476
6	O	477-478
months	O	479-485
,	O	485-486
and	O	487-490
one	O	491-494
had	O	495-498
the	O	499-502
seizures	B	503-511
persist	O	512-519
.	O	519-520

The	O	521-524
child	O	525-530
in	O	531-533
whom	O	534-538
the	O	539-542
seizures	B	543-551
persisted	O	552-561
was	O	562-565
later	O	566-571
found	O	572-577
to	O	578-580
have	O	581-585
ceroid	B	586-592
lipofuscinosis	I	593-607
.	O	607-608

The	O	609-612
other	O	613-618
children	O	619-627
are	O	628-631
doing	O	632-637
well	O	638-642
on	O	643-645
other	O	646-651
anticonvulsants	O	652-667
.	O	667-668

Naloxone	O	0-8
reversal	O	9-17
of	O	18-20
hypotension	B	21-32
due	O	33-36
to	O	37-39
captopril	O	40-49
overdose	B	50-58
.	O	58-59

The	O	60-63
hemodynamic	O	64-75
effects	O	76-83
of	O	84-86
captopril	O	87-96
and	O	97-100
other	O	101-106
angiotensin	O	107-118
-	O	118-119
converting	O	119-129
enzyme	O	130-136
inhibitors	O	137-147
may	O	148-151
be	O	152-154
mediated	O	155-163
by	O	164-166
the	O	167-170
endogenous	O	171-181
opioid	O	182-188
system	O	189-195
.	O	195-196

The	O	197-200
opioid	O	201-207
antagonist	O	208-218
naloxone	O	219-227
has	O	228-231
been	O	232-236
shown	O	237-242
to	O	243-245
block	O	246-251
or	O	252-254
reverse	O	255-262
the	O	263-266
hypotensive	B	267-278
actions	O	279-286
of	O	287-289
captopril	O	290-299
.	O	299-300

We	O	301-303
report	O	304-310
a	O	311-312
case	O	313-317
of	O	318-320
an	O	321-323
intentional	O	324-335
captopril	O	336-345
overdose	B	346-354
,	O	354-355
manifested	O	356-366
by	O	367-369
marked	O	370-376
hypotension	B	377-388
,	O	388-389
that	O	390-394
resolved	O	395-403
promptly	O	404-412
with	O	413-417
the	O	418-421
administration	O	422-436
of	O	437-439
naloxone	O	440-448
.	O	448-449

To	O	450-452
our	O	453-456
knowledge	O	457-466
,	O	466-467
this	O	468-472
is	O	473-475
the	O	476-479
first	O	480-485
reported	O	486-494
case	O	495-499
of	O	500-502
captopril	O	503-512
-	O	512-513
induced	O	513-520
hypotension	B	521-532
treated	O	533-540
with	O	541-545
naloxone	O	546-554
.	O	554-555

Our	O	556-559
experience	O	560-570
demonstrates	O	571-583
a	O	584-585
possible	O	586-594
role	O	595-599
of	O	600-602
naloxone	O	603-611
in	O	612-614
the	O	615-618
reversal	O	619-627
of	O	628-630
hypotension	B	631-642
resulting	O	643-652
from	O	653-657
captopril	O	658-667
.	O	667-668

Carbamazepine	O	0-13
-	O	13-14
induced	O	14-21
cardiac	B	22-29
dysfunction	I	30-41
.	O	41-42

Characterization	O	43-59
of	O	60-62
two	O	63-66
distinct	O	67-75
clinical	O	76-84
syndromes	O	85-94
.	O	94-95

A	O	96-97
patient	O	98-105
with	O	106-110
sinus	O	111-116
bradycardia	B	117-128
and	O	129-132
atrioventricular	B	133-149
block	I	150-155
,	O	155-156
induced	O	157-164
by	O	165-167
carbamazepine	O	168-181
,	O	181-182
prompted	O	183-191
an	O	192-194
extensive	O	195-204
literature	O	205-215
review	O	216-222
of	O	223-225
all	O	226-229
previously	O	230-240
reported	O	241-249
cases	O	250-255
.	O	255-256

From	O	257-261
the	O	262-265
analysis	O	266-274
of	O	275-277
these	O	278-283
cases	O	284-289
,	O	289-290
two	O	291-294
distinct	O	295-303
forms	O	304-309
of	O	310-312
carbamazepine	O	313-326
-	O	326-327
associated	O	327-337
cardiac	B	338-345
dysfunction	I	346-357
emerged	O	358-365
.	O	365-366

One	O	367-370
patient	O	371-378
group	O	379-384
developed	O	385-394
sinus	B	395-400
tachycardias	I	401-413
in	O	414-416
the	O	417-420
setting	O	421-428
of	O	429-431
a	O	432-433
massive	O	434-441
carbamazepine	O	442-455
overdose	B	456-464
.	O	464-465

The	O	466-469
second	O	470-476
group	O	477-482
consisted	O	483-492
almost	O	493-499
exclusively	O	500-511
of	O	512-514
elderly	O	515-522
women	O	523-528
who	O	529-532
developed	O	533-542
potentially	O	543-554
life	O	555-559
-	O	559-560
threatening	O	560-571
bradyarrhythmias	B	572-588
or	O	589-591
atrioventricular	B	592-608
conduction	I	609-619
delay	I	620-625
,	O	625-626
associated	O	627-637
with	O	638-642
either	O	643-649
therapeutic	O	650-661
or	O	662-664
modestly	O	665-673
elevated	O	674-682
carbamazepine	O	683-696
serum	O	697-702
levels	O	703-709
.	O	709-710

Because	O	711-718
carbamazepine	O	719-732
is	O	733-735
widely	O	736-742
used	O	743-747
in	O	748-750
the	O	751-754
treatment	O	755-764
of	O	765-767
many	O	768-772
neurologic	O	773-783
and	O	784-787
psychiatric	B	788-799
conditions	O	800-810
,	O	810-811
the	O	812-815
recognition	O	816-827
of	O	828-830
the	O	831-834
latter	O	835-841
syndrome	O	842-850
has	O	851-854
important	O	855-864
implications	O	865-877
for	O	878-881
the	O	882-885
use	O	886-889
of	O	890-892
this	O	893-897
drug	O	898-902
in	O	903-905
elderly	O	906-913
patients	O	914-922
.	O	922-923

Glutamatergic	O	0-13
neurotransmission	O	14-31
mediated	O	32-40
by	O	41-43
NMDA	O	44-48
receptors	O	49-58
in	O	59-61
the	O	62-65
inferior	O	66-74
colliculus	O	75-85
can	O	86-89
modulate	O	90-98
haloperidol	O	99-110
-	O	110-111
induced	O	111-118
catalepsy	B	119-128
.	O	128-129

The	O	130-133
inferior	O	134-142
colliculus	O	143-153
(	O	154-155
IC	O	155-157
)	O	157-158
is	O	159-161
primarily	O	162-171
involved	O	172-180
in	O	181-183
the	O	184-187
processing	O	188-198
of	O	199-201
auditory	O	202-210
information	O	211-222
,	O	222-223
but	O	224-227
it	O	228-230
is	O	231-233
distinguished	O	234-247
from	O	248-252
other	O	253-258
auditory	O	259-267
nuclei	O	268-274
in	O	275-277
the	O	278-281
brainstem	O	282-291
by	O	292-294
its	O	295-298
connections	O	299-310
with	O	311-315
structures	O	316-326
of	O	327-329
the	O	330-333
motor	O	334-339
system	O	340-346
.	O	346-347

Functional	O	348-358
evidence	O	359-367
relating	O	368-376
the	O	377-380
IC	O	381-383
to	O	384-386
motor	O	387-392
behavior	O	393-401
derives	O	402-409
from	O	410-414
experiments	O	415-426
showing	O	427-434
that	O	435-439
activation	O	440-450
of	O	451-453
the	O	454-457
IC	O	458-460
by	O	461-463
electrical	O	464-474
stimulation	O	475-486
or	O	487-489
excitatory	O	490-500
amino	O	501-506
acid	O	507-511
microinjection	O	512-526
causes	O	527-533
freezing	O	534-542
,	O	542-543
escape	O	544-550
-	O	550-551
like	O	551-555
behavior	O	556-564
,	O	564-565
and	O	566-569
immobility	O	570-580
.	O	580-581

However	O	582-589
,	O	589-590
the	O	591-594
nature	O	595-601
of	O	602-604
this	O	605-609
immobility	O	610-620
is	O	621-623
still	O	624-629
unclear	O	630-637
.	O	637-638

The	O	639-642
present	O	643-650
study	O	651-656
examined	O	657-665
the	O	666-669
influence	O	670-679
of	O	680-682
excitatory	O	683-693
amino	O	694-699
acid	O	700-704
-	O	704-705
mediated	O	705-713
mechanisms	O	714-724
in	O	725-727
the	O	728-731
IC	O	732-734
on	O	735-737
the	O	738-741
catalepsy	B	742-751
induced	O	752-759
by	O	760-762
the	O	763-766
dopamine	O	767-775
receptor	O	776-784
blocker	O	785-792
haloperidol	O	793-804
administered	O	805-817
systemically	O	818-830
(	O	831-832
1	O	832-833
or	O	834-836
0	O	837-838
.	O	838-839
5	O	839-840
mg	O	841-843
/	O	843-844
kg	O	844-846
)	O	846-847
in	O	848-850
rats	O	851-855
.	O	855-856

Haloperidol	O	857-868
-	O	868-869
induced	O	869-876
catalepsy	B	877-886
was	O	887-890
challenged	O	891-901
with	O	902-906
prior	O	907-912
intracollicular	O	913-928
microinjections	O	929-944
of	O	945-947
glutamate	O	948-957
NMDA	O	958-962
receptor	O	963-971
antagonists	O	972-983
,	O	983-984
MK	O	985-987
-	O	987-988
801	O	988-991
(	O	992-993
15	O	993-995
or	O	996-998
30	O	999-1001
mmol	O	1002-1006
/	O	1006-1007
0	O	1007-1008
.	O	1008-1009
5	O	1009-1010
microl	O	1011-1017
)	O	1017-1018
and	O	1019-1022
AP7	O	1023-1026
(	O	1027-1028
10	O	1028-1030
or	O	1031-1033
20	O	1034-1036
nmol	O	1037-1041
/	O	1041-1042
0	O	1042-1043
.	O	1043-1044
5	O	1044-1045
microl	O	1046-1052
)	O	1052-1053
,	O	1053-1054
or	O	1055-1057
of	O	1058-1060
the	O	1061-1064
NMDA	O	1065-1069
receptor	O	1070-1078
agonist	O	1079-1086
N	O	1087-1088
-	O	1088-1089
methyl	O	1089-1095
-	O	1088-1089
d	O	1096-1097
-	O	1088-1089
aspartate	O	1098-1107
(	O	1108-1109
NMDA	O	1109-1113
,	O	1113-1114
20	O	1115-1117
or	O	1118-1120
30	O	1121-1123
nmol	O	1124-1128
/	O	1128-1129
0	O	1129-1130
.	O	1130-1131
5	O	1131-1132
microl	O	1133-1139
)	O	1139-1140
.	O	1140-1141

The	O	1142-1145
results	O	1146-1153
showed	O	1154-1160
that	O	1161-1165
intracollicular	O	1166-1181
microinjection	O	1182-1196
of	O	1197-1199
MK	O	1200-1202
-	O	1202-1203
801	O	1203-1206
and	O	1207-1210
AP7	O	1211-1214
previous	O	1215-1223
to	O	1224-1226
systemic	O	1227-1235
injections	O	1236-1246
of	O	1247-1249
haloperidol	O	1250-1261
significantly	O	1262-1275
attenuated	O	1276-1286
the	O	1287-1290
catalepsy	B	1291-1300
,	O	1300-1301
as	O	1302-1304
indicated	O	1305-1314
by	O	1315-1317
a	O	1318-1319
reduced	O	1320-1327
latency	O	1328-1335
to	O	1336-1338
step	O	1339-1343
down	O	1344-1348
from	O	1349-1353
a	O	1354-1355
horizontal	O	1356-1366
bar	O	1367-1370
.	O	1370-1371

Accordingly	O	1372-1383
,	O	1383-1384
intracollicular	O	1385-1400
microinjection	O	1401-1415
of	O	1416-1418
NMDA	O	1419-1423
increased	O	1424-1433
the	O	1434-1437
latency	O	1438-1445
to	O	1446-1448
step	O	1449-1453
down	O	1454-1458
the	O	1459-1462
bar	O	1463-1466
.	O	1466-1467

These	O	1468-1473
findings	O	1474-1482
suggest	O	1483-1490
that	O	1491-1495
glutamate	O	1496-1505
-	O	1505-1506
mediated	O	1506-1514
mechanisms	O	1515-1525
in	O	1526-1528
the	O	1529-1532
neural	O	1533-1539
circuits	O	1540-1548
at	O	1549-1551
the	O	1552-1555
IC	O	1556-1558
level	O	1559-1564
influence	O	1565-1574
haloperidol	O	1575-1586
-	O	1586-1587
induced	O	1587-1594
catalepsy	B	1595-1604
and	O	1605-1608
participate	O	1609-1620
in	O	1621-1623
the	O	1624-1627
regulation	O	1628-1638
of	O	1639-1641
motor	O	1642-1647
activity	O	1648-1656
.	O	1656-1657

Metabotropic	O	0-12
glutamate	O	13-22
7	O	23-24
receptor	O	25-33
subtype	O	34-41
modulates	O	42-51
motor	O	52-57
symptoms	O	58-66
in	O	67-69
rodent	O	70-76
models	O	77-83
of	O	84-86
Parkinson	B	87-96
'	I	96-97
s	I	93-94
disease	I	99-106
.	O	106-107

Metabotropic	O	108-120
glutamate	O	121-130
(	O	131-132
mGlu	O	132-136
)	O	136-137
receptors	O	138-147
modulate	O	148-156
synaptic	O	157-165
transmission	O	166-178
in	O	179-181
the	O	182-185
central	O	186-193
nervous	O	194-201
system	O	202-208
and	O	209-212
represent	O	213-222
promising	O	223-232
therapeutic	O	233-244
targets	O	245-252
for	O	253-256
symptomatic	O	257-268
treatment	O	269-278
of	O	279-281
Parkinson	B	282-291
'	I	291-292
s	I	288-289
disease	I	294-301
(	O	302-303
PD	B	303-305
)	O	305-306
.	O	306-307

Among	O	308-313
the	O	314-317
eight	O	318-323
mGlu	O	324-328
receptor	O	329-337
subtypes	O	338-346
,	O	346-347
mGlu7	O	348-353
receptor	O	354-362
is	O	363-365
prominently	O	366-377
expressed	O	378-387
in	O	388-390
the	O	391-394
basal	O	395-400
ganglia	O	401-408
,	O	408-409
but	O	410-413
its	O	414-417
role	O	418-422
in	O	423-425
restoring	O	426-435
motor	O	436-441
function	O	442-450
in	O	451-453
animal	O	454-460
models	O	461-467
of	O	468-470
PD	B	471-473
is	O	474-476
not	O	477-480
known	O	481-486
.	O	486-487

The	O	488-491
effects	O	492-499
of	O	500-502
N	O	503-504
,	O	504-505
N	O	503-504
'	O	506-507
-	O	507-508
dibenzhydrylethane	O	508-526
-	O	507-508
1	O	527-528
,	O	504-505
2	O	529-530
-	O	507-508
diamine	O	531-538
dihydrochloride	O	539-554
(	O	555-556
AMN082	O	556-562
)	O	562-563
,	O	563-564
the	O	565-568
first	O	569-574
selective	O	575-584
allosteric	O	585-595
activator	O	596-605
of	O	606-608
mGlu7	O	609-614
receptors	O	615-624
,	O	624-625
were	O	626-630
thus	O	631-635
tested	O	636-642
in	O	643-645
different	O	646-655
rodent	O	656-662
models	O	663-669
of	O	670-672
PD	B	673-675
.	O	675-676

Here	O	677-681
,	O	681-682
we	O	683-685
show	O	686-690
that	O	691-695
oral	O	696-700
(	O	701-702
5	O	702-703
mg	O	704-706
/	O	706-707
kg	O	707-709
)	O	709-710
or	O	711-713
intrastriatal	O	714-727
administration	O	728-742
(	O	743-744
0	O	744-745
.	O	745-746
1	O	746-747
and	O	748-751
0	O	752-753
.	O	753-754
5	O	754-755
nmol	O	756-760
)	O	760-761
of	O	762-764
AMN082	O	765-771
reverses	O	772-780
haloperidol	O	781-792
-	O	792-793
induced	O	793-800
catalepsy	B	801-810
in	O	811-813
rats	O	814-818
.	O	818-819

AMN082	O	820-826
(	O	827-828
2	O	828-829
.	O	829-830
5	O	830-831
and	O	832-835
5	O	836-837
mg	O	838-840
/	O	840-841
kg	O	841-843
)	O	843-844
reduces	O	845-852
apomorphine	O	853-864
-	O	864-865
induced	O	865-872
rotations	O	873-882
in	O	883-885
unilateral	O	886-896
6	O	897-898
-	O	898-899
hydroxydopamine	O	899-914
(	O	915-916
6	O	916-917
-	O	917-918
OHDA	O	918-922
)	O	922-923
-	O	917-918
lesioned	O	924-932
rats	O	933-937
.	O	937-938

In	O	939-941
a	O	942-943
more	O	944-948
complex	O	949-956
task	O	957-961
commonly	O	962-970
used	O	971-975
to	O	976-978
evaluate	O	979-987
major	O	988-993
akinetic	B	994-1002
symptoms	O	1003-1011
of	O	1012-1014
PD	B	1015-1017
patients	O	1018-1026
,	O	1026-1027
5	O	1028-1029
mg	O	1030-1032
/	O	1032-1033
kg	O	1033-1035
AMN082	O	1036-1042
reverses	O	1043-1051
the	O	1052-1055
increased	O	1056-1065
reaction	O	1066-1074
time	O	1075-1079
to	O	1080-1082
respond	O	1083-1090
to	O	1091-1093
a	O	1094-1095
cue	O	1096-1099
of	O	1100-1102
bilateral	O	1103-1112
6	O	1113-1114
-	O	1114-1115
OHDA	O	1115-1119
-	O	1114-1115
lesioned	O	1120-1128
rats	O	1129-1133
.	O	1133-1134

In	O	1135-1137
addition	O	1138-1146
,	O	1146-1147
AMN082	O	1148-1154
reduces	O	1155-1162
the	O	1163-1166
duration	O	1167-1175
of	O	1176-1178
haloperidol	O	1179-1190
-	O	1190-1191
induced	O	1191-1198
catalepsy	B	1199-1208
in	O	1209-1211
a	O	1212-1213
mGlu7	O	1214-1219
receptor	O	1220-1228
-	O	1228-1229
dependent	O	1229-1238
manner	O	1239-1245
in	O	1246-1248
wild	O	1249-1253
-	O	1253-1254
type	O	1254-1258
but	O	1259-1262
not	O	1263-1266
mGlu7	O	1267-1272
receptor	O	1273-1281
knockout	O	1282-1290
mice	O	1291-1295
.	O	1295-1296

Higher	O	1297-1303
doses	O	1304-1309
of	O	1310-1312
AMN082	O	1313-1319
(	O	1320-1321
10	O	1321-1323
and	O	1324-1327
20	O	1328-1330
mg	O	1331-1333
/	O	1333-1334
kg	O	1334-1336
p	O	1337-1338
.	O	1338-1339
o	O	1339-1340
.	O	1338-1339
)	O	1341-1342
have	O	1343-1347
no	O	1348-1350
effect	O	1351-1357
on	O	1358-1360
the	O	1361-1364
same	O	1365-1369
models	O	1370-1376
of	O	1377-1379
PD	B	1380-1382
.	O	1382-1383

Overall	O	1384-1391
these	O	1392-1397
findings	O	1398-1406
suggest	O	1407-1414
that	O	1415-1419
mGlu7	O	1420-1425
receptor	O	1426-1434
activation	O	1435-1445
can	O	1446-1449
reverse	O	1450-1457
motor	O	1458-1463
dysfunction	O	1464-1475
associated	O	1476-1486
with	O	1487-1491
reduced	O	1492-1499
dopamine	O	1500-1508
activity	O	1509-1517
.	O	1517-1518

Selective	O	1519-1528
ligands	O	1529-1536
of	O	1537-1539
mGlu7	O	1540-1545
receptor	O	1546-1554
subtypes	O	1555-1563
may	O	1564-1567
thus	O	1568-1572
be	O	1573-1575
considered	O	1576-1586
as	O	1587-1589
promising	O	1590-1599
compounds	O	1600-1609
for	O	1610-1613
the	O	1614-1617
development	O	1618-1629
of	O	1630-1632
antiparkinsonian	O	1633-1649
therapeutic	O	1650-1661
strategies	O	1662-1672
.	O	1672-1673

Nimodipine	O	0-10
prevents	O	11-19
memory	B	20-26
impairment	I	27-37
caused	O	38-44
by	O	45-47
nitroglycerin	O	48-61
-	O	61-62
induced	O	62-69
hypotension	B	70-81
in	O	82-84
adult	O	85-90
mice	O	91-95
.	O	95-96

BACKGROUND	O	97-107
:	O	107-108
Hypotension	B	109-120
and	O	121-124
a	O	125-126
resultant	O	127-136
decrease	O	137-145
in	O	146-148
cerebral	O	149-157
blood	O	158-163
flow	O	164-168
have	O	169-173
been	O	174-178
implicated	O	179-189
in	O	190-192
the	O	193-196
development	O	197-208
of	O	209-211
cognitive	B	212-221
dysfunction	I	222-233
.	O	233-234

We	O	235-237
tested	O	238-244
the	O	245-248
hypothesis	O	249-259
that	O	260-264
nimodipine	O	265-275
(	O	276-277
NIMO	O	277-281
)	O	281-282
administered	O	283-295
at	O	296-298
the	O	299-302
onset	O	303-308
of	O	309-311
nitroglycerin	O	312-325
(	O	326-327
NTG	O	327-330
)	O	330-331
-	O	331-332
induced	O	332-339
hypotension	B	340-351
would	O	352-357
preserve	O	358-366
long	O	367-371
-	O	371-372
term	O	372-376
associative	O	377-388
memory	O	389-395
.	O	395-396

METHODS	O	397-404
:	O	404-405
The	O	406-409
passive	O	410-417
avoidance	O	418-427
(	O	428-429
PA	O	429-431
)	O	431-432
paradigm	O	433-441
was	O	442-445
used	O	446-450
to	O	451-453
assess	O	454-460
memory	O	461-467
retention	O	468-477
.	O	477-478

For	O	479-482
PA	O	483-485
training	O	486-494
,	O	494-495
latencies	O	496-505
(	O	506-507
seconds	O	507-514
)	O	514-515
were	O	516-520
recorded	O	521-529
for	O	530-533
entry	O	534-539
from	O	540-544
a	O	545-546
suspended	O	547-556
platform	O	557-565
into	O	566-570
a	O	571-572
Plexiglas	O	573-582
tube	O	583-587
where	O	588-593
a	O	594-595
shock	O	596-601
was	O	602-605
automatically	O	606-619
delivered	O	620-629
.	O	629-630

Latencies	O	631-640
were	O	641-645
recorded	O	646-654
48	O	655-657
h	O	658-659
later	O	660-665
for	O	666-669
a	O	670-671
testing	O	672-679
trial	O	680-685
.	O	685-686

Ninety	O	687-693
-	O	693-694
six	O	694-697
Swiss	O	698-703
-	O	703-704
Webster	O	704-711
mice	O	712-716
(	O	717-718
30	O	718-720
-	O	720-721
35	O	721-723
g	O	724-725
,	O	725-726
6	O	727-728
-	O	728-729
8	O	729-730
wk	O	731-733
)	O	733-734
,	O	734-735
were	O	736-740
randomized	O	741-751
into	O	752-756
6	O	757-758
groups	O	759-765
1	O	766-767
)	O	767-768
saline	O	769-775
(	O	776-777
control	O	777-784
)	O	784-785
,	O	785-786
2	O	787-788
)	O	788-789
NTG	O	790-793
immediately	O	794-805
after	O	806-811
learning	O	812-820
,	O	820-821
3	O	822-823
)	O	823-824
NTG	O	825-828
3	O	829-830
h	O	831-832
after	O	833-838
learning	O	839-847
,	O	847-848
4	O	849-850
)	O	850-851
NTG	O	852-855
and	O	856-859
NIMO	O	860-864
,	O	864-865
5	O	866-867
)	O	867-868
vehicle	O	869-876
,	O	876-877
and	O	878-881
6	O	882-883
)	O	883-884
NIMO	O	885-889
alone	O	890-895
.	O	895-896

The	O	897-900
extent	O	901-907
of	O	908-910
hypotension	B	911-922
and	O	923-926
changes	O	927-934
in	O	935-937
brain	O	938-943
tissue	O	944-950
oxygenation	O	951-962
(	O	963-964
PbtO	O	964-968
(	O	963-964
2	O	969-970
)	O	970-971
)	O	970-971
and	O	973-976
in	O	977-979
cerebral	O	980-988
blood	O	989-994
flow	O	995-999
were	O	1000-1004
studied	O	1005-1012
in	O	1013-1015
a	O	1016-1017
separate	O	1018-1026
group	O	1027-1032
of	O	1033-1035
animals	O	1036-1043
.	O	1043-1044

RESULTS	O	1045-1052
:	O	1052-1053
All	O	1054-1057
groups	O	1058-1064
exhibited	O	1065-1074
similar	O	1075-1082
training	O	1083-1091
latencies	O	1092-1101
(	O	1102-1103
17	O	1103-1105
.	O	1105-1106
0	O	1106-1107
+	O	1108-1109
/	O	1109-1110
-	O	1110-1111
4	O	1112-1113
.	O	1113-1114
6	O	1114-1115
s	O	1116-1117
)	O	1117-1118
.	O	1118-1119

Mice	O	1120-1124
subjected	O	1125-1134
to	O	1135-1137
hypotensive	B	1138-1149
episodes	O	1150-1158
showed	O	1159-1165
a	O	1166-1167
significant	O	1168-1179
decrease	O	1180-1188
in	O	1189-1191
latency	O	1192-1199
time	O	1200-1204
(	O	1205-1206
178	O	1206-1209
+	O	1210-1211
/	O	1211-1212
-	O	1212-1213
156	O	1214-1217
s	O	1218-1219
)	O	1219-1220
compared	O	1221-1229
with	O	1230-1234
those	O	1235-1240
injected	O	1241-1249
with	O	1250-1254
saline	O	1255-1261
,	O	1261-1262
NTG	O	1263-1266
+	O	1267-1268
NIMO	O	1269-1273
,	O	1273-1274
or	O	1275-1277
delayed	O	1278-1285
NTG	O	1286-1289
(	O	1290-1291
580	O	1291-1294
+	O	1295-1296
/	O	1296-1297
-	O	1297-1298
81	O	1299-1301
s	O	1302-1303
,	O	1303-1304
557	O	1305-1308
+	O	1309-1310
/	O	1310-1311
-	O	1311-1312
67	O	1313-1315
s	O	1316-1317
,	O	1317-1318
and	O	1319-1322
493	O	1323-1326
+	O	1327-1328
/	O	1328-1329
-	O	1329-1330
146	O	1331-1334
s	O	1335-1336
,	O	1336-1337
respectively	O	1338-1350
)	O	1350-1351
.	O	1351-1352

A	O	1353-1354
Kruskal	O	1355-1362
-	O	1362-1363
Wallis	O	1363-1369
1	O	1370-1371
-	O	1371-1372
way	O	1372-1375
analysis	O	1376-1384
of	O	1385-1387
variance	O	1388-1396
indicated	O	1397-1406
a	O	1407-1408
significant	O	1409-1420
difference	O	1421-1431
among	O	1432-1437
the	O	1438-1441
4	O	1442-1443
treatment	O	1444-1453
groups	O	1454-1460
(	O	1461-1462
H	O	1462-1463
=	O	1464-1465
15	O	1466-1468
.	O	1468-1469
34	O	1469-1471
;	O	1471-1472

P	O	1473-1474
<	O	1475-1476
0	O	1477-1478
.	O	1478-1479
001	O	1479-1482
)	O	1482-1483
.	O	1478-1479

In	O	1485-1487
a	O	1488-1489
separate	O	1490-1498
group	O	1499-1504
of	O	1505-1507
mice	O	1508-1512
not	O	1513-1516
subjected	O	1517-1526
to	O	1527-1529
behavioral	O	1530-1540
studies	O	1541-1548
,	O	1548-1549
the	O	1550-1553
same	O	1554-1558
dose	O	1559-1563
of	O	1564-1566
NTG	O	1567-1570
(	O	1571-1572
n	O	1572-1573
=	O	1574-1575
3	O	1576-1577
)	O	1577-1578
and	O	1579-1582
NTG	O	1583-1586
+	O	1587-1588
NIMO	O	1589-1593
(	O	1594-1595
n	O	1595-1596
=	O	1597-1598
3	O	1599-1600
)	O	1600-1601
caused	O	1602-1608
mean	O	1609-1613
arterial	O	1614-1622
blood	O	1623-1628
pressure	O	1629-1637
to	O	1638-1640
decrease	O	1641-1649
from	O	1650-1654
85	O	1655-1657
.	O	1657-1658
9	O	1658-1659
+	O	1660-1661
/	O	1661-1662
-	O	1662-1663
3	O	1664-1665
.	O	1665-1666
8	O	1666-1667
mm	O	1668-1670
Hg	O	1671-1673
sem	O	1674-1677
to	O	1678-1680
31	O	1681-1683
.	O	1683-1684
6	O	1684-1685
+	O	1686-1687
/	O	1687-1688
-	O	1688-1689
0	O	1690-1691
.	O	1691-1692
8	O	1692-1693
mm	O	1694-1696
Hg	O	1697-1699
sem	O	1700-1703
and	O	1704-1707
from	O	1708-1712
86	O	1713-1715
.	O	1715-1716
2	O	1716-1717
+	O	1718-1719
/	O	1719-1720
-	O	1720-1721
3	O	1722-1723
.	O	1723-1724
7	O	1724-1725
mm	O	1726-1728
Hg	O	1729-1731
sem	O	1732-1735
to	O	1736-1738
32	O	1739-1741
.	O	1741-1742
6	O	1742-1743
+	O	1744-1745
/	O	1745-1746
-	O	1746-1747
0	O	1748-1749
.	O	1749-1750
2	O	1750-1751
mm	O	1752-1754
Hg	O	1755-1757
sem	O	1758-1761
,	O	1761-1762
respectively	O	1763-1775
.	O	1775-1776

Mean	O	1777-1781
arterial	O	1782-1790
blood	O	1791-1796
pressure	O	1797-1805
in	O	1806-1808
mice	O	1809-1813
treated	O	1814-1821
with	O	1822-1826
NIMO	O	1827-1831
alone	O	1832-1837
decreased	O	1838-1847
from	O	1848-1852
88	O	1853-1855
.	O	1855-1856
1	O	1856-1857
+	O	1858-1859
/	O	1859-1860
-	O	1860-1861
3	O	1862-1863
.	O	1863-1864
8	O	1864-1865
mm	O	1866-1868
Hg	O	1869-1871
to	O	1872-1874
80	O	1875-1877
.	O	1877-1878
0	O	1876-1877
+	O	1880-1881
/	O	1881-1882
-	O	1882-1883
2	O	1884-1885
.	O	1885-1886
9	O	1886-1887
mm	O	1888-1890
Hg	O	1891-1893
.	O	1893-1894

The	O	1895-1898
intergroup	O	1899-1909
difference	O	1910-1920
was	O	1921-1924
statistically	O	1925-1938
significant	O	1939-1950
(	O	1951-1952
P	O	1952-1953
<	O	1954-1955
0	O	1956-1957
.	O	1957-1958
05	O	1958-1960
)	O	1960-1961
.	O	1957-1958

PbtO	O	1963-1967
(	O	1967-1968
2	O	1968-1969
)	O	1969-1970
decreased	O	1971-1980
from	O	1981-1985
51	O	1986-1988
.	O	1988-1989
7	O	1989-1990
+	O	1991-1992
/	O	1992-1993
-	O	1993-1994
4	O	1995-1996
.	O	1996-1997
5	O	1997-1998
mm	O	1999-2001
Hg	O	2002-2004
sem	O	2005-2008
to	O	2009-2011
33	O	2012-2014
.	O	2014-2015
8	O	2015-2016
+	O	2017-2018
/	O	2018-2019
-	O	2019-2020
5	O	2021-2022
.	O	2022-2023
2	O	2023-2024
mm	O	2025-2027
Hg	O	2028-2030
sem	O	2031-2034
in	O	2035-2037
the	O	2038-2041
NTG	O	2042-2045
group	O	2046-2051
and	O	2052-2055
from	O	2056-2060
38	O	2061-2063
.	O	2063-2064
6	O	2064-2065
+	O	2066-2067
/	O	2067-2068
-	O	2068-2069
6	O	2070-2071
.	O	2071-2072
1	O	2072-2073
mm	O	2074-2076
Hg	O	2077-2079
sem	O	2080-2083
to	O	2084-2086
25	O	2087-2089
.	O	2089-2090
4	O	2090-2091
+	O	2092-2093
/	O	2093-2094
-	O	2094-2095
2	O	2096-2097
.	O	2097-2098
0	O	2098-2099
mm	O	2100-2102
Hg	O	2103-2105
sem	O	2106-2109
in	O	2110-2112
the	O	2113-2116
NTG	O	2117-2120
+	O	2121-2122
NIMO	O	2123-2127
groups	O	2128-2134
,	O	2134-2135
respectively	O	2136-2148
.	O	2148-2149

There	O	2150-2155
were	O	2156-2160
no	O	2161-2163
significant	O	2164-2175
differences	O	2176-2187
among	O	2188-2193
groups	O	2194-2200
.	O	2200-2201

CONCLUSION	O	2202-2212
:	O	2212-2213
In	O	2214-2216
a	O	2217-2218
PA	O	2219-2221
retention	O	2222-2231
paradigm	O	2232-2240
,	O	2240-2241
the	O	2242-2245
injection	O	2246-2255
of	O	2256-2258
NTG	O	2259-2262
immediately	O	2263-2274
after	O	2275-2280
learning	O	2281-2289
produced	O	2290-2298
a	O	2299-2300
significant	O	2301-2312
impairment	O	2313-2323
of	O	2324-2326
long	O	2327-2331
-	O	2331-2332
term	O	2332-2336
associative	O	2337-2348
memory	O	2349-2355
in	O	2356-2358
mice	O	2359-2363
,	O	2363-2364
whereas	O	2365-2372
delayed	O	2373-2380
induced	O	2381-2388
hypotension	B	2389-2400
had	O	2401-2404
no	O	2405-2407
effect	O	2408-2414
.	O	2414-2415

NIMO	O	2416-2420
attenuated	O	2421-2431
the	O	2432-2435
disruption	O	2436-2446
in	O	2447-2449
consolidation	O	2450-2463
of	O	2464-2466
long	O	2467-2471
-	O	2471-2472
term	O	2472-2476
memory	O	2477-2483
caused	O	2484-2490
by	O	2491-2493
NTG	O	2494-2497
but	O	2498-2501
did	O	2502-2505
not	O	2506-2509
improve	O	2510-2517
latency	O	2518-2525
in	O	2526-2528
the	O	2529-2532
absence	O	2533-2540
of	O	2541-2543
hypotension	B	2544-2555
.	O	2555-2556

The	O	2557-2560
observed	O	2561-2569
effect	O	2570-2576
of	O	2577-2579
NIMO	O	2580-2584
may	O	2585-2588
have	O	2589-2593
been	O	2594-2598
attributable	O	2599-2611
to	O	2612-2614
the	O	2615-2618
preservation	O	2619-2631
of	O	2632-2634
calcium	O	2635-2642
homeostasis	O	2643-2654
during	O	2655-2661
hypotension	B	2662-2673
,	O	2673-2674
because	O	2675-2682
there	O	2683-2688
were	O	2689-2693
no	O	2694-2696
differences	O	2697-2708
in	O	2709-2711
the	O	2712-2715
PbtO	O	2716-2720
(	O	2720-2721
2	O	2721-2722
)	O	2722-2723
indices	O	2724-2731
among	O	2732-2737
groups	O	2738-2744
.	O	2744-2745

Fatal	O	0-5
haemopericardium	B	6-22
and	O	23-26
gastrointestinal	B	27-43
haemorrhage	I	44-55
due	O	56-59
to	O	60-62
possible	O	63-71
interaction	O	72-83
of	O	84-86
cranberry	O	87-96
juice	O	97-102
with	O	103-107
warfarin	O	108-116
.	O	116-117

We	O	118-120
report	O	121-127
a	O	128-129
case	O	130-134
of	O	135-137
fatal	O	138-143
internal	O	144-152
haemorrhage	B	153-164
in	O	165-167
an	O	168-170
elderly	O	171-178
man	O	179-182
who	O	183-186
consumed	O	187-195
only	O	196-200
cranberry	O	201-210
juice	O	211-216
for	O	217-220
two	O	221-224
weeks	O	225-230
while	O	231-236
maintaining	O	237-248
his	O	249-252
usual	O	253-258
dosage	O	259-265
of	O	266-268
warfarin	O	269-277
.	O	277-278

We	O	279-281
propose	O	282-289
that	O	290-294
naturally	O	295-304
occurring	O	305-314
compounds	O	315-324
such	O	325-329
as	O	330-332
flavonoids	O	333-343
,	O	343-344
which	O	345-350
are	O	351-354
present	O	355-362
in	O	363-365
fruit	O	366-371
juices	O	372-378
,	O	378-379
may	O	380-383
increase	O	384-392
the	O	393-396
potency	O	397-404
of	O	405-407
warfarin	O	408-416
by	O	417-419
competing	O	420-429
for	O	430-433
the	O	434-437
enzymes	O	438-445
that	O	446-450
normally	O	451-459
inactivate	O	460-470
warfarin	O	471-479
.	O	479-480

While	O	481-486
traditionally	O	487-500
regarded	O	501-509
as	O	510-512
foodstuffs	O	513-523
,	O	523-524
consumption	O	525-536
of	O	537-539
fruit	O	540-545
juices	O	546-552
should	O	553-559
be	O	560-562
considered	O	563-573
when	O	574-578
patients	O	579-587
develop	O	588-595
adverse	O	596-603
drug	O	604-608
reactions	O	609-618
.	O	618-619

Isoproterenol	O	0-13
induces	O	14-21
primary	O	22-29
loss	O	30-34
of	O	35-37
dystrophin	O	38-48
in	O	49-51
rat	O	52-55
hearts	O	56-62
:	O	62-63
correlation	O	64-75
with	O	76-80
myocardial	B	81-91
injury	I	92-98
.	O	98-99

The	O	100-103
mechanism	O	104-113
of	O	114-116
isoproterenol	O	117-130
-	O	130-131
induced	O	131-138
myocardial	B	139-149
damage	I	150-156
is	O	157-159
unknown	O	160-167
,	O	167-168
but	O	169-172
a	O	173-174
mismatch	O	175-183
of	O	184-186
oxygen	O	187-193
supply	O	194-200
vs	O	201-203
.	O	203-204
demand	O	205-211
following	O	212-221
coronary	O	222-230
hypotension	B	231-242
and	O	243-246
myocardial	B	247-257
hyperactivity	I	258-271
is	O	272-274
the	O	275-278
best	O	279-283
explanation	O	284-295
for	O	296-299
the	O	300-303
complex	O	304-311
morphological	O	312-325
alterations	O	326-337
observed	O	338-346
.	O	346-347

Severe	O	348-354
alterations	O	355-366
in	O	367-369
the	O	370-373
structural	O	374-384
integrity	O	385-394
of	O	395-397
the	O	398-401
sarcolemma	O	402-412
of	O	413-415
cardiomyocytes	O	416-430
have	O	431-435
been	O	436-440
demonstrated	O	441-453
to	O	454-456
be	O	457-459
caused	O	460-466
by	O	467-469
isoproterenol	O	470-483
.	O	483-484

Taking	O	485-491
into	O	492-496
account	O	497-504
that	O	505-509
the	O	510-513
sarcolemmal	O	514-525
integrity	O	526-535
is	O	536-538
stabilized	O	539-549
by	O	550-552
the	O	553-556
dystrophin	O	557-567
-	O	567-568
glycoprotein	O	568-580
complex	O	581-588
(	O	589-590
DGC	O	590-593
)	O	593-594
that	O	595-599
connects	O	600-608
actin	O	609-614
and	O	615-618
laminin	O	619-626
in	O	627-629
contractile	O	630-641
machinery	O	642-651
and	O	652-655
extracellular	O	656-669
matrix	O	670-676
and	O	677-680
by	O	681-683
integrins	O	684-693
,	O	693-694
this	O	695-699
study	O	700-705
tests	O	706-711
the	O	712-715
hypothesis	O	716-726
that	O	727-731
isoproterenol	O	732-745
affects	O	746-753
sarcolemmal	O	754-765
stability	O	766-775
through	O	776-783
changes	O	784-791
in	O	792-794
the	O	795-798
DGC	O	799-802
and	O	803-806
integrins	O	807-816
.	O	816-817

We	O	818-820
found	O	821-826
different	O	827-836
sensitivity	O	837-848
of	O	849-851
the	O	852-855
DGC	O	856-859
and	O	860-863
integrin	O	864-872
to	O	873-875
isoproterenol	O	876-889
subcutaneous	O	890-902
administration	O	903-917
.	O	917-918

Immunofluorescent	O	919-936
staining	O	937-945
revealed	O	946-954
that	O	955-959
dystrophin	O	960-970
is	O	971-973
the	O	974-977
most	O	978-982
sensitive	O	983-992
among	O	993-998
the	O	999-1002
structures	O	1003-1013
connecting	O	1014-1024
the	O	1025-1028
actin	O	1029-1034
in	O	1035-1037
the	O	1038-1041
cardiomyocyte	O	1042-1055
cytoskeleton	O	1056-1068
and	O	1069-1072
the	O	1073-1076
extracellular	O	1077-1090
matrix	O	1091-1097
.	O	1097-1098

The	O	1099-1102
sarcomeric	O	1103-1113
actin	O	1114-1119
dissolution	O	1120-1131
occurred	O	1132-1140
after	O	1141-1146
the	O	1147-1150
reduction	O	1151-1160
or	O	1161-1163
loss	O	1164-1168
of	O	1169-1171
dystrophin	O	1172-1182
.	O	1182-1183

Subsequently	O	1184-1196
,	O	1196-1197
after	O	1198-1203
lysis	O	1204-1209
of	O	1210-1212
myofilaments	O	1213-1225
,	O	1225-1226
gamma	O	1227-1232
-	O	1232-1233
sarcoglycan	O	1233-1244
,	O	1244-1245
beta	O	1246-1250
-	O	1250-1251
dystroglycan	O	1251-1263
,	O	1263-1264
beta1	O	1265-1270
-	O	1270-1271
integrin	O	1271-1279
,	O	1279-1280
and	O	1281-1284
laminin	O	1285-1292
alpha	O	1293-1298
-	O	1298-1299
2	O	1299-1300
expressions	O	1301-1312
were	O	1313-1317
reduced	O	1318-1325
followed	O	1326-1334
by	O	1335-1337
their	O	1338-1343
breakdown	O	1344-1353
,	O	1353-1354
as	O	1355-1357
epiphenomena	O	1358-1370
of	O	1371-1373
the	O	1374-1377
myocytolytic	O	1378-1390
process	O	1391-1398
.	O	1398-1399

In	O	1400-1402
conclusion	O	1403-1413
,	O	1413-1414
administration	O	1415-1429
of	O	1430-1432
isoproterenol	O	1433-1446
to	O	1447-1449
rats	O	1450-1454
results	O	1455-1462
in	O	1463-1465
primary	O	1466-1473
loss	O	1474-1478
of	O	1479-1481
dystrophin	O	1482-1492
,	O	1492-1493
the	O	1494-1497
most	O	1498-1502
sensitive	O	1503-1512
among	O	1513-1518
the	O	1519-1522
structural	O	1523-1533
proteins	O	1534-1542
that	O	1543-1547
form	O	1548-1552
the	O	1553-1556
DGC	O	1557-1560
that	O	1561-1565
connects	O	1566-1574
the	O	1575-1578
extracellular	O	1579-1592
matrix	O	1593-1599
and	O	1600-1603
the	O	1604-1607
cytoskeleton	O	1608-1620
in	O	1621-1623
cardiomyocyte	O	1624-1637
.	O	1637-1638

These	O	1639-1644
changes	O	1645-1652
,	O	1652-1653
related	O	1654-1661
to	O	1662-1664
ischaemic	B	1665-1674
injury	I	1675-1681
,	O	1681-1682
explain	O	1683-1690
the	O	1691-1694
severe	O	1695-1701
alterations	O	1702-1713
in	O	1714-1716
the	O	1717-1720
structural	O	1721-1731
integrity	O	1732-1741
of	O	1742-1744
the	O	1745-1748
sarcolemma	O	1749-1759
of	O	1760-1762
cardiomyocytes	O	1763-1777
and	O	1778-1781
hence	O	1782-1787
severe	O	1788-1794
and	O	1795-1798
irreversible	O	1799-1811
injury	O	1812-1818
induced	O	1819-1826
by	O	1827-1829
isoproterenol	O	1830-1843
.	O	1843-1844

High	O	0-4
fat	O	5-8
diet	O	9-13
-	O	13-14
fed	O	14-17
obese	B	18-23
rats	O	24-28
are	O	29-32
highly	O	33-39
sensitive	O	40-49
to	O	50-52
doxorubicin	O	53-64
-	O	64-65
induced	O	65-72
cardiotoxicity	B	73-87
.	O	87-88

Often	O	89-94
,	O	94-95
chemotherapy	O	96-108
by	O	109-111
doxorubicin	O	112-123
(	O	124-125
Adriamycin	O	125-135
)	O	135-136
is	O	137-139
limited	O	140-147
due	O	148-151
to	O	152-154
life	O	155-159
threatening	O	160-171
cardiotoxicity	B	172-186
in	O	187-189
patients	O	190-198
during	O	199-205
and	O	206-209
posttherapy	O	210-221
.	O	221-222

Recently	O	223-231
,	O	231-232
we	O	233-235
have	O	236-240
shown	O	241-246
that	O	247-251
moderate	O	252-260
diet	O	261-265
restriction	O	266-277
remarkably	O	278-288
protects	O	289-297
against	O	298-305
doxorubicin	O	306-317
-	O	317-318
induced	O	318-325
cardiotoxicity	B	326-340
.	O	340-341

This	O	342-346
cardioprotection	O	347-363
is	O	364-366
accompanied	O	367-378
by	O	379-381
decreased	O	382-391
cardiac	O	392-399
oxidative	O	400-409
stress	O	410-416
and	O	417-420
triglycerides	O	421-434
and	O	435-438
increased	O	439-448
cardiac	O	449-456
fatty	O	457-462
-	O	462-463
acid	O	463-467
oxidation	O	468-477
,	O	477-478
ATP	O	479-482
synthesis	O	483-492
,	O	492-493
and	O	494-497
upregulated	O	498-509
JAK	O	510-513
/	O	513-514
STAT3	O	514-519
pathway	O	520-527
.	O	527-528

In	O	529-531
the	O	532-535
current	O	536-543
study	O	544-549
,	O	549-550
we	O	551-553
investigated	O	554-566
whether	O	567-574
a	O	575-576
physiological	O	577-590
intervention	O	591-603
by	O	604-606
feeding	O	607-614
40	O	615-617
%	O	617-618
high	O	619-623
fat	O	624-627
diet	O	628-632
(	O	633-634
HFD	O	634-637
)	O	637-638
,	O	638-639
which	O	640-645
induces	O	646-653
obesity	B	654-661
in	O	662-664
male	O	665-669
Sprague	O	670-677
-	O	677-678
Dawley	O	678-684
rats	O	685-689
(	O	690-691
250	O	691-694
-	O	694-695
275	O	695-698
g	O	699-700
)	O	700-701
,	O	701-702
sensitizes	O	703-713
to	O	714-716
doxorubicin	O	717-728
-	O	728-729
induced	O	729-736
cardiotoxicity	B	737-751
.	O	751-752

A	O	753-754
LD	O	755-757
(	O	757-758
10	O	758-760
)	O	760-761
dose	O	762-766
(	O	767-768
8	O	768-769
mg	O	770-772
doxorubicin	O	773-784
/	O	784-785
kg	O	785-787
,	O	787-788
ip	O	789-791
)	O	791-792
administered	O	793-805
on	O	806-808
day	O	809-812
43	O	813-815
of	O	816-818
the	O	819-822
HFD	O	823-826
feeding	O	827-834
regimen	O	835-842
led	O	843-846
to	O	847-849
higher	O	850-856
cardiotoxicity	B	857-871
,	O	871-872
cardiac	B	873-880
dysfunction	I	881-892
,	O	892-893
lipid	O	894-899
peroxidation	O	900-912
,	O	912-913
and	O	914-917
80	O	918-920
%	O	920-921
mortality	O	922-931
in	O	932-934
the	O	935-938
obese	B	939-944
(	O	945-946
OB	B	946-948
)	O	948-949
rats	O	950-954
in	O	955-957
the	O	958-961
absence	O	962-969
of	O	970-972
any	O	973-976
significant	O	977-988
renal	B	989-994
or	I	995-997
hepatic	I	998-1005
toxicity	I	1006-1014
.	O	1014-1015

Doxorubicin	O	1016-1027
toxicokinetics	O	1028-1042
studies	O	1043-1050
revealed	O	1051-1059
no	O	1060-1062
change	O	1063-1069
in	O	1070-1072
accumulation	O	1073-1085
of	O	1086-1088
doxorubicin	O	1089-1100
and	O	1101-1104
doxorubicinol	O	1105-1118
(	O	1119-1120
toxic	O	1120-1125
metabolite	O	1126-1136
)	O	1136-1137
in	O	1138-1140
the	O	1141-1144
normal	O	1145-1151
diet	O	1152-1156
-	O	1156-1157
fed	O	1157-1160
(	O	1161-1162
ND	O	1162-1164
)	O	1164-1165
and	O	1166-1169
OB	B	1170-1172
hearts	O	1173-1179
.	O	1179-1180

Mechanistic	O	1181-1192
studies	O	1193-1200
revealed	O	1201-1209
that	O	1210-1214
OB	B	1215-1217
rats	O	1218-1222
are	O	1223-1226
sensitized	O	1227-1237
due	O	1238-1241
to	O	1242-1244
:	O	1244-1245
(	O	1246-1247
1	O	1247-1248
)	O	1248-1249
higher	O	1250-1256
oxyradical	O	1257-1267
stress	O	1268-1274
leading	O	1275-1282
to	O	1283-1285
upregulation	O	1286-1298
of	O	1299-1301
uncoupling	O	1302-1312
proteins	O	1313-1321
2	O	1322-1323
and	O	1324-1327
3	O	1328-1329
,	O	1329-1330
(	O	1331-1332
2	O	1332-1333
)	O	1333-1334
downregulation	O	1335-1349
of	O	1350-1352
cardiac	O	1353-1360
peroxisome	O	1361-1371
proliferators	O	1372-1385
activated	O	1386-1395
receptor	O	1396-1404
-	O	1404-1405
alpha	O	1405-1410
,	O	1410-1411
(	O	1412-1413
3	O	1413-1414
)	O	1414-1415
decreased	O	1416-1425
plasma	O	1426-1432
adiponectin	O	1433-1444
levels	O	1445-1451
,	O	1451-1452
(	O	1453-1454
4	O	1454-1455
)	O	1455-1456
decreased	O	1457-1466
cardiac	O	1467-1474
fatty	O	1475-1480
-	O	1480-1481
acid	O	1481-1485
oxidation	O	1486-1495
(	O	1496-1497
666	O	1497-1500
.	O	1500-1501
9	O	1501-1502
+	O	1502-1503
/	O	1503-1504
-	O	1504-1505
14	O	1505-1507
.	O	1500-1501
0	O	1508-1509

nmol	O	1510-1514
/	O	1514-1515
min	O	1515-1518
/	O	1514-1515
g	O	1519-1520
heart	O	1521-1526
in	O	1527-1529
ND	O	1530-1532
versus	O	1533-1539
400	O	1540-1543
.	O	1543-1544
2	O	1544-1545
+	O	1545-1546
/	O	1546-1547
-	O	1547-1548
11	O	1548-1550
.	O	1543-1544
8	O	1551-1552

nmol	O	1553-1557
/	O	1557-1558
min	O	1558-1561
/	O	1557-1558
g	O	1562-1563
heart	O	1564-1569
in	O	1570-1572
OB	B	1573-1575
)	O	1575-1576
,	O	1576-1577
(	O	1578-1579
5	O	1579-1580
)	O	1580-1581
decreased	O	1582-1591
mitochondrial	O	1592-1605
AMP	O	1606-1609
-	O	1609-1610
alpha2	O	1610-1616
protein	O	1617-1624
kinase	O	1625-1631
,	O	1631-1632
and	O	1633-1636
(	O	1637-1638
6	O	1638-1639
)	O	1639-1640
86	O	1641-1643
%	O	1643-1644
drop	O	1645-1649
in	O	1650-1652
cardiac	O	1653-1660
ATP	O	1661-1664
levels	O	1665-1671
accompanied	O	1672-1683
by	O	1684-1686
decreased	O	1687-1696
ATP	O	1697-1700
/	O	1700-1701
ADP	O	1701-1704
ratio	O	1705-1710
after	O	1711-1716
doxorubicin	O	1717-1728
administration	O	1729-1743
.	O	1743-1744

Decreased	O	1745-1754
cardiac	O	1755-1762
erythropoietin	O	1763-1777
and	O	1778-1781
increased	O	1782-1791
SOCS3	O	1792-1797
further	O	1798-1805
downregulated	O	1806-1819
the	O	1820-1823
cardioprotective	O	1824-1840
JAK	O	1841-1844
/	O	1844-1845
STAT3	O	1845-1850
pathway	O	1851-1858
.	O	1858-1859

In	O	1860-1862
conclusion	O	1863-1873
,	O	1873-1874
HFD	O	1875-1878
-	O	1878-1879
induced	O	1879-1886
obese	B	1887-1892
rats	O	1893-1897
are	O	1898-1901
highly	O	1902-1908
sensitized	O	1909-1919
to	O	1920-1922
doxorubicin	O	1923-1934
-	O	1934-1935
induced	O	1935-1942
cardiotoxicity	B	1943-1957
by	O	1958-1960
substantially	O	1961-1974
downregulating	O	1975-1989
cardiac	O	1990-1997
mitochondrial	O	1998-2011
ATP	O	2012-2015
generation	O	2016-2026
,	O	2026-2027
increasing	O	2028-2038
oxidative	O	2039-2048
stress	O	2049-2055
and	O	2056-2059
downregulating	O	2060-2074
the	O	2075-2078
JAK	O	2079-2082
/	O	2082-2083
STAT3	O	2083-2088
pathway	O	2089-2096
.	O	2096-2097

Complete	O	0-8
atrioventricular	B	9-25
block	I	26-31
secondary	O	32-41
to	O	42-44
lithium	O	45-52
therapy	O	53-60
.	O	60-61

Sinus	B	62-67
node	I	68-72
dysfunction	I	73-84
has	O	85-88
been	O	89-93
reported	O	94-102
most	O	103-107
frequently	O	108-118
among	O	119-124
the	O	125-128
adverse	O	129-136
cardiovascular	O	137-151
effects	O	152-159
of	O	160-162
lithium	O	163-170
.	O	170-171

In	O	172-174
the	O	175-178
present	O	179-186
case	O	187-191
,	O	191-192
complete	O	193-201
atrioventricular	B	202-218
(	I	219-220
AV	I	220-222
)	I	222-223
block	I	224-229
with	O	230-234
syncopal	B	235-243
attacks	I	244-251
developed	O	252-261
secondary	O	262-271
to	O	272-274
lithium	O	275-282
therapy	O	283-290
,	O	290-291
necessitating	O	292-305
permanent	O	306-315
pacemaker	O	316-325
implantation	O	326-338
.	O	338-339

Serum	O	340-345
lithium	O	346-353
levels	O	354-360
remained	O	361-369
under	O	370-375
or	O	376-378
within	O	379-385
the	O	386-389
therapeutic	O	390-401
range	O	402-407
during	O	408-414
the	O	415-418
syncopal	B	419-427
attacks	I	428-435
.	O	435-436

Lithium	O	437-444
should	O	445-451
be	O	452-454
used	O	455-459
with	O	460-464
extreme	O	465-472
caution	O	473-480
,	O	480-481
especially	O	482-492
in	O	493-495
patients	O	496-504
with	O	505-509
mild	O	510-514
disturbance	O	515-526
of	O	527-529
AV	O	530-532
conduction	O	533-543
.	O	543-544

Neuroleptic	B	0-11
malignant	I	12-21
syndrome	I	22-30
induced	O	31-38
by	O	39-41
ziprasidone	O	42-53
on	O	54-56
the	O	57-60
second	O	61-67
day	O	68-71
of	O	72-74
treatment	O	75-84
.	O	84-85

Neuroleptic	B	86-97
malignant	I	98-107
syndrome	I	108-116
(	O	117-118
NMS	B	118-121
)	O	121-122
is	O	123-125
the	O	126-129
rarest	O	130-136
and	O	137-140
most	O	141-145
serious	O	146-153
of	O	154-156
the	O	157-160
neuroleptic	O	161-172
-	O	172-173
induced	O	173-180
movement	B	181-189
disorders	I	190-199
.	O	199-200

We	O	201-203
describe	O	204-212
a	O	213-214
case	O	215-219
of	O	220-222
neuroleptic	B	223-234
malignant	I	235-244
syndrome	I	245-253
(	O	254-255
NMS	B	255-258
)	O	258-259
associated	O	260-270
with	O	271-275
the	O	276-279
use	O	280-283
of	O	284-286
ziprasidone	O	287-298
.	O	298-299

Although	O	300-308
conventional	O	309-321
neuroleptics	O	322-334
are	O	335-338
more	O	339-343
frequently	O	344-354
associated	O	355-365
with	O	366-370
NMS	B	371-374
,	O	374-375
atypical	O	376-384
antipsychotic	O	385-398
drugs	O	399-404
like	O	405-409
ziprasidone	O	410-421
may	O	422-425
also	O	426-430
be	O	431-433
a	O	434-435
cause	O	436-441
.	O	441-442

The	O	443-446
patient	O	447-454
is	O	455-457
a	O	458-459
24	O	460-462
-	O	462-463
year	O	463-467
-	O	462-463
old	O	468-471
male	O	472-476
with	O	477-481
a	O	482-483
history	O	484-491
of	O	492-494
schizophrenia	B	495-508
who	O	509-512
developed	O	513-522
signs	O	523-528
and	O	529-532
symptoms	O	533-541
of	O	542-544
NMS	B	545-548
after	O	549-554
2	O	555-556
days	O	557-561
of	O	562-564
treatment	O	565-574
with	O	575-579
an	O	580-582
80	O	583-585
-	O	585-586
mg	O	586-588
/	O	588-589
day	O	589-592
dose	O	593-597
of	O	598-600
orally	O	601-607
administrated	O	608-621
ziprasidone	O	622-633
.	O	633-634

This	O	635-639
case	O	640-644
is	O	645-647
the	O	648-651
earliest	O	652-660
(	O	661-662
second	O	662-668
day	O	669-672
of	O	673-675
treatment	O	676-685
)	O	685-686
NMS	B	687-690
due	O	691-694
to	O	695-697
ziprasidone	O	698-709
reported	O	710-718
in	O	719-721
the	O	722-725
literature	O	726-736
.	O	736-737

Role	O	0-4
of	O	5-7
mangiferin	O	8-18
on	O	19-21
biochemical	O	22-33
alterations	O	34-45
and	O	46-49
antioxidant	O	50-61
status	O	62-68
in	O	69-71
isoproterenol	O	72-85
-	O	85-86
induced	O	86-93
myocardial	B	94-104
infarction	I	105-115
in	O	116-118
rats	O	119-123
.	O	123-124

The	O	125-128
current	O	129-136
study	O	137-142
dealt	O	143-148
with	O	149-153
the	O	154-157
protective	O	158-168
role	O	169-173
of	O	174-176
mangiferin	O	177-187
,	O	187-188
a	O	189-190
polyphenol	O	191-201
from	O	202-206
Mangifera	O	207-216
indica	O	217-223
Linn	O	224-228
.	O	228-229

(	O	230-231
Anacardiaceae	O	231-244
)	O	244-245
,	O	245-246
on	O	247-249
isoproterenol	O	250-263
(	O	264-265
ISPH	O	265-269
)	O	269-270
-	O	270-271
induced	O	271-278
myocardial	B	279-289
infarction	I	290-300
(	O	301-302
MI	B	302-304
)	O	304-305
in	O	306-308
rats	O	309-313
through	O	314-321
its	O	322-325
antioxidative	O	326-339
mechanism	O	340-349
.	O	349-350

Subcutaneous	O	351-363
injection	O	364-373
of	O	374-376
ISPH	O	377-381
(	O	382-383
200	O	383-386
mg	O	387-389
/	O	389-390
kg	O	390-392
body	O	393-397
weight	O	398-404
in	O	405-407
1	O	408-409
ml	O	410-412
saline	O	413-419
)	O	419-420
to	O	421-423
rats	O	424-428
for	O	429-432
2	O	433-434
consecutive	O	435-446
days	O	447-451
caused	O	452-458
myocardial	B	459-469
damage	I	470-476
in	O	477-479
rat	O	480-483
heart	O	484-489
,	O	489-490
which	O	491-496
was	O	497-500
determined	O	501-511
by	O	512-514
the	O	515-518
increased	O	519-528
activity	O	529-537
of	O	538-540
serum	O	541-546
lactate	O	547-554
dehydrogenase	O	555-568
(	O	569-570
LDH	O	570-573
)	O	573-574
and	O	575-578
creatine	O	579-587
phosphokinase	O	588-601
isoenzymes	O	602-612
(	O	613-614
CK	O	614-616
-	O	616-617
MB	O	617-619
)	O	619-620
,	O	620-621
increased	O	622-631
uric	O	632-636
acid	O	637-641
level	O	642-647
and	O	648-651
reduced	O	652-659
plasma	O	660-666
iron	O	667-671
binding	O	672-679
capacity	O	680-688
.	O	688-689

The	O	690-693
protective	O	694-704
role	O	705-709
of	O	710-712
mangiferin	O	713-723
was	O	724-727
analyzed	O	728-736
by	O	737-739
triphenyl	O	740-749
tetrazolium	O	750-761
chloride	O	762-770
(	O	771-772
TTC	O	772-775
)	O	775-776
test	O	777-781
used	O	782-786
for	O	787-790
macroscopic	O	791-802
enzyme	O	803-809
mapping	O	810-817
assay	O	818-823
of	O	824-826
the	O	827-830
ischemic	B	831-839
myocardium	I	840-850
.	O	850-851

The	O	852-855
heart	O	856-861
tissue	O	862-868
antioxidant	O	869-880
enzymes	O	881-888
such	O	889-893
as	O	894-896
superoxide	O	897-907
dismutase	O	908-917
,	O	917-918
catalase	O	919-927
,	O	927-928
glutathione	O	929-940
peroxidase	O	941-951
,	O	951-952
glutathione	O	953-964
transferase	O	965-976
and	O	977-980
glutathione	O	981-992
reductase	O	993-1002
activities	O	1003-1013
,	O	1013-1014
non	O	1015-1018
-	O	1018-1019
enzymic	O	1019-1026
antioxidants	O	1027-1039
such	O	1040-1044
as	O	1045-1047
cerruloplasmin	O	1048-1062
,	O	1062-1063
Vitamin	O	1064-1071
C	O	1072-1073
,	O	1073-1074
Vitamin	O	1075-1082
E	O	1083-1084
and	O	1085-1088
glutathione	O	1089-1100
levels	O	1101-1107
were	O	1108-1112
altered	O	1113-1120
in	O	1121-1123
MI	B	1124-1126
rats	O	1127-1131
.	O	1131-1132

Upon	O	1133-1137
pretreatment	O	1138-1150
with	O	1151-1155
mangiferin	O	1156-1166
(	O	1167-1168
100	O	1168-1171
mg	O	1172-1174
/	O	1174-1175
kg	O	1175-1177
body	O	1178-1182
weight	O	1183-1189
suspended	O	1190-1199
in	O	1200-1202
2	O	1203-1204
ml	O	1205-1207
of	O	1208-1210
dimethyl	O	1211-1219
sulphoxide	O	1220-1230
)	O	1230-1231
given	O	1232-1237
intraperitoneally	O	1238-1255
for	O	1256-1259
28	O	1260-1262
days	O	1263-1267
to	O	1268-1270
MI	B	1271-1273
rats	O	1274-1278
protected	O	1279-1288
the	O	1289-1292
above	O	1293-1298
-	O	1298-1299
mentioned	O	1299-1308
parameters	O	1309-1319
to	O	1320-1322
fall	O	1323-1327
from	O	1328-1332
the	O	1333-1336
normal	O	1337-1343
levels	O	1344-1350
.	O	1350-1351

Activities	O	1352-1362
of	O	1363-1365
heart	O	1366-1371
tissue	O	1372-1378
enzymic	O	1379-1386
antioxidants	O	1387-1399
and	O	1400-1403
serum	O	1404-1409
non	O	1410-1413
-	O	1413-1414
enzymic	O	1414-1421
antioxidants	O	1422-1434
levels	O	1435-1441
rose	O	1442-1446
significantly	O	1447-1460
upon	O	1461-1465
mangiferin	O	1466-1476
administration	O	1477-1491
as	O	1492-1494
compared	O	1495-1503
to	O	1504-1506
ISPH	O	1507-1511
-	O	1511-1512
induced	O	1512-1519
MI	B	1520-1522
rats	O	1523-1527
.	O	1527-1528

From	O	1529-1533
the	O	1534-1537
present	O	1538-1545
study	O	1546-1551
it	O	1552-1554
is	O	1555-1557
concluded	O	1558-1567
that	O	1568-1572
mangiferin	O	1573-1583
exerts	O	1584-1590
a	O	1591-1592
beneficial	O	1593-1603
effect	O	1604-1610
against	O	1611-1618
ISPH	O	1619-1623
-	O	1623-1624
induced	O	1624-1631
MI	B	1632-1634
due	O	1635-1638
to	O	1639-1641
its	O	1642-1645
antioxidant	O	1646-1657
potential	O	1658-1667
,	O	1667-1668
which	O	1669-1674
regulated	O	1675-1684
the	O	1685-1688
tissues	O	1689-1696
defense	O	1697-1704
system	O	1705-1711
against	O	1712-1719
cardiac	B	1720-1727
damage	I	1728-1734
.	O	1734-1735

Remifentanil	O	0-12
pretreatment	O	13-25
reduces	O	26-33
myoclonus	B	34-43
after	O	44-49
etomidate	O	50-59
.	O	59-60

STUDY	O	61-66
OBJECTIVE	O	67-76
:	O	76-77
The	O	78-81
aim	O	82-85
of	O	86-88
the	O	89-92
study	O	93-98
was	O	99-102
to	O	103-105
compare	O	106-113
the	O	114-117
effect	O	118-124
of	O	125-127
pretreatment	O	128-140
with	O	141-145
remifentanil	O	146-158
1	O	159-160
microg	O	161-167
/	O	167-168
kg	O	168-170
and	O	171-174
the	O	175-178
effect	O	179-185
of	O	186-188
gender	O	189-195
on	O	196-198
the	O	199-202
incidence	O	203-212
of	O	213-215
myoclonus	B	216-225
after	O	226-231
anesthesia	O	232-242
induction	O	243-252
with	O	253-257
etomidate	O	258-267
.	O	267-268

DESIGN	O	269-275
:	O	275-276
This	O	277-281
was	O	282-285
a	O	286-287
randomized	O	288-298
,	O	298-299
double	O	300-306
-	O	306-307
blind	O	307-312
study	O	313-318
.	O	318-319

SETTING	O	320-327
:	O	327-328
The	O	329-332
study	O	333-338
was	O	339-342
conducted	O	343-352
at	O	353-355
a	O	356-357
university	O	358-368
hospital	O	369-377
.	O	377-378

PATIENTS	O	379-387
:	O	387-388
Sixty	O	389-394
patients	O	395-403
were	O	404-408
pretreated	O	409-419
in	O	420-422
a	O	423-424
randomized	O	425-435
double	O	436-442
-	O	442-443
blinded	O	443-450
fashion	O	451-458
with	O	459-463
remifentanil	O	464-476
1	O	477-478
microg	O	479-485
/	O	485-486
kg	O	486-488
or	O	489-491
placebo	O	492-499
.	O	499-500

Two	O	501-504
minutes	O	505-512
after	O	513-518
remifentanil	O	519-531
or	O	532-534
placebo	O	535-542
injection	O	543-552
,	O	552-553
etomidate	O	554-563
0	O	564-565
.	O	565-566
3	O	566-567
mg	O	568-570
/	O	570-571
kg	O	571-573
was	O	574-577
given	O	578-583
.	O	583-584

MEASUREMENTS	O	585-597
:	O	597-598
Myoclonus	B	599-608
was	O	609-612
recorded	O	613-621
with	O	622-626
a	O	627-628
scale	O	629-634
of	O	635-637
0	O	638-639
to	O	640-642
3	O	643-644
.	O	644-645
The	O	646-649
grade	O	650-655
of	O	656-658
sedation	O	659-667
(	O	668-669
none	O	669-673
,	O	673-674
mild	O	675-679
,	O	679-680
moderate	O	681-689
,	O	689-690
severe	O	691-697
)	O	697-698
,	O	698-699
nausea	B	700-706
,	O	706-707
pruritus	B	708-716
,	O	716-717
and	O	718-721
apnea	B	722-727
were	O	728-732
recorded	O	733-741
after	O	742-747
injection	O	748-757
of	O	758-760
both	O	761-765
drugs	O	766-771
.	O	771-772

MAIN	O	773-777
RESULTS	O	778-785
:	O	785-786
The	O	787-790
incidence	O	791-800
of	O	801-803
myoclonus	B	804-813
was	O	814-817
significantly	O	818-831
lower	O	832-837
in	O	838-840
the	O	841-844
remifentanil	O	845-857
group	O	858-863
(	O	864-865
6	O	865-866
.	O	866-867
7	O	867-868
%	O	868-869
)	O	869-870
than	O	871-875
in	O	876-878
the	O	879-882
placebo	O	883-890
group	O	891-896
(	O	897-898
70	O	898-900
%	O	900-901
)	O	901-902
(	O	903-904
P	O	904-905
<	O	906-907
0	O	908-909
.	O	909-910
001	O	910-913
)	O	913-914
.	O	909-910

None	O	916-920
of	O	921-923
the	O	924-927
patients	O	928-936
experienced	O	937-948
sedation	O	949-957
,	O	957-958
apnea	B	959-964
,	O	964-965
nausea	B	966-972
,	O	972-973
or	O	974-976
pruritus	B	977-985
after	O	986-991
injection	O	992-1001
of	O	1002-1004
both	O	1005-1009
drugs	O	1010-1015
.	O	1015-1016

In	O	1017-1019
the	O	1020-1023
placebo	O	1024-1031
group	O	1032-1037
,	O	1037-1038
male	O	1039-1043
patients	O	1044-1052
were	O	1053-1057
associated	O	1058-1068
with	O	1069-1073
significantly	O	1074-1087
increased	O	1088-1097
incidence	O	1098-1107
of	O	1108-1110
myoclonus	B	1111-1120
after	O	1121-1126
etomidate	O	1127-1136
administration	O	1137-1151
.	O	1151-1152

CONCLUSION	O	1153-1163
:	O	1163-1164
Pretreatment	O	1165-1177
with	O	1178-1182
remifentanil	O	1183-1195
1	O	1196-1197
microg	O	1198-1204
/	O	1204-1205
kg	O	1205-1207
reduced	O	1208-1215
myoclonus	B	1216-1225
after	O	1226-1231
etomidate	O	1232-1241
induction	O	1242-1251
without	O	1252-1259
side	O	1260-1264
effects	O	1265-1272
such	O	1273-1277
as	O	1278-1280
sedation	O	1281-1289
,	O	1289-1290
apnea	B	1291-1296
,	O	1296-1297
nausea	B	1298-1304
,	O	1304-1305
or	O	1306-1308
pruritus	B	1309-1317
.	O	1317-1318

Men	O	1319-1322
experience	O	1323-1333
increased	O	1334-1343
incidence	O	1344-1353
of	O	1354-1356
myoclonus	B	1357-1366
than	O	1367-1371
women	O	1372-1377
after	O	1378-1383
etomidate	O	1384-1393
administration	O	1394-1408
.	O	1408-1409

Daidzein	O	0-8
activates	O	9-18
choline	O	19-26
acetyltransferase	O	27-44
from	O	45-49
MC	O	50-52
-	O	52-53
IXC	O	53-56
cells	O	57-62
and	O	63-66
improves	O	67-75
drug	O	76-80
-	O	80-81
induced	O	81-88
amnesia	B	89-96
.	O	96-97

The	O	98-101
choline	O	102-109
acetyltransferase	O	110-127
(	O	128-129
ChAT	O	129-133
)	O	133-134
activator	O	135-144
,	O	144-145
which	O	146-151
enhances	O	152-160
cholinergic	O	161-172
transmission	O	173-185
via	O	186-189
an	O	190-192
augmentation	O	193-205
of	O	206-208
the	O	209-212
enzymatic	O	213-222
production	O	223-233
of	O	234-236
acetylcholine	O	237-250
(	O	251-252
ACh	O	252-255
)	O	255-256
,	O	256-257
is	O	258-260
an	O	261-263
important	O	264-273
factor	O	274-280
in	O	281-283
the	O	284-287
treatment	O	288-297
of	O	298-300
Alzheimer	B	301-310
'	I	310-311
s	I	311-312
disease	I	313-320
(	O	321-322
AD	B	322-324
)	O	324-325
.	O	325-326

Methanolic	O	327-337
extracts	O	338-346
from	O	347-351
Pueraria	O	352-360
thunbergiana	O	361-373
exhibited	O	374-383
an	O	384-386
activation	O	387-397
effect	O	398-404
(	O	405-406
46	O	406-408
%	O	408-409
)	O	409-410
on	O	411-413
ChAT	O	414-418
in	O	419-421
vitro	O	422-427
.	O	427-428

Via	O	429-432
the	O	433-436
sequential	O	437-447
isolation	O	448-457
of	O	458-460
Pueraria	O	461-469
thunbergiana	O	470-482
,	O	482-483
the	O	484-487
active	O	488-494
component	O	495-504
was	O	505-508
ultimately	O	509-519
identified	O	520-530
as	O	531-533
daidzein	O	534-542
(	O	543-544
4	O	544-545
'	O	545-546
,	O	546-547
7	O	547-548
-	O	548-549
dihydroxy	O	549-558
-	O	548-549
isoflavone	O	559-569
)	O	569-570
.	O	570-571

In	O	572-574
order	O	575-580
to	O	581-583
investigate	O	584-595
the	O	596-599
effects	O	600-607
of	O	608-610
daidzein	O	611-619
from	O	620-624
Pueraria	O	625-633
thunbergiana	O	634-646
on	O	647-649
scopolamine	O	650-661
-	O	661-662
induced	O	662-669
impairments	B	670-681
of	I	682-684
learning	I	685-693
and	I	694-697
memory	I	698-704
,	O	704-705
we	O	706-708
conducted	O	709-718
a	O	719-720
series	O	721-727
of	O	728-730
in	O	731-733
vivo	O	734-738
tests	O	739-744
.	O	744-745

Administration	O	746-760
of	O	761-763
daidzein	O	764-772
(	O	773-774
4	O	774-775
.	O	775-776
5	O	776-777
mg	O	778-780
/	O	780-781
kg	O	781-783
body	O	784-788
weight	O	789-795
)	O	795-796
to	O	797-799
mice	O	800-804
was	O	805-808
shown	O	809-814
significantly	O	815-828
to	O	829-831
reverse	O	832-839
scopolamine	O	840-851
-	O	851-852
induced	O	852-859
amnesia	B	860-867
,	O	867-868
according	O	869-878
to	O	879-881
the	O	882-885
results	O	886-893
of	O	894-896
a	O	897-898
Y	O	899-900
-	O	900-901
maze	O	901-905
test	O	906-910
.	O	910-911

Injections	O	912-922
of	O	923-925
scopolamine	O	926-937
into	O	938-942
mice	O	943-947
resulted	O	948-956
in	O	957-959
impaired	O	960-968
performance	O	969-980
on	O	981-983
Y	O	984-985
-	O	985-986
maze	O	986-990
tests	O	991-996
(	O	997-998
a	O	998-999
37	O	1000-1002
%	O	1002-1003
decreases	O	1004-1013
in	O	1014-1016
alternation	O	1017-1028
behavior	O	1029-1037
)	O	1037-1038
.	O	1038-1039

By	O	1040-1042
way	O	1043-1046
of	O	1047-1049
contrast	O	1050-1058
,	O	1058-1059
mice	O	1060-1064
treated	O	1065-1072
with	O	1073-1077
daidzein	O	1078-1086
prior	O	1087-1092
to	O	1093-1095
the	O	1096-1099
scopolamine	O	1100-1111
injections	O	1112-1122
were	O	1123-1127
noticeably	O	1128-1138
protected	O	1139-1148
from	O	1149-1153
this	O	1154-1158
performance	O	1159-1170
impairment	O	1171-1181
(	O	1182-1183
an	O	1183-1185
approximately	O	1186-1199
12	O	1200-1202
%	O	1202-1203
-	O	1203-1204
21	O	1204-1206
%	O	1202-1203
decrease	O	1208-1216
in	O	1217-1219
alternation	O	1220-1231
behavior	O	1232-1240
)	O	1240-1241
.	O	1241-1242

These	O	1243-1248
results	O	1249-1256
indicate	O	1257-1265
that	O	1266-1270
daidzein	O	1271-1279
might	O	1280-1285
play	O	1286-1290
a	O	1291-1292
role	O	1293-1297
in	O	1298-1300
acetylcholine	O	1301-1314
biosynthesis	O	1315-1327
as	O	1328-1330
a	O	1331-1332
ChAT	O	1333-1337
activator	O	1338-1347
,	O	1347-1348
and	O	1349-1352
that	O	1353-1357
it	O	1358-1360
also	O	1361-1365
ameliorates	O	1366-1377
scopolamine	O	1378-1389
-	O	1389-1390
induced	O	1390-1397
amnesia	B	1398-1405
.	O	1405-1406

Possible	O	0-8
azithromycin	O	9-21
-	O	21-22
associated	O	22-32
hiccups	B	33-40
.	O	40-41

OBJECTIVE	O	42-51
:	O	51-52
To	O	53-55
report	O	56-62
a	O	63-64
case	O	65-69
of	O	70-72
persistent	O	73-83
hiccups	B	84-91
associated	O	92-102
by	O	103-105
azithromycin	O	106-118
therapy	O	119-126
.	O	126-127

CASE	O	128-132
SUMMARY	O	133-140
:	O	140-141
A	O	142-143
76	O	144-146
-	O	146-147
year	O	147-151
-	O	146-147
old	O	152-155
man	O	156-159
presented	O	160-169
with	O	170-174
persistent	O	175-185
hiccups	B	186-193
after	O	194-199
beginning	O	200-209
azithromycin	O	210-222
for	O	223-226
the	O	227-230
treatment	O	231-240
of	O	241-243
pharyngitis	B	244-255
.	O	255-256

Hiccups	B	257-264
were	O	265-269
persistent	O	270-280
and	O	281-284
exhausting	O	285-295
.	O	295-296

Discontinuation	O	297-312
of	O	313-315
azithromycin	O	316-328
and	O	329-332
therapy	O	333-340
with	O	341-345
baclofen	O	346-354
finally	O	355-362
resolved	O	363-371
hiccups	B	372-379
.	O	379-380

No	O	381-383
organic	O	384-391
cause	O	392-397
of	O	398-400
hiccups	B	401-408
was	O	409-412
identified	O	413-423
despite	O	424-431
extensive	O	432-441
investigation	O	442-455
.	O	455-456

DISCUSSION	O	457-467
:	O	467-468
Pharmacotherapeutic	O	469-488
agents	O	489-495
have	O	496-500
been	O	501-505
uncommonly	O	506-516
associated	O	517-527
with	O	528-532
hiccups	B	533-540
.	O	540-541

Corticosteroids	O	542-557
(	O	558-559
dexamethasone	O	559-572
and	O	573-576
methylprednisolone	O	577-595
)	O	595-596
,	O	596-597
benzodiazepines	O	598-613
(	O	614-615
midazolam	O	615-624
)	O	624-625
and	O	626-629
general	O	630-637
anaesthesia	O	638-649
have	O	650-654
been	O	655-659
the	O	660-663
specific	O	664-672
agents	O	673-679
mentioned	O	680-689
most	O	690-694
frequently	O	695-705
in	O	706-708
the	O	709-712
literature	O	713-723
as	O	724-726
being	O	727-732
associated	O	733-743
with	O	744-748
the	O	749-752
development	O	753-764
of	O	765-767
hiccups	B	768-775
.	O	775-776

Few	O	777-780
cases	O	781-786
of	O	787-789
drug	O	790-794
-	O	794-795
induced	O	795-802
hiccups	B	803-810
have	O	811-815
been	O	816-820
reported	O	821-829
related	O	830-837
to	O	838-840
macrolide	O	841-850
antimicrobials	O	851-865
.	O	865-866

Using	O	867-872
the	O	873-876
Naranjo	O	877-884
adverse	O	885-892
effect	O	893-899
reaction	O	900-908
probability	O	909-920
scale	O	921-926
this	O	927-931
event	O	932-937
could	O	938-943
be	O	944-946
classified	O	947-957
as	O	958-960
possible	O	961-969
(	O	970-971
score	O	971-976
5	O	977-978
points	O	979-985
)	O	985-986
,	O	986-987
mostly	O	988-994
because	O	995-1002
of	O	1003-1005
the	O	1006-1009
close	O	1010-1015
temporal	O	1016-1024
sequence	O	1025-1033
,	O	1033-1034
previous	O	1035-1043
reports	O	1044-1051
on	O	1052-1054
this	O	1055-1059
reaction	O	1060-1068
with	O	1069-1073
other	O	1074-1079
macrolides	O	1080-1090
and	O	1091-1094
the	O	1095-1098
absence	O	1099-1106
of	O	1107-1109
any	O	1110-1113
alternative	O	1114-1125
explanation	O	1126-1137
for	O	1138-1141
hiccups	B	1142-1149
.	O	1149-1150

Our	O	1151-1154
hypothesis	O	1155-1165
is	O	1166-1168
that	O	1169-1173
a	O	1174-1175
vagal	O	1176-1181
mechanism	O	1182-1191
mediated	O	1192-1200
by	O	1201-1203
azithromycin	O	1204-1216
could	O	1217-1222
be	O	1223-1225
the	O	1226-1229
pathogenesis	O	1230-1242
of	O	1243-1245
hiccups	B	1246-1253
in	O	1254-1256
our	O	1257-1260
patient	O	1261-1268
.	O	1268-1269

CONCLUSIONS	O	1270-1281
:	O	1281-1282
Diagnosis	O	1283-1292
of	O	1293-1295
drug	O	1296-1300
-	O	1300-1301
induced	O	1301-1308
hiccups	B	1309-1316
is	O	1317-1319
difficult	O	1320-1329
and	O	1330-1333
often	O	1334-1339
achieved	O	1340-1348
only	O	1349-1353
by	O	1354-1356
a	O	1357-1358
process	O	1359-1366
of	O	1367-1369
elimination	O	1370-1381
.	O	1381-1382

However	O	1383-1390
,	O	1390-1391
macrolide	O	1392-1401
antimicrobials	O	1402-1416
have	O	1417-1421
been	O	1422-1426
reported	O	1427-1435
to	O	1436-1438
be	O	1439-1441
associated	O	1442-1452
with	O	1453-1457
hiccups	B	1458-1465
and	O	1466-1469
vagal	O	1470-1475
mechanism	O	1476-1485
could	O	1486-1491
explain	O	1492-1499
the	O	1500-1503
development	O	1504-1515
of	O	1516-1518
this	O	1519-1523
side	O	1524-1528
-	O	1528-1529
effect	O	1529-1535
.	O	1535-1536

Time	O	0-4
trends	O	5-11
in	O	12-14
warfarin	O	15-23
-	O	23-24
associated	O	24-34
hemorrhage	B	35-45
.	O	45-46

The	O	47-50
annual	O	51-57
incidence	O	58-67
of	O	68-70
warfarin	O	71-79
-	O	79-80
related	O	80-87
bleeding	B	88-96
at	O	97-99
Brigham	O	100-107
and	O	108-111
Women	O	112-117
'	O	117-118
s	O	118-119
Hospital	O	120-128
increased	O	129-138
from	O	139-143
0	O	144-145
.	O	145-146
97	O	146-148
/	O	148-149
1	O	149-150
,	O	150-151
000	O	151-154
patient	O	155-162
admissions	O	163-173
in	O	174-176
the	O	177-180
first	O	181-186
time	O	187-191
period	O	192-198
(	O	199-200
January	O	200-207
1995	O	208-212
to	O	213-215
October	O	216-223
1998	O	224-228
)	O	228-229
to	O	230-232
1	O	233-234
.	O	234-235
19	O	235-237
/	O	237-238
1	O	233-234
,	O	239-240
000	O	240-243
patient	O	244-251
admissions	O	252-262
in	O	263-265
the	O	266-269
second	O	270-276
time	O	277-281
period	O	282-288
(	O	289-290
November	O	290-298
1998	O	299-303
to	O	304-306
August	O	307-313
2002	O	314-318
)	O	318-319
of	O	320-322
this	O	323-327
study	O	328-333
.	O	333-334

The	O	335-338
proportion	O	339-349
of	O	350-352
patients	O	353-361
with	O	362-366
major	O	367-372
and	O	373-376
intracranial	B	377-389
bleeding	I	390-398
increased	O	399-408
from	O	409-413
20	O	414-416
.	O	416-417
2	O	414-415
%	O	418-419
and	O	420-423
1	O	424-425
.	O	425-426
9	O	426-427
%	O	427-428
,	O	428-429
respectively	O	430-442
,	O	442-443
in	O	444-446
the	O	447-450
first	O	451-456
time	O	457-461
period	O	462-468
,	O	468-469
to	O	470-472
33	O	473-475
.	O	475-476
3	O	473-474
%	O	477-478
and	O	479-482
7	O	483-484
.	O	484-485
8	O	485-486
%	O	486-487
,	O	487-488
respectively	O	489-501
,	O	501-502
in	O	503-505
the	O	506-509
second	O	510-516
.	O	516-517

Fatal	O	0-5
haemorrhagic	B	6-18
myocarditis	I	19-30
secondary	O	31-40
to	O	41-43
cyclophosphamide	O	44-60
therapy	O	61-68
.	O	68-69

Haemorrhagic	B	70-82
myocarditis	I	83-94
is	O	95-97
a	O	98-99
rare	O	100-104
but	O	105-108
important	O	109-118
complication	O	119-131
of	O	132-134
cyclophosphamide	O	135-151
therapy	O	152-159
.	O	159-160

Echocardiographic	O	161-178
identification	O	179-193
of	O	194-196
the	O	197-200
disorder	O	201-209
can	O	210-213
be	O	214-216
made	O	217-221
.	O	221-222

We	O	223-225
believe	O	226-233
that	O	234-238
the	O	239-242
ultrasound	O	243-253
features	O	254-262
of	O	263-265
this	O	266-270
disorder	O	271-279
have	O	280-284
not	O	285-288
been	O	289-293
previously	O	294-304
reported	O	305-313
.	O	313-314

Glyceryl	O	0-8
trinitrate	O	9-19
induces	O	20-27
attacks	O	28-35
of	O	36-38
migraine	B	39-47
without	I	48-55
aura	I	56-60
in	O	61-63
sufferers	O	64-73
of	O	74-76
migraine	B	77-85
with	I	86-90
aura	I	91-95
.	O	95-96

Migraine	B	97-105
with	I	106-110
aura	I	111-115
and	O	116-119
migraine	B	120-128
without	I	129-136
aura	I	137-141
have	O	142-146
the	O	147-150
same	O	151-155
pain	B	156-160
phase	O	161-166
,	O	166-167
thus	O	168-172
indicating	O	173-183
that	O	184-188
migraine	B	189-197
with	I	198-202
aura	I	203-207
and	O	208-211
migraine	B	212-220
without	I	221-228
aura	I	229-233
share	O	234-239
a	O	240-241
common	O	242-248
pathway	O	249-256
of	O	257-259
nociception	O	260-271
.	O	271-272

In	O	273-275
recent	O	276-282
years	O	283-288
,	O	288-289
increasing	O	290-300
evidence	O	301-309
has	O	310-313
suggested	O	314-323
that	O	324-328
the	O	329-332
messenger	O	333-342
molecule	O	343-351
nitric	O	352-358
oxide	O	359-364
(	O	365-366
NO	O	366-368
)	O	368-369
is	O	370-372
involved	O	373-381
in	O	382-384
pain	B	385-389
mechanisms	O	390-400
of	O	401-403
migraine	B	404-412
without	I	413-420
aura	I	421-425
.	O	425-426

In	O	427-429
order	O	430-435
to	O	436-438
clarify	O	439-446
whether	O	447-454
the	O	455-458
same	O	459-463
is	O	464-466
true	O	467-471
for	O	472-475
migraine	B	476-484
with	I	485-489
aura	I	490-494
,	O	494-495
in	O	496-498
the	O	499-502
present	O	503-510
study	O	511-516
we	O	517-519
examined	O	520-528
the	O	529-532
headache	B	533-541
response	O	542-550
to	O	551-553
intravenous	O	554-565
infusion	O	566-574
of	O	575-577
glyceryl	O	578-586
trinitrate	O	587-597
(	O	598-599
GTN	O	599-602
)	O	602-603
(	O	604-605
0	O	605-606
.	O	606-607
5	O	607-608
microg	O	609-615
/	O	615-616
kg	O	616-618
/	O	615-616
min	O	619-622
for	O	623-626
20	O	627-629
min	O	630-633
)	O	633-634
in	O	635-637
12	O	638-640
sufferers	O	641-650
of	O	651-653
migraine	B	654-662
with	I	663-667
aura	I	668-672
.	O	672-673

The	O	674-677
specific	O	678-686
aim	O	687-690
was	O	691-694
to	O	695-697
elucidate	O	698-707
whether	O	708-715
an	O	716-718
aura	O	719-723
and	O	724-727
/	O	727-728
or	O	728-730
an	O	731-733
attack	O	734-740
of	O	741-743
migraine	B	744-752
without	I	753-760
aura	I	761-765
could	O	766-771
be	O	772-774
induced	O	775-782
.	O	782-783

Fourteen	O	784-792
healthy	O	793-800
subjects	O	801-809
served	O	810-816
as	O	817-819
controls	O	820-828
.	O	828-829

Aura	O	830-834
symptoms	O	835-843
were	O	844-848
not	O	849-852
elicited	O	853-861
in	O	862-864
any	O	865-868
subject	O	869-876
.	O	876-877

Headache	B	878-886
was	O	887-890
more	O	891-895
severe	O	896-902
in	O	903-905
migraineurs	B	906-917
than	O	918-922
in	O	923-925
the	O	926-929
controls	O	930-938
during	O	939-945
and	O	946-949
immediately	O	950-961
after	O	962-967
GTN	O	968-971
infusion	O	972-980
(	O	981-982
p	O	982-983
=	O	983-984
0	O	984-985
.	O	985-986
037	O	986-989
)	O	989-990
as	O	991-993
well	O	994-998
as	O	999-1001
during	O	1002-1008
the	O	1009-1012
following	O	1013-1022
11	O	1023-1025
h	O	1026-1027
(	O	1028-1029
p	O	1029-1030
=	O	1031-1032
0	O	1033-1034
.	O	1034-1035
008	O	1035-1038
)	O	1038-1039
.	O	1034-1035

In	O	1041-1043
the	O	1044-1047
controls	O	1048-1056
,	O	1056-1057
the	O	1058-1061
GTN	O	1062-1065
-	O	1065-1066
induced	O	1066-1073
headache	B	1074-1082
gradually	O	1083-1092
disappeared	O	1093-1104
,	O	1104-1105
whereas	O	1106-1113
in	O	1114-1116
migraineurs	B	1117-1128
peak	O	1129-1133
headache	B	1134-1142
intensity	O	1143-1152
occurred	O	1153-1161
at	O	1162-1164
a	O	1165-1166
mean	O	1167-1171
time	O	1172-1176
of	O	1177-1179
240	O	1180-1183
min	O	1184-1187
post	O	1188-1192
-	O	1192-1193
infusion	O	1193-1201
.	O	1201-1202

At	O	1203-1205
this	O	1206-1210
time	O	1211-1215
the	O	1216-1219
induced	O	1220-1227
headache	B	1228-1236
in	O	1237-1239
6	O	1240-1241
of	O	1242-1244
12	O	1245-1247
migraineurs	B	1248-1259
fulfilled	O	1260-1269
the	O	1270-1273
diagnostic	O	1274-1284
criteria	O	1285-1293
for	O	1294-1297
migraine	B	1298-1306
without	I	1307-1314
aura	I	1315-1319
of	O	1320-1322
the	O	1323-1326
International	O	1327-1340
Headache	B	1341-1349
Society	O	1350-1357
.	O	1357-1358

The	O	1359-1362
results	O	1363-1370
therefore	O	1371-1380
suggest	O	1381-1388
that	O	1389-1393
NO	O	1394-1396
is	O	1397-1399
involved	O	1400-1408
in	O	1409-1411
the	O	1412-1415
pain	B	1416-1420
mechanisms	O	1421-1431
of	O	1432-1434
migraine	B	1435-1443
with	I	1444-1448
aura	I	1449-1453
.	O	1453-1454

Since	O	1455-1460
cortical	O	1461-1469
spreading	O	1470-1479
depression	B	1480-1490
has	O	1491-1494
been	O	1495-1499
shown	O	1500-1505
to	O	1506-1508
liberate	O	1509-1517
NO	O	1518-1520
in	O	1521-1523
animals	O	1524-1531
,	O	1531-1532
this	O	1533-1537
finding	O	1538-1545
may	O	1546-1549
help	O	1550-1554
our	O	1555-1558
understanding	O	1559-1572
of	O	1573-1575
the	O	1576-1579
coupling	O	1580-1588
between	O	1589-1596
cortical	O	1597-1605
spreading	O	1606-1615
depression	B	1616-1626
and	O	1627-1630
headache	B	1631-1639
in	O	1640-1642
migraine	B	1643-1651
with	I	1652-1656
aura	I	1657-1661
.	O	1661-1662

Stroke	B	0-6
and	O	7-10
cocaine	O	11-18
or	O	19-21
amphetamine	O	22-33
use	O	34-37
.	O	37-38

The	O	39-42
association	O	43-54
of	O	55-57
cocaine	O	58-65
and	O	66-69
amphetamine	O	70-81
use	O	82-85
with	O	86-90
hemorrhagic	O	91-102
and	O	103-106
ischemic	B	107-115
stroke	B	116-122
is	O	123-125
based	O	126-131
almost	O	132-138
solely	O	139-145
on	O	146-148
data	O	149-153
from	O	154-158
case	O	159-163
series	O	164-170
.	O	170-171

The	O	172-175
limited	O	176-183
number	O	184-190
of	O	191-193
epidemiologic	O	194-207
studies	O	208-215
of	O	216-218
stroke	B	219-225
and	O	226-229
use	O	230-233
of	O	234-236
cocaine	O	237-244
and	O	245-248
/	O	248-249
or	O	249-251
amphetamine	O	252-263
have	O	264-268
been	O	269-273
done	O	274-278
in	O	279-281
settings	O	282-290
that	O	291-295
serve	O	296-301
mostly	O	302-308
the	O	309-312
poor	O	313-317
and	O	318-321
/	O	321-322
or	O	322-324
minorities	O	325-335
.	O	335-336

This	O	337-341
case	O	342-346
-	O	346-347
control	O	347-354
study	O	355-360
was	O	361-364
conducted	O	365-374
in	O	375-377
the	O	378-381
defined	O	382-389
population	O	390-400
comprising	O	401-411
members	O	412-419
of	O	420-422
Kaiser	O	423-429
Permanente	O	430-440
of	O	441-443
Northern	O	444-452
and	O	453-456
Southern	O	457-465
California	O	466-476
.	O	476-477

We	O	478-480
attempted	O	481-490
to	O	491-493
identify	O	494-502
all	O	503-506
incident	O	507-515
strokes	B	516-523
in	O	524-526
women	O	527-532
ages	O	533-537
15	O	538-540
-	O	540-541
44	O	541-543
years	O	544-549
during	O	550-556
a	O	557-558
3	O	559-560
-	O	560-561
year	O	561-565
period	O	566-572
using	O	573-578
hospital	O	579-587
admission	O	588-597
and	O	598-601
discharge	O	602-611
records	O	612-619
,	O	619-620
emergency	O	621-630
department	O	631-641
logs	O	642-646
,	O	646-647
and	O	648-651
payment	O	652-659
requests	O	660-668
for	O	669-672
out	O	673-676
-	O	676-677
of	O	677-679
-	O	676-677
plan	O	680-684
hospitalizations	O	685-701
.	O	701-702

We	O	703-705
selected	O	706-714
controls	O	715-723
,	O	723-724
matched	O	725-732
on	O	733-735
age	O	736-739
and	O	740-743
facility	O	744-752
of	O	753-755
usual	O	756-761
care	O	762-766
,	O	766-767
at	O	768-770
random	O	771-777
from	O	778-782
healthy	O	783-790
members	O	791-798
of	O	799-801
the	O	802-805
health	O	806-812
plan	O	813-817
.	O	817-818

We	O	819-821
obtained	O	822-830
information	O	831-842
in	O	843-845
face	O	846-850
-	O	850-851
to	O	851-853
-	O	850-851
face	O	846-850
interviews	O	859-869
.	O	869-870

There	O	871-876
were	O	877-881
347	O	882-885
confirmed	O	886-895
stroke	B	896-902
cases	O	903-908
and	O	909-912
1	O	913-914
,	O	914-915
021	O	915-918
controls	O	919-927
.	O	927-928

The	O	929-932
univariate	O	933-943
matched	O	944-951
odds	O	952-956
ratio	O	957-962
for	O	963-966
stroke	B	967-973
in	O	974-976
women	O	977-982
who	O	983-986
admitted	O	987-995
to	O	996-998
using	O	999-1004
cocaine	O	1005-1012
and	O	1013-1016
/	O	1016-1017
or	O	1017-1019
amphetamine	O	1020-1031
was	O	1032-1035
8	O	1036-1037
.	O	1037-1038
5	O	1038-1039
(	O	1040-1041
95	O	1041-1043
%	O	1043-1044
confidence	O	1045-1055
interval	O	1056-1064
=	O	1065-1066
3	O	1067-1068
.	O	1068-1069
6	O	1069-1070
-	O	1070-1071
20	O	1071-1073
.	O	1068-1069
0	O	1072-1073
)	O	1075-1076
.	O	1068-1069

After	O	1078-1083
further	O	1084-1091
adjustment	O	1092-1102
for	O	1103-1106
potential	O	1107-1116
confounders	O	1117-1128
,	O	1128-1129
the	O	1130-1133
odds	O	1134-1138
ratio	O	1139-1144
in	O	1145-1147
women	O	1148-1153
who	O	1154-1157
reported	O	1158-1166
using	O	1167-1172
cocaine	O	1173-1180
and	O	1181-1184
/	O	1184-1185
or	O	1185-1187
amphetamine	O	1188-1199
was	O	1200-1203
7	O	1204-1205
.	O	1205-1206
0	O	1206-1207
(	O	1208-1209
95	O	1209-1211
%	O	1211-1212
confidence	O	1213-1223
interval	O	1224-1232
=	O	1233-1234
2	O	1235-1236
.	O	1236-1237
8	O	1237-1238
-	O	1238-1239
17	O	1239-1241
.	O	1236-1237
9	O	1242-1243
)	O	1243-1244
.	O	1236-1237

The	O	1246-1249
use	O	1250-1253
of	O	1254-1256
cocaine	O	1257-1264
and	O	1265-1268
/	O	1268-1269
or	O	1269-1271
amphetamine	O	1272-1283
is	O	1284-1286
a	O	1287-1288
strong	O	1289-1295
risk	O	1296-1300
factor	O	1301-1307
for	O	1308-1311
stroke	B	1312-1318
in	O	1319-1321
this	O	1322-1326
socioeconomically	O	1327-1344
heterogeneous	O	1345-1358
,	O	1358-1359
insured	O	1360-1367
urban	O	1368-1373
population	O	1374-1384
.	O	1384-1385

Prevention	O	0-10
of	O	11-13
breast	B	14-20
cancer	I	21-27
with	O	28-32
tamoxifen	O	33-42
:	O	42-43
preliminary	O	44-55
findings	O	56-64
from	O	65-69
the	O	70-73
Italian	O	74-81
randomised	O	82-92
trial	O	93-98
among	O	99-104
hysterectomised	O	105-120
women	O	121-126
.	O	126-127

Italian	O	128-135
Tamoxifen	O	136-145
Prevention	O	146-156
Study	O	157-162
.	O	162-163

BACKGROUND	O	164-174
:	O	174-175
Tamoxifen	O	176-185
is	O	186-188
a	O	189-190
candidate	O	191-200
chemopreventive	O	201-216
agent	O	217-222
in	O	223-225
breast	B	226-232
cancer	I	233-239
,	O	239-240
although	O	241-249
the	O	250-253
drug	O	254-258
may	O	259-262
be	O	263-265
associated	O	266-276
with	O	277-281
the	O	282-285
development	O	286-297
of	O	298-300
endometrial	B	301-312
cancer	I	313-319
.	O	319-320

Therefore	O	321-330
we	O	331-333
did	O	334-337
a	O	338-339
trial	O	340-345
in	O	346-348
hysterectomised	O	349-364
women	O	365-370
of	O	371-373
tamoxifen	O	374-383
as	O	384-386
a	O	387-388
chemopreventive	O	389-404
.	O	404-405

METHODS	O	406-413
:	O	413-414
In	O	415-417
October	O	418-425
,	O	425-426
1992	O	427-431
,	O	431-432
we	O	433-435
started	O	436-443
a	O	444-445
double	O	446-452
-	O	452-453
blind	O	453-458
placebo	O	459-466
-	O	466-467
controlled	O	467-477
,	O	477-478
randomised	O	479-489
trial	O	490-495
of	O	496-498
tamoxifen	O	499-508
in	O	509-511
women	O	512-517
(	O	518-519
mainly	O	519-525
in	O	526-528
Italy	O	529-534
)	O	534-535
who	O	536-539
did	O	540-543
not	O	544-547
have	O	548-552
breast	B	553-559
cancer	I	560-566
and	O	567-570
who	O	571-574
had	O	575-578
had	O	579-582
a	O	583-584
hysterectomy	O	585-597
.	O	597-598

Women	O	599-604
were	O	605-609
randomised	O	610-620
to	O	621-623
receive	O	624-631
tamoxifen	O	632-641
20	O	642-644
mg	O	645-647
per	O	648-651
day	O	652-655
or	O	656-658
placebo	O	659-666
,	O	666-667
both	O	668-672
orally	O	673-679
for	O	680-683
5	O	684-685
years	O	686-691
.	O	691-692

The	O	693-696
original	O	697-705
plan	O	706-710
was	O	711-714
to	O	715-717
follow	O	718-724
the	O	725-728
intervention	O	729-741
phase	O	742-747
by	O	748-750
5	O	751-752
years	O	753-758
'	O	758-759
follow	O	760-766
-	O	766-767
up	O	767-769
.	O	769-770

In	O	771-773
June	O	774-778
,	O	778-779
1997	O	780-784
,	O	784-785
the	O	786-789
trialists	O	790-799
and	O	800-803
the	O	804-807
data	O	808-812
-	O	812-813
monitoring	O	813-823
committee	O	824-833
decided	O	834-841
to	O	842-844
end	O	845-848
recruitment	O	849-860
primarily	O	861-870
because	O	871-878
of	O	879-881
the	O	882-885
number	O	886-892
of	O	893-895
women	O	896-901
dropping	O	902-910
out	O	911-914
of	O	915-917
the	O	918-921
study	O	922-927
.	O	927-928

Recruitment	O	929-940
ended	O	941-946
on	O	947-949
July	O	950-954
11	O	955-957
,	O	957-958
1997	O	959-963
,	O	963-964
and	O	965-968
the	O	969-972
study	O	973-978
will	O	979-983
continue	O	984-992
as	O	993-995
planned	O	996-1003
.	O	1003-1004

The	O	1005-1008
primary	O	1009-1016
endpoints	O	1017-1026
are	O	1027-1030
the	O	1031-1034
occurrence	O	1035-1045
of	O	1046-1048
and	O	1049-1052
deaths	O	1053-1059
from	O	1060-1064
breast	B	1065-1071
cancer	I	1072-1078
.	O	1078-1079

This	O	1080-1084
preliminary	O	1085-1096
interim	O	1097-1104
analysis	O	1105-1113
is	O	1114-1116
based	O	1117-1122
on	O	1123-1125
intention	O	1126-1135
-	O	1135-1136
to	O	1136-1138
-	O	1135-1136
treat	O	1139-1144
.	O	1144-1145

FINDINGS	O	1146-1154
:	O	1154-1155
5408	O	1156-1160
women	O	1161-1166
were	O	1167-1171
randomised	O	1172-1182
;	O	1182-1183
participating	O	1184-1197
women	O	1198-1203
have	O	1204-1208
a	O	1209-1210
median	O	1211-1217
follow	O	1218-1224
-	O	1224-1225
up	O	1225-1227
of	O	1228-1230
46	O	1231-1233
months	O	1234-1240
for	O	1241-1244
major	O	1245-1250
endpoints	O	1251-1260
.	O	1260-1261

41	O	1262-1264
cases	O	1265-1270
of	O	1271-1273
breast	B	1274-1280
cancer	I	1281-1287
occurred	O	1288-1296
so	O	1297-1299
far	O	1300-1303
;	O	1303-1304
there	O	1305-1310
have	O	1311-1315
been	O	1316-1320
no	O	1321-1323
deaths	O	1324-1330
from	O	1331-1335
breast	B	1336-1342
cancer	I	1343-1349
.	O	1349-1350

There	O	1351-1356
is	O	1357-1359
no	O	1360-1362
difference	O	1363-1373
in	O	1374-1376
breast	B	1377-1383
-	I	1383-1384
cancer	I	1384-1390
frequency	O	1391-1400
between	O	1401-1408
the	O	1409-1412
placebo	O	1413-1420
(	O	1421-1422
22	O	1422-1424
cases	O	1425-1430
)	O	1430-1431
and	O	1432-1435
tamoxifen	O	1436-1445
(	O	1446-1447
19	O	1447-1449
)	O	1449-1450
arms	O	1451-1455
.	O	1455-1456

There	O	1457-1462
is	O	1463-1465
a	O	1466-1467
statistically	O	1468-1481
significant	O	1482-1493
reduction	O	1494-1503
of	O	1504-1506
breast	B	1507-1513
cancer	I	1514-1520
among	O	1521-1526
women	O	1527-1532
receiving	O	1533-1542
tamoxifen	O	1543-1552
who	O	1553-1556
also	O	1557-1561
used	O	1562-1566
hormone	O	1567-1574
-	O	1574-1575
replacement	O	1575-1586
therapy	O	1587-1594
during	O	1595-1601
the	O	1602-1605
trial	O	1606-1611
:	O	1611-1612
among	O	1613-1618
390	O	1619-1622
women	O	1623-1628
on	O	1629-1631
such	O	1632-1636
therapy	O	1637-1644
and	O	1645-1648
allocated	O	1649-1658
to	O	1659-1661
placebo	O	1662-1669
,	O	1669-1670
we	O	1671-1673
found	O	1674-1679
eight	O	1680-1685
cases	O	1686-1691
of	O	1692-1694
breast	B	1695-1701
cancer	I	1702-1708
compared	O	1709-1717
with	O	1718-1722
one	O	1723-1726
case	O	1727-1731
among	O	1732-1737
362	O	1738-1741
women	O	1742-1747
allocated	O	1748-1757
to	O	1758-1760
tamoxifen	O	1761-1770
.	O	1770-1771

Compared	O	1772-1780
with	O	1781-1785
the	O	1786-1789
placebo	O	1790-1797
group	O	1798-1803
,	O	1803-1804
there	O	1805-1810
was	O	1811-1814
a	O	1815-1816
significantly	O	1817-1830
increased	O	1831-1840
risk	O	1841-1845
of	O	1846-1848
vascular	B	1849-1857
events	I	1858-1864
and	O	1865-1868
hypertriglyceridaemia	B	1869-1890
among	O	1891-1896
women	O	1897-1902
on	O	1903-1905
tamoxifen	O	1906-1915
.	O	1915-1916

INTERPRETATION	O	1917-1931
:	O	1931-1932
Although	O	1933-1941
this	O	1942-1946
preliminary	O	1947-1958
analysis	O	1959-1967
has	O	1968-1971
low	O	1972-1975
power	O	1976-1981
,	O	1981-1982
in	O	1983-1985
this	O	1986-1990
cohort	O	1991-1997
of	O	1998-2000
women	O	2001-2006
at	O	2007-2009
low	O	2010-2013
-	O	2013-2014
to	O	2014-2016
-	O	2013-2014
normal	O	2017-2023
risk	O	2024-2028
of	O	2029-2031
breast	B	2032-2038
cancer	I	2039-2045
,	O	2045-2046
the	O	2047-2050
postulated	O	2051-2061
protective	O	2062-2072
effects	O	2073-2080
of	O	2081-2083
tamoxifen	O	2084-2093
are	O	2094-2097
not	O	2098-2101
yet	O	2102-2105
apparent	O	2106-2114
.	O	2114-2115

Women	O	2116-2121
using	O	2122-2127
hormone	O	2128-2135
-	O	2135-2136
replacement	O	2136-2147
therapy	O	2148-2155
appear	O	2156-2162
to	O	2163-2165
have	O	2166-2170
benefited	O	2171-2180
from	O	2181-2185
use	O	2186-2189
of	O	2190-2192
tamoxifen	O	2193-2202
.	O	2202-2203

There	O	2204-2209
were	O	2210-2214
no	O	2215-2217
deaths	O	2218-2224
from	O	2225-2229
breast	B	2230-2236
cancer	I	2237-2243
recorded	O	2244-2252
in	O	2253-2255
women	O	2256-2261
in	O	2262-2264
the	O	2265-2268
study	O	2269-2274
.	O	2274-2275

It	O	2276-2278
is	O	2279-2281
essential	O	2282-2291
to	O	2292-2294
continue	O	2295-2303
follow	O	2304-2310
-	O	2310-2311
up	O	2311-2313
to	O	2314-2316
quantify	O	2317-2325
the	O	2326-2329
long	O	2330-2334
-	O	2334-2335
term	O	2335-2339
risks	O	2340-2345
and	O	2346-2349
benefits	O	2350-2358
of	O	2359-2361
tamoxifen	O	2362-2371
therapy	O	2372-2379
.	O	2379-2380

A	O	0-1
measure	O	2-9
of	O	10-12
pupillary	B	13-22
oscillation	I	23-34
as	O	35-37
a	O	38-39
marker	O	40-46
of	O	47-49
cocaine	O	50-57
-	O	57-58
induced	O	58-65
paranoia	B	66-74
.	O	74-75

Cocaine	O	76-83
-	O	83-84
induced	O	84-91
paranoia	B	92-100
(	O	101-102
CIP	B	102-105
)	O	105-106
remains	O	107-114
an	O	115-117
important	O	118-127
drug	O	128-132
-	O	132-133
induced	O	133-140
model	O	141-146
of	O	147-149
idiopathic	O	150-160
paranoia	B	161-169
for	O	170-173
which	O	174-179
no	O	180-182
psychophysiologic	O	183-200
marker	O	201-207
has	O	208-211
yet	O	212-215
emerged	O	216-223
.	O	223-224

Measures	O	225-233
of	O	234-236
pupillary	B	237-246
oscillation	I	247-258
were	O	259-263
able	O	264-268
to	O	269-271
significantly	O	272-285
distinguish	O	286-297
a	O	298-299
group	O	300-305
of	O	306-308
abstinent	O	309-318
crack	O	319-324
cocaine	O	325-332
abusers	O	333-340
endorsing	O	341-350
past	O	351-355
CIP	B	356-359
(	O	360-361
n	O	361-362
=	O	363-364
32	O	365-367
)	O	367-368
from	O	369-373
another	O	374-381
group	O	382-387
of	O	388-390
crack	O	391-396
addicts	O	397-404
who	O	405-408
denied	O	409-415
past	O	416-420
CIP	B	421-424
(	O	425-426
n	O	426-427
=	O	428-429
29	O	430-432
)	O	432-433
.	O	433-434

Seizures	B	0-8
induced	O	9-16
by	O	17-19
combined	O	20-28
levomepromazine	O	29-44
-	O	44-45
fluvoxamine	O	45-56
treatment	O	57-66
.	O	66-67

We	O	68-70
report	O	71-77
a	O	78-79
case	O	80-84
of	O	85-87
combined	O	88-96
levomepromazine	O	97-112
-	O	112-113
fluvoxamine	O	113-124
treatment	O	125-134
-	O	134-135
induced	O	135-142
seizures	B	143-151
.	O	151-152

It	O	153-155
seems	O	156-161
that	O	162-166
combined	O	167-175
treatment	O	176-185
of	O	186-188
fluvoxamine	O	189-200
with	O	201-205
phenothiazines	O	206-220
may	O	221-224
possess	O	225-232
proconvulsive	O	233-246
activity	O	247-255
.	O	255-256

Why	O	0-3
may	O	4-7
epsilon	O	8-15
-	O	15-16
aminocaproic	O	16-28
acid	O	29-33
(	O	34-35
EACA	O	35-39
)	O	39-40
induce	O	41-47
myopathy	B	48-56
in	O	57-59
man	O	60-63
?	O	63-64

Report	O	65-71
of	O	72-74
a	O	75-76
case	O	77-81
and	O	82-85
literature	O	86-96
review	O	97-103
.	O	103-104

A	O	105-106
case	O	107-111
of	O	112-114
necrotizing	B	115-126
myopathy	I	127-135
due	O	136-139
to	O	140-142
a	O	143-144
short	O	145-150
epsilon	O	151-158
-	O	158-159
aminocaproic	O	159-171
acid	O	172-176
(	O	177-178
EACA	O	178-182
)	O	182-183
treatment	O	184-193
in	O	194-196
a	O	197-198
72	O	199-201
year	O	202-206
-	O	206-207
old	O	207-210
patient	O	211-218
with	O	219-223
subarachnoid	B	224-236
haemorrhage	I	237-248
(	O	249-250
SAH	B	250-253
)	O	253-254
is	O	255-257
described	O	258-267
.	O	267-268

Pathogenetic	O	269-281
hypotheses	O	282-292
are	O	293-296
discussed	O	297-306
.	O	306-307

Comparison	O	0-10
of	O	11-13
the	O	14-17
effectiveness	O	18-31
of	O	32-34
ranitidine	O	35-45
and	O	46-49
cimetidine	O	50-60
in	O	61-63
inhibiting	O	64-74
acid	O	75-79
secretion	O	80-89
in	O	90-92
patients	O	93-101
with	O	102-106
gastric	O	107-114
hypersecretory	O	115-129
states	O	130-136
.	O	136-137

The	O	138-141
H2	O	142-144
-	O	144-145
histamine	O	145-154
receptor	O	155-163
antagonists	O	164-175
ranitidine	O	176-186
and	O	187-190
cimetidine	O	191-201
were	O	202-206
compared	O	207-215
for	O	216-219
their	O	220-225
abilities	O	226-235
to	O	236-238
control	O	239-246
gastric	O	247-254
acid	O	255-259
hypersecretion	O	260-274
on	O	275-277
a	O	278-279
short	O	280-285
-	O	285-286
and	O	287-290
long	O	291-295
-	O	295-296
term	O	296-300
basis	O	301-306
in	O	307-309
22	O	310-312
patients	O	313-321
with	O	322-326
gastric	O	327-334
acid	O	335-339
hypersecretory	O	340-354
states	O	355-361
.	O	361-362

Nineteen	O	363-371
patients	O	372-380
had	O	381-384
Zollinger	B	385-394
-	I	394-395
Ellison	I	395-402
syndrome	I	403-411
,	O	411-412
one	O	413-416
patient	O	417-424
had	O	425-428
systemic	B	429-437
mastocytosis	I	438-450
,	O	450-451
and	O	452-455
two	O	456-459
patients	O	460-468
had	O	469-472
idiopathic	O	473-483
hypersecretion	O	484-498
.	O	498-499

The	O	500-503
rates	O	504-509
of	O	510-512
onset	O	513-518
of	O	519-521
the	O	522-525
action	O	526-532
of	O	533-535
cimetidine	O	536-546
and	O	547-550
ranitidine	O	551-561
were	O	562-566
the	O	567-570
same	O	571-575
.	O	575-576

The	O	577-580
actions	O	581-588
of	O	589-591
both	O	592-596
drugs	O	597-602
were	O	603-607
increased	O	608-617
by	O	618-620
anticholinergic	O	621-636
agents	O	637-643
,	O	643-644
and	O	645-648
there	O	649-654
was	O	655-658
a	O	659-660
close	O	661-666
correlation	O	667-678
between	O	679-686
the	O	687-690
daily	O	691-696
maintenance	O	697-708
dose	O	709-713
of	O	714-716
each	O	717-721
drug	O	722-726
needed	O	727-733
to	O	734-736
control	O	737-744
acid	O	745-749
secretion	O	750-759
.	O	759-760

However	O	761-768
,	O	768-769
ranitidine	O	770-780
was	O	781-784
threefold	O	785-794
more	O	795-799
potent	O	800-806
than	O	807-811
cimetidine	O	812-822
both	O	823-827
in	O	828-830
acute	O	831-836
inhibition	O	837-847
studies	O	848-855
and	O	856-859
in	O	860-862
the	O	863-866
median	O	867-873
maintenance	O	874-885
dose	O	886-890
needed	O	891-897
(	O	898-899
1	O	899-900
.	O	900-901
2	O	901-902
g	O	903-904
per	O	905-908
day	O	909-912
for	O	913-916
ranitidine	O	917-927
and	O	928-931
3	O	932-933
.	O	933-934
6	O	934-935
g	O	936-937
per	O	938-941
day	O	942-945
for	O	946-949
cimetidine	O	950-960
)	O	960-961
.	O	961-962

Sixty	O	963-968
percent	O	969-976
of	O	977-979
the	O	980-983
males	O	984-989
developed	O	990-999
breast	O	1000-1006
changes	O	1007-1014
or	O	1015-1017
impotence	B	1018-1027
while	O	1028-1033
taking	O	1034-1040
cimetidine	O	1041-1051
and	O	1052-1055
in	O	1056-1058
all	O	1059-1062
cases	O	1063-1068
these	O	1069-1074
changes	O	1075-1082
disappeared	O	1083-1094
when	O	1095-1099
cimetidine	O	1100-1110
was	O	1111-1114
replaced	O	1115-1123
by	O	1124-1126
ranitidine	O	1127-1137
.	O	1137-1138

Treatment	O	1139-1148
with	O	1149-1153
high	O	1154-1158
doses	O	1159-1164
of	O	1165-1167
cimetidine	O	1168-1178
(	O	1179-1180
one	O	1180-1183
to	O	1184-1186
60	O	1187-1189
months	O	1190-1196
;	O	1196-1197
median	O	1198-1204
,	O	1204-1205
11	O	1206-1208
months	O	1209-1215
)	O	1215-1216
or	O	1217-1219
ranitidine	O	1220-1230
(	O	1231-1232
two	O	1232-1235
to	O	1236-1238
31	O	1239-1241
months	O	1242-1248
;	O	1248-1249
median	O	1250-1256
,	O	1256-1257
14	O	1258-1260
months	O	1261-1267
)	O	1267-1268
was	O	1269-1272
not	O	1273-1276
associated	O	1277-1287
with	O	1288-1292
hepatic	B	1293-1300
or	I	1301-1303
hematologic	I	1304-1315
toxicity	I	1316-1324
or	O	1325-1327
alterations	O	1328-1339
of	O	1340-1342
serum	O	1343-1348
gastrin	O	1349-1356
concentrations	O	1357-1371
,	O	1371-1372
but	O	1373-1376
ranitidine	O	1377-1387
therapy	O	1388-1395
was	O	1396-1399
associated	O	1400-1410
with	O	1411-1415
a	O	1416-1417
significantly	O	1418-1431
lower	O	1432-1437
serum	O	1438-1443
creatinine	O	1444-1454
level	O	1455-1460
than	O	1461-1465
seen	O	1466-1470
with	O	1471-1475
cimetidine	O	1476-1486
therapy	O	1487-1494
.	O	1494-1495

The	O	1496-1499
results	O	1500-1507
show	O	1508-1512
that	O	1513-1517
both	O	1518-1522
drugs	O	1523-1528
can	O	1529-1532
adequately	O	1533-1543
inhibit	O	1544-1551
acid	O	1552-1556
secretion	O	1557-1566
in	O	1567-1569
patients	O	1570-1578
with	O	1579-1583
gastric	O	1584-1591
hypersecretory	O	1592-1606
states	O	1607-1613
.	O	1613-1614

Both	O	1615-1619
are	O	1620-1623
safe	O	1624-1628
at	O	1629-1631
high	O	1632-1636
doses	O	1637-1642
,	O	1642-1643
but	O	1644-1647
ranitidine	O	1648-1658
is	O	1659-1661
threefold	O	1662-1671
more	O	1672-1676
potent	O	1677-1683
and	O	1684-1687
does	O	1688-1692
not	O	1693-1696
cause	O	1697-1702
the	O	1703-1706
antiandrogen	O	1707-1719
side	O	1720-1724
effects	O	1725-1732
frequently	O	1733-1743
seen	O	1744-1748
with	O	1749-1753
high	O	1754-1758
doses	O	1759-1764
of	O	1765-1767
cimetidine	O	1768-1778
.	O	1778-1779

A	O	0-1
catch	O	2-7
in	O	8-10
the	O	11-14
Reye	B	15-19
.	O	19-20

Twenty	O	21-27
-	O	27-28
six	O	28-31
cases	O	32-37
of	O	38-40
Reye	B	41-45
syndrome	I	46-54
from	O	55-59
The	O	60-63
Children	O	64-72
'	O	72-73
s	O	73-74
Hospital	O	75-83
,	O	83-84
Camperdown	O	85-95
,	O	95-96
Australia	O	97-106
,	O	106-107
occurring	O	108-117
between	O	118-125
1973	O	126-130
and	O	131-134
1982	O	135-139
were	O	140-144
reviewed	O	145-153
.	O	153-154

Of	O	155-157
these	O	158-163
,	O	163-164
20	O	165-167
cases	O	168-173
met	O	174-177
the	O	178-181
US	O	182-184
Public	O	185-191
Health	O	192-198
Service	O	199-206
Centers	O	207-214
for	O	215-218
Disease	O	219-226
Control	O	227-234
criteria	O	235-243
for	O	244-247
the	O	248-251
diagnosis	O	252-261
of	O	262-264
Reye	B	265-269
syndrome	I	270-278
.	O	278-279

Aspirin	O	280-287
or	O	288-290
salicylate	O	291-301
ingestion	O	302-311
had	O	312-315
occurred	O	316-324
in	O	325-327
only	O	328-332
one	O	333-336
of	O	337-339
the	O	340-343
20	O	344-346
cases	O	347-352
(	O	353-354
5	O	354-355
%	O	355-356
)	O	356-357
,	O	357-358
and	O	359-362
paracetamol	O	363-374
(	O	375-376
acetaminophen	O	376-389
)	O	389-390
had	O	391-394
been	O	395-399
administered	O	400-412
in	O	413-415
only	O	416-420
six	O	421-424
of	O	425-427
the	O	428-431
cases	O	432-437
(	O	438-439
30	O	439-441
%	O	441-442
)	O	442-443
.	O	443-444

Pathologic	O	445-455
confirmation	O	456-468
of	O	469-471
the	O	472-475
diagnosis	O	476-485
of	O	486-488
Reye	B	489-493
syndrome	I	494-502
was	O	503-506
accomplished	O	507-519
in	O	520-522
90	O	523-525
%	O	525-526
of	O	527-529
the	O	530-533
cases	O	534-539
.	O	539-540

The	O	541-544
incidence	O	545-554
of	O	555-557
Reye	B	558-562
syndrome	I	563-571
in	O	572-574
New	O	575-578
South	O	579-584
Wales	O	585-590
,	O	590-591
Australia	O	592-601
,	O	601-602
is	O	603-605
estimated	O	606-615
from	O	616-620
this	O	621-625
study	O	626-631
to	O	632-634
be	O	635-637
approximately	O	638-651
nine	O	652-656
cases	O	657-662
per	O	663-666
1	O	667-668
million	O	669-676
children	O	677-685
compared	O	686-694
with	O	695-699
recent	O	700-706
US	O	707-709
data	O	710-714
of	O	715-717
ten	O	718-721
to	O	722-724
20	O	725-727
cases	O	728-733
per	O	734-737
1	O	738-739
million	O	740-747
children	O	748-756
and	O	757-760
three	O	761-766
to	O	767-769
seven	O	770-775
cases	O	776-781
per	O	782-785
1	O	786-787
million	O	788-795
children	O	796-804
in	O	805-807
Great	O	808-813
Britain	O	814-821
.	O	821-822

The	O	823-826
mortality	O	827-836
for	O	837-840
these	O	841-846
Reye	B	847-851
syndrome	I	852-860
cases	O	861-866
in	O	867-869
Australia	O	870-879
was	O	880-883
45	O	884-886
%	O	886-887
as	O	888-890
compared	O	891-899
with	O	900-904
a	O	905-906
32	O	907-909
%	O	909-910
case	O	911-915
-	O	915-916
fatality	O	916-924
rate	O	925-929
in	O	930-932
the	O	933-936
United	O	937-943
States	O	944-950
.	O	950-951

In	O	952-954
Australia	O	955-964
,	O	964-965
the	O	966-969
pediatric	O	970-979
usage	O	980-985
of	O	986-988
aspirin	O	989-996
has	O	997-1000
been	O	1001-1005
extremely	O	1006-1015
low	O	1016-1019
for	O	1020-1023
the	O	1024-1027
past	O	1028-1032
25	O	1033-1035
years	O	1036-1041
(	O	1042-1043
less	O	1043-1047
than	O	1048-1052
1	O	1053-1054
%	O	1054-1055
of	O	1056-1058
total	O	1059-1064
dosage	O	1065-1071
units	O	1072-1077
sold	O	1078-1082
)	O	1082-1083
,	O	1083-1084
with	O	1085-1089
paracetamol	O	1090-1101
(	O	1102-1103
acetaminophen	O	1103-1116
)	O	1116-1117
dominating	O	1118-1128
the	O	1129-1132
pediatric	O	1133-1142
analgesic	O	1143-1152
and	O	1153-1156
antipyretic	O	1157-1168
market	O	1169-1175
.	O	1175-1176

Reye	B	1177-1181
syndrome	I	1182-1190
may	O	1191-1194
be	O	1195-1197
disappearing	O	1198-1210
from	O	1211-1215
Australia	O	1216-1225
despite	O	1226-1233
a	O	1234-1235
total	O	1236-1241
lack	O	1242-1246
of	O	1247-1249
association	O	1250-1261
with	O	1262-1266
salicylates	O	1267-1278
or	O	1279-1281
aspirin	O	1282-1289
ingestion	O	1290-1299
,	O	1299-1300
since	O	1301-1306
there	O	1307-1312
were	O	1313-1317
no	O	1318-1320
cases	O	1321-1326
found	O	1327-1332
at	O	1333-1335
The	O	1336-1339
Children	O	1340-1348
'	O	1348-1349
s	O	1349-1350
Hospital	O	1351-1359
in	O	1360-1362
1983	O	1363-1367
,	O	1367-1368
1984	O	1369-1373
,	O	1373-1374
or	O	1375-1377
1985	O	1378-1382
.	O	1382-1383

St	B	0-2
.	I	2-3
Anthony	I	4-11
'	I	11-12
s	I	12-13
fire	I	14-18
,	O	18-19
then	O	20-24
and	O	25-28
now	O	29-32
:	O	32-33
a	O	34-35
case	O	36-40
report	O	41-47
and	O	48-51
historical	O	52-62
review	O	63-69
.	O	69-70

A	O	71-72
rare	O	73-77
case	O	78-82
of	O	83-85
morbid	O	86-92
vasospasm	B	93-102
,	O	102-103
together	O	104-112
with	O	113-117
striking	O	118-126
angiographic	O	127-139
findings	O	140-148
,	O	148-149
is	O	150-152
described	O	153-162
secondary	O	163-172
to	O	173-175
the	O	176-179
ingestion	O	180-189
of	O	190-192
methysergide	O	193-205
by	O	206-208
a	O	209-210
48	O	211-213
-	O	213-214
year	O	214-218
-	O	213-214
old	O	219-222
woman	O	223-228
.	O	228-229

A	O	230-231
brief	O	232-237
review	O	238-244
of	O	245-247
the	O	248-251
literature	O	252-262
on	O	263-265
similar	O	266-273
cases	O	274-279
is	O	280-282
presented	O	283-292
.	O	292-293

A	O	294-295
discussion	O	296-306
of	O	307-309
the	O	310-313
history	O	314-321
of	O	322-324
ergot	O	325-330
includes	O	331-339
its	O	340-343
original	O	344-352
discovery	O	353-362
,	O	362-363
the	O	364-367
epidemics	O	368-377
of	O	378-380
gangrene	B	381-389
that	O	390-394
it	O	395-397
has	O	398-401
caused	O	402-408
through	O	409-416
the	O	417-420
ages	O	421-425
and	O	426-429
its	O	430-433
past	O	434-438
and	O	439-442
present	O	443-450
role	O	451-455
in	O	456-458
the	O	459-462
management	O	463-473
of	O	474-476
migraine	B	477-485
headache	I	486-494
.	O	494-495

Despite	O	496-503
the	O	504-507
advent	O	508-514
of	O	515-517
calcium	O	518-525
channel	O	526-533
blockers	O	534-542
and	O	543-546
beta	O	547-551
-	O	551-552
adrenergic	O	552-562
antagonists	O	563-574
,	O	574-575
ergot	O	576-581
preparations	O	582-594
continue	O	595-603
to	O	604-606
play	O	607-611
a	O	612-613
major	O	614-619
role	O	620-624
in	O	625-627
migraine	B	628-636
therapy	O	637-644
,	O	644-645
so	O	646-648
that	O	649-653
the	O	654-657
danger	O	658-664
of	O	665-667
St	B	668-670
.	I	670-671
Anthony	I	672-679
'	I	679-680
s	I	680-681
fire	I	682-686
persists	O	687-695
.	O	695-696

Beta	O	0-4
-	O	4-5
2	O	5-6
-	O	4-5
adrenoceptor	O	7-19
-	O	4-5
mediated	O	20-28
hypokalemia	B	29-40
and	O	41-44
its	O	45-48
abolishment	O	49-60
by	O	61-63
oxprenolol	O	64-74
.	O	74-75

The	O	76-79
time	O	80-84
course	O	85-91
and	O	92-95
concentration	O	96-109
-	O	109-110
effect	O	110-116
relationship	O	117-129
of	O	130-132
terbutaline	O	133-144
-	O	144-145
induced	O	145-152
hypokalemia	B	153-164
was	O	165-168
studied	O	169-176
,	O	176-177
using	O	178-183
computer	O	184-192
-	O	192-193
aided	O	193-198
pharmacokinetic	O	199-214
-	O	214-215
dynamic	O	215-222
modeling	O	223-231
.	O	231-232

Subsequently	O	233-245
we	O	246-248
investigated	O	249-261
the	O	262-265
efficacy	O	266-274
of	O	275-277
oxprenolol	O	278-288
in	O	289-291
antagonizing	O	292-304
such	O	305-309
hypokalemia	B	310-321
,	O	321-322
together	O	323-331
with	O	332-336
the	O	337-340
pharmacokinetic	O	341-356
interaction	O	357-368
between	O	369-376
both	O	377-381
drugs	O	382-387
.	O	387-388

Six	O	389-392
healthy	O	393-400
subjects	O	401-409
were	O	410-414
given	O	415-420
a	O	421-422
0	O	423-424
.	O	424-425
5	O	425-426
mg	O	427-429
subcutaneous	O	430-442
dose	O	443-447
of	O	448-450
terbutaline	O	451-462
on	O	463-465
two	O	466-469
occasions	O	470-479
:	O	479-480
1	O	481-482
hour	O	483-487
after	O	488-493
oral	O	494-498
administration	O	499-513
of	O	514-516
a	O	517-518
placebo	O	519-526
and	O	527-530
1	O	531-532
hour	O	533-537
after	O	538-543
80	O	544-546
mg	O	547-549
oxprenolol	O	550-560
orally	O	561-567
.	O	567-568

In	O	569-571
the	O	572-575
7	O	576-577
-	O	577-578
hour	O	578-582
period	O	583-589
after	O	590-595
terbutaline	O	596-607
administration	O	608-622
,	O	622-623
plasma	O	624-630
samples	O	631-638
were	O	639-643
taken	O	644-649
for	O	650-653
determination	O	654-667
of	O	668-670
plasma	O	671-677
potassium	O	678-687
levels	O	688-694
and	O	695-698
drug	O	699-703
concentrations	O	704-718
.	O	718-719

The	O	720-723
sigmoid	O	724-731
Emax	O	732-736
model	O	737-742
offered	O	743-750
a	O	751-752
good	O	753-757
description	O	758-769
of	O	770-772
the	O	773-776
relation	O	777-785
between	O	786-793
terbutaline	O	794-805
concentrations	O	806-820
and	O	821-824
potassium	O	825-834
effects	O	835-842
.	O	842-843

Oxprenolol	O	844-854
caused	O	855-861
decreases	O	862-871
of	O	872-874
65	O	875-877
%	O	877-878
and	O	879-882
56	O	883-885
%	O	885-886
of	O	887-889
terbutaline	O	890-901
volume	O	902-908
of	O	909-911
distribution	O	912-924
and	O	925-928
clearance	O	929-938
,	O	938-939
respectively	O	940-952
,	O	952-953
and	O	954-957
an	O	958-960
increase	O	961-969
of	O	970-972
130	O	973-976
%	O	976-977
of	O	978-980
its	O	981-984
AUC	O	985-988
.	O	988-989

In	O	990-992
spite	O	993-998
of	O	999-1001
higher	O	1002-1008
terbutaline	O	1009-1020
concentrations	O	1021-1035
after	O	1036-1041
oxprenolol	O	1042-1052
pretreatment	O	1053-1065
,	O	1065-1066
the	O	1067-1070
hypokalemia	B	1071-1082
was	O	1083-1086
almost	O	1087-1093
completely	O	1094-1104
antagonized	O	1105-1116
by	O	1117-1119
the	O	1120-1123
beta	O	1124-1128
2	O	1129-1130
-	O	1130-1131
blocking	O	1131-1139
action	O	1140-1146
.	O	1146-1147

Midline	O	0-7
B3	O	8-10
serotonin	O	11-20
nerves	O	21-27
in	O	28-30
rat	O	31-34
medulla	O	35-42
are	O	43-46
involved	O	47-55
in	O	56-58
hypotensive	B	59-70
effect	O	71-77
of	O	78-80
methyldopa	O	81-91
.	O	91-92

Previous	O	93-101
experiments	O	102-113
in	O	114-116
this	O	117-121
laboratory	O	122-132
have	O	133-137
shown	O	138-143
that	O	144-148
microinjection	O	149-163
of	O	164-166
methyldopa	O	167-177
onto	O	178-182
the	O	183-186
ventrolateral	O	187-200
cells	O	201-206
of	O	207-209
the	O	210-213
B3	O	214-216
serotonin	O	217-226
neurons	O	227-234
in	O	235-237
the	O	238-241
medulla	O	242-249
elicits	O	250-257
a	O	258-259
hypotensive	B	260-271
response	O	272-280
mediated	O	281-289
by	O	290-292
a	O	293-294
projection	O	295-305
descending	O	306-316
into	O	317-321
the	O	322-325
spinal	O	326-332
cord	O	333-337
.	O	337-338

The	O	339-342
present	O	343-350
experiments	O	351-362
were	O	363-367
designed	O	368-376
to	O	377-379
investigate	O	380-391
the	O	392-395
role	O	396-400
of	O	401-403
the	O	404-407
midline	O	408-415
cells	O	416-421
of	O	422-424
the	O	425-428
B3	O	429-431
serotonin	O	432-441
neurons	O	442-449
in	O	450-452
the	O	453-456
medulla	O	457-464
,	O	464-465
coinciding	O	466-476
with	O	477-481
the	O	482-485
raphe	O	486-491
magnus	O	492-498
.	O	498-499

In	O	500-502
spontaneously	O	503-516
hypertensive	B	517-529
,	O	529-530
stroke	B	531-537
-	O	537-538
prone	O	538-543
rats	O	544-548
,	O	548-549
microinjection	O	550-564
of	O	565-567
methyldopa	O	568-578
into	O	579-583
the	O	584-587
area	O	588-592
of	O	593-595
the	O	596-599
midline	O	600-607
B3	O	608-610
serotonin	O	611-620
cell	O	621-625
group	O	626-631
in	O	632-634
the	O	635-638
ventral	O	639-646
medulla	O	647-654
caused	O	655-661
a	O	662-663
potent	O	664-670
hypotension	B	671-682
of	O	683-685
30	O	686-688
-	O	688-689
40	O	689-691
mm	O	692-694
Hg	O	695-697
,	O	697-698
which	O	699-704
was	O	705-708
maximal	O	709-716
2	O	717-718
-	O	718-719
3	O	719-720
h	O	721-722
after	O	723-728
administration	O	729-743
and	O	744-747
was	O	748-751
abolished	O	752-761
by	O	762-764
the	O	765-768
serotonin	O	769-778
neurotoxin	O	779-789
5	O	790-791
,	O	791-792
7	O	792-793
-	O	793-794
dihydroxytryptamine	O	794-813
(	O	814-815
5	O	815-816
,	O	816-817
7	O	817-818
-	O	818-819
DHT	O	819-822
)	O	822-823
injected	O	824-832
intracerebroventricularly	O	833-858
.	O	858-859

However	O	860-867
,	O	867-868
intraspinal	O	869-880
injection	O	881-890
of	O	891-893
5	O	894-895
,	O	895-896
7	O	896-897
-	O	897-898
DHT	O	898-901
to	O	902-904
produce	O	905-912
a	O	913-914
more	O	915-919
selective	O	920-929
lesion	O	930-936
of	O	937-939
only	O	940-944
descending	O	945-955
serotonin	O	956-965
projections	O	966-977
in	O	978-980
the	O	981-984
spinal	O	985-991
cord	O	992-996
did	O	997-1000
not	O	1001-1004
affect	O	1005-1011
this	O	1012-1016
hypotension	B	1017-1028
.	O	1028-1029

Further	O	1030-1037
,	O	1037-1038
5	O	1039-1040
,	O	1040-1041
7	O	1041-1042
-	O	1042-1043
DHT	O	1043-1046
lesion	O	1047-1053
of	O	1054-1056
serotonin	O	1057-1066
nerves	O	1067-1073
travelling	O	1074-1084
in	O	1085-1087
the	O	1088-1091
median	O	1092-1098
forebrain	O	1099-1108
bundle	O	1109-1115
,	O	1115-1116
one	O	1117-1120
of	O	1121-1123
the	O	1124-1127
main	O	1128-1132
ascending	O	1133-1142
pathways	O	1143-1151
from	O	1152-1156
the	O	1157-1160
B3	O	1161-1163
serotonin	O	1164-1173
cells	O	1174-1179
,	O	1179-1180
did	O	1181-1184
not	O	1185-1188
affect	O	1189-1195
the	O	1196-1199
fall	O	1200-1204
in	O	1205-1207
blood	O	1208-1213
pressure	O	1214-1222
associated	O	1223-1233
with	O	1234-1238
a	O	1239-1240
midline	O	1241-1248
B3	O	1249-1251
serotonin	O	1252-1261
methyldopa	O	1262-1272
injection	O	1273-1282
.	O	1282-1283

It	O	1284-1286
is	O	1287-1289
concluded	O	1290-1299
therefore	O	1300-1309
that	O	1310-1314
,	O	1314-1315
unlike	O	1316-1322
the	O	1323-1326
ventrolateral	O	1327-1340
B3	O	1341-1343
cells	O	1344-1349
which	O	1350-1355
mediate	O	1356-1363
a	O	1364-1365
methyldopa	O	1366-1376
-	O	1376-1377
induced	O	1377-1384
hypotension	B	1385-1396
via	O	1397-1400
descending	O	1401-1411
projections	O	1412-1423
,	O	1423-1424
the	O	1425-1428
midline	O	1429-1436
serotonin	O	1437-1446
B3	O	1447-1449
cells	O	1450-1455
in	O	1456-1458
the	O	1459-1462
medulla	O	1463-1470
contribute	O	1471-1481
to	O	1482-1484
the	O	1485-1488
hypotensive	B	1489-1500
action	O	1501-1507
of	O	1508-1510
methyldopa	O	1511-1521
,	O	1521-1522
either	O	1523-1529
by	O	1530-1532
way	O	1533-1536
of	O	1537-1539
an	O	1540-1542
ascending	O	1543-1552
projection	O	1553-1563
which	O	1564-1569
does	O	1570-1574
not	O	1575-1578
pass	O	1579-1583
through	O	1584-1591
the	O	1592-1595
median	O	1596-1602
forebrain	O	1603-1612
bundle	O	1613-1619
,	O	1619-1620
or	O	1621-1623
through	O	1624-1631
a	O	1632-1633
projection	O	1634-1644
restricted	O	1645-1655
to	O	1656-1658
the	O	1659-1662
caudal	O	1663-1669
brainstem	O	1670-1679
.	O	1679-1680

Yohimbine	O	0-9
treatment	O	10-19
of	O	20-22
sexual	B	23-29
side	I	30-34
effects	I	35-42
induced	O	43-50
by	O	51-53
serotonin	O	54-63
reuptake	O	64-72
blockers	O	73-81
.	O	81-82

BACKGROUND	O	83-93
:	O	93-94
Preclinical	O	95-106
and	O	107-110
clinical	O	111-119
studies	O	120-127
suggest	O	128-135
that	O	136-140
yohimbine	O	141-150
facilitates	O	151-162
sexual	O	163-169
behavior	O	170-178
and	O	179-182
may	O	183-186
be	O	187-189
helpful	O	190-197
in	O	198-200
the	O	201-204
treatment	O	205-214
of	O	215-217
male	B	218-222
impotence	I	223-232
.	O	232-233

A	O	234-235
single	O	236-242
case	O	243-247
report	O	248-254
suggests	O	255-263
that	O	264-268
yohimbine	O	269-278
may	O	279-282
be	O	283-285
used	O	286-290
to	O	291-293
treat	O	294-299
the	O	300-303
sexual	B	304-310
side	I	311-315
effects	I	316-323
of	O	324-326
clomipramine	O	327-339
.	O	339-340

This	O	341-345
study	O	346-351
evaluated	O	352-361
yohimbine	O	362-371
as	O	372-374
a	O	375-376
treatment	O	377-386
for	O	387-390
the	O	391-394
sexual	B	395-401
side	I	402-406
effects	I	407-414
caused	O	415-421
by	O	422-424
serotonin	O	425-434
reuptake	O	435-443
blockers	O	444-452
.	O	452-453

METHOD	O	454-460
:	O	460-461
Six	O	462-465
patients	O	466-474
with	O	475-479
either	O	480-486
obsessive	B	487-496
compulsive	I	497-507
disorder	I	508-516
,	O	516-517
trichotillomania	B	518-534
,	O	534-535
anxiety	B	536-543
,	O	543-544
or	O	545-547
affective	B	548-557
disorders	I	558-567
who	O	568-571
suffered	O	572-580
sexual	B	581-587
side	I	588-592
effects	I	593-600
after	O	601-606
treatment	O	607-616
with	O	617-621
serotonin	O	622-631
reuptake	O	632-640
blockers	O	641-649
were	O	650-654
given	O	655-660
yohimbine	O	661-670
on	O	671-673
a	O	674-675
p	O	676-677
.	O	677-678
r	O	678-679
.	O	677-678
n	O	680-681
.	O	677-678

basis	O	683-688
in	O	689-691
an	O	692-694
open	O	695-699
clinical	O	700-708
trial	O	709-714
.	O	714-715

Various	O	716-723
doses	O	724-729
of	O	730-732
yohimbine	O	733-742
were	O	743-747
used	O	748-752
to	O	753-755
determine	O	756-765
the	O	766-769
ideal	O	770-775
dose	O	776-780
for	O	781-784
each	O	785-789
patient	O	790-797
.	O	797-798

RESULTS	O	799-806
:	O	806-807
Five	O	808-812
of	O	813-815
the	O	816-819
six	O	820-823
patients	O	824-832
experienced	O	833-844
improved	O	845-853
sexual	O	854-860
functioning	O	861-872
after	O	873-878
taking	O	879-885
yohimbine	O	886-895
.	O	895-896

One	O	897-900
patient	O	901-908
who	O	909-912
failed	O	913-919
to	O	920-922
comply	O	923-929
with	O	930-934
yohimbine	O	935-944
treatment	O	945-954
had	O	955-958
no	O	959-961
therapeutic	O	962-973
effects	O	974-981
.	O	981-982

Side	O	983-987
effects	O	988-995
of	O	996-998
yohimbine	O	999-1008
included	O	1009-1017
excessive	O	1018-1027
sweating	O	1028-1036
,	O	1036-1037
increased	O	1038-1047
anxiety	B	1048-1055
,	O	1055-1056
and	O	1057-1060
a	O	1061-1062
wound	O	1063-1068
-	O	1068-1069
up	O	1069-1071
feeling	O	1072-1079
in	O	1080-1082
some	O	1083-1087
patients	O	1088-1096
.	O	1096-1097

CONCLUSION	O	1098-1108
:	O	1108-1109
The	O	1110-1113
results	O	1114-1121
of	O	1122-1124
this	O	1125-1129
study	O	1130-1135
indicate	O	1136-1144
that	O	1145-1149
yohimbine	O	1150-1159
may	O	1160-1163
be	O	1164-1166
an	O	1167-1169
effective	O	1170-1179
treatment	O	1180-1189
for	O	1190-1193
the	O	1194-1197
sexual	B	1198-1204
side	I	1205-1209
effects	I	1210-1217
caused	O	1218-1224
by	O	1225-1227
serotonin	O	1228-1237
reuptake	O	1238-1246
blockers	O	1247-1255
.	O	1255-1256

Future	O	1257-1263
controlled	O	1264-1274
studies	O	1275-1282
are	O	1283-1286
needed	O	1287-1293
to	O	1294-1296
further	O	1297-1304
investigate	O	1305-1316
the	O	1317-1320
effectiveness	O	1321-1334
and	O	1335-1338
safety	O	1339-1345
of	O	1346-1348
yohimbine	O	1349-1358
for	O	1359-1362
this	O	1363-1367
indication	O	1368-1378
.	O	1378-1379

Hypersensitivity	B	0-16
immune	O	17-23
reaction	O	24-32
as	O	33-35
a	O	36-37
mechanism	O	38-47
for	O	48-51
dilevalol	O	52-61
-	O	61-62
associated	O	62-72
hepatitis	B	73-82
.	O	82-83

OBJECTIVE	O	84-93
:	O	93-94
To	O	95-97
assess	O	98-104
lymphocyte	O	105-115
reactivity	O	116-126
to	O	127-129
dilevalol	O	130-139
and	O	140-143
to	O	144-146
serum	O	147-152
containing	O	153-163
putative	O	164-172
ex	O	173-175
vivo	O	176-180
dilevalol	O	181-190
antigens	O	191-199
or	O	200-202
metabolites	O	203-214
in	O	215-217
a	O	218-219
case	O	220-224
of	O	225-227
dilevalol	O	228-237
-	O	237-238
induced	O	238-245
liver	B	246-251
injury	I	252-258
.	O	258-259

PATIENT	O	260-267
:	O	267-268
A	O	269-270
58	O	271-273
-	O	273-274
year	O	274-278
-	O	273-274
old	O	279-282
woman	O	283-288
with	O	289-293
a	O	294-295
clinical	O	296-304
diagnosis	O	305-314
of	O	315-317
dilevalol	O	318-327
-	O	327-328
induced	O	328-335
liver	B	336-341
injury	I	342-348
.	O	348-349

METHODS	O	350-357
:	O	357-358
Peripheral	O	359-369
blood	O	370-375
mononuclear	O	376-387
cells	O	388-393
collected	O	394-403
from	O	404-408
the	O	409-412
patient	O	413-420
were	O	421-425
cultured	O	426-434
in	O	435-437
the	O	438-441
presence	O	442-450
of	O	451-453
a	O	454-455
solution	O	456-464
of	O	465-467
dilevalol	O	468-477
and	O	478-481
also	O	482-486
with	O	487-491
sera	O	492-496
collected	O	497-506
from	O	507-511
a	O	512-513
volunteer	O	514-523
before	O	524-530
and	O	531-534
after	O	535-540
dilevalol	O	541-550
intake	O	551-557
.	O	557-558

A	O	559-560
similar	O	561-568
protocol	O	569-577
was	O	578-581
performed	O	582-591
with	O	592-596
lymphocytes	O	597-608
from	O	609-613
a	O	614-615
healthy	O	616-623
subject	O	624-631
.	O	631-632

RESULTS	O	633-640
:	O	640-641
No	O	642-644
lymphocyte	O	645-655
proliferation	O	656-669
was	O	670-673
observed	O	674-682
either	O	683-689
in	O	690-692
the	O	693-696
patient	O	697-704
or	O	705-707
in	O	708-710
the	O	711-714
healthy	O	715-722
volunteer	O	723-732
in	O	733-735
the	O	736-739
presence	O	740-748
of	O	749-751
dilevalol	O	752-761
solutions	O	762-771
.	O	771-772

A	O	773-774
significant	O	775-786
proliferative	O	787-800
response	O	801-809
to	O	810-812
serum	O	813-818
collected	O	819-828
after	O	829-834
dilevalol	O	835-844
intake	O	845-851
was	O	852-855
observed	O	856-864
in	O	865-867
the	O	868-871
case	O	872-876
of	O	877-879
the	O	880-883
patient	O	884-891
compared	O	892-900
with	O	901-905
the	O	906-909
proliferative	O	910-923
response	O	924-932
to	O	933-935
the	O	936-939
serum	O	940-945
collected	O	946-955
before	O	956-962
the	O	963-966
drug	O	967-971
intake	O	972-978
.	O	978-979

No	O	980-982
reactivity	O	983-993
was	O	994-997
found	O	998-1003
when	O	1004-1008
lymphocytes	O	1009-1020
from	O	1021-1025
the	O	1026-1029
healthy	O	1030-1037
subject	O	1038-1045
were	O	1046-1050
tested	O	1051-1057
under	O	1058-1063
similar	O	1064-1071
conditions	O	1072-1082
.	O	1082-1083

CONCLUSIONS	O	1084-1095
:	O	1095-1096
The	O	1097-1100
methodology	O	1101-1112
used	O	1113-1117
allowed	O	1118-1125
the	O	1126-1129
detection	O	1130-1139
of	O	1140-1142
lymphocyte	O	1143-1153
sensitization	O	1154-1167
to	O	1168-1170
sera	O	1171-1175
containing	O	1176-1186
ex	O	1187-1189
vivo	O	1190-1194
-	O	1194-1195
prepared	O	1195-1203
dilevalol	O	1204-1213
antigens	O	1214-1222
,	O	1222-1223
suggesting	O	1224-1234
the	O	1235-1238
involvement	O	1239-1250
of	O	1251-1253
an	O	1254-1256
immunologic	O	1257-1268
mechanism	O	1269-1278
in	O	1279-1281
dilevalol	O	1282-1291
-	O	1291-1292
induced	O	1292-1299
liver	B	1300-1305
injury	I	1306-1312
.	O	1312-1313

Reversible	O	0-10
myocardial	B	11-21
hypertrophy	I	22-33
induced	O	34-41
by	O	42-44
tacrolimus	O	45-55
in	O	56-58
a	O	59-60
pediatric	O	61-70
heart	O	71-76
transplant	O	77-87
recipient	O	88-97
:	O	97-98
case	O	99-103
report	O	104-110
.	O	110-111

Tacrolimus	O	112-122
is	O	123-125
a	O	126-127
potent	O	128-134
immunosuppressant	O	135-152
that	O	153-157
is	O	158-160
frequently	O	161-171
used	O	172-176
in	O	177-179
organ	O	180-185
transplantation	O	186-201
.	O	201-202

However	O	203-210
,	O	210-211
adverse	O	212-219
effects	O	220-227
include	O	228-235
cardiac	B	236-243
toxicity	I	244-252
.	O	252-253

Herein	O	254-260
we	O	261-263
describe	O	264-272
transient	O	273-282
myocardial	B	283-293
hypertrophy	I	294-305
induced	O	306-313
by	O	314-316
tacrolimus	O	317-327
after	O	328-333
heart	O	334-339
transplantation	O	340-355
.	O	355-356

The	O	357-360
hypertrophy	B	361-372
caused	O	373-379
no	O	380-382
clinical	O	383-391
symptoms	O	392-400
but	O	401-404
was	O	405-408
noted	O	409-414
because	O	415-422
of	O	423-425
elevation	O	426-435
of	O	436-438
plasma	O	439-445
brain	O	446-451
natriuretic	O	452-463
peptide	O	464-471
concentration	O	472-485
and	O	486-489
confirmed	O	490-499
at	O	500-502
echocardiography	O	503-519
.	O	519-520

Initially	O	521-530
,	O	530-531
allograft	O	532-541
rejection	O	542-551
was	O	552-555
feared	O	556-562
;	O	562-563
however	O	564-571
,	O	571-572
myocardial	O	573-583
biopsy	O	584-590
samples	O	591-598
revealed	O	599-607
only	O	608-612
interstitial	O	613-625
edema	B	626-631
and	O	632-635
mild	O	636-640
myocardial	B	641-651
hypertrophy	I	652-663
;	O	663-664
neither	O	665-672
cellular	O	673-681
nor	O	682-685
humoral	O	686-693
rejection	O	694-703
was	O	704-707
detected	O	708-716
.	O	716-717

The	O	718-721
blood	O	722-727
tacrolimus	O	728-738
concentration	O	739-752
was	O	753-756
higher	O	757-763
than	O	764-768
usual	O	769-774
at	O	775-777
that	O	778-782
time	O	783-787
;	O	787-788
thus	O	789-793
,	O	793-794
tacrolimus	O	795-805
dosage	O	806-812
was	O	813-816
reduced	O	817-824
.	O	824-825

Myocardial	B	826-836
hypertrophy	I	837-848
completely	O	849-859
resolved	O	860-868
upon	O	869-873
reducing	O	874-882
the	O	883-886
target	O	887-893
concentration	O	894-907
of	O	908-910
tacrolimus	O	911-921
and	O	922-925
did	O	926-929
not	O	930-933
recur	O	934-939
,	O	939-940
as	O	941-943
confirmed	O	944-953
at	O	954-956
echocardiography	O	957-973
and	O	974-977
myocardial	O	978-988
biopsy	O	989-995
.	O	995-996

Thus	O	997-1001
,	O	1001-1002
we	O	1003-1005
conclude	O	1006-1014
that	O	1015-1019
tacrolimus	O	1020-1030
induces	O	1031-1038
reversible	O	1039-1049
myocardial	B	1050-1060
hypertrophy	I	1061-1072
.	O	1072-1073

In	O	1074-1076
patients	O	1077-1085
receiving	O	1086-1095
tacrolimus	O	1096-1106
therapy	O	1107-1114
,	O	1114-1115
blood	O	1116-1121
concentration	O	1122-1135
should	O	1136-1142
be	O	1143-1145
carefully	O	1146-1155
controlled	O	1156-1166
and	O	1167-1170
extreme	O	1171-1178
attention	O	1179-1188
paid	O	1189-1193
to	O	1194-1196
cardiac	O	1197-1204
involvement	O	1205-1216
.	O	1216-1217

Comparison	O	0-10
of	O	11-13
unilateral	O	14-24
pallidotomy	O	25-36
and	O	37-40
subthalamotomy	O	41-55
findings	O	56-64
in	O	65-67
advanced	O	68-76
idiopathic	B	77-87
Parkinson	I	88-97
'	I	97-98
s	I	94-95
disease	I	100-107
.	O	107-108

A	O	109-110
prospective	O	111-122
,	O	122-123
randomized	O	124-134
,	O	134-135
double	O	136-142
-	O	142-143
blind	O	143-148
pilot	O	149-154
study	O	155-160
to	O	161-163
compare	O	164-171
the	O	172-175
results	O	176-183
of	O	184-186
stereotactic	O	187-199
unilateral	O	200-210
pallidotomy	O	211-222
and	O	223-226
subthalamotomy	O	227-241
in	O	242-244
advanced	O	245-253
idiopathic	B	254-264
Parkinson	I	265-274
'	I	274-275
s	I	271-272
disease	I	277-284
(	O	285-286
PD	B	286-288
)	O	288-289
refractory	O	290-300
to	O	301-303
medical	O	304-311
treatment	O	312-321
was	O	322-325
designed	O	326-334
.	O	334-335

Ten	O	336-339
consecutive	O	340-351
patients	O	352-360
(	O	361-362
mean	O	362-366
age	O	367-370
,	O	370-371
58	O	372-374
.	O	374-375
4	O	375-376
+	O	377-378
/	O	378-379
-	O	379-380
6	O	381-382
.	O	382-383
8	O	383-384
years	O	385-390
;	O	390-391
7	O	392-393
men	O	394-397
,	O	397-398
3	O	399-400
women	O	401-406
)	O	406-407
with	O	408-412
similar	O	413-420
characteristics	O	421-436
at	O	437-439
the	O	440-443
duration	O	444-452
of	O	453-455
disease	O	456-463
(	O	464-465
mean	O	465-469
disease	O	470-477
time	O	478-482
,	O	482-483
8	O	484-485
.	O	485-486
4	O	486-487
+	O	488-489
/	O	489-490
-	O	490-491
3	O	492-493
.	O	493-494
5	O	494-495
years	O	496-501
)	O	501-502
,	O	502-503
disabling	O	504-513
motor	O	514-519
fluctuations	O	520-532
(	O	533-534
Hoehn	O	534-539
_	O	540-541
Yahr	O	542-546
stage	O	547-552
3	O	553-554
-	O	554-555
5	O	555-556
in	O	557-559
off	O	560-563
-	O	563-564
drug	O	564-568
phases	O	569-575
)	O	575-576
and	O	577-580
levodopa	O	581-589
-	O	589-590
induced	O	590-597
dyskinesias	B	598-609
were	O	610-614
selected	O	615-623
.	O	623-624

All	O	625-628
patients	O	629-637
had	O	638-641
bilateral	O	642-651
symptoms	O	652-660
and	O	661-664
their	O	665-670
levodopa	O	671-679
equivalent	O	680-690
dosing	O	691-697
were	O	698-702
analysed	O	703-711
.	O	711-712

Six	O	713-716
patients	O	717-725
were	O	726-730
operated	O	731-739
on	O	740-742
in	O	743-745
the	O	746-749
globus	O	750-756
pallidus	O	757-765
interna	O	766-773
(	O	774-775
GPi	O	775-778
)	O	778-779
and	O	780-783
four	O	784-788
in	O	789-791
the	O	792-795
subthalamic	O	796-807
nucleus	O	808-815
(	O	816-817
STN	O	817-820
)	O	820-821
.	O	821-822

Clinical	O	823-831
evaluation	O	832-842
included	O	843-851
the	O	852-855
use	O	856-859
of	O	860-862
the	O	863-866
Unified	O	867-874
Parkinson	B	875-884
'	I	884-885
s	I	881-882
Disease	I	887-894
Rating	O	895-901
Scale	O	902-907
(	O	908-909
UPDRS	O	909-914
)	O	914-915
,	O	915-916
Hoehn	O	917-922
_	O	922-923
Yahr	O	923-927
score	O	928-933
and	O	934-937
Schwab	O	938-944
England	O	945-952
activities	O	953-963
of	O	964-966
daily	O	967-972
living	O	973-979
(	O	980-981
ADL	O	981-984
)	O	984-985
score	O	986-991
in	O	992-994
'	O	995-996
on	O	996-998
'	O	995-996
-	O	999-1000
and	O	1001-1004
'	O	1005-1006
off	O	1006-1009
'	O	1005-1006
-	O	1010-1011
drug	O	1011-1015
conditions	O	1016-1026
before	O	1027-1033
surgery	O	1034-1041
and	O	1042-1045
6	O	1046-1047
months	O	1048-1054
after	O	1055-1060
surgery	O	1061-1068
.	O	1068-1069

There	O	1070-1075
was	O	1076-1079
statistically	O	1080-1093
significant	O	1094-1105
improvement	O	1106-1117
in	O	1118-1120
all	O	1121-1124
contralateral	O	1125-1138
major	O	1139-1144
parkinsonian	B	1145-1157
motor	O	1158-1163
signs	O	1164-1169
in	O	1170-1172
all	O	1173-1176
patients	O	1177-1185
followed	O	1186-1194
for	O	1195-1198
6	O	1199-1200
months	O	1201-1207
.	O	1207-1208

Levodopa	O	1209-1217
equivalent	O	1218-1228
daily	O	1229-1234
intake	O	1235-1241
was	O	1242-1245
significantly	O	1246-1259
reduced	O	1260-1267
in	O	1268-1270
the	O	1271-1274
STN	O	1275-1278
group	O	1279-1284
.	O	1284-1285

Changes	O	1286-1293
in	O	1294-1296
UPDRS	O	1297-1302
,	O	1302-1303
Hoehn	O	1304-1309
_	O	1310-1311
Yahr	O	1312-1316
and	O	1317-1320
Schwab	O	1321-1327
England	O	1328-1335
ADL	O	1336-1339
scores	O	1340-1346
were	O	1347-1351
similar	O	1352-1359
in	O	1360-1362
both	O	1363-1367
groups	O	1368-1374
.	O	1374-1375

Cognitive	O	1376-1385
functions	O	1386-1395
were	O	1396-1400
unchanged	O	1401-1410
in	O	1411-1413
both	O	1414-1418
groups	O	1419-1425
.	O	1425-1426

Complications	O	1427-1440
were	O	1441-1445
observed	O	1446-1454
in	O	1455-1457
two	O	1458-1461
patients	O	1462-1470
:	O	1470-1471
one	O	1472-1475
had	O	1476-1479
a	O	1480-1481
left	O	1482-1486
homonymous	B	1487-1497
hemianopsia	I	1498-1509
after	O	1510-1515
pallidotomy	O	1516-1527
and	O	1528-1531
another	O	1532-1539
one	O	1540-1543
developed	O	1544-1553
left	O	1554-1558
hemiballistic	O	1559-1572
movements	O	1573-1582
3	O	1583-1584
days	O	1585-1589
after	O	1590-1595
subthalamotomy	O	1596-1610
which	O	1611-1616
partly	O	1617-1623
improved	O	1624-1632
within	O	1633-1639
1	O	1640-1641
month	O	1642-1647
with	O	1648-1652
Valproate	O	1653-1662
1000	O	1663-1667
mg	O	1668-1670
/	O	1670-1671
day	O	1671-1674
.	O	1674-1675

The	O	1676-1679
findings	O	1680-1688
of	O	1689-1691
this	O	1692-1696
study	O	1697-1702
suggest	O	1703-1710
that	O	1711-1715
lesions	O	1716-1723
of	O	1724-1726
the	O	1727-1730
unilateral	O	1731-1741
STN	O	1742-1745
and	O	1746-1749
GPi	O	1750-1753
are	O	1754-1757
equally	O	1758-1765
effective	O	1766-1775
treatment	O	1776-1785
for	O	1786-1789
patients	O	1790-1798
with	O	1799-1803
advanced	O	1804-1812
PD	B	1813-1815
refractory	O	1816-1826
to	O	1827-1829
medical	O	1830-1837
treatment	O	1838-1847
.	O	1847-1848

Protective	O	0-10
effects	O	11-18
of	O	19-21
antithrombin	O	22-34
on	O	35-37
puromycin	O	38-47
aminonucleoside	O	48-63
nephrosis	B	64-73
in	O	74-76
rats	O	77-81
.	O	81-82

We	O	83-85
investigated	O	86-98
the	O	99-102
effects	O	103-110
of	O	111-113
antithrombin	O	114-126
,	O	126-127
a	O	128-129
plasma	O	130-136
inhibitor	O	137-146
of	O	147-149
coagulation	O	150-161
factors	O	162-169
,	O	169-170
in	O	171-173
rats	O	174-178
with	O	179-183
puromycin	O	184-193
aminonucleoside	O	194-209
-	O	209-210
induced	O	210-217
nephrosis	B	218-227
,	O	227-228
which	O	229-234
is	O	235-237
an	O	238-240
experimental	O	241-253
model	O	254-259
of	O	260-262
human	O	263-268
nephrotic	B	269-278
syndrome	I	279-287
.	O	287-288

Antithrombin	O	289-301
(	O	302-303
50	O	303-305
or	O	306-308
500	O	309-312
IU	O	313-315
/	O	315-316
kg	O	316-318
/	O	315-316
i	O	319-320
.	O	320-321
v	O	321-322
.	O	320-321
)	O	323-324
was	O	325-328
administered	O	329-341
to	O	342-344
rats	O	345-349
once	O	350-354
a	O	355-356
day	O	357-360
for	O	361-364
10	O	365-367
days	O	368-372
immediately	O	373-384
after	O	385-390
the	O	391-394
injection	O	395-404
of	O	405-407
puromycin	O	408-417
aminonucleoside	O	418-433
(	O	434-435
50	O	435-437
mg	O	438-440
/	O	440-441
kg	O	441-443
/	O	440-441
i	O	444-445
.	O	445-446
v	O	446-447
.	O	445-446
)	O	448-449
.	O	445-446

Treatment	O	451-460
with	O	461-465
antithrombin	O	466-478
attenuated	O	479-489
the	O	490-493
puromycin	O	494-503
aminonucleoside	O	504-519
-	O	519-520
induced	O	520-527
hematological	B	528-541
abnormalities	I	542-555
.	O	555-556

Puromycin	O	557-566
aminonucleoside	O	567-582
-	O	582-583
induced	O	583-590
renal	B	591-596
dysfunction	I	597-608
and	O	609-612
hyperlipidemia	B	613-627
were	O	628-632
also	O	633-637
suppressed	O	638-648
.	O	648-649

Histopathological	O	650-667
examination	O	668-679
revealed	O	680-688
severe	O	689-695
renal	B	696-701
damage	I	702-708
such	O	709-713
as	O	714-716
proteinaceous	O	717-730
casts	O	731-736
in	O	737-739
tubuli	O	740-746
and	O	747-750
tubular	O	751-758
expansion	O	759-768
in	O	769-771
the	O	772-775
kidney	O	776-782
of	O	783-785
control	O	786-793
rats	O	794-798
,	O	798-799
while	O	800-805
an	O	806-808
improvement	O	809-820
of	O	821-823
the	O	824-827
damage	O	828-834
was	O	835-838
seen	O	839-843
in	O	844-846
antithrombin	O	847-859
-	O	859-860
treated	O	860-867
rats	O	868-872
.	O	872-873

In	O	874-876
addition	O	877-885
,	O	885-886
antithrombin	O	887-899
treatment	O	900-909
markedly	O	910-918
suppressed	O	919-929
puromycin	O	930-939
aminonucleoside	O	940-955
-	O	955-956
induced	O	956-963
apoptosis	O	964-973
of	O	974-976
renal	O	977-982
tubular	O	983-990
epithelial	O	991-1001
cells	O	1002-1007
.	O	1007-1008

Furthermore	O	1009-1020
,	O	1020-1021
puromycin	O	1022-1031
aminonucleoside	O	1032-1047
-	O	1047-1048
induced	O	1048-1055
increases	O	1056-1065
in	O	1066-1068
renal	O	1069-1074
cytokine	O	1075-1083
content	O	1084-1091
were	O	1092-1096
also	O	1097-1101
decreased	O	1102-1111
.	O	1111-1112

These	O	1113-1118
findings	O	1119-1127
suggest	O	1128-1135
that	O	1136-1140
thrombin	O	1141-1149
plays	O	1150-1155
an	O	1156-1158
important	O	1159-1168
role	O	1169-1173
in	O	1174-1176
the	O	1177-1180
pathogenesis	O	1181-1193
of	O	1194-1196
puromycin	O	1197-1206
aminonucleoside	O	1207-1222
-	O	1222-1223
induced	O	1223-1230
nephrotic	B	1231-1240
syndrome	I	1241-1249
.	O	1249-1250

Treatment	O	1251-1260
with	O	1261-1265
antithrombin	O	1266-1278
may	O	1279-1282
be	O	1283-1285
clinically	O	1286-1296
effective	O	1297-1306
in	O	1307-1309
patients	O	1310-1318
with	O	1319-1323
nephrotic	B	1324-1333
syndrome	I	1334-1342
.	O	1342-1343

Reverse	O	0-7
or	O	8-10
inverted	O	11-19
left	B	20-24
ventricular	I	25-36
apical	I	37-43
ballooning	I	44-54
syndrome	I	55-63
(	O	64-65
reverse	O	65-72
Takotsubo	B	73-82
cardiomyopathy	I	83-97
)	O	97-98
in	O	99-101
a	O	102-103
young	O	104-109
woman	O	110-115
in	O	116-118
the	O	119-122
setting	O	123-130
of	O	131-133
amphetamine	O	134-145
use	O	146-149
.	O	149-150

Transient	O	151-160
left	B	161-165
ventricular	I	166-177
apical	I	178-184
ballooning	I	185-195
syndrome	I	196-204
was	O	205-208
first	O	209-214
described	O	215-224
in	O	225-227
Japan	O	228-233
as	O	234-236
"	O	237-238
Takotsubo	B	238-247
cardiomyopathy	I	248-262
.	O	262-263
"	O	263-264

This	O	265-269
syndrome	O	270-278
has	O	279-282
been	O	283-287
identified	O	288-298
in	O	299-301
many	O	302-306
other	O	307-312
countries	O	313-322
.	O	322-323

Many	O	324-328
variations	O	329-339
of	O	340-342
this	O	343-347
syndrome	O	348-356
have	O	357-361
been	O	362-366
recently	O	367-375
described	O	376-385
in	O	386-388
the	O	389-392
literature	O	393-403
.	O	403-404

One	O	405-408
of	O	409-411
the	O	412-415
rarest	O	416-422
is	O	423-425
the	O	426-429
reverse	O	430-437
type	O	438-442
of	O	443-445
this	O	446-450
syndrome	O	451-459
,	O	459-460
with	O	461-465
hyperdynamic	O	466-478
apex	O	479-483
and	O	484-487
complete	O	488-496
akinesia	B	497-505
of	O	506-508
the	O	509-512
base	O	513-517
(	O	518-519
as	O	519-521
opposed	O	522-529
to	O	530-532
the	O	533-536
classic	O	537-544
apical	B	545-551
ballooning	I	552-562
)	O	562-563
.	O	563-564

In	O	565-567
this	O	568-572
article	O	573-580
,	O	580-581
we	O	582-584
report	O	585-591
an	O	592-594
interesting	O	595-606
case	O	607-611
of	O	612-614
a	O	615-616
young	O	617-622
woman	O	623-628
who	O	629-632
presented	O	633-642
with	O	643-647
this	O	648-652
rare	O	653-657
type	O	658-662
of	O	663-665
reverse	O	666-673
apical	B	674-680
ballooning	I	681-691
syndrome	I	692-700
occurring	O	701-710
after	O	711-716
amphetamine	O	717-728
use	O	729-732
.	O	732-733

This	O	734-738
report	O	739-745
is	O	746-748
followed	O	749-757
by	O	758-760
review	O	761-767
of	O	768-770
the	O	771-774
literature	O	775-785
.	O	785-786

Attenuated	O	0-10
disruption	O	11-21
of	O	22-24
prepulse	O	25-33
inhibition	O	34-44
by	O	45-47
dopaminergic	O	48-60
stimulation	O	61-72
after	O	73-78
maternal	O	79-87
deprivation	O	88-99
and	O	100-103
adolescent	O	104-114
corticosterone	O	115-129
treatment	O	130-139
in	O	140-142
rats	O	143-147
.	O	147-148

The	O	149-152
development	O	153-164
of	O	165-167
schizophrenia	B	168-181
may	O	182-185
include	O	186-193
an	O	194-196
early	O	197-202
neurodevelopmental	O	203-221
stress	O	222-228
component	O	229-238
which	O	239-244
increases	O	245-254
vulnerability	O	255-268
to	O	269-271
later	O	272-277
stressful	O	278-287
life	O	288-292
events	O	293-299
,	O	299-300
in	O	301-303
combination	O	304-315
leading	O	316-323
to	O	324-326
overt	O	327-332
disease	O	333-340
.	O	340-341

We	O	342-344
investigated	O	345-357
the	O	358-361
effect	O	362-368
of	O	369-371
an	O	372-374
early	O	375-380
stress	O	381-387
,	O	387-388
in	O	389-391
the	O	392-395
form	O	396-400
of	O	401-403
maternal	O	404-412
deprivation	O	413-424
,	O	424-425
combined	O	426-434
with	O	435-439
a	O	440-441
later	O	442-447
stress	O	448-454
,	O	454-455
simulated	O	456-465
by	O	466-468
chronic	O	469-476
periadolescent	O	477-491
corticosterone	O	492-506
treatment	O	507-516
,	O	516-517
on	O	518-520
behaviour	O	521-530
in	O	531-533
rats	O	534-538
.	O	538-539

Acute	O	540-545
treatment	O	546-555
with	O	556-560
apomorphine	O	561-572
caused	O	573-579
disruption	O	580-590
of	O	591-593
prepulse	O	594-602
inhibition	O	603-613
(	O	614-615
PPI	O	615-618
)	O	618-619
in	O	620-622
controls	O	623-631
and	O	632-635
in	O	636-638
rats	O	639-643
that	O	644-648
had	O	649-652
undergone	O	653-662
either	O	663-669
maternal	O	670-678
deprivation	O	679-690
or	O	691-693
corticosterone	O	694-708
treatment	O	709-718
,	O	718-719
but	O	720-723
was	O	724-727
surprisingly	O	728-740
absent	O	741-747
in	O	748-750
rats	O	751-755
that	O	756-760
had	O	761-764
undergone	O	765-774
the	O	775-778
combined	O	779-787
early	O	788-793
and	O	794-797
late	O	798-802
stress	O	803-809
.	O	809-810

Amphetamine	O	811-822
treatment	O	823-832
significantly	O	833-846
disrupted	O	847-856
PPI	O	857-860
in	O	861-863
both	O	864-868
non	O	869-872
-	O	872-873
deprived	O	873-881
groups	O	882-888
,	O	888-889
but	O	890-893
was	O	894-897
absent	O	898-904
in	O	905-907
both	O	908-912
maternally	O	913-923
deprived	O	924-932
groups	O	933-939
.	O	939-940

The	O	941-944
serotonin	O	945-954
-	O	954-955
1A	O	955-957
receptor	O	958-966
agonist	O	967-974
,	O	974-975
8	O	976-977
-	O	977-978
OH	O	978-980
-	O	977-978
DPAT	O	981-985
,	O	985-986
induced	O	987-994
a	O	995-996
significant	O	997-1008
disruption	O	1009-1019
of	O	1020-1022
PPI	O	1023-1026
in	O	1027-1029
all	O	1030-1033
groups	O	1034-1040
.	O	1040-1041

Amphetamine	O	1042-1053
-	O	1053-1054
induced	O	1054-1061
locomotor	B	1062-1071
hyperactivity	I	1072-1085
was	O	1086-1089
similar	O	1090-1097
in	O	1098-1100
all	O	1101-1104
groups	O	1105-1111
.	O	1111-1112

These	O	1113-1118
results	O	1119-1126
show	O	1127-1131
an	O	1132-1134
inhibitory	O	1135-1145
interaction	O	1146-1157
of	O	1158-1160
early	O	1161-1166
stress	O	1167-1173
,	O	1173-1174
caused	O	1175-1181
by	O	1182-1184
maternal	O	1185-1193
deprivation	O	1194-1205
,	O	1205-1206
combined	O	1207-1215
with	O	1216-1220
'	O	1221-1222
adolescent	O	1222-1232
'	O	1221-1222
stress	O	1234-1240
,	O	1240-1241
simulated	O	1242-1251
by	O	1252-1254
corticosterone	O	1255-1269
treatment	O	1270-1279
,	O	1279-1280
on	O	1281-1283
dopaminergic	O	1284-1296
regulation	O	1297-1307
of	O	1308-1310
PPI	O	1311-1314
.	O	1314-1315

The	O	1316-1319
altered	O	1320-1327
effects	O	1328-1335
of	O	1336-1338
apomorphine	O	1339-1350
and	O	1351-1354
amphetamine	O	1355-1366
could	O	1367-1372
indicate	O	1373-1381
differential	O	1382-1394
changes	O	1395-1402
in	O	1403-1405
dopamine	O	1406-1414
receptor	O	1415-1423
signalling	O	1424-1434
leading	O	1435-1442
to	O	1443-1445
functional	O	1446-1456
desensitisation	O	1457-1472
,	O	1472-1473
or	O	1474-1476
altered	O	1477-1484
modulation	O	1485-1495
of	O	1496-1498
sensory	O	1499-1506
gating	O	1507-1513
in	O	1514-1516
the	O	1517-1520
nucleus	O	1521-1528
accumbens	O	1529-1538
by	O	1539-1541
limbic	O	1542-1548
structures	O	1549-1559
such	O	1560-1564
as	O	1565-1567
the	O	1568-1571
hippocampus	O	1572-1583
.	O	1583-1584

Peripheral	O	0-10
iron	O	11-15
dextran	O	16-23
induced	O	24-31
degeneration	B	32-44
of	I	45-47
dopaminergic	I	48-60
neurons	I	61-68
in	O	69-71
rat	O	72-75
substantia	O	76-86
nigra	O	87-92
.	O	92-93

Iron	O	94-98
accumulation	O	99-111
is	O	112-114
considered	O	115-125
to	O	126-128
be	O	129-131
involved	O	132-140
in	O	141-143
the	O	144-147
pathogenesis	O	148-160
of	O	161-163
Parkinson	B	164-173
'	I	173-174
s	I	170-171
disease	I	176-183
.	O	183-184

To	O	185-187
demonstrate	O	188-199
the	O	200-203
relationship	O	204-216
between	O	217-224
peripheral	O	225-235
iron	O	236-240
overload	O	241-249
and	O	250-253
dopaminergic	O	254-266
neuron	O	267-273
loss	O	274-278
in	O	279-281
rat	O	282-285
substantia	O	286-296
nigra	O	297-302
(	O	303-304
SN	O	304-306
)	O	306-307
,	O	307-308
in	O	309-311
the	O	312-315
present	O	316-323
study	O	324-329
we	O	330-332
used	O	333-337
fast	O	338-342
cyclic	O	343-349
voltammetry	O	350-361
,	O	361-362
tyrosine	O	363-371
hydroxylase	O	372-383
(	O	384-385
TH	O	385-387
)	O	387-388
immunohistochemistry	O	389-409
,	O	409-410
Perls	O	411-416
'	O	416-417
iron	O	418-422
staining	O	423-431
,	O	431-432
and	O	433-436
high	O	437-441
performance	O	442-453
liquid	O	454-460
chromatography	O	461-475
-	O	475-476
electrochemical	O	476-491
detection	O	492-501
to	O	502-504
study	O	505-510
the	O	511-514
degeneration	B	515-527
of	I	528-530
dopaminergic	I	531-543
neurons	I	544-551
and	O	552-555
increased	O	556-565
iron	O	566-570
content	O	571-578
in	O	579-581
the	O	582-585
SN	O	586-588
of	O	589-591
iron	O	592-596
dextran	O	597-604
overloaded	O	605-615
animals	O	616-623
.	O	623-624

The	O	625-628
findings	O	629-637
showed	O	638-644
that	O	645-649
peripheral	O	650-660
iron	O	661-665
dextran	O	666-673
overload	O	674-682
increased	O	683-692
the	O	693-696
iron	O	697-701
staining	O	702-710
positive	O	711-719
cells	O	720-725
and	O	726-729
reduced	O	730-737
the	O	738-741
number	O	742-748
of	O	749-751
TH	O	752-754
-	O	754-755
immunoreactive	O	755-769
neurons	O	770-777
in	O	778-780
the	O	781-784
SN	O	785-787
.	O	787-788

As	O	789-791
a	O	792-793
result	O	794-800
,	O	800-801
dopamine	O	802-810
release	O	811-818
and	O	819-822
content	O	823-830
,	O	830-831
as	O	832-834
well	O	835-839
as	O	840-842
its	O	843-846
metabolites	O	847-858
contents	O	859-867
were	O	868-872
decreased	O	873-882
in	O	883-885
caudate	O	886-893
putamen	O	894-901
.	O	901-902

Even	O	903-907
more	O	908-912
dramatic	O	913-921
changes	O	922-929
were	O	930-934
found	O	935-940
in	O	941-943
chronic	O	944-951
overload	O	952-960
group	O	961-966
.	O	966-967

These	O	968-973
results	O	974-981
suggest	O	982-989
that	O	990-994
peripheral	O	995-1005
iron	O	1006-1010
dextran	O	1011-1018
can	O	1019-1022
increase	O	1023-1031
the	O	1032-1035
iron	O	1036-1040
level	O	1041-1046
in	O	1047-1049
the	O	1050-1053
SN	O	1054-1056
,	O	1056-1057
where	O	1058-1063
excessive	O	1064-1073
iron	O	1074-1078
causes	O	1079-1085
the	O	1086-1089
degeneration	B	1090-1102
of	I	1103-1105
dopaminergic	I	1106-1118
neurons	I	1119-1126
.	O	1126-1127

The	O	1128-1131
chronic	O	1132-1139
iron	O	1140-1144
overload	O	1145-1153
may	O	1154-1157
be	O	1158-1160
more	O	1161-1165
destructive	O	1166-1177
to	O	1178-1180
dopaminergic	O	1181-1193
neurons	O	1194-1201
than	O	1202-1206
the	O	1207-1210
acute	O	1211-1216
iron	O	1217-1221
overload	O	1222-1230
.	O	1230-1231

Warfarin	O	0-8
-	O	8-9
induced	O	9-16
leukocytoclastic	B	17-33
vasculitis	I	34-44
.	O	44-45

Skin	O	46-50
reactions	O	51-60
associated	O	61-71
with	O	72-76
oral	O	77-81
coumarin	O	82-90
-	O	90-91
derived	O	91-98
anticoagulants	O	99-113
are	O	114-117
an	O	118-120
uncommon	O	121-129
occurrence	O	130-140
.	O	140-141

Leukocytoclastic	B	142-158
vasculitis	I	159-169
(	O	170-171
LV	B	171-173
)	O	173-174
is	O	175-177
primarily	O	178-187
a	O	188-189
cutaneous	B	190-199
small	I	200-205
vessel	I	206-212
vasculitis	I	213-223
,	O	223-224
though	O	225-231
systemic	O	232-240
involvement	O	241-252
may	O	253-256
be	O	257-259
encountered	O	260-271
.	O	271-272

We	O	273-275
report	O	276-282
4	O	283-284
patients	O	285-293
with	O	294-298
late	O	299-303
-	O	303-304
onset	O	304-309
LV	B	310-312
probably	O	313-321
due	O	322-325
to	O	326-328
warfarin	O	329-337
.	O	337-338

All	O	339-342
4	O	343-344
patients	O	345-353
presented	O	354-363
with	O	364-368
skin	B	369-373
eruptions	I	374-383
that	O	384-388
developed	O	389-398
after	O	399-404
receiving	O	405-414
warfarin	O	415-423
for	O	424-427
several	O	428-435
years	O	436-441
.	O	441-442

The	O	443-446
results	O	447-454
of	O	455-457
skin	B	458-462
lesion	I	463-469
biopsies	O	470-478
were	O	479-483
available	O	484-493
in	O	494-496
3	O	497-498
patients	O	499-507
,	O	507-508
confirming	O	509-519
LV	B	520-522
Cutaneous	I	523-532
lesions	I	533-540
resolved	O	541-549
in	O	550-552
all	O	553-556
patients	O	557-565
after	O	566-571
warfarin	O	572-580
was	O	581-584
discontinued	O	585-597
.	O	597-598

In	O	599-601
2	O	602-603
of	O	604-606
the	O	607-610
4	O	611-612
patients	O	613-621
,	O	621-622
rechallenge	O	623-634
with	O	635-639
warfarin	O	640-648
led	O	649-652
to	O	653-655
recurrence	O	656-666
of	O	667-669
the	O	670-673
lesions	O	674-681
.	O	681-682

LV	B	683-685
may	O	686-689
be	O	690-692
a	O	693-694
late	O	695-699
-	O	699-700
onset	O	700-705
adverse	O	706-713
reaction	O	714-722
associated	O	723-733
with	O	734-738
warfarin	O	739-747
therapy	O	748-755
.	O	755-756

The	O	0-3
activation	O	4-14
of	O	15-17
spinal	O	18-24
N	O	25-26
-	O	26-27
methyl	O	27-33
-	O	26-27
D	O	34-35
-	O	26-27
aspartate	O	36-45
receptors	O	46-55
may	O	56-59
contribute	O	60-70
to	O	71-73
degeneration	O	74-86
of	O	87-89
spinal	O	90-96
motor	O	97-102
neurons	O	103-110
induced	O	111-118
by	O	119-121
neuraxial	O	122-131
morphine	O	132-140
after	O	141-146
a	O	147-148
noninjurious	O	149-161
interval	O	162-170
of	O	171-173
spinal	B	174-180
cord	I	181-185
ischemia	I	186-194
.	O	194-195

We	O	196-198
investigated	O	199-211
the	O	212-215
relationship	O	216-228
between	O	229-236
the	O	237-240
degeneration	O	241-253
of	O	254-256
spinal	O	257-263
motor	O	264-269
neurons	O	270-277
and	O	278-281
activation	O	282-292
of	O	293-295
N	O	296-297
-	O	297-298
methyl	O	298-304
-	O	297-298
d	O	305-306
-	O	297-298
aspartate	O	307-316
(	O	317-318
NMDA	O	318-322
)	O	322-323
receptors	O	324-333
after	O	334-339
neuraxial	O	340-349
morphine	O	350-358
following	O	359-368
a	O	369-370
noninjurious	O	371-383
interval	O	384-392
of	O	393-395
aortic	B	396-402
occlusion	I	403-412
in	O	413-415
rats	O	416-420
.	O	420-421

Spinal	B	422-428
cord	I	429-433
ischemia	I	434-442
was	O	443-446
induced	O	447-454
by	O	455-457
aortic	B	458-464
occlusion	I	465-474
for	O	475-478
6	O	479-480
min	O	481-484
with	O	485-489
a	O	490-491
balloon	O	492-499
catheter	O	500-508
.	O	508-509

In	O	510-512
a	O	513-514
microdialysis	O	515-528
study	O	529-534
,	O	534-535
10	O	536-538
muL	O	539-542
of	O	543-545
saline	O	546-552
(	O	553-554
group	O	554-559
C	O	560-561
;	O	561-562
n	O	563-564
=	O	565-566
8	O	567-568
)	O	568-569
or	O	570-572
30	O	573-575
mug	O	576-579
of	O	580-582
morphine	O	583-591
(	O	592-593
group	O	593-598
M	O	599-600
;	O	600-601
n	O	602-603
=	O	604-605
8	O	606-607
)	O	607-608
was	O	609-612
injected	O	613-621
intrathecally	O	622-635
(	O	636-637
IT	O	637-639
)	O	639-640
0	O	641-642
.	O	642-643
5	O	643-644
h	O	645-646
after	O	647-652
reflow	O	653-659
,	O	659-660
and	O	661-664
30	O	665-667
mug	O	668-671
of	O	672-674
morphine	O	675-683
(	O	684-685
group	O	685-690
SM	O	691-693
;	O	693-694
n	O	695-696
=	O	697-698
8	O	699-700
)	O	700-701
or	O	702-704
10	O	705-707
muL	O	708-711
of	O	712-714
saline	O	715-721
(	O	722-723
group	O	723-728
SC	O	729-731
;	O	731-732
n	O	733-734
=	O	735-736
8	O	737-738
)	O	738-739
was	O	740-743
injected	O	744-752
IT	O	753-755
0	O	756-757
.	O	757-758
5	O	758-759
h	O	760-761
after	O	762-767
sham	O	768-772
operation	O	773-782
.	O	782-783

Microdialysis	O	784-797
samples	O	798-805
were	O	806-810
collected	O	811-820
preischemia	O	821-832
,	O	832-833
before	O	834-840
IT	O	841-843
injection	O	844-853
,	O	853-854
and	O	855-858
at	O	859-861
2	O	862-863
,	O	863-864
4	O	865-866
,	O	866-867
8	O	868-869
,	O	869-870
24	O	871-873
,	O	873-874
and	O	875-878
48	O	879-881
h	O	882-883
of	O	884-886
reperfusion	O	887-898
(	O	899-900
after	O	900-905
IT	O	906-908
injection	O	909-918
)	O	918-919
.	O	919-920

Second	O	921-927
,	O	927-928
we	O	929-931
investigated	O	932-944
the	O	945-948
effect	O	949-955
of	O	956-958
IT	O	959-961
MK	O	962-964
-	O	964-965
801	O	965-968
(	O	969-970
30	O	970-972
mug	O	973-976
)	O	976-977
on	O	978-980
the	O	981-984
histopathologic	O	985-1000
changes	O	1001-1008
in	O	1009-1011
the	O	1012-1015
spinal	O	1016-1022
cord	O	1023-1027
after	O	1028-1033
morphine	O	1034-1042
-	O	1042-1043
induced	O	1043-1050
spastic	B	1051-1058
paraparesis	I	1059-1070
.	O	1070-1071

After	O	1072-1077
IT	O	1078-1080
morphine	O	1081-1089
,	O	1089-1090
the	O	1091-1094
cerebrospinal	O	1095-1108
fluid	O	1109-1114
(	O	1115-1116
CSF	O	1116-1119
)	O	1119-1120
glutamate	O	1121-1130
concentration	O	1131-1144
was	O	1145-1148
increased	O	1149-1158
in	O	1159-1161
group	O	1162-1167
M	O	1168-1169
relative	O	1170-1178
to	O	1179-1181
both	O	1182-1186
baseline	O	1187-1195
and	O	1196-1199
group	O	1200-1205
C	O	1206-1207
(	O	1208-1209
P	O	1209-1210
<	O	1211-1212
0	O	1213-1214
.	O	1214-1215
05	O	1215-1217
)	O	1217-1218
.	O	1214-1215

This	O	1220-1224
increase	O	1225-1233
persisted	O	1234-1243
for	O	1244-1247
8	O	1248-1249
hrs	O	1250-1253
.	O	1253-1254

IT	O	1255-1257
MK	O	1258-1260
-	O	1260-1261
801	O	1261-1264
significantly	O	1265-1278
reduced	O	1279-1286
the	O	1287-1290
number	O	1291-1297
of	O	1298-1300
dark	O	1301-1305
-	O	1305-1306
stained	O	1306-1313
alpha	O	1314-1319
-	O	1319-1320
motoneurons	O	1320-1331
after	O	1332-1337
morphine	O	1338-1346
-	O	1346-1347
induced	O	1347-1354
spastic	B	1355-1362
paraparesis	I	1363-1374
compared	O	1375-1383
with	O	1384-1388
the	O	1389-1392
saline	O	1393-1399
group	O	1400-1405
.	O	1405-1406

These	O	1407-1412
data	O	1413-1417
indicate	O	1418-1426
that	O	1427-1431
IT	O	1432-1434
morphine	O	1435-1443
induces	O	1444-1451
spastic	B	1452-1459
paraparesis	I	1460-1471
with	O	1472-1476
a	O	1477-1478
concomitant	O	1479-1490
increase	O	1491-1499
in	O	1500-1502
CSF	O	1503-1506
glutamate	O	1507-1516
,	O	1516-1517
which	O	1518-1523
is	O	1524-1526
involved	O	1527-1535
in	O	1536-1538
NMDA	O	1539-1543
receptor	O	1544-1552
activation	O	1553-1563
.	O	1563-1564

We	O	1565-1567
suggest	O	1568-1575
that	O	1576-1580
opioids	O	1581-1588
may	O	1589-1592
be	O	1593-1595
neurotoxic	B	1596-1606
in	O	1607-1609
the	O	1610-1613
setting	O	1614-1621
of	O	1622-1624
spinal	B	1625-1631
cord	I	1632-1636
ischemia	I	1637-1645
via	O	1646-1649
NMDA	O	1650-1654
receptor	O	1655-1663
activation	O	1664-1674
.	O	1674-1675

Reduced	O	0-7
sodium	O	8-14
channel	O	15-22
density	O	23-30
,	O	30-31
altered	O	32-39
voltage	O	40-47
dependence	O	48-58
of	O	59-61
inactivation	O	62-74
,	O	74-75
and	O	76-79
increased	O	80-89
susceptibility	O	90-104
to	O	105-107
seizures	B	108-116
in	O	117-119
mice	O	120-124
lacking	O	125-132
sodium	O	133-139
channel	O	140-147
beta	O	148-152
2	O	153-154
-	O	154-155
subunits	O	155-163
.	O	163-164

Sodium	O	165-171
channel	O	172-179
beta	O	180-184
-	O	184-185
subunits	O	185-193
modulate	O	194-202
channel	O	203-210
gating	O	211-217
,	O	217-218
assembly	O	219-227
,	O	227-228
and	O	229-232
cell	O	233-237
surface	O	238-245
expression	O	246-256
in	O	257-259
heterologous	O	260-272
cell	O	273-277
systems	O	278-285
.	O	285-286

We	O	287-289
generated	O	290-299
beta2	O	300-305
(	O	305-306
-	O	306-307
/	O	307-308
-	O	306-307
)	O	309-310
mice	O	311-315
to	O	316-318
investigate	O	319-330
the	O	331-334
role	O	335-339
of	O	340-342
beta2	O	343-348
in	O	349-351
control	O	352-359
of	O	360-362
sodium	O	363-369
channel	O	370-377
density	O	378-385
,	O	385-386
localization	O	387-399
,	O	399-400
and	O	401-404
function	O	405-413
in	O	414-416
neurons	O	417-424
in	O	425-427
vivo	O	428-432
.	O	432-433

Measurements	O	434-446
of	O	447-449
[	O	450-451
(	O	451-452
3	O	452-453
)	O	453-454
H	O	454-455
]	O	455-456
saxitoxin	O	456-465
(	O	466-467
STX	O	467-470
)	O	470-471
binding	O	472-479
showed	O	480-486
a	O	487-488
significant	O	489-500
reduction	O	501-510
in	O	511-513
the	O	514-517
level	O	518-523
of	O	524-526
plasma	O	527-533
membrane	O	534-542
sodium	O	543-549
channels	O	550-558
in	O	559-561
beta2	O	562-567
(	O	567-568
-	O	568-569
/	O	569-570
-	O	568-569
)	O	571-572
neurons	O	573-580
.	O	580-581

The	O	582-585
loss	O	586-590
of	O	591-593
beta2	O	594-599
resulted	O	600-608
in	O	609-611
negative	O	612-620
shifts	O	621-627
in	O	628-630
the	O	631-634
voltage	O	635-642
dependence	O	643-653
of	O	654-656
inactivation	O	657-669
as	O	670-672
well	O	673-677
as	O	678-680
significant	O	681-692
decreases	O	693-702
in	O	703-705
sodium	O	706-712
current	O	713-720
density	O	721-728
in	O	729-731
acutely	O	732-739
dissociated	O	740-751
hippocampal	O	752-763
neurons	O	764-771
.	O	771-772

The	O	773-776
integral	O	777-785
of	O	786-788
the	O	789-792
compound	O	793-801
action	O	802-808
potential	O	809-818
in	O	819-821
optic	O	822-827
nerve	O	828-833
was	O	834-837
significantly	O	838-851
reduced	O	852-859
,	O	859-860
and	O	861-864
the	O	865-868
threshold	O	869-878
for	O	879-882
action	O	883-889
potential	O	890-899
generation	O	900-910
was	O	911-914
increased	O	915-924
,	O	924-925
indicating	O	926-936
a	O	937-938
reduction	O	939-948
in	O	949-951
the	O	952-955
level	O	956-961
of	O	962-964
functional	O	965-975
plasma	O	976-982
membrane	O	983-991
sodium	O	992-998
channels	O	999-1007
.	O	1007-1008

In	O	1009-1011
contrast	O	1012-1020
,	O	1020-1021
the	O	1022-1025
conduction	O	1026-1036
velocity	O	1037-1045
,	O	1045-1046
the	O	1047-1050
number	O	1051-1057
and	O	1058-1061
size	O	1062-1066
of	O	1067-1069
axons	O	1070-1075
in	O	1076-1078
the	O	1079-1082
optic	O	1083-1088
nerve	O	1089-1094
,	O	1094-1095
and	O	1096-1099
the	O	1100-1103
specific	O	1104-1112
localization	O	1113-1125
of	O	1126-1128
Na	O	1129-1131
(	O	1131-1132
v	O	1132-1133
)	O	1133-1134
1	O	1134-1135
.	O	1135-1136
6	O	1136-1137
channels	O	1138-1146
in	O	1147-1149
the	O	1150-1153
nodes	O	1154-1159
of	O	1160-1162
Ranvier	O	1163-1170
were	O	1171-1175
unchanged	O	1176-1185
.	O	1185-1186

beta2	O	1187-1192
(	O	1192-1193
-	O	1193-1194
/	O	1194-1195
-	O	1193-1194
)	O	1196-1197
mice	O	1198-1202
displayed	O	1203-1212
increased	O	1213-1222
susceptibility	O	1223-1237
to	O	1238-1240
seizures	B	1241-1249
,	O	1249-1250
as	O	1251-1253
indicated	O	1254-1263
by	O	1264-1266
reduced	O	1267-1274
latency	O	1275-1282
and	O	1283-1286
threshold	O	1287-1296
for	O	1297-1300
pilocarpine	O	1301-1312
-	O	1312-1313
induced	O	1313-1320
seizures	B	1321-1329
,	O	1329-1330
but	O	1331-1334
seemed	O	1335-1341
normal	O	1342-1348
in	O	1349-1351
other	O	1352-1357
neurological	O	1358-1370
tests	O	1371-1376
.	O	1376-1377

Our	O	1378-1381
observations	O	1382-1394
show	O	1395-1399
that	O	1400-1404
beta2	O	1405-1410
-	O	1410-1411
subunits	O	1411-1419
play	O	1420-1424
an	O	1425-1427
important	O	1428-1437
role	O	1438-1442
in	O	1443-1445
the	O	1446-1449
regulation	O	1450-1460
of	O	1461-1463
sodium	O	1464-1470
channel	O	1471-1478
density	O	1479-1486
and	O	1487-1490
function	O	1491-1499
in	O	1500-1502
neurons	O	1503-1510
in	O	1511-1513
vivo	O	1514-1518
and	O	1519-1522
are	O	1523-1526
required	O	1527-1535
for	O	1536-1539
normal	O	1540-1546
action	O	1547-1553
potential	O	1554-1563
generation	O	1564-1574
and	O	1575-1578
control	O	1579-1586
of	O	1587-1589
excitability	O	1590-1602
.	O	1602-1603

Screening	O	0-9
for	O	10-13
stimulant	O	14-23
use	O	24-27
in	O	28-30
adult	O	31-36
emergency	O	37-46
department	O	47-57
seizure	B	58-65
patients	O	66-74
.	O	74-75

OBJECTIVE	O	76-85
:	O	85-86
The	O	87-90
objective	O	91-100
of	O	101-103
this	O	104-108
study	O	109-114
was	O	115-118
to	O	119-121
determine	O	122-131
the	O	132-135
prevalence	O	136-146
of	O	147-149
positive	O	150-158
plasma	O	159-165
drug	O	166-170
screening	O	171-180
for	O	181-184
cocaine	O	185-192
or	O	193-195
amphetamine	O	196-207
in	O	208-210
adult	O	211-216
emergency	O	217-226
department	O	227-237
seizure	B	238-245
patients	O	246-254
.	O	254-255

METHODS	O	256-263
:	O	263-264
This	O	265-269
prospective	O	270-281
study	O	282-287
evaluated	O	288-297
consecutive	O	298-309
eligible	O	310-318
seizure	B	319-326
patients	O	327-335
who	O	336-339
had	O	340-343
a	O	344-345
plasma	O	346-352
sample	O	353-359
collected	O	360-369
as	O	370-372
part	O	373-377
of	O	378-380
their	O	381-386
clinical	O	387-395
evaluation	O	396-406
.	O	406-407

Plasma	O	408-414
was	O	415-418
tested	O	419-425
for	O	426-429
amphetamine	O	430-441
and	O	442-445
the	O	446-449
cocaine	O	450-457
metabolite	O	458-468
benzoylecgonine	O	469-484
using	O	485-490
enzyme	O	491-497
-	O	497-498
mediated	O	498-506
immunoassay	O	507-518
methodology	O	519-530
.	O	530-531

Plasma	O	532-538
samples	O	539-546
with	O	547-551
benzoylecgonine	O	552-567
greater	O	568-575
than	O	576-580
150	O	581-584
ng	O	585-587
/	O	587-588
mL	O	588-590
or	O	591-593
an	O	594-596
amphetamine	O	597-608
greater	O	609-616
than	O	617-621
500	O	622-625
ng	O	626-628
/	O	628-629
mL	O	629-631
were	O	632-636
defined	O	637-644
as	O	645-647
positive	O	648-656
.	O	656-657

Patient	O	658-665
demographics	O	666-678
,	O	678-679
history	O	680-687
of	O	688-690
underlying	O	691-701
drug	O	702-706
or	O	707-709
alcohol	O	710-717
-	O	717-718
related	O	718-725
seizure	B	726-733
disorder	O	734-742
,	O	742-743
estimated	O	744-753
time	O	754-758
from	O	759-763
seizure	B	764-771
to	O	772-774
sample	O	775-781
collection	O	782-792
,	O	792-793
history	O	794-801
or	O	802-804
suspicion	O	805-814
of	O	815-817
cocaine	B	818-825
or	I	826-828
amphetamine	I	829-840
abuse	I	841-846
,	O	846-847
results	O	848-855
of	O	856-858
clinical	O	859-867
urine	O	868-873
testing	O	874-881
for	O	882-885
drugs	O	886-891
of	O	892-894
abuse	O	895-900
,	O	900-901
and	O	902-905
assay	O	906-911
results	O	912-919
were	O	920-924
recorded	O	925-933
without	O	934-941
patient	O	942-949
identifiers	O	950-961
.	O	961-962

RESULTS	O	963-970
:	O	970-971
Fourteen	O	972-980
of	O	981-983
248	O	984-987
(	O	988-989
5	O	989-990
.	O	990-991
6	O	991-992
%	O	992-993
,	O	993-994
95	O	995-997
%	O	997-998
CI	O	999-1001
2	O	1002-1003
.	O	1003-1004
7	O	1004-1005
%	O	1005-1006
-	O	1006-1007
8	O	1007-1008
.	O	1003-1004
5	O	1009-1010
%	O	1005-1006
)	O	1011-1012

plasma	O	1013-1019
samples	O	1020-1027
were	O	1028-1032
positive	O	1033-1041
by	O	1042-1044
immunoassay	O	1045-1056
testing	O	1057-1064
for	O	1065-1068
benzoylecgonine	O	1069-1084
and	O	1085-1088
no	O	1089-1091
samples	O	1092-1099
(	O	1100-1101
0	O	1101-1102
%	O	1102-1103
,	O	1103-1104
95	O	1105-1107
%	O	1107-1108
CI	O	1109-1111
0	O	1112-1113
-	O	1113-1114
1	O	1114-1115
.	O	1115-1116
2	O	1116-1117
%	O	1117-1118
)	O	1118-1119
were	O	1120-1124
positive	O	1125-1133
for	O	1134-1137
amphetamine	O	1138-1149
.	O	1149-1150

Positive	O	1151-1159
test	O	1160-1164
results	O	1165-1172
were	O	1173-1177
more	O	1178-1182
common	O	1183-1189
in	O	1190-1192
patient	O	1193-1200
visits	O	1201-1207
where	O	1208-1213
there	O	1214-1219
was	O	1220-1223
a	O	1224-1225
history	O	1226-1233
or	O	1234-1236
suspicion	O	1237-1246
of	O	1247-1249
cocaine	B	1250-1257
or	I	1258-1260
amphetamine	I	1261-1272
abuse	I	1273-1278
(	O	1279-1280
p	O	1280-1281
<	O	1282-1283
0	O	1284-1285
.	O	1285-1286
0005	O	1286-1290
)	O	1290-1291
.	O	1285-1286

CONCLUSIONS	O	1293-1304
:	O	1304-1305
During	O	1306-1312
this	O	1313-1317
study	O	1318-1323
period	O	1324-1330
,	O	1330-1331
routine	O	1332-1339
plasma	O	1340-1346
screening	O	1347-1356
for	O	1357-1360
cocaine	O	1361-1368
and	O	1369-1372
amphetamines	O	1373-1385
in	O	1386-1388
adult	O	1389-1394
seizure	B	1395-1402
patients	O	1403-1411
had	O	1412-1415
a	O	1416-1417
low	O	1418-1421
yield	O	1422-1427
.	O	1427-1428

As	O	1429-1431
a	O	1432-1433
result	O	1434-1440
,	O	1440-1441
routine	O	1442-1449
plasma	O	1450-1456
screening	O	1457-1466
would	O	1467-1472
yield	O	1473-1478
few	O	1479-1482
cases	O	1483-1488
of	O	1489-1491
stimulant	O	1492-1501
drug	O	1502-1506
in	O	1507-1509
which	O	1510-1515
there	O	1516-1521
was	O	1522-1525
neither	O	1526-1533
a	O	1534-1535
history	O	1536-1543
nor	O	1544-1547
suspicion	O	1548-1557
of	O	1558-1560
drug	B	1561-1565
abuse	I	1566-1571
in	O	1572-1574
this	O	1575-1579
population	O	1580-1590
.	O	1590-1591

Evidence	O	0-8
of	O	9-11
functional	O	12-22
somatotopy	O	23-33
in	O	34-36
GPi	O	37-40
from	O	41-45
results	O	46-53
of	O	54-56
pallidotomy	O	57-68
.	O	68-69

The	O	70-73
objective	O	74-83
of	O	84-86
this	O	87-91
study	O	92-97
was	O	98-101
to	O	102-104
explore	O	105-112
the	O	113-116
functional	O	117-127
anatomy	O	128-135
of	O	136-138
the	O	139-142
globus	O	143-149
pallidus	O	150-158
internus	O	159-167
(	O	168-169
GPi	O	169-172
)	O	172-173
by	O	174-176
studying	O	177-185
the	O	186-189
effects	O	190-197
of	O	198-200
unilateral	O	201-211
pallidotomy	O	212-223
on	O	224-226
parkinsonian	B	227-239
'	O	240-241
off	O	241-244
'	O	240-241
signs	O	246-251
and	O	252-255
levodopa	O	256-264
-	O	264-265
induced	O	265-272
dyskinesias	B	273-284
(	O	285-286
LID	B	286-289
)	O	289-290
.	O	290-291

We	O	292-294
found	O	295-300
significant	O	301-312
positive	O	313-321
correlations	O	322-334
between	O	335-342
the	O	343-346
preoperative	O	347-359
levodopa	O	360-368
responsiveness	O	369-383
of	O	384-386
motor	O	387-392
signs	O	393-398
and	O	399-402
the	O	403-406
levodopa	O	407-415
responsiveness	O	416-430
of	O	431-433
scores	O	434-440
in	O	441-443
timed	O	444-449
tests	O	450-455
(	O	456-457
Core	O	457-461
Assessment	O	462-472
Program	O	473-480
for	O	481-484
Intracerebral	O	485-498
Transplantations	O	499-515
)	O	515-516
in	O	517-519
the	O	520-523
contralateral	O	524-537
limbs	O	538-543
and	O	544-547
the	O	548-551
improvement	O	552-563
in	O	564-566
these	O	567-572
scores	O	573-579
after	O	580-585
surgery	O	586-593
,	O	593-594
whereas	O	595-602
there	O	603-608
was	O	609-612
no	O	613-615
correlation	O	616-627
with	O	628-632
the	O	633-636
improvement	O	637-648
in	O	649-651
LID	B	652-655
.	O	655-656

We	O	657-659
also	O	660-664
found	O	665-670
a	O	671-672
highly	O	673-679
significant	O	680-691
correlation	O	692-703
(	O	704-705
P	O	705-706
:	O	706-707
<	O	708-709
0	O	710-711
.	O	711-712
0001	O	712-716
,	O	716-717
r	O	718-719
=	O	720-721
0	O	722-723
.	O	723-724
8	O	724-725
)	O	725-726
between	O	727-734
the	O	735-738
volume	O	739-745
of	O	746-748
the	O	749-752
ventral	O	753-760
lesion	O	761-767
in	O	768-770
the	O	771-774
GPi	O	775-778
and	O	779-782
the	O	783-786
improvement	O	787-798
in	O	799-801
LID	B	802-805
in	O	806-808
the	O	809-812
contralateral	O	813-826
limbs	O	827-832
,	O	832-833
whereas	O	834-841
there	O	842-847
was	O	848-851
no	O	852-854
correlation	O	855-866
between	O	867-874
the	O	875-878
ventral	O	879-886
volume	O	887-893
and	O	894-897
the	O	898-901
improvement	O	902-913
in	O	914-916
parkinsonian	B	917-929
'	O	930-931
off	O	931-934
'	O	930-931
signs	O	936-941
.	O	941-942

The	O	943-946
volumes	O	947-954
of	O	955-957
the	O	958-961
total	O	962-967
lesion	O	968-974
cylinder	O	975-983
and	O	984-987
the	O	988-991
dorsal	O	992-998
lesion	O	999-1005
did	O	1006-1009
not	O	1010-1013
correlate	O	1014-1023
with	O	1024-1028
the	O	1029-1032
outcome	O	1033-1040
of	O	1041-1043
either	O	1044-1050
dyskinesias	B	1051-1062
or	O	1063-1065
parkinsonian	B	1066-1078
'	O	1079-1080
off	O	1080-1083
'	O	1079-1080
signs	O	1085-1090
.	O	1090-1091

The	O	1092-1095
differential	O	1096-1108
predictive	O	1109-1119
value	O	1120-1125
of	O	1126-1128
levodopa	O	1129-1137
responsiveness	O	1138-1152
for	O	1153-1156
the	O	1157-1160
outcome	O	1161-1168
of	O	1169-1171
parkinsonian	B	1172-1184
'	O	1185-1186
off	O	1186-1189
'	O	1185-1186
signs	O	1191-1196
and	O	1197-1200
LID	B	1201-1204
and	O	1205-1208
the	O	1209-1212
different	O	1213-1222
correlations	O	1223-1235
of	O	1236-1238
ventral	O	1239-1246
lesion	O	1247-1253
volume	O	1254-1260
with	O	1261-1265
dyskinesias	B	1266-1277
and	O	1278-1281
parkinsonian	B	1282-1294
'	O	1295-1296
off	O	1296-1299
'	O	1295-1296
signs	O	1301-1306
indicate	O	1307-1315
that	O	1316-1320
different	O	1321-1330
anatomical	O	1331-1341
or	O	1342-1344
pathophysiological	O	1345-1363
substrates	O	1364-1374
may	O	1375-1378
be	O	1379-1381
responsible	O	1382-1393
for	O	1394-1397
the	O	1398-1401
generation	O	1402-1412
of	O	1413-1415
parkinsonian	B	1416-1428
'	O	1429-1430
off	O	1430-1433
'	O	1429-1430
signs	O	1435-1440
and	O	1441-1444
dyskinesias	B	1445-1456
.	O	1456-1457

Whereas	O	1458-1465
cells	O	1466-1471
in	O	1472-1474
a	O	1475-1476
wider	O	1477-1482
area	O	1483-1487
of	O	1488-1490
the	O	1491-1494
GPi	O	1495-1498
may	O	1499-1502
be	O	1503-1505
implicated	O	1506-1516
in	O	1517-1519
parkinsonism	B	1520-1532
,	O	1532-1533
the	O	1534-1537
ventral	O	1538-1545
GPi	O	1546-1549
seems	O	1550-1555
to	O	1556-1558
be	O	1559-1561
crucial	O	1562-1569
for	O	1570-1573
the	O	1574-1577
manifestation	O	1578-1591
of	O	1592-1594
LID	B	1595-1598
.	O	1598-1599

We	O	1600-1602
suggest	O	1603-1610
that	O	1611-1615
our	O	1616-1619
observations	O	1620-1632
are	O	1633-1636
additional	O	1637-1647
proof	O	1648-1653
of	O	1654-1656
the	O	1657-1660
functional	O	1661-1671
somatotopy	O	1672-1682
of	O	1683-1685
the	O	1686-1689
systems	O	1690-1697
within	O	1698-1704
the	O	1705-1708
GPi	O	1709-1712
that	O	1713-1717
mediate	O	1718-1725
parkinsonism	B	1726-1738
and	O	1739-1742
dyskinesias	B	1743-1754
,	O	1754-1755
especially	O	1756-1766
along	O	1767-1772
the	O	1773-1776
dorsoventral	O	1777-1789
trajectory	O	1790-1800
used	O	1801-1805
in	O	1806-1808
pallidotomy	O	1809-1820
.	O	1820-1821

The	O	1822-1825
outcome	O	1826-1833
of	O	1834-1836
pallidotomy	O	1837-1848
in	O	1849-1851
which	O	1852-1857
the	O	1858-1861
lesion	O	1862-1868
involves	O	1869-1877
the	O	1878-1881
ventral	O	1882-1889
and	O	1890-1893
dorsal	O	1894-1900
GPi	O	1901-1904
could	O	1905-1910
be	O	1911-1913
the	O	1914-1917
net	O	1918-1921
effect	O	1922-1928
of	O	1929-1931
alteration	O	1932-1942
in	O	1943-1945
the	O	1946-1949
activity	O	1950-1958
of	O	1959-1961
pathways	O	1962-1970
which	O	1971-1976
mediate	O	1977-1984
different	O	1985-1994
symptoms	O	1995-2003
,	O	2003-2004
and	O	2005-2008
hence	O	2009-2014
could	O	2015-2020
be	O	2021-2023
variable	O	2024-2032
.	O	2032-2033

Pain	B	0-4
responses	O	5-14
in	O	15-17
methadone	O	18-27
-	O	27-28
maintained	O	28-38
opioid	O	39-45
abusers	O	46-53
.	O	53-54

Providing	O	55-64
pain	B	65-69
management	O	70-80
for	O	81-84
known	O	85-90
opioid	O	91-97
abusers	O	98-105
is	O	106-108
a	O	109-110
challenging	O	111-122
clinical	O	123-131
task	O	132-136
,	O	136-137
in	O	138-140
part	O	141-145
because	O	146-153
little	O	154-160
is	O	161-163
known	O	164-169
about	O	170-175
their	O	176-181
pain	B	182-186
experience	O	187-197
and	O	198-201
analgesic	O	202-211
requirements	O	212-224
.	O	224-225

This	O	226-230
study	O	231-236
was	O	237-240
designed	O	241-249
to	O	250-252
describe	O	253-261
pain	B	262-266
tolerance	O	267-276
and	O	277-280
analgesic	O	281-290
response	O	291-299
in	O	300-302
a	O	303-304
sample	O	305-311
of	O	312-314
opioid	B	315-321
addicts	I	322-329
stabilized	O	330-340
in	O	341-343
methadone	O	344-353
-	O	353-354
maintenance	O	354-365
(	O	366-367
MM	O	367-369
)	O	369-370
treatment	O	371-380
(	O	381-382
n	O	382-383
=	O	384-385
60	O	386-388
)	O	388-389
in	O	390-392
comparison	O	393-403
to	O	404-406
matched	O	407-414
nondependent	O	415-427
control	O	428-435
subjects	O	436-444
(	O	445-446
n	O	446-447
=	O	448-449
60	O	450-452
)	O	452-453
.	O	453-454

By	O	455-457
using	O	458-463
a	O	464-465
placebo	O	466-473
-	O	473-474
controlled	O	474-484
,	O	484-485
two	O	486-489
-	O	489-490
way	O	490-493
factorial	O	494-503
design	O	504-510
,	O	510-511
tolerance	O	512-521
to	O	522-524
cold	O	525-529
-	O	529-530
pressor	O	530-537
(	O	538-539
CP	O	539-541
)	O	541-542
pain	B	543-547
was	O	548-551
examined	O	552-560
,	O	560-561
both	O	562-566
before	O	567-573
and	O	574-577
after	O	578-583
oral	O	584-588
administration	O	589-603
of	O	604-606
therapeutic	O	607-618
doses	O	619-624
of	O	625-627
common	O	628-634
opioid	O	635-641
(	O	642-643
hydromorphone	O	643-656
2	O	657-658
mg	O	659-661
)	O	661-662
and	O	663-666
nonsteroidal	O	667-679
anti	O	680-684
-	O	684-685
inflammatory	O	685-697
(	O	698-699
ketorolac	O	699-708
10	O	709-711
mg	O	712-714
)	O	714-715
analgesic	O	716-725
agents	O	726-732
.	O	732-733

Results	O	734-741
showed	O	742-748
that	O	749-753
MM	O	754-756
individuals	O	757-768
were	O	769-773
significantly	O	774-787
less	O	788-792
tolerant	O	793-801
of	O	802-804
CP	O	805-807
pain	B	808-812
than	O	813-817
control	O	818-825
subjects	O	826-834
,	O	834-835
replicating	O	836-847
previous	O	848-856
work	O	857-861
.	O	861-862

Analgesic	O	863-872
effects	O	873-880
were	O	881-885
significant	O	886-897
neither	O	898-905
for	O	906-909
medication	O	910-920
nor	O	921-924
group	O	925-930
.	O	930-931

These	O	932-937
data	O	938-942
indicate	O	943-951
that	O	952-956
MM	O	957-959
opioid	O	960-966
abusers	O	967-974
represent	O	975-984
a	O	985-986
pain	B	987-991
-	I	991-992
intolerant	I	992-1002
subset	O	1003-1009
of	O	1010-1012
clinical	O	1013-1021
patients	O	1022-1030
.	O	1030-1031

Their	O	1032-1037
complaints	O	1038-1048
of	O	1049-1051
pain	B	1052-1056
should	O	1057-1063
be	O	1064-1066
evaluated	O	1067-1076
seriously	O	1077-1086
and	O	1087-1090
managed	O	1091-1098
aggressively	O	1099-1111
.	O	1111-1112

Urine	O	0-5
N	O	6-7
-	O	7-8
acetyl	O	8-14
-	O	7-8
beta	O	15-19
-	O	7-8
D	O	20-21
-	O	7-8
glucosaminidase	O	22-37
-	O	7-8
-	O	7-8
a	O	8-9
marker	O	41-47
of	O	48-50
tubular	O	51-58
damage	O	59-65
?	O	65-66

BACKGROUND	O	67-77
:	O	77-78
Although	O	79-87
an	O	88-90
indicator	O	91-100
of	O	101-103
renal	B	104-109
tubular	I	110-117
dysfunction	I	118-129
,	O	129-130
an	O	131-133
increased	O	134-143
urinary	O	144-151
N	O	152-153
-	O	153-154
acetyl	O	154-160
-	O	153-154
beta	O	161-165
-	O	153-154
D	O	166-167
-	O	153-154
glucosaminidase	O	168-183
(	O	184-185
NAG	O	185-188
)	O	188-189
activity	O	190-198
might	O	199-204
reflect	O	205-212
increased	O	213-222
lysosomal	O	223-232
activity	O	233-241
in	O	242-244
renal	O	245-250
tubular	O	251-258
cells	O	259-264
.	O	264-265

METHODS	O	266-273
:	O	273-274
Puromycin	O	275-284
aminonucleoside	O	285-300
(	O	301-302
PAN	O	302-305
)	O	305-306
was	O	307-310
administered	O	311-323
to	O	324-326
Sprague	O	327-334
Dawley	O	335-341
rats	O	342-346
to	O	347-349
induce	O	350-356
proteinuria	B	357-368
.	O	368-369

Total	O	370-375
protein	O	376-383
,	O	383-384
albumin	O	385-392
,	O	392-393
NAG	O	394-397
activity	O	398-406
and	O	407-410
protein	O	411-418
electrophoretic	O	419-434
pattern	O	435-442
were	O	443-447
assessed	O	448-456
in	O	457-459
daily	O	460-465
urine	O	466-471
samples	O	472-479
for	O	480-483
33	O	484-486
days	O	487-491
.	O	491-492

The	O	493-496
morphological	O	497-510
appearance	O	511-521
of	O	522-524
the	O	525-528
kidneys	O	529-536
was	O	537-540
examined	O	541-549
on	O	550-552
days	O	553-557
three	O	558-563
,	O	563-564
four	O	565-569
,	O	569-570
six	O	571-574
,	O	574-575
eight	O	576-581
and	O	582-585
thirty	O	586-592
three	O	593-598
and	O	599-602
the	O	603-606
NAG	O	607-610
isoenzyme	O	611-620
patterns	O	621-629
on	O	630-632
days	O	633-637
zero	O	638-642
,	O	642-643
four	O	644-648
,	O	648-649
eight	O	650-655
and	O	656-659
thirty	O	660-666
three	O	667-672
.	O	672-673

RESULTS	O	674-681
:	O	681-682
Following	O	683-692
intravenous	O	693-704
PAN	O	705-708
urine	O	709-714
volume	O	715-721
and	O	722-725
urine	O	726-731
NAG	O	732-735
activity	O	736-744
increased	O	745-754
significantly	O	755-768
by	O	769-771
day	O	772-775
two	O	776-779
,	O	779-780
but	O	781-784
returned	O	785-793
to	O	794-796
normal	O	797-803
by	O	804-806
day	O	807-810
four	O	811-815
.	O	815-816

After	O	817-822
day	O	823-826
four	O	827-831
all	O	832-835
treated	O	836-843
animals	O	844-851
exhibited	O	852-861
a	O	862-863
marked	O	864-870
rise	O	871-875
in	O	876-878
urine	O	879-884
albumin	O	885-892
,	O	892-893
total	O	894-899
protein	O	900-907
excretion	O	908-917
and	O	918-921
NAG	O	922-925
activity	O	926-934
.	O	934-935

Electrophoresis	O	936-951
showed	O	952-958
a	O	959-960
generalised	O	961-972
increase	O	973-981
in	O	982-984
middle	O	985-991
and	O	992-995
high	O	996-1000
molecular	O	1001-1010
weight	O	1011-1017
urine	O	1018-1023
proteins	O	1024-1032
from	O	1033-1037
day	O	1038-1041
four	O	1042-1046
onwards	O	1047-1054
.	O	1054-1055

Protein	O	1056-1063
droplets	O	1064-1072
first	O	1073-1078
appeared	O	1079-1087
prominent	O	1088-1097
in	O	1098-1100
tubular	O	1101-1108
cells	O	1109-1114
on	O	1115-1117
day	O	1118-1121
four	O	1122-1126
.	O	1126-1127

Peak	O	1128-1132
urine	O	1133-1138
NAG	O	1139-1142
activity	O	1143-1151
and	O	1152-1155
a	O	1156-1157
change	O	1158-1164
in	O	1165-1167
NAG	O	1168-1171
isoenzyme	O	1172-1181
pattern	O	1182-1189
coincided	O	1190-1199
with	O	1200-1204
both	O	1205-1209
the	O	1210-1213
peak	O	1214-1218
proteinuria	B	1219-1230
and	O	1231-1234
the	O	1235-1238
reduction	O	1239-1248
in	O	1249-1251
intracellular	O	1252-1265
protein	O	1266-1273
and	O	1274-1277
NAG	O	1278-1281
droplets	O	1282-1290
(	O	1291-1292
day	O	1292-1295
six	O	1296-1299
onwards	O	1300-1307
)	O	1307-1308
.	O	1308-1309

CONCLUSIONS	O	1310-1321
:	O	1321-1322
This	O	1323-1327
animal	O	1328-1334
model	O	1335-1340
demonstrates	O	1341-1353
that	O	1354-1358
an	O	1359-1361
increase	O	1362-1370
in	O	1371-1373
lysosomal	O	1374-1383
turnover	O	1384-1392
and	O	1393-1396
hence	O	1397-1402
urine	O	1403-1408
NAG	O	1409-1412
activity	O	1413-1421
,	O	1421-1422
occurs	O	1423-1429
when	O	1430-1434
increased	O	1435-1444
protein	O	1445-1452
is	O	1453-1455
presented	O	1456-1465
to	O	1466-1468
the	O	1469-1472
tubular	O	1473-1480
cells	O	1481-1486
.	O	1486-1487

Urine	O	1488-1493
NAG	O	1494-1497
activity	O	1498-1506
is	O	1507-1509
thus	O	1510-1514
a	O	1515-1516
measure	O	1517-1524
of	O	1525-1527
altered	O	1528-1535
function	O	1536-1544
in	O	1545-1547
the	O	1548-1551
renal	O	1552-1557
tubules	O	1558-1565
and	O	1566-1569
not	O	1570-1573
simply	O	1574-1580
an	O	1581-1583
indicator	O	1584-1593
of	O	1594-1596
damage	O	1597-1603
.	O	1603-1604

Over	O	0-4
expression	O	5-15
of	O	16-18
vascular	O	19-27
endothelial	O	28-39
growth	O	40-46
factor	O	47-53
and	O	54-57
its	O	58-61
receptor	O	62-70
during	O	71-77
the	O	78-81
development	O	82-93
of	O	94-96
estrogen	O	97-105
-	O	105-106
induced	O	106-113
rat	O	114-117
pituitary	B	118-127
tumors	I	128-134
may	O	135-138
mediate	O	139-146
estrogen	O	147-155
-	O	155-156
initiated	O	156-165
tumor	B	166-171
angiogenesis	O	172-184
.	O	184-185

Estrogens	O	186-195
,	O	195-196
which	O	197-202
have	O	203-207
been	O	208-212
associated	O	213-223
with	O	224-228
several	O	229-236
types	O	237-242
of	O	243-245
human	O	246-251
and	O	252-255
animal	O	256-262
cancers	B	263-270
,	O	270-271
can	O	272-275
induce	O	276-282
tumor	B	283-288
angiogenesis	O	289-301
in	O	302-304
the	O	305-308
pituitary	O	309-318
of	O	319-321
Fischer	O	322-329
344	O	330-333
rats	O	334-338
.	O	338-339

The	O	340-343
mechanistic	O	344-355
details	O	356-363
of	O	364-366
tumor	B	367-372
angiogenesis	O	373-385
induction	O	386-395
,	O	395-396
during	O	397-403
estrogen	O	404-412
carcinogenesis	B	413-427
,	O	427-428
are	O	429-432
still	O	433-438
unknown	O	439-446
.	O	446-447

To	O	448-450
elucidate	O	451-460
the	O	461-464
role	O	465-469
of	O	470-472
estrogen	O	473-481
in	O	482-484
the	O	485-488
regulation	O	489-499
of	O	500-502
tumor	B	503-508
angiogenesis	O	509-521
in	O	522-524
the	O	525-528
pituitary	O	529-538
of	O	539-541
female	O	542-548
rats	O	549-553
,	O	553-554
the	O	555-558
density	O	559-566
of	O	567-569
blood	O	570-575
vessels	O	576-583
was	O	584-587
analysed	O	588-596
using	O	597-602
factor	O	603-609
VIII	O	610-614
related	O	615-622
antigen	O	623-630
(	O	631-632
FVIIIRAg	O	632-640
)	O	640-641
immunohistochemistry	O	642-662
and	O	663-666
the	O	667-670
expression	O	671-681
of	O	682-684
vascular	O	685-693
endothelial	O	694-705
growth	O	706-712
factor	O	713-719
/	O	719-720
vascular	O	720-728
permeability	O	729-741
factor	O	742-748
(	O	749-750
VEGF	O	750-754
/	O	754-755
VPF	O	755-758
)	O	758-759
was	O	760-763
examined	O	764-772
by	O	773-775
Western	O	776-783
blot	O	784-788
and	O	789-792
immunohistochemical	O	793-812
analysis	O	813-821
.	O	821-822

The	O	823-826
expression	O	827-837
of	O	838-840
VEGF	O	841-845
receptor	O	846-854
(	O	855-856
VEGFR	O	856-861
-	O	861-862
2	O	862-863
/	O	863-864
Flk	O	864-867
-	O	861-862
1	O	868-869
/	O	863-864
KDR	O	870-873
)	O	873-874
was	O	875-878
also	O	879-883
examined	O	884-892
by	O	893-895
immunohistochemistry	O	896-916
.	O	916-917

The	O	918-921
results	O	922-929
demonstrated	O	930-942
that	O	943-947
17beta	O	948-954
-	O	954-955
estradiol	O	955-964
(	O	965-966
E2	O	966-968
)	O	968-969
induces	O	970-977
neovascularization	O	978-996
,	O	996-997
as	O	998-1000
well	O	1001-1005
as	O	1006-1008
the	O	1009-1012
growth	O	1013-1019
and	O	1020-1023
enlargement	O	1024-1035
of	O	1036-1038
blood	O	1039-1044
vessels	O	1045-1052
after	O	1053-1058
7	O	1059-1060
days	O	1061-1065
of	O	1066-1068
exposure	O	1069-1077
.	O	1077-1078

The	O	1079-1082
high	O	1083-1087
tumor	B	1088-1093
angiogenic	O	1094-1104
potential	O	1105-1114
was	O	1115-1118
associated	O	1119-1129
with	O	1130-1134
an	O	1135-1137
elevated	O	1138-1146
VEGF	O	1147-1151
/	O	1151-1152
VPF	O	1152-1155
protein	O	1156-1163
expression	O	1164-1174
in	O	1175-1177
the	O	1178-1181
E2	O	1182-1184
exposed	O	1185-1192
pituitary	O	1193-1202
of	O	1203-1205
ovariectomized	O	1206-1220
(	O	1221-1222
OVEX	O	1222-1226
)	O	1226-1227
rats	O	1228-1232
.	O	1232-1233

VEGF	O	1234-1238
/	O	1238-1239
VPF	O	1239-1242
and	O	1243-1246
FVIIIRAg	O	1247-1255
immunohistochemistry	O	1256-1276
and	O	1277-1280
endothelial	O	1281-1292
specific	O	1293-1301
lectin	O	1302-1308
(	O	1309-1310
UEA1	O	1310-1314
)	O	1314-1315
binding	O	1316-1323
studies	O	1324-1331
,	O	1331-1332
indicate	O	1333-1341
that	O	1342-1346
the	O	1347-1350
elevation	O	1351-1360
of	O	1361-1363
VEGF	O	1364-1368
protein	O	1369-1376
expression	O	1377-1387
initially	O	1388-1397
occurred	O	1398-1406
in	O	1407-1409
both	O	1410-1414
blood	O	1415-1420
vessels	O	1421-1428
and	O	1429-1432
non	O	1433-1436
-	O	1436-1437
endothelial	O	1437-1448
cells	O	1449-1454
.	O	1454-1455

After	O	1456-1461
15	O	1462-1464
days	O	1465-1469
of	O	1470-1472
E2	O	1473-1475
exposure	O	1476-1484
,	O	1484-1485
VEGF	O	1486-1490
/	O	1490-1491
VPF	O	1491-1494
protein	O	1495-1502
expression	O	1503-1513
,	O	1513-1514
in	O	1515-1517
the	O	1518-1521
non	O	1522-1525
-	O	1525-1526
endothelial	O	1526-1537
cell	O	1538-1542
population	O	1543-1553
,	O	1553-1554
sharply	O	1555-1562
declined	O	1563-1571
and	O	1572-1575
was	O	1576-1579
restricted	O	1580-1590
to	O	1591-1593
the	O	1594-1597
blood	O	1598-1603
vessels	O	1604-1611
.	O	1611-1612

The	O	1613-1616
function	O	1617-1625
of	O	1626-1628
non	O	1629-1632
-	O	1632-1633
endothelial	O	1633-1644
-	O	1632-1633
derived	O	1645-1652
VEGF	O	1653-1657
is	O	1658-1660
not	O	1661-1664
clear	O	1665-1670
.	O	1670-1671

Furthermore	O	1672-1683
,	O	1683-1684
immunohistochemical	O	1685-1704
studies	O	1705-1712
demonstrated	O	1713-1725
that	O	1726-1730
VEGFR	O	1731-1736
-	O	1736-1737
2	O	1737-1738
(	O	1739-1740
flk	O	1740-1743
-	O	1743-1744
1	O	1744-1745
/	O	1745-1746
KDR	O	1746-1749
)	O	1749-1750
,	O	1750-1751
expression	O	1752-1762
was	O	1763-1766
elevated	O	1767-1775
significantly	O	1776-1789
in	O	1790-1792
the	O	1793-1796
endothelial	O	1797-1808
cells	O	1809-1814
of	O	1815-1817
microblood	O	1818-1828
vessels	O	1829-1836
after	O	1837-1842
7	O	1843-1844
days	O	1845-1849
of	O	1850-1852
E2	O	1853-1855
exposure	O	1856-1864
.	O	1864-1865

These	O	1866-1871
findings	O	1872-1880
suggest	O	1881-1888
that	O	1889-1893
over	O	1894-1898
expression	O	1899-1909
of	O	1910-1912
VEGF	O	1913-1917
and	O	1918-1921
its	O	1922-1925
receptor	O	1926-1934
(	O	1935-1936
VEGFR	O	1936-1941
-	O	1941-1942
2	O	1942-1943
)	O	1943-1944
may	O	1945-1948
play	O	1949-1953
an	O	1954-1956
important	O	1957-1966
role	O	1967-1971
in	O	1972-1974
the	O	1975-1978
initial	O	1979-1986
step	O	1987-1991
of	O	1992-1994
the	O	1995-1998
regulation	O	1999-2009
of	O	2010-2012
estrogen	O	2013-2021
induced	O	2022-2029
tumor	B	2030-2035
angiogenesis	O	2036-2048
in	O	2049-2051
the	O	2052-2055
rat	O	2056-2059
pituitary	O	2060-2069
.	O	2069-2070

Pravastatin	O	0-11
-	O	11-12
associated	O	12-22
myopathy	B	23-31
.	O	31-32

Report	O	33-39
of	O	40-42
a	O	43-44
case	O	45-49
.	O	49-50

A	O	51-52
case	O	53-57
of	O	58-60
acute	O	61-66
inflammatory	B	67-79
myopathy	I	80-88
associated	O	89-99
with	O	100-104
the	O	105-108
use	O	109-112
of	O	113-115
pravastatin	O	116-127
,	O	127-128
a	O	129-130
new	O	131-134
hydrophilic	O	135-146
3	O	147-148
-	O	148-149
hydroxy	O	149-156
-	O	148-149
3	O	147-148
methylglutaril	O	159-173
coenzyme	O	174-182
A	O	183-184
reductase	O	185-194
inhibitor	O	195-204
,	O	204-205
is	O	206-208
reported	O	209-217
.	O	217-218

The	O	219-222
patient	O	223-230
,	O	230-231
a	O	232-233
69	O	234-236
-	O	236-237
year	O	237-241
-	O	236-237
old	O	242-245
man	O	246-249
was	O	250-253
affected	O	254-262
by	O	263-265
non	B	266-269
-	I	269-270
insulin	I	270-277
-	I	269-270
dependent	I	278-287
diabetes	I	288-296
mellitus	I	297-305
and	O	306-309
hypertension	B	310-322
.	O	322-323

He	O	324-326
assumed	O	327-334
pravastatin	O	335-346
(	O	347-348
20	O	348-350
mg	O	351-353
/	O	353-354
day	O	354-357
)	O	357-358
because	O	359-366
of	O	367-369
hypercholesterolemia	B	370-390
.	O	390-391

He	O	392-394
was	O	395-398
admitted	O	399-407
with	O	408-412
acute	O	413-418
myopathy	B	419-427
of	O	428-430
the	O	431-434
lower	O	435-440
limbs	O	441-446
which	O	447-452
resolved	O	453-461
in	O	462-464
a	O	465-466
few	O	467-470
days	O	471-475
after	O	476-481
pravastatin	O	482-493
discontinuation	O	494-509
.	O	509-510

A	O	511-512
previously	O	513-523
unknown	O	524-531
hypothyroidism	B	532-546
,	O	546-547
probably	O	548-556
due	O	557-560
to	O	561-563
chronic	O	564-571
autoimmune	B	572-582
thyroiditis	I	583-594
,	O	594-595
was	O	596-599
evidenced	O	600-609
.	O	609-610

Muscle	O	611-617
biopsy	O	618-624
(	O	625-626
left	O	626-630
gastrocnemius	O	631-644
)	O	644-645
revealed	O	646-654
a	O	655-656
perimysial	O	657-667
and	O	668-671
endomysial	O	672-682
inflammatory	O	683-695
infiltrate	O	696-706
with	O	707-711
a	O	712-713
prevalence	O	714-724
of	O	725-727
CD4	O	728-731
+	O	731-732
lymphocytes	O	733-744
.	O	744-745

While	O	746-751
lovastatin	O	752-762
and	O	763-766
simvastatin	O	767-778
have	O	779-783
been	O	784-788
associated	O	789-799
with	O	800-804
toxic	O	805-810
myopathy	B	811-819
,	O	819-820
pravastatin	O	821-832
-	O	832-833
associated	O	833-843
myopathy	B	844-852
could	O	853-858
represent	O	859-868
a	O	869-870
distinct	O	871-879
,	O	879-880
inflammatory	O	881-893
entity	O	894-900
.	O	900-901

Dose	O	0-4
-	O	4-5
effect	O	5-11
and	O	12-15
structure	O	16-25
-	O	25-26
function	O	26-34
relationships	O	35-48
in	O	49-51
doxorubicin	O	52-63
cardiomyopathy	B	64-78
.	O	78-79

The	O	80-83
cardiomyopathy	B	84-98
(	O	99-100
CM	B	100-102
)	O	102-103
produced	O	104-112
by	O	113-115
the	O	116-119
anticancer	O	120-130
drug	O	131-135
doxorubicin	O	136-147
(	O	148-149
DXR	O	149-152
)	O	152-153
(	O	154-155
Adriamycin	O	155-165
)	O	165-166
provides	O	167-175
a	O	176-177
unique	O	178-184
opportunity	O	185-196
to	O	197-199
analyze	O	200-207
dose	O	208-212
-	O	212-213
effect	O	213-219
and	O	220-223
structure	O	224-233
-	O	233-234
function	O	234-242
relationships	O	243-256
during	O	257-263
development	O	264-275
of	O	276-278
myocardial	B	279-289
disease	I	290-297
.	O	297-298

We	O	299-301
measured	O	302-310
the	O	311-314
degree	O	315-321
of	O	322-324
morphologic	O	325-336
damage	O	337-343
by	O	344-346
ultrastructural	O	347-362
examination	O	363-374
of	O	375-377
endomyocardial	O	378-392
biopsy	O	393-399
and	O	400-403
the	O	404-407
degree	O	408-414
of	O	415-417
performance	O	418-429
abnormally	O	430-440
by	O	441-443
right	O	444-449
heart	O	450-455
catheterization	O	456-471
in	O	472-474
patients	O	475-483
receiving	O	484-493
DXR	O	494-497
.	O	497-498

Morphologic	O	499-510
damage	O	511-517
was	O	518-521
variable	O	522-530
but	O	531-534
was	O	535-538
proportional	O	539-551
to	O	552-554
the	O	555-558
total	O	559-564
cumulative	O	565-575
DXR	O	576-579
dose	O	580-584
between	O	585-592
100	O	593-596
and	O	597-600
600	O	601-604
mg	O	605-607
/	O	607-608
m2	O	608-610
.	O	610-611

Performance	O	612-623
abnormalities	O	624-637
correlated	O	638-648
weakly	O	649-655
with	O	656-660
dose	O	661-665
,	O	665-666
exhibited	O	667-676
a	O	677-678
curvilinear	O	679-690
relationship	O	691-703
,	O	703-704
and	O	705-708
had	O	709-712
a	O	713-714
"	O	715-716
threshold	O	716-725
"	O	715-716
for	O	727-730
expression	O	731-741
.	O	741-742

Catheterization	O	743-758
abnormalities	O	759-772
correlated	O	773-783
well	O	784-788
with	O	789-793
morphologic	O	794-805
damage	O	806-812
(	O	813-814
r	O	814-815
=	O	816-817
0	O	818-819
.	O	819-820
57	O	820-822
to	O	823-825
0	O	826-827
.	O	827-828
78	O	828-830
)	O	830-831
in	O	832-834
a	O	835-836
subgroup	O	837-845
of	O	846-848
patients	O	849-857
in	O	858-860
whom	O	861-865
exercise	O	866-874
hemodynamics	O	875-887
were	O	888-892
measured	O	893-901
,	O	901-902
and	O	903-906
this	O	907-911
relationship	O	912-924
also	O	925-929
exhibited	O	930-939
a	O	940-941
curvilinear	O	942-953
,	O	953-954
threshold	O	955-964
configuration	O	965-978
.	O	978-979

In	O	980-982
DXR	O	983-986
-	O	986-987
CM	B	987-989
myocardial	B	990-1000
damage	I	1001-1007
is	O	1008-1010
proportional	O	1011-1023
to	O	1024-1026
the	O	1027-1030
degree	O	1031-1037
of	O	1038-1040
cytotoxic	O	1041-1050
insult	O	1051-1057
(	O	1058-1059
DXR	O	1059-1062
dose	O	1063-1067
)	O	1067-1068
while	O	1069-1074
myocardial	O	1075-1085
function	O	1086-1094
is	O	1095-1097
preserved	O	1098-1107
until	O	1108-1113
a	O	1114-1115
critical	O	1116-1124
dose	O	1125-1129
or	O	1130-1132
degree	O	1133-1139
of	O	1140-1142
damage	O	1143-1149
is	O	1150-1152
reached	O	1153-1160
,	O	1160-1161
after	O	1162-1167
which	O	1168-1173
myocardial	O	1174-1184
performance	O	1185-1196
deteriorates	O	1197-1209
rapidly	O	1210-1217
.	O	1217-1218

Fatal	O	0-5
aplastic	B	6-14
anemia	I	15-21
following	O	22-31
topical	O	32-39
administration	O	40-54
of	O	55-57
ophthalmic	O	58-68
chloramphenicol	O	69-84
.	O	84-85

A	O	86-87
73	O	88-90
-	O	90-91
year	O	91-95
-	O	90-91
old	O	96-99
woman	O	100-105
died	O	106-110
of	O	111-113
aplastic	B	114-122
anemia	I	123-129
less	O	130-134
than	O	135-139
two	O	140-143
months	O	144-150
after	O	151-156
undergoing	O	157-167
cataract	B	168-176
extraction	O	177-187
and	O	188-191
beginning	O	192-201
topical	O	202-209
therapy	O	210-217
with	O	218-222
chloramphenicol	O	223-238
.	O	238-239

The	O	240-243
first	O	244-249
signs	O	250-255
of	O	256-258
pancytopenia	B	259-271
began	O	272-277
within	O	278-284
one	O	285-288
month	O	289-294
of	O	295-297
the	O	298-301
surgery	O	302-309
.	O	309-310

The	O	311-314
pattern	O	315-322
of	O	323-325
the	O	326-329
aplastic	B	330-338
anemia	I	339-345
was	O	346-349
associated	O	350-360
with	O	361-365
an	O	366-368
idiosyncratic	O	369-382
response	O	383-391
to	O	392-394
chloramphenicol	O	395-410
.	O	410-411

This	O	412-416
was	O	417-420
the	O	421-424
second	O	425-431
report	O	432-438
of	O	439-441
fatal	O	442-447
aplastic	B	448-456
anemia	I	457-463
after	O	464-469
topical	O	470-477
treatment	O	478-487
with	O	488-492
chloramphenicol	O	493-508
for	O	509-512
ocular	O	513-519
conditions	O	520-530
,	O	530-531
although	O	532-540
two	O	541-544
cases	O	545-550
of	O	551-553
reversible	O	554-564
bone	B	565-569
marrow	I	570-576
hypoplasia	I	577-587
have	O	588-592
also	O	593-597
been	O	598-602
reported	O	603-611
.	O	611-612

Any	O	613-616
other	O	617-622
suspected	O	623-632
cases	O	633-638
of	O	639-641
ocular	B	642-648
toxicity	I	649-657
associated	O	658-668
with	O	669-673
topically	O	674-683
applied	O	684-691
chloramphenicol	O	692-707
should	O	708-714
be	O	715-717
reported	O	718-726
to	O	727-729
the	O	730-733
National	O	734-742
Registry	O	743-751
of	O	752-754
Drug	O	755-759
-	O	759-760
Induced	O	760-767
Ocular	O	768-774
Side	O	775-779
Effects	O	780-787
,	O	787-788
Oregon	O	789-795
Health	O	796-802
Sciences	O	803-811
University	O	812-822
,	O	822-823
Portland	O	824-832
,	O	832-833
OR	O	834-836
97201	O	837-842
.	O	842-843

Bradycardia	B	0-11
due	O	12-15
to	O	16-18
trihexyphenidyl	O	19-34
hydrochloride	O	35-48
.	O	48-49

A	O	50-51
chronic	O	52-59
schizophrenic	B	60-73
patient	O	74-81
was	O	82-85
treated	O	86-93
with	O	94-98
an	O	99-101
anticholinergic	O	102-117
drug	O	118-122
,	O	122-123
trihexyphenidyl	O	124-139
hydrochloride	O	140-153
.	O	153-154

The	O	155-158
patient	O	159-166
developed	O	167-176
,	O	176-177
paradoxically	O	178-191
,	O	191-192
sinus	O	193-198
bradycardia	B	199-210
.	O	210-211

The	O	212-215
reaction	O	216-224
was	O	225-228
specific	O	229-237
to	O	238-240
trihexyphenidyl	O	241-256
and	O	257-260
not	O	261-264
to	O	265-267
other	O	268-273
anticholinergic	O	274-289
drugs	O	290-295
.	O	295-296

This	O	297-301
antidyskinetic	O	302-316
drug	O	317-321
is	O	322-324
widely	O	325-331
used	O	332-336
in	O	337-339
clinical	O	340-348
psychiatric	B	349-360
practice	O	361-369
and	O	370-373
physicians	O	374-384
should	O	385-391
be	O	392-394
aware	O	395-400
of	O	401-403
this	O	404-408
side	O	409-413
effect	O	414-420
.	O	420-421

Experimental	O	0-12
cyclosporine	O	13-25
nephrotoxicity	B	26-40
:	O	40-41
risk	O	42-46
of	O	47-49
concomitant	O	50-61
chemotherapy	O	62-74
.	O	74-75

The	O	76-79
role	O	80-84
of	O	85-87
cyclosporine	O	88-100
(	O	101-102
CSA	O	102-105
)	O	105-106
alone	O	107-112
or	O	113-115
in	O	116-118
combination	O	119-130
with	O	131-135
various	O	136-143
chemotherapeutics	O	144-161
in	O	162-164
the	O	165-168
development	O	169-180
of	O	181-183
renal	B	184-189
toxicity	I	190-198
was	O	199-202
evaluated	O	203-212
in	O	213-215
rats	O	216-220
.	O	220-221

Administration	O	222-236
of	O	237-239
20	O	240-242
mg	O	243-245
/	O	245-246
kg	O	246-248
/	O	245-246
day	O	249-252
CSA	O	253-256
for	O	257-260
4	O	261-262
weeks	O	263-268
caused	O	269-275
renal	O	276-281
functional	O	282-292
and	O	293-296
structural	O	297-307
changes	O	308-315
similar	O	316-323
to	O	324-326
those	O	327-332
reported	O	333-341
in	O	342-344
man	O	345-348
.	O	348-349

The	O	350-353
combined	O	354-362
administration	O	363-377
of	O	378-380
CSA	O	381-384
and	O	385-388
various	O	389-396
chemotherapeutic	O	397-413
drugs	O	414-419
with	O	420-424
a	O	425-426
nephrotoxic	B	427-438
potential	O	439-448
,	O	448-449
such	O	450-454
as	O	455-457
gentamicin	O	458-468
(	O	469-470
at	O	470-472
therapeutic	O	473-484
doses	O	485-490
)	O	490-491
,	O	491-492
amphothericin	O	493-506
B	O	507-508
and	O	509-512
ketoconazole	O	513-525
,	O	525-526
which	O	527-532
are	O	533-536
frequently	O	537-547
used	O	548-552
in	O	553-555
immunosuppressed	O	556-572
patients	O	573-581
,	O	581-582
did	O	583-586
not	O	587-590
aggravate	O	591-600
the	O	601-604
CSA	O	605-608
induced	O	609-616
toxicity	B	617-625
in	O	626-628
the	O	629-632
rat	O	633-636
model	O	637-642
.	O	642-643

Gentamicin	O	644-654
at	O	655-657
toxic	O	658-663
doses	O	664-669
,	O	669-670
however	O	671-678
,	O	678-679
increased	O	680-689
CSA	O	690-693
nephrotoxicity	B	694-708
.	O	708-709

Thus	O	710-714
,	O	714-715
the	O	716-719
nephrotoxicity	B	720-734
induced	O	735-742
by	O	743-745
CSA	O	746-749
has	O	750-753
a	O	754-755
different	O	756-765
pathogenetic	O	766-778
mechanism	O	779-788
.	O	788-789

Receptor	O	0-8
mechanisms	O	9-19
of	O	20-22
nicotine	O	23-31
-	O	31-32
induced	O	32-39
locomotor	B	40-49
hyperactivity	I	50-63
in	O	64-66
chronic	O	67-74
nicotine	O	75-83
-	O	83-84
treated	O	84-91
rats	O	92-96
.	O	96-97

Rats	O	98-102
were	O	103-107
pretreated	O	108-118
with	O	119-123
saline	O	124-130
or	O	131-133
nicotine	O	134-142
(	O	143-144
1	O	144-145
.	O	145-146
5	O	146-147
mg	O	148-150
/	O	150-151
kg	O	151-153
per	O	154-157
day	O	158-161
)	O	161-162
by	O	163-165
subcutaneously	O	166-180
implanting	O	181-191
each	O	192-196
animal	O	197-203
with	O	204-208
an	O	209-211
Alzet	O	212-217
osmotic	O	218-225
mini	O	226-230
-	O	230-231
pump	O	231-235
which	O	236-241
continuously	O	242-254
released	O	255-263
saline	O	264-270
or	O	271-273
nicotine	O	274-282
for	O	283-286
1	O	287-288
,	O	288-289
5	O	290-291
and	O	292-295
14	O	296-298
days	O	299-303
.	O	303-304

At	O	305-307
the	O	308-311
end	O	312-315
of	O	316-318
each	O	319-323
pretreatment	O	324-336
period	O	337-343
,	O	343-344
animals	O	345-352
were	O	353-357
used	O	358-362
for	O	363-366
(	O	367-368
i	O	368-369
)	O	369-370
determining	O	371-382
their	O	383-388
locomotor	O	389-398
response	O	399-407
to	O	408-410
acutely	O	411-418
injected	O	419-427
nicotine	O	428-436
(	O	437-438
0	O	438-439
.	O	439-440
2	O	440-441
mg	O	442-444
/	O	444-445
kg	O	445-447
,	O	447-448
s	O	449-450
.	O	450-451
c	O	451-452
.	O	450-451
)	O	453-454
and	O	455-458
(	O	459-460
ii	O	460-462
)	O	462-463
measuring	O	464-473
the	O	474-477
density	O	478-485
of	O	486-488
L	O	489-490
-	O	490-491
[	O	491-492
3H	O	492-494
]	O	494-495
nicotine	O	495-503
and	O	504-507
[	O	508-509
3H	O	509-511
]	O	511-512
spiperone	O	512-521
binding	O	522-529
sites	O	530-535
in	O	536-538
the	O	539-542
striatum	O	543-551
.	O	551-552

We	O	553-555
observed	O	556-564
no	O	565-567
changes	O	568-575
in	O	576-578
nicotine	O	579-587
-	O	587-588
induced	O	588-595
locomotor	O	596-605
response	O	606-614
,	O	614-615
striatal	O	616-624
L	O	625-626
-	O	626-627
[	O	627-628
3H	O	628-630
]	O	630-631
nicotine	O	631-639
and	O	640-643
[	O	644-645
3H	O	645-647
]	O	647-648
spiperone	O	648-657
binding	O	658-665
in	O	666-668
the	O	669-672
animals	O	673-680
pretreated	O	681-691
with	O	692-696
nicotine	O	697-705
for	O	706-709
1	O	710-711
day	O	712-715
.	O	715-716

In	O	717-719
rats	O	720-724
which	O	725-730
were	O	731-735
pretreated	O	736-746
with	O	747-751
nicotine	O	752-760
for	O	761-764
5	O	765-766
days	O	767-771
,	O	771-772
there	O	773-778
was	O	779-782
a	O	783-784
significant	O	785-796
increase	O	797-805
in	O	806-808
the	O	809-812
nicotine	O	813-821
-	O	821-822
stimulated	O	822-832
locomotor	O	833-842
response	O	843-851
which	O	852-857
was	O	858-861
associated	O	862-872
with	O	873-877
an	O	878-880
increase	O	881-889
in	O	890-892
the	O	893-896
number	O	897-903
of	O	904-906
L	O	907-908
-	O	908-909
[	O	909-910
3H	O	910-912
]	O	912-913
nicotine	O	913-921
binding	O	922-929
sites	O	930-935
and	O	936-939
also	O	940-944
with	O	945-949
an	O	950-952
elevated	O	953-961
dopamine	O	962-970
(	O	971-972
DA	O	972-974
)	O	974-975
level	O	976-981
in	O	982-984
the	O	985-988
striatum	O	989-997
.	O	997-998

The	O	999-1002
number	O	1003-1009
of	O	1010-1012
striatal	O	1013-1021
[	O	1022-1023
3H	O	1023-1025
]	O	1025-1026
spiperone	O	1026-1035
binding	O	1036-1043
sites	O	1044-1049
was	O	1050-1053
not	O	1054-1057
affected	O	1058-1066
.	O	1066-1067

In	O	1068-1070
animals	O	1071-1078
pretreated	O	1079-1089
with	O	1090-1094
nicotine	O	1095-1103
for	O	1104-1107
14	O	1108-1110
days	O	1111-1115
,	O	1115-1116
the	O	1117-1120
nicotine	O	1121-1129
-	O	1129-1130
induced	O	1130-1137
locomotor	O	1138-1147
response	O	1148-1156
remained	O	1157-1165
to	O	1166-1168
be	O	1169-1171
potentiated	O	1172-1183
.	O	1183-1184

However	O	1185-1192
,	O	1192-1193
this	O	1194-1198
response	O	1199-1207
was	O	1208-1211
correlated	O	1212-1222
with	O	1223-1227
an	O	1228-1230
elevated	O	1231-1239
number	O	1240-1246
of	O	1247-1249
striatal	O	1250-1258
[	O	1259-1260
3H	O	1260-1262
]	O	1262-1263
spiperone	O	1263-1272
binding	O	1273-1280
sites	O	1281-1286
,	O	1286-1287
whereas	O	1288-1295
the	O	1296-1299
number	O	1300-1306
of	O	1307-1309
striatal	O	1310-1318
L	O	1319-1320
-	O	1320-1321
[	O	1321-1322
3H	O	1322-1324
]	O	1324-1325
nicotine	O	1325-1333
binding	O	1334-1341
sites	O	1342-1347
and	O	1348-1351
the	O	1352-1355
striatal	O	1356-1364
DA	O	1365-1367
level	O	1368-1373
were	O	1374-1378
normal	O	1379-1385
.	O	1385-1386

These	O	1387-1392
results	O	1393-1400
suggest	O	1401-1408
that	O	1409-1413
chronic	O	1414-1421
nicotine	O	1422-1430
-	O	1430-1431
treated	O	1431-1438
rats	O	1439-1443
develop	O	1444-1451
locomotor	B	1452-1461
hyperactivity	I	1462-1475
in	O	1476-1478
response	O	1479-1487
to	O	1488-1490
nicotine	O	1491-1499
initially	O	1500-1509
due	O	1510-1513
to	O	1514-1516
increases	O	1517-1526
of	O	1527-1529
both	O	1530-1534
the	O	1535-1538
density	O	1539-1546
of	O	1547-1549
nicotinic	O	1550-1559
receptors	O	1560-1569
and	O	1570-1573
DA	O	1574-1576
concentration	O	1577-1590
,	O	1590-1591
followed	O	1592-1600
by	O	1601-1603
inducing	O	1604-1612
DA	O	1613-1615
receptor	O	1616-1624
supersensitivity	O	1625-1641
in	O	1642-1644
the	O	1645-1648
striatum	O	1649-1657
.	O	1657-1658

Hydrocortisone	O	0-14
-	O	14-15
induced	O	15-22
hypertension	B	23-35
in	O	36-38
humans	O	39-45
:	O	45-46
pressor	O	47-54
responsiveness	O	55-69
and	O	70-73
sympathetic	O	74-85
function	O	86-94
.	O	94-95

Oral	O	96-100
hydrocortisone	O	101-115
increases	O	116-125
blood	O	126-131
pressure	O	132-140
and	O	141-144
enhances	O	145-153
pressor	O	154-161
responsiveness	O	162-176
in	O	177-179
normal	O	180-186
human	O	187-192
subjects	O	193-201
.	O	201-202

We	O	203-205
studied	O	206-213
the	O	214-217
effects	O	218-225
of	O	226-228
1	O	229-230
week	O	231-235
of	O	236-238
oral	O	239-243
hydrocortisone	O	244-258
(	O	259-260
200	O	260-263
mg	O	264-266
/	O	266-267
day	O	267-270
)	O	270-271
on	O	272-274
blood	O	275-280
pressure	O	281-289
,	O	289-290
cardiac	O	291-298
output	O	299-305
,	O	305-306
total	O	307-312
peripheral	O	313-323
resistance	O	324-334
,	O	334-335
forearm	O	336-343
vascular	O	344-352
resistance	O	353-363
,	O	363-364
and	O	365-368
norepinephrine	O	369-383
spillover	O	384-393
to	O	394-396
plasma	O	397-403
in	O	404-406
eight	O	407-412
healthy	O	413-420
male	O	421-425
volunteers	O	426-436
.	O	436-437

Although	O	438-446
diastolic	O	447-456
blood	O	457-462
pressure	O	463-471
remained	O	472-480
unchanged	O	481-490
,	O	490-491
systolic	O	492-500
blood	O	501-506
pressure	O	507-515
increased	O	516-525
from	O	526-530
119	O	531-534
to	O	535-537
135	O	538-541
mm	O	542-544
Hg	O	545-547
(	O	548-549
SED	O	549-552
+	O	553-554
/	O	554-555
-	O	555-556
3	O	557-558
.	O	558-559
4	O	559-560
,	O	560-561
p	O	562-563
less	O	564-568
than	O	569-573
0	O	574-575
.	O	575-576
01	O	576-578
)	O	578-579
,	O	579-580
associated	O	581-591
with	O	592-596
an	O	597-599
increased	B	600-609
cardiac	I	610-617
output	I	618-624
(	O	625-626
5	O	626-627
.	O	627-628
85	O	628-630
-	O	630-631
7	O	631-632
.	O	627-628
73	O	633-635

l	O	636-637
/	O	637-638
min	O	638-641
,	O	641-642
SED	O	643-646
+	O	647-648
/	O	648-649
-	O	649-650
0	O	651-652
.	O	652-653
46	O	653-655
,	O	655-656
p	O	657-658
less	O	659-663
than	O	664-668
0	O	669-670
.	O	670-671
01	O	671-673
)	O	673-674
.	O	670-671

Total	O	676-681
peripheral	O	682-692
vascular	O	693-701
resistance	O	702-712
fell	O	713-717
from	O	718-722
15	O	723-725
.	O	725-726
1	O	723-724
to	O	728-730
12	O	731-733
.	O	733-734
2	O	732-733
mm	O	736-738
Hg	O	739-741
/	O	741-742
l	O	742-743
/	O	741-742
min	O	744-747
(	O	748-749
SED	O	749-752
+	O	753-754
/	O	754-755
-	O	755-756
1	O	757-758
.	O	758-759
03	O	759-761
,	O	761-762
p	O	763-764
less	O	765-769
than	O	770-774
0	O	775-776
.	O	776-777
05	O	777-779
)	O	779-780
.	O	776-777

Resting	O	782-789
forearm	O	790-797
vascular	O	798-806
resistance	O	807-817
remained	O	818-826
unchanged	O	827-836
,	O	836-837
but	O	838-841
the	O	842-845
reflex	O	846-852
response	O	853-861
to	O	862-864
the	O	865-868
cold	O	869-873
pressor	O	874-881
test	O	882-886
was	O	887-890
accentuated	O	891-902
,	O	902-903
the	O	904-907
rise	O	908-912
in	O	913-915
resistance	O	916-926
increasing	O	927-937
from	O	938-942
10	O	943-945
.	O	945-946
5	O	946-947
mm	O	948-950
Hg	O	951-953
/	O	953-954
ml	O	954-956
/	O	953-954
100	O	957-960
ml	O	961-963
/	O	963-964
min	O	964-967
(	O	968-969
R	O	969-970
units	O	971-976
)	O	976-977
before	O	978-984
treatment	O	985-994
to	O	995-997
32	O	998-1000
.	O	1000-1001
6	O	1001-1002
R	O	1003-1004
units	O	1005-1010
after	O	1011-1016
treatment	O	1017-1026
(	O	1027-1028
SED	O	1028-1031
+	O	1032-1033
/	O	1033-1034
-	O	1034-1035
6	O	1036-1037
.	O	1037-1038
4	O	1038-1039
,	O	1039-1040
p	O	1041-1042
less	O	1043-1047
than	O	1048-1052
0	O	1053-1054
.	O	1054-1055
025	O	1055-1058
)	O	1058-1059
.	O	1054-1055

The	O	1061-1064
rise	O	1065-1069
in	O	1070-1072
forearm	O	1073-1080
vascular	O	1081-1089
resistance	O	1090-1100
accompanying	O	1101-1113
intra	O	1114-1119
-	O	1119-1120
arterial	O	1120-1128
norepinephrine	O	1129-1143
(	O	1144-1145
25	O	1145-1147
,	O	1147-1148
50	O	1149-1151
,	O	1151-1152
and	O	1153-1156
100	O	1157-1160
ng	O	1161-1163
/	O	1163-1164
min	O	1164-1167
)	O	1167-1168
was	O	1169-1172
also	O	1173-1177
significantly	O	1178-1191
greater	O	1192-1199
after	O	1200-1205
hydrocortisone	O	1206-1220
,	O	1220-1221
increasing	O	1222-1232
from	O	1233-1237
an	O	1238-1240
average	O	1241-1248
of	O	1249-1251
14	O	1252-1254
.	O	1254-1255
9	O	1255-1256
+	O	1257-1258
/	O	1258-1259
-	O	1259-1260
2	O	1261-1262
.	O	1262-1263
4	O	1263-1264
R	O	1265-1266
units	O	1267-1272
before	O	1273-1279
treatment	O	1280-1289
to	O	1290-1292
35	O	1293-1295
.	O	1295-1296
1	O	1296-1297
+	O	1298-1299
/	O	1299-1300
-	O	1300-1301
5	O	1302-1303
.	O	1303-1304
5	O	1302-1303
R	O	1306-1307
units	O	1308-1313
after	O	1314-1319
hydrocortisone	O	1320-1334
(	O	1335-1336
SED	O	1336-1339
+	O	1340-1341
/	O	1341-1342
-	O	1342-1343
6	O	1344-1345
.	O	1345-1346
0	O	1346-1347
,	O	1347-1348
p	O	1349-1350
less	O	1351-1355
than	O	1356-1360
0	O	1361-1362
.	O	1362-1363
05	O	1363-1365
)	O	1365-1366
.	O	1362-1363

A	O	1368-1369
shift	O	1370-1375
to	O	1376-1378
the	O	1379-1382
left	O	1383-1387
in	O	1388-1390
the	O	1391-1394
dose	O	1395-1399
-	O	1399-1400
response	O	1400-1408
relation	O	1409-1417
and	O	1418-1421
fall	O	1422-1426
in	O	1427-1429
threshold	O	1430-1439
suggested	O	1440-1449
increased	O	1450-1459
sensitivity	O	1460-1471
to	O	1472-1474
norepinephrine	O	1475-1489
after	O	1490-1495
treatment	O	1496-1505
.	O	1505-1506

Measurement	O	1507-1518
of	O	1519-1521
resting	O	1522-1529
norepinephrine	O	1530-1544
spillover	O	1545-1554
rate	O	1555-1559
to	O	1560-1562
plasma	O	1563-1569
and	O	1570-1573
norepinephrine	O	1574-1588
uptake	O	1589-1595
indicated	O	1596-1605
that	O	1606-1610
overall	O	1611-1618
resting	O	1619-1626
sympathetic	O	1627-1638
nervous	O	1639-1646
system	O	1647-1653
activity	O	1654-1662
was	O	1663-1666
not	O	1667-1670
increased	O	1671-1680
.	O	1680-1681

The	O	1682-1685
rise	B	1686-1690
in	I	1691-1693
resting	I	1694-1701
blood	I	1702-1707
pressure	I	1708-1716
with	O	1717-1721
hydrocortisone	O	1722-1736
is	O	1737-1739
associated	O	1740-1750
with	O	1751-1755
an	O	1756-1758
increased	B	1759-1768
cardiac	I	1769-1776
output	I	1777-1783
(	O	1784-1785
presumably	O	1785-1795
due	O	1796-1799
to	O	1800-1802
increased	O	1803-1812
blood	O	1813-1818
volume	O	1819-1825
)	O	1825-1826
.	O	1826-1827
(	O	1827-1828
ABSTRACT	O	1828-1836

TRUNCATED	O	1837-1846
AT	O	1847-1849
250	O	1850-1853
WORDS	O	1854-1859
)	O	1859-1860

Effects	O	0-7
of	O	8-10
suprofen	O	11-19
on	O	20-22
the	O	23-26
isolated	O	27-35
perfused	O	36-44
rat	O	45-48
kidney	O	49-55
.	O	55-56

Although	O	57-65
suprofen	O	66-74
has	O	75-78
been	O	79-83
associated	O	84-94
with	O	95-99
the	O	100-103
development	O	104-115
of	O	116-118
acute	B	119-124
renal	I	125-130
failure	I	131-138
in	O	139-141
greater	O	142-149
than	O	150-154
100	O	155-158
subjects	O	159-167
,	O	167-168
the	O	169-172
mechanism	O	173-182
of	O	183-185
damage	O	186-192
remains	O	193-200
unclear	O	201-208
.	O	208-209

The	O	210-213
direct	O	214-220
nephrotoxic	B	221-232
effects	O	233-240
of	O	241-243
a	O	244-245
single	O	246-252
dose	O	253-257
of	O	258-260
15	O	261-263
mg	O	264-266
of	O	267-269
suprofen	O	270-278
were	O	279-283
compared	O	284-292
in	O	293-295
the	O	296-299
recirculating	O	300-313
isolated	O	314-322
rat	O	323-326
kidney	O	327-333
perfused	O	334-342
with	O	343-347
cell	O	348-352
-	O	352-353
free	O	353-357
buffer	O	358-364
with	O	365-369
or	O	370-372
without	O	373-380
the	O	381-384
addition	O	385-393
of	O	394-396
5	O	397-398
mg	O	399-401
/	O	401-402
dL	O	402-404
of	O	405-407
uric	O	408-412
acid	O	413-417
.	O	417-418

There	O	419-424
were	O	425-429
no	O	430-432
significant	O	433-444
differences	O	445-456
in	O	457-459
renal	O	460-465
sodium	O	466-472
excretion	O	473-482
,	O	482-483
oxygen	O	484-490
consumption	O	491-502
,	O	502-503
or	O	504-506
urinary	O	507-514
flow	O	515-519
rates	O	520-525
in	O	526-528
kidneys	O	529-536
perfused	O	537-545
with	O	546-550
suprofen	O	551-559
compared	O	560-568
with	O	569-573
the	O	574-577
drug	O	578-582
-	O	582-583
free	O	583-587
control	O	588-595
groups	O	596-602
.	O	602-603

In	O	604-606
contrast	O	607-615
,	O	615-616
a	O	617-618
significant	O	619-630
decline	O	631-638
in	O	639-641
glomerular	O	642-652
filtration	O	653-663
rate	O	664-668
was	O	669-672
found	O	673-678
after	O	679-684
the	O	685-688
introduction	O	689-701
of	O	702-704
suprofen	O	705-713
to	O	714-716
the	O	717-720
kidney	O	721-727
perfused	O	728-736
with	O	737-741
uric	O	742-746
acid	O	747-751
;	O	751-752
no	O	753-755
changes	O	756-763
were	O	764-768
found	O	769-774
with	O	775-779
suprofen	O	780-788
in	O	789-791
the	O	792-795
absence	O	796-803
of	O	804-806
uric	O	807-811
acid	O	812-816
.	O	816-817

A	O	818-819
significant	O	820-831
decrease	O	832-840
in	O	841-843
the	O	844-847
baseline	O	848-856
excretion	O	857-866
rate	O	867-871
of	O	872-874
uric	O	875-879
acid	O	880-884
was	O	885-888
found	O	889-894
in	O	895-897
rats	O	898-902
given	O	903-908
suprofen	O	909-917
,	O	917-918
compared	O	919-927
with	O	928-932
drug	O	933-937
-	O	937-938
free	O	938-942
controls	O	943-951
.	O	951-952

However	O	953-960
,	O	960-961
the	O	962-965
fractional	O	966-976
excretion	O	977-986
of	O	987-989
uric	O	990-994
acid	O	995-999
was	O	1000-1003
unchanged	O	1004-1013
between	O	1014-1021
the	O	1022-1025
groups	O	1026-1032
over	O	1033-1037
the	O	1038-1041
experimental	O	1042-1054
period	O	1055-1061
.	O	1061-1062

In	O	1063-1065
summary	O	1066-1073
,	O	1073-1074
suprofen	O	1075-1083
causes	O	1084-1090
acute	B	1091-1096
declines	I	1097-1105
in	I	1106-1108
renal	I	1109-1114
function	I	1115-1123
,	O	1123-1124
most	O	1125-1129
likely	O	1130-1136
by	O	1137-1139
directly	O	1140-1148
altering	O	1149-1157
the	O	1158-1161
intrarenal	O	1162-1172
distribution	O	1173-1185
of	O	1186-1188
uric	O	1189-1193
acid	O	1194-1198
.	O	1198-1199

Cocaine	O	0-7
-	O	7-8
induced	O	8-15
brainstem	O	16-25
seizures	B	26-34
and	O	35-38
behavior	O	39-47
.	O	47-48

A	O	49-50
variety	O	51-58
of	O	59-61
abnormal	O	62-70
sensory	O	71-78
/	O	78-79
motor	O	79-84
behaviors	O	85-94
associated	O	95-105
with	O	106-110
electrical	O	111-121
discharges	O	122-132
recorded	O	133-141
from	O	142-146
the	O	147-150
bilateral	O	151-160
brainstem	O	161-170
were	O	171-175
induced	O	176-183
in	O	184-186
adult	O	187-192
WKY	O	193-196
rats	O	197-201
by	O	202-204
mechanical	O	205-215
(	O	216-217
electrode	O	217-226
implants	O	227-235
)	O	235-236
and	O	237-240
DC	O	241-243
electrical	O	244-254
current	O	255-262
stimulations	O	263-275
and	O	276-279
by	O	280-282
acute	O	283-288
and	O	289-292
chronic	O	293-300
administration	O	301-315
of	O	316-318
cocaine	O	319-326
.	O	326-327

The	O	328-331
electrode	O	332-341
implant	O	342-349
implicated	O	350-360
one	O	361-364
side	O	365-369
or	O	370-372
the	O	373-376
other	O	377-382
of	O	383-385
the	O	386-389
reticular	O	390-399
system	O	400-406
of	O	407-409
the	O	410-413
brainstem	O	414-423
but	O	424-427
subjects	O	428-436
were	O	437-441
not	O	442-445
incapacitated	O	446-459
by	O	460-462
the	O	463-466
stimulations	O	467-479
.	O	479-480

Cocaine	O	481-488
(	O	489-490
40	O	490-492
mg	O	493-495
/	O	495-496
kg	O	496-498
)	O	498-499
was	O	500-503
injected	O	504-512
subcutaneously	O	513-527
for	O	528-531
an	O	532-534
acute	O	535-540
experiment	O	541-551
and	O	552-555
subsequent	O	556-566
20	O	567-569
mg	O	570-572
/	O	572-573
kg	O	573-575
doses	O	576-581
twice	O	582-587
daily	O	588-593
for	O	594-597
3	O	598-599
days	O	600-604
in	O	605-607
a	O	608-609
chronic	O	610-617
study	O	618-623
.	O	623-624

Cocaine	O	625-632
generated	O	633-642
more	O	643-647
abnormal	O	648-656
behaviors	O	657-666
in	O	667-669
the	O	670-673
brainstem	O	674-683
perturbation	O	684-696
group	O	697-702
,	O	702-703
especially	O	704-714
the	O	715-718
electrically	O	719-731
perturbated	O	732-743
subjects	O	744-752
.	O	752-753

The	O	754-757
abnormal	O	758-766
behaviors	O	767-776
were	O	777-781
yawning	O	782-789
,	O	789-790
retrocollis	O	791-802
,	O	802-803
hyperactivity	B	804-817
,	O	817-818
hypersensitivity	B	819-835
,	O	835-836
"	O	837-838
beating	O	838-845
drum	O	846-850
"	O	850-851
behavior	O	852-860
,	O	860-861
squealing	O	862-871
,	O	871-872
head	O	873-877
bobbing	O	878-885
,	O	885-886
circling	O	887-895
,	O	895-896
sniffing	O	897-905
,	O	905-906
abnormal	O	907-915
posturing	O	916-925
,	O	925-926
and	O	927-930
facial	O	931-937
twitching	O	938-947
.	O	947-948

Shifts	O	949-955
in	O	956-958
the	O	959-962
power	O	963-968
frequency	O	969-978
spectra	O	979-986
of	O	987-989
the	O	990-993
discharge	O	994-1003
patterns	O	1004-1012
were	O	1013-1017
noted	O	1018-1023
between	O	1024-1031
quiet	O	1032-1037
and	O	1038-1041
pacing	O	1042-1048
behavioral	O	1049-1059
states	O	1060-1066
.	O	1066-1067

Hypersensitivity	B	1068-1084
to	O	1085-1087
various	O	1088-1095
auditory	O	1096-1104
,	O	1104-1105
tactile	O	1106-1113
,	O	1113-1114
and	O	1115-1118
visual	O	1119-1125
stimulation	O	1126-1137
was	O	1138-1141
present	O	1142-1149
and	O	1150-1153
shifts	O	1154-1160
in	O	1161-1163
the	O	1164-1167
brainstem	O	1168-1177
ambient	O	1178-1185
power	O	1186-1191
spectral	O	1192-1200
frequency	O	1201-1210
occurred	O	1211-1219
in	O	1220-1222
response	O	1223-1231
to	O	1232-1234
tactile	O	1235-1242
stimulation	O	1243-1254
.	O	1254-1255

These	O	1256-1261
findings	O	1262-1270
suggest	O	1271-1278
that	O	1279-1283
the	O	1284-1287
brainstem	O	1288-1297
generates	O	1298-1307
and	O	1308-1311
propagates	O	1312-1322
pathological	O	1323-1335
discharges	O	1336-1346
that	O	1347-1351
can	O	1352-1355
be	O	1356-1358
elicited	O	1359-1367
by	O	1368-1370
mechanical	O	1371-1381
and	O	1382-1385
DC	O	1386-1388
electrical	O	1389-1399
perturbation	O	1400-1412
.	O	1412-1413

Cocaine	O	1414-1421
was	O	1422-1425
found	O	1426-1431
to	O	1432-1434
activate	O	1435-1443
the	O	1444-1447
discharge	O	1448-1457
system	O	1458-1464
and	O	1465-1468
thus	O	1469-1473
induce	O	1474-1480
abnormal	O	1481-1489
behaviors	O	1490-1499
that	O	1500-1504
are	O	1505-1508
generated	O	1509-1518
at	O	1519-1521
the	O	1522-1525
discharge	O	1526-1535
site	O	1536-1540
and	O	1541-1544
at	O	1545-1547
distant	O	1548-1555
sites	O	1556-1561
to	O	1562-1564
which	O	1565-1570
the	O	1571-1574
discharge	O	1575-1584
propagates	O	1585-1595
.	O	1595-1596

Cognitive	O	1597-1606
functions	O	1607-1616
may	O	1617-1620
also	O	1621-1625
be	O	1626-1628
involved	O	1629-1637
since	O	1638-1643
dopaminergic	O	1644-1656
and	O	1657-1660
serotonergic	O	1661-1673
cellular	O	1674-1682
elements	O	1683-1691
at	O	1692-1694
the	O	1695-1698
brainstem	O	1699-1708
level	O	1709-1714
are	O	1715-1718
also	O	1719-1723
implicated	O	1724-1734
.	O	1734-1735

Increased	O	0-9
sulfation	O	10-19
and	O	20-23
decreased	O	24-33
7alpha	O	34-40
-	O	40-41
hydroxylation	O	41-54
of	O	55-57
deoxycholic	O	58-69
acid	O	70-74
in	O	75-77
ethinyl	O	78-85
estradiol	O	86-95
-	O	95-96
induced	O	96-103
cholestasis	B	104-115
in	O	116-118
rats	O	119-123
.	O	123-124

Deoxycholic	O	125-136
acid	O	137-141
conjugation	O	142-153
,	O	153-154
transport	O	155-164
capacity	O	165-173
,	O	173-174
and	O	175-178
metabolism	O	179-189
were	O	190-194
compared	O	195-203
in	O	204-206
control	O	207-214
and	O	215-218
ethinyl	O	219-226
estradiol	O	227-236
-	O	236-237
treated	O	237-244
rats	O	245-249
.	O	249-250

Control	O	251-258
rats	O	259-263
were	O	264-268
found	O	269-274
to	O	275-277
have	O	278-282
a	O	283-284
lower	O	285-290
capacity	O	291-299
to	O	300-302
transport	O	303-312
deoxycholic	O	313-324
acid	O	325-329
than	O	330-334
taurodeoxycholic	O	335-351
acid	O	352-356
,	O	356-357
and	O	358-361
both	O	362-366
were	O	367-371
decreased	O	372-381
by	O	382-384
ethinyl	O	385-392
estradiol	O	393-402
treatment	O	403-412
.	O	412-413

During	O	414-420
[	O	421-422
24	O	422-424
-	O	424-425
14C	O	425-428
]	O	428-429
sodium	O	429-435
deoxycholate	O	436-448
infusion	O	449-457
,	O	457-458
[	O	459-460
14C	O	460-463
]	O	463-464
biliary	O	464-471
bile	O	472-476
acid	O	477-481
secretion	O	482-491
increased	O	492-501
,	O	501-502
but	O	503-506
bile	O	507-511
flow	O	512-516
did	O	517-520
not	O	521-524
change	O	525-531
significantly	O	532-545
in	O	546-548
either	O	549-555
control	O	556-563
or	O	564-566
ethinyl	O	567-574
estradiol	O	575-584
-	O	584-585
treated	O	585-592
rats	O	593-597
.	O	597-598

Ethinyl	O	599-606
estradiol	O	607-616
-	O	616-617
treated	O	617-624
animals	O	625-632
excreted	O	633-641
significantly	O	642-655
less	O	656-660
14C	O	661-664
as	O	665-667
taurocholic	O	668-679
acid	O	680-684
than	O	685-689
did	O	690-693
control	O	694-701
animals	O	702-709
,	O	709-710
consistent	O	711-721
with	O	722-726
an	O	727-729
impairment	O	730-740
of	O	741-743
7alpha	O	744-750
-	O	750-751
hydroxylation	O	751-764
of	O	765-767
taurodeoxycholic	O	768-784
acid	O	785-789
.	O	789-790

Ethinyl	O	791-798
estradiol	O	799-808
treatment	O	809-818
did	O	819-822
not	O	823-826
impair	O	827-833
conjugation	O	834-845
of	O	846-848
deoxycholic	O	849-860
acid	O	861-865
,	O	865-866
but	O	867-870
did	O	871-874
result	O	875-881
in	O	882-884
an	O	885-887
increase	O	888-896
in	O	897-899
sulfation	O	900-909
of	O	910-912
taurodeoxycholic	O	913-929
acid	O	930-934
from	O	935-939
1	O	940-941
.	O	941-942
5	O	942-943
%	O	943-944
in	O	945-947
controls	O	948-956
to	O	957-959
nearly	O	960-966
4	O	967-968
.	O	968-969
0	O	969-970
%	O	970-971
(	O	972-973
P	O	973-974
less	O	975-979
than	O	980-984
0	O	985-986
.	O	986-987
01	O	987-989
)	O	989-990
.	O	986-987

These	O	992-997
results	O	998-1005
are	O	1006-1009
consistent	O	1010-1020
with	O	1021-1025
the	O	1026-1029
hypothesis	O	1030-1040
that	O	1041-1045
the	O	1046-1049
rat	O	1050-1053
has	O	1054-1057
a	O	1058-1059
poorer	O	1060-1066
tolerance	O	1067-1076
for	O	1077-1080
deoxycholic	O	1081-1092
acid	O	1093-1097
than	O	1098-1102
do	O	1103-1105
certain	O	1106-1113
other	O	1114-1119
species	O	1120-1127
.	O	1127-1128

Furthermore	O	1129-1140
,	O	1140-1141
the	O	1142-1145
rat	O	1146-1149
converts	O	1150-1158
deoxycholic	O	1159-1170
acid	O	1171-1175
,	O	1175-1176
a	O	1177-1178
poor	O	1179-1183
choleretic	O	1184-1194
,	O	1194-1195
to	O	1196-1198
taurocholic	O	1199-1210
acid	O	1211-1215
,	O	1215-1216
a	O	1217-1218
good	O	1219-1223
choleretic	O	1224-1234
.	O	1234-1235

When	O	1236-1240
this	O	1241-1245
conversion	O	1246-1256
is	O	1257-1259
impaired	O	1260-1268
with	O	1269-1273
ethinyl	O	1274-1281
estradiol	O	1282-1291
treatment	O	1292-1301
,	O	1301-1302
sulfation	O	1303-1312
may	O	1313-1316
be	O	1317-1319
an	O	1320-1322
important	O	1323-1332
alternate	O	1333-1342
pathway	O	1343-1350
for	O	1351-1354
excretion	O	1355-1364
of	O	1365-1367
this	O	1368-1372
potentially	O	1373-1384
harmful	O	1385-1392
bile	O	1393-1397
acid	O	1398-1402
.	O	1402-1403

Effects	O	0-7
of	O	8-10
ouabain	O	11-18
on	O	19-21
myocardial	O	22-32
oxygen	O	33-39
supply	O	40-46
and	O	47-50
demand	O	51-57
in	O	58-60
patients	O	61-69
with	O	70-74
chronic	O	75-82
coronary	B	83-91
artery	I	92-98
disease	I	99-106
.	O	106-107

A	O	108-109
hemodynamic	O	110-121
,	O	121-122
volumetric	O	123-133
,	O	133-134
and	O	135-138
metabolic	O	139-148
study	O	149-154
in	O	155-157
patients	O	158-166
without	O	167-174
heart	B	175-180
failure	I	181-188
.	O	188-189

The	O	190-193
effects	O	194-201
of	O	202-204
digitalis	O	205-214
glycosides	O	215-225
on	O	226-228
myocardial	O	229-239
oxygen	O	240-246
supply	O	247-253
and	O	254-257
demand	O	258-264
are	O	265-268
of	O	269-271
particular	O	272-282
interest	O	283-291
in	O	292-294
the	O	295-298
presence	O	299-307
of	O	308-310
obstructive	O	311-322
coronary	B	323-331
artery	I	332-338
disease	I	339-346
,	O	346-347
but	O	348-351
have	O	352-356
not	O	357-360
been	O	361-365
measured	O	366-374
previously	O	375-385
in	O	386-388
man	O	389-392
.	O	392-393

We	O	394-396
assessed	O	397-405
the	O	406-409
effects	O	410-417
of	O	418-420
ouabain	O	421-428
(	O	429-430
0	O	430-431
.	O	431-432
015	O	432-435
mg	O	436-438
/	O	438-439
kg	O	439-441
body	O	442-446
weight	O	447-453
)	O	453-454
on	O	455-457
hemodynamic	O	458-469
,	O	469-470
volumetric	O	471-481
,	O	481-482
and	O	483-486
metabolic	O	487-496
parameters	O	497-507
in	O	508-510
11	O	511-513
patients	O	514-522
with	O	523-527
severe	O	528-534
chronic	O	535-542
coronary	B	543-551
artery	I	552-558
disease	I	559-566
without	O	567-574
clinical	O	575-583
congestive	B	584-594
heart	I	595-600
failure	I	601-608
.	O	608-609

Because	O	610-617
the	O	618-621
protocol	O	622-630
was	O	631-634
long	O	635-639
and	O	640-643
involved	O	644-652
interventions	O	653-666
which	O	667-672
might	O	673-678
affect	O	679-685
the	O	686-689
determinations	O	690-704
,	O	704-705
we	O	706-708
also	O	709-713
studied	O	714-721
in	O	722-724
nine	O	725-729
patients	O	730-738
using	O	739-744
an	O	745-747
identical	O	748-757
protocol	O	758-766
except	O	767-773
that	O	774-778
ouabain	O	779-786
administration	O	787-801
was	O	802-805
omitted	O	806-813
.	O	813-814

Left	O	815-819
ventricular	O	820-831
end	O	832-835
-	O	835-836
diastolic	O	836-845
pressure	O	846-854
and	O	855-858
left	O	859-863
ventricular	O	864-875
end	O	876-879
-	O	879-880
diastolic	O	880-889
volume	O	890-896
fell	O	897-901
in	O	902-904
each	O	905-909
patient	O	910-917
given	O	918-923
ouabain	O	924-931
,	O	931-932
even	O	933-937
though	O	938-944
they	O	945-949
were	O	950-954
initially	O	955-964
elevated	O	965-973
in	O	974-976
only	O	977-981
two	O	982-985
patients	O	986-994
.	O	994-995

Left	O	996-1000
ventricular	O	1001-1012
end	O	1013-1016
-	O	1016-1017
diastolic	O	1017-1026
pressure	O	1027-1035
fell	O	1036-1040
from	O	1041-1045
11	O	1046-1048
.	O	1048-1049
5	O	1049-1050
+	O	1050-1051
/	O	1051-1052
-	O	1052-1053
1	O	1046-1047
.	O	1048-1049
4	O	1055-1056

(	O	1057-1058
mean	O	1058-1062
+	O	1062-1063
/	O	1063-1064
-	O	1064-1065
SE	O	1065-1067
)	O	1067-1068
to	O	1069-1071
5	O	1072-1073
.	O	1073-1074
6	O	1074-1075
+	O	1075-1076
/	O	1076-1077
-	O	1077-1078
0	O	1078-1079
.	O	1073-1074
9	O	1080-1081

mm	O	1082-1084
Hg	O	1085-1087
(	O	1088-1089
P	O	1089-1090
less	O	1091-1095
than	O	1096-1100
0	O	1101-1102
.	O	1102-1103
001	O	1103-1106
)	O	1106-1107
and	O	1108-1111
left	O	1112-1116
ventricular	O	1117-1128
end	O	1129-1132
-	O	1132-1133
diastolic	O	1133-1142
volume	O	1143-1149
fell	O	1150-1154
from	O	1155-1159
100	O	1160-1163
+	O	1163-1164
/	O	1164-1165
-	O	1165-1166
17	O	1166-1168
to	O	1169-1171
82	O	1172-1174
+	O	1174-1175
/	O	1175-1176
-	O	1176-1177
12	O	1177-1179
ml	O	1180-1182
/	O	1182-1183
m2	O	1183-1185
(	O	1186-1187
P	O	1187-1188
less	O	1189-1193
than	O	1194-1198
0	O	1199-1200
.	O	1200-1201
01	O	1201-1203
)	O	1203-1204
1	O	1205-1206
h	O	1207-1208
after	O	1209-1214
ouabain	O	1215-1222
infusion	O	1223-1231
was	O	1232-1235
completed	O	1236-1245
.	O	1245-1246

The	O	1247-1250
maximum	O	1251-1258
velocity	O	1259-1267
of	O	1268-1270
contractile	O	1271-1282
element	O	1283-1290
shortening	O	1291-1301
increased	O	1302-1311
from	O	1312-1316
1	O	1317-1318
.	O	1318-1319
68	O	1319-1321
+	O	1321-1322
/	O	1322-1323
-	O	1323-1324
0	O	1324-1325
.	O	1318-1319
11	O	1326-1328

ml	O	1329-1331
/	O	1331-1332
s	O	1332-1333
to	O	1334-1336
2	O	1337-1338
.	O	1338-1339
18	O	1339-1341
+	O	1341-1342
/	O	1342-1343
-	O	1343-1344
0	O	1344-1345
.	O	1338-1339
21	O	1346-1348

muscle	O	1349-1355
-	O	1355-1356
lengths	O	1356-1363
/	O	1363-1364
s	O	1351-1352
(	O	1366-1367
P	O	1367-1368
less	O	1369-1373
than	O	1374-1378
0	O	1379-1380
.	O	1380-1381
05	O	1381-1383
)	O	1383-1384
and	O	1385-1388
is	O	1389-1391
consistent	O	1392-1402
with	O	1403-1407
an	O	1408-1410
increase	O	1411-1419
in	O	1420-1422
contractility	O	1423-1436
.	O	1436-1437

No	O	1438-1440
significant	O	1441-1452
change	O	1453-1459
in	O	1460-1462
these	O	1463-1468
parameters	O	1469-1479
occurred	O	1480-1488
in	O	1489-1491
the	O	1492-1495
control	O	1496-1503
patients	O	1504-1512
.	O	1512-1513

No	O	1514-1516
significant	O	1517-1528
change	O	1529-1535
in	O	1536-1538
myocardial	O	1539-1549
oxygen	O	1550-1556
consumption	O	1557-1568
occurred	O	1569-1577
after	O	1578-1583
ouabain	O	1584-1591
administration	O	1592-1606
but	O	1607-1610
this	O	1611-1615
may	O	1616-1619
be	O	1620-1622
related	O	1623-1630
to	O	1631-1633
a	O	1634-1635
greater	O	1636-1643
decrease	O	1644-1652
in	O	1653-1655
mean	O	1656-1660
arterial	O	1661-1669
pressure	O	1670-1678
in	O	1679-1681
the	O	1682-1685
ouabain	O	1686-1693
patients	O	1694-1702
than	O	1703-1707
in	O	1708-1710
the	O	1711-1714
control	O	1715-1722
patients	O	1723-1731
.	O	1731-1732

We	O	1733-1735
conclude	O	1736-1744
that	O	1745-1749
in	O	1750-1752
patients	O	1753-1761
with	O	1762-1766
chronic	O	1767-1774
coronary	B	1775-1783
artery	I	1784-1790
disease	I	1791-1798
who	O	1799-1802
are	O	1803-1806
not	O	1807-1810
in	O	1811-1813
clinical	O	1814-1822
congestive	B	1823-1833
heart	I	1834-1839
failure	I	1840-1847
left	B	1848-1852
ventricular	I	1853-1864
end	I	1865-1868
-	I	1868-1869
diastolic	I	1869-1878
volume	I	1879-1885
falls	I	1886-1891
after	O	1892-1897
ouabain	O	1898-1905
administration	O	1906-1920
even	O	1921-1925
when	O	1926-1930
it	O	1931-1933
is	O	1934-1936
initially	O	1937-1946
normal	O	1947-1953
.	O	1953-1954

Though	O	1955-1961
this	O	1962-1966
fall	O	1967-1971
would	O	1972-1977
be	O	1978-1980
associated	O	1981-1991
with	O	1992-1996
a	O	1997-1998
decrease	O	1999-2007
in	O	2008-2010
wall	O	2011-2015
tension	O	2016-2023
,	O	2023-2024
and	O	2025-2028
,	O	2028-2029
therefore	O	2030-2039
,	O	2039-2040
of	O	2041-2043
myocardial	O	2044-2054
oxygen	O	2055-2061
consumption	O	2062-2073
,	O	2073-2074
it	O	2075-2077
may	O	2078-2081
not	O	2082-2085
be	O	2086-2088
of	O	2089-2091
sufficient	O	2092-2102
magnitude	O	2103-2112
to	O	2113-2115
prevent	O	2116-2123
a	O	2124-2125
net	O	2126-2129
increase	O	2130-2138
in	O	2139-2141
myocardial	O	2142-2152
oxygen	O	2153-2159
consumption	O	2160-2171
.	O	2171-2172

Nevertheless	O	2173-2185
,	O	2185-2186
compensatory	O	2187-2199
mechanisms	O	2200-2210
prevent	O	2211-2218
a	O	2219-2220
deterioration	O	2221-2234
of	O	2235-2237
resting	O	2238-2245
myocardial	O	2246-2256
metabolism	O	2257-2267
.	O	2267-2268

Prolongation	B	0-12
of	I	13-15
the	I	16-19
QT	I	20-22
interval	I	23-31
related	O	32-39
to	O	40-42
cisapride	O	43-52
-	O	52-53
diltiazem	O	53-62
interaction	O	63-74
.	O	74-75

Cisapride	O	76-85
,	O	85-86
a	O	87-88
cytochrome	O	89-99
P450	O	100-104
3A4	O	105-108
(	O	109-110
CYP3A4	O	110-116
)	O	116-117
substrate	O	118-127
,	O	127-128
is	O	129-131
widely	O	132-138
prescribed	O	139-149
for	O	150-153
the	O	154-157
treatment	O	158-167
of	O	168-170
gastrointestinal	B	171-187
motility	I	188-196
disorders	I	197-206
.	O	206-207

Prolongation	B	208-220
of	I	221-223
QT	I	224-226
interval	I	227-235
,	O	235-236
torsades	B	237-245
de	I	246-248
pointes	I	249-256
,	O	256-257
and	O	258-261
sudden	B	262-268
cardiac	I	269-276
death	I	277-282
have	O	283-287
been	O	288-292
reported	O	293-301
after	O	302-307
concomitant	O	308-319
administration	O	320-334
with	O	335-339
erythromycin	O	340-352
or	O	353-355
azole	O	356-361
antifungal	O	362-372
agents	O	373-379
,	O	379-380
but	O	381-384
not	O	385-388
with	O	389-393
other	O	394-399
CYP3A4	O	400-406
inhibitors	O	407-417
.	O	417-418

A	O	419-420
possible	O	421-429
drug	O	430-434
interaction	O	435-446
occurred	O	447-455
in	O	456-458
a	O	459-460
45	O	461-463
-	O	463-464
year	O	464-468
-	O	463-464
old	O	469-472
woman	O	473-478
who	O	479-482
was	O	483-486
taking	O	487-493
cisapride	O	494-503
for	O	504-507
gastroesophageal	B	508-524
reflux	I	525-531
disorder	I	532-540
and	O	541-544
diltiazem	O	545-554
,	O	554-555
an	O	556-558
agent	O	559-564
that	O	565-569
has	O	570-573
inhibitory	O	574-584
effect	O	585-591
on	O	592-594
CYP3A4	O	595-601
,	O	601-602
for	O	603-606
hypertension	B	607-619
.	O	619-620

The	O	621-624
patient	O	625-632
was	O	633-636
in	O	637-639
near	O	640-644
syncope	B	645-652
and	O	653-656
had	O	657-660
QT	B	661-663
-	I	663-664
interval	I	664-672
prolongation	I	673-685
.	O	685-686

After	O	687-692
discontinuing	O	693-706
cisapride	O	707-716
,	O	716-717
the	O	718-721
QT	O	722-724
interval	O	725-733
returned	O	734-742
to	O	743-745
normal	O	746-752
and	O	753-756
symptoms	O	757-765
did	O	766-769
not	O	770-773
recur	O	774-779
.	O	779-780

We	O	781-783
suggest	O	784-791
that	O	792-796
caution	O	797-804
be	O	805-807
taken	O	808-813
when	O	814-818
cisapride	O	819-828
is	O	829-831
prescribed	O	832-842
with	O	843-847
any	O	848-851
potent	O	852-858
inhibitor	O	859-868
of	O	869-871
CYP3A4	O	872-878
,	O	878-879
including	O	880-889
diltiazem	O	890-899
.	O	899-900

Paclitaxel	O	0-10
combined	O	11-19
with	O	20-24
carboplatin	O	25-36
in	O	37-39
the	O	40-43
first	O	44-49
-	O	49-50
line	O	50-54
treatment	O	55-64
of	O	65-67
advanced	O	68-76
ovarian	B	77-84
cancer	I	85-91
.	O	91-92

In	O	93-95
a	O	96-97
phase	O	98-103
I	O	104-105
study	O	106-111
to	O	112-114
determine	O	115-124
the	O	125-128
maximum	O	129-136
tolerated	O	137-146
dose	O	147-151
of	O	152-154
paclitaxel	O	155-165
(	O	166-167
Taxol	O	167-172
;	O	172-173
Bristol	O	174-181
-	O	181-182
Myers	O	182-187
Squibb	O	188-194
Company	O	195-202
,	O	202-203
Princeton	O	204-213
,	O	213-214
NJ	O	215-217
)	O	217-218
given	O	219-224
as	O	225-227
a	O	228-229
3	O	230-231
-	O	231-232
hour	O	232-236
infusion	O	237-245
in	O	246-248
combination	O	249-260
with	O	261-265
carboplatin	O	266-277
administered	O	278-290
every	O	291-296
21	O	297-299
days	O	300-304
to	O	305-307
women	O	308-313
with	O	314-318
advanced	O	319-327
ovarian	B	328-335
cancer	I	336-342
,	O	342-343
paclitaxel	O	344-354
doses	O	355-360
were	O	361-365
escalated	O	366-375
as	O	376-378
follows	O	379-386
:	O	386-387
level	O	388-393
1	O	394-395
,	O	395-396
135	O	397-400
mg	O	401-403
/	O	403-404
m2	O	404-406
;	O	406-407
level	O	408-413
2	O	414-415
,	O	415-416
160	O	417-420
mg	O	421-423
/	O	423-424
m2	O	424-426
;	O	426-427
level	O	428-433
3	O	434-435
,	O	435-436
185	O	437-440
mg	O	441-443
/	O	443-444
m2	O	444-446
;	O	446-447
and	O	448-451
level	O	452-457
4	O	458-459
,	O	459-460
210	O	460-463
mg	O	464-466
/	O	466-467
m2	O	467-469
.	O	469-470

The	O	471-474
fixed	O	475-480
dose	O	481-485
of	O	486-488
carboplatin	O	489-500
at	O	501-503
levels	O	504-510
1	O	511-512
through	O	513-520
4	O	521-522
was	O	523-526
given	O	527-532
to	O	533-535
achieve	O	536-543
an	O	544-546
area	O	547-551
under	O	552-557
the	O	558-561
concentration	O	562-575
-	O	575-576
time	O	576-580
curve	O	581-586
(	O	587-588
AUC	O	588-591
)	O	591-592
of	O	593-595
5	O	596-597
using	O	598-603
the	O	604-607
Calvert	O	608-615
formula	O	616-623
.	O	623-624

In	O	625-627
levels	O	628-634
5	O	635-636
and	O	637-640
6	O	641-642
the	O	643-646
carboplatin	O	647-658
dose	O	659-663
was	O	664-667
targeted	O	668-676
at	O	677-679
AUCs	O	680-684
of	O	685-687
6	O	688-689
and	O	690-693
7	O	694-695
.	O	695-696
5	O	696-697
,	O	697-698
respectively	O	699-711
,	O	711-712
combined	O	713-721
with	O	722-726
a	O	727-728
fixed	O	729-734
paclitaxel	O	735-745
dose	O	746-750
of	O	751-753
185	O	754-757
mg	O	758-760
/	O	760-761
m2	O	761-763
.	O	763-764

To	O	765-767
date	O	768-772
,	O	772-773
30	O	774-776
previously	O	777-787
untreated	O	788-797
patients	O	798-806
,	O	806-807
all	O	808-811
with	O	812-816
a	O	817-818
good	O	819-823
performance	O	824-835
status	O	836-842
(	O	843-844
Eastern	O	844-851
Cooperative	O	852-863
Oncology	O	864-872
Group	O	873-878
0	O	879-880
to	O	881-883
2	O	884-885
)	O	885-886
have	O	887-891
been	O	892-896
entered	O	897-904
into	O	905-909
this	O	910-914
ongoing	O	915-922
study	O	923-928
.	O	928-929

The	O	930-933
dose	O	934-938
-	O	938-939
limiting	O	939-947
toxicity	B	948-956
of	O	957-959
the	O	960-963
combination	O	964-975
was	O	976-979
myelosuppression	B	980-996
(	O	997-998
leukopenia	B	998-1008
,	O	1008-1009
granulocytopenia	B	1010-1026
,	O	1026-1027
and	O	1028-1031
thrombocytopenia	B	1032-1048
)	O	1048-1049
.	O	1049-1050

Neurotoxicity	B	1051-1064
was	O	1065-1068
largely	O	1069-1076
moderate	O	1077-1085
.	O	1085-1086

So	O	1087-1089
far	O	1090-1093
,	O	1093-1094
14	O	1095-1097
patients	O	1098-1106
are	O	1107-1110
evaluable	O	1111-1120
for	O	1121-1124
response	O	1125-1133
;	O	1133-1134
of	O	1135-1137
these	O	1138-1143
,	O	1143-1144
eight	O	1145-1150
(	O	1151-1152
57	O	1152-1154
%	O	1154-1155
)	O	1155-1156
showed	O	1157-1163
objective	O	1164-1173
(	O	1174-1175
complete	O	1175-1183
or	O	1184-1186
partial	O	1187-1194
)	O	1194-1195
response	O	1196-1204
and	O	1205-1208
disease	O	1209-1216
stabilized	O	1217-1227
in	O	1228-1230
six	O	1231-1234
patients	O	1235-1243
.	O	1243-1244

No	O	1245-1247
patient	O	1248-1255
had	O	1256-1259
disease	O	1260-1267
progression	O	1268-1279
.	O	1279-1280

We	O	1281-1283
conclude	O	1284-1292
that	O	1293-1297
the	O	1298-1301
combination	O	1302-1313
of	O	1314-1316
paclitaxel	O	1317-1327
185	O	1328-1331
mg	O	1332-1334
/	O	1334-1335
m2	O	1335-1337
administered	O	1338-1350
as	O	1351-1353
a	O	1354-1355
3	O	1356-1357
-	O	1357-1358
hour	O	1358-1362
infusion	O	1363-1371
followed	O	1372-1380
immediately	O	1381-1392
by	O	1393-1395
a	O	1396-1397
1	O	1398-1399
-	O	1399-1400
hour	O	1400-1404
infusion	O	1405-1413
of	O	1414-1416
carboplatin	O	1417-1428
at	O	1429-1431
an	O	1432-1434
AUC	O	1435-1438
of	O	1439-1441
6	O	1442-1443
can	O	1444-1447
be	O	1448-1450
administered	O	1451-1463
safely	O	1464-1470
in	O	1471-1473
a	O	1474-1475
21	O	1476-1478
-	O	1478-1479
day	O	1479-1482
schedule	O	1483-1491
in	O	1492-1494
the	O	1495-1498
outpatient	O	1499-1509
setting	O	1510-1517
.	O	1517-1518

The	O	1519-1522
recommended	O	1523-1534
dose	O	1535-1539
for	O	1540-1543
phase	O	1544-1549
III	O	1550-1553
studies	O	1554-1561
is	O	1562-1564
paclitaxel	O	1565-1575
185	O	1576-1579
mg	O	1580-1582
/	O	1582-1583
m2	O	1583-1585
and	O	1586-1589
carboplatin	O	1590-1601
AUC	O	1602-1605
6	O	1606-1607
.	O	1607-1608

Treatment	O	0-9
of	O	10-12
tacrolimus	O	13-23
-	O	23-24
related	O	24-31
adverse	O	32-39
effects	O	40-47
by	O	48-50
conversion	O	51-61
to	O	62-64
cyclosporine	O	65-77
in	O	78-80
liver	O	81-86
transplant	O	87-97
recipients	O	98-108
.	O	108-109

When	O	110-114
tacrolimus	O	115-125
side	O	126-130
effects	O	131-138
persist	O	139-146
despite	O	147-154
dose	O	155-159
reduction	O	160-169
,	O	169-170
conversion	O	171-181
to	O	182-184
cyclosporine	O	185-197
-	O	197-198
based	O	198-203
immunosuppression	O	204-221
(	O	222-223
CyA	O	223-226
)	O	226-227
is	O	228-230
necessary	O	231-240
.	O	240-241

We	O	242-244
characterized	O	245-258
tacrolimus	O	259-269
side	O	270-274
effects	O	275-282
that	O	283-287
warranted	O	288-297
discontinuation	O	298-313
of	O	314-316
the	O	317-320
drug	O	321-325
,	O	325-326
and	O	327-330
outcomes	O	331-339
after	O	340-345
conversion	O	346-356
.	O	356-357

Of	O	358-360
388	O	361-364
liver	O	365-370
recipients	O	371-381
who	O	382-385
received	O	386-394
tacrolimus	O	395-405
as	O	406-408
primary	O	409-416
immunosuppression	O	417-434
,	O	434-435
70	O	436-438
required	O	439-447
conversion	O	448-458
to	O	459-461
CyA	O	462-465
.	O	465-466

We	O	467-469
recorded	O	470-478
indication	O	479-489
for	O	490-493
conversion	O	494-504
,	O	504-505
whether	O	506-513
conversion	O	514-524
was	O	525-528
early	O	529-534
or	O	535-537
late	O	538-542
after	O	543-548
transplantation	O	549-564
,	O	564-565
tacrolimus	O	566-576
dose	O	577-581
and	O	582-585
trough	O	586-592
blood	O	593-598
level	O	599-604
at	O	605-607
conversion	O	608-618
,	O	618-619
and	O	620-623
incidence	O	624-633
of	O	634-636
rejection	O	637-646
after	O	647-652
conversion	O	653-663
.	O	663-664

Conversion	O	665-675
was	O	676-679
early	O	680-685
in	O	686-688
29	O	689-691
patients	O	692-700
(	O	701-702
41	O	702-704
.	O	704-705
4	O	702-703
%	O	706-707
)	O	707-708
and	O	709-712
late	O	713-717
in	O	718-720
41	O	721-723
(	O	724-725
58	O	725-727
.	O	727-728
6	O	728-729
%	O	729-730
)	O	730-731
.	O	727-728

Indications	O	733-744
for	O	745-748
early	O	749-754
conversion	O	755-765
were	O	766-770
neurotoxicity	B	771-784
(	O	785-786
20	O	786-788
)	O	788-789
,	O	789-790
(	B	791-792
insulin	I	792-799
-	I	799-800
dependent	I	800-809
)	I	809-810
diabetes	I	811-819
mellitus	I	820-828
(	O	829-830
IDDM	B	830-834
)	O	834-835
(	O	836-837
5	O	837-838
)	O	838-839
,	O	839-840
nephrotoxicity	B	841-855
(	O	856-857
3	O	857-858
)	O	858-859
,	O	859-860
gastrointestinal	B	861-877
(	I	878-879
GI	I	879-881
)	I	881-882
toxicity	I	883-891
(	O	892-893
6	O	893-894
)	O	894-895
,	O	895-896
and	O	897-900
cardiomyopathy	B	901-915
(	O	916-917
1	O	917-918
)	O	918-919
,	O	919-920
and	O	921-924
for	O	925-928
late	O	929-933
conversion	O	934-944
were	O	945-949
neurotoxicity	B	950-963
(	O	964-965
15	O	965-967
)	O	967-968
,	O	968-969
IDDM	B	970-974
(	O	975-976
12	O	976-978
)	O	978-979
,	O	979-980
nephrotoxicity	B	981-995
(	O	996-997
3	O	997-998
)	O	998-999
,	O	999-1000
GI	B	1001-1003
toxicity	I	1004-1012
(	O	1013-1014
5	O	1014-1015
)	O	1015-1016
,	O	1016-1017
hepatotoxicity	B	1018-1032
(	O	1033-1034
6	O	1034-1035
)	O	1035-1036
,	O	1036-1037
post	B	1038-1042
-	I	1042-1043
transplant	I	1043-1053
lmphoproliferate	I	1054-1070
disease	I	1071-1078
(	O	1079-1080
PTLD	B	1080-1084
)	O	1084-1085
(	O	1086-1087
2	O	1087-1088
)	O	1088-1089
,	O	1089-1090
cardiomyopathy	B	1091-1105
(	O	1106-1107
1	O	1107-1108
)	O	1108-1109
,	O	1109-1110
hemolytic	B	1111-1120
anemia	I	1121-1127
(	O	1128-1129
1	O	1129-1130
)	O	1130-1131
,	O	1131-1132
and	O	1133-1136
pruritus	B	1137-1145
(	O	1146-1147
1	O	1147-1148
)	O	1148-1149
.	O	1149-1150

All	O	1151-1154
early	O	1155-1160
-	O	1160-1161
conversion	O	1161-1171
patients	O	1172-1180
showed	O	1181-1187
improvement	O	1188-1199
/	O	1199-1200
resolution	O	1200-1210
of	O	1211-1213
symptoms	O	1214-1222
.	O	1222-1223

Among	O	1224-1229
late	O	1230-1234
-	O	1234-1235
conversion	O	1235-1245
patients	O	1246-1254
,	O	1254-1255
37	O	1256-1258
(	O	1259-1260
90	O	1260-1262
.	O	1262-1263
2	O	1263-1264
%	O	1264-1265
)	O	1265-1266
had	O	1267-1270
improvement	O	1271-1282
/	O	1282-1283
resolution	O	1283-1293
;	O	1293-1294
in	O	1295-1297
4	O	1298-1299
(	O	1300-1301
9	O	1301-1302
.	O	1302-1303
8	O	1303-1304
%	O	1304-1305
)	O	1305-1306
,	O	1306-1307

adverse	O	1308-1315
effects	O	1316-1323
persisted	O	1324-1333
.	O	1333-1334

The	O	1335-1338
overall	O	1339-1346
rejection	O	1347-1356
rate	O	1357-1361
was	O	1362-1365
30	O	1366-1368
%	O	1368-1369
.	O	1369-1370

Sixty	O	1371-1376
-	O	1376-1377
two	O	1377-1380
patients	O	1381-1389
(	O	1390-1391
88	O	1391-1393
.	O	1393-1394
6	O	1394-1395
%	O	1395-1396
)	O	1396-1397
are	O	1398-1401
alive	O	1402-1407
with	O	1408-1412
functioning	O	1413-1424
grafts	O	1425-1431
686	O	1432-1435
+	O	1436-1437
/	O	1437-1438
-	O	1438-1439
362	O	1440-1443
days	O	1444-1448
(	O	1449-1450
range	O	1450-1455
,	O	1455-1456
154	O	1457-1460
-	O	1460-1461
1433	O	1461-1465
days	O	1466-1470
)	O	1470-1471
after	O	1472-1477
conversion	O	1478-1488
.	O	1488-1489

When	O	1490-1494
tacrolimus	O	1495-1505
side	O	1506-1510
effects	O	1511-1518
are	O	1519-1522
unresponsive	O	1523-1535
to	O	1536-1538
dose	O	1539-1543
reduction	O	1544-1553
,	O	1553-1554
conversion	O	1555-1565
to	O	1566-1568
CyA	O	1569-1572
can	O	1573-1576
be	O	1577-1579
accomplished	O	1580-1592
safely	O	1593-1599
,	O	1599-1600
with	O	1601-1605
no	O	1606-1608
increased	O	1609-1618
risk	O	1619-1623
of	O	1624-1626
rejection	O	1627-1636
and	O	1637-1640
excellent	O	1641-1650
long	O	1651-1655
-	O	1655-1656
term	O	1656-1660
outcome	O	1661-1668
.	O	1668-1669

Relative	O	0-8
efficacy	O	9-17
and	O	18-21
toxicity	B	22-30
of	O	31-33
netilmicin	O	34-44
and	O	45-48
tobramycin	O	49-59
in	O	60-62
oncology	O	63-71
patients	O	72-80
.	O	80-81

We	O	82-84
prospectively	O	85-98
compared	O	99-107
the	O	108-111
efficacy	O	112-120
and	O	121-124
safety	O	125-131
of	O	132-134
netilmicin	O	135-145
sulfate	O	146-153
or	O	154-156
tobramycin	O	157-167
sulfate	O	168-175
in	O	176-178
conjunction	O	179-190
with	O	191-195
piperacillin	O	196-208
sodium	O	209-215
in	O	216-218
118	O	219-222
immunocompromised	O	223-240
patients	O	241-249
with	O	250-254
presumed	O	255-263
severe	O	264-270
infections	B	271-281
.	O	281-282

The	O	283-286
two	O	287-290
treatment	O	291-300
regimens	O	301-309
were	O	310-314
equally	O	315-322
efficacious	O	323-334
.	O	334-335

Nephrotoxicity	B	336-350
occurred	O	351-359
in	O	360-362
a	O	363-364
similar	O	365-372
proportion	O	373-383
in	O	384-386
patients	O	387-395
treated	O	396-403
with	O	404-408
netilmicin	O	409-419
and	O	420-423
tobramycin	O	424-434
(	O	435-436
17	O	436-438
%	O	438-439
vs	O	440-442
11	O	443-445
%	O	445-446
)	O	446-447
.	O	447-448

Ototoxicity	B	449-460
occurred	O	461-469
in	O	470-472
four	O	473-477
(	O	478-479
9	O	479-480
.	O	480-481
5	O	481-482
%	O	482-483
)	O	483-484
of	O	485-487
42	O	488-490
netilmicin	O	491-501
and	O	502-505
piperacillin	O	506-518
and	O	519-522
in	O	523-525
12	O	526-528
(	O	529-530
22	O	530-532
%	O	532-533
)	O	533-534
of	O	535-537
54	O	538-540
tobramycin	O	541-551
and	O	552-555
piperacillin	O	556-568
-	O	568-569
treated	O	569-576
patients	O	577-585
.	O	585-586

Of	O	587-589
those	O	590-595
evaluated	O	596-605
with	O	606-610
posttherapy	O	611-622
audiograms	O	623-633
,	O	633-634
three	O	635-640
of	O	641-643
four	O	644-648
netilmicin	O	649-659
and	O	660-663
piperacillin	O	664-676
-	O	676-677
treated	O	677-684
patients	O	685-693
had	O	694-697
auditory	O	698-706
thresholds	O	707-717
return	O	718-724
to	O	725-727
baseline	O	728-736
compared	O	737-745
with	O	746-750
one	O	751-754
of	O	755-757
nine	O	758-762
tobramycin	O	763-773
and	O	774-777
piperacillin	O	778-790
-	O	790-791
treated	O	791-798
patients	O	799-807
.	O	807-808

The	O	809-812
number	O	813-819
of	O	820-822
greater	O	823-830
than	O	831-835
or	O	836-838
equal	O	839-844
to	O	845-847
15	O	848-850
-	O	850-851
dB	O	851-853
increases	O	854-863
in	O	864-866
auditory	O	867-875
threshold	O	876-885
as	O	886-888
a	O	889-890
proportion	O	891-901
of	O	902-904
total	O	905-910
greater	O	911-918
than	O	919-923
or	O	924-926
equal	O	927-932
to	O	933-935
15	O	936-938
-	O	938-939
dB	O	939-941
changes	O	942-949
(	O	950-951
increases	O	951-960
and	O	961-964
decreases	O	965-974
)	O	974-975
was	O	976-979
significantly	O	980-993
lower	O	994-999
in	O	1000-1002
netilmicin	O	1003-1013
and	O	1014-1017
piperacillin	O	1018-1030
-	O	1030-1031
vs	O	1032-1034
tobramycin	O	1035-1045
and	O	1046-1049
piperacillin	O	1050-1062
-	O	1062-1063
treated	O	1063-1070
patients	O	1071-1079
(	O	1080-1081
18	O	1081-1083
of	O	1084-1086
78	O	1087-1089
vs	O	1090-1092
67	O	1093-1095
of	O	1096-1098
115	O	1099-1102
)	O	1102-1103
.	O	1103-1104

We	O	1105-1107
conclude	O	1108-1116
that	O	1117-1121
aminoglycoside	O	1122-1136
-	O	1136-1137
associated	O	1137-1147
ototoxicity	B	1148-1159
was	O	1160-1163
less	O	1164-1168
severe	O	1169-1175
and	O	1176-1179
more	O	1180-1184
often	O	1185-1190
reversible	O	1191-1201
with	O	1202-1206
netilmicin	O	1207-1217
than	O	1218-1222
with	O	1223-1227
tobramycin	O	1228-1238
.	O	1238-1239

Effect	O	0-6
of	O	7-9
prostaglandin	O	10-23
synthetase	O	24-34
inhibitors	O	35-45
on	O	46-48
experimentally	O	49-63
induced	O	64-71
convulsions	B	72-83
in	O	84-86
rats	O	87-91
.	O	91-92

To	O	93-95
investigate	O	96-107
the	O	108-111
relationship	O	112-124
of	O	125-127
prostaglandins	O	128-142
(	O	143-144
PGs	O	144-147
)	O	147-148
to	O	149-151
seizure	B	152-159
induction	O	160-169
,	O	169-170
the	O	171-174
effects	O	175-182
of	O	183-185
six	O	186-189
PG	O	190-192
synthetase	O	193-203
inhibitors	O	204-214
on	O	215-217
convulsions	B	218-229
induced	O	230-237
by	O	238-240
flurothyl	O	241-250
,	O	250-251
picrotoxin	O	252-262
,	O	262-263
pentetrazol	O	264-275
(	O	276-277
PTZ	O	277-280
)	O	280-281
,	O	281-282
electroshock	O	283-295
or	O	296-298
bicuculline	O	299-310
were	O	311-315
evaluated	O	316-325
.	O	325-326

Ibuprofen	O	327-336
,	O	336-337
sulindac	O	338-346
,	O	346-347
mefenamic	O	348-357
acid	O	358-362
,	O	362-363
and	O	364-367
low	O	368-371
dose	O	372-376
meclofenamic	O	377-389
acid	O	390-394
increased	O	395-404
the	O	405-408
latency	O	409-416
-	O	416-417
to	O	417-419
-	O	416-417
onset	O	420-425
in	O	426-428
the	O	429-432
flurothyl	O	433-442
and	O	443-446
/	O	446-447
or	O	447-449
PTZ	O	450-453
models	O	454-460
;	O	460-461
the	O	462-465
electroshock	O	466-478
,	O	478-479
picrotoxin	O	480-490
and	O	491-494
bicuculline	O	495-506
models	O	507-513
were	O	514-518
not	O	519-522
significantly	O	523-536
affected	O	537-545
by	O	546-548
any	O	549-552
of	O	553-555
the	O	556-559
pretreatment	O	560-572
agents	O	573-579
.	O	579-580

These	O	581-586
results	O	587-594
suggest	O	595-602
that	O	603-607
PGs	O	608-611
are	O	612-615
involved	O	616-624
in	O	625-627
the	O	628-631
mechanism	O	632-641
(	O	641-642
s	O	639-640
)	O	643-644
underlying	O	645-655
fluorthyl	O	656-665
-	O	665-666
and	O	667-670
PTZ	O	671-674
-	O	674-675
induced	O	675-682
convulsions	B	683-694
,	O	694-695
but	O	696-699
not	O	700-703
picrotoxin	O	704-714
-	O	714-715
,	O	715-716
electroshock	O	717-729
-	O	729-730
,	O	730-731
or	O	732-734
bicuculline	O	735-746
-	O	746-747
induced	O	747-754
convulsions	B	755-766
.	O	766-767

Angiotensin	O	0-11
-	O	11-12
converting	O	12-22
enzyme	O	23-29
(	O	30-31
ACE	O	31-34
)	O	34-35
inhibitor	O	36-45
-	O	45-46
associated	O	46-56
angioedema	B	57-67
of	O	68-70
the	O	71-74
stomach	O	75-82
and	O	83-86
small	O	87-92
intestine	O	93-102
:	O	102-103
a	O	104-105
case	O	106-110
report	O	111-117
.	O	117-118

This	O	119-123
is	O	124-126
a	O	127-128
case	O	129-133
report	O	134-140
on	O	141-143
a	O	144-145
45	O	146-148
-	O	148-149
year	O	149-153
old	O	154-157
African	O	158-165
-	O	165-166
American	O	166-174
female	O	175-181
with	O	182-186
newly	O	187-192
diagnosed	O	193-202
hypertension	B	203-215
,	O	215-216
who	O	217-220
was	O	221-224
started	O	225-232
on	O	233-235
a	O	236-237
combination	O	238-249
pill	O	250-254
of	O	255-257
amlodipine	O	258-268
/	O	268-269
benazapril	O	269-279
10	O	280-282
/	O	282-283
5	O	283-284
mg	O	285-287
.	O	287-288

The	O	289-292
very	O	293-297
next	O	298-302
day	O	303-306
,	O	306-307
she	O	308-311
presented	O	312-321
at	O	322-324
the	O	325-328
emergency	O	329-338
room	O	339-343
(	O	344-345
ER	O	345-347
)	O	347-348
with	O	349-353
abdominal	B	354-363
pain	I	364-368
,	O	368-369
nausea	B	370-376
and	O	377-380
vomiting	B	381-389
.	O	389-390

Physical	O	391-399
exam	O	400-404
,	O	404-405
complete	O	406-414
metabolic	O	415-424
panel	O	425-430
,	O	430-431
and	O	432-435
hemogram	O	436-444
were	O	445-449
in	O	450-452
the	O	453-456
normal	O	457-463
range	O	464-469
.	O	469-470

She	O	471-474
was	O	475-478
discharged	O	479-489
from	O	490-494
the	O	495-498
ER	O	499-501
after	O	502-507
a	O	508-509
few	O	510-513
hours	O	514-519
of	O	520-522
treatment	O	523-532
with	O	533-537
fluid	O	538-543
and	O	544-547
analgesics	O	548-558
.	O	558-559

However	O	560-567
,	O	567-568
she	O	569-572
returned	O	573-581
to	O	582-584
the	O	585-588
ER	O	589-591
the	O	592-595
next	O	596-600
day	O	601-604
with	O	605-609
the	O	610-613
same	O	614-618
complaints	O	619-629
.	O	629-630

This	O	631-635
time	O	636-640
the	O	641-644
physical	O	645-653
exam	O	654-658
was	O	659-662
significant	O	663-674
for	O	675-678
a	O	679-680
distended	O	681-690
abdomen	O	691-698
with	O	699-703
dullness	O	704-712
to	O	713-715
percussion	O	716-726
.	O	726-727

CT	O	728-730
scan	O	731-735
of	O	736-738
the	O	739-742
abdomen	O	743-750
revealed	O	751-759
markedly	O	760-768
thickened	O	769-778
antrum	O	779-785
of	O	786-788
the	O	789-792
stomach	O	793-800
,	O	800-801
duodenum	O	802-810
and	O	811-814
jejunum	O	815-822
,	O	822-823
along	O	824-829
with	O	830-834
fluid	O	835-840
in	O	841-843
the	O	844-847
abdominal	O	848-857
and	O	858-861
pelvic	O	862-868
cavity	O	869-875
.	O	875-876

Angiotensin	O	877-888
-	O	888-889
converting	O	889-899
enzyme	O	900-906
inhibitor	O	907-916
(	O	917-918
ACEI	O	918-922
)	O	922-923
-	O	923-924
induced	O	924-931
angioedema	B	932-942
was	O	943-946
suspected	O	947-956
,	O	956-957
and	O	958-961
anti	O	962-966
-	O	966-967
hypertensive	B	967-979
medications	O	980-991
were	O	992-996
discontinued	O	997-1009
.	O	1009-1010

Her	O	1011-1014
symptoms	O	1015-1023
improved	O	1024-1032
within	O	1033-1039
the	O	1040-1043
next	O	1044-1048
24	O	1049-1051
hours	O	1052-1057
,	O	1057-1058
and	O	1059-1062
repeat	O	1063-1069
CT	O	1070-1072
after	O	1073-1078
72	O	1079-1081
hours	O	1082-1087
revealed	O	1088-1096
marked	O	1097-1103
improvement	O	1104-1115
in	O	1116-1118
stomach	O	1119-1126
and	O	1127-1130
small	O	1131-1136
bowel	O	1137-1142
thickening	O	1143-1153
and	O	1154-1157
resolution	O	1158-1168
of	O	1169-1171
ascites	B	1172-1179
.	O	1179-1180

The	O	1181-1184
recognition	O	1185-1196
of	O	1197-1199
angiotensin	O	1200-1211
-	O	1211-1212
converting	O	1212-1222
enzyme	O	1223-1229
(	O	1230-1231
ACE	O	1231-1234
)	O	1234-1235
and	O	1236-1239
angiotensin	O	1240-1251
receptor	O	1252-1260
blocker	O	1261-1268
(	O	1269-1270
ARB	O	1270-1273
)	O	1273-1274
intestinal	B	1275-1285
angioedema	I	1286-1296
constitutes	O	1297-1308
a	O	1309-1310
challenge	O	1311-1320
to	O	1321-1323
primary	O	1324-1331
care	O	1332-1336
physicians	O	1337-1347
,	O	1347-1348
internists	O	1349-1359
,	O	1359-1360
emergency	O	1361-1370
room	O	1371-1375
personal	O	1376-1384
and	O	1385-1388
surgeons	O	1389-1397
.	O	1397-1398

Valproic	O	0-8
acid	O	9-13
I	O	14-15
:	O	15-16
time	O	17-21
course	O	22-28
of	O	29-31
lipid	O	32-37
peroxidation	O	38-50
biomarkers	O	51-61
,	O	61-62
liver	B	63-68
toxicity	I	69-77
,	O	77-78
and	O	79-82
valproic	O	83-91
acid	O	92-96
metabolite	O	97-107
levels	O	108-114
in	O	115-117
rats	O	118-122
.	O	122-123

A	O	124-125
single	O	126-132
dose	O	133-137
of	O	138-140
valproic	O	141-149
acid	O	150-154
(	O	155-156
VPA	O	156-159
)	O	159-160
,	O	160-161
which	O	162-167
is	O	168-170
a	O	171-172
widely	O	173-179
used	O	180-184
antiepileptic	O	185-198
drug	O	199-203
,	O	203-204
is	O	205-207
associated	O	208-218
with	O	219-223
oxidative	O	224-233
stress	O	234-240
in	O	241-243
rats	O	244-248
,	O	248-249
as	O	250-252
recently	O	253-261
demonstrated	O	262-274
by	O	275-277
elevated	O	278-286
levels	O	287-293
of	O	294-296
15	O	297-299
-	O	299-300
F	O	300-301
(	O	301-302
2t	O	302-304
)	O	304-305
-	O	299-300
isoprostane	O	306-317
(	O	318-319
15	O	319-321
-	O	321-322
F	O	322-323
(	O	318-319
2t	O	324-326
)	O	326-327
-	O	321-322
IsoP	O	328-332
)	O	326-327
.	O	333-334

To	O	335-337
determine	O	338-347
whether	O	348-355
there	O	356-361
was	O	362-365
a	O	366-367
temporal	O	368-376
relationship	O	377-389
between	O	390-397
VPA	O	398-401
-	O	401-402
associated	O	402-412
oxidative	O	413-422
stress	O	423-429
and	O	430-433
hepatotoxicity	B	434-448
,	O	448-449
adult	O	450-455
male	O	456-460
Sprague	O	461-468
-	O	468-469
Dawley	O	469-475
rats	O	476-480
were	O	481-485
treated	O	486-493
ip	O	494-496
with	O	497-501
VPA	O	502-505
(	O	506-507
500	O	507-510
mg	O	511-513
/	O	513-514
kg	O	514-516
)	O	516-517
or	O	518-520
0	O	521-522
.	O	522-523
9	O	523-524
%	O	524-525
saline	O	526-532
(	O	533-534
vehicle	O	534-541
)	O	541-542
once	O	543-547
daily	O	548-553
for	O	554-557
2	O	558-559
,	O	559-560
4	O	561-562
,	O	562-563
7	O	564-565
,	O	565-566
10	O	567-569
,	O	569-570
or	O	571-573
14	O	574-576
days	O	577-581
.	O	581-582

Oxidative	O	583-592
stress	O	593-599
was	O	600-603
assessed	O	604-612
by	O	613-615
determining	O	616-627
plasma	O	628-634
and	O	635-638
liver	O	639-644
levels	O	645-651
of	O	652-654
15	O	655-657
-	O	657-658
F	O	658-659
(	O	659-660
2t	O	660-662
)	O	662-663
-	O	657-658
IsoP	O	664-668
,	O	668-669
lipid	O	670-675
hydroperoxides	O	676-690
(	O	691-692
LPO	O	692-695
)	O	695-696
,	O	696-697
and	O	698-701
thiobarbituric	O	702-716
acid	O	717-721
reactive	O	722-730
substances	O	731-741
(	O	742-743
TBARs	O	743-748
)	O	748-749
.	O	749-750

Plasma	O	751-757
and	O	758-761
liver	O	762-767
15	O	768-770
-	O	770-771
F	O	771-772
(	O	772-773
2t	O	773-775
)	O	775-776
-	O	770-771
IsoP	O	777-781
were	O	782-786
elevated	O	787-795
and	O	796-799
reached	O	800-807
a	O	808-809
plateau	O	810-817
after	O	818-823
day	O	824-827
2	O	828-829
of	O	830-832
VPA	O	833-836
treatment	O	837-846
compared	O	847-855
to	O	856-858
control	O	859-866
.	O	866-867

Liver	O	868-873
LPO	O	874-877
levels	O	878-884
were	O	885-889
not	O	890-893
elevated	O	894-902
until	O	903-908
day	O	909-912
7	O	913-914
of	O	915-917
treatment	O	918-927
(	O	928-929
1	O	929-930
.	O	930-931
8	O	931-932
-	O	932-933
fold	O	933-937
versus	O	938-944
control	O	945-952
,	O	952-953
p	O	954-955
<	O	956-957
0	O	958-959
.	O	959-960
05	O	960-962
)	O	962-963
.	O	959-960

Liver	O	965-970
and	O	971-974
plasma	O	975-981
TBARs	O	982-987
were	O	988-992
not	O	993-996
increased	O	997-1006
until	O	1007-1012
14	O	1013-1015
days	O	1016-1020
(	O	1021-1022
2	O	1022-1023
-	O	1023-1024
fold	O	1024-1028
vs	O	1029-1031
.	O	1031-1032
control	O	1033-1040
,	O	1040-1041
p	O	1042-1043
<	O	1044-1045
0	O	1046-1047
.	O	1047-1048
05	O	1048-1050
)	O	1050-1051
.	O	1047-1048

Liver	B	1053-1058
toxicity	I	1059-1067
was	O	1068-1071
evaluated	O	1072-1081
based	O	1082-1087
on	O	1088-1090
serum	O	1091-1096
levels	O	1097-1103
of	O	1104-1106
alpha	O	1107-1112
-	O	1112-1113
glutathione	O	1113-1124
S	O	1125-1126
-	O	1126-1127
transferase	O	1127-1138
(	O	1139-1140
alpha	O	1140-1145
-	O	1145-1146
GST	O	1146-1149
)	O	1149-1150
and	O	1151-1154
by	O	1155-1157
histology	O	1158-1167
.	O	1167-1168

Serum	O	1169-1174
alpha	O	1175-1180
-	O	1180-1181
GST	O	1181-1184
levels	O	1185-1191
were	O	1192-1196
significantly	O	1197-1210
elevated	O	1211-1219
by	O	1220-1222
day	O	1223-1226
4	O	1227-1228
,	O	1228-1229
which	O	1230-1235
corresponded	O	1236-1248
to	O	1249-1251
hepatotoxicity	B	1252-1266
as	O	1267-1269
shown	O	1270-1275
by	O	1276-1278
the	O	1279-1282
increasing	O	1283-1293
incidence	O	1294-1303
of	O	1304-1306
inflammation	B	1307-1319
of	O	1320-1322
the	O	1323-1326
liver	O	1327-1332
capsule	O	1333-1340
,	O	1340-1341
necrosis	B	1342-1350
,	O	1350-1351
and	O	1352-1355
steatosis	B	1356-1365
throughout	O	1366-1376
the	O	1377-1380
study	O	1381-1386
.	O	1386-1387

The	O	1388-1391
liver	O	1392-1397
levels	O	1398-1404
of	O	1405-1407
beta	O	1408-1412
-	O	1412-1413
oxidation	O	1413-1422
metabolites	O	1423-1434
of	O	1435-1437
VPA	O	1438-1441
were	O	1442-1446
decreased	O	1447-1456
by	O	1457-1459
day	O	1460-1463
14	O	1464-1466
,	O	1466-1467
while	O	1468-1473
the	O	1474-1477
levels	O	1478-1484
of	O	1485-1487
4	O	1488-1489
-	O	1489-1490
ene	O	1490-1493
-	O	1489-1490
VPA	O	1494-1497
and	O	1498-1501
(	O	1502-1503
E	O	1503-1504
)	O	1504-1505
-	O	1505-1506
2	O	1506-1507
,	O	1507-1508
4	O	1508-1509
-	O	1505-1506
diene	O	1510-1515
-	O	1505-1506
VPA	O	1516-1519
were	O	1520-1524
not	O	1525-1528
elevated	O	1529-1537
throughout	O	1538-1548
the	O	1549-1552
study	O	1553-1558
.	O	1558-1559

Overall	O	1560-1567
,	O	1567-1568
these	O	1569-1574
findings	O	1575-1583
indicate	O	1584-1592
that	O	1593-1597
VPA	O	1598-1601
treatment	O	1602-1611
results	O	1612-1619
in	O	1620-1622
oxidative	O	1623-1632
stress	O	1633-1639
,	O	1639-1640
as	O	1641-1643
measured	O	1644-1652
by	O	1653-1655
levels	O	1656-1662
of	O	1663-1665
15	O	1666-1668
-	O	1668-1669
F	O	1669-1670
(	O	1670-1671
2t	O	1671-1673
)	O	1673-1674
-	O	1668-1669
IsoP	O	1675-1679
,	O	1679-1680
which	O	1681-1686
precedes	O	1687-1695
the	O	1696-1699
onset	O	1700-1705
of	O	1706-1708
necrosis	B	1709-1717
,	O	1717-1718
steatosis	B	1719-1728
,	O	1728-1729
and	O	1730-1733
elevated	O	1734-1742
levels	O	1743-1749
of	O	1750-1752
serum	O	1753-1758
alpha	O	1759-1764
-	O	1764-1765
GST	O	1765-1768
.	O	1768-1769

Pheochromocytoma	B	0-16
unmasked	O	17-25
by	O	26-28
amisulpride	O	29-40
and	O	41-44
tiapride	O	45-53
.	O	53-54

OBJECTIVE	O	55-64
:	O	64-65
To	O	66-68
describe	O	69-77
the	O	78-81
unmasking	O	82-91
of	O	92-94
pheochromocytoma	B	95-111
in	O	112-114
a	O	115-116
patient	O	117-124
treated	O	125-132
with	O	133-137
amisulpride	O	138-149
and	O	150-153
tiapride	O	154-162
.	O	162-163

CASE	O	164-168
SUMMARY	O	169-176
:	O	176-177
A	O	178-179
42	O	180-182
-	O	182-183
year	O	183-187
-	O	182-183
old	O	188-191
white	O	192-197
man	O	198-201
developed	O	202-211
acute	O	212-217
hypertension	B	218-230
with	O	231-235
severe	O	236-242
headache	B	243-251
and	O	252-255
vomiting	B	256-264
2	O	265-266
hours	O	267-272
after	O	273-278
the	O	279-282
first	O	283-288
doses	O	289-294
of	O	295-297
amisulpride	O	298-309
100	O	310-313
mg	O	314-316
and	O	317-320
tiapride	O	321-329
100	O	330-333
mg	O	334-336
.	O	336-337

Both	O	338-342
drugs	O	343-348
were	O	349-353
immediately	O	354-365
discontinued	O	366-378
,	O	378-379
and	O	380-383
the	O	384-387
patient	O	388-395
recovered	O	396-405
after	O	406-411
subsequent	O	412-422
nicardipine	O	423-434
and	O	435-438
verapamil	O	439-448
treatment	O	449-458
.	O	458-459

Abdominal	O	460-469
ultrasound	O	470-480
showed	O	481-487
an	O	488-490
adrenal	O	491-498
mass	O	499-503
,	O	503-504
and	O	505-508
postoperative	O	509-522
histologic	O	523-533
examination	O	534-545
confirmed	O	546-555
the	O	556-559
diagnosis	O	560-569
of	O	570-572
pheochromocytoma	B	573-589
.	O	589-590

DISCUSSION	O	591-601
:	O	601-602
Drug	O	603-607
-	O	607-608
induced	O	608-615
symptoms	O	616-624
of	O	625-627
pheochromocytoma	B	628-644
are	O	645-648
often	O	649-654
associated	O	655-665
with	O	666-670
the	O	671-674
use	O	675-678
of	O	679-681
substituted	O	682-693
benzamide	O	694-703
drugs	O	704-709
,	O	709-710
but	O	711-714
the	O	715-718
underlying	O	719-729
mechanism	O	730-739
is	O	740-742
unknown	O	743-750
.	O	750-751

In	O	752-754
our	O	755-758
case	O	759-763
,	O	763-764
use	O	765-768
of	O	769-771
the	O	772-775
Naranjo	O	776-783
probability	O	784-795
scale	O	796-801
indicated	O	802-811
a	O	812-813
possible	O	814-822
relationship	O	823-835
between	O	836-843
the	O	844-847
hypertensive	B	848-860
crisis	O	861-867
and	O	868-871
amisulpride	O	872-883
and	O	884-887
tiapride	O	888-896
therapy	O	897-904
.	O	904-905

CONCLUSIONS	O	906-917
:	O	917-918
As	O	919-921
of	O	922-924
March	O	925-930
24	O	931-933
,	O	933-934
2005	O	935-939
,	O	939-940
this	O	941-945
is	O	946-948
the	O	949-952
first	O	953-958
reported	O	959-967
case	O	968-972
of	O	973-975
amisulpride	O	976-987
-	O	987-988
and	O	989-992
tiapride	O	993-1001
-	O	1001-1002
induced	O	1002-1009
hypertensive	B	1010-1022
crisis	O	1023-1029
in	O	1030-1032
a	O	1033-1034
patient	O	1035-1042
with	O	1043-1047
pheochromocytoma	B	1048-1064
.	O	1064-1065

Physicians	O	1066-1076
and	O	1077-1080
other	O	1081-1086
healthcare	O	1087-1097
professionals	O	1098-1111
should	O	1112-1118
be	O	1119-1121
aware	O	1122-1127
of	O	1128-1130
this	O	1131-1135
potential	O	1136-1145
adverse	O	1146-1153
effect	O	1154-1160
of	O	1161-1163
tiapride	O	1164-1172
and	O	1173-1176
amisulpride	O	1177-1188
.	O	1188-1189

Quantitative	O	0-12
drug	O	13-17
levels	O	18-24
in	O	25-27
stimulant	O	28-37
psychosis	B	38-47
:	O	47-48
relationship	O	49-61
to	O	62-64
symptom	O	65-72
severity	O	73-81
,	O	81-82
catecholamines	O	83-97
and	O	98-101
hyperkinesia	B	102-114
.	O	114-115

To	O	116-118
examine	O	119-126
the	O	127-130
relationship	O	131-143
between	O	144-151
quantitative	O	152-164
stimulant	O	165-174
drug	O	175-179
levels	O	180-186
,	O	186-187
catecholamines	O	188-202
,	O	202-203
and	O	204-207
psychotic	B	208-217
symptoms	I	218-226
,	O	226-227
nineteen	O	228-236
patients	O	237-245
in	O	246-248
a	O	249-250
psychiatric	B	251-262
emergency	O	263-272
service	O	273-280
with	O	281-285
a	O	286-287
diagnosis	O	288-297
of	O	298-300
amphetamine	O	301-312
-	O	312-313
or	O	314-316
cocaine	O	317-324
-	O	324-325
induced	O	325-332
psychosis	B	333-342
were	O	343-347
interviewed	O	348-359
,	O	359-360
and	O	361-364
plasma	O	365-371
and	O	372-375
urine	O	376-381
were	O	382-386
collected	O	387-396
for	O	397-400
quantitative	O	401-413
assays	O	414-420
of	O	421-423
stimulant	O	424-433
drug	O	434-438
and	O	439-442
catecholamine	O	443-456
metabolite	O	457-467
levels	O	468-474
.	O	474-475

Methamphetamine	O	476-491
or	O	492-494
amphetamine	O	495-506
levels	O	507-513
were	O	514-518
related	O	519-526
to	O	527-529
several	O	530-537
psychopathology	O	538-553
scores	O	554-560
and	O	561-564
the	O	565-568
global	O	569-575
hyperkinesia	B	576-588
rating	O	589-595
.	O	595-596

HVA	O	597-600
levels	O	601-607
were	O	608-612
related	O	613-620
to	O	621-623
global	O	624-630
hyperkinesia	B	631-643
but	O	644-647
not	O	648-651
to	O	652-654
psychopathology	O	655-670
ratings	O	671-678
.	O	678-679

Although	O	680-688
many	O	689-693
other	O	694-699
factors	O	700-707
such	O	708-712
as	O	713-715
sensitization	O	716-729
may	O	730-733
play	O	734-738
a	O	739-740
role	O	741-745
,	O	745-746
intensity	O	747-756
of	O	757-759
stimulant	O	760-769
-	O	769-770
induced	O	770-777
psychotic	B	778-787
symptoms	I	788-796
and	O	797-800
stereotypies	B	801-813
appears	O	814-821
to	O	822-824
be	O	825-827
at	O	828-830
least	O	831-836
in	O	837-839
part	O	840-844
dose	O	845-849
-	O	849-850
related	O	850-857
.	O	857-858

Delayed	O	0-7
asystolic	B	8-17
cardiac	B	18-25
arrest	I	26-32
after	O	33-38
diltiazem	O	39-48
overdose	B	49-57
;	O	57-58
resuscitation	O	59-72
with	O	73-77
high	O	78-82
dose	O	83-87
intravenous	O	88-99
calcium	O	100-107
.	O	107-108

A	O	109-110
51	O	111-113
year	O	114-118
old	O	119-122
man	O	123-126
took	O	127-131
a	O	132-133
mixed	O	134-139
overdose	B	140-148
including	O	149-158
1	O	159-160
.	O	160-161
8	O	161-162
-	O	162-163
3	O	163-164
.	O	160-161
6	O	165-166
g	O	167-168
of	O	169-171
diltiazem	O	172-181
,	O	181-182
paracetamol	O	183-194
,	O	194-195
aspirin	O	196-203
,	O	203-204
isosorbide	O	205-215
nitrate	O	216-223
,	O	223-224
and	O	225-228
alcohol	O	229-236
.	O	236-237

He	O	238-240
initially	O	241-250
presented	O	251-260
to	O	261-263
hospital	O	264-272
after	O	273-278
six	O	279-282
hours	O	283-288
with	O	289-293
mild	O	294-298
hypotension	B	299-310
and	O	311-314
was	O	315-318
treated	O	319-326
with	O	327-331
activated	O	332-341
charcoal	O	342-350
and	O	351-354
intravenous	O	355-366
fluids	O	367-373
.	O	373-374

Eighteen	O	375-383
hours	O	384-389
after	O	390-395
the	O	396-399
overdose	B	400-408
he	O	409-411
had	O	412-415
two	O	416-419
generalised	O	420-431
tonic	B	432-437
-	I	437-438
clonic	I	438-444
seizures	I	445-453
.	O	453-454

The	O	455-458
patient	O	459-466
remained	O	467-475
unresponsive	O	476-488
with	O	489-493
junctional	O	494-504
bradycardia	B	505-516
,	O	516-517
unrecordable	O	518-530
blood	O	531-536
pressure	O	537-545
,	O	545-546
and	O	547-550
then	O	551-555
became	O	556-562
asystolic	B	563-572
.	O	572-573

He	O	574-576
was	O	577-580
resuscitated	O	581-593
with	O	594-598
high	O	599-603
dose	O	604-608
(	O	609-610
13	O	610-612
.	O	612-613
5	O	613-614
g	O	615-616
)	O	616-617
intravenous	O	618-629
calcium	O	630-637
and	O	638-641
adrenaline	O	642-652
(	O	653-654
epinephrine	O	654-665
)	O	665-666
.	O	666-667

He	O	668-670
required	O	671-679
inotropic	O	680-689
support	O	690-697
and	O	698-701
temporary	O	702-711
pacing	O	712-718
over	O	719-723
the	O	724-727
next	O	728-732
48	O	733-735
hours	O	736-741
.	O	741-742

This	O	743-747
case	O	748-752
suggests	O	753-761
there	O	762-767
is	O	768-770
a	O	771-772
role	O	773-777
for	O	778-781
aggressive	O	782-792
high	O	793-797
dose	O	798-802
intravenous	O	803-814
calcium	O	815-822
therapy	O	823-830
in	O	831-833
severe	O	834-840
diltiazem	O	841-850
overdose	B	851-859
,	O	859-860
particularly	O	861-873
with	O	874-878
the	O	879-882
onset	O	883-888
of	O	889-891
asystole	B	892-900
.	O	900-901

It	O	902-904
should	O	905-911
be	O	912-914
considered	O	915-925
early	O	926-931
in	O	932-934
cases	O	935-940
of	O	941-943
cardiac	B	944-951
arrest	I	952-958
after	O	959-964
diltiazem	O	965-974
overdose	B	975-983
.	O	983-984

The	O	985-988
case	O	989-993
also	O	994-998
highlights	O	999-1009
the	O	1010-1013
problems	O	1014-1022
with	O	1023-1027
delayed	O	1028-1035
toxicity	B	1036-1044
when	O	1045-1049
whole	O	1050-1055
bowel	O	1056-1061
irrigation	O	1062-1072
is	O	1073-1075
not	O	1076-1079
administered	O	1080-1092
.	O	1092-1093

Renal	B	0-5
papillary	I	6-15
necrosis	I	16-24
due	O	25-28
to	O	29-31
naproxen	O	32-40
.	O	40-41

A	O	42-43
31	O	44-46
-	O	46-47
year	O	47-51
-	O	46-47
old	O	52-55
man	O	56-59
with	O	60-64
rheumatoid	B	65-75
arthritis	I	76-85
,	O	85-86
who	O	87-90
had	O	91-94
previously	O	95-105
been	O	106-110
treated	O	111-118
with	O	119-123
sulindac	O	124-132
,	O	132-133
fenoprofen	O	134-144
calcium	O	145-152
,	O	152-153
high	O	154-158
dose	O	159-163
salicylates	O	164-175
and	O	176-179
gold	O	180-184
salts	O	185-190
,	O	190-191
developed	O	192-201
renal	B	202-207
papillary	I	208-217
necrosis	I	218-226
(	O	227-228
RPN	B	228-231
)	O	231-232
4	O	233-234
months	O	235-241
after	O	242-247
institution	O	248-259
of	O	260-262
naproxen	O	263-271
therapy	O	272-279
.	O	279-280

No	O	281-283
other	O	284-289
factor	O	290-296
predisposing	O	297-309
to	O	310-312
RPN	B	313-316
could	O	317-322
be	O	323-325
discovered	O	326-336
.	O	336-337

Sulindac	O	338-346
was	O	347-350
substituted	O	351-362
for	O	363-366
naproxen	O	367-375
and	O	376-379
no	O	380-382
further	O	383-390
adverse	O	391-398
renal	O	399-404
effects	O	405-412
occurred	O	413-421
over	O	422-426
the	O	427-430
next	O	431-435
12	O	436-438
months	O	439-445
.	O	445-446

We	O	447-449
review	O	450-456
previous	O	457-465
reports	O	466-473
linking	O	474-481
RPN	B	482-485
to	O	486-488
antiinflammatory	O	489-505
drug	O	506-510
use	O	511-514
and	O	515-518
discuss	O	519-526
possible	O	527-535
advantages	O	536-546
of	O	547-549
sulindac	O	550-558
in	O	559-561
patients	O	562-570
who	O	571-574
have	O	575-579
experienced	O	580-591
renal	B	592-597
toxicity	I	598-606
from	O	607-611
other	O	612-617
antiinflammatory	O	618-634
agents	O	635-641
.	O	641-642

Adverse	O	0-7
interaction	O	8-19
between	O	20-27
beta	O	28-32
-	O	32-33
adrenergic	O	33-43
blocking	O	44-52
drugs	O	53-58
and	O	59-62
verapamil	O	63-72
-	O	72-73
-	O	72-73
report	O	74-80
of	O	81-83
three	O	84-89
cases	O	90-95
.	O	95-96

Three	O	97-102
patients	O	103-111
with	O	112-116
ischaemic	B	117-126
heart	I	127-132
disease	I	133-140
developed	O	141-150
profound	O	151-159
cardiac	B	160-167
failure	I	168-175
,	O	175-176
hypotension	B	177-188
and	O	189-192
bradycardia	B	193-204
during	O	205-211
combined	O	212-220
therapy	O	221-228
with	O	229-233
verapamil	O	234-243
and	O	244-247
beta	O	248-252
-	O	252-253
adrenergic	O	253-263
blocking	O	264-272
drugs	O	273-278
.	O	278-279

This	O	280-284
clinical	O	285-293
picture	O	294-301
resolved	O	302-310
completely	O	311-321
with	O	322-326
cessation	O	327-336
of	O	337-339
the	O	340-343
combined	O	344-352
therapy	O	353-360
.	O	360-361

Baseline	O	362-370
left	O	371-375
ventricular	O	376-387
function	O	388-396
,	O	396-397
assessed	O	398-406
by	O	407-409
cardiac	O	410-417
catheterisation	O	418-433
or	O	434-436
nuclear	O	437-444
angiography	O	445-456
,	O	456-457
was	O	458-461
normal	O	462-468
in	O	469-471
two	O	472-475
patients	O	476-484
and	O	485-488
only	O	489-493
mildly	O	494-500
reduced	O	501-508
in	O	509-511
the	O	512-515
other	O	516-521
.	O	521-522

Simultaneously	O	523-537
administration	O	538-552
of	O	553-555
beta	O	556-560
-	O	560-561
adrenergic	O	561-571
blocking	O	572-580
drugs	O	581-586
and	O	587-590
verapamil	O	591-600
may	O	601-604
result	O	605-611
in	O	612-614
profound	O	615-623
adverse	O	624-631
interactions	O	632-644
and	O	645-648
should	O	649-655
only	O	656-660
be	O	661-663
administered	O	664-676
with	O	677-681
great	O	682-687
caution	O	688-695
.	O	695-696

Adverse	O	0-7
reactions	O	8-17
to	O	18-20
bendrofluazide	O	21-35
and	O	36-39
propranolol	O	40-51
for	O	52-55
the	O	56-59
treatment	O	60-69
of	O	70-72
mild	O	73-77
hypertension	B	78-90
.	O	90-91

Report	O	92-98
of	O	99-101
Medical	O	102-109
Research	O	110-118
Council	O	119-126
Working	O	127-134
Party	O	135-140
on	O	141-143
Mild	O	144-148
to	O	149-151
Moderate	O	152-160
Hypertension	B	161-173
.	O	173-174

Participants	O	175-187
in	O	188-190
the	O	191-194
Medical	O	195-202
Research	O	203-211
Council	O	212-219
treatment	O	220-229
trial	O	230-235
for	O	236-239
mild	O	240-244
hypertension	B	245-257
are	O	258-261
randomly	O	262-270
allocated	O	271-280
to	O	281-283
one	O	284-287
of	O	288-290
four	O	291-295
treatment	O	296-305
groups	O	306-312
:	O	312-313
bendrofluazide	O	314-328
,	O	328-329
propranolol	O	330-341
,	O	341-342
or	O	343-345
a	O	346-347
placebo	O	348-355
for	O	356-359
either	O	360-366
of	O	367-369
these	O	370-375
drugs	O	376-381
.	O	381-382

The	O	383-386
trial	O	387-392
is	O	393-395
single	O	396-402
-	O	402-403
blind	O	403-408
.	O	408-409

23	O	410-412
582	O	413-416
patient	O	417-424
-	O	424-425
years	O	425-430
of	O	431-433
observation	O	434-445
have	O	446-450
been	O	451-455
completed	O	456-465
so	O	466-468
far	O	469-472
,	O	472-473
10	O	474-476
684	O	477-480
on	O	481-483
active	O	484-490
drugs	O	491-496
and	O	497-500
12	O	501-503
898	O	504-507
on	O	508-510
placebos	O	511-519
.	O	519-520

The	O	521-524
results	O	525-532
show	O	533-537
an	O	538-540
association	O	541-552
between	O	553-560
bendrofluazide	O	561-575
treatment	O	576-585
and	O	586-589
impotence	B	590-599
,	O	599-600
and	O	601-604
impotence	B	605-614
also	O	615-619
occurred	O	620-628
more	O	629-633
frequently	O	634-644
in	O	645-647
patients	O	648-656
taking	O	657-663
propranolol	O	664-675
than	O	676-680
in	O	681-683
those	O	684-689
taking	O	690-696
placebos	O	697-705
.	O	705-706

Other	O	707-712
adverse	O	713-720
reactions	O	721-730
significantly	O	731-744
linked	O	745-751
with	O	752-756
active	O	757-763
drugs	O	764-769
include	O	770-777
impaired	B	778-786
glucose	I	787-794
tolerance	I	795-804
in	O	805-807
men	O	808-811
and	O	812-815
women	O	816-821
and	O	822-825
gout	B	826-830
in	O	831-833
men	O	834-837
,	O	837-838
associated	O	839-849
with	O	850-854
bendrofluazide	O	855-869
treatment	O	870-879
,	O	879-880
and	O	881-884
Raynaud	B	885-892
'	I	892-893
s	I	893-894
phenomenon	I	895-905
and	O	906-909
dyspnoea	B	910-918
in	O	919-921
men	O	922-925
and	O	926-929
women	O	930-935
taking	O	936-942
propranolol	O	943-954
.	O	954-955

No	O	956-958
corneal	B	959-966
disease	I	967-974
is	O	975-977
known	O	978-983
to	O	984-986
have	O	987-991
occurred	O	992-1000
in	O	1001-1003
the	O	1004-1007
propranolol	O	1008-1019
group	O	1020-1025
.	O	1025-1026

Mean	O	1027-1031
serum	O	1032-1037
potassium	O	1038-1047
level	O	1048-1053
fell	O	1054-1058
,	O	1058-1059
and	O	1060-1063
urea	O	1064-1068
and	O	1069-1072
uric	O	1073-1077
acid	O	1078-1082
levels	O	1083-1089
rose	O	1090-1094
,	O	1094-1095
in	O	1096-1098
men	O	1099-1102
and	O	1103-1106
women	O	1107-1112
taking	O	1113-1119
bendrofluazide	O	1120-1134
.	O	1134-1135

In	O	1136-1138
the	O	1139-1142
propranolol	O	1143-1154
group	O	1155-1160
,	O	1160-1161
serum	O	1162-1167
potassium	O	1168-1177
and	O	1178-1181
uric	O	1182-1186
acid	O	1187-1191
levels	O	1192-1198
rose	O	1199-1203
in	O	1204-1206
both	O	1207-1211
sexes	O	1212-1217
,	O	1217-1218
but	O	1219-1222
the	O	1223-1226
urea	O	1227-1231
level	O	1232-1237
rose	O	1238-1242
significantly	O	1243-1256
in	O	1257-1259
women	O	1260-1265
only	O	1266-1270
.	O	1270-1271

Dexmedetomidine	O	0-15
and	O	16-19
cardiac	O	20-27
protection	O	28-38
for	O	39-42
non	O	43-46
-	O	46-47
cardiac	O	47-54
surgery	O	55-62
:	O	62-63
a	O	64-65
meta	O	66-70
-	O	70-71
analysis	O	71-79
of	O	80-82
randomised	O	83-93
controlled	O	94-104
trials	O	105-111
.	O	111-112

We	O	113-115
conducted	O	116-125
a	O	126-127
systematic	O	128-138
review	O	139-145
of	O	146-148
the	O	149-152
effects	O	153-160
of	O	161-163
dexmedetomidine	O	164-179
on	O	180-182
cardiac	O	183-190
outcomes	O	191-199
following	O	200-209
non	O	210-213
-	O	213-214
cardiac	O	214-221
surgery	O	222-229
.	O	229-230

We	O	231-233
included	O	234-242
prospective	O	243-254
,	O	254-255
randomised	O	256-266
peri	O	267-271
-	O	271-272
operative	O	272-281
studies	O	282-289
of	O	290-292
dexmedetomidine	O	293-308
that	O	309-313
reported	O	314-322
mortality	O	323-332
,	O	332-333
cardiac	O	334-341
morbidity	O	342-351
or	O	352-354
adverse	O	355-362
drug	O	363-367
events	O	368-374
.	O	374-375

A	O	376-377
PubMed	O	378-384
Central	O	385-392
and	O	393-396
EMBASE	O	397-403
search	O	404-410
was	O	411-414
conducted	O	415-424
up	O	425-427
to	O	428-430
July	O	431-435
2007	O	436-440
.	O	440-441

The	O	442-445
reference	O	446-455
lists	O	456-461
of	O	462-464
identified	O	465-475
papers	O	476-482
were	O	483-487
examined	O	488-496
for	O	497-500
further	O	501-508
trials	O	509-515
.	O	515-516

Of	O	517-519
425	O	520-523
studies	O	524-531
identified	O	532-542
,	O	542-543
20	O	544-546
were	O	547-551
included	O	552-560
in	O	561-563
the	O	564-567
meta	O	568-572
-	O	572-573
analysis	O	573-581
(	O	582-583
840	O	583-586
patients	O	587-595
)	O	595-596
.	O	596-597

Dexmedetomidine	O	598-613
was	O	614-617
associated	O	618-628
with	O	629-633
a	O	634-635
trend	O	636-641
towards	O	642-649
improved	O	650-658
cardiac	O	659-666
outcomes	O	667-675
;	O	675-676
all	O	677-680
-	O	680-681
cause	O	681-686
mortality	O	687-696
(	O	697-698
OR	O	698-700
0	O	701-702
.	O	702-703
27	O	703-705
,	O	705-706
95	O	707-709
%	O	709-710
CI	O	711-713
0	O	714-715
.	O	715-716
01	O	716-718
-	O	718-719
7	O	719-720
.	O	715-716
13	O	721-723
,	O	723-724

p	O	725-726
=	O	727-728
0	O	729-730
.	O	730-731
44	O	731-733
)	O	733-734
,	O	734-735
non	O	736-739
-	O	739-740
fatal	O	740-745
myocardial	B	746-756
infarction	I	757-767
(	O	768-769
OR	O	769-771
0	O	772-773
.	O	773-774
26	O	774-776
,	O	776-777
95	O	778-780
%	O	780-781
CI	O	782-784
0	O	785-786
.	O	786-787
04	O	787-789
-	O	789-790
1	O	790-791
.	O	786-787
60	O	792-794
,	O	794-795

p	O	796-797
=	O	798-799
0	O	800-801
.	O	801-802
14	O	802-804
)	O	804-805
,	O	805-806
and	O	807-810
myocardial	B	811-821
ischaemia	I	822-831
(	O	832-833
OR	O	833-835
0	O	836-837
.	O	837-838
65	O	838-840
,	O	840-841
95	O	842-844
%	O	844-845
CI	O	846-848
0	O	849-850
.	O	850-851
26	O	851-853
-	O	853-854
1	O	854-855
.	O	850-851
63	O	856-858
,	O	858-859

p	O	860-861
=	O	862-863
0	O	864-865
.	O	865-866
36	O	866-868
)	O	868-869
.	O	865-866

Peri	O	871-875
-	O	875-876
operative	O	876-885
hypotension	B	886-897
(	O	898-899
26	O	899-901
%	O	901-902
,	O	902-903
OR	O	904-906
3	O	907-908
.	O	908-909
80	O	909-911
,	O	911-912
95	O	913-915
%	O	915-916
CI	O	917-919
1	O	920-921
.	O	921-922
91	O	922-924
-	O	924-925
7	O	925-926
.	O	921-922
54	O	927-929
,	O	929-930

p	O	931-932
=	O	933-934
0	O	935-936
.	O	936-937
0001	O	937-941
)	O	941-942
and	O	943-946
bradycardia	B	947-958
(	O	959-960
17	O	960-962
%	O	962-963
,	O	963-964
OR	O	965-967
5	O	968-969
.	O	969-970
45	O	970-972
,	O	972-973
95	O	974-976
%	O	976-977
CI	O	978-980
2	O	981-982
.	O	982-983
98	O	983-985
-	O	985-986
9	O	983-984
.	O	982-983
95	O	988-990
,	O	990-991

p	O	992-993
<	O	994-995
0	O	996-997
.	O	997-998
00001	O	998-1003
)	O	1003-1004
were	O	1005-1009
significantly	O	1010-1023
increased	O	1024-1033
.	O	1033-1034

An	O	1035-1037
anticholinergic	O	1038-1053
did	O	1054-1057
not	O	1058-1061
reduce	O	1062-1068
the	O	1069-1072
incidence	O	1073-1082
of	O	1083-1085
bradycardia	B	1086-1097
(	O	1098-1099
p	O	1099-1100
=	O	1101-1102
0	O	1103-1104
.	O	1104-1105
43	O	1105-1107
)	O	1107-1108
.	O	1104-1105

A	O	1110-1111
randomised	O	1112-1122
placebo	O	1123-1130
-	O	1130-1131
controlled	O	1131-1141
trial	O	1142-1147
of	O	1148-1150
dexmedetomidine	O	1151-1166
is	O	1167-1169
warranted	O	1170-1179
.	O	1179-1180

Differential	O	0-12
diagnosis	O	13-22
of	O	23-25
high	O	26-30
serum	O	31-36
creatine	O	37-45
kinase	O	46-52
levels	O	53-59
in	O	60-62
systemic	B	63-71
lupus	I	72-77
erythematosus	I	78-91
.	O	91-92

We	O	93-95
report	O	96-102
the	O	103-106
clinical	O	107-115
and	O	116-119
bioptic	O	120-127
findings	O	128-136
for	O	137-140
a	O	141-142
57	O	143-145
-	O	145-146
year	O	146-150
-	O	145-146
old	O	151-154
woman	O	155-160
with	O	161-165
severe	O	166-172
chloroquine	O	173-184
-	O	184-185
induced	O	185-192
myopathy	B	193-201
.	O	201-202

Since	O	203-208
1989	O	209-213
,	O	213-214
she	O	215-218
had	O	219-222
been	O	223-227
suffering	O	228-237
from	O	238-242
systemic	B	243-251
lupus	I	252-257
erythematosus	I	258-271
(	O	272-273
SLE	B	273-276
)	O	276-277
with	O	278-282
renal	B	283-288
involvement	I	289-300
and	O	301-304
undergone	O	305-314
periods	O	315-322
of	O	323-325
treatment	O	326-335
with	O	336-340
azathioprine	O	341-353
and	O	354-357
cyclophosphamide	O	358-374
.	O	374-375

Additional	O	376-386
therapy	O	387-394
with	O	395-399
chloroquine	O	400-411
(	O	412-413
CQ	O	413-415
)	O	415-416
was	O	417-420
started	O	421-428
because	O	429-436
of	O	437-439
arthralgia	B	440-450
.	O	450-451

At	O	452-454
the	O	455-458
same	O	459-463
time	O	464-468
,	O	468-469
slightly	O	470-478
increased	O	479-488
creatine	O	489-497
kinase	O	498-504
(	O	505-506
CK	O	506-508
)	O	508-509
levels	O	510-516
were	O	517-521
noted	O	522-527
.	O	527-528

Myositis	B	529-537
was	O	538-541
suspected	O	542-551
,	O	551-552
and	O	553-556
the	O	557-560
patient	O	561-568
was	O	569-572
treated	O	573-580
with	O	581-585
steroids	O	586-594
.	O	594-595

The	O	596-599
CK	O	600-602
increase	O	603-611
persisted	O	612-621
,	O	621-622
however	O	623-630
,	O	630-631
and	O	632-635
she	O	636-639
developed	O	640-649
progressive	O	650-661
muscular	B	662-670
weakness	I	671-679
and	O	680-683
muscular	B	684-692
atrophy	I	693-700
.	O	700-701

Routine	O	702-709
controls	O	710-718
revealed	O	719-727
markedly	O	728-736
elevated	O	737-745
CK	O	746-748
levels	O	749-755
of	O	756-758
1	O	759-760
,	O	760-761
700	O	761-764
U	O	765-766
/	O	766-767
l	O	767-768
.	O	768-769

The	O	770-773
neurological	O	774-786
and	O	787-790
electrophysiological	O	791-811
findings	O	812-820
were	O	821-825
not	O	826-829
typical	O	830-837
of	O	838-840
myositis	B	841-849
.	O	849-850

Thus	O	851-855
,	O	855-856
muscle	O	857-863
biopsy	O	864-870
of	O	871-873
the	O	874-877
deltoid	O	878-885
muscle	O	886-892
was	O	893-896
performed	O	897-906
in	O	907-909
order	O	910-915
to	O	916-918
exclude	O	919-926
polymyositis	B	927-939
or	O	940-942
toxic	O	943-948
myopathy	B	949-957
.	O	957-958

As	O	959-961
it	O	962-964
revealed	O	965-973
chloroquine	O	974-985
-	O	985-986
induced	O	986-993
myopathy	B	994-1002
,	O	1002-1003
medication	O	1004-1014
was	O	1015-1018
stopped	O	1019-1026
.	O	1026-1027

Discriminating	O	1028-1042
between	O	1043-1050
primary	O	1051-1058
SLE	B	1059-1062
-	O	1062-1063
induced	O	1063-1070
affection	B	1071-1080
of	I	1081-1083
the	I	1084-1087
musculoskeletal	I	1088-1103
system	I	1104-1110
and	O	1111-1114
drug	O	1115-1119
-	O	1119-1120
induced	O	1120-1127
side	O	1128-1132
effects	O	1133-1140
is	O	1141-1143
important	O	1144-1153
for	O	1154-1157
appropriate	O	1158-1169
treatment	O	1170-1179
of	O	1180-1182
SLE	B	1183-1186
patients	O	1187-1195
.	O	1195-1196

Intravenous	O	0-11
ribavirin	O	12-21
treatment	O	22-31
for	O	32-35
severe	O	36-42
adenovirus	B	43-53
disease	I	54-61
in	O	62-64
immunocompromised	O	65-82
children	O	83-91
.	O	91-92

BACKGROUND	O	93-103
:	O	103-104
Adenovirus	O	105-115
is	O	116-118
an	O	119-121
important	O	122-131
cause	O	132-137
of	O	138-140
morbidity	O	141-150
and	O	151-154
mortality	O	155-164
in	O	165-167
the	O	168-171
immunocompromised	O	172-189
host	O	190-194
.	O	194-195

The	O	196-199
incidence	O	200-209
of	O	210-212
severe	O	213-219
adenovirus	B	220-230
disease	I	231-238
in	O	239-241
pediatrics	O	242-252
is	O	253-255
increasing	O	256-266
in	O	267-269
association	O	270-281
with	O	282-286
growing	O	287-294
numbers	O	295-302
of	O	303-305
immunocompromised	O	306-323
children	O	324-332
,	O	332-333
where	O	334-339
case	O	340-344
fatality	O	345-353
rates	O	354-359
as	O	360-362
high	O	363-367
as	O	368-370
50	O	371-373
%	O	373-374
to	O	375-377
80	O	378-380
%	O	380-381
have	O	382-386
been	O	387-391
reported	O	392-400
.	O	400-401

There	O	402-407
are	O	408-411
no	O	412-414
approved	O	415-423
antiviral	O	424-433
agents	O	434-440
with	O	441-445
proven	O	446-452
efficacy	O	453-461
for	O	462-465
the	O	466-469
treatment	O	470-479
of	O	480-482
severe	O	483-489
adenovirus	B	490-500
disease	I	501-508
,	O	508-509
nor	O	510-513
are	O	514-517
there	O	518-523
any	O	524-527
prospective	O	528-539
randomized	O	540-550
,	O	550-551
controlled	O	552-562
trials	O	563-569
of	O	570-572
potentially	O	573-584
useful	O	585-591
anti	O	592-596
-	O	596-597
adenovirus	O	597-607
therapies	O	608-617
.	O	617-618

Apparent	O	619-627
clinical	O	628-636
success	O	637-644
in	O	645-647
the	O	648-651
treatment	O	652-661
of	O	662-664
severe	O	665-671
adenovirus	B	672-682
disease	I	683-690
is	O	691-693
limited	O	694-701
to	O	702-704
a	O	705-706
few	O	707-710
case	O	711-715
reports	O	716-723
and	O	724-727
small	O	728-733
series	O	734-740
.	O	740-741

Experience	O	742-752
is	O	753-755
greatest	O	756-764
with	O	765-769
intravenous	O	770-781
ribavirin	O	782-791
and	O	792-795
cidofovir	O	796-805
.	O	805-806

Ribavirin	O	807-816
,	O	816-817
a	O	818-819
guanosine	O	820-829
analogue	O	830-838
,	O	838-839
has	O	840-843
broad	O	844-849
antiviral	O	850-859
activity	O	860-868
against	O	869-876
both	O	877-881
RNA	O	882-885
and	O	886-889
DNA	O	890-893
viruses	O	894-901
,	O	901-902
including	O	903-912
documented	O	913-923
activity	O	924-932
against	O	933-940
adenovirus	O	941-951
in	O	952-954
vitro	O	955-960
.	O	960-961

Ribavirin	O	962-971
is	O	972-974
licensed	O	975-983
in	O	984-986
aerosol	O	987-994
form	O	995-999
for	O	1000-1003
the	O	1004-1007
treatment	O	1008-1017
of	O	1018-1020
respiratory	B	1021-1032
syncytial	I	1033-1042
virus	I	1043-1048
infection	I	1049-1058
,	O	1058-1059
and	O	1060-1063
orally	O	1064-1070
in	O	1071-1073
combination	O	1074-1085
with	O	1086-1090
interferon	O	1091-1101
to	O	1102-1104
treat	O	1105-1110
hepatitis	B	1111-1120
C	I	1121-1122
.	O	1122-1123
Intravenous	O	1124-1135
ribavirin	O	1136-1145
is	O	1146-1148
the	O	1149-1152
treatment	O	1153-1162
of	O	1163-1165
choice	O	1166-1172
for	O	1173-1176
infection	B	1177-1186
with	I	1187-1191
hemorrhagic	I	1192-1203
fever	I	1204-1209
viruses	I	1210-1217
.	O	1217-1218

The	O	1219-1222
most	O	1223-1227
common	O	1228-1234
adverse	O	1235-1242
effect	O	1243-1249
of	O	1250-1252
intravenous	O	1253-1264
ribavirin	O	1265-1274
is	O	1275-1277
reversible	O	1278-1288
mild	O	1289-1293
anemia	B	1294-1300
.	O	1300-1301

The	O	1302-1305
use	O	1306-1309
of	O	1310-1312
cidofovir	O	1313-1322
in	O	1323-1325
severe	O	1326-1332
adenovirus	B	1333-1343
infection	I	1344-1353
has	O	1354-1357
been	O	1358-1362
limited	O	1363-1370
by	O	1371-1373
adverse	O	1374-1381
effects	O	1382-1389
,	O	1389-1390
the	O	1391-1394
most	O	1395-1399
significant	O	1400-1411
of	O	1412-1414
which	O	1415-1420
is	O	1421-1423
nephrotoxicity	B	1424-1438
.	O	1438-1439

OBJECTIVE	O	1440-1449
:	O	1449-1450
We	O	1451-1453
report	O	1454-1460
our	O	1461-1464
experience	O	1465-1475
with	O	1476-1480
intravenous	O	1481-1492
ribavirin	O	1493-1502
therapy	O	1503-1510
for	O	1511-1514
severe	O	1515-1521
adenovirus	B	1522-1532
disease	I	1533-1540
in	O	1541-1543
a	O	1544-1545
series	O	1546-1552
of	O	1553-1555
immunocompromised	O	1556-1573
children	O	1574-1582
and	O	1583-1586
review	O	1587-1593
the	O	1594-1597
literature	O	1598-1608
.	O	1608-1609

DESIGN	O	1610-1616
/	O	1616-1617
METHODS	O	1617-1624
:	O	1624-1625
We	O	1626-1628
retrospectively	O	1629-1644
reviewed	O	1645-1653
the	O	1654-1657
medical	O	1658-1665
records	O	1666-1673
of	O	1674-1676
5	O	1677-1678
children	O	1679-1687
treated	O	1688-1695
with	O	1696-1700
intravenous	O	1701-1712
ribavirin	O	1713-1722
for	O	1723-1726
documented	O	1727-1737
severe	O	1738-1744
adenovirus	B	1745-1755
disease	I	1756-1763
.	O	1763-1764

Two	O	1765-1768
patients	O	1769-1777
developed	O	1778-1787
adenovirus	O	1788-1798
hemorrhagic	B	1799-1810
cystitis	I	1811-1819
after	O	1820-1825
cardiac	O	1826-1833
and	O	1834-1837
bone	O	1838-1842
marrow	O	1843-1849
transplants	O	1850-1861
,	O	1861-1862
respectively	O	1863-1875
.	O	1875-1876

The	O	1877-1880
bone	O	1881-1885
marrow	O	1886-1892
transplant	O	1893-1903
patient	O	1904-1911
also	O	1912-1916
received	O	1917-1925
intravenous	O	1926-1937
cidofovir	O	1938-1947
for	O	1948-1951
progressive	O	1952-1963
disseminated	O	1964-1976
disease	O	1977-1984
.	O	1984-1985

An	O	1986-1988
additional	O	1989-1999
3	O	2000-2001
children	O	2002-2010
developed	O	2011-2020
adenovirus	B	2021-2031
pneumonia	I	2032-2041
;	O	2041-2042
2	O	2043-2044
were	O	2045-2049
neonates	O	2050-2058
,	O	2058-2059
1	O	2060-2061
of	O	2062-2064
whom	O	2065-2069
had	O	2070-2073
partial	O	2074-2081
DiGeorge	B	2082-2090
syndrome	I	2091-2099
.	O	2099-2100

The	O	2101-2104
remaining	O	2105-2114
infant	O	2115-2121
had	O	2122-2125
recently	O	2126-2134
undergone	O	2135-2144
a	O	2145-2146
cardiac	O	2147-2154
transplant	O	2155-2165
.	O	2165-2166

Intravenous	O	2167-2178
ribavirin	O	2179-2188
was	O	2189-2192
administered	O	2193-2205
on	O	2206-2208
a	O	2209-2210
compassionate	O	2211-2224
-	O	2224-2225
use	O	2225-2228
protocol	O	2229-2237
.	O	2237-2238

RESULTS	O	2239-2246
:	O	2246-2247
Complete	O	2248-2256
clinical	O	2257-2265
recovery	O	2266-2274
followed	O	2275-2283
later	O	2284-2289
by	O	2290-2292
viral	O	2293-2298
clearance	O	2299-2308
was	O	2309-2312
observed	O	2313-2321
in	O	2322-2324
2	O	2325-2326
children	O	2327-2335
:	O	2335-2336
the	O	2337-2340
cardiac	O	2341-2348
transplant	O	2349-2359
recipient	O	2360-2369
with	O	2370-2374
adenovirus	O	2375-2385
hemorrhagic	B	2386-2397
cystitis	I	2398-2406
and	O	2407-2410
the	O	2411-2414
immunocompetent	O	2415-2430
neonate	O	2431-2438
with	O	2439-2443
adenovirus	B	2444-2454
pneumonia	I	2455-2464
.	O	2464-2465

The	O	2466-2469
remaining	O	2470-2479
3	O	2480-2481
children	O	2482-2490
died	O	2491-2495
of	O	2496-2498
adenovirus	B	2499-2509
disease	I	2510-2517
.	O	2517-2518

Intravenous	O	2519-2530
ribavirin	O	2531-2540
therapy	O	2541-2548
was	O	2549-2552
well	O	2553-2557
tolerated	O	2558-2567
.	O	2567-2568

Use	O	2569-2572
of	O	2573-2575
cidofovir	O	2576-2585
in	O	2586-2588
1	O	2589-2590
child	O	2591-2596
was	O	2597-2600
associated	O	2601-2611
with	O	2612-2616
progressive	B	2617-2628
renal	I	2629-2634
failure	I	2635-2642
and	O	2643-2646
neutropenia	B	2647-2658
.	O	2658-2659

DISCUSSION	O	2660-2670
:	O	2670-2671
Our	O	2672-2675
series	O	2676-2682
of	O	2683-2685
patients	O	2686-2694
is	O	2695-2697
representative	O	2698-2712
of	O	2713-2715
the	O	2716-2719
spectrum	O	2720-2728
of	O	2729-2731
immunocompromised	O	2732-2749
children	O	2750-2758
at	O	2759-2761
greatest	O	2762-2770
risk	O	2771-2775
for	O	2776-2779
severe	O	2780-2786
adenovirus	B	2787-2797
disease	I	2798-2805
,	O	2805-2806
namely	O	2807-2813
solid	O	2814-2819
-	O	2819-2820
organ	O	2820-2825
and	O	2826-2829
bone	O	2830-2834
marrow	O	2835-2841
transplant	O	2842-2852
recipients	O	2853-2863
,	O	2863-2864
neonates	O	2865-2873
,	O	2873-2874
and	O	2875-2878
children	O	2879-2887
with	O	2888-2892
immunodeficiency	B	2893-2909
.	O	2909-2910

Although	O	2911-2919
intravenous	O	2920-2931
ribavirin	O	2932-2941
was	O	2942-2945
not	O	2946-2949
effective	O	2950-2959
for	O	2960-2963
all	O	2964-2967
children	O	2968-2976
with	O	2977-2981
severe	O	2982-2988
adenovirus	B	2989-2999
disease	I	3000-3007
in	O	3008-3010
this	O	3011-3015
series	O	3016-3022
or	O	3023-3025
in	O	3026-3028
the	O	3029-3032
literature	O	3033-3043
,	O	3043-3044
therapy	O	3045-3052
is	O	3053-3055
unlikely	O	3056-3064
to	O	3065-3067
be	O	3068-3070
of	O	3071-3073
benefit	O	3074-3081
if	O	3082-3084
begun	O	3085-3090
late	O	3091-3095
in	O	3096-3098
the	O	3099-3102
course	O	3103-3109
of	O	3110-3112
the	O	3113-3116
infection	B	3117-3126
.	O	3126-3127

Early	O	3128-3133
identification	O	3134-3148
,	O	3148-3149
eg	O	3150-3152
by	O	3153-3155
polymerase	O	3156-3166
chain	O	3167-3172
reaction	O	3173-3181
of	O	3182-3184
those	O	3185-3190
patients	O	3191-3199
at	O	3200-3202
risk	O	3203-3207
of	O	3208-3210
disseminated	O	3211-3223
adenovirus	B	3224-3234
disease	I	3235-3242
may	O	3243-3246
permit	O	3247-3253
earlier	O	3254-3261
antiviral	O	3262-3271
treatment	O	3272-3281
and	O	3282-3285
better	O	3286-3292
evaluation	O	3293-3303
of	O	3304-3306
therapeutic	O	3307-3318
response	O	3319-3327
.	O	3327-3328

CONCLUSIONS	O	3329-3340
:	O	3340-3341
Two	O	3342-3345
of	O	3346-3348
5	O	3349-3350
children	O	3351-3359
with	O	3360-3364
severe	O	3365-3371
adenovirus	B	3372-3382
disease	I	3383-3390
treated	O	3391-3398
with	O	3399-3403
intravenous	O	3404-3415
ribavirin	O	3416-3425
recovered	O	3426-3435
.	O	3435-3436

The	O	3437-3440
availability	O	3441-3453
of	O	3454-3456
newer	O	3457-3462
rapid	O	3463-3468
diagnostic	O	3469-3479
techniques	O	3480-3490
,	O	3490-3491
such	O	3492-3496
as	O	3497-3499
polymerase	O	3500-3510
chain	O	3511-3516
reaction	O	3517-3525
,	O	3525-3526
may	O	3527-3530
make	O	3531-3535
earlier	O	3536-3543
,	O	3543-3544
more	O	3545-3549
effective	O	3550-3559
treatment	O	3560-3569
of	O	3570-3572
adenovirus	B	3573-3583
infection	I	3584-3593
possible	O	3594-3602
.	O	3602-3603

Given	O	3604-3609
the	O	3610-3613
seriousness	O	3614-3625
and	O	3626-3629
increasing	O	3630-3640
prevalence	O	3641-3651
of	O	3652-3654
adenovirus	B	3655-3665
disease	I	3666-3673
in	O	3674-3676
certain	O	3677-3684
hosts	O	3685-3690
,	O	3690-3691
especially	O	3692-3702
children	O	3703-3711
,	O	3711-3712
a	O	3713-3714
large	O	3715-3720
,	O	3720-3721
multicenter	O	3722-3733
clinical	O	3734-3742
trial	O	3743-3748
of	O	3749-3751
potentially	O	3752-3763
useful	O	3764-3770
anti	O	3771-3775
-	O	3775-3776
adenoviral	O	3776-3786
therapies	O	3787-3796
,	O	3796-3797
such	O	3798-3802
as	O	3803-3805
intravenous	O	3806-3817
ribavirin	O	3818-3827
,	O	3827-3828
is	O	3829-3831
clearly	O	3832-3839
required	O	3840-3848
to	O	3849-3851
demonstrate	O	3852-3863
the	O	3864-3867
most	O	3868-3872
effective	O	3873-3882
and	O	3883-3886
least	O	3887-3892
toxic	O	3893-3898
therapy	O	3899-3906
.	O	3906-3907

Hepatotoxicity	B	0-14
of	O	15-17
amiodarone	O	18-28
.	O	28-29

Amiodarone	O	30-40
has	O	41-44
proved	O	45-51
very	O	52-56
effective	O	57-66
in	O	67-69
the	O	70-73
treatment	O	74-83
of	O	84-86
otherwise	O	87-96
resistant	O	97-106
cardiac	O	107-114
tachyarrhythmias	B	115-131
.	O	131-132

The	O	133-136
use	O	137-140
of	O	141-143
amiodarone	O	144-154
has	O	155-158
,	O	158-159
however	O	160-167
,	O	167-168
been	O	169-173
limited	O	174-181
due	O	182-185
to	O	186-188
its	O	189-192
serious	O	193-200
side	O	201-205
-	O	205-206
effects	O	206-213
.	O	213-214

A	O	215-216
patient	O	217-224
with	O	225-229
cholestatic	B	230-241
hepatitis	I	242-251
due	O	252-255
to	O	256-258
amiodarone	O	259-269
treatment	O	270-279
is	O	280-282
presented	O	283-292
below	O	293-298
and	O	299-302
a	O	303-304
review	O	305-311
of	O	312-314
the	O	315-318
hepatotoxicity	B	319-333
of	O	334-336
amiodarone	O	337-347
is	O	348-350
given	O	351-356
.	O	356-357

It	O	358-360
is	O	361-363
concluded	O	364-373
that	O	374-378
solid	O	379-384
evidence	O	385-393
exists	O	394-400
of	O	401-403
hepatic	B	404-411
injury	I	412-418
due	O	419-422
to	O	423-425
amiodarone	O	426-436
treatment	O	437-446
,	O	446-447
including	O	448-457
steatosis	B	458-467
,	O	467-468
alterations	O	469-480
resembling	O	481-491
alcoholic	B	492-501
hepatitis	I	502-511
,	O	511-512
cholestatic	B	513-524
hepatitis	I	525-534
and	O	535-538
micronodular	O	539-551
cirrhosis	B	552-561
of	I	562-564
the	I	565-568
liver	I	569-574
.	O	574-575

Patients	O	576-584
receiving	O	585-594
amiodarone	O	595-605
should	O	606-612
be	O	613-615
regularly	O	616-625
screened	O	626-634
with	O	635-639
respect	O	640-647
to	O	648-650
hepatic	O	651-658
enzyme	O	659-665
levels	O	666-672
.	O	672-673

Therapy	O	674-681
should	O	682-688
be	O	689-691
discontinued	O	692-704
on	O	705-707
the	O	708-711
suspicion	O	712-721
of	O	722-724
cholestatic	B	725-736
injury	I	737-743
or	O	744-746
hepatomegaly	B	747-759
.	O	759-760

Catalepsy	B	0-9
induced	O	10-17
by	O	18-20
combinations	O	21-33
of	O	34-36
ketamine	O	37-45
and	O	46-49
morphine	O	50-58
:	O	58-59
potentiation	O	60-72
,	O	72-73
antagonism	O	74-84
,	O	84-85
tolerance	O	86-95
and	O	96-99
cross	O	100-105
-	O	105-106
tolerance	O	106-115
in	O	116-118
the	O	119-122
rat	O	123-126
.	O	126-127

Previous	O	128-136
studies	O	137-144
demonstrated	O	145-157
that	O	158-162
both	O	163-167
ketamine	O	168-176
and	O	177-180
morphine	O	181-189
induced	O	190-197
analgesia	B	198-207
and	O	208-211
catalepsy	B	212-221
in	O	222-224
the	O	225-228
rat	O	229-232
.	O	232-233

Pre	O	234-237
-	O	237-238
treatment	O	238-247
with	O	248-252
ketamine	O	253-261
produced	O	262-270
cross	O	271-276
-	O	276-277
tolerance	O	277-286
to	O	287-289
morphine	O	290-298
,	O	298-299
whereas	O	300-307
pretreatment	O	308-320
with	O	321-325
morphine	O	326-334
did	O	335-338
not	O	339-342
induce	O	343-349
cross	O	350-355
-	O	355-356
tolerance	O	356-365
to	O	366-368
ketamine	O	369-377
but	O	378-381
rather	O	382-388
augmented	O	389-398
the	O	399-402
cataleptic	B	403-413
response	O	414-422
;	O	422-423
this	O	424-428
augmentation	O	429-441
was	O	442-445
attributed	O	446-456
to	O	457-459
residual	O	460-468
morphine	O	469-477
in	O	478-480
the	O	481-484
brain	O	485-490
.	O	490-491

The	O	492-495
present	O	496-503
studies	O	504-511
explored	O	512-520
the	O	521-524
duration	O	525-533
of	O	534-536
the	O	537-540
loss	O	541-545
of	O	546-548
righting	O	549-557
reflex	O	558-564
induced	O	565-572
by	O	573-575
sub	O	576-579
-	O	579-580
effective	O	580-589
doses	O	590-595
of	O	596-598
ketamine	O	599-607
and	O	608-611
morphine	O	612-620
,	O	620-621
administered	O	622-634
simultaneously	O	635-649
.	O	649-650

There	O	651-656
was	O	657-660
mutual	O	661-667
potentiation	O	668-680
between	O	681-688
sub	O	689-692
-	O	692-693
effective	O	693-702
doses	O	703-708
of	O	709-711
ketamine	O	712-720
and	O	721-724
morphine	O	725-733
,	O	733-734
but	O	735-738
sub	O	739-742
-	O	742-743
effective	O	743-752
doses	O	753-758
of	O	759-761
ketamine	O	762-770
partly	O	771-777
antagonized	O	778-789
fully	O	790-795
-	O	795-796
effective	O	796-805
doses	O	806-811
of	O	812-814
morphine	O	815-823
.	O	823-824

Latency	O	825-832
to	O	833-835
the	O	836-839
loss	O	840-844
of	O	845-847
righting	O	848-856
reflex	O	857-863
,	O	863-864
rigidity	B	865-873
and	O	874-877
behavior	O	878-886
on	O	887-889
recovery	O	890-898
,	O	898-899
reflected	O	900-909
the	O	910-913
relative	O	914-922
predominance	O	923-935
of	O	936-938
ketamine	O	939-947
or	O	948-950
morphine	O	951-959
in	O	960-962
each	O	963-967
combination	O	968-979
.	O	979-980

Naloxone	O	981-989
inhibited	O	990-999
the	O	1000-1003
induced	O	1004-1011
cataleptic	B	1012-1022
effects	O	1023-1030
.	O	1030-1031

The	O	1032-1035
degree	O	1036-1042
and	O	1043-1046
time	O	1047-1051
course	O	1052-1058
of	O	1059-1061
development	O	1062-1073
of	O	1074-1076
tolerance	O	1077-1086
to	O	1087-1089
daily	O	1090-1095
administration	O	1096-1110
of	O	1111-1113
sub	O	1114-1117
-	O	1117-1118
effective	O	1118-1127
dose	O	1128-1132
combinations	O	1133-1145
of	O	1146-1148
ketamine	O	1149-1157
and	O	1158-1161
morphine	O	1162-1170
were	O	1171-1175
similar	O	1176-1183
.	O	1183-1184

Rats	O	1185-1189
,	O	1189-1190
tolerant	O	1191-1199
to	O	1200-1202
ketamine	O	1203-1211
-	O	1211-1212
dominant	O	1212-1220
combinations	O	1221-1233
,	O	1233-1234
were	O	1235-1239
cross	O	1240-1245
-	O	1245-1246
tolerant	O	1246-1254
to	O	1255-1257
both	O	1258-1262
drugs	O	1263-1268
,	O	1268-1269
while	O	1270-1275
those	O	1276-1281
tolerant	O	1282-1290
to	O	1291-1293
morphine	O	1294-1302
-	O	1302-1303
dominant	O	1303-1311
combinations	O	1312-1324
were	O	1325-1329
cross	O	1330-1335
-	O	1335-1336
tolerant	O	1336-1344
to	O	1345-1347
morphine	O	1348-1356
but	O	1357-1360
showed	O	1361-1367
either	O	1368-1374
no	O	1375-1377
cross	O	1378-1383
-	O	1383-1384
tolerance	O	1384-1393
or	O	1394-1396
an	O	1397-1399
augmented	O	1400-1409
response	O	1410-1418
to	O	1419-1421
ketamine	O	1422-1430
.	O	1430-1431

While	O	1432-1437
the	O	1438-1441
mutual	O	1442-1448
potentiation	O	1449-1461
,	O	1461-1462
antagonism	O	1463-1473
and	O	1474-1477
tolerance	O	1478-1487
suggest	O	1488-1495
common	O	1496-1502
mechanisms	O	1503-1513
for	O	1514-1517
the	O	1518-1521
induced	O	1522-1529
catalepsy	B	1530-1539
,	O	1539-1540
differences	O	1541-1552
in	O	1553-1555
latency	O	1556-1563
,	O	1563-1564
rigidity	B	1565-1573
and	O	1574-1577
behavior	O	1578-1586
,	O	1586-1587
asymmetry	O	1588-1597
of	O	1598-1600
cross	O	1601-1606
-	O	1606-1607
tolerance	O	1607-1616
and	O	1617-1620
a	O	1621-1622
widely	O	1623-1629
-	O	1629-1630
different	O	1630-1639
ID50	O	1640-1644
for	O	1645-1648
naloxone	O	1649-1657
would	O	1658-1663
argue	O	1664-1669
against	O	1670-1677
an	O	1678-1680
action	O	1681-1687
at	O	1688-1690
a	O	1691-1692
single	O	1693-1699
opioid	O	1700-1706
site	O	1707-1711
.	O	1711-1712

Acute	B	0-5
renal	I	6-11
failure	I	12-19
in	O	20-22
patients	O	23-31
with	O	32-36
AIDS	B	37-41
on	O	42-44
tenofovir	O	45-54
while	O	55-60
receiving	O	61-70
prolonged	O	71-80
vancomycin	O	81-91
course	O	92-98
for	O	99-102
osteomyelitis	B	103-116
.	O	116-117

Renal	B	118-123
failure	I	124-131
developed	O	132-141
after	O	142-147
a	O	148-149
prolonged	O	150-159
course	O	160-166
of	O	167-169
vancomycin	O	170-180
therapy	O	181-188
in	O	189-191
2	O	192-193
patients	O	194-202
who	O	203-206
were	O	207-211
receiving	O	212-221
tenofovir	O	222-231
disoproxil	O	232-242
fumarate	O	243-251
as	O	252-254
part	O	255-259
of	O	260-262
an	O	263-265
antiretroviral	O	266-280
regimen	O	281-288
.	O	288-289

Tenofovir	O	290-299
has	O	300-303
been	O	304-308
implicated	O	309-319
in	O	320-322
the	O	323-326
development	O	327-338
of	O	339-341
Fanconi	B	342-349
syndrome	I	350-358
and	O	359-362
renal	B	363-368
insufficiency	I	369-382
because	O	383-390
of	O	391-393
its	O	394-397
effects	O	398-405
on	O	406-408
the	O	409-412
proximal	O	413-421
renal	O	422-427
tubule	O	428-434
.	O	434-435

Vancomycin	O	436-446
nephrotoxicity	B	447-461
is	O	462-464
infrequent	O	465-475
but	O	476-479
may	O	480-483
result	O	484-490
from	O	491-495
coadministration	O	496-512
with	O	513-517
a	O	518-519
nephrotoxic	B	520-531
agent	O	532-537
.	O	537-538

Clinicians	O	539-549
should	O	550-556
be	O	557-559
aware	O	560-565
that	O	566-570
tenofovir	O	571-580
may	O	581-584
raise	O	585-590
the	O	591-594
risk	O	595-599
of	O	600-602
renal	B	603-608
failure	I	609-616
during	O	617-623
prolonged	O	624-633
administration	O	634-648
of	O	649-651
vancomycin	O	652-662
.	O	662-663

Delayed	O	0-7
leukoencephalopathy	B	8-27
with	O	28-32
stroke	B	33-39
-	O	39-40
like	O	40-44
presentation	O	45-57
in	O	58-60
chemotherapy	O	61-73
recipients	O	74-84
.	O	84-85

BACKGROUND	O	86-96
:	O	96-97
A	O	98-99
transient	O	100-109
leukoencephalopathy	B	110-129
mimicking	O	130-139
cerebrovascular	B	140-155
accident	I	156-164
has	O	165-168
been	O	169-173
described	O	174-183
as	O	184-186
a	O	187-188
complication	O	189-201
of	O	202-204
chemotherapy	O	205-217
,	O	217-218
most	O	219-223
commonly	O	224-232
in	O	233-235
recipients	O	236-246
of	O	247-249
intrathecal	O	250-261
methotrexate	O	262-274
for	O	275-278
childhood	O	279-288
leukaemia	B	289-298
.	O	298-299

Recently	O	300-308
published	O	309-318
neuroimaging	O	319-331
data	O	332-336
suggest	O	337-344
a	O	345-346
common	O	347-353
pathophysiology	O	354-369
associated	O	370-380
with	O	381-385
a	O	386-387
variety	O	388-395
of	O	396-398
chemotherapy	O	399-411
agents	O	412-418
and	O	419-422
modes	O	423-428
of	O	429-431
administration	O	432-446
.	O	446-447

METHODS	O	448-455
:	O	455-456
We	O	457-459
reviewed	O	460-468
the	O	469-472
medical	O	473-480
literature	O	481-491
for	O	492-495
single	O	496-502
reports	O	503-510
and	O	511-514
case	O	515-519
series	O	520-526
of	O	527-529
patients	O	530-538
presenting	O	539-549
with	O	550-554
stroke	B	555-561
-	O	561-562
like	O	562-566
episodes	O	567-575
while	O	576-581
receiving	O	582-591
systemic	O	592-600
or	O	601-603
intrathecal	O	604-615
chemotherapy	O	616-628
.	O	628-629

We	O	630-632
only	O	633-637
included	O	638-646
studies	O	647-654
providing	O	655-664
detailed	O	665-673
neuroimaging	O	674-686
data	O	687-691
.	O	691-692

Patients	O	693-701
with	O	702-706
cerebrovascular	B	707-722
accidents	I	723-732
were	O	733-737
excluded	O	738-746
.	O	746-747

RESULTS	O	748-755
:	O	755-756
We	O	757-759
identified	O	760-770
27	O	771-773
reports	O	774-781
of	O	782-784
toxic	O	785-790
leukoencephalopathy	B	791-810
in	O	811-813
patients	O	814-822
treated	O	823-830
with	O	831-835
methotrexate	O	836-848
(	O	849-850
intrathecal	O	850-861
,	O	861-862
systemic	O	863-871
)	O	871-872
,	O	872-873
5	O	874-875
-	O	875-876
fluorouracil	O	876-888
and	O	889-892
its	O	893-896
derivative	O	897-907
carmofur	O	908-916
,	O	916-917
and	O	918-921
capecitabine	O	922-934
.	O	934-935

Diffusion	O	936-945
weighted	O	946-954
imaging	O	955-962
(	O	963-964
DWI	O	964-967
)	O	967-968
of	O	969-971
all	O	972-975
patients	O	976-984
revealed	O	985-993
well	O	994-998
demarcated	O	999-1009
hyperintense	O	1010-1022
lesions	B	1023-1030
within	I	1031-1037
the	I	1038-1041
subcortical	I	1042-1053
white	I	1054-1059
matter	I	1060-1066
of	O	1067-1069
the	O	1070-1073
cerebral	O	1074-1082
hemispheres	O	1083-1094
and	O	1095-1098
the	O	1099-1102
corpus	O	1103-1109
callosum	O	1110-1118
,	O	1118-1119
corresponding	O	1120-1133
to	O	1134-1136
areas	O	1137-1142
of	O	1143-1145
decreased	O	1146-1155
proton	O	1156-1162
diffusion	O	1163-1172
on	O	1173-1175
apparent	O	1176-1184
diffusion	O	1185-1194
coefficient	O	1195-1206
(	O	1207-1208
ADC	O	1208-1211
)	O	1211-1212
maps	O	1213-1217
(	O	1218-1219
available	O	1219-1228
in	O	1229-1231
21	O	1232-1234
/	O	1234-1235
27	O	1235-1237
patients	O	1238-1246
)	O	1246-1247
.	O	1247-1248

Lesions	O	1249-1256
exceeded	O	1257-1265
the	O	1266-1269
confines	O	1270-1278
of	O	1279-1281
adjacent	O	1282-1290
vascular	O	1291-1299
territories	O	1300-1311
.	O	1311-1312

Complete	O	1313-1321
resolution	O	1322-1332
of	O	1333-1335
symptoms	O	1336-1344
within	O	1345-1351
1	O	1352-1353
-	O	1353-1354
4	O	1354-1355
days	O	1356-1360
was	O	1361-1364
accompanied	O	1365-1376
by	O	1377-1379
normalisation	O	1380-1393
of	O	1394-1396
ADC	O	1397-1400
abnormalities	O	1401-1414
.	O	1414-1415

However	O	1416-1423
,	O	1423-1424
fluid	O	1425-1430
attenuated	O	1431-1441
inversion	O	1442-1451
recovery	O	1452-1460
(	O	1461-1462
FLAIR	O	1462-1467
)	O	1467-1468
sequences	O	1469-1478
frequently	O	1479-1489
revealed	O	1490-1498
persistent	O	1499-1509
white	B	1510-1515
matter	I	1516-1522
abnormalities	I	1523-1536
.	O	1536-1537

CONCLUSIONS	O	1538-1549
:	O	1549-1550
Several	O	1551-1558
pathophysiological	O	1559-1577
models	O	1578-1584
of	O	1585-1587
delayed	O	1588-1595
leukoencephalopathy	B	1596-1615
after	O	1616-1621
exposure	O	1622-1630
to	O	1631-1633
intrathecal	O	1634-1645
or	O	1646-1648
systemic	O	1649-1657
chemotherapy	O	1658-1670
have	O	1671-1675
been	O	1676-1680
proposed	O	1681-1689
.	O	1689-1690

DWI	O	1691-1694
findings	O	1695-1703
in	O	1704-1706
this	O	1707-1711
cohort	O	1712-1718
are	O	1719-1722
indicative	O	1723-1733
of	O	1734-1736
cytotoxic	B	1737-1746
oedema	I	1747-1753
within	I	1754-1760
cerebral	I	1761-1769
white	I	1770-1775
matter	I	1776-1782
and	O	1783-1786
lend	O	1787-1791
support	O	1792-1799
to	O	1800-1802
an	O	1803-1805
at	O	1806-1808
least	O	1809-1814
partially	O	1815-1824
reversible	O	1825-1835
metabolic	O	1836-1845
derangement	O	1846-1857
as	O	1858-1860
the	O	1861-1864
basis	O	1865-1870
for	O	1871-1874
this	O	1875-1879
syndrome	O	1880-1888
.	O	1888-1889

Down	O	0-4
-	O	4-5
regulation	O	5-15
of	O	16-18
norepinephrine	O	19-33
transporter	O	34-45
function	O	46-54
induced	O	55-62
by	O	63-65
chronic	O	66-73
administration	O	74-88
of	O	89-91
desipramine	O	92-103
linking	O	104-111
to	O	112-114
the	O	115-118
alteration	O	119-129
of	O	130-132
sensitivity	O	133-144
of	O	145-147
local	O	148-153
-	O	153-154
anesthetics	O	154-165
-	O	153-154
induced	O	166-173
convulsions	B	174-185
and	O	186-189
the	O	190-193
counteraction	O	194-207
by	O	208-210
co	O	211-213
-	O	213-214
administration	O	214-228
with	O	229-233
local	O	234-239
anesthetics	O	240-251
.	O	251-252

Alterations	O	253-264
of	O	265-267
norepinephrine	O	268-282
transporter	O	283-294
(	O	295-296
NET	O	296-299
)	O	299-300
function	O	301-309
by	O	310-312
chronic	O	313-320
inhibition	O	321-331
of	O	332-334
NET	O	335-338
in	O	339-341
relation	O	342-350
to	O	351-353
sensitization	O	354-367
to	O	368-370
seizures	B	371-379
induce	O	380-386
by	O	387-389
cocaine	O	390-397
and	O	398-401
local	O	402-407
anesthetics	O	408-419
were	O	420-424
studied	O	425-432
in	O	433-435
mice	O	436-440
.	O	440-441

Daily	O	442-447
administration	O	448-462
of	O	463-465
desipramine	O	466-477
,	O	477-478
an	O	479-481
inhibitor	O	482-491
of	O	492-494
the	O	495-498
NET	O	499-502
,	O	502-503
for	O	504-507
5	O	508-509
days	O	510-514
decreased	O	515-524
[	O	525-526
(	O	526-527
3	O	527-528
)	O	528-529
H	O	529-530
]	O	530-531
norepinephrine	O	531-545
uptake	O	546-552
in	O	553-555
the	O	556-559
P2	O	560-562
fractions	O	563-572
of	O	573-575
hippocampus	O	576-587
but	O	588-591
not	O	592-595
cortex	O	596-602
,	O	602-603
striatum	O	604-612
or	O	613-615
amygdalae	O	616-625
.	O	625-626

Co	O	627-629
-	O	629-630
administration	O	630-644
of	O	645-647
lidocaine	O	648-657
,	O	657-658
bupivacaine	O	659-670
or	O	671-673
tricaine	O	674-682
with	O	683-687
desipramine	O	688-699
reversed	O	700-708
this	O	709-713
effect	O	714-720
.	O	720-721

Daily	O	722-727
treatment	O	728-737
of	O	738-740
cocaine	O	741-748
increased	O	749-758
[	O	759-760
(	O	760-761
3	O	761-762
)	O	762-763
H	O	763-764
]	O	764-765
norepinephrine	O	765-779
uptake	O	780-786
into	O	787-791
the	O	792-795
hippocampus	O	796-807
.	O	807-808

Daily	O	809-814
administration	O	815-829
of	O	830-832
desipramine	O	833-844
increased	O	845-854
the	O	855-858
incidence	O	859-868
of	O	869-871
appearance	O	872-882
of	O	883-885
lidocaine	O	886-895
-	O	895-896
induced	O	896-903
convulsions	B	904-915
and	O	916-919
decreased	O	920-929
that	O	930-934
of	O	935-937
cocaine	O	938-945
-	O	945-946
induced	O	946-953
convulsions	B	954-965
.	O	965-966

Co	O	967-969
-	O	969-970
administration	O	970-984
of	O	985-987
lidocaine	O	988-997
with	O	998-1002
desipramine	O	1003-1014
reversed	O	1015-1023
the	O	1024-1027
changes	O	1028-1035
of	O	1036-1038
convulsive	B	1039-1049
activity	O	1050-1058
of	O	1059-1061
lidocaine	O	1062-1071
and	O	1072-1075
cocaine	O	1076-1083
induced	O	1084-1091
by	O	1092-1094
repeated	O	1095-1103
administration	O	1104-1118
of	O	1119-1121
desipramine	O	1122-1133
.	O	1133-1134

These	O	1135-1140
results	O	1141-1148
suggest	O	1149-1156
that	O	1157-1161
down	O	1162-1166
-	O	1166-1167
regulation	O	1167-1177
of	O	1178-1180
hippocampal	O	1181-1192
NET	O	1193-1196
induced	O	1197-1204
by	O	1205-1207
chronic	O	1208-1215
administration	O	1216-1230
of	O	1231-1233
desipramine	O	1234-1245
may	O	1246-1249
be	O	1250-1252
relevant	O	1253-1261
to	O	1262-1264
desipramine	O	1265-1276
-	O	1276-1277
induced	O	1277-1284
sensitization	O	1285-1298
of	O	1299-1301
lidocaine	O	1302-1311
convulsions	B	1312-1323
.	O	1323-1324

Inhibition	O	1325-1335
of	O	1336-1338
Na	O	1339-1341
(	O	1341-1342
+	O	1342-1343
)	O	1343-1344
channels	O	1345-1353
by	O	1354-1356
local	O	1357-1362
anesthetics	O	1363-1374
may	O	1375-1378
regulate	O	1379-1387
desipramine	O	1388-1399
-	O	1399-1400
induced	O	1400-1407
down	O	1408-1412
-	O	1412-1413
regulation	O	1413-1423
of	O	1424-1426
NET	O	1427-1430
function	O	1431-1439
.	O	1439-1440

Repeated	O	1441-1449
administration	O	1450-1464
of	O	1465-1467
cocaine	O	1468-1475
induces	O	1476-1483
up	O	1484-1486
-	O	1486-1487
regulation	O	1487-1497
of	O	1498-1500
hippocampal	O	1501-1512
NET	O	1513-1516
function	O	1517-1525
.	O	1525-1526

Desipramine	O	1527-1538
-	O	1538-1539
induced	O	1539-1546
sensitization	O	1547-1560
of	O	1561-1563
lidocaine	O	1564-1573
seizures	B	1574-1582
may	O	1583-1586
have	O	1587-1591
a	O	1592-1593
mechanism	O	1594-1603
distinct	O	1604-1612
from	O	1613-1617
kindling	O	1618-1626
resulting	O	1627-1636
from	O	1637-1641
repeated	O	1642-1650
administration	O	1651-1665
of	O	1666-1668
cocaine	O	1669-1676
.	O	1676-1677

Definition	O	0-10
and	O	11-14
management	O	15-25
of	O	26-28
anemia	B	29-35
in	O	36-38
patients	O	39-47
infected	B	48-56
with	I	57-61
hepatitis	I	62-71
C	I	72-73
virus	I	74-79
.	O	79-80

Chronic	B	81-88
infection	I	89-98
with	I	99-103
hepatitis	I	104-113
C	I	114-115
virus	I	116-121
(	O	122-123
HCV	O	123-126
)	O	126-127
can	O	128-131
progress	O	132-140
to	O	141-143
cirrhosis	B	144-153
,	O	153-154
hepatocellular	B	155-169
carcinoma	I	170-179
,	O	179-180
and	O	181-184
end	B	185-188
-	I	188-189
stage	I	189-194
liver	I	195-200
disease	I	201-208
.	O	208-209

The	O	210-213
current	O	214-221
best	O	222-226
treatment	O	227-236
for	O	237-240
HCV	B	241-244
infection	I	245-254
is	O	255-257
combination	O	258-269
therapy	O	270-277
with	O	278-282
pegylated	O	283-292
interferon	O	293-303
and	O	304-307
ribavirin	O	308-317
.	O	317-318

Although	O	319-327
this	O	328-332
regimen	O	333-340
produces	O	341-349
sustained	O	350-359
virologic	O	360-369
responses	O	370-379
(	O	380-381
SVRs	O	381-385
)	O	385-386
in	O	387-389
approximately	O	390-403
50	O	404-406
%	O	406-407
of	O	408-410
patients	O	411-419
,	O	419-420
it	O	421-423
can	O	424-427
be	O	428-430
associated	O	431-441
with	O	442-446
a	O	447-448
potentially	O	449-460
dose	O	461-465
-	O	465-466
limiting	O	466-474
hemolytic	B	475-484
anemia	I	485-491
.	O	491-492

Hemoglobin	O	493-503
concentrations	O	504-518
decrease	O	519-527
mainly	O	528-534
as	O	535-537
a	O	538-539
result	O	540-546
of	O	547-549
ribavirin	O	550-559
-	O	559-560
induced	O	560-567
hemolysis	B	568-577
,	O	577-578
and	O	579-582
this	O	583-587
anemia	B	588-594
can	O	595-598
be	O	599-601
problematic	O	602-613
in	O	614-616
patients	O	617-625
with	O	626-630
HCV	B	631-634
infection	I	635-644
,	O	644-645
especially	O	646-656
those	O	657-662
who	O	663-666
have	O	667-671
comorbid	O	672-680
renal	B	681-686
or	I	687-689
cardiovascular	I	690-704
disorders	I	705-714
.	O	714-715

In	O	716-718
general	O	719-726
,	O	726-727
anemia	B	728-734
can	O	735-738
increase	O	739-747
the	O	748-751
risk	O	752-756
of	O	757-759
morbidity	O	760-769
and	O	770-773
mortality	O	774-783
,	O	783-784
and	O	785-788
may	O	789-792
have	O	793-797
negative	O	798-806
effects	O	807-814
on	O	815-817
cerebral	O	818-826
function	O	827-835
and	O	836-839
quality	O	840-847
of	O	848-850
life	O	851-855
.	O	855-856

Although	O	857-865
ribavirin	O	866-875
-	O	875-876
associated	O	876-886
anemia	B	887-893
can	O	894-897
be	O	898-900
reversed	O	901-909
by	O	910-912
dose	O	913-917
reduction	O	918-927
or	O	928-930
discontinuation	O	931-946
,	O	946-947
this	O	948-952
approach	O	953-961
compromises	O	962-973
outcomes	O	974-982
by	O	983-985
significantly	O	986-999
decreasing	O	1000-1010
SVR	O	1011-1014
rates	O	1015-1020
.	O	1020-1021

Recombinant	O	1022-1033
human	O	1034-1039
erythropoietin	O	1040-1054
has	O	1055-1058
been	O	1059-1063
used	O	1064-1068
to	O	1069-1071
manage	O	1072-1078
ribavirin	O	1079-1088
-	O	1088-1089
associated	O	1089-1099
anemia	B	1100-1106
but	O	1107-1110
has	O	1111-1114
other	O	1115-1120
potential	O	1121-1130
disadvantages	O	1131-1144
.	O	1144-1145

Viramidine	O	1146-1156
,	O	1156-1157
a	O	1158-1159
liver	O	1160-1165
-	O	1165-1166
targeting	O	1166-1175
prodrug	O	1176-1183
of	O	1184-1186
ribavirin	O	1187-1196
,	O	1196-1197
has	O	1198-1201
the	O	1202-1205
potential	O	1206-1215
to	O	1216-1218
maintain	O	1219-1227
the	O	1228-1231
virologic	O	1232-1241
efficacy	O	1242-1250
of	O	1251-1253
ribavirin	O	1254-1263
while	O	1264-1269
decreasing	O	1270-1280
the	O	1281-1284
risk	O	1285-1289
of	O	1290-1292
hemolytic	B	1293-1302
anemia	I	1303-1309
in	O	1310-1312
patients	O	1313-1321
with	O	1322-1326
chronic	B	1327-1334
hepatitis	I	1335-1344
C	I	1345-1346
.	O	1346-1347

Calcium	O	0-7
carbonate	O	8-17
toxicity	B	18-26
:	O	26-27
the	O	28-31
updated	O	32-39
milk	B	40-44
-	I	44-45
alkali	I	45-51
syndrome	I	52-60
;	O	60-61
report	O	62-68
of	O	69-71
3	O	72-73
cases	O	74-79
and	O	80-83
review	O	84-90
of	O	91-93
the	O	94-97
literature	O	98-108
.	O	108-109

OBJECTIVE	O	110-119
:	O	119-120
To	O	121-123
describe	O	124-132
3	O	133-134
patients	O	135-143
with	O	144-148
calcium	O	149-156
carbonate	O	157-166
-	O	166-167
induced	O	167-174
hypercalcemia	B	175-188
and	O	189-192
gain	O	193-197
insights	O	198-206
into	O	207-211
the	O	212-215
cause	O	216-221
and	O	222-225
management	O	226-236
of	O	237-239
the	O	240-243
milk	B	244-248
-	I	248-249
alkali	I	249-255
syndrome	I	256-264
.	O	264-265

METHODS	O	266-273
:	O	273-274
We	O	275-277
report	O	278-284
the	O	285-288
clinical	O	289-297
and	O	298-301
laboratory	O	302-312
data	O	313-317
in	O	318-320
3	O	321-322
patients	O	323-331
who	O	332-335
presented	O	336-345
with	O	346-350
severe	O	351-357
hypercalcemia	B	358-371
(	O	372-373
corrected	O	373-382
serum	O	383-388
calcium	O	389-396
>	O	397-398
or	O	399-401
=	O	402-403
14	O	404-406
mg	O	407-409
/	O	409-410
dL	O	410-412
)	O	412-413
and	O	414-417
review	O	418-424
the	O	425-428
pertinent	O	429-438
literature	O	439-449
on	O	450-452
milk	B	453-457
-	I	457-458
alkali	I	458-464
syndrome	I	465-473
.	O	473-474

RESULTS	O	475-482
:	O	482-483
The	O	484-487
3	O	488-489
patients	O	490-498
had	O	499-502
acute	B	503-508
renal	I	509-514
insufficiency	I	515-528
,	O	528-529
relative	O	530-538
metabolic	B	539-548
alkalosis	I	549-558
,	O	558-559
and	O	560-563
low	O	564-567
parathyroid	O	568-579
hormone	O	580-587
(	O	588-589
PTH	O	589-592
)	O	592-593
,	O	593-594
PTH	O	595-598
-	O	598-599
related	O	599-606
peptide	O	607-614
,	O	614-615
and	O	616-619
1	O	620-621
,	O	621-622
25	O	622-624
-	O	624-625
dihydroxyvitamin	O	625-641
D	O	642-643
concentrations	O	644-658
.	O	658-659

No	O	660-662
malignant	O	663-672
lesion	O	673-679
was	O	680-683
found	O	684-689
.	O	689-690

Treatment	O	691-700
included	O	701-709
aggressive	O	710-720
hydration	O	721-730
and	O	731-734
varied	O	735-741
amounts	O	742-749
of	O	750-752
furosemide	O	753-763
.	O	763-764

The	O	765-768
2	O	769-770
patients	O	771-779
with	O	780-784
the	O	785-788
higher	O	789-795
serum	O	796-801
calcium	O	802-809
concentrations	O	810-824
received	O	825-833
pamidronate	O	834-845
intravenously	O	846-859
(	O	860-861
60	O	861-863
and	O	864-867
30	O	868-870
mg	O	871-873
,	O	873-874
respectively	O	875-887
)	O	887-888
,	O	888-889
which	O	890-895
caused	O	896-902
severe	O	903-909
hypocalcemia	B	910-922
.	O	922-923

Of	O	924-926
the	O	927-930
3	O	931-932
patients	O	933-941
,	O	941-942
2	O	943-944
were	O	945-949
ingesting	O	950-959
acceptable	O	960-970
doses	O	971-976
of	O	977-979
elemental	O	980-989
calcium	O	990-997
(	O	998-999
1	O	999-1000
g	O	1001-1002
and	O	1003-1006
2	O	1007-1008
g	O	1009-1010
daily	O	1011-1016
,	O	1016-1017
respectively	O	1018-1030
)	O	1030-1031
in	O	1032-1034
the	O	1035-1038
form	O	1039-1043
of	O	1044-1046
calcium	O	1047-1054
carbonate	O	1055-1064
.	O	1064-1065

In	O	1066-1068
addition	O	1069-1077
to	O	1078-1080
our	O	1081-1084
highlighted	O	1085-1096
cases	O	1097-1102
,	O	1102-1103
we	O	1104-1106
review	O	1107-1113
the	O	1114-1117
history	O	1118-1125
,	O	1125-1126
classification	O	1127-1141
,	O	1141-1142
pathophysiologic	O	1143-1159
features	O	1160-1168
,	O	1168-1169
and	O	1170-1173
treatment	O	1174-1183
of	O	1184-1186
milk	B	1187-1191
-	I	1191-1192
alkali	I	1192-1198
syndrome	I	1199-1207
and	O	1208-1211
summarize	O	1212-1221
the	O	1222-1225
cases	O	1226-1231
reported	O	1232-1240
from	O	1241-1245
early	O	1246-1251
1995	O	1252-1256
to	O	1257-1259
November	O	1260-1268
2003	O	1269-1273
.	O	1273-1274

CONCLUSION	O	1275-1285
:	O	1285-1286
Milk	B	1287-1291
-	I	1291-1292
alkali	I	1292-1298
syndrome	I	1299-1307
may	O	1308-1311
be	O	1312-1314
a	O	1315-1316
common	O	1317-1323
cause	O	1324-1329
of	O	1330-1332
unexplained	O	1333-1344
hypercalcemia	B	1345-1358
and	O	1359-1362
can	O	1363-1366
be	O	1367-1369
precipitated	O	1370-1382
by	O	1383-1385
small	O	1386-1391
amounts	O	1392-1399
of	O	1400-1402
orally	O	1403-1409
ingested	O	1410-1418
calcium	O	1419-1426
carbonate	O	1427-1436
in	O	1437-1439
susceptible	O	1440-1451
persons	O	1452-1459
.	O	1459-1460

Treatment	O	1461-1470
with	O	1471-1475
hydration	O	1476-1485
,	O	1485-1486
furosemide	O	1487-1497
,	O	1497-1498
and	O	1499-1502
discontinuation	O	1503-1518
of	O	1519-1521
the	O	1522-1525
calcium	O	1526-1533
and	O	1534-1537
vitamin	O	1538-1545
D	O	1546-1547
source	O	1548-1554
is	O	1555-1557
adequate	O	1558-1566
.	O	1566-1567

Pamidronate	O	1568-1579
treatment	O	1580-1589
is	O	1590-1592
associated	O	1593-1603
with	O	1604-1608
considerable	O	1609-1621
risk	O	1622-1626
for	O	1627-1630
hypocalcemia	B	1631-1643
,	O	1643-1644
even	O	1645-1649
in	O	1650-1652
cases	O	1653-1658
of	O	1659-1661
initially	O	1662-1671
severe	O	1672-1678
hypercalcemia	B	1679-1692
.	O	1692-1693

Management	O	0-10
strategies	O	11-21
for	O	22-25
ribavirin	O	26-35
-	O	35-36
induced	O	36-43
hemolytic	B	44-53
anemia	I	54-60
in	O	61-63
the	O	64-67
treatment	O	68-77
of	O	78-80
hepatitis	B	81-90
C	I	91-92
:	O	92-93
clinical	O	94-102
and	O	103-106
economic	O	107-115
implications	O	116-128
.	O	128-129

OBJECTIVES	O	130-140
:	O	140-141
Recently	O	142-150
published	O	151-160
studies	O	161-168
have	O	169-173
demonstrated	O	174-186
increased	O	187-196
efficacy	O	197-205
and	O	206-209
cost	O	210-214
-	O	214-215
effectiveness	O	215-228
of	O	229-231
combination	O	232-243
therapy	O	244-251
with	O	252-256
interferon	O	257-267
and	O	268-271
alpha	O	272-277
-	O	277-278
2b	O	278-280
/	O	280-281
ribavirin	O	281-290
compared	O	291-299
with	O	300-304
interferon	O	305-315
-	O	315-316
alpha	O	316-321
monotherapy	O	322-333
in	O	334-336
the	O	337-340
treatment	O	341-350
of	O	351-353
chronic	B	354-361
hepatitis	I	362-371
C	I	372-373
(	O	374-375
CHC	B	375-378
)	O	378-379
.	O	379-380

Combination	O	381-392
therapy	O	393-400
is	O	401-403
associated	O	404-414
with	O	415-419
a	O	420-421
clinically	O	422-432
important	O	433-442
adverse	O	443-450
effect	O	451-457
:	O	457-458
ribavirin	O	459-468
-	O	468-469
induced	O	469-476
hemolytic	B	477-486
anemia	I	487-493
(	O	494-495
RIHA	B	495-499
)	O	499-500
.	O	500-501

The	O	502-505
objective	O	506-515
of	O	516-518
this	O	519-523
study	O	524-529
was	O	530-533
to	O	534-536
evaluate	O	537-545
the	O	546-549
direct	O	550-556
health	O	557-563
-	O	563-564
care	O	564-568
costs	O	569-574
and	O	575-578
management	O	579-589
of	O	590-592
RIHA	B	593-597
during	O	598-604
treatment	O	605-614
of	O	615-617
CHC	B	618-621
in	O	622-624
a	O	625-626
clinical	O	627-635
trial	O	636-641
setting	O	642-649
.	O	649-650

METHODS	O	651-658
:	O	658-659
A	O	660-661
systematic	O	662-672
literature	O	673-683
review	O	684-690
was	O	691-694
conducted	O	695-704
to	O	705-707
synthesize	O	708-718
information	O	719-730
on	O	731-733
the	O	734-737
incidence	O	738-747
and	O	748-751
management	O	752-762
of	O	763-765
RIHA	B	766-770
.	O	770-771

Decision	O	772-780
-	O	780-781
analytic	O	781-789
techniques	O	790-800
were	O	801-805
used	O	806-810
to	O	811-813
estimate	O	814-822
the	O	823-826
cost	O	827-831
of	O	832-834
treating	O	835-843
RIHA	B	844-848
.	O	848-849

Uncertainty	O	850-861
was	O	862-865
evaluated	O	866-875
using	O	876-881
sensitivity	O	882-893
analyses	O	894-902
.	O	902-903

RESULTS	O	904-911
:	O	911-912
RIHA	B	913-917
,	O	917-918
defined	O	919-926
as	O	927-929
a	O	930-931
reduction	O	932-941
in	O	942-944
hemoglobin	O	945-955
to	O	956-958
less	O	959-963
than	O	964-968
100	O	969-972
g	O	973-974
/	O	974-975
L	O	975-976
,	O	976-977
occurs	O	978-984
in	O	985-987
approximately	O	988-1001
7	O	1002-1003
%	O	1003-1004
to	O	1005-1007
9	O	1008-1009
%	O	1009-1010
of	O	1011-1013
patients	O	1014-1022
treated	O	1023-1030
with	O	1031-1035
combination	O	1036-1047
therapy	O	1048-1055
.	O	1055-1056

The	O	1057-1060
standard	O	1061-1069
of	O	1070-1072
care	O	1073-1077
for	O	1078-1081
management	O	1082-1092
of	O	1093-1095
RIHA	B	1096-1100
is	O	1101-1103
reduction	O	1104-1113
or	O	1114-1116
discontinuation	O	1117-1132
of	O	1133-1135
the	O	1136-1139
ribavirin	O	1140-1149
dosage	O	1150-1156
.	O	1156-1157

We	O	1158-1160
estimated	O	1161-1170
the	O	1171-1174
direct	O	1175-1181
cost	O	1182-1186
of	O	1187-1189
treating	O	1190-1198
clinically	O	1199-1209
significant	O	1210-1221
RIHA	B	1222-1226
to	O	1227-1229
be	O	1230-1232
170	O	1234-1237
per	O	1238-1241
patient	O	1242-1249
receiving	O	1250-1259
combination	O	1260-1271
therapy	O	1272-1279
per	O	1280-1283
48	O	1284-1286
-	O	1286-1287
week	O	1287-1291
treatment	O	1292-1301
course	O	1302-1308
(	O	1309-1310
range	O	1310-1315
68	O	1317-1319
-	O	1319-1320
692	O	1321-1324
)	O	1324-1325
.	O	1325-1326

The	O	1327-1330
results	O	1331-1338
of	O	1339-1341
the	O	1342-1345
one	O	1346-1349
-	O	1349-1350
way	O	1350-1353
sensitivity	O	1354-1365
analyses	O	1366-1374
ranged	O	1375-1381
from	O	1382-1386
57	O	1388-1390
to	O	1391-1393
317	O	1395-1398
.	O	1398-1399

In	O	1400-1402
comparison	O	1403-1413
,	O	1413-1414
the	O	1415-1418
cost	O	1419-1423
of	O	1424-1426
48	O	1427-1429
weeks	O	1430-1435
of	O	1436-1438
combination	O	1439-1450
therapy	O	1451-1458
is	O	1459-1461
16	O	1463-1465
,	O	1465-1466
459	O	1466-1469
.	O	1469-1470

CONCLUSIONS	O	1471-1482
:	O	1482-1483
The	O	1484-1487
direct	O	1488-1494
cost	O	1495-1499
of	O	1500-1502
treating	O	1503-1511
clinically	O	1512-1522
significant	O	1523-1534
RIHA	B	1535-1539
is	O	1540-1542
1	O	1543-1544
%	O	1544-1545
(	O	1546-1547
170	O	1548-1551
/	O	1551-1552
16	O	1553-1555
,	O	1555-1556
459	O	1556-1559
)	O	1559-1560
of	O	1561-1563
drug	O	1564-1568
treatment	O	1569-1578
costs	O	1579-1584
.	O	1584-1585

Questions	O	1586-1595
remain	O	1596-1602
about	O	1603-1608
the	O	1609-1612
optimal	O	1613-1620
dose	O	1621-1625
of	O	1626-1628
ribavirin	O	1629-1638
and	O	1639-1642
the	O	1643-1646
incidence	O	1647-1656
of	O	1657-1659
RIHA	B	1660-1664
in	O	1665-1667
a	O	1668-1669
real	O	1670-1674
-	O	1674-1675
world	O	1675-1680
population	O	1681-1691
.	O	1691-1692

Despite	O	1693-1700
these	O	1701-1706
uncertainties	O	1707-1720
,	O	1720-1721
this	O	1722-1726
initial	O	1727-1734
evaluation	O	1735-1745
of	O	1746-1748
the	O	1749-1752
direct	O	1753-1759
cost	O	1760-1764
of	O	1765-1767
treating	O	1768-1776
RIHA	B	1777-1781
provides	O	1782-1790
an	O	1791-1793
estimate	O	1794-1802
of	O	1803-1805
the	O	1806-1809
cost	O	1810-1814
and	O	1815-1818
management	O	1819-1829
implications	O	1830-1842
of	O	1843-1845
this	O	1846-1850
clinically	O	1851-1861
important	O	1862-1871
adverse	O	1872-1879
effect	O	1880-1886
.	O	1886-1887

Effects	O	0-7
of	O	8-10
amine	O	11-16
pretreatment	O	17-29
on	O	30-32
ketamine	O	33-41
catatonia	B	42-51
in	O	52-54
pinealectomized	O	55-70
or	O	71-73
hypophysectomized	O	74-91
animals	O	92-99
.	O	99-100

The	O	101-104
present	O	105-112
studies	O	113-120
were	O	121-125
designed	O	126-134
to	O	135-137
clarify	O	138-145
the	O	146-149
role	O	150-154
of	O	155-157
catecholamines	O	158-172
and	O	173-176
pineal	O	177-183
idolamines	O	184-194
on	O	195-197
ketamine	O	198-206
-	O	206-207
induced	O	207-214
catatonia	B	215-224
in	O	225-227
the	O	228-231
intact	O	232-238
,	O	238-239
pinealectomized	O	240-255
or	O	256-258
hypophysectomized	O	259-276
chick	O	277-282
and	O	283-286
rat	O	287-290
.	O	290-291

In	O	292-294
the	O	295-298
pinealectomized	O	299-314
chick	O	315-320
,	O	320-321
pretreatment	O	322-334
with	O	335-339
dopamine	O	340-348
increased	O	349-358
the	O	359-362
duration	O	363-371
of	O	372-374
catatonia	B	375-384
(	O	385-386
DOC	O	386-389
)	O	389-390
after	O	391-396
ketamine	O	397-405
,	O	405-406
but	O	407-410
pretreatment	O	411-423
with	O	424-428
norepinephrine	O	429-443
did	O	444-447
not	O	448-451
.	O	451-452

The	O	453-456
pineal	O	457-463
indolamines	O	464-475
exhibited	O	476-485
mixed	O	486-491
actions	O	492-499
.	O	499-500

Serotonin	O	501-510
and	O	511-514
N	O	515-516
-	O	516-517
acetyl	O	517-523
serotonin	O	524-533
which	O	534-539
augmented	O	540-549
ketamine	O	550-558
DOC	O	559-562
,	O	562-563
did	O	564-567
not	O	568-571
do	O	572-574
so	O	575-577
in	O	578-580
the	O	581-584
absence	O	585-592
of	O	593-595
the	O	596-599
pineal	O	600-606
gland	O	607-612
,	O	612-613
whereas	O	614-621
melatonin	O	622-631
potentiated	O	632-643
the	O	644-647
ketamine	O	648-656
DOC	O	657-660
in	O	661-663
both	O	664-668
the	O	669-672
intact	O	673-679
and	O	680-683
pinealectomized	O	684-699
chick	O	700-705
.	O	705-706

Ketamine	O	707-715
was	O	716-719
more	O	720-724
potent	O	725-731
in	O	732-734
the	O	735-738
hypophysectomized	O	739-756
chick	O	757-762
and	O	763-766
the	O	767-770
circadian	O	771-780
rhythm	O	781-787
noted	O	788-793
in	O	794-796
the	O	797-800
intact	O	801-807
chick	O	808-813
was	O	814-817
absent	O	818-824
;	O	824-825
furthermore	O	826-837
,	O	837-838
melatonin	O	839-848
did	O	849-852
not	O	853-856
augment	O	857-864
the	O	865-868
ketamine	O	869-877
DOC	O	878-881
whereas	O	882-889
dopamine	O	890-898
continued	O	899-908
to	O	909-911
do	O	912-914
so	O	915-917
.	O	917-918

This	O	919-923
study	O	924-929
did	O	930-933
not	O	934-937
demonstrate	O	938-949
a	O	950-951
species	O	952-959
difference	O	960-970
regarding	O	971-980
the	O	981-984
role	O	985-989
of	O	990-992
the	O	993-996
amines	O	997-1003
on	O	1004-1006
the	O	1007-1010
pineal	O	1011-1017
in	O	1018-1020
spite	O	1021-1026
of	O	1027-1029
the	O	1030-1033
immature	O	1034-1042
blood	O	1043-1048
-	O	1048-1049
brain	O	1049-1054
barrier	O	1055-1062
in	O	1063-1065
the	O	1066-1069
young	O	1070-1075
chick	O	1076-1081
and	O	1082-1085
the	O	1086-1089
intact	O	1090-1096
barrier	O	1097-1104
in	O	1105-1107
the	O	1108-1111
rat	O	1112-1115
.	O	1115-1116

In	O	1117-1119
addition	O	1120-1128
,	O	1128-1129
these	O	1130-1135
data	O	1136-1140
indicate	O	1141-1149
a	O	1150-1151
direct	O	1152-1158
role	O	1159-1163
of	O	1164-1166
the	O	1167-1170
pituitary	O	1171-1180
in	O	1181-1183
the	O	1184-1187
augmentation	O	1188-1200
of	O	1201-1203
ketamine	O	1204-1212
DOC	O	1213-1216
induced	O	1217-1224
by	O	1225-1227
melatonin	O	1228-1237
.	O	1237-1238

Furthermore	O	1239-1250
,	O	1250-1251
dopamine	O	1252-1260
appeared	O	1261-1269
to	O	1270-1272
act	O	1273-1276
on	O	1277-1279
systems	O	1280-1287
more	O	1288-1292
closely	O	1293-1300
involved	O	1301-1309
with	O	1310-1314
the	O	1315-1318
induction	O	1319-1328
of	O	1329-1331
ketamine	O	1332-1340
catatonia	B	1341-1350
rather	O	1351-1357
than	O	1358-1362
directly	O	1363-1371
on	O	1372-1374
the	O	1375-1378
pituitary	O	1379-1388
.	O	1388-1389

Multicenter	O	0-11
,	O	11-12
double	O	13-19
-	O	19-20
blind	O	20-25
,	O	25-26
multiple	O	27-35
-	O	35-36
dose	O	36-40
,	O	40-41
parallel	O	42-50
-	O	50-51
groups	O	51-57
efficacy	O	58-66
and	O	67-70
safety	O	71-77
trial	O	78-83
of	O	84-86
azelastine	O	87-97
,	O	97-98
chlorpheniramine	O	99-115
,	O	115-116
and	O	117-120
placebo	O	121-128
in	O	129-131
the	O	132-135
treatment	O	136-145
of	O	146-148
spring	B	149-155
allergic	I	156-164
rhinitis	I	165-173
.	O	173-174

Azelastine	O	175-185
,	O	185-186
a	O	187-188
novel	O	189-194
antiallergic	O	195-207
medication	O	208-218
,	O	218-219
was	O	220-223
compared	O	224-232
with	O	233-237
chlorpheniramine	O	238-254
maleate	O	255-262
and	O	263-266
placebo	O	267-274
for	O	275-278
efficacy	O	279-287
and	O	288-291
safety	O	292-298
in	O	299-301
the	O	302-305
treatment	O	306-315
of	O	316-318
spring	B	319-325
allergic	I	326-334
rhinitis	I	335-343
in	O	344-346
a	O	347-348
multicenter	O	349-360
,	O	360-361
double	O	362-368
-	O	368-369
blind	O	369-374
,	O	374-375
multiple	O	376-384
-	O	384-385
dose	O	385-389
,	O	389-390
parallel	O	391-399
-	O	399-400
groups	O	400-406
study	O	407-412
.	O	412-413

One	O	414-417
hundred	O	418-425
fifty	O	426-431
-	O	431-432
five	O	432-436
subjects	O	437-445
participated	O	446-458
.	O	458-459

Subjects	O	460-468
ranged	O	469-475
in	O	476-478
age	O	479-482
from	O	483-487
18	O	488-490
to	O	491-493
60	O	494-496
years	O	497-502
of	O	503-505
age	O	506-509
and	O	510-513
had	O	514-517
at	O	518-520
least	O	521-526
a	O	527-528
2	O	529-530
-	O	530-531
year	O	531-535
history	O	536-543
of	O	544-546
spring	B	547-553
allergic	I	554-562
rhinitis	I	563-571
,	O	571-572
confirmed	O	573-582
by	O	583-585
positive	O	586-594
skin	O	595-599
test	O	600-604
to	O	605-607
spring	O	608-614
aeroallergens	O	615-628
.	O	628-629

Medications	O	630-641
were	O	642-646
given	O	647-652
four	O	653-657
times	O	658-663
daily	O	664-669
;	O	669-670
the	O	671-674
azelastine	O	675-685
groups	O	686-692
received	O	693-701
0	O	702-703
.	O	703-704
5	O	704-705
,	O	705-706
1	O	707-708
.	O	708-709
0	O	709-710
,	O	710-711
or	O	712-714
2	O	715-716
.	O	716-717
0	O	717-718
mg	O	719-721
in	O	722-724
the	O	725-728
morning	O	729-736
and	O	737-740
evening	O	741-748
with	O	749-753
placebo	O	754-761
in	O	762-764
the	O	765-768
early	O	769-774
and	O	775-778
late	O	779-783
afternoon	O	784-793
;	O	793-794
the	O	795-798
chlorpheniramine	O	799-815
group	O	816-821
received	O	822-830
4	O	831-832
.	O	832-833
0	O	833-834
mg	O	835-837
four	O	838-842
times	O	843-848
daily	O	849-854
.	O	854-855

Daily	O	856-861
subject	O	862-869
symptom	O	870-877
cards	O	878-883
were	O	884-888
completed	O	889-898
during	O	899-905
a	O	906-907
screening	O	908-917
period	O	918-924
to	O	925-927
assess	O	928-934
pretreatment	O	935-947
symptoms	O	948-956
and	O	957-960
during	O	961-967
a	O	968-969
4	O	970-971
-	O	971-972
week	O	972-976
treatment	O	977-986
period	O	987-993
while	O	994-999
subjects	O	1000-1008
received	O	1009-1017
study	O	1018-1023
medications	O	1024-1035
.	O	1035-1036

Individual	O	1037-1047
symptoms	O	1048-1056
,	O	1056-1057
total	O	1058-1063
symptoms	O	1064-1072
,	O	1072-1073
and	O	1074-1077
major	O	1078-1083
symptoms	O	1084-1092
were	O	1093-1097
compared	O	1098-1106
to	O	1107-1109
determine	O	1110-1119
efficacy	O	1120-1128
of	O	1129-1131
medication	O	1132-1142
.	O	1142-1143

Elicited	O	1144-1152
,	O	1152-1153
volunteered	O	1154-1165
,	O	1165-1166
and	O	1167-1170
observed	O	1171-1179
adverse	O	1180-1187
experiences	O	1188-1199
were	O	1200-1204
recorded	O	1205-1213
for	O	1214-1217
each	O	1218-1222
subject	O	1223-1230
and	O	1231-1234
compared	O	1235-1243
among	O	1244-1249
groups	O	1250-1256
.	O	1256-1257

Vital	O	1258-1263
signs	O	1264-1269
,	O	1269-1270
body	O	1271-1275
weights	O	1276-1283
,	O	1283-1284
serum	O	1285-1290
chemistry	O	1291-1300
values	O	1301-1307
,	O	1307-1308
complete	O	1309-1317
blood	O	1318-1323
cell	O	1324-1328
counts	O	1329-1335
,	O	1335-1336
urine	O	1337-1342
studies	O	1343-1350
,	O	1350-1351
and	O	1352-1355
electrocardiograms	O	1356-1374
were	O	1375-1379
obtained	O	1380-1388
for	O	1389-1392
each	O	1393-1397
subject	O	1398-1405
and	O	1406-1409
compared	O	1410-1418
among	O	1419-1424
groups	O	1425-1431
.	O	1431-1432

Symptoms	O	1433-1441
relief	O	1442-1448
in	O	1449-1451
the	O	1452-1455
group	O	1456-1461
receiving	O	1462-1471
the	O	1472-1475
highest	O	1476-1483
concentration	O	1484-1497
of	O	1498-1500
azelastine	O	1501-1511
(	O	1512-1513
2	O	1513-1514
.	O	1514-1515
0	O	1515-1516
mg	O	1517-1519
twice	O	1520-1525
daily	O	1526-1531
)	O	1531-1532
was	O	1533-1536
statistically	O	1537-1550
greater	O	1551-1558
than	O	1559-1563
in	O	1564-1566
the	O	1567-1570
placebo	O	1571-1578
group	O	1579-1584
during	O	1585-1591
all	O	1592-1595
weeks	O	1596-1601
of	O	1602-1604
the	O	1605-1608
study	O	1609-1614
.	O	1614-1615

Lower	O	1616-1621
doses	O	1622-1627
of	O	1628-1630
azelastine	O	1631-1641
were	O	1642-1646
statistically	O	1647-1660
more	O	1661-1665
effective	O	1666-1675
than	O	1676-1680
placebo	O	1681-1688
only	O	1689-1693
during	O	1694-1700
portions	O	1701-1709
of	O	1710-1712
the	O	1713-1716
first	O	1717-1722
3	O	1723-1724
weeks	O	1725-1730
of	O	1731-1733
the	O	1734-1737
study	O	1738-1743
.	O	1743-1744

In	O	1745-1747
contrast	O	1748-1756
,	O	1756-1757
although	O	1758-1766
the	O	1767-1770
chlorpheniramine	O	1771-1787
group	O	1788-1793
did	O	1794-1797
have	O	1798-1802
fewer	O	1803-1808
symptoms	O	1809-1817
than	O	1818-1822
the	O	1823-1826
placebo	O	1827-1834
group	O	1835-1840
during	O	1841-1847
the	O	1848-1851
study	O	1852-1857
,	O	1857-1858
the	O	1859-1862
difference	O	1863-1873
never	O	1874-1879
reached	O	1880-1887
statistical	O	1888-1899
significance	O	1900-1912
during	O	1913-1919
any	O	1920-1923
week	O	1924-1928
of	O	1929-1931
the	O	1932-1935
study	O	1936-1941
.	O	1941-1942

There	O	1943-1948
were	O	1949-1953
no	O	1954-1956
serious	O	1957-1964
side	O	1965-1969
effects	O	1970-1977
in	O	1978-1980
any	O	1981-1984
of	O	1985-1987
the	O	1988-1991
treatment	O	1992-2001
groups	O	2002-2008
.	O	2008-2009

Drowsiness	B	2010-2020
and	O	2021-2024
altered	B	2025-2032
taste	I	2033-2038
perception	I	2039-2049
were	O	2050-2054
increased	O	2055-2064
significantly	O	2065-2078
over	O	2079-2083
placebo	O	2084-2091
only	O	2092-2096
in	O	2097-2099
the	O	2100-2103
high	O	2104-2108
-	O	2108-2109
dose	O	2109-2113
azelastine	O	2114-2124
group	O	2125-2130
.	O	2130-2131

Azelastine	O	2132-2142
appears	O	2143-2150
to	O	2151-2153
be	O	2154-2156
a	O	2157-2158
safe	O	2159-2163
,	O	2163-2164
efficacious	O	2165-2176
medication	O	2177-2187
for	O	2188-2191
seasonal	B	2192-2200
allergic	I	2201-2209
rhinitis	I	2210-2218
.	O	2218-2219

Obsolete	O	0-8
but	O	9-12
dangerous	O	13-22
antacid	O	23-30
preparations	O	31-43
.	O	43-44

One	O	45-48
case	O	49-53
of	O	54-56
acute	O	57-62
hypercalcaemia	B	63-77
and	O	78-81
two	O	82-85
of	O	86-88
recurrent	O	89-98
nephrolithiasis	B	99-114
are	O	115-118
reported	O	119-127
in	O	128-130
patients	O	131-139
who	O	140-143
had	O	144-147
regularly	O	148-157
consumed	O	158-166
large	O	167-172
amounts	O	173-180
of	O	181-183
calcium	O	184-191
carbon	O	192-198
-	O	198-199
ate	O	199-202
-	O	198-199
sodium	O	203-209
bicarbonate	O	210-221
powders	O	222-229
for	O	230-233
more	O	234-238
than	O	239-243
20	O	244-246
years	O	247-252
.	O	252-253

The	O	254-257
powders	O	258-265
had	O	266-269
been	O	270-274
obtained	O	275-283
from	O	284-288
pharmacists	O	289-300
unknown	O	301-308
to	O	309-311
the	O	312-315
patients	O	316-324
'	O	324-325
medical	O	326-333
practitioners	O	334-347
.	O	347-348

It	O	349-351
is	O	352-354
suggested	O	355-364
that	O	365-369
these	O	370-375
preparations	O	376-388
were	O	389-393
responsible	O	394-405
for	O	406-409
the	O	410-413
patient	O	414-421
'	O	421-422
s	O	422-423
problems	O	424-432
,	O	432-433
and	O	434-437
that	O	438-442
such	O	443-447
powders	O	448-455
should	O	456-462
no	O	463-465
longer	O	466-472
be	O	473-475
freely	O	476-482
obtainable	O	483-493
.	O	493-494

Prolonged	O	0-9
paralysis	B	10-19
due	O	20-23
to	O	24-26
nondepolarizing	O	27-42
neuromuscular	O	43-56
blocking	O	57-65
agents	O	66-72
and	O	73-76
corticosteroids	O	77-92
.	O	92-93

The	O	94-97
long	O	98-102
-	O	102-103
term	O	103-107
use	O	108-111
of	O	112-114
nondepolarizing	O	115-130
neuromuscular	O	131-144
blocking	O	145-153
agents	O	154-160
(	O	161-162
ND	O	162-164
-	O	164-165
NMBA	O	165-169
)	O	169-170
has	O	171-174
recently	O	175-183
been	O	184-188
implicated	O	189-199
as	O	200-202
a	O	203-204
cause	O	205-210
of	O	211-213
prolonged	O	214-223
muscle	B	224-230
weakness	I	231-239
,	O	239-240
although	O	241-249
the	O	250-253
site	O	254-258
of	O	259-261
the	O	262-265
lesion	O	266-272
and	O	273-276
the	O	277-280
predisposing	O	281-293
factors	O	294-301
have	O	302-306
been	O	307-311
unclear	O	312-319
.	O	319-320

We	O	321-323
report	O	324-330
3	O	331-332
patients	O	333-341
(	O	342-343
age	O	343-346
37	O	347-349
-	O	349-350
52	O	350-352
years	O	353-358
)	O	358-359
with	O	360-364
acute	O	365-370
respiratory	B	371-382
insufficiency	I	383-396
who	O	397-400
developed	O	401-410
prolonged	O	411-420
weakness	B	421-429
following	O	430-439
the	O	440-443
discontinuation	O	444-459
of	O	460-462
ND	O	463-465
-	O	465-466
NMBAs	O	466-471
.	O	471-472

Two	O	473-476
patients	O	477-485
also	O	486-490
received	O	491-499
intravenous	O	500-511
corticosteroids	O	512-527
.	O	527-528

Renal	O	529-534
function	O	535-543
was	O	544-547
normal	O	548-554
but	O	555-558
hepatic	O	559-566
function	O	567-575
was	O	576-579
impaired	O	580-588
in	O	589-591
all	O	592-595
patients	O	596-604
,	O	604-605
and	O	606-609
all	O	610-613
had	O	614-617
acidosis	B	618-626
.	O	626-627

Electrophysiologic	O	628-646
studies	O	647-654
revealed	O	655-663
low	O	664-667
amplitude	O	668-677
compound	O	678-686
motor	O	687-692
action	O	693-699
potentials	O	700-710
,	O	710-711
normal	O	712-718
sensory	O	719-726
studies	O	727-734
,	O	734-735
and	O	736-739
fibrillations	O	740-753
.	O	753-754

Repetitive	O	755-765
stimulation	O	766-777
at	O	778-780
2	O	781-782
Hz	O	783-785
showed	O	786-792
a	O	793-794
decremental	O	795-806
response	O	807-815
in	O	816-818
2	O	819-820
patients	O	821-829
.	O	829-830

The	O	831-834
serum	O	835-840
vecuronium	O	841-851
level	O	852-857
measured	O	858-866
in	O	867-869
1	O	870-871
patient	O	872-879
14	O	880-882
days	O	883-887
after	O	888-893
the	O	894-897
drug	O	898-902
had	O	903-906
been	O	907-911
discontinued	O	912-924
was	O	925-928
172	O	929-932
ng	O	933-935
/	O	935-936
mL	O	936-938
.	O	938-939

A	O	940-941
muscle	O	942-948
biopsy	O	949-955
in	O	956-958
this	O	959-963
patient	O	964-971
showed	O	972-978
loss	B	979-983
of	I	984-986
thick	I	987-992
,	I	992-993
myosin	I	994-1000
filaments	I	1001-1010
.	O	1010-1011

The	O	1012-1015
weakness	B	1016-1024
in	O	1025-1027
these	O	1028-1033
patients	O	1034-1042
is	O	1043-1045
due	O	1046-1049
to	O	1050-1052
pathology	B	1053-1062
at	I	1063-1065
both	I	1066-1070
the	I	1071-1074
neuromuscular	I	1075-1088
junction	I	1089-1097
(	O	1098-1099
most	O	1099-1103
likely	O	1104-1110
due	O	1111-1114
to	O	1115-1117
ND	O	1118-1120
-	O	1120-1121
NMBA	O	1121-1125
)	O	1125-1126
and	O	1127-1130
muscle	O	1131-1137
(	O	1138-1139
most	O	1139-1143
likely	O	1144-1150
due	O	1151-1154
to	O	1155-1157
corticosteroids	O	1158-1173
)	O	1173-1174
.	O	1174-1175

Hepatic	B	1176-1183
dysfunction	I	1184-1195
and	O	1196-1199
acidosis	B	1200-1208
are	O	1209-1212
contributing	O	1213-1225
risk	O	1226-1230
factors	O	1231-1238
.	O	1238-1239

Prostaglandin	O	0-13
E2	O	14-16
-	O	16-17
induced	O	17-24
bladder	B	25-32
hyperactivity	I	33-46
in	O	47-49
normal	O	50-56
,	O	56-57
conscious	O	58-67
rats	O	68-72
:	O	72-73
involvement	O	74-85
of	O	86-88
tachykinins	O	89-100
?	O	100-101

In	O	102-104
normal	O	105-111
conscious	O	112-121
rats	O	122-126
investigated	O	127-139
by	O	140-142
continuous	O	143-153
cystometry	O	154-164
,	O	164-165
intravesically	O	166-180
instilled	O	181-190
prostaglandin	O	191-204
(	O	205-206
PG	O	206-208
)	O	208-209
E2	O	210-212
facilitated	O	213-224
micturition	O	225-236
and	O	237-240
increased	O	241-250
basal	O	251-256
intravesical	O	257-269
pressure	O	270-278
.	O	278-279

The	O	280-283
effect	O	284-290
was	O	291-294
attenuated	O	295-305
by	O	306-308
both	O	309-313
the	O	314-317
NK1	O	318-321
receptor	O	322-330
selective	O	331-340
antagonist	O	341-351
RP	O	352-354
67	O	355-357
,	O	357-358
580	O	358-361
and	O	362-365
the	O	366-369
NK2	O	370-373
receptor	O	374-382
selective	O	383-392
antagonist	O	393-403
SR	O	404-406
48	O	407-409
,	O	409-410
968	O	410-413
,	O	409-410
given	O	415-420
intra	O	421-426
-	O	426-427
arterially	O	427-437
,	O	437-438
suggesting	O	439-449
that	O	450-454
it	O	455-457
was	O	458-461
mediated	O	462-470
by	O	471-473
stimulation	O	474-485
of	O	486-488
both	O	489-493
NK1	O	494-497
and	O	498-501
NK2	O	502-505
receptors	O	506-515
.	O	515-516

Intra	O	517-522
-	O	522-523
arterially	O	523-533
given	O	534-539
PGE2	O	540-544
produced	O	545-553
a	O	554-555
distinct	O	556-564
increase	O	565-573
in	O	574-576
bladder	O	577-584
pressure	O	585-593
before	O	594-600
initiating	O	601-611
a	O	612-613
micturition	O	614-625
reflex	O	626-632
,	O	632-633
indicating	O	634-644
that	O	645-649
the	O	650-653
PG	O	654-656
had	O	657-660
a	O	661-662
direct	O	663-669
contractant	O	670-681
effect	O	682-688
on	O	689-691
the	O	692-695
detrusor	O	696-704
smooth	O	705-711
muscle	O	712-718
.	O	718-719

The	O	720-723
effect	O	724-730
of	O	731-733
intra	O	734-739
-	O	739-740
arterial	O	740-748
PGE2	O	749-753
could	O	754-759
not	O	760-763
be	O	764-766
blocked	O	767-774
by	O	775-777
intra	O	778-783
-	O	783-784
arterial	O	784-792
RP	O	793-795
67	O	796-798
,	O	798-799
580	O	799-802
or	O	803-805
SR	O	806-808
48	O	809-811
,	O	811-812
968	O	812-815
,	O	811-812
which	O	817-822
opens	O	823-828
the	O	829-832
possibility	O	833-844
that	O	845-849
the	O	850-853
micturition	O	854-865
reflex	O	866-872
elicited	O	873-881
by	O	882-884
intra	O	885-890
-	O	890-891
arterial	O	891-899
PGE2	O	900-904
was	O	905-908
mediated	O	909-917
by	O	918-920
pathways	O	921-929
other	O	930-935
than	O	936-940
the	O	941-944
reflex	O	945-951
initiated	O	952-961
when	O	962-966
the	O	967-970
PG	O	971-973
was	O	974-977
given	O	978-983
intravesically	O	984-998
.	O	998-999

The	O	1000-1003
present	O	1004-1011
results	O	1012-1019
thus	O	1020-1024
suggest	O	1025-1032
that	O	1033-1037
intra	O	1038-1043
-	O	1043-1044
arterial	O	1044-1052
PGE2	O	1053-1057
,	O	1057-1058
given	O	1059-1064
near	O	1065-1069
the	O	1070-1073
bladder	O	1074-1081
,	O	1081-1082
may	O	1083-1086
initiate	O	1087-1095
micturition	O	1096-1107
in	O	1108-1110
the	O	1111-1114
normal	O	1115-1121
rat	O	1122-1125
chiefly	O	1126-1133
by	O	1134-1136
directly	O	1137-1145
contracting	O	1146-1157
the	O	1158-1161
smooth	O	1162-1168
muscle	O	1169-1175
of	O	1176-1178
the	O	1179-1182
detrusor	O	1183-1191
.	O	1191-1192

However	O	1193-1200
,	O	1200-1201
when	O	1202-1206
given	O	1207-1212
intravesically	O	1213-1227
,	O	1227-1228
PGE2	O	1229-1233
may	O	1234-1237
stimulate	O	1238-1247
micturition	O	1248-1259
by	O	1260-1262
releasing	O	1263-1272
tachykinins	O	1273-1284
from	O	1285-1289
nerves	O	1290-1296
in	O	1297-1299
and	O	1300-1303
/	O	1303-1304
or	O	1304-1306
immediately	O	1307-1318
below	O	1319-1324
the	O	1325-1328
urothelium	O	1329-1339
.	O	1339-1340

These	O	1341-1346
tachykinins	O	1347-1358
,	O	1358-1359
in	O	1360-1362
turn	O	1363-1367
,	O	1367-1368
initiate	O	1369-1377
a	O	1378-1379
micturition	O	1380-1391
reflex	O	1392-1398
by	O	1399-1401
stimulating	O	1402-1413
NK1	O	1414-1417
and	O	1418-1421
NK2	O	1422-1425
receptors	O	1426-1435
.	O	1435-1436

Prostanoids	O	1437-1448
may	O	1449-1452
,	O	1452-1453
via	O	1454-1457
release	O	1458-1465
of	O	1466-1468
tachykinins	O	1469-1480
,	O	1480-1481
contribute	O	1482-1492
to	O	1493-1495
both	O	1496-1500
urge	O	1501-1505
and	O	1506-1509
bladder	B	1510-1517
hyperactivity	I	1518-1531
seen	O	1532-1536
in	O	1537-1539
inflammatory	O	1540-1552
conditions	O	1553-1563
of	O	1564-1566
the	O	1567-1570
lower	O	1571-1576
urinary	O	1577-1584
tract	O	1585-1590
.	O	1590-1591

Thiazide	O	0-8
diuretics	O	9-18
,	O	18-19
hypokalemia	B	20-31
and	O	32-35
cardiac	B	36-43
arrhythmias	I	44-55
.	O	55-56

Thiazide	O	57-65
diuretics	O	66-75
are	O	76-79
widely	O	80-86
accepted	O	87-95
as	O	96-98
the	O	99-102
cornerstone	O	103-114
of	O	115-117
antihypertensive	O	118-134
treatment	O	135-144
programs	O	145-153
.	O	153-154

Hypokalemia	B	155-166
is	O	167-169
a	O	170-171
commonly	O	172-180
encountered	O	181-192
metabolic	O	193-202
consequence	O	203-214
of	O	215-217
chronic	O	218-225
thiazide	O	226-234
therapy	O	235-242
.	O	242-243

We	O	244-246
treated	O	247-254
38	O	255-257
patients	O	258-266
(	O	267-268
22	O	268-270
low	O	271-274
renin	O	275-280
,	O	280-281
16	O	282-284
normal	O	285-291
renin	O	292-297
)	O	297-298
with	O	299-303
moderate	O	304-312
diastolic	B	313-322
hypertension	I	323-335
with	O	336-340
hydrochlorothiazide	O	341-360
(	O	361-362
HCTC	O	362-366
)	O	366-367
administered	O	368-380
on	O	381-383
a	O	384-385
twice	O	386-391
daily	O	392-397
schedule	O	398-406
.	O	406-407

Initial	O	408-415
dose	O	416-420
was	O	421-424
50	O	425-427
mg	O	428-430
and	O	431-434
the	O	435-438
dose	O	439-443
was	O	444-447
increased	O	448-457
at	O	458-460
monthly	O	461-468
intervals	O	469-478
to	O	479-481
100	O	482-485
mg	O	486-488
,	O	488-489
150	O	490-493
mg	O	494-496
and	O	497-500
200	O	501-504
mg	O	505-507
daily	O	508-513
until	O	514-519
blood	O	520-525
pressure	O	526-534
normalized	O	535-545
.	O	545-546

The	O	547-550
serum	O	551-556
K	O	557-558
during	O	559-565
the	O	566-569
control	O	570-577
period	O	578-584
was	O	585-588
4	O	589-590
.	O	590-591
5	O	591-592
+	O	593-594
/	O	594-595
-	O	595-596
0	O	597-598
.	O	598-599
2	O	599-600
mEq	O	601-604
/	O	604-605
l	O	605-606
an	O	607-609
on	O	610-612
50	O	613-615
,	O	615-616
100	O	617-620
,	O	620-621
150	O	622-625
and	O	626-629
200	O	630-633
mg	O	634-636
HCTZ	O	637-641
daily	O	642-647
3	O	648-649
.	O	649-650
9	O	650-651
+	O	652-653
/	O	653-654
-	O	654-655
0	O	656-657
.	O	657-658
3	O	658-659
,	O	659-660
3	O	661-662
.	O	662-663
4	O	663-664
+	O	665-666
/	O	666-667
-	O	667-668
0	O	669-670
.	O	670-671
2	O	671-672
,	O	672-673
2	O	674-675
.	O	675-676
9	O	676-677
+	O	678-679
/	O	679-680
-	O	680-681
0	O	682-683
.	O	683-684
2	O	684-685
,	O	685-686
and	O	687-690
2	O	691-692
.	O	692-693
4	O	693-694
+	O	695-696
/	O	696-697
-	O	697-698
0	O	699-700
.	O	700-701
3	O	701-702
mEq	O	703-706
/	O	706-707
l	O	707-708
,	O	708-709
respectively	O	710-722
.	O	722-723

Corresponding	O	724-737
figures	O	738-745
for	O	746-749
whole	O	750-755
body	O	756-760
K	O	761-762
were	O	763-767
4107	O	768-772
+	O	773-774
/	O	774-775
-	O	775-776
208	O	777-780
,	O	780-781
3722	O	782-786
+	O	787-788
/	O	788-789
-	O	789-790
319	O	791-794
,	O	794-795
3628	O	796-800
+	O	801-802
/	O	802-803
-	O	803-804
257	O	805-808
,	O	808-809
3551	O	810-814
+	O	815-816
/	O	816-817
-	O	817-818
336	O	819-822
,	O	822-823
and	O	824-827
3269	O	828-832
+	O	833-834
/	O	834-835
-	O	835-836
380	O	837-840
mEq	O	841-844
,	O	844-845
respectively	O	846-858
.	O	858-859

In	O	860-862
13	O	863-865
patients	O	866-874
we	O	875-877
observed	O	878-886
the	O	887-890
effects	O	891-898
of	O	899-901
HCTZ	O	902-906
therapy	O	907-914
(	O	915-916
100	O	916-919
mg	O	920-922
daily	O	923-928
)	O	928-929
on	O	930-932
the	O	933-936
occurrence	O	937-947
of	O	948-950
PVC	O	951-954
'	O	954-955
s	O	955-956
during	O	957-963
rest	O	964-968
as	O	969-971
well	O	972-976
as	O	977-979
during	O	980-986
static	O	987-993
and	O	994-997
dynamic	O	998-1005
exercise	O	1006-1014
.	O	1014-1015

During	O	1016-1022
rest	O	1023-1027
we	O	1028-1030
observed	O	1031-1039
0	O	1040-1041
.	O	1041-1042
6	O	1042-1043
+	O	1044-1045
/	O	1045-1046
-	O	1046-1047
0	O	1048-1049
.	O	1049-1050
08	O	1050-1052
PVC	O	1053-1056
beats	O	1057-1062
/	O	1062-1063
min	O	1063-1066
+	O	1067-1068
/	O	1068-1069
-	O	1069-1070
SEM	O	1071-1074
and	O	1075-1078
during	O	1079-1085
static	O	1086-1092
and	O	1093-1096
dynamic	O	1097-1104
exercise	O	1105-1113
0	O	1114-1115
.	O	1115-1116
6	O	1116-1117
+	O	1118-1119
/	O	1119-1120
-	O	1120-1121
0	O	1122-1123
.	O	1123-1124
06	O	1124-1126
and	O	1127-1130
0	O	1131-1132
.	O	1132-1133
8	O	1133-1134
+	O	1135-1136
/	O	1136-1137
-	O	1137-1138
0	O	1139-1140
.	O	1140-1141
15	O	1141-1143
,	O	1143-1144
respectively	O	1145-1157
.	O	1157-1158

Corresponding	O	1159-1172
figures	O	1173-1180
during	O	1181-1187
HCTZ	O	1188-1192
therapy	O	1193-1200
100	O	1201-1204
mg	O	1205-1207
daily	O	1208-1213
were	O	1214-1218
1	O	1219-1220
.	O	1220-1221
4	O	1221-1222
+	O	1223-1224
/	O	1224-1225
-	O	1225-1226
0	O	1227-1228
.	O	1228-1229
1	O	1229-1230
,	O	1230-1231
3	O	1232-1233
.	O	1233-1234
6	O	1234-1235
+	O	1236-1237
/	O	1237-1238
-	O	1238-1239
0	O	1240-1241
.	O	1241-1242
7	O	1242-1243
and	O	1244-1247
5	O	1248-1249
.	O	1249-1250
7	O	1250-1251
4	O	1252-1253
/	O	1253-1254
-	O	1254-1255
0	O	1256-1257
.	O	1257-1258
8	O	1258-1259
,	O	1259-1260
respectively	O	1261-1273
.	O	1273-1274

The	O	1275-1278
occurrence	O	1279-1289
of	O	1290-1292
PVC	O	1293-1296
'	O	1296-1297
s	O	1297-1298
correlated	O	1299-1309
significantly	O	1310-1323
with	O	1324-1328
the	O	1329-1332
fall	O	1333-1337
in	O	1338-1340
serum	O	1341-1346
K	O	1347-1348
+	O	1348-1349
observed	O	1350-1358
r	O	1359-1360
=	O	1361-1362
0	O	1363-1364
.	O	1364-1365
72	O	1365-1367
,	O	1367-1368
p	O	1369-1370
less	O	1371-1375
than	O	1376-1380
0	O	1381-1382
.	O	1382-1383
001	O	1383-1386
.	O	1382-1383

In	O	1388-1390
conclusion	O	1391-1401
we	O	1402-1404
found	O	1405-1410
that	O	1411-1415
thiazide	O	1416-1424
diuretics	O	1425-1434
cause	O	1435-1440
hypokalemia	B	1441-1452
and	O	1453-1456
depletion	O	1457-1466
of	O	1467-1469
body	O	1470-1474
potassium	O	1475-1484
.	O	1484-1485

The	O	1486-1489
more	O	1490-1494
profound	O	1495-1503
hypokalemia	B	1504-1515
,	O	1515-1516
the	O	1517-1520
greater	O	1521-1528
the	O	1529-1532
propensity	O	1533-1543
for	O	1544-1547
the	O	1548-1551
occurrence	O	1552-1562
of	O	1563-1565
PVC	O	1566-1569
'	O	1569-1570
s	O	1570-1571
.	O	1571-1572

Diuretics	O	0-9
,	O	9-10
potassium	O	11-20
and	O	21-24
arrhythmias	B	25-36
in	O	37-39
hypertensive	B	40-52
coronary	B	53-61
disease	I	62-69
.	O	69-70

It	O	71-73
has	O	74-77
been	O	78-82
proposed	O	83-91
that	O	92-96
modest	O	97-103
changes	O	104-111
in	O	112-114
plasma	O	115-121
potassium	O	122-131
can	O	132-135
alter	O	136-141
the	O	142-145
tendency	O	146-154
towards	O	155-162
cardiac	B	163-170
arrhythmias	I	171-182
.	O	182-183

If	O	184-186
this	O	187-191
were	O	192-196
so	O	197-199
,	O	199-200
patients	O	201-209
with	O	210-214
coronary	B	215-223
artery	I	224-230
disease	I	231-238
might	O	239-244
be	O	245-247
especially	O	248-258
susceptible	O	259-270
.	O	270-271

Thus	O	272-276
,	O	276-277
myocardial	O	278-288
electrical	O	289-299
excitability	O	300-312
was	O	313-316
measured	O	317-325
in	O	326-328
patients	O	329-337
with	O	338-342
mild	O	343-347
essential	O	348-357
hypertension	B	358-370
and	O	371-374
known	O	375-380
coronary	B	381-389
artery	I	390-396
disease	I	397-404
after	O	405-410
8	O	411-412
weeks	O	413-418
of	O	419-421
treatment	O	422-431
with	O	432-436
a	O	437-438
potassium	O	439-448
-	O	448-449
conserving	O	449-459
diuretic	O	460-468
(	O	469-470
amiloride	O	470-479
)	O	479-480
and	O	481-484
a	O	485-486
similar	O	487-494
period	O	495-501
on	O	502-504
a	O	505-506
potassium	O	507-516
-	O	516-517
losing	O	517-523
diuretic	O	524-532
(	O	533-534
chlorthalidone	O	534-548
)	O	548-549
in	O	550-552
a	O	553-554
randomised	O	555-565
study	O	566-571
.	O	571-572

Plasma	O	573-579
potassium	O	580-589
concentrations	O	590-604
were	O	605-609
on	O	610-612
average	O	613-620
1	O	621-622
mmol	O	623-627
/	O	627-628
L	O	628-629
lower	O	630-635
during	O	636-642
the	O	643-646
chlorthalidone	O	647-661
phase	O	662-667
compared	O	668-676
to	O	677-679
amiloride	O	680-689
therapy	O	690-697
.	O	697-698

Blood	O	699-704
pressure	O	705-713
and	O	714-717
volume	O	718-724
states	O	725-731
as	O	732-734
assessed	O	735-743
by	O	744-746
bodyweight	O	747-757
,	O	757-758
plasma	O	759-765
renin	O	766-771
and	O	772-775
noradrenaline	O	776-789
(	O	790-791
norepinephrine	O	791-805
)	O	805-806
concentrations	O	807-821
were	O	822-826
similar	O	827-834
on	O	835-837
the	O	838-841
2	O	842-843
regimens	O	844-852
.	O	852-853

Compared	O	854-862
to	O	863-865
amiloride	O	866-875
treatment	O	876-885
,	O	885-886
the	O	887-890
chlorthalidone	O	891-905
phase	O	906-911
was	O	912-915
associated	O	916-926
with	O	927-931
an	O	932-934
increased	O	935-944
frequency	O	945-954
of	O	955-957
ventricular	B	958-969
ectopic	I	970-977
beats	I	978-983
(	O	984-985
24	O	985-987
-	O	987-988
hour	O	988-992
Holter	O	993-999
monitoring	O	1000-1010
)	O	1010-1011
and	O	1012-1015
a	O	1016-1017
higher	O	1018-1024
Lown	O	1025-1029
grading	O	1030-1037
,	O	1037-1038
increased	O	1039-1048
upslope	O	1049-1056
and	O	1057-1060
duration	O	1061-1069
of	O	1070-1072
the	O	1073-1076
monophasic	O	1077-1087
action	O	1088-1094
potential	O	1095-1104
,	O	1104-1105
prolonged	O	1106-1115
ventricular	O	1116-1127
effective	O	1128-1137
refractory	O	1138-1148
period	O	1149-1155
,	O	1155-1156
and	O	1157-1160
increased	O	1161-1170
electrical	O	1171-1181
instability	O	1182-1193
during	O	1194-1200
programmed	O	1201-1211
ventricular	O	1212-1223
stimulation	O	1224-1235
.	O	1235-1236

The	O	1237-1240
above	O	1241-1246
results	O	1247-1254
indicate	O	1255-1263
that	O	1264-1268
because	O	1269-1276
potassium	O	1277-1286
-	O	1286-1287
losing	O	1287-1293
diuretic	O	1294-1302
therapy	O	1303-1310
can	O	1311-1314
increase	O	1315-1323
myocardial	O	1324-1334
electrical	O	1335-1345
excitability	O	1346-1358
in	O	1359-1361
patients	O	1362-1370
with	O	1371-1375
ischaemic	B	1376-1385
heart	I	1386-1391
disease	I	1392-1399
,	O	1399-1400
even	O	1401-1405
minor	O	1406-1411
falls	O	1412-1417
in	O	1418-1420
plasma	O	1421-1427
potassium	O	1428-1437
concentrations	O	1438-1452
are	O	1453-1456
probably	O	1457-1465
best	O	1466-1470
avoided	O	1471-1478
in	O	1479-1481
such	O	1482-1486
patients	O	1487-1495
.	O	1495-1496

GABA	O	0-4
involvement	O	5-16
in	O	17-19
naloxone	O	20-28
induced	O	29-36
reversal	O	37-45
of	O	46-48
respiratory	B	49-60
paralysis	I	61-70
produced	O	71-79
by	O	80-82
thiopental	O	83-93
.	O	93-94

No	O	95-97
agent	O	98-103
is	O	104-106
yet	O	107-110
available	O	111-120
to	O	121-123
reverse	O	124-131
respiratory	B	132-143
paralysis	I	144-153
produced	O	154-162
by	O	163-165
CNS	O	166-169
depressants	O	170-181
,	O	181-182
such	O	183-187
as	O	188-190
general	O	191-198
anesthetics	O	199-210
.	O	210-211

In	O	212-214
this	O	215-219
study	O	220-225
naloxone	O	226-234
reversed	O	235-243
respiratory	B	244-255
paralysis	I	256-265
induced	O	266-273
by	O	274-276
thiopental	O	277-287
in	O	288-290
rats	O	291-295
.	O	295-296

25	O	297-299
mg	O	300-302
/	O	302-303
kg	O	303-305
,	O	305-306
i	O	307-308
.	O	308-309
v	O	309-310
.	O	308-309

thiopental	O	312-322
produced	O	323-331
anesthesia	O	332-342
without	O	343-350
altering	O	351-359
respiratory	O	360-371
rate	O	372-376
,	O	376-377
increased	O	378-387
GABA	O	388-392
,	O	392-393
decreased	O	394-403
glutamate	O	404-413
,	O	413-414
and	O	415-418
had	O	419-422
no	O	423-425
effect	O	426-432
on	O	433-435
aspartate	O	436-445
or	O	446-448
glycine	O	449-456
levels	O	457-463
compared	O	464-472
to	O	473-475
controls	O	476-484
in	O	485-487
rat	O	488-491
cortex	O	492-498
and	O	499-502
brain	O	503-508
stem	O	509-513
.	O	513-514

Pretreatment	O	515-527
of	O	528-530
rats	O	531-535
with	O	536-540
thiosemicarbazide	O	541-558
for	O	559-562
30	O	563-565
minutes	O	566-573
abolished	O	574-583
the	O	584-587
anesthetic	O	588-598
action	O	599-605
as	O	606-608
well	O	609-613
as	O	614-616
the	O	617-620
respiratory	O	621-632
depressant	O	633-643
action	O	644-650
of	O	651-653
thiopental	O	654-664
.	O	664-665

50	O	666-668
mg	O	669-671
/	O	671-672
kg	O	672-674
,	O	674-675
i	O	676-677
.	O	677-678
v	O	678-679
.	O	677-678

thiopental	O	681-691
produced	O	692-700
respiratory	B	701-712
arrest	I	713-719
with	O	720-724
further	O	725-732
increase	O	733-741
in	O	742-744
GABA	O	745-749
and	O	750-753
decrease	O	754-762
in	O	763-765
glutamate	O	766-775
again	O	776-781
in	O	782-784
cortex	O	785-791
and	O	792-795
brain	O	796-801
stem	O	802-806
without	O	807-814
affecting	O	815-824
any	O	825-828
of	O	829-831
the	O	832-835
amino	O	836-841
acids	O	842-847
studied	O	848-855
in	O	856-858
four	O	859-863
regions	O	864-871
of	O	872-874
rat	O	875-878
brain	O	879-884
.	O	884-885

Naloxone	O	886-894
(	O	895-896
2	O	896-897
.	O	897-898
5	O	898-899
mg	O	900-902
/	O	902-903
kg	O	903-905
,	O	905-906
i	O	907-908
.	O	908-909
v	O	909-910
.	O	908-909
)	O	911-912
reversed	O	913-921
respiratory	B	922-933
paralysis	I	934-943
,	O	943-944
glutamate	O	945-954
and	O	955-958
GABA	O	959-963
levels	O	964-970
to	O	971-973
control	O	974-981
values	O	982-988
in	O	989-991
brain	O	992-997
stem	O	998-1002
and	O	1003-1006
cortex	O	1007-1013
with	O	1014-1018
no	O	1019-1021
changes	O	1022-1029
in	O	1030-1032
caudate	O	1033-1040
or	O	1041-1043
cerebellum	O	1044-1054
.	O	1054-1055

These	O	1056-1061
data	O	1062-1066
suggest	O	1067-1074
naloxone	O	1075-1083
reverses	O	1084-1092
respiratory	B	1093-1104
paralysis	I	1105-1114
produced	O	1115-1123
by	O	1124-1126
thiopental	O	1127-1137
and	O	1138-1141
involves	O	1142-1150
GABA	O	1151-1155
in	O	1156-1158
its	O	1159-1162
action	O	1163-1169
.	O	1169-1170

National	O	0-8
project	O	9-16
on	O	17-19
the	O	20-23
prevention	O	24-34
of	O	35-37
mother	O	38-44
-	O	44-45
to	O	45-47
-	O	44-45
infant	O	48-54
infection	B	55-64
by	I	65-67
hepatitis	I	68-77
B	I	78-79
virus	I	80-85
in	O	86-88
Japan	O	89-94
.	O	94-95

In	O	96-98
Japan	O	99-104
,	O	104-105
a	O	106-107
nationwide	O	108-118
prevention	O	119-129
program	O	130-137
against	O	138-145
mother	O	146-152
-	O	152-153
to	O	153-155
-	O	152-153
infant	O	156-162
infection	B	163-172
by	I	173-175
hepatitis	I	176-185
B	I	186-187
virus	I	188-193
(	O	194-195
HBV	O	195-198
)	O	198-199
started	O	200-207
in	O	208-210
1985	O	211-215
.	O	215-216

This	O	217-221
program	O	222-229
consists	O	230-238
of	O	239-241
double	O	242-248
screenings	O	249-259
of	O	260-262
pregnant	O	263-271
women	O	272-277
and	O	278-281
prophylactic	O	282-294
treatment	O	295-304
to	O	305-307
the	O	308-311
infants	O	312-319
born	O	320-324
to	O	325-327
both	O	328-332
hepatitis	O	333-342
B	O	343-344
surface	O	345-352
antigen	O	353-360
(	O	361-362
HBsAg	O	362-367
)	O	367-368
and	O	369-372
hepatitis	O	373-382
B	O	383-384
e	O	385-386
antigen	O	387-394
(	O	395-396
HBeAg	O	396-401
)	O	401-402
positive	O	403-411
mothers	O	412-419
.	O	419-420

These	O	421-426
infants	O	427-434
are	O	435-438
treated	O	439-446
with	O	447-451
two	O	452-455
injections	O	456-466
of	O	467-469
hepatitis	B	470-479
B	I	480-481
immune	O	482-488
globulin	O	489-497
(	O	498-499
HBIG	O	499-503
)	O	503-504
and	O	505-508
at	O	509-511
least	O	512-517
three	O	518-523
injections	O	524-534
of	O	535-537
plasma	O	538-544
derived	O	545-552
hepatitis	O	553-562
B	O	563-564
vaccine	O	565-572
.	O	572-573

We	O	574-576
sent	O	577-581
questionnaires	O	582-596
about	O	597-602
the	O	603-606
numbers	O	607-614
of	O	615-617
each	O	618-622
procedure	O	623-632
or	O	633-635
examination	O	636-647
during	O	648-654
nine	O	655-659
months	O	660-666
of	O	667-669
investigation	O	670-683
period	O	684-690
to	O	691-693
each	O	694-698
local	O	699-704
government	O	705-715
in	O	716-718
1986	O	719-723
and	O	724-727
1987	O	728-732
.	O	732-733

93	O	734-736
.	O	736-737
4	O	737-738
%	O	738-739
pregnant	O	740-748
women	O	749-754
had	O	755-758
the	O	759-762
chance	O	763-769
to	O	770-772
be	O	773-775
examined	O	776-784
for	O	785-788
HBsAg	O	789-794
,	O	794-795
and	O	796-799
the	O	800-803
positive	O	804-812
rate	O	813-817
was	O	818-821
1	O	822-823
.	O	823-824
4	O	824-825
to	O	826-828
1	O	829-830
.	O	830-831
5	O	831-832
%	O	832-833
.	O	830-831

The	O	835-838
HBeAg	O	839-844
positive	O	845-853
rate	O	854-858
in	O	859-861
HBsAg	O	862-867
positive	O	868-876
was	O	877-880
23	O	881-883
to	O	884-886
26	O	887-889
%	O	889-890
.	O	890-891

The	O	892-895
HBsAg	O	896-901
positive	O	902-910
rate	O	911-915
in	O	916-918
neonates	O	919-927
and	O	928-931
in	O	932-934
infants	O	935-942
before	O	943-949
two	O	950-953
months	O	954-960
were	O	961-965
3	O	966-967
%	O	967-968
and	O	969-972
2	O	973-974
%	O	974-975
respectively	O	976-988
.	O	988-989

Some	O	990-994
problems	O	995-1003
may	O	1004-1007
arise	O	1008-1013
,	O	1013-1014
because	O	1015-1022
27	O	1023-1025
to	O	1026-1028
30	O	1029-1031
%	O	1031-1032
of	O	1033-1035
infants	O	1036-1043
need	O	1044-1048
the	O	1049-1052
fourth	O	1053-1059
vaccination	O	1060-1071
in	O	1072-1074
some	O	1075-1079
restricted	O	1080-1090
areas	O	1091-1096
.	O	1096-1097

Nociceptive	O	0-11
effects	O	12-19
induced	O	20-27
by	O	28-30
intrathecal	O	31-42
administration	O	43-57
of	O	58-60
prostaglandin	O	61-74
D2	O	75-77
,	O	77-78
E2	O	79-81
,	O	81-82
or	O	83-85
F2	O	86-88
alpha	O	89-94
to	O	95-97
conscious	O	98-107
mice	O	108-112
.	O	112-113

The	O	114-117
effects	O	118-125
of	O	126-128
intrathecal	O	129-140
administration	O	141-155
of	O	156-158
prostaglandins	O	159-173
on	O	174-176
pain	B	177-181
responses	O	182-191
in	O	192-194
conscious	O	195-204
mice	O	205-209
were	O	210-214
evaluated	O	215-224
by	O	225-227
using	O	228-233
hot	O	234-237
plate	O	238-243
and	O	244-247
acetic	O	248-254
acid	O	255-259
writhing	O	260-268
tests	O	269-274
.	O	274-275

Prostaglandin	O	276-289
D2	O	290-292
(	O	293-294
0	O	294-295
.	O	295-296
5	O	296-297
-	O	297-298
3	O	298-299
ng	O	300-302
/	O	302-303
mouse	O	303-308
)	O	308-309
had	O	310-313
a	O	314-315
hyperalgesic	B	316-328
action	O	329-335
on	O	336-338
the	O	339-342
response	O	343-351
to	O	352-354
a	O	355-356
hot	O	357-360
plate	O	361-366
during	O	367-373
a	O	374-375
3	O	376-377
-	O	377-378
60	O	378-380
min	O	381-384
period	O	385-391
after	O	392-397
injection	O	398-407
.	O	407-408

Prostaglandin	O	409-422
E2	O	423-425
showed	O	426-432
a	O	433-434
hyperalgesic	B	435-447
effect	O	448-454
at	O	455-457
doses	O	458-463
of	O	464-466
1	O	467-468
pg	O	469-471
to	O	472-474
10	O	475-477
ng	O	478-480
/	O	480-481
mouse	O	481-486
,	O	486-487
but	O	488-491
the	O	492-495
effect	O	496-502
lasted	O	503-509
shorter	O	510-517
(	O	518-519
3	O	519-520
-	O	520-521
30	O	521-523
min	O	524-527
)	O	527-528
than	O	529-533
that	O	534-538
of	O	539-541
prostaglandin	O	542-555
D2	O	556-558
.	O	558-559

Similar	O	560-567
results	O	568-575
were	O	576-580
obtained	O	581-589
by	O	590-592
acetic	O	593-599
acid	O	600-604
writhing	O	605-613
tests	O	614-619
.	O	619-620

The	O	621-624
hyperalgesic	B	625-637
effect	O	638-644
of	O	645-647
prostaglandin	O	648-661
D2	O	662-664
was	O	665-668
blocked	O	669-676
by	O	677-679
simultaneous	O	680-692
injection	O	693-702
of	O	703-705
a	O	706-707
substance	O	708-717
P	O	718-719
antagonist	O	720-730
(	O	731-732
greater	O	732-739
than	O	740-744
or	O	745-747
equal	O	748-753
to	O	754-756
100	O	757-760
ng	O	761-763
)	O	763-764
but	O	765-768
not	O	769-772
by	O	773-775
AH6809	O	776-782
,	O	782-783
a	O	784-785
prostanoid	O	786-796
EP1	O	797-800
-	O	800-801
receptor	O	801-809
antagonist	O	810-820
.	O	820-821

Conversely	O	822-832
,	O	832-833
prostaglandin	O	834-847
E2	O	848-850
-	O	850-851
induced	O	851-858
hyperalgesia	B	859-871
was	O	872-875
blocked	O	876-883
by	O	884-886
AH6809	O	887-893
(	O	894-895
greater	O	895-902
than	O	903-907
or	O	908-910
equal	O	911-916
to	O	917-919
500	O	920-923
ng	O	924-926
)	O	926-927
but	O	928-931
not	O	932-935
by	O	936-938
the	O	939-942
substance	O	943-952
P	O	953-954
antagonist	O	955-965
.	O	965-966

Prostaglandin	O	967-980
F2	O	981-983
alpha	O	984-989
had	O	990-993
little	O	994-1000
effect	O	1001-1007
on	O	1008-1010
pain	B	1011-1015
responses	O	1016-1025
.	O	1025-1026

These	O	1027-1032
results	O	1033-1040
demonstrate	O	1041-1052
that	O	1053-1057
both	O	1058-1062
prostaglandin	O	1063-1076
D2	O	1077-1079
and	O	1080-1083
prostaglandin	O	1084-1097
E2	O	1098-1100
exert	O	1101-1106
hyperalgesia	B	1107-1119
in	O	1120-1122
the	O	1123-1126
spinal	O	1127-1133
cord	O	1134-1138
,	O	1138-1139
but	O	1140-1143
in	O	1144-1146
different	O	1147-1156
ways	O	1157-1161
.	O	1161-1162

Swallowing	O	0-10
-	O	10-11
induced	O	11-18
atrial	B	19-25
tachyarrhythmia	I	26-41
triggered	O	42-51
by	O	52-54
salbutamol	O	55-65
:	O	65-66
case	O	67-71
report	O	72-78
and	O	79-82
review	O	83-89
of	O	90-92
the	O	93-96
literature	O	97-107
.	O	107-108

CASE	O	109-113
:	O	113-114
A	O	115-116
49	O	117-119
-	O	119-120
year	O	120-124
-	O	119-120
old	O	125-128
patient	O	129-136
experienced	O	137-148
chest	O	149-154
discomfort	O	155-165
while	O	166-171
swallowing	O	172-182
.	O	182-183

On	O	184-186
electrocardiogram	O	187-204
,	O	204-205
episodes	O	206-214
of	O	215-217
atrial	B	218-224
tachyarrhythmia	I	225-240
were	O	241-245
recorded	O	246-254
immediately	O	255-266
after	O	267-272
swallowing	O	273-283
;	O	283-284
24	O	285-287
-	O	287-288
hour	O	288-292
Holter	O	293-299
monitoring	O	300-310
recorded	O	311-319
several	O	320-327
events	O	328-334
.	O	334-335

The	O	336-339
arrhythmia	B	340-350
resolved	O	351-359
after	O	360-365
therapy	O	366-373
with	O	374-378
atenolol	O	379-387
,	O	387-388
but	O	389-392
recurred	O	393-401
a	O	402-403
year	O	404-408
later	O	409-414
.	O	414-415

The	O	416-419
patient	O	420-427
noticed	O	428-435
that	O	436-440
before	O	441-447
these	O	448-453
episodes	O	454-462
he	O	463-465
had	O	466-469
been	O	470-474
using	O	475-480
an	O	481-483
inhalator	O	484-493
of	O	494-496
salbutamol	O	497-507
.	O	507-508

After	O	509-514
stopping	O	515-523
the	O	524-527
beta	O	528-532
-	O	532-533
agonist	O	533-540
,	O	540-541
and	O	542-545
after	O	546-551
a	O	552-553
week	O	554-558
with	O	559-563
the	O	564-567
atenolol	O	568-576
,	O	576-577
the	O	578-581
arrhythmia	B	582-592
disappeared	O	593-604
.	O	604-605

DISCUSSION	O	606-616
:	O	616-617
Swallowing	O	618-628
-	O	628-629
induced	O	629-636
atrial	B	637-643
tachyarrhythmia	I	644-659
(	O	660-661
SIAT	B	661-665
)	O	665-666
is	O	667-669
a	O	670-671
rare	O	672-676
phenomenon	O	677-687
.	O	687-688

Fewer	O	689-694
than	O	695-699
50	O	700-702
cases	O	703-708
of	O	709-711
SIAT	B	712-716
have	O	717-721
been	O	722-726
described	O	727-736
in	O	737-739
the	O	740-743
literature	O	744-754
.	O	754-755

This	O	756-760
article	O	761-768
summarizes	O	769-779
all	O	780-783
the	O	784-787
cases	O	788-793
published	O	794-803
,	O	803-804
creating	O	805-813
a	O	814-815
comprehensive	O	816-829
review	O	830-836
of	O	837-839
the	O	840-843
current	O	844-851
knowledge	O	852-861
and	O	862-865
approach	O	866-874
to	O	875-877
SIAT	B	878-882
.	O	882-883

It	O	884-886
discusses	O	887-896
demographics	O	897-909
,	O	909-910
clinical	O	911-919
characteristics	O	920-935
and	O	936-939
types	O	940-945
of	O	946-948
arrhythmia	B	949-959
,	O	959-960
postulated	O	961-971
mechanisms	O	972-982
of	O	983-985
SIAT	B	986-990
,	O	990-991
and	O	992-995
different	O	996-1005
treatment	O	1006-1015
possibilities	O	1016-1029
such	O	1030-1034
as	O	1035-1037
medications	O	1038-1049
,	O	1049-1050
surgery	O	1051-1058
,	O	1058-1059
and	O	1060-1063
radiofrequency	O	1064-1078
catheter	O	1079-1087
ablation	O	1088-1096
(	O	1097-1098
RFCA	O	1098-1102
)	O	1102-1103
.	O	1103-1104

CONCLUSION	O	1105-1115
:	O	1115-1116
Salbutamol	O	1117-1127
is	O	1128-1130
presented	O	1131-1140
here	O	1141-1145
as	O	1146-1148
a	O	1149-1150
possible	O	1151-1159
trigger	O	1160-1167
for	O	1168-1171
SIAT	B	1172-1176
.	O	1176-1177

Although	O	1178-1186
it	O	1187-1189
is	O	1190-1192
difficult	O	1193-1202
to	O	1203-1205
define	O	1206-1212
causality	O	1213-1222
in	O	1223-1225
a	O	1226-1227
case	O	1228-1232
report	O	1233-1239
,	O	1239-1240
it	O	1241-1243
is	O	1244-1246
logical	O	1247-1254
to	O	1255-1257
think	O	1258-1263
that	O	1264-1268
a	O	1269-1270
beta	O	1271-1275
-	O	1275-1276
agonist	O	1276-1283
like	O	1284-1288
salbutamol	O	1289-1299
(	O	1300-1301
known	O	1301-1306
to	O	1307-1309
induce	O	1310-1316
tachycardia	B	1317-1328
)	O	1328-1329
may	O	1330-1333
be	O	1334-1336
the	O	1337-1340
trigger	O	1341-1348
of	O	1349-1351
adrenergic	O	1352-1362
reflexes	O	1363-1371
originating	O	1372-1383
in	O	1384-1386
the	O	1387-1390
esophagus	O	1391-1400
while	O	1401-1406
swallowing	O	1407-1417
and	O	1418-1421
that	O	1422-1426
a	O	1427-1428
beta	O	1429-1433
-	O	1433-1434
blocker	O	1434-1441
such	O	1442-1446
as	O	1447-1449
atenolol	O	1450-1458
(	O	1459-1460
that	O	1460-1464
blocks	O	1465-1471
the	O	1472-1475
adrenergic	O	1476-1486
activity	O	1487-1495
)	O	1495-1496
may	O	1497-1500
relieve	O	1501-1508
it	O	1509-1511
.	O	1511-1512

Coenzyme	O	0-8
Q10	O	9-12
treatment	O	13-22
ameliorates	O	23-34
acute	O	35-40
cisplatin	O	41-50
nephrotoxicity	B	51-65
in	O	66-68
mice	O	69-73
.	O	73-74

The	O	75-78
nephroprotective	O	79-95
effect	O	96-102
of	O	103-105
coenzyme	O	106-114
Q10	O	115-118
was	O	119-122
investigated	O	123-135
in	O	136-138
mice	O	139-143
with	O	144-148
acute	B	149-154
renal	I	155-160
injury	I	161-167
induced	O	168-175
by	O	176-178
a	O	179-180
single	O	181-187
i	O	188-189
.	O	189-190
p	O	190-191
.	O	189-190
injection	O	193-202
of	O	203-205
cisplatin	O	206-215
(	O	216-217
5	O	217-218
mg	O	219-221
/	O	221-222
kg	O	222-224
)	O	224-225
.	O	225-226

Coenzyme	O	227-235
Q10	O	236-239
treatment	O	240-249
(	O	250-251
10	O	251-253
mg	O	254-256
/	O	256-257
kg	O	257-259
/	O	256-257
day	O	260-263
,	O	263-264
i	O	265-266
.	O	266-267
p	O	267-268
.	O	266-267
)	O	269-270
was	O	271-274
applied	O	275-282
for	O	283-286
6	O	287-288
consecutive	O	289-300
days	O	301-305
,	O	305-306
starting	O	307-315
1	O	316-317
day	O	318-321
before	O	322-328
cisplatin	O	329-338
administration	O	339-353
.	O	353-354

Coenzyme	O	355-363
Q10	O	364-367
significantly	O	368-381
reduced	O	382-389
blood	O	390-395
urea	O	396-400
nitrogen	O	401-409
and	O	410-413
serum	O	414-419
creatinine	O	420-430
levels	O	431-437
which	O	438-443
were	O	444-448
increased	O	449-458
by	O	459-461
cisplatin	O	462-471
.	O	471-472

Coenzyme	O	473-481
Q10	O	482-485
significantly	O	486-499
compensated	O	500-511
deficits	O	512-520
in	O	521-523
the	O	524-527
antioxidant	O	528-539
defense	O	540-547
mechanisms	O	548-558
(	O	559-560
reduced	O	560-567
glutathione	O	568-579
level	O	580-585
and	O	586-589
superoxide	O	590-600
dismutase	O	601-610
activity	O	611-619
)	O	619-620
,	O	620-621
suppressed	O	622-632
lipid	O	633-638
peroxidation	O	639-651
,	O	651-652
decreased	O	653-662
the	O	663-666
elevations	O	667-677
of	O	678-680
tumor	B	681-686
necrosis	B	687-695
factor	O	696-702
-	O	702-703
alpha	O	703-708
,	O	708-709
nitric	O	710-716
oxide	O	717-722
and	O	723-726
platinum	O	727-735
ion	O	736-739
concentration	O	740-753
,	O	753-754
and	O	755-758
attenuated	O	759-769
the	O	770-773
reductions	O	774-784
of	O	785-787
selenium	O	788-796
and	O	797-800
zinc	O	801-805
ions	O	806-810
in	O	811-813
renal	O	814-819
tissue	O	820-826
resulted	O	827-835
from	O	836-840
cisplatin	O	841-850
administration	O	851-865
.	O	865-866

Also	O	867-871
,	O	871-872
histopathological	O	873-890
renal	B	891-896
tissue	I	897-903
damage	I	904-910
mediated	O	911-919
by	O	920-922
cisplatin	O	923-932
was	O	933-936
ameliorated	O	937-948
by	O	949-951
coenzyme	O	952-960
Q10	O	961-964
treatment	O	965-974
.	O	974-975

Immunohistochemical	O	976-995
analysis	O	996-1004
revealed	O	1005-1013
that	O	1014-1018
coenzyme	O	1019-1027
Q10	O	1028-1031
significantly	O	1032-1045
decreased	O	1046-1055
the	O	1056-1059
cisplatin	O	1060-1069
-	O	1069-1070
induced	O	1070-1077
overexpression	O	1078-1092
of	O	1093-1095
inducible	O	1096-1105
nitric	O	1106-1112
oxide	O	1113-1118
synthase	O	1119-1127
,	O	1127-1128
nuclear	O	1129-1136
factor	O	1137-1143
-	O	1143-1144
kappaB	O	1144-1150
,	O	1150-1151
caspase	O	1152-1159
-	O	1159-1160
3	O	1160-1161
and	O	1162-1165
p53	O	1166-1169
in	O	1170-1172
renal	O	1173-1178
tissue	O	1179-1185
.	O	1185-1186

It	O	1187-1189
was	O	1190-1193
concluded	O	1194-1203
that	O	1204-1208
coenzyme	O	1209-1217
Q10	O	1218-1221
represents	O	1222-1232
a	O	1233-1234
potential	O	1235-1244
therapeutic	O	1245-1256
option	O	1257-1263
to	O	1264-1266
protect	O	1267-1274
against	O	1275-1282
acute	O	1283-1288
cisplatin	O	1289-1298
nephrotoxicity	B	1299-1313
commonly	O	1314-1322
encountered	O	1323-1334
in	O	1335-1337
clinical	O	1338-1346
practice	O	1347-1355
.	O	1355-1356

Metformin	O	0-9
prevents	O	10-18
experimental	O	19-31
gentamicin	O	32-42
-	O	42-43
induced	O	43-50
nephropathy	B	51-62
by	O	63-65
a	O	66-67
mitochondria	O	68-80
-	O	80-81
dependent	O	81-90
pathway	O	91-98
.	O	98-99

The	O	100-103
antidiabetic	O	104-116
drug	O	117-121
metformin	O	122-131
can	O	132-135
diminish	O	136-144
apoptosis	O	145-154
induced	O	155-162
by	O	163-165
oxidative	O	166-175
stress	O	176-182
in	O	183-185
endothelial	O	186-197
cells	O	198-203
and	O	204-207
prevent	O	208-215
vascular	B	216-224
dysfunction	I	225-236
even	O	237-241
in	O	242-244
nondiabetic	O	245-256
patients	O	257-265
.	O	265-266

Here	O	267-271
we	O	272-274
tested	O	275-281
whether	O	282-289
it	O	290-292
has	O	293-296
a	O	297-298
beneficial	O	299-309
effect	O	310-316
in	O	317-319
a	O	320-321
rat	O	322-325
model	O	326-331
of	O	332-334
gentamicin	O	335-345
toxicity	B	346-354
.	O	354-355

Mitochondrial	O	356-369
analysis	O	370-378
,	O	378-379
respiration	O	380-391
intensity	O	392-401
,	O	401-402
levels	O	403-409
of	O	410-412
reactive	O	413-421
oxygen	O	422-428
species	O	429-436
,	O	436-437
permeability	O	438-450
transition	O	451-461
,	O	461-462
and	O	463-466
cytochrome	O	467-477
c	O	478-479
release	O	480-487
were	O	488-492
assessed	O	493-501
3	O	502-503
and	O	504-507
6	O	508-509
days	O	510-514
after	O	515-520
gentamicin	O	521-531
administration	O	532-546
.	O	546-547

Metformin	O	548-557
treatment	O	558-567
fully	O	568-573
blocked	O	574-581
gentamicin	O	582-592
-	O	592-593
mediated	O	593-601
acute	B	602-607
renal	I	608-613
failure	I	614-621
.	O	621-622

This	O	623-627
was	O	628-631
accompanied	O	632-643
by	O	644-646
a	O	647-648
lower	O	649-654
activity	O	655-663
of	O	664-666
N	O	667-668
-	O	668-669
acetyl	O	669-675
-	O	668-669
beta	O	676-680
-	O	668-669
D	O	681-682
-	O	668-669
glucosaminidase	O	683-698
,	O	698-699
together	O	700-708
with	O	709-713
a	O	714-715
decrease	O	716-724
of	O	725-727
lipid	O	728-733
peroxidation	O	734-746
and	O	747-750
increase	O	751-759
of	O	760-762
antioxidant	O	763-774
systems	O	775-782
.	O	782-783

Metformin	O	784-793
also	O	794-798
protected	O	799-808
the	O	809-812
kidney	O	813-819
from	O	820-824
histological	O	825-837
damage	O	838-844
6	O	845-846
days	O	847-851
after	O	852-857
gentamicin	O	858-868
administration	O	869-883
.	O	883-884

These	O	885-890
in	O	891-893
vivo	O	894-898
markers	O	899-906
of	O	907-909
kidney	B	910-916
dysfunction	I	917-928
and	O	929-932
their	O	933-938
correction	O	939-949
by	O	950-952
metformin	O	953-962
were	O	963-967
complemented	O	968-980
by	O	981-983
in	O	984-986
vitro	O	987-992
studies	O	993-1000
of	O	1001-1003
mitochondrial	O	1004-1017
function	O	1018-1026
.	O	1026-1027

We	O	1028-1030
found	O	1031-1036
that	O	1037-1041
gentamicin	O	1042-1052
treatment	O	1053-1062
depleted	O	1063-1071
respiratory	O	1072-1083
components	O	1084-1094
(	O	1095-1096
cytochrome	O	1096-1106
c	O	1107-1108
,	O	1108-1109
NADH	O	1110-1114
)	O	1114-1115
,	O	1115-1116
probably	O	1117-1125
due	O	1126-1129
to	O	1130-1132
the	O	1133-1136
opening	O	1137-1144
of	O	1145-1147
mitochondrial	O	1148-1161
transition	O	1162-1172
pores	O	1173-1178
.	O	1178-1179

These	O	1180-1185
injuries	O	1186-1194
,	O	1194-1195
partly	O	1196-1202
mediated	O	1203-1211
by	O	1212-1214
a	O	1215-1216
rise	O	1217-1221
in	O	1222-1224
reactive	O	1225-1233
oxygen	O	1234-1240
species	O	1241-1248
from	O	1249-1253
the	O	1254-1257
electron	O	1258-1266
transfer	O	1267-1275
chain	O	1276-1281
,	O	1281-1282
were	O	1283-1287
significantly	O	1288-1301
decreased	O	1302-1311
by	O	1312-1314
metformin	O	1315-1324
.	O	1324-1325

Thus	O	1326-1330
,	O	1330-1331
our	O	1332-1335
study	O	1336-1341
suggests	O	1342-1350
that	O	1351-1355
pleiotropic	O	1356-1367
effects	O	1368-1375
of	O	1376-1378
metformin	O	1379-1388
can	O	1389-1392
lessen	O	1393-1399
gentamicin	O	1400-1410
nephrotoxicity	B	1411-1425
and	O	1426-1429
improve	O	1430-1437
mitochondrial	O	1438-1451
homeostasis	O	1452-1463
.	O	1463-1464

Sedation	O	0-8
depth	O	9-14
during	O	15-21
spinal	O	22-28
anesthesia	O	29-39
and	O	40-43
the	O	44-47
development	O	48-59
of	O	60-62
postoperative	B	63-76
delirium	I	77-85
in	O	86-88
elderly	O	89-96
patients	O	97-105
undergoing	O	106-116
hip	B	117-120
fracture	I	121-129
repair	O	130-136
.	O	136-137

OBJECTIVE	O	138-147
:	O	147-148
To	O	149-151
determine	O	152-161
whether	O	162-169
limiting	O	170-178
intraoperative	O	179-193
sedation	O	194-202
depth	O	203-208
during	O	209-215
spinal	O	216-222
anesthesia	O	223-233
for	O	234-237
hip	B	238-241
fracture	I	242-250
repair	O	251-257
in	O	258-260
elderly	O	261-268
patients	O	269-277
can	O	278-281
decrease	O	282-290
the	O	291-294
prevalence	O	295-305
of	O	306-308
postoperative	B	309-322
delirium	I	323-331
.	O	331-332

PATIENTS	O	333-341
AND	O	342-345
METHODS	O	346-353
:	O	353-354
We	O	355-357
performed	O	358-367
a	O	368-369
double	O	370-376
-	O	376-377
blind	O	377-382
,	O	382-383
randomized	O	384-394
controlled	O	395-405
trial	O	406-411
at	O	412-414
an	O	415-417
academic	O	418-426
medical	O	427-434
center	O	435-441
of	O	442-444
elderly	O	445-452
patients	O	453-461
(	O	462-463
>	O	463-464
or	O	464-466
=	O	466-467
65	O	467-469
years	O	470-475
)	O	475-476
without	O	477-484
preoperative	O	485-497
delirium	B	498-506
or	O	507-509
severe	O	510-516
dementia	B	517-525
who	O	526-529
underwent	O	530-539
hip	B	540-543
fracture	I	544-552
repair	O	553-559
under	O	560-565
spinal	O	566-572
anesthesia	O	573-583
with	O	584-588
propofol	O	589-597
sedation	O	598-606
.	O	606-607

Sedation	O	608-616
depth	O	617-622
was	O	623-626
titrated	O	627-635
using	O	636-641
processed	O	642-651
electroencephalography	O	652-674
with	O	675-679
the	O	680-683
bispectral	O	684-694
index	O	695-700
(	O	701-702
BIS	O	702-705
)	O	705-706
,	O	706-707
and	O	708-711
patients	O	712-720
were	O	721-725
randomized	O	726-736
to	O	737-739
receive	O	740-747
either	O	748-754
deep	O	755-759
(	O	760-761
BIS	O	761-764
,	O	764-765
approximately	O	766-779
50	O	780-782
)	O	782-783
or	O	784-786
light	O	787-792
(	O	793-794
BIS	O	794-797
,	O	797-798
>	O	799-800
or	O	800-802
=	O	802-803
80	O	803-805
)	O	805-806
sedation	O	807-815
.	O	815-816

Postoperative	B	817-830
delirium	I	831-839
was	O	840-843
assessed	O	844-852
as	O	853-855
defined	O	856-863
by	O	864-866
Diagnostic	O	867-877
and	O	878-881
Statistical	O	882-893
Manual	O	894-900
of	O	901-903
Mental	B	904-910
Disorders	I	911-920
(	O	921-922
Third	O	922-927
Edition	O	928-935
Revised	O	936-943
)	O	943-944
criteria	O	945-953
using	O	954-959
the	O	960-963
Confusion	O	964-973
Assessment	O	974-984
Method	O	985-991
beginning	O	992-1001
at	O	1002-1004
any	O	1005-1008
time	O	1009-1013
from	O	1014-1018
the	O	1019-1022
second	O	1023-1029
day	O	1030-1033
after	O	1034-1039
surgery	O	1040-1047
.	O	1047-1048

RESULTS	O	1049-1056
:	O	1056-1057
From	O	1058-1062
April	O	1063-1068
2	O	1069-1070
,	O	1070-1071
2005	O	1072-1076
,	O	1076-1077
through	O	1078-1085
October	O	1086-1093
30	O	1094-1096
,	O	1096-1097
2008	O	1098-1102
,	O	1102-1103
a	O	1104-1105
total	O	1106-1111
of	O	1112-1114
114	O	1115-1118
patients	O	1119-1127
were	O	1128-1132
randomized	O	1133-1143
.	O	1143-1144

The	O	1145-1148
prevalence	O	1149-1159
of	O	1160-1162
postoperative	B	1163-1176
delirium	I	1177-1185
was	O	1186-1189
significantly	O	1190-1203
lower	O	1204-1209
in	O	1210-1212
the	O	1213-1216
light	O	1217-1222
sedation	O	1223-1231
group	O	1232-1237
(	O	1238-1239
11	O	1239-1241
/	O	1241-1242
57	O	1242-1244
[	O	1245-1246
19	O	1246-1248
%	O	1248-1249
]	O	1249-1250
vs	O	1251-1253
23	O	1254-1256
/	O	1256-1257
57	O	1257-1259
[	O	1260-1261
40	O	1261-1263
%	O	1263-1264
]	O	1264-1265
in	O	1266-1268
the	O	1269-1272
deep	O	1273-1277
sedation	O	1278-1286
group	O	1287-1292
;	O	1292-1293
P	O	1294-1295
=	O	1295-1296
.	O	1296-1297
02	O	1297-1299
)	O	1299-1300
,	O	1300-1301
indicating	O	1302-1312
that	O	1313-1317
1	O	1318-1319
incident	O	1320-1328
of	O	1329-1331
delirium	B	1332-1340
will	O	1341-1345
be	O	1346-1348
prevented	O	1349-1358
for	O	1359-1362
every	O	1363-1368
4	O	1369-1370
.	O	1370-1371
7	O	1371-1372
patients	O	1373-1381
treated	O	1382-1389
with	O	1390-1394
light	O	1395-1400
sedation	O	1401-1409
.	O	1409-1410

The	O	1411-1414
mean	O	1415-1419
+	O	1420-1421
/	O	1421-1422
-	O	1422-1423
SD	O	1424-1426
number	O	1427-1433
of	O	1434-1436
days	O	1437-1441
of	O	1442-1444
delirium	B	1445-1453
during	O	1454-1460
hospitalization	O	1461-1476
was	O	1477-1480
lower	O	1481-1486
in	O	1487-1489
the	O	1490-1493
light	O	1494-1499
sedation	O	1500-1508
group	O	1509-1514
than	O	1515-1519
in	O	1520-1522
the	O	1523-1526
deep	O	1527-1531
sedation	O	1532-1540
group	O	1541-1546
(	O	1547-1548
0	O	1548-1549
.	O	1549-1550
5	O	1550-1551
+	O	1551-1552
/	O	1552-1553
-	O	1553-1554
1	O	1554-1555
.	O	1549-1550
5	O	1550-1551
days	O	1558-1562
vs	O	1563-1565
1	O	1566-1567
.	O	1567-1568
4	O	1568-1569
+	O	1569-1570
/	O	1570-1571
-	O	1571-1572
4	O	1568-1569
.	O	1567-1568
0	O	1574-1575

days	O	1576-1580
;	O	1580-1581
P	O	1582-1583
=	O	1583-1584
.	O	1584-1585
01	O	1585-1587
)	O	1587-1588
.	O	1584-1585

CONCLUSION	O	1590-1600
:	O	1600-1601
The	O	1602-1605
use	O	1606-1609
of	O	1610-1612
light	O	1613-1618
propofol	O	1619-1627
sedation	O	1628-1636
decreased	O	1637-1646
the	O	1647-1650
prevalence	O	1651-1661
of	O	1662-1664
postoperative	B	1665-1678
delirium	I	1679-1687
by	O	1688-1690
50	O	1691-1693
%	O	1693-1694
compared	O	1695-1703
with	O	1704-1708
deep	O	1709-1713
sedation	O	1714-1722
.	O	1722-1723

Limiting	O	1724-1732
depth	O	1733-1738
of	O	1739-1741
sedation	O	1742-1750
during	O	1751-1757
spinal	O	1758-1764
anesthesia	O	1765-1775
is	O	1776-1778
a	O	1779-1780
simple	O	1781-1787
,	O	1787-1788
safe	O	1789-1793
,	O	1793-1794
and	O	1795-1798
cost	O	1799-1803
-	O	1803-1804
effective	O	1804-1813
intervention	O	1814-1826
for	O	1827-1830
preventing	O	1831-1841
postoperative	B	1842-1855
delirium	I	1856-1864
in	O	1865-1867
elderly	O	1868-1875
patients	O	1876-1884
that	O	1885-1889
could	O	1890-1895
be	O	1896-1898
widely	O	1899-1905
and	O	1906-1909
readily	O	1910-1917
adopted	O	1918-1925
.	O	1925-1926

Sorafenib	O	0-9
-	O	9-10
induced	O	10-17
acute	O	18-23
myocardial	B	24-34
infarction	I	35-45
due	O	46-49
to	O	50-52
coronary	B	53-61
artery	I	62-68
spasm	I	69-74
.	O	74-75

A	O	76-77
65	O	78-80
-	O	80-81
year	O	81-85
-	O	80-81
old	O	86-89
man	O	90-93
with	O	94-98
advanced	O	99-107
renal	B	108-113
cell	I	114-118
carcinoma	I	119-128
was	O	129-132
admitted	O	133-141
due	O	142-145
to	O	146-148
continuing	O	149-159
chest	B	160-165
pain	I	166-170
at	O	171-173
rest	O	174-178
.	O	178-179

Two	O	180-183
weeks	O	184-189
before	O	190-196
his	O	197-200
admission	O	201-210
,	O	210-211
sorafenib	O	212-221
had	O	222-225
been	O	226-230
started	O	231-238
.	O	238-239

He	O	240-242
was	O	243-246
diagnosed	O	247-256
with	O	257-261
non	O	262-265
-	O	265-266
ST	O	266-268
-	O	265-266
elevation	O	269-278
myocardial	B	279-289
infarction	I	290-300
by	O	301-303
laboratory	O	304-314
data	O	315-319
and	O	320-323
electrocardiogram	O	324-341
.	O	341-342

Enhanced	O	343-351
heart	O	352-357
magnetic	O	358-366
resonance	O	367-376
imaging	O	377-384
also	O	385-389
showed	O	390-396
subendocardial	B	397-411
infarction	I	412-422
.	O	422-423

However	O	424-431
,	O	431-432
there	O	433-438
was	O	439-442
no	O	443-445
stenosis	O	446-454
in	O	455-457
coronary	O	458-466
arteries	O	467-475
on	O	476-478
angiography	O	479-490
.	O	490-491

Coronary	B	492-500
artery	I	501-507
spasm	I	508-513
was	O	514-517
induced	O	518-525
by	O	526-528
a	O	529-530
provocative	O	531-542
test	O	543-547
.	O	547-548

Cessation	O	549-558
of	O	559-561
sorafenib	O	562-571
and	O	572-575
administration	O	576-590
of	O	591-593
Ca	O	594-596
-	O	596-597
channel	O	597-604
blocker	O	605-612
and	O	613-616
nitrates	O	617-625
ameliorated	O	626-637
his	O	638-641
symptoms	O	642-650
,	O	650-651
but	O	652-655
relapse	O	656-663
occurred	O	664-672
after	O	673-678
resumption	O	679-689
of	O	690-692
sorafenib	O	693-702
.	O	702-703

Addition	O	704-712
of	O	713-715
oral	O	716-720
nicorandil	O	721-731
reduced	O	732-739
his	O	740-743
symptoms	O	744-752
and	O	753-756
maintained	O	757-767
stable	B	768-774
angina	I	775-781
status	O	782-788
.	O	788-789

We	O	790-792
report	O	793-799
the	O	800-803
first	O	804-809
case	O	810-814
of	O	815-817
sorafenib	O	818-827
-	O	827-828
induced	O	828-835
coronary	B	836-844
artery	I	845-851
spasm	I	852-857
.	O	857-858

Sorafenib	O	859-868
is	O	869-871
a	O	872-873
multikinase	O	874-885
inhibitor	O	886-895
that	O	896-900
targets	O	901-908
signaling	O	909-918
pathways	O	919-927
necessary	O	928-937
for	O	938-941
cellular	O	942-950
proliferation	O	951-964
and	O	965-968
survival	O	969-977
.	O	977-978

On	O	979-981
the	O	982-985
other	O	986-991
hand	O	992-996
,	O	996-997
the	O	998-1001
Rho	O	1002-1005
/	O	1005-1006
ROCK	O	1006-1010
pathway	O	1011-1018
has	O	1019-1022
an	O	1023-1025
important	O	1026-1035
role	O	1036-1040
in	O	1041-1043
the	O	1044-1047
pathogenesis	O	1048-1060
of	O	1061-1063
coronary	B	1064-1072
artery	I	1073-1079
spasm	I	1080-1085
.	O	1085-1086

Our	O	1087-1090
report	O	1091-1097
may	O	1098-1101
show	O	1102-1106
an	O	1107-1109
adverse	O	1110-1117
effect	O	1118-1124
on	O	1125-1127
the	O	1128-1131
Rho	O	1132-1135
/	O	1135-1136
ROCK	O	1136-1140
pathway	O	1141-1148
by	O	1149-1151
sorafenib	O	1152-1161
use	O	1162-1165
.	O	1165-1166

Anxiogenic	O	0-10
potential	O	11-20
of	O	21-23
ciprofloxacin	O	24-37
and	O	38-41
norfloxacin	O	42-53
in	O	54-56
rats	O	57-61
.	O	61-62

INTRODUCTION	O	63-75
:	O	75-76
The	O	77-80
possible	O	81-89
anxiogenic	O	90-100
effects	O	101-108
of	O	109-111
fluoroquinolones	O	112-128
,	O	128-129
namely	O	130-136
ciprofloxacin	O	137-150
and	O	151-154
norfloxacin	O	155-166
,	O	166-167
were	O	168-172
investigated	O	173-185
in	O	186-188
adult	O	189-194
Charles	O	195-202
Foster	O	203-209
albino	O	210-216
rats	O	217-221
of	O	222-224
either	O	225-231
sex	O	232-235
,	O	235-236
weighing	O	237-245
150	O	246-249
-	O	249-250
200	O	250-253
g	O	254-255
.	O	255-256

METHODS	O	257-264
:	O	264-265
The	O	266-269
drugs	O	270-275
were	O	276-280
given	O	281-286
orally	O	287-293
,	O	293-294
in	O	295-297
doses	O	298-303
of	O	304-306
50	O	307-309
mg	O	310-312
/	O	312-313
kg	O	313-315
for	O	316-319
five	O	320-324
consecutive	O	325-336
days	O	337-341
and	O	342-345
the	O	346-349
experiments	O	350-361
were	O	362-366
performed	O	367-376
on	O	377-379
the	O	380-383
fifth	O	384-389
day	O	390-393
.	O	393-394

The	O	395-398
tests	O	399-404
included	O	405-413
open	O	414-418
-	O	418-419
field	O	419-424
exploratory	O	425-436
behaviour	O	437-446
,	O	446-447
elevated	O	448-456
plus	O	457-461
maze	O	462-466
and	O	467-470
elevated	O	471-479
zero	O	480-484
maze	O	485-489
,	O	489-490
social	O	491-497
interaction	O	498-509
and	O	510-513
novelty	O	514-521
-	O	521-522
suppressed	O	522-532
feeding	O	533-540
latency	O	541-548
behaviour	O	549-558
.	O	558-559

RESULTS	O	560-567
:	O	567-568
The	O	569-572
results	O	573-580
indicate	O	581-589
that	O	590-594
ciprofloxacin	O	595-608
-	O	608-609
and	O	610-613
norfloxacin	O	614-625
-	O	625-626
treated	O	626-633
rats	O	634-638
showed	O	639-645
anxious	B	646-653
behaviour	I	654-663
in	O	664-666
comparison	O	667-677
to	O	678-680
control	O	681-688
rats	O	689-693
in	O	694-696
all	O	697-700
the	O	701-704
parameters	O	705-715
studied	O	716-723
.	O	723-724

However	O	725-732
,	O	732-733
ciprofloxacin	O	734-747
-	O	747-748
and	O	749-752
norfloxacin	O	753-764
-	O	764-765
treated	O	765-772
rats	O	773-777
did	O	778-781
not	O	782-785
differ	O	786-792
significantly	O	793-806
from	O	807-811
each	O	812-816
other	O	817-822
in	O	823-825
various	O	826-833
behavioural	O	834-845
parameters	O	846-856
.	O	856-857

CONCLUSION	O	858-868
:	O	868-869
The	O	870-873
present	O	874-881
experimental	O	882-894
findings	O	895-903
substantiate	O	904-916
the	O	917-920
clinically	O	921-931
observed	O	932-940
anxiogenic	O	941-951
potential	O	952-961
of	O	962-964
ciprofloxacin	O	965-978
and	O	979-982
norfloxacin	O	983-994
.	O	994-995

Myocardial	O	0-10
Fas	O	11-14
ligand	O	15-21
expression	O	22-32
increases	O	33-42
susceptibility	O	43-57
to	O	58-60
AZT	O	61-64
-	O	64-65
induced	O	65-72
cardiomyopathy	B	73-87
.	O	87-88

BACKGROUND	O	89-99
:	O	99-100
Dilated	B	101-108
cardiomyopathy	I	109-123
(	O	124-125
DCM	B	125-128
)	O	128-129
and	O	130-133
myocarditis	B	134-145
occur	O	146-151
in	O	152-154
many	O	155-159
HIV	B	160-163
-	I	163-164
infected	I	164-172
individuals	O	173-184
,	O	184-185
resulting	O	186-195
in	O	196-198
symptomatic	O	199-210
heart	B	211-216
failure	I	217-224
in	O	225-227
up	O	228-230
to	O	231-233
5	O	234-235
%	O	235-236
of	O	237-239
patients	O	240-248
.	O	248-249

Highly	O	250-256
active	O	257-263
antiretroviral	O	264-278
therapy	O	279-286
(	O	287-288
HAART	O	288-293
)	O	293-294
has	O	295-298
significantly	O	299-312
reduced	O	313-320
morbidity	O	321-330
and	O	331-334
mortality	O	335-344
of	O	345-347
acquired	B	348-356
immunodeficiency	I	357-373
syndrome	I	374-382
(	O	383-384
AIDS	B	384-388
)	O	388-389
,	O	389-390
but	O	391-394
has	O	395-398
resulted	O	399-407
in	O	408-410
an	O	411-413
increase	O	414-422
in	O	423-425
cardiac	B	426-433
and	I	434-437
skeletal	I	438-446
myopathies	I	447-457
.	O	457-458

METHODS	O	459-466
AND	O	467-470
RESULTS	O	471-478
:	O	478-479
In	O	480-482
order	O	483-488
to	O	489-491
investigate	O	492-503
whether	O	504-511
the	O	512-515
HAART	O	516-521
component	O	522-531
zidovudine	O	532-542
(	O	543-544
3	O	544-545
'	O	545-546
-	O	546-547
azido	O	547-552
-	O	546-547
2	O	553-554
'	O	545-546
,	O	555-556
3	O	544-545
'	O	545-546
-	O	546-547
deoxythymidine	O	559-573
;	O	573-574
AZT	O	575-578
)	O	578-579
triggers	O	580-588
the	O	589-592
Fas	O	593-596
-	O	596-597
dependent	O	597-606
cell	O	607-611
-	O	611-612
death	O	612-617
pathway	O	618-625
and	O	626-629
cause	O	630-635
cytoskeletal	O	636-648
disruption	O	649-659
in	O	660-662
a	O	663-664
murine	O	665-671
model	O	672-677
of	O	678-680
DCM	B	681-684
,	O	684-685
8	O	686-687
-	O	687-688
week	O	688-692
-	O	687-688
old	O	693-696
transgenic	O	697-707
(	O	708-709
expressing	O	709-719
Fas	O	720-723
ligand	O	724-730
in	O	731-733
the	O	734-737
myocardium	O	738-748
:	O	748-749
FasL	O	750-754
Tg	O	755-757
)	O	757-758
and	O	759-762
non	O	763-766
-	O	766-767
transgenic	O	767-777
(	O	778-779
NTg	O	779-782
)	O	782-783
mice	O	784-788
received	O	789-797
water	O	798-803
ad	O	804-806
libitum	O	807-814
containing	O	815-825
different	O	826-835
concentrations	O	836-850
of	O	851-853
AZT	O	854-857
(	O	858-859
0	O	859-860
,	O	860-861
0	O	862-863
.	O	863-864
07	O	864-866
,	O	866-867
0	O	868-869
.	O	869-870
2	O	870-871
,	O	871-872
and	O	873-876
0	O	877-878
.	O	878-879
7	O	879-880
mg	O	881-883
/	O	883-884
ml	O	884-886
)	O	886-887
.	O	887-888

After	O	889-894
6	O	895-896
weeks	O	897-902
,	O	902-903
cardiac	O	904-911
function	O	912-920
was	O	921-924
assessed	O	925-933
by	O	934-936
echocardiography	O	937-953
and	O	954-957
morphology	O	958-968
was	O	969-972
assessed	O	973-981
by	O	982-984
histopathologic	O	985-1000
and	O	1001-1004
immunohistochemical	O	1005-1024
methods	O	1025-1032
.	O	1032-1033

NTg	O	1034-1037
and	O	1038-1041
untreated	O	1042-1051
FasL	O	1052-1056
Tg	O	1057-1059
mice	O	1060-1064
showed	O	1065-1071
little	O	1072-1078
or	O	1079-1081
no	O	1082-1084
change	O	1085-1091
in	O	1092-1094
cardiac	O	1095-1102
structure	O	1103-1112
or	O	1113-1115
function	O	1116-1124
.	O	1124-1125

In	O	1126-1128
contrast	O	1129-1137
,	O	1137-1138
AZT	O	1139-1142
-	O	1142-1143
treated	O	1143-1150
FasL	O	1151-1155
Tg	O	1156-1158
mice	O	1159-1163
developed	O	1164-1173
cardiac	B	1174-1181
dilation	I	1182-1190
and	O	1191-1194
depressed	O	1195-1204
cardiac	O	1205-1212
function	O	1213-1221
in	O	1222-1224
a	O	1225-1226
dose	O	1227-1231
-	O	1231-1232
dependent	O	1232-1241
manner	O	1242-1248
,	O	1248-1249
with	O	1250-1254
concomitant	O	1255-1266
inflammatory	O	1267-1279
infiltration	O	1280-1292
of	O	1293-1295
both	O	1296-1300
ventricles	O	1301-1311
.	O	1311-1312

These	O	1313-1318
changes	O	1319-1326
were	O	1327-1331
associated	O	1332-1342
with	O	1343-1347
an	O	1348-1350
increased	O	1351-1360
sarcolemmal	O	1361-1372
expression	O	1373-1383
of	O	1384-1386
Fas	O	1387-1390
and	O	1391-1394
FasL	O	1395-1399
,	O	1399-1400
as	O	1401-1403
well	O	1404-1408
as	O	1409-1411
increased	O	1412-1421
activation	O	1422-1432
of	O	1433-1435
caspase	O	1436-1443
3	O	1444-1445
,	O	1445-1446
translocation	O	1447-1460
of	O	1461-1463
calpain	O	1464-1471
1	O	1472-1473
to	O	1474-1476
the	O	1477-1480
sarcolemma	O	1481-1491
and	O	1492-1495
sarcomere	O	1496-1505
,	O	1505-1506
and	O	1507-1510
increased	O	1511-1520
numbers	O	1521-1528
of	O	1529-1531
cells	O	1532-1537
undergoing	O	1538-1548
apoptosis	O	1549-1558
.	O	1558-1559

These	O	1560-1565
were	O	1566-1570
associated	O	1571-1581
with	O	1582-1586
changes	O	1587-1594
in	O	1595-1597
dystrophin	O	1598-1608
and	O	1609-1612
cardiac	O	1613-1620
troponin	O	1621-1629
I	O	1630-1631
localization	O	1632-1644
,	O	1644-1645
as	O	1646-1648
well	O	1649-1653
as	O	1654-1656
loss	O	1657-1661
of	O	1662-1664
sarcolemmal	O	1665-1676
integrity	O	1677-1686
.	O	1686-1687

CONCLUSIONS	O	1688-1699
:	O	1699-1700
The	O	1701-1704
expression	O	1705-1715
of	O	1716-1718
Fas	O	1719-1722
ligand	O	1723-1729
in	O	1730-1732
the	O	1733-1736
myocardium	O	1737-1747
,	O	1747-1748
as	O	1749-1751
identified	O	1752-1762
in	O	1763-1765
HIV	O	1766-1769
-	O	1769-1770
positive	O	1770-1778
patients	O	1779-1787
,	O	1787-1788
might	O	1789-1794
increase	O	1795-1803
the	O	1804-1807
susceptibility	O	1808-1822
to	O	1823-1825
HAART	O	1826-1831
-	O	1831-1832
induced	O	1832-1839
cardiomyopathy	B	1840-1854
due	O	1855-1858
to	O	1859-1861
activation	O	1862-1872
of	O	1873-1875
apoptotic	O	1876-1885
pathways	O	1886-1894
,	O	1894-1895
resulting	O	1896-1905
in	O	1906-1908
cardiac	B	1909-1916
dilation	I	1917-1925
and	I	1926-1929
dysfunction	I	1930-1941
.	O	1941-1942

Valproate	O	0-9
-	O	9-10
induced	O	10-17
chorea	B	18-24
and	O	25-28
encephalopathy	B	29-43
in	O	44-46
atypical	O	47-55
nonketotic	B	56-66
hyperglycinemia	I	67-82
.	O	82-83

Nonketotic	B	84-94
hyperglycinemia	I	95-110
is	O	111-113
a	O	114-115
disorder	B	116-124
of	I	125-127
amino	I	128-133
acid	I	134-138
metabolism	I	139-149
in	O	150-152
which	O	153-158
a	O	159-160
defect	O	161-167
in	O	168-170
the	O	171-174
glycine	O	175-182
cleavage	O	183-191
system	O	192-198
leads	O	199-204
to	O	205-207
an	O	208-210
accumulation	O	211-223
of	O	224-226
glycine	O	227-234
in	O	235-237
the	O	238-241
brain	O	242-247
and	O	248-251
other	O	252-257
body	O	258-262
compartments	O	263-275
.	O	275-276

In	O	277-279
the	O	280-283
classical	O	284-293
form	O	294-298
it	O	299-301
presents	O	302-310
as	O	311-313
neonatal	O	314-322
apnea	B	323-328
,	O	328-329
intractable	O	330-341
seizures	B	342-350
,	O	350-351
and	O	352-355
hypotonia	B	356-365
,	O	365-366
followed	O	367-375
by	O	376-378
significant	O	379-390
psychomotor	B	391-402
retardation	I	403-414
.	O	414-415

An	O	416-418
important	O	419-428
subset	O	429-435
of	O	436-438
children	O	439-447
with	O	448-452
nonketotic	B	453-463
hyperglycinemia	I	464-479
are	O	480-483
atypical	O	484-492
variants	O	493-501
who	O	502-505
present	O	506-513
in	O	514-516
a	O	517-518
heterogeneous	O	519-532
manner	O	533-539
.	O	539-540

This	O	541-545
report	O	546-552
describes	O	553-562
a	O	563-564
patient	O	565-572
with	O	573-577
mild	O	578-582
language	B	583-591
delay	I	592-597
and	O	598-601
mental	B	602-608
retardation	I	609-620
,	O	620-621
who	O	622-625
was	O	626-629
found	O	630-635
to	O	636-638
have	O	639-643
nonketotic	B	644-654
hyperglycinemia	I	655-670
following	O	671-680
her	O	681-684
presentation	O	685-697
with	O	698-702
acute	O	703-708
encephalopathy	B	709-723
and	O	724-727
chorea	B	728-734
shortly	O	735-742
after	O	743-748
initiation	O	749-759
of	O	760-762
valproate	O	763-772
therapy	O	773-780
.	O	780-781

Microinjection	O	0-14
of	O	15-17
ritanserin	O	18-28
into	O	29-33
the	O	34-37
CA1	O	38-41
region	O	42-48
of	O	49-51
hippocampus	O	52-63
improves	O	64-72
scopolamine	O	73-84
-	O	84-85
induced	O	85-92
amnesia	B	93-100
in	O	101-103
adult	O	104-109
male	O	110-114
rats	O	115-119
.	O	119-120

The	O	121-124
effect	O	125-131
of	O	132-134
ritanserin	O	135-145
(	O	146-147
5	O	147-148
-	O	148-149
HT2	O	149-152
antagonist	O	153-163
)	O	163-164
on	O	165-167
scopolamine	O	168-179
(	O	180-181
muscarinic	O	181-191
cholinergic	O	192-203
antagonist	O	204-214
)	O	214-215
-	O	215-216
induced	O	216-223
amnesia	B	224-231
in	O	232-234
Morris	O	235-241
water	O	242-247
maze	O	248-252
(	O	253-254
MWM	O	254-257
)	O	257-258
was	O	259-262
investigated	O	263-275
.	O	275-276

Rats	O	277-281
were	O	282-286
divided	O	287-294
into	O	295-299
eight	O	300-305
groups	O	306-312
and	O	313-316
bilaterally	O	317-328
cannulated	O	329-339
into	O	340-344
CA1	O	345-348
region	O	349-355
of	O	356-358
the	O	359-362
hippocampus	O	363-374
.	O	374-375

One	O	376-379
week	O	380-384
later	O	385-390
,	O	390-391
they	O	392-396
received	O	397-405
repeatedly	O	406-416
vehicles	O	417-425
(	O	426-427
saline	O	427-433
,	O	433-434
DMSO	O	435-439
,	O	439-440
saline	O	441-447
+	O	447-448
DMSO	O	448-452
)	O	452-453
,	O	453-454
scopolamine	O	455-466
(	O	467-468
2	O	468-469
microg	O	470-476
/	O	476-477
0	O	477-478
.	O	478-479
5	O	479-480

microl	O	481-487
saline	O	488-494
/	O	494-495
side	O	495-499
;	O	499-500
30	O	501-503
min	O	504-507
before	O	508-514
training	O	515-523
)	O	523-524
,	O	524-525
ritanserin	O	526-536
(	O	537-538
2	O	538-539
,	O	539-540
4	O	541-542
and	O	543-546
8	O	547-548
microg	O	549-555
/	O	555-556
0	O	556-557
.	O	557-558
5	O	558-559

microl	O	560-566
DMSO	O	567-571
/	O	571-572
side	O	572-576
;	O	576-577
20	O	578-580
min	O	581-584
before	O	585-591
training	O	592-600
)	O	600-601
and	O	602-605
scopolamine	O	606-617
(	O	618-619
2	O	619-620
microg	O	621-627
/	O	627-628
0	O	628-629
.	O	629-630
5	O	630-631

microl	O	632-638
;	O	638-639
30	O	640-642
min	O	643-646
before	O	647-653
ritanserin	O	654-664
injection	O	665-674
)	O	674-675
+	O	675-676
ritanserin	O	676-686
(	O	687-688
4	O	688-689
microg	O	690-696
/	O	696-697
0	O	697-698
.	O	698-699
5	O	699-700

microl	O	701-707
DMSO	O	708-712
)	O	712-713
through	O	714-721
cannulae	O	722-730
each	O	731-735
day	O	736-739
.	O	739-740

Animals	O	741-748
were	O	749-753
tested	O	754-760
for	O	761-764
four	O	765-769
consecutive	O	770-781
days	O	782-786
(	O	787-788
4	O	788-789
trial	O	790-795
/	O	795-796
day	O	796-799
)	O	799-800
in	O	801-803
MWM	O	804-807
during	O	808-814
which	O	815-820
the	O	821-824
position	O	825-833
of	O	834-836
hidden	O	837-843
platform	O	844-852
was	O	853-856
unchanged	O	857-866
.	O	866-867

In	O	868-870
the	O	871-874
fifth	O	875-880
day	O	881-884
,	O	884-885
the	O	886-889
platform	O	890-898
was	O	899-902
elevated	O	903-911
above	O	912-917
the	O	918-921
water	O	922-927
surface	O	928-935
in	O	936-938
another	O	939-946
position	O	947-955
to	O	956-958
evaluate	O	959-967
the	O	968-971
function	O	972-980
of	O	981-983
motor	O	984-989
,	O	989-990
motivational	O	991-1003
and	O	1004-1007
visual	O	1008-1014
systems	O	1015-1022
.	O	1022-1023

The	O	1024-1027
results	O	1028-1035
showed	O	1036-1042
a	O	1043-1044
significant	O	1045-1056
increase	O	1057-1065
in	O	1066-1068
escape	O	1069-1075
latencies	O	1076-1085
and	O	1086-1089
traveled	O	1090-1098
distances	O	1099-1108
to	O	1109-1111
find	O	1112-1116
platform	O	1117-1125
in	O	1126-1128
scopolamine	O	1129-1140
-	O	1140-1141
treated	O	1141-1148
group	O	1149-1154
as	O	1155-1157
compared	O	1158-1166
to	O	1167-1169
saline	O	1170-1176
group	O	1177-1182
.	O	1182-1183

Ritanserin	O	1184-1194
-	O	1194-1195
treated	O	1195-1202
rats	O	1203-1207
(	O	1208-1209
4	O	1209-1210
microg	O	1211-1217
/	O	1217-1218
0	O	1218-1219
.	O	1219-1220
5	O	1220-1221

microl	O	1222-1228
/	O	1228-1229
side	O	1229-1233
)	O	1233-1234
showed	O	1235-1241
a	O	1242-1243
significant	O	1244-1255
decrease	O	1256-1264
in	O	1265-1267
the	O	1268-1271
mentioned	O	1272-1281
parameters	O	1282-1292
as	O	1293-1295
compared	O	1296-1304
to	O	1305-1307
DMSO	O	1308-1312
-	O	1312-1313
treated	O	1313-1320
group	O	1321-1326
.	O	1326-1327

However	O	1328-1335
,	O	1335-1336
scopolamine	O	1337-1348
and	O	1349-1352
ritanserin	O	1353-1363
co	O	1364-1366
-	O	1366-1367
administration	O	1367-1381
resulted	O	1382-1390
in	O	1391-1393
a	O	1394-1395
significant	O	1396-1407
decrease	O	1408-1416
in	O	1417-1419
escape	O	1420-1426
latencies	O	1427-1436
and	O	1437-1440
traveled	O	1441-1449
distances	O	1450-1459
as	O	1460-1462
compared	O	1463-1471
to	O	1472-1474
the	O	1475-1478
scopolamine	O	1479-1490
-	O	1490-1491
treated	O	1491-1498
rats	O	1499-1503
.	O	1503-1504

Our	O	1505-1508
findings	O	1509-1517
show	O	1518-1522
that	O	1523-1527
microinjection	O	1528-1542
of	O	1543-1545
ritanserin	O	1546-1556
into	O	1557-1561
the	O	1562-1565
CA1	O	1566-1569
region	O	1570-1576
of	O	1577-1579
the	O	1580-1583
hippocampus	O	1584-1595
improves	O	1596-1604
the	O	1605-1608
scopolamine	O	1609-1620
-	O	1620-1621
induced	O	1621-1628
amnesia	B	1629-1636
.	O	1636-1637

Hypoxia	B	0-7
in	O	8-10
renal	B	11-16
disease	I	17-24
with	O	25-29
proteinuria	B	30-41
and	O	42-45
/	O	45-46
or	O	46-48
glomerular	O	49-59
hypertension	B	60-72
.	O	72-73

Despite	O	74-81
the	O	82-85
increasing	O	86-96
need	O	97-101
to	O	102-104
identify	O	105-113
and	O	114-117
quantify	O	118-126
tissue	O	127-133
oxygenation	O	134-145
at	O	146-148
the	O	149-152
cellular	O	153-161
level	O	162-167
,	O	167-168
relatively	O	169-179
few	O	180-183
methods	O	184-191
have	O	192-196
been	O	197-201
available	O	202-211
.	O	211-212

In	O	213-215
this	O	216-220
study	O	221-226
,	O	226-227
we	O	228-230
developed	O	231-240
a	O	241-242
new	O	243-246
hypoxia	B	247-254
-	O	254-255
responsive	O	255-265
reporter	O	266-274
vector	O	275-281
using	O	282-287
a	O	288-289
hypoxia	B	290-297
-	O	297-298
responsive	O	298-308
element	O	309-316
of	O	317-319
the	O	320-323
5	O	324-325
'	O	325-326
vascular	O	327-335
endothelial	O	336-347
growth	O	348-354
factor	O	355-361
untranslated	O	362-374
region	O	375-381
and	O	382-385
generated	O	386-395
a	O	396-397
novel	O	398-403
hypoxia	B	404-411
-	O	411-412
sensing	O	412-419
transgenic	O	420-430
rat	O	431-434
.	O	434-435

We	O	436-438
then	O	439-443
applied	O	444-451
this	O	452-456
animal	O	457-463
model	O	464-469
to	O	470-472
the	O	473-476
detection	O	477-486
of	O	487-489
tubulointerstitial	O	490-508
hypoxia	B	509-516
in	O	517-519
the	O	520-523
diseased	B	524-532
kidney	I	533-539
.	O	539-540

With	O	541-545
this	O	546-550
model	O	551-556
,	O	556-557
we	O	558-560
were	O	561-565
able	O	566-570
to	O	571-573
identify	O	574-582
diffuse	O	583-590
cortical	O	591-599
hypoxia	B	600-607
in	O	608-610
the	O	611-614
puromycin	O	615-624
aminonucleoside	O	625-640
-	O	640-641
induced	O	641-648
nephrotic	B	649-658
syndrome	I	659-667
and	O	668-671
focal	O	672-677
and	O	678-681
segmental	O	682-691
hypoxia	B	692-699
in	O	700-702
the	O	703-706
remnant	O	707-714
kidney	O	715-721
model	O	722-727
.	O	727-728

Expression	O	729-739
of	O	740-742
the	O	743-746
hypoxia	B	747-754
-	O	754-755
responsive	O	755-765
transgene	O	766-775
increased	O	776-785
throughout	O	786-796
the	O	797-800
observation	O	801-812
period	O	813-819
,	O	819-820
reaching	O	821-829
2	O	830-831
.	O	831-832
2	O	830-831
-	O	833-834
fold	O	834-838
at	O	839-841
2	O	842-843
weeks	O	844-849
in	O	850-852
the	O	853-856
puromycin	O	857-866
aminonucleoside	O	867-882
model	O	883-888
and	O	889-892
2	O	893-894
.	O	894-895
6	O	895-896
-	O	896-897
fold	O	897-901
at	O	902-904
4	O	905-906
weeks	O	907-912
in	O	913-915
the	O	916-919
remnant	O	920-927
kidney	O	928-934
model	O	935-940
,	O	940-941
whereas	O	942-949
that	O	950-954
of	O	955-957
vascular	O	958-966
endothelial	O	967-978
growth	O	979-985
factor	O	986-992
showed	O	993-999
a	O	1000-1001
mild	O	1002-1006
decrease	O	1007-1015
,	O	1015-1016
reflecting	O	1017-1027
distinct	O	1028-1036
behaviors	O	1037-1046
of	O	1047-1049
the	O	1050-1053
two	O	1054-1057
genes	O	1058-1063
.	O	1063-1064

The	O	1065-1068
degree	O	1069-1075
of	O	1076-1078
hypoxia	B	1079-1086
showed	O	1087-1093
a	O	1094-1095
positive	O	1096-1104
correlation	O	1105-1116
with	O	1117-1121
microscopic	O	1122-1133
tubulointerstitial	B	1134-1152
injury	I	1153-1159
in	O	1160-1162
both	O	1163-1167
models	O	1168-1174
.	O	1174-1175

Finally	O	1176-1183
,	O	1183-1184
we	O	1185-1187
identified	O	1188-1198
the	O	1199-1202
localization	O	1203-1215
of	O	1216-1218
proliferating	O	1219-1232
cell	O	1233-1237
nuclear	O	1238-1245
antigen	O	1246-1253
-	O	1253-1254
positive	O	1254-1262
,	O	1262-1263
ED	O	1264-1266
-	O	1266-1267
1	O	1267-1268
-	O	1266-1267
positive	O	1269-1277
,	O	1277-1278
and	O	1279-1282
terminal	O	1283-1291
dUTP	O	1292-1296
nick	O	1297-1301
-	O	1301-1302
end	O	1302-1305
labeled	O	1306-1313
-	O	1313-1314
positive	O	1314-1322
cells	O	1323-1328
in	O	1329-1331
the	O	1332-1335
hypoxic	B	1336-1343
cortical	O	1344-1352
area	O	1353-1357
in	O	1358-1360
the	O	1361-1364
remnant	O	1365-1372
kidney	O	1373-1379
model	O	1380-1385
.	O	1385-1386

We	O	1387-1389
propose	O	1390-1397
here	O	1398-1402
a	O	1403-1404
possible	O	1405-1413
pathological	O	1414-1426
tie	O	1427-1430
between	O	1431-1438
chronic	O	1439-1446
tubulointerstitial	O	1447-1465
hypoxia	B	1466-1473
and	O	1474-1477
progressive	O	1478-1489
glomerular	B	1490-1500
diseases	I	1501-1509
.	O	1509-1510

Consensus	O	0-9
statement	O	10-19
concerning	O	20-30
cardiotoxicity	B	31-45
occurring	O	46-55
during	O	56-62
haematopoietic	O	63-77
stem	O	78-82
cell	O	83-87
transplantation	O	88-103
in	O	104-106
the	O	107-110
treatment	O	111-120
of	O	121-123
autoimmune	B	124-134
diseases	I	135-143
,	O	143-144
with	O	145-149
special	O	150-157
reference	O	158-167
to	O	168-170
systemic	B	171-179
sclerosis	I	180-189
and	O	190-193
multiple	B	194-202
sclerosis	I	203-212
.	O	212-213

Autologous	O	214-224
haematopoietic	O	225-239
stem	O	240-244
cell	O	245-249
transplantation	O	250-265
is	O	266-268
now	O	269-272
a	O	273-274
feasible	O	275-283
and	O	284-287
effective	O	288-297
treatment	O	298-307
for	O	308-311
selected	O	312-320
patients	O	321-329
with	O	330-334
severe	O	335-341
autoimmune	B	342-352
diseases	I	353-361
.	O	361-362

Worldwide	O	363-372
,	O	372-373
over	O	374-378
650	O	379-382
patients	O	383-391
have	O	392-396
been	O	397-401
transplanted	O	402-414
in	O	415-417
the	O	418-421
context	O	422-429
of	O	430-432
phase	O	433-438
I	O	439-440
and	O	441-444
II	O	445-447
clinical	O	448-456
trials	O	457-463
.	O	463-464

The	O	465-468
results	O	469-476
are	O	477-480
encouraging	O	481-492
enough	O	493-499
to	O	500-502
begin	O	503-508
randomised	O	509-519
phase	O	520-525
III	O	526-529
trials	O	530-536
.	O	536-537

However	O	538-545
,	O	545-546
as	O	547-549
predicted	O	550-559
,	O	559-560
significant	O	561-572
transplant	O	573-583
-	O	583-584
related	O	584-591
morbidity	O	592-601
and	O	602-605
mortality	O	606-615
have	O	616-620
been	O	621-625
observed	O	626-634
.	O	634-635

This	O	636-640
is	O	641-643
primarily	O	644-653
due	O	654-657
to	O	658-660
complications	O	661-674
related	O	675-682
to	O	683-685
either	O	686-692
the	O	693-696
stage	O	697-702
of	O	703-705
the	O	706-709
disease	O	710-717
at	O	718-720
transplant	O	721-731
or	O	732-734
due	O	735-738
to	O	739-741
infections	B	742-752
.	O	752-753

The	O	754-757
number	O	758-764
of	O	765-767
deaths	O	768-774
related	O	775-782
to	O	783-785
cardiac	B	786-793
toxicity	I	794-802
is	O	803-805
low	O	806-809
.	O	809-810

However	O	811-818
,	O	818-819
caution	O	820-827
is	O	828-830
required	O	831-839
when	O	840-844
cyclophosphamide	O	845-861
or	O	862-864
anthracyclines	O	865-879
such	O	880-884
as	O	885-887
mitoxantrone	O	888-900
are	O	901-904
used	O	905-909
in	O	910-912
patients	O	913-921
with	O	922-926
a	O	927-928
possible	O	929-937
underlying	O	938-948
heart	B	949-954
damage	I	955-961
,	O	961-962
for	O	963-966
example	O	967-974
,	O	974-975
systemic	B	976-984
sclerosis	I	985-994
patients	O	995-1003
.	O	1003-1004

In	O	1005-1007
November	O	1008-1016
2002	O	1017-1021
,	O	1021-1022
a	O	1023-1024
meeting	O	1025-1032
was	O	1033-1036
held	O	1037-1041
in	O	1042-1044
Florence	O	1045-1053
,	O	1053-1054
bringing	O	1055-1063
together	O	1064-1072
a	O	1073-1074
number	O	1075-1081
of	O	1082-1084
experts	O	1085-1092
in	O	1093-1095
various	O	1096-1103
fields	O	1104-1110
,	O	1110-1111
including	O	1112-1121
rheumatology	O	1122-1134
,	O	1134-1135
cardiology	O	1136-1146
,	O	1146-1147
neurology	O	1148-1157
,	O	1157-1158
pharmacology	O	1159-1171
and	O	1172-1175
transplantation	O	1176-1191
medicine	O	1192-1200
.	O	1200-1201

The	O	1202-1205
object	O	1206-1212
of	O	1213-1215
the	O	1216-1219
meeting	O	1220-1227
was	O	1228-1231
to	O	1232-1234
analyse	O	1235-1242
existing	O	1243-1251
data	O	1252-1256
,	O	1256-1257
both	O	1258-1262
published	O	1263-1272
or	O	1273-1275
available	O	1276-1285
,	O	1285-1286
in	O	1287-1289
the	O	1290-1293
European	O	1294-1302
Group	O	1303-1308
for	O	1309-1312
Blood	O	1313-1318
and	O	1319-1322
Marrow	O	1323-1329
Transplantation	O	1330-1345
autoimmune	B	1346-1356
disease	I	1357-1364
database	O	1365-1373
,	O	1373-1374
and	O	1375-1378
to	O	1379-1381
propose	O	1382-1389
a	O	1390-1391
safe	O	1392-1396
approach	O	1397-1405
to	O	1406-1408
such	O	1409-1413
patients	O	1414-1422
.	O	1422-1423

A	O	1424-1425
full	O	1426-1430
cardiological	O	1431-1444
assessment	O	1445-1455
before	O	1456-1462
and	O	1463-1466
during	O	1467-1473
the	O	1474-1477
transplant	O	1478-1488
emerged	O	1489-1496
as	O	1497-1499
the	O	1500-1503
major	O	1504-1509
recommendation	O	1510-1524
.	O	1524-1525

Immunohistochemical	O	0-19
study	O	20-25
on	O	26-28
inducible	O	29-38
type	O	39-43
of	O	44-46
nitric	O	47-53
oxide	O	54-59
(	O	60-61
iNOS	O	61-65
)	O	65-66
,	O	66-67
basic	O	68-73
fibroblast	O	74-84
growth	O	85-91
factor	O	92-98
(	O	99-100
bFGF	O	100-104
)	O	104-105
and	O	106-109
tumor	B	110-115
growth	O	116-122
factor	O	123-129
-	O	129-130
beta1	O	130-135
(	O	136-137
TGF	O	137-140
-	O	140-141
beta1	O	141-146
)	O	146-147
in	O	148-150
arteritis	B	151-160
induced	O	161-168
in	O	169-171
rats	O	172-176
by	O	177-179
fenoldopam	O	180-190
and	O	191-194
theophylline	O	195-207
,	O	207-208
vasodilators	O	209-221
.	O	221-222

Arteritis	B	223-232
induced	O	233-240
in	O	241-243
rats	O	244-248
by	O	249-251
vasodilators	O	252-264
,	O	264-265
fenoldopam	O	266-276
and	O	277-280
theophylline	O	281-293
,	O	293-294
was	O	295-298
examined	O	299-307
immunohistochemically	O	308-329
for	O	330-333
expressions	O	334-345
of	O	346-348
inducible	O	349-358
type	O	359-363
of	O	364-366
nitric	O	367-373
oxide	O	374-379
synthase	O	380-388
(	O	389-390
iNOS	O	390-394
)	O	394-395
,	O	395-396
basic	O	397-402
fibroblast	O	403-413
growth	O	414-420
factor	O	421-427
(	O	428-429
bFGF	O	429-433
)	O	433-434
and	O	435-438
tumor	B	439-444
growth	O	445-451
factor	O	452-458
-	O	458-459
beta1	O	459-464
(	O	465-466
TGF	O	466-469
-	O	469-470
beta1	O	470-475
)	O	475-476
.	O	476-477

Rats	O	478-482
were	O	483-487
administered	O	488-500
fenoldopam	O	501-511
for	O	512-515
24	O	516-518
hours	O	519-524
by	O	525-527
intravenous	O	528-539
infusion	O	540-548
with	O	549-553
or	O	554-556
without	O	557-564
following	O	565-574
repeated	O	575-583
daily	O	584-589
oral	O	590-594
administrations	O	595-610
of	O	611-613
theophylline	O	614-626
.	O	626-627

Irrespective	O	628-640
of	O	641-643
theophylline	O	644-656
administration	O	657-671
,	O	671-672
iNOS	O	673-677
antigens	O	678-686
were	O	687-691
remarkably	O	692-702
abundant	O	703-711
in	O	712-714
ED	O	715-717
-	O	717-718
1	O	718-719
-	O	717-718
positive	O	720-728
cells	O	729-734
on	O	735-737
day	O	738-741
5	O	742-743
and	O	744-747
8	O	748-749
post	O	750-754
-	O	754-755
fenoldopam	O	755-765
-	O	754-755
infusion	O	766-774
(	O	775-776
DPI	O	776-779
)	O	779-780
;	O	780-781
bFGF	O	782-786
antigens	O	787-795
were	O	796-800
remarkably	O	801-811
abundant	O	812-820
in	O	821-823
ED	O	824-826
-	O	826-827
1	O	827-828
-	O	826-827
positive	O	829-837
cells	O	838-843
on	O	844-846
1	O	847-848
and	O	849-852
3	O	853-854
DPI	O	855-858
;	O	858-859
TGF	O	860-863
-	O	863-864
beta1	O	864-869
antigens	O	870-878
were	O	879-883
observed	O	884-892
in	O	893-895
ED	O	896-898
-	O	898-899
1	O	899-900
-	O	898-899
positive	O	901-909
cells	O	910-915
on	O	916-918
and	O	919-922
after	O	923-928
5	O	929-930
DPI	O	931-934
.	O	934-935

These	O	936-941
results	O	942-949
suggest	O	950-957
that	O	958-962
the	O	963-966
peak	O	967-971
expression	O	972-982
of	O	983-985
iNOS	O	986-990
antigen	O	991-998
was	O	999-1002
followed	O	1003-1011
by	O	1012-1014
that	O	1015-1019
of	O	1020-1022
bFGF	O	1023-1027
antigen	O	1028-1035
,	O	1035-1036
and	O	1037-1040
bFGF	O	1041-1045
may	O	1046-1049
have	O	1050-1054
a	O	1055-1056
suppressive	O	1057-1068
effect	O	1069-1075
on	O	1076-1078
iNOS	O	1079-1083
expression	O	1084-1094
in	O	1095-1097
these	O	1098-1103
rat	O	1104-1107
arteritis	B	1108-1117
models	O	1118-1124
.	O	1124-1125

On	O	1126-1128
the	O	1129-1132
other	O	1133-1138
hand	O	1139-1143
,	O	1143-1144
TGF	O	1145-1148
-	O	1148-1149
beta1	O	1149-1154
was	O	1155-1158
not	O	1159-1162
considered	O	1163-1173
to	O	1174-1176
have	O	1177-1181
a	O	1182-1183
suppressive	O	1184-1195
effect	O	1196-1202
on	O	1203-1205
iNOS	O	1206-1210
expression	O	1211-1221
in	O	1222-1224
these	O	1225-1230
models	O	1231-1237
.	O	1237-1238

Low	O	0-3
-	O	3-4
molecular	O	4-13
-	O	3-4
weight	O	14-20
heparin	O	21-28
for	O	29-32
the	O	33-36
treatment	O	37-46
of	O	47-49
patients	O	50-58
with	O	59-63
mechanical	O	64-74
heart	O	75-80
valves	O	81-87
.	O	87-88

BACKGROUND	O	89-99
:	O	99-100
The	O	101-104
interruption	O	105-117
of	O	118-120
oral	O	121-125
anticoagulant	O	126-139
(	O	140-141
OAC	O	141-144
)	O	144-145
administration	O	146-160
is	O	161-163
sometimes	O	164-173
indicated	O	174-183
in	O	184-186
patients	O	187-195
with	O	196-200
mechanical	O	201-211
heart	O	212-217
valves	O	218-224
,	O	224-225
mainly	O	226-232
before	O	233-239
noncardiac	O	240-250
surgery	O	251-258
,	O	258-259
non	O	260-263
-	O	263-264
surgical	O	264-272
interventions	O	273-286
,	O	286-287
and	O	288-291
pregnancy	O	292-301
.	O	301-302

Unfractionated	O	303-317
heparin	O	318-325
(	O	326-327
UH	O	327-329
)	O	329-330
is	O	331-333
currently	O	334-343
the	O	344-347
substitute	O	348-358
for	O	359-362
selected	O	363-371
patients	O	372-380
.	O	380-381

Low	O	382-385
-	O	385-386
molecular	O	386-395
-	O	385-386
weight	O	396-402
heparin	O	403-410
(	O	411-412
LMWH	O	412-416
)	O	416-417
offers	O	418-424
theoretical	O	425-436
advantages	O	437-447
over	O	448-452
UH	O	453-455
,	O	455-456
but	O	457-460
is	O	461-463
not	O	464-467
currently	O	468-477
considered	O	478-488
in	O	489-491
clinical	O	492-500
guidelines	O	501-511
as	O	512-514
an	O	515-517
alternative	O	518-529
to	O	530-532
UH	O	533-535
in	O	536-538
patients	O	539-547
with	O	548-552
prosthetic	O	553-563
valves	O	564-570
.	O	570-571

HYPOTHESIS	O	572-582
:	O	582-583
The	O	584-587
aim	O	588-591
of	O	592-594
the	O	595-598
present	O	599-606
study	O	607-612
was	O	613-616
to	O	617-619
review	O	620-626
the	O	627-630
data	O	631-635
accumulated	O	636-647
so	O	648-650
far	O	651-654
on	O	655-657
the	O	658-661
use	O	662-665
of	O	666-668
LMWH	O	669-673
in	O	674-676
this	O	677-681
patient	O	682-689
population	O	690-700
and	O	701-704
to	O	705-707
discuss	O	708-715
its	O	716-719
applicability	O	720-733
in	O	734-736
common	O	737-743
practice	O	744-752
.	O	752-753

METHODS	O	754-761
:	O	761-762
For	O	763-766
this	O	767-771
paper	O	772-777
,	O	777-778
the	O	779-782
current	O	783-790
medical	O	791-798
literature	O	799-809
on	O	810-812
LMWH	O	813-817
in	O	818-820
patients	O	821-829
with	O	830-834
mechanical	O	835-845
heart	O	846-851
valves	O	852-858
was	O	859-862
extensively	O	863-874
reviewed	O	875-883
.	O	883-884

RESULTS	O	885-892
:	O	892-893
There	O	894-899
were	O	900-904
eight	O	905-910
series	O	911-917
and	O	918-921
six	O	922-925
case	O	926-930
reports	O	931-938
.	O	938-939

None	O	940-944
of	O	945-947
the	O	948-951
studies	O	952-959
was	O	960-963
randomized	O	964-974
,	O	974-975
and	O	976-979
only	O	980-984
one	O	985-988
was	O	989-992
prospective	O	993-1004
.	O	1004-1005

Data	O	1006-1010
to	O	1011-1013
establish	O	1014-1023
the	O	1024-1027
thromboembolic	B	1028-1042
risk	O	1043-1047
were	O	1048-1052
incomplete	O	1053-1063
.	O	1063-1064

After	O	1065-1070
excluding	O	1071-1080
case	O	1081-1085
reports	O	1086-1093
,	O	1093-1094
the	O	1095-1098
following	O	1099-1108
groups	O	1109-1115
were	O	1116-1120
constructed	O	1121-1132
:	O	1132-1133
(	O	1134-1135
a	O	1135-1136
)	O	1136-1137
short	O	1138-1143
-	O	1143-1144
term	O	1144-1148
administration	O	1149-1163
,	O	1163-1164
after	O	1165-1170
valve	O	1171-1176
insertion	O	1177-1186
(	O	1187-1188
n	O	1188-1189
=	O	1190-1191
212	O	1192-1195
)	O	1195-1196
;	O	1196-1197
(	O	1198-1199
b	O	1199-1200
)	O	1200-1201
short	O	1202-1207
-	O	1207-1208
term	O	1208-1212
,	O	1212-1213
perioperative	O	1214-1227
(	O	1228-1229
noncardiac	O	1229-1239
)	O	1239-1240
/	O	1240-1241
periprocedural	O	1241-1255
(	O	1256-1257
n	O	1257-1258
=	O	1259-1260
114	O	1261-1264
)	O	1264-1265
;	O	1265-1266
(	O	1267-1268
c	O	1268-1269
)	O	1269-1270
long	O	1271-1275
-	O	1275-1276
term	O	1276-1280
,	O	1280-1281
due	O	1282-1285
to	O	1286-1288
intolerance	O	1289-1300
to	O	1301-1303
OAC	O	1304-1307
(	O	1308-1309
n	O	1309-1310
=	O	1311-1312
16	O	1313-1315
)	O	1315-1316
;	O	1316-1317
(	O	1318-1319
d	O	1319-1320
)	O	1320-1321
long	O	1322-1326
-	O	1326-1327
term	O	1327-1331
,	O	1331-1332
in	O	1333-1335
pregnancy	O	1336-1345
(	O	1346-1347
n	O	1347-1348
=	O	1349-1350
10	O	1351-1353
)	O	1353-1354
.	O	1354-1355

The	O	1356-1359
incidence	O	1360-1369
rate	O	1370-1374
of	O	1375-1377
thromboembolism	B	1378-1393
was	O	1394-1397
0	O	1398-1399
.	O	1399-1400
9	O	1400-1401
%	O	1401-1402
for	O	1403-1406
all	O	1407-1410
the	O	1411-1414
studies	O	1415-1422
and	O	1423-1426
0	O	1427-1428
.	O	1428-1429
5	O	1429-1430
,	O	1430-1431
0	O	1432-1433
,	O	1433-1434
20	O	1435-1437
,	O	1437-1438
and	O	1439-1442
0	O	1443-1444
%	O	1444-1445
in	O	1446-1448
groups	O	1449-1455
a	O	1456-1457
,	O	1457-1458
b	O	1459-1460
,	O	1460-1461
c	O	1462-1463
,	O	1463-1464
and	O	1465-1468
d	O	1469-1470
,	O	1470-1471
respectively	O	1472-1484
;	O	1484-1485
for	O	1486-1489
hemorrhage	B	1490-1500
,	O	1500-1501
the	O	1502-1505
overall	O	1506-1513
rate	O	1514-1518
was	O	1519-1522
3	O	1523-1524
.	O	1524-1525
4	O	1525-1526
%	O	1526-1527
(	O	1528-1529
3	O	1529-1530
.	O	1530-1531
8	O	1531-1532
,	O	1532-1533
2	O	1534-1535
.	O	1535-1536
6	O	1536-1537
,	O	1537-1538
10	O	1539-1541
,	O	1541-1542
and	O	1543-1546
0	O	1547-1548
%	O	1548-1549
for	O	1550-1553
the	O	1554-1557
respective	O	1558-1568
groups	O	1569-1575
)	O	1575-1576
.	O	1576-1577

CONCLUSIONS	O	1578-1589
:	O	1589-1590
In	O	1591-1593
patients	O	1594-1602
with	O	1603-1607
mechanical	O	1608-1618
heart	O	1619-1624
valves	O	1625-1631
,	O	1631-1632
short	O	1633-1638
-	O	1638-1639
term	O	1639-1643
LMWH	O	1644-1648
therapy	O	1649-1656
compares	O	1657-1665
favorably	O	1666-1675
with	O	1676-1680
UH	O	1681-1683
.	O	1683-1684

Data	O	1685-1689
on	O	1690-1692
mid	O	1693-1696
-	O	1696-1697
and	O	1698-1701
long	O	1702-1706
-	O	1706-1707
term	O	1707-1711
LMWH	O	1712-1716
administration	O	1717-1731
in	O	1732-1734
these	O	1735-1740
patients	O	1741-1749
are	O	1750-1753
sparse	O	1754-1760
.	O	1760-1761

Further	O	1762-1769
randomized	O	1770-1780
studies	O	1781-1788
are	O	1789-1792
needed	O	1793-1799
to	O	1800-1802
confirm	O	1803-1810
the	O	1811-1814
safety	O	1815-1821
and	O	1822-1825
precise	O	1826-1833
indications	O	1834-1845
for	O	1846-1849
the	O	1850-1853
use	O	1854-1857
of	O	1858-1860
LMWH	O	1861-1865
in	O	1866-1868
patients	O	1869-1877
with	O	1878-1882
mechanical	O	1883-1893
heart	O	1894-1899
valves	O	1900-1906
.	O	1906-1907

Topiramate	O	0-10
-	O	10-11
induced	O	11-18
nephrolithiasis	B	19-34
.	O	34-35

Topiramate	O	36-46
is	O	47-49
a	O	50-51
recently	O	52-60
developed	O	61-70
antiepileptic	O	71-84
medication	O	85-95
that	O	96-100
is	O	101-103
becoming	O	104-112
more	O	113-117
widely	O	118-124
prescribed	O	125-135
because	O	136-143
of	O	144-146
its	O	147-150
efficacy	O	151-159
in	O	160-162
treating	O	163-171
refractory	B	172-182
seizures	I	183-191
.	O	191-192

Urologists	O	193-203
should	O	204-210
be	O	211-213
aware	O	214-219
that	O	220-224
this	O	225-229
medication	O	230-240
can	O	241-244
cause	O	245-250
metabolic	B	251-260
acidosis	I	261-269
in	O	270-272
patients	O	273-281
secondary	O	282-291
to	O	292-294
inhibition	O	295-305
of	O	306-308
carbonic	O	309-317
anhydrase	O	318-327
.	O	327-328

In	O	329-331
addition	O	332-340
,	O	340-341
a	O	342-343
distal	O	344-350
tubular	O	351-358
acidification	O	359-372
defect	O	373-379
may	O	380-383
result	O	384-390
,	O	390-391
thus	O	392-396
impairing	O	397-406
the	O	407-410
normal	O	411-417
compensatory	O	418-430
drop	O	431-435
in	O	436-438
urine	O	439-444
pH	O	445-447
.	O	447-448

These	O	449-454
factors	O	455-462
can	O	463-466
lead	O	467-471
to	O	472-474
the	O	475-478
development	O	479-490
of	O	491-493
calcium	O	494-501
phosphate	O	502-511
nephrolithiasis	B	512-527
.	O	527-528

We	O	529-531
report	O	532-538
the	O	539-542
first	O	543-548
two	O	549-552
cases	O	553-558
of	O	559-561
topiramate	O	562-572
-	O	572-573
induced	O	573-580
nephrolithiasis	B	581-596
in	O	597-599
the	O	600-603
urologic	O	604-612
literature	O	613-623
.	O	623-624

Spironolactone	O	0-14
:	O	14-15
is	O	16-18
it	O	19-21
a	O	22-23
novel	O	24-29
drug	O	30-34
for	O	35-38
the	O	39-42
prevention	O	43-53
of	O	54-56
amphotericin	O	57-69
B	O	70-71
-	O	71-72
related	O	72-79
hypokalemia	B	80-91
in	O	92-94
cancer	B	95-101
patients	O	102-110
?	O	110-111

OBJECTIVE	O	112-121
:	O	121-122
Nephrotoxicity	B	123-137
is	O	138-140
the	O	141-144
major	O	145-150
adverse	O	151-158
effect	O	159-165
of	O	166-168
amphotericin	O	169-181
B	O	182-183
(	O	184-185
AmB	O	185-188
)	O	188-189
,	O	189-190
often	O	191-196
limiting	O	197-205
administration	O	206-220
of	O	221-223
full	O	224-228
dosage	O	229-235
.	O	235-236

Selective	O	237-246
distal	O	247-253
tubular	O	254-261
epithelial	O	262-272
toxicity	B	273-281
seems	O	282-287
to	O	288-290
be	O	291-293
responsible	O	294-305
for	O	306-309
the	O	310-313
profound	O	314-322
potassium	O	323-332
wasting	O	333-340
that	O	341-345
is	O	346-348
a	O	349-350
major	O	351-356
clinical	O	357-365
side	O	366-370
effect	O	371-377
of	O	378-380
treatment	O	381-390
with	O	391-395
AmB	O	396-399
.	O	399-400

Potassium	O	401-410
depletion	O	411-420
also	O	421-425
potentiates	O	426-437
the	O	438-441
tubular	O	442-449
toxicity	B	450-458
of	O	459-461
AmB	O	462-465
.	O	465-466

This	O	467-471
study	O	472-477
was	O	478-481
designed	O	482-490
to	O	491-493
assess	O	494-500
the	O	501-504
ability	O	505-512
of	O	513-515
spironolactone	O	516-530
to	O	531-533
reduce	O	534-540
potassium	O	541-550
requirements	O	551-563
and	O	564-567
to	O	568-570
prevent	O	571-578
hypokalemia	B	579-590
in	O	591-593
neutropenic	B	594-605
patients	O	606-614
on	O	615-617
AmB	O	618-621
treatment	O	622-631
.	O	631-632

METHODS	O	633-640
:	O	640-641
In	O	642-644
this	O	645-649
study	O	650-655
26	O	656-658
patients	O	659-667
with	O	668-672
various	O	673-680
hematological	B	681-694
disorders	I	695-704
were	O	705-709
randomized	O	710-720
to	O	721-723
receive	O	724-731
either	O	732-738
intravenous	O	739-750
AmB	O	751-754
alone	O	755-760
or	O	761-763
AmB	O	764-767
and	O	768-771
oral	O	772-776
spironolactone	O	777-791
100	O	792-795
mg	O	796-798
twice	O	799-804
daily	O	805-810
when	O	811-815
developing	O	816-826
a	O	827-828
proven	O	829-835
or	O	836-838
suspected	O	839-848
fungal	B	849-855
infection	I	856-865
.	O	865-866

RESULTS	O	867-874
:	O	874-875
Patients	O	876-884
receiving	O	885-894
concomitant	O	895-906
AmB	O	907-910
and	O	911-914
spironolactone	O	915-929
had	O	930-933
significantly	O	934-947
higher	O	948-954
plasma	O	955-961
potassium	O	962-971
levels	O	972-978
than	O	979-983
those	O	984-989
receiving	O	990-999
AmB	O	1000-1003
alone	O	1004-1009
(	O	1010-1011
P	O	1011-1012
=	O	1013-1014
0	O	1015-1016
.	O	1016-1017
0027	O	1017-1021
)	O	1021-1022
.	O	1016-1017

Those	O	1024-1029
patients	O	1030-1038
receiving	O	1039-1048
AmB	O	1049-1052
and	O	1053-1056
spironolactone	O	1057-1071
required	O	1072-1080
significantly	O	1081-1094
less	O	1095-1099
potassium	O	1100-1109
supplementation	O	1110-1125
to	O	1126-1128
maintain	O	1129-1137
their	O	1138-1143
plasma	O	1144-1150
potassium	O	1151-1160
within	O	1161-1167
the	O	1168-1171
normal	O	1172-1178
range	O	1179-1184
(	O	1185-1186
P	O	1186-1187
=	O	1188-1189
0	O	1190-1191
.	O	1191-1192
022	O	1192-1195
)	O	1195-1196
.	O	1191-1192

Moreover	O	1198-1206
,	O	1206-1207
urinary	O	1208-1215
potassium	O	1216-1225
losses	O	1226-1232
were	O	1233-1237
significantly	O	1238-1251
less	O	1252-1256
in	O	1257-1259
patients	O	1260-1268
receiving	O	1269-1278
AmB	O	1279-1282
and	O	1283-1286
spironolactone	O	1287-1301
than	O	1302-1306
those	O	1307-1312
receiving	O	1313-1322
AmB	O	1323-1326
alone	O	1327-1332
(	O	1333-1334
P	O	1334-1335
=	O	1336-1337
0	O	1338-1339
.	O	1339-1340
040	O	1340-1343
)	O	1343-1344
.	O	1339-1340

CONCLUSION	O	1346-1356
:	O	1356-1357
This	O	1358-1362
study	O	1363-1368
showed	O	1369-1375
that	O	1376-1380
spironolactone	O	1381-1395
can	O	1396-1399
reduce	O	1400-1406
potassium	O	1407-1416
requirements	O	1417-1429
and	O	1430-1433
prevent	O	1434-1441
hypokalemia	B	1442-1453
by	O	1454-1456
reducing	O	1457-1465
urinary	O	1466-1473
potassium	O	1474-1483
loss	O	1484-1488
in	O	1489-1491
neutropenic	B	1492-1503
patients	O	1504-1512
on	O	1513-1515
AmB	O	1516-1519
treatment	O	1520-1529
.	O	1529-1530

Dopamine	O	0-8
D2	O	9-11
receptor	O	12-20
signaling	O	21-30
controls	O	31-39
neuronal	O	40-48
cell	O	49-53
death	O	54-59
induced	O	60-67
by	O	68-70
muscarinic	O	71-81
and	O	82-85
glutamatergic	O	86-99
drugs	O	100-105
.	O	105-106

Dopamine	O	107-115
(	O	116-117
DA	O	117-119
)	O	119-120
,	O	120-121
through	O	122-129
D1	O	130-132
/	O	132-133
D2	O	133-135
receptor	O	136-144
-	O	144-145
mediated	O	145-153
signaling	O	154-163
,	O	163-164
plays	O	165-170
a	O	171-172
major	O	173-178
role	O	179-183
in	O	184-186
the	O	187-190
control	O	191-198
of	O	199-201
epileptic	B	202-211
seizures	I	212-220
arising	O	221-228
in	O	229-231
the	O	232-235
limbic	O	236-242
system	O	243-249
.	O	249-250

Excitotoxicity	B	251-265
leading	O	266-273
to	O	274-276
neuronal	O	277-285
cell	O	286-290
death	O	291-296
in	O	297-299
the	O	300-303
affected	O	304-312
areas	O	313-318
is	O	319-321
a	O	322-323
major	O	324-329
consequence	O	330-341
of	O	342-344
seizures	B	345-353
at	O	354-356
the	O	357-360
cellular	O	361-369
level	O	370-375
.	O	375-376

In	O	377-379
this	O	380-384
respect	O	385-392
,	O	392-393
little	O	394-400
is	O	401-403
known	O	404-409
about	O	410-415
the	O	416-419
role	O	420-424
of	O	425-427
DA	O	428-430
receptors	O	431-440
in	O	441-443
the	O	444-447
occurrence	O	448-458
of	O	459-461
epilepsy	B	462-470
-	O	470-471
induced	O	471-478
neuronal	O	479-487
cell	O	488-492
death	O	493-498
.	O	498-499

Here	O	500-504
we	O	505-507
analyze	O	508-515
the	O	516-519
occurrence	O	520-530
of	O	531-533
seizures	B	534-542
and	O	543-546
neurotoxicity	B	547-560
in	O	561-563
D2R	O	564-567
-	O	568-569
/	O	569-570
-	O	568-569
mice	O	572-576
treated	O	577-584
with	O	585-589
the	O	590-593
cholinergic	O	594-605
agonist	O	606-613
pilocarpine	O	614-625
.	O	625-626

We	O	627-629
compared	O	630-638
these	O	639-644
results	O	645-652
with	O	653-657
those	O	658-663
previously	O	664-674
obtained	O	675-683
with	O	684-688
kainic	O	689-695
acid	O	696-700
(	O	701-702
KA	O	702-704
)	O	704-705
,	O	705-706
a	O	707-708
potent	O	709-715
glutamate	O	716-725
agonist	O	726-733
.	O	733-734

Importantly	O	735-746
,	O	746-747
D2R	O	748-751
-	O	752-753
/	O	753-754
-	O	752-753
mice	O	756-760
develop	O	761-768
seizures	B	769-777
at	O	778-780
doses	O	781-786
of	O	787-789
both	O	790-794
drugs	O	795-800
that	O	801-805
are	O	806-809
not	O	810-813
epileptogenic	O	814-827
for	O	828-831
WT	O	832-834
littermates	O	835-846
and	O	847-850
show	O	851-855
greater	O	856-863
neurotoxicity	B	864-877
.	O	877-878

However	O	879-886
,	O	886-887
pilocarpine	O	888-899
-	O	899-900
induced	O	900-907
seizures	B	908-916
result	O	917-923
in	O	924-926
a	O	927-928
more	O	929-933
widespread	O	934-944
neuronal	O	945-953
death	O	954-959
in	O	960-962
both	O	963-967
WT	O	968-970
and	O	971-974
D2R	O	975-978
-	O	979-980
/	O	980-981
-	O	979-980
brains	O	983-989
in	O	990-992
comparison	O	993-1003
to	O	1004-1006
KA	O	1007-1009
.	O	1009-1010

Thus	O	1011-1015
,	O	1015-1016
the	O	1017-1020
absence	O	1021-1028
of	O	1029-1031
D2R	O	1032-1035
lowers	O	1036-1042
the	O	1043-1046
threshold	O	1047-1056
for	O	1057-1060
seizures	B	1061-1069
induced	O	1070-1077
by	O	1078-1080
both	O	1081-1085
glutamate	O	1086-1095
and	O	1096-1099
acetylcholine	O	1100-1113
.	O	1113-1114

Moreover	O	1115-1123
,	O	1123-1124
the	O	1125-1128
dopaminergic	O	1129-1141
control	O	1142-1149
of	O	1150-1152
epilepsy	B	1153-1161
-	O	1161-1162
induced	O	1162-1169
neurodegeneration	B	1170-1187
seems	O	1188-1193
to	O	1194-1196
be	O	1197-1199
mediated	O	1200-1208
by	O	1209-1211
distinct	O	1212-1220
interactions	O	1221-1233
of	O	1234-1236
D2R	O	1237-1240
signaling	O	1241-1250
with	O	1251-1255
these	O	1256-1261
two	O	1262-1265
neurotransmitters	O	1266-1283
.	O	1283-1284

Treatment	O	0-9
of	O	10-12
risperidone	O	13-24
-	O	24-25
induced	O	25-32
hyperprolactinemia	B	33-51
with	O	52-56
a	O	57-58
dopamine	O	59-67
agonist	O	68-75
in	O	76-78
children	O	79-87
.	O	87-88

BACKGROUND	O	89-99
:	O	99-100
Risperidone	O	101-112
,	O	112-113
a	O	114-115
potent	O	116-122
antagonist	O	123-133
of	O	134-136
both	O	137-141
serotonergic	O	142-154
(	O	155-156
5HT2A	O	156-161
)	O	161-162
and	O	163-166
dopaminergic	O	167-179
D2	O	180-182
receptors	O	183-192
is	O	193-195
associated	O	196-206
with	O	207-211
hyperprolactinemia	B	212-230
in	O	231-233
adults	O	234-240
and	O	241-244
children	O	245-253
.	O	253-254

Chronically	O	255-266
elevated	O	267-275
prolactin	O	276-285
levels	O	286-292
in	O	293-295
children	O	296-304
with	O	305-309
prolactinomas	B	310-323
may	O	324-327
be	O	328-330
associated	O	331-341
with	O	342-346
arrested	O	347-355
growth	O	356-362
and	O	363-366
development	O	367-378
resulting	O	379-388
in	O	389-391
either	O	392-398
delayed	B	399-406
puberty	I	407-414
or	O	415-417
short	O	418-423
stature	O	424-431
.	O	431-432

These	O	433-438
possibilities	O	439-452
stress	O	453-459
the	O	460-463
importance	O	464-474
of	O	475-477
developing	O	478-488
a	O	489-490
safe	O	491-495
and	O	496-499
effective	O	500-509
approach	O	510-518
to	O	519-521
drug	O	522-526
-	O	526-527
induced	O	527-534
hyperprolactinemia	B	535-553
in	O	554-556
youth	O	557-562
.	O	562-563

We	O	564-566
report	O	567-573
the	O	574-577
successful	O	578-588
treatment	O	589-598
of	O	599-601
risperidone	O	602-613
-	O	613-614
induced	O	614-621
hyperprolactinemia	B	622-640
with	O	641-645
cabergoline	O	646-657
in	O	658-660
youth	O	661-666
.	O	666-667

METHODS	O	668-675
:	O	675-676
We	O	677-679
undertook	O	680-689
a	O	690-691
retrospective	O	692-705
case	O	706-710
review	O	711-717
of	O	718-720
four	O	721-725
children	O	726-734
with	O	735-739
risperidone	O	740-751
-	O	751-752
induced	O	752-759
hyperprolactinemia	B	760-778
treated	O	779-786
with	O	787-791
cabergoline	O	792-803
.	O	803-804

RESULTS	O	805-812
:	O	812-813
Four	O	814-818
males	O	819-824
(	O	825-826
age	O	826-829
6	O	830-831
-	O	831-832
11	O	832-834
years	O	835-840
)	O	840-841
with	O	842-846
Diagnostic	O	847-857
and	O	858-861
Statistical	O	862-873
Manual	O	874-880
of	O	881-883
Mental	B	884-890
Disorders	I	891-900
(	O	901-902
fourth	O	902-908
edition	O	909-916
)	O	916-917
bipolar	B	918-925
disorder	I	926-934
or	O	935-937
psychoses	B	938-947
,	O	947-948
with	O	949-953
risperidone	O	954-965
-	O	965-966
induced	O	966-973
elevations	O	974-984
in	O	985-987
serum	O	988-993
prolactin	O	994-1003
levels	O	1004-1010
(	O	1011-1012
57	O	1012-1014
.	O	1014-1015
5	O	1012-1013
-	O	1016-1017
129	O	1017-1020
ng	O	1021-1023
/	O	1023-1024
mL	O	1024-1026
,	O	1026-1027
normal	O	1028-1034
5	O	1035-1036
-	O	1036-1037
15	O	1037-1039
ng	O	1040-1042
/	O	1042-1043
mL	O	1043-1045
)	O	1045-1046
,	O	1046-1047
were	O	1048-1052
treated	O	1053-1060
with	O	1061-1065
cabergoline	O	1066-1077
(	O	1078-1079
mean	O	1079-1083
dose	O	1084-1088
2	O	1089-1090
.	O	1090-1091
13	O	1091-1093
+	O	1094-1095
/	O	1095-1096
-	O	1096-1097
0	O	1098-1099
.	O	1099-1100
09	O	1100-1102
mg	O	1103-1105
/	O	1105-1106
week	O	1106-1110
)	O	1110-1111
.	O	1111-1112

When	O	1113-1117
serum	O	1118-1123
prolactin	O	1124-1133
levels	O	1134-1140
normalized	O	1141-1151
in	O	1152-1154
all	O	1155-1158
four	O	1159-1163
subjects	O	1164-1172
(	O	1173-1174
mean	O	1174-1178
11	O	1179-1181
.	O	1181-1182
2	O	1182-1183
+	O	1184-1185
/	O	1185-1186
-	O	1186-1187
10	O	1188-1190
.	O	1190-1191
9	O	1191-1192
ng	O	1193-1195
/	O	1195-1196
mL	O	1196-1198
)	O	1198-1199
,	O	1199-1200
the	O	1201-1204
cabergoline	O	1205-1216
dose	O	1217-1221
was	O	1222-1225
reduced	O	1226-1233
to	O	1234-1236
1	O	1237-1238
mg	O	1239-1241
/	O	1241-1242
week	O	1242-1246
in	O	1247-1249
three	O	1250-1255
of	O	1256-1258
four	O	1259-1263
subjects	O	1264-1272
.	O	1272-1273

The	O	1274-1277
mean	O	1278-1282
duration	O	1283-1291
of	O	1292-1294
therapy	O	1295-1302
with	O	1303-1307
cabergoline	O	1308-1319
was	O	1320-1323
523	O	1324-1327
.	O	1327-1328
5	O	1324-1325
+	O	1330-1331
/	O	1331-1332
-	O	1332-1333
129	O	1334-1337
.	O	1337-1338
7	O	1338-1339
days	O	1340-1344
,	O	1344-1345
and	O	1346-1349
the	O	1350-1353
mean	O	1354-1358
duration	O	1359-1367
of	O	1368-1370
therapy	O	1371-1378
with	O	1379-1383
risperidone	O	1384-1395
was	O	1396-1399
788	O	1400-1403
.	O	1403-1404
5	O	1404-1405
+	O	1406-1407
/	O	1407-1408
-	O	1408-1409
162	O	1410-1413
.	O	1413-1414
5	O	1414-1415
days	O	1416-1420
.	O	1420-1421

Cabergoline	O	1422-1433
was	O	1434-1437
well	O	1438-1442
tolerated	O	1443-1452
without	O	1453-1460
adverse	O	1461-1468
effects	O	1469-1476
.	O	1476-1477

CONCLUSIONS	O	1478-1489
:	O	1489-1490
Cabergoline	O	1491-1502
may	O	1503-1506
be	O	1507-1509
useful	O	1510-1516
for	O	1517-1520
the	O	1521-1524
treatment	O	1525-1534
of	O	1535-1537
risperidone	O	1538-1549
-	O	1549-1550
induced	O	1550-1557
hyperprolactinemia	B	1558-1576
in	O	1577-1579
youth	O	1580-1585
;	O	1585-1586
however	O	1587-1594
,	O	1594-1595
further	O	1596-1603
research	O	1604-1612
is	O	1613-1615
needed	O	1616-1622
.	O	1622-1623

Cholestatic	B	0-11
jaundice	I	12-20
associated	O	21-31
with	O	32-36
the	O	37-40
use	O	41-44
of	O	45-47
metformin	O	48-57
.	O	57-58

We	O	59-61
report	O	62-68
a	O	69-70
patient	O	71-78
who	O	79-82
developed	O	83-92
cholestatic	B	93-104
jaundice	I	105-113
shortly	O	114-121
after	O	122-127
initiation	O	128-138
of	O	139-141
treatment	O	142-151
with	O	152-156
metformin	O	157-166
hydrochloride	O	167-180
.	O	180-181

Ultrasound	O	182-192
of	O	193-195
the	O	196-199
liver	O	200-205
and	O	206-209
abdominal	O	210-219
CT	O	220-222
were	O	223-227
normal	O	228-234
.	O	234-235

An	O	236-238
ERCP	O	239-243
showed	O	244-250
normal	O	251-257
biliary	O	258-265
anatomy	O	266-273
.	O	273-274

A	O	275-276
percutaneous	O	277-289
liver	O	290-295
biopsy	O	296-302
was	O	303-306
obtained	O	307-315
showing	O	316-323
marked	O	324-330
cholestasis	B	331-342
,	O	342-343
with	O	344-348
portal	O	349-355
edema	B	356-361
,	O	361-362
ductular	O	363-371
proliferation	O	372-385
,	O	385-386
and	O	387-390
acute	O	391-396
inflammation	B	397-409
.	O	409-410

Metformin	O	411-420
hydrochloride	O	421-434
was	O	435-438
discontinued	O	439-451
,	O	451-452
and	O	453-456
the	O	457-460
patient	O	461-468
'	O	468-469
s	O	469-470
jaundice	B	471-479
resolved	O	480-488
slowly	O	489-495
over	O	496-500
a	O	501-502
period	O	503-509
of	O	510-512
several	O	513-520
months	O	521-527
.	O	527-528

Given	O	529-534
the	O	535-538
onset	O	539-544
of	O	545-547
his	O	548-551
jaundice	B	552-560
2	O	561-562
wk	O	563-565
after	O	566-571
the	O	572-575
initiation	O	576-586
of	O	587-589
metformin	O	590-599
,	O	599-600
we	O	601-603
believe	O	604-611
that	O	612-616
this	O	617-621
case	O	622-626
represents	O	627-637
an	O	638-640
example	O	641-648
of	O	649-651
metformin	O	652-661
-	O	661-662
associated	O	662-672
hepatotoxicity	B	673-687
,	O	687-688
the	O	689-692
first	O	693-698
such	O	699-703
case	O	704-708
reported	O	709-717
.	O	717-718

Electro	O	0-7
-	O	7-8
oculography	O	8-19
,	O	19-20
electroretinography	O	21-40
,	O	40-41
visual	O	42-48
evoked	O	49-55
potentials	O	56-66
,	O	66-67
and	O	68-71
multifocal	O	72-82
electroretinography	O	83-102
in	O	103-105
patients	O	106-114
with	O	115-119
vigabatrin	O	120-130
-	O	130-131
attributed	O	131-141
visual	B	142-148
field	I	149-154
constriction	I	155-167
.	O	167-168

PURPOSE	O	169-176
:	O	176-177
Symptomatic	O	178-189
visual	B	190-196
field	I	197-202
constriction	I	203-215
thought	O	216-223
to	O	224-226
be	O	227-229
associated	O	230-240
with	O	241-245
vigabatrin	O	246-256
has	O	257-260
been	O	261-265
reported	O	266-274
.	O	274-275

The	O	276-279
current	O	280-287
study	O	288-293
investigated	O	294-306
the	O	307-310
visual	O	311-317
fields	O	318-324
and	O	325-328
visual	O	329-335
electrophysiology	O	336-353
of	O	354-356
eight	O	357-362
patients	O	363-371
with	O	372-376
known	O	377-382
vigabatrin	O	383-393
-	O	393-394
attributed	O	394-404
visual	B	405-411
field	I	412-417
loss	I	418-422
,	O	422-423
three	O	424-429
of	O	430-432
whom	O	433-437
were	O	438-442
reported	O	443-451
previously	O	452-462
.	O	462-463

Six	O	464-467
of	O	468-470
the	O	471-474
patients	O	475-483
were	O	484-488
no	O	489-491
longer	O	492-498
receiving	O	499-508
vigabatrin	O	509-519
.	O	519-520

METHODS	O	521-528
:	O	528-529
The	O	530-533
central	O	534-541
and	O	542-545
peripheral	O	546-556
fields	O	557-563
were	O	564-568
examined	O	569-577
with	O	578-582
the	O	583-586
Humphrey	O	587-595
Visual	O	596-602
Field	O	603-608
Analyzer	O	609-617
.	O	617-618

Full	O	619-623
visual	O	624-630
electrophysiology	O	631-648
,	O	648-649
including	O	650-659
flash	O	660-665
electroretinography	O	666-685
(	O	686-687
ERG	O	687-690
)	O	690-691
,	O	691-692
pattern	O	693-700
electroretinography	O	701-720
,	O	720-721
multifocal	O	722-732
ERG	O	733-736
using	O	737-742
the	O	743-746
VERIS	O	747-752
system	O	753-759
,	O	759-760
electro	O	761-768
-	O	768-769
oculography	O	769-780
,	O	780-781
and	O	782-785
flash	O	786-791
and	O	792-795
pattern	O	796-803
visual	O	804-810
evoked	O	811-817
potentials	O	818-828
,	O	828-829
was	O	830-833
undertaken	O	834-844
.	O	844-845

RESULTS	O	846-853
:	O	853-854
Seven	O	855-860
patients	O	861-869
showed	O	870-876
marked	O	877-883
visual	B	884-890
field	I	891-896
constriction	I	897-909
with	O	910-914
some	O	915-919
sparing	O	920-927
of	O	928-930
the	O	931-934
temporal	O	935-943
visual	O	944-950
field	O	951-956
.	O	956-957

The	O	958-961
eighth	O	962-968
exhibited	O	969-978
concentric	O	979-989
constriction	O	990-1002
.	O	1002-1003

Most	O	1004-1008
electrophysiological	O	1009-1029
responses	O	1030-1039
were	O	1040-1044
usually	O	1045-1052
just	O	1053-1057
within	O	1058-1064
normal	O	1065-1071
limits	O	1072-1078
;	O	1078-1079
two	O	1080-1083
patients	O	1084-1092
had	O	1093-1096
subnormal	O	1097-1106
Arden	O	1107-1112
electro	O	1113-1120
-	O	1120-1121
oculography	O	1121-1132
indices	O	1133-1140
;	O	1140-1141
and	O	1142-1145
one	O	1146-1149
patient	O	1150-1157
showed	O	1158-1164
an	O	1165-1167
abnormally	O	1168-1178
delayed	O	1179-1186
photopic	O	1187-1195
b	O	1196-1197
wave	O	1198-1202
.	O	1202-1203

However	O	1204-1211
,	O	1211-1212
five	O	1213-1217
patients	O	1218-1226
showed	O	1227-1233
delayed	O	1234-1241
30	O	1242-1244
-	O	1244-1245
Hz	O	1245-1247
flicker	O	1248-1255
b	O	1256-1257
waves	O	1258-1263
,	O	1263-1264
and	O	1265-1268
seven	O	1269-1274
patients	O	1275-1283
showed	O	1284-1290
delayed	O	1291-1298
oscillatory	O	1299-1310
potentials	O	1311-1321
.	O	1321-1322

Multifocal	O	1323-1333
ERG	O	1334-1337
showed	O	1338-1344
abnormalities	O	1345-1358
that	O	1359-1363
sometimes	O	1364-1373
correlated	O	1374-1384
with	O	1385-1389
the	O	1390-1393
visual	O	1394-1400
field	O	1401-1406
appearance	O	1407-1417
and	O	1418-1421
confirmed	O	1422-1431
that	O	1432-1436
the	O	1437-1440
deficit	O	1441-1448
occurs	O	1449-1455
at	O	1456-1458
the	O	1459-1462
retinal	O	1463-1470
level	O	1471-1476
.	O	1476-1477

CONCLUSION	O	1478-1488
:	O	1488-1489
Marked	O	1490-1496
visual	B	1497-1503
field	I	1504-1509
constriction	I	1510-1522
appears	O	1523-1530
to	O	1531-1533
be	O	1534-1536
associated	O	1537-1547
with	O	1548-1552
vigabatrin	O	1553-1563
therapy	O	1564-1571
.	O	1571-1572

The	O	1573-1576
field	O	1577-1582
defects	O	1583-1590
and	O	1591-1594
some	O	1595-1599
electrophysiological	O	1600-1620
abnormalities	O	1621-1634
persist	O	1635-1642
when	O	1643-1647
vigabatrin	O	1648-1658
therapy	O	1659-1666
is	O	1667-1669
withdrawn	O	1670-1679
.	O	1679-1680

Conversion	O	0-10
to	O	11-13
rapamycin	O	14-23
immunosuppression	O	24-41
in	O	42-44
renal	O	45-50
transplant	O	51-61
recipients	O	62-72
:	O	72-73
report	O	74-80
of	O	81-83
an	O	84-86
initial	O	87-94
experience	O	95-105
.	O	105-106

BACKGROUND	O	107-117
:	O	117-118
The	O	119-122
aim	O	123-126
of	O	127-129
this	O	130-134
study	O	135-140
is	O	141-143
to	O	144-146
evaluate	O	147-155
the	O	156-159
effects	O	160-167
of	O	168-170
RAPA	O	171-175
conversion	O	176-186
in	O	187-189
patients	O	190-198
undergoing	O	199-209
cyclosporine	O	210-222
(	O	223-224
CsA	O	224-227
)	O	227-228
or	O	229-231
tacrolimus	O	232-242
(	O	243-244
Tac	O	244-247
)	O	247-248
toxicity	B	249-257
.	O	257-258

METHODS	O	259-266
:	O	266-267
Twenty	O	268-274
renal	O	275-280
transplant	O	281-291
recipients	O	292-302
were	O	303-307
switched	O	308-316
to	O	317-319
fixed	O	320-325
dose	O	326-330
rapamycin	O	331-340
(	O	341-342
RAPA	O	342-346
)	O	346-347
(	O	348-349
5	O	349-350
mg	O	351-353
/	O	353-354
day	O	354-357
)	O	357-358
0	O	359-360
to	O	361-363
204	O	364-367
months	O	368-374
posttransplant	O	375-389
.	O	389-390

Drug	O	391-395
monitoring	O	396-406
was	O	407-410
not	O	411-414
initially	O	415-424
used	O	425-429
to	O	430-432
adjust	O	433-439
doses	O	440-445
.	O	445-446

The	O	447-450
indications	O	451-462
for	O	463-466
switch	O	467-473
were	O	474-478
chronic	O	479-486
CsA	O	487-490
or	O	491-493
Tac	O	494-497
nephrotoxicity	B	498-512
(	O	513-514
12	O	514-516
)	O	516-517
,	O	517-518
acute	O	519-524
CsA	O	525-528
or	O	529-531
Tac	O	532-535
toxicity	B	536-544
(	O	545-546
3	O	546-547
)	O	547-548
,	O	548-549
severe	O	550-556
facial	B	557-563
dysmorphism	I	564-575
(	O	576-577
2	O	577-578
)	O	578-579
,	O	579-580
posttransplant	B	581-595
lymphoproliferative	I	596-615
disorder	I	616-624
(	O	625-626
PTLD	B	626-630
)	O	630-631
in	O	632-634
remission	O	635-644
(	O	645-646
2	O	646-647
)	O	647-648
,	O	648-649
and	O	650-653
hepatotoxicity	B	654-668
in	O	669-671
1	O	672-673
.	O	673-674
Follow	O	675-681
-	O	681-682
up	O	682-684
is	O	685-687
7	O	688-689
to	O	690-692
24	O	693-695
months	O	696-702
.	O	702-703

RESULTS	O	704-711
:	O	711-712
In	O	713-715
the	O	716-719
12	O	720-722
patients	O	723-731
switched	O	732-740
because	O	741-748
of	O	749-751
chronic	O	752-759
nephrotoxicity	B	760-774
there	O	775-780
was	O	781-784
a	O	785-786
significant	O	787-798
decrease	O	799-807
in	O	808-810
serum	O	811-816
creatinine	O	817-827
[	O	828-829
233	O	829-832
+	O	832-833
/	O	833-834
-	O	834-835
34	O	835-837
to	O	838-840
210	O	841-844
+	O	844-845
/	O	845-846
-	O	846-847
56	O	847-849
micromol	O	850-858
/	O	858-859
liter	O	859-864
(	O	865-866
P	O	866-867
<	O	867-868
0	O	868-869
.	O	869-870
05	O	870-872
)	O	872-873
at	O	874-876
6	O	877-878
months	O	879-885
]	O	885-886
.	O	886-887

Facial	B	888-894
dysmorphism	I	895-906
improved	O	907-915
in	O	916-918
two	O	919-922
patients	O	923-931
.	O	931-932

No	O	933-935
relapse	O	936-943
of	O	944-946
PTLD	B	947-951
was	O	952-955
observed	O	956-964
.	O	964-965

Five	O	966-970
patients	O	971-979
developed	O	980-989
pneumonia	B	990-999
(	O	1000-1001
two	O	1001-1004
Pneumocystis	B	1005-1017
carinii	I	1018-1025
pneumonia	I	1026-1035
,	O	1035-1036
one	O	1037-1040
infectious	B	1041-1051
mononucleosis	I	1052-1065
with	O	1066-1070
polyclonal	O	1071-1081
PTLD	B	1082-1086
lung	O	1087-1091
infiltrate	O	1092-1102
)	O	1102-1103
and	O	1104-1107
two	O	1108-1111
had	O	1112-1115
bronchiolitis	B	1116-1129
obliterans	I	1130-1140
.	O	1140-1141

There	O	1142-1147
were	O	1148-1152
no	O	1153-1155
deaths	O	1156-1162
.	O	1162-1163

RAPA	O	1164-1168
was	O	1169-1172
discontinued	O	1173-1185
in	O	1186-1188
four	O	1189-1193
patients	O	1194-1202
,	O	1202-1203
because	O	1204-1211
of	O	1212-1214
pneumonia	B	1215-1224
in	O	1225-1227
two	O	1228-1231
,	O	1231-1232
PTLD	B	1233-1237
in	O	1238-1240
one	O	1241-1244
,	O	1244-1245
and	O	1246-1249
oral	O	1250-1254
aphtous	B	1255-1262
ulcers	I	1263-1269
in	O	1270-1272
one	O	1273-1276
.	O	1276-1277

RAPA	O	1278-1282
levels	O	1283-1289
were	O	1290-1294
high	O	1295-1299
(	O	1300-1301
>	O	1301-1302
15	O	1302-1304
ng	O	1305-1307
/	O	1307-1308
ml	O	1308-1310
)	O	1310-1311
in	O	1312-1314
7	O	1315-1316
of	O	1317-1319
13	O	1320-1322
(	O	1323-1324
54	O	1324-1326
%	O	1326-1327
)	O	1327-1328
patients	O	1329-1337
.	O	1337-1338

CONCLUSIONS	O	1339-1350
:	O	1350-1351
RAPA	O	1352-1356
conversion	O	1357-1367
provides	O	1368-1376
adequate	O	1377-1385
immunosuppression	O	1386-1403
to	O	1404-1406
enable	O	1407-1413
CsA	O	1414-1417
withdrawal	O	1418-1428
.	O	1428-1429

However	O	1430-1437
,	O	1437-1438
when	O	1439-1443
converting	O	1444-1454
patients	O	1455-1463
to	O	1464-1466
RAPA	O	1467-1471
drug	O	1472-1476
levels	O	1477-1483
should	O	1484-1490
be	O	1491-1493
monitored	O	1494-1503
to	O	1504-1506
avoid	O	1507-1512
over	O	1513-1517
-	O	1517-1518
immunosuppression	O	1518-1535
and	O	1536-1539
adequate	O	1540-1548
antiviral	O	1549-1558
and	O	1559-1562
Pneumocystis	B	1563-1575
carinii	I	1576-1583
pneumonia	I	1584-1593
prophylaxis	O	1594-1605
should	O	1606-1612
be	O	1613-1615
given	O	1616-1621
.	O	1621-1622

Worsening	O	0-9
of	O	10-12
levodopa	O	13-21
-	O	21-22
induced	O	22-29
dyskinesias	B	30-41
by	O	42-44
motor	O	45-50
and	O	51-54
mental	O	55-61
tasks	O	62-67
.	O	67-68

Ten	O	69-72
patients	O	73-81
who	O	82-85
had	O	86-89
Parkinson	B	90-99
'	I	99-100
s	I	96-97
disease	I	102-109
with	O	110-114
disabling	O	115-124
dyskinesia	B	125-135
were	O	136-140
included	O	141-149
in	O	150-152
this	O	153-157
study	O	158-163
to	O	164-166
evaluate	O	167-175
the	O	176-179
role	O	180-184
of	O	185-187
mental	O	188-194
(	O	195-196
mental	O	196-202
calculation	O	203-214
)	O	214-215
and	O	216-219
motor	O	220-225
(	O	226-227
flexion	O	227-234
/	O	234-235
extension	O	235-244
of	O	245-247
right	O	248-253
fingers	O	254-261
,	O	261-262
flexion	O	263-270
/	O	270-271
extension	O	271-280
of	O	281-283
left	O	284-288
fingers	O	289-296
,	O	296-297
flexion	O	298-305
/	O	305-306
extension	O	306-315
of	O	316-318
the	O	319-322
neck	O	323-327
,	O	327-328
speaking	O	329-337
aloud	O	338-343
)	O	343-344
tasks	O	345-350
on	O	351-353
the	O	354-357
worsening	O	358-367
of	O	368-370
peak	O	371-375
-	O	375-376
dose	O	376-380
dyskinesia	B	381-391
following	O	392-401
administration	O	402-416
of	O	417-419
an	O	420-422
effective	O	423-432
single	O	433-439
dose	O	440-444
of	O	445-447
apomorphine	O	448-459
.	O	459-460

Compared	O	461-469
with	O	470-474
the	O	475-478
score	O	479-484
at	O	485-487
rest	O	488-492
(	O	493-494
1	O	494-495
.	O	495-496
3	O	496-497
+	O	497-498
/	O	498-499
-	O	499-500
0	O	500-501
.	O	495-496
3	O	496-497
)	O	503-504
,	O	504-505

a	O	506-507
significant	O	508-519
aggravation	O	520-531
of	O	532-534
the	O	535-538
dyskinesia	B	539-549
score	O	550-555
was	O	556-559
observed	O	560-568
during	O	569-575
speaking	O	576-584
aloud	O	585-590
(	O	591-592
5	O	592-593
.	O	593-594
2	O	594-595
+	O	595-596
/	O	596-597
-	O	597-598
1	O	598-599
.	O	593-594
1	O	598-599
,	O	601-602

p	O	603-604
<	O	604-605
0	O	605-606
.	O	606-607
05	O	607-609
)	O	609-610
,	O	610-611
movements	O	612-621
of	O	622-624
right	O	625-630
(	O	631-632
4	O	632-633
.	O	633-634
5	O	634-635
+	O	635-636
/	O	636-637
-	O	637-638
1	O	638-639
.	O	633-634
0	O	640-641
,	O	641-642

p	O	643-644
<	O	644-645
0	O	645-646
.	O	646-647
05	O	647-649
)	O	649-650
and	O	651-654
left	O	655-659
(	O	660-661
3	O	661-662
.	O	662-663
7	O	663-664
+	O	664-665
/	O	665-666
-	O	666-667
0	O	667-668
.	O	662-663
8	O	669-670
,	O	670-671

p	O	672-673
<	O	673-674
0	O	674-675
.	O	675-676
05	O	676-678
)	O	678-679
fingers	O	680-687
,	O	687-688
movements	O	689-698
of	O	699-701
the	O	702-705
neck	O	706-710
(	O	711-712
5	O	712-713
.	O	713-714
1	O	714-715
+	O	715-716
/	O	716-717
-	O	717-718
1	O	714-715
.	O	713-714
0	O	720-721
,	O	721-722

p	O	723-724
<	O	724-725
0	O	725-726
.	O	726-727
05	O	727-729
)	O	729-730
,	O	730-731
and	O	732-735
mental	O	736-742
calculation	O	743-754
(	O	755-756
3	O	756-757
.	O	757-758
1	O	758-759
+	O	759-760
/	O	760-761
-	O	761-762
1	O	758-759
.	O	757-758
0	O	764-765
,	O	765-766

p	O	767-768
<	O	768-769
0	O	769-770
.	O	770-771
05	O	771-773
)	O	773-774
.	O	770-771

These	O	776-781
results	O	782-789
suggest	O	790-797
that	O	798-802
activation	O	803-813
tasks	O	814-819
such	O	820-824
as	O	825-827
"	O	828-829
speaking	O	829-837
aloud	O	838-843
"	O	843-844
could	O	845-850
be	O	851-853
used	O	854-858
for	O	859-862
objective	O	863-872
assessment	O	873-883
of	O	884-886
dyskinesia	B	887-897
severity	O	898-906
.	O	906-907

Structural	B	0-10
and	I	11-14
functional	I	15-25
impairment	I	26-36
of	I	37-39
mitochondria	I	40-52
in	O	53-55
adriamycin	O	56-66
-	O	66-67
induced	O	67-74
cardiomyopathy	B	75-89
in	O	90-92
mice	O	93-97
:	O	97-98
suppression	O	99-110
of	O	111-113
cytochrome	O	114-124
c	O	125-126
oxidase	O	127-134
II	O	135-137
gene	O	138-142
expression	O	143-153
.	O	153-154

The	O	155-158
use	O	159-162
of	O	163-165
adriamycin	O	166-176
(	O	177-178
ADR	O	178-181
)	O	181-182
in	O	183-185
cancer	B	186-192
chemotherapy	O	193-205
has	O	206-209
been	O	210-214
limited	O	215-222
due	O	223-226
to	O	227-229
its	O	230-233
cumulative	O	234-244
cardiovascular	B	245-259
toxicity	I	260-268
.	O	268-269

Earlier	O	270-277
observations	O	278-290
that	O	291-295
ADR	O	296-299
interacts	O	300-309
with	O	310-314
mitochondrial	O	315-328
cytochrome	O	329-339
c	O	340-341
oxidase	O	342-349
(	O	350-351
COX	O	351-354
)	O	354-355
and	O	356-359
suppresses	O	360-370
its	O	371-374
enzyme	O	375-381
activity	O	382-390
led	O	391-394
us	O	395-397
to	O	398-400
investigate	O	401-412
ADR	O	413-416
'	O	416-417
s	O	417-418
action	O	419-425
on	O	426-428
the	O	429-432
cardiovascular	O	433-447
functions	O	448-457
and	O	458-461
heart	O	462-467
mitochondrial	O	468-481
morphology	O	482-492
in	O	493-495
Balb	O	496-500
-	O	500-501
c	O	501-502
mice	O	503-507
i	O	508-509
.	O	509-510
p	O	510-511
.	O	509-510
treated	O	513-520
with	O	521-525
ADR	O	526-529
for	O	530-533
several	O	534-541
weeks	O	542-547
.	O	547-548

At	O	549-551
various	O	552-559
times	O	560-565
during	O	566-572
treatment	O	573-582
,	O	582-583
the	O	584-587
animals	O	588-595
were	O	596-600
assessed	O	601-609
for	O	610-613
cardiovascular	O	614-628
functions	O	629-638
by	O	639-641
electrocardiography	O	642-661
and	O	662-665
for	O	666-669
heart	O	670-675
tissue	O	676-682
damage	O	683-689
by	O	690-692
electron	O	693-701
microscopy	O	702-712
.	O	712-713

In	O	714-716
parallel	O	717-725
,	O	725-726
total	O	727-732
RNA	O	733-736
was	O	737-740
extracted	O	741-750
from	O	751-755
samples	O	756-763
of	O	764-766
dissected	O	767-776
heart	O	777-782
and	O	783-786
analyzed	O	787-795
by	O	796-798
Northern	O	799-807
blot	O	808-812
hybridization	O	813-826
to	O	827-829
determine	O	830-839
the	O	840-843
steady	O	844-850
-	O	850-851
state	O	851-856
level	O	857-862
of	O	863-865
three	O	866-871
RNA	O	872-875
transcripts	O	876-887
encoded	O	888-895
by	O	896-898
the	O	899-902
COXII	O	903-908
,	O	908-909
COXIII	O	910-916
,	O	916-917
and	O	918-921
COXIV	O	922-927
genes	O	928-933
.	O	933-934

Similarly	O	935-944
,	O	944-945
samples	O	946-953
obtained	O	954-962
from	O	963-967
the	O	968-971
liver	O	972-977
of	O	978-980
the	O	981-984
same	O	985-989
animals	O	990-997
were	O	998-1002
analyzed	O	1003-1011
for	O	1012-1015
comparative	O	1016-1027
studies	O	1028-1035
.	O	1035-1036

Our	O	1037-1040
results	O	1041-1048
indicated	O	1049-1058
that	O	1059-1063
1	O	1064-1065
)	O	1065-1066
treatment	O	1067-1076
of	O	1077-1079
mice	O	1080-1084
with	O	1085-1089
ADR	O	1090-1093
caused	O	1094-1100
cardiovascular	B	1101-1115
arrhythmias	I	1116-1127
characterized	O	1128-1141
by	O	1142-1144
bradycardia	B	1145-1156
,	O	1156-1157
extension	O	1158-1167
of	O	1168-1170
ventricular	O	1171-1182
depolarization	O	1183-1197
time	O	1198-1202
(	O	1203-1204
tQRS	O	1204-1208
)	O	1208-1209
,	O	1209-1210
and	O	1211-1214
failure	O	1215-1222
of	O	1223-1225
QRS	O	1226-1229
at	O	1230-1232
high	O	1233-1237
concentrations	O	1238-1252
(	O	1253-1254
10	O	1254-1256
-	O	1256-1257
14	O	1257-1259
mg	O	1260-1262
/	O	1262-1263
kg	O	1263-1265
body	O	1266-1270
weight	O	1271-1277
cumulative	O	1278-1288
dose	O	1289-1293
)	O	1293-1294
;	O	1294-1295
2	O	1296-1297
)	O	1297-1298
the	O	1299-1302
heart	O	1303-1308
mitochondria	O	1309-1321
underwent	O	1322-1331
swelling	B	1332-1340
,	O	1340-1341
fusion	O	1342-1348
,	O	1348-1349
dissolution	O	1350-1361
,	O	1361-1362
and	O	1363-1366
/	O	1366-1367
or	O	1367-1369
disruption	O	1370-1380
of	O	1381-1383
mitochondrial	O	1384-1397
cristae	O	1398-1405
after	O	1406-1411
several	O	1412-1419
weeks	O	1420-1425
of	O	1426-1428
treatment	O	1429-1438
.	O	1438-1439

Such	O	1440-1444
abnormalities	O	1445-1458
were	O	1459-1463
not	O	1464-1467
observed	O	1468-1476
in	O	1477-1479
the	O	1480-1483
mitochondria	O	1484-1496
of	O	1497-1499
liver	O	1500-1505
tissue	O	1506-1512
;	O	1512-1513
and	O	1514-1517
3	O	1518-1519
)	O	1519-1520
among	O	1521-1526
the	O	1527-1530
three	O	1531-1536
genes	O	1537-1542
of	O	1543-1545
COX	O	1546-1549
enzyme	O	1550-1556
examined	O	1557-1565
,	O	1565-1566
only	O	1567-1571
COXII	O	1572-1577
gene	O	1578-1582
expression	O	1583-1593
was	O	1594-1597
suppressed	O	1598-1608
by	O	1609-1611
ADR	O	1612-1615
treatment	O	1616-1625
,	O	1625-1626
mainly	O	1627-1633
after	O	1634-1639
8	O	1640-1641
weeks	O	1642-1647
in	O	1648-1650
both	O	1651-1655
heart	O	1656-1661
and	O	1662-1665
liver	O	1666-1671
.	O	1671-1672

Knowing	O	1673-1680
that	O	1681-1685
heart	O	1686-1691
mitochondria	O	1692-1704
represent	O	1705-1714
almost	O	1715-1721
40	O	1722-1724
%	O	1724-1725
of	O	1726-1728
heart	O	1729-1734
muscle	O	1735-1741
by	O	1742-1744
weight	O	1745-1751
,	O	1751-1752
we	O	1753-1755
conclude	O	1756-1764
that	O	1765-1769
the	O	1770-1773
deteriorating	O	1774-1787
effects	O	1788-1795
of	O	1796-1798
ADR	O	1799-1802
on	O	1803-1805
cardiovascular	O	1806-1820
function	O	1821-1829
involve	O	1830-1837
mitochondrial	B	1838-1851
structural	I	1852-1862
and	I	1863-1866
functional	I	1867-1877
impairment	I	1878-1888
.	O	1888-1889

Enhanced	O	0-8
bradycardia	B	9-20
induced	O	21-28
by	O	29-31
beta	O	32-36
-	O	36-37
adrenoceptor	O	37-49
antagonists	O	50-61
in	O	62-64
rats	O	65-69
pretreated	O	70-80
with	O	81-85
isoniazid	O	86-95
.	O	95-96

High	O	97-101
doses	O	102-107
of	O	108-110
isoniazid	O	111-120
increase	O	121-129
hypotension	B	130-141
induced	O	142-149
by	O	150-152
vasodilators	O	153-165
and	O	166-169
change	O	170-176
the	O	177-180
accompanying	O	181-193
reflex	O	194-200
tachycardia	B	201-212
to	O	213-215
bradycardia	B	216-227
,	O	227-228
an	O	229-231
interaction	O	232-243
attributed	O	244-254
to	O	255-257
decreased	O	258-267
synthesis	O	268-277
of	O	278-280
brain	O	281-286
gamma	O	287-292
-	O	292-293
aminobutyric	O	293-305
acid	O	306-310
(	O	311-312
GABA	O	312-316
)	O	316-317
.	O	317-318

In	O	319-321
the	O	322-325
present	O	326-333
study	O	334-339
,	O	339-340
the	O	341-344
possible	O	345-353
enhancement	O	354-365
by	O	366-368
isoniazid	O	369-378
of	O	379-381
bradycardia	B	382-393
induced	O	394-401
by	O	402-404
beta	O	405-409
-	O	409-410
adrenoceptor	O	410-422
antagonists	O	423-434
was	O	435-438
determined	O	439-449
in	O	450-452
rats	O	453-457
anaesthetised	O	458-471
with	O	472-476
chloralose	O	477-487
-	O	487-488
urethane	O	488-496
.	O	496-497

Isoniazid	O	498-507
significantly	O	508-521
increased	O	522-531
bradycardia	B	532-543
after	O	544-549
propranolol	O	550-561
,	O	561-562
pindolol	O	563-571
,	O	571-572
labetalol	O	573-582
and	O	583-586
atenolol	O	587-595
,	O	595-596
as	O	597-599
well	O	600-604
as	O	605-607
after	O	608-613
clonidine	O	614-623
,	O	623-624
but	O	625-628
not	O	629-632
after	O	633-638
hexamethonium	O	639-652
or	O	653-655
carbachol	O	656-665
.	O	665-666

Enhancement	O	667-678
was	O	679-682
not	O	683-686
observed	O	687-695
in	O	696-698
rats	O	699-703
pretreated	O	704-714
with	O	715-719
methylatropine	O	720-734
or	O	735-737
previously	O	738-748
vagotomised	O	749-760
.	O	760-761

These	O	762-767
results	O	768-775
are	O	776-779
compatible	O	780-790
with	O	791-795
interference	O	796-808
by	O	809-811
isoniazid	O	812-821
with	O	822-826
GABAergic	O	827-836
inhibition	O	837-847
of	O	848-850
cardiac	O	851-858
parasympathetic	O	859-874
tone	O	875-879
.	O	879-880

Such	O	881-885
interference	O	886-898
could	O	899-904
be	O	905-907
exerted	O	908-915
centrally	O	916-925
,	O	925-926
possibly	O	927-935
at	O	936-938
the	O	939-942
nucleus	O	943-950
ambiguus	O	951-959
,	O	959-960
or	O	961-963
peripherally	O	964-976
at	O	977-979
the	O	980-983
sinus	O	984-989
node	O	990-994
.	O	994-995

Epileptogenic	O	0-13
activity	O	14-22
of	O	23-25
folic	O	26-31
acid	O	32-36
after	O	37-42
drug	O	43-47
induces	O	48-55
SLE	B	56-59
(	O	60-61
folic	O	61-66
acid	O	67-71
and	O	72-75
epilepsy	B	76-84
)	O	84-85
OBJECTIVE	O	86-95
:	O	95-96
To	O	97-99
study	O	100-105
the	O	106-109
effect	O	110-116
of	O	117-119
folic	O	120-125
acid	O	126-130
-	O	130-131
containing	O	131-141
multivitamin	O	142-154
supplementation	O	155-170
in	O	171-173
epileptic	B	174-183
women	O	184-189
before	O	190-196
and	O	197-200
during	O	201-207
pregnancy	O	208-217
in	O	218-220
order	O	221-226
to	O	227-229
determine	O	230-239
the	O	240-243
rate	O	244-248
of	O	249-251
structural	O	252-262
birth	B	263-268
defects	I	269-276
and	O	277-280
epilepsy	B	281-289
-	O	289-290
related	O	290-297
side	O	298-302
effects	O	303-310
.	O	310-311

STUDY	O	312-317
DESIGN	O	318-324
:	O	324-325
First	O	326-331
a	O	332-333
randomised	O	334-344
trial	O	345-350
,	O	350-351
later	O	352-357
periconception	O	358-372
care	O	373-377
including	O	378-387
in	O	388-390
total	O	391-396
12225	O	397-402
females	O	403-410
.	O	410-411

RESULTS	O	412-419
:	O	419-420
Of	O	421-423
60	O	424-426
epileptic	B	427-436
women	O	437-442
with	O	443-447
periconceptional	O	448-464
folic	O	465-470
acid	O	471-475
(	O	476-477
0	O	477-478
.	O	478-479
8	O	479-480
mg	O	481-483
)	O	483-484
-	O	484-485
containing	O	485-495
multivitamin	O	496-508
supplementation	O	509-524
,	O	524-525
no	O	526-528
one	O	529-532
developed	O	533-542
epilepsy	B	543-551
-	O	551-552
related	O	552-559
side	O	560-564
effects	O	565-572
during	O	573-579
the	O	580-583
periconception	O	584-598
period	O	599-605
.	O	605-606

One	O	607-610
epileptic	B	611-620
woman	O	621-626
delivered	O	627-636
a	O	637-638
newborn	O	639-646
with	O	647-651
cleft	B	652-657
lip	I	658-661
and	I	662-665
palate	I	666-672
.	O	672-673

Another	O	674-681
patient	O	682-689
exhibited	O	690-699
with	O	700-704
a	O	705-706
cluster	O	707-714
of	O	715-717
seizures	B	718-726
after	O	727-732
the	O	733-736
periconception	O	737-751
period	O	752-758
using	O	759-764
another	O	765-772
multivitamin	O	773-785
.	O	785-786

This	O	787-791
22	O	792-794
-	O	794-795
year	O	795-799
-	O	794-795
old	O	800-803
epileptic	B	804-813
woman	O	814-819
was	O	820-823
treated	O	824-831
continuously	O	832-844
by	O	845-847
carbamazepine	O	848-861
and	O	862-865
a	O	866-867
folic	O	868-873
acid	O	874-878
(	O	879-880
1	O	880-881
mg	O	882-884
)	O	884-885
-	O	885-886
containing	O	886-896
multivitamin	O	897-909
from	O	910-914
the	O	915-918
20th	O	919-923
week	O	924-928
of	O	929-931
gestation	O	932-941
.	O	941-942

She	O	943-946
developed	O	947-956
status	B	957-963
epilepticus	I	964-975
and	O	976-979
later	O	980-985
symptoms	O	986-994
of	O	995-997
systemic	B	998-1006
lupus	I	1007-1012
erythematodes	I	1013-1026
.	O	1026-1027

Her	O	1028-1031
pregnancy	O	1032-1041
ended	O	1042-1047
with	O	1048-1052
stillbirth	B	1053-1063
.	O	1063-1064

CONCLUSIONS	O	1065-1076
:	O	1076-1077
The	O	1078-1081
epileptic	B	1082-1091
pregnant	O	1092-1100
patient	O	1101-1108
'	O	1108-1109
s	O	1109-1110
autoimmune	B	1111-1121
disease	I	1122-1129
(	O	1130-1131
probably	O	1131-1139
drug	O	1140-1144
-	O	1144-1145
induced	O	1145-1152
lupus	B	1153-1158
)	O	1158-1159
could	O	1160-1165
damage	O	1166-1172
the	O	1173-1176
blood	O	1177-1182
-	O	1182-1183
brain	O	1183-1188
barrier	O	1189-1196
,	O	1196-1197
therefore	O	1198-1207
the	O	1208-1211
therapeutic	O	1212-1223
dose	O	1224-1228
(	O	1229-1230
>	O	1230-1231
or	O	1232-1234
=	O	1235-1236
1	O	1236-1237
mg	O	1238-1240
)	O	1240-1241
of	O	1242-1244
folic	O	1245-1250
acid	O	1251-1255
triggered	O	1256-1265
a	O	1266-1267
cluster	O	1268-1275
of	O	1276-1278
seizures	B	1279-1287
.	O	1287-1288

Physiological	O	1289-1302
dose	O	1303-1307
(	O	1308-1309
<	O	1309-1310
1	O	1310-1311
mg	O	1312-1314
)	O	1314-1315
of	O	1316-1318
folic	O	1319-1324
acid	O	1325-1329
both	O	1330-1334
in	O	1335-1337
healthy	O	1338-1345
and	O	1346-1349
60	O	1350-1352
epileptic	B	1353-1362
women	O	1363-1368
,	O	1368-1369
all	O	1370-1373
without	O	1374-1381
any	O	1382-1385
autoimmune	B	1386-1396
disease	I	1397-1404
,	O	1404-1405
did	O	1406-1409
not	O	1410-1413
increase	O	1414-1422
the	O	1423-1426
risk	O	1427-1431
for	O	1432-1435
epileptic	B	1436-1445
seizures	I	1446-1454
.	O	1454-1455

Effects	O	0-7
of	O	8-10
cisapride	O	11-20
on	O	21-23
symptoms	O	24-32
and	O	33-36
postcibal	O	37-46
small	O	47-52
-	O	52-53
bowel	O	53-58
motor	O	59-64
function	O	65-73
in	O	74-76
patients	O	77-85
with	O	86-90
irritable	B	91-100
bowel	I	101-106
syndrome	I	107-115
.	O	115-116

BACKGROUND	O	117-127
:	O	127-128
Irritable	B	129-138
bowel	I	139-144
syndrome	I	145-153
is	O	154-156
a	O	157-158
common	O	159-165
cause	O	166-171
of	O	172-174
abdominal	B	175-184
pain	I	185-189
and	O	190-193
discomfort	O	194-204
and	O	205-208
may	O	209-212
be	O	213-215
related	O	216-223
to	O	224-226
disordered	B	227-237
gastrointestinal	I	238-254
motility	I	255-263
.	O	263-264

Our	O	265-268
aim	O	269-272
was	O	273-276
to	O	277-279
assess	O	280-286
the	O	287-290
effects	O	291-298
of	O	299-301
long	O	302-306
-	O	306-307
term	O	307-311
treatment	O	312-321
with	O	322-326
a	O	327-328
prokinetic	O	329-339
agent	O	340-345
,	O	345-346
cisapride	O	347-356
,	O	356-357
on	O	358-360
postprandial	O	361-373
jejunal	O	374-381
motility	O	382-390
and	O	391-394
symptoms	O	395-403
in	O	404-406
the	O	407-410
irritable	B	411-420
bowel	I	421-426
syndrome	I	427-435
(	O	436-437
IBS	B	437-440
)	O	440-441
.	O	441-442

METHODS	O	443-450
:	O	450-451
Thirty	O	452-458
-	O	458-459
eight	O	459-464
patients	O	465-473
with	O	474-478
IBS	B	479-482
(	O	483-484
constipation	B	484-496
-	O	496-497
predominant	O	497-508
,	O	508-509
n	O	510-511
=	O	512-513
17	O	514-516
;	O	516-517
diarrhoea	B	518-527
-	O	527-528
predominant	O	528-539
,	O	539-540
n	O	541-542
=	O	543-544
21	O	545-547
)	O	547-548
underwent	O	549-558
24	O	559-561
-	O	561-562
h	O	562-563
ambulatory	O	564-574
jejunal	O	575-582
manometry	O	583-592
before	O	593-599
and	O	600-603
after	O	604-609
12	O	610-612
week	O	613-617
'	O	617-618
s	O	618-619
treatment	O	620-629
[	O	630-631
cisapride	O	631-640
,	O	640-641
5	O	642-643
mg	O	644-646
three	O	647-652
times	O	653-658
daily	O	659-664
(	O	665-666
n	O	666-667
=	O	668-669
19	O	670-672
)	O	672-673
or	O	674-676
placebo	O	677-684
(	O	685-686
n	O	686-687
=	O	688-689
19	O	690-692
)	O	692-693
]	O	693-694
.	O	694-695

RESULTS	O	696-703
:	O	703-704
In	O	705-707
diarrhoea	B	708-717
-	O	717-718
predominant	O	718-729
patients	O	730-738
significant	O	739-750
differences	O	751-762
in	O	763-765
contraction	O	766-777
characteristics	O	778-793
were	O	794-798
observed	O	799-807
between	O	808-815
the	O	816-819
cisapride	O	820-829
and	O	830-833
placebo	O	834-841
groups	O	842-848
.	O	848-849

In	O	850-852
cisapride	O	853-862
-	O	862-863
treated	O	863-870
diarrhoea	B	871-880
-	O	880-881
predominant	O	881-892
patients	O	893-901
the	O	902-905
mean	O	906-910
contraction	O	911-922
amplitude	O	923-932
was	O	933-936
higher	O	937-943
(	O	944-945
29	O	945-947
.	O	947-948
3	O	948-949
+	O	950-951
/	O	951-952
-	O	952-953
3	O	954-955
.	O	955-956
2	O	956-957
versus	O	958-964
24	O	965-967
.	O	967-968
9	O	968-969
+	O	970-971
/	O	971-972
-	O	972-973
2	O	974-975
.	O	975-976
6	O	976-977
mm	O	978-980
Hg	O	981-983
,	O	983-984
cisapride	O	985-994
versus	O	995-1001
placebo	O	1002-1009
(	O	1010-1011
P	O	1011-1012
<	O	1013-1014
0	O	1015-1016
.	O	1016-1017
001	O	1017-1020
)	O	1020-1021
;	O	1021-1022
pretreatment	O	1023-1035
,	O	1035-1036
25	O	1037-1039
.	O	1039-1040
7	O	1040-1041
+	O	1042-1043
/	O	1043-1044
-	O	1044-1045
6	O	1046-1047
.	O	1047-1048
0	O	1048-1049
mm	O	1050-1052
Hg	O	1053-1055
)	O	1055-1056
,	O	1056-1057
the	O	1058-1061
mean	O	1062-1066
contraction	O	1067-1078
duration	O	1079-1087
longer	O	1088-1094
(	O	1095-1096
3	O	1096-1097
.	O	1097-1098
4	O	1098-1099
+	O	1100-1101
/	O	1101-1102
-	O	1102-1103
0	O	1104-1105
.	O	1105-1106
2	O	1106-1107
versus	O	1108-1114
3	O	1115-1116
.	O	1116-1117
0	O	1117-1118
+	O	1119-1120
/	O	1120-1121
-	O	1121-1122
0	O	1123-1124
.	O	1124-1125
2	O	1125-1126
sec	O	1127-1130
,	O	1130-1131
cisapride	O	1132-1141
versus	O	1142-1148
placebo	O	1149-1156
(	O	1157-1158
P	O	1158-1159
<	O	1160-1161
0	O	1162-1163
.	O	1163-1164
001	O	1164-1167
)	O	1167-1168
;	O	1168-1169
pretreatment	O	1170-1182
,	O	1182-1183
3	O	1184-1185
.	O	1185-1186
1	O	1186-1187
+	O	1188-1189
/	O	1189-1190
-	O	1190-1191
0	O	1192-1193
.	O	1193-1194
5	O	1194-1195
sec	O	1196-1199
)	O	1199-1200
,	O	1200-1201
and	O	1202-1205
the	O	1206-1209
mean	O	1210-1214
contraction	O	1215-1226
frequency	O	1227-1236
lower	O	1237-1242
(	O	1243-1244
2	O	1244-1245
.	O	1245-1246
0	O	1246-1247
+	O	1248-1249
/	O	1249-1250
-	O	1250-1251
0	O	1252-1253
.	O	1253-1254
2	O	1254-1255
versus	O	1256-1262
2	O	1263-1264
.	O	1264-1265
5	O	1265-1266
+	O	1267-1268
/	O	1268-1269
-	O	1269-1270
0	O	1271-1272
.	O	1272-1273
4	O	1273-1274
cont	O	1275-1279
.	O	1279-1280
/	O	1280-1281
min	O	1281-1284
,	O	1284-1285

cisapride	O	1286-1295
versus	O	1296-1302
placebo	O	1303-1310
(	O	1311-1312
P	O	1312-1313
<	O	1314-1315
0	O	1316-1317
.	O	1317-1318
001	O	1318-1321
)	O	1321-1322
;	O	1322-1323
pretreatment	O	1324-1336
,	O	1336-1337
2	O	1338-1339
.	O	1339-1340
5	O	1340-1341
+	O	1342-1343
/	O	1343-1344
-	O	1344-1345
1	O	1346-1347
.	O	1347-1348
1	O	1346-1347
cont	O	1350-1354
.	O	1354-1355
/	O	1355-1356
min	O	1356-1359
]	O	1359-1360

than	O	1361-1365
patients	O	1366-1374
treated	O	1375-1382
with	O	1383-1387
placebo	O	1388-1395
.	O	1395-1396

No	O	1397-1399
significant	O	1400-1411
differences	O	1412-1423
in	O	1424-1426
jejunal	O	1427-1434
motility	O	1435-1443
were	O	1444-1448
found	O	1449-1454
in	O	1455-1457
the	O	1458-1461
constipation	B	1462-1474
-	O	1474-1475
predominant	O	1475-1486
IBS	B	1487-1490
group	O	1491-1496
.	O	1496-1497

Symptoms	O	1498-1506
were	O	1507-1511
assessed	O	1512-1520
by	O	1521-1523
using	O	1524-1529
a	O	1530-1531
visual	O	1532-1538
analogue	O	1539-1547
scale	O	1548-1553
before	O	1554-1560
and	O	1561-1564
after	O	1565-1570
treatment	O	1571-1580
.	O	1580-1581

Symptom	O	1582-1589
scores	O	1590-1596
relating	O	1597-1605
to	O	1606-1608
the	O	1609-1612
severity	O	1613-1621
of	O	1622-1624
constipation	B	1625-1637
were	O	1638-1642
lower	O	1643-1648
in	O	1649-1651
cisapride	O	1652-1661
-	O	1661-1662
treated	O	1662-1669
constipation	B	1670-1682
-	O	1682-1683
predominant	O	1683-1694
IBS	B	1695-1698
patients	O	1699-1707
[	O	1708-1709
score	O	1709-1714
,	O	1714-1715
54	O	1716-1718
+	O	1719-1720
/	O	1720-1721
-	O	1721-1722
5	O	1723-1724
versus	O	1725-1731
67	O	1732-1734
+	O	1735-1736
/	O	1736-1737
-	O	1737-1738
14	O	1739-1741
mm	O	1742-1744
,	O	1744-1745
cisapride	O	1746-1755
versus	O	1756-1762
placebo	O	1763-1770
(	O	1771-1772
P	O	1772-1773
<	O	1774-1775
0	O	1776-1777
.	O	1777-1778
05	O	1778-1780
)	O	1780-1781
;	O	1781-1782
pretreatment	O	1783-1795
,	O	1795-1796
62	O	1797-1799
+	O	1800-1801
/	O	1801-1802
-	O	1802-1803
19	O	1804-1806
mm	O	1807-1809
]	O	1809-1810
.	O	1810-1811

Diarrhoea	B	1812-1821
-	O	1821-1822
predominant	O	1822-1833
IBS	B	1834-1837
patients	O	1838-1846
had	O	1847-1850
a	O	1851-1852
higher	O	1853-1859
pain	B	1860-1864
score	O	1865-1870
after	O	1871-1876
cisapride	O	1877-1886
therapy	O	1887-1894
[	O	1895-1896
score	O	1896-1901
,	O	1901-1902
55	O	1903-1905
+	O	1906-1907
/	O	1907-1908
-	O	1908-1909
15	O	1910-1912
versus	O	1913-1919
34	O	1920-1922
+	O	1923-1924
/	O	1924-1925
-	O	1925-1926
12	O	1927-1929
mm	O	1930-1932
,	O	1932-1933
cisapride	O	1934-1943
versus	O	1944-1950
placebo	O	1951-1958
(	O	1959-1960
P	O	1960-1961
<	O	1962-1963
0	O	1964-1965
.	O	1965-1966
05	O	1966-1968
)	O	1968-1969
;	O	1969-1970
pretreatment	O	1971-1983
,	O	1983-1984
67	O	1985-1987
+	O	1988-1989
/	O	1989-1990
-	O	1990-1991
19	O	1992-1994
mm	O	1995-1997
]	O	1997-1998
.	O	1998-1999

CONCLUSION	O	2000-2010
:	O	2010-2011
Cisapride	O	2012-2021
affects	O	2022-2029
jejunal	O	2030-2037
contraction	O	2038-2049
characteristics	O	2050-2065
and	O	2066-2069
some	O	2070-2074
symptoms	O	2075-2083
in	O	2084-2086
IBS	B	2087-2090
.	O	2090-2091

Clarithromycin	O	0-14
-	O	14-15
induced	O	15-22
ventricular	B	23-34
tachycardia	I	35-46
.	O	46-47

Clarithromycin	O	48-62
is	O	63-65
a	O	66-67
relatively	O	68-78
new	O	79-82
macrolide	O	83-92
antibiotic	O	93-103
that	O	104-108
offers	O	109-115
twice	O	116-121
-	O	121-122
daily	O	122-127
dosing	O	128-134
.	O	134-135

It	O	136-138
differs	O	139-146
from	O	147-151
erythromycin	O	152-164
only	O	165-169
in	O	170-172
the	O	173-176
methylation	O	177-188
of	O	189-191
the	O	192-195
hydroxyl	O	196-204
group	O	205-210
at	O	211-213
position	O	214-222
6	O	223-224
.	O	224-225

Although	O	226-234
the	O	235-238
side	O	239-243
-	O	243-244
effect	O	244-250
profile	O	251-258
of	O	259-261
erythromycin	O	262-274
is	O	275-277
established	O	278-289
,	O	289-290
including	O	291-300
gastroenteritis	B	301-316
and	O	317-320
interactions	O	321-333
with	O	334-338
other	O	339-344
drugs	O	345-350
subject	O	351-358
to	O	359-361
hepatic	O	362-369
mixed	O	370-375
-	O	375-376
function	O	376-384
oxidase	O	385-392
metabolism	O	393-403
,	O	403-404
experience	O	405-415
with	O	416-420
the	O	421-424
newer	O	425-430
macrolides	O	431-441
is	O	442-444
still	O	445-450
being	O	451-456
recorded	O	457-465
.	O	465-466

Cardiotoxicity	B	467-481
has	O	482-485
been	O	486-490
demonstrated	O	491-503
after	O	504-509
both	O	510-514
intravenous	O	515-526
and	O	527-530
oral	O	531-535
administration	O	536-550
of	O	551-553
erythromycin	O	554-566
but	O	567-570
has	O	571-574
never	O	575-580
been	O	581-585
reported	O	586-594
with	O	595-599
the	O	600-603
newer	O	604-609
macrolides	O	610-620
.	O	620-621

We	O	622-624
report	O	625-631
a	O	632-633
case	O	634-638
of	O	639-641
ventricular	B	642-653
dysrhythmias	I	654-666
that	O	667-671
occurred	O	672-680
after	O	681-686
six	O	687-690
therapeutic	O	691-702
doses	O	703-708
of	O	709-711
clarithromycin	O	712-726
.	O	726-727

The	O	728-731
dysrhythmias	B	732-744
resolved	O	745-753
after	O	754-759
discontinuation	O	760-775
of	O	776-778
the	O	779-782
drug	O	783-787
.	O	787-788

Persistent	O	0-10
nephrogenic	B	11-22
diabetes	I	23-31
insipidus	I	32-41
following	O	42-51
lithium	O	52-59
therapy	O	60-67
.	O	67-68

We	O	69-71
report	O	72-78
the	O	79-82
case	O	83-87
of	O	88-90
a	O	91-92
patient	O	93-100
who	O	101-104
developed	O	105-114
severe	O	115-121
hypernatraemic	O	122-136
dehydration	B	137-148
following	O	149-158
a	O	159-160
head	B	161-165
injury	I	166-172
.	O	172-173

Ten	O	174-177
years	O	178-183
previously	O	184-194
he	O	195-197
had	O	198-201
been	O	202-206
diagnosed	O	207-216
to	O	217-219
have	O	220-224
lithium	O	225-232
-	O	232-233
induced	O	233-240
nephrogenic	B	241-252
diabetes	I	253-261
insipidus	I	262-271
,	O	271-272
and	O	273-276
lithium	O	277-284
therapy	O	285-292
had	O	293-296
been	O	297-301
discontinued	O	302-314
.	O	314-315

He	O	316-318
remained	O	319-327
thirsty	O	328-335
and	O	336-339
polyuric	B	340-348
despite	O	349-356
cessation	O	357-366
of	O	367-369
lithium	O	370-377
and	O	378-381
investigations	O	382-396
on	O	397-399
admission	O	400-409
showed	O	410-416
him	O	417-420
to	O	421-423
have	O	424-428
normal	O	429-435
osmoregulated	O	436-449
thirst	O	450-456
and	O	457-460
vasopressin	O	461-472
secretion	O	473-482
,	O	482-483
with	O	484-488
clear	O	489-494
evidence	O	495-503
of	O	504-506
nephrogenic	B	507-518
diabetes	I	519-527
insipidus	I	528-537
.	O	537-538

Lithium	O	539-546
induced	O	547-554
nephrogenic	B	555-566
diabetes	I	567-575
insipidus	I	576-585
is	O	586-588
considered	O	589-599
to	O	600-602
be	O	603-605
reversible	O	606-616
on	O	617-619
cessation	O	620-629
of	O	630-632
therapy	O	633-640
but	O	641-644
polyuria	B	645-653
persisted	O	654-663
in	O	664-666
this	O	667-671
patient	O	672-679
for	O	680-683
ten	O	684-687
years	O	688-693
after	O	694-699
lithium	O	700-707
was	O	708-711
stopped	O	712-719
.	O	719-720

We	O	721-723
discuss	O	724-731
the	O	732-735
possible	O	736-744
renal	O	745-750
mechanisms	O	751-761
and	O	762-765
the	O	766-769
implications	O	770-782
for	O	783-786
management	O	787-797
of	O	798-800
patients	O	801-809
with	O	810-814
lithium	O	815-822
-	O	822-823
induced	O	823-830
nephrogenic	B	831-842
diabetes	I	843-851
insipidus	I	852-861
.	O	861-862

Late	O	0-4
cardiotoxicity	B	5-19
after	O	20-25
treatment	O	26-35
for	O	36-39
a	O	40-41
malignant	O	42-51
bone	B	52-56
tumor	I	57-62
.	O	62-63

Cardiac	O	64-71
function	O	72-80
was	O	81-84
assessed	O	85-93
in	O	94-96
long	O	97-101
-	O	101-102
term	O	102-106
survivors	O	107-116
of	O	117-119
malignant	O	120-129
bone	B	130-134
tumors	I	135-141
who	O	142-145
were	O	146-150
treated	O	151-158
according	O	159-168
to	O	169-171
Rosen	O	172-177
'	O	177-178
s	O	174-175
T5	O	180-182
or	O	183-185
T10	O	186-189
protocol	O	190-198
,	O	198-199
both	O	200-204
including	O	205-214
doxorubicin	O	215-226
.	O	226-227

Thirty	O	228-234
-	O	234-235
one	O	235-238
patients	O	239-247
,	O	247-248
age	O	249-252
10	O	253-255
-	O	255-256
45	O	256-258
years	O	259-264
(	O	265-266
median	O	266-272
age	O	273-276
17	O	277-279
.	O	279-280
8	O	280-281
years	O	282-287
)	O	287-288
were	O	289-293
evaluated	O	294-303
2	O	304-305
.	O	305-306
3	O	306-307
-	O	307-308
14	O	308-310
.	O	305-306
1	O	308-309
years	O	313-318
(	O	319-320
median	O	320-326
8	O	327-328
.	O	328-329
9	O	329-330
years	O	331-336
)	O	336-337
following	O	338-347
completion	O	348-358
of	O	359-361
treatment	O	362-371
.	O	371-372

Cumulative	O	373-383
doses	O	384-389
of	O	390-392
doxorubicin	O	393-404
were	O	405-409
225	O	410-413
-	O	413-414
550	O	414-417
mg	O	418-420
/	O	420-421
m2	O	421-423
(	O	424-425
median	O	425-431
dose	O	432-436
360	O	437-440
)	O	440-441
.	O	441-442

The	O	443-446
evaluation	O	447-457
consisted	O	458-467
of	O	468-470
a	O	471-472
history	O	473-480
,	O	480-481
physical	O	482-490
examination	O	491-502
,	O	502-503
electrocardiogram	O	504-521
(	O	522-523
ECG	O	523-526
)	O	526-527
,	O	527-528
signal	O	529-535
averaged	O	536-544
ECG	O	545-548
,	O	548-549
24	O	550-552
-	O	552-553
hour	O	553-557
ambulatory	O	558-568
ECG	O	569-572
,	O	572-573
echocardiography	O	574-590
and	O	591-594
radionuclide	O	595-607
angiography	O	608-619
.	O	619-620

Eighteen	O	621-629
of	O	630-632
31	O	633-635
(	O	636-637
58	O	637-639
%	O	639-640
)	O	640-641
patients	O	642-650
showed	O	651-657
cardiac	B	658-665
toxicity	I	666-674
,	O	674-675
defined	O	676-683
as	O	684-686
having	O	687-693
one	O	694-697
or	O	698-700
more	O	701-705
of	O	706-708
the	O	709-712
following	O	713-722
abnormalities	O	723-736
:	O	736-737
late	O	738-742
potentials	O	743-753
,	O	753-754
complex	O	755-762
ventricular	B	763-774
arrhythmias	I	775-786
,	O	786-787
left	O	788-792
ventricular	B	793-804
dilation	I	805-813
,	O	813-814
decreased	O	815-824
shortening	O	825-835
fraction	O	836-844
,	O	844-845
or	O	846-848
decreased	O	849-858
ejection	O	859-867
fraction	O	868-876
.	O	876-877

The	O	878-881
incidence	O	882-891
of	O	892-894
cardiac	B	895-902
abnormalities	I	903-916
increased	O	917-926
with	O	927-931
length	O	932-938
of	O	939-941
follow	O	942-948
-	O	948-949
up	O	949-951
(	O	952-953
P	O	953-954
<	O	954-955
or	O	956-958
=	O	959-960
.	O	961-962
05	O	962-964
)	O	964-965
.	O	961-962

No	O	967-969
correlation	O	970-981
could	O	982-987
be	O	988-990
demonstrated	O	991-1003
between	O	1004-1011
cumulative	O	1012-1022
dose	O	1023-1027
of	O	1028-1030
doxorubicin	O	1031-1042
and	O	1043-1046
cardiac	O	1047-1054
status	O	1055-1061
,	O	1061-1062
except	O	1063-1069
for	O	1070-1073
heart	O	1074-1079
rate	O	1080-1084
variability	O	1085-1096
.	O	1096-1097

When	O	1098-1102
adjusted	O	1103-1111
to	O	1112-1114
body	O	1115-1119
surface	O	1120-1127
area	O	1128-1132
,	O	1132-1133
the	O	1134-1137
left	O	1138-1142
ventricular	O	1143-1154
posterior	O	1155-1164
wall	O	1165-1169
thickness	O	1170-1179
(	O	1180-1181
LVPW	O	1181-1185
index	O	1186-1191
)	O	1191-1192
was	O	1193-1196
decreased	O	1197-1206
in	O	1207-1209
all	O	1210-1213
patients	O	1214-1222
.	O	1222-1223

The	O	1224-1227
incidence	O	1228-1237
of	O	1238-1240
doxorubicin	O	1241-1252
-	O	1252-1253
induced	O	1253-1260
cardiotoxicity	B	1261-1275
is	O	1276-1278
high	O	1279-1283
and	O	1284-1287
increases	O	1288-1297
with	O	1298-1302
follow	O	1303-1309
-	O	1309-1310
up	O	1310-1312
,	O	1312-1313
irrespective	O	1314-1326
of	O	1327-1329
cumulative	O	1330-1340
dose	O	1341-1345
.	O	1345-1346

Life	O	1347-1351
-	O	1351-1352
long	O	1352-1356
cardiac	O	1357-1364
follow	O	1365-1371
-	O	1371-1372
up	O	1372-1374
in	O	1375-1377
these	O	1378-1383
patients	O	1384-1392
is	O	1393-1395
warranted	O	1396-1405
.	O	1405-1406

The	O	1407-1410
results	O	1411-1418
of	O	1419-1421
our	O	1422-1425
study	O	1426-1431
suggest	O	1432-1439
that	O	1440-1444
heart	O	1445-1450
rate	O	1451-1455
variability	O	1456-1467
and	O	1468-1471
LVPW	O	1472-1476
index	O	1477-1482
could	O	1483-1488
be	O	1489-1491
sensitive	O	1492-1501
indicators	O	1502-1512
for	O	1513-1516
cardiotoxicity	B	1517-1531
.	O	1531-1532

Venous	B	0-6
complications	I	7-20
of	O	21-23
midazolam	O	24-33
versus	O	34-40
diazepam	O	41-49
.	O	49-50

Although	O	51-59
some	O	60-64
studies	O	65-72
have	O	73-77
suggested	O	78-87
fewer	O	88-93
venous	B	94-100
complications	I	101-114
are	O	115-118
associated	O	119-129
with	O	130-134
midazolam	O	135-144
than	O	145-149
with	O	150-154
diazepam	O	155-163
for	O	164-167
endoscopic	O	168-178
procedures	O	179-189
,	O	189-190
this	O	191-195
variable	O	196-204
has	O	205-208
not	O	209-212
been	O	213-217
well	O	218-222
documented	O	223-233
.	O	233-234

We	O	235-237
prospectively	O	238-251
evaluated	O	252-261
the	O	262-265
incidence	O	266-275
of	O	276-278
venous	B	279-285
complications	I	286-299
after	O	300-305
intravenous	O	306-317
injection	O	318-327
of	O	328-330
diazepam	O	331-339
or	O	340-342
midazolam	O	343-352
in	O	353-355
122	O	356-359
consecutive	O	360-371
patients	O	372-380
undergoing	O	381-391
colonoscopy	O	392-403
and	O	404-407
esophagogastroduodenoscopy	O	408-434
.	O	434-435

Overall	O	436-443
,	O	443-444
venous	B	445-451
complications	I	452-465
were	O	466-470
more	O	471-475
frequent	O	476-484
with	O	485-489
diazepam	O	490-498
(	O	499-500
22	O	500-502
of	O	503-505
62	O	506-508
patients	O	509-517
)	O	517-518
than	O	519-523
with	O	524-528
midazolam	O	529-538
(	O	539-540
4	O	540-541
of	O	542-544
60	O	545-547
patients	O	548-556
)	O	556-557
(	O	558-559
p	O	559-560
<	O	561-562
0	O	563-564
.	O	564-565
001	O	565-568
)	O	568-569
.	O	564-565

A	O	571-572
palpable	O	573-581
venous	O	582-588
cord	O	589-593
was	O	594-597
present	O	598-605
in	O	606-608
23	O	609-611
%	O	611-612
(	O	613-614
14	O	614-616
of	O	617-619
62	O	620-622
)	O	622-623
of	O	624-626
patients	O	627-635
in	O	636-638
the	O	639-642
diazepam	O	643-651
group	O	652-657
,	O	657-658
compared	O	659-667
with	O	668-672
2	O	673-674
%	O	674-675
(	O	676-677
1	O	677-678
of	O	679-681
60	O	682-684
patients	O	685-693
)	O	693-694
in	O	695-697
the	O	698-701
midazolam	O	702-711
group	O	712-717
(	O	718-719
p	O	719-720
<	O	721-722
0	O	723-724
.	O	724-725
002	O	725-728
)	O	728-729
.	O	724-725

Pain	B	731-735
at	O	736-738
the	O	739-742
injection	O	743-752
site	O	753-757
occurred	O	758-766
in	O	767-769
35	O	770-772
%	O	772-773
(	O	774-775
22	O	775-777
of	O	778-780
62	O	781-783
)	O	783-784
of	O	785-787
patients	O	788-796
in	O	797-799
the	O	800-803
diazepam	O	804-812
group	O	813-818
compared	O	819-827
with	O	828-832
7	O	833-834
%	O	834-835
(	O	836-837
4	O	837-838
of	O	839-841
60	O	842-844
patients	O	845-853
)	O	853-854
in	O	855-857
the	O	858-861
midazolam	O	862-871
group	O	872-877
(	O	878-879
p	O	879-880
<	O	881-882
0	O	883-884
.	O	884-885
001	O	885-888
)	O	888-889
.	O	884-885

Swelling	B	891-899
and	O	900-903
warmth	O	904-910
at	O	911-913
the	O	914-917
injection	O	918-927
site	O	928-932
were	O	933-937
not	O	938-941
significantly	O	942-955
different	O	956-965
between	O	966-973
the	O	974-977
two	O	978-981
groups	O	982-988
.	O	988-989

Smoking	O	990-997
,	O	997-998
nonsteroidal	O	999-1011
anti	O	1012-1016
-	O	1016-1017
inflammatory	O	1017-1029
drug	O	1030-1034
use	O	1035-1038
,	O	1038-1039
intravenous	O	1040-1051
catheter	O	1052-1060
site	O	1061-1065
,	O	1065-1066
dwell	O	1067-1072
time	O	1073-1077
of	O	1078-1080
the	O	1081-1084
needle	O	1085-1091
,	O	1091-1092
alcohol	O	1093-1100
use	O	1101-1104
,	O	1104-1105
and	O	1106-1109
pain	B	1110-1114
during	O	1115-1121
the	O	1122-1125
injection	O	1126-1135
had	O	1136-1139
no	O	1140-1142
effect	O	1143-1149
on	O	1150-1152
the	O	1153-1156
incidence	O	1157-1166
of	O	1167-1169
venous	B	1170-1176
complications	I	1177-1190
.	O	1190-1191

Tetany	B	0-6
and	O	7-10
rhabdomyolysis	B	11-25
due	O	26-29
to	O	30-32
surreptitious	O	33-46
furosemide	O	47-57
-	O	57-58
-	O	57-58
importance	O	59-69
of	O	70-72
magnesium	O	73-82
supplementation	O	83-98
.	O	98-99

Diuretics	O	100-109
may	O	110-113
induce	O	114-120
hypokalemia	B	121-132
,	O	132-133
hypocalcemia	B	134-146
and	O	147-150
hypomagnesemia	B	151-165
.	O	165-166

While	O	167-172
severe	O	173-179
hypokalemia	B	180-191
may	O	192-195
cause	O	196-201
muscle	B	202-208
weakness	I	209-217
,	O	217-218
severe	O	219-225
hypomagnesemia	B	226-240
is	O	241-243
associated	O	244-254
with	O	255-259
muscle	B	260-266
spasms	I	267-273
and	O	274-277
tetany	B	278-284
which	O	285-290
cannot	O	291-297
be	O	298-300
corrected	O	301-310
by	O	311-313
potassium	O	314-323
and	O	324-327
calcium	O	328-335
supplementation	O	336-351
alone	O	352-357
(	O	358-359
1	O	359-360
,	O	360-361
2	O	361-362
)	O	362-363
.	O	363-364

Surreptitious	O	365-378
diuretic	O	379-387
ingestion	O	388-397
has	O	398-401
been	O	402-406
described	O	407-416
,	O	416-417
mainly	O	418-424
in	O	425-427
women	O	428-433
who	O	434-437
are	O	438-441
concerned	O	442-451
that	O	452-456
they	O	457-461
are	O	462-465
obese	B	466-471
or	O	472-474
edematous	B	475-484
.	O	484-485

Symptomatic	O	486-497
hypokalemia	B	498-509
has	O	510-513
been	O	514-518
reported	O	519-527
in	O	528-530
such	O	531-535
patients	O	536-544
(	O	545-546
3	O	546-547
-	O	547-548
7	O	548-549
)	O	549-550
and	O	551-554
in	O	555-557
one	O	558-561
case	O	562-566
hypocalcemia	B	567-579
was	O	580-583
observed	O	584-592
(	O	593-594
8	O	594-595
)	O	595-596
,	O	596-597
but	O	598-601
the	O	602-605
effects	O	606-613
of	O	614-616
magnesium	O	617-626
depletion	O	627-636
were	O	637-641
not	O	642-645
noted	O	646-651
in	O	652-654
these	O	655-660
patients	O	661-669
.	O	669-670

Loss	O	0-4
of	O	5-7
glutamate	O	8-17
decarboxylase	O	18-31
mRNA	O	32-36
-	O	36-37
containing	O	37-47
neurons	O	48-55
in	O	56-58
the	O	59-62
rat	O	63-66
dentate	O	67-74
gyrus	O	75-80
following	O	81-90
pilocarpine	O	91-102
-	O	102-103
induced	O	103-110
seizures	B	111-119
.	O	119-120

In	O	121-123
situ	O	124-128
hybridization	O	129-142
methods	O	143-150
were	O	151-155
used	O	156-160
to	O	161-163
determine	O	164-173
if	O	174-176
glutamic	O	177-185
acid	O	186-190
decarboxylase	O	191-204
(	O	205-206
GAD	O	206-209
)	O	209-210
mRNA	O	211-215
-	O	215-216
containing	O	216-226
neurons	O	227-234
within	O	235-241
the	O	242-245
hilus	O	246-251
of	O	252-254
the	O	255-258
dentate	O	259-266
gyrus	O	267-272
are	O	273-276
vulnerable	O	277-287
to	O	288-290
seizure	B	291-298
-	O	298-299
induced	O	299-306
damage	O	307-313
in	O	314-316
a	O	317-318
model	O	319-324
of	O	325-327
chronic	O	328-335
seizures	B	336-344
.	O	344-345

Sprague	O	346-353
-	O	353-354
Dawley	O	354-360
rats	O	361-365
were	O	366-370
injected	O	371-379
intraperitoneally	O	380-397
with	O	398-402
pilocarpine	O	403-414
,	O	414-415
and	O	416-419
the	O	420-423
hippocampal	O	424-435
formation	O	436-445
was	O	446-449
studied	O	450-457
histologically	O	458-472
at	O	473-475
1	O	476-477
,	O	477-478
2	O	479-480
,	O	480-481
4	O	482-483
,	O	483-484
and	O	485-488
8	O	489-490
week	O	491-495
intervals	O	496-505
after	O	506-511
pilocarpine	O	512-523
-	O	523-524
induced	O	524-531
seizures	B	532-540
.	O	540-541

In	O	542-544
situ	O	545-549
hybridization	O	550-563
histochemistry	O	564-578
,	O	578-579
using	O	580-585
a	O	586-587
digoxigenin	O	588-599
-	O	599-600
labeled	O	600-607
GAD	O	608-611
cRNA	O	612-616
probe	O	617-622
,	O	622-623
demonstrated	O	624-636
a	O	637-638
substantial	O	639-650
decrease	O	651-659
in	O	660-662
the	O	663-666
number	O	667-673
of	O	674-676
GAD	O	677-680
mRNA	O	681-685
-	O	685-686
containing	O	686-696
neurons	O	697-704
in	O	705-707
the	O	708-711
hilus	O	712-717
of	O	718-720
the	O	721-724
dentate	O	725-732
gyrus	O	733-738
in	O	739-741
the	O	742-745
pilocarpine	O	746-757
-	O	757-758
treated	O	758-765
rats	O	766-770
as	O	771-773
compared	O	774-782
to	O	783-785
controls	O	786-794
at	O	795-797
all	O	798-801
time	O	802-806
intervals	O	807-816
.	O	816-817

Additional	O	818-828
neuronanatomical	O	829-845
studies	O	846-853
,	O	853-854
including	O	855-864
cresyl	O	865-871
violet	O	872-878
staining	O	879-887
,	O	887-888
neuronal	B	889-897
degeneration	I	898-910
methods	O	911-918
,	O	918-919
and	O	920-923
histochemical	O	924-937
localization	O	938-950
of	O	951-953
glial	O	954-959
fibrillary	O	960-970
acidic	O	971-977
protein	O	978-985
,	O	985-986
suggested	O	987-996
that	O	997-1001
the	O	1002-1005
decrease	O	1006-1014
in	O	1015-1017
the	O	1018-1021
number	O	1022-1028
of	O	1029-1031
GAD	O	1032-1035
mRNA	O	1036-1040
-	O	1040-1041
containing	O	1041-1051
neurons	O	1052-1059
was	O	1060-1063
related	O	1064-1071
to	O	1072-1074
neuronal	B	1075-1083
loss	I	1084-1088
rather	O	1089-1095
than	O	1096-1100
to	O	1101-1103
a	O	1104-1105
decrease	O	1106-1114
in	O	1115-1117
GAD	O	1118-1121
mRNA	O	1122-1126
levels	O	1127-1133
.	O	1133-1134

The	O	1135-1138
loss	O	1139-1143
of	O	1144-1146
GAD	O	1147-1150
mRNA	O	1151-1155
-	O	1155-1156
containing	O	1156-1166
neurons	O	1167-1174
in	O	1175-1177
the	O	1178-1181
hilus	O	1182-1187
contrasted	O	1188-1198
with	O	1199-1203
the	O	1204-1207
relative	O	1208-1216
preservation	O	1217-1229
of	O	1230-1232
labeled	O	1233-1240
putative	O	1241-1249
basket	O	1250-1256
cells	O	1257-1262
along	O	1263-1268
the	O	1269-1272
inner	O	1273-1278
margin	O	1279-1285
of	O	1286-1288
the	O	1289-1292
granule	O	1293-1300
cell	O	1301-1305
layer	O	1306-1311
.	O	1311-1312

Quantitative	O	1313-1325
analyses	O	1326-1334
of	O	1335-1337
labeled	O	1338-1345
neurons	O	1346-1353
in	O	1354-1356
three	O	1357-1362
regions	O	1363-1370
of	O	1371-1373
the	O	1374-1377
dentate	O	1378-1385
gyrus	O	1386-1391
in	O	1392-1394
the	O	1395-1398
1	O	1399-1400
and	O	1401-1404
2	O	1405-1406
week	O	1407-1411
groups	O	1412-1418
showed	O	1419-1425
statistically	O	1426-1439
significant	O	1440-1451
decreases	O	1452-1461
in	O	1462-1464
the	O	1465-1468
mean	O	1469-1473
number	O	1474-1480
of	O	1481-1483
GAD	O	1484-1487
mRNA	O	1488-1492
-	O	1492-1493
containing	O	1493-1503
neurons	O	1504-1511
in	O	1512-1514
the	O	1515-1518
hilus	O	1519-1524
of	O	1525-1527
both	O	1528-1532
groups	O	1533-1539
of	O	1540-1542
experimental	O	1543-1555
animals	O	1556-1563
.	O	1563-1564

No	O	1565-1567
significant	O	1568-1579
differences	O	1580-1591
were	O	1592-1596
found	O	1597-1602
in	O	1603-1605
the	O	1606-1609
molecular	O	1610-1619
layer	O	1620-1625
or	O	1626-1628
the	O	1629-1632
granule	O	1633-1640
cell	O	1641-1645
layer	O	1646-1651
,	O	1651-1652
which	O	1653-1658
included	O	1659-1667
labeled	O	1668-1675
neurons	O	1676-1683
along	O	1684-1689
the	O	1690-1693
lower	O	1694-1699
margin	O	1700-1706
of	O	1707-1709
the	O	1710-1713
granule	O	1714-1721
cell	O	1722-1726
layer	O	1727-1732
.	O	1732-1733

The	O	1734-1737
results	O	1738-1745
indicate	O	1746-1754
that	O	1755-1759
,	O	1759-1760
in	O	1761-1763
this	O	1764-1768
model	O	1769-1774
,	O	1774-1775
a	O	1776-1777
subpopulation	O	1778-1791
of	O	1792-1794
GAD	O	1795-1798
mRNA	O	1799-1803
-	O	1803-1804
containing	O	1804-1814
neurons	O	1815-1822
within	O	1823-1829
the	O	1830-1833
dentate	O	1834-1841
gyrus	O	1842-1847
is	O	1848-1850
selectively	O	1851-1862
vulnerable	O	1863-1873
to	O	1874-1876
seizure	B	1877-1884
-	O	1884-1885
induced	O	1885-1892
damage	O	1893-1899
.	O	1899-1900

Such	O	1901-1905
differential	O	1906-1918
vulnerability	O	1919-1932
appears	O	1933-1940
to	O	1941-1943
be	O	1944-1946
another	O	1947-1954
indication	O	1955-1965
of	O	1966-1968
the	O	1969-1972
heterogeneity	O	1973-1986
of	O	1987-1989
GABA	O	1990-1994
neurons	O	1995-2002
.	O	2002-2003

Protective	O	0-10
effect	O	11-17
of	O	18-20
misoprostol	O	21-32
on	O	33-35
indomethacin	O	36-48
induced	O	49-56
renal	B	57-62
dysfunction	I	63-74
in	O	75-77
elderly	O	78-85
patients	O	86-94
.	O	94-95

OBJECTIVE	O	96-105
:	O	105-106
To	O	107-109
evaluate	O	110-118
the	O	119-122
possible	O	123-131
protective	O	132-142
effects	O	143-150
of	O	151-153
misoprostol	O	154-165
on	O	166-168
renal	O	169-174
function	O	175-183
in	O	184-186
hospitalized	O	187-199
elderly	O	200-207
patients	O	208-216
treated	O	217-224
with	O	225-229
indomethacin	O	230-242
.	O	242-243

METHODS	O	244-251
:	O	251-252
Forty	O	253-258
-	O	258-259
five	O	259-263
hospitalized	O	264-276
elderly	O	277-284
patients	O	285-293
(	O	294-295
>	O	295-296
65	O	297-299
years	O	300-305
old	O	306-309
)	O	309-310
who	O	311-314
required	O	315-323
therapy	O	324-331
with	O	332-336
nonsteroidal	O	337-349
antiinflammatory	O	350-366
drugs	O	367-372
(	O	373-374
NSAID	O	374-379
)	O	379-380
were	O	381-385
randomly	O	386-394
assigned	O	395-403
to	O	404-406
receive	O	407-414
either	O	415-421
indomethacin	O	422-434
,	O	434-435
150	O	436-439
mg	O	440-442
/	O	442-443
day	O	443-446
(	O	447-448
Group	O	448-453
A	O	454-455
)	O	455-456
,	O	456-457
or	O	458-460
indomethacin	O	461-473
150	O	474-477
mg	O	478-480
/	O	480-481
day	O	481-484
plus	O	485-489
misoprostol	O	490-501
at	O	502-504
0	O	505-506
.	O	506-507
6	O	507-508
mg	O	509-511
/	O	511-512
day	O	512-515
(	O	516-517
Group	O	517-522
B	O	523-524
)	O	524-525
.	O	525-526

Laboratory	O	527-537
variables	O	538-547
of	O	548-550
renal	O	551-556
function	O	557-565
[	O	566-567
serum	O	567-572
creatinine	O	573-583
,	O	583-584
blood	O	585-590
urea	O	591-595
nitrogen	O	596-604
(	O	605-606
BUN	O	606-609
)	O	609-610
and	O	611-614
electrolytes	O	615-627
]	O	627-628
were	O	629-633
evaluated	O	634-643
before	O	644-650
initiation	O	651-661
of	O	662-664
therapy	O	665-672
and	O	673-676
every	O	677-682
2	O	683-684
days	O	685-689
,	O	689-690
until	O	691-696
termination	O	697-708
of	O	709-711
the	O	712-715
study	O	716-721
(	O	722-723
a	O	723-724
period	O	725-731
of	O	732-734
at	O	735-737
least	O	738-743
6	O	744-745
days	O	746-750
)	O	750-751
.	O	751-752

Response	O	753-761
to	O	762-764
treatment	O	765-774
was	O	775-778
estimated	O	779-788
by	O	789-791
the	O	792-795
visual	O	796-802
analog	O	803-809
scale	O	810-815
for	O	816-819
severity	O	820-828
of	O	829-831
pain	B	832-836
.	O	836-837

RESULTS	O	838-845
:	O	845-846
Forty	O	847-852
-	O	852-853
two	O	853-856
patients	O	857-865
completed	O	866-875
the	O	876-879
study	O	880-885
,	O	885-886
22	O	887-889
in	O	890-892
Group	O	893-898
A	O	899-900
and	O	901-904
20	O	905-907
in	O	908-910
Group	O	911-916
B	O	917-918
.	O	918-919
BUN	O	920-923
and	O	924-927
creatinine	O	928-938
increased	O	939-948
by	O	949-951
>	O	952-953
50	O	954-956
%	O	956-957
of	O	958-960
baseline	O	961-969
levels	O	970-976
in	O	977-979
54	O	980-982
and	O	983-986
45	O	987-989
%	O	989-990
of	O	991-993
Group	O	994-999
A	O	1000-1001
patients	O	1002-1010
,	O	1010-1011
respectively	O	1012-1024
,	O	1024-1025
compared	O	1026-1034
to	O	1035-1037
only	O	1038-1042
20	O	1043-1045
and	O	1046-1049
10	O	1050-1052
%	O	1052-1053
of	O	1054-1056
Group	O	1057-1062
B	O	1063-1064
patients	O	1065-1073
(	O	1074-1075
p	O	1075-1076
<	O	1077-1078
0	O	1079-1080
.	O	1080-1081
05	O	1081-1083
)	O	1083-1084
.	O	1080-1081

Potassium	O	1086-1095
(	O	1096-1097
K	O	1097-1098
)	O	1098-1099
increment	O	1100-1109
of	O	1110-1112
0	O	1113-1114
.	O	1114-1115
6	O	1115-1116
mEq	O	1117-1120
/	O	1120-1121
l	O	1121-1122
or	O	1123-1125
more	O	1126-1130
was	O	1131-1134
observed	O	1135-1143
in	O	1144-1146
50	O	1147-1149
%	O	1149-1150
of	O	1151-1153
Group	O	1154-1159
A	O	1160-1161
,	O	1161-1162
but	O	1163-1166
in	O	1167-1169
only	O	1170-1174
15	O	1175-1177
%	O	1177-1178
of	O	1179-1181
Group	O	1182-1187
B	O	1188-1189
patients	O	1190-1198
(	O	1199-1200
p	O	1200-1201
<	O	1202-1203
0	O	1204-1205
.	O	1205-1206
05	O	1206-1208
)	O	1208-1209
.	O	1205-1206

The	O	1211-1214
mean	O	1215-1219
increments	O	1220-1230
in	O	1231-1233
BUN	O	1234-1237
,	O	1237-1238
creatinine	O	1239-1249
,	O	1249-1250
and	O	1251-1254
K	O	1255-1256
were	O	1257-1261
reduced	O	1262-1269
by	O	1270-1272
63	O	1273-1275
,	O	1275-1276
80	O	1277-1279
,	O	1279-1280
and	O	1281-1284
42	O	1285-1287
%	O	1287-1288
,	O	1288-1289
respectively	O	1290-1302
,	O	1302-1303
in	O	1304-1306
Group	O	1307-1312
B	O	1313-1314
patients	O	1315-1323
compared	O	1324-1332
to	O	1333-1335
Group	O	1336-1341
A	O	1342-1343
.	O	1343-1344
Response	O	1345-1353
to	O	1354-1356
treatment	O	1357-1366
did	O	1367-1370
not	O	1371-1374
differ	O	1375-1381
significantly	O	1382-1395
between	O	1396-1403
the	O	1404-1407
2	O	1408-1409
groups	O	1410-1416
.	O	1416-1417

CONCLUSION	O	1418-1428
:	O	1428-1429
Hospitalized	O	1430-1442
elderly	O	1443-1450
patients	O	1451-1459
are	O	1460-1463
at	O	1464-1466
risk	O	1467-1471
for	O	1472-1475
developing	O	1476-1486
indomethacin	O	1487-1499
related	O	1500-1507
renal	B	1508-1513
dysfunction	I	1514-1525
.	O	1525-1526

Addition	O	1527-1535
of	O	1536-1538
misoprostol	O	1539-1550
can	O	1551-1554
minimize	O	1555-1563
this	O	1564-1568
renal	B	1569-1574
impairment	I	1575-1585
without	O	1586-1593
affecting	O	1594-1603
pain	B	1604-1608
control	O	1609-1616
.	O	1616-1617

Nephrotoxic	B	0-11
effects	O	12-19
of	O	20-22
aminoglycoside	O	23-37
treatment	O	38-47
on	O	48-50
renal	O	51-56
protein	O	57-64
reabsorption	O	65-77
and	O	78-81
accumulation	O	82-94
.	O	94-95

To	O	96-98
quantify	O	99-107
the	O	108-111
effects	O	112-119
of	O	120-122
gentamicin	O	123-133
,	O	133-134
kanamycin	O	135-144
and	O	145-148
netilmicin	O	149-159
on	O	160-162
renal	O	163-168
protein	O	169-176
reabsorption	O	177-189
and	O	190-193
accumulation	O	194-206
,	O	206-207
these	O	208-213
drugs	O	214-219
were	O	220-224
administered	O	225-237
to	O	238-240
rats	O	241-245
intraperitoneally	O	246-263
(	O	264-265
30	O	265-267
mg	O	268-270
/	O	270-271
kg	O	271-273
/	O	270-271
day	O	274-277
)	O	277-278
for	O	279-282
7	O	283-284
,	O	284-285
14	O	286-288
or	O	289-291
21	O	292-294
days	O	295-299
.	O	299-300

Scanning	O	301-309
electron	O	310-318
microscopy	O	319-329
of	O	330-332
the	O	333-336
glomerular	O	337-347
endothelia	O	348-358
,	O	358-359
urinary	O	360-367
measurements	O	368-380
of	O	381-383
sodium	O	384-390
,	O	390-391
potassium	O	392-401
,	O	401-402
endogenous	O	403-413
lysozyme	O	414-422
,	O	422-423
N	O	424-425
-	O	425-426
acetyl	O	426-432
-	O	425-426
beta	O	433-437
-	O	425-426
D	O	438-439
-	O	425-426
glucosaminidase	O	440-455
(	O	456-457
NAG	O	457-460
)	O	460-461
as	O	462-464
well	O	465-469
as	O	470-472
clearance	O	473-482
and	O	483-486
accumulation	O	487-499
experiments	O	500-511
after	O	512-517
i	O	518-519
.	O	519-520
v	O	520-521
.	O	519-520

administration	O	523-537
of	O	538-540
egg	O	541-544
-	O	544-545
white	O	545-550
lysozyme	O	551-559
and	O	560-563
measurements	O	564-576
of	O	577-579
inulin	O	580-586
clearance	O	587-596
(	O	597-598
GFR	O	598-601
)	O	601-602
were	O	603-607
done	O	608-612
in	O	613-615
each	O	616-620
treatment	O	621-630
group	O	631-636
.	O	636-637

Gentamicin	O	638-648
administration	O	649-663
decreased	O	664-673
diameter	O	674-682
,	O	682-683
density	O	684-691
and	O	692-695
shape	O	696-701
of	O	702-704
endothelial	O	705-716
fenestrae	O	717-726
.	O	726-727

Kanamycin	O	728-737
and	O	738-741
netilmicin	O	742-752
appeared	O	753-761
to	O	762-764
have	O	765-769
no	O	770-772
effect	O	773-779
at	O	780-782
the	O	783-786
dose	O	787-791
used	O	792-796
.	O	796-797

All	O	798-801
three	O	802-807
aminoglycosides	O	808-823
decreased	O	824-833
GFR	O	834-837
and	O	838-841
increased	O	842-851
urinary	O	852-859
excretion	O	860-869
of	O	870-872
sodium	O	873-879
and	O	880-883
potassium	O	884-893
.	O	893-894

While	O	895-900
gentamicin	O	901-911
and	O	912-915
kanamycin	O	916-925
decreased	O	926-935
the	O	936-939
percentage	O	940-950
reabsorption	O	951-963
and	O	964-967
accumulation	O	968-980
of	O	981-983
lysozyme	O	984-992
after	O	993-998
i	O	999-1000
.	O	1000-1001
v	O	1001-1002
.	O	1000-1001

administration	O	1004-1018
of	O	1019-1021
egg	O	1022-1025
-	O	1025-1026
white	O	1026-1031
lysozyme	O	1032-1040
netilmicin	O	1041-1051
had	O	1052-1055
no	O	1056-1058
effect	O	1059-1065
.	O	1065-1066

Daily	O	1067-1072
excretion	O	1073-1082
of	O	1083-1085
total	O	1086-1091
protein	O	1092-1099
,	O	1099-1100
endogenous	O	1101-1111
lysozyme	O	1112-1120
and	O	1121-1124
NAG	O	1125-1128
increased	O	1129-1138
only	O	1139-1143
after	O	1144-1149
treatment	O	1150-1159
with	O	1160-1164
kanamycin	O	1165-1174
and	O	1175-1178
gentamicin	O	1179-1189
.	O	1189-1190

Thus	O	1191-1195
,	O	1195-1196
aminoglycosides	O	1197-1212
may	O	1213-1216
act	O	1217-1220
as	O	1221-1223
nephrotoxicants	O	1224-1239
at	O	1240-1242
glomerular	O	1243-1253
and	O	1254-1257
/	O	1257-1258
or	O	1258-1260
tubular	O	1261-1268
level	O	1269-1274
inducing	O	1275-1283
impairment	B	1284-1294
of	I	1295-1297
renal	I	1298-1303
reabsorption	I	1304-1316
and	O	1317-1320
accumulation	O	1321-1333
of	O	1334-1336
proteins	O	1337-1345
.	O	1345-1346

Pharmacology	O	0-12
of	O	13-15
GYKI	O	16-20
-	O	20-21
41	O	21-23
099	O	24-27
(	O	28-29
chlorpropanol	O	29-42
,	O	42-43
Tobanum	O	44-51
)	O	51-52
a	O	53-54
new	O	55-58
potent	O	59-65
beta	O	66-70
-	O	70-71
adrenergic	O	71-81
antagonist	O	82-92
.	O	92-93

The	O	94-97
compound	O	98-106
GYKI	O	107-111
-	O	111-112
41	O	112-114
099	O	115-118
,	O	118-119
as	O	120-122
a	O	123-124
beta	O	125-129
-	O	129-130
adrenergic	O	130-140
antagonist	O	141-151
,	O	151-152
is	O	153-155
3	O	156-157
-	O	157-158
8	O	158-159
times	O	160-165
more	O	166-170
potent	O	171-177
than	O	178-182
propranolol	O	183-194
in	O	195-197
vitro	O	198-203
and	O	204-207
in	O	208-210
vivo	O	211-215
.	O	215-216

Its	O	217-220
antiarrhythmic	O	221-235
effectiveness	O	236-249
surpasses	O	250-259
that	O	260-264
of	O	265-267
propranolol	O	268-279
and	O	280-283
pindolol	O	284-292
inhibiting	O	293-303
the	O	304-307
ouabain	O	308-315
arrhythmia	B	316-326
in	O	327-329
dogs	O	330-334
and	O	335-338
cats	O	339-343
.	O	343-344

GYKI	O	345-349
-	O	349-350
41	O	350-352
900	O	353-356
has	O	357-360
a	O	361-362
negligible	O	363-373
cardiodepressant	O	374-390
activity	O	391-399
;	O	399-400
it	O	401-403
is	O	404-406
not	O	407-410
cardioselective	O	411-426
.	O	426-427

The	O	428-431
compound	O	432-440
shows	O	441-446
a	O	447-448
rapid	O	449-454
and	O	455-458
long	O	459-463
lasting	O	464-471
effect	O	472-478
.	O	478-479

There	O	480-485
was	O	486-489
a	O	490-491
prolonged	O	492-501
elimination	O	502-513
of	O	514-516
the	O	517-520
radioactivity	O	521-534
after	O	535-540
the	O	541-544
injection	O	545-554
of	O	555-557
14C	O	558-561
-	O	561-562
41	O	562-564
099	O	565-568
to	O	569-571
rats	O	572-576
and	O	577-580
dogs	O	581-585
.	O	585-586

The	O	587-590
half	O	591-595
life	O	596-600
of	O	601-603
the	O	604-607
unlabeled	O	608-617
substance	O	618-627
in	O	628-630
humans	O	631-637
was	O	638-641
more	O	642-646
than	O	647-651
10	O	652-654
hours	O	655-660
.	O	660-661

Chorea	B	0-6
associated	O	7-17
with	O	18-22
oral	O	23-27
contraception	O	28-41
.	O	41-42

Three	O	43-48
patients	O	49-57
developed	O	58-67
chorea	B	68-74
while	O	75-80
receiving	O	81-90
oral	O	91-95
contraceptives	O	96-110
.	O	110-111

Two	O	112-115
were	O	116-120
young	O	121-126
patients	O	127-135
whose	O	136-141
chorea	B	142-148
developed	O	149-158
long	O	159-163
after	O	164-169
treatment	O	170-179
had	O	180-183
been	O	184-188
started	O	189-196
and	O	197-200
disappeared	O	201-212
soon	O	213-217
after	O	218-223
it	O	224-226
had	O	227-230
been	O	231-235
discontinued	O	236-248
.	O	248-249

The	O	250-253
third	O	254-259
patient	O	260-267
had	O	268-271
acute	O	272-277
amphetamine	O	278-289
-	O	289-290
induced	O	290-297
chorea	B	298-304
after	O	305-310
prolonged	O	311-320
oral	O	321-325
contraception	O	326-339
.	O	339-340

Prolonged	O	341-350
administration	O	351-365
of	O	366-368
female	O	369-375
sex	O	376-379
hormones	O	380-388
is	O	389-391
a	O	392-393
possible	O	394-402
cause	O	403-408
of	O	409-411
chorea	B	412-418
in	O	419-421
women	O	422-427
who	O	428-431
have	O	432-436
not	O	437-440
previously	O	441-451
had	O	452-455
chorea	B	456-462
or	O	463-465
rheumatic	B	466-475
fever	I	476-481
.	O	481-482

Reversal	O	0-8
of	O	9-11
ammonia	O	12-19
coma	B	20-24
in	O	25-27
rats	O	28-32
by	O	33-35
L	O	36-37
-	O	37-38
dopa	O	38-42
:	O	42-43
a	O	44-45
peripheral	O	46-56
effect	O	57-63
.	O	63-64

Ammonia	O	65-72
coma	B	73-77
was	O	78-81
produced	O	82-90
in	O	91-93
rats	O	94-98
within	O	99-105
10	O	106-108
to	O	109-111
15	O	112-114
minutes	O	115-122
of	O	123-125
an	O	126-128
intraperitonealinjection	O	129-153
of	O	154-156
1	O	157-158
.	O	158-159
7	O	159-160
mmol	O	161-165
NH4CL	O	166-171
.	O	171-172

This	O	173-177
coma	B	178-182
was	O	183-186
prevented	O	187-196
with	O	197-201
1	O	202-203
.	O	203-204
68	O	204-206
mmol	O	207-211
L	O	212-213
-	O	213-214
dopa	O	214-218
given	O	219-224
by	O	225-227
gastric	O	228-235
intubation	O	236-246
15	O	247-249
minutes	O	250-257
before	O	258-264
the	O	265-268
ammonium	O	269-277
salt	O	278-282
injection	O	283-292
.	O	292-293

The	O	294-297
effect	O	298-304
of	O	305-307
L	O	308-309
-	O	309-310
dopa	O	310-314
was	O	315-318
correlated	O	319-329
with	O	330-334
a	O	335-336
decrease	O	337-345
in	O	346-348
blood	O	349-354
and	O	355-358
brain	O	359-364
ammonia	O	365-372
,	O	372-373
an	O	374-376
increase	O	377-385
in	O	386-388
brain	O	389-394
dopamine	O	395-403
,	O	403-404
and	O	405-408
an	O	409-411
increase	O	412-420
in	O	421-423
renal	O	424-429
excretion	O	430-439
of	O	440-442
ammonia	O	443-450
and	O	451-454
urea	O	455-459
.	O	459-460

Intraventricular	O	461-477
infusion	O	478-486
of	O	487-489
dopamine	O	490-498
sufficient	O	499-509
to	O	510-512
raise	O	513-518
the	O	519-522
brain	O	523-528
dopamine	O	529-537
to	O	538-540
the	O	541-544
same	O	545-549
extent	O	550-556
did	O	557-560
not	O	561-564
prevent	O	565-572
the	O	573-576
ammonia	O	577-584
coma	B	585-589
nor	O	590-593
affect	O	594-600
the	O	601-604
blood	O	605-610
and	O	611-614
brain	O	615-620
ammonia	O	621-628
concentrations	O	629-643
.	O	643-644

Bilateral	O	645-654
nephrectomy	O	655-666
eliminated	O	667-677
the	O	678-681
beneficial	O	682-692
effect	O	693-699
of	O	700-702
L	O	703-704
-	O	704-705
dopa	O	705-709
on	O	710-712
blood	O	713-718
and	O	719-722
brain	O	723-728
ammonia	O	729-736
and	O	737-740
the	O	741-744
ammonia	O	745-752
coma	B	753-757
was	O	758-761
not	O	762-765
prevented	O	766-775
.	O	775-776

Thus	O	777-781
,	O	781-782
the	O	783-786
reduction	O	787-796
in	O	797-799
blood	O	800-805
and	O	806-809
brain	O	810-815
ammonia	O	816-823
and	O	824-827
the	O	828-831
prevention	O	832-842
of	O	843-845
ammonia	O	846-853
coma	B	854-858
after	O	859-864
L	O	865-866
-	O	866-867
dopa	O	867-871
,	O	871-872
can	O	873-876
be	O	877-879
accounted	O	880-889
for	O	890-893
by	O	894-896
the	O	897-900
peripheral	O	901-911
effect	O	912-918
of	O	919-921
dopamine	O	922-930
on	O	931-933
renal	O	934-939
function	O	940-948
rather	O	949-955
than	O	956-960
its	O	961-964
central	O	965-972
action	O	973-979
.	O	979-980

These	O	981-986
results	O	987-994
provide	O	995-1002
a	O	1003-1004
reasonable	O	1005-1015
explanation	O	1016-1027
for	O	1028-1031
the	O	1032-1035
beneficial	O	1036-1046
effects	O	1047-1054
observed	O	1055-1063
in	O	1064-1066
some	O	1067-1071
encephalopathic	B	1072-1087
patients	O	1088-1096
receiving	O	1097-1106
L	O	1107-1108
-	O	1108-1109
dopa	O	1109-1113
.	O	1113-1114

Heparin	O	0-7
-	O	7-8
induced	O	8-15
thrombocytopenia	B	16-32
after	O	33-38
liver	O	39-44
transplantation	O	45-60
.	O	60-61

BACKGROUND	O	62-72
:	O	72-73
Unfractionated	O	74-88
heparin	O	89-96
sodium	O	97-103
(	O	104-105
UFH	O	105-108
)	O	108-109
or	O	110-112
low	O	113-116
-	O	116-117
molecular	O	117-126
weight	O	127-133
heparin	O	134-141
(	O	142-143
LMWH	O	143-147
)	O	147-148
is	O	149-151
used	O	152-156
in	O	157-159
anticoagulant	O	160-173
protocols	O	174-183
at	O	184-186
several	O	187-194
institutions	O	195-207
to	O	208-210
prevent	O	211-218
thrombosis	B	219-229
after	O	230-235
liver	O	236-241
transplantation	O	242-257
.	O	257-258

Heparin	O	259-266
-	O	266-267
induced	O	267-274
thrombocytopenia	B	275-291
(	O	292-293
HIT	B	293-296
)	O	296-297
is	O	298-300
an	O	301-303
adverse	O	304-311
immune	O	312-318
-	O	318-319
mediated	O	319-327
reaction	O	328-336
to	O	337-339
heparin	O	340-347
,	O	347-348
resulting	O	349-358
in	O	359-361
platelet	O	362-370
count	O	371-376
decreases	O	377-386
of	O	387-389
more	O	390-394
than	O	395-399
50	O	400-402
%	O	402-403
.	O	403-404

The	O	405-408
frequencies	O	409-420
of	O	421-423
HIT	B	424-427
after	O	428-433
liver	O	434-439
transplantation	O	440-455
and	O	456-459
platelet	O	460-468
factor	O	469-475
4	O	476-477
/	O	477-478
heparin	O	478-485
-	O	485-486
reactive	O	486-494
antibody	O	495-503
(	O	504-505
HIT	B	505-508
antibody	O	509-517
)	O	517-518
positivity	O	519-529
in	O	530-532
liver	O	533-538
transplantation	O	539-554
patients	O	555-563
,	O	563-564
however	O	565-572
,	O	572-573
are	O	574-577
unknown	O	578-585
.	O	585-586

PATIENTS	O	587-595
AND	O	596-599
METHODS	O	600-607
:	O	607-608
The	O	609-612
32	O	613-615
men	O	616-619
and	O	620-623
20	O	624-626
women	O	627-632
underwent	O	633-642
living	O	643-649
donor	O	650-655
liver	O	656-661
transplantation	O	662-677
.	O	677-678

We	O	679-681
started	O	682-689
LMWH	O	690-694
(	O	695-696
25	O	696-698
IU	O	699-701
/	O	701-702
kg	O	702-704
/	O	701-702
h	O	705-706
)	O	706-707
on	O	708-710
postoperative	O	711-724
day	O	725-728
(	O	729-730
POD	O	730-733
)	O	733-734
1	O	735-736
,	O	736-737
switching	O	738-747
to	O	748-750
UFH	O	751-754
(	O	755-756
5000	O	756-760
U	O	761-762
/	O	762-763
d	O	763-764
)	O	764-765
on	O	766-768
POD	O	769-772
2	O	773-774
or	O	775-777
3	O	778-779
.	O	779-780

The	O	781-784
dose	O	785-789
of	O	790-792
UFH	O	793-796
was	O	797-800
changed	O	801-808
according	O	809-818
to	O	819-821
the	O	822-825
activated	O	826-835
clotting	O	836-844
time	O	845-849
level	O	850-855
.	O	855-856

HIT	B	857-860
antibody	O	861-869
levels	O	870-876
were	O	877-881
measured	O	882-890
the	O	891-894
day	O	895-898
before	O	899-905
surgery	O	906-913
and	O	914-917
on	O	918-920
POD	O	921-924
7	O	925-926
and	O	927-930
14	O	931-933
.	O	933-934

Platelet	O	935-943
count	O	944-949
was	O	950-953
measured	O	954-962
daily	O	963-968
for	O	969-972
3	O	973-974
weeks	O	975-980
.	O	980-981

RESULTS	O	982-989
:	O	989-990
The	O	991-994
average	O	995-1002
platelet	O	1003-1011
counts	O	1012-1018
preoperatively	O	1019-1033
,	O	1033-1034
and	O	1035-1038
on	O	1039-1041
POD	O	1042-1045
7	O	1046-1047
,	O	1047-1048
14	O	1049-1051
,	O	1051-1052
and	O	1053-1056
21	O	1057-1059
were	O	1060-1064
65	O	1065-1067
,	O	1067-1068
88	O	1069-1071
,	O	1071-1072
149	O	1073-1076
,	O	1076-1077
and	O	1078-1081
169	O	1082-1085
x	O	1086-1087
10	O	1088-1090
(	O	1090-1091
9	O	1091-1092
)	O	1092-1093
/	O	1093-1094
L	O	1094-1095
,	O	1095-1096
respectively	O	1097-1109
.	O	1109-1110

Two	O	1111-1114
patients	O	1115-1123
developed	O	1124-1133
hepatic	O	1134-1141
artery	O	1142-1148
thrombosis	B	1149-1159
on	O	1160-1162
POD	O	1163-1166
11	O	1167-1169
and	O	1170-1173
19	O	1174-1176
,	O	1176-1177
respectively	O	1178-1190
,	O	1190-1191
although	O	1192-1200
they	O	1201-1205
were	O	1206-1210
HIT	B	1211-1214
antibody	O	1215-1223
-	O	1223-1224
negative	O	1224-1232
and	O	1233-1236
their	O	1237-1242
platelet	O	1243-1251
counts	O	1252-1258
were	O	1259-1263
stable	O	1264-1270
.	O	1270-1271

In	O	1272-1274
2	O	1275-1276
other	O	1277-1282
patients	O	1283-1291
,	O	1291-1292
the	O	1293-1296
platelet	O	1297-1305
count	O	1306-1311
decreased	O	1312-1321
suddenly	O	1322-1330
from	O	1331-1335
107	O	1336-1339
x	O	1340-1341
10	O	1342-1344
(	O	1344-1345
9	O	1345-1346
)	O	1346-1347
/	O	1347-1348
L	O	1348-1349
on	O	1350-1352
POD	O	1353-1356
4	O	1357-1358
to	O	1359-1361
65	O	1362-1364
x	O	1365-1366
10	O	1367-1369
(	O	1369-1370
9	O	1370-1371
)	O	1371-1372
/	O	1372-1373
L	O	1373-1374
on	O	1375-1377
POD	O	1378-1381
6	O	1382-1383
and	O	1384-1387
from	O	1388-1392
76	O	1393-1395
x	O	1396-1397
10	O	1398-1400
(	O	1400-1401
9	O	1401-1402
)	O	1402-1403
/	O	1403-1404
L	O	1404-1405
on	O	1406-1408
POD	O	1409-1412
7	O	1413-1414
to	O	1415-1417
33	O	1418-1420
x	O	1421-1422
10	O	1423-1425
(	O	1425-1426
9	O	1426-1427
)	O	1427-1428
/	O	1428-1429
L	O	1429-1430
on	O	1431-1433
POD	O	1434-1437
9	O	1438-1439
,	O	1439-1440
respectively	O	1441-1453
.	O	1453-1454

The	O	1455-1458
heparin	O	1459-1466
-	O	1466-1467
induced	O	1467-1474
platelet	B	1475-1483
aggregation	I	1484-1495
test	O	1496-1500
was	O	1501-1504
negative	O	1505-1513
in	O	1514-1516
these	O	1517-1522
patients	O	1523-1531
.	O	1531-1532

The	O	1533-1536
percentage	O	1537-1547
of	O	1548-1550
HIT	B	1551-1554
antibody	O	1555-1563
-	O	1563-1564
positive	O	1564-1572
patients	O	1573-1581
was	O	1582-1585
0	O	1586-1587
.	O	1587-1588
5	O	1588-1589
%	O	1589-1590
preoperatively	O	1591-1605
,	O	1605-1606
5	O	1607-1608
.	O	1608-1609
6	O	1609-1610
%	O	1610-1611
on	O	1612-1614
POD	O	1615-1618
7	O	1619-1620
,	O	1620-1621
and	O	1622-1625
5	O	1626-1627
.	O	1627-1628
6	O	1628-1629
%	O	1629-1630
on	O	1631-1633
POD	O	1634-1637
14	O	1638-1640
.	O	1640-1641

None	O	1642-1646
of	O	1647-1649
the	O	1650-1653
subjects	O	1654-1662
/	O	1662-1663
patients	O	1663-1671
developed	O	1672-1681
UFH	O	1682-1685
-	O	1685-1686
related	O	1686-1693
HIT	B	1694-1697
.	O	1697-1698

CONCLUSIONS	O	1699-1710
:	O	1710-1711
In	O	1712-1714
our	O	1715-1718
series	O	1719-1725
,	O	1725-1726
the	O	1727-1730
occurrence	O	1731-1741
of	O	1742-1744
HIT	B	1745-1748
after	O	1749-1754
liver	O	1755-1760
transplantation	O	1761-1776
was	O	1777-1780
uncommon	O	1781-1789
.	O	1789-1790

PTU	O	0-3
-	O	3-4
associated	O	4-14
vasculitis	B	15-25
in	O	26-28
a	O	29-30
girl	O	31-35
with	O	36-40
Turner	B	41-47
Syndrome	I	48-56
and	O	57-60
Graves	B	61-67
'	I	67-68
disease	I	69-76
.	O	76-77

Palpable	O	78-86
purpura	B	87-94
is	O	95-97
a	O	98-99
concerning	O	100-110
clinical	O	111-119
finding	O	120-127
in	O	128-130
pediatric	O	131-140
patients	O	141-149
and	O	150-153
can	O	154-157
have	O	158-162
many	O	163-167
causes	O	168-174
,	O	174-175
including	O	176-185
infectious	O	186-196
and	O	197-200
autoimmune	O	201-211
processes	O	212-221
.	O	221-222

A	O	223-224
rare	O	225-229
cause	O	230-235
,	O	235-236
drug	O	237-241
-	O	241-242
induced	O	242-249
vasculitis	B	250-260
,	O	260-261
may	O	262-265
result	O	266-272
from	O	273-277
the	O	278-281
production	O	282-292
of	O	293-295
antineutrophil	O	296-310
cytoplasmic	O	311-322
antibodies	O	323-333
(	O	334-335
ANCAs	O	335-340
)	O	340-341
in	O	342-344
response	O	345-353
to	O	354-356
a	O	357-358
medication	O	359-369
.	O	369-370

We	O	371-373
report	O	374-380
a	O	381-382
girl	O	383-387
with	O	388-392
Turner	B	393-399
syndrome	I	400-408
and	O	409-412
Graves	B	413-419
'	I	419-420
disease	I	421-428
who	O	429-432
presented	O	433-442
with	O	443-447
palpable	O	448-456
purpuric	B	457-465
lesions	I	466-473
.	O	473-474

The	O	475-478
diagnosis	O	479-488
of	O	489-491
propylthiouracil	O	492-508
(	O	509-510
PTU	O	510-513
)	O	513-514
-	O	514-515
associated	O	515-525
vasculitis	B	526-536
was	O	537-540
made	O	541-545
by	O	546-548
observation	O	549-560
of	O	561-563
consistent	O	564-574
clinical	O	575-583
features	O	584-592
,	O	592-593
the	O	594-597
detection	O	598-607
of	O	608-610
elevated	O	611-619
ANA	O	620-623
and	O	624-627
ANCA	O	628-632
in	O	633-635
the	O	636-639
blood	O	640-645
,	O	645-646
and	O	647-650
the	O	651-654
observed	O	655-663
clinical	O	664-672
resolution	O	673-683
of	O	684-686
symptoms	O	687-695
following	O	696-705
withdrawal	O	706-716
of	O	717-719
PTU	O	720-723
.	O	723-724

Subsequent	O	725-735
treatment	O	736-745
of	O	746-748
persistent	O	749-759
hyperthyroidism	B	760-775
with	O	776-780
radioablation	O	781-794
did	O	795-798
not	O	799-802
result	O	803-809
in	O	810-812
an	O	813-815
exacerbation	O	816-828
of	O	829-831
the	O	832-835
vasculitis	B	836-846
,	O	846-847
a	O	848-849
complication	O	850-862
described	O	863-872
in	O	873-875
prior	O	876-881
case	O	882-886
reports	O	887-894
.	O	894-895

Succinylcholine	O	0-15
-	O	15-16
induced	O	16-23
masseter	B	24-32
muscle	I	33-39
rigidity	I	40-48
during	O	49-55
bronchoscopic	O	56-69
removal	O	70-77
of	O	78-80
a	O	81-82
tracheal	O	83-91
foreign	O	92-99
body	O	100-104
.	O	104-105

Masseter	B	106-114
muscle	I	115-121
rigidity	I	122-130
during	O	131-137
general	O	138-145
anesthesia	O	146-156
is	O	157-159
considered	O	160-170
an	O	171-173
early	O	174-179
warning	O	180-187
sign	O	188-192
of	O	193-195
a	O	196-197
possible	O	198-206
episode	O	207-214
of	O	215-217
malignant	B	218-227
hyperthermia	I	228-240
.	O	240-241

The	O	242-245
decision	O	246-254
whether	O	255-262
to	O	263-265
continue	O	266-274
or	O	275-277
discontinue	O	278-289
the	O	290-293
procedure	O	294-303
depends	O	304-311
on	O	312-314
the	O	315-318
urgency	O	319-326
of	O	327-329
the	O	330-333
surgery	O	334-341
and	O	342-345
severity	O	346-354
of	O	355-357
masseter	B	358-366
muscle	I	367-373
rigidity	I	374-382
.	O	382-383

Here	O	384-388
,	O	388-389
we	O	390-392
describe	O	393-401
a	O	402-403
case	O	404-408
of	O	409-411
severe	O	412-418
masseter	B	419-427
muscle	I	428-434
rigidity	I	435-443
(	O	444-445
jaw	B	445-448
of	I	449-451
steel	I	452-457
)	O	457-458
after	O	459-464
succinylcholine	O	465-480
(	O	481-482
Sch	O	482-485
)	O	485-486
administration	O	487-501
during	O	502-508
general	O	509-516
anesthetic	O	517-527
management	O	528-538
for	O	539-542
rigid	O	543-548
bronchoscopic	O	549-562
removal	O	563-570
of	O	571-573
a	O	574-575
tracheal	O	576-584
foreign	O	585-592
body	O	593-597
.	O	597-598

Anesthesia	O	599-609
was	O	610-613
continued	O	614-623
uneventfully	O	624-636
with	O	637-641
propofol	O	642-650
infusion	O	651-659
while	O	660-665
all	O	666-669
facilities	O	670-680
were	O	681-685
available	O	686-695
to	O	696-698
detect	O	699-705
and	O	706-709
treat	O	710-715
malignant	B	716-725
hyperthermia	I	726-738
.	O	738-739

Minor	O	0-5
neurological	B	6-18
dysfunction	I	19-30
,	O	30-31
cognitive	O	32-41
development	O	42-53
,	O	53-54
and	O	55-58
somatic	O	59-66
development	O	67-78
at	O	79-81
the	O	82-85
age	O	86-89
of	O	90-92
3	O	93-94
to	O	95-97
7	O	98-99
years	O	100-105
after	O	106-111
dexamethasone	O	112-125
treatment	O	126-135
in	O	136-138
very	O	139-143
-	O	143-144
low	O	144-147
birth	O	148-153
-	O	153-154
weight	O	154-160
infants	O	161-168
.	O	168-169

The	O	170-173
objective	O	174-183
of	O	184-186
this	O	187-191
study	O	192-197
was	O	198-201
to	O	202-204
assess	O	205-211
minor	O	212-217
neurological	B	218-230
dysfunction	I	231-242
,	O	242-243
cognitive	O	244-253
development	O	254-265
,	O	265-266
and	O	267-270
somatic	O	271-278
development	O	279-290
after	O	291-296
dexamethasone	O	297-310
therapy	O	311-318
in	O	319-321
very	O	322-326
-	O	326-327
low	O	327-330
-	O	326-327
birthweight	O	331-342
infants	O	343-350
.	O	350-351

Thirty	O	352-358
-	O	358-359
three	O	359-364
children	O	365-373
after	O	374-379
dexamethasone	O	380-393
treatment	O	394-403
were	O	404-408
matched	O	409-416
to	O	417-419
33	O	420-422
children	O	423-431
without	O	432-439
dexamethasone	O	440-453
treatment	O	454-463
.	O	463-464

Data	O	465-469
were	O	470-474
assessed	O	475-483
at	O	484-486
the	O	487-490
age	O	491-494
of	O	495-497
3	O	498-499
-	O	499-500
7	O	500-501
years	O	502-507
.	O	507-508

Dexamethasone	O	509-522
was	O	523-526
started	O	527-534
between	O	535-542
the	O	543-546
7th	O	547-550
and	O	551-554
the	O	555-558
28th	O	559-563
day	O	564-567
of	O	568-570
life	O	571-575
over	O	576-580
7	O	581-582
days	O	583-587
with	O	588-592
a	O	593-594
total	O	595-600
dose	O	601-605
of	O	606-608
2	O	609-610
.	O	610-611
35	O	611-613
mg	O	614-616
/	O	616-617
kg	O	617-619
/	O	616-617
day	O	620-623
.	O	623-624

Exclusion	O	625-634
criteria	O	635-643
were	O	644-648
asphyxia	B	649-657
,	O	657-658
malformations	B	659-672
,	O	672-673
major	O	674-679
surgical	O	680-688
interventions	O	689-702
,	O	702-703
small	O	704-709
for	O	710-713
gestational	O	714-725
age	O	726-729
,	O	729-730
intraventricular	O	731-747
haemorrhage	B	748-759
grades	O	760-766
III	O	767-770
and	O	771-774
IV	O	775-777
,	O	777-778
periventricular	B	779-794
leukomalacia	I	795-807
,	O	807-808
and	O	809-812
severe	O	813-819
psychomotor	B	820-831
retardation	I	832-843
.	O	843-844

Each	O	845-849
child	O	850-855
was	O	856-859
examined	O	860-868
by	O	869-871
a	O	872-873
neuropediatrician	O	874-891
for	O	892-895
minor	O	896-901
neurological	B	902-914
dysfunctions	I	915-927
and	O	928-931
tested	O	932-938
by	O	939-941
a	O	942-943
psychologist	O	944-956
for	O	957-960
cognitive	O	961-970
development	O	971-982
with	O	983-987
a	O	988-989
Kaufman	O	990-997
Assessment	O	998-1008
Battery	O	1009-1016
for	O	1017-1020
Children	O	1021-1029
and	O	1030-1033
a	O	1034-1035
Draw	O	1036-1040
-	O	1040-1041
a	O	1038-1039
-	O	1040-1041
Man	O	1043-1046
Test	O	1047-1051
.	O	1051-1052

There	O	1053-1058
were	O	1059-1063
no	O	1064-1066
differences	O	1067-1078
in	O	1079-1081
demographic	O	1082-1093
data	O	1094-1098
,	O	1098-1099
growth	O	1100-1106
,	O	1106-1107
and	O	1108-1111
socio	O	1112-1117
-	O	1117-1118
economic	O	1118-1126
status	O	1127-1133
between	O	1134-1141
the	O	1142-1145
two	O	1146-1149
groups	O	1150-1156
.	O	1156-1157

Fine	O	1158-1162
motor	O	1163-1168
skills	O	1169-1175
and	O	1176-1179
gross	O	1180-1185
motor	O	1186-1191
function	O	1192-1200
were	O	1201-1205
significantly	O	1206-1219
better	O	1220-1226
in	O	1227-1229
the	O	1230-1233
control	O	1234-1241
group	O	1242-1247
(	O	1248-1249
p	O	1249-1250
<	O	1250-1251
0	O	1251-1252
.	O	1252-1253
01	O	1253-1255
)	O	1255-1256
.	O	1252-1253

In	O	1258-1260
the	O	1261-1264
Draw	O	1265-1269
-	O	1269-1270
a	O	1267-1268
-	O	1269-1270
Man	O	1272-1275
Test	O	1276-1280
,	O	1280-1281
the	O	1282-1285
control	O	1286-1293
group	O	1294-1299
showed	O	1300-1306
better	O	1307-1313
results	O	1314-1321
(	O	1322-1323
p	O	1323-1324
<	O	1324-1325
0	O	1325-1326
.	O	1326-1327
001	O	1327-1330
)	O	1330-1331
.	O	1326-1327

There	O	1333-1338
were	O	1339-1343
no	O	1344-1346
differences	O	1347-1358
in	O	1359-1361
development	O	1362-1373
of	O	1374-1376
speech	O	1377-1383
,	O	1383-1384
social	O	1385-1391
development	O	1392-1403
,	O	1403-1404
and	O	1405-1408
the	O	1409-1412
Kaufman	O	1413-1420
Assessment	O	1421-1431
Battery	O	1432-1439
for	O	1440-1443
Children	O	1444-1452
.	O	1452-1453

After	O	1454-1459
dexamethasone	O	1460-1473
treatment	O	1474-1483
,	O	1483-1484
children	O	1485-1493
showed	O	1494-1500
a	O	1501-1502
higher	O	1503-1509
rate	O	1510-1514
of	O	1515-1517
minor	O	1518-1523
neurological	B	1524-1536
dysfunctions	I	1537-1549
.	O	1549-1550

Neurological	O	1551-1563
development	O	1564-1575
was	O	1576-1579
affected	O	1580-1588
even	O	1589-1593
without	O	1594-1601
neurological	O	1602-1614
diagnosis	O	1615-1624
.	O	1624-1625

Further	O	1626-1633
long	O	1634-1638
-	O	1638-1639
term	O	1639-1643
follow	O	1644-1650
-	O	1650-1651
up	O	1651-1653
studies	O	1654-1661
will	O	1662-1666
be	O	1667-1669
necessary	O	1670-1679
to	O	1680-1682
fully	O	1683-1688
evaluate	O	1689-1697
the	O	1698-1701
impact	O	1702-1708
of	O	1709-1711
dexamethasone	O	1712-1725
on	O	1726-1728
neurological	O	1729-1741
and	O	1742-1745
cognitive	O	1746-1755
development	O	1756-1767
.	O	1767-1768

Force	O	0-5
overflow	O	6-14
and	O	15-18
levodopa	O	19-27
-	O	27-28
induced	O	28-35
dyskinesias	B	36-47
in	O	48-50
Parkinson	B	51-60
'	I	60-61
s	I	57-58
disease	I	63-70
.	O	70-71

We	O	72-74
assessed	O	75-83
force	O	84-89
coordination	O	90-102
of	O	103-105
the	O	106-109
hand	O	110-114
in	O	115-117
Parkinson	B	118-127
'	I	127-128
s	I	124-125
disease	I	130-137
and	O	138-141
its	O	142-145
relationship	O	146-158
to	O	159-161
motor	O	162-167
complications	O	168-181
of	O	182-184
levodopa	O	185-193
therapy	O	194-201
,	O	201-202
particularly	O	203-215
to	O	216-218
levodopa	O	219-227
-	O	227-228
induced	O	228-235
dyskinesias	B	236-247
(	O	248-249
LID	B	249-252
)	O	252-253
.	O	253-254

We	O	255-257
studied	O	258-265
two	O	266-269
groups	O	270-276
of	O	277-279
Parkinson	B	280-289
'	I	289-290
s	I	286-287
disease	I	292-299
patients	O	300-308
with	O	309-313
(	O	314-315
Parkinson	B	315-324
'	I	324-325
s	I	321-322
disease	I	327-334
+	O	335-336
LID	B	337-340
,	O	340-341
n	O	342-343
=	O	344-345
23	O	346-348
)	O	348-349
and	O	350-353
without	O	354-361
levodopa	O	362-370
-	O	370-371
induced	O	371-378
dyskinesias	B	379-390
(	O	391-392
Parkinson	B	392-401
'	I	401-402
s	I	398-399
disease	I	404-411
-	O	412-413
LID	B	414-417
,	O	417-418
n	O	419-420
=	O	421-422
10	O	423-425
)	O	425-426
,	O	426-427
and	O	428-431
age	O	432-435
-	O	435-436
matched	O	436-443
healthy	O	444-451
controls	O	452-460
.	O	460-461

The	O	462-465
motor	O	466-471
score	O	472-477
of	O	478-480
the	O	481-484
Unified	O	485-492
Parkinson	B	493-502
'	I	502-503
s	I	499-500
Disease	I	505-512
Rating	O	513-519
Scale	O	520-525
,	O	525-526
a	O	527-528
dyskinesia	B	529-539
score	O	540-545
and	O	546-549
force	O	550-555
in	O	556-558
a	O	559-560
grip	O	561-565
-	O	565-566
lift	O	566-570
paradigm	O	571-579
were	O	580-584
assessed	O	585-593
ON	O	594-596
and	O	597-600
OFF	O	601-604
levodopa	O	605-613
.	O	613-614

A	O	615-616
pathological	O	617-629
increase	O	630-638
of	O	639-641
forces	O	642-648
was	O	649-652
seen	O	653-657
in	O	658-660
ON	O	661-663
-	O	663-664
state	O	664-669
in	O	670-672
Parkinson	B	673-682
'	I	682-683
s	I	679-680
disease	I	685-692
+	O	693-694
LID	B	695-698
only	O	699-703
.	O	703-704

In	O	705-707
Parkinson	B	708-717
'	I	717-718
s	I	714-715
disease	I	720-727
+	O	728-729
LID	B	730-733
,	O	733-734
the	O	735-738
force	O	739-744
involved	O	745-753
in	O	754-756
pressing	O	757-765
down	O	766-770
the	O	771-774
object	O	775-781
before	O	782-788
lifting	O	789-796
was	O	797-800
significantly	O	801-814
increased	O	815-824
by	O	825-827
levodopa	O	828-836
(	O	837-838
by	O	838-840
61	O	841-843
%	O	843-844
,	O	844-845
P	O	846-847
<	O	848-849
0	O	850-851
.	O	851-852
05	O	852-854
)	O	854-855
.	O	851-852

An	O	857-859
overshooting	O	860-872
of	O	873-875
peak	O	876-880
grip	O	881-885
force	O	886-891
by	O	892-894
51	O	895-897
%	O	897-898
(	O	899-900
P	O	900-901
<	O	902-903
0	O	904-905
.	O	905-906
05	O	906-908
)	O	908-909
and	O	910-913
of	O	914-916
static	O	917-923
grip	O	924-928
force	O	929-934
by	O	935-937
45	O	938-940
%	O	940-941
(	O	942-943
P	O	943-944
<	O	945-946
0	O	947-948
.	O	948-949
01	O	949-951
)	O	951-952
was	O	953-956
observed	O	957-965
in	O	966-968
the	O	969-972
ON	O	973-975
-	O	975-976
compared	O	977-985
with	O	986-990
the	O	991-994
OFF	O	995-998
-	O	998-999
drug	O	999-1003
condition	O	1004-1013
.	O	1013-1014

In	O	1015-1017
contrast	O	1018-1026
,	O	1026-1027
no	O	1028-1030
excessive	O	1031-1040
force	O	1041-1046
was	O	1047-1050
found	O	1051-1056
in	O	1057-1059
Parkinson	B	1060-1069
'	I	1069-1070
s	I	1066-1067
disease	I	1072-1079
-	O	1080-1081
LID	B	1082-1085
.	O	1085-1086
Peak	O	1087-1091
grip	O	1092-1096
force	O	1097-1102
in	O	1103-1105
ON	O	1106-1108
-	O	1108-1109
state	O	1109-1114
was	O	1115-1118
140	O	1119-1122
%	O	1122-1123
(	O	1124-1125
P	O	1125-1126
<	O	1127-1128
0	O	1129-1130
.	O	1130-1131
05	O	1131-1133
)	O	1133-1134
higher	O	1135-1141
in	O	1142-1144
Parkinson	B	1145-1154
'	I	1154-1155
s	I	1151-1152
disease	I	1157-1164
+	O	1165-1166
LID	B	1167-1170
than	O	1171-1175
in	O	1176-1178
Parkinson	B	1179-1188
'	I	1188-1189
s	I	1185-1186
disease	I	1191-1198
-	O	1199-1200
LID	B	1201-1204
,	O	1204-1205
while	O	1206-1211
static	O	1212-1218
grip	O	1219-1223
force	O	1224-1229
was	O	1230-1233
increased	O	1234-1243
by	O	1244-1246
138	O	1247-1250
%	O	1250-1251
(	O	1252-1253
P	O	1253-1254
<	O	1255-1256
0	O	1257-1258
.	O	1258-1259
01	O	1259-1261
)	O	1261-1262
between	O	1263-1270
groups	O	1271-1277
.	O	1277-1278

Severity	O	1279-1287
of	O	1288-1290
peak	O	1291-1295
-	O	1295-1296
dose	O	1296-1300
dyskinesias	B	1301-1312
was	O	1313-1316
strongly	O	1317-1325
correlated	O	1326-1336
with	O	1337-1341
grip	O	1342-1346
force	O	1347-1352
in	O	1353-1355
ON	O	1356-1358
-	O	1358-1359
state	O	1359-1364
(	O	1365-1366
r	O	1366-1367
=	O	1368-1369
0	O	1370-1371
.	O	1371-1372
79	O	1372-1374
with	O	1375-1379
peak	O	1380-1384
force	O	1385-1390
,	O	1390-1391
P	O	1392-1393
<	O	1394-1395
0	O	1396-1397
.	O	1397-1398
01	O	1398-1400
)	O	1400-1401
.	O	1397-1398

No	O	1403-1405
correlation	O	1406-1417
was	O	1418-1421
observed	O	1422-1430
between	O	1431-1438
forces	O	1439-1445
and	O	1446-1449
the	O	1450-1453
motor	O	1454-1459
score	O	1460-1465
as	O	1466-1468
well	O	1469-1473
as	O	1474-1476
with	O	1477-1481
the	O	1482-1485
daily	O	1486-1491
dose	O	1492-1496
of	O	1497-1499
dopaminergic	O	1500-1512
medication	O	1513-1523
.	O	1523-1524

Force	O	1525-1530
excess	O	1531-1537
was	O	1538-1541
only	O	1542-1546
observed	O	1547-1555
in	O	1556-1558
patients	O	1559-1567
with	O	1568-1572
LID	B	1573-1576
and	O	1577-1580
motor	O	1581-1586
fluctuations	O	1587-1599
.	O	1599-1600

A	O	1601-1602
close	O	1603-1608
relationship	O	1609-1621
was	O	1622-1625
seen	O	1626-1630
between	O	1631-1638
the	O	1639-1642
overshooting	O	1643-1655
of	O	1656-1658
forces	O	1659-1665
and	O	1666-1669
dyskinesias	B	1670-1681
in	O	1682-1684
the	O	1685-1688
ON	O	1689-1691
-	O	1691-1692
drug	O	1692-1696
condition	O	1697-1706
.	O	1706-1707

We	O	1708-1710
postulate	O	1711-1720
that	O	1721-1725
both	O	1726-1730
LID	B	1731-1734
and	O	1735-1738
grip	O	1739-1743
force	O	1744-1749
excess	O	1750-1756
share	O	1757-1762
common	O	1763-1769
pathophysiological	O	1770-1788
mechanisms	O	1789-1799
related	O	1800-1807
to	O	1808-1810
motor	O	1811-1816
fluctuations	O	1817-1829
.	O	1829-1830

Postinfarction	O	0-14
ventricular	B	15-26
septal	I	27-33
defect	I	34-40
associated	O	41-51
with	O	52-56
long	O	57-61
-	O	61-62
term	O	62-66
steroid	O	67-74
therapy	O	75-82
.	O	82-83

Two	O	84-87
cases	O	88-93
of	O	94-96
postinfarction	O	97-111
ventricular	B	112-123
septal	I	124-130
rupture	I	131-138
in	O	139-141
patients	O	142-150
on	O	151-153
long	O	154-158
-	O	158-159
term	O	159-163
steroid	O	164-171
therapy	O	172-179
are	O	180-183
presented	O	184-193
and	O	194-197
the	O	198-201
favourable	O	202-212
outcome	O	213-220
in	O	221-223
both	O	224-228
cases	O	229-234
described	O	235-244
.	O	244-245

A	O	246-247
possible	O	248-256
association	O	257-268
between	O	269-276
steroid	O	277-284
therapy	O	285-292
and	O	293-296
subsequent	O	297-307
postinfarction	O	308-322
septal	B	323-329
rupture	I	330-337
is	O	338-340
discussed	O	341-350
.	O	350-351

Angioedema	B	0-10
associated	O	11-21
with	O	22-26
droperidol	O	27-37
administration	O	38-52
.	O	52-53

Angioedema	B	54-64
,	O	64-65
also	O	66-70
known	O	71-76
as	O	77-79
angioneurotic	B	80-93
edema	I	94-99
or	O	100-102
Quincke	B	103-110
'	I	110-111
s	I	111-112
disease	I	113-120
,	O	120-121
is	O	122-124
a	O	125-126
well	O	127-131
-	O	131-132
demarcated	O	132-142
,	O	142-143
localized	O	144-153
edema	B	154-159
involving	O	160-169
the	O	170-173
subcutaneous	O	174-186
tissues	O	187-194
that	O	195-199
may	O	200-203
cause	O	204-209
upper	B	210-215
-	I	215-216
airway	I	216-222
obstruction	I	223-234
.	O	234-235

We	O	236-238
report	O	239-245
the	O	246-249
case	O	250-254
of	O	255-257
a	O	258-259
previously	O	260-270
healthy	O	271-278
19	O	279-281
-	O	281-282
year	O	282-286
-	O	281-282
old	O	287-290
man	O	291-294
with	O	295-299
no	O	300-302
known	O	303-308
drug	B	309-313
allergies	I	314-323
in	O	324-326
whom	O	327-331
angioedema	B	332-342
with	O	343-347
significant	O	348-359
tongue	B	360-366
swelling	I	367-375
and	O	376-379
protrusion	O	380-390
developed	O	391-400
within	O	401-407
10	O	408-410
minutes	O	411-418
of	O	419-421
the	O	422-425
administration	O	426-440
of	O	441-443
a	O	444-445
single	O	446-452
IV	O	453-455
dose	O	456-460
of	O	461-463
droperidol	O	464-474
.	O	474-475

Clarithromycin	O	0-14
-	O	14-15
associated	O	15-25
visual	B	26-32
hallucinations	I	33-47
in	O	48-50
a	O	51-52
patient	O	53-60
with	O	61-65
chronic	B	66-73
renal	I	74-79
failure	I	80-87
on	O	88-90
continuous	O	91-101
ambulatory	O	102-112
peritoneal	O	113-123
dialysis	O	124-132
.	O	132-133

Visual	B	134-140
hallucinations	I	141-155
are	O	156-159
a	O	160-161
rare	O	162-166
event	O	167-172
in	O	173-175
chronic	B	176-183
renal	I	184-189
failure	I	190-197
and	O	198-201
not	O	202-205
related	O	206-213
to	O	214-216
uremia	B	217-223
per	O	224-227
se	O	228-230
.	O	230-231

Unreported	O	232-242
in	O	243-245
the	O	246-249
literature	O	250-260
is	O	261-263
visual	B	264-270
hallucinations	I	271-285
occurring	O	286-295
in	O	296-298
association	O	299-310
with	O	311-315
the	O	316-319
new	O	320-323
macrolide	O	324-333
antibiotic	O	334-344
,	O	344-345
clarithromycin	O	346-360
.	O	360-361

We	O	362-364
describe	O	365-373
such	O	374-378
a	O	379-380
case	O	381-385
in	O	386-388
a	O	389-390
patient	O	391-398
with	O	399-403
end	B	404-407
-	I	407-408
stage	I	408-413
renal	I	414-419
disease	I	420-427
(	O	428-429
ESRD	B	429-433
)	O	433-434
maintained	O	435-445
on	O	446-448
continuous	O	449-459
ambulatory	O	460-470
peritoneal	O	471-481
dialysis	O	482-490
(	O	491-492
CAPD	O	492-496
)	O	496-497
.	O	497-498

The	O	499-502
combination	O	503-514
of	O	515-517
a	O	518-519
relatively	O	520-530
high	O	531-535
dose	O	536-540
of	O	541-543
clarithromycin	O	544-558
in	O	559-561
face	O	562-566
of	O	567-569
chronic	B	570-577
renal	I	578-583
failure	I	584-591
in	O	592-594
a	O	595-596
functionally	O	597-609
anephric	O	610-618
patient	O	619-626
,	O	626-627
with	O	628-632
underlying	O	633-643
aluminum	O	644-652
intoxication	O	653-665
,	O	665-666
may	O	667-670
have	O	671-675
facilitated	O	676-687
the	O	688-691
appearance	O	692-702
of	O	703-705
this	O	706-710
neurotoxic	B	711-721
side	O	722-726
effect	O	727-733
.	O	733-734

It	O	735-737
is	O	738-740
important	O	741-750
to	O	751-753
understand	O	754-764
the	O	765-768
pharmacokinetics	O	769-785
of	O	786-788
medications	O	789-800
in	O	801-803
face	O	804-808
of	O	809-811
chronic	B	812-819
renal	I	820-825
failure	I	826-833
,	O	833-834
the	O	835-838
possibility	O	839-850
of	O	851-853
drug	O	854-858
interactions	O	859-871
,	O	871-872
and	O	873-876
how	O	877-880
these	O	881-886
factors	O	887-894
should	O	895-901
help	O	902-906
guide	O	907-912
medication	O	913-923
therapy	O	924-931
in	O	932-934
the	O	935-938
ESRD	B	939-943
patient	O	944-951
.	O	951-952

Acute	O	0-5
renal	B	6-11
toxicity	I	12-20
of	O	21-23
doxorubicin	O	24-35
(	O	36-37
adriamycin	O	37-47
)	O	47-48
-	O	48-49
loaded	O	49-55
cyanoacrylate	O	56-69
nanoparticles	O	70-83
.	O	83-84

Acute	O	85-90
doxorubicin	O	91-102
-	O	102-103
loaded	O	103-109
nanoparticle	O	110-122
(	O	123-124
DXNP	O	124-128
)	O	128-129
renal	B	130-135
toxicity	I	136-144
was	O	145-148
explored	O	149-157
in	O	158-160
both	O	161-165
normal	O	166-172
rats	O	173-177
and	O	178-181
rats	O	182-186
with	O	187-191
experimental	O	192-204
glomerulonephritis	B	205-223
.	O	223-224

In	O	225-227
normal	O	228-234
rats	O	235-239
,	O	239-240
2	O	241-242
/	O	242-243
6	O	243-244
rats	O	245-249
given	O	250-255
free	O	256-260
doxorubicin	O	261-272
(	O	273-274
DX	O	274-276
)	O	276-277
(	O	278-279
5	O	279-280
mg	O	281-283
/	O	283-284
kg	O	284-286
)	O	286-287
died	O	288-292
within	O	293-299
one	O	300-303
week	O	304-308
,	O	308-309
whereas	O	310-317
all	O	318-321
control	O	322-329
animals	O	330-337
and	O	338-341
all	O	342-345
rats	O	346-350
having	O	351-357
received	O	358-366
free	O	367-371
NP	O	372-374
or	O	375-377
DXNP	O	378-382
survived	O	383-391
.	O	391-392

A	O	393-394
3	O	395-396
times	O	397-402
higher	O	403-409
proteinuria	B	410-421
appeared	O	422-430
in	O	431-433
animals	O	434-441
treated	O	442-449
with	O	450-454
DXNP	O	455-459
than	O	460-464
in	O	465-467
those	O	468-473
treated	O	474-481
with	O	482-486
DX	O	487-489
.	O	489-490

Free	O	491-495
NP	O	496-498
did	O	499-502
not	O	503-506
provoke	O	507-514
any	O	515-518
proteinuria	B	519-530
.	O	530-531

Two	O	532-535
hr	O	536-538
post	O	539-543
-	O	543-544
injection	O	544-553
,	O	553-554
DXNP	O	555-559
was	O	560-563
2	O	564-565
.	O	565-566
7	O	566-567
times	O	568-573
more	O	574-578
concentrated	O	579-591
in	O	592-594
kidneys	O	595-602
than	O	603-607
free	O	608-612
DX	O	613-615
(	O	616-617
p	O	617-618
<	O	619-620
0	O	621-622
.	O	622-623
025	O	623-626
)	O	626-627
.	O	622-623

In	O	629-631
rats	O	632-636
with	O	637-641
immune	O	642-648
experimental	O	649-661
glomerulonephritis	B	662-680
,	O	680-681
5	O	682-683
/	O	683-684
6	O	684-685
rats	O	686-690
given	O	691-696
DX	O	697-699
died	O	700-704
within	O	705-711
7	O	712-713
days	O	714-718
,	O	718-719
in	O	720-722
contrast	O	723-731
to	O	732-734
animals	O	735-742
treated	O	743-750
by	O	751-753
DXNP	O	754-758
,	O	758-759
NP	O	760-762
,	O	762-763
or	O	764-766
untreated	O	767-776
,	O	776-777
which	O	778-783
all	O	784-787
survived	O	788-796
.	O	796-797

Proteinuria	B	798-809
appeared	O	810-818
in	O	819-821
all	O	822-825
series	O	826-832
,	O	832-833
but	O	834-837
was	O	838-841
2	O	842-843
-	O	843-844
5	O	844-845
times	O	846-851
more	O	852-856
intense	O	857-864
(	O	865-866
p	O	866-867
>	O	868-869
0	O	870-871
.	O	871-872
001	O	872-875
)	O	875-876
and	O	877-880
prolonged	O	881-890
after	O	891-896
doxorubicin	O	897-908
treatment	O	909-918
(	O	919-920
400	O	920-923
-	O	923-924
700	O	924-927
mg	O	928-930
/	O	930-931
day	O	931-934
)	O	934-935
,	O	935-936
without	O	937-944
significant	O	945-956
difference	O	957-967
between	O	968-975
DXNP	O	976-980
and	O	981-984
DX	O	985-987
.	O	987-988

Rats	O	989-993
treated	O	994-1001
by	O	1002-1004
unloaded	O	1005-1013
NP	O	1014-1016
behaved	O	1017-1024
as	O	1025-1027
controls	O	1028-1036
.	O	1036-1037

These	O	1038-1043
results	O	1044-1051
demonstrate	O	1052-1063
that	O	1064-1068
,	O	1068-1069
in	O	1070-1072
these	O	1073-1078
experimental	O	1079-1091
conditions	O	1092-1102
,	O	1102-1103
DXNP	O	1104-1108
killed	O	1109-1115
less	O	1116-1120
animals	O	1121-1128
than	O	1129-1133
free	O	1134-1138
DX	O	1139-1141
,	O	1141-1142
despite	O	1143-1150
of	O	1151-1153
an	O	1154-1156
enhanced	O	1157-1165
renal	B	1166-1171
toxicity	I	1172-1180
of	O	1181-1183
the	O	1184-1187
former	O	1188-1194
.	O	1194-1195

Both	O	1196-1200
effects	O	1201-1208
(	O	1209-1210
better	O	1210-1216
survival	O	1217-1225
and	O	1226-1229
nephrosis	B	1230-1239
)	O	1239-1240
are	O	1241-1244
most	O	1245-1249
probably	O	1250-1258
related	O	1259-1266
to	O	1267-1269
an	O	1270-1272
enhanced	O	1273-1281
capture	O	1282-1289
of	O	1290-1292
DXNP	O	1293-1297
by	O	1298-1300
cells	O	1301-1306
of	O	1307-1309
the	O	1310-1313
mononuclear	O	1314-1325
phagocyte	O	1326-1335
system	O	1336-1342
,	O	1342-1343
including	O	1344-1353
mesangial	O	1354-1363
cells	O	1364-1369
.	O	1369-1370

Etoposide	O	0-9
-	O	9-10
related	O	10-17
myocardial	B	18-28
infarction	I	29-39
.	O	39-40

The	O	41-44
occurrence	O	45-55
of	O	56-58
a	O	59-60
myocardial	B	61-71
infarction	I	72-82
is	O	83-85
reported	O	86-94
after	O	95-100
chemotherapy	O	101-113
containing	O	114-124
etoposide	O	125-134
,	O	134-135
in	O	136-138
a	O	139-140
man	O	141-144
with	O	145-149
no	O	150-152
risk	O	153-157
factors	O	158-165
for	O	166-169
coronary	B	170-178
heart	I	179-184
disease	I	185-192
.	O	192-193

Possible	O	194-202
causal	O	203-209
mechanisms	O	210-220
are	O	221-224
discussed	O	225-234
.	O	234-235

Subjective	O	0-10
assessment	O	11-21
of	O	22-24
sexual	B	25-31
dysfunction	I	32-43
of	O	44-46
patients	O	47-55
on	O	56-58
long	O	59-63
-	O	63-64
term	O	64-68
administration	O	69-83
of	O	84-86
digoxin	O	87-94
.	O	94-95

Various	O	96-103
data	O	104-108
suggest	O	109-116
that	O	117-121
male	O	122-126
patients	O	127-135
who	O	136-139
have	O	140-144
received	O	145-153
digoxin	O	154-161
on	O	162-164
a	O	165-166
longterm	O	167-175
basis	O	176-181
have	O	182-186
increased	O	187-196
levels	O	197-203
of	O	204-206
serum	O	207-212
estrogen	O	213-221
and	O	222-225
decreased	O	226-235
levels	O	236-242
of	O	243-245
plasma	O	246-252
testosterone	O	253-265
and	O	266-269
luteinizing	O	270-281
hormone	O	282-289
(	O	290-291
LH	O	291-293
)	O	293-294
.	O	294-295

This	O	296-300
study	O	301-306
was	O	307-310
undertaken	O	311-321
to	O	322-324
investigate	O	325-336
the	O	337-340
links	O	341-346
between	O	347-354
the	O	355-358
long	O	359-363
-	O	363-364
term	O	364-368
administration	O	369-383
of	O	384-386
digoxin	O	387-394
therapy	O	395-402
and	O	403-406
sexual	O	407-413
behavior	O	414-422
,	O	422-423
and	O	424-427
the	O	428-431
effect	O	432-438
of	O	439-441
digoxin	O	442-449
on	O	450-452
plasma	O	453-459
levels	O	460-466
of	O	467-469
estradiol	O	470-479
,	O	479-480
testosterone	O	481-493
,	O	493-494
and	O	495-498
LH	O	499-501
.	O	501-502

The	O	503-506
patients	O	507-515
of	O	516-518
the	O	519-522
study	O	523-528
and	O	529-532
control	O	533-540
group	O	541-546
(	O	547-548
without	O	548-555
digoxin	O	556-563
)	O	563-564
were	O	565-569
of	O	570-572
similar	O	573-580
cardiac	O	581-588
functional	O	589-599
capacity	O	600-608
and	O	609-612
age	O	613-616
(	O	617-618
25	O	618-620
-	O	620-621
40	O	621-623
years	O	624-629
)	O	629-630
and	O	631-634
were	O	635-639
randomly	O	640-648
selected	O	649-657
from	O	658-662
the	O	663-666
rheumatic	B	667-676
heart	I	677-682
disease	I	683-690
patients	O	691-699
.	O	699-700

A	O	701-702
subjective	O	703-713
assessment	O	714-724
of	O	725-727
sexual	O	728-734
behavior	O	735-743
in	O	744-746
the	O	747-750
study	O	751-756
and	O	757-760
control	O	761-768
groups	O	769-775
was	O	776-779
carried	O	780-787
out	O	788-791
,	O	791-792
using	O	793-798
parameters	O	799-809
such	O	810-814
as	O	815-817
sexual	O	818-824
desire	O	825-831
,	O	831-832
sexual	O	833-839
excitement	O	840-850
,	O	850-851
and	O	852-855
frequency	O	856-865
of	O	866-868
sexual	O	869-875
relations	O	876-885
.	O	885-886

Personal	O	887-895
interviews	O	896-906
and	O	907-910
a	O	911-912
questionnaire	O	913-926
were	O	927-931
also	O	932-936
used	O	937-941
for	O	942-945
the	O	946-949
evaluation	O	950-960
of	O	961-963
sexual	O	964-970
behavior	O	971-979
.	O	979-980

The	O	981-984
findings	O	985-993
support	O	994-1001
the	O	1002-1005
reports	O	1006-1013
concerning	O	1014-1024
digoxin	O	1025-1032
effect	O	1033-1039
on	O	1040-1042
plasma	O	1043-1049
estradiol	O	1050-1059
,	O	1059-1060
testosterone	O	1061-1073
,	O	1073-1074
and	O	1075-1078
LH	O	1079-1081
.	O	1081-1082

The	O	1083-1086
differences	O	1087-1098
in	O	1099-1101
the	O	1102-1105
means	O	1106-1111
were	O	1112-1116
significant	O	1117-1128
.	O	1128-1129

Tests	O	1130-1135
used	O	1136-1140
to	O	1141-1143
evaluate	O	1144-1152
the	O	1153-1156
changes	O	1157-1164
in	O	1165-1167
sexual	O	1168-1174
behavior	O	1175-1183
showed	O	1184-1190
a	O	1191-1192
significant	O	1193-1204
decrease	B	1205-1213
in	I	1214-1216
sexual	I	1217-1223
desire	I	1224-1230
,	O	1230-1231
sexual	O	1232-1238
excitement	O	1239-1249
phase	O	1250-1255
(	O	1256-1257
erection	O	1257-1265
)	O	1265-1266
,	O	1266-1267
and	O	1268-1271
frequency	O	1272-1281
of	O	1282-1284
sexual	O	1285-1291
relations	O	1292-1301
in	O	1302-1304
the	O	1305-1308
study	O	1309-1314
group	O	1315-1320
.	O	1320-1321

Fatal	O	0-5
aplastic	B	6-14
anemia	I	15-21
due	O	22-25
to	O	26-28
indomethacin	O	29-41
-	O	41-42
-	O	41-42
lymphocyte	O	43-53
transformation	O	54-68
tests	O	69-74
in	O	75-77
vitro	O	78-83
.	O	83-84

Although	O	85-93
indomethacin	O	94-106
has	O	107-110
been	O	111-115
implicated	O	116-126
as	O	127-129
a	O	130-131
possible	O	132-140
cause	O	141-146
of	O	147-149
aplastic	B	150-158
anemia	I	159-165
on	O	166-168
the	O	169-172
basis	O	173-178
of	O	179-181
a	O	182-183
few	O	184-187
clinical	O	188-196
observations	O	197-209
,	O	209-210
its	O	211-214
role	O	215-219
has	O	220-223
not	O	224-227
been	O	228-232
definitely	O	233-243
established	O	244-255
.	O	255-256

A	O	257-258
case	O	259-263
of	O	264-266
fatal	O	267-272
aplastic	B	273-281
anemia	I	282-288
is	O	289-291
described	O	292-301
in	O	302-304
which	O	305-310
no	O	311-313
drugs	O	314-319
other	O	320-325
than	O	326-330
allopurinol	O	331-342
and	O	343-346
indomethacin	O	347-359
were	O	360-364
given	O	365-370
.	O	370-371

Indomethacin	O	372-384
was	O	385-388
first	O	389-394
given	O	395-400
four	O	401-405
weeks	O	406-411
prior	O	412-417
to	O	418-420
the	O	421-424
onset	O	425-430
of	O	431-433
symptoms	O	434-442
.	O	442-443

A	O	444-445
positive	O	446-454
lymphocyte	O	455-465
transformation	O	466-480
test	O	481-485
with	O	486-490
indomethacin	O	491-503
in	O	504-506
vitro	O	507-512
further	O	513-520
substantiates	O	521-534
the	O	535-538
potential	O	539-548
role	O	549-553
of	O	554-556
this	O	557-561
drug	O	562-566
in	O	567-569
causing	O	570-577
aplastic	B	578-586
anemia	I	587-593
in	O	594-596
a	O	597-598
susceptible	O	599-610
patient	O	611-618
.	O	618-619

Fortunately	O	620-631
,	O	631-632
this	O	633-637
seems	O	638-643
to	O	644-646
be	O	647-649
a	O	650-651
very	O	652-656
rare	O	657-661
complication	O	662-674
.	O	674-675

Plasma	O	0-6
and	O	7-10
urinary	O	11-18
lipids	O	19-25
and	O	26-29
lipoproteins	O	30-42
during	O	43-49
the	O	50-53
development	O	54-65
of	O	66-68
nephrotic	B	69-78
syndrome	I	79-87
induced	O	88-95
in	O	96-98
the	O	99-102
rat	O	103-106
by	O	107-109
puromycin	O	110-119
aminonucleoside	O	120-135
.	O	135-136

This	O	137-141
study	O	142-147
was	O	148-151
undertaken	O	152-162
to	O	163-165
ascertain	O	166-175
whether	O	176-183
the	O	184-187
alterations	O	188-199
of	O	200-202
plasma	O	203-209
lipoproteins	O	210-222
found	O	223-228
in	O	229-231
nephrotic	B	232-241
syndrome	I	242-250
induced	O	251-258
by	O	259-261
puromycin	O	262-271
aminonucleoside	O	272-287
were	O	288-292
due	O	293-296
to	O	297-299
nephrotic	B	300-309
syndrome	I	310-318
per	O	319-322
se	O	323-325
,	O	325-326
or	O	327-329
,	O	329-330
at	O	331-333
least	O	334-339
in	O	340-342
part	O	343-347
,	O	347-348
to	O	349-351
the	O	352-355
aminonucleoside	O	356-371
.	O	371-372

The	O	373-376
purpose	O	377-384
of	O	385-387
the	O	388-391
present	O	392-399
study	O	400-405
was	O	406-409
to	O	410-412
investigate	O	413-424
the	O	425-428
changes	O	429-436
in	O	437-439
plasma	O	440-446
and	O	447-450
urinary	O	451-458
lipoproteins	O	459-471
during	O	472-478
the	O	479-482
administration	O	483-497
of	O	498-500
puromycin	O	501-510
aminonucleoside	O	511-526
(	O	527-528
20	O	528-530
mg	O	531-533
/	O	533-534
kg	O	534-536
for	O	537-540
7	O	541-542
days	O	543-547
)	O	547-548
and	O	549-552
the	O	553-556
subsequent	O	557-567
development	O	568-579
of	O	580-582
nephrotic	B	583-592
syndrome	I	593-601
.	O	601-602

Since	O	603-608
massive	O	609-616
albuminuria	B	617-628
occurred	O	629-637
after	O	638-643
6	O	644-645
days	O	646-650
of	O	651-653
treatment	O	654-663
,	O	663-664
the	O	665-668
time	O	669-673
-	O	673-674
course	O	674-680
study	O	681-686
was	O	687-690
divided	O	691-698
into	O	699-703
two	O	704-707
stages	O	708-714
:	O	714-715
pre	O	716-719
-	O	719-720
nephrotic	B	720-729
stage	O	730-735
(	O	736-737
day	O	737-740
1	O	741-742
-	O	742-743
5	O	743-744
)	O	744-745
and	O	746-749
nephrotic	B	750-759
stage	O	760-765
(	O	766-767
day	O	767-770
6	O	771-772
-	O	772-773
11	O	773-775
)	O	775-776
.	O	776-777

In	O	778-780
pre	O	781-784
-	O	784-785
nephrotic	B	785-794
stage	O	795-800
the	O	801-804
plasma	O	805-811
level	O	812-817
of	O	818-820
fatty	O	821-826
acids	O	827-832
,	O	832-833
triacylglycerol	O	834-849
and	O	850-853
VLDL	O	854-858
decreased	O	859-868
while	O	869-874
that	O	875-879
of	O	880-882
phospholipid	O	883-895
,	O	895-896
cholesteryl	O	897-908
esters	O	909-915
and	O	916-919
HDL	O	920-923
remained	O	924-932
constant	O	933-941
.	O	941-942

Plasma	O	943-949
apolipoprotein	O	950-964
A	O	965-966
-	O	966-967
I	O	967-968
tended	O	969-975
to	O	976-978
increase	O	979-987
(	O	988-989
40	O	989-991
%	O	991-992
increase	O	993-1001
at	O	1002-1004
day	O	1005-1008
5	O	1009-1010
)	O	1010-1011
.	O	1011-1012

At	O	1013-1015
the	O	1016-1019
beginning	O	1020-1029
of	O	1030-1032
nephrotic	B	1033-1042
stage	O	1043-1048
(	O	1049-1050
day	O	1050-1053
6	O	1054-1055
)	O	1055-1056
the	O	1057-1060
concentration	O	1061-1074
of	O	1075-1077
plasma	O	1078-1084
albumin	O	1085-1092
dropped	O	1093-1100
to	O	1101-1103
a	O	1104-1105
very	O	1106-1110
low	O	1111-1114
level	O	1115-1120
,	O	1120-1121
while	O	1122-1127
that	O	1128-1132
of	O	1133-1135
apolipoprotein	O	1136-1150
A	O	1151-1152
-	O	1152-1153
I	O	1153-1154
increased	O	1155-1164
abruptly	O	1165-1173
(	O	1174-1175
4	O	1175-1176
-	O	1176-1177
fold	O	1177-1181
increase	O	1182-1190
)	O	1190-1191
and	O	1192-1195
continued	O	1196-1205
to	O	1206-1208
rise	O	1209-1213
,	O	1213-1214
although	O	1215-1223
less	O	1224-1228
steeply	O	1229-1236
,	O	1236-1237
in	O	1238-1240
the	O	1241-1244
following	O	1245-1254
days	O	1255-1259
.	O	1259-1260

The	O	1261-1264
plasma	O	1265-1271
concentration	O	1272-1285
of	O	1286-1288
HDL	O	1289-1292
followed	O	1293-1301
the	O	1302-1305
same	O	1306-1310
pattern	O	1311-1318
.	O	1318-1319

Plasma	O	1320-1326
VLDL	O	1327-1331
and	O	1332-1335
LDL	O	1336-1339
increased	O	1340-1349
at	O	1350-1352
a	O	1353-1354
later	O	1355-1360
stage	O	1361-1366
(	O	1367-1368
day	O	1368-1371
9	O	1372-1373
)	O	1373-1374
.	O	1374-1375

Plasma	O	1376-1382
apolipoprotein	O	1383-1397
A	O	1398-1399
-	O	1399-1400
I	O	1400-1401
was	O	1402-1405
found	O	1406-1411
not	O	1412-1415
only	O	1416-1420
in	O	1421-1423
HDL	O	1424-1427
(	O	1428-1429
1	O	1429-1430
.	O	1430-1431
063	O	1431-1434
-	O	1434-1435
1	O	1429-1430
.	O	1430-1431
210	O	1437-1440

g	O	1441-1442
/	O	1442-1443
ml	O	1443-1445
)	O	1445-1446
but	O	1447-1450
also	O	1451-1455
in	O	1456-1458
the	O	1459-1462
LDL	O	1463-1466
density	O	1467-1474
class	O	1475-1480
(	O	1481-1482
1	O	1482-1483
.	O	1483-1484
025	O	1484-1487
-	O	1487-1488
1	O	1482-1483
.	O	1483-1484
050	O	1490-1493

g	O	1494-1495
/	O	1495-1496
ml	O	1496-1498
)	O	1498-1499
.	O	1499-1500

In	O	1501-1503
the	O	1504-1507
pre	O	1508-1511
-	O	1511-1512
nephrotic	B	1512-1521
stage	O	1522-1527
lipoproteinuria	O	1528-1543
was	O	1544-1547
negligible	O	1548-1558
,	O	1558-1559
while	O	1560-1565
in	O	1566-1568
the	O	1569-1572
early	O	1573-1578
nephrotic	B	1579-1588
stage	O	1589-1594
the	O	1595-1598
urinary	O	1599-1606
loss	O	1607-1611
of	O	1612-1614
plasma	O	1615-1621
lipoproteins	O	1622-1634
consisted	O	1635-1644
mainly	O	1645-1651
of	O	1652-1654
HDL	O	1655-1658
.	O	1658-1659

These	O	1660-1665
observations	O	1666-1678
indicate	O	1679-1687
that	O	1688-1692
puromycin	O	1693-1702
aminonucleoside	O	1703-1718
alters	O	1719-1725
plasma	O	1726-1732
lipoproteins	O	1733-1745
by	O	1746-1748
lowering	O	1749-1757
VLDL	O	1758-1762
and	O	1763-1766
increasing	O	1767-1777
HDL	O	1778-1781
.	O	1781-1782

It	O	1783-1785
is	O	1786-1788
likely	O	1789-1795
that	O	1796-1800
the	O	1801-1804
early	O	1805-1810
and	O	1811-1814
striking	O	1815-1823
increase	O	1824-1832
of	O	1833-1835
plasma	O	1836-1842
HDL	O	1843-1846
found	O	1847-1852
in	O	1853-1855
nephrotic	B	1856-1865
rats	O	1866-1870
is	O	1871-1873
related	O	1874-1881
to	O	1882-1884
a	O	1885-1886
direct	O	1887-1893
effect	O	1894-1900
of	O	1901-1903
the	O	1904-1907
drug	O	1908-1912
on	O	1913-1915
HDL	O	1916-1919
metabolism	O	1920-1930
.	O	1930-1931

Circulating	O	0-11
lysosomal	O	12-21
enzymes	O	22-29
and	O	30-33
acute	B	34-39
hepatic	I	40-47
necrosis	I	48-56
.	O	56-57

The	O	58-61
activities	O	62-72
of	O	73-75
the	O	76-79
lysosomal	O	80-89
enzymes	O	90-97
acid	O	98-102
and	O	103-106
neutral	O	107-114
protease	O	115-123
,	O	123-124
N	O	125-126
-	O	126-127
acetylglucosaminidase	O	127-148
,	O	148-149
and	O	150-153
acid	O	154-158
phosphatase	O	159-170
were	O	171-175
measured	O	176-184
in	O	185-187
the	O	188-191
serum	O	192-197
of	O	198-200
patients	O	201-209
with	O	210-214
fulminant	B	215-224
hepatic	I	225-232
failure	I	233-240
.	O	240-241

Acid	O	242-246
protease	O	247-255
(	O	256-257
cathepsin	O	257-266
D	O	267-268
)	O	268-269
activity	O	270-278
was	O	279-282
increased	O	283-292
about	O	293-298
tenfold	O	299-306
in	O	307-309
patients	O	310-318
who	O	319-322
died	O	323-327
and	O	328-331
nearly	O	332-338
fourfold	O	339-347
in	O	348-350
those	O	351-356
who	O	357-360
survived	O	361-369
fulminant	B	370-379
hepatic	I	380-387
failure	I	388-395
after	O	396-401
paracetamol	O	402-413
overdose	B	414-422
,	O	422-423
whereas	O	424-431
activities	O	432-442
were	O	443-447
increased	O	448-457
equally	O	458-465
in	O	466-468
patients	O	469-477
with	O	478-482
fulminant	B	483-492
hepatic	I	493-500
failure	I	501-508
due	O	509-512
to	O	513-515
viral	B	516-521
hepatitis	I	522-531
whether	O	532-539
or	O	540-542
not	O	543-546
they	O	547-551
survived	O	552-560
.	O	560-561

A	O	562-563
correlation	O	564-575
was	O	576-579
found	O	580-585
between	O	586-593
serum	O	594-599
acid	O	600-604
protease	O	605-613
activity	O	614-622
and	O	623-626
prothrombin	O	627-638
time	O	639-643
,	O	643-644
and	O	645-648
the	O	649-652
increase	O	653-661
in	O	662-664
cathepsin	O	665-674
D	O	675-676
activity	O	677-685
was	O	686-689
sustained	O	690-699
over	O	700-704
several	O	705-712
days	O	713-717
compared	O	718-726
with	O	727-731
aspartate	O	732-741
aminotransferase	O	742-758
,	O	758-759
which	O	760-765
showed	O	766-772
a	O	773-774
sharp	O	775-780
early	O	781-786
peak	O	787-791
and	O	792-795
then	O	796-800
a	O	801-802
fall	O	803-807
.	O	807-808

Circulating	O	809-820
lysosomal	O	821-830
proteases	O	831-840
can	O	841-844
damage	O	845-851
other	O	852-857
organs	O	858-864
,	O	864-865
and	O	866-869
measurement	O	870-881
of	O	882-884
their	O	885-890
activity	O	891-899
may	O	900-903
therefore	O	904-913
be	O	914-916
of	O	917-919
added	O	920-925
value	O	926-931
in	O	932-934
assessing	O	935-944
prognosis	O	945-954
in	O	955-957
this	O	958-962
condition	O	963-972
.	O	972-973

Transketolase	O	0-13
abnormality	O	14-25
in	O	26-28
tolazamide	O	29-39
-	O	39-40
induced	O	40-47
Wernicke	B	48-56
'	I	56-57
s	I	57-58
encephalopathy	I	59-73
.	O	73-74

We	O	75-77
studied	O	78-85
a	O	86-87
thiamine	O	88-96
-	O	96-97
dependent	O	97-106
enzyme	O	107-113
,	O	113-114
transketolase	O	115-128
,	O	128-129
from	O	130-134
fibroblasts	O	135-146
of	O	147-149
a	O	150-151
diabetic	B	152-160
patient	O	161-168
who	O	169-172
developed	O	173-182
Wernicke	B	183-191
'	I	191-192
s	I	192-193
encephalopathy	I	194-208
when	O	209-213
treated	O	214-221
with	O	222-226
tolazamide	O	227-237
,	O	237-238
in	O	239-241
order	O	242-247
to	O	248-250
delineate	O	251-260
if	O	261-263
this	O	264-268
patient	O	269-276
also	O	277-281
had	O	282-285
transketolase	O	286-299
abnormality	O	300-311
[	O	312-313
high	O	313-317
Km	O	318-320
for	O	321-324
thiamine	O	325-333
pyrophosphate	O	334-347
(	O	348-349
TPP	O	349-352
)	O	352-353
]	O	353-354
,	O	354-355
as	O	356-358
previously	O	359-369
reported	O	370-378
in	O	379-381
postalcoholic	O	382-395
Wernicke	B	396-404
-	I	404-405
Korsakoff	I	405-414
syndrome	I	415-423
.	O	423-424

In	O	425-427
addition	O	428-436
to	O	437-439
this	O	440-444
patient	O	445-452
,	O	452-453
we	O	454-456
also	O	457-461
studied	O	462-469
this	O	470-474
enzyme	O	475-481
from	O	482-486
three	O	487-492
diabetic	B	493-501
kindreds	O	502-510
without	O	511-518
any	O	519-522
history	O	523-530
of	O	531-533
Wernicke	B	534-542
'	I	542-543
s	I	543-544
encephalopathy	I	545-559
and	O	560-563
from	O	564-568
four	O	569-573
normal	O	574-580
controls	O	581-589
.	O	589-590

We	O	591-593
found	O	594-599
that	O	600-604
the	O	605-608
above	O	609-614
-	O	614-615
mentioned	O	615-624
patient	O	625-632
and	O	633-636
one	O	637-640
of	O	641-643
the	O	644-647
diabetic	B	648-656
kindreds	O	657-665
with	O	666-670
no	O	671-673
history	O	674-681
of	O	682-684
Wernicke	B	685-693
'	I	693-694
s	I	694-695
encephalopathy	I	696-710
had	O	711-714
abnormal	O	715-723
transketolase	O	724-737
as	O	738-740
determined	O	741-751
by	O	752-754
its	O	755-758
Km	O	759-761
for	O	762-765
TPP	O	766-769
.	O	769-770

These	O	771-776
data	O	777-781
suggest	O	782-789
a	O	790-791
similarity	O	792-802
between	O	803-810
postalcoholic	O	811-824
Wernicke	B	825-833
-	I	833-834
Korsakoff	I	834-843
syndrome	I	844-852
and	O	853-856
the	O	857-860
patient	O	861-868
with	O	869-873
tolazamide	O	874-884
-	O	884-885
induced	O	885-892
Wernicke	B	893-901
'	I	901-902
s	I	902-903
encephalopathy	I	904-918
from	O	919-923
the	O	924-927
standpoint	O	928-938
of	O	939-941
transketolase	O	942-955
abnormality	O	956-967
.	O	967-968

Mechanisms	O	0-10
of	O	11-13
myocardial	B	14-24
ischemia	I	25-33
induced	O	34-41
by	O	42-44
epinephrine	O	45-56
:	O	56-57
comparison	O	58-68
with	O	69-73
exercise	O	74-82
-	O	82-83
induced	O	83-90
ischemia	B	91-99
.	O	99-100

The	O	101-104
role	O	105-109
of	O	110-112
epinephrine	O	113-124
in	O	125-127
eliciting	O	128-137
myocardial	B	138-148
ischemia	I	149-157
was	O	158-161
examined	O	162-170
in	O	171-173
patients	O	174-182
with	O	183-187
coronary	B	188-196
artery	I	197-203
disease	I	204-211
.	O	211-212

Objective	O	213-222
signs	O	223-228
of	O	229-231
ischemia	B	232-240
and	O	241-244
factors	O	245-252
increasing	O	253-263
myocardial	O	264-274
oxygen	O	275-281
consumption	O	282-293
were	O	294-298
compared	O	299-307
during	O	308-314
epinephrine	O	315-326
infusion	O	327-335
and	O	336-339
supine	O	340-346
bicycle	O	347-354
exercise	O	355-363
.	O	363-364

Both	O	365-369
epinephrine	O	370-381
and	O	382-385
exercise	O	386-394
produced	O	395-403
myocardial	B	404-414
ischemia	I	415-423
as	O	424-426
evidenced	O	427-436
by	O	437-439
ST	O	440-442
segment	O	443-450
depression	B	451-461
and	O	462-465
angina	B	466-472
.	O	472-473

However	O	474-481
,	O	481-482
the	O	483-486
mechanisms	O	487-497
of	O	498-500
myocardial	B	501-511
ischemia	I	512-520
induced	O	521-528
by	O	529-531
epinephrine	O	532-543
were	O	544-548
significantly	O	549-562
different	O	563-572
from	O	573-577
those	O	578-583
of	O	584-586
exercise	O	587-595
.	O	595-596

Exercise	O	597-605
-	O	605-606
induced	O	606-613
myocardial	B	614-624
ischemia	I	625-633
was	O	634-637
marked	O	638-644
predominantly	O	645-658
by	O	659-661
increased	O	662-671
heart	O	672-677
rate	O	678-682
and	O	683-686
rate	O	687-691
-	O	691-692
pressure	O	692-700
product	O	701-708
with	O	709-713
a	O	714-715
minor	O	716-721
contribution	O	722-734
of	O	735-737
end	O	738-741
-	O	741-742
diastolic	O	742-751
volume	O	752-758
,	O	758-759
while	O	760-765
epinephrine	O	766-777
-	O	777-778
induced	O	778-785
ischemia	B	786-794
was	O	795-798
characterized	O	799-812
by	O	813-815
a	O	816-817
marked	O	818-824
increase	O	825-833
in	O	834-836
contractility	O	837-850
and	O	851-854
a	O	855-856
less	O	857-861
pronounced	O	862-872
increase	O	873-881
in	O	882-884
heart	O	885-890
rate	O	891-895
and	O	896-899
rate	O	900-904
-	O	904-905
pressure	O	905-913
product	O	914-921
.	O	921-922

These	O	923-928
findings	O	929-937
indicate	O	938-946
that	O	947-951
ischemia	B	952-960
produced	O	961-969
by	O	970-972
epinephrine	O	973-984
,	O	984-985
as	O	986-988
may	O	989-992
occur	O	993-998
during	O	999-1005
states	O	1006-1012
of	O	1013-1015
emotional	O	1016-1025
distress	O	1026-1034
,	O	1034-1035
has	O	1036-1039
a	O	1040-1041
mechanism	O	1042-1051
distinct	O	1052-1060
from	O	1061-1065
that	O	1066-1070
due	O	1071-1074
to	O	1075-1077
physical	O	1078-1086
exertion	O	1087-1095
.	O	1095-1096

Transient	O	0-9
contralateral	B	10-23
rotation	I	24-32
following	O	33-42
unilateral	O	43-53
substantia	B	54-64
nigra	I	65-70
lesion	I	71-77
reflects	O	78-86
susceptibility	O	87-101
of	O	102-104
the	O	105-108
nigrostriatal	O	109-122
system	O	123-129
to	O	130-132
exhaustion	O	133-143
by	O	144-146
amphetamine	O	147-158
.	O	158-159

Following	O	160-169
unilateral	O	170-180
6	O	181-182
-	O	182-183
OHDA	O	183-187
induced	O	188-195
SN	B	196-198
lesion	I	199-205
,	O	205-206
a	O	207-208
transient	O	209-218
period	O	219-225
of	O	226-228
contralateral	B	229-242
rotation	I	243-251
has	O	252-255
been	O	256-260
reported	O	261-269
to	O	270-272
precede	O	273-280
the	O	281-284
predominant	O	285-296
ipsilateral	B	297-308
circling	I	309-317
.	O	317-318

In	O	319-321
order	O	322-327
to	O	328-330
clarify	O	331-338
the	O	339-342
nature	O	343-349
of	O	350-352
this	O	353-357
initial	O	358-365
contralateral	B	366-379
rotation	I	380-388
we	O	389-391
examined	O	392-400
the	O	401-404
effect	O	405-411
of	O	412-414
the	O	415-418
duration	O	419-427
of	O	428-430
recovery	O	431-439
period	O	440-446
after	O	447-452
the	O	453-456
lesion	O	457-463
,	O	463-464
on	O	465-467
amphetamine	O	468-479
-	O	479-480
induced	O	480-487
rotational	B	488-498
behavior	I	499-507
.	O	507-508

Three	O	509-514
days	O	515-519
post	O	520-524
lesion	O	525-531
,	O	531-532
most	O	533-537
rats	O	538-542
circled	O	543-550
predominantly	O	551-564
contralaterally	O	565-580
to	O	581-583
the	O	584-587
lesion	O	588-594
.	O	594-595

Such	O	596-600
contralateral	B	601-614
rotation	I	615-623
may	O	624-627
result	O	628-634
from	O	635-639
either	O	640-646
degeneration	O	647-659
-	O	659-660
induced	O	660-667
breakdown	O	668-677
of	O	678-680
the	O	681-684
DA	O	685-687
pool	O	688-692
,	O	692-693
or	O	694-696
lesion	O	697-703
-	O	703-704
induced	O	704-711
increase	O	712-720
of	O	721-723
DA	O	724-726
turnover	O	727-735
in	O	736-738
the	O	739-742
spared	O	743-749
neurons	O	750-757
.	O	757-758

A	O	759-760
substantial	O	761-772
degree	O	773-779
of	O	780-782
contralateral	O	783-796
preference	O	797-807
was	O	808-811
still	O	812-817
evident	O	818-825
when	O	826-830
amphetamine	O	831-842
was	O	843-846
administered	O	847-859
for	O	860-863
the	O	864-867
first	O	868-873
time	O	874-878
24	O	879-881
days	O	882-886
after	O	887-892
lesioning	O	893-902
,	O	902-903
indicating	O	904-914
involvement	O	915-926
of	O	927-929
spared	O	930-936
cells	O	937-942
in	O	943-945
the	O	946-949
contralateral	B	950-963
rotation	I	964-972
.	O	972-973

However	O	974-981
,	O	981-982
regardless	O	983-993
of	O	994-996
the	O	997-1000
duration	O	1001-1009
of	O	1010-1012
recovery	O	1013-1021
(	O	1022-1023
and	O	1023-1026
irrespective	O	1027-1039
of	O	1040-1042
either	O	1043-1049
lesion	O	1050-1056
volume	O	1057-1063
,	O	1063-1064
amphetamine	O	1065-1076
dose	O	1077-1081
,	O	1081-1082
or	O	1083-1085
post	O	1086-1090
-	O	1090-1091
lesion	O	1091-1097
motor	O	1098-1103
exercise	O	1104-1112
)	O	1112-1113
,	O	1113-1114
amphetamine	O	1115-1126
-	O	1126-1127
induced	O	1127-1134
rotation	B	1135-1143
tended	O	1144-1150
to	O	1151-1153
become	O	1154-1160
gradually	O	1161-1170
more	O	1171-1175
ipsilateral	O	1176-1187
as	O	1188-1190
the	O	1191-1194
observation	O	1195-1206
session	O	1207-1214
progressed	O	1215-1225
,	O	1225-1226
and	O	1227-1230
all	O	1231-1234
rats	O	1235-1239
circled	O	1240-1247
ipsilaterally	O	1248-1261
to	O	1262-1264
the	O	1265-1268
lesion	O	1269-1275
in	O	1276-1278
response	O	1279-1287
to	O	1288-1290
further	O	1291-1298
amphetamine	O	1299-1310
injections	O	1311-1321
.	O	1321-1322

These	O	1323-1328
findings	O	1329-1337
suggest	O	1338-1345
that	O	1346-1350
amphetamine	O	1351-1362
has	O	1363-1366
an	O	1367-1369
irreversible	O	1370-1382
effect	O	1383-1389
on	O	1390-1392
the	O	1393-1396
post	O	1397-1401
-	O	1401-1402
lesion	O	1402-1408
DA	O	1409-1411
pool	O	1412-1416
contributing	O	1417-1429
to	O	1430-1432
contralateral	B	1433-1446
rotation	I	1447-1455
.	O	1455-1456

Thyroid	O	0-7
function	O	8-16
and	O	17-20
urine	O	21-26
-	O	26-27
concentrating	O	27-40
ability	O	41-48
during	O	49-55
lithium	O	56-63
treatment	O	64-73
.	O	73-74

It	O	75-77
has	O	78-81
been	O	82-86
suggested	O	87-96
that	O	97-101
adenylate	O	102-111
cyclase	O	112-119
inhibition	O	120-130
may	O	131-134
be	O	135-137
important	O	138-147
in	O	148-150
the	O	151-154
development	O	155-166
of	O	167-169
both	O	170-174
nephrogenic	B	175-186
diabetes	I	187-195
insipidus	I	196-205
and	O	206-209
hypothyroidism	B	210-224
during	O	225-231
lithium	O	232-239
treatment	O	240-249
.	O	249-250

We	O	251-253
measured	O	254-262
serum	O	263-268
thyroxine	O	269-278
and	O	279-282
urine	O	283-288
-	O	288-289
concentrating	O	289-302
ability	O	303-310
(	O	311-312
Umax	O	312-316
)	O	316-317
in	O	318-320
response	O	321-329
to	O	330-332
desmopressin	O	333-345
(	O	346-347
DDAVP	O	347-352
)	O	352-353
in	O	354-356
85	O	357-359
patients	O	360-368
receiving	O	369-378
lithium	O	379-386
.	O	386-387

Hypothyroidism	B	388-402
developed	O	403-412
in	O	413-415
eight	O	416-421
patients	O	422-430
while	O	431-436
they	O	437-441
were	O	442-446
taking	O	447-453
lithium	O	454-461
.	O	461-462

Impaired	O	463-471
Umax	O	472-476
was	O	477-480
found	O	481-486
in	O	487-489
both	O	490-494
euthyroid	O	495-504
and	O	505-508
hypothyroid	B	509-520
patients	O	521-529
while	O	530-535
some	O	536-540
hypothyroid	B	541-552
patients	O	553-561
concentrated	O	562-574
their	O	575-580
urine	O	581-586
well	O	587-591
.	O	591-592

It	O	593-595
is	O	596-598
concluded	O	599-608
that	O	609-613
the	O	614-617
dominant	O	618-626
mechanisms	O	627-637
by	O	638-640
which	O	641-646
lithium	O	647-654
exerts	O	655-661
these	O	662-667
two	O	668-671
effects	O	672-679
are	O	680-683
different	O	684-693
.	O	693-694

Sensitivity	O	0-11
of	O	12-14
erythroid	O	15-24
progenitor	O	25-35
colonies	O	36-44
to	O	45-47
erythropoietin	O	48-62
in	O	63-65
azidothymidine	O	66-80
treated	O	81-88
immunodeficient	B	89-104
mice	O	105-109
.	O	109-110

The	O	111-114
anaemia	B	115-122
induced	O	123-130
by	O	131-133
3	O	134-135
'	O	135-136
-	O	136-137
azido	O	137-142
-	O	136-137
3	O	134-135
'	O	135-136
dideoxythymidine	O	145-161
(	O	162-163
AZT	O	163-166
)	O	166-167
is	O	168-170
poorly	O	171-177
understood	O	178-188
.	O	188-189

We	O	190-192
have	O	193-197
used	O	198-202
a	O	203-204
murine	O	205-211
model	O	212-217
of	O	218-220
AIDS	B	221-225
,	O	225-226
infection	B	227-236
of	O	237-239
female	O	240-246
C57BL	O	247-252
/	O	252-253
6	O	253-254
mice	O	255-259
with	O	260-264
LP	O	265-267
-	O	267-268
BM5	O	268-271
murine	O	272-278
leukaemia	B	279-288
(	O	289-290
MuLV	O	290-294
)	O	294-295
virus	O	296-301
,	O	301-302
to	O	303-305
determine	O	306-315
if	O	316-318
AZT	O	319-322
-	O	322-323
induced	O	323-330
anaemia	B	331-338
is	O	339-341
due	O	342-345
,	O	345-346
in	O	347-349
part	O	350-354
,	O	354-355
to	O	356-358
decreased	O	359-368
responsiveness	O	369-383
of	O	384-386
erythropoietic	O	387-401
precursors	O	402-412
(	O	413-414
BFU	O	414-417
-	O	417-418
e	O	418-419
)	O	419-420
to	O	421-423
erythropoietin	O	424-438
(	O	439-440
EPO	O	440-443
)	O	443-444
.	O	444-445

Mice	O	446-450
in	O	451-453
the	O	454-457
early	O	458-463
stage	O	464-469
of	O	470-472
LP	O	473-475
-	O	475-476
BM5	O	476-479
MuLV	O	480-484
disease	O	485-492
were	O	493-497
given	O	498-503
AZT	O	504-507
in	O	508-510
their	O	511-516
drinking	O	517-525
water	O	526-531
at	O	532-534
1	O	535-536
.	O	536-537
0	O	537-538
and	O	539-542
2	O	543-544
.	O	544-545
5	O	545-546
mg	O	547-549
/	O	549-550
ml	O	550-552
.	O	552-553

AZT	O	554-557
produced	O	558-566
anaemia	B	567-574
in	O	575-577
both	O	578-582
groups	O	583-589
,	O	589-590
in	O	591-593
a	O	594-595
dose	O	596-600
-	O	600-601
dependent	O	601-610
fashion	O	611-618
.	O	618-619

Despite	O	620-627
the	O	628-631
anaemia	B	632-639
,	O	639-640
the	O	641-644
number	O	645-651
of	O	652-654
splenic	O	655-662
and	O	663-666
bone	O	667-671
marrow	O	672-678
BFU	O	679-682
-	O	682-683
e	O	683-684
in	O	685-687
AZT	O	688-691
treated	O	692-699
mice	O	700-704
increased	O	705-714
up	O	715-717
to	O	718-720
five	O	721-725
-	O	725-726
fold	O	726-730
over	O	731-735
levels	O	736-742
observed	O	743-751
in	O	752-754
infected	O	755-763
untreated	O	764-773
animals	O	774-781
after	O	782-787
15	O	788-790
d	O	791-792
of	O	793-795
treatment	O	796-805
.	O	805-806

Colony	O	807-813
formation	O	814-823
by	O	824-826
splenic	O	827-834
and	O	835-838
bone	O	839-843
marrow	O	844-850
BFUe	O	851-855
was	O	856-859
stimulated	O	860-870
at	O	871-873
lower	O	874-879
concentrations	O	880-894
of	O	895-897
EPO	O	898-901
in	O	902-904
mice	O	905-909
receiving	O	910-919
AZT	O	920-923
for	O	924-927
15	O	928-930
d	O	931-932
than	O	933-937
for	O	938-941
infected	O	942-950
,	O	950-951
untreated	O	952-961
mice	O	962-966
.	O	966-967

By	O	968-970
day	O	971-974
30	O	975-977
,	O	977-978
sensitivity	O	979-990
of	O	991-993
both	O	994-998
splenic	O	999-1006
and	O	1007-1010
bone	O	1011-1015
marrow	O	1016-1022
BFU	O	1023-1026
-	O	1026-1027
e	O	1027-1028
of	O	1029-1031
treated	O	1032-1039
animals	O	1040-1047
returned	O	1048-1056
to	O	1057-1059
that	O	1060-1064
observed	O	1065-1073
from	O	1074-1078
cells	O	1079-1084
of	O	1085-1087
infected	O	1088-1096
untreated	O	1097-1106
animals	O	1107-1114
.	O	1114-1115

The	O	1116-1119
mean	O	1120-1124
plasma	O	1125-1131
levels	O	1132-1138
of	O	1139-1141
EPO	O	1142-1145
observed	O	1146-1154
in	O	1155-1157
AZT	O	1158-1161
treated	O	1162-1169
mice	O	1170-1174
were	O	1175-1179
appropriate	O	1180-1191
for	O	1192-1195
the	O	1196-1199
degree	O	1200-1206
of	O	1207-1209
anaemia	B	1210-1217
observed	O	1218-1226
when	O	1227-1231
compared	O	1232-1240
with	O	1241-1245
phenylhydrazine	O	1246-1261
(	O	1262-1263
PHZ	O	1263-1266
)	O	1266-1267
treated	O	1268-1275
mice	O	1276-1280
.	O	1280-1281

The	O	1282-1285
numbers	O	1286-1293
of	O	1294-1296
BFU	O	1297-1300
-	O	1300-1301
e	O	1301-1302
and	O	1303-1306
the	O	1307-1310
percentage	O	1311-1321
of	O	1322-1324
bone	O	1325-1329
marrow	O	1330-1336
erythroblasts	O	1337-1350
observed	O	1351-1359
were	O	1360-1364
comparable	O	1365-1375
in	O	1376-1378
AZT	O	1379-1382
and	O	1383-1386
PHZ	O	1387-1390
treated	O	1391-1398
mice	O	1399-1403
with	O	1404-1408
similar	O	1409-1416
degrees	O	1417-1424
of	O	1425-1427
anaemia	B	1428-1435
.	O	1435-1436

However	O	1437-1444
,	O	1444-1445
reticulocytosis	B	1446-1461
was	O	1462-1465
inappropriate	O	1466-1479
for	O	1480-1483
the	O	1484-1487
degree	O	1488-1494
of	O	1495-1497
anaemia	B	1498-1505
observed	O	1506-1514
in	O	1515-1517
AZT	O	1518-1521
treated	O	1522-1529
infected	O	1530-1538
mice	O	1539-1543
.	O	1543-1544

AZT	O	1545-1548
-	O	1548-1549
induced	O	1549-1556
peripheral	O	1557-1567
anaemia	B	1568-1575
in	O	1576-1578
the	O	1579-1582
face	O	1583-1587
of	O	1588-1590
increased	O	1591-1600
numbers	O	1601-1608
of	O	1609-1611
BFU	O	1612-1615
-	O	1615-1616
e	O	1616-1617
and	O	1618-1621
increased	O	1622-1631
levels	O	1632-1638
of	O	1639-1641
plasma	O	1642-1648
EPO	O	1649-1652
suggest	O	1653-1660
a	O	1661-1662
lesion	O	1663-1669
in	O	1670-1672
terminal	O	1673-1681
differentiation	O	1682-1697
.	O	1697-1698

Detection	O	0-9
of	O	10-12
abnormal	O	13-21
cardiac	O	22-29
adrenergic	O	30-40
neuron	O	41-47
activity	O	48-56
in	O	57-59
adriamycin	O	60-70
-	O	70-71
induced	O	71-78
cardiomyopathy	B	79-93
with	O	94-98
iodine	O	99-105
-	O	105-106
125	O	106-109
-	O	105-106
metaiodobenzylguanidine	O	110-133
.	O	133-134

Radiolabeled	O	135-147
metaiodobenzylguanidine	O	148-171
(	O	172-173
MIBG	O	173-177
)	O	177-178
,	O	178-179
an	O	180-182
analog	O	183-189
of	O	190-192
norepinephrine	O	193-207
(	O	208-209
NE	O	209-211
)	O	211-212
,	O	212-213
serves	O	214-220
as	O	221-223
an	O	224-226
index	O	227-232
of	O	233-235
adrenergic	O	236-246
neuron	O	247-253
integrity	O	254-263
and	O	264-267
function	O	268-276
.	O	276-277

Using	O	278-283
a	O	284-285
rat	O	286-289
model	O	290-295
of	O	296-298
adriamycin	O	299-309
-	O	309-310
induced	O	310-317
cardiomyopathy	B	318-332
,	O	332-333
we	O	334-336
tested	O	337-343
the	O	344-347
hypothesis	O	348-358
that	O	359-363
abnormal	O	364-372
cardiac	O	373-380
adrenergic	O	381-391
neuron	O	392-398
activity	O	399-407
may	O	408-411
appear	O	412-418
and	O	419-422
be	O	423-425
exacerbated	O	426-437
dose	O	438-442
-	O	442-443
dependently	O	443-454
in	O	455-457
adriamycin	O	458-468
cardiomyopathy	B	469-483
.	O	483-484

The	O	485-488
degree	O	489-495
of	O	496-498
vacuolar	B	499-507
degeneration	I	508-520
of	I	521-523
myocardial	I	524-534
cells	I	535-540
was	O	541-544
analyzed	O	545-553
in	O	554-556
relation	O	557-565
to	O	566-568
the	O	569-572
duration	O	573-581
of	O	582-584
adriamycin	O	585-595
treatment	O	596-605
(	O	606-607
2	O	607-608
mg	O	609-611
/	O	611-612
kg	O	612-614
,	O	614-615
once	O	616-620
a	O	621-622
week	O	623-627
)	O	627-628
.	O	628-629

There	O	630-635
were	O	636-640
no	O	641-643
abnormalities	O	644-657
or	O	658-660
only	O	661-665
isolated	O	666-674
degeneration	O	675-687
in	O	688-690
the	O	691-694
1	O	695-696
-	O	696-697
or	O	698-700
2	O	701-702
-	O	702-703
wk	O	703-705
treatment	O	706-715
groups	O	716-722
,	O	722-723
isolated	O	724-732
or	O	733-735
scattered	O	736-745
degeneration	O	746-758
in	O	759-761
half	O	762-766
of	O	767-769
the	O	770-773
3	O	774-775
-	O	775-776
wk	O	776-778
group	O	779-784
,	O	784-785
frequent	O	786-794
scattered	O	795-804
degeneration	O	805-817
in	O	818-820
the	O	821-824
4	O	825-826
-	O	826-827
wk	O	827-829
group	O	830-835
,	O	835-836
scattered	O	837-846
or	O	847-849
focal	O	850-855
degeneration	O	856-868
in	O	869-871
the	O	872-875
5	O	876-877
-	O	877-878
wk	O	878-880
group	O	881-886
,	O	886-887
and	O	888-891
extensive	O	892-901
degeneration	O	902-914
in	O	915-917
the	O	918-921
8	O	922-923
-	O	923-924
wk	O	924-926
group	O	927-932
.	O	932-933

Myocardial	O	934-944
accumulation	O	945-957
of	O	958-960
[	O	961-962
125I	O	962-966
]	O	966-967
MIBG	O	967-971
4	O	972-973
hr	O	974-976
after	O	977-982
intravenous	O	983-994
injection	O	995-1004
did	O	1005-1008
not	O	1009-1012
differ	O	1013-1019
between	O	1020-1027
the	O	1028-1031
controls	O	1032-1040
and	O	1041-1044
the	O	1045-1048
groups	O	1049-1055
treated	O	1056-1063
3	O	1064-1065
wk	O	1066-1068
or	O	1069-1071
less	O	1072-1076
.	O	1076-1077

However	O	1078-1085
,	O	1085-1086
the	O	1087-1090
4	O	1091-1092
-	O	1092-1093
wk	O	1093-1095
group	O	1096-1101
had	O	1102-1105
a	O	1106-1107
slightly	O	1108-1116
lower	O	1117-1122
accumulation	O	1123-1135
in	O	1136-1138
the	O	1139-1142
right	O	1143-1148
ventricular	O	1149-1160
wall	O	1161-1165
(	O	1166-1167
82	O	1167-1169
%	O	1169-1170
of	O	1171-1173
the	O	1174-1177
control	O	1178-1185
)	O	1185-1186
and	O	1187-1190
significantly	O	1191-1204
lower	O	1205-1210
accumulation	O	1211-1223
in	O	1224-1226
the	O	1227-1230
left	O	1231-1235
ventricular	O	1236-1247
wall	O	1248-1252
(	O	1253-1254
about	O	1254-1259
66	O	1260-1262
%	O	1262-1263
of	O	1264-1266
the	O	1267-1270
control	O	1271-1278
:	O	1278-1279
p	O	1280-1281
less	O	1282-1286
than	O	1287-1291
0	O	1292-1293
.	O	1293-1294
05	O	1294-1296
)	O	1296-1297
.	O	1293-1294

In	O	1299-1301
the	O	1302-1305
5	O	1306-1307
-	O	1307-1308
wk	O	1308-1310
group	O	1311-1316
,	O	1316-1317
MIBG	O	1318-1322
accumulation	O	1323-1335
in	O	1336-1338
the	O	1339-1342
right	O	1343-1348
and	O	1349-1352
left	O	1353-1357
ventricular	O	1358-1369
wall	O	1370-1374
was	O	1375-1378
35	O	1379-1381
%	O	1381-1382
and	O	1383-1386
27	O	1387-1389
%	O	1389-1390
of	O	1391-1393
that	O	1394-1398
in	O	1399-1401
controls	O	1402-1410
,	O	1410-1411
respectively	O	1412-1424
(	O	1425-1426
p	O	1426-1427
less	O	1428-1432
than	O	1433-1437
0	O	1438-1439
.	O	1439-1440
001	O	1440-1443
)	O	1443-1444
.	O	1439-1440

In	O	1446-1448
the	O	1449-1452
8	O	1453-1454
-	O	1454-1455
wk	O	1455-1457
group	O	1458-1463
,	O	1463-1464
MIBG	O	1465-1469
accumulation	O	1470-1482
in	O	1483-1485
the	O	1486-1489
right	O	1490-1495
and	O	1496-1499
left	O	1500-1504
ventricular	O	1505-1516
wall	O	1517-1521
was	O	1522-1525
18	O	1526-1528
%	O	1528-1529
and	O	1530-1533
14	O	1534-1536
%	O	1536-1537
of	O	1538-1540
that	O	1541-1545
in	O	1546-1548
controls	O	1549-1557
,	O	1557-1558
respectively	O	1559-1571
(	O	1572-1573
p	O	1573-1574
less	O	1575-1579
than	O	1580-1584
0	O	1585-1586
.	O	1586-1587
001	O	1587-1590
)	O	1590-1591
.	O	1586-1587

Thus	O	1593-1597
,	O	1597-1598
MIBG	O	1599-1603
accumulation	O	1604-1616
in	O	1617-1619
the	O	1620-1623
myocardium	O	1624-1634
decreased	O	1635-1644
in	O	1645-1647
an	O	1648-1650
adriamycin	O	1651-1661
dose	O	1662-1666
-	O	1666-1667
dependent	O	1667-1676
manner	O	1677-1683
.	O	1683-1684

The	O	1685-1688
appearance	O	1689-1699
of	O	1700-1702
impaired	O	1703-1711
cardiac	O	1712-1719
adrenergic	O	1720-1730
neuron	O	1731-1737
activity	O	1738-1746
in	O	1747-1749
the	O	1750-1753
presence	O	1754-1762
of	O	1763-1765
slight	O	1766-1772
myocardial	B	1773-1783
impairment	I	1784-1794
(	O	1795-1796
scattered	O	1796-1805
or	O	1806-1808
focal	O	1809-1814
vacuolar	B	1815-1823
degeneration	I	1824-1836
)	O	1836-1837
indicates	O	1838-1847
that	O	1848-1852
MIBG	O	1853-1857
scintigraphy	O	1858-1870
may	O	1871-1874
be	O	1875-1877
a	O	1878-1879
useful	O	1880-1886
method	O	1887-1893
for	O	1894-1897
detection	O	1898-1907
of	O	1908-1910
adriamycin	O	1911-1921
-	O	1921-1922
induced	O	1922-1929
cardiomyopathy	B	1930-1944
.	O	1944-1945

Amnestic	B	0-8
syndrome	I	9-17
associated	O	18-28
with	O	29-33
propranolol	O	34-45
toxicity	B	46-54
:	O	54-55
a	O	56-57
case	O	58-62
report	O	63-69
.	O	69-70

An	O	71-73
elderly	O	74-81
woman	O	82-87
developed	O	88-97
an	O	98-100
Alzheimer	B	101-110
-	O	110-111
like	O	111-115
subacute	O	116-124
dementia	B	125-133
as	O	134-136
a	O	137-138
result	O	139-145
of	O	146-148
propranolol	O	149-160
toxicity	B	161-169
.	O	169-170

Analysis	O	171-179
of	O	180-182
the	O	183-186
manifestations	O	187-201
showed	O	202-208
that	O	209-213
severe	O	214-220
impairment	O	221-231
of	O	232-234
memory	O	235-241
accounted	O	242-251
for	O	252-255
virtually	O	256-265
all	O	266-269
of	O	270-272
the	O	273-276
abnormalities	O	277-290
.	O	290-291

There	O	292-297
is	O	298-300
evidence	O	301-309
that	O	310-314
cerebral	O	315-323
reactions	O	324-333
to	O	334-336
drug	O	337-341
toxicity	B	342-350
can	O	351-354
exhibit	O	355-362
patterns	O	363-371
that	O	372-376
suggest	O	377-384
highly	O	385-391
selective	O	392-401
involvement	O	402-413
of	O	414-416
functional	O	417-427
subdivisions	O	428-440
of	O	441-443
the	O	444-447
brain	O	448-453
.	O	453-454

Biphasic	O	0-8
response	O	9-17
of	O	18-20
the	O	21-24
SA	O	25-27
node	O	28-32
of	O	33-35
the	O	36-39
dog	O	40-43
heart	O	44-49
in	O	50-52
vivo	O	53-57
to	O	58-60
selective	O	61-70
administration	O	71-85
of	O	86-88
ketamine	O	89-97
.	O	97-98

Effect	O	99-105
of	O	106-108
ketamine	O	109-117
on	O	118-120
the	O	121-124
SA	O	125-127
node	O	128-132
of	O	133-135
the	O	136-139
dog	O	140-143
heart	O	144-149
was	O	150-153
studied	O	154-161
in	O	162-164
vivo	O	165-169
using	O	170-175
a	O	176-177
selective	O	178-187
perfusion	O	188-197
technique	O	198-207
of	O	208-210
the	O	211-214
SA	O	215-217
node	O	218-222
artery	O	223-229
.	O	229-230

Injections	O	231-241
of	O	242-244
ketamine	O	245-253
in	O	254-256
doses	O	257-262
from	O	263-267
100	O	268-271
microgram	O	272-281
to	O	282-284
3	O	285-286
mg	O	287-289
into	O	290-294
the	O	295-298
artery	O	299-305
produced	O	306-314
a	O	315-316
depression	B	317-327
of	O	328-330
the	O	331-334
SA	O	335-337
nodal	O	338-343
activity	O	344-352
by	O	353-355
a	O	356-357
direct	O	358-364
action	O	365-371
.	O	371-372

This	O	373-377
depression	B	378-388
was	O	389-392
followed	O	393-401
by	O	402-404
the	O	405-408
sudden	O	409-415
appearance	O	416-426
of	O	427-429
a	O	430-431
stimulatory	O	432-443
phase	O	444-449
.	O	449-450

Bilateral	O	451-460
vagotomy	O	461-469
and	O	470-473
sympathectomy	O	474-487
or	O	488-490
prior	O	491-496
administration	O	497-511
of	O	512-514
a	O	515-516
ganglion	O	517-525
blocker	O	526-533
failed	O	534-540
to	O	541-543
inhibit	O	544-551
the	O	552-555
occurrence	O	556-566
of	O	567-569
the	O	570-573
ketamine	O	574-582
-	O	582-583
induced	O	583-590
tachycardia	B	591-602
,	O	602-603
while	O	604-609
it	O	610-612
was	O	613-616
completely	O	617-627
abolished	O	628-637
in	O	638-640
the	O	641-644
reserpinized	O	645-657
dogs	O	658-662
or	O	663-665
by	O	666-668
a	O	669-670
prior	O	671-676
injection	O	677-686
of	O	687-689
a	O	690-691
beta	O	692-696
-	O	696-697
blocking	O	697-705
agent	O	706-711
into	O	712-716
the	O	717-720
SA	O	721-723
node	O	724-728
artery	O	729-735
.	O	735-736

This	O	737-741
may	O	742-745
indicate	O	746-754
that	O	755-759
an	O	760-762
activation	O	763-773
of	O	774-776
the	O	777-780
peripheral	O	781-791
adrenergic	O	792-802
mechanism	O	803-812
plays	O	813-818
an	O	819-821
important	O	822-831
role	O	832-836
in	O	837-839
the	O	840-843
induction	O	844-853
of	O	854-856
the	O	857-860
excitatory	O	861-871
effect	O	872-878
of	O	879-881
ketamine	O	882-890
injected	O	891-899
in	O	900-902
the	O	903-906
SA	O	907-909
node	O	910-914
artery	O	915-921
.	O	921-922

The	O	0-3
use	O	4-7
of	O	8-10
serum	O	11-16
cholinesterase	O	17-31
in	O	32-34
succinylcholine	O	35-50
apnoea	B	51-57
.	O	57-58

Fifteen	O	59-66
patients	O	67-75
demonstrating	O	76-89
unexpected	O	90-100
prolonged	O	101-110
apnoea	B	111-117
lasting	O	118-125
several	O	126-133
hours	O	134-139
after	O	140-145
succinylcholine	O	146-161
have	O	162-166
been	O	167-171
treated	O	172-179
by	O	180-182
a	O	183-184
new	O	185-188
preparation	O	189-200
of	O	201-203
human	O	204-209
serum	O	210-215
cholinesterase	O	216-230
.	O	230-231

Adequate	O	232-240
spontaneous	O	241-252
respiration	O	253-264
was	O	265-268
re	O	269-271
-	O	271-272
established	O	272-283
in	O	284-286
an	O	287-289
average	O	290-297
period	O	298-304
of	O	305-307
ten	O	308-311
minutes	O	312-319
after	O	320-325
the	O	326-329
injection	O	330-339
.	O	339-340

In	O	341-343
12	O	344-346
patients	O	347-355
biochemical	O	356-367
genetic	O	368-375
examinations	O	376-388
confirmed	O	389-398
the	O	399-402
presence	O	403-411
of	O	412-414
an	O	415-417
atypical	O	418-426
serum	O	427-432
cholinesterase	O	433-447
.	O	447-448

In	O	449-451
three	O	452-457
patients	O	458-466
none	O	467-471
of	O	472-474
the	O	475-478
usual	O	479-484
variants	O	485-493
were	O	494-498
found	O	499-504
.	O	504-505

It	O	506-508
is	O	509-511
therefore	O	512-521
supposed	O	522-530
that	O	531-535
other	O	536-541
unknown	O	542-549
variants	O	550-558
of	O	559-561
serum	O	562-567
cholinesterase	O	568-582
exist	O	583-588
which	O	589-594
cannot	O	595-601
hydrolyze	O	602-611
succinylcholine	O	612-627
.	O	627-628

The	O	629-632
use	O	633-636
of	O	637-639
serum	O	640-645
cholinesterase	O	646-660
in	O	661-663
succinylcholine	O	664-679
apnoea	B	680-686
provided	O	687-695
considerable	O	696-708
relief	O	709-715
to	O	716-718
both	O	719-723
patient	O	724-731
and	O	732-735
anaesthetist	O	736-748
.	O	748-749

Orthostatic	B	0-11
hypotension	I	12-23
occurs	O	24-30
following	O	31-40
alpha	O	41-46
2	O	47-48
-	O	48-49
adrenoceptor	O	49-61
blockade	O	62-70
in	O	71-73
chronic	O	74-81
prazosin	O	82-90
-	O	90-91
pretreated	O	91-101
conscious	O	102-111
spontaneously	O	112-125
hypertensive	B	126-138
rats	O	139-143
.	O	143-144
1	O	145-146
.	O	146-147

Studies	O	148-155
were	O	156-160
performed	O	161-170
to	O	171-173
evaluate	O	174-182
whether	O	183-190
chronic	O	191-198
prazosin	O	199-207
treatment	O	208-217
alters	O	218-224
the	O	225-228
alpha	O	229-234
2	O	235-236
-	O	236-237
adrenoceptor	O	237-249
function	O	250-258
for	O	259-262
orthostatic	O	263-274
control	O	275-282
of	O	283-285
arterial	O	286-294
blood	O	295-300
pressure	O	301-309
in	O	310-312
conscious	O	313-322
spontaneously	O	323-336
hypertensive	B	337-349
rats	O	350-354
(	O	355-356
SHR	O	356-359
)	O	359-360
.	O	360-361

2	O	362-363
.	O	363-364
Conscious	O	365-374
SHR	O	375-378
(	O	379-380
male	O	380-384
300	O	385-388
-	O	388-389
350	O	389-392
g	O	393-394
)	O	394-395
were	O	396-400
subjected	O	401-410
to	O	411-413
90	O	414-416
degrees	O	417-424
head	O	425-429
-	O	429-430
up	O	430-432
tilts	O	433-438
for	O	439-442
60	O	443-445
s	O	446-447
following	O	448-457
acute	O	458-463
administration	O	464-478
of	O	479-481
prazosin	O	482-490
(	O	491-492
0	O	492-493
.	O	493-494
1	O	494-495
mg	O	496-498
kg	O	499-501
-	O	501-502
1	O	502-503
i	O	504-505
.	O	505-506
p	O	506-507
.	O	505-506
)	O	508-509
or	O	510-512
rauwolscine	O	513-524
(	O	525-526
3	O	526-527
mg	O	528-530
kg	O	531-533
-	O	533-534
1	O	534-535
i	O	536-537
.	O	537-538
v	O	538-539
.	O	537-538
)	O	540-541
.	O	537-538

Orthostatic	B	543-554
hypotension	I	555-566
was	O	567-570
determined	O	571-581
by	O	582-584
the	O	585-588
average	O	589-596
decrease	O	597-605
(	O	606-607
%	O	607-608
)	O	608-609
in	O	610-612
mean	O	613-617
arterial	O	618-626
pressure	O	627-635
(	O	636-637
MAP	O	637-640
femoral	O	641-648
)	O	648-649
over	O	650-654
the	O	655-658
60	O	659-661
-	O	661-662
s	O	662-663
tilt	O	664-668
period	O	669-675
.	O	675-676

The	O	677-680
basal	O	681-686
MAP	O	687-690
of	O	691-693
conscious	O	694-703
SHR	O	704-707
was	O	708-711
reduced	O	712-719
to	O	720-722
a	O	723-724
similar	O	725-732
extent	O	733-739
by	O	740-742
prazosin	O	743-751
(	O	752-753
-	O	753-754
23	O	754-756
%	O	756-757
(	O	752-753
-	O	753-754
)	O	759-760
-	O	753-754
26	O	761-763
%	O	756-757
MAP	O	765-768
)	O	768-769
and	O	770-773
rauwolscine	O	774-785
(	O	786-787
-	O	787-788
16	O	788-790
%	O	790-791
(	O	786-787
-	O	787-788
)	O	793-794
-	O	787-788
33	O	795-797
%	O	790-791
MAP	O	799-802
)	O	802-803
.	O	803-804

However	O	805-812
,	O	812-813
the	O	814-817
head	O	818-822
-	O	822-823
up	O	823-825
tilt	O	826-830
induced	O	831-838
orthostatic	B	839-850
hypotension	I	851-862
in	O	863-865
the	O	866-869
SHR	O	870-873
treated	O	874-881
with	O	882-886
prazosin	O	887-895
(	O	896-897
-	O	897-898
16	O	898-900
%	O	900-901
MAP	O	902-905
,	O	905-906
n	O	907-908
=	O	909-910
6	O	911-912
)	O	912-913
,	O	913-914
but	O	915-918
not	O	919-922
in	O	923-925
the	O	926-929
SHR	O	930-933
treated	O	934-941
with	O	942-946
rauwolscine	O	947-958
(	O	959-960
less	O	960-964
than	O	965-969
+	O	970-971
2	O	971-972
%	O	972-973
MAP	O	974-977
,	O	977-978
n	O	979-980
=	O	981-982
6	O	983-984
)	O	984-985
.	O	985-986

3	O	987-988
.	O	988-989
Conscious	O	990-999
SHR	O	1000-1003
were	O	1004-1008
treated	O	1009-1016
for	O	1017-1020
4	O	1021-1022
days	O	1023-1027
with	O	1028-1032
prazosin	O	1033-1041
at	O	1042-1044
2	O	1045-1046
mg	O	1047-1049
kg	O	1050-1052
-	O	1052-1053
1	O	1053-1054
day	O	1055-1058
-	O	1058-1059
1	O	1059-1060
i	O	1061-1062
.	O	1062-1063
p	O	1063-1064
.	O	1062-1063
for	O	1066-1069
chronic	O	1070-1077
alpha	O	1078-1083
1	O	1084-1085
-	O	1085-1086
adrenoceptor	O	1086-1098
blockade	O	1099-1107
.	O	1107-1108

MAP	O	1109-1112
in	O	1113-1115
conscious	O	1116-1125
SHR	O	1126-1129
after	O	1130-1135
chronic	O	1136-1143
prazosin	O	1144-1152
treatment	O	1153-1162
was	O	1163-1166
14	O	1167-1169
%	O	1169-1170
lower	O	1171-1176
than	O	1177-1181
in	O	1182-1184
the	O	1185-1188
untreated	O	1189-1198
SHR	O	1199-1202
(	O	1203-1204
n	O	1204-1205
=	O	1206-1207
8	O	1208-1209
)	O	1209-1210
.	O	1210-1211

Head	O	1212-1216
-	O	1216-1217
up	O	1217-1219
tilts	O	1220-1225
in	O	1226-1228
these	O	1229-1234
rats	O	1235-1239
did	O	1240-1243
not	O	1244-1247
produce	O	1248-1255
orthostatic	B	1256-1267
hypotension	I	1268-1279
when	O	1280-1284
performed	O	1285-1294
either	O	1295-1301
prior	O	1302-1307
to	O	1308-1310
or	O	1311-1313
after	O	1314-1319
acute	O	1320-1325
dosing	O	1326-1332
of	O	1333-1335
prazosin	O	1336-1344
(	O	1345-1346
0	O	1346-1347
.	O	1347-1348
1	O	1348-1349
mg	O	1350-1352
kg	O	1353-1355
-	O	1355-1356
1	O	1356-1357
i	O	1358-1359
.	O	1359-1360
p	O	1360-1361
.	O	1359-1360
)	O	1362-1363
.	O	1359-1360

Conversely	O	1365-1375
,	O	1375-1376
administration	O	1377-1391
of	O	1392-1394
rauwolscine	O	1395-1406
(	O	1407-1408
3	O	1408-1409
mg	O	1410-1412
kg	O	1413-1415
-	O	1415-1416
1	O	1416-1417
i	O	1418-1419
.	O	1419-1420
v	O	1420-1421
.	O	1419-1420
)	O	1422-1423
in	O	1424-1426
chronic	O	1427-1434
prazosin	O	1435-1443
treated	O	1444-1451
SHR	O	1452-1455
decreased	O	1456-1465
the	O	1466-1469
basal	O	1470-1475
MAP	O	1476-1479
by	O	1480-1482
12	O	1483-1485
-	O	1485-1486
31	O	1486-1488
%	O	1488-1489
(	O	1490-1491
n	O	1491-1492
=	O	1493-1494
4	O	1495-1496
)	O	1496-1497
,	O	1497-1498
and	O	1499-1502
subsequent	O	1503-1513
tilts	O	1514-1519
induced	O	1520-1527
further	O	1528-1535
drops	O	1536-1541
of	O	1542-1544
MAP	O	1545-1548
by	O	1549-1551
19	O	1552-1554
-	O	1554-1555
23	O	1555-1557
%	O	1557-1558
in	O	1559-1561
these	O	1562-1567
rats	O	1568-1572
.	O	1572-1573

4	O	1574-1575
.	O	1575-1576
The	O	1577-1580
pressor	O	1581-1588
responses	O	1589-1598
and	O	1599-1602
bradycardia	B	1603-1614
to	O	1615-1617
the	O	1618-1621
alpha	O	1622-1627
1	O	1628-1629
-	O	1629-1630
agonist	O	1630-1637
cirazoline	O	1638-1648
(	O	1649-1650
0	O	1650-1651
.	O	1651-1652
6	O	1652-1653
and	O	1654-1657
2	O	1658-1659
micrograms	O	1660-1670
kg	O	1671-1673
-	O	1673-1674
1	O	1674-1675
i	O	1676-1677
.	O	1677-1678
v	O	1678-1679
.	O	1677-1678
)	O	1680-1681
,	O	1681-1682
the	O	1683-1686
alpha	O	1687-1692
2	O	1693-1694
-	O	1694-1695
agonist	O	1695-1702
Abbott	O	1703-1709
-	O	1709-1710
53693	O	1710-1715
(	O	1716-1717
1	O	1717-1718
and	O	1719-1722
3	O	1723-1724
micrograms	O	1725-1735
kg	O	1736-1738
-	O	1738-1739
1	O	1739-1740
i	O	1741-1742
.	O	1742-1743
v	O	1743-1744
.	O	1742-1743
)	O	1745-1746
,	O	1746-1747
and	O	1748-1751
noradrenaline	O	1752-1765
(	O	1766-1767
0	O	1767-1768
.	O	1768-1769
1	O	1769-1770
and	O	1771-1774
1	O	1775-1776
.	O	1776-1777
0	O	1777-1778
micrograms	O	1779-1789
kg	O	1790-1792
-	O	1792-1793
1	O	1793-1794
i	O	1795-1796
.	O	1796-1797
v	O	1797-1798
.	O	1796-1797
)	O	1799-1800
were	O	1801-1805
determined	O	1806-1816
in	O	1817-1819
conscious	O	1820-1829
SHR	O	1830-1833
with	O	1834-1838
and	O	1839-1842
without	O	1843-1850
chronic	O	1851-1858
prazosin	O	1859-1867
pretreatment	O	1868-1880
.	O	1880-1881

Both	O	1882-1886
the	O	1887-1890
pressor	O	1891-1898
and	O	1899-1902
bradycardia	B	1903-1914
effects	O	1915-1922
of	O	1923-1925
cirazoline	O	1926-1936
were	O	1937-1941
abolished	O	1942-1951
in	O	1952-1954
chronic	O	1955-1962
prazosin	O	1963-1971
treated	O	1972-1979
SHR	O	1980-1983
(	O	1984-1985
n	O	1985-1986
=	O	1987-1988
4	O	1989-1990
)	O	1990-1991
as	O	1992-1994
compared	O	1995-2003
to	O	2004-2006
the	O	2007-2010
untreated	O	2011-2020
SHR	O	2021-2024
(	O	2025-2026
n	O	2026-2027
=	O	2028-2029
4	O	2030-2031
)	O	2031-2032
.	O	2032-2033

On	O	2034-2036
the	O	2037-2040
other	O	2041-2046
hand	O	2047-2051
,	O	2051-2052
the	O	2053-2056
pressor	O	2057-2064
effects	O	2065-2072
of	O	2073-2075
Abbott	O	2076-2082
-	O	2082-2083
53693	O	2083-2088
were	O	2089-2093
similar	O	2094-2101
in	O	2102-2104
both	O	2105-2109
groups	O	2110-2116
of	O	2117-2119
SHR	O	2120-2123
,	O	2123-2124
but	O	2125-2128
the	O	2129-2132
accompanying	O	2133-2145
bradycardia	B	2146-2157
was	O	2158-2161
greater	O	2162-2169
in	O	2170-2172
SHR	O	2173-2176
with	O	2177-2181
chronic	O	2182-2189
prazosin	O	2190-2198
treatment	O	2199-2208
than	O	2209-2213
without	O	2214-2221
such	O	2222-2226
treatment	O	2227-2236
.	O	2236-2237

Furthermore	O	2238-2249
,	O	2249-2250
the	O	2251-2254
bradycardia	B	2255-2266
that	O	2267-2271
accompanied	O	2272-2283
the	O	2284-2287
noradrenaline	O	2288-2301
-	O	2301-2302
induced	O	2302-2309
pressor	O	2310-2317
effect	O	2318-2324
in	O	2325-2327
SHR	O	2328-2331
was	O	2332-2335
similar	O	2336-2343
with	O	2344-2348
and	O	2349-2352
without	O	2353-2360
chronic	O	2361-2368
prazosin	O	2369-2377
treatment	O	2378-2387
despite	O	2388-2395
a	O	2396-2397
47	O	2398-2400
-	O	2400-2401
71	O	2401-2403
%	O	2403-2404
reduction	O	2405-2414
of	O	2415-2417
the	O	2418-2421
pressor	O	2422-2429
effect	O	2430-2436
in	O	2437-2439
chronic	O	2440-2447
alpha	O	2448-2453
1	O	2454-2455
-	O	2455-2456
receptor	O	2456-2464
blocked	O	2465-2472
SHR	O	2473-2476
.	O	2476-2477
(	O	2477-2478
ABSTRACT	O	2478-2486
TRUNCATED	O	2487-2496
AT	O	2497-2499
400	O	2500-2503
WORDS	O	2504-2509
)	O	2509-2510

Coexistence	O	0-11
of	O	12-14
cerebral	B	15-23
venous	I	24-30
sinus	I	31-36
and	I	37-40
internal	I	41-49
carotid	I	50-57
artery	I	58-64
thrombosis	I	65-75
associated	O	76-86
with	O	87-91
exogenous	O	92-101
sex	O	102-105
hormones	O	106-114
.	O	114-115

A	O	116-117
case	O	118-122
report	O	123-129
.	O	129-130

A	O	131-132
forty	O	133-138
-	O	138-139
six	O	139-142
year	O	143-147
-	O	147-148
old	O	148-151
premenopausal	O	152-165
woman	O	166-171
developed	O	172-181
headache	B	182-190
,	O	190-191
nausea	B	192-198
and	O	199-202
vomiting	B	203-211
,	O	211-212
left	O	213-217
hemiparesis	B	218-229
and	O	230-233
seizure	B	234-241
two	O	242-245
days	O	246-250
after	O	251-256
parenteral	O	257-267
use	O	268-271
of	O	272-274
progesterone	O	275-287
and	O	288-291
estradiol	O	292-301
.	O	301-302

Diabetes	B	303-311
mellitus	I	312-320
(	O	321-322
DM	B	322-324
)	O	324-325
was	O	326-329
found	O	330-335
during	O	336-342
admission	O	343-352
.	O	352-353

Computed	O	354-362
tomography	O	363-373
showed	O	374-380
a	O	381-382
hemorrhagic	B	383-394
infarct	I	395-402
in	O	403-405
the	O	406-409
right	O	410-415
frontal	O	416-423
lobe	O	424-428
and	O	429-432
increased	O	433-442
density	O	443-450
in	O	451-453
the	O	454-457
superior	O	458-466
sagittal	O	467-475
sinus	O	476-481
(	O	482-483
SSS	O	483-486
)	O	486-487
.	O	487-488

Left	O	489-493
carotid	O	494-501
angiography	O	502-513
found	O	514-519
occlusion	B	520-529
of	I	530-532
the	I	533-536
left	I	537-541
internal	I	542-550
carotid	I	551-558
artery	I	559-565
(	O	566-567
ICA	O	567-570
)	O	570-571
.	O	571-572

Right	O	573-578
carotid	O	579-586
angiograms	O	587-597
failed	O	598-604
to	O	605-607
show	O	608-612
the	O	613-616
SSS	O	617-620
and	O	621-624
inferior	O	625-633
sagittal	O	634-642
sinus	O	643-648
,	O	648-649
suggestive	O	650-660
of	O	661-663
venous	B	664-670
sinus	I	671-676
thrombosis	I	677-687
.	O	687-688

Coexistence	O	689-700
of	O	701-703
the	O	704-707
cerebral	B	708-716
artery	I	717-723
and	I	724-727
the	I	728-731
venous	I	732-738
sinus	I	739-744
occlusion	I	745-754
has	O	755-758
been	O	759-763
described	O	764-773
infrequently	O	774-786
.	O	786-787

In	O	788-790
this	O	791-795
case	O	796-800
,	O	800-801
the	O	802-805
authors	O	806-813
postulate	O	814-823
that	O	824-828
the	O	829-832
use	O	833-836
of	O	837-839
estradiol	O	840-849
and	O	850-853
progesterone	O	854-866
and	O	867-870
the	O	871-874
underlying	O	875-885
DM	B	886-888
increased	O	889-898
vascular	O	899-907
thrombogenicity	O	908-923
,	O	923-924
which	O	925-930
provided	O	931-939
a	O	940-941
common	O	942-948
denominator	O	949-960
for	O	961-964
thrombosis	B	965-975
of	I	976-978
both	I	979-983
the	I	984-987
ICA	I	988-991
and	I	992-995
the	I	996-999
venous	I	1000-1006
sinus	I	1007-1012
.	O	1012-1013

Chloroquine	O	0-11
related	O	12-19
complete	O	20-28
heart	B	29-34
block	I	35-40
with	O	41-45
blindness	B	46-55
:	O	55-56
case	O	57-61
report	O	62-68
.	O	68-69

A	O	70-71
27	O	72-74
-	O	74-75
year	O	75-79
old	O	80-83
African	O	84-91
woman	O	92-97
with	O	98-102
history	O	103-110
of	O	111-113
regular	O	114-121
chloroquine	O	122-133
ingestion	O	134-143
presented	O	144-153
with	O	154-158
progressive	O	159-170
deterioration	B	171-184
of	I	185-187
vision	I	188-194
,	O	194-195
easy	O	196-200
fatiguability	B	201-214
,	O	214-215
dyspnoea	B	216-224
,	O	224-225
dizziness	B	226-235
progressing	O	236-247
to	O	248-250
syncopal	B	251-259
attacks	I	260-267
.	O	267-268

Ophthalmological	O	269-285
assessment	O	286-296
revealed	O	297-305
features	O	306-314
of	O	315-317
chloroquine	O	318-329
retinopathy	B	330-341
,	O	341-342
cardiac	O	343-350
assessment	O	351-361
revealed	O	362-370
features	O	371-379
of	O	380-382
heart	B	383-388
failure	I	389-396
and	O	397-400
a	O	401-402
complete	O	403-411
heart	B	412-417
block	I	418-423
with	O	424-428
right	B	429-434
bundle	I	435-441
branch	I	442-448
block	I	449-454
pattern	O	455-462
.	O	462-463

The	O	464-467
heart	B	468-473
block	I	474-479
was	O	480-483
treated	O	484-491
by	O	492-494
pacemaker	O	495-504
insertion	O	505-514
and	O	515-518
the	O	519-522
heart	B	523-528
failure	I	529-536
resolved	O	537-545
spontaneously	O	546-559
following	O	560-569
chloroquine	O	570-581
discontinuation	O	582-597
.	O	597-598

She	O	599-602
however	O	603-610
remains	O	611-618
blind	B	619-624
.	O	624-625

Systemic	O	0-8
toxicity	B	9-17
and	O	18-21
resuscitation	O	22-35
in	O	36-38
bupivacaine	O	39-50
-	O	50-51
,	O	51-52
levobupivacaine	O	53-68
-	O	68-69
,	O	69-70
or	O	71-73
ropivacaine	O	74-85
-	O	85-86
infused	O	86-93
rats	O	94-98
.	O	98-99

We	O	100-102
compared	O	103-111
the	O	112-115
systemic	O	116-124
toxicity	B	125-133
of	O	134-136
bupivacaine	O	137-148
,	O	148-149
levobupivacaine	O	150-165
,	O	165-166
and	O	167-170
ropivacaine	O	171-182
in	O	183-185
anesthetized	O	186-198
rats	O	199-203
.	O	203-204

We	O	205-207
also	O	208-212
compared	O	213-221
the	O	222-225
ability	O	226-233
to	O	234-236
resuscitate	O	237-248
rats	O	249-253
after	O	254-259
lethal	O	260-266
doses	O	267-272
of	O	273-275
these	O	276-281
local	O	282-287
anesthetics	O	288-299
.	O	299-300

Bupivacaine	O	301-312
,	O	312-313
levobupivacaine	O	314-329
,	O	329-330
or	O	331-333
ropivacaine	O	334-345
was	O	346-349
infused	O	350-357
at	O	358-360
a	O	361-362
rate	O	363-367
of	O	368-370
2	O	371-372
mg	O	373-375
.	O	375-376

kg	O	377-379
(	O	379-380
-	O	380-381
1	O	381-382
)	O	382-383
.	O	383-384

min	O	385-388
(	O	388-389
-	O	389-390
1	O	390-391
)	O	391-392
while	O	393-398
electrocardiogram	O	399-416
,	O	416-417
electroencephalogram	O	418-438
,	O	438-439
and	O	440-443
arterial	O	444-452
pressure	O	453-461
were	O	462-466
continuously	O	467-479
monitored	O	480-489
.	O	489-490

When	O	491-495
asystole	B	496-504
was	O	505-508
recorded	O	509-517
,	O	517-518
drug	O	519-523
infusion	O	524-532
was	O	533-536
stopped	O	537-544
and	O	545-548
a	O	549-550
resuscitation	O	551-564
sequence	O	565-573
was	O	574-577
begun	O	578-583
.	O	583-584

Epinephrine	O	585-596
0	O	597-598
.	O	598-599
01	O	599-601
mg	O	602-604
/	O	604-605
kg	O	605-607
was	O	608-611
administered	O	612-624
at	O	625-627
1	O	628-629
-	O	629-630
min	O	630-633
intervals	O	634-643
while	O	644-649
external	O	650-658
cardiac	O	659-666
compressions	O	667-679
were	O	680-684
applied	O	685-692
.	O	692-693

Resuscitation	O	694-707
was	O	708-711
considered	O	712-722
successful	O	723-733
when	O	734-738
a	O	739-740
systolic	O	741-749
arterial	O	750-758
pressure	O	759-767
>	O	768-769
or	O	770-772
=	O	773-774
100	O	774-777
mm	O	778-780
Hg	O	781-783
was	O	784-787
achieved	O	788-796
within	O	797-803
5	O	804-805
min	O	806-809
.	O	809-810

The	O	811-814
cumulative	O	815-825
doses	O	826-831
of	O	832-834
levobupivacaine	O	835-850
and	O	851-854
ropivacaine	O	855-866
that	O	867-871
produced	O	872-880
seizures	B	881-889
were	O	890-894
similar	O	895-902
and	O	903-906
were	O	907-911
larger	O	912-918
than	O	919-923
those	O	924-929
of	O	930-932
bupivacaine	O	933-944
.	O	944-945

The	O	946-949
cumulative	O	950-960
doses	O	961-966
of	O	967-969
levobupivacaine	O	970-985
that	O	986-990
produced	O	991-999
dysrhythmias	B	1000-1012
and	O	1013-1016
asystole	B	1017-1025
were	O	1026-1030
smaller	O	1031-1038
than	O	1039-1043
the	O	1044-1047
corresponding	O	1048-1061
doses	O	1062-1067
of	O	1068-1070
ropivacaine	O	1071-1082
,	O	1082-1083
but	O	1084-1087
they	O	1088-1092
were	O	1093-1097
larger	O	1098-1104
than	O	1105-1109
those	O	1110-1115
of	O	1116-1118
bupivacaine	O	1119-1130
.	O	1130-1131

The	O	1132-1135
number	O	1136-1142
of	O	1143-1145
successful	O	1146-1156
resuscitations	O	1157-1171
did	O	1172-1175
not	O	1176-1179
differ	O	1180-1186
among	O	1187-1192
groups	O	1193-1199
.	O	1199-1200

However	O	1201-1208
,	O	1208-1209
a	O	1210-1211
smaller	O	1212-1219
dose	O	1220-1224
of	O	1225-1227
epinephrine	O	1228-1239
was	O	1240-1243
required	O	1244-1252
in	O	1253-1255
the	O	1256-1259
Ropivacaine	O	1260-1271
group	O	1272-1277
than	O	1278-1282
in	O	1283-1285
the	O	1286-1289
other	O	1290-1295
groups	O	1296-1302
.	O	1302-1303

We	O	1304-1306
conclude	O	1307-1315
that	O	1316-1320
the	O	1321-1324
systemic	O	1325-1333
toxicity	B	1334-1342
of	O	1343-1345
levobupivacaine	O	1346-1361
is	O	1362-1364
intermediate	O	1365-1377
between	O	1378-1385
that	O	1386-1390
of	O	1391-1393
ropivacaine	O	1394-1405
and	O	1406-1409
bupivacaine	O	1410-1421
when	O	1422-1426
administered	O	1427-1439
at	O	1440-1442
the	O	1443-1446
same	O	1447-1451
rate	O	1452-1456
and	O	1457-1460
that	O	1461-1465
ropivacaine	O	1466-1477
-	O	1477-1478
induced	O	1478-1485
cardiac	B	1486-1493
arrest	I	1494-1500
appears	O	1501-1508
to	O	1509-1511
be	O	1512-1514
more	O	1515-1519
susceptible	O	1520-1531
to	O	1532-1534
treatment	O	1535-1544
than	O	1545-1549
that	O	1550-1554
induced	O	1555-1562
by	O	1563-1565
bupivacaine	O	1566-1577
or	O	1578-1580
levobupivacaine	O	1581-1596
.	O	1596-1597

22	O	0-2
-	O	2-3
oxacalcitriol	O	3-16
suppresses	O	17-27
secondary	B	28-37
hyperparathyroidism	I	38-57
without	O	58-65
inducing	O	66-74
low	B	75-78
bone	I	79-83
turnover	I	84-92
in	O	93-95
dogs	O	96-100
with	O	101-105
renal	B	106-111
failure	I	112-119
.	O	119-120

BACKGROUND	O	121-131
:	O	131-132
Calcitriol	O	133-143
therapy	O	144-151
suppresses	O	152-162
serum	O	163-168
levels	O	169-175
of	O	176-178
parathyroid	O	179-190
hormone	O	191-198
(	O	199-200
PTH	O	200-203
)	O	203-204
in	O	205-207
patients	O	208-216
with	O	217-221
renal	B	222-227
failure	I	228-235
but	O	236-239
has	O	240-243
several	O	244-251
drawbacks	O	252-261
,	O	261-262
including	O	263-272
hypercalcemia	B	273-286
and	O	287-290
/	O	290-291
or	O	291-293
marked	O	294-300
suppression	B	301-312
of	I	313-315
bone	I	316-320
turnover	I	321-329
,	O	329-330
which	O	331-336
may	O	337-340
lead	O	341-345
to	O	346-348
adynamic	B	349-357
bone	I	358-362
disease	I	363-370
.	O	370-371

A	O	372-373
new	O	374-377
vitamin	O	378-385
D	O	386-387
analogue	O	388-396
,	O	396-397
22	O	398-400
-	O	400-401
oxacalcitriol	O	401-414
(	O	415-416
OCT	O	416-419
)	O	419-420
,	O	420-421
has	O	422-425
been	O	426-430
shown	O	431-436
to	O	437-439
have	O	440-444
promising	O	445-454
characteristics	O	455-470
.	O	470-471

This	O	472-476
study	O	477-482
was	O	483-486
undertaken	O	487-497
to	O	498-500
determine	O	501-510
the	O	511-514
effects	O	515-522
of	O	523-525
OCT	O	526-529
on	O	530-532
serum	O	533-538
PTH	O	539-542
levels	O	543-549
and	O	550-553
bone	O	554-558
turnover	O	559-567
in	O	568-570
states	O	571-577
of	O	578-580
normal	O	581-587
or	O	588-590
impaired	B	591-599
renal	I	600-605
function	I	606-614
.	O	614-615

METHODS	O	616-623
:	O	623-624
Sixty	O	625-630
dogs	O	631-635
were	O	636-640
either	O	641-647
nephrectomized	O	648-662
(	O	663-664
Nx	O	664-666
,	O	666-667
N	O	668-669
=	O	670-671
38	O	672-674
)	O	674-675
or	O	676-678
sham	O	679-683
-	O	683-684
operated	O	684-692
(	O	693-694
Sham	O	694-698
,	O	698-699
N	O	700-701
=	O	702-703
22	O	704-706
)	O	706-707
.	O	707-708

The	O	709-712
animals	O	713-720
received	O	721-729
supplemental	O	730-742
phosphate	O	743-752
to	O	753-755
enhance	O	756-763
PTH	O	764-767
secretion	O	768-777
.	O	777-778

Fourteen	O	779-787
weeks	O	788-793
after	O	794-799
the	O	800-803
start	O	804-809
of	O	810-812
phosphate	O	813-822
supplementation	O	823-838
,	O	838-839
half	O	840-844
of	O	845-847
the	O	848-851
Nx	O	852-854
and	O	855-858
Sham	O	859-863
dogs	O	864-868
received	O	869-877
doses	O	878-883
of	O	884-886
OCT	O	887-890
(	O	891-892
three	O	892-897
times	O	898-903
per	O	904-907
week	O	908-912
)	O	912-913
;	O	913-914
the	O	915-918
other	O	919-924
half	O	925-929
were	O	930-934
given	O	935-940
vehicle	O	941-948
for	O	949-952
60	O	953-955
weeks	O	956-961
.	O	961-962

Thereafter	O	963-973
,	O	973-974
the	O	975-978
treatment	O	979-988
modalities	O	989-999
for	O	1000-1003
a	O	1004-1005
subset	O	1006-1012
of	O	1013-1015
animals	O	1016-1023
were	O	1024-1028
crossed	O	1029-1036
over	O	1037-1041
for	O	1042-1045
an	O	1046-1048
additional	O	1049-1059
eight	O	1060-1065
months	O	1066-1072
.	O	1072-1073

Biochemical	O	1074-1085
and	O	1086-1089
hormonal	O	1090-1098
indices	O	1099-1106
of	O	1107-1109
calcium	O	1110-1117
and	O	1118-1121
bone	O	1122-1126
metabolism	O	1127-1137
were	O	1138-1142
measured	O	1143-1151
throughout	O	1152-1162
the	O	1163-1166
study	O	1167-1172
,	O	1172-1173
and	O	1174-1177
bone	O	1178-1182
biopsies	O	1183-1191
were	O	1192-1196
done	O	1197-1201
at	O	1202-1204
baseline	O	1205-1213
,	O	1213-1214
60	O	1215-1217
weeks	O	1218-1223
after	O	1224-1229
OCT	O	1230-1233
or	O	1234-1236
vehicle	O	1237-1244
treatment	O	1245-1254
,	O	1254-1255
and	O	1256-1259
at	O	1260-1262
the	O	1263-1266
end	O	1267-1270
of	O	1271-1273
the	O	1274-1277
crossover	O	1278-1287
period	O	1288-1294
.	O	1294-1295

RESULTS	O	1296-1303
:	O	1303-1304
In	O	1305-1307
Nx	O	1308-1310
dogs	O	1311-1315
,	O	1315-1316
OCT	O	1317-1320
significantly	O	1321-1334
decreased	O	1335-1344
serum	O	1345-1350
PTH	O	1351-1354
levels	O	1355-1361
soon	O	1362-1366
after	O	1367-1372
the	O	1373-1376
induction	O	1377-1386
of	O	1387-1389
renal	B	1390-1395
insufficiency	I	1396-1409
.	O	1409-1410

In	O	1411-1413
long	O	1414-1418
-	O	1418-1419
standing	O	1419-1427
secondary	B	1428-1437
hyperparathyroidism	I	1438-1457
,	O	1457-1458
OCT	O	1459-1462
(	O	1463-1464
0	O	1464-1465
.	O	1465-1466
03	O	1466-1468
microg	O	1469-1475
/	O	1475-1476
kg	O	1476-1478
)	O	1478-1479
stabilized	O	1480-1490
serum	O	1491-1496
PTH	O	1497-1500
levels	O	1501-1507
during	O	1508-1514
the	O	1515-1518
first	O	1519-1524
months	O	1525-1531
.	O	1531-1532

Serum	O	1533-1538
PTH	O	1539-1542
levels	O	1543-1549
rose	O	1550-1554
thereafter	O	1555-1565
,	O	1565-1566
but	O	1567-1570
the	O	1571-1574
rise	O	1575-1579
was	O	1580-1583
less	O	1584-1588
pronounced	O	1589-1599
compared	O	1600-1608
with	O	1609-1613
baseline	O	1614-1622
than	O	1623-1627
the	O	1628-1631
rise	O	1632-1636
seen	O	1637-1641
in	O	1642-1644
Nx	O	1645-1647
control	O	1648-1655
.	O	1655-1656

These	O	1657-1662
effects	O	1663-1670
were	O	1671-1675
accompanied	O	1676-1687
by	O	1688-1690
episodes	O	1691-1699
of	O	1700-1702
hypercalcemia	B	1703-1716
and	O	1717-1720
hyperphosphatemia	B	1721-1738
.	O	1738-1739

In	O	1740-1742
animals	O	1743-1750
with	O	1751-1755
normal	O	1756-1762
renal	O	1763-1768
function	O	1769-1777
,	O	1777-1778
OCT	O	1779-1782
induced	O	1783-1790
a	O	1791-1792
transient	O	1793-1802
decrease	O	1803-1811
in	O	1812-1814
serum	O	1815-1820
PTH	O	1821-1824
levels	O	1825-1831
at	O	1832-1834
a	O	1835-1836
dose	O	1837-1841
of	O	1842-1844
0	O	1845-1846
.	O	1846-1847
1	O	1847-1848
microg	O	1849-1855
/	O	1855-1856
kg	O	1856-1858
,	O	1858-1859
which	O	1860-1865
was	O	1866-1869
not	O	1870-1873
sustained	O	1874-1883
with	O	1884-1888
lowering	O	1889-1897
of	O	1898-1900
the	O	1901-1904
doses	O	1905-1910
.	O	1910-1911

In	O	1912-1914
Nx	O	1915-1917
dogs	O	1918-1922
,	O	1922-1923
OCT	O	1924-1927
reversed	O	1928-1936
abnormal	O	1937-1945
bone	O	1946-1950
formation	O	1951-1960
,	O	1960-1961
such	O	1962-1966
as	O	1967-1969
woven	B	1970-1975
osteoid	I	1976-1983
and	O	1984-1987
fibrosis	B	1988-1996
,	O	1996-1997
but	O	1998-2001
did	O	2002-2005
not	O	2006-2009
significantly	O	2010-2023
alter	O	2024-2029
the	O	2030-2033
level	O	2034-2039
of	O	2040-2042
bone	O	2043-2047
turnover	O	2048-2056
.	O	2056-2057

In	O	2058-2060
addition	O	2061-2069
,	O	2069-2070
OCT	O	2071-2074
improved	O	2075-2083
mineralization	O	2084-2098
lag	O	2099-2102
time	O	2103-2107
,	O	2107-2108
(	O	2109-2110
that	O	2110-2114
is	O	2115-2117
,	O	2117-2118
the	O	2119-2122
rate	O	2123-2127
at	O	2128-2130
which	O	2131-2136
osteoid	O	2137-2144
mineralizes	O	2145-2156
)	O	2156-2157
in	O	2158-2160
both	O	2161-2165
Nx	O	2166-2168
and	O	2169-2172
Sham	O	2173-2177
dogs	O	2178-2182
.	O	2182-2183

CONCLUSIONS	O	2184-2195
:	O	2195-2196
These	O	2197-2202
results	O	2203-2210
indicate	O	2211-2219
that	O	2220-2224
even	O	2225-2229
though	O	2230-2236
OCT	O	2237-2240
does	O	2241-2245
not	O	2246-2249
completely	O	2250-2260
prevent	O	2261-2268
the	O	2269-2272
occurrence	O	2273-2283
of	O	2284-2286
hypercalcemia	B	2287-2300
in	O	2301-2303
experimental	O	2304-2316
dogs	O	2317-2321
with	O	2322-2326
renal	B	2327-2332
insufficiency	I	2333-2346
,	O	2346-2347
it	O	2348-2350
may	O	2351-2354
be	O	2355-2357
of	O	2358-2360
use	O	2361-2364
in	O	2365-2367
the	O	2368-2371
management	O	2372-2382
of	O	2383-2385
secondary	B	2386-2395
hyperparathyroidism	I	2396-2415
because	O	2416-2423
it	O	2424-2426
does	O	2427-2431
not	O	2432-2435
induce	O	2436-2442
low	B	2443-2446
bone	I	2447-2451
turnover	I	2452-2460
and	O	2461-2464
,	O	2464-2465
therefore	O	2466-2475
,	O	2475-2476
does	O	2477-2481
not	O	2482-2485
increase	O	2486-2494
the	O	2495-2498
risk	O	2499-2503
of	O	2504-2506
adynamic	B	2507-2515
bone	I	2516-2520
disease	I	2521-2528
.	O	2528-2529

Chemotherapy	O	0-12
of	O	13-15
advanced	O	16-24
inoperable	O	25-35
non	B	36-39
-	I	39-40
small	I	40-45
cell	I	46-50
lung	I	51-55
cancer	I	56-62
with	O	63-67
paclitaxel	O	68-78
:	O	78-79
a	O	80-81
phase	O	82-87
II	O	88-90
trial	O	91-96
.	O	96-97

Paclitaxel	O	98-108
(	O	109-110
Taxol	O	110-115
;	O	115-116
Bristol	O	117-124
-	O	124-125
Myers	O	125-130
Squibb	O	131-137
Company	O	138-145
,	O	145-146
Princeton	O	147-156
,	O	156-157
NJ	O	158-160
)	O	160-161
has	O	162-165
demonstrated	O	166-178
significant	O	179-190
antineoplastic	O	191-205
activity	O	206-214
against	O	215-222
different	O	223-232
tumor	B	233-238
types	O	239-244
,	O	244-245
notably	O	246-253
ovarian	B	254-261
and	I	262-265
breast	I	266-272
carcinoma	I	273-282
.	O	282-283

Two	O	284-287
phase	O	288-293
II	O	294-296
trials	O	297-303
of	O	304-306
24	O	307-309
-	O	309-310
hour	O	310-314
paclitaxel	O	315-325
infusions	O	326-335
in	O	336-338
chemotherapy	O	339-351
-	O	351-352
naive	O	352-357
patients	O	358-366
with	O	367-371
stage	O	372-377
IIIB	O	378-382
or	O	383-385
IV	O	386-388
non	B	389-392
-	I	392-393
small	I	393-398
cell	I	399-403
lung	I	404-408
cancer	I	409-415
(	O	416-417
NSCLC	B	417-422
)	O	422-423
reported	O	424-432
response	O	433-441
rates	O	442-447
of	O	448-450
21	O	451-453
%	O	453-454
and	O	455-458
24	O	459-461
%	O	461-462
.	O	462-463

Leukopenia	B	464-474
was	O	475-478
dose	O	479-483
limiting	O	484-492
:	O	492-493
as	O	494-496
many	O	497-501
as	O	502-504
62	O	505-507
.	O	507-508
5	O	508-509
%	O	509-510
of	O	511-513
patients	O	514-522
experienced	O	523-534
grade	O	535-540
4	O	541-542
leukopenia	B	543-553
.	O	553-554

We	O	555-557
investigated	O	558-570
the	O	571-574
efficacy	O	575-583
and	O	584-587
toxicity	B	588-596
of	O	597-599
a	O	600-601
3	O	602-603
-	O	603-604
hour	O	604-608
paclitaxel	O	609-619
infusion	O	620-628
in	O	629-631
a	O	632-633
phase	O	634-639
II	O	640-642
trial	O	643-648
in	O	649-651
patients	O	652-660
with	O	661-665
inoperable	O	666-676
stage	O	677-682
IIIB	O	683-687
or	O	688-690
IV	O	691-693
NSCLC	B	694-699
.	O	699-700

The	O	701-704
58	O	705-707
patients	O	708-716
treated	O	717-724
(	O	725-726
41	O	726-728
men	O	729-732
and	O	733-736
17	O	737-739
women	O	740-745
)	O	745-746
had	O	747-750
a	O	751-752
median	O	753-759
age	O	760-763
of	O	764-766
59	O	767-769
years	O	770-775
(	O	776-777
age	O	777-780
range	O	781-786
,	O	786-787
25	O	788-790
to	O	791-793
75	O	794-796
)	O	796-797
and	O	798-801
a	O	802-803
performance	O	804-815
status	O	816-822
of	O	823-825
0	O	826-827
through	O	828-835
2	O	836-837
.	O	837-838
Most	O	839-843
patients	O	844-852
(	O	853-854
72	O	854-856
.	O	856-857
4	O	857-858
%	O	858-859
)	O	859-860
had	O	861-864
stage	O	865-870
IV	O	871-873
NSCLC	B	874-879
.	O	879-880

Paclitaxel	O	881-891
225	O	892-895
mg	O	896-898
/	O	898-899
m2	O	899-901
was	O	902-905
infused	O	906-913
over	O	914-918
3	O	919-920
hours	O	921-926
every	O	927-932
3	O	933-934
weeks	O	935-940
with	O	941-945
standard	O	946-954
prophylactic	O	955-967
premedication	O	968-981
.	O	981-982

Of	O	983-985
50	O	986-988
patients	O	989-997
evaluable	O	998-1007
for	O	1008-1011
response	O	1012-1020
,	O	1020-1021
12	O	1022-1024
(	O	1025-1026
24	O	1026-1028
%	O	1028-1029
)	O	1029-1030
had	O	1031-1034
partial	O	1035-1042
remission	O	1043-1052
,	O	1052-1053
26	O	1054-1056
(	O	1057-1058
52	O	1058-1060
%	O	1060-1061
)	O	1061-1062
had	O	1063-1066
no	O	1067-1069
change	O	1070-1076
,	O	1076-1077
and	O	1078-1081
12	O	1082-1084
had	O	1085-1088
disease	O	1089-1096
progression	O	1097-1108
(	O	1109-1110
24	O	1110-1112
%	O	1112-1113
)	O	1113-1114
.	O	1114-1115

Hematologic	O	1116-1127
toxicities	B	1128-1138
were	O	1139-1143
mild	O	1144-1148
:	O	1148-1149
only	O	1150-1154
one	O	1155-1158
patient	O	1159-1166
(	O	1167-1168
2	O	1168-1169
%	O	1169-1170
)	O	1170-1171
developed	O	1172-1181
grade	O	1182-1187
3	O	1188-1189
or	O	1190-1192
4	O	1193-1194
neutropenia	B	1195-1206
,	O	1206-1207
while	O	1208-1213
29	O	1214-1216
%	O	1216-1217
had	O	1218-1221
grade	O	1222-1227
1	O	1228-1229
or	O	1230-1232
2	O	1233-1234
.	O	1234-1235
Grade	O	1236-1241
1	O	1242-1243
or	O	1244-1246
2	O	1247-1248
polyneuropathy	B	1249-1263
affected	O	1264-1272
56	O	1273-1275
%	O	1275-1276
of	O	1277-1279
patients	O	1280-1288
while	O	1289-1294
only	O	1295-1299
one	O	1300-1303
(	O	1304-1305
2	O	1305-1306
%	O	1306-1307
)	O	1307-1308
experienced	O	1309-1320
severe	O	1321-1327
polyneuropathy	B	1328-1342
.	O	1342-1343

Similarly	O	1344-1353
,	O	1353-1354
grade	O	1355-1360
1	O	1361-1362
or	O	1363-1365
2	O	1366-1367
myalgia	B	1368-1375
/	O	1375-1376
arthralgia	B	1376-1386
was	O	1387-1390
observed	O	1391-1399
in	O	1400-1402
63	O	1403-1405
.	O	1405-1406
2	O	1406-1407
%	O	1407-1408
of	O	1409-1411
patients	O	1412-1420
,	O	1420-1421
but	O	1422-1425
only	O	1426-1430
14	O	1431-1433
.	O	1433-1434
3	O	1434-1435
%	O	1435-1436
experienced	O	1437-1448
grade	O	1449-1454
3	O	1455-1456
or	O	1457-1459
4	O	1460-1461
.	O	1461-1462
Nausea	B	1463-1469
and	O	1470-1473
vomiting	B	1474-1482
were	O	1483-1487
infrequent	O	1488-1498
,	O	1498-1499
with	O	1500-1504
14	O	1505-1507
%	O	1507-1508
of	O	1509-1511
patients	O	1512-1520
experiencing	O	1521-1533
grade	O	1534-1539
1	O	1540-1541
or	O	1542-1544
2	O	1545-1546
and	O	1547-1550
only	O	1551-1555
2	O	1556-1557
%	O	1557-1558
experiencing	O	1559-1571
grade	O	1572-1577
3	O	1578-1579
or	O	1580-1582
4	O	1583-1584
.	O	1584-1585
Paclitaxel	O	1586-1596
is	O	1597-1599
thus	O	1600-1604
an	O	1605-1607
active	O	1608-1614
single	O	1615-1621
agent	O	1622-1627
in	O	1628-1630
this	O	1631-1635
patient	O	1636-1643
population	O	1644-1654
,	O	1654-1655
with	O	1656-1660
a	O	1661-1662
3	O	1663-1664
-	O	1664-1665
hour	O	1665-1669
infusion	O	1670-1678
proving	O	1679-1686
comparably	O	1687-1697
effective	O	1698-1707
to	O	1708-1710
a	O	1711-1712
24	O	1713-1715
-	O	1715-1716
hour	O	1716-1720
infusion	O	1721-1729
and	O	1730-1733
superior	O	1734-1742
in	O	1743-1745
terms	O	1746-1751
of	O	1752-1754
the	O	1755-1758
incidence	O	1759-1768
of	O	1769-1771
hematologic	O	1772-1783
and	O	1784-1787
nonhematologic	O	1788-1802
toxicity	B	1803-1811
.	O	1811-1812

Further	O	1813-1820
phase	O	1821-1826
II	O	1827-1829
studies	O	1830-1837
with	O	1838-1842
paclitaxel	O	1843-1853
combined	O	1854-1862
with	O	1863-1867
other	O	1868-1873
drugs	O	1874-1879
active	O	1880-1886
against	O	1887-1894
NSCLC	B	1895-1900
are	O	1901-1904
indicated	O	1905-1914
,	O	1914-1915
and	O	1916-1919
phase	O	1920-1925
III	O	1926-1929
studies	O	1930-1937
comparing	O	1938-1947
paclitaxel	O	1948-1958
with	O	1959-1963
standard	O	1964-1972
chemotherapy	O	1973-1985
remain	O	1986-1992
to	O	1993-1995
be	O	1996-1998
completed	O	1999-2008
.	O	2008-2009

Cerebral	B	0-8
hemorrhage	I	9-19
associated	O	20-30
with	O	31-35
phenylpropanolamine	O	36-55
in	O	56-58
combination	O	59-70
with	O	71-75
caffeine	O	76-84
.	O	84-85

Phenylpropanolamine	O	86-105
(	O	106-107
PPA	O	107-110
)	O	110-111
is	O	112-114
a	O	115-116
drug	O	117-121
that	O	122-126
has	O	127-130
been	O	131-135
associated	O	136-146
with	O	147-151
serious	O	152-159
side	O	160-164
effects	O	165-172
including	O	173-182
stroke	B	183-189
.	O	189-190

It	O	191-193
is	O	194-196
often	O	197-202
combined	O	203-211
with	O	212-216
caffeine	O	217-225
in	O	226-228
diet	O	229-233
preparations	O	234-246
and	O	247-250
"	O	251-252
look	O	252-256
-	O	256-257
alike	O	257-262
"	O	251-252
pills	O	264-269
.	O	269-270

In	O	271-273
order	O	274-279
to	O	280-282
determine	O	283-292
if	O	293-295
PPA	O	296-299
/	O	299-300
caffeine	O	300-308
can	O	309-312
lead	O	313-317
to	O	318-320
stroke	B	321-327
in	O	328-330
normotensive	O	331-343
and	O	344-347
/	O	347-348
or	O	348-350
hypertensive	B	351-363
rats	O	364-368
,	O	368-369
we	O	370-372
administered	O	373-385
the	O	386-389
combination	O	390-401
in	O	402-404
six	O	405-408
times	O	409-414
the	O	415-418
allowed	O	419-426
human	O	427-432
dose	O	433-437
calculated	O	438-448
on	O	449-451
a	O	452-453
per	O	454-457
weight	O	458-464
basis	O	465-470
for	O	471-474
the	O	475-478
rats	O	479-483
two	O	484-487
times	O	488-493
per	O	494-497
day	O	498-501
for	O	502-505
five	O	506-510
days	O	511-515
.	O	515-516

Subarachnoid	B	517-529
and	I	530-533
cerebral	I	534-542
hemorrhage	I	543-553
was	O	554-557
noted	O	558-563
in	O	564-566
18	O	567-569
%	O	569-570
of	O	571-573
the	O	574-577
hypertensive	B	578-590
rats	O	591-595
.	O	595-596

A	O	597-598
single	O	599-605
PPA	O	606-609
/	O	609-610
caffeine	O	610-618
administration	O	619-633
(	O	634-635
same	O	635-639
dose	O	640-644
)	O	644-645
lead	O	646-650
to	O	651-653
acute	O	654-659
hypertension	B	660-672
in	O	673-675
both	O	676-680
the	O	681-684
normotensive	O	685-697
and	O	698-701
hypertensive	B	702-714
animals	O	715-722
.	O	722-723

These	O	724-729
results	O	730-737
suggest	O	738-745
that	O	746-750
PPA	O	751-754
/	O	754-755
caffeine	O	755-763
can	O	764-767
lead	O	768-772
to	O	773-775
cerebral	B	776-784
hemorrhage	I	785-795
in	O	796-798
previously	O	799-809
hypertensive	B	810-822
animals	O	823-830
when	O	831-835
administered	O	836-848
in	O	849-851
greater	O	852-859
than	O	860-864
the	O	865-868
allowed	O	869-876
dosage	O	877-883
.	O	883-884

An	O	885-887
acute	O	888-893
elevation	O	894-903
in	O	904-906
blood	O	907-912
pressure	O	913-921
may	O	922-925
be	O	926-928
a	O	929-930
contributing	O	931-943
factor	O	944-950
.	O	950-951

Long	O	0-4
-	O	4-5
term	O	5-9
efficacy	O	10-18
and	O	19-22
toxicity	B	23-31
of	O	32-34
high	O	35-39
-	O	39-40
dose	O	40-44
amiodarone	O	45-55
therapy	O	56-63
for	O	64-67
ventricular	B	68-79
tachycardia	I	80-91
or	O	92-94
ventricular	B	95-106
fibrillation	I	107-119
.	O	119-120

Amiodarone	O	121-131
was	O	132-135
administered	O	136-148
to	O	149-151
154	O	152-155
patients	O	156-164
who	O	165-168
had	O	169-172
sustained	O	173-182
,	O	182-183
symptomatic	O	184-195
ventricular	B	196-207
tachycardia	I	208-219
(	O	220-221
VT	B	221-223
)	O	223-224
(	O	225-226
n	O	226-227
=	O	228-229
118	O	230-233
)	O	233-234
or	O	235-237
a	O	238-239
cardiac	B	240-247
arrest	I	248-254
(	O	255-256
n	O	256-257
=	O	258-259
36	O	260-262
)	O	262-263
and	O	264-267
who	O	268-271
were	O	272-276
refractory	O	277-287
to	O	288-290
conventional	O	291-303
antiarrhythmic	O	304-318
drugs	O	319-324
.	O	324-325

The	O	326-329
loading	O	330-337
dose	O	338-342
was	O	343-346
800	O	347-350
mg	O	351-353
/	O	353-354
day	O	354-357
for	O	358-361
6	O	362-363
weeks	O	364-369
and	O	370-373
the	O	374-377
maintenance	O	378-389
dose	O	390-394
was	O	395-398
600	O	399-402
mg	O	403-405
/	O	405-406
day	O	406-409
.	O	409-410

Sixty	O	411-416
-	O	416-417
nine	O	417-421
percent	O	422-429
of	O	430-432
patients	O	433-441
continued	O	442-451
treatment	O	452-461
with	O	462-466
amiodarone	O	467-477
and	O	478-481
had	O	482-485
no	O	486-488
recurrence	O	489-499
of	O	500-502
symptomatic	O	503-514
VT	B	515-517
or	O	518-520
ventricular	B	521-532
fibrillation	I	533-545
(	O	546-547
VF	B	547-549
)	O	549-550
over	O	551-555
a	O	556-557
follow	O	558-564
-	O	564-565
up	O	565-567
of	O	568-570
6	O	571-572
to	O	573-575
52	O	576-578
months	O	579-585
(	O	586-587
mean	O	587-591
+	O	592-593
/	O	593-594
-	O	594-595
standard	O	596-604
deviation	O	605-614
14	O	615-617
.	O	617-618
2	O	618-619
+	O	620-621
/	O	621-622
-	O	622-623
8	O	624-625
.	O	625-626
2	O	626-627
)	O	627-628
.	O	625-626

Six	O	630-633
percent	O	634-641
of	O	642-644
the	O	645-648
patients	O	649-657
had	O	658-661
a	O	662-663
nonfatal	O	664-672
recurrence	O	673-683
of	O	684-686
VT	B	687-689
and	O	690-693
were	O	694-698
successfully	O	699-711
managed	O	712-719
by	O	720-722
continuing	O	723-733
amiodarone	O	734-744
at	O	745-747
a	O	748-749
higher	O	750-756
dose	O	757-761
or	O	762-764
by	O	765-767
the	O	768-771
addition	O	772-780
of	O	781-783
a	O	784-785
conventional	O	786-798
antiarrhythmic	O	799-813
drug	O	814-818
.	O	818-819

One	O	820-823
or	O	824-826
more	O	827-831
adverse	O	832-839
drug	O	840-844
reactions	O	845-854
occurred	O	855-863
in	O	864-866
51	O	867-869
%	O	869-870
of	O	871-873
patients	O	874-882
.	O	882-883

Adverse	O	884-891
effects	O	892-899
forced	O	900-906
a	O	907-908
reduction	O	909-918
in	O	919-921
the	O	922-925
dose	O	926-930
of	O	931-933
amiodarone	O	934-944
in	O	945-947
41	O	948-950
%	O	950-951
and	O	952-955
discontinuation	O	956-971
of	O	972-974
amiodarone	O	975-985
in	O	986-988
10	O	989-991
%	O	991-992
of	O	993-995
patients	O	996-1004
.	O	1004-1005

The	O	1006-1009
most	O	1010-1014
common	O	1015-1021
symptomatic	O	1022-1033
adverse	O	1034-1041
reactions	O	1042-1051
were	O	1052-1056
tremor	B	1057-1063
or	O	1064-1066
ataxia	B	1067-1073
(	O	1074-1075
35	O	1075-1077
%	O	1077-1078
)	O	1078-1079
,	O	1079-1080
nausea	B	1081-1087
and	O	1088-1091
anorexia	B	1092-1100
(	O	1101-1102
8	O	1102-1103
%	O	1103-1104
)	O	1104-1105
,	O	1105-1106
visual	B	1107-1113
halos	I	1114-1119
or	I	1120-1122
blurring	I	1123-1131
(	O	1132-1133
6	O	1133-1134
%	O	1134-1135
)	O	1135-1136
,	O	1136-1137
thyroid	B	1138-1145
function	I	1146-1154
abnormalities	I	1155-1168
(	O	1169-1170
6	O	1170-1171
%	O	1171-1172
)	O	1172-1173
and	O	1174-1177
pulmonary	B	1178-1187
interstitial	I	1188-1200
infiltrates	I	1201-1212
(	O	1213-1214
5	O	1214-1215
%	O	1215-1216
)	O	1216-1217
.	O	1217-1218

Although	O	1219-1227
large	O	1228-1233
-	O	1233-1234
dose	O	1234-1238
amiodarone	O	1239-1249
is	O	1250-1252
highly	O	1253-1259
effective	O	1260-1269
in	O	1270-1272
the	O	1273-1276
long	O	1277-1281
-	O	1281-1282
term	O	1282-1286
treatment	O	1287-1296
of	O	1297-1299
VT	B	1300-1302
or	O	1303-1305
VF	B	1306-1308
refractory	O	1309-1319
to	O	1320-1322
conventional	O	1323-1335
antiarrhythmic	O	1336-1350
drugs	O	1351-1356
,	O	1356-1357
it	O	1358-1360
causes	O	1361-1367
significant	O	1368-1379
toxicity	B	1380-1388
in	O	1389-1391
approximately	O	1392-1405
50	O	1406-1408
%	O	1408-1409
of	O	1410-1412
patients	O	1413-1421
.	O	1421-1422

However	O	1423-1430
,	O	1430-1431
when	O	1432-1436
the	O	1437-1440
dose	O	1441-1445
is	O	1446-1448
adjusted	O	1449-1457
based	O	1458-1463
on	O	1464-1466
clinical	O	1467-1475
response	O	1476-1484
or	O	1485-1487
the	O	1488-1491
development	O	1492-1503
of	O	1504-1506
adverse	O	1507-1514
effects	O	1515-1522
,	O	1522-1523
75	O	1524-1526
%	O	1526-1527
of	O	1528-1530
patients	O	1531-1539
with	O	1540-1544
VT	B	1545-1547
or	O	1548-1550
VF	B	1551-1553
can	O	1554-1557
be	O	1558-1560
successfully	O	1561-1573
managed	O	1574-1581
with	O	1582-1586
amiodarone	O	1587-1597
.	O	1597-1598

Effect	O	0-6
of	O	7-9
calcium	O	10-17
chloride	O	18-26
and	O	27-30
4	O	31-32
-	O	32-33
aminopyridine	O	33-46
therapy	O	47-54
on	O	55-57
desipramine	O	58-69
toxicity	B	70-78
in	O	79-81
rats	O	82-86
.	O	86-87

BACKGROUND	O	88-98
:	O	98-99
Hypotension	B	100-111
is	O	112-114
a	O	115-116
major	O	117-122
contributor	O	123-134
to	O	135-137
mortality	O	138-147
in	O	148-150
tricyclic	O	151-160
antidepressant	O	161-175
overdose	B	176-184
.	O	184-185

Recent	O	186-192
data	O	193-197
suggest	O	198-205
that	O	206-210
tricyclic	O	211-220
antidepressants	O	221-236
inhibit	O	237-244
calcium	O	245-252
influx	O	253-259
in	O	260-262
some	O	263-267
tissues	O	268-275
.	O	275-276

This	O	277-281
study	O	282-287
addressed	O	288-297
the	O	298-301
potential	O	302-311
role	O	312-316
of	O	317-319
calcium	O	320-327
channel	O	328-335
blockade	O	336-344
in	O	345-347
tricyclic	O	348-357
antidepressant	O	358-372
-	O	372-373
induced	O	373-380
hypotension	B	381-392
.	O	392-393

METHODS	O	394-401
:	O	401-402
Two	O	403-406
interventions	O	407-420
were	O	421-425
studied	O	426-433
that	O	434-438
have	O	439-443
been	O	444-448
shown	O	449-454
previously	O	455-465
to	O	466-468
improve	O	469-476
blood	O	477-482
pressure	O	483-491
with	O	492-496
calcium	O	497-504
channel	O	505-512
blocker	O	513-520
overdose	B	521-529
.	O	529-530

CaCl2	O	531-536
and	O	537-540
4	O	541-542
-	O	542-543
aminopyridine	O	543-556
.	O	556-557

Anesthetized	O	558-570
rats	O	571-575
received	O	576-584
the	O	585-588
tricyclic	O	589-598
antidepressant	O	599-613
desipramine	O	614-625
IP	O	626-628
to	O	629-631
produce	O	632-639
hypotension	B	640-651
,	O	651-652
QRS	O	653-656
prolongation	O	657-669
,	O	669-670
and	O	671-674
bradycardia	B	675-686
.	O	686-687

Fifteen	O	688-695
min	O	696-699
later	O	700-705
,	O	705-706
animals	O	707-714
received	O	715-723
CaCl2	O	724-729
,	O	729-730
NaHCO3	O	731-737
,	O	737-738
or	O	739-741
saline	O	742-748
.	O	748-749

In	O	750-752
a	O	753-754
second	O	755-761
experiment	O	762-772
,	O	772-773
rats	O	774-778
received	O	779-787
tricyclic	O	788-797
antidepressant	O	798-812
desipramine	O	813-824
IP	O	825-827
followed	O	828-836
in	O	837-839
15	O	840-842
min	O	843-846
by	O	847-849
4	O	850-851
-	O	851-852
aminopyridine	O	852-865
or	O	866-868
saline	O	869-875
.	O	875-876

RESULTS	O	877-884
:	O	884-885
NaHCO3	O	886-892
briefly	O	893-900
(	O	901-902
5	O	902-903
min	O	904-907
)	O	907-908
reversed	O	909-917
hypotension	B	918-929
and	O	930-933
QRS	O	934-937
prolongation	O	938-950
.	O	950-951

CaCl2	O	952-957
and	O	958-961
4	O	962-963
-	O	963-964
aminopyridine	O	964-977
failed	O	978-984
to	O	985-987
improve	O	988-995
blood	O	996-1001
pressure	O	1002-1010
.	O	1010-1011

The	O	1012-1015
incidence	O	1016-1025
of	O	1026-1028
ventricular	B	1029-1040
arrhythmias	I	1041-1052
(	O	1053-1054
p	O	1054-1055
=	O	1056-1057
0	O	1058-1059
.	O	1059-1060
004	O	1060-1063
)	O	1063-1064
and	O	1065-1068
seizures	B	1069-1077
(	O	1078-1079
p	O	1079-1080
=	O	1081-1082
0	O	1083-1084
.	O	1084-1085
03	O	1085-1087
)	O	1087-1088
in	O	1089-1091
the	O	1092-1095
CaCl2	O	1096-1101
group	O	1102-1107
was	O	1108-1111
higher	O	1112-1118
than	O	1119-1123
the	O	1124-1127
other	O	1128-1133
groups	O	1134-1140
.	O	1140-1141

CONCLUSION	O	1142-1152
:	O	1152-1153
The	O	1154-1157
administration	O	1158-1172
of	O	1173-1175
CaCl2	O	1176-1181
or	O	1182-1184
4	O	1185-1186
-	O	1186-1187
aminopyridine	O	1187-1200
did	O	1201-1204
not	O	1205-1208
reverse	O	1209-1216
tricyclic	O	1217-1226
antidepressant	O	1227-1241
-	O	1241-1242
induced	O	1242-1249
hypotension	B	1250-1261
in	O	1262-1264
rats	O	1265-1269
.	O	1269-1270

CaCl2	O	1271-1276
therapy	O	1277-1284
may	O	1285-1288
possibly	O	1289-1297
worsen	O	1298-1304
both	O	1305-1309
cardiovascular	B	1310-1324
and	I	1325-1328
central	I	1329-1336
nervous	I	1337-1344
system	I	1345-1351
toxicity	I	1352-1360
.	O	1360-1361

These	O	1362-1367
findings	O	1368-1376
do	O	1377-1379
not	O	1380-1383
support	O	1384-1391
a	O	1392-1393
role	O	1394-1398
for	O	1399-1402
calcium	O	1403-1410
channel	O	1411-1418
inhibition	O	1419-1429
in	O	1430-1432
the	O	1433-1436
pathogenesis	O	1437-1449
of	O	1450-1452
tricyclic	O	1453-1462
antidepressant	O	1463-1477
-	O	1477-1478
induced	O	1478-1485
hypotension	B	1486-1497
.	O	1497-1498

Phase	O	0-5
I	O	6-7
trial	O	8-13
of	O	14-16
13	O	17-19
-	O	19-20
cis	O	20-23
-	O	19-20
retinoic	O	24-32
acid	O	33-37
in	O	38-40
children	O	41-49
with	O	50-54
neuroblastoma	B	55-68
following	O	69-78
bone	O	79-83
marrow	O	84-90
transplantation	O	91-106
.	O	106-107

PURPOSE	O	108-115
:	O	115-116
Treatment	O	117-126
of	O	127-129
neuroblastoma	B	130-143
cell	O	144-148
lines	O	149-154
with	O	155-159
13	O	160-162
-	O	162-163
cis	O	163-166
-	O	162-163
retinoic	O	167-175
acid	O	176-180
(	O	181-182
cis	O	182-185
-	O	185-186
RA	O	186-188
)	O	188-189
can	O	190-193
cause	O	194-199
sustained	O	200-209
inhibition	O	210-220
of	O	221-223
proliferation	O	224-237
.	O	237-238

Since	O	239-244
cis	O	245-248
-	O	248-249
RA	O	249-251
has	O	252-255
demonstrated	O	256-268
clinical	O	269-277
responses	O	278-287
in	O	288-290
neuroblastoma	B	291-304
patients	O	305-313
,	O	313-314
it	O	315-317
may	O	318-321
be	O	322-324
effective	O	325-334
in	O	335-337
preventing	O	338-348
relapse	O	349-356
after	O	357-362
cytotoxic	O	363-372
therapy	O	373-380
.	O	380-381

This	O	382-386
phase	O	387-392
I	O	393-394
trial	O	395-400
was	O	401-404
designed	O	405-413
to	O	414-416
determine	O	417-426
the	O	427-430
maximal	O	431-438
-	O	438-439
tolerated	O	439-448
dosage	O	449-455
(	O	456-457
MTD	O	457-460
)	O	460-461
,	O	461-462
toxicities	B	463-473
,	O	473-474
and	O	475-478
pharmacokinetics	O	479-495
of	O	496-498
cis	O	499-502
-	O	502-503
RA	O	503-505
administered	O	506-518
on	O	519-521
an	O	522-524
intermittent	O	525-537
schedule	O	538-546
in	O	547-549
children	O	550-558
with	O	559-563
neuroblastoma	B	564-577
following	O	578-587
bone	O	588-592
marrow	O	593-599
transplantation	O	600-615
(	O	616-617
BMT	O	617-620
)	O	620-621
.	O	621-622

PATIENTS	O	623-631
AND	O	632-635
METHODS	O	636-643
:	O	643-644
Fifty	O	645-650
-	O	650-651
one	O	651-654
assessable	O	655-665
patients	O	666-674
,	O	674-675
2	O	676-677
to	O	678-680
12	O	681-683
years	O	684-689
of	O	690-692
age	O	693-696
,	O	696-697
were	O	698-702
treated	O	703-710
with	O	711-715
oral	O	716-720
cis	O	721-724
-	O	724-725
RA	O	725-727
administered	O	728-740
in	O	741-743
two	O	744-747
equally	O	748-755
divided	O	756-763
doses	O	764-769
daily	O	770-775
for	O	776-779
2	O	780-781
weeks	O	782-787
,	O	787-788
followed	O	789-797
by	O	798-800
a	O	801-802
2	O	803-804
-	O	804-805
week	O	805-809
rest	O	810-814
period	O	815-821
,	O	821-822
for	O	823-826
up	O	827-829
to	O	830-832
12	O	833-835
courses	O	836-843
.	O	843-844

The	O	845-848
dose	O	849-853
was	O	854-857
escalated	O	858-867
from	O	868-872
100	O	873-876
to	O	877-879
200	O	880-883
mg	O	884-886
/	O	886-887
m2	O	887-889
/	O	886-887
d	O	890-891
until	O	892-897
dose	O	898-902
-	O	902-903
limiting	O	903-911
toxicity	B	912-920
(	O	921-922
DLT	O	922-925
)	O	925-926
was	O	927-930
observed	O	931-939
.	O	939-940

A	O	941-942
single	O	943-949
intrapatient	O	950-962
dose	O	963-967
escalation	O	968-978
was	O	979-982
permitted	O	983-992
.	O	992-993

RESULTS	O	994-1001
:	O	1001-1002
The	O	1003-1006
MTD	O	1007-1010
of	O	1011-1013
cis	O	1014-1017
-	O	1017-1018
RA	O	1018-1020
was	O	1021-1024
160	O	1025-1028
mg	O	1029-1031
/	O	1031-1032
m2	O	1032-1034
/	O	1031-1032
d	O	1035-1036
.	O	1036-1037

Dose	O	1038-1042
-	O	1042-1043
limiting	O	1043-1051
toxicities	B	1052-1062
in	O	1063-1065
six	O	1066-1069
of	O	1070-1072
nine	O	1073-1077
patients	O	1078-1086
at	O	1087-1089
200	O	1090-1093
mg	O	1094-1096
/	O	1096-1097
m2	O	1097-1099
/	O	1096-1097
d	O	1100-1101
included	O	1102-1110
hypercalcemia	B	1111-1124
(	O	1125-1126
n	O	1126-1127
=	O	1128-1129
3	O	1130-1131
)	O	1131-1132
,	O	1132-1133
rash	B	1134-1138
(	O	1139-1140
n	O	1140-1141
=	O	1142-1143
2	O	1144-1145
)	O	1145-1146
,	O	1146-1147
and	O	1148-1151
anemia	B	1152-1158
/	O	1158-1159
thrombocytopenia	B	1159-1175
/	O	1158-1159
emesis	B	1176-1182
/	O	1158-1159
rash	B	1183-1187
(	O	1188-1189
n	O	1189-1190
=	O	1191-1192
1	O	1193-1194
)	O	1194-1195
.	O	1195-1196

All	O	1197-1200
toxicities	B	1201-1211
resolved	O	1212-1220
after	O	1221-1226
cis	O	1227-1230
-	O	1230-1231
RA	O	1231-1233
was	O	1234-1237
discontinued	O	1238-1250
.	O	1250-1251

Three	O	1252-1257
complete	O	1258-1266
responses	O	1267-1276
were	O	1277-1281
observed	O	1282-1290
in	O	1291-1293
marrow	O	1294-1300
metastases	B	1301-1311
.	O	1311-1312

Serum	O	1313-1318
levels	O	1319-1325
of	O	1326-1328
7	O	1329-1330
.	O	1330-1331
4	O	1331-1332
+	O	1333-1334
/	O	1334-1335
-	O	1335-1336
3	O	1337-1338
.	O	1338-1339
0	O	1339-1340
mumol	O	1341-1346
/	O	1346-1347
L	O	1347-1348
(	O	1349-1350
peak	O	1350-1354
)	O	1354-1355
and	O	1356-1359
4	O	1360-1361
.	O	1361-1362
0	O	1362-1363
+	O	1364-1365
/	O	1365-1366
-	O	1366-1367
2	O	1368-1369
.	O	1369-1370
8	O	1370-1371
mumol	O	1372-1377
/	O	1377-1378
L	O	1378-1379
(	O	1380-1381
trough	O	1381-1387
)	O	1387-1388
at	O	1389-1391
the	O	1392-1395
MTD	O	1396-1399
were	O	1400-1404
maintained	O	1405-1415
during	O	1416-1422
14	O	1423-1425
days	O	1426-1430
of	O	1431-1433
therapy	O	1434-1441
.	O	1441-1442

The	O	1443-1446
DLT	O	1447-1450
correlated	O	1451-1461
with	O	1462-1466
serum	O	1467-1472
levels	O	1473-1479
>	O	1480-1481
or	O	1482-1484
=	O	1485-1486
10	O	1487-1489
mumol	O	1490-1495
/	O	1495-1496
L	O	1496-1497
.	O	1497-1498

CONCLUSION	O	1499-1509
:	O	1509-1510
The	O	1511-1514
MTD	O	1515-1518
of	O	1519-1521
cis	O	1522-1525
-	O	1525-1526
RA	O	1526-1528
given	O	1529-1534
on	O	1535-1537
this	O	1538-1542
intermittent	O	1543-1555
schedule	O	1556-1564
was	O	1565-1568
160	O	1569-1572
mg	O	1573-1575
/	O	1575-1576
m2	O	1576-1578
/	O	1575-1576
d	O	1579-1580
.	O	1580-1581

Serum	O	1582-1587
levels	O	1588-1594
known	O	1595-1600
to	O	1601-1603
be	O	1604-1606
effective	O	1607-1616
against	O	1617-1624
neuroblastoma	B	1625-1638
in	O	1639-1641
vitro	O	1642-1647
were	O	1648-1652
achieved	O	1653-1661
at	O	1662-1664
this	O	1665-1669
dose	O	1670-1674
.	O	1674-1675

The	O	1676-1679
DLT	O	1680-1683
included	O	1684-1692
hypercalcemia	B	1693-1706
,	O	1706-1707
and	O	1708-1711
may	O	1712-1715
be	O	1716-1718
predicted	O	1719-1728
by	O	1729-1731
serum	O	1732-1737
cis	O	1738-1741
-	O	1741-1742
RA	O	1742-1744
levels	O	1745-1751
.	O	1751-1752

Monitoring	O	1753-1763
of	O	1764-1766
serum	O	1767-1772
calcium	O	1773-1780
and	O	1781-1784
cis	O	1785-1788
-	O	1788-1789
RA	O	1789-1791
levels	O	1792-1798
is	O	1799-1801
indicated	O	1802-1811
in	O	1812-1814
future	O	1815-1821
trials	O	1822-1828
.	O	1828-1829

Effect	O	0-6
of	O	7-9
calcium	O	10-17
chloride	O	18-26
on	O	27-29
gross	O	30-35
behavioural	O	36-47
changes	O	48-55
produced	O	56-64
by	O	65-67
carbachol	O	68-77
and	O	78-81
eserine	O	82-89
in	O	90-92
cats	O	93-97
.	O	97-98

The	O	99-102
effect	O	103-109
of	O	110-112
calcium	O	113-120
chloride	O	121-129
injected	O	130-138
into	O	139-143
the	O	144-147
cerebral	O	148-156
ventricles	O	157-167
of	O	168-170
group	O	171-176
-	O	176-177
housed	O	177-183
unanaesthetized	O	184-199
cats	O	200-204
upon	O	205-209
vocalization	O	210-222
(	O	223-224
rage	O	224-228
,	O	228-229
hissing	O	230-237
and	O	238-241
snarling	O	242-250
)	O	250-251
,	O	251-252
fighting	O	253-261
(	O	262-263
attack	O	263-269
with	O	270-274
paws	O	275-279
and	O	280-283
claws	O	284-289
,	O	289-290
defense	O	291-298
with	O	299-303
paws	O	304-308
and	O	309-312
claws	O	313-318
and	O	319-322
biting	O	323-329
)	O	329-330
,	O	330-331
mydriasis	B	332-341
,	O	341-342
tremor	B	343-349
and	O	350-353
clonic	B	354-360
-	I	360-361
tonic	I	361-366
convulsions	I	367-378
produced	O	379-387
by	O	388-390
carbachol	O	391-400
and	O	401-404
eserine	O	405-412
injected	O	413-421
similarly	O	422-431
was	O	432-435
investigated	O	436-448
.	O	448-449

Calcium	O	450-457
chloride	O	458-466
depressed	O	467-476
or	O	477-479
almost	O	480-486
completely	O	487-497
abolished	O	498-507
the	O	508-511
vocalization	O	512-524
and	O	525-528
fighting	O	529-537
due	O	538-541
to	O	542-544
carbachol	O	545-554
and	O	555-558
eserine	O	559-566
.	O	566-567

On	O	568-570
the	O	571-574
other	O	575-580
hand	O	581-585
,	O	585-586
mydriasis	B	587-596
,	O	596-597
tremor	B	598-604
and	O	605-608
clonic	B	609-615
-	I	615-616
tonic	I	616-621
convulsions	I	622-633
evoked	O	634-640
by	O	641-643
carbachol	O	644-653
and	O	654-657
eserine	O	658-665
were	O	666-670
not	O	671-674
significantly	O	675-688
changed	O	689-696
by	O	697-699
calcium	O	700-707
chloride	O	708-716
.	O	716-717

It	O	718-720
is	O	721-723
apparent	O	724-732
that	O	733-737
calcium	O	738-745
chloride	O	746-754
can	O	755-758
"	O	759-760
dissociate	O	760-770
"	O	759-760
vocalization	O	772-784
and	O	785-788
fighting	O	789-797
from	O	798-802
autonomic	O	803-812
and	O	813-816
motor	O	817-822
phenomena	O	823-832
such	O	833-837
as	O	838-840
mydriasis	B	841-850
,	O	850-851
tremor	B	852-858
and	O	859-862
clonic	B	863-869
-	I	869-870
tonic	I	870-875
convulsions	I	876-887
caused	O	888-894
by	O	895-897
carbachol	O	898-907
and	O	908-911
eserine	O	912-919
.	O	919-920

Calcium	O	921-928
chloride	O	929-937
inhibited	O	938-947
the	O	948-951
vocalization	O	952-964
and	O	965-968
fighting	O	969-977
produced	O	978-986
by	O	987-989
carbachol	O	990-999
and	O	1000-1003
eserine	O	1004-1011
most	O	1012-1016
probably	O	1017-1025
by	O	1026-1028
a	O	1029-1030
nonspecific	O	1031-1042
stabilizing	O	1043-1054
action	O	1055-1061
on	O	1062-1064
central	O	1065-1072
muscarinic	O	1073-1083
cholinoceptive	O	1084-1098
sites	O	1099-1104
.	O	1104-1105

These	O	1106-1111
results	O	1112-1119
further	O	1120-1127
support	O	1128-1135
the	O	1136-1139
view	O	1140-1144
that	O	1145-1149
calcium	O	1150-1157
ions	O	1158-1162
in	O	1163-1165
excess	O	1166-1172
have	O	1173-1177
an	O	1178-1180
atropine	O	1181-1189
-	O	1189-1190
like	O	1190-1194
action	O	1195-1201
also	O	1202-1206
in	O	1207-1209
the	O	1210-1213
central	O	1214-1221
nervous	O	1222-1229
system	O	1230-1236
.	O	1236-1237

Multiple	O	0-8
side	O	9-13
effects	O	14-21
of	O	22-24
penicillamine	O	25-38
therapy	O	39-46
in	O	47-49
one	O	50-53
patient	O	54-61
with	O	62-66
rheumatoid	B	67-77
arthritis	I	78-87
.	O	87-88

Skin	B	89-93
rashes	I	94-100
,	O	100-101
proteinuria	B	102-113
,	O	113-114
systemic	B	115-123
lupus	I	124-129
erythematosus	I	130-143
,	O	143-144
polymyositis	B	145-157
and	O	158-161
myasthenia	B	162-172
gravis	I	173-179
have	O	180-184
all	O	185-188
been	O	189-193
recorded	O	194-202
as	O	203-205
complications	O	206-219
of	O	220-222
penicillamine	O	223-236
therapy	O	237-244
in	O	245-247
patients	O	248-256
with	O	257-261
rheumatoid	B	262-272
arthritis	I	273-282
.	O	282-283

A	O	284-285
patient	O	286-293
who	O	294-297
had	O	298-301
developed	O	302-311
all	O	312-315
5	O	316-317
is	O	318-320
now	O	321-324
described	O	325-334
.	O	334-335

The	O	336-339
skin	B	340-344
lesion	I	345-351
resembled	O	352-361
elastosis	B	362-371
perforans	I	372-381
serpiginosa	I	382-393
,	O	393-394
which	O	395-400
has	O	401-404
been	O	405-409
reported	O	410-418
as	O	419-421
a	O	422-423
rare	O	424-428
side	O	429-433
effect	O	434-440
in	O	441-443
patients	O	444-452
with	O	453-457
Wilson	B	458-464
'	I	464-465
s	I	461-462
disease	I	467-474
but	O	475-478
not	O	479-482
in	O	483-485
patients	O	486-494
with	O	495-499
rheumatoid	B	500-510
arthritis	I	511-520
treated	O	521-528
with	O	529-533
penicillamine	O	534-547
.	O	547-548

Electrocardiographic	O	0-20
changes	O	21-28
and	O	29-32
cardiac	B	33-40
arrhythmias	I	41-52
in	O	53-55
patients	O	56-64
receiving	O	65-74
psychotropic	O	75-87
drugs	O	88-93
.	O	93-94

Eight	O	95-100
patients	O	101-109
had	O	110-113
cardiac	O	114-121
manifestations	O	122-136
that	O	137-141
were	O	142-146
life	O	147-151
-	O	151-152
threatening	O	152-163
in	O	164-166
five	O	167-171
while	O	172-177
taking	O	178-184
psychotropic	O	185-197
drugs	O	198-203
,	O	203-204
either	O	205-211
phenothiazines	O	212-226
or	O	227-229
tricyclic	O	230-239
antidepressants	O	240-255
.	O	255-256

Although	O	257-265
most	O	266-270
patients	O	271-279
were	O	280-284
receiving	O	285-294
several	O	295-302
drugs	O	303-308
,	O	308-309
Mellaril	O	310-318
(	O	319-320
thioridazine	O	320-332
)	O	332-333
appeared	O	334-342
to	O	343-345
be	O	346-348
responsible	O	349-360
for	O	361-364
five	O	365-369
cases	O	370-375
of	O	376-378
ventricular	B	379-390
tachycardia	I	391-402
,	O	402-403
one	O	404-407
of	O	408-410
which	O	411-416
was	O	417-420
fatal	O	421-426
in	O	427-429
a	O	430-431
35	O	432-434
year	O	435-439
old	O	440-443
woman	O	444-449
.	O	449-450

Supraventricular	B	451-467
tachycardia	I	468-479
developed	O	480-489
in	O	490-492
one	O	493-496
patient	O	497-504
receiving	O	505-514
Thorazine	O	515-524
(	O	525-526
chlorpromazine	O	526-540
)	O	540-541
.	O	541-542

Aventyl	O	543-550
(	O	551-552
nortriptyline	O	552-565
)	O	565-566
and	O	567-570
Elavil	O	571-577
(	O	578-579
amitriptyline	O	579-592
)	O	592-593
each	O	594-598
produced	O	599-607
left	B	608-612
bundle	I	613-619
branch	I	620-626
block	I	627-632
in	O	633-635
a	O	636-637
73	O	638-640
year	O	641-645
old	O	646-649
woman	O	650-655
.	O	655-656

Electrocardiographic	O	657-677
T	O	678-679
and	O	680-683
U	O	684-685
wave	O	686-690
abnormalities	O	691-704
were	O	705-709
present	O	710-717
in	O	718-720
most	O	721-725
patients	O	726-734
.	O	734-735

The	O	736-739
ventricular	B	740-751
arrhythmias	I	752-763
responded	O	764-773
to	O	774-776
intravenous	O	777-788
administration	O	789-803
of	O	804-806
lidocaine	O	807-816
and	O	817-820
to	O	821-823
direct	O	824-830
current	O	831-838
electric	O	839-847
shock	O	848-853
;	O	853-854
ventricular	O	855-866
pacing	O	867-873
was	O	874-877
required	O	878-886
in	O	887-889
some	O	890-894
instances	O	895-904
and	O	905-908
intravenous	O	909-920
administration	O	921-935
of	O	936-938
propranolol	O	939-950
combined	O	951-959
with	O	960-964
ventricular	O	965-976
pacing	O	977-983
in	O	984-986
one	O	987-990
.	O	990-991

The	O	992-995
tachyarrhythmias	B	996-1012
generally	O	1013-1022
subsided	O	1023-1031
within	O	1032-1038
48	O	1039-1041
hours	O	1042-1047
after	O	1048-1053
administration	O	1054-1068
of	O	1069-1071
the	O	1072-1075
drugs	O	1076-1081
was	O	1082-1085
stopped	O	1086-1093
.	O	1093-1094

Five	O	1095-1099
of	O	1100-1102
the	O	1103-1106
eight	O	1107-1112
patients	O	1113-1121
were	O	1122-1126
50	O	1127-1129
years	O	1130-1135
of	O	1136-1138
age	O	1139-1142
or	O	1143-1145
younger	O	1146-1153
;	O	1153-1154
only	O	1155-1159
one	O	1160-1163
clearly	O	1164-1171
had	O	1172-1175
antecedent	O	1176-1186
heart	B	1187-1192
disease	I	1193-1200
.	O	1200-1201

Major	O	1202-1207
cardiac	B	1208-1215
arrhythmias	I	1216-1227
are	O	1228-1231
a	O	1232-1233
potential	O	1234-1243
hazard	O	1244-1250
in	O	1251-1253
patients	O	1254-1262
without	O	1263-1270
heart	B	1271-1276
disease	I	1277-1284
who	O	1285-1288
are	O	1289-1292
receiving	O	1293-1302
customary	O	1303-1312
therapeutic	O	1313-1324
doses	O	1325-1330
of	O	1331-1333
psychotropic	O	1334-1346
drugs	O	1347-1352
.	O	1352-1353

A	O	1354-1355
prospective	O	1356-1367
clinical	O	1368-1376
trial	O	1377-1382
is	O	1383-1385
suggested	O	1386-1395
to	O	1396-1398
quantify	O	1399-1407
the	O	1408-1411
risk	O	1412-1416
of	O	1417-1419
cardiac	B	1420-1427
complications	I	1428-1441
to	O	1442-1444
patients	O	1445-1453
receiving	O	1454-1463
phenothiazines	O	1464-1478
or	O	1479-1481
tricyclic	O	1482-1491
antidepressant	O	1492-1506
drugs	O	1507-1512
.	O	1512-1513

Serotonergic	O	0-12
drugs	O	13-18
,	O	18-19
benzodiazepines	O	20-35
and	O	36-39
baclofen	O	40-48
block	O	49-54
muscimol	O	55-63
-	O	63-64
induced	O	64-71
myoclonic	B	72-81
jerks	I	82-87
in	O	88-90
a	O	91-92
strain	O	93-99
of	O	100-102
mice	O	103-107
.	O	107-108

In	O	109-111
male	O	112-116
Swiss	O	117-122
mice	O	123-127
,	O	127-128
muscimol	O	129-137
produced	O	138-146
myoclonic	B	147-156
jerks	I	157-162
.	O	162-163

A	O	164-165
3	O	166-167
mg	O	168-170
/	O	170-171
kg	O	171-173
(	O	174-175
i	O	175-176
.	O	176-177
p	O	177-178
.	O	176-177
)	O	179-180
dose	O	181-185
induced	O	186-193
this	O	194-198
response	O	199-207
in	O	208-210
all	O	211-214
of	O	215-217
the	O	218-221
mice	O	222-226
tested	O	227-233
and	O	234-237
the	O	238-241
peak	O	242-246
response	O	247-255
of	O	256-258
73	O	259-261
jerks	O	262-267
per	O	268-271
min	O	272-275
was	O	276-279
observed	O	280-288
between	O	289-296
27	O	297-299
and	O	300-303
45	O	304-306
min	O	307-310
.	O	310-311

Increasing	O	312-322
the	O	323-326
brain	O	327-332
serotonin	O	333-342
levels	O	343-349
by	O	350-352
the	O	353-356
administration	O	357-371
of	O	372-374
5	O	375-376
-	O	376-377
hydroxytryptophan	O	377-394
(	O	395-396
80	O	396-398
-	O	398-399
160	O	399-402
mg	O	403-405
/	O	405-406
kg	O	406-408
)	O	408-409
in	O	410-412
combination	O	413-424
with	O	425-429
a	O	430-431
peripheral	O	432-442
decarboxylase	O	443-456
inhibitor	O	457-466
resulted	O	467-475
in	O	476-478
an	O	479-481
inhibition	O	482-492
of	O	493-495
the	O	496-499
muscimol	O	500-508
effect	O	509-515
.	O	515-516

However	O	517-524
,	O	524-525
in	O	526-528
a	O	529-530
similar	O	531-538
experiment	O	539-549
l	O	550-551
-	O	551-552
dopa	O	552-556
(	O	557-558
80	O	558-560
-	O	560-561
160	O	561-564
mg	O	565-567
/	O	567-568
kg	O	568-570
)	O	570-571
was	O	572-575
without	O	576-583
effect	O	584-590
.	O	590-591

In	O	592-594
doses	O	595-600
of	O	601-603
3	O	604-605
-	O	605-606
10	O	606-608
mg	O	609-611
/	O	611-612
kg	O	612-614
,	O	614-615
the	O	616-619
serotonin	O	620-629
receptor	O	630-638
agonist	O	639-646
MK	O	647-649
-	O	649-650
212	O	650-653
caused	O	654-660
a	O	661-662
dose	O	663-667
-	O	667-668
dependent	O	668-677
blockade	O	678-686
of	O	687-689
the	O	690-693
response	O	694-702
of	O	703-705
muscimol	O	706-714
.	O	714-715

Of	O	716-718
the	O	719-722
benzodiazepines	O	723-738
,	O	738-739
clonazepam	O	740-750
(	O	751-752
0	O	752-753
.	O	753-754
1	O	754-755
-	O	755-756
0	O	752-753
.	O	753-754
3	O	758-759
mg	O	760-762
/	O	762-763
kg	O	763-765
)	O	765-766
was	O	767-770
found	O	771-776
to	O	777-779
be	O	780-782
several	O	783-790
fold	O	791-795
more	O	796-800
potent	O	801-807
than	O	808-812
diazepam	O	813-821
(	O	822-823
0	O	823-824
.	O	824-825
3	O	825-826
-	O	826-827
3	O	825-826
mg	O	829-831
/	O	831-832
kg	O	832-834
)	O	834-835
in	O	836-838
blocking	O	839-847
the	O	848-851
myoclonic	B	852-861
jerks	I	862-867
.	O	867-868

While	O	869-874
(	O	875-876
-	O	876-877
)	O	877-878
-	O	876-877
baclofen	O	879-887
(	O	888-889
1	O	889-890
-	O	890-891
3	O	891-892
mg	O	893-895
/	O	895-896
kg	O	896-898
)	O	898-899
proved	O	900-906
to	O	907-909
be	O	910-912
an	O	913-915
effective	O	916-925
antagonist	O	926-936
of	O	937-939
muscimol	O	940-948
,	O	948-949
its	O	950-953
(	O	954-955
+	O	955-956
)	O	956-957
-	O	957-958
isomer	O	958-964
(	O	965-966
5	O	966-967
-	O	967-968
20	O	968-970
mg	O	971-973
/	O	973-974
kg	O	974-976
)	O	976-977
lacked	O	978-984
this	O	985-989
property	O	990-998
.	O	998-999

Considering	O	1000-1011
the	O	1012-1015
fact	O	1016-1020
that	O	1021-1025
5	O	1026-1027
-	O	1027-1028
HTP	O	1028-1031
and	O	1032-1035
the	O	1036-1039
benzodiazepines	O	1040-1055
have	O	1056-1060
been	O	1061-1065
found	O	1066-1071
to	O	1072-1074
be	O	1075-1077
beneficial	O	1078-1088
in	O	1089-1091
the	O	1092-1095
management	O	1096-1106
of	O	1107-1109
clinical	O	1110-1118
myoclonus	B	1119-1128
,	O	1128-1129
the	O	1130-1133
muscimol	O	1134-1142
-	O	1142-1143
induced	O	1143-1150
myoclonus	B	1151-1160
seems	O	1161-1166
to	O	1167-1169
be	O	1170-1172
a	O	1173-1174
satisfactory	O	1175-1187
animal	O	1188-1194
model	O	1195-1200
that	O	1201-1205
may	O	1206-1209
prove	O	1210-1215
useful	O	1216-1222
for	O	1223-1226
the	O	1227-1230
development	O	1231-1242
of	O	1243-1245
new	O	1246-1249
drug	O	1250-1254
treatments	O	1255-1265
for	O	1266-1269
this	O	1270-1274
condition	O	1275-1284
.	O	1284-1285

Our	O	1286-1289
present	O	1290-1297
study	O	1298-1303
indicated	O	1304-1313
the	O	1314-1317
possible	O	1318-1326
value	O	1327-1332
of	O	1333-1335
MK	O	1336-1338
-	O	1338-1339
212	O	1339-1342
and	O	1343-1346
(	O	1347-1348
-	O	1348-1349
)	O	1349-1350
-	O	1348-1349
baclofen	O	1351-1359
in	O	1360-1362
the	O	1363-1366
management	O	1367-1377
of	O	1378-1380
clinical	O	1381-1389
myoclonus	B	1390-1399
.	O	1399-1400

Hyperglycemic	B	0-13
acidotic	I	14-22
coma	I	23-27
and	O	28-31
death	O	32-37
in	O	38-40
Kearns	B	41-47
-	I	47-48
Sayre	I	48-53
syndrome	I	54-62
.	O	62-63

This	O	64-68
paper	O	69-74
presents	O	75-83
the	O	84-87
clinical	O	88-96
and	O	97-100
metabolic	O	101-110
findings	O	111-119
in	O	120-122
two	O	123-126
young	O	127-132
boys	O	133-137
with	O	138-142
long	O	143-147
-	O	147-148
standing	O	148-156
Kearns	B	157-163
-	I	163-164
Sayre	I	164-169
syndrome	I	170-178
.	O	178-179

Following	O	180-189
short	O	190-195
exposure	O	196-204
to	O	205-207
oral	O	208-212
prednisone	O	213-223
,	O	223-224
both	O	225-229
boys	O	230-234
developed	O	235-244
lethargy	B	245-253
,	O	253-254
increasing	O	255-265
somnolence	B	266-276
,	O	276-277
polydipsia	B	278-288
,	O	288-289
polyphagia	B	290-300
,	O	300-301
and	O	302-305
polyuria	B	306-314
.	O	314-315

Both	O	316-320
presented	O	321-330
in	O	331-333
the	O	334-337
emergency	O	338-347
room	O	348-352
with	O	353-357
profound	O	358-366
coma	B	367-371
,	O	371-372
hypotension	B	373-384
,	O	384-385
severe	O	386-392
hyperglycemia	B	393-406
,	O	406-407
and	O	408-411
acidosis	B	412-420
.	O	420-421

Nonketotic	O	422-432
lactic	B	433-439
acidosis	I	440-448
was	O	449-452
present	O	453-460
in	O	461-463
one	O	464-467
and	O	468-471
ketosis	B	472-479
without	O	480-487
a	O	488-489
known	O	490-495
serum	O	496-501
lactate	O	502-509
level	O	510-515
was	O	516-519
present	O	520-527
in	O	528-530
the	O	531-534
other	O	535-540
.	O	540-541

Respiratory	B	542-553
failure	I	554-561
rapidly	O	562-569
ensued	O	570-576
and	O	577-580
both	O	581-585
patients	O	586-594
expired	O	595-602
in	O	603-605
spite	O	606-611
of	O	612-614
efforts	O	615-622
at	O	623-625
resuscitation	O	626-639
.	O	639-640

We	O	641-643
believe	O	644-651
these	O	652-657
two	O	658-661
cases	O	662-667
represent	O	668-677
a	O	678-679
newly	O	680-685
described	O	686-695
and	O	696-699
catastrophic	O	700-712
metabolic	B	713-722
-	I	722-723
endocrine	I	723-732
failure	I	733-740
in	O	741-743
the	O	744-747
Kearns	B	748-754
-	I	754-755
Sayre	I	755-760
syndrome	I	761-769
.	O	769-770

Effects	O	0-7
of	O	8-10
active	O	11-17
constituents	O	18-30
of	O	31-33
Crocus	O	34-40
sativus	O	41-48
L	O	49-50
.	O	50-51
,	O	51-52
crocin	O	53-59
on	O	60-62
streptozocin	O	63-75
-	O	75-76
induced	O	76-83
model	O	84-89
of	O	90-92
sporadic	O	93-101
Alzheimer	B	102-111
'	I	111-112
s	I	112-113
disease	I	114-121
in	O	122-124
male	O	125-129
rats	O	130-134
.	O	134-135

BACKGROUND	O	136-146
:	O	146-147
The	O	148-151
involvement	O	152-163
of	O	164-166
water	O	167-172
-	O	172-173
soluble	O	173-180
carotenoids	O	181-192
,	O	192-193
crocins	O	194-201
,	O	201-202
as	O	203-205
the	O	206-209
main	O	210-214
and	O	215-218
active	O	219-225
components	O	226-236
of	O	237-239
Crocus	O	240-246
sativus	O	247-254
L	O	255-256
.	O	256-257
extract	O	258-265
in	O	266-268
learning	O	269-277
and	O	278-281
memory	O	282-288
processes	O	289-298
has	O	299-302
been	O	303-307
proposed	O	308-316
.	O	316-317

In	O	318-320
the	O	321-324
present	O	325-332
study	O	333-338
,	O	338-339
the	O	340-343
effect	O	344-350
of	O	351-353
crocins	O	354-361
on	O	362-364
sporadic	O	365-373
Alzheimer	B	374-383
'	I	383-384
s	I	384-385
disease	I	386-393
induced	O	394-401
by	O	402-404
intracerebroventricular	O	405-428
(	O	429-430
icv	O	430-433
)	O	433-434
streptozocin	O	435-447
(	O	448-449
STZ	O	449-452
)	O	452-453
in	O	454-456
male	O	457-461
rats	O	462-466
was	O	467-470
investigated	O	471-483
.	O	483-484

METHODS	O	485-492
:	O	492-493
Male	O	494-498
adult	O	499-504
Wistar	O	505-511
rats	O	512-516
(	O	517-518
n	O	518-519
=	O	520-521
90	O	522-524
and	O	525-528
260	O	529-532
-	O	532-533
290	O	533-536
g	O	537-538
)	O	538-539
were	O	540-544
divided	O	545-552
into	O	553-557
1	O	558-559
,	O	559-560
control	O	561-568
;	O	568-569
2	O	570-571
and	O	572-575
3	O	576-577
,	O	577-578
crocins	O	579-586
(	O	587-588
15	O	588-590
and	O	591-594
30	O	595-597
mg	O	598-600
/	O	600-601
kg	O	601-603
)	O	603-604
;	O	604-605
4	O	606-607
,	O	607-608
STZ	O	609-612
;	O	612-613
5	O	614-615
and	O	616-619
6	O	620-621
,	O	621-622
STZ	O	623-626
+	O	627-628
crocins	O	629-636
(	O	637-638
15	O	638-640
and	O	641-644
30	O	645-647
mg	O	648-650
/	O	650-651
kg	O	651-653
)	O	653-654
groups	O	655-661
.	O	661-662

In	O	663-665
Alzheimer	B	666-675
'	I	675-676
s	I	676-677
disease	I	678-685
groups	O	686-692
,	O	692-693
rats	O	694-698
were	O	699-703
injected	O	704-712
with	O	713-717
STZ	O	718-721
-	O	721-722
icv	O	722-725
bilaterally	O	726-737
(	O	738-739
3	O	739-740
mg	O	741-743
/	O	743-744
kg	O	744-746
)	O	746-747
in	O	748-750
first	O	751-756
day	O	757-760
and	O	761-764
3	O	765-766
days	O	767-771
later	O	772-777
,	O	777-778
a	O	779-780
similar	O	781-788
STZ	O	789-792
-	O	792-793
icv	O	793-796
application	O	797-808
was	O	809-812
repeated	O	813-821
.	O	821-822

In	O	823-825
STZ	O	826-829
+	O	830-831
crocin	O	832-838
animal	O	839-845
groups	O	846-852
,	O	852-853
crocin	O	854-860
was	O	861-864
applied	O	865-872
in	O	873-875
doses	O	876-881
of	O	882-884
15	O	885-887
and	O	888-891
30	O	892-894
mg	O	895-897
/	O	897-898
kg	O	898-900
,	O	900-901
i	O	902-903
.	O	903-904
p	O	904-905
.	O	903-904
,	O	906-907
one	O	908-911
day	O	912-915
pre	O	916-919
-	O	919-920
surgery	O	920-927
and	O	928-931
continued	O	932-941
for	O	942-945
three	O	946-951
weeks	O	952-957
.	O	957-958

Prescription	O	959-971
of	O	972-974
crocin	O	975-981
in	O	982-984
each	O	985-989
dose	O	990-994
was	O	995-998
repeated	O	999-1007
once	O	1008-1012
for	O	1013-1016
two	O	1017-1020
days	O	1021-1025
.	O	1025-1026

However	O	1027-1034
,	O	1034-1035
the	O	1036-1039
learning	O	1040-1048
and	O	1049-1052
memory	O	1053-1059
performance	O	1060-1071
was	O	1072-1075
assessed	O	1076-1084
using	O	1085-1090
passive	O	1091-1098
avoidance	O	1099-1108
paradigm	O	1109-1117
,	O	1117-1118
and	O	1119-1122
for	O	1123-1126
spatial	O	1127-1134
cognition	O	1135-1144
evaluation	O	1145-1155
,	O	1155-1156
Y	O	1157-1158
-	O	1158-1159
maze	O	1159-1163
task	O	1164-1168
was	O	1169-1172
used	O	1173-1177
.	O	1177-1178

RESULTS	O	1179-1186
:	O	1186-1187
It	O	1188-1190
was	O	1191-1194
found	O	1195-1200
out	O	1201-1204
that	O	1205-1209
crocin	O	1210-1216
(	O	1217-1218
30	O	1218-1220
mg	O	1221-1223
/	O	1223-1224
kg	O	1224-1226
)	O	1226-1227
-	O	1227-1228
treated	O	1228-1235
STZ	O	1236-1239
-	O	1239-1240
injected	O	1240-1248
rats	O	1249-1253
show	O	1254-1258
higher	O	1259-1265
correct	O	1266-1273
choices	O	1274-1281
and	O	1282-1285
lower	O	1286-1291
errors	O	1292-1298
in	O	1299-1301
Y	O	1302-1303
-	O	1303-1304
maze	O	1304-1308
than	O	1309-1313
vehicle	O	1314-1321
-	O	1321-1322
treated	O	1322-1329
STZ	O	1330-1333
-	O	1333-1334
injected	O	1334-1342
rats	O	1343-1347
.	O	1347-1348

In	O	1349-1351
addition	O	1352-1360
,	O	1360-1361
crocin	O	1362-1368
in	O	1369-1371
the	O	1372-1375
mentioned	O	1376-1385
dose	O	1386-1390
could	O	1391-1396
significantly	O	1397-1410
attenuated	O	1411-1421
learning	B	1422-1430
and	I	1431-1434
memory	I	1435-1441
impairment	I	1442-1452
in	O	1453-1455
treated	O	1456-1463
STZ	O	1464-1467
-	O	1467-1468
injected	O	1468-1476
group	O	1477-1482
in	O	1483-1485
passive	O	1486-1493
avoidance	O	1494-1503
test	O	1504-1508
.	O	1508-1509

CONCLUSION	O	1510-1520
:	O	1520-1521
Therefore	O	1522-1531
,	O	1531-1532
these	O	1533-1538
results	O	1539-1546
demonstrate	O	1547-1558
the	O	1559-1562
effectiveness	O	1563-1576
of	O	1577-1579
crocin	O	1580-1586
(	O	1587-1588
30	O	1588-1590
mg	O	1591-1593
/	O	1593-1594
kg	O	1594-1596
)	O	1596-1597
in	O	1598-1600
antagonizing	O	1601-1613
the	O	1614-1617
cognitive	B	1618-1627
deficits	I	1628-1636
caused	O	1637-1643
by	O	1644-1646
STZ	O	1647-1650
-	O	1650-1651
icv	O	1651-1654
in	O	1655-1657
rats	O	1658-1662
and	O	1663-1666
its	O	1667-1670
potential	O	1671-1680
in	O	1681-1683
the	O	1684-1687
treatment	O	1688-1697
of	O	1698-1700
neurodegenerative	B	1701-1718
diseases	I	1719-1727
such	O	1728-1732
as	O	1733-1735
Alzheimer	B	1736-1745
'	I	1745-1746
s	I	1746-1747
disease	I	1748-1755
.	O	1755-1756

Rosaceiform	O	0-11
dermatitis	B	12-22
associated	O	23-33
with	O	34-38
topical	O	39-46
tacrolimus	O	47-57
treatment	O	58-67
.	O	67-68

We	O	69-71
describe	O	72-80
herein	O	81-87
3	O	88-89
patients	O	90-98
who	O	99-102
developed	O	103-112
rosacea	B	113-120
-	O	120-121
like	O	121-125
dermatitis	B	126-136
eruptions	B	137-146
while	O	147-152
using	O	153-158
0	O	159-160
.	O	160-161
03	O	161-163
%	O	163-164
or	O	165-167
0	O	168-169
.	O	169-170
1	O	170-171
%	O	171-172
tacrolimus	O	173-183
ointment	O	184-192
for	O	193-196
facial	B	197-203
dermatitis	I	204-214
.	O	214-215

Skin	O	216-220
biopsy	O	221-227
specimens	O	228-237
showed	O	238-244
telangiectasia	B	245-259
and	O	260-263
noncaseating	O	264-276
epithelioid	O	277-288
granulomatous	O	289-302
tissue	O	303-309
formation	O	310-319
in	O	320-322
the	O	323-326
papillary	O	327-336
to	O	337-339
mid	O	340-343
dermis	O	344-350
.	O	350-351

Continuous	O	352-362
topical	O	363-370
use	O	371-374
of	O	375-377
immunomodulators	O	378-394
such	O	395-399
as	O	400-402
tacrolimus	O	403-413
or	O	414-416
pimecrolimus	O	417-429
should	O	430-436
be	O	437-439
regarded	O	440-448
as	O	449-451
a	O	452-453
potential	O	454-463
cause	O	464-469
of	O	470-472
rosaceiform	O	473-484
dermatitis	B	485-495
,	O	495-496
although	O	497-505
many	O	506-510
cases	O	511-516
have	O	517-521
not	O	522-525
been	O	526-530
reported	O	531-539
.	O	539-540

A	O	0-1
novel	O	2-7
animal	O	8-14
model	O	15-20
to	O	21-23
evaluate	O	24-32
the	O	33-36
ability	O	37-44
of	O	45-47
a	O	48-49
drug	O	50-54
delivery	O	55-63
system	O	64-70
to	O	71-73
promote	O	74-81
the	O	82-85
passage	O	86-93
through	O	94-101
the	O	102-105
BBB	O	106-109
.	O	109-110

The	O	111-114
purpose	O	115-122
of	O	123-125
this	O	126-130
investigation	O	131-144
was	O	145-148
to	O	149-151
explore	O	152-159
the	O	160-163
potentiality	O	164-176
of	O	177-179
a	O	180-181
novel	O	182-187
animal	O	188-194
model	O	195-200
to	O	201-203
be	O	204-206
used	O	207-211
for	O	212-215
the	O	216-219
in	O	220-222
vivo	O	223-227
evaluation	O	228-238
of	O	239-241
the	O	242-245
ability	O	246-253
of	O	254-256
a	O	257-258
drug	O	259-263
delivery	O	264-272
system	O	273-279
to	O	280-282
promote	O	283-290
the	O	291-294
passage	O	295-302
through	O	303-310
the	O	311-314
blood	O	315-320
-	O	320-321
brain	O	321-326
barrier	O	327-334
(	O	335-336
BBB	O	336-339
)	O	339-340
and	O	341-344
/	O	344-345
or	O	345-347
to	O	348-350
improve	O	351-358
the	O	359-362
brain	O	363-368
localization	O	369-381
of	O	382-384
a	O	385-386
bioactive	O	387-396
compound	O	397-405
.	O	405-406

A	O	407-408
Tween	O	409-414
80	O	415-417
-	O	417-418
coated	O	418-424
poly	O	425-429
-	O	429-430
L	O	430-431
-	O	429-430
lactid	O	432-438
acid	O	439-443
nanoparticles	O	444-457
was	O	458-461
used	O	462-466
as	O	467-469
a	O	470-471
model	O	472-477
of	O	478-480
colloidal	O	481-490
drug	O	491-495
delivery	O	496-504
system	O	505-511
,	O	511-512
able	O	513-517
to	O	518-520
trespass	O	521-529
the	O	530-533
BBB	O	534-537
.	O	537-538

Tacrine	O	539-546
,	O	546-547
administered	O	548-560
in	O	561-563
LiCl	O	564-568
pre	O	569-572
-	O	572-573
treated	O	573-580
rats	O	581-585
,	O	585-586
induces	O	587-594
electrocorticographic	O	595-616
seizures	B	617-625
and	O	626-629
delayed	O	630-637
hippocampal	B	638-649
damage	I	650-656
.	O	656-657

The	O	658-661
toxic	O	662-667
effects	O	668-675
of	O	676-678
tacrine	O	679-686
-	O	686-687
loaded	O	687-693
poly	O	694-698
-	O	698-699
L	O	699-700
-	O	698-699
lactid	O	701-707
acid	O	708-712
nanoparticles	O	713-726
(	O	727-728
5mg	O	728-731
/	O	731-732
kg	O	732-734
)	O	734-735
,	O	735-736
a	O	737-738
saline	O	739-745
solution	O	746-754
of	O	755-757
tacrine	O	758-765
(	O	766-767
5mg	O	767-770
/	O	770-771
kg	O	771-773
)	O	773-774
and	O	775-778
an	O	779-781
empty	O	782-787
colloidal	O	788-797
nanoparticle	O	798-810
suspension	O	811-821
were	O	822-826
compared	O	827-835
following	O	836-845
i	O	846-847
.	O	847-848
p	O	848-849
.	O	847-848
administration	O	851-865
in	O	866-868
LiCl	O	869-873
-	O	873-874
pre	O	874-877
-	O	873-874
treated	O	878-885
Wistar	O	886-892
rats	O	893-897
.	O	897-898

All	O	899-902
the	O	903-906
animals	O	907-914
treated	O	915-922
with	O	923-927
tacrine	O	928-935
-	O	935-936
loaded	O	936-942
nanoparticles	O	943-956
showed	O	957-963
an	O	964-966
earlier	O	967-974
outcome	O	975-982
of	O	983-985
CNS	O	986-989
adverse	O	990-997
symptoms	O	998-1006
,	O	1006-1007
i	O	1008-1009
.	O	1009-1010
e	O	1010-1011
.	O	1009-1010
epileptic	B	1013-1022
onset	O	1023-1028
,	O	1028-1029
with	O	1030-1034
respect	O	1035-1042
to	O	1043-1045
those	O	1046-1051
animals	O	1052-1059
treated	O	1060-1067
with	O	1068-1072
the	O	1073-1076
free	O	1077-1081
compound	O	1082-1090
(	O	1091-1092
10	O	1092-1094
min	O	1095-1098
vs	O	1099-1101
.	O	1101-1102
22	O	1103-1105
min	O	1106-1109
respectively	O	1110-1122
)	O	1122-1123
.	O	1123-1124

In	O	1125-1127
addition	O	1128-1136
,	O	1136-1137
tacrine	O	1138-1145
-	O	1145-1146
loaded	O	1146-1152
nanoparticles	O	1153-1166
administration	O	1167-1181
induced	O	1182-1189
damage	B	1190-1196
of	I	1197-1199
neuronal	I	1200-1208
cells	I	1209-1214
in	O	1215-1217
CA1	O	1218-1221
field	O	1222-1227
of	O	1228-1230
the	O	1231-1234
hippocampus	O	1235-1246
in	O	1247-1249
all	O	1250-1253
treated	O	1254-1261
animals	O	1262-1269
,	O	1269-1270
while	O	1271-1276
the	O	1277-1280
saline	O	1281-1287
solution	O	1288-1296
of	O	1297-1299
tacrine	O	1300-1307
only	O	1308-1312
in	O	1313-1315
60	O	1316-1318
%	O	1318-1319
of	O	1320-1322
animals	O	1323-1330
.	O	1330-1331

Empty	O	1332-1337
nanoparticles	O	1338-1351
provided	O	1352-1360
similar	O	1361-1368
results	O	1369-1376
to	O	1377-1379
control	O	1380-1387
(	O	1388-1389
saline	O	1389-1395
-	O	1395-1396
treated	O	1396-1403
)	O	1403-1404
group	O	1405-1410
of	O	1411-1413
animals	O	1414-1421
.	O	1421-1422

In	O	1423-1425
conclusion	O	1426-1436
,	O	1436-1437
the	O	1438-1441
evaluation	O	1442-1452
of	O	1453-1455
time	O	1456-1460
-	O	1460-1461
to	O	1461-1463
-	O	1460-1461
onset	O	1464-1469
of	O	1470-1472
symptoms	O	1473-1481
and	O	1482-1485
the	O	1486-1489
severity	O	1490-1498
of	O	1499-1501
neurodegenerative	O	1502-1519
processes	O	1520-1529
induced	O	1530-1537
by	O	1538-1540
the	O	1541-1544
tacrine	O	1545-1552
-	O	1552-1553
lithium	O	1553-1560
model	O	1561-1566
of	O	1567-1569
epilepsy	B	1570-1578
in	O	1579-1581
the	O	1582-1585
rat	O	1586-1589
,	O	1589-1590
could	O	1591-1596
be	O	1597-1599
used	O	1600-1604
to	O	1605-1607
evaluate	O	1608-1616
preliminarily	O	1617-1630
the	O	1631-1634
capability	O	1635-1645
of	O	1646-1648
a	O	1649-1650
drug	O	1651-1655
delivery	O	1656-1664
system	O	1665-1671
to	O	1672-1674
trespass	O	1675-1683
(	O	1684-1685
or	O	1685-1687
not	O	1688-1691
)	O	1691-1692
the	O	1693-1696
BBB	O	1697-1700
in	O	1701-1703
vivo	O	1704-1708
.	O	1708-1709

The	O	0-3
antiarrhythmic	O	4-18
effect	O	19-25
and	O	26-29
possible	O	30-38
ionic	O	39-44
mechanisms	O	45-55
of	O	56-58
pilocarpine	O	59-70
on	O	71-73
animal	O	74-80
models	O	81-87
.	O	87-88

This	O	89-93
study	O	94-99
was	O	100-103
designed	O	104-112
to	O	113-115
evaluate	O	116-124
the	O	125-128
effects	O	129-136
of	O	137-139
pilocarpine	O	140-151
and	O	152-155
explore	O	156-163
the	O	164-167
underlying	O	168-178
ionic	O	179-184
mechanism	O	185-194
,	O	194-195
using	O	196-201
both	O	202-206
aconitine	O	207-216
-	O	216-217
induced	O	217-224
rat	O	225-228
and	O	229-232
ouabain	O	233-240
-	O	240-241
induced	O	241-248
guinea	O	249-255
pig	O	256-259
arrhythmia	B	260-270
models	O	271-277
.	O	277-278

Confocal	O	279-287
microscopy	O	288-298
was	O	299-302
used	O	303-307
to	O	308-310
measure	O	311-318
intracellular	O	319-332
free	O	333-337
-	O	337-338
calcium	O	338-345
concentrations	O	346-360
(	O	361-362
[	O	362-363
Ca	O	363-365
(	O	361-362
2	O	366-367
+	O	367-368
)	O	368-369
]	O	369-370
(	O	361-362
i	O	371-372
)	O	368-369
)	O	368-369
in	O	375-377
isolated	O	378-386
myocytes	O	387-395
.	O	395-396

The	O	397-400
current	O	401-408
data	O	409-413
showed	O	414-420
that	O	421-425
pilocarpine	O	426-437
significantly	O	438-451
delayed	O	452-459
onset	O	460-465
of	O	466-468
arrhythmias	B	469-480
,	O	480-481
decreased	O	482-491
the	O	492-495
time	O	496-500
course	O	501-507
of	O	508-510
ventricular	B	511-522
tachycardia	I	523-534
and	I	535-538
fibrillation	I	539-551
,	O	551-552
reduced	O	553-560
arrhythmia	B	561-571
score	O	572-577
,	O	577-578
and	O	579-582
increased	O	583-592
the	O	593-596
survival	O	597-605
time	O	606-610
of	O	611-613
arrhythmic	B	614-624
rats	O	625-629
and	O	630-633
guinea	O	634-640
pigs	O	641-645
.	O	645-646

[	O	647-648
Ca	O	648-650
(	O	650-651
2	O	651-652
+	O	652-653
)	O	653-654
]	O	654-655
(	O	650-651
i	O	656-657
)	O	653-654
overload	O	659-667
induced	O	668-675
by	O	676-678
aconitine	O	679-688
or	O	689-691
ouabain	O	692-699
was	O	700-703
reduced	O	704-711
in	O	712-714
isolated	O	715-723
myocytes	O	724-732
pretreated	O	733-743
with	O	744-748
pilocarpine	O	749-760
.	O	760-761

Moreover	O	762-770
,	O	770-771
M	O	772-773
(	O	773-774
3	O	774-775
)	O	775-776
-	O	776-777
muscarinic	O	777-787
acetylcholine	O	788-801
receptor	O	802-810
(	O	811-812
mAChR	O	812-817
)	O	817-818
antagonist	O	819-829
4	O	830-831
-	O	831-832
DAMP	O	832-836
(	O	837-838
4	O	838-839
-	O	839-840
diphenylacetoxy	O	840-855
-	O	839-840
N	O	856-857
-	O	839-840
methylpiperidine	O	858-874
-	O	839-840
methiodide	O	875-885
)	O	885-886
partially	O	887-896
abolished	O	897-906
the	O	907-910
beneficial	O	911-921
effects	O	922-929
of	O	930-932
pilocarpine	O	933-944
.	O	944-945

These	O	946-951
data	O	952-956
suggest	O	957-964
that	O	965-969
pilocarpine	O	970-981
produced	O	982-990
antiarrhythmic	O	991-1005
actions	O	1006-1013
on	O	1014-1016
arrhythmic	B	1017-1027
rat	O	1028-1031
and	O	1032-1035
guinea	O	1036-1042
pig	O	1043-1046
models	O	1047-1053
induced	O	1054-1061
by	O	1062-1064
aconitine	O	1065-1074
or	O	1075-1077
ouabain	O	1078-1085
via	O	1086-1089
stimulating	O	1090-1101
the	O	1102-1105
cardiac	O	1106-1113
M	O	1114-1115
(	O	1115-1116
3	O	1116-1117
)	O	1117-1118
-	O	1118-1119
mAChR	O	1119-1124
.	O	1124-1125

The	O	1126-1129
mechanism	O	1130-1139
may	O	1140-1143
be	O	1144-1146
related	O	1147-1154
to	O	1155-1157
the	O	1158-1161
improvement	O	1162-1173
of	O	1174-1176
Ca	O	1177-1179
(	O	1179-1180
2	O	1180-1181
+	O	1181-1182
)	O	1182-1183
handling	O	1184-1192
.	O	1192-1193

Disulfiram	O	0-10
-	O	10-11
induced	O	11-18
transient	O	19-28
optic	B	29-34
and	I	35-38
peripheral	I	39-49
neuropathy	I	50-60
:	O	60-61
a	O	62-63
case	O	64-68
report	O	69-75
.	O	75-76

AIM	O	77-80
:	O	80-81
To	O	82-84
report	O	85-91
a	O	92-93
case	O	94-98
of	O	99-101
optic	B	102-107
and	I	108-111
peripheral	I	112-122
neuropathy	I	123-133
after	O	134-139
chronic	O	140-147
use	O	148-151
of	O	152-154
disulfiram	O	155-165
for	O	166-169
alcohol	B	170-177
dependence	I	178-188
management	O	189-199
.	O	199-200

MATERIALS	O	201-210
AND	O	211-214
METHODS	O	215-222
:	O	222-223
A	O	224-225
case	O	226-230
report	O	231-237
.	O	237-238

RESULTS	O	239-246
:	O	246-247
A	O	248-249
57	O	250-252
-	O	252-253
year	O	253-257
-	O	252-253
old	O	258-261
male	O	262-266
presented	O	267-276
with	O	277-281
gradual	O	282-289
loss	B	290-294
of	I	295-297
vision	I	298-304
in	O	305-307
both	O	308-312
eyes	O	313-317
with	O	318-322
intermittent	O	323-335
headaches	B	336-345
for	O	346-349
2	O	350-351
months	O	352-358
.	O	358-359

He	O	360-362
also	O	363-367
complained	O	368-378
of	O	379-381
paraesthesia	B	382-394
with	O	395-399
numbness	B	400-408
in	O	409-411
both	O	412-416
feet	O	417-421
.	O	421-422

His	O	423-426
vision	O	427-433
was	O	434-437
6	O	438-439
/	O	439-440
15	O	440-442
and	O	443-446
2	O	447-448
/	O	448-449
60	O	449-451
in	O	452-454
the	O	455-458
right	O	459-464
and	O	465-468
left	O	469-473
eyes	O	474-478
,	O	478-479
respectively	O	480-492
.	O	492-493

Fundoscopy	O	494-504
revealed	O	505-513
bilaterally	O	514-525
swollen	O	526-533
optic	O	534-539
nerve	O	540-545
heads	O	546-551
.	O	551-552

Visual	O	553-559
field	O	560-565
testing	O	566-573
confirmed	O	574-583
bilateral	O	584-593
central	O	594-601
-	O	601-602
caecal	O	602-608
scotomata	B	609-618
.	O	618-619

He	O	620-622
had	O	623-626
been	O	627-631
taking	O	632-638
disulfiram	O	639-649
for	O	650-653
alcohol	B	654-661
dependence	I	662-672
for	O	673-676
the	O	677-680
preceding	O	681-690
3	O	691-692
years	O	693-698
.	O	698-699

Disulfiram	O	700-710
discontinuation	O	711-726
lead	O	727-731
to	O	732-734
an	O	735-737
immediate	O	738-747
symptomatic	O	748-759
improvement	O	760-771
.	O	771-772

CONCLUSION	O	773-783
:	O	783-784
Physicians	O	785-795
initiating	O	796-806
long	O	807-811
-	O	811-812
term	O	812-816
disulfiram	O	817-827
therapy	O	828-835
should	O	836-842
be	O	843-845
aware	O	846-851
of	O	852-854
these	O	855-860
adverse	O	861-868
effects	O	869-876
.	O	876-877

They	O	878-882
should	O	883-889
recommend	O	890-899
annual	O	900-906
ophthalmic	O	907-917
reviews	O	918-925
with	O	926-930
visual	O	931-937
field	O	938-943
testing	O	944-951
.	O	951-952

Patients	O	953-961
should	O	962-968
be	O	969-971
reassured	O	972-981
with	O	982-986
respect	O	987-994
to	O	995-997
the	O	998-1001
reversibility	O	1002-1015
of	O	1016-1018
these	O	1019-1024
adverse	O	1025-1032
effects	O	1033-1040
.	O	1040-1041

Sustained	O	0-9
clinical	O	10-18
improvement	O	19-30
of	O	31-33
a	O	34-35
patient	O	36-43
with	O	44-48
decompensated	O	49-62
hepatitis	B	63-72
B	I	73-74
virus	O	75-80
-	O	80-81
related	O	81-88
cirrhosis	B	89-98
after	O	99-104
treatment	O	105-114
with	O	115-119
lamivudine	O	120-130
monotherapy	O	131-142
.	O	142-143

Hepatitis	B	144-153
B	I	154-155
virus	I	156-161
(	I	162-163
HBV	I	163-166
)	I	166-167
infection	I	168-177
,	O	177-178
which	O	179-184
causes	O	185-191
liver	B	192-197
cirrhosis	I	198-207
and	O	208-211
hepatocellular	B	212-226
carcinoma	I	227-236
,	O	236-237
remains	O	238-245
a	O	246-247
major	O	248-253
health	O	254-260
problem	O	261-268
in	O	269-271
Asian	O	272-277
countries	O	278-287
.	O	287-288

Recent	O	289-295
development	O	296-307
of	O	308-310
vaccine	O	311-318
for	O	319-322
prevention	O	323-333
is	O	334-336
reported	O	337-345
to	O	346-348
be	O	349-351
successful	O	352-362
in	O	363-365
reducing	O	366-374
the	O	375-378
size	O	379-383
of	O	384-386
chronically	O	387-398
infected	O	399-407
carriers	O	408-416
,	O	416-417
although	O	418-426
the	O	427-430
standard	O	431-439
medical	O	440-447
therapies	O	448-457
have	O	458-462
not	O	463-466
been	O	467-471
established	O	472-483
up	O	484-486
to	O	487-489
now	O	490-493
.	O	493-494

In	O	495-497
this	O	498-502
report	O	503-509
,	O	509-510
we	O	511-513
encountered	O	514-525
a	O	526-527
patient	O	528-535
with	O	536-540
decompensated	O	541-554
HBV	O	555-558
-	O	558-559
related	O	559-566
cirrhosis	B	567-576
who	O	577-580
exhibited	O	581-590
the	O	591-594
dramatic	O	595-603
improvements	O	604-616
after	O	617-622
antiviral	O	623-632
therapy	O	633-640
.	O	640-641

The	O	642-645
patient	O	646-653
was	O	654-657
a	O	658-659
50	O	660-662
-	O	662-663
year	O	663-667
-	O	662-663
old	O	668-671
woman	O	672-677
.	O	677-678

Previous	O	679-687
conventional	O	688-700
medical	O	701-708
treatments	O	709-719
were	O	720-724
not	O	725-728
effective	O	729-738
for	O	739-742
this	O	743-747
patient	O	748-755
,	O	755-756
thus	O	757-761
this	O	762-766
patient	O	767-774
had	O	775-778
been	O	779-783
referred	O	784-792
to	O	793-795
our	O	796-799
hospital	O	800-808
.	O	808-809

However	O	810-817
,	O	817-818
the	O	819-822
administration	O	823-837
of	O	838-840
lamivudine	O	841-851
,	O	851-852
a	O	853-854
reverse	O	855-862
transcriptase	O	863-876
inhibitor	O	877-886
,	O	886-887
for	O	888-891
23	O	892-894
months	O	895-901
dramatically	O	902-914
improved	O	915-923
her	O	924-927
liver	O	928-933
severity	O	934-942
.	O	942-943

During	O	944-950
this	O	951-955
period	O	956-962
,	O	962-963
no	O	964-966
drug	O	967-971
resistant	O	972-981
mutant	O	982-988
HBV	O	989-992
emerged	O	993-1000
,	O	1000-1001
and	O	1002-1005
the	O	1006-1009
serum	O	1010-1015
HBV	O	1016-1019
-	O	1019-1020
DNA	O	1020-1023
level	O	1024-1029
was	O	1030-1033
continuously	O	1034-1046
suppressed	O	1047-1057
.	O	1057-1058

These	O	1059-1064
virological	O	1065-1076
responses	O	1077-1086
were	O	1087-1091
also	O	1092-1096
maintained	O	1097-1107
even	O	1108-1112
after	O	1113-1118
the	O	1119-1122
antiviral	O	1123-1132
therapy	O	1133-1140
was	O	1141-1144
discontinued	O	1145-1157
.	O	1157-1158

Moreover	O	1159-1167
,	O	1167-1168
both	O	1169-1173
hepatitis	O	1174-1183
B	O	1184-1185
surface	O	1186-1193
antigen	O	1194-1201
and	O	1202-1205
e	O	1206-1207
antigen	O	1208-1215
were	O	1216-1220
observed	O	1221-1229
to	O	1230-1232
have	O	1233-1237
disappeared	O	1238-1249
in	O	1250-1252
this	O	1253-1257
patient	O	1258-1265
.	O	1265-1266

The	O	1267-1270
administration	O	1271-1285
of	O	1286-1288
lamivudine	O	1289-1299
to	O	1300-1302
patients	O	1303-1311
with	O	1312-1316
HBV	O	1317-1320
-	O	1320-1321
related	O	1321-1328
cirrhosis	B	1329-1338
,	O	1338-1339
like	O	1340-1344
our	O	1345-1348
present	O	1349-1356
case	O	1357-1361
,	O	1361-1362
should	O	1363-1369
be	O	1370-1372
considered	O	1373-1383
as	O	1384-1386
an	O	1387-1389
initial	O	1390-1397
medical	O	1398-1405
therapeutic	O	1406-1417
option	O	1418-1424
,	O	1424-1425
especially	O	1426-1436
in	O	1437-1439
countries	O	1440-1449
where	O	1450-1455
liver	O	1456-1461
transplantation	O	1462-1477
is	O	1478-1480
not	O	1481-1484
reliably	O	1485-1493
available	O	1494-1503
.	O	1503-1504

Dual	O	0-4
effects	O	5-12
of	O	13-15
melatonin	O	16-25
on	O	26-28
barbiturate	O	29-40
-	O	40-41
induced	O	41-48
narcosis	B	49-57
in	O	58-60
rats	O	61-65
.	O	65-66

Melatonin	O	67-76
affects	O	77-84
the	O	85-88
circadian	O	89-98
sleep	O	99-104
/	O	104-105
wake	O	105-109
cycle	O	110-115
,	O	115-116
but	O	117-120
it	O	121-123
is	O	124-126
not	O	127-130
clear	O	131-136
whether	O	137-144
it	O	145-147
may	O	148-151
influence	O	152-161
drug	O	162-166
-	O	166-167
induced	O	167-174
narcosis	B	175-183
.	O	183-184

Sodium	O	185-191
thiopenthal	O	192-203
was	O	204-207
administered	O	208-220
intraperitoneally	O	221-238
into	O	239-243
male	O	244-248
rats	O	249-253
pre	O	254-257
-	O	257-258
treated	O	258-265
with	O	266-270
melatonin	O	271-280
(	O	281-282
0	O	282-283
.	O	283-284
05	O	284-286
,	O	286-287
0	O	288-289
.	O	289-290
5	O	290-291
,	O	291-292
5	O	293-294
and	O	295-298
50	O	299-301
mg	O	302-304
/	O	304-305
kg	O	305-307
)	O	307-308
.	O	308-309

Melatonin	O	310-319
pre	O	320-323
-	O	323-324
treatment	O	324-333
affected	O	334-342
in	O	343-345
a	O	346-347
dual	O	348-352
manner	O	353-359
barbiturate	O	360-371
narcosis	B	372-380
,	O	380-381
however	O	382-389
,	O	389-390
no	O	391-393
dose	O	394-398
-	O	398-399
effect	O	399-405
correlation	O	406-417
was	O	418-421
found	O	422-427
.	O	427-428

In	O	429-431
particular	O	432-442
,	O	442-443
low	O	444-447
doses	O	448-453
reduced	O	454-461
the	O	462-465
latency	O	466-473
to	O	474-476
and	O	477-480
prolonged	O	481-490
the	O	491-494
duration	O	495-503
of	O	504-506
barbiturate	O	507-518
narcosis	B	519-527
.	O	527-528

In	O	529-531
contrast	O	532-540
,	O	540-541
the	O	542-545
highest	O	546-553
dose	O	554-558
of	O	559-561
melatonin	O	562-571
(	O	572-573
50	O	573-575
mg	O	576-578
/	O	578-579
kg	O	579-581
)	O	581-582
caused	O	583-589
a	O	590-591
paradoxical	O	592-603
increase	O	604-612
in	O	613-615
the	O	616-619
latency	O	620-627
and	O	628-631
produced	O	632-640
a	O	641-642
sustained	O	643-652
reduction	O	653-662
of	O	663-665
the	O	666-669
duration	O	670-678
of	O	679-681
narcosis	B	682-690
,	O	690-691
and	O	692-695
a	O	696-697
reduction	O	698-707
in	O	708-710
mortality	O	711-720
rate	O	721-725
.	O	725-726

Melatonin	O	727-736
0	O	737-738
.	O	738-739
5	O	739-740
and	O	741-744
5	O	745-746
mg	O	747-749
/	O	749-750
kg	O	750-752
influenced	O	753-763
the	O	764-767
duration	O	768-776
but	O	777-780
not	O	781-784
the	O	785-788
latency	O	789-796
of	O	797-799
ketamine	O	800-808
-	O	808-809
or	O	810-812
diazepam	O	813-821
-	O	821-822
induced	O	822-829
narcosis	B	830-838
.	O	838-839

Thus	O	840-844
,	O	844-845
the	O	846-849
dual	O	850-854
action	O	855-861
of	O	862-864
melatonin	O	865-874
on	O	875-877
pharmacological	O	878-893
narcosis	B	894-902
seems	O	903-908
to	O	909-911
be	O	912-914
specific	O	915-923
for	O	924-927
the	O	928-931
barbiturate	O	932-943
mechanism	O	944-953
of	O	954-956
action	O	957-963
.	O	963-964

Effects	O	0-7
of	O	8-10
NIK	O	11-14
-	O	14-15
247	O	15-18
on	O	19-21
cholinesterase	O	22-36
and	O	37-40
scopolamine	O	41-52
-	O	52-53
induced	O	53-60
amnesia	B	61-68
.	O	68-69

The	O	70-73
effects	O	74-81
of	O	82-84
NIK	O	85-88
-	O	88-89
247	O	89-92
on	O	93-95
cholinesterase	O	96-110
,	O	110-111
scopolamine	O	112-123
-	O	123-124
induced	O	124-131
amnesia	B	132-139
and	O	140-143
spontaneous	O	144-155
movement	O	156-164
were	O	165-169
examined	O	170-178
and	O	179-182
compared	O	183-191
with	O	192-196
those	O	197-202
of	O	203-205
the	O	206-209
well	O	210-214
-	O	214-215
known	O	215-220
cholinesterase	O	221-235
inhibitors	O	236-246
tacrine	O	247-254
and	O	255-258
E	O	259-260
-	O	260-261
2020	O	261-265
.	O	265-266

NIK	O	267-270
-	O	270-271
247	O	271-274
,	O	274-275
tacrine	O	276-283
and	O	284-287
E	O	288-289
-	O	289-290
2020	O	290-294
all	O	295-298
strongly	O	299-307
inhibited	O	308-317
acetylcholinesterase	O	318-338
(	O	339-340
AChE	O	340-344
)	O	344-345
in	O	346-348
human	O	349-354
red	O	355-358
blood	O	359-364
cells	O	365-370
(	O	371-372
IC50s	O	372-377
=	O	378-379
1	O	380-381
.	O	381-382
0	O	382-383
x	O	384-385
10	O	386-388
(	O	388-389
-	O	389-390
6	O	390-391
)	O	391-392
,	O	392-393
2	O	394-395
.	O	395-396
9	O	396-397
x	O	398-399
10	O	400-402
(	O	402-403
-	O	403-404
7	O	404-405
)	O	405-406
and	O	407-410
3	O	411-412
.	O	412-413
7	O	413-414
x	O	415-416
10	O	417-419
(	O	419-420
-	O	420-421
8	O	421-422
)	O	422-423
M	O	424-425
,	O	425-426
respectively	O	427-439
)	O	439-440
.	O	440-441

In	O	442-444
addition	O	445-453
,	O	453-454
NIK	O	455-458
-	O	458-459
247	O	459-462
and	O	463-466
tacrine	O	467-474
,	O	474-475
but	O	476-479
not	O	480-483
E	O	484-485
-	O	485-486
2020	O	486-490
,	O	490-491
strongly	O	492-500
inhibited	O	501-510
butyrylcholinestrase	O	511-531
(	O	532-533
BuChE	O	533-538
)	O	538-539
in	O	540-542
human	O	543-548
serum	O	549-554
.	O	554-555

All	O	556-559
three	O	560-565
drugs	O	566-571
produced	O	572-580
mixed	O	581-586
inhibition	O	587-597
of	O	598-600
AChE	O	601-605
activity	O	606-614
.	O	614-615

Moreover	O	616-624
,	O	624-625
the	O	626-629
inhibitory	O	630-640
effect	O	641-647
of	O	648-650
NIK	O	651-654
-	O	654-655
247	O	655-658
on	O	659-661
AChE	O	662-666
was	O	667-670
reversible	O	671-681
.	O	681-682

All	O	683-686
compounds	O	687-696
at	O	697-699
0	O	700-701
.	O	701-702
1	O	702-703
-	O	703-704
1	O	702-703
mg	O	706-708
/	O	708-709
kg	O	709-711
p	O	712-713
.	O	713-714
o	O	714-715
.	O	713-714
significantly	O	717-730
improved	O	731-739
the	O	740-743
amnesia	B	744-751
induced	O	752-759
by	O	760-762
scopolamine	O	763-774
(	O	775-776
0	O	776-777
.	O	777-778
5	O	778-779
mg	O	780-782
/	O	782-783
kg	O	783-785
s	O	786-787
.	O	787-788
c	O	788-789
.	O	787-788
)	O	790-791
in	O	792-794
rats	O	795-799
performing	O	800-810
a	O	811-812
passive	O	813-820
avoidance	O	821-830
task	O	831-835
.	O	835-836

The	O	837-840
three	O	841-846
compounds	O	847-856
at	O	857-859
1	O	860-861
and	O	862-865
3	O	866-867
mg	O	868-870
/	O	870-871
kg	O	871-873
p	O	874-875
.	O	875-876
o	O	876-877
.	O	875-876
did	O	879-882
not	O	883-886
significantly	O	887-900
decrease	O	901-909
spontaneous	O	910-921
movement	O	922-930
by	O	931-933
rats	O	934-938
.	O	938-939

These	O	940-945
findings	O	946-954
suggest	O	955-962
that	O	963-967
NIK	O	968-971
-	O	971-972
247	O	972-975
at	O	976-978
a	O	979-980
low	O	981-984
dose	O	985-989
(	O	990-991
0	O	991-992
.	O	992-993
1	O	993-994
-	O	994-995
1	O	993-994
mg	O	997-999
/	O	999-1000
kg	O	1000-1002
p	O	1003-1004
.	O	1004-1005
o	O	1005-1006
.	O	1004-1005
)	O	1007-1008
improves	O	1009-1017
scopolamine	O	1018-1029
-	O	1029-1030
induced	O	1030-1037
amnesia	B	1038-1045
but	O	1046-1049
does	O	1050-1054
not	O	1055-1058
affect	O	1059-1065
spontaneous	O	1066-1077
movement	O	1078-1086
.	O	1086-1087

The	O	1088-1091
findings	O	1092-1100
suggest	O	1101-1108
that	O	1109-1113
NIK	O	1114-1117
-	O	1117-1118
247	O	1118-1121
may	O	1122-1125
be	O	1126-1128
a	O	1129-1130
useful	O	1131-1137
drug	O	1138-1142
for	O	1143-1146
the	O	1147-1150
treatment	O	1151-1160
of	O	1161-1163
Alzheimer	B	1164-1173
'	I	1173-1174
s	I	1174-1175
disease	I	1176-1183
.	O	1183-1184

Nightmares	O	0-10
and	O	11-14
hallucinations	B	15-29
after	O	30-35
long	O	36-40
-	O	40-41
term	O	41-45
intake	O	46-52
of	O	53-55
tramadol	O	56-64
combined	O	65-73
with	O	74-78
antidepressants	O	79-94
.	O	94-95

Tramadol	O	96-104
is	O	105-107
a	O	108-109
weak	O	110-114
opioid	O	115-121
with	O	122-126
effects	O	127-134
on	O	135-137
adrenergic	O	138-148
and	O	149-152
serotonergic	O	153-165
neurotransmission	O	166-183
that	O	184-188
is	O	189-191
used	O	192-196
to	O	197-199
treat	O	200-205
cancer	B	206-212
pain	B	213-217
and	O	218-221
chronic	O	222-229
non	O	230-233
malignant	O	234-243
pain	B	244-248
.	O	248-249

This	O	250-254
drug	O	255-259
was	O	260-263
initiated	O	264-273
in	O	274-276
association	O	277-288
with	O	289-293
paroxetine	O	294-304
and	O	305-308
dosulepine	O	309-319
hydrochloride	O	320-333
in	O	334-336
a	O	337-338
tetraparetic	B	339-351
patient	O	352-359
with	O	360-364
chronic	B	365-372
pain	I	373-377
.	O	377-378

Fifty	O	379-384
-	O	384-385
six	O	385-388
days	O	389-393
after	O	394-399
initiation	O	400-410
of	O	411-413
the	O	414-417
treatment	O	418-427
the	O	428-431
patient	O	432-439
presented	O	440-449
hallucinations	B	450-464
that	O	465-469
only	O	470-474
stopped	O	475-482
after	O	483-488
the	O	489-492
withdrawal	O	493-503
of	O	504-506
psycho	O	507-513
-	O	513-514
active	O	514-520
drugs	O	521-526
and	O	527-530
tramadol	O	531-539
.	O	539-540

The	O	541-544
case	O	545-549
report	O	550-556
questions	O	557-566
the	O	567-570
long	O	571-575
term	O	576-580
use	O	581-584
of	O	585-587
pain	B	588-592
killers	O	593-600
combined	O	601-609
with	O	610-614
psycho	O	615-621
-	O	621-622
active	O	622-628
drugs	O	629-634
in	O	635-637
chronic	O	638-645
non	O	646-649
malignant	O	650-659
pain	B	660-664
,	O	664-665
especially	O	666-676
if	O	677-679
pain	B	680-684
is	O	685-687
under	O	688-693
control	O	694-701
.	O	701-702

Apparent	O	0-8
cure	O	9-13
of	O	14-16
rheumatoid	B	17-27
arthritis	I	28-37
by	O	38-40
bone	O	41-45
marrow	O	46-52
transplantation	O	53-68
.	O	68-69

We	O	70-72
describe	O	73-81
the	O	82-85
induction	O	86-95
of	O	96-98
sustained	O	99-108
remissions	O	109-119
and	O	120-123
possible	O	124-132
cure	O	133-137
of	O	138-140
severe	O	141-147
erosive	O	148-155
rheumatoid	B	156-166
arthritis	I	167-176
(	O	177-178
RA	B	178-180
)	O	180-181
by	O	182-184
bone	O	185-189
marrow	O	190-196
transplantation	O	197-212
(	O	213-214
BMT	O	214-217
)	O	217-218
in	O	219-221
2	O	222-223
patients	O	224-232
.	O	232-233

BMT	O	234-237
was	O	238-241
used	O	242-246
to	O	247-249
treat	O	250-255
severe	O	256-262
aplastic	B	263-271
anemia	I	272-278
which	O	279-284
was	O	285-288
caused	O	289-295
by	O	296-298
gold	O	299-303
in	O	304-306
one	O	307-310
case	O	311-315
and	O	316-319
D	O	320-321
-	O	321-322
penicillamine	O	322-335
in	O	336-338
the	O	339-342
other	O	343-348
.	O	348-349

In	O	350-352
the	O	353-356
8	O	357-358
and	O	359-362
6	O	363-364
years	O	365-370
since	O	371-376
the	O	377-380
transplants	O	381-392
(	O	393-394
representing	O	394-406
8	O	407-408
and	O	409-412
4	O	413-414
years	O	415-420
since	O	421-426
cessation	O	427-436
of	O	437-439
all	O	440-443
immunosuppressive	O	444-461
therapy	O	462-469
,	O	469-470
respectively	O	471-483
)	O	483-484
,	O	484-485
the	O	486-489
RA	B	490-492
in	O	493-495
each	O	496-500
case	O	501-505
has	O	506-509
been	O	510-514
completely	O	515-525
quiescent	O	526-535
.	O	535-536

Although	O	537-545
short	O	546-551
term	O	552-556
remission	O	557-566
of	O	567-569
severe	O	570-576
RA	B	577-579
following	O	580-589
BMT	O	590-593
has	O	594-597
been	O	598-602
reported	O	603-611
,	O	611-612
these	O	613-618
are	O	619-622
the	O	623-626
first	O	627-632
cases	O	633-638
for	O	639-642
which	O	643-648
prolonged	O	649-658
followup	O	659-667
has	O	668-671
been	O	672-676
available	O	677-686
.	O	686-687

This	O	688-692
experience	O	693-703
raises	O	704-710
the	O	711-714
question	O	715-723
of	O	724-726
the	O	727-730
role	O	731-735
of	O	736-738
BMT	O	739-742
itself	O	743-749
as	O	750-752
a	O	753-754
therapeutic	O	755-766
option	O	767-773
for	O	774-777
patients	O	778-786
with	O	787-791
uncontrolled	O	792-804
destructive	O	805-816
synovitis	B	817-826
.	O	826-827

Urinary	O	0-7
enzymes	O	8-15
and	O	16-19
protein	O	20-27
patterns	O	28-36
as	O	37-39
indicators	O	40-50
of	O	51-53
injury	B	54-60
to	I	61-63
different	I	64-73
regions	I	74-81
of	I	82-84
the	I	85-88
kidney	I	89-95
.	O	95-96

Acute	B	97-102
experimental	I	103-115
models	I	116-122
of	I	123-125
renal	I	126-131
damage	I	132-138
to	O	139-141
the	O	142-145
proximal	O	146-154
tubular	O	155-162
,	O	162-163
glomerular	O	164-174
,	O	174-175
and	O	176-179
papillary	O	180-189
regions	O	190-197
of	O	198-200
the	O	201-204
rat	O	205-208
were	O	209-213
produced	O	214-222
by	O	223-225
administration	O	226-240
of	O	241-243
hexachloro	O	244-254
-	O	254-255
1	O	255-256
:	O	256-257
3	O	257-258
-	O	254-255
butadiene	O	259-268
(	O	269-270
HCBD	O	270-274
)	O	274-275
,	O	275-276
puromycin	O	277-286
aminonucleoside	O	287-302
(	O	303-304
PAN	O	304-307
)	O	307-308
,	O	308-309
and	O	310-313
2	O	314-315
-	O	315-316
bromoethylamine	O	316-331
(	O	332-333
BEA	O	333-336
)	O	336-337
,	O	337-338
respectively	O	339-351
.	O	351-352

Several	O	353-360
routine	O	361-368
indicators	O	369-379
of	O	380-382
nephrotoxicity	B	383-397
,	O	397-398
the	O	399-402
enzymes	O	403-410
alkaline	O	411-419
phosphatase	O	420-431
and	O	432-435
N	O	436-437
-	O	437-438
acetyl	O	438-444
-	O	437-438
beta	O	445-449
-	O	437-438
glucosaminidase	O	450-465
,	O	465-466
and	O	467-470
the	O	471-474
molecular	O	475-484
weight	O	485-491
of	O	492-494
protein	B	495-502
excretion	I	503-512
were	O	513-517
determined	O	518-528
on	O	529-531
urine	O	532-537
samples	O	538-545
.	O	545-546

Tubular	O	547-554
damage	O	555-561
produced	O	562-570
by	O	571-573
HCBD	O	574-578
or	O	579-581
BEA	O	582-585
was	O	586-589
discriminated	O	590-603
both	O	604-608
quantitatively	O	609-623
and	O	624-627
qualitatively	O	628-641
from	O	642-646
glomerular	B	647-657
damage	I	658-664
produced	O	665-673
by	O	674-676
PAN	O	677-680
.	O	680-681

The	O	682-685
latter	O	686-692
was	O	693-696
characterized	O	697-710
by	O	711-713
a	O	714-715
pronounced	O	716-726
increase	O	727-735
in	O	736-738
protein	B	739-746
excretion	I	747-756
,	O	756-757
especially	O	758-768
proteins	O	769-777
with	O	778-782
molecular	O	783-792
weight	O	793-799
greater	O	800-807
than	O	808-812
40	O	813-815
,	O	815-816
000	O	816-819
Da	O	820-822
.	O	822-823

In	O	824-826
contrast	O	827-835
,	O	835-836
protein	B	837-844
excretion	I	845-854
in	O	855-857
tubular	O	858-865
damage	O	866-872
was	O	873-876
raised	O	877-883
only	O	884-888
slightly	O	889-897
and	O	898-901
characterized	O	902-915
by	O	916-918
excretion	B	919-928
of	I	929-931
proteins	I	932-940
of	O	941-943
a	O	944-945
wide	O	946-950
range	O	951-956
of	O	957-959
molecular	O	960-969
weights	O	970-977
.	O	977-978

Proximal	O	979-987
tubular	O	988-995
damage	O	996-1002
caused	O	1003-1009
by	O	1010-1012
HCBD	O	1013-1017
and	O	1018-1021
papillary	O	1022-1031
damage	O	1032-1038
caused	O	1039-1045
by	O	1046-1048
BEA	O	1049-1052
were	O	1053-1057
distinguished	O	1058-1071
both	O	1072-1076
by	O	1077-1079
conventional	O	1080-1092
urinalysis	O	1093-1103
(	O	1104-1105
volume	O	1105-1111
and	O	1112-1115
specific	O	1116-1124
gravity	O	1125-1132
)	O	1132-1133
and	O	1134-1137
by	O	1138-1140
measurement	O	1141-1152
of	O	1153-1155
the	O	1156-1159
two	O	1160-1163
urinary	O	1164-1171
enzymes	O	1172-1179
.	O	1179-1180

Alkaline	O	1181-1189
phosphatase	O	1190-1201
and	O	1202-1205
glucose	O	1206-1213
were	O	1214-1218
markedly	O	1219-1227
and	O	1228-1231
transiently	O	1232-1243
elevated	O	1244-1252
in	O	1253-1255
proximal	O	1256-1264
tubular	O	1265-1272
damage	O	1273-1279
and	O	1280-1283
N	O	1284-1285
-	O	1285-1286
acetyl	O	1286-1292
-	O	1285-1286
beta	O	1293-1297
-	O	1285-1286
glucosaminidase	O	1298-1313
showed	O	1314-1320
a	O	1321-1322
sustained	O	1323-1332
elevation	O	1333-1342
in	O	1343-1345
papillary	O	1346-1355
damage	O	1356-1362
.	O	1362-1363

It	O	1364-1366
is	O	1367-1369
concluded	O	1370-1379
that	O	1380-1384
both	O	1385-1389
selective	O	1390-1399
urinary	O	1400-1407
enzymes	O	1408-1415
and	O	1416-1419
the	O	1420-1423
molecular	O	1424-1433
weight	O	1434-1440
pattern	O	1441-1448
of	O	1449-1451
urinary	O	1452-1459
proteins	O	1460-1468
can	O	1469-1472
be	O	1473-1475
used	O	1476-1480
to	O	1481-1483
provide	O	1484-1491
diagnostic	O	1492-1502
information	O	1503-1514
about	O	1515-1520
the	O	1521-1524
possible	O	1525-1533
site	O	1534-1538
of	O	1539-1541
renal	B	1542-1547
damage	I	1548-1554
.	O	1554-1555

Neuromuscular	B	0-13
blockade	I	14-22
with	O	23-27
magnesium	O	28-37
sulfate	O	38-45
and	O	46-49
nifedipine	O	50-60
.	O	60-61

A	O	62-63
patient	O	64-71
who	O	72-75
received	O	76-84
tocolysis	O	85-94
with	O	95-99
nifedipine	O	100-110
developed	O	111-120
neuromuscular	B	121-134
blockade	I	135-143
after	O	144-149
500	O	150-153
mg	O	154-156
of	O	157-159
magnesium	O	160-169
sulfate	O	170-177
was	O	178-181
administered	O	182-194
.	O	194-195

This	O	196-200
reaction	O	201-209
demonstrates	O	210-222
that	O	223-227
nifedipine	O	228-238
can	O	239-242
seriously	O	243-252
potentiate	O	253-263
the	O	264-267
toxicity	B	268-276
of	O	277-279
magnesium	O	280-289
.	O	289-290

Caution	O	291-298
should	O	299-305
be	O	306-308
exercised	O	309-318
when	O	319-323
these	O	324-329
two	O	330-333
tocolytics	O	334-344
are	O	345-348
combined	O	349-357
.	O	357-358

Ifosfamide	O	0-10
continuous	O	11-21
infusion	O	22-30
without	O	31-38
mesna	O	39-44
.	O	44-45

A	O	46-47
phase	O	48-53
I	O	54-55
trial	O	56-61
of	O	62-64
a	O	65-66
14	O	67-69
-	O	69-70
day	O	70-73
cycle	O	74-79
.	O	79-80

Twenty	O	81-87
patients	O	88-96
received	O	97-105
27	O	106-108
courses	O	109-116
of	O	117-119
ifosfamide	O	120-130
administered	O	131-143
as	O	144-146
a	O	147-148
24	O	149-151
-	O	151-152
hour	O	152-156
continuous	O	157-167
infusion	O	168-176
for	O	177-180
14	O	181-183
days	O	184-188
without	O	189-196
Mesna	O	197-202
.	O	202-203

The	O	204-207
goal	O	208-212
of	O	213-215
the	O	216-219
study	O	220-225
was	O	226-229
to	O	230-232
deliver	O	233-240
a	O	241-242
dose	O	243-247
rate	O	248-252
and	O	253-256
total	O	257-262
cumulative	O	263-273
dose	O	274-278
of	O	279-281
ifosfamide	O	282-292
that	O	293-297
would	O	298-303
be	O	304-306
comparable	O	307-317
to	O	318-320
standard	O	321-329
bolus	O	330-335
or	O	336-338
short	O	339-344
-	O	344-345
term	O	345-349
infusions	O	350-359
administered	O	360-372
with	O	373-377
Mesna	O	378-383
.	O	383-384

Dose	O	385-389
escalations	O	390-401
proceeded	O	402-411
from	O	412-416
200	O	417-420
to	O	421-423
300	O	424-427
,	O	427-428
400	O	429-432
,	O	432-433
450	O	434-437
,	O	437-438
500	O	439-442
,	O	442-443
and	O	444-447
550	O	448-451
mg	O	452-454
/	O	454-455
m2	O	455-457
/	O	454-455
d	O	458-459
.	O	459-460

Four	O	461-465
patients	O	466-474
developed	O	475-484
transient	O	485-494
microscopic	O	495-506
hematuria	B	507-516
at	O	517-519
400	O	520-523
,	O	523-524
450	O	525-528
,	O	528-529
and	O	530-533
500	O	534-537
mg	O	538-540
/	O	540-541
m2	O	541-543
/	O	540-541
d	O	544-545
.	O	545-546

There	O	547-552
were	O	553-557
no	O	558-560
instances	O	561-570
of	O	571-573
macroscopic	O	574-585
hematuria	B	586-595
.	O	595-596

At	O	597-599
550	O	600-603
mg	O	604-606
/	O	606-607
m2	O	607-609
/	O	606-607
d	O	610-611
,	O	611-612
three	O	613-618
patients	O	619-627
experienced	O	628-639
nonurologic	O	640-651
toxicity	B	652-660
;	O	660-661
confusion	B	662-671
(	O	672-673
1	O	673-674
)	O	674-675
,	O	675-676
nausea	B	677-683
(	O	684-685
1	O	685-686
)	O	686-687
,	O	687-688
and	O	689-692
Grade	O	693-698
2	O	699-700
leukopenia	B	701-711
(	O	712-713
1	O	713-714
)	O	714-715
.	O	715-716

The	O	717-720
recommended	O	721-732
dose	O	733-737
of	O	738-740
500	O	741-744
mg	O	745-747
/	O	747-748
m2	O	748-750
/	O	747-748
d	O	751-752
delivers	O	753-761
a	O	762-763
total	O	764-769
dose	O	770-774
of	O	775-777
7	O	778-779
g	O	780-781
/	O	781-782
m2	O	782-784
per	O	785-788
cycle	O	789-794
,	O	794-795
which	O	796-801
is	O	802-804
comparable	O	805-815
to	O	816-818
that	O	819-823
delivered	O	824-833
in	O	834-836
clinical	O	837-845
practice	O	846-854
for	O	855-858
bolus	O	859-864
or	O	865-867
short	O	868-873
-	O	873-874
term	O	874-878
infusion	O	879-887
.	O	887-888

Because	O	889-896
few	O	897-900
patients	O	901-909
received	O	910-918
multiple	O	919-927
courses	O	928-935
over	O	936-940
time	O	941-945
,	O	945-946
the	O	947-950
cumulative	O	951-961
effects	O	962-969
are	O	970-973
indeterminate	O	974-987
in	O	988-990
the	O	991-994
present	O	995-1002
trial	O	1003-1008
.	O	1008-1009

The	O	1010-1013
frequency	O	1014-1023
and	O	1024-1027
predictability	O	1028-1042
of	O	1043-1045
hematuria	B	1046-1055
are	O	1056-1059
not	O	1060-1063
precise	O	1064-1071
,	O	1071-1072
and	O	1073-1076
at	O	1077-1079
least	O	1080-1085
daily	O	1086-1091
monitoring	O	1092-1102
by	O	1103-1105
urine	O	1106-1111
Hematest	O	1112-1120
is	O	1121-1123
essential	O	1124-1133
,	O	1133-1134
adding	O	1135-1141
Mesna	O	1142-1147
to	O	1148-1150
the	O	1151-1154
infusate	O	1155-1163
in	O	1164-1166
patients	O	1167-1175
with	O	1176-1180
persistent	O	1181-1191
hematuria	B	1192-1201
.	O	1201-1202

The	O	1203-1206
protracted	O	1207-1217
infusion	O	1218-1226
schedule	O	1227-1235
for	O	1236-1239
ifosfamide	O	1240-1250
permits	O	1251-1258
convenient	O	1259-1269
outpatient	O	1270-1280
administration	O	1281-1295
without	O	1296-1303
Mesna	O	1304-1309
and	O	1310-1313
reduces	O	1314-1321
the	O	1322-1325
drug	O	1326-1330
cost	O	1331-1335
of	O	1336-1338
clinical	O	1339-1347
usage	O	1348-1353
of	O	1354-1356
this	O	1357-1361
agent	O	1362-1367
by	O	1368-1370
up	O	1371-1373
to	O	1374-1376
890	O	1378-1381
per	O	1382-1385
cycle	O	1386-1391
.	O	1391-1392

Clinical	O	1393-1401
activity	O	1402-1410
was	O	1411-1414
demonstrated	O	1415-1427
in	O	1428-1430
a	O	1431-1432
single	O	1433-1439
patient	O	1440-1447
,	O	1447-1448
but	O	1449-1452
a	O	1453-1454
comparative	O	1455-1466
trial	O	1467-1472
of	O	1473-1475
standard	O	1476-1484
bolus	O	1485-1490
schedules	O	1491-1500
with	O	1501-1505
the	O	1506-1509
protracted	O	1510-1520
infusion	O	1521-1529
schedule	O	1530-1538
will	O	1539-1543
be	O	1544-1546
necessary	O	1547-1556
to	O	1557-1559
determine	O	1560-1569
if	O	1570-1572
the	O	1573-1576
clinical	O	1577-1585
effectiveness	O	1586-1599
of	O	1600-1602
the	O	1603-1606
drug	O	1607-1611
is	O	1612-1614
maintained	O	1615-1625
.	O	1625-1626

Myocardial	B	0-10
infarction	I	11-21
in	O	22-24
pregnancy	O	25-34
associated	O	35-45
with	O	46-50
clomiphene	O	51-61
citrate	O	62-69
for	O	70-73
ovulation	O	74-83
induction	O	84-93
:	O	93-94
a	O	95-96
case	O	97-101
report	O	102-108
.	O	108-109

BACKGROUND	O	110-120
:	O	120-121
Clomiphene	O	122-132
citrate	O	133-140
(	O	141-142
CC	O	142-144
)	O	144-145
is	O	146-148
commonly	O	149-157
prescribed	O	158-168
for	O	169-172
ovulation	O	173-182
induction	O	183-192
.	O	192-193

It	O	194-196
is	O	197-199
considered	O	200-210
safe	O	211-215
,	O	215-216
with	O	217-221
minimal	O	222-229
side	O	230-234
effects	O	235-242
.	O	242-243

Thromboembolism	B	244-259
is	O	260-262
a	O	263-264
rare	O	265-269
but	O	270-273
life	O	274-278
-	O	278-279
threatening	O	279-290
complication	O	291-303
that	O	304-308
has	O	309-312
been	O	313-317
reported	O	318-326
after	O	327-332
ovulation	O	333-342
induction	O	343-352
with	O	353-357
CC	O	358-360
.	O	360-361

Spontaneous	O	362-373
coronary	B	374-382
thrombosis	I	383-393
or	O	394-396
thromboembolism	B	397-412
with	O	413-417
subsequent	O	418-428
clot	O	429-433
lysis	O	434-439
has	O	440-443
been	O	444-448
suggested	O	449-458
as	O	459-461
one	O	462-465
of	O	466-468
the	O	469-472
most	O	473-477
common	O	478-484
causes	O	485-491
of	O	492-494
myocardial	B	495-505
infarction	I	506-516
(	O	517-518
MI	B	518-520
)	O	520-521
during	O	522-528
pregnancy	O	529-538
,	O	538-539
with	O	540-544
a	O	545-546
subsequently	O	547-559
normal	O	560-566
coronary	O	567-575
angiogram	O	576-585
.	O	585-586

CASE	O	587-591
:	O	591-592
A	O	593-594
33	O	595-597
-	O	597-598
year	O	598-602
-	O	597-598
old	O	603-606
woman	O	607-612
with	O	613-617
a	O	618-619
5	O	620-621
-	O	621-622
week	O	622-626
gestation	O	627-636
had	O	637-640
recently	O	641-649
received	O	650-658
CC	O	659-661
for	O	662-665
ovulation	O	666-675
induction	O	676-685
and	O	686-689
presented	O	690-699
with	O	700-704
chest	B	705-710
pain	I	711-715
.	O	715-716

An	O	717-719
electrocardiogram	O	720-737
showed	O	738-744
a	O	745-746
lateral	O	747-754
and	O	755-758
anterior	O	759-767
wall	O	768-772
myocardial	B	773-783
infarction	I	784-794
.	O	794-795

Cardiac	O	796-803
enzymes	O	804-811
showed	O	812-818
a	O	819-820
peak	O	821-825
rise	O	826-830
in	O	831-833
troponin	O	834-842
I	O	843-844
to	O	845-847
9	O	848-849
.	O	849-850
10	O	850-852
ng	O	853-855
/	O	855-856
mL	O	856-858
.	O	858-859

An	O	860-862
initial	O	863-870
exercise	O	871-879
stress	O	880-886
test	O	887-891
was	O	892-895
normal	O	896-902
.	O	902-903

At	O	904-906
the	O	907-910
time	O	911-915
of	O	916-918
admission	O	919-928
,	O	928-929
the	O	930-933
patient	O	934-941
was	O	942-945
at	O	946-948
high	O	949-953
risk	O	954-958
of	O	959-961
radiation	B	962-971
injury	I	972-978
to	O	979-981
the	O	982-985
fetus	O	986-991
,	O	991-992
so	O	993-995
a	O	996-997
coronary	O	998-1006
angiogram	O	1007-1016
was	O	1017-1020
postponed	O	1021-1030
until	O	1031-1036
the	O	1037-1040
second	O	1041-1047
trimester	O	1048-1057
.	O	1057-1058

It	O	1059-1061
showed	O	1062-1068
normal	O	1069-1075
coronary	O	1076-1084
vessels	O	1085-1092
.	O	1092-1093

CONCLUSION	O	1094-1104
:	O	1104-1105
This	O	1106-1110
appears	O	1111-1118
to	O	1119-1121
be	O	1122-1124
the	O	1125-1128
first	O	1129-1134
reported	O	1135-1143
case	O	1144-1148
documenting	O	1149-1160
a	O	1161-1162
possible	O	1163-1171
association	O	1172-1183
between	O	1184-1191
CC	O	1192-1194
and	O	1195-1198
myocardial	B	1199-1209
infarction	I	1210-1220
.	O	1220-1221

Thrombosis	B	1222-1232
might	O	1233-1238
be	O	1239-1241
a	O	1242-1243
rare	O	1244-1248
but	O	1249-1252
hazardous	O	1253-1262
complication	O	1263-1275
of	O	1276-1278
CC	O	1279-1281
.	O	1281-1282

Given	O	1283-1288
this	O	1289-1293
life	O	1294-1298
-	O	1298-1299
threatening	O	1299-1310
complication	O	1311-1323
,	O	1323-1324
appropriate	O	1325-1336
prophylactic	O	1337-1349
measures	O	1350-1358
should	O	1359-1365
be	O	1366-1368
used	O	1369-1373
in	O	1374-1376
high	O	1377-1381
-	O	1381-1382
risk	O	1382-1386
woman	O	1387-1392
undergoing	O	1393-1403
ovarian	O	1404-1411
stimulation	O	1412-1423
.	O	1423-1424

Hepatonecrosis	B	0-14
and	O	15-18
cholangitis	B	19-30
related	O	31-38
to	O	39-41
long	O	42-46
-	O	46-47
term	O	47-51
phenobarbital	O	52-65
therapy	O	66-73
:	O	73-74
an	O	75-77
autopsy	O	78-85
report	O	86-92
of	O	93-95
two	O	96-99
patients	O	100-108
.	O	108-109

Phenobarbital	O	110-123
(	O	124-125
PB	O	125-127
)	O	127-128
has	O	129-132
a	O	133-134
reputation	O	135-145
for	O	146-149
safety	O	150-156
,	O	156-157
and	O	158-161
it	O	162-164
is	O	165-167
commonly	O	168-176
believed	O	177-185
that	O	186-190
PB	O	191-193
-	O	193-194
related	O	194-201
increases	O	202-211
in	O	212-214
serum	O	215-220
aminotransferase	O	221-237
levels	O	238-244
do	O	245-247
not	O	248-251
indicate	O	252-260
or	O	261-263
predict	O	264-271
the	O	272-275
development	O	276-287
of	O	288-290
significant	O	291-302
chronic	O	303-310
liver	B	311-316
disease	I	317-324
.	O	324-325

Here	O	326-330
we	O	331-333
report	O	334-340
of	O	341-343
two	O	344-347
adult	O	348-353
patients	O	354-362
with	O	363-367
a	O	368-369
long	O	370-374
history	O	375-382
of	O	383-385
epilepsy	B	386-394
treated	O	395-402
with	O	403-407
PB	O	408-410
who	O	411-414
died	O	415-419
suddenly	O	420-428
:	O	428-429
one	O	430-433
as	O	434-436
consequence	O	437-448
of	O	449-451
cardiac	B	452-459
arrest	I	460-466
,	O	466-467
the	O	468-471
other	O	472-477
of	O	478-480
acute	O	481-486
bronchopneumonia	B	487-503
.	O	503-504

At	O	505-507
autopsy	O	508-515
,	O	515-516
analysis	O	517-525
of	O	526-528
liver	O	529-534
parenchyma	O	535-545
revealed	O	546-554
rich	O	555-559
portal	O	560-566
inflammatory	O	567-579
infiltrate	O	580-590
,	O	590-591
which	O	592-597
consisted	O	598-607
of	O	608-610
mixed	O	611-616
eosinophil	O	617-627
and	O	628-631
monocyte	O	632-640
cells	O	641-646
,	O	646-647
associated	O	648-658
with	O	659-663
several	O	664-671
foci	O	672-676
of	O	677-679
necrosis	B	680-688
surrounded	O	689-699
by	O	700-702
a	O	703-704
hard	O	705-709
ring	O	710-714
of	O	715-717
non	O	718-721
-	O	721-722
specific	O	722-730
granulomatous	O	731-744
tissue	O	745-751
.	O	751-752

Inflammatory	O	753-765
reactions	O	766-775
of	O	776-778
internal	O	779-787
and	O	788-791
external	O	792-800
hepatic	O	801-808
biliary	O	809-816
ducts	O	817-822
were	O	823-827
also	O	828-832
seen	O	833-837
.	O	837-838

Our	O	839-842
findings	O	843-851
illustrate	O	852-862
that	O	863-867
PB	O	868-870
may	O	871-874
be	O	875-877
associated	O	878-888
with	O	889-893
chronic	O	894-901
liver	B	902-907
damage	I	908-914
,	O	914-915
which	O	916-921
may	O	922-925
lead	O	926-930
to	O	931-933
more	O	934-938
serious	O	939-946
and	O	947-950
deleterious	O	951-962
consequences	O	963-975
.	O	975-976

For	O	977-980
this	O	981-985
reason	O	986-992
,	O	992-993
each	O	994-998
clinician	O	999-1008
should	O	1009-1015
recognize	O	1016-1025
this	O	1026-1030
entity	O	1031-1037
in	O	1038-1040
the	O	1041-1044
differential	O	1045-1057
diagnosis	O	1058-1067
of	O	1068-1070
PB	O	1071-1073
-	O	1073-1074
related	O	1074-1081
asymptomatic	O	1082-1094
chronic	B	1095-1102
hepatic	I	1103-1110
enzyme	I	1111-1117
dysfunction	I	1118-1129
.	O	1129-1130

Ethambutol	O	0-10
-	O	10-11
associated	O	11-21
optic	B	22-27
neuropathy	I	28-38
.	O	38-39

INTRODUCTION	O	40-52
:	O	52-53
Ethambutol	O	54-64
is	O	65-67
used	O	68-72
in	O	73-75
the	O	76-79
treatment	O	80-89
of	O	90-92
tuberculosis	B	93-105
,	O	105-106
which	O	107-112
is	O	113-115
still	O	116-121
prevalent	O	122-131
in	O	132-134
Southeast	O	135-144
Asia	O	145-149
,	O	149-150
and	O	151-154
can	O	155-158
be	O	159-161
associated	O	162-172
with	O	173-177
permanent	O	178-187
visual	B	188-194
loss	I	195-199
.	O	199-200

We	O	201-203
report	O	204-210
3	O	211-212
cases	O	213-218
which	O	219-224
presented	O	225-234
with	O	235-239
bitemporal	B	240-250
hemianopia	I	251-261
.	O	261-262

CLINICAL	O	263-271
PICTURE	O	272-279
:	O	279-280
Three	O	281-286
patients	O	287-295
with	O	296-300
ethambutol	O	301-311
-	O	311-312
associated	O	312-322
toxic	O	323-328
optic	B	329-334
neuropathy	I	335-345
are	O	346-349
described	O	350-359
.	O	359-360

All	O	361-364
3	O	365-366
patients	O	367-375
had	O	376-379
loss	B	380-384
of	I	385-387
central	I	388-395
visual	I	396-402
acuity	I	403-409
,	I	409-410
colour	I	411-417
vision	I	418-424
(	I	425-426
Ishihara	I	426-434
)	I	434-435
and	I	436-439
visual	I	440-446
field	I	447-452
.	O	452-453

The	O	454-457
visual	B	458-464
field	I	465-470
loss	I	471-475
had	O	476-479
a	O	480-481
bitemporal	O	482-492
flavour	O	493-500
,	O	500-501
suggesting	O	502-512
involvement	O	513-524
of	O	525-527
the	O	528-531
optic	O	532-537
chiasm	O	538-544
.	O	544-545

TREATMENT	O	546-555
:	O	555-556
Despite	O	557-564
stopping	O	565-573
ethambutol	O	574-584
on	O	585-587
diagnosis	O	588-597
,	O	597-598
visual	O	599-605
function	O	606-614
continued	O	615-624
to	O	625-627
deteriorate	O	628-639
for	O	640-643
a	O	644-645
few	O	646-649
months	O	650-656
.	O	656-657

Subsequent	O	658-668
improvement	O	669-680
was	O	681-684
mild	O	685-689
in	O	690-692
2	O	693-694
cases	O	695-700
.	O	700-701

In	O	702-704
the	O	705-708
third	O	709-714
case	O	715-719
,	O	719-720
visual	O	721-727
acuity	O	728-734
and	O	735-738
colour	O	739-745
vision	O	746-752
normalised	O	753-763
but	O	764-767
the	O	768-771
optic	O	772-777
discs	O	778-783
were	O	784-788
pale	O	789-793
.	O	793-794

OUTCOME	O	795-802
:	O	802-803
All	O	804-807
3	O	808-809
patients	O	810-818
had	O	819-822
some	O	823-827
permanent	O	828-837
loss	B	838-842
of	I	843-845
visual	I	846-852
function	I	853-861
.	O	861-862

CONCLUSIONS	O	863-874
:	O	874-875
Ethambutol	O	876-886
usage	O	887-892
is	O	893-895
associated	O	896-906
with	O	907-911
permanent	O	912-921
visual	B	922-928
loss	I	929-933
and	O	934-937
should	O	938-944
be	O	945-947
avoided	O	948-955
if	O	956-958
possible	O	959-967
or	O	968-970
used	O	971-975
with	O	976-980
caution	O	981-988
and	O	989-992
proper	O	993-999
ophthalmological	O	1000-1016
follow	O	1017-1023
-	O	1023-1024
up	O	1024-1026
.	O	1026-1027

The	O	1028-1031
author	O	1032-1038
postulates	O	1039-1049
that	O	1050-1054
in	O	1055-1057
cases	O	1058-1063
of	O	1064-1066
ethambutol	O	1067-1077
associated	O	1078-1088
chiasmopathy	O	1089-1101
,	O	1101-1102
ethambutol	O	1103-1113
may	O	1114-1117
initially	O	1118-1127
affect	O	1128-1134
the	O	1135-1138
optic	O	1139-1144
nerves	O	1145-1151
and	O	1152-1155
subsequently	O	1156-1168
progress	O	1169-1177
to	O	1178-1180
involve	O	1181-1188
the	O	1189-1192
optic	O	1193-1198
chiasm	O	1199-1205
.	O	1205-1206

Tolerability	O	0-12
of	O	13-15
nimesulide	O	16-26
and	O	27-30
paracetamol	O	31-42
in	O	43-45
patients	O	46-54
with	O	55-59
NSAID	O	60-65
-	O	65-66
induced	O	66-73
urticaria	B	74-83
/	O	83-84
angioedema	B	84-94
.	O	94-95
Previous	O	96-104
studies	O	105-112
evaluated	O	113-122
the	O	123-126
tolerance	O	127-136
of	O	137-139
nimesulide	O	140-150
and	O	151-154
paracetamol	O	155-166
in	O	167-169
subjects	O	170-178
with	O	179-183
cutaneous	O	184-193
,	O	193-194
respiratory	O	195-206
and	O	207-210
anaphylactoid	O	211-224
reactions	O	225-234
induced	O	235-242
by	O	243-245
nonsteroidal	O	246-258
anti	O	259-263
-	O	263-264
inflammatory	O	264-276
drugs	O	277-282
(	O	283-284
NSAIDs	O	284-290
)	O	290-291
.	O	291-292

In	O	293-295
this	O	296-300
study	O	301-306
we	O	307-309
investigated	O	310-322
tolerability	O	323-335
and	O	336-339
reliability	O	340-351
of	O	352-354
nimesulide	O	355-365
and	O	366-369
paracetamol	O	370-381
in	O	382-384
a	O	385-386
very	O	387-391
large	O	392-397
number	O	398-404
of	O	405-407
patients	O	408-416
with	O	417-421
an	O	422-424
exclusive	O	425-434
well	O	435-439
-	O	439-440
documented	O	440-450
history	O	451-458
of	O	459-461
NSAID	O	462-467
-	O	467-468
induced	O	468-475
urticaria	B	476-485
/	O	485-486
angioedema	B	486-496
.	O	496-497
Furthermore	O	498-509
,	O	509-510
we	O	511-513
evaluated	O	514-523
whether	O	524-531
some	O	532-536
factors	O	537-544
have	O	545-549
the	O	550-553
potential	O	554-563
to	O	564-566
increase	O	567-575
the	O	576-579
risk	O	580-584
of	O	585-587
reaction	O	588-596
to	O	597-599
paracetamol	O	600-611
and	O	612-615
nimesulide	O	616-626
.	O	626-627

A	O	628-629
single	O	630-636
-	O	636-637
placebo	O	637-644
-	O	636-637
controlled	O	645-655
oral	O	656-660
challenge	O	661-670
procedure	O	671-680
with	O	681-685
nimesulide	O	686-696
or	O	697-699
paracetamol	O	700-711
was	O	712-715
applied	O	716-723
to	O	724-726
829	O	727-730
patients	O	731-739
with	O	740-744
a	O	745-746
history	O	747-754
of	O	755-757
NSAID	O	758-763
-	O	763-764
induced	O	764-771
urticaria	B	772-781
/	O	781-782
angioedema	B	782-792
.	O	792-793

A	O	794-795
total	O	796-801
of	O	802-804
75	O	805-807
/	O	807-808
829	O	808-811
(	O	812-813
9	O	813-814
.	O	814-815
4	O	815-816
%	O	816-817
)	O	817-818
patients	O	819-827
experienced	O	828-839
reactions	O	840-849
to	O	850-852
nimesulide	O	853-863
or	O	864-866
paracetamol	O	867-878
.	O	878-879

Of	O	880-882
the	O	883-886
715	O	887-890
patients	O	891-899
tested	O	900-906
with	O	907-911
nimesulide	O	912-922
62	O	923-925
(	O	926-927
8	O	927-928
.	O	928-929
6	O	929-930
%	O	930-931
)	O	931-932
showed	O	933-939
a	O	940-941
positive	O	942-950
test	O	951-955
,	O	955-956
while	O	957-962
of	O	963-965
114	O	966-969
subjects	O	970-978
submitted	O	979-988
to	O	989-991
the	O	992-995
challenge	O	996-1005
with	O	1006-1010
paracetamol	O	1011-1022
,	O	1022-1023
13	O	1024-1026
(	O	1027-1028
9	O	1028-1029
.	O	1029-1030
6	O	1030-1031
%	O	1031-1032
)	O	1032-1033

did	O	1034-1037
not	O	1038-1041
tolerate	O	1042-1050
this	O	1051-1055
drug	O	1056-1060
.	O	1060-1061

Furthermore	O	1062-1073
,	O	1073-1074
18	O	1075-1077
.	O	1077-1078
28	O	1078-1080
%	O	1080-1081
of	O	1082-1084
patients	O	1085-1093
with	O	1094-1098
a	O	1099-1100
history	O	1101-1108
of	O	1109-1111
chronic	O	1112-1119
urticaria	B	1120-1129
and	O	1130-1133
11	O	1134-1136
.	O	1136-1137
8	O	1137-1138
%	O	1138-1139
of	O	1140-1142
subjects	O	1143-1151
with	O	1152-1156
an	O	1157-1159
history	O	1160-1167
of	O	1168-1170
NSAID	O	1171-1176
-	O	1176-1177
induced	O	1177-1184
urticaria	B	1185-1194
/	O	1194-1195
angioedema	B	1195-1205
or	O	1206-1208
angioedema	B	1209-1219
alone	O	1220-1225
(	O	1226-1227
with	O	1227-1231
or	O	1232-1234
without	O	1235-1242
chronic	O	1243-1250
urticaria	B	1251-1260
)	O	1260-1261
resulted	O	1262-1270
to	O	1271-1273
be	O	1274-1276
intolerant	O	1277-1287
to	O	1288-1290
alternative	O	1291-1302
drugs	O	1303-1308
.	O	1308-1309

Taken	O	1310-1315
together	O	1316-1324
,	O	1324-1325
our	O	1326-1329
results	O	1330-1337
confirm	O	1338-1345
the	O	1346-1349
good	O	1350-1354
tolerability	O	1355-1367
of	O	1368-1370
nimesulide	O	1371-1381
and	O	1382-1385
paracetamol	O	1386-1397
in	O	1398-1400
patients	O	1401-1409
who	O	1410-1413
experienced	O	1414-1425
urticaria	B	1426-1435
/	O	1435-1436
angioedema	B	1436-1446
caused	O	1447-1453
by	O	1454-1456
NSAIDs	O	1457-1463
.	O	1463-1464

However	O	1465-1472
,	O	1472-1473
the	O	1474-1477
risk	O	1478-1482
of	O	1483-1485
reaction	O	1486-1494
to	O	1495-1497
these	O	1498-1503
alternative	O	1504-1515
study	O	1516-1521
drugs	O	1522-1527
is	O	1528-1530
statistically	O	1531-1544
increased	O	1545-1554
by	O	1555-1557
a	O	1558-1559
history	O	1560-1567
of	O	1568-1570
chronic	O	1571-1578
urticaria	B	1579-1588
and	O	1589-1592
,	O	1592-1593
above	O	1594-1599
all	O	1600-1603
,	O	1603-1604
by	O	1605-1607
a	O	1608-1609
history	O	1610-1617
of	O	1618-1620
NSAID	O	1621-1626
-	O	1626-1627
induced	O	1627-1634
angioedema	B	1635-1645
.	O	1645-1646

Effects	O	0-7
of	O	8-10
verapamil	O	11-20
on	O	21-23
atrial	B	24-30
fibrillation	I	31-43
and	O	44-47
its	O	48-51
electrophysiological	O	52-72
determinants	O	73-85
in	O	86-88
dogs	O	89-93
.	O	93-94

BACKGROUND	O	95-105
:	O	105-106
Atrial	B	107-113
tachycardia	I	114-125
-	O	125-126
induced	O	126-133
remodeling	O	134-144
promotes	O	145-153
the	O	154-157
occurrence	O	158-168
and	O	169-172
maintenance	O	173-184
of	O	185-187
atrial	B	188-194
fibrillation	I	195-207
(	O	208-209
AF	B	209-211
)	O	211-212
and	O	213-216
decreases	O	217-226
L	O	227-228
-	O	228-229
type	O	229-233
Ca	O	234-236
(	O	236-237
2	O	237-238
+	O	238-239
)	O	239-240
current	O	241-248
.	O	248-249

There	O	250-255
is	O	256-258
also	O	259-263
a	O	264-265
clinical	O	266-274
suggestion	O	275-285
that	O	286-290
acute	O	291-296
L	O	297-298
-	O	298-299
type	O	299-303
Ca	O	304-306
(	O	306-307
2	O	307-308
)	O	308-309
channel	O	310-317
blockade	O	318-326
can	O	327-330
promote	O	331-338
AF	B	339-341
,	O	341-342
consistent	O	343-353
with	O	354-358
an	O	359-361
AF	B	362-364
promoting	O	365-374
effect	O	375-381
of	O	382-384
Ca	O	385-387
(	O	387-388
2	O	388-389
+	O	389-390
)	O	390-391
channel	O	392-399
inhibition	O	400-410
.	O	410-411

METHODS	O	412-419
:	O	419-420
To	O	421-423
evaluate	O	424-432
the	O	433-436
potential	O	437-446
mechanisms	O	447-457
of	O	458-460
AF	B	461-463
promotion	O	464-473
by	O	474-476
Ca	O	477-479
(	O	479-480
2	O	480-481
+	O	481-482
)	O	482-483
channel	O	484-491
blockers	O	492-500
,	O	500-501
we	O	502-504
administered	O	505-517
verapamil	O	518-527
to	O	528-530
morphine	O	531-539
-	O	539-540
chloralose	O	540-550
anesthetized	O	551-563
dogs	O	564-568
.	O	568-569

Diltiazem	O	570-579
was	O	580-583
used	O	584-588
as	O	589-591
a	O	592-593
comparison	O	594-604
drug	O	605-609
and	O	610-613
autonomic	O	614-623
blockade	O	624-632
with	O	633-637
atropine	O	638-646
and	O	647-650
nadolol	O	651-658
was	O	659-662
applied	O	663-670
in	O	671-673
some	O	674-678
experiments	O	679-690
.	O	690-691

Epicardial	O	692-702
mapping	O	703-710
with	O	711-715
240	O	716-719
epicardial	O	720-730
electrodes	O	731-741
was	O	742-745
used	O	746-750
to	O	751-753
evaluate	O	754-762
activation	O	763-773
during	O	774-780
AF	B	781-783
.	O	783-784

RESULTS	O	785-792
:	O	792-793
Verapamil	O	794-803
caused	O	804-810
AF	B	811-813
promotion	O	814-823
in	O	824-826
six	O	827-830
dogs	O	831-835
,	O	835-836
increasing	O	837-847
mean	O	848-852
duration	O	853-861
of	O	862-864
AF	B	865-867
induced	O	868-875
by	O	876-878
burst	O	879-884
pacing	O	885-891
,	O	891-892
from	O	893-897
8	O	898-899
+	O	899-900
/	O	900-901
-	O	901-902
4	O	902-903
s	O	904-905
(	O	906-907
mean	O	907-911
+	O	911-912
/	O	912-913
-	O	913-914
S	O	914-915
.	O	915-916
E	O	916-917
.	O	915-916
)	O	918-919
to	O	920-922
95	O	923-925
+	O	925-926
/	O	926-927
-	O	927-928
39	O	928-930
s	O	931-932
(	O	933-934
P	O	934-935
<	O	935-936
0	O	936-937
.	O	937-938
01	O	938-940
vs	O	941-943
.	O	943-944
control	O	945-952
)	O	952-953
at	O	954-956
a	O	957-958
loading	O	959-966
dose	O	967-971
of	O	972-974
0	O	975-976
.	O	976-977
1	O	977-978
mg	O	979-981
/	O	981-982
kg	O	982-984
and	O	985-988
228	O	989-992
+	O	992-993
/	O	993-994
-	O	994-995
101	O	995-998
s	O	999-1000
(	O	1001-1002
P	O	1002-1003
<	O	1003-1004
0	O	1004-1005
.	O	1005-1006
0005	O	1006-1010
vs	O	1011-1013
.	O	1013-1014
control	O	1015-1022
)	O	1022-1023
at	O	1024-1026
a	O	1027-1028
dose	O	1029-1033
of	O	1034-1036
0	O	1037-1038
.	O	1038-1039
2	O	1039-1040
mg	O	1041-1043
/	O	1043-1044
kg	O	1044-1046
.	O	1046-1047

Underlying	O	1048-1058
electrophysiological	O	1059-1079
mechanisms	O	1080-1090
were	O	1091-1095
studied	O	1096-1103
in	O	1104-1106
detail	O	1107-1113
in	O	1114-1116
five	O	1117-1121
additional	O	1122-1132
dogs	O	1133-1137
under	O	1138-1143
control	O	1144-1151
conditions	O	1152-1162
and	O	1163-1166
in	O	1167-1169
the	O	1170-1173
presence	O	1174-1182
of	O	1183-1185
the	O	1186-1189
higher	O	1190-1196
dose	O	1197-1201
of	O	1202-1204
verapamil	O	1205-1214
.	O	1214-1215

In	O	1216-1218
these	O	1219-1224
experiments	O	1225-1236
,	O	1236-1237
verapamil	O	1238-1247
shortened	O	1248-1257
mean	O	1258-1262
effective	O	1263-1272
refractory	O	1273-1283
period	O	1284-1290
(	O	1291-1292
ERP	O	1292-1295
)	O	1295-1296
from	O	1297-1301
122	O	1302-1305
+	O	1305-1306
/	O	1306-1307
-	O	1307-1308
5	O	1308-1309
to	O	1310-1312
114	O	1313-1316
+	O	1316-1317
/	O	1317-1318
-	O	1318-1319
4	O	1315-1316
ms	O	1321-1323
(	O	1324-1325
P	O	1325-1326
<	O	1326-1327
0	O	1327-1328
.	O	1328-1329
02	O	1329-1331
)	O	1331-1332
at	O	1333-1335
a	O	1336-1337
cycle	O	1338-1343
length	O	1344-1350
of	O	1351-1353
300	O	1354-1357
ms	O	1358-1360
,	O	1360-1361
decreased	O	1362-1371
ERP	O	1372-1375
heterogeneity	O	1376-1389
(	O	1390-1391
from	O	1391-1395
15	O	1396-1398
+	O	1398-1399
/	O	1399-1400
-	O	1400-1401
1	O	1396-1397
to	O	1403-1405
10	O	1406-1408
+	O	1408-1409
/	O	1409-1410
-	O	1410-1411
1	O	1406-1407
%	O	1412-1413
,	O	1413-1414
P	O	1415-1416
<	O	1416-1417
0	O	1417-1418
.	O	1418-1419
05	O	1419-1421
)	O	1421-1422
,	O	1422-1423
heterogeneously	O	1424-1439
accelerated	O	1440-1451
atrial	O	1452-1458
conduction	O	1459-1469
and	O	1470-1473
decreased	O	1474-1483
the	O	1484-1487
cycle	O	1488-1493
length	O	1494-1500
of	O	1501-1503
AF	B	1504-1506
(	O	1507-1508
94	O	1508-1510
+	O	1510-1511
/	O	1511-1512
-	O	1512-1513
4	O	1509-1510
to	O	1515-1517
84	O	1518-1520
+	O	1520-1521
/	O	1521-1522
-	O	1522-1523
3	O	1523-1524
ms	O	1525-1527
,	O	1527-1528
P	O	1529-1530
<	O	1530-1531
0	O	1531-1532
.	O	1532-1533
005	O	1533-1536
)	O	1536-1537
.	O	1532-1533

Diltiazem	O	1539-1548
did	O	1549-1552
not	O	1553-1556
affect	O	1557-1563
ERP	O	1564-1567
,	O	1567-1568
AF	B	1569-1571
cycle	O	1572-1577
length	O	1578-1584
or	O	1585-1587
AF	B	1588-1590
duration	O	1591-1599
,	O	1599-1600
but	O	1601-1604
produced	O	1605-1613
conduction	O	1614-1624
acceleration	O	1625-1637
similar	O	1638-1645
to	O	1646-1648
that	O	1649-1653
caused	O	1654-1660
by	O	1661-1663
verapamil	O	1664-1673
(	O	1674-1675
n	O	1675-1676
=	O	1676-1677
5	O	1677-1678
)	O	1678-1679
.	O	1679-1680

In	O	1681-1683
the	O	1684-1687
presence	O	1688-1696
of	O	1697-1699
autonomic	O	1700-1709
blockade	O	1710-1718
,	O	1718-1719
verapamil	O	1720-1729
failed	O	1730-1736
to	O	1737-1739
promote	O	1740-1747
AF	B	1748-1750
and	O	1751-1754
increased	O	1755-1764
,	O	1764-1765
rather	O	1766-1772
than	O	1773-1777
decreasing	O	1778-1788
,	O	1788-1789
refractoriness	O	1790-1804
.	O	1804-1805

Neither	O	1806-1813
verapamil	O	1814-1823
nor	O	1824-1827
diltiazem	O	1828-1837
affected	O	1838-1846
atrial	O	1847-1853
conduction	O	1854-1864
in	O	1865-1867
the	O	1868-1871
presence	O	1872-1880
of	O	1881-1883
autonomic	O	1884-1893
blockade	O	1894-1902
.	O	1902-1903

Epicardial	O	1904-1914
mapping	O	1915-1922
suggested	O	1923-1932
that	O	1933-1937
verapamil	O	1938-1947
promoted	O	1948-1956
AF	B	1957-1959
by	O	1960-1962
increasing	O	1963-1973
the	O	1974-1977
number	O	1978-1984
of	O	1985-1987
simultaneous	O	1988-2000
wavefronts	O	2001-2011
reflected	O	2012-2021
by	O	2022-2024
separate	O	2025-2033
zones	O	2034-2039
of	O	2040-2042
reactivation	O	2043-2055
in	O	2056-2058
each	O	2059-2063
cycle	O	2064-2069
.	O	2069-2070

CONCLUSIONS	O	2071-2082
:	O	2082-2083
Verapamil	O	2084-2093
promotes	O	2094-2102
AF	B	2103-2105
in	O	2106-2108
normal	O	2109-2115
dogs	O	2116-2120
by	O	2121-2123
promoting	O	2124-2133
multiple	O	2134-2142
circuit	O	2143-2150
reentry	O	2151-2158
,	O	2158-2159
an	O	2160-2162
effect	O	2163-2169
dependent	O	2170-2179
on	O	2180-2182
intact	O	2183-2189
autonomic	O	2190-2199
tone	O	2200-2204
and	O	2205-2208
not	O	2209-2212
shared	O	2213-2219
by	O	2220-2222
diltiazem	O	2223-2232
.	O	2232-2233

Hypotension	B	0-11
,	O	11-12
bradycardia	B	13-24
,	O	24-25
and	O	26-29
asystole	B	30-38
after	O	39-44
high	O	45-49
-	O	49-50
dose	O	50-54
intravenous	O	55-66
methylprednisolone	O	67-85
in	O	86-88
a	O	89-90
monitored	O	91-100
patient	O	101-108
.	O	108-109

We	O	110-112
report	O	113-119
a	O	120-121
case	O	122-126
of	O	127-129
hypotension	B	130-141
,	O	141-142
bradycardia	B	143-154
,	O	154-155
and	O	156-159
asystole	B	160-168
after	O	169-174
intravenous	O	175-186
administration	O	187-201
of	O	202-204
high	O	205-209
-	O	209-210
dose	O	210-214
methylprednisolone	O	215-233
in	O	234-236
a	O	237-238
73	O	239-241
-	O	241-242
year	O	242-246
-	O	241-242
old	O	247-250
patient	O	251-258
who	O	259-262
underwent	O	263-272
electrocardiographic	O	273-293
(	O	294-295
ECG	O	295-298
)	O	298-299
monitoring	O	300-310
throughout	O	311-321
the	O	322-325
episode	O	326-333
.	O	333-334

There	O	335-340
was	O	341-344
a	O	345-346
history	O	347-354
of	O	355-357
ischemic	B	358-366
cardiac	B	367-374
disease	I	375-382
9	O	383-384
years	O	385-390
earlier	O	391-398
.	O	398-399

The	O	400-403
patient	O	404-411
was	O	412-415
admitted	O	416-424
with	O	425-429
a	O	430-431
pulmonary	B	432-441
-	I	441-442
renal	I	442-447
syndrome	I	448-456
with	O	457-461
hemoptysis	B	462-472
,	O	472-473
rapidly	O	474-481
progressive	O	482-493
renal	B	494-499
failure	I	500-507
,	O	507-508
and	O	509-512
hypoxemia	B	513-522
that	O	523-527
required	O	528-536
mechanical	O	537-547
ventilation	O	548-559
in	O	560-562
the	O	563-566
intensive	O	567-576
care	O	577-581
unit	O	582-586
.	O	586-587

After	O	588-593
receiving	O	594-603
advanced	O	604-612
cardiopulmonary	O	613-628
resuscitation	O	629-642
,	O	642-643
the	O	644-647
patient	O	648-655
recovered	O	656-665
cardiac	O	666-673
rhythm	O	674-680
.	O	680-681

The	O	682-685
ECG	O	686-689
showed	O	690-696
a	O	697-698
junctional	O	699-709
rhythm	O	710-716
without	O	717-724
ventricular	B	725-736
arrhythmia	I	737-747
.	O	747-748

This	O	749-753
study	O	754-759
reviews	O	760-767
the	O	768-771
current	O	772-779
proposed	O	780-788
mechanisms	O	789-799
of	O	800-802
sudden	B	803-809
death	I	810-815
after	O	816-821
a	O	822-823
high	O	824-828
dose	O	829-833
of	O	834-836
intravenous	O	837-848
methylprednisolone	O	849-867
(	O	868-869
IVMP	O	869-873
)	O	873-874
.	O	874-875

These	O	876-881
mechanisms	O	882-892
are	O	893-896
not	O	897-900
well	O	901-905
understood	O	906-916
because	O	917-924
,	O	924-925
in	O	926-928
most	O	929-933
cases	O	934-939
,	O	939-940
the	O	941-944
patients	O	945-953
were	O	954-958
not	O	959-962
monitored	O	963-972
at	O	973-975
the	O	976-979
moment	O	980-986
of	O	987-989
the	O	990-993
event	O	994-999
.	O	999-1000

Rapid	O	1001-1006
infusion	O	1007-1015
and	O	1016-1019
underlying	O	1020-1030
cardiac	B	1031-1038
disease	I	1039-1046
were	O	1047-1051
important	O	1052-1061
risk	O	1062-1066
factors	O	1067-1074
in	O	1075-1077
the	O	1078-1081
case	O	1082-1086
reported	O	1087-1095
here	O	1096-1100
,	O	1100-1101
and	O	1102-1105
the	O	1106-1109
authors	O	1110-1117
discount	O	1118-1126
ventricular	B	1127-1138
arrhythmia	I	1139-1149
as	O	1150-1152
the	O	1153-1156
main	O	1157-1161
mechanism	O	1162-1171
.	O	1171-1172

Lifetime	O	0-8
treatment	O	9-18
of	O	19-21
mice	O	22-26
with	O	27-31
azidothymidine	O	32-46
(	O	47-48
AZT	O	48-51
)	O	51-52
produces	O	53-61
myelodysplasia	B	62-76
.	O	76-77

AZT	O	78-81
has	O	82-85
induced	O	86-93
a	O	94-95
macrocytic	B	96-106
anemia	I	107-113
in	O	114-116
AIDS	B	117-121
patients	O	122-130
on	O	131-133
long	O	134-138
term	O	139-143
AZT	O	144-147
therapy	O	148-155
.	O	155-156

It	O	157-159
is	O	160-162
generally	O	163-172
assumed	O	173-180
that	O	181-185
DNA	O	186-189
elongation	O	190-200
is	O	201-203
stopped	O	204-211
by	O	212-214
the	O	215-218
insertion	O	219-228
of	O	229-231
AZT	O	232-235
into	O	236-240
the	O	241-244
chain	O	245-250
in	O	251-253
place	O	254-259
of	O	260-262
thymidine	O	263-272
thus	O	273-277
preventing	O	278-288
the	O	289-292
phosphate	O	293-302
hydroxyl	O	303-311
linkages	O	312-320
and	O	321-324
therefore	O	325-334
suppresses	O	335-345
hemopoietic	O	346-357
progenitor	O	358-368
cell	O	369-373
proliferation	O	374-387
in	O	388-390
an	O	391-393
early	O	394-399
stage	O	400-405
of	O	406-408
differentiation	O	409-424
.	O	424-425

CBA	O	426-429
/	O	429-430
Ca	O	430-432
male	O	433-437
mice	O	438-442
started	O	443-450
on	O	451-453
AZT	O	454-457
0	O	458-459
.	O	459-460
75	O	460-462
mg	O	463-465
/	O	465-466
ml	O	466-468
H2O	O	469-472
at	O	473-475
84	O	476-478
days	O	479-483
of	O	484-486
age	O	487-490
and	O	491-494
kept	O	495-499
on	O	500-502
it	O	503-505
for	O	506-509
687	O	510-513
days	O	514-518
when	O	519-523
dosage	O	524-530
reduced	O	531-538
to	O	539-541
0	O	542-543
.	O	543-544
5	O	544-545
mg	O	546-548
/	O	548-549
ml	O	549-551
H2O	O	552-555
for	O	556-559
a	O	560-561
group	O	562-567
,	O	567-568
another	O	569-576
group	O	577-582
removed	O	583-590
from	O	591-595
AZT	O	596-599
to	O	600-602
see	O	603-606
recovery	O	607-615
,	O	615-616
and	O	617-620
third	O	621-626
group	O	627-632
remained	O	633-641
on	O	642-644
0	O	645-646
.	O	646-647
75	O	647-649
mg	O	650-652
.	O	652-653

At	O	654-656
687	O	657-660
days	O	661-665
mice	O	666-670
that	O	671-675
had	O	676-679
been	O	680-684
on	O	685-687
0	O	688-689
.	O	689-690
75	O	690-692
mg	O	693-695
had	O	696-699
average	O	700-707
platelet	O	708-716
counts	O	717-723
of	O	724-726
2	O	727-728
.	O	728-729
5	O	729-730
x	O	731-732
10	O	733-735
(	O	735-736
6	O	736-737
)	O	737-738
.	O	738-739

Histological	O	740-752
examination	O	753-764
on	O	765-767
9	O	768-769
of	O	770-772
10	O	773-775
mice	O	776-780
with	O	781-785
such	O	786-790
thrombocytopenia	B	791-807
showed	O	808-814
changes	O	815-822
compatible	O	823-833
with	O	834-838
myelodysplastic	B	839-854
syndrome	I	855-863
(	O	864-865
MDS	B	865-868
)	O	868-869
.	O	869-870

A	O	871-872
variety	O	873-880
of	O	881-883
histological	O	884-896
patterns	O	897-905
was	O	906-909
observed	O	910-918
.	O	918-919

There	O	920-925
were	O	926-930
two	O	931-934
cases	O	935-940
of	O	941-943
hypocellular	O	944-956
myelodysplasia	B	957-971
,	O	971-972
two	O	973-976
cases	O	977-982
of	O	983-985
hypersegmented	O	986-1000
myelodysplastic	B	1001-1016
granulocytosis	O	1017-1031
,	O	1031-1032
two	O	1033-1036
cases	O	1037-1042
of	O	1043-1045
hypercellular	O	1046-1059
marrow	O	1060-1066
with	O	1067-1071
abnormal	O	1072-1080
megakaryocytes	O	1081-1095
with	O	1096-1100
bizarre	O	1101-1108
nuclei	O	1109-1115
,	O	1115-1116
one	O	1117-1120
case	O	1121-1125
of	O	1126-1128
megakaryocytic	O	1129-1143
myelosis	O	1144-1152
associated	O	1153-1163
with	O	1164-1168
a	O	1169-1170
hyperplastic	B	1171-1183
marrow	I	1184-1190
,	O	1190-1191
dysmyelopoiesis	B	1192-1207
and	O	1208-1211
a	O	1212-1213
hypocellular	B	1214-1226
marrow	I	1227-1233
and	O	1234-1237
two	O	1238-1241
cases	O	1242-1247
of	O	1248-1250
myelodysplasia	B	1251-1265
with	O	1266-1270
dyserythropoiesis	B	1271-1288
,	O	1288-1289
hemosiderosis	B	1290-1303
and	O	1304-1307
a	O	1308-1309
hypocellular	B	1310-1322
marrow	I	1323-1329
.	O	1329-1330

Above	O	1331-1336
mentioned	O	1337-1346
AZT	O	1347-1350
incorporation	O	1351-1364
may	O	1365-1368
have	O	1369-1373
induced	O	1374-1381
an	O	1382-1384
ineffective	O	1385-1396
hemopoiesis	O	1397-1408
in	O	1409-1411
the	O	1412-1415
primitive	O	1416-1425
hemopoietic	O	1426-1437
progenitor	O	1438-1448
cells	O	1449-1454
,	O	1454-1455
which	O	1456-1461
is	O	1462-1464
known	O	1465-1470
to	O	1471-1473
be	O	1474-1476
seen	O	1477-1481
commonly	O	1482-1490
in	O	1491-1493
the	O	1494-1497
myelodysplastic	B	1498-1513
syndrome	I	1514-1522
.	O	1522-1523

Influence	O	0-9
of	O	10-12
diet	O	13-17
free	O	18-22
of	O	23-25
NAD	O	26-29
-	O	29-30
precursors	O	30-40
on	O	41-43
acetaminophen	O	44-57
hepatotoxicity	B	58-72
in	O	73-75
mice	O	76-80
.	O	80-81

Recently	O	82-90
,	O	90-91
we	O	92-94
demonstrated	O	95-107
the	O	108-111
hepatoprotective	O	112-128
effects	O	129-136
of	O	137-139
nicotinic	O	140-149
acid	O	150-154
amide	O	155-160
,	O	160-161
a	O	162-163
selective	O	164-173
inhibitor	O	174-183
of	O	184-186
poly	O	187-191
(	O	191-192
ADP	O	192-195
-	O	195-196
ribose	O	196-202
)	O	202-203
polymerase	O	204-214
(	O	215-216
PARP	O	216-220
;	O	220-221
EC	O	222-224
2	O	225-226
.	O	226-227
4	O	227-228
.	O	226-227
2	O	225-226
.	O	226-227
30	O	231-233
)	O	233-234
on	O	235-237
mice	O	238-242
suffering	O	243-252
from	O	253-257
acetaminophen	O	258-271
(	O	272-273
AAP	O	273-276
)	O	276-277
-	O	277-278
hepatitis	B	278-287
,	O	287-288
suggesting	O	289-299
that	O	300-304
the	O	305-308
AAP	O	309-312
-	O	312-313
induced	O	313-320
liver	B	321-326
injury	I	327-333
involves	O	334-342
a	O	343-344
step	O	345-349
which	O	350-355
depends	O	356-363
on	O	364-366
adenoribosylation	O	367-384
.	O	384-385

The	O	386-389
present	O	390-397
study	O	398-403
investigates	O	404-416
the	O	417-420
effects	O	421-428
of	O	429-431
a	O	432-433
diet	O	434-438
free	O	439-443
of	O	444-446
precursors	O	447-457
of	O	458-460
NAD	O	461-464
,	O	464-465
the	O	466-469
substrate	O	470-479
on	O	480-482
which	O	483-488
PARP	O	489-493
acts	O	494-498
,	O	498-499
in	O	500-502
female	O	503-509
NMRI	O	510-514
mice	O	515-519
with	O	520-524
AAP	O	525-528
hepatitis	B	529-538
and	O	539-542
evaluates	O	543-552
the	O	553-556
influence	O	557-566
of	O	567-569
simultaneous	O	570-582
ethanol	O	583-590
consumption	O	591-602
in	O	603-605
these	O	606-611
animals	O	612-619
.	O	619-620

Liver	B	621-626
injuries	I	627-635
were	O	636-640
quantified	O	641-651
as	O	652-654
serum	O	655-660
activities	O	661-671
of	O	672-674
glutamate	O	675-684
-	O	684-685
oxaloacetate	O	685-697
transaminase	O	698-710
(	O	711-712
GOT	O	712-715
)	O	715-716
and	O	717-720
glutamate	O	721-730
-	O	730-731
pyruvate	O	731-739
transaminase	O	740-752
(	O	753-754
GPT	O	754-757
)	O	757-758
.	O	758-759

While	O	760-765
AAP	O	766-769
caused	O	770-776
a	O	777-778
117	O	779-782
-	O	782-783
fold	O	783-787
elevation	O	788-797
of	O	798-800
serum	O	801-806
transaminase	O	807-819
activities	O	820-830
in	O	831-833
mice	O	834-838
kept	O	839-843
on	O	844-846
a	O	847-848
standard	O	849-857
laboratory	O	858-868
diet	O	869-873
,	O	873-874
which	O	875-880
was	O	881-884
significantly	O	885-898
exacerbated	O	899-910
by	O	911-913
ethanol	O	914-921
and	O	922-925
inhibited	O	926-935
by	O	936-938
nicotinic	O	939-948
acid	O	949-953
amide	O	954-959
(	O	960-961
NAA	O	961-964
)	O	964-965
,	O	965-966
adverse	O	967-974
effects	O	975-982
were	O	983-987
noted	O	988-993
in	O	994-996
animals	O	997-1004
fed	O	1005-1008
a	O	1009-1010
diet	O	1011-1015
free	O	1016-1020
of	O	1021-1023
precursors	O	1024-1034
of	O	1035-1037
NAD	O	1038-1041
.	O	1041-1042

In	O	1043-1045
these	O	1046-1051
animals	O	1052-1059
,	O	1059-1060
only	O	1061-1065
minor	O	1066-1071
increases	O	1072-1081
of	O	1082-1084
serum	O	1085-1090
transaminase	O	1091-1103
activities	O	1104-1114
were	O	1115-1119
measured	O	1120-1128
in	O	1129-1131
the	O	1132-1135
presence	O	1136-1144
of	O	1145-1147
AAP	O	1148-1151
,	O	1151-1152
and	O	1153-1156
unlike	O	1157-1163
the	O	1164-1167
exacerbation	O	1168-1180
caused	O	1181-1187
by	O	1188-1190
ethanol	O	1191-1198
in	O	1199-1201
mice	O	1202-1206
on	O	1207-1209
a	O	1210-1211
standard	O	1212-1220
diet	O	1221-1225
,	O	1225-1226
the	O	1227-1230
liver	B	1231-1236
damage	I	1237-1243
was	O	1244-1247
inhibited	O	1248-1257
by	O	1258-1260
50	O	1261-1263
%	O	1263-1264
by	O	1265-1267
ethanol	O	1268-1275
.	O	1275-1276

A	O	1277-1278
further	O	1279-1286
64	O	1287-1289
%	O	1289-1290
reduction	O	1291-1300
of	O	1301-1303
hepatitis	B	1304-1313
was	O	1314-1317
observed	O	1318-1326
,	O	1326-1327
when	O	1328-1332
NAA	O	1333-1336
was	O	1337-1340
given	O	1341-1346
to	O	1347-1349
ethanol	O	1350-1357
/	O	1357-1358
AAP	O	1358-1361
-	O	1361-1362
mice	O	1362-1366
.	O	1366-1367

Our	O	1368-1371
results	O	1372-1379
provide	O	1380-1387
evidence	O	1388-1396
that	O	1397-1401
the	O	1402-1405
AAP	O	1406-1409
-	O	1409-1410
induced	O	1410-1417
hepatitis	B	1418-1427
and	O	1428-1431
its	O	1432-1435
exacerbation	O	1436-1448
by	O	1449-1451
ethanol	O	1452-1459
can	O	1460-1463
either	O	1464-1470
be	O	1471-1473
reduced	O	1474-1481
by	O	1482-1484
end	O	1485-1488
-	O	1488-1489
product	O	1489-1496
inhibition	O	1497-1507
of	O	1508-1510
PARP	O	1511-1515
by	O	1516-1518
NAA	O	1519-1522
or	O	1523-1525
by	O	1526-1528
dietary	O	1529-1536
depletion	O	1537-1546
of	O	1547-1549
the	O	1550-1553
enzyme	O	1554-1560
'	O	1560-1561
s	O	1561-1562
substrate	O	1563-1572
NAD	O	1573-1576
.	O	1576-1577

We	O	1578-1580
see	O	1581-1584
the	O	1585-1588
main	O	1589-1593
application	O	1594-1605
of	O	1606-1608
NAA	O	1609-1612
as	O	1613-1615
for	O	1616-1619
the	O	1620-1623
combinational	O	1624-1637
use	O	1638-1641
in	O	1642-1644
pharmaceutical	O	1645-1659
preparations	O	1660-1672
of	O	1673-1675
acetaminophen	O	1676-1689
in	O	1690-1692
order	O	1693-1698
to	O	1699-1701
avoid	O	1702-1707
hepatic	B	1708-1715
damage	I	1716-1722
in	O	1723-1725
patients	O	1726-1734
treated	O	1735-1742
with	O	1743-1747
this	O	1748-1752
widely	O	1753-1759
used	O	1760-1764
analgesic	O	1765-1774
.	O	1774-1775

Antiarrhythmic	O	0-14
plasma	O	15-21
concentrations	O	22-36
of	O	37-39
cibenzoline	O	40-51
on	O	52-54
canine	O	55-61
ventricular	B	62-73
arrhythmias	I	74-85
.	O	85-86

Using	O	87-92
two	O	93-96
-	O	96-97
stage	O	97-102
coronary	O	103-111
ligation	O	112-120
-	O	120-121
,	O	121-122
digitalis	O	123-132
-	O	132-133
,	O	133-134
and	O	135-138
adrenaline	O	139-149
-	O	149-150
induced	O	150-157
canine	O	158-164
ventricular	B	165-176
arrhythmias	I	177-188
,	O	188-189
antiarrhythmic	O	190-204
effects	O	205-212
of	O	213-215
cibenzoline	O	216-227
were	O	228-232
examined	O	233-241
and	O	242-245
the	O	246-249
minimum	O	250-257
effective	O	258-267
plasma	O	268-274
concentration	O	275-288
for	O	289-292
each	O	293-297
arrhythmia	B	298-308
model	O	309-314
was	O	315-318
determined	O	319-329
.	O	329-330

Cibenzoline	O	331-342
suppressed	O	343-353
all	O	354-357
the	O	358-361
arrhythmias	B	362-373
,	O	373-374
and	O	375-378
the	O	379-382
minimum	O	383-390
effective	O	391-400
plasma	O	401-407
concentrations	O	408-422
for	O	423-426
arrhythmias	B	427-438
induced	O	439-446
by	O	447-449
24	O	450-452
-	O	452-453
h	O	453-454
coronary	O	455-463
ligation	O	464-472
,	O	472-473
48	O	474-476
-	O	476-477
h	O	477-478
coronary	O	479-487
ligation	O	488-496
,	O	496-497
digitalis	O	498-507
,	O	507-508
and	O	509-512
adrenaline	O	513-523
were	O	524-528
1	O	529-530
.	O	530-531
9	O	531-532
+	O	533-534
/	O	534-535
-	O	535-536
0	O	537-538
.	O	538-539
9	O	539-540
(	O	541-542
by	O	542-544
8	O	545-546
mg	O	547-549
/	O	549-550
kg	O	550-552
i	O	553-554
.	O	554-555
v	O	555-556
.	O	554-555
)	O	557-558
,	O	558-559
1	O	560-561
.	O	561-562
6	O	562-563
+	O	564-565
/	O	565-566
-	O	566-567
0	O	568-569
.	O	569-570
5	O	570-571
(	O	572-573
by	O	573-575
8	O	576-577
mg	O	578-580
/	O	580-581
kg	O	581-583
i	O	584-585
.	O	585-586
v	O	586-587
.	O	585-586
)	O	588-589
,	O	589-590
0	O	591-592
.	O	592-593
6	O	593-594
+	O	595-596
/	O	596-597
-	O	597-598
0	O	599-600
.	O	600-601
2	O	601-602
(	O	603-604
by	O	604-606
2	O	607-608
mg	O	609-611
/	O	611-612
kg	O	612-614
i	O	615-616
.	O	616-617
v	O	617-618
.	O	616-617
)	O	619-620
,	O	620-621
and	O	622-625
3	O	626-627
.	O	627-628
5	O	628-629
+	O	630-631
/	O	631-632
-	O	632-633
1	O	634-635
.	O	635-636
3	O	636-637
(	O	638-639
by	O	639-641
5	O	642-643
mg	O	644-646
/	O	646-647
kg	O	647-649
i	O	650-651
.	O	651-652
v	O	652-653
.	O	651-652
)	O	654-655
micrograms	O	656-666
/	O	666-667
ml	O	667-669
,	O	669-670
respectively	O	671-683
(	O	684-685
mean	O	685-689
+	O	690-691
/	O	691-692
-	O	692-693
SDM	O	694-697
,	O	697-698
n	O	699-700
=	O	701-702
6	O	703-704
-	O	704-705
7	O	705-706
)	O	706-707
.	O	707-708

The	O	709-712
concentration	O	713-726
for	O	727-730
adrenaline	O	731-741
-	O	741-742
induced	O	742-749
arrhythmia	B	750-760
was	O	761-764
significantly	O	765-778
higher	O	779-785
than	O	786-790
those	O	791-796
for	O	797-800
the	O	801-804
other	O	805-810
types	O	811-816
of	O	817-819
arrhythmias	B	820-831
.	O	831-832

This	O	833-837
pharmacological	O	838-853
profile	O	854-861
is	O	862-864
similar	O	865-872
to	O	873-875
those	O	876-881
of	O	882-884
mexiletine	O	885-895
and	O	896-899
tocainide	O	900-909
,	O	909-910
and	O	911-914
all	O	915-918
three	O	919-924
drugs	O	925-930
have	O	931-935
central	O	936-943
nervous	O	944-951
system	O	952-958
(	O	959-960
CNS	O	960-963
)	O	963-964
stimulant	O	965-974
action	O	975-981
.	O	981-982

Because	O	983-990
cibenzoline	O	991-1002
had	O	1003-1006
only	O	1007-1011
weak	O	1012-1016
hypotensive	B	1017-1028
and	O	1029-1032
sinus	O	1033-1038
node	O	1039-1043
depressive	B	1044-1054
effects	O	1055-1062
and	O	1063-1066
was	O	1067-1070
found	O	1071-1076
to	O	1077-1079
be	O	1080-1082
orally	O	1083-1089
active	O	1090-1096
when	O	1097-1101
given	O	1102-1107
to	O	1108-1110
coronary	O	1111-1119
ligation	O	1120-1128
arrhythmia	B	1129-1139
dogs	O	1140-1144
,	O	1144-1145
its	O	1146-1149
clinical	O	1150-1158
usefulness	O	1159-1169
is	O	1170-1172
expected	O	1173-1181
.	O	1181-1182

Immunopathology	O	0-15
of	O	16-18
penicillamine	O	19-32
-	O	32-33
induced	O	33-40
glomerular	B	41-51
disease	I	52-59
.	O	59-60

Four	O	61-65
patients	O	66-74
with	O	75-79
rheumatoid	B	80-90
arthritis	I	91-100
developed	O	101-110
heavy	O	111-116
proteinuria	B	117-128
after	O	129-134
five	O	135-139
to	O	140-142
12	O	143-145
months	O	146-152
of	O	153-155
treatment	O	156-165
with	O	166-170
D	O	171-172
-	O	172-173
penicillamine	O	173-186
.	O	186-187

Light	O	188-193
microscopy	O	194-204
of	O	205-207
renal	O	208-213
biopsy	O	214-220
samples	O	221-228
showed	O	229-235
minimal	O	236-243
glomerular	O	244-254
capillary	O	255-264
wall	O	265-269
thickening	O	270-280
and	O	281-284
mesangial	O	285-294
matrix	O	295-301
increase	O	302-310
,	O	310-311
or	O	312-314
no	O	315-317
departure	O	318-327
from	O	328-332
normal	O	333-339
.	O	339-340

Electron	O	341-349
microscopy	O	350-360
,	O	360-361
however	O	362-369
,	O	369-370
revealed	O	371-379
subepithelial	O	380-393
electron	O	394-402
-	O	402-403
dense	O	403-408
deposits	O	409-417
,	O	417-418
fusion	O	419-425
of	O	426-428
epithelial	O	429-439
cell	O	440-444
foot	O	445-449
processes	O	450-459
,	O	459-460
and	O	461-464
evidence	O	465-473
of	O	474-476
mesangial	O	477-486
cell	O	487-491
hyperactivity	O	492-505
.	O	505-506

Immunofluorescence	O	507-525
microscopy	O	526-536
demonstrated	O	537-549
granular	O	550-558
capillary	O	559-568
wall	O	569-573
deposits	O	574-582
of	O	583-585
IgG	O	586-589
and	O	590-593
C3	O	594-596
.	O	596-597

The	O	598-601
findings	O	602-610
were	O	611-615
similar	O	616-623
to	O	624-626
those	O	627-632
in	O	633-635
early	O	636-641
membranous	B	642-652
glomerulonephritis	I	653-671
,	O	671-672
differences	O	673-684
being	O	685-690
observed	O	691-699
however	O	700-707
in	O	708-710
the	O	711-714
results	O	715-722
of	O	723-725
staining	O	726-734
for	O	735-738
the	O	739-742
early	O	743-748
-	O	748-749
acting	O	749-755
complement	O	756-766
components	O	767-777
C1q	O	778-781
and	O	782-785
C4	O	786-788
.	O	788-789

It	O	790-792
is	O	793-795
tentatively	O	796-807
concluded	O	808-817
that	O	818-822
complement	O	823-833
was	O	834-837
activated	O	838-847
by	O	848-850
the	O	851-854
classical	O	855-864
pathway	O	865-872
.	O	872-873

Ventricular	B	0-11
fibrillation	I	12-24
from	O	25-29
diatrizoate	O	30-41
with	O	42-46
and	O	47-50
without	O	51-58
chelating	O	59-68
agents	O	69-75
.	O	75-76

The	O	77-80
toxicity	B	81-89
of	O	90-92
Renografin	O	93-103
76	O	104-106
%	O	106-107
was	O	108-111
compared	O	112-120
with	O	121-125
that	O	126-130
of	O	131-133
Hypaque	O	134-141
76	O	142-144
%	O	144-145
by	O	146-148
selective	O	149-158
injection	O	159-168
of	O	169-171
each	O	172-176
into	O	177-181
the	O	182-185
right	O	186-191
coronary	O	192-200
artery	O	201-207
of	O	208-210
dogs	O	211-215
.	O	215-216

Renografin	O	217-227
contains	O	228-236
the	O	237-240
chelating	O	241-250
agents	O	251-257
sodium	O	258-264
citrate	O	265-272
and	O	273-276
disodium	O	277-285
edetate	O	286-293
,	O	293-294
while	O	295-300
Hypaque	O	301-308
contains	O	309-317
calcium	O	318-325
disodium	O	326-334
edetate	O	335-342
and	O	343-346
no	O	347-349
sodium	O	350-356
citrate	O	357-364
.	O	364-365

Ventricular	B	366-377
fibrillation	I	378-390
occurred	O	391-399
significantly	O	400-413
more	O	414-418
often	O	419-424
with	O	425-429
Renografin	O	430-440
,	O	440-441
suggesting	O	442-452
that	O	453-457
chelating	O	458-467
agents	O	468-474
contribute	O	475-485
to	O	486-488
toxicity	B	489-497
in	O	498-500
coronary	O	501-509
angiography	O	510-521
.	O	521-522

Rapid	O	0-5
reversal	O	6-14
of	O	15-17
anticoagulation	O	18-33
reduces	O	34-41
hemorrhage	B	42-52
volume	O	53-59
in	O	60-62
a	O	63-64
mouse	O	65-70
model	O	71-76
of	O	77-79
warfarin	O	80-88
-	O	88-89
associated	O	89-99
intracerebral	B	100-113
hemorrhage	I	114-124
.	O	124-125

Warfarin	O	126-134
-	O	134-135
associated	O	135-145
intracerebral	B	146-159
hemorrhage	I	160-170
(	O	171-172
W	O	172-173
-	O	173-174
ICH	B	174-177
)	O	177-178
is	O	179-181
a	O	182-183
severe	O	184-190
type	O	191-195
of	O	196-198
stroke	B	199-205
.	O	205-206

There	O	207-212
is	O	213-215
no	O	216-218
consensus	O	219-228
on	O	229-231
the	O	232-235
optimal	O	236-243
treatment	O	244-253
for	O	254-257
W	O	258-259
-	O	259-260
ICH	B	260-263
.	O	263-264

Using	O	265-270
a	O	271-272
mouse	O	273-278
model	O	279-284
,	O	284-285
we	O	286-288
tested	O	289-295
whether	O	296-303
the	O	304-307
rapid	O	308-313
reversal	O	314-322
of	O	323-325
anticoagulation	O	326-341
using	O	342-347
human	O	348-353
prothrombin	O	354-365
complex	O	366-373
concentrate	O	374-385
(	O	386-387
PCC	O	387-390
)	O	390-391
can	O	392-395
reduce	O	396-402
hemorrhagic	O	403-414
blood	O	415-420
volume	O	421-427
.	O	427-428

Male	O	429-433
CD	O	434-436
-	O	436-437
1	O	437-438
mice	O	439-443
were	O	444-448
treated	O	449-456
with	O	457-461
warfarin	O	462-470
(	O	471-472
2	O	472-473
mg	O	474-476
/	O	476-477
kg	O	477-479
over	O	480-484
24	O	485-487
h	O	488-489
)	O	489-490
,	O	490-491
resulting	O	492-501
in	O	502-504
a	O	505-506
mean	O	507-511
(	O	512-513
+	O	513-514
/	O	514-515
-	O	515-516
s	O	516-517
.	O	517-518
d	O	518-519
.	O	517-518
)	O	520-521

International	O	522-535
Normalized	O	536-546
Ratio	O	547-552
of	O	553-555
3	O	556-557
.	O	557-558
5	O	558-559
+	O	559-560
/	O	560-561
-	O	561-562
0	O	562-563
.	O	557-558
9	O	564-565
.	O	557-558

First	O	567-572
,	O	572-573
we	O	574-576
showed	O	577-583
that	O	584-588
an	O	589-591
intravenous	O	592-603
administration	O	604-618
of	O	619-621
human	O	622-627
PCC	O	628-631
rapidly	O	632-639
reversed	O	640-648
anticoagulation	O	649-664
in	O	665-667
mice	O	668-672
.	O	672-673

Second	O	674-680
,	O	680-681
a	O	682-683
stereotactic	O	684-696
injection	O	697-706
of	O	707-709
collagenase	O	710-721
was	O	722-725
administered	O	726-738
to	O	739-741
induce	O	742-748
hemorrhage	B	749-759
in	O	760-762
the	O	763-766
right	O	767-772
striatum	O	773-781
.	O	781-782

Forty	O	783-788
-	O	788-789
five	O	789-793
minutes	O	794-801
later	O	802-807
,	O	807-808
the	O	809-812
animals	O	813-820
were	O	821-825
randomly	O	826-834
treated	O	835-842
with	O	843-847
PCC	O	848-851
(	O	852-853
100	O	853-856
U	O	857-858
/	O	858-859
kg	O	859-861
)	O	861-862
or	O	863-865
saline	O	866-872
i	O	873-874
.	O	874-875
v	O	875-876
.	O	874-875

(	O	878-879
n	O	879-880
=	O	880-881
12	O	881-883
per	O	884-887
group	O	888-893
)	O	893-894
.	O	894-895

Twenty	O	896-902
-	O	902-903
four	O	903-907
hours	O	908-913
after	O	914-919
hemorrhage	B	920-930
induction	O	931-940
,	O	940-941
hemorrhagic	O	942-953
blood	O	954-959
volume	O	960-966
was	O	967-970
quantified	O	971-981
using	O	982-987
a	O	988-989
photometric	O	990-1001
hemoglobin	O	1002-1012
assay	O	1013-1018
.	O	1018-1019

The	O	1020-1023
mean	O	1024-1028
hemorrhagic	O	1029-1040
blood	O	1041-1046
volume	O	1047-1053
was	O	1054-1057
reduced	O	1058-1065
in	O	1066-1068
PCC	O	1069-1072
-	O	1072-1073
treated	O	1073-1080
animals	O	1081-1088
(	O	1089-1090
6	O	1090-1091
.	O	1091-1092
5	O	1092-1093
+	O	1093-1094
/	O	1094-1095
-	O	1095-1096
3	O	1096-1097
.	O	1091-1092
1	O	1098-1099
microL	O	1100-1106
)	O	1106-1107
compared	O	1108-1116
with	O	1117-1121
saline	O	1122-1128
controls	O	1129-1137
(	O	1138-1139
15	O	1139-1141
.	O	1141-1142
3	O	1142-1143
+	O	1143-1144
/	O	1144-1145
-	O	1145-1146
11	O	1146-1148
.	O	1141-1142
2	O	1149-1150

microL	O	1151-1157
,	O	1157-1158
P	O	1159-1160
=	O	1160-1161
0	O	1161-1162
.	O	1162-1163
015	O	1163-1166
)	O	1166-1167
.	O	1162-1163

In	O	1169-1171
the	O	1172-1175
saline	O	1176-1182
group	O	1183-1188
,	O	1188-1189
45	O	1190-1192
%	O	1192-1193
of	O	1194-1196
the	O	1197-1200
mice	O	1201-1205
developed	O	1206-1215
large	O	1216-1221
hematomas	B	1222-1231
(	O	1232-1233
i	O	1233-1234
.	O	1234-1235
e	O	1235-1236
.	O	1234-1235
,	O	1237-1238
>	O	1239-1240
15	O	1240-1242
microL	O	1243-1249
)	O	1249-1250
.	O	1250-1251

In	O	1252-1254
contrast	O	1255-1263
,	O	1263-1264
such	O	1265-1269
extensive	O	1270-1279
lesions	O	1280-1287
were	O	1288-1292
never	O	1293-1298
found	O	1299-1304
in	O	1305-1307
the	O	1308-1311
PCC	O	1312-1315
group	O	1316-1321
.	O	1321-1322

We	O	1323-1325
provide	O	1326-1333
experimental	O	1334-1346
data	O	1347-1351
suggesting	O	1352-1362
PCC	O	1363-1366
to	O	1367-1369
be	O	1370-1372
an	O	1373-1375
effective	O	1376-1385
acute	O	1386-1391
treatment	O	1392-1401
for	O	1402-1405
W	O	1406-1407
-	O	1407-1408
ICH	B	1408-1411
in	O	1412-1414
terms	O	1415-1420
of	O	1421-1423
reducing	O	1424-1432
hemorrhagic	O	1433-1444
blood	O	1445-1450
volume	O	1451-1457
.	O	1457-1458

Future	O	1459-1465
studies	O	1466-1473
are	O	1474-1477
needed	O	1478-1484
to	O	1485-1487
assess	O	1488-1494
the	O	1495-1498
therapeutic	O	1499-1510
potential	O	1511-1520
emerging	O	1521-1529
from	O	1530-1534
our	O	1535-1538
finding	O	1539-1546
for	O	1547-1550
human	O	1551-1556
W	O	1557-1558
-	O	1558-1559
ICH	B	1559-1562
.	O	1562-1563

Impact	O	0-6
of	O	7-9
alcohol	O	10-17
exposure	O	18-26
after	O	27-32
pregnancy	O	33-42
recognition	O	43-54
on	O	55-57
ultrasonographic	O	58-74
fetal	O	75-80
growth	O	81-87
measures	O	88-96
.	O	96-97

BACKGROUND	O	98-108
:	O	108-109
More	O	110-114
than	O	115-119
3	O	120-121
decades	O	122-129
after	O	130-135
Jones	O	136-141
and	O	142-145
Smith	O	146-151
(	O	152-153
1973	O	153-157
)	O	157-158
reported	O	159-167
on	O	168-170
the	O	171-174
devastation	O	175-186
caused	O	187-193
by	O	194-196
alcohol	O	197-204
exposure	O	205-213
on	O	214-216
fetal	O	217-222
development	O	223-234
,	O	234-235
the	O	236-239
rates	O	240-245
of	O	246-248
heavy	O	249-254
drinking	O	255-263
during	O	264-270
pregnancy	O	271-280
remain	O	281-287
relatively	O	288-298
unchanged	O	299-308
.	O	308-309

Early	O	310-315
identification	O	316-330
of	O	331-333
fetal	O	334-339
alcohol	O	340-347
exposure	O	348-356
and	O	357-360
maternal	O	361-369
abstinence	O	370-380
led	O	381-384
to	O	385-387
better	O	388-394
infant	O	395-401
outcomes	O	402-410
.	O	410-411

This	O	412-416
study	O	417-422
examined	O	423-431
the	O	432-435
utility	O	436-443
of	O	444-446
biometry	O	447-455
for	O	456-459
detecting	O	460-469
alcohol	O	470-477
-	O	477-478
related	O	478-485
fetal	O	486-491
growth	B	492-498
impairment	I	499-509
.	O	509-510

METHODS	O	511-518
:	O	518-519
We	O	520-522
obtained	O	523-531
fetal	O	532-537
ultrasound	O	538-548
measures	O	549-557
from	O	558-562
routine	O	563-570
ultrasound	O	571-581
examinations	O	582-594
for	O	595-598
167	O	599-602
pregnant	O	603-611
hazardous	O	612-621
drinkers	O	622-630
who	O	631-634
were	O	635-639
enrolled	O	640-648
in	O	649-651
a	O	652-653
brief	O	654-659
alcohol	O	660-667
intervention	O	668-680
study	O	681-686
.	O	686-687

The	O	688-691
fetal	O	692-697
measures	O	698-706
for	O	707-710
women	O	711-716
who	O	717-720
quit	O	721-725
after	O	726-731
learning	O	732-740
of	O	741-743
their	O	744-749
pregnancies	O	750-761
were	O	762-766
compared	O	767-775
with	O	776-780
measures	O	781-789
for	O	790-793
women	O	794-799
who	O	800-803
continued	O	804-813
some	O	814-818
drinking	O	819-827
throughout	O	828-838
the	O	839-842
course	O	843-849
of	O	850-852
their	O	853-858
pregnancies	O	859-870
.	O	870-871

Because	O	872-879
intensity	O	880-889
of	O	890-892
alcohol	O	893-900
consumption	O	901-912
is	O	913-915
associated	O	916-926
with	O	927-931
poorer	O	932-938
fetal	O	939-944
outcomes	O	945-953
,	O	953-954
separate	O	955-963
analyses	O	964-972
were	O	973-977
conducted	O	978-987
for	O	988-991
the	O	992-995
heavy	O	996-1001
(	O	1002-1003
average	O	1003-1010
of	O	1011-1013
>	O	1014-1015
or	O	1015-1017
=	O	1017-1018
5	O	1018-1019
drinks	O	1020-1026
per	O	1027-1030
drinking	O	1031-1039
day	O	1040-1043
)	O	1043-1044
alcohol	O	1045-1052
consumers	O	1053-1062
.	O	1062-1063

Fetal	O	1064-1069
measures	O	1070-1078
from	O	1079-1083
the	O	1084-1087
heavy	O	1088-1093
-	O	1093-1094
exposed	O	1094-1101
fetuses	O	1102-1109
were	O	1110-1114
also	O	1115-1119
compared	O	1120-1128
with	O	1129-1133
measures	O	1134-1142
from	O	1143-1147
a	O	1148-1149
nondrinking	O	1150-1161
group	O	1162-1167
that	O	1168-1172
was	O	1173-1176
representative	O	1177-1191
of	O	1192-1194
normal	O	1195-1201
,	O	1201-1202
uncomplicated	O	1203-1216
pregnancies	O	1217-1228
from	O	1229-1233
our	O	1234-1237
clinics	O	1238-1245
.	O	1245-1246

Analyses	O	1247-1255
of	O	1256-1258
covariance	O	1259-1269
were	O	1270-1274
used	O	1275-1279
to	O	1280-1282
determine	O	1283-1292
whether	O	1293-1300
there	O	1301-1306
were	O	1307-1311
differences	O	1312-1323
between	O	1324-1331
groups	O	1332-1338
after	O	1339-1344
controlling	O	1345-1356
for	O	1357-1360
influences	O	1361-1371
of	O	1372-1374
gestational	O	1375-1386
age	O	1387-1390
and	O	1391-1394
drug	B	1395-1399
abuse	I	1400-1405
.	O	1405-1406

RESULTS	O	1407-1414
:	O	1414-1415
Nearly	O	1416-1422
half	O	1423-1427
of	O	1428-1430
the	O	1431-1434
pregnant	O	1435-1443
drinkers	O	1444-1452
abstained	O	1453-1462
after	O	1463-1468
learning	O	1469-1477
of	O	1478-1480
their	O	1481-1486
pregnancies	O	1487-1498
.	O	1498-1499

When	O	1500-1504
women	O	1505-1510
reportedly	O	1511-1521
quit	O	1522-1526
drinking	O	1527-1535
early	O	1536-1541
in	O	1542-1544
their	O	1545-1550
pregnancies	O	1551-1562
,	O	1562-1563
fetal	O	1564-1569
growth	O	1570-1576
measures	O	1577-1585
were	O	1586-1590
not	O	1591-1594
significantly	O	1595-1608
different	O	1609-1618
from	O	1619-1623
a	O	1624-1625
non	O	1626-1629
-	O	1629-1630
alcohol	O	1630-1637
-	O	1629-1630
exposed	O	1638-1645
group	O	1646-1651
,	O	1651-1652
regardless	O	1653-1663
of	O	1664-1666
prior	O	1667-1672
drinking	O	1673-1681
patterns	O	1682-1690
.	O	1690-1691

Any	O	1692-1695
alcohol	O	1696-1703
consumption	O	1704-1715
postpregnancy	O	1716-1729
recognition	O	1730-1741
among	O	1742-1747
the	O	1748-1751
heavy	O	1752-1757
drinkers	O	1758-1766
resulted	O	1767-1775
in	O	1776-1778
reduced	B	1779-1786
cerebellar	I	1787-1797
growth	I	1798-1804
as	O	1805-1807
well	O	1808-1812
as	O	1813-1815
decreased	B	1816-1825
cranial	I	1826-1833
to	I	1834-1836
body	I	1837-1841
growth	I	1842-1848
in	O	1849-1851
comparison	O	1852-1862
with	O	1863-1867
women	O	1868-1873
who	O	1874-1877
either	O	1878-1884
quit	O	1885-1889
drinking	O	1890-1898
or	O	1899-1901
who	O	1902-1905
were	O	1906-1910
nondrinkers	O	1911-1922
.	O	1922-1923

Amphetamine	O	1924-1935
abuse	O	1936-1941
was	O	1942-1945
predictive	O	1946-1956
of	O	1957-1959
larger	O	1960-1966
cranial	O	1967-1974
to	O	1975-1977
body	O	1978-1982
growth	O	1983-1989
ratios	O	1990-1996
.	O	1996-1997

CONCLUSIONS	O	1998-2009
:	O	2009-2010
Alterations	O	2011-2022
in	O	2023-2025
fetal	O	2026-2031
biometric	O	2032-2041
measurements	O	2042-2054
were	O	2055-2059
observed	O	2060-2068
among	O	2069-2074
the	O	2075-2078
heavy	O	2079-2084
drinkers	O	2085-2093
only	O	2094-2098
when	O	2099-2103
they	O	2104-2108
continued	O	2109-2118
drinking	O	2119-2127
after	O	2128-2133
becoming	O	2134-2142
aware	O	2143-2148
of	O	2149-2151
their	O	2152-2157
pregnancies	O	2158-2169
.	O	2169-2170

Although	O	2171-2179
the	O	2180-2183
reliance	O	2184-2192
on	O	2193-2195
self	O	2196-2200
-	O	2200-2201
reported	O	2201-2209
drinking	O	2210-2218
is	O	2219-2221
a	O	2222-2223
limitation	O	2224-2234
in	O	2235-2237
this	O	2238-2242
study	O	2243-2248
,	O	2248-2249
these	O	2250-2255
findings	O	2256-2264
support	O	2265-2272
the	O	2273-2276
benefits	O	2277-2285
of	O	2286-2288
early	O	2289-2294
abstinence	O	2295-2305
and	O	2306-2309
the	O	2310-2313
potential	O	2314-2323
for	O	2324-2327
ultrasound	O	2328-2338
examinations	O	2339-2351
in	O	2352-2354
the	O	2355-2358
detection	O	2359-2368
of	O	2369-2371
fetal	O	2372-2377
alcohol	O	2378-2385
effects	O	2386-2393
.	O	2393-2394

Urinary	O	0-7
symptoms	O	8-16
and	O	17-20
quality	O	21-28
of	O	29-31
life	O	32-36
changes	O	37-44
in	O	45-47
Thai	O	48-52
women	O	53-58
with	O	59-63
overactive	B	64-74
bladder	I	75-82
after	O	83-88
tolterodine	O	89-100
treatment	O	101-110
.	O	110-111

OBJECTIVES	O	112-122
:	O	122-123
To	O	124-126
study	O	127-132
the	O	133-136
urinary	O	137-144
symptoms	O	145-153
and	O	154-157
quality	O	158-165
of	O	166-168
life	O	169-173
changes	O	174-181
in	O	182-184
Thai	O	185-189
women	O	190-195
with	O	196-200
overactive	B	201-211
bladder	I	212-219
(	O	220-221
OAB	B	221-224
)	O	224-225
after	O	226-231
tolterodine	O	232-243
treatment	O	244-253
.	O	253-254

MATERIAL	O	255-263
AND	O	264-267
METHOD	O	268-274
:	O	274-275
Thirty	O	276-282
women	O	283-288
(	O	289-290
aged	O	290-294
30	O	295-297
-	O	297-298
77	O	298-300
years	O	301-306
)	O	306-307
diagnosed	O	308-317
as	O	318-320
having	O	321-327
OAB	B	328-331
at	O	332-334
the	O	335-338
Gynecology	O	339-349
Clinic	O	350-356
,	O	356-357
King	O	358-362
Chulalongkorn	O	363-376
Memorial	O	377-385
Hospital	O	386-394
from	O	395-399
January	O	400-407
to	O	408-410
April	O	411-416
2004	O	417-421
were	O	422-426
included	O	427-435
in	O	436-438
the	O	439-442
present	O	443-450
study	O	451-456
.	O	456-457

Tolterodine	O	458-469
2	O	470-471
mg	O	472-474
,	O	474-475
twice	O	476-481
daily	O	482-487
was	O	488-491
given	O	492-497
.	O	497-498

After	O	499-504
8	O	505-506
weeks	O	507-512
treatment	O	513-522
,	O	522-523
changes	O	524-531
in	O	532-534
micturition	O	535-546
diary	O	547-552
variables	O	553-562
and	O	563-566
tolerability	O	567-579
were	O	580-584
determined	O	585-595
.	O	595-596

Short	O	597-602
form	O	603-607
36	O	608-610
(	O	611-612
SF36	O	612-616
)	O	616-617
questionaires	O	618-631
(	O	632-633
Thai	O	633-637
version	O	638-645
)	O	645-646
were	O	647-651
given	O	652-657
before	O	658-664
and	O	665-668
after	O	669-674
8	O	675-676
weeks	O	677-682
of	O	683-685
treatment	O	686-695
.	O	695-696

RESULTS	O	697-704
:	O	704-705
At	O	706-708
8	O	709-710
weeks	O	711-716
,	O	716-717
all	O	718-721
micturition	O	722-733
per	O	734-737
day	O	738-741
decreased	O	742-751
from	O	752-756
16	O	757-759
.	O	759-760
7	O	761-762
+	O	763-764
/	O	764-765
-	O	765-766
5	O	767-768
.	O	768-769
3	O	770-771
to	O	772-774
6	O	775-776
.	O	776-777
7	O	778-779
+	O	780-781
/	O	781-782
-	O	782-783
2	O	784-785
.	O	785-786
4	O	786-787
times	O	788-793
per	O	794-797
day	O	798-801
.	O	801-802

The	O	803-806
number	O	807-813
of	O	814-816
nocturia	B	817-825
episodes	O	826-834
decreased	O	835-844
from	O	845-849
5	O	850-851
.	O	851-852
4	O	852-853
+	O	854-855
/	O	855-856
-	O	856-857
4	O	858-859
.	O	859-860
2	O	860-861
to	O	862-864
1	O	865-866
.	O	866-867
1	O	865-866
+	O	869-870
/	O	870-871
-	O	871-872
1	O	873-874
.	O	874-875
0	O	875-876
times	O	877-882
per	O	883-886
night	O	887-892
.	O	892-893

The	O	894-897
most	O	898-902
common	O	903-909
side	O	910-914
effect	O	915-921
was	O	922-925
dry	B	926-929
month	I	930-935
in	O	936-938
5	O	939-940
cases	O	941-946
(	O	947-948
16	O	948-950
.	O	950-951
7	O	951-952
%	O	952-953
)	O	953-954
with	O	955-959
2	O	960-961
cases	O	962-967
reporting	O	968-977
a	O	978-979
moderate	O	980-988
degree	O	989-995
and	O	996-999
1	O	1000-1001
case	O	1002-1006
with	O	1007-1011
severe	O	1012-1018
degree	O	1019-1025
.	O	1025-1026

Only	O	1027-1031
one	O	1032-1035
case	O	1036-1040
(	O	1041-1042
3	O	1042-1043
.	O	1043-1044
3	O	1042-1043
%	O	1045-1046
)	O	1046-1047
withdrew	O	1048-1056
from	O	1057-1061
the	O	1062-1065
present	O	1066-1073
study	O	1074-1079
due	O	1080-1083
to	O	1084-1086
a	O	1087-1088
severe	O	1089-1095
dry	B	1096-1099
mouth	I	1100-1105
.	O	1105-1106

The	O	1107-1110
SF	O	1111-1113
-	O	1113-1114
36	O	1114-1116
scores	O	1117-1123
changed	O	1124-1131
significantly	O	1132-1145
in	O	1146-1148
the	O	1149-1152
domains	O	1153-1160
of	O	1161-1163
physical	O	1164-1172
functioning	O	1173-1184
,	O	1184-1185
role	O	1186-1190
function	O	1191-1199
emotional	O	1200-1209
,	O	1209-1210
social	O	1211-1217
function	O	1218-1226
and	O	1227-1230
mental	O	1231-1237
heath	O	1238-1243
.	O	1243-1244

CONCLUSION	O	1245-1255
:	O	1255-1256
Tolterodine	O	1257-1268
was	O	1269-1272
well	O	1273-1277
tolerated	O	1278-1287
and	O	1288-1291
its	O	1292-1295
effects	O	1296-1303
improved	O	1304-1312
the	O	1313-1316
quality	O	1317-1324
of	O	1325-1327
life	O	1328-1332
in	O	1333-1335
Thai	O	1336-1340
women	O	1341-1346
with	O	1347-1351
OAB	B	1352-1355
.	O	1355-1356

Absence	O	0-7
of	O	8-10
acute	O	11-16
cerebral	O	17-25
vasoconstriction	O	26-42
after	O	43-48
cocaine	O	49-56
-	O	56-57
associated	O	57-67
subarachnoid	B	68-80
hemorrhage	I	81-91
.	O	91-92

INTRODUCTION	O	93-105
:	O	105-106
Cocaine	O	107-114
use	O	115-118
has	O	119-122
been	O	123-127
associated	O	128-138
with	O	139-143
neurovascular	B	144-157
complications	I	158-171
,	O	171-172
including	O	173-182
arterial	O	183-191
vasoconstriction	O	192-208
and	O	209-212
vasculitis	B	213-223
.	O	223-224

However	O	225-232
,	O	232-233
there	O	234-239
are	O	240-243
few	O	244-247
studies	O	248-255
of	O	256-258
angiographic	O	259-271
effects	O	272-279
of	O	280-282
cocaine	O	283-290
on	O	291-293
human	O	294-299
cerebral	O	300-308
arteries	O	309-317
.	O	317-318

Information	O	319-330
on	O	331-333
these	O	334-339
effects	O	340-347
could	O	348-353
be	O	354-356
obtained	O	357-365
from	O	366-370
angiograms	O	371-381
of	O	382-384
patients	O	385-393
with	O	394-398
cocaine	O	399-406
-	O	406-407
associated	O	407-417
subarachnoid	B	418-430
hemorrhage	I	431-441
(	O	442-443
SAH	B	443-446
)	O	446-447
who	O	448-451
underwent	O	452-461
angiography	O	462-473
shortly	O	474-481
after	O	482-487
cocaine	O	488-495
use	O	496-499
.	O	499-500

METHODS	O	501-508
:	O	508-509
We	O	510-512
screened	O	513-521
patients	O	522-530
with	O	531-535
SAH	B	536-539
retrospectively	O	540-555
and	O	556-559
identified	O	560-570
those	O	571-576
with	O	577-581
positive	O	582-590
urine	O	591-596
toxicology	O	597-607
for	O	608-611
cocaine	O	612-619
or	O	620-622
its	O	623-626
metabolites	O	627-638
.	O	638-639

Quantitative	O	640-652
arterial	O	653-661
diameter	O	662-670
measurements	O	671-683
from	O	684-688
angiograms	O	689-699
of	O	700-702
these	O	703-708
patients	O	709-717
were	O	718-722
compared	O	723-731
to	O	732-734
measurements	O	735-747
from	O	748-752
control	O	753-760
patients	O	761-769
with	O	770-774
SAH	B	775-778
who	O	779-782
were	O	783-787
matched	O	788-795
for	O	796-799
factors	O	800-807
known	O	808-813
to	O	814-816
influence	O	817-826
arterial	O	827-835
diameter	O	836-844
.	O	844-845

Qualitative	O	846-857
comparisons	O	858-869
of	O	870-872
small	O	873-878
artery	O	879-885
changes	O	886-893
also	O	894-898
were	O	899-903
made	O	904-908
.	O	908-909

RESULTS	O	910-917
:	O	917-918
Thirteen	O	919-927
patients	O	928-936
with	O	937-941
positive	O	942-950
cocaine	O	951-958
toxicology	O	959-969
were	O	970-974
compared	O	975-983
to	O	984-986
26	O	987-989
controls	O	990-998
.	O	998-999

There	O	1000-1005
were	O	1006-1010
no	O	1011-1013
significant	O	1014-1025
differences	O	1026-1037
between	O	1038-1045
groups	O	1046-1052
in	O	1053-1055
the	O	1056-1059
mean	O	1060-1064
diameters	O	1065-1074
of	O	1075-1077
the	O	1078-1081
intradural	O	1082-1092
internal	O	1093-1101
carotid	O	1102-1109
,	O	1109-1110
sphenoidal	O	1111-1121
segment	O	1122-1129
of	O	1130-1132
the	O	1133-1136
middle	O	1137-1143
cerebral	O	1144-1152
,	O	1152-1153
precommunicating	O	1154-1170
segment	O	1171-1178
of	O	1179-1181
the	O	1182-1185
anterior	O	1186-1194
cerebral	O	1195-1203
,	O	1203-1204
or	O	1205-1207
basilar	O	1208-1215
arteries	O	1216-1224
(	O	1225-1226
p	O	1226-1227
greater	O	1228-1235
than	O	1236-1240
0	O	1241-1242
.	O	1242-1243
05	O	1243-1245
for	O	1246-1249
all	O	1250-1253
comparisons	O	1254-1265
,	O	1265-1266
unpaired	O	1267-1275
t	O	1276-1277
-	O	1277-1278
tests	O	1278-1283
)	O	1283-1284
.	O	1284-1285

There	O	1286-1291
also	O	1292-1296
were	O	1297-1301
no	O	1302-1304
significant	O	1305-1316
differences	O	1317-1328
between	O	1329-1336
groups	O	1337-1343
when	O	1344-1348
expressing	O	1349-1359
diameters	O	1360-1369
as	O	1370-1372
the	O	1373-1376
sum	O	1377-1380
of	O	1381-1383
the	O	1384-1387
precommunicating	O	1388-1404
segment	O	1405-1412
of	O	1413-1415
the	O	1416-1419
anterior	O	1420-1428
cerebral	O	1429-1437
+	O	1438-1439
sphenoidal	O	1440-1450
segment	O	1451-1458
of	O	1459-1461
the	O	1462-1465
middle	O	1466-1472
cerebral	O	1473-1481
+	O	1482-1483
supraclinoid	O	1484-1496
internal	O	1497-1505
carotid	O	1506-1513
artery	O	1514-1520
+	O	1521-1522
basilar	O	1523-1530
artery	O	1531-1537
divided	O	1538-1545
by	O	1546-1548
the	O	1549-1552
diameter	O	1553-1561
of	O	1562-1564
the	O	1565-1568
petrous	O	1569-1576
internal	O	1577-1585
carotid	O	1586-1593
artery	O	1594-1600
(	O	1601-1602
p	O	1602-1603
greater	O	1604-1611
than	O	1612-1616
0	O	1617-1618
.	O	1618-1619
05	O	1619-1621
,	O	1621-1622
unpaired	O	1623-1631
t	O	1632-1633
-	O	1633-1634
tests	O	1634-1639
)	O	1639-1640
.	O	1640-1641

Qualitative	O	1642-1653
assessments	O	1654-1665
showed	O	1666-1672
two	O	1673-1676
arterial	O	1677-1685
irregularities	O	1686-1700
in	O	1701-1703
the	O	1704-1707
distal	O	1708-1714
vasculature	O	1715-1726
in	O	1727-1729
each	O	1730-1734
group	O	1735-1740
.	O	1740-1741

CONCLUSION	O	1742-1752
:	O	1752-1753
No	O	1754-1756
quantitative	O	1757-1769
evidence	O	1770-1778
for	O	1779-1782
narrowing	O	1783-1792
of	O	1793-1795
large	O	1796-1801
cerebral	O	1802-1810
arteries	O	1811-1819
or	O	1820-1822
qualitative	O	1823-1834
angiographic	O	1835-1847
evidence	O	1848-1856
for	O	1857-1860
distal	O	1861-1867
narrowing	O	1868-1877
or	O	1878-1880
vasculitis	B	1881-1891
could	O	1892-1897
be	O	1898-1900
found	O	1901-1906
in	O	1907-1909
patients	O	1910-1918
who	O	1919-1922
underwent	O	1923-1932
angiography	O	1933-1944
after	O	1945-1950
aneurysmal	B	1951-1961
SAH	B	1962-1965
associated	O	1966-1976
with	O	1977-1981
cocaine	O	1982-1989
use	O	1990-1993
.	O	1993-1994

Atrial	B	0-6
fibrillation	I	7-19
following	O	20-29
chemotherapy	O	30-42
for	O	43-46
stage	O	47-52
IIIE	O	53-57
diffuse	O	58-65
large	O	66-71
B	O	72-73
-	O	73-74
cell	O	74-78
gastric	B	79-86
lymphoma	I	87-95
in	O	96-98
a	O	99-100
patient	O	101-108
with	O	109-113
myotonic	B	114-122
dystrophy	I	123-132
(	O	133-134
Steinert	B	134-142
'	I	142-143
s	I	143-144
disease	I	145-152
)	O	152-153
.	O	153-154

The	O	155-158
authors	O	159-166
describe	O	167-175
the	O	176-179
unusual	O	180-187
association	O	188-199
between	O	200-207
diffuse	O	208-215
B	O	216-217
-	O	217-218
cell	O	218-222
gastric	B	223-230
lymphoma	I	231-239
and	O	240-243
myotonic	B	244-252
dystrophy	I	253-262
,	O	262-263
the	O	264-267
most	O	268-272
common	O	273-279
form	O	280-284
of	O	285-287
adult	O	288-293
muscular	B	294-302
dystrophy	I	303-312
,	O	312-313
and	O	314-317
sudden	O	318-324
atrial	B	325-331
fibrillation	I	332-344
following	O	345-354
one	O	355-358
cycle	O	359-364
of	O	365-367
doxorubicin	O	368-379
-	O	379-380
based	O	380-385
chemotherapy	O	386-398
in	O	399-401
the	O	402-405
same	O	406-410
patient	O	411-418
.	O	418-419

Atrial	B	420-426
fibrillation	I	427-439
or	O	440-442
other	O	443-448
cardiac	B	449-456
arrhythmias	I	457-468
are	O	469-472
unusual	O	473-480
complications	O	481-494
in	O	495-497
patients	O	498-506
treated	O	507-514
with	O	515-519
chemotherapy	O	520-532
.	O	532-533

The	O	534-537
cardiac	B	538-545
toxicity	I	546-554
intrinsically	O	555-568
associated	O	569-579
with	O	580-584
the	O	585-588
aggressive	O	589-599
chemotherapy	O	600-612
employed	O	613-621
could	O	622-627
function	O	628-636
as	O	637-639
a	O	640-641
triggering	O	642-652
factor	O	653-659
for	O	660-663
the	O	664-667
arrhythmia	B	668-678
in	O	679-681
the	O	682-685
predisposed	O	686-697
myocardium	O	698-708
of	O	709-711
this	O	712-716
patient	O	717-724
.	O	724-725

A	O	0-1
phase	O	2-7
II	O	8-10
study	O	11-16
of	O	17-19
thalidomide	O	20-31
in	O	32-34
advanced	O	35-43
metastatic	O	44-54
renal	B	55-60
cell	I	61-65
carcinoma	I	66-75
.	O	75-76

OBJECTIVES	O	77-87
:	O	87-88
To	O	89-91
evaluate	O	92-100
the	O	101-104
toxicity	B	105-113
and	O	114-117
activity	O	118-126
of	O	127-129
thalidomide	O	130-141
in	O	142-144
patients	O	145-153
with	O	154-158
advanced	O	159-167
metastatic	O	168-178
renal	B	179-184
cell	I	185-189
cancer	I	190-196
and	O	197-200
to	O	201-203
measure	O	204-211
changes	O	212-219
of	O	220-222
one	O	223-226
angiogenic	O	227-237
factor	O	238-244
,	O	244-245
vascular	O	246-254
endothelial	O	255-266
growth	O	267-273
factor	O	274-280
(	O	281-282
VEGF	O	282-286
)	O	286-287
165	O	287-290
,	O	290-291
with	O	292-296
therapy	O	297-304
.	O	304-305

PATIENTS	O	306-314
AND	O	315-318
METHODS	O	319-326
:	O	326-327
29	O	328-330
patients	O	331-339
were	O	340-344
enrolled	O	345-353
on	O	354-356
a	O	357-358
study	O	359-364
of	O	365-367
thalidomide	O	368-379
using	O	380-385
an	O	386-388
intra	O	389-394
-	O	394-395
patient	O	395-402
dose	O	403-407
escalation	O	408-418
schedule	O	419-427
.	O	427-428

Patients	O	429-437
began	O	438-443
thalidomide	O	444-455
at	O	456-458
400	O	459-462
mg	O	463-465
/	O	465-466
d	O	466-467
and	O	468-471
escalated	O	472-481
as	O	482-484
tolerated	O	485-494
to	O	495-497
1200	O	498-502
mg	O	503-505
/	O	505-506
d	O	506-507
by	O	508-510
day	O	511-514
54	O	515-517
.	O	517-518

Fifty	O	519-524
-	O	524-525
nine	O	525-529
per	O	530-533
cent	O	534-538
of	O	539-541
patients	O	542-550
had	O	551-554
had	O	555-558
previous	O	559-567
therapy	O	568-575
with	O	576-580
IL	O	581-583
-	O	583-584
2	O	584-585
and	O	586-589
52	O	590-592
%	O	592-593
were	O	594-598
performance	O	599-610
status	O	611-617
2	O	618-619
or	O	620-622
3	O	623-624
.	O	624-625
Systemic	O	626-634
plasma	O	635-641
VEGF165	O	642-649
levels	O	650-656
were	O	657-661
measured	O	662-670
by	O	671-673
dual	O	674-678
monoclonal	O	679-689
ELISA	O	690-695
in	O	696-698
8	O	699-700
patients	O	701-709
.	O	709-710

RESULTS	O	711-718
:	O	718-719
24	O	720-722
patients	O	723-731
were	O	732-736
evaluable	O	737-746
for	O	747-750
response	O	751-759
with	O	760-764
one	O	765-768
partial	O	769-776
response	O	777-785
of	O	786-788
11	O	789-791
months	O	792-798
duration	O	799-807
of	O	808-810
a	O	811-812
patient	O	813-820
with	O	821-825
hepatic	O	826-833
and	O	834-837
pulmonary	O	838-847
metastases	B	848-858
(	O	859-860
4	O	860-861
%	O	861-862
)	O	862-863
,	O	863-864
one	O	865-868
minor	O	869-874
response	O	875-883
,	O	883-884
and	O	885-888
2	O	889-890
patients	O	891-899
stable	O	900-906
for	O	907-910
over	O	911-915
6	O	916-917
months	O	918-924
.	O	924-925

Somnolence	B	926-936
and	O	937-940
constipation	B	941-953
were	O	954-958
prominent	O	959-968
toxicities	B	969-979
and	O	980-983
most	O	984-988
patients	O	989-997
could	O	998-1003
not	O	1004-1007
tolerate	O	1008-1016
the	O	1017-1020
1200	O	1021-1025
mg	O	1026-1028
/	O	1028-1029
day	O	1029-1032
dose	O	1033-1037
level	O	1038-1043
.	O	1043-1044

Systemic	O	1045-1053
plasma	O	1054-1060
VEGF165	O	1061-1068
levels	O	1069-1075
did	O	1076-1079
not	O	1080-1083
change	O	1084-1090
with	O	1091-1095
therapy	O	1096-1103
.	O	1103-1104

CONCLUSION	O	1105-1115
:	O	1115-1116
These	O	1117-1122
results	O	1123-1130
are	O	1131-1134
consistent	O	1135-1145
with	O	1146-1150
a	O	1151-1152
low	O	1153-1156
level	O	1157-1162
of	O	1163-1165
activity	O	1166-1174
of	O	1175-1177
thalidomide	O	1178-1189
in	O	1190-1192
renal	B	1193-1198
cell	I	1199-1203
carcinoma	I	1204-1213
.	O	1213-1214

Administration	O	1215-1229
of	O	1230-1232
doses	O	1233-1238
over	O	1239-1243
800	O	1244-1247
mg	O	1248-1250
/	O	1250-1251
day	O	1251-1254
was	O	1255-1258
difficult	O	1259-1268
to	O	1269-1271
achieve	O	1272-1279
in	O	1280-1282
this	O	1283-1287
patient	O	1288-1295
population	O	1296-1306
,	O	1306-1307
however	O	1308-1315
lower	O	1316-1321
doses	O	1322-1327
were	O	1328-1332
practical	O	1333-1342
.	O	1342-1343

The	O	1344-1347
dose	O	1348-1352
-	O	1352-1353
response	O	1353-1361
relationship	O	1362-1374
,	O	1374-1375
if	O	1376-1378
any	O	1379-1382
,	O	1382-1383
of	O	1384-1386
thalidomide	O	1387-1398
for	O	1399-1402
renal	B	1403-1408
cell	I	1409-1413
carcinoma	I	1414-1423
is	O	1424-1426
unclear	O	1427-1434
.	O	1434-1435

The	O	0-3
striatum	O	4-12
as	O	13-15
a	O	16-17
target	O	18-24
for	O	25-28
anti	O	29-33
-	O	33-34
rigor	O	34-39
effects	O	40-47
of	O	48-50
an	O	51-53
antagonist	O	54-64
of	O	65-67
mGluR1	O	68-74
,	O	74-75
but	O	76-79
not	O	80-83
an	O	84-86
agonist	O	87-94
of	O	95-97
group	O	98-103
II	O	104-106
metabotropic	O	107-119
glutamate	O	120-129
receptors	O	130-139
.	O	139-140

The	O	141-144
aim	O	145-148
of	O	149-151
the	O	152-155
present	O	156-163
study	O	164-169
was	O	170-173
to	O	174-176
find	O	177-181
out	O	182-185
whether	O	186-193
the	O	194-197
metabotropic	O	198-210
receptor	O	211-219
1	O	220-221
(	O	222-223
mGluR1	O	223-229
)	O	229-230
and	O	231-234
group	O	235-240
II	O	241-243
mGluRs	O	244-250
,	O	250-251
localized	O	252-261
in	O	262-264
the	O	265-268
striatum	O	269-277
,	O	277-278
are	O	279-282
involved	O	283-291
in	O	292-294
antiparkinsonian	O	295-311
-	O	311-312
like	O	312-316
effects	O	317-324
in	O	325-327
rats	O	328-332
.	O	332-333

Haloperidol	O	334-345
(	O	346-347
1	O	347-348
mg	O	349-351
/	O	351-352
kg	O	352-354
ip	O	355-357
)	O	357-358
induced	O	359-366
parkinsonian	B	367-379
-	O	379-380
like	O	380-384
muscle	B	385-391
rigidity	I	392-400
,	O	400-401
measured	O	402-410
as	O	411-413
an	O	414-416
increased	O	417-426
resistance	O	427-437
of	O	438-440
a	O	441-442
rat	O	443-446
'	O	446-447
s	O	447-448
hind	O	449-453
foot	O	454-458
to	O	459-461
passive	O	462-469
flexion	O	470-477
and	O	478-481
extension	O	482-491
at	O	492-494
the	O	495-498
ankle	O	499-504
joint	O	505-510
.	O	510-511

(	O	512-513
RS	O	513-515
)	O	515-516
-	O	516-517
1	O	517-518
-	O	516-517
aminoindan	O	519-529
-	O	516-517
1	O	517-518
,	O	531-532
5	O	532-533
-	O	516-517
dicarboxylic	O	534-546
acid	O	547-551
(	O	552-553
AIDA	O	553-557
;	O	557-558
0	O	559-560
.	O	560-561
5	O	561-562
-	O	562-563
15	O	563-565
microg	O	566-572
/	O	572-573
0	O	573-574
.	O	574-575
5	O	575-576

microl	O	577-583
)	O	583-584
,	O	584-585
a	O	586-587
potent	O	588-594
and	O	595-598
selective	O	599-608
mGluR1	O	609-615
antagonist	O	616-626
,	O	626-627
or	O	628-630
(	O	631-632
2R	O	632-634
,	O	634-635
4R	O	635-637
)	O	637-638
-	O	638-639
4	O	635-636
-	O	638-639
aminopyrrolidine	O	641-657
-	O	638-639
2	O	632-633
,	O	634-635
4	O	635-636
-	O	638-639
dicarboxylate	O	662-675
(	O	676-677
2R	O	677-679
,	O	679-680
4R	O	680-682
-	O	682-683
APDC	O	683-687
;	O	687-688
7	O	689-690
.	O	690-691
5	O	691-692
-	O	692-693
15	O	693-695
microg	O	696-702
/	O	702-703
0	O	703-704
.	O	704-705
5	O	705-706

microl	O	707-713
)	O	713-714
,	O	714-715
a	O	716-717
selective	O	718-727
group	O	728-733
II	O	734-736
agonist	O	737-744
,	O	744-745
was	O	746-749
injected	O	750-758
bilaterally	O	759-770
into	O	771-775
the	O	776-779
striatum	O	780-788
of	O	789-791
haloperidol	O	792-803
-	O	803-804
treated	O	804-811
animals	O	812-819
.	O	819-820

AIDA	O	821-825
in	O	826-828
doses	O	829-834
of	O	835-837
7	O	838-839
.	O	839-840
5	O	840-841
-	O	841-842
15	O	842-844
microg	O	845-851
/	O	851-852
0	O	852-853
.	O	853-854
5	O	854-855

microl	O	856-862
diminished	O	863-873
the	O	874-877
haloperidol	O	878-889
-	O	889-890
induced	O	890-897
muscle	B	898-904
rigidity	I	905-913
.	O	913-914

In	O	915-917
contrast	O	918-926
,	O	926-927
2R	O	928-930
,	O	930-931
4R	O	931-933
-	O	933-934
APDC	O	934-938
injections	O	939-949
were	O	950-954
ineffective	O	955-966
.	O	966-967

The	O	968-971
present	O	972-979
results	O	980-987
may	O	988-991
suggest	O	992-999
that	O	1000-1004
the	O	1005-1008
blockade	O	1009-1017
of	O	1018-1020
striatal	O	1021-1029
mGluR1	O	1030-1036
,	O	1036-1037
but	O	1038-1041
not	O	1042-1045
the	O	1046-1049
stimulation	O	1050-1061
of	O	1062-1064
group	O	1065-1070
II	O	1071-1073
mGluRs	O	1074-1080
,	O	1080-1081
may	O	1082-1085
ameliorate	O	1086-1096
parkinsonian	B	1097-1109
muscle	B	1110-1116
rigidity	I	1117-1125
.	O	1125-1126

Acute	O	0-5
cholestatic	B	6-17
hepatitis	I	18-27
after	O	28-33
exposure	O	34-42
to	O	43-45
isoflurane	O	46-56
.	O	56-57

OBJECTIVE	O	58-67
:	O	67-68
To	O	69-71
report	O	72-78
a	O	79-80
case	O	81-85
of	O	86-88
acute	O	89-94
cholestatic	B	95-106
hepatitis	I	107-116
following	O	117-126
exposure	O	127-135
to	O	136-138
the	O	139-142
inhalational	O	143-155
anesthetic	O	156-166
isoflurane	O	167-177
.	O	177-178

CASE	O	179-183
SUMMARY	O	184-191
:	O	191-192
A	O	193-194
70	O	195-197
-	O	197-198
year	O	198-202
-	O	197-198
old	O	203-206
healthy	O	207-214
woman	O	215-220
from	O	221-225
Iraq	O	226-230
developed	O	231-240
acute	O	241-246
cholestatic	B	247-258
hepatitis	I	259-268
3	O	269-270
weeks	O	271-276
following	O	277-286
repair	O	287-293
of	O	294-296
the	O	297-300
right	O	301-306
rotator	O	307-314
cuff	O	315-319
under	O	320-325
general	O	326-333
anesthesia	O	334-344
.	O	344-345

There	O	346-351
was	O	352-355
no	O	356-358
evidence	O	359-367
for	O	368-371
viral	O	372-377
,	O	377-378
autoimmune	O	379-389
,	O	389-390
or	O	391-393
metabolic	O	394-403
causes	O	404-410
of	O	411-413
hepatitis	B	414-423
.	O	423-424

No	O	425-427
other	O	428-433
medications	O	434-445
were	O	446-450
involved	O	451-459
except	O	460-466
for	O	467-470
dipyrone	O	471-479
for	O	480-483
analgesia	B	484-493
.	O	493-494

The	O	495-498
alanine	O	499-506
aminotransferase	O	507-523
was	O	524-527
elevated	O	528-536
to	O	537-539
a	O	540-541
peak	O	542-546
concentration	O	547-560
of	O	561-563
1533	O	564-568
U	O	569-570
/	O	570-571
L	O	571-572
and	O	573-576
the	O	577-580
serum	O	581-586
bilirubin	O	587-596
reached	O	597-604
a	O	605-606
peak	O	607-611
of	O	612-614
17	O	615-617
.	O	617-618
0	O	618-619
mg	O	620-622
/	O	622-623
dL	O	623-625
.	O	625-626

There	O	627-632
was	O	633-636
slow	O	637-641
improvement	O	642-653
over	O	654-658
4	O	659-660
months	O	661-667
.	O	667-668

Accidental	O	669-679
reexposure	O	680-690
by	O	691-693
the	O	694-697
patient	O	698-705
to	O	706-708
dipyrone	O	709-717
was	O	718-721
uneventful	O	722-732
.	O	732-733

DISCUSSION	O	734-744
:	O	744-745
The	O	746-749
clinical	O	750-758
and	O	759-762
histologic	O	763-773
picture	O	774-781
of	O	782-784
this	O	785-789
case	O	790-794
resembles	O	795-804
halothane	B	805-814
hepatitis	I	815-824
,	O	824-825
which	O	826-831
has	O	832-835
a	O	836-837
significant	O	838-849
mortality	O	850-859
rate	O	860-864
.	O	864-865

CONCLUSIONS	O	866-877
:	O	877-878
Isoflurane	O	879-889
,	O	889-890
a	O	891-892
common	O	893-899
anesthetic	O	900-910
agent	O	911-916
,	O	916-917
can	O	918-921
cause	O	922-927
severe	O	928-934
cholestatic	B	935-946
hepatitis	I	947-956
.	O	956-957

Calcitonin	O	0-10
gene	O	11-15
-	O	15-16
related	O	16-23
peptide	O	24-31
levels	O	32-38
during	O	39-45
nitric	O	46-52
oxide	O	53-58
-	O	58-59
induced	O	59-66
headache	B	67-75
in	O	76-78
patients	O	79-87
with	O	88-92
chronic	O	93-100
tension	B	101-108
-	I	108-109
type	I	109-113
headache	I	114-122
.	O	122-123

It	O	124-126
has	O	127-130
been	O	131-135
proposed	O	136-144
that	O	145-149
nitric	O	150-156
oxide	O	157-162
(	O	163-164
NO	O	164-166
)	O	166-167
induced	O	168-175
headache	B	176-184
in	O	185-187
primary	B	188-195
headaches	I	196-205
may	O	206-209
be	O	210-212
associated	O	213-223
with	O	224-228
release	O	229-236
of	O	237-239
calcitonin	O	240-250
gene	O	251-255
-	O	255-256
related	O	256-263
peptide	O	264-271
(	O	272-273
CGRP	O	273-277
)	O	277-278
.	O	278-279

In	O	280-282
the	O	283-286
present	O	287-294
study	O	295-300
we	O	301-303
aimed	O	304-309
to	O	310-312
investigate	O	313-324
plasma	O	325-331
levels	O	332-338
of	O	339-341
CGRP	O	342-346
during	O	347-353
headache	B	354-362
induced	O	363-370
by	O	371-373
the	O	374-377
NO	O	378-380
donor	O	381-386
glyceryl	O	387-395
trinitrate	O	396-406
(	O	407-408
GTN	O	408-411
)	O	411-412
in	O	413-415
16	O	416-418
patients	O	419-427
with	O	428-432
chronic	O	433-440
tension	B	441-448
-	I	448-449
type	I	449-453
headache	I	454-462
and	O	463-466
16	O	467-469
healthy	O	470-477
controls	O	478-486
.	O	486-487

The	O	488-491
subjects	O	492-500
were	O	501-505
randomly	O	506-514
allocated	O	515-524
to	O	525-527
receive	O	528-535
0	O	536-537
.	O	537-538
5	O	538-539
microg	O	540-546
/	O	546-547
kg	O	547-549
/	O	546-547
min	O	550-553
GTN	O	554-557
or	O	558-560
placebo	O	561-568
over	O	569-573
20	O	574-576
min	O	577-580
on	O	581-583
two	O	584-587
headache	B	588-596
-	O	596-597
free	O	597-601
days	O	602-606
.	O	606-607

Blood	O	608-613
samples	O	614-621
were	O	622-626
collected	O	627-636
at	O	637-639
baseline	O	640-648
,	O	648-649
10	O	650-652
,	O	652-653
20	O	654-656
and	O	657-660
60	O	661-663
min	O	664-667
after	O	668-673
start	O	674-679
of	O	680-682
infusion	O	683-691
.	O	691-692

Both	O	693-697
patients	O	698-706
and	O	707-710
controls	O	711-719
developed	O	720-729
significantly	O	730-743
stronger	O	744-752
immediate	O	753-762
headache	B	763-771
on	O	772-774
the	O	775-778
GTN	O	779-782
day	O	783-786
than	O	787-791
on	O	792-794
the	O	795-798
placebo	O	799-806
day	O	807-810
and	O	811-814
the	O	815-818
headache	B	819-827
was	O	828-831
significantly	O	832-845
more	O	846-850
pronounced	O	851-861
in	O	862-864
patients	O	865-873
than	O	874-878
in	O	879-881
controls	O	882-890
.	O	890-891

There	O	892-897
was	O	898-901
no	O	902-904
difference	O	905-915
between	O	916-923
the	O	924-927
area	O	928-932
under	O	933-938
the	O	939-942
CGRP	O	943-947
curve	O	948-953
(	O	954-955
AUCCGRP	O	955-962
)	O	962-963
on	O	964-966
GTN	O	967-970
vs	O	971-973
.	O	973-974
placebo	O	975-982
day	O	983-986
in	O	987-989
either	O	990-996
patients	O	997-1005
(	O	1006-1007
P	O	1007-1008
=	O	1008-1009
0	O	1009-1010
.	O	1010-1011
65	O	1011-1013
)	O	1013-1014
or	O	1015-1017
controls	O	1018-1026
(	O	1027-1028
P	O	1028-1029
=	O	1029-1030
0	O	1030-1031
.	O	1031-1032
48	O	1032-1034
)	O	1034-1035
.	O	1031-1032

The	O	1037-1040
AUCCGRP	O	1041-1048
recorded	O	1049-1057
on	O	1058-1060
the	O	1061-1064
GTN	O	1065-1068
day	O	1069-1072
did	O	1073-1076
not	O	1077-1080
differ	O	1081-1087
between	O	1088-1095
patients	O	1096-1104
and	O	1105-1108
controls	O	1109-1117
(	O	1118-1119
P	O	1119-1120
=	O	1120-1121
0	O	1121-1122
.	O	1122-1123
36	O	1123-1125
)	O	1125-1126
.	O	1122-1123

Both	O	1128-1132
in	O	1133-1135
patients	O	1136-1144
and	O	1145-1148
controls	O	1149-1157
,	O	1157-1158
CGRP	O	1159-1163
levels	O	1164-1170
changed	O	1171-1178
significantly	O	1179-1192
over	O	1193-1197
time	O	1198-1202
,	O	1202-1203
on	O	1204-1206
both	O	1207-1211
the	O	1212-1215
GTN	O	1216-1219
and	O	1220-1223
placebo	O	1224-1231
days	O	1232-1236
(	O	1237-1238
P	O	1238-1239
<	O	1240-1241
0	O	1242-1243
.	O	1243-1244
05	O	1244-1246
)	O	1246-1247
.	O	1243-1244

The	O	1249-1252
present	O	1253-1260
study	O	1261-1266
indicates	O	1267-1276
that	O	1277-1281
NO	O	1282-1284
-	O	1284-1285
induced	O	1285-1292
immediate	O	1293-1302
headache	B	1303-1311
is	O	1312-1314
not	O	1315-1318
associated	O	1319-1329
with	O	1330-1334
release	O	1335-1342
of	O	1343-1345
CGRP	O	1346-1350
.	O	1350-1351

Myocardial	B	0-10
ischemia	I	11-19
due	O	20-23
to	O	24-26
coronary	B	27-35
artery	I	36-42
spasm	I	43-48
during	O	49-55
dobutamine	O	56-66
stress	O	67-73
echocardiography	O	74-90
.	O	90-91

Dobutamine	O	92-102
stress	O	103-109
echocardiography	O	110-126
(	O	127-128
DSE	O	128-131
)	O	131-132
is	O	133-135
a	O	136-137
useful	O	138-144
and	O	145-148
safe	O	149-153
provocation	O	154-165
test	O	166-170
for	O	171-174
myocardial	B	175-185
ischemia	I	186-194
.	O	194-195

Until	O	196-201
now	O	202-205
,	O	205-206
the	O	207-210
test	O	211-215
has	O	216-219
been	O	220-224
focused	O	225-232
only	O	233-237
on	O	238-240
the	O	241-244
organic	O	245-252
lesion	O	253-259
in	O	260-262
the	O	263-266
coronary	O	267-275
artery	O	276-282
,	O	282-283
and	O	284-287
positive	O	288-296
DSE	O	297-300
has	O	301-304
indicated	O	305-314
the	O	315-318
presence	O	319-327
of	O	328-330
significant	O	331-342
fixed	O	343-348
coronary	B	349-357
artery	I	358-364
stenosis	I	365-373
.	O	373-374

The	O	375-378
aim	O	379-382
of	O	383-385
the	O	386-389
present	O	390-397
study	O	398-403
is	O	404-406
to	O	407-409
examine	O	410-417
whether	O	418-425
myocardial	B	426-436
ischemia	I	437-445
due	O	446-449
to	O	450-452
coronary	B	453-461
spasm	I	462-467
is	O	468-470
induced	O	471-478
by	O	479-481
dobutamine	O	482-492
.	O	492-493

We	O	494-496
performed	O	497-506
DSE	O	507-510
on	O	511-513
51	O	514-516
patients	O	517-525
with	O	526-530
coronary	B	531-539
spastic	I	540-547
angina	I	548-554
but	O	555-558
without	O	559-566
significant	O	567-578
fixed	O	579-584
coronary	B	585-593
artery	I	594-600
stenosis	I	601-609
.	O	609-610

All	O	611-614
patients	O	615-623
had	O	624-627
anginal	B	628-635
attacks	O	636-643
at	O	644-646
rest	O	647-651
with	O	652-656
ST	O	657-659
elevation	O	660-669
on	O	670-672
the	O	673-676
electrocardiogram	O	677-694
(	O	695-696
variant	B	696-703
angina	I	704-710
)	O	710-711
.	O	711-712

Coronary	O	713-721
spasm	O	722-727
was	O	728-731
induced	O	732-739
by	O	740-742
intracoronary	O	743-756
injection	O	757-766
of	O	767-769
acetylcholine	O	770-783
,	O	783-784
and	O	785-788
no	O	789-791
fixed	O	792-797
coronary	B	798-806
artery	I	807-813
stenosis	I	814-822
was	O	823-826
documented	O	827-837
on	O	838-840
angiograms	O	841-851
in	O	852-854
all	O	855-858
patients	O	859-867
.	O	867-868

DSE	O	869-872
was	O	873-876
performed	O	877-886
with	O	887-891
intravenous	O	892-903
dobutamine	O	904-914
infusion	O	915-923
with	O	924-928
an	O	929-931
incremental	O	932-943
doses	O	944-949
of	O	950-952
5	O	953-954
,	O	954-955
10	O	956-958
,	O	958-959
20	O	960-962
,	O	962-963
30	O	964-966
,	O	966-967
and	O	968-971
40	O	972-974
microg	O	975-981
/	O	981-982
kg	O	982-984
/	O	981-982
min	O	985-988
every	O	989-994
5	O	995-996
minutes	O	997-1004
.	O	1004-1005

Of	O	1006-1008
the	O	1009-1012
51	O	1013-1015
patients	O	1016-1024
,	O	1024-1025
7	O	1026-1027
patients	O	1028-1036
showed	O	1037-1043
asynergy	O	1044-1052
with	O	1053-1057
ST	O	1058-1060
elevation	O	1061-1070
.	O	1070-1071

All	O	1072-1075
7	O	1076-1077
patients	O	1078-1086
(	O	1087-1088
13	O	1088-1090
.	O	1090-1091
7	O	1091-1092
%	O	1092-1093
)	O	1093-1094
had	O	1095-1098
chest	B	1099-1104
pain	I	1105-1109
during	O	1110-1116
asynergy	O	1117-1125
,	O	1125-1126
and	O	1127-1130
both	O	1131-1135
chest	B	1136-1141
pain	I	1142-1146
and	O	1147-1150
electrocardiographic	O	1151-1171
changes	O	1172-1179
were	O	1180-1184
preceded	O	1185-1193
by	O	1194-1196
asynergy	O	1197-1205
.	O	1205-1206

These	O	1207-1212
findings	O	1213-1221
indicate	O	1222-1230
that	O	1231-1235
dobutamine	O	1236-1246
can	O	1247-1250
provoke	O	1251-1258
coronary	B	1259-1267
spasm	I	1268-1273
in	O	1274-1276
some	O	1277-1281
patients	O	1282-1290
with	O	1291-1295
coronary	B	1296-1304
spastic	I	1305-1312
angina	I	1313-1319
.	O	1319-1320

When	O	1321-1325
DSE	O	1326-1329
is	O	1330-1332
performed	O	1333-1342
to	O	1343-1345
evaluate	O	1346-1354
coronary	B	1355-1363
artery	I	1364-1370
disease	I	1371-1378
,	O	1378-1379
not	O	1380-1383
only	O	1384-1388
fixed	O	1389-1394
coronary	B	1395-1403
stenosis	I	1404-1412
,	O	1412-1413
but	O	1414-1417
also	O	1418-1422
coronary	B	1423-1431
spasm	I	1432-1437
should	O	1438-1444
be	O	1445-1447
considered	O	1448-1458
as	O	1459-1461
a	O	1462-1463
genesis	O	1464-1471
of	O	1472-1474
asynergy	O	1475-1483
.	O	1483-1484

Nitric	O	0-6
oxide	O	7-12
synthase	O	13-21
expression	O	22-32
in	O	33-35
the	O	36-39
course	O	40-46
of	O	47-49
lead	O	50-54
-	O	54-55
induced	O	55-62
hypertension	B	63-75
.	O	75-76

We	O	77-79
recently	O	80-88
showed	O	89-95
elevated	O	96-104
reactive	O	105-113
oxygen	O	114-120
species	O	121-128
(	O	129-130
ROS	O	130-133
)	O	133-134
,	O	134-135
reduced	O	136-143
urinary	O	144-151
excretion	O	152-161
of	O	162-164
NO	O	165-167
metabolites	O	168-179
(	O	180-181
NOx	O	181-184
)	O	184-185
,	O	185-186
and	O	187-190
increased	O	191-200
NO	O	201-203
sequestration	O	204-217
as	O	218-220
nitrotyrosine	O	221-234
in	O	235-237
various	O	238-245
tissues	O	246-253
in	O	254-256
rats	O	257-261
with	O	262-266
lead	O	267-271
-	O	271-272
induced	O	272-279
hypertension	B	280-292
.	O	292-293

This	O	294-298
study	O	299-304
was	O	305-308
designed	O	309-317
to	O	318-320
discern	O	321-328
whether	O	329-336
the	O	337-340
reduction	O	341-350
in	O	351-353
urinary	O	354-361
NOx	O	362-365
in	O	366-368
lead	O	369-373
-	O	373-374
induced	O	374-381
hypertension	B	382-394
is	O	395-397
,	O	397-398
in	O	399-401
part	O	402-406
,	O	406-407
due	O	408-411
to	O	412-414
depressed	O	415-424
NO	O	425-427
synthase	O	428-436
(	O	437-438
NOS	O	438-441
)	O	441-442
expression	O	443-453
.	O	453-454

Male	O	455-459
Sprague	O	460-467
-	O	467-468
Dawley	O	468-474
rats	O	475-479
were	O	480-484
randomly	O	485-493
assigned	O	494-502
to	O	503-505
a	O	506-507
lead	O	508-512
-	O	512-513
treated	O	513-520
group	O	521-526
(	O	527-528
given	O	528-533
lead	O	534-538
acetate	O	539-546
,	O	546-547
100	O	548-551
ppm	O	552-555
,	O	555-556
in	O	557-559
drinking	O	560-568
water	O	569-574
and	O	575-578
regular	O	579-586
rat	O	587-590
chow	O	591-595
)	O	595-596
,	O	596-597
a	O	598-599
group	O	600-605
given	O	606-611
lead	O	612-616
and	O	617-620
vitamin	O	621-628
E	O	629-630
-	O	630-631
fortified	O	631-640
chow	O	641-645
,	O	645-646
or	O	647-649
a	O	650-651
normal	O	652-658
control	O	659-666
group	O	667-672
given	O	673-678
either	O	679-685
regular	O	686-693
food	O	694-698
and	O	699-702
water	O	703-708
or	O	709-711
vitamin	O	712-719
E	O	720-721
-	O	721-722
fortified	O	722-731
food	O	732-736
for	O	737-740
12	O	741-743
weeks	O	744-749
.	O	749-750

Tail	O	751-755
blood	O	756-761
pressure	O	762-770
,	O	770-771
urinary	O	772-779
NOx	O	780-783
excretion	O	784-793
,	O	793-794
plasma	O	795-801
malondialdehyde	O	802-817
(	O	818-819
MDA	O	819-822
)	O	822-823
,	O	823-824
and	O	825-828
endothelial	O	829-840
and	O	841-844
inducible	O	845-854
NOS	O	855-858
(	O	859-860
eNOS	O	860-864
and	O	865-868
iNOS	O	869-873
)	O	873-874
isotypes	O	875-883
in	O	884-886
the	O	887-890
aorta	O	891-896
and	O	897-900
kidney	O	901-907
were	O	908-912
measured	O	913-921
.	O	921-922

The	O	923-926
lead	O	927-931
-	O	931-932
treated	O	932-939
group	O	940-945
exhibited	O	946-955
a	O	956-957
rise	O	958-962
in	O	963-965
blood	O	966-971
pressure	O	972-980
and	O	981-984
plasma	O	985-991
MDA	O	992-995
concentration	O	996-1009
,	O	1009-1010
a	O	1011-1012
fall	O	1013-1017
in	O	1018-1020
urinary	O	1021-1028
NOx	O	1029-1032
excretion	O	1033-1042
,	O	1042-1043
and	O	1044-1047
a	O	1048-1049
paradoxical	O	1050-1061
rise	O	1062-1066
in	O	1067-1069
vascular	O	1070-1078
and	O	1079-1082
renal	O	1083-1088
tissue	O	1089-1095
eNOS	O	1096-1100
and	O	1101-1104
iNOS	O	1105-1109
expression	O	1110-1120
.	O	1120-1121

Vitamin	O	1122-1129
E	O	1130-1131
supplementation	O	1132-1147
ameliorated	O	1148-1159
hypertension	B	1160-1172
,	O	1172-1173
lowered	O	1174-1181
plasma	O	1182-1188
MDA	O	1189-1192
concentration	O	1193-1206
,	O	1206-1207
and	O	1208-1211
raised	O	1212-1218
urinary	O	1219-1226
NOx	O	1227-1230
excretion	O	1231-1240
while	O	1241-1246
significantly	O	1247-1260
lowering	O	1261-1269
vascular	O	1270-1278
,	O	1278-1279
but	O	1280-1283
not	O	1284-1287
renal	O	1288-1293
,	O	1293-1294
tissue	O	1295-1301
eNOS	O	1302-1306
and	O	1307-1310
iNOS	O	1311-1315
expression	O	1316-1326
.	O	1326-1327

Vitamin	O	1328-1335
E	O	1336-1337
supplementation	O	1338-1353
had	O	1354-1357
no	O	1358-1360
effect	O	1361-1367
on	O	1368-1370
either	O	1371-1377
blood	O	1378-1383
pressure	O	1384-1392
,	O	1392-1393
plasma	O	1394-1400
MDA	O	1401-1404
,	O	1404-1405
or	O	1406-1408
NOS	O	1409-1412
expression	O	1413-1423
in	O	1424-1426
the	O	1427-1430
control	O	1431-1438
group	O	1439-1444
.	O	1444-1445

The	O	1446-1449
study	O	1450-1455
also	O	1456-1460
revealed	O	1461-1469
significant	O	1470-1481
inhibition	O	1482-1492
of	O	1493-1495
NOS	O	1496-1499
enzymatic	O	1500-1509
activity	O	1510-1518
by	O	1519-1521
lead	O	1522-1526
in	O	1527-1529
cell	O	1530-1534
-	O	1534-1535
free	O	1535-1539
preparations	O	1540-1552
.	O	1552-1553

In	O	1554-1556
conclusion	O	1557-1567
,	O	1567-1568
lead	O	1569-1573
-	O	1573-1574
induced	O	1574-1581
hypertension	B	1582-1594
in	O	1595-1597
this	O	1598-1602
model	O	1603-1608
was	O	1609-1612
associated	O	1613-1623
with	O	1624-1628
a	O	1629-1630
compensatory	O	1631-1643
upregulation	O	1644-1656
of	O	1657-1659
renal	O	1660-1665
and	O	1666-1669
vascular	O	1670-1678
eNOS	O	1679-1683
and	O	1684-1687
iNOS	O	1688-1692
expression	O	1693-1703
.	O	1703-1704

This	O	1705-1709
is	O	1710-1712
,	O	1712-1713
in	O	1714-1716
part	O	1717-1721
,	O	1721-1722
due	O	1723-1726
to	O	1727-1729
ROS	O	1730-1733
-	O	1733-1734
mediated	O	1734-1742
NO	O	1743-1745
inactivation	O	1746-1758
,	O	1758-1759
lead	O	1760-1764
-	O	1764-1765
associated	O	1765-1775
inhibition	O	1776-1786
of	O	1787-1789
NOS	O	1790-1793
activity	O	1794-1802
,	O	1802-1803
and	O	1804-1807
perhaps	O	1808-1815
stimulatory	O	1816-1827
actions	O	1828-1835
of	O	1836-1838
increased	O	1839-1848
shear	O	1849-1854
stress	O	1855-1861
associated	O	1862-1872
with	O	1873-1877
hypertension	B	1878-1890
.	O	1890-1891

Risk	O	0-4
for	O	5-8
valvular	B	9-17
heart	I	18-23
disease	I	24-31
among	O	32-37
users	O	38-43
of	O	44-46
fenfluramine	O	47-59
and	O	60-63
dexfenfluramine	O	64-79
who	O	80-83
underwent	O	84-93
echocardiography	O	94-110
before	O	111-117
use	O	118-121
of	O	122-124
medication	O	125-135
.	O	135-136

BACKGROUND	O	137-147
:	O	147-148
Because	O	149-156
uncontrolled	O	157-169
echocardiographic	O	170-187
surveys	O	188-195
suggested	O	196-205
that	O	206-210
up	O	211-213
to	O	214-216
30	O	217-219
%	O	219-220
to	O	221-223
38	O	224-226
%	O	226-227
of	O	228-230
users	O	231-236
of	O	237-239
fenfluramine	O	240-252
and	O	253-256
dexfenfluramine	O	257-272
had	O	273-276
valvular	B	277-285
disease	I	286-293
,	O	293-294
these	O	295-300
drugs	O	301-306
were	O	307-311
withdrawn	O	312-321
from	O	322-326
the	O	327-330
market	O	331-337
.	O	337-338

OBJECTIVE	O	339-348
:	O	348-349
To	O	350-352
determine	O	353-362
the	O	363-366
risk	O	367-371
for	O	372-375
new	O	376-379
or	O	380-382
worsening	O	383-392
valvular	B	393-401
abnormalities	I	402-415
among	O	416-421
users	O	422-427
of	O	428-430
fenfluramine	O	431-443
or	O	444-446
dexfenfluramine	O	447-462
who	O	463-466
underwent	O	467-476
echocardiography	O	477-493
before	O	494-500
they	O	501-505
began	O	506-511
to	O	512-514
take	O	515-519
these	O	520-525
medications	O	526-537
.	O	537-538

DESIGN	O	539-545
:	O	545-546
Cohort	O	547-553
study	O	554-559
.	O	559-560

SETTING	O	561-568
:	O	568-569
Academic	O	570-578
primary	O	579-586
care	O	587-591
practices	O	592-601
.	O	601-602

PATIENTS	O	603-611
:	O	611-612
46	O	613-615
patients	O	616-624
who	O	625-628
used	O	629-633
fenfluramine	O	634-646
or	O	647-649
dexfenfluramine	O	650-665
for	O	666-669
14	O	670-672
days	O	673-677
or	O	678-680
more	O	681-685
and	O	686-689
had	O	690-693
echocardiograms	O	694-709
obtained	O	710-718
before	O	719-725
therapy	O	726-733
.	O	733-734

MEASUREMENTS	O	735-747
:	O	747-748
Follow	O	749-755
-	O	755-756
up	O	756-758
echocardiography	O	759-775
.	O	775-776

The	O	777-780
primary	O	781-788
outcome	O	789-796
was	O	797-800
new	O	801-804
or	O	805-807
worsening	O	808-817
valvulopathy	B	818-830
,	O	830-831
defined	O	832-839
as	O	840-842
progression	O	843-854
of	O	855-857
either	O	858-864
aortic	B	865-871
or	I	872-874
mitral	I	875-881
regurgitation	I	882-895
by	O	896-898
at	O	899-901
least	O	902-907
one	O	908-911
degree	O	912-918
of	O	919-921
severity	O	922-930
and	O	931-934
disease	O	935-942
that	O	943-947
met	O	948-951
U	O	952-953
.	O	953-954
S	O	954-955
.	O	953-954
Food	O	957-961
and	O	962-965
Drug	O	966-970
Administration	O	971-985
criteria	O	986-994
(	O	995-996
at	O	996-998
least	O	999-1004
mild	O	1005-1009
aortic	B	1010-1016
regurgitation	I	1017-1030
or	O	1031-1033
moderate	O	1034-1042
mitral	B	1043-1049
regurgitation	I	1050-1063
)	O	1063-1064
.	O	1064-1065

RESULTS	O	1066-1073
:	O	1073-1074
Two	O	1075-1078
patients	O	1079-1087
(	O	1088-1089
4	O	1089-1090
.	O	1090-1091
3	O	1091-1092
%	O	1092-1093
[	O	1094-1095
95	O	1095-1097
%	O	1097-1098
CI	O	1099-1101
,	O	1101-1102
0	O	1103-1104
.	O	1104-1105
6	O	1105-1106
%	O	1106-1107
to	O	1108-1110
14	O	1111-1113
.	O	1113-1114
8	O	1114-1115
%	O	1115-1116
]	O	1116-1117
)	O	1117-1118
receiving	O	1119-1128
fenfluramine	O	1129-1141
-	O	1141-1142
phentermine	O	1142-1153
developed	O	1154-1163
valvular	B	1164-1172
heart	I	1173-1178
disease	I	1179-1186
.	O	1186-1187

One	O	1188-1191
had	O	1192-1195
baseline	O	1196-1204
bicuspid	B	1205-1213
aortic	I	1214-1220
valve	I	1221-1226
and	O	1227-1230
mild	O	1231-1235
aortic	B	1236-1242
regurgitation	I	1243-1256
that	O	1257-1261
progressed	O	1262-1272
to	O	1273-1275
moderate	O	1276-1284
regurgitation	O	1285-1298
.	O	1298-1299

The	O	1300-1303
second	O	1304-1310
patient	O	1311-1318
developed	O	1319-1328
new	O	1329-1332
moderate	O	1333-1341
aortic	B	1342-1348
insufficiency	I	1349-1362
.	O	1362-1363

CONCLUSION	O	1364-1374
:	O	1374-1375
Users	O	1376-1381
of	O	1382-1384
diet	O	1385-1389
medications	O	1390-1401
are	O	1402-1405
at	O	1406-1408
risk	O	1409-1413
for	O	1414-1417
valvular	B	1418-1426
heart	I	1427-1432
disease	I	1433-1440
.	O	1440-1441

However	O	1442-1449
,	O	1449-1450
the	O	1451-1454
incidence	O	1455-1464
may	O	1465-1468
be	O	1469-1471
lower	O	1472-1477
than	O	1478-1482
that	O	1483-1487
reported	O	1488-1496
previously	O	1497-1507
.	O	1507-1508

Carboplatin	O	0-11
toxic	O	12-17
effects	O	18-25
on	O	26-28
the	O	29-32
peripheral	O	33-43
nervous	O	44-51
system	O	52-58
of	O	59-61
the	O	62-65
rat	O	66-69
.	O	69-70

BACKGROUND	O	71-81
:	O	81-82
The	O	83-86
most	O	87-91
striking	O	92-100
of	O	101-103
carboplatin	O	104-115
'	O	115-116
s	O	116-117
advantages	O	118-128
(	O	129-130
CBDCA	O	130-135
)	O	135-136
over	O	137-141
cisplatin	O	142-151
(	O	152-153
CDDP	O	153-157
)	O	157-158
is	O	159-161
its	O	162-165
markedly	O	166-174
reduced	O	175-182
rate	O	183-187
of	O	188-190
neurotoxic	B	191-201
effects	O	202-209
.	O	209-210

However	O	211-218
,	O	218-219
the	O	220-223
use	O	224-227
of	O	228-230
CBDCA	O	231-236
higher	O	237-243
-	O	243-244
intensity	O	244-253
schedules	O	254-263
and	O	264-267
the	O	268-271
association	O	272-283
with	O	284-288
other	O	289-294
neurotoxic	B	295-305
drugs	O	306-311
in	O	312-314
polychemotherapy	O	315-331
may	O	332-335
cause	O	336-341
some	O	342-346
concern	O	347-354
about	O	355-360
its	O	361-364
safety	O	365-371
with	O	372-376
respect	O	377-384
to	O	385-387
peripheral	B	388-398
nervous	I	399-406
system	I	407-413
damage	I	414-420
.	O	420-421

MATERIALS	O	422-431
AND	O	432-435
METHODS	O	436-443
:	O	443-444
Two	O	445-448
different	O	449-458
schedules	O	459-468
of	O	469-471
CBDCA	O	472-477
administration	O	478-492
(	O	493-494
10	O	494-496
mg	O	497-499
/	O	499-500
kg	O	500-502
and	O	503-506
15	O	507-509
mg	O	510-512
/	O	512-513
kg	O	513-515
i	O	516-517
.	O	517-518
p	O	518-519
.	O	517-518
twice	O	521-526
a	O	527-528
week	O	529-533
for	O	534-537
nine	O	538-542
times	O	543-548
)	O	548-549
were	O	550-554
evaluated	O	555-564
in	O	565-567
Wistar	O	568-574
rats	O	575-579
.	O	579-580

Neurotoxicity	B	581-594
was	O	595-598
assessed	O	599-607
for	O	608-611
behavioral	O	612-622
(	O	623-624
tail	O	624-628
-	O	628-629
flick	O	629-634
test	O	635-639
)	O	639-640
,	O	640-641
neurophysiological	O	642-660
(	O	661-662
nerve	O	662-667
conduction	O	668-678
velocity	O	679-687
in	O	688-690
the	O	691-694
tail	O	695-699
nerve	O	700-705
)	O	705-706
,	O	706-707
morphological	O	708-721
,	O	721-722
morphometrical	O	723-737
and	O	738-741
analytical	O	742-752
effects	O	753-760
.	O	760-761

RESULTS	O	762-769
:	O	769-770
CBDCA	O	771-776
administration	O	777-791
induced	O	792-799
dose	O	800-804
-	O	804-805
dependent	O	805-814
peripheral	B	815-825
neurotoxicity	I	826-839
.	O	839-840

Pain	B	841-845
perception	O	846-856
and	O	857-860
nerve	O	861-866
conduction	O	867-877
velocity	O	878-886
in	O	887-889
the	O	890-893
tail	O	894-898
were	O	899-903
significantly	O	904-917
impaired	O	918-926
,	O	926-927
particularly	O	928-940
after	O	941-946
the	O	947-950
high	O	951-955
-	O	955-956
dose	O	956-960
treatment	O	961-970
.	O	970-971

The	O	972-975
dorsal	O	976-982
root	O	983-987
ganglia	O	988-995
sensory	O	996-1003
neurons	O	1004-1011
and	O	1012-1015
,	O	1015-1016
to	O	1017-1019
a	O	1020-1021
lesser	O	1022-1028
extent	O	1029-1035
,	O	1035-1036
satellite	O	1037-1046
cells	O	1047-1052
showed	O	1053-1059
the	O	1060-1063
same	O	1064-1068
changes	O	1069-1076
as	O	1077-1079
those	O	1080-1085
induced	O	1086-1093
by	O	1094-1096
CDDP	O	1097-1101
,	O	1101-1102
mainly	O	1103-1109
affecting	O	1110-1119
the	O	1120-1123
nucleus	O	1124-1131
and	O	1132-1135
nucleolus	O	1136-1145
of	O	1146-1148
ganglionic	O	1149-1159
sensory	O	1160-1167
neurons	O	1168-1175
.	O	1175-1176

Moreover	O	1177-1185
,	O	1185-1186
significant	O	1187-1198
amounts	O	1199-1206
of	O	1207-1209
platinum	O	1210-1218
were	O	1219-1223
detected	O	1224-1232
in	O	1233-1235
the	O	1236-1239
dorsal	O	1240-1246
root	O	1247-1251
ganglia	O	1252-1259
and	O	1260-1263
kidney	O	1264-1270
after	O	1271-1276
CBDCA	O	1277-1282
treatment	O	1283-1292
.	O	1292-1293

CONCLUSIONS	O	1294-1305
:	O	1305-1306
CBDCA	O	1307-1312
is	O	1313-1315
neurotoxic	B	1316-1326
in	O	1327-1329
our	O	1330-1333
model	O	1334-1339
,	O	1339-1340
and	O	1341-1344
the	O	1345-1348
type	O	1349-1353
of	O	1354-1356
pathological	O	1357-1369
changes	O	1370-1377
it	O	1378-1380
induces	O	1381-1388
are	O	1389-1392
so	O	1393-1395
closely	O	1396-1403
similar	O	1404-1411
to	O	1412-1414
those	O	1415-1420
caused	O	1421-1427
by	O	1428-1430
CDDP	O	1431-1435
that	O	1436-1440
it	O	1441-1443
is	O	1444-1446
probable	O	1447-1455
that	O	1456-1460
neurotoxicity	B	1461-1474
is	O	1475-1477
induced	O	1478-1485
in	O	1486-1488
the	O	1489-1492
two	O	1493-1496
drugs	O	1497-1502
by	O	1503-1505
the	O	1506-1509
same	O	1510-1514
mechanism	O	1515-1524
.	O	1524-1525

This	O	1526-1530
model	O	1531-1536
can	O	1537-1540
be	O	1541-1543
used	O	1544-1548
alone	O	1549-1554
or	O	1555-1557
in	O	1558-1560
combination	O	1561-1572
with	O	1573-1577
other	O	1578-1583
drugs	O	1584-1589
to	O	1590-1592
explore	O	1593-1600
the	O	1601-1604
effect	O	1605-1611
of	O	1612-1614
CBDCA	O	1615-1620
on	O	1621-1623
the	O	1624-1627
peripheral	O	1628-1638
nervous	O	1639-1646
system	O	1647-1653
.	O	1653-1654

Iatrogenic	O	0-10
risks	O	11-16
of	O	17-19
endometrial	B	20-31
carcinoma	I	32-41
after	O	42-47
treatment	O	48-57
for	O	58-61
breast	B	62-68
cancer	I	69-75
in	O	76-78
a	O	79-80
large	O	81-86
French	O	87-93
case	O	94-98
-	O	98-99
control	O	99-106
study	O	107-112
.	O	112-113

F	O	114-115
d	O	117-118
ration	O	120-126
Nationale	O	127-136
des	O	137-140
Centres	O	141-148
de	O	149-151
Lutte	O	152-157
Contre	O	158-164
le	O	165-167
Cancer	O	168-174
(	O	175-176
FNCLCC	O	176-182
)	O	182-183
.	O	183-184

Since	O	185-190
tamoxifen	O	191-200
is	O	201-203
widely	O	204-210
used	O	211-215
in	O	216-218
breast	B	219-225
cancer	I	226-232
treatment	O	233-242
and	O	243-246
has	O	247-250
been	O	251-255
proposed	O	256-264
for	O	265-268
the	O	269-272
prevention	O	273-283
of	O	284-286
breast	B	287-293
cancer	I	294-300
,	O	300-301
its	O	302-305
endometrial	O	306-317
iatrogenic	O	318-328
effects	O	329-336
must	O	337-341
be	O	342-344
carefully	O	345-354
examined	O	355-363
.	O	363-364

We	O	365-367
have	O	368-372
investigated	O	373-385
the	O	386-389
association	O	390-401
between	O	402-409
endometrial	B	410-421
cancer	I	422-428
and	O	429-432
tamoxifen	O	433-442
use	O	443-446
or	O	447-449
other	O	450-455
treatments	O	456-466
in	O	467-469
women	O	470-475
treated	O	476-483
for	O	484-487
breast	B	488-494
cancer	I	495-501
in	O	502-504
a	O	505-506
case	O	507-511
-	O	511-512
control	O	512-519
study	O	520-525
.	O	525-526

Cases	O	527-532
of	O	533-535
endometrial	B	536-547
cancer	I	548-554
diagnosed	O	555-564
after	O	565-570
breast	B	571-577
cancer	I	578-584
(	O	585-586
n	O	586-587
=	O	588-589
135	O	590-593
)	O	593-594
and	O	595-598
467	O	599-602
controls	O	603-611
matched	O	612-619
for	O	620-623
age	O	624-627
,	O	627-628
year	O	629-633
of	O	634-636
diagnosis	O	637-646
of	O	647-649
breast	B	650-656
cancer	I	657-663
and	O	664-667
hospital	O	668-676
and	O	677-680
survival	O	681-689
time	O	690-694
with	O	695-699
an	O	700-702
intact	O	703-709
uterus	O	710-716
were	O	717-721
included	O	722-730
.	O	730-731

Women	O	732-737
who	O	738-741
had	O	742-745
received	O	746-754
tamoxifen	O	755-764
were	O	765-769
significantly	O	770-783
more	O	784-788
likely	O	789-795
to	O	796-798
have	O	799-803
endometrial	B	804-815
cancer	I	816-822
diagnosed	O	823-832
than	O	833-837
those	O	838-843
who	O	844-847
had	O	848-851
not	O	852-855
(	O	856-857
crude	O	857-862
relative	O	863-871
risk	O	872-876
=	O	877-878
4	O	879-880
.	O	880-881
9	O	881-882
,	O	882-883
p	O	884-885
=	O	886-887
0	O	888-889
.	O	889-890
0001	O	890-894
)	O	894-895
.	O	889-890

Univariate	O	897-907
and	O	908-911
adjusted	O	912-920
analyses	O	921-929
showed	O	930-936
that	O	937-941
the	O	942-945
risk	O	946-950
increased	O	951-960
with	O	961-965
the	O	966-969
length	O	970-976
of	O	977-979
treatment	O	980-989
(	O	990-991
p	O	991-992
=	O	993-994
0	O	995-996
.	O	996-997
0001	O	997-1001
)	O	1001-1002
or	O	1003-1005
the	O	1006-1009
cumulative	O	1010-1020
dose	O	1021-1025
of	O	1026-1028
tamoxifen	O	1029-1038
received	O	1039-1047
(	O	1048-1049
p	O	1049-1050
=	O	1051-1052
0	O	1053-1054
.	O	1054-1055
0001	O	1055-1059
)	O	1059-1060
,	O	1060-1061
irrespective	O	1062-1074
of	O	1075-1077
the	O	1078-1081
daily	O	1082-1087
dose	O	1088-1092
.	O	1092-1093

Women	O	1094-1099
who	O	1100-1103
had	O	1104-1107
undergone	O	1108-1117
pelvic	O	1118-1124
radiotherapy	O	1125-1137
also	O	1138-1142
had	O	1143-1146
a	O	1147-1148
higher	O	1149-1155
risk	O	1156-1160
(	O	1161-1162
crude	O	1162-1167
relative	O	1168-1176
risk	O	1177-1181
=	O	1182-1183
7	O	1184-1185
.	O	1185-1186
8	O	1186-1187
,	O	1187-1188
p	O	1189-1190
=	O	1191-1192
0	O	1193-1194
.	O	1194-1195
0001	O	1195-1199
)	O	1199-1200
.	O	1194-1195

After	O	1202-1207
adjusting	O	1208-1217
for	O	1218-1221
confounding	O	1222-1233
factors	O	1234-1241
,	O	1241-1242
the	O	1243-1246
risk	O	1247-1251
was	O	1252-1255
higher	O	1256-1262
for	O	1263-1266
tamoxifen	O	1267-1276
users	O	1277-1282
(	O	1283-1284
p	O	1284-1285
=	O	1286-1287
0	O	1288-1289
.	O	1289-1290
0012	O	1290-1294
)	O	1294-1295
,	O	1295-1296
treatment	O	1297-1306
for	O	1307-1310
more	O	1311-1315
than	O	1316-1320
3	O	1321-1322
years	O	1323-1328
(	O	1329-1330
all	O	1330-1333
p	O	1334-1335
<	O	1336-1337
0	O	1338-1339
.	O	1339-1340
03	O	1340-1342
)	O	1342-1343
and	O	1344-1347
pelvic	O	1348-1354
radiotherapy	O	1355-1367
(	O	1368-1369
p	O	1369-1370
=	O	1371-1372
0	O	1373-1374
.	O	1374-1375
012	O	1375-1378
)	O	1378-1379
.	O	1374-1375

Women	O	1381-1386
who	O	1387-1390
had	O	1391-1394
endometrial	B	1395-1406
cancer	I	1407-1413
and	O	1414-1417
had	O	1418-1421
received	O	1422-1430
tamoxifen	O	1431-1440
had	O	1441-1444
more	O	1445-1449
advanced	B	1450-1458
disease	I	1459-1466
and	O	1467-1470
poorer	O	1471-1477
prognosis	O	1478-1487
than	O	1488-1492
those	O	1493-1498
with	O	1499-1503
endometrial	B	1504-1515
cancer	I	1516-1522
who	O	1523-1526
had	O	1527-1530
not	O	1531-1534
received	O	1535-1543
this	O	1544-1548
treatment	O	1549-1558
.	O	1558-1559

Our	O	1560-1563
results	O	1564-1571
suggest	O	1572-1579
a	O	1580-1581
causal	O	1582-1588
role	O	1589-1593
of	O	1594-1596
tamoxifen	O	1597-1606
in	O	1607-1609
endometrial	B	1610-1621
cancer	I	1622-1628
,	O	1628-1629
particularly	O	1630-1642
when	O	1643-1647
used	O	1648-1652
as	O	1653-1655
currently	O	1656-1665
proposed	O	1666-1674
for	O	1675-1678
breast	B	1679-1685
cancer	I	1686-1692
prevention	O	1693-1703
.	O	1703-1704

Pelvic	O	1705-1711
radiotherapy	O	1712-1724
may	O	1725-1728
be	O	1729-1731
an	O	1732-1734
additional	O	1735-1745
iatrogenic	O	1746-1756
factor	O	1757-1763
for	O	1764-1767
women	O	1768-1773
with	O	1774-1778
breast	B	1779-1785
cancer	I	1786-1792
.	O	1792-1793

Endometrial	B	1794-1805
cancers	I	1806-1813
diagnosed	O	1814-1823
in	O	1824-1826
women	O	1827-1832
treated	O	1833-1840
with	O	1841-1845
tamoxifen	O	1846-1855
have	O	1856-1860
poorer	O	1861-1867
prognosis	O	1868-1877
.	O	1877-1878

Women	O	1879-1884
who	O	1885-1888
receive	O	1889-1896
tamoxifen	O	1897-1906
for	O	1907-1910
breast	B	1911-1917
cancer	I	1918-1924
should	O	1925-1931
be	O	1932-1934
offered	O	1935-1942
gynaecological	O	1943-1957
surveillance	O	1958-1970
during	O	1971-1977
and	O	1978-1981
after	O	1982-1987
treatment	O	1988-1997
.	O	1997-1998

A	O	1999-2000
long	O	2001-2005
-	O	2005-2006
term	O	2006-2010
evaluation	O	2011-2021
of	O	2022-2024
the	O	2025-2028
risk	O	2029-2033
-	O	2033-2034
benefit	O	2034-2041
ratio	O	2042-2047
of	O	2048-2050
tamoxifen	O	2051-2060
as	O	2061-2063
a	O	2064-2065
preventive	O	2066-2076
treatment	O	2077-2086
for	O	2087-2090
breast	B	2091-2097
cancer	I	2098-2104
is	O	2105-2107
clearly	O	2108-2115
warranted	O	2116-2125
.	O	2125-2126

Granulosa	B	0-9
cell	I	10-14
tumor	I	15-20
of	I	21-23
the	I	24-27
ovary	I	28-33
associated	O	34-44
with	O	45-49
antecedent	O	50-60
tamoxifen	O	61-70
use	O	71-74
.	O	74-75

BACKGROUND	O	76-86
:	O	86-87
Increased	O	88-97
attention	O	98-107
has	O	108-111
been	O	112-116
focused	O	117-124
recently	O	125-133
on	O	134-136
the	O	137-140
estrogenic	O	141-151
effects	O	152-159
of	O	160-162
tamoxifen	O	163-172
.	O	172-173

Review	O	174-180
of	O	181-183
the	O	184-187
literature	O	188-198
reveals	O	199-206
an	O	207-209
association	O	210-221
between	O	222-229
tamoxifen	O	230-239
use	O	240-243
and	O	244-247
gynecologic	O	248-259
tumors	B	260-266
.	O	266-267

CASE	O	268-272
:	O	272-273
A	O	274-275
52	O	276-278
-	O	278-279
year	O	279-283
-	O	278-279
old	O	284-287
postmenopausal	O	288-302
woman	O	303-308
was	O	309-312
treated	O	313-320
with	O	321-325
tamoxifen	O	326-335
for	O	336-339
stage	O	340-345
II	O	346-348
estrogen	O	349-357
receptor	O	358-366
-	O	366-367
positive	O	367-375
breast	B	376-382
carcinoma	I	383-392
.	O	392-393

Her	O	394-397
aspartate	O	398-407
transaminase	O	408-420
and	O	421-424
alanine	O	425-432
transaminase	O	433-445
levels	O	446-452
increase	O	453-461
markedly	O	462-470
after	O	471-476
6	O	477-478
months	O	479-485
of	O	486-488
tamoxifen	O	489-498
use	O	499-502
.	O	502-503

After	O	504-509
an	O	510-512
additional	O	513-523
17	O	524-526
months	O	527-533
of	O	534-536
elevated	O	537-545
serum	O	546-551
transaminases	O	552-565
,	O	565-566
the	O	567-570
patient	O	571-578
was	O	579-582
found	O	583-588
to	O	589-591
have	O	592-596
a	O	597-598
stage	O	599-604
Ic	O	605-607
granulosa	B	608-617
cell	I	618-622
tumor	I	623-628
of	I	629-631
the	I	632-635
ovary	I	636-641
.	O	641-642

CONCLUSION	O	643-653
:	O	653-654
Patients	O	655-663
with	O	664-668
tamoxifen	O	669-678
-	O	678-679
induced	O	679-686
liver	B	687-692
dysfunction	I	693-704
may	O	705-708
be	O	709-711
at	O	712-714
increased	O	715-724
risk	O	725-729
for	O	730-733
granulosa	B	734-743
cell	I	744-748
tumors	I	749-755
because	O	756-763
of	O	764-766
alterations	O	767-778
in	O	779-781
tamoxifen	O	782-791
metabolism	O	792-802
.	O	802-803

A	O	0-1
murine	O	2-8
model	O	9-14
of	O	15-17
adenomyosis	B	18-29
:	O	29-30
the	O	31-34
effects	O	35-42
of	O	43-45
hyperprolactinemia	B	46-64
induced	O	65-72
by	O	73-75
fluoxetine	O	76-86
hydrochloride	O	87-100
,	O	100-101
a	O	102-103
selective	O	104-113
serotonin	O	114-123
reuptake	O	124-132
inhibitor	O	133-142
,	O	142-143
on	O	144-146
adenomyosis	B	147-158
induction	O	159-168
in	O	169-171
Wistar	O	172-178
albino	O	179-185
rats	O	186-190
.	O	190-191

OBJECTIVE	O	192-201
:	O	201-202
The	O	203-206
aim	O	207-210
of	O	211-213
this	O	214-218
study	O	219-224
was	O	225-228
to	O	229-231
investigate	O	232-243
whether	O	244-251
fluoxetine	O	252-262
given	O	263-268
to	O	269-271
castrated	O	272-281
and	O	282-285
noncastrated	O	286-298
rats	O	299-303
caused	O	304-310
hyperprolactinemia	B	311-329
and	O	330-333
its	O	334-337
effects	O	338-345
with	O	346-350
respect	O	351-358
to	O	359-361
adenomyosis	B	362-373
.	O	373-374

DESIGN	O	375-381
:	O	381-382
Fluoxetine	O	383-393
,	O	393-394
a	O	395-396
serotonin	O	397-406
reuptake	O	407-415
inhibitor	O	416-425
,	O	425-426
was	O	427-430
given	O	431-436
to	O	437-439
Wistar	O	440-446
Albino	O	447-453
rats	O	454-458
for	O	459-462
98	O	463-465
days	O	466-470
to	O	471-473
produce	O	474-481
hyperprolactinemia	B	482-500
.	O	500-501

The	O	502-505
drug	O	506-510
was	O	511-514
given	O	515-520
to	O	521-523
two	O	524-527
groups	O	528-534
consisting	O	535-545
of	O	546-548
castrated	O	549-558
and	O	559-562
noncastrated	O	563-575
rats	O	576-580
and	O	581-584
compared	O	585-593
to	O	594-596
two	O	597-600
groups	O	601-607
of	O	608-610
castrated	O	611-620
and	O	621-624
noncastrated	O	625-637
controls	O	638-646
.	O	646-647

Prolactin	O	648-657
levels	O	658-664
were	O	665-669
measured	O	670-678
and	O	679-682
the	O	683-686
uteri	O	687-692
of	O	693-695
the	O	696-699
rats	O	700-704
were	O	705-709
removed	O	710-717
for	O	718-721
histopathological	O	722-739
analysis	O	740-748
at	O	749-751
the	O	752-755
end	O	756-759
of	O	760-762
98	O	763-765
days	O	766-770
.	O	770-771

SETTING	O	772-779
:	O	779-780
Marmara	O	781-788
University	O	789-799
School	O	800-806
of	O	807-809
Medicine	O	810-818
,	O	818-819
Department	O	820-830
of	O	831-833
Histology	O	834-843
and	O	844-847
Embryology	O	848-858
,	O	858-859
Zeynep	O	860-866
Kamil	O	867-872
Women	O	873-878
and	O	879-882
Children	O	883-891
'	O	891-892
s	O	892-893
Hospital	O	894-902
.	O	902-903

MAIN	O	904-908
OUTCOME	O	909-916
MEASURES	O	917-925
:	O	925-926
Serum	O	927-932
prolactin	O	933-942
levels	O	943-949
,	O	949-950
uterine	O	951-958
histopathology	O	959-973
.	O	973-974

RESULTS	O	975-982
:	O	982-983
The	O	984-987
prolactin	O	988-997
levels	O	998-1004
of	O	1005-1007
castrated	O	1008-1017
and	O	1018-1021
noncastrated	O	1022-1034
groups	O	1035-1041
treated	O	1042-1049
with	O	1050-1054
fluoxetine	O	1055-1065
were	O	1066-1070
statistically	O	1071-1084
significantly	O	1085-1098
higher	O	1099-1105
when	O	1106-1110
compared	O	1111-1119
to	O	1120-1122
their	O	1123-1128
respective	O	1129-1139
control	O	1140-1147
groups	O	1148-1154
.	O	1154-1155

Histological	O	1156-1168
studies	O	1169-1176
revealed	O	1177-1185
11	O	1186-1188
cases	O	1189-1194
of	O	1195-1197
adenomyosis	B	1198-1209
,	O	1209-1210
all	O	1211-1214
within	O	1215-1221
the	O	1222-1225
noncastrated	O	1226-1238
group	O	1239-1244
receiving	O	1245-1254
fluoxetine	O	1255-1265
.	O	1265-1266

CONCLUSION	O	1267-1277
:	O	1277-1278
It	O	1279-1281
was	O	1282-1285
suggested	O	1286-1295
that	O	1296-1300
high	O	1301-1305
serum	O	1306-1311
prolactin	O	1312-1321
levels	O	1322-1328
cause	O	1329-1334
degeneration	O	1335-1347
of	O	1348-1350
myometrial	O	1351-1361
cells	O	1362-1367
in	O	1368-1370
the	O	1371-1374
presence	O	1375-1383
of	O	1384-1386
ovarian	O	1387-1394
steroids	O	1395-1403
that	O	1404-1408
results	O	1409-1416
in	O	1417-1419
a	O	1420-1421
myometrial	O	1422-1432
invasion	O	1433-1441
by	O	1442-1444
endometrial	O	1445-1456
stroma	O	1457-1463
.	O	1463-1464

This	O	1465-1469
invasion	O	1470-1478
eventually	O	1479-1489
progresses	O	1490-1500
to	O	1501-1503
adenomyosis	B	1504-1515
.	O	1515-1516

Effects	O	0-7
of	O	8-10
deliberate	O	11-21
hypotension	B	22-33
induced	O	34-41
by	O	42-44
labetalol	O	45-54
with	O	55-59
isoflurane	O	60-70
on	O	71-73
neuropsychological	O	74-92
function	O	93-101
.	O	101-102

The	O	103-106
effect	O	107-113
of	O	114-116
deliberate	O	117-127
hypotension	B	128-139
on	O	140-142
brain	O	143-148
function	O	149-157
measured	O	158-166
by	O	167-169
neuropsychological	O	170-188
tests	O	189-194
was	O	195-198
studied	O	199-206
in	O	207-209
41	O	210-212
adult	O	213-218
patients	O	219-227
.	O	227-228

Twenty	O	229-235
-	O	235-236
four	O	236-240
patients	O	241-249
were	O	250-254
anaesthetized	O	255-268
for	O	269-272
middle	O	273-279
-	O	279-280
ear	O	280-283
surgery	O	284-291
with	O	292-296
deliberate	O	297-307
hypotension	B	308-319
induced	O	320-327
by	O	328-330
labetalol	O	331-340
with	O	341-345
isoflurane	O	346-356
(	O	357-358
hypotensive	B	358-369
group	O	370-375
)	O	375-376
.	O	376-377

Seventeen	O	378-387
patients	O	388-396
without	O	397-404
hypotension	B	405-416
served	O	417-423
as	O	424-426
a	O	427-428
control	O	429-436
group	O	437-442
.	O	442-443

The	O	444-447
mean	O	448-452
arterial	O	453-461
pressure	O	462-470
was	O	471-474
77	O	475-477
+	O	478-479
/	O	479-480
-	O	480-481
2	O	482-483
mmHg	O	484-488
(	O	489-490
10	O	490-492
.	O	492-493
3	O	493-494
+	O	495-496
/	O	496-497
-	O	497-498
0	O	499-500
.	O	500-501
3	O	501-502
kPa	O	503-506
)	O	506-507
before	O	508-514
hypotension	B	515-526
and	O	527-530
50	O	531-533
+	O	534-535
/	O	535-536
-	O	536-537
0	O	538-539
mmHg	O	540-544
(	O	545-546
6	O	546-547
.	O	547-548
7	O	548-549
+	O	550-551
/	O	551-552
-	O	552-553
0	O	554-555
.	O	555-556
0	O	554-555
kPa	O	558-561
)	O	561-562
during	O	563-569
hypotension	B	570-581
in	O	582-584
the	O	585-588
hypotensive	B	589-600
group	O	601-606
,	O	606-607
and	O	608-611
86	O	612-614
+	O	615-616
/	O	616-617
-	O	617-618
2	O	619-620
mmHg	O	621-625
(	O	626-627
11	O	627-629
.	O	629-630
5	O	630-631
+	O	632-633
/	O	633-634
-	O	634-635
0	O	636-637
.	O	637-638
3	O	638-639
kPa	O	640-643
)	O	643-644
during	O	645-651
anaesthesia	O	652-663
in	O	664-666
the	O	667-670
control	O	671-678
group	O	679-684
.	O	684-685

The	O	686-689
following	O	690-699
psychological	O	700-713
tests	O	714-719
were	O	720-724
performed	O	725-734
:	O	734-735
four	O	736-740
subtests	O	741-749
of	O	750-752
the	O	753-756
Wechsler	O	757-765
Adult	O	766-771
Intelligence	O	772-784
Scale	O	785-790
(	O	791-792
similarities	O	792-804
,	O	804-805
digit	O	806-811
span	O	812-816
,	O	816-817
vocabulary	O	818-828
and	O	829-832
digit	O	833-838
symbol	O	839-845
)	O	845-846
,	O	846-847
Trail	O	848-853
-	O	853-854
Making	O	854-860
tests	O	861-866
A	O	867-868
and	O	869-872
B	O	873-874
,	O	874-875
Zung	O	876-880
tests	O	881-886
(	O	887-888
self	O	888-892
-	O	892-893
rating	O	893-899
anxiety	B	900-907
scale	O	908-913
and	O	914-917
self	O	918-922
-	O	922-923
rating	O	923-929
depression	B	930-940
scale	O	941-946
)	O	946-947
and	O	948-951
two	O	952-955
-	O	955-956
part	O	956-960
memory	O	961-967
test	O	968-972
battery	O	973-980
with	O	981-985
immediate	O	986-995
and	O	996-999
delayed	O	1000-1007
recall	O	1008-1014
.	O	1014-1015

The	O	1016-1019
tests	O	1020-1025
were	O	1026-1030
performed	O	1031-1040
preoperatively	O	1041-1055
and	O	1056-1059
2	O	1060-1061
days	O	1062-1066
postoperatively	O	1067-1082
.	O	1082-1083

There	O	1084-1089
were	O	1090-1094
no	O	1095-1097
statistically	O	1098-1111
significant	O	1112-1123
differences	O	1124-1135
between	O	1136-1143
the	O	1144-1147
groups	O	1148-1154
in	O	1155-1157
any	O	1158-1161
of	O	1162-1164
the	O	1165-1168
tests	O	1169-1174
in	O	1175-1177
the	O	1178-1181
changes	O	1182-1189
from	O	1190-1194
preoperative	O	1195-1207
value	O	1208-1213
to	O	1214-1216
postoperative	O	1217-1230
value	O	1231-1236
.	O	1236-1237

The	O	1238-1241
results	O	1242-1249
indicate	O	1250-1258
that	O	1259-1263
hypotension	B	1264-1275
induced	O	1276-1283
by	O	1284-1286
labetalol	O	1287-1296
with	O	1297-1301
isoflurane	O	1302-1312
has	O	1313-1316
no	O	1317-1319
significant	O	1320-1331
harmful	O	1332-1339
effects	O	1340-1347
on	O	1348-1350
mental	O	1351-1357
functions	O	1358-1367
compared	O	1368-1376
to	O	1377-1379
normotensive	O	1380-1392
anaesthesia	O	1393-1404
.	O	1404-1405

Auditory	O	0-8
disturbance	O	9-20
associated	O	21-31
with	O	32-36
interscalene	O	37-49
brachial	O	50-58
plexus	O	59-65
block	O	66-71
.	O	71-72

We	O	73-75
performed	O	76-85
an	O	86-88
audiometric	O	89-100
study	O	101-106
in	O	107-109
20	O	110-112
patients	O	113-121
who	O	122-125
underwent	O	126-135
surgery	O	136-143
of	O	144-146
the	O	147-150
shoulder	O	151-159
region	O	160-166
under	O	167-172
an	O	173-175
interscalene	O	176-188
brachial	O	189-197
plexus	O	198-204
block	O	205-210
(	O	211-212
IBPB	O	212-216
)	O	216-217
.	O	217-218

Bupivacaine	O	219-230
0	O	231-232
.	O	232-233
75	O	233-235
%	O	235-236
with	O	237-241
adrenaline	O	242-252
was	O	253-256
given	O	257-262
followed	O	263-271
by	O	272-274
a	O	275-276
24	O	277-279
-	O	279-280
hr	O	280-282
continuous	O	283-293
infusion	O	294-302
of	O	303-305
0	O	306-307
.	O	307-308
25	O	308-310
%	O	310-311
bupivacaine	O	312-323
.	O	323-324

Three	O	325-330
audiometric	O	331-342
threshold	O	343-352
measurements	O	353-365
(	O	366-367
0	O	367-368
.	O	368-369
25	O	369-371
-	O	371-372
18	O	372-374
kHz	O	375-378
)	O	378-379
were	O	380-384
made	O	385-389
:	O	389-390
the	O	391-394
first	O	395-400
before	O	401-407
IBPB	O	408-412
,	O	412-413
the	O	414-417
second	O	418-424
2	O	425-426
-	O	426-427
6	O	427-428
h	O	429-430
after	O	431-436
surgery	O	437-444
and	O	445-448
the	O	449-452
third	O	453-458
on	O	459-461
the	O	462-465
first	O	466-471
day	O	472-475
after	O	476-481
operation	O	482-491
.	O	491-492

In	O	493-495
four	O	496-500
patients	O	501-509
hearing	B	510-517
impairment	I	518-528
on	O	529-531
the	O	532-535
side	O	536-540
of	O	541-543
the	O	544-547
block	O	548-553
was	O	554-557
demonstrated	O	558-570
after	O	571-576
operation	O	577-586
,	O	586-587
in	O	588-590
three	O	591-596
measurements	O	597-609
on	O	610-612
the	O	613-616
day	O	617-620
of	O	621-623
surgery	O	624-631
and	O	632-635
in	O	636-638
one	O	639-642
on	O	643-645
the	O	646-649
following	O	650-659
day	O	660-663
.	O	663-664

The	O	665-668
frequencies	O	669-680
at	O	681-683
which	O	684-689
the	O	690-693
impairment	O	694-704
occurred	O	705-713
varied	O	714-720
between	O	721-728
patients	O	729-737
;	O	737-738
in	O	739-741
one	O	742-745
only	O	746-750
low	O	751-754
frequencies	O	755-766
(	O	767-768
0	O	768-769
.	O	769-770
25	O	770-772
-	O	772-773
0	O	768-769
.	O	769-770
5	O	771-772
kHz	O	777-780
)	O	780-781
were	O	782-786
involved	O	787-795
.	O	795-796

The	O	797-800
maximum	O	801-808
change	O	809-815
in	O	816-818
threshold	O	819-828
was	O	829-832
35	O	833-835
dB	O	836-838
at	O	839-841
6	O	842-843
kHz	O	844-847
measured	O	848-856
at	O	857-859
the	O	860-863
end	O	864-867
of	O	868-870
the	O	871-874
continuous	O	875-885
infusion	O	886-894
of	O	895-897
bupivacaine	O	898-909
.	O	909-910

This	O	911-915
patient	O	916-923
had	O	924-927
hearing	O	928-935
threshold	O	936-945
changes	O	946-953
(	O	954-955
15	O	955-957
-	O	957-958
20	O	958-960
dB	O	961-963
)	O	963-964
at	O	965-967
6	O	968-969
-	O	969-970
10	O	970-972
kHz	O	973-976
on	O	977-979
the	O	980-983
opposite	O	984-992
side	O	993-997
also	O	998-1002
.	O	1002-1003

IBPB	O	1004-1008
may	O	1009-1012
cause	O	1013-1018
transient	O	1019-1028
auditory	B	1029-1037
dysfunction	I	1038-1049
in	O	1050-1052
the	O	1053-1056
ipsilateral	O	1057-1068
ear	O	1069-1072
,	O	1072-1073
possibly	O	1074-1082
via	O	1083-1086
an	O	1087-1089
effect	O	1090-1096
on	O	1097-1099
sympathetic	O	1100-1111
innervation	O	1112-1123
.	O	1123-1124

Midazolam	O	0-9
compared	O	10-18
with	O	19-23
thiopentone	O	24-35
as	O	36-38
an	O	39-41
induction	O	42-51
agent	O	52-57
.	O	57-58

In	O	59-61
patients	O	62-70
premedicated	O	71-83
with	O	84-88
scopolamine	O	89-100
+	O	101-102
morphine	O	103-111
(	O	112-113
+	O	113-114
5	O	114-115
mg	O	116-118
nitrazepam	O	119-129
the	O	130-133
evening	O	134-141
before	O	142-148
surgery	O	149-156
)	O	156-157
,	O	157-158
the	O	159-162
sleep	O	163-168
-	O	168-169
inducing	O	169-177
effect	O	178-184
of	O	185-187
midazolam	O	188-197
0	O	198-199
.	O	199-200
15	O	200-202
mg	O	203-205
/	O	205-206
kg	O	206-208
i	O	209-210
.	O	210-211
v	O	211-212
.	O	210-211
was	O	214-217
clearly	O	218-225
slower	O	226-232
in	O	233-235
onset	O	236-241
than	O	242-246
that	O	247-251
of	O	252-254
thiopentone	O	255-266
4	O	267-268
.	O	268-269
67	O	269-271
mg	O	272-274
/	O	274-275
kg	O	275-277
i	O	278-279
.	O	279-280
v	O	280-281
.	O	279-280

Somewhat	O	283-291
fewer	O	292-297
cardiovascular	O	298-312
and	O	313-316
local	O	317-322
sequelae	O	323-331
were	O	332-336
found	O	337-342
in	O	343-345
the	O	346-349
midazolam	O	350-359
group	O	360-365
,	O	365-366
but	O	367-370
,	O	370-371
although	O	372-380
apnoea	B	381-387
occurred	O	388-396
less	O	397-401
often	O	402-407
in	O	408-410
the	O	411-414
midazolam	O	415-424
group	O	425-430
it	O	431-433
lasted	O	434-440
longer	O	441-447
.	O	447-448

On	O	449-451
the	O	452-455
whole	O	456-461
,	O	461-462
the	O	463-466
differences	O	467-478
between	O	479-486
midazolam	O	487-496
and	O	497-500
thiopentone	O	501-512
had	O	513-516
no	O	517-519
apparent	O	520-528
clinical	O	529-537
consequences	O	538-550
.	O	550-551

Midazolam	O	552-561
is	O	562-564
a	O	565-566
new	O	567-570
alternative	O	571-582
agent	O	583-588
for	O	589-592
induction	O	593-602
in	O	603-605
combination	O	606-617
anaesthesia	O	618-629
.	O	629-630

Cardiotoxic	B	0-11
and	O	12-15
possible	O	16-24
leukemogenic	O	25-37
effects	O	38-45
of	O	46-48
adriamycin	O	49-59
in	O	60-62
nonhuman	O	63-71
primates	O	72-80
.	O	80-81

10	O	82-84
monkeys	O	85-92
(	O	93-94
macaques	O	94-102
)	O	102-103
received	O	104-112
adriamycin	O	113-123
by	O	124-126
monthly	O	127-134
intravenous	O	135-146
injections	O	147-157
at	O	158-160
12	O	161-163
mg	O	164-166
/	O	166-167
m2	O	167-169
(	O	170-171
1	O	171-172
mg	O	173-175
/	O	175-176
kg	O	176-178
)	O	178-179
.	O	179-180

8	O	181-182
of	O	183-185
the	O	186-189
10	O	190-192
monkeys	O	193-200
developed	O	201-210
congestive	B	211-221
heart	I	222-227
failure	I	228-235
at	O	236-238
an	O	239-241
average	O	242-249
cumulative	O	250-260
adriamycin	O	261-271
dose	O	272-276
(	O	277-278
310	O	278-281
mg	O	282-284
/	O	284-285
m2	O	285-287
)	O	287-288
well	O	289-293
below	O	294-299
that	O	300-304
considered	O	305-315
the	O	316-319
safe	O	320-324
upper	O	325-330
limit	O	331-336
(	O	337-338
550	O	338-341
mg	O	342-344
/	O	344-345
m2	O	345-347
)	O	347-348
in	O	349-351
man	O	352-355
.	O	355-356

Histologically	O	357-371
,	O	371-372
the	O	373-376
myocardial	B	377-387
lesions	I	388-395
resembled	O	396-405
those	O	406-411
found	O	412-417
in	O	418-420
human	O	421-426
anthracycline	O	427-440
-	O	440-441
induced	O	441-448
cardiomyopathy	B	449-463
.	O	463-464
1	O	465-466
of	O	467-469
the	O	470-473
10	O	474-476
monkeys	O	477-484
developed	O	485-494
acute	B	495-500
myeloblastic	I	501-513
leukemia	I	514-522
after	O	523-528
receiving	O	529-538
324	O	539-542
mg	O	543-545
/	O	545-546
m2	O	546-548
of	O	549-551
adriamycin	O	552-562
;	O	562-563
the	O	564-567
10th	O	568-572
monkey	O	573-579
is	O	580-582
alive	O	583-588
and	O	589-592
well	O	593-597
26	O	598-600
months	O	601-607
after	O	608-613
the	O	614-617
last	O	618-622
dose	O	623-627
of	O	628-630
drug	O	631-635
.	O	635-636

Our	O	637-640
results	O	641-648
suggest	O	649-656
that	O	657-661
adriamycin	O	662-672
is	O	673-675
a	O	676-677
more	O	678-682
potent	O	683-689
cardiotoxin	O	690-701
in	O	702-704
monkeys	O	705-712
than	O	713-717
in	O	718-720
man	O	721-724
,	O	724-725
and	O	726-729
that	O	730-734
leukemia	B	735-743
may	O	744-747
be	O	748-750
a	O	751-752
consequence	O	753-764
of	O	765-767
prolonged	O	768-777
treatment	O	778-787
with	O	788-792
this	O	793-797
drug	O	798-802
.	O	802-803

Doxorubicin	O	0-11
cardiomyopathy	B	12-26
in	O	27-29
children	O	30-38
with	O	39-43
left	O	44-48
-	O	48-49
sided	O	49-54
Wilms	B	55-60
tumor	I	61-66
.	O	66-67

Two	O	68-71
children	O	72-80
with	O	81-85
Wilms	B	86-91
tumor	I	92-97
of	O	98-100
the	O	101-104
left	O	105-109
kidney	O	110-116
experienced	O	117-128
severe	O	129-135
anthracycline	O	136-149
cardiomyopathy	B	150-164
after	O	165-170
irradiation	O	171-182
to	O	183-185
the	O	186-189
tumor	B	190-195
bed	O	196-199
and	O	200-203
conventional	O	204-216
dosage	O	217-223
of	O	224-226
doxorubicin	O	227-238
.	O	238-239

The	O	240-243
cardiomyopathy	B	244-258
is	O	259-261
attributed	O	262-272
1	O	273-274
)	O	274-275
to	O	276-278
the	O	279-282
fact	O	283-287
that	O	288-292
radiation	O	293-302
fields	O	303-309
for	O	310-313
left	O	314-318
Wilms	B	319-324
tumor	I	325-330
include	O	331-338
the	O	339-342
lower	O	343-348
portion	O	349-356
of	O	357-359
the	O	360-363
heart	O	364-369
and	O	370-373
2	O	374-375
)	O	375-376
to	O	377-379
the	O	380-383
interaction	O	384-395
of	O	396-398
doxorubicin	O	399-410
and	O	411-414
irradiation	O	415-426
on	O	427-429
cardiac	O	430-437
muscle	O	438-444
.	O	444-445

It	O	446-448
is	O	449-451
recommended	O	452-463
that	O	464-468
doxorubicin	O	469-480
dosage	O	481-487
be	O	488-490
sharply	O	491-498
restricted	O	499-509
in	O	510-512
children	O	513-521
with	O	522-526
Wilms	B	527-532
tumor	I	533-538
of	O	539-541
the	O	542-545
left	O	546-550
kidney	O	551-557
who	O	558-561
receive	O	562-569
postoperative	O	570-583
irradiation	O	584-595
.	O	595-596

Promotional	O	0-11
effects	O	12-19
of	O	20-22
testosterone	O	23-35
and	O	36-39
dietary	O	40-47
fat	O	48-51
on	O	52-54
prostate	O	55-63
carcinogenesis	B	64-78
in	O	79-81
genetically	O	82-93
susceptible	O	94-105
rats	O	106-110
.	O	110-111

Germfree	O	112-120
(	O	121-122
GF	O	122-124
)	O	124-125
Lobund	O	126-132
strain	O	133-139
Wistar	O	140-146
(	O	147-148
LW	O	148-150
)	O	150-151
rats	O	152-156
,	O	156-157
fed	O	158-161
vegetable	O	162-171
diet	O	172-176
L	O	177-178
-	O	178-179
485	O	179-182
,	O	182-183
have	O	184-188
developed	O	189-198
prostate	B	199-207
adenocarcinomas	I	208-223
spontaneously	O	224-237
(	O	238-239
10	O	239-241
%	O	241-242
incidence	O	243-252
)	O	252-253
at	O	254-256
average	O	257-264
age	O	265-268
34	O	269-271
months	O	272-278
.	O	278-279

Conventional	O	280-292
LW	O	293-295
rats	O	296-300
,	O	300-301
implanted	O	302-311
with	O	312-316
testosterone	O	317-329
at	O	330-332
age	O	333-336
4	O	337-338
months	O	339-345
,	O	345-346
developed	O	347-356
a	O	357-358
higher	O	359-365
incidence	O	366-375
of	O	376-378
prostate	B	379-387
cancer	I	388-394
after	O	395-400
an	O	401-403
average	O	404-411
interval	O	412-420
of	O	421-423
14	O	424-426
months	O	427-433
:	O	433-434
24	O	435-437
%	O	437-438
had	O	439-442
developed	O	443-452
gross	O	453-458
tumors	B	459-465
,	O	465-466
and	O	467-470
40	O	471-473
%	O	473-474
when	O	475-479
it	O	480-482
included	O	483-491
microscopic	O	492-503
tumors	B	504-510
.	O	510-511

Preliminary	O	512-523
results	O	524-531
indicate	O	532-540
that	O	541-545
testosterone	O	546-558
-	O	558-559
treated	O	559-566
LW	O	567-569
rats	O	570-574
that	O	575-579
were	O	580-584
fed	O	585-588
the	O	589-592
same	O	593-597
diet	O	598-602
,	O	602-603
which	O	604-609
was	O	610-613
supplemented	O	614-626
with	O	627-631
corn	O	632-636
oil	O	637-640
up	O	641-643
to	O	644-646
20	O	647-649
%	O	649-650
fat	O	651-654
,	O	654-655
developed	O	656-665
prostate	B	666-674
cancer	I	675-681
after	O	682-687
intervals	O	688-697
of	O	698-700
6	O	701-702
-	O	702-703
12	O	703-705
months	O	706-712
.	O	712-713

Aged	O	714-718
GF	O	719-721
Sprague	O	722-729
-	O	729-730
Dawley	O	730-736
(	O	737-738
SD	O	738-740
)	O	740-741
rats	O	742-746
have	O	747-751
not	O	752-755
developed	O	756-765
prostate	B	766-774
cancer	I	775-781
spontaneously	O	782-795
.	O	795-796

Conventional	O	797-809
SD	O	810-812
rats	O	813-817
fed	O	818-821
diet	O	822-826
L	O	827-828
-	O	828-829
485	O	829-832
and	O	833-836
treated	O	837-844
with	O	845-849
testosterone	O	850-862
developed	O	863-872
only	O	873-877
prostatitis	B	878-889
.	O	889-890

Experimental	O	891-903
designs	O	904-911
should	O	912-918
consider	O	919-927
genetic	O	928-935
susceptibility	O	936-950
as	O	951-953
a	O	954-955
basic	O	956-961
prerequisite	O	962-974
for	O	975-978
studies	O	979-986
on	O	987-989
experimental	O	990-1002
prostate	B	1003-1011
cancer	I	1012-1018
.	O	1018-1019

Mitomycin	O	0-9
C	O	10-11
associated	O	12-22
hemolytic	B	23-32
uremic	I	33-39
syndrome	I	40-48
.	O	48-49

Mitomycin	O	50-59
C	O	60-61
associated	O	62-72
Hemolytic	B	73-82
Uremic	I	83-89
Syndrome	I	90-98
(	O	99-100
HUS	B	100-103
)	O	103-104
is	O	105-107
a	O	108-109
potentially	O	110-121
fatal	O	122-127
but	O	128-131
uncommon	O	132-140
condition	O	141-150
that	O	151-155
is	O	156-158
not	O	159-162
yet	O	163-166
widely	O	167-173
recognised	O	174-184
.	O	184-185

It	O	186-188
consists	O	189-197
of	O	198-200
microangiopathic	O	201-217
hemolytic	B	218-227
anemia	I	228-234
,	O	234-235
thrombocytopenia	B	236-252
and	O	253-256
progressive	O	257-268
renal	B	269-274
failure	I	275-282
associated	O	283-293
with	O	294-298
mitomycin	O	299-308
C	O	309-310
treatment	O	311-320
and	O	321-324
affects	O	325-332
about	O	333-338
10	O	339-341
%	O	341-342
of	O	343-345
patients	O	346-354
treated	O	355-362
with	O	363-367
this	O	368-372
agent	O	373-378
.	O	378-379

The	O	380-383
renal	B	384-389
failure	I	390-397
usually	O	398-405
develops	O	406-414
about	O	415-420
8	O	421-422
-	O	422-423
10	O	423-425
mth	O	426-429
after	O	430-435
start	O	436-441
of	O	442-444
mitomycin	O	445-454
C	O	455-456
treatment	O	457-466
and	O	467-470
the	O	471-474
mortality	O	475-484
is	O	485-487
approximately	O	488-501
60	O	502-504
%	O	504-505
from	O	506-510
renal	B	511-516
failure	I	517-524
or	O	525-527
pulmonary	B	528-537
edema	I	538-543
.	O	543-544

Renal	B	545-550
lesions	I	551-558
are	O	559-562
similar	O	563-570
to	O	571-573
those	O	574-579
seen	O	580-584
in	O	585-587
idiopathic	O	588-598
HUS	B	599-602
and	O	603-606
include	O	607-614
arteriolar	O	615-625
fibrin	O	626-632
thrombi	B	633-640
,	O	640-641
expanded	O	642-650
subendothelial	O	651-665
zones	O	666-671
in	O	672-674
glomerular	O	675-685
capillary	O	686-695
walls	O	696-701
,	O	701-702
ischemic	B	703-711
wrinkling	O	712-721
of	O	722-724
glomerular	O	725-735
basement	O	736-744
membranes	O	745-754
and	O	755-758
mesangiolysis	O	759-772
.	O	772-773

The	O	774-777
mechanism	O	778-787
of	O	788-790
action	O	791-797
is	O	798-800
postulated	O	801-811
as	O	812-814
mitomycin	O	815-824
C	O	825-826
-	O	826-827
induced	O	827-834
endothelial	O	835-846
cell	O	847-851
damage	O	852-858
.	O	858-859

We	O	860-862
describe	O	863-871
the	O	872-875
clinical	O	876-884
course	O	885-891
and	O	892-895
pathological	O	896-908
findings	O	909-917
in	O	918-920
a	O	921-922
65	O	923-925
yr	O	926-928
-	O	928-929
old	O	929-932
man	O	933-936
with	O	937-941
gastric	B	942-949
adenocarcinoma	I	950-964
who	O	965-968
developed	O	969-978
renal	B	979-984
failure	I	985-992
and	O	993-996
thrombocytopenia	B	997-1013
while	O	1014-1019
on	O	1020-1022
treatment	O	1023-1032
with	O	1033-1037
mitomycin	O	1038-1047
C	O	1048-1049
and	O	1050-1053
died	O	1054-1058
in	O	1059-1061
pulmonary	B	1062-1071
edema	I	1072-1077
.	O	1077-1078

Continuous	O	0-10
ambulatory	O	11-21
ECG	O	22-25
monitoring	O	26-36
during	O	37-43
fluorouracil	O	44-56
therapy	O	57-64
:	O	64-65
a	O	66-67
prospective	O	68-79
study	O	80-85
.	O	85-86

Although	O	87-95
there	O	96-101
have	O	102-106
been	O	107-111
anecdotal	O	112-121
reports	O	122-129
of	O	130-132
cardiac	B	133-140
toxicity	I	141-149
associated	O	150-160
with	O	161-165
fluorouracil	O	166-178
(	O	179-180
5	O	180-181
-	O	181-182
FU	O	182-184
)	O	184-185
therapy	O	186-193
,	O	193-194
this	O	195-199
phenomenon	O	200-210
has	O	211-214
not	O	215-218
been	O	219-223
studied	O	224-231
in	O	232-234
a	O	235-236
systematic	O	237-247
fashion	O	248-255
.	O	255-256

We	O	257-259
prospectively	O	260-273
performed	O	274-283
continuous	O	284-294
ambulatory	O	295-305
ECG	O	306-309
monitoring	O	310-320
on	O	321-323
25	O	324-326
patients	O	327-335
undergoing	O	336-346
5	O	347-348
-	O	348-349
FU	O	349-351
infusion	O	352-360
for	O	361-364
treatment	O	365-374
of	O	375-377
solid	O	378-383
tumors	B	384-390
in	O	391-393
order	O	394-399
to	O	400-402
assess	O	403-409
the	O	410-413
incidence	O	414-423
of	O	424-426
ischemic	B	427-435
ST	O	436-438
changes	O	439-446
.	O	446-447

Patients	O	448-456
were	O	457-461
monitored	O	462-471
for	O	472-475
23	O	476-478
+	O	479-480
/	O	480-481
-	O	481-482
4	O	483-484
hours	O	485-490
before	O	491-497
5	O	498-499
-	O	499-500
FU	O	500-502
infusion	O	503-511
,	O	511-512
and	O	513-516
98	O	517-519
+	O	520-521
/	O	521-522
-	O	522-523
9	O	524-525
hours	O	526-531
during	O	532-538
5	O	539-540
-	O	540-541
FU	O	541-543
infusion	O	544-552
.	O	552-553

Anginal	B	554-561
episodes	O	562-570
were	O	571-575
rare	O	576-580
:	O	580-581
only	O	582-586
one	O	587-590
patient	O	591-598
had	O	599-602
angina	B	603-609
(	O	610-611
during	O	611-617
5	O	618-619
-	O	619-620
FU	O	620-622
infusion	O	623-631
)	O	631-632
.	O	632-633

However	O	634-641
,	O	641-642
asymptomatic	O	643-655
ST	O	656-658
changes	O	659-666
(	O	667-668
greater	O	668-675
than	O	676-680
or	O	681-683
equal	O	684-689
to	O	690-692
1	O	693-694
mm	O	695-697
ST	O	698-700
deviation	O	701-710
)	O	710-711
were	O	712-716
common	O	717-723
:	O	723-724
six	O	725-728
of	O	729-731
25	O	732-734
patients	O	735-743
(	O	744-745
24	O	745-747
%	O	747-748
)	O	748-749
had	O	750-753
ST	O	754-756
changes	O	757-764
before	O	765-771
5	O	772-773
-	O	773-774
FU	O	774-776
infusion	O	777-785
v	O	786-787
17	O	788-790
(	O	791-792
68	O	792-794
%	O	794-795
)	O	795-796
during	O	797-803
5	O	804-805
-	O	805-806
FU	O	806-808
infusion	O	809-817
(	O	818-819
P	O	819-820
less	O	821-825
than	O	826-830
.	O	831-832
002	O	832-835
)	O	835-836
.	O	831-832

The	O	838-841
incidence	O	842-851
of	O	852-854
ischemic	B	855-863
episodes	O	864-872
per	O	873-876
patient	O	877-884
per	O	885-888
hour	O	889-893
was	O	894-897
0	O	898-899
.	O	899-900
05	O	900-902
+	O	903-904
/	O	904-905
-	O	905-906
0	O	907-908
.	O	908-909
02	O	909-911
prior	O	912-917
to	O	918-920
5	O	921-922
-	O	922-923
FU	O	923-925
infusion	O	926-934
v	O	935-936
0	O	937-938
.	O	938-939
13	O	939-941
+	O	942-943
/	O	943-944
-	O	944-945
0	O	946-947
.	O	947-948
03	O	948-950
during	O	951-957
5	O	958-959
-	O	959-960
FU	O	960-962
infusion	O	963-971
(	O	972-973
P	O	973-974
less	O	975-979
than	O	980-984
.	O	985-986
001	O	986-989
)	O	989-990
;	O	990-991
the	O	992-995
duration	O	996-1004
of	O	1005-1007
ECG	O	1008-1011
changes	O	1012-1019
was	O	1020-1023
0	O	1024-1025
.	O	1025-1026
6	O	1026-1027
+	O	1028-1029
/	O	1029-1030
-	O	1030-1031
0	O	1032-1033
.	O	1033-1034
3	O	1034-1035
minutes	O	1036-1043
per	O	1044-1047
patient	O	1048-1055
per	O	1056-1059
hour	O	1060-1064
before	O	1065-1071
5	O	1072-1073
-	O	1073-1074
FU	O	1074-1076
v	O	1077-1078
1	O	1079-1080
.	O	1080-1081
9	O	1081-1082
+	O	1083-1084
/	O	1084-1085
-	O	1085-1086
0	O	1087-1088
.	O	1088-1089
5	O	1089-1090
minutes	O	1091-1098
per	O	1099-1102
patient	O	1103-1110
per	O	1111-1114
hour	O	1115-1119
during	O	1120-1126
5	O	1127-1128
-	O	1128-1129
FU	O	1129-1131
(	O	1132-1133
P	O	1133-1134
less	O	1135-1139
than	O	1140-1144
.	O	1145-1146
01	O	1146-1148
)	O	1148-1149
.	O	1145-1146

ECG	O	1151-1154
changes	O	1155-1162
were	O	1163-1167
more	O	1168-1172
common	O	1173-1179
among	O	1180-1185
patients	O	1186-1194
with	O	1195-1199
known	O	1200-1205
coronary	B	1206-1214
artery	I	1215-1221
disease	I	1222-1229
.	O	1229-1230

There	O	1231-1236
were	O	1237-1241
two	O	1242-1245
cases	O	1246-1251
of	O	1252-1254
sudden	B	1255-1261
death	I	1262-1267
,	O	1267-1268
both	O	1269-1273
of	O	1274-1276
which	O	1277-1282
occurred	O	1283-1291
at	O	1292-1294
the	O	1295-1298
end	O	1299-1302
of	O	1303-1305
the	O	1306-1309
chemotherapy	O	1310-1322
course	O	1323-1329
.	O	1329-1330

We	O	1331-1333
conclude	O	1334-1342
that	O	1343-1347
5	O	1348-1349
-	O	1349-1350
FU	O	1350-1352
infusion	O	1353-1361
is	O	1362-1364
associated	O	1365-1375
with	O	1376-1380
a	O	1381-1382
significant	O	1383-1394
increase	O	1395-1403
in	O	1404-1406
silent	O	1407-1413
ST	O	1414-1416
segment	O	1417-1424
deviation	O	1425-1434
suggestive	O	1435-1445
of	O	1446-1448
ischemia	B	1449-1457
,	O	1457-1458
particularly	O	1459-1471
among	O	1472-1477
patients	O	1478-1486
with	O	1487-1491
coronary	B	1492-1500
artery	I	1501-1507
disease	I	1508-1515
.	O	1515-1516

The	O	1517-1520
mechanism	O	1521-1530
and	O	1531-1534
clinical	O	1535-1543
significance	O	1544-1556
of	O	1557-1559
these	O	1560-1565
ECG	O	1566-1569
changes	O	1570-1577
remain	O	1578-1584
to	O	1585-1587
be	O	1588-1590
determined	O	1591-1601
.	O	1601-1602

Lethal	O	0-6
anuria	B	7-13
complicating	O	14-26
high	O	27-31
dose	O	32-36
ifosfamide	O	37-47
chemotherapy	O	48-60
in	O	61-63
a	O	64-65
breast	B	66-72
cancer	I	73-79
patient	O	80-87
with	O	88-92
an	O	93-95
impaired	B	96-104
renal	I	105-110
function	I	111-119
.	O	119-120

A	O	121-122
sixty	O	123-128
-	O	128-129
year	O	129-133
-	O	128-129
old	O	134-137
woman	O	138-143
with	O	144-148
advanced	O	149-157
breast	B	158-164
cancer	I	165-171
,	O	171-172
previously	O	173-183
treated	O	184-191
with	O	192-196
cisplatin	O	197-206
,	O	206-207
developed	O	208-217
an	O	218-220
irreversible	O	221-233
lethal	O	234-240
renal	B	241-246
failure	I	247-254
with	O	255-259
anuria	B	260-266
,	O	266-267
the	O	268-271
day	O	272-275
after	O	276-281
5	O	282-283
g	O	284-285
/	O	285-286
m2	O	286-288
bolus	O	289-294
ifosfamide	O	295-305
.	O	305-306

Postrenal	B	307-316
failure	I	317-324
was	O	325-328
excluded	O	329-337
by	O	338-340
echography	O	341-351
.	O	351-352

A	O	353-354
prerenal	O	355-363
component	O	364-373
could	O	374-379
have	O	380-384
contributed	O	385-396
to	O	397-399
renal	B	400-405
failure	I	406-413
because	O	414-421
of	O	422-424
a	O	425-426
transient	O	427-436
hypotension	B	437-448
,	O	448-449
due	O	450-453
to	O	454-456
an	O	457-459
increasing	O	460-470
ascitis	O	471-478
,	O	478-479
occurring	O	480-489
just	O	490-494
before	O	495-501
anuria	B	502-508
.	O	508-509

However	O	510-517
,	O	517-518
correction	O	519-529
of	O	530-532
the	O	533-536
hemodynamic	O	537-548
parameters	O	549-559
did	O	560-563
not	O	564-567
improve	O	568-575
renal	O	576-581
function	O	582-590
.	O	590-591

Ifosfamide	O	592-602
is	O	603-605
a	O	606-607
known	O	608-613
nephrotoxic	B	614-625
drug	O	626-630
with	O	631-635
demonstrated	O	636-648
tubulopathies	B	649-662
.	O	662-663

We	O	664-666
strongly	O	667-675
suspect	O	676-683
that	O	684-688
this	O	689-693
lethal	O	694-700
anuria	B	701-707
was	O	708-711
mainly	O	712-718
due	O	719-722
to	O	723-725
ifosfamide	O	726-736
,	O	736-737
occurring	O	738-747
in	O	748-750
a	O	751-752
patient	O	753-760
having	O	761-767
received	O	768-776
previous	O	777-785
cisplatin	O	786-795
chemotherapy	O	796-808
and	O	809-812
with	O	813-817
poor	O	818-822
kidney	O	823-829
perfusion	O	830-839
due	O	840-843
to	O	844-846
transient	O	847-856
hypotension	B	857-868
.	O	868-869

We	O	870-872
recommend	O	873-882
careful	O	883-890
use	O	891-894
of	O	895-897
ifosfamide	O	898-908
in	O	909-911
patients	O	912-920
pretreated	O	921-931
with	O	932-936
nephrotoxic	B	937-948
chemotherapy	O	949-961
and	O	962-965
inadequate	O	966-976
renal	O	977-982
perfusion	O	983-992
.	O	992-993

Central	O	0-7
vein	B	8-12
thrombosis	I	13-23
and	O	24-27
topical	O	28-35
dipivalyl	O	36-45
epinephrine	O	46-57
.	O	57-58

A	O	59-60
report	O	61-67
is	O	68-70
given	O	71-76
on	O	77-79
an	O	80-82
83	O	83-85
-	O	85-86
year	O	86-90
-	O	85-86
old	O	91-94
female	O	95-101
who	O	102-105
acquired	O	106-114
central	O	115-122
vein	B	123-127
thrombosis	I	128-138
in	O	139-141
her	O	142-145
seeing	O	146-152
eye	O	153-156
one	O	157-160
day	O	161-164
after	O	165-170
having	O	171-177
started	O	178-185
topical	O	186-193
medication	O	194-204
with	O	205-209
dipivalyl	O	210-219
epinephrine	O	220-231
for	O	232-235
advanced	O	236-244
glaucoma	B	245-253
discovered	O	254-264
in	O	265-267
the	O	268-271
other	O	272-277
eye	O	278-281
.	O	281-282

From	O	283-287
present	O	288-295
knowledge	O	296-305
about	O	306-311
the	O	312-315
effects	O	316-323
of	O	324-326
adrenergic	O	327-337
eye	O	338-341
drops	O	342-347
on	O	348-350
ocular	O	351-357
blood	O	358-363
circulation	O	364-375
,	O	375-376
it	O	377-379
is	O	380-382
difficult	O	383-392
to	O	393-395
suggest	O	396-403
an	O	404-406
association	O	407-418
between	O	419-426
the	O	427-430
two	O	431-434
events	O	435-441
,	O	441-442
which	O	443-448
may	O	449-452
be	O	453-455
coincidental	O	456-468
only	O	469-473
.	O	473-474

Amelioration	O	0-12
of	O	13-15
bendrofluazide	O	16-30
-	O	30-31
induced	O	31-38
hypokalemia	B	39-50
by	O	51-53
timolol	O	54-61
.	O	61-62

The	O	63-66
beta	O	67-71
adrenergic	O	72-82
blocking	O	83-91
drug	O	92-96
,	O	96-97
timolol	O	98-105
,	O	105-106
tended	O	107-113
to	O	114-116
correct	O	117-124
the	O	125-128
hypokalemia	B	129-140
of	O	141-143
short	O	144-149
-	O	149-150
term	O	150-154
bendrofluazide	O	155-169
treatment	O	170-179
in	O	180-182
6	O	183-184
healthy	O	185-192
male	O	193-197
subjects	O	198-206
and	O	207-210
although	O	211-219
the	O	220-223
effect	O	224-230
was	O	231-234
small	O	235-240
it	O	241-243
was	O	244-247
significant	O	248-259
.	O	259-260

Timolol	O	261-268
also	O	269-273
reduced	O	274-281
the	O	282-285
rise	O	286-290
in	O	291-293
plasma	O	294-300
aldosterone	O	301-312
and	O	313-316
urine	O	317-322
potassium	O	323-332
excretion	O	333-342
following	O	343-352
bendrofluazide	O	353-367
and	O	368-371
increased	O	372-381
the	O	382-385
urine	O	386-391
sodium	O	392-398
/	O	398-399
potassium	O	399-408
ratio	O	409-414
.	O	414-415

There	O	416-421
was	O	422-425
no	O	426-428
evidence	O	429-437
of	O	438-440
a	O	441-442
shift	O	443-448
of	O	449-451
potassium	O	452-461
from	O	462-466
the	O	467-470
intracellular	O	471-484
to	O	485-487
the	O	488-491
extracellular	O	492-505
space	O	506-511
.	O	511-512

A	O	0-1
cross	O	2-7
-	O	7-8
sectional	O	8-17
evaluation	O	18-28
of	O	29-31
the	O	32-35
effect	O	36-42
of	O	43-45
risperidone	O	46-57
and	O	58-61
selective	O	62-71
serotonin	O	72-81
reuptake	O	82-90
inhibitors	O	91-101
on	O	102-104
bone	O	105-109
mineral	O	110-117
density	O	118-125
in	O	126-128
boys	O	129-133
.	O	133-134

OBJECTIVE	O	135-144
:	O	144-145
The	O	146-149
aim	O	150-153
of	O	154-156
the	O	157-160
present	O	161-168
study	O	169-174
was	O	175-178
to	O	179-181
investigate	O	182-193
the	O	194-197
effect	O	198-204
of	O	205-207
risperidone	O	208-219
-	O	219-220
induced	O	220-227
hyperprolactinemia	B	228-246
on	O	247-249
trabecular	O	250-260
bone	O	261-265
mineral	O	266-273
density	O	274-281
(	O	282-283
BMD	O	283-286
)	O	286-287
in	O	288-290
children	O	291-299
and	O	300-303
adolescents	O	304-315
.	O	315-316

METHOD	O	317-323
:	O	323-324
Medically	O	325-334
healthy	O	335-342
7	O	343-344
-	O	344-345
to	O	346-348
17	O	349-351
-	O	351-352
year	O	352-356
-	O	351-352
old	O	357-360
males	O	361-366
chronically	O	367-378
treated	O	379-386
,	O	386-387
in	O	388-390
a	O	391-392
naturalistic	O	393-405
setting	O	406-413
,	O	413-414
with	O	415-419
risperidone	O	420-431
were	O	432-436
recruited	O	437-446
for	O	447-450
this	O	451-455
cross	O	456-461
-	O	461-462
sectional	O	462-471
study	O	472-477
through	O	478-485
child	O	486-491
psychiatry	O	492-502
outpatient	O	503-513
clinics	O	514-521
between	O	522-529
November	O	530-538
2005	O	539-543
and	O	544-547
June	O	548-552
2007	O	553-557
.	O	557-558

Anthropometric	O	559-573
measurements	O	574-586
and	O	587-590
laboratory	O	591-601
testing	O	602-609
were	O	610-614
conducted	O	615-624
.	O	624-625

The	O	626-629
clinical	O	630-638
diagnoses	O	639-648
were	O	649-653
based	O	654-659
on	O	660-662
chart	O	663-668
review	O	669-675
,	O	675-676
and	O	677-680
developmental	O	681-694
and	O	695-698
treatment	O	699-708
history	O	709-716
was	O	717-720
obtained	O	721-729
from	O	730-734
the	O	735-738
medical	O	739-746
record	O	747-753
.	O	753-754

Volumetric	O	755-765
BMD	O	766-769
of	O	770-772
the	O	773-776
ultradistal	O	777-788
radius	O	789-795
was	O	796-799
measured	O	800-808
using	O	809-814
peripheral	O	815-825
quantitative	O	826-838
computed	O	839-847
tomography	O	848-858
,	O	858-859
and	O	860-863
areal	O	864-869
BMD	O	870-873
of	O	874-876
the	O	877-880
lumbar	O	881-887
spine	O	888-893
was	O	894-897
estimated	O	898-907
using	O	908-913
dual	O	914-918
-	O	918-919
energy	O	919-925
x	O	926-927
-	O	927-928
ray	O	928-931
absorptiometry	O	932-946
.	O	946-947

RESULTS	O	948-955
:	O	955-956
Hyperprolactinemia	B	957-975
was	O	976-979
present	O	980-987
in	O	988-990
49	O	991-993
%	O	993-994
of	O	995-997
83	O	998-1000
boys	O	1001-1005
(	O	1006-1007
n	O	1007-1008
=	O	1009-1010
41	O	1011-1013
)	O	1013-1014
treated	O	1015-1022
with	O	1023-1027
risperidone	O	1028-1039
for	O	1040-1043
a	O	1044-1045
mean	O	1046-1050
of	O	1051-1053
2	O	1054-1055
.	O	1055-1056
9	O	1056-1057
years	O	1058-1063
.	O	1063-1064

Serum	O	1065-1070
testosterone	O	1071-1083
concentration	O	1084-1097
increased	O	1098-1107
with	O	1108-1112
pubertal	O	1113-1121
status	O	1122-1128
but	O	1129-1132
was	O	1133-1136
not	O	1137-1140
affected	O	1141-1149
by	O	1150-1152
hyperprolactinemia	B	1153-1171
.	O	1171-1172

As	O	1173-1175
expected	O	1176-1184
,	O	1184-1185
bone	O	1186-1190
mineral	O	1191-1198
content	O	1199-1206
and	O	1207-1210
BMD	O	1211-1214
increased	O	1215-1224
with	O	1225-1229
sexual	O	1230-1236
maturity	O	1237-1245
.	O	1245-1246

After	O	1247-1252
adjusting	O	1253-1262
for	O	1263-1266
the	O	1267-1270
stage	O	1271-1276
of	O	1277-1279
sexual	O	1280-1286
development	O	1287-1298
and	O	1299-1302
height	O	1303-1309
and	O	1310-1313
BMI	O	1314-1317
z	O	1318-1319
scores	O	1320-1326
,	O	1326-1327
serum	O	1328-1333
prolactin	O	1334-1343
was	O	1344-1347
negatively	O	1348-1358
associated	O	1359-1369
with	O	1370-1374
trabecular	O	1375-1385
volumetric	O	1386-1396
BMD	O	1397-1400
at	O	1401-1403
the	O	1404-1407
ultradistal	O	1408-1419
radius	O	1420-1426
(	O	1427-1428
P	O	1428-1429
<	O	1430-1431
.	O	1432-1433
03	O	1433-1435
)	O	1435-1436
.	O	1432-1433

Controlling	O	1438-1449
for	O	1450-1453
relevant	O	1454-1462
covariates	O	1463-1473
,	O	1473-1474
we	O	1475-1477
also	O	1478-1482
found	O	1483-1488
treatment	O	1489-1498
with	O	1499-1503
selective	O	1504-1513
serotonin	O	1514-1523
reuptake	O	1524-1532
inhibitors	O	1533-1543
(	O	1544-1545
SSRIs	O	1545-1550
)	O	1550-1551
to	O	1552-1554
be	O	1555-1557
associated	O	1558-1568
with	O	1569-1573
lower	O	1574-1579
trabecular	O	1580-1590
BMD	O	1591-1594
at	O	1595-1597
the	O	1598-1601
radius	O	1602-1608
(	O	1609-1610
P	O	1610-1611
=	O	1612-1613
.	O	1614-1615
03	O	1615-1617
)	O	1617-1618

and	O	1619-1622
BMD	O	1623-1626
z	O	1627-1628
score	O	1629-1634
at	O	1635-1637
the	O	1638-1641
lumbar	O	1642-1648
spine	O	1649-1654
(	O	1655-1656
P	O	1656-1657
<	O	1658-1659
.	O	1660-1661
05	O	1661-1663
)	O	1663-1664
.	O	1660-1661

These	O	1666-1671
findings	O	1672-1680
became	O	1681-1687
more	O	1688-1692
marked	O	1693-1699
when	O	1700-1704
the	O	1705-1708
analysis	O	1709-1717
was	O	1718-1721
restricted	O	1722-1732
to	O	1733-1735
non	O	1736-1739
-	O	1739-1740
Hispanic	O	1740-1748
white	O	1749-1754
patients	O	1755-1763
.	O	1763-1764

Of	O	1765-1767
13	O	1768-1770
documented	O	1771-1781
fractures	B	1782-1791
,	O	1791-1792
3	O	1793-1794
occurred	O	1795-1803
after	O	1804-1809
risperidone	O	1810-1821
and	O	1822-1825
SSRIs	O	1826-1831
were	O	1832-1836
started	O	1837-1844
,	O	1844-1845
and	O	1846-1849
none	O	1850-1854
occurred	O	1855-1863
in	O	1864-1866
patients	O	1867-1875
with	O	1876-1880
hyperprolactinemia	B	1881-1899
.	O	1899-1900

CONCLUSIONS	O	1901-1912
:	O	1912-1913
This	O	1914-1918
is	O	1919-1921
the	O	1922-1925
first	O	1926-1931
study	O	1932-1937
to	O	1938-1940
link	O	1941-1945
risperidone	O	1946-1957
-	O	1957-1958
induced	O	1958-1965
hyperprolactinemia	B	1966-1984
and	O	1985-1988
SSRI	O	1989-1993
treatment	O	1994-2003
to	O	2004-2006
lower	O	2007-2012
BMD	O	2013-2016
in	O	2017-2019
children	O	2020-2028
and	O	2029-2032
adolescents	O	2033-2044
.	O	2044-2045

Future	O	2046-2052
research	O	2053-2061
should	O	2062-2068
evaluate	O	2069-2077
the	O	2078-2081
longitudinal	O	2082-2094
course	O	2095-2101
of	O	2102-2104
this	O	2105-2109
adverse	O	2110-2117
event	O	2118-2123
to	O	2124-2126
determine	O	2127-2136
its	O	2137-2140
temporal	O	2141-2149
stability	O	2150-2159
and	O	2160-2163
whether	O	2164-2171
a	O	2172-2173
higher	O	2174-2180
fracture	O	2181-2189
rate	O	2190-2194
ensues	O	2195-2201
.	O	2201-2202

Seizures	B	0-8
associated	O	9-19
with	O	20-24
levofloxacin	O	25-37
:	O	37-38
case	O	39-43
presentation	O	44-56
and	O	57-60
literature	O	61-71
review	O	72-78
.	O	78-79

PURPOSE	O	80-87
:	O	87-88
We	O	89-91
present	O	92-99
a	O	100-101
case	O	102-106
of	O	107-109
a	O	110-111
patient	O	112-119
who	O	120-123
developed	O	124-133
seizures	B	134-142
shortly	O	143-150
after	O	151-156
initiating	O	157-167
treatment	O	168-177
with	O	178-182
levofloxacin	O	183-195
and	O	196-199
to	O	200-202
discuss	O	203-210
the	O	211-214
potential	O	215-224
drug	O	225-229
-	O	229-230
drug	O	225-229
interactions	O	235-247
related	O	248-255
to	O	256-258
the	O	259-262
inhibition	O	263-273
of	O	274-276
cytochrome	O	277-287
P450	O	288-292
(	O	293-294
CYP	O	294-297
)	O	297-298
1A2	O	299-302
in	O	303-305
this	O	306-310
case	O	311-315
,	O	315-316
as	O	317-319
well	O	320-324
as	O	325-327
in	O	328-330
other	O	331-336
cases	O	337-342
,	O	342-343
of	O	344-346
levofloxacin	O	347-359
-	O	359-360
induced	O	360-367
seizures	B	368-376
.	O	376-377

METHODS	O	378-385
:	O	385-386
Several	O	387-394
biomedical	O	395-405
databases	O	406-415
were	O	416-420
searched	O	421-429
including	O	430-439
MEDLINE	O	440-447
,	O	447-448
Cochrane	O	449-457
and	O	458-461
Ovid	O	462-466
.	O	466-467

The	O	468-471
main	O	472-476
search	O	477-483
terms	O	484-489
utilized	O	490-498
were	O	499-503
case	O	504-508
report	O	509-515
and	O	516-519
levofloxacin	O	520-532
.	O	532-533

The	O	534-537
search	O	538-544
was	O	545-548
limited	O	549-556
to	O	557-559
studies	O	560-567
published	O	568-577
in	O	578-580
English	O	581-588
.	O	588-589

RESULTS	O	590-597
:	O	597-598
Six	O	599-602
cases	O	603-608
of	O	609-611
levofloxacin	O	612-624
-	O	624-625
induced	O	625-632
seizures	B	633-641
have	O	642-646
been	O	647-651
reported	O	652-660
in	O	661-663
the	O	664-667
literature	O	668-678
.	O	678-679

Drug	O	680-684
-	O	684-685
drug	O	685-689
interactions	O	690-702
related	O	703-710
to	O	711-713
the	O	714-717
inhibition	O	718-728
of	O	729-731
CYP1A2	O	732-738
by	O	739-741
levofloxacin	O	742-754
are	O	755-758
likely	O	759-765
involved	O	766-774
in	O	775-777
the	O	778-781
clinical	O	782-790
outcome	O	791-798
of	O	799-801
these	O	802-807
cases	O	808-813
.	O	813-814

CONCLUSIONS	O	815-826
:	O	826-827
Clinicians	O	828-838
are	O	839-842
exhorted	O	843-851
to	O	852-854
pay	O	855-858
close	O	859-864
attention	O	865-874
when	O	875-879
initiating	O	880-890
levofloxacin	O	891-903
therapy	O	904-911
in	O	912-914
patients	O	915-923
taking	O	924-930
medications	O	931-942
with	O	943-947
epileptogenic	O	948-961
properties	O	962-972
that	O	973-977
are	O	978-981
CYP1A2	O	982-988
substrates	O	989-999
.	O	999-1000

Mice	O	0-4
lacking	O	5-12
mPGES	O	13-18
-	O	18-19
1	O	19-20
are	O	21-24
resistant	O	25-34
to	O	35-37
lithium	O	38-45
-	O	45-46
induced	O	46-53
polyuria	B	54-62
.	O	62-63

Cyclooxygenase	O	64-78
-	O	78-79
2	O	79-80
activity	O	81-89
is	O	90-92
required	O	93-101
for	O	102-105
the	O	106-109
development	O	110-121
of	O	122-124
lithium	O	125-132
-	O	132-133
induced	O	133-140
polyuria	B	141-149
.	O	149-150

However	O	151-158
,	O	158-159
the	O	160-163
involvement	O	164-175
of	O	176-178
a	O	179-180
specific	O	181-189
,	O	189-190
terminal	O	191-199
prostaglandin	O	200-213
(	O	214-215
PG	O	215-217
)	O	217-218
isomerase	O	219-228
has	O	229-232
not	O	233-236
been	O	237-241
evaluated	O	242-251
.	O	251-252

The	O	253-256
present	O	257-264
study	O	265-270
was	O	271-274
undertaken	O	275-285
to	O	286-288
assess	O	289-295
lithium	O	296-303
-	O	303-304
induced	O	304-311
polyuria	B	312-320
in	O	321-323
mice	O	324-328
deficient	O	329-338
in	O	339-341
microsomal	O	342-352
prostaglandin	O	353-366
E	O	367-368
synthase	O	369-377
-	O	377-378
1	O	378-379
(	O	380-381
mPGES	O	381-386
-	O	386-387
1	O	387-388
)	O	388-389
.	O	389-390

A	O	391-392
2	O	393-394
-	O	394-395
wk	O	395-397
administration	O	398-412
of	O	413-415
LiCl	O	416-420
(	O	421-422
4	O	422-423
mmol	O	424-428
.	O	428-429
kg	O	429-431
(	O	431-432
-	O	432-433
1	O	433-434
)	O	434-435
.	O	428-429
day	O	436-439
(	O	431-432
-	O	432-433
1	O	433-434
)	O	434-435

ip	O	444-446
)	O	446-447
in	O	448-450
mPGES	O	451-456
-	O	456-457
1	O	457-458
+	O	459-460
/	O	460-461
+	O	459-460
mice	O	463-467
led	O	468-471
to	O	472-474
a	O	475-476
marked	O	477-483
polyuria	B	484-492
with	O	493-497
hyposmotic	O	498-508
urine	O	509-514
.	O	514-515

This	O	516-520
was	O	521-524
associated	O	525-535
with	O	536-540
elevated	O	541-549
renal	O	550-555
mPGES	O	556-561
-	O	561-562
1	O	562-563
protein	O	564-571
expression	O	572-582
and	O	583-586
increased	O	587-596
urine	O	597-602
PGE	O	603-606
(	O	606-607
2	O	607-608
)	O	608-609
excretion	O	610-619
.	O	619-620

In	O	621-623
contrast	O	624-632
,	O	632-633
mPGES	O	634-639
-	O	639-640
1	O	640-641
-	O	642-643
/	O	643-644
-	O	642-643
mice	O	646-650
were	O	651-655
largely	O	656-663
resistant	O	664-673
to	O	674-676
lithium	O	677-684
-	O	684-685
induced	O	685-692
polyuria	B	693-701
and	O	702-705
a	O	706-707
urine	O	708-713
concentrating	O	714-727
defect	O	728-734
,	O	734-735
accompanied	O	736-747
by	O	748-750
nearly	O	751-757
complete	O	758-766
blockade	O	767-775
of	O	776-778
high	O	779-783
urine	O	784-789
PGE	O	790-793
(	O	793-794
2	O	794-795
)	O	795-796
and	O	797-800
cAMP	O	801-805
output	O	806-812
.	O	812-813

Immunoblotting	O	814-828
,	O	828-829
immunohistochemistry	O	830-850
,	O	850-851
and	O	852-855
quantitative	O	856-868
(	O	869-870
q	O	870-871
)	O	871-872
RT	O	873-875
-	O	875-876
PCR	O	876-879
consistently	O	880-892
detected	O	893-901
a	O	902-903
significant	O	904-915
decrease	O	916-924
in	O	925-927
aquaporin	O	928-937
-	O	937-938
2	O	938-939
(	O	940-941
AQP2	O	941-945
)	O	945-946
protein	O	947-954
expression	O	955-965
in	O	966-968
both	O	969-973
the	O	974-977
renal	O	978-983
cortex	O	984-990
and	O	991-994
medulla	O	995-1002
of	O	1003-1005
lithium	O	1006-1013
-	O	1013-1014
treated	O	1014-1021
+	O	1022-1023
/	O	1023-1024
+	O	1022-1023
mice	O	1026-1030
.	O	1030-1031

This	O	1032-1036
decrease	O	1037-1045
was	O	1046-1049
significantly	O	1050-1063
attenuated	O	1064-1074
in	O	1075-1077
the	O	1078-1081
-	O	1082-1083
/	O	1083-1084
-	O	1082-1083
mice	O	1086-1090
.	O	1090-1091

qRT	O	1092-1095
-	O	1095-1096
PCR	O	1096-1099
detected	O	1100-1108
similar	O	1109-1116
patterns	O	1117-1125
of	O	1126-1128
changes	O	1129-1136
in	O	1137-1139
AQP2	O	1140-1144
mRNA	O	1145-1149
in	O	1150-1152
the	O	1153-1156
medulla	O	1157-1164
but	O	1165-1168
not	O	1169-1172
in	O	1173-1175
the	O	1176-1179
cortex	O	1180-1186
.	O	1186-1187

Similarly	O	1188-1197
,	O	1197-1198
the	O	1199-1202
total	O	1203-1208
protein	O	1209-1216
abundance	O	1217-1226
of	O	1227-1229
the	O	1230-1233
Na	O	1234-1236
-	O	1236-1237
K	O	1237-1238
-	O	1236-1237
2Cl	O	1239-1242
cotransporter	O	1243-1256
(	O	1257-1258
NKCC2	O	1258-1263
)	O	1263-1264
in	O	1265-1267
the	O	1268-1271
medulla	O	1272-1279
but	O	1280-1283
not	O	1284-1287
in	O	1288-1290
the	O	1291-1294
cortex	O	1295-1301
of	O	1302-1304
the	O	1305-1308
+	O	1309-1310
/	O	1310-1311
+	O	1309-1310
mice	O	1313-1317
was	O	1318-1321
significantly	O	1322-1335
reduced	O	1336-1343
by	O	1344-1346
lithium	O	1347-1354
treatment	O	1355-1364
.	O	1364-1365

In	O	1366-1368
contrast	O	1369-1377
,	O	1377-1378
the	O	1379-1382
dowregulation	O	1383-1396
of	O	1397-1399
renal	O	1400-1405
medullary	O	1406-1415
NKCC2	O	1416-1421
expression	O	1422-1432
was	O	1433-1436
significantly	O	1437-1450
attenuated	O	1451-1461
in	O	1462-1464
the	O	1465-1468
-	O	1469-1470
/	O	1470-1471
-	O	1469-1470
mice	O	1473-1477
.	O	1477-1478

We	O	1479-1481
conclude	O	1482-1490
that	O	1491-1495
mPGES	O	1496-1501
-	O	1501-1502
1	O	1502-1503
-	O	1501-1502
derived	O	1504-1511
PGE	O	1512-1515
(	O	1515-1516
2	O	1516-1517
)	O	1517-1518
mediates	O	1519-1527
lithium	O	1528-1535
-	O	1535-1536
induced	O	1536-1543
polyuria	B	1544-1552
likely	O	1553-1559
via	O	1560-1563
inhibition	O	1564-1574
of	O	1575-1577
AQP2	O	1578-1582
and	O	1583-1586
NKCC2	O	1587-1592
expression	O	1593-1603
.	O	1603-1604

Identification	O	0-14
of	O	15-17
a	O	18-19
simple	O	20-26
and	O	27-30
sensitive	O	31-40
microplate	O	41-51
method	O	52-58
for	O	59-62
the	O	63-66
detection	O	67-76
of	O	77-79
oversulfated	O	80-92
chondroitin	O	93-104
sulfate	O	105-112
in	O	113-115
heparin	O	116-123
products	O	124-132
.	O	132-133

Heparin	O	134-141
is	O	142-144
a	O	145-146
commonly	O	147-155
implemented	O	156-167
anticoagulant	O	168-181
used	O	182-186
to	O	187-189
treat	O	190-195
critically	O	196-206
ill	O	207-210
patients	O	211-219
.	O	219-220

Recently	O	221-229
,	O	229-230
a	O	231-232
number	O	233-239
of	O	240-242
commercial	O	243-253
lots	O	254-258
of	O	259-261
heparin	O	262-269
products	O	270-278
were	O	279-283
found	O	284-289
to	O	290-292
be	O	293-295
contaminated	O	296-308
with	O	309-313
an	O	314-316
oversulfated	O	317-329
chondroitin	O	330-341
sulfate	O	342-349
(	O	350-351
OSCS	O	351-355
)	O	355-356
derivative	O	357-367
that	O	368-372
could	O	373-378
elicit	O	379-385
a	O	386-387
hypotensive	B	388-399
response	O	400-408
in	O	409-411
pigs	O	412-416
following	O	417-426
a	O	427-428
single	O	429-435
high	O	436-440
-	O	440-441
dose	O	441-445
infusion	O	446-454
.	O	454-455

Using	O	456-461
both	O	462-466
contaminated	O	467-479
heparin	O	480-487
products	O	488-496
and	O	497-500
the	O	501-504
synthetically	O	505-518
produced	O	519-527
derivative	O	528-538
,	O	538-539
we	O	540-542
showed	O	543-549
that	O	550-554
the	O	555-558
OSCS	O	559-563
produces	O	564-572
dose	O	573-577
-	O	577-578
dependent	O	578-587
hypotension	B	588-599
in	O	600-602
pigs	O	603-607
.	O	607-608

The	O	609-612
no	O	613-615
observed	O	616-624
effect	O	625-631
level	O	632-637
(	O	638-639
NOEL	O	639-643
)	O	643-644
for	O	645-648
this	O	649-653
contaminant	O	654-665
appears	O	666-673
to	O	674-676
be	O	677-679
approximately	O	680-693
1mg	O	694-697
/	O	697-698
kg	O	698-700
,	O	700-701
corresponding	O	702-715
to	O	716-718
a	O	719-720
contamination	O	721-734
level	O	735-740
of	O	741-743
approximately	O	744-757
3	O	758-759
%	O	759-760
.	O	760-761

We	O	762-764
also	O	765-769
demonstrated	O	770-782
that	O	783-787
OSCS	O	788-792
can	O	793-796
be	O	797-799
identified	O	800-810
in	O	811-813
heparin	O	814-821
products	O	822-830
using	O	831-836
a	O	837-838
simple	O	839-845
,	O	845-846
inexpensive	O	847-858
,	O	858-859
commercially	O	860-872
available	O	873-882
heparin	O	883-890
enzyme	O	891-897
immunoassay	O	898-909
(	O	910-911
EIA	O	911-914
)	O	914-915
kit	O	916-919
that	O	920-924
has	O	925-928
a	O	929-930
limit	O	931-936
of	O	937-939
detection	O	940-949
of	O	950-952
approximately	O	953-966
0	O	967-968
.	O	968-969
1	O	969-970
%	O	970-971
,	O	971-972
well	O	973-977
below	O	978-983
the	O	984-987
NOEL	O	988-992
.	O	992-993

This	O	994-998
kit	O	999-1002
may	O	1003-1006
provide	O	1007-1014
a	O	1015-1016
useful	O	1017-1023
method	O	1024-1030
to	O	1031-1033
test	O	1034-1038
heparin	O	1039-1046
products	O	1047-1055
for	O	1056-1059
contamination	O	1060-1073
with	O	1074-1078
oversulfated	O	1079-1091
GAG	O	1092-1095
derivatives	O	1096-1107
.	O	1107-1108

Doxorubicin	O	0-11
cardiomyopathy	B	12-26
-	O	26-27
induced	O	27-34
inflammation	B	35-47
and	O	48-51
apoptosis	O	52-61
are	O	62-65
attenuated	O	66-76
by	O	77-79
gene	O	80-84
deletion	O	85-93
of	O	94-96
the	O	97-100
kinin	O	101-106
B1	O	107-109
receptor	O	110-118
.	O	118-119

Clinical	O	120-128
use	O	129-132
of	O	133-135
the	O	136-139
anthracycline	O	140-153
doxorubicin	O	154-165
(	O	166-167
DOX	O	167-170
)	O	170-171
is	O	172-174
limited	O	175-182
by	O	183-185
its	O	186-189
cardiotoxic	B	190-201
effects	O	202-209
,	O	209-210
which	O	211-216
are	O	217-220
attributed	O	221-231
to	O	232-234
the	O	235-238
induction	O	239-248
of	O	249-251
apoptosis	O	252-261
.	O	261-262

To	O	263-265
elucidate	O	266-275
the	O	276-279
possible	O	280-288
role	O	289-293
of	O	294-296
the	O	297-300
kinin	O	301-306
B1	O	307-309
receptor	O	310-318
(	O	319-320
B1R	O	320-323
)	O	323-324
during	O	325-331
the	O	332-335
development	O	336-347
of	O	348-350
DOX	O	351-354
cardiomyopathy	B	355-369
,	O	369-370
we	O	371-373
studied	O	374-381
B1R	O	382-385
knockout	O	386-394
mice	O	395-399
(	O	400-401
B1R	O	401-404
(	O	400-401
-	O	405-406
/	O	406-407
-	O	405-406
)	O	408-409
)	O	408-409
by	O	411-413
investigating	O	414-427
cardiac	O	428-435
inflammation	B	436-448
and	O	449-452
apoptosis	O	453-462
after	O	463-468
induction	O	469-478
of	O	479-481
DOX	O	482-485
-	O	485-486
induced	O	486-493
cardiomyopathy	B	494-508
.	O	508-509

DOX	O	510-513
control	O	514-521
mice	O	522-526
showed	O	527-533
cardiac	B	534-541
dysfunction	I	542-553
measured	O	554-562
by	O	563-565
pressure	O	566-574
-	O	574-575
volume	O	575-581
loops	O	582-587
in	O	588-590
vivo	O	591-595
.	O	595-596

This	O	597-601
was	O	602-605
associated	O	606-616
with	O	617-621
a	O	622-623
reduced	O	624-631
activation	O	632-642
state	O	643-648
of	O	649-651
AKT	O	652-655
,	O	655-656
as	O	657-659
well	O	660-664
as	O	665-667
an	O	668-670
increased	O	671-680
bax	O	681-684
/	O	684-685
bcl2	O	685-689
ratio	O	690-695
in	O	696-698
Western	O	699-706
blots	O	707-712
,	O	712-713
indicating	O	714-724
cardiac	B	725-732
apoptosis	I	733-742
.	O	742-743

Furthermore	O	744-755
,	O	755-756
mRNA	O	757-761
levels	O	762-768
of	O	769-771
the	O	772-775
proinflammatory	O	776-791
cytokine	O	792-800
interleukin	O	801-812
6	O	813-814
were	O	815-819
increased	O	820-829
in	O	830-832
the	O	833-836
cardiac	O	837-844
tissue	O	845-851
.	O	851-852

In	O	853-855
DOX	O	856-859
B1R	O	860-863
(	O	863-864
-	O	864-865
/	O	865-866
-	O	864-865
)	O	867-868
mice	O	869-873
,	O	873-874
cardiac	B	875-882
dysfunction	I	883-894
was	O	895-898
improved	O	899-907
compared	O	908-916
to	O	917-919
DOX	O	920-923
control	O	924-931
mice	O	932-936
,	O	936-937
which	O	938-943
was	O	944-947
associated	O	948-958
with	O	959-963
normalization	O	964-977
of	O	978-980
the	O	981-984
bax	O	985-988
/	O	988-989
bcl	O	989-992
-	O	992-993
2	O	993-994
ratio	O	995-1000
and	O	1001-1004
interleukin	O	1005-1016
6	O	1017-1018
,	O	1018-1019
as	O	1020-1022
well	O	1023-1027
as	O	1028-1030
AKT	O	1031-1034
activation	O	1035-1045
state	O	1046-1051
.	O	1051-1052

These	O	1053-1058
findings	O	1059-1067
suggest	O	1068-1075
that	O	1076-1080
B1R	O	1081-1084
is	O	1085-1087
detrimental	O	1088-1099
in	O	1100-1102
DOX	O	1103-1106
cardiomyopathy	B	1107-1121
in	O	1122-1124
that	O	1125-1129
it	O	1130-1132
mediates	O	1133-1141
the	O	1142-1145
inflammatory	O	1146-1158
response	O	1159-1167
and	O	1168-1171
apoptosis	O	1172-1181
.	O	1181-1182

These	O	1183-1188
insights	O	1189-1197
might	O	1198-1203
have	O	1204-1208
useful	O	1209-1215
implications	O	1216-1228
for	O	1229-1232
future	O	1233-1239
studies	O	1240-1247
utilizing	O	1248-1257
B1R	O	1258-1261
antagonists	O	1262-1273
for	O	1274-1277
treatment	O	1278-1287
of	O	1288-1290
human	O	1291-1296
DOX	O	1297-1300
cardiomyopathy	B	1301-1315
.	O	1315-1316

Hepatotoxicity	B	0-14
associated	O	15-25
with	O	26-30
sulfasalazine	O	31-44
in	O	45-47
inflammatory	O	48-60
arthritis	B	61-70
:	O	70-71
A	O	72-73
case	O	74-78
series	O	79-85
from	O	86-90
a	O	91-92
local	O	93-98
surveillance	O	99-111
of	O	112-114
serious	O	115-122
adverse	O	123-130
events	O	131-137
.	O	137-138

BACKGROUND	O	139-149
:	O	149-150
Spontaneous	O	151-162
reporting	O	163-172
systems	O	173-180
for	O	181-184
adverse	O	185-192
drug	O	193-197
reactions	O	198-207
(	O	208-209
ADRs	O	209-213
)	O	213-214
are	O	215-218
handicapped	O	219-230
by	O	231-233
under	O	234-239
-	O	239-240
reporting	O	240-249
and	O	250-253
limited	O	254-261
detail	O	262-268
on	O	269-271
individual	O	272-282
cases	O	283-288
.	O	288-289

We	O	290-292
report	O	293-299
an	O	300-302
investigation	O	303-316
from	O	317-321
a	O	322-323
local	O	324-329
surveillance	O	330-342
for	O	343-346
serious	O	347-354
adverse	O	355-362
drug	O	363-367
reactions	O	368-377
associated	O	378-388
with	O	389-393
disease	O	394-401
modifying	O	402-411
anti	O	412-416
-	O	416-417
rheumatic	O	417-426
drugs	O	427-432
that	O	433-437
was	O	438-441
triggered	O	442-451
by	O	452-454
the	O	455-458
occurrence	O	459-469
of	O	470-472
liver	B	473-478
failure	I	479-486
in	O	487-489
two	O	490-493
of	O	494-496
our	O	497-500
patients	O	501-509
.	O	509-510

METHODS	O	511-518
:	O	518-519
Serious	O	520-527
ADR	O	528-531
reports	O	532-539
have	O	540-544
been	O	545-549
solicited	O	550-559
from	O	560-564
local	O	565-570
clinicians	O	571-581
by	O	582-584
regular	O	585-592
postcards	O	593-602
over	O	603-607
the	O	608-611
past	O	612-616
seven	O	617-622
years	O	623-628
.	O	628-629

Patients	O	630-638
'	O	638-639
,	O	639-640
who	O	641-644
had	O	645-648
hepatotoxicity	B	649-663
on	O	664-666
sulfasalazine	O	667-680
and	O	681-684
met	O	685-688
a	O	689-690
definition	O	691-701
of	O	702-704
a	O	705-706
serious	O	707-714
ADR	O	715-718
,	O	718-719
were	O	720-724
identified	O	725-735
.	O	735-736

Two	O	737-740
clinicians	O	741-751
reviewed	O	752-760
structured	O	761-771
case	O	772-776
reports	O	777-784
and	O	785-788
assessed	O	789-797
causality	O	798-807
by	O	808-810
consensus	O	811-820
and	O	821-824
by	O	825-827
using	O	828-833
a	O	834-835
causality	O	836-845
assessment	O	846-856
instrument	O	857-867
.	O	867-868

The	O	869-872
likely	O	873-879
frequency	O	880-889
of	O	890-892
hepatotoxicity	B	893-907
with	O	908-912
sulfasalazine	O	913-926
was	O	927-930
estimated	O	931-940
by	O	941-943
making	O	944-950
a	O	951-952
series	O	953-959
of	O	960-962
conservative	O	963-975
assumptions	O	976-987
.	O	987-988

RESULTS	O	989-996
:	O	996-997
Ten	O	998-1001
cases	O	1002-1007
were	O	1008-1012
identified	O	1013-1023
:	O	1023-1024
eight	O	1025-1030
occurred	O	1031-1039
during	O	1040-1046
surveillance	O	1047-1059
.	O	1059-1060

Eight	O	1061-1066
patients	O	1067-1075
were	O	1076-1080
hospitalised	O	1081-1093
,	O	1093-1094
two	O	1095-1098
in	O	1099-1101
hepatic	B	1102-1109
failure	I	1110-1117
-	O	1118-1119
one	O	1120-1123
died	O	1124-1128
after	O	1129-1134
a	O	1135-1136
liver	O	1137-1142
transplant	O	1143-1153
.	O	1153-1154

All	O	1155-1158
but	O	1159-1162
one	O	1163-1166
event	O	1167-1172
occurred	O	1173-1181
within	O	1182-1188
6	O	1189-1190
weeks	O	1191-1196
of	O	1197-1199
treatment	O	1200-1209
.	O	1209-1210

Seven	O	1211-1216
patients	O	1217-1225
had	O	1226-1229
a	O	1230-1231
skin	B	1232-1236
rash	I	1237-1241
,	O	1241-1242
three	O	1243-1248
eosinophilia	B	1249-1261
and	O	1262-1265
one	O	1266-1269
interstitial	B	1270-1282
nephritis	I	1283-1292
.	O	1292-1293

Five	O	1294-1298
patients	O	1299-1307
were	O	1308-1312
of	O	1313-1315
Black	O	1316-1321
British	O	1322-1329
of	O	1330-1332
African	O	1333-1340
or	O	1341-1343
Caribbean	O	1344-1353
descent	O	1354-1361
.	O	1361-1362

Liver	O	1363-1368
enzymes	O	1369-1376
showed	O	1377-1383
a	O	1384-1385
hepatocellular	O	1386-1400
pattern	O	1401-1408
in	O	1409-1411
four	O	1412-1416
cases	O	1417-1422
and	O	1423-1426
a	O	1427-1428
mixed	O	1429-1434
pattern	O	1435-1442
in	O	1443-1445
six	O	1446-1449
.	O	1449-1450

Drug	O	1451-1455
-	O	1455-1456
related	O	1456-1463
hepatotoxicity	B	1464-1478
was	O	1479-1482
judged	O	1483-1489
probable	O	1490-1498
or	O	1499-1501
highly	O	1502-1508
probable	O	1509-1517
in	O	1518-1520
8	O	1521-1522
patients	O	1523-1531
.	O	1531-1532

The	O	1533-1536
likely	O	1537-1543
frequency	O	1544-1553
of	O	1554-1556
serious	O	1557-1564
hepatotoxicity	B	1565-1579
with	O	1580-1584
sulfasalazine	O	1585-1598
was	O	1599-1602
estimated	O	1603-1612
at	O	1613-1615
0	O	1616-1617
.	O	1617-1618
4	O	1618-1619
%	O	1619-1620
of	O	1621-1623
treated	O	1624-1631
patients	O	1632-1640
.	O	1640-1641

CONCLUSION	O	1642-1652
:	O	1652-1653
Serious	O	1654-1661
hepatotoxicity	B	1662-1676
associated	O	1677-1687
with	O	1688-1692
sulfasalazine	O	1693-1706
appears	O	1707-1714
to	O	1715-1717
be	O	1718-1720
under	O	1721-1726
-	O	1726-1727
appreciated	O	1727-1738
and	O	1739-1742
intensive	O	1743-1752
monitoring	O	1753-1763
and	O	1764-1767
vigilance	O	1768-1777
in	O	1778-1780
the	O	1781-1784
first	O	1785-1790
6	O	1791-1792
weeks	O	1793-1798
of	O	1799-1801
treatment	O	1802-1811
is	O	1812-1814
especially	O	1815-1825
important	O	1826-1835
.	O	1835-1836

An	O	0-2
evaluation	O	3-13
of	O	14-16
amikacin	O	17-25
nephrotoxicity	B	26-40
in	O	41-43
the	O	44-47
hematology	O	48-58
/	O	58-59
oncology	O	59-67
population	O	68-78
.	O	78-79

Amikacin	O	80-88
is	O	89-91
an	O	92-94
aminoglycoside	O	95-109
commonly	O	110-118
used	O	119-123
to	O	124-126
provide	O	127-134
empirical	O	135-144
double	O	145-151
gram	O	152-156
-	O	156-157
negative	O	157-165
treatment	O	166-175
for	O	176-179
febrile	B	180-187
neutropenia	I	188-199
and	O	200-203
other	O	204-209
suspected	O	210-219
infections	B	220-230
.	O	230-231

Strategies	O	232-242
of	O	243-245
extended	O	246-254
-	O	254-255
interval	O	255-263
and	O	264-267
conventional	O	268-280
dosing	O	281-287
have	O	288-292
been	O	293-297
utilized	O	298-306
extensively	O	307-318
in	O	319-321
the	O	322-325
general	O	326-333
medical	O	334-341
population	O	342-352
;	O	352-353
however	O	354-361
,	O	361-362
data	O	363-367
are	O	368-371
lacking	O	372-379
to	O	380-382
support	O	383-390
a	O	391-392
dosing	O	393-399
strategy	O	400-408
in	O	409-411
the	O	412-415
hematology	O	416-426
/	O	426-427
oncology	O	427-435
population	O	436-446
.	O	446-447

To	O	448-450
evaluate	O	451-459
amikacin	O	460-468
-	O	468-469
associated	O	469-479
nephrotoxicity	B	480-494
in	O	495-497
an	O	498-500
adult	O	501-506
hematology	O	507-517
/	O	517-518
oncology	O	518-526
population	O	527-537
,	O	537-538
a	O	539-540
prospective	O	541-552
,	O	552-553
randomized	O	554-564
,	O	564-565
open	O	566-570
-	O	570-571
label	O	571-576
trial	O	577-582
was	O	583-586
conducted	O	587-596
at	O	597-599
a	O	600-601
university	O	602-612
-	O	612-613
affiliated	O	613-623
medical	O	624-631
center	O	632-638
.	O	638-639

Forty	O	640-645
patients	O	646-654
with	O	655-659
a	O	660-661
diagnosis	O	662-671
consistent	O	672-682
with	O	683-687
a	O	688-689
hematologic	B	690-701
/	I	701-702
oncologic	I	702-711
disorder	I	712-720
that	O	721-725
required	O	726-734
treatment	O	735-744
with	O	745-749
an	O	750-752
aminoglycoside	O	753-767
were	O	768-772
randomized	O	773-783
to	O	784-786
either	O	787-793
conventional	O	794-806
or	O	807-809
extended	O	810-818
-	O	818-819
interval	O	819-827
amikacin	O	828-836
.	O	836-837

The	O	838-841
occurrence	O	842-852
of	O	853-855
nephrotoxicity	B	856-870
by	O	871-873
means	O	874-879
of	O	880-882
an	O	883-885
increase	O	886-894
in	O	895-897
serum	O	898-903
creatinine	O	904-914
and	O	915-918
evaluation	O	919-929
of	O	930-932
efficacy	O	933-941
via	O	942-945
amikacin	O	946-954
serum	O	955-960
concentrations	O	961-975
with	O	976-980
respective	O	981-991
pathogens	O	992-1001
were	O	1002-1006
assessed	O	1007-1015
.	O	1015-1016

The	O	1017-1020
occurrence	O	1021-1031
of	O	1032-1034
nephrotoxicity	B	1035-1049
was	O	1050-1053
similar	O	1054-1061
between	O	1062-1069
the	O	1070-1073
conventional	O	1074-1086
and	O	1087-1090
extended	O	1091-1099
-	O	1099-1100
interval	O	1100-1108
groups	O	1109-1115
,	O	1115-1116
at	O	1117-1119
10	O	1120-1122
%	O	1122-1123
and	O	1124-1127
5	O	1128-1129
%	O	1129-1130
,	O	1130-1131
respectively	O	1132-1144
(	O	1145-1146
P	O	1146-1147
=	O	1148-1149
1	O	1150-1151
.	O	1151-1152
00	O	1152-1154
)	O	1154-1155
.	O	1151-1152

Six	O	1157-1160
patients	O	1161-1169
in	O	1170-1172
the	O	1173-1176
conventional	O	1177-1189
group	O	1190-1195
had	O	1196-1199
a	O	1200-1201
positive	O	1202-1210
culture	O	1211-1218
,	O	1218-1219
compared	O	1220-1228
with	O	1229-1233
none	O	1234-1238
in	O	1239-1241
the	O	1242-1245
extended	O	1246-1254
-	O	1254-1255
interval	O	1255-1263
group	O	1264-1269
(	O	1270-1271
P	O	1271-1272
=	O	1273-1274
0	O	1275-1276
.	O	1276-1277
002	O	1277-1280
)	O	1280-1281
.	O	1276-1277

The	O	1283-1286
occurrence	O	1287-1297
of	O	1298-1300
nephrotoxicity	B	1301-1315
was	O	1316-1319
similar	O	1320-1327
between	O	1328-1335
the	O	1336-1339
two	O	1340-1343
dosing	O	1344-1350
regimens	O	1351-1359
,	O	1359-1360
but	O	1361-1364
the	O	1365-1368
distribution	O	1369-1381
of	O	1382-1384
risk	O	1385-1389
factors	O	1390-1397
was	O	1398-1401
variable	O	1402-1410
between	O	1411-1418
the	O	1419-1422
two	O	1423-1426
groups	O	1427-1433
.	O	1433-1434

Efficacy	O	1435-1443
could	O	1444-1449
not	O	1450-1453
be	O	1454-1456
assessed	O	1457-1465
.	O	1465-1466

Memory	O	0-6
function	O	7-15
and	O	16-19
serotonin	O	20-29
transporter	O	30-41
promoter	O	42-50
gene	O	51-55
polymorphism	O	56-68
in	O	69-71
ecstasy	O	72-79
(	O	80-81
MDMA	O	81-85
)	O	85-86
users	O	87-92
.	O	92-93

Although	O	94-102
3	O	103-104
,	O	104-105
4	O	105-106
-	O	106-107
methylenedioxymethamphetamine	O	107-136
(	O	137-138
MDMA	O	138-142
or	O	143-145
ecstasy	O	146-153
)	O	153-154
has	O	155-158
been	O	159-163
shown	O	164-169
to	O	170-172
damage	O	173-179
brain	O	180-185
serotonin	O	186-195
(	O	196-197
5	O	197-198
-	O	198-199
HT	O	199-201
)	O	201-202
neurons	O	203-210
in	O	211-213
animals	O	214-221
and	O	222-225
possibly	O	226-234
humans	O	235-241
,	O	241-242
little	O	243-249
is	O	250-252
known	O	253-258
about	O	259-264
the	O	265-268
long	O	269-273
-	O	273-274
term	O	274-278
consequences	O	279-291
of	O	292-294
MDMA	O	295-299
-	O	299-300
induced	O	300-307
5	O	308-309
-	O	309-310
HT	O	310-312
neurotoxic	B	313-323
lesions	I	324-331
on	O	332-334
functions	O	335-344
in	O	345-347
which	O	348-353
5	O	354-355
-	O	355-356
HT	O	356-358
is	O	359-361
involved	O	362-370
,	O	370-371
such	O	372-376
as	O	377-379
cognitive	O	380-389
function	O	390-398
.	O	398-399

Because	O	400-407
5	O	408-409
-	O	409-410
HT	O	410-412
transporters	O	413-425
play	O	426-430
a	O	431-432
key	O	433-436
element	O	437-444
in	O	445-447
the	O	448-451
regulation	O	452-462
of	O	463-465
synaptic	O	466-474
5	O	475-476
-	O	476-477
HT	O	477-479
transmission	O	480-492
it	O	493-495
may	O	496-499
be	O	500-502
important	O	503-512
to	O	513-515
control	O	516-523
for	O	524-527
the	O	528-531
potential	O	532-541
covariance	O	542-552
effect	O	553-559
of	O	560-562
a	O	563-564
polymorphism	O	565-577
in	O	578-580
the	O	581-584
5	O	585-586
-	O	586-587
HT	O	587-589
transporter	O	590-601
promoter	O	602-610
gene	O	611-615
region	O	616-622
(	O	623-624
5	O	624-625
-	O	625-626
HTTLPR	O	626-632
)	O	632-633
when	O	634-638
studying	O	639-647
the	O	648-651
effects	O	652-659
of	O	660-662
MDMA	O	663-667
as	O	668-670
well	O	671-675
as	O	676-678
cognitive	O	679-688
functioning	O	689-700
.	O	700-701

The	O	702-705
aim	O	706-709
of	O	710-712
the	O	713-716
study	O	717-722
was	O	723-726
to	O	727-729
investigate	O	730-741
the	O	742-745
effects	O	746-753
of	O	754-756
moderate	O	757-765
and	O	766-769
heavy	O	770-775
MDMA	O	776-780
use	O	781-784
on	O	785-787
cognitive	O	788-797
function	O	798-806
,	O	806-807
as	O	808-810
well	O	811-815
as	O	816-818
the	O	819-822
effects	O	823-830
of	O	831-833
long	O	834-838
-	O	838-839
term	O	839-843
abstention	O	844-854
from	O	855-859
MDMA	O	860-864
,	O	864-865
in	O	866-868
subjects	O	869-877
genotyped	O	878-887
for	O	888-891
5	O	892-893
-	O	893-894
HTTLPR	O	894-900
.	O	900-901

A	O	902-903
second	O	904-910
aim	O	911-914
of	O	915-917
the	O	918-921
study	O	922-927
was	O	928-931
to	O	932-934
determine	O	935-944
whether	O	945-952
these	O	953-958
effects	O	959-966
differ	O	967-973
for	O	974-977
females	O	978-985
and	O	986-989
males	O	990-995
.	O	995-996

Fifteen	O	997-1004
moderate	O	1005-1013
MDMA	O	1014-1018
users	O	1019-1024
(	O	1025-1026
<	O	1026-1027
55	O	1027-1029
lifetime	O	1030-1038
tablets	O	1039-1046
)	O	1046-1047
,	O	1047-1048
22	O	1049-1051
heavy	O	1052-1057
MDMA	O	1058-1062
+	O	1062-1063
users	O	1064-1069
(	O	1070-1071
>	O	1071-1072
55	O	1072-1074
lifetime	O	1075-1083
tablets	O	1084-1091
)	O	1091-1092
,	O	1092-1093
16	O	1094-1096
ex	O	1097-1099
-	O	1099-1100
MDMA	O	1100-1104
+	O	1104-1105
users	O	1106-1111
(	O	1112-1113
last	O	1113-1117
tablet	O	1118-1124
>	O	1125-1126
1	O	1127-1128
year	O	1129-1133
ago	O	1134-1137
)	O	1137-1138
and	O	1139-1142
13	O	1143-1145
controls	O	1146-1154
were	O	1155-1159
compared	O	1160-1168
on	O	1169-1171
a	O	1172-1173
battery	O	1174-1181
of	O	1182-1184
neuropsychological	O	1185-1203
tests	O	1204-1209
.	O	1209-1210

DNA	O	1211-1214
from	O	1215-1219
peripheral	O	1220-1230
nuclear	O	1231-1238
blood	O	1239-1244
cells	O	1245-1250
was	O	1251-1254
genotyped	O	1255-1264
for	O	1265-1268
5	O	1269-1270
-	O	1270-1271
HTTLPR	O	1271-1277
using	O	1278-1283
standard	O	1284-1292
polymerase	O	1293-1303
chain	O	1304-1309
reaction	O	1310-1318
methods	O	1319-1326
.	O	1326-1327
A	O	1327-1328
significant	O	1329-1340
group	O	1341-1346
effect	O	1347-1353
was	O	1354-1357
observed	O	1358-1366
only	O	1367-1371
on	O	1372-1374
memory	O	1375-1381
function	O	1382-1390
tasks	O	1391-1396
(	O	1397-1398
p	O	1398-1399
=	O	1400-1401
0	O	1402-1403
.	O	1403-1404
04	O	1404-1406
)	O	1406-1407
but	O	1408-1411
not	O	1412-1415
on	O	1416-1418
reaction	O	1419-1427
times	O	1428-1433
(	O	1434-1435
p	O	1435-1436
=	O	1437-1438
0	O	1439-1440
.	O	1440-1441
61	O	1441-1443
)	O	1443-1444
or	O	1445-1447
attention	O	1448-1457
/	O	1457-1458
executive	O	1458-1467
functioning	O	1468-1479
(	O	1480-1481
p	O	1481-1482
=	O	1483-1484
0	O	1485-1486
.	O	1486-1487
59	O	1487-1489
)	O	1489-1490
.	O	1486-1487

Heavy	O	1492-1497
and	O	1498-1501
ex	O	1502-1504
-	O	1504-1505
MDMA	O	1505-1509
+	O	1509-1510
users	O	1511-1516
performed	O	1517-1526
significantly	O	1527-1540
poorer	O	1541-1547
on	O	1548-1550
memory	O	1551-1557
tasks	O	1558-1563
than	O	1564-1568
controls	O	1569-1577
.	O	1577-1578

In	O	1579-1581
contrast	O	1582-1590
,	O	1590-1591
no	O	1592-1594
evidence	O	1595-1603
of	O	1604-1606
memory	B	1607-1613
impairment	I	1614-1624
was	O	1625-1628
observed	O	1629-1637
in	O	1638-1640
moderate	O	1641-1649
MDMA	O	1650-1654
users	O	1655-1660
.	O	1660-1661

No	O	1662-1664
significant	O	1665-1676
effect	O	1677-1683
of	O	1684-1686
5	O	1687-1688
-	O	1688-1689
HTTLPR	O	1689-1695
or	O	1696-1698
gender	O	1699-1705
was	O	1706-1709
observed	O	1710-1718
.	O	1718-1719

While	O	1720-1725
the	O	1726-1729
use	O	1730-1733
of	O	1734-1736
MDMA	O	1737-1741
in	O	1742-1744
quantities	O	1745-1755
that	O	1756-1760
may	O	1761-1764
be	O	1765-1767
considered	O	1768-1778
"	O	1779-1780
moderate	O	1780-1788
"	O	1779-1780
is	O	1790-1792
not	O	1793-1796
associated	O	1797-1807
with	O	1808-1812
impaired	B	1813-1821
memory	I	1822-1828
functioning	I	1829-1840
,	O	1840-1841
heavy	O	1842-1847
use	O	1848-1851
of	O	1852-1854
MDMA	O	1855-1859
use	O	1860-1863
may	O	1864-1867
lead	O	1868-1872
to	O	1873-1875
long	O	1876-1880
lasting	O	1881-1888
memory	B	1889-1895
impairments	I	1896-1907
.	O	1907-1908

No	O	1909-1911
effect	O	1912-1918
of	O	1919-1921
5	O	1922-1923
-	O	1923-1924
HTTLPR	O	1924-1930
or	O	1931-1933
gender	O	1934-1940
on	O	1941-1943
memory	O	1944-1950
function	O	1951-1959
or	O	1960-1962
MDMA	O	1963-1967
use	O	1968-1971
was	O	1972-1975
observed	O	1976-1984
.	O	1984-1985

Aging	O	0-5
process	O	6-13
of	O	14-16
epithelial	O	17-27
cells	O	28-33
of	O	34-36
the	O	37-40
rat	O	41-44
prostate	O	45-53
lateral	O	54-61
lobe	O	62-66
in	O	67-69
experimental	O	70-82
hyperprolactinemia	B	83-101
induced	O	102-109
by	O	110-112
haloperidol	O	113-124
.	O	124-125

The	O	126-129
aim	O	130-133
of	O	134-136
the	O	137-140
study	O	141-146
was	O	147-150
to	O	151-153
examine	O	154-161
the	O	162-165
influence	O	166-175
of	O	176-178
hyperprolactinemia	B	179-197
,	O	197-198
induced	O	199-206
by	O	207-209
haloperidol	O	210-221
(	O	222-223
HAL	O	223-226
)	O	226-227
on	O	228-230
age	O	231-234
related	O	235-242
morphology	O	243-253
and	O	254-257
function	O	258-266
changes	O	267-274
of	O	275-277
epithelial	O	278-288
cells	O	289-294
in	O	295-297
rat	O	298-301
prostate	O	302-310
lateral	O	311-318
lobe	O	319-323
.	O	323-324

The	O	325-328
study	O	329-334
was	O	335-338
performed	O	339-348
on	O	349-351
sexually	O	352-360
mature	O	361-367
male	O	368-372
rats	O	373-377
.	O	377-378

Serum	O	379-384
concentrations	O	385-399
of	O	400-402
prolactin	O	403-412
(	O	413-414
PRL	O	414-417
)	O	417-418
and	O	419-422
testosterone	O	423-435
(	O	436-437
T	O	437-438
)	O	438-439
were	O	440-444
measured	O	445-453
.	O	453-454

Tissue	O	455-461
sections	O	462-470
were	O	471-475
evaluated	O	476-485
with	O	486-490
light	O	491-496
and	O	497-500
electron	O	501-509
microscopy	O	510-520
.	O	520-521

Immunohistochemical	O	522-541
reactions	O	542-551
for	O	552-555
Anti	O	556-560
-	O	560-561
Proliferating	O	561-574
Cell	O	575-579
Nuclear	O	580-587
Antigen	O	588-595
(	O	596-597
PCNA	O	597-601
)	O	601-602
were	O	603-607
performed	O	608-617
.	O	617-618

In	O	619-621
rats	O	622-626
of	O	627-629
the	O	630-633
experimental	O	634-646
group	O	647-652
,	O	652-653
the	O	654-657
mean	O	658-662
concentration	O	663-676
of	O	677-679
:	O	679-680
PRL	O	681-684
was	O	685-688
more	O	689-693
than	O	694-698
twice	O	699-704
higher	O	705-711
,	O	711-712
whereas	O	713-720
T	O	721-722
concentration	O	723-736
was	O	737-740
almost	O	741-747
twice	O	748-753
lower	O	754-759
than	O	760-764
that	O	765-769
in	O	770-772
the	O	773-776
control	O	777-784
group	O	785-790
.	O	790-791

Light	O	792-797
microscopy	O	798-808
visualized	O	809-819
the	O	820-823
following	O	824-833
:	O	833-834
hypertrophy	B	835-846
and	O	847-850
epithelium	O	851-861
hyperplasia	B	862-873
of	O	874-876
the	O	877-880
glandular	O	881-890
ducts	O	891-896
,	O	896-897
associated	O	898-908
with	O	909-913
increased	O	914-923
PCNA	O	924-928
expression	O	929-939
.	O	939-940

Electron	O	941-949
microscopy	O	950-960
revealed	O	961-969
changes	O	970-977
in	O	978-980
columnar	O	981-989
epithelial	O	990-1000
cells	O	1001-1006
,	O	1006-1007
concerning	O	1008-1018
organelles	O	1019-1029
,	O	1029-1030
engaged	O	1031-1038
in	O	1039-1041
protein	O	1042-1049
synthesis	O	1050-1059
and	O	1060-1063
secretion	O	1064-1073
.	O	1073-1074

Does	O	0-4
supplemental	O	5-17
vitamin	O	18-25
C	O	26-27
increase	O	28-36
cardiovascular	B	37-51
disease	I	52-59
risk	O	60-64
in	O	65-67
women	O	68-73
with	O	74-78
diabetes	B	79-87
?	O	87-88

BACKGROUND	O	89-99
:	O	99-100
Vitamin	O	101-108
C	O	109-110
acts	O	111-115
as	O	116-118
a	O	119-120
potent	O	121-127
antioxidant	O	128-139
;	O	139-140
however	O	141-148
,	O	148-149
it	O	150-152
can	O	153-156
also	O	157-161
be	O	162-164
a	O	165-166
prooxidant	O	167-177
and	O	178-181
glycate	O	182-189
protein	O	190-197
under	O	198-203
certain	O	204-211
circumstances	O	212-225
in	O	226-228
vitro	O	229-234
.	O	234-235

These	O	236-241
observations	O	242-254
led	O	255-258
us	O	259-261
to	O	262-264
hypothesize	O	265-276
that	O	277-281
a	O	282-283
high	O	284-288
intake	O	289-295
of	O	296-298
vitamin	O	299-306
C	O	307-308
in	O	309-311
diabetic	B	312-320
persons	O	321-328
might	O	329-334
promote	O	335-342
atherosclerosis	B	343-358
.	O	358-359

OBJECTIVE	O	360-369
:	O	369-370
The	O	371-374
objective	O	375-384
was	O	385-388
to	O	389-391
examine	O	392-399
the	O	400-403
relation	O	404-412
between	O	413-420
vitamin	O	421-428
C	O	429-430
intake	O	431-437
and	O	438-441
mortality	O	442-451
from	O	452-456
cardiovascular	B	457-471
disease	I	472-479
.	O	479-480

DESIGN	O	481-487
:	O	487-488
We	O	489-491
studied	O	492-499
the	O	500-503
relation	O	504-512
between	O	513-520
vitamin	O	521-528
C	O	529-530
intake	O	531-537
and	O	538-541
mortality	O	542-551
from	O	552-556
total	O	557-562
cardiovascular	B	563-577
disease	I	578-585
(	O	586-587
n	O	587-588
=	O	589-590
281	O	591-594
)	O	594-595
,	O	595-596
coronary	B	597-605
artery	I	606-612
disease	I	613-620
(	O	621-622
n	O	622-623
=	O	624-625
175	O	626-629
)	O	629-630
,	O	630-631
and	O	632-635
stroke	B	636-642
(	O	643-644
n	O	644-645
=	O	646-647
57	O	648-650
)	O	650-651
in	O	652-654
1923	O	655-659
postmenopausal	O	660-674
women	O	675-680
who	O	681-684
reported	O	685-693
being	O	694-699
diabetic	B	700-708
at	O	709-711
baseline	O	712-720
.	O	720-721

Diet	O	722-726
was	O	727-730
assessed	O	731-739
with	O	740-744
a	O	745-746
food	O	747-751
-	O	751-752
frequency	O	752-761
questionnaire	O	762-775
at	O	776-778
baseline	O	779-787
,	O	787-788
and	O	789-792
subjects	O	793-801
initially	O	802-811
free	O	812-816
of	O	817-819
coronary	B	820-828
artery	I	829-835
disease	I	836-843
were	O	844-848
prospectively	O	849-862
followed	O	863-871
for	O	872-875
15	O	876-878
y	O	879-880
.	O	880-881

RESULTS	O	882-889
:	O	889-890
After	O	891-896
adjustment	O	897-907
for	O	908-911
cardiovascular	B	912-926
disease	I	927-934
risk	O	935-939
factors	O	940-947
,	O	947-948
type	O	949-953
of	O	954-956
diabetes	B	957-965
medication	O	966-976
used	O	977-981
,	O	981-982
duration	O	983-991
of	O	992-994
diabetes	B	995-1003
,	O	1003-1004
and	O	1005-1008
intakes	O	1009-1016
of	O	1017-1019
folate	O	1020-1026
,	O	1026-1027
vitamin	O	1028-1035
E	O	1036-1037
,	O	1037-1038
and	O	1039-1042
beta	O	1043-1047
-	O	1047-1048
carotene	O	1048-1056
,	O	1056-1057
the	O	1058-1061
adjusted	O	1062-1070
relative	O	1071-1079
risks	O	1080-1085
of	O	1086-1088
total	O	1089-1094
cardiovascular	B	1095-1109
disease	I	1110-1117
mortality	O	1118-1127
were	O	1128-1132
1	O	1133-1134
.	O	1134-1135
0	O	1135-1136
,	O	1136-1137
0	O	1138-1139
.	O	1139-1140
97	O	1140-1142
,	O	1142-1143
1	O	1144-1145
.	O	1145-1146
11	O	1146-1148
,	O	1148-1149
1	O	1150-1151
.	O	1151-1152
47	O	1152-1154
,	O	1154-1155
and	O	1156-1159
1	O	1160-1161
.	O	1161-1162
84	O	1162-1164
(	O	1165-1166
P	O	1166-1167
for	O	1168-1171
trend	O	1172-1177
<	O	1178-1179
0	O	1180-1181
.	O	1181-1182
01	O	1182-1184
)	O	1184-1185
across	O	1186-1192
quintiles	O	1193-1202
of	O	1203-1205
total	O	1206-1211
vitamin	O	1212-1219
C	O	1220-1221
intake	O	1222-1228
from	O	1229-1233
food	O	1234-1238
and	O	1239-1242
supplements	O	1243-1254
.	O	1254-1255

Adjusted	O	1256-1264
relative	O	1265-1273
risks	O	1274-1279
of	O	1280-1282
coronary	B	1283-1291
artery	I	1292-1298
disease	I	1299-1306
were	O	1307-1311
1	O	1312-1313
.	O	1313-1314
0	O	1314-1315
,	O	1315-1316
0	O	1317-1318
.	O	1318-1319
81	O	1319-1321
,	O	1321-1322
0	O	1323-1324
.	O	1324-1325
99	O	1325-1327
,	O	1327-1328
1	O	1329-1330
.	O	1330-1331
26	O	1331-1333
,	O	1333-1334
and	O	1335-1338
1	O	1339-1340
.	O	1340-1341
91	O	1341-1343
(	O	1344-1345
P	O	1345-1346
for	O	1347-1350
trend	O	1351-1356
=	O	1357-1358
0	O	1359-1360
.	O	1360-1361
01	O	1361-1363
)	O	1363-1364
and	O	1365-1368
of	O	1369-1371
stroke	B	1372-1378
were	O	1379-1383
1	O	1384-1385
.	O	1385-1386
0	O	1386-1387
,	O	1387-1388
0	O	1389-1390
.	O	1390-1391
52	O	1391-1393
,	O	1393-1394
1	O	1395-1396
.	O	1396-1397
23	O	1397-1399
,	O	1399-1400
2	O	1401-1402
.	O	1402-1403
22	O	1403-1405
,	O	1405-1406
and	O	1407-1410
2	O	1411-1412
.	O	1412-1413
57	O	1413-1415
(	O	1416-1417
P	O	1417-1418
for	O	1419-1422
trend	O	1423-1428
<	O	1429-1430
0	O	1431-1432
.	O	1432-1433
01	O	1433-1435
)	O	1435-1436
.	O	1432-1433

When	O	1438-1442
dietary	O	1443-1450
and	O	1451-1454
supplemental	O	1455-1467
vitamin	O	1468-1475
C	O	1476-1477
were	O	1478-1482
analyzed	O	1483-1491
separately	O	1492-1502
,	O	1502-1503
only	O	1504-1508
supplemental	O	1509-1521
vitamin	O	1522-1529
C	O	1530-1531
showed	O	1532-1538
a	O	1539-1540
positive	O	1541-1549
association	O	1550-1561
with	O	1562-1566
mortality	O	1567-1576
endpoints	O	1577-1586
.	O	1586-1587

Vitamin	O	1588-1595
C	O	1596-1597
intake	O	1598-1604
was	O	1605-1608
unrelated	O	1609-1618
to	O	1619-1621
mortality	O	1622-1631
from	O	1632-1636
cardiovascular	B	1637-1651
disease	I	1652-1659
in	O	1660-1662
the	O	1663-1666
nondiabetic	O	1667-1678
subjects	O	1679-1687
at	O	1688-1690
baseline	O	1691-1699
.	O	1699-1700

CONCLUSION	O	1701-1711
:	O	1711-1712
A	O	1713-1714
high	O	1715-1719
vitamin	O	1720-1727
C	O	1728-1729
intake	O	1730-1736
from	O	1737-1741
supplements	O	1742-1753
is	O	1754-1756
associated	O	1757-1767
with	O	1768-1772
an	O	1773-1775
increased	O	1776-1785
risk	O	1786-1790
of	O	1791-1793
cardiovascular	B	1794-1808
disease	I	1809-1816
mortality	O	1817-1826
in	O	1827-1829
postmenopausal	O	1830-1844
women	O	1845-1850
with	O	1851-1855
diabetes	B	1856-1864
.	O	1864-1865

Absolute	O	0-8
and	O	9-12
attributable	O	13-25
risk	O	26-30
of	O	31-33
venous	B	34-40
thromboembolism	I	41-56
in	O	57-59
women	O	60-65
on	O	66-68
combined	O	69-77
cyproterone	O	78-89
acetate	O	90-97
and	O	98-101
ethinylestradiol	O	102-118
.	O	118-119

OBJECTIVE	O	120-129
:	O	129-130
To	O	131-133
achieve	O	134-141
absolute	O	142-150
risk	O	151-155
estimates	O	156-165
of	O	166-168
venous	B	169-175
thromboembolism	I	176-191
(	O	192-193
VTE	B	193-196
)	O	196-197
among	O	198-203
women	O	204-209
on	O	210-212
cyproterone	O	213-224
acetate	O	225-232
plus	O	233-237
ethinylestradiol	O	238-254
(	O	255-256
CPA	O	256-259
/	O	259-260
EE	O	260-262
)	O	262-263
,	O	263-264
and	O	265-268
among	O	269-274
women	O	275-280
on	O	281-283
combined	O	284-292
oral	O	293-297
contraceptives	O	298-312
(	O	313-314
COCs	O	314-318
)	O	318-319
.	O	319-320

METHODS	O	321-328
:	O	328-329
From	O	330-334
the	O	335-338
Danish	O	339-345
National	O	346-354
Register	O	355-363
of	O	364-366
Patients	O	367-375
(	O	376-377
NRP	O	377-380
)	O	380-381
,	O	381-382
1996	O	383-387
to	O	388-390
1998	O	391-395
,	O	395-396
the	O	397-400
records	O	401-408
of	O	409-411
1	O	412-413
.	O	413-414
1	O	412-413
million	O	416-423
Danish	O	424-430
women	O	431-436
,	O	436-437
ages	O	438-442
15	O	443-445
to	O	446-448
44	O	449-451
years	O	452-457
,	O	457-458
were	O	459-463
searched	O	464-472
for	O	473-476
evidence	O	477-485
of	O	486-488
VTE	B	489-492
.	O	492-493

COC	O	494-497
use	O	498-501
was	O	502-505
ascertained	O	506-517
through	O	518-525
mailed	O	526-532
questionnaires	O	533-547
.	O	547-548

Sales	O	549-554
statistics	O	555-565
of	O	566-568
COCs	O	569-573
and	O	574-577
CPA	O	578-581
/	O	581-582
EE	O	582-584
were	O	585-589
provided	O	590-598
through	O	599-606
Danish	O	607-613
Drug	O	614-618
Statistics	O	619-629
.	O	629-630

RESULTS	O	631-638
:	O	638-639
During	O	640-646
the	O	647-650
time	O	651-655
frame	O	656-661
of	O	662-664
the	O	665-668
study	O	669-674
,	O	674-675
330	O	676-679
women	O	680-685
were	O	686-690
found	O	691-696
to	O	697-699
have	O	700-704
had	O	705-708
VTE	B	709-712
while	O	713-718
on	O	719-721
COCs	O	722-726
.	O	726-727

Of	O	728-730
these	O	731-736
women	O	737-742
,	O	742-743
67	O	744-746
were	O	747-751
on	O	752-754
levonorgestrel	O	755-769
-	O	769-770
containing	O	770-780
COCs	O	781-785
.	O	785-786

Eleven	O	787-793
were	O	794-798
on	O	799-801
CPA	O	802-805
/	O	805-806
EE	O	806-808
.	O	808-809

The	O	810-813
corresponding	O	814-827
absolute	O	828-836
risk	O	837-841
of	O	842-844
VTE	B	845-848
was	O	849-852
3	O	853-854
.	O	854-855
4	O	855-856
(	O	857-858
range	O	858-863
,	O	863-864
3	O	865-866
.	O	866-867
1	O	867-868
-	O	868-869
3	O	865-866
.	O	866-867
8	O	871-872
)	O	872-873

per	O	874-877
10	O	878-880
000	O	881-884
women	O	885-890
years	O	891-896
among	O	897-902
the	O	903-906
women	O	907-912
on	O	913-915
COCs	O	916-920
,	O	920-921
4	O	922-923
.	O	923-924
2	O	924-925
(	O	926-927
range	O	927-932
,	O	932-933
3	O	934-935
.	O	935-936
2	O	936-937
-	O	937-938
5	O	938-939
.	O	935-936
2	O	936-937
)	O	941-942
per	O	943-946
10	O	947-949
000	O	950-953
women	O	954-959
years	O	960-965
among	O	966-971
women	O	972-977
on	O	978-980
levonorgestrel	O	981-995
-	O	995-996
containing	O	996-1006
COCs	O	1007-1011
,	O	1011-1012
and	O	1013-1016
3	O	1017-1018
.	O	1018-1019
1	O	1019-1020
(	O	1021-1022
range	O	1022-1027
,	O	1027-1028
1	O	1029-1030
.	O	1030-1031
3	O	1031-1032
-	O	1032-1033
4	O	1033-1034
.	O	1030-1031
9	O	1035-1036
)	O	1036-1037

per	O	1038-1041
10	O	1042-1044
000	O	1045-1048
women	O	1049-1054
years	O	1055-1060
among	O	1061-1066
the	O	1067-1070
women	O	1071-1076
on	O	1077-1079
CPA	O	1080-1083
/	O	1083-1084
EE	O	1084-1086
.	O	1086-1087

CONCLUSION	O	1088-1098
:	O	1098-1099
Our	O	1100-1103
results	O	1104-1111
suggest	O	1112-1119
the	O	1120-1123
absolute	O	1124-1132
risk	O	1133-1137
of	O	1138-1140
VTE	B	1141-1144
among	O	1145-1150
Danish	O	1151-1157
women	O	1158-1163
on	O	1164-1166
COCs	O	1167-1171
is	O	1172-1174
similar	O	1175-1182
to	O	1183-1185
that	O	1186-1190
among	O	1191-1196
women	O	1197-1202
taking	O	1203-1209
CPA	O	1210-1213
/	O	1213-1214
EE	O	1214-1216
.	O	1216-1217

Effect	O	0-6
of	O	7-9
lindane	O	10-17
on	O	18-20
hepatic	O	21-28
and	O	29-32
brain	O	33-38
cytochrome	O	39-49
P450s	O	50-55
and	O	56-59
influence	O	60-69
of	O	70-72
P450	O	73-77
modulation	O	78-88
in	O	89-91
lindane	O	92-99
induced	O	100-107
neurotoxicity	B	108-121
.	O	121-122

Oral	O	123-127
administration	O	128-142
of	O	143-145
lindane	O	146-153
(	O	154-155
2	O	155-156
.	O	156-157
5	O	157-158
,	O	158-159
5	O	160-161
,	O	161-162
10	O	163-165
and	O	166-169
15	O	170-172
mg	O	173-175
/	O	175-176
kg	O	176-178
,	O	178-179
body	O	180-184
weight	O	185-191
)	O	191-192
for	O	193-196
5	O	197-198
days	O	199-203
was	O	204-207
found	O	208-213
to	O	214-216
produce	O	217-224
a	O	225-226
dose	O	227-231
-	O	231-232
dependent	O	232-241
increase	O	242-250
in	O	251-253
the	O	254-257
activity	O	258-266
of	O	267-269
P450	O	270-274
dependent	O	275-284
7	O	285-286
-	O	286-287
ethoxyresorufin	O	287-302
-	O	286-287
O	O	303-304
-	O	286-287
deethylase	O	305-315
(	O	316-317
EROD	O	317-321
)	O	321-322
,	O	322-323
7	O	324-325
-	O	325-326
pentoxyresorufin	O	326-342
-	O	325-326
O	O	343-344
-	O	325-326
dealkylase	O	345-355
(	O	356-357
PROD	O	357-361
)	O	361-362
and	O	363-366
N	O	367-368
-	O	368-369
nitrosodimethylamine	O	369-389
demethylase	O	390-401
(	O	402-403
NDMA	O	403-407
-	O	407-408
d	O	408-409
)	O	409-410
in	O	411-413
rat	O	414-417
brain	O	418-423
and	O	424-427
liver	O	428-433
.	O	433-434

A	O	435-436
significant	O	437-448
increase	O	449-457
in	O	458-460
the	O	461-464
hepatic	O	465-472
and	O	473-476
brain	O	477-482
P450	O	483-487
monooxygenases	O	488-502
was	O	503-506
also	O	507-511
observed	O	512-520
when	O	521-525
the	O	526-529
duration	O	530-538
of	O	539-541
exposure	O	542-550
of	O	551-553
low	O	554-557
dose	O	558-562
(	O	563-564
2	O	564-565
.	O	565-566
5	O	566-567
mg	O	568-570
/	O	570-571
kg	O	571-573
)	O	573-574
of	O	575-577
lindane	O	578-585
was	O	586-589
increased	O	590-599
from	O	600-604
5	O	605-606
days	O	607-611
to	O	612-614
15	O	615-617
or	O	618-620
21	O	621-623
days	O	624-628
.	O	628-629

As	O	630-632
observed	O	633-641
with	O	642-646
different	O	647-656
doses	O	657-662
,	O	662-663
the	O	664-667
magnitude	O	668-677
of	O	678-680
induction	O	681-690
in	O	691-693
the	O	694-697
activity	O	698-706
of	O	707-709
P450	O	710-714
monooxygenases	O	715-729
was	O	730-733
several	O	734-741
fold	O	742-746
higher	O	747-753
in	O	754-756
liver	O	757-762
microsomes	O	763-773
when	O	774-778
compared	O	779-787
with	O	788-792
the	O	793-796
brain	O	797-802
.	O	802-803

Western	O	804-811
blotting	O	812-820
studies	O	821-828
have	O	829-833
indicated	O	834-843
that	O	844-848
the	O	849-852
increase	O	853-861
in	O	862-864
the	O	865-868
P450	O	869-873
enzymes	O	874-881
could	O	882-887
be	O	888-890
due	O	891-894
to	O	895-897
the	O	898-901
increase	O	902-910
in	O	911-913
the	O	914-917
expression	O	918-928
of	O	929-931
P450	O	932-936
1A1	O	937-940
/	O	940-941
1A2	O	941-944
,	O	944-945
2B1	O	946-949
/	O	949-950
2B2	O	950-953
and	O	954-957
2E1	O	958-961
isoenzymes	O	962-972
.	O	972-973

In	O	974-976
vitro	O	977-982
studies	O	983-990
using	O	991-996
organic	O	997-1004
inhibitors	O	1005-1015
specific	O	1016-1024
for	O	1025-1028
individual	O	1029-1039
P450	O	1040-1044
isoenzymes	O	1045-1055
and	O	1056-1059
antibody	O	1060-1068
inhibition	O	1069-1079
experiments	O	1080-1091
have	O	1092-1096
further	O	1097-1104
demonstrated	O	1105-1117
that	O	1118-1122
the	O	1123-1126
increase	O	1127-1135
in	O	1136-1138
the	O	1139-1142
activity	O	1143-1151
of	O	1152-1154
PROD	O	1155-1159
,	O	1159-1160
EROD	O	1161-1165
and	O	1166-1169
NDMA	O	1170-1174
-	O	1174-1175
d	O	1175-1176
are	O	1177-1180
due	O	1181-1184
to	O	1185-1187
the	O	1188-1191
increase	O	1192-1200
in	O	1201-1203
the	O	1204-1207
levels	O	1208-1214
of	O	1215-1217
P450	O	1218-1222
2B1	O	1223-1226
/	O	1226-1227
2B2	O	1227-1230
,	O	1230-1231
1A1	O	1232-1235
/	O	1235-1236
1A2	O	1236-1239
and	O	1240-1243
2E1	O	1244-1247
isoenzymes	O	1248-1258
,	O	1258-1259
respectively	O	1260-1272
.	O	1272-1273

Induction	O	1274-1283
studies	O	1284-1291
have	O	1292-1296
further	O	1297-1304
shown	O	1305-1310
that	O	1311-1315
while	O	1316-1321
pretreatment	O	1322-1334
of	O	1335-1337
3	O	1338-1339
-	O	1339-1340
methylcholanthrene	O	1340-1358
(	O	1359-1360
MC	O	1360-1362
)	O	1362-1363
,	O	1363-1364
an	O	1365-1367
inducer	O	1368-1375
of	O	1376-1378
P4501A1	O	1379-1386
/	O	1386-1387
1A2	O	1387-1390
,	O	1390-1391
did	O	1392-1395
not	O	1396-1399
produce	O	1400-1407
any	O	1408-1411
significant	O	1412-1423
effect	O	1424-1430
in	O	1431-1433
the	O	1434-1437
incidence	O	1438-1447
of	O	1448-1450
lindane	O	1451-1458
induced	O	1459-1466
convulsions	B	1467-1478
,	O	1478-1479
pretreatment	O	1480-1492
with	O	1493-1497
phenobarbital	O	1498-1511
(	O	1512-1513
PB	O	1513-1515
)	O	1515-1516
,	O	1516-1517
an	O	1518-1520
inducer	O	1521-1528
of	O	1529-1531
P450	O	1532-1536
2B1	O	1537-1540
/	O	1540-1541
2B2	O	1541-1544
or	O	1545-1547
ethanol	O	1548-1555
,	O	1555-1556
an	O	1557-1559
inducer	O	1560-1567
of	O	1568-1570
P450	O	1571-1575
2E1	O	1576-1579
catalysed	O	1580-1589
reactions	O	1590-1599
,	O	1599-1600
significantly	O	1601-1614
increased	O	1615-1624
the	O	1625-1628
incidence	O	1629-1638
of	O	1639-1641
lindane	O	1642-1649
induced	O	1650-1657
convulsions	B	1658-1669
.	O	1669-1670

Similarly	O	1671-1680
,	O	1680-1681
when	O	1682-1686
the	O	1687-1690
P450	O	1691-1695
-	O	1695-1696
mediated	O	1696-1704
metabolism	O	1705-1715
of	O	1716-1718
lindane	O	1719-1726
was	O	1727-1730
blocked	O	1731-1738
by	O	1739-1741
cobalt	O	1742-1748
chloride	O	1749-1757
incidence	O	1758-1767
of	O	1768-1770
convulsions	B	1771-1782
was	O	1783-1786
increased	O	1787-1796
in	O	1797-1799
animals	O	1800-1807
treated	O	1808-1815
with	O	1816-1820
lindane	O	1821-1828
indicating	O	1829-1839
that	O	1840-1844
lindane	O	1845-1852
per	O	1853-1856
se	O	1857-1859
or	O	1860-1862
its	O	1863-1866
metabolites	O	1867-1878
formed	O	1879-1885
by	O	1886-1888
PB	O	1889-1891
or	O	1892-1894
ethanol	O	1895-1902
inducible	O	1903-1912
P450	O	1913-1917
isoenzymes	O	1918-1928
are	O	1929-1932
involved	O	1933-1941
in	O	1942-1944
its	O	1945-1948
neurobehavioral	O	1949-1964
toxicity	B	1965-1973
.	O	1973-1974

Seizure	B	0-7
associated	O	8-18
with	O	19-23
sleep	B	24-29
deprivation	I	30-41
and	O	42-45
sustained	O	46-55
-	O	55-56
release	O	56-63
bupropion	O	64-73
.	O	73-74

This	O	75-79
case	O	80-84
report	O	85-91
describes	O	92-101
a	O	102-103
generalized	O	104-115
seizure	B	116-123
associated	O	124-134
with	O	135-139
sustained	O	140-149
-	O	149-150
release	O	150-157
bupropion	O	158-167
use	O	168-171
and	O	172-175
sleep	B	176-181
deprivation	I	182-193
.	O	193-194

The	O	195-198
subject	O	199-206
,	O	206-207
a	O	208-209
31	O	210-212
-	O	212-213
year	O	213-217
-	O	212-213
old	O	218-221
female	O	222-228
smoker	O	229-235
,	O	235-236
was	O	237-240
participating	O	241-254
in	O	255-257
a	O	258-259
clinical	O	260-268
trial	O	269-274
evaluating	O	275-285
an	O	286-288
investigational	O	289-304
medication	O	305-315
for	O	316-319
smoking	O	320-327
cessation	O	328-337
that	O	338-342
used	O	343-347
sustained	O	348-357
-	O	357-358
release	O	358-365
bupropion	O	366-375
as	O	376-378
an	O	379-381
active	O	382-388
control	O	389-396
.	O	396-397

After	O	398-403
5	O	404-405
weeks	O	406-411
of	O	412-414
bupropion	O	415-424
use	O	425-428
,	O	428-429
the	O	430-433
subject	O	434-441
experienced	O	442-453
a	O	454-455
generalized	O	456-467
tonic	O	468-473
clonic	O	474-480
seizure	B	481-488
after	O	489-494
staying	O	495-502
up	O	503-505
nearly	O	506-512
all	O	513-516
night	O	517-522
packing	O	523-530
and	O	531-534
moving	O	535-541
to	O	542-544
a	O	545-546
new	O	547-550
residence	O	551-560
.	O	560-561

The	O	562-565
patient	O	566-573
had	O	574-577
no	O	578-580
other	O	581-586
risk	O	587-591
factors	O	592-599
for	O	600-603
seizures	B	604-612
.	O	612-613

We	O	614-616
suggest	O	617-624
that	O	625-629
sleep	B	630-635
deprivation	I	636-647
may	O	648-651
add	O	652-655
to	O	656-658
the	O	659-662
risk	O	663-667
of	O	668-670
bupropion	O	671-680
-	O	680-681
associated	O	681-691
seizures	B	692-700
.	O	700-701

Nephrotoxic	B	0-11
effects	O	12-19
in	O	20-22
high	O	23-27
-	O	27-28
risk	O	28-32
patients	O	33-41
undergoing	O	42-52
angiography	O	53-64
.	O	64-65

BACKGROUND	O	66-76
:	O	76-77
The	O	78-81
use	O	82-85
of	O	86-88
iodinated	O	89-98
contrast	O	99-107
medium	O	108-114
can	O	115-118
result	O	119-125
in	O	126-128
nephropathy	B	129-140
.	O	140-141

Whether	O	142-149
iso	O	150-153
-	O	153-154
osmolar	O	154-161
contrast	O	162-170
medium	O	171-177
is	O	178-180
less	O	181-185
nephrotoxic	B	186-197
than	O	198-202
low	O	203-206
-	O	206-207
osmolar	O	207-214
contrast	O	215-223
medium	O	224-230
in	O	231-233
high	O	234-238
-	O	238-239
risk	O	239-243
patients	O	244-252
is	O	253-255
uncertain	O	256-265
.	O	265-266

METHODS	O	267-274
:	O	274-275
We	O	276-278
conducted	O	279-288
a	O	289-290
randomized	O	291-301
,	O	301-302
double	O	303-309
-	O	309-310
blind	O	310-315
,	O	315-316
prospective	O	317-328
,	O	328-329
multicenter	O	330-341
study	O	342-347
comparing	O	348-357
the	O	358-361
nephrotoxic	B	362-373
effects	O	374-381
of	O	382-384
an	O	385-387
iso	O	388-391
-	O	391-392
osmolar	O	392-399
,	O	399-400
dimeric	O	401-408
,	O	408-409
nonionic	O	410-418
contrast	O	419-427
medium	O	428-434
,	O	434-435
iodixanol	O	436-445
,	O	445-446
with	O	447-451
those	O	452-457
of	O	458-460
a	O	461-462
low	O	463-466
-	O	466-467
osmolar	O	467-474
,	O	474-475
nonionic	O	476-484
,	O	484-485
monomeric	O	486-495
contrast	O	496-504
medium	O	505-511
,	O	511-512
iohexol	O	513-520
.	O	520-521

The	O	522-525
study	O	526-531
involved	O	532-540
129	O	541-544
patients	O	545-553
with	O	554-558
diabetes	B	559-567
with	O	568-572
serum	O	573-578
creatinine	O	579-589
concentrations	O	590-604
of	O	605-607
1	O	608-609
.	O	609-610
5	O	610-611
to	O	612-614
3	O	615-616
.	O	616-617
5	O	617-618
mg	O	619-621
per	O	622-625
deciliter	O	626-635
who	O	636-639
underwent	O	640-649
coronary	O	650-658
or	O	659-661
aortofemoral	O	662-674
angiography	O	675-686
.	O	686-687

The	O	688-691
primary	O	692-699
end	O	700-703
point	O	704-709
was	O	710-713
the	O	714-717
peak	O	718-722
increase	O	723-731
from	O	732-736
base	O	737-741
line	O	742-746
in	O	747-749
the	O	750-753
creatinine	O	754-764
concentration	O	765-778
during	O	779-785
the	O	786-789
three	O	790-795
days	O	796-800
after	O	801-806
angiography	O	807-818
.	O	818-819

Other	O	820-825
end	O	826-829
points	O	830-836
were	O	837-841
an	O	842-844
increase	O	845-853
in	O	854-856
the	O	857-860
creatinine	O	861-871
concentration	O	872-885
of	O	886-888
0	O	889-890
.	O	890-891
5	O	891-892
mg	O	893-895
per	O	896-899
deciliter	O	900-909
or	O	910-912
more	O	913-917
,	O	917-918
an	O	919-921
increase	O	922-930
of	O	931-933
1	O	934-935
.	O	935-936
0	O	936-937
mg	O	938-940
per	O	941-944
deciliter	O	945-954
or	O	955-957
more	O	958-962
,	O	962-963
and	O	964-967
a	O	968-969
change	O	970-976
in	O	977-979
the	O	980-983
creatinine	O	984-994
concentration	O	995-1008
from	O	1009-1013
day	O	1014-1017
0	O	1018-1019
to	O	1020-1022
day	O	1023-1026
7	O	1027-1028
.	O	1028-1029
RESULTS	O	1030-1037
:	O	1037-1038
The	O	1039-1042
creatinine	O	1043-1053
concentration	O	1054-1067
increased	O	1068-1077
significantly	O	1078-1091
less	O	1092-1096
in	O	1097-1099
patients	O	1100-1108
who	O	1109-1112
received	O	1113-1121
iodixanol	O	1122-1131
.	O	1131-1132

From	O	1133-1137
day	O	1138-1141
0	O	1142-1143
to	O	1144-1146
day	O	1147-1150
3	O	1151-1152
,	O	1152-1153
the	O	1154-1157
mean	O	1158-1162
peak	O	1163-1167
increase	O	1168-1176
in	O	1177-1179
creatinine	O	1180-1190
was	O	1191-1194
0	O	1195-1196
.	O	1196-1197
13	O	1197-1199
mg	O	1200-1202
per	O	1203-1206
deciliter	O	1207-1216
in	O	1217-1219
the	O	1220-1223
iodixanol	O	1224-1233
group	O	1234-1239
and	O	1240-1243
0	O	1244-1245
.	O	1245-1246
55	O	1246-1248
mg	O	1249-1251
per	O	1252-1255
deciliter	O	1256-1265
in	O	1266-1268
the	O	1269-1272
iohexol	O	1273-1280
group	O	1281-1286
(	O	1287-1288
P	O	1288-1289
=	O	1289-1290
0	O	1290-1291
.	O	1291-1292
001	O	1292-1295
;	O	1295-1296
the	O	1297-1300
increase	O	1301-1309
with	O	1310-1314
iodixanol	O	1315-1324
minus	O	1325-1330
the	O	1331-1334
increase	O	1335-1343
with	O	1344-1348
iohexol	O	1349-1356
,	O	1356-1357
-	O	1358-1359
0	O	1359-1360
.	O	1360-1361
42	O	1361-1363
mg	O	1364-1366
per	O	1367-1370
deciliter	O	1371-1380
[	O	1381-1382
95	O	1382-1384
percent	O	1385-1392
confidence	O	1393-1403
interval	O	1404-1412
,	O	1412-1413
-	O	1414-1415
0	O	1415-1416
.	O	1416-1417
73	O	1417-1419
to	O	1420-1422
-	O	1423-1424
0	O	1424-1425
.	O	1425-1426
22	O	1426-1428
]	O	1428-1429
)	O	1429-1430
.	O	1425-1426

Two	O	1432-1435
of	O	1436-1438
the	O	1439-1442
64	O	1443-1445
patients	O	1446-1454
in	O	1455-1457
the	O	1458-1461
iodixanol	O	1462-1471
group	O	1472-1477
(	O	1478-1479
3	O	1479-1480
percent	O	1481-1488
)	O	1488-1489
had	O	1490-1493
an	O	1494-1496
increase	O	1497-1505
in	O	1506-1508
the	O	1509-1512
creatinine	O	1513-1523
concentration	O	1524-1537
of	O	1538-1540
0	O	1541-1542
.	O	1542-1543
5	O	1543-1544
mg	O	1545-1547
per	O	1548-1551
deciliter	O	1552-1561
or	O	1562-1564
more	O	1565-1569
,	O	1569-1570
as	O	1571-1573
compared	O	1574-1582
with	O	1583-1587
17	O	1588-1590
of	O	1591-1593
the	O	1594-1597
65	O	1598-1600
patients	O	1601-1609
in	O	1610-1612
the	O	1613-1616
iohexol	O	1617-1624
group	O	1625-1630
(	O	1631-1632
26	O	1632-1634
percent	O	1635-1642
)	O	1642-1643
(	O	1644-1645
P	O	1645-1646
=	O	1646-1647
0	O	1647-1648
.	O	1648-1649
002	O	1649-1652
;	O	1652-1653

odds	O	1654-1658
ratio	O	1659-1664
for	O	1665-1668
such	O	1669-1673
an	O	1674-1676
increase	O	1677-1685
in	O	1686-1688
the	O	1689-1692
iodixanol	O	1693-1702
group	O	1703-1708
,	O	1708-1709
0	O	1710-1711
.	O	1711-1712
09	O	1712-1714
[	O	1715-1716
95	O	1716-1718
percent	O	1719-1726
confidence	O	1727-1737
interval	O	1738-1746
,	O	1746-1747
0	O	1748-1749
.	O	1749-1750
02	O	1750-1752
to	O	1753-1755
0	O	1756-1757
.	O	1757-1758
41	O	1758-1760
]	O	1760-1761
)	O	1761-1762
.	O	1757-1758

No	O	1764-1766
patient	O	1767-1774
receiving	O	1775-1784
iodixanol	O	1785-1794
had	O	1795-1798
an	O	1799-1801
increase	O	1802-1810
of	O	1811-1813
1	O	1814-1815
.	O	1815-1816
0	O	1816-1817
mg	O	1818-1820
per	O	1821-1824
deciliter	O	1825-1834
or	O	1835-1837
more	O	1838-1842
,	O	1842-1843
but	O	1844-1847
10	O	1848-1850
patients	O	1851-1859
in	O	1860-1862
the	O	1863-1866
iohexol	O	1867-1874
group	O	1875-1880
(	O	1881-1882
15	O	1882-1884
percent	O	1885-1892
)	O	1892-1893
did	O	1894-1897
.	O	1897-1898

The	O	1899-1902
mean	O	1903-1907
change	O	1908-1914
in	O	1915-1917
the	O	1918-1921
creatinine	O	1922-1932
concentration	O	1933-1946
from	O	1947-1951
day	O	1952-1955
0	O	1956-1957
to	O	1958-1960
day	O	1961-1964
7	O	1965-1966
was	O	1967-1970
0	O	1971-1972
.	O	1972-1973
07	O	1973-1975
mg	O	1976-1978
per	O	1979-1982
deciliter	O	1983-1992
in	O	1993-1995
the	O	1996-1999
iodixanol	O	2000-2009
group	O	2010-2015
and	O	2016-2019
0	O	2020-2021
.	O	2021-2022
24	O	2022-2024
mg	O	2025-2027
per	O	2028-2031
deciliter	O	2032-2041
in	O	2042-2044
the	O	2045-2048
iohexol	O	2049-2056
group	O	2057-2062
(	O	2063-2064
P	O	2064-2065
=	O	2065-2066
0	O	2066-2067
.	O	2067-2068
003	O	2068-2071
;	O	2071-2072

value	O	2073-2078
in	O	2079-2081
the	O	2082-2085
iodixanol	O	2086-2095
group	O	2096-2101
minus	O	2102-2107
the	O	2108-2111
value	O	2112-2117
in	O	2118-2120
the	O	2121-2124
iohexol	O	2125-2132
group	O	2133-2138
,	O	2138-2139
-	O	2140-2141
0	O	2141-2142
.	O	2142-2143
17	O	2143-2145
mg	O	2146-2148
per	O	2149-2152
deciliter	O	2153-2162
[	O	2163-2164
95	O	2164-2166
percent	O	2167-2174
confidence	O	2175-2185
interval	O	2186-2194
,	O	2194-2195
-	O	2196-2197
0	O	2197-2198
.	O	2198-2199
34	O	2199-2201
to	O	2202-2204
-	O	2205-2206
0	O	2206-2207
.	O	2207-2208
07	O	2208-2210
]	O	2210-2211
)	O	2211-2212
.	O	2207-2208

CONCLUSIONS	O	2214-2225
:	O	2225-2226
Nephropathy	B	2227-2238
induced	O	2239-2246
by	O	2247-2249
contrast	O	2250-2258
medium	O	2259-2265
may	O	2266-2269
be	O	2270-2272
less	O	2273-2277
likely	O	2278-2284
to	O	2285-2287
develop	O	2288-2295
in	O	2296-2298
high	O	2299-2303
-	O	2303-2304
risk	O	2304-2308
patients	O	2309-2317
when	O	2318-2322
iodixanol	O	2323-2332
is	O	2333-2335
used	O	2336-2340
rather	O	2341-2347
than	O	2348-2352
a	O	2353-2354
low	O	2355-2358
-	O	2358-2359
osmolar	O	2359-2366
,	O	2366-2367
nonionic	O	2368-2376
contrast	O	2377-2385
medium	O	2386-2392
.	O	2392-2393

Experimental	O	0-12
cranial	O	13-20
pain	B	21-25
elicited	O	26-34
by	O	35-37
capsaicin	O	38-47
:	O	47-48
a	O	49-50
PET	O	51-54
study	O	55-60
.	O	60-61

Using	O	62-67
a	O	68-69
positron	O	70-78
emission	O	79-87
tomography	O	88-98
(	O	99-100
PET	O	100-103
)	O	103-104
study	O	105-110
it	O	111-113
was	O	114-117
shown	O	118-123
recently	O	124-132
that	O	133-137
in	O	138-140
migraine	B	141-149
without	O	150-157
aura	O	158-162
certain	O	163-170
areas	O	171-176
in	O	177-179
the	O	180-183
brain	O	184-189
stem	O	190-194
were	O	195-199
activated	O	200-209
during	O	210-216
the	O	217-220
headache	B	221-229
state	O	230-235
,	O	235-236
but	O	237-240
not	O	241-244
in	O	245-247
the	O	248-251
headache	B	252-260
free	O	261-265
interval	O	266-274
.	O	274-275

It	O	276-278
was	O	279-282
suggested	O	283-292
that	O	293-297
this	O	298-302
brain	O	303-308
stem	O	309-313
activation	O	314-324
is	O	325-327
inherent	O	328-336
to	O	337-339
the	O	340-343
migraine	B	344-352
attack	O	353-359
itself	O	360-366
and	O	367-370
represents	O	371-381
the	O	382-385
so	O	386-388
called	O	389-395
'	O	396-397
migraine	B	397-405
generator	O	406-415
'	O	415-416
.	O	416-417

To	O	418-420
test	O	421-425
this	O	426-430
hypothesis	O	431-441
we	O	442-444
performed	O	445-454
an	O	455-457
experimental	O	458-470
pain	B	471-475
study	O	476-481
in	O	482-484
seven	O	485-490
healthy	O	491-498
volunteers	O	499-509
,	O	509-510
using	O	511-516
the	O	517-520
same	O	521-525
positioning	O	526-537
in	O	538-540
the	O	541-544
PET	O	545-548
scanner	O	549-556
as	O	557-559
in	O	560-562
the	O	563-566
migraine	B	567-575
patients	O	576-584
.	O	584-585

A	O	586-587
small	O	588-593
amount	O	594-600
of	O	601-603
capsaicin	O	604-613
was	O	614-617
administered	O	618-630
subcutaneously	O	631-645
in	O	646-648
the	O	649-652
right	O	653-658
forehead	O	659-667
to	O	668-670
evoke	O	671-676
a	O	677-678
burning	O	679-686
painful	B	687-694
sensation	O	695-704
in	O	705-707
the	O	708-711
first	O	712-717
division	O	718-726
of	O	727-729
the	O	730-733
trigeminal	O	734-744
nerve	O	745-750
.	O	750-751

Increases	O	752-761
of	O	762-764
regional	O	765-773
cerebral	O	774-782
blood	O	783-788
flow	O	789-793
(	O	794-795
rCBF	O	795-799
)	O	799-800
were	O	801-805
found	O	806-811
bilaterally	O	812-823
in	O	824-826
the	O	827-830
insula	O	831-837
,	O	837-838
in	O	839-841
the	O	842-845
anterior	O	846-854
cingulate	O	855-864
cortex	O	865-871
,	O	871-872
the	O	873-876
cavernous	O	877-886
sinus	O	887-892
and	O	893-896
the	O	897-900
cerebellum	O	901-911
.	O	911-912

Using	O	913-918
the	O	919-922
same	O	923-927
stereotactic	O	928-940
space	O	941-946
limits	O	947-953
as	O	954-956
in	O	957-959
the	O	960-963
above	O	964-969
mentioned	O	970-979
migraine	B	980-988
study	O	989-994
no	O	995-997
brain	O	998-1003
stem	O	1004-1008
activation	O	1009-1019
was	O	1020-1023
found	O	1024-1029
in	O	1030-1032
the	O	1033-1036
acute	O	1037-1042
pain	B	1043-1047
state	O	1048-1053
compared	O	1054-1062
to	O	1063-1065
the	O	1066-1069
pain	B	1070-1074
free	O	1075-1079
state	O	1080-1085
.	O	1085-1086

The	O	1087-1090
increase	O	1091-1099
of	O	1100-1102
activation	O	1103-1113
in	O	1114-1116
the	O	1117-1120
region	O	1121-1127
of	O	1128-1130
the	O	1131-1134
cavernous	O	1135-1144
sinus	O	1145-1150
however	O	1151-1158
,	O	1158-1159
suggests	O	1160-1168
that	O	1169-1173
this	O	1174-1178
structure	O	1179-1188
is	O	1189-1191
more	O	1192-1196
likely	O	1197-1203
to	O	1204-1206
be	O	1207-1209
involved	O	1210-1218
in	O	1219-1221
trigeminal	O	1222-1232
transmitted	O	1233-1244
pain	B	1245-1249
as	O	1250-1252
such	O	1253-1257
,	O	1257-1258
rather	O	1259-1265
than	O	1266-1270
in	O	1271-1273
a	O	1274-1275
specific	O	1276-1284
type	O	1285-1289
of	O	1290-1292
headache	B	1293-1301
as	O	1302-1304
was	O	1305-1308
suggested	O	1309-1318
for	O	1319-1322
cluster	B	1323-1330
headache	I	1331-1339
.	O	1339-1340

Neuroleptic	B	0-11
malignant	I	12-21
syndrome	I	22-30
with	O	31-35
risperidone	O	36-47
.	O	47-48

Neuroleptic	B	49-60
malignant	I	61-70
syndrome	I	71-79
is	O	80-82
thought	O	83-90
to	O	91-93
be	O	94-96
a	O	97-98
result	O	99-105
of	O	106-108
dopamine	O	109-117
D2	O	118-120
receptor	O	121-129
blockade	O	130-138
in	O	139-141
the	O	142-145
striatum	O	146-154
of	O	155-157
the	O	158-161
basal	O	162-167
ganglia	O	168-175
.	O	175-176

Risperidone	O	177-188
,	O	188-189
a	O	190-191
benzisoxazole	O	192-205
derivative	O	206-216
antipsychotic	O	217-230
,	O	230-231
has	O	232-235
high	O	236-240
serotonin	O	241-250
5	O	251-252
-	O	252-253
HT2	O	253-256
receptor	O	257-265
blockade	O	266-274
and	O	275-278
dose	O	279-283
-	O	283-284
related	O	284-291
D2	O	292-294
receptor	O	295-303
blockade	O	304-312
.	O	312-313

The	O	314-317
high	O	318-322
ratio	O	323-328
is	O	329-331
believed	O	332-340
to	O	341-343
impart	O	344-350
the	O	351-354
low	O	355-358
frequency	O	359-368
of	O	369-371
extrapyramidal	B	372-386
symptoms	I	387-395
with	O	396-400
risperidone	O	401-412
at	O	413-415
low	O	416-419
dosages	O	420-427
.	O	427-428

With	O	429-433
this	O	434-438
low	O	439-442
frequency	O	443-452
of	O	453-455
extrapyramidal	B	456-470
symptoms	I	471-479
,	O	479-480
it	O	481-483
was	O	484-487
thought	O	488-495
the	O	496-499
frequency	O	500-509
of	O	510-512
neuroleptic	B	513-524
malignant	I	525-534
syndrome	I	535-543
might	O	544-549
also	O	550-554
be	O	555-557
lowered	O	558-565
.	O	565-566

A	O	567-568
73	O	569-571
-	O	571-572
year	O	572-576
-	O	571-572
old	O	577-580
woman	O	581-586
developed	O	587-596
neuroleptic	B	597-608
malignant	I	609-618
syndrome	I	619-627
after	O	628-633
monotherapy	O	634-645
with	O	646-650
risperidone	O	651-662
.	O	662-663

The	O	664-667
syndrome	O	668-676
reversed	O	677-685
after	O	686-691
discontinuing	O	692-705
risperidone	O	706-717
and	O	718-721
starting	O	722-730
treatment	O	731-740
with	O	741-745
dantrolene	O	746-756
and	O	757-760
bromocriptine	O	761-774
.	O	774-775

It	O	776-778
appears	O	779-786
that	O	787-791
the	O	792-795
protection	O	796-806
from	O	807-811
extrapyramidal	O	812-826
side	O	827-831
effects	O	832-839
observed	O	840-848
with	O	849-853
risperidone	O	854-865
does	O	866-870
not	O	871-874
ensure	O	875-881
protection	O	882-892
from	O	893-897
neuroleptic	B	898-909
malignant	I	910-919
syndrome	I	920-928
.	O	928-929

Hepatic	O	0-7
and	O	8-11
extrahepatic	O	12-24
angiotensinogen	O	25-40
gene	O	41-45
expression	O	46-56
in	O	57-59
rats	O	60-64
with	O	65-69
acute	O	70-75
nephrotic	B	76-85
syndrome	I	86-94
.	O	94-95

Plasma	O	96-102
concentration	O	103-116
and	O	117-120
urine	O	121-126
excretion	O	127-136
of	O	137-139
the	O	140-143
renin	O	144-149
-	O	149-150
angiotensin	O	150-161
system	O	162-168
proteins	O	169-177
are	O	178-181
altered	O	182-189
in	O	190-192
rats	O	193-197
with	O	198-202
nephrotic	B	203-212
syndrome	I	213-221
(	O	222-223
NS	B	223-225
)	O	225-226
.	O	226-227

In	O	228-230
this	O	231-235
work	O	236-240
the	O	241-244
messenger	O	245-254
ribonucleic	O	255-266
acid	O	267-271
(	O	272-273
mRNA	O	273-277
)	O	277-278
levels	O	279-285
of	O	286-288
angiotensinogen	O	289-304
(	O	305-306
Ao	O	306-308
)	O	308-309
were	O	310-314
analyzed	O	315-323
with	O	324-328
the	O	329-332
slot	O	333-337
-	O	337-338
blot	O	338-342
hybridization	O	343-356
technique	O	357-366
in	O	367-369
liver	O	370-375
and	O	376-379
other	O	380-385
extrahepatic	O	386-398
tissues	O	399-406
:	O	406-407
kidney	O	408-414
,	O	414-415
heart	O	416-421
,	O	421-422
brain	O	423-428
,	O	428-429
and	O	430-433
adrenal	O	434-441
gland	O	442-447
from	O	448-452
control	O	453-460
,	O	460-461
nephrotic	B	462-471
,	O	471-472
and	O	473-476
pair	O	477-481
-	O	481-482
fed	O	482-485
(	O	486-487
PF	O	487-489
)	O	489-490
rats	O	491-495
.	O	495-496

NS	B	497-499
was	O	500-503
induced	O	504-511
by	O	512-514
a	O	515-516
single	O	517-523
injection	O	524-533
of	O	534-536
puromycin	O	537-546
amino	O	547-552
-	O	552-553
nucleoside	O	553-563
(	O	564-565
PAN	O	565-568
)	O	568-569
.	O	569-570

Although	O	571-579
a	O	580-581
great	O	582-587
urinary	O	588-595
excretion	O	596-605
and	O	606-609
half	O	610-614
-	O	614-615
normal	O	615-621
plasma	O	622-628
levels	O	629-635
of	O	636-638
Ao	O	639-641
were	O	642-646
observed	O	647-655
on	O	656-658
day	O	659-662
6	O	663-664
after	O	665-670
PAN	O	671-674
injection	O	675-684
,	O	684-685
when	O	686-690
NS	B	691-693
was	O	694-697
clearly	O	698-705
established	O	706-717
,	O	717-718
hepatic	O	719-726
Ao	O	727-729
mRNA	O	730-734
levels	O	735-741
did	O	742-745
not	O	746-749
change	O	750-756
.	O	756-757

Furthermore	O	758-769
,	O	769-770
the	O	771-774
Ao	O	775-777
mRNA	O	778-782
levels	O	783-789
did	O	790-793
not	O	794-797
change	O	798-804
in	O	805-807
any	O	808-811
of	O	812-814
the	O	815-818
extrahepatic	O	819-831
tissues	O	832-839
studied	O	840-847
on	O	848-850
day	O	851-854
6	O	855-856
,	O	856-857
nor	O	858-861
did	O	862-865
its	O	866-869
hepatic	O	870-877
levels	O	878-884
at	O	885-887
days	O	888-892
1	O	893-894
,	O	894-895
3	O	896-897
,	O	897-898
5	O	899-900
,	O	900-901
or	O	902-904
7	O	905-906
after	O	907-912
PAN	O	913-916
injection	O	917-926
.	O	926-927

These	O	928-933
data	O	934-938
suggest	O	939-946
that	O	947-951
the	O	952-955
hepatic	O	956-963
and	O	964-967
extrahepatic	O	968-980
Ao	O	981-983
mRNA	O	984-988
levels	O	989-995
are	O	996-999
unaltered	O	1000-1009
during	O	1010-1016
the	O	1017-1020
development	O	1021-1032
of	O	1033-1035
the	O	1036-1039
acute	O	1040-1045
NS	B	1046-1048
induced	O	1049-1056
by	O	1057-1059
PAN	O	1060-1063
.	O	1063-1064

Cyclophosphamide	O	0-16
associated	O	17-27
bladder	B	28-35
cancer	I	36-42
-	O	42-43
-	O	42-43
a	I	37-38
highly	O	46-52
aggressive	O	53-63
disease	O	64-71
:	O	71-72
analysis	O	73-81
of	O	82-84
12	O	85-87
cases	O	88-93
.	O	93-94

PURPOSE	O	95-102
:	O	102-103
We	O	104-106
gained	O	107-113
knowledge	O	114-123
of	O	124-126
the	O	127-130
etiology	O	131-139
,	O	139-140
treatment	O	141-150
and	O	151-154
prevention	O	155-165
of	O	166-168
cyclophosphamide	O	169-185
associated	O	186-196
urothelial	B	197-207
cancer	I	208-214
.	O	214-215

MATERIALS	O	216-225
AND	O	226-229
METHODS	O	230-237
:	O	237-238
The	O	239-242
medical	O	243-250
records	O	251-258
of	O	259-261
6	O	262-263
men	O	264-267
and	O	268-271
6	O	272-273
women	O	274-279
(	O	280-281
mean	O	281-285
age	O	286-289
55	O	290-292
years	O	293-298
)	O	298-299
with	O	300-304
cyclophosphamide	O	305-321
associated	O	322-332
bladder	B	333-340
cancer	I	341-347
were	O	348-352
reviewed	O	353-361
.	O	361-362

RESULTS	O	363-370
:	O	370-371
All	O	372-375
tumors	B	376-382
were	O	383-387
grade	O	388-393
3	O	394-395
or	O	396-398
4	O	399-400
transitional	O	401-413
cell	O	414-418
carcinoma	B	419-428
.	O	428-429

Of	O	430-432
the	O	433-436
5	O	437-438
patients	O	439-447
initially	O	448-457
treated	O	458-465
with	O	466-470
endoscopic	O	471-481
resection	O	482-491
alone	O	492-497
only	O	498-502
1	O	503-504
is	O	505-507
alive	O	508-513
without	O	514-521
disease	O	522-529
.	O	529-530

Of	O	531-533
the	O	534-537
6	O	538-539
patients	O	540-548
who	O	549-552
underwent	O	553-562
early	O	563-568
cystectomy	O	569-579
4	O	580-581
were	O	582-586
alive	O	587-592
at	O	593-595
24	O	596-598
to	O	599-601
111	O	602-605
months	O	606-612
.	O	612-613

The	O	614-617
remaining	O	618-627
patient	O	628-635
with	O	636-640
extensive	O	641-650
cancer	B	651-657
underwent	O	658-667
partial	O	668-675
cystectomy	O	676-686
for	O	687-690
palliation	O	691-701
and	O	702-705
died	O	706-710
3	O	711-712
months	O	713-719
later	O	720-725
.	O	725-726

CONCLUSIONS	O	727-738
:	O	738-739
Cyclophosphamide	O	740-756
associated	O	757-767
bladder	B	768-775
tumor	I	776-781
is	O	782-784
an	O	785-787
aggressive	O	788-798
disease	O	799-806
.	O	806-807

However	O	808-815
,	O	815-816
long	O	817-821
-	O	821-822
term	O	822-826
survival	O	827-835
is	O	836-838
possible	O	839-847
when	O	848-852
radical	O	853-860
cystectomy	O	861-871
is	O	872-874
performed	O	875-884
for	O	885-888
bladder	B	889-896
tumors	I	897-903
with	O	904-908
any	O	909-912
sign	O	913-917
of	O	918-920
invasion	O	921-929
and	O	930-933
for	O	934-937
recurrent	O	938-947
high	O	948-952
grade	O	953-958
disease	O	959-966
,	O	966-967
even	O	968-972
when	O	973-977
noninvasive	O	978-989
.	O	989-990

Leg	B	0-3
and	I	4-7
back	I	8-12
pain	I	13-17
after	O	18-23
spinal	O	24-30
anaesthesia	O	31-42
involving	O	43-52
hyperbaric	O	53-63
5	O	64-65
%	O	65-66
lignocaine	O	67-77
.	O	77-78

Fifty	O	79-84
-	O	84-85
four	O	85-89
patients	O	90-98
,	O	98-99
aged	O	100-104
27	O	105-107
-	O	107-108
90	O	108-110
years	O	111-116
,	O	116-117
who	O	118-121
were	O	122-126
given	O	127-132
lignocaine	O	133-143
5	O	144-145
%	O	145-146
in	O	147-149
6	O	150-151
.	O	151-152
8	O	152-153
%	O	153-154
glucose	O	155-162
solution	O	163-171
for	O	172-175
spinal	O	176-182
anaesthesia	O	183-194
were	O	195-199
studied	O	200-207
.	O	207-208

Thirteen	O	209-217
of	O	218-220
these	O	221-226
patients	O	227-235
experienced	O	236-247
pain	B	248-252
in	I	253-255
the	I	256-259
legs	I	260-264
and	I	265-268
/	I	268-269
or	I	269-271
back	I	272-276
after	O	277-282
recovery	O	283-291
from	O	292-296
anaesthesia	O	297-308
.	O	308-309

The	O	310-313
patients	O	314-322
affected	O	323-331
were	O	332-336
younger	O	337-344
(	O	345-346
p	O	346-347
<	O	348-349
0	O	350-351
.	O	351-352
05	O	352-354
)	O	354-355
and	O	356-359
the	O	360-363
site	O	364-368
of	O	369-371
the	O	372-375
dural	O	376-381
puncture	O	382-390
was	O	391-394
higher	O	395-401
(	O	402-403
p	O	403-404
<	O	405-406
0	O	407-408
.	O	408-409
01	O	409-411
)	O	411-412
than	O	413-417
those	O	418-423
individuals	O	424-435
without	O	436-443
pain	B	444-448
.	O	448-449

Five	O	450-454
of	O	455-457
the	O	458-461
13	O	462-464
patients	O	465-473
(	O	474-475
38	O	475-477
%	O	477-478
)	O	478-479
with	O	480-484
pain	B	485-489
and	O	490-493
seven	O	494-499
of	O	500-502
the	O	503-506
41	O	507-509
patients	O	510-518
(	O	519-520
17	O	520-522
%	O	522-523
)	O	523-524
without	O	525-532
pain	B	533-537
admitted	O	538-546
to	O	547-549
a	O	550-551
high	O	552-556
alcohol	O	557-564
intake	O	565-571
,	O	571-572
which	O	573-578
might	O	579-584
be	O	585-587
a	O	588-589
contributing	O	590-602
factor	O	603-609
.	O	609-610

Leg	B	611-614
and	I	615-618
/	I	618-619
or	I	619-621
back	I	622-626
pain	I	627-631
is	O	632-634
associated	O	635-645
with	O	646-650
the	O	651-654
intrathecal	O	655-666
use	O	667-670
of	O	671-673
hyperbaric	O	674-684
5	O	685-686
%	O	686-687
lignocaine	O	688-698
.	O	698-699

Acute	O	0-5
blood	O	6-11
pressure	O	12-20
elevations	O	21-31
with	O	32-36
caffeine	O	37-45
in	O	46-48
men	O	49-52
with	O	53-57
borderline	O	58-68
systemic	O	69-77
hypertension	B	78-90
.	O	90-91

Whether	O	92-99
the	O	100-103
vasoconstrictive	O	104-120
actions	O	121-128
of	O	129-131
caffeine	O	132-140
are	O	141-144
enhanced	O	145-153
in	O	154-156
hypertensive	B	157-169
persons	O	170-177
has	O	178-181
not	O	182-185
been	O	186-190
demonstrated	O	191-203
.	O	203-204

Thus	O	205-209
,	O	209-210
caffeine	O	211-219
(	O	220-221
3	O	221-222
.	O	222-223
3	O	221-222
mg	O	225-227
/	O	227-228
kg	O	228-230
)	O	230-231
versus	O	232-238
placebo	O	239-246
was	O	247-250
tested	O	251-257
in	O	258-260
48	O	261-263
healthy	O	264-271
men	O	272-275
(	O	276-277
aged	O	277-281
20	O	282-284
to	O	285-287
35	O	288-290
years	O	291-296
)	O	296-297
selected	O	298-306
after	O	307-312
screening	O	313-322
on	O	323-325
2	O	326-327
separate	O	328-336
occasions	O	337-346
.	O	346-347

Borderline	O	348-358
hypertensive	B	359-371
men	O	372-375
(	O	376-377
n	O	377-378
=	O	379-380
24	O	381-383
)	O	383-384
were	O	385-389
selected	O	390-398
with	O	399-403
screening	O	404-413
systolic	O	414-422
blood	O	423-428
pressure	O	429-437
(	O	438-439
BP	O	439-441
)	O	441-442
of	O	443-445
140	O	446-449
to	O	450-452
160	O	453-456
mm	O	457-459
Hg	O	460-462
and	O	463-466
/	O	466-467
or	O	467-469
diastolic	O	470-479
BP	O	480-482
90	O	483-485
to	O	486-488
99	O	489-491
mm	O	492-494
Hg	O	495-497
.	O	497-498

Low	O	499-502
-	O	502-503
risk	O	503-507
controls	O	508-516
(	O	517-518
n	O	518-519
=	O	520-521
24	O	522-524
)	O	524-525
reported	O	526-534
no	O	535-537
parental	O	538-546
history	O	547-554
of	O	555-557
hypertension	B	558-570
and	O	571-574
had	O	575-578
screening	O	579-588
BP	O	589-591
<	O	592-593
130	O	594-597
/	O	597-598
85	O	598-600
mm	O	601-603
Hg	O	604-606
.	O	606-607

Participants	O	608-620
were	O	621-625
then	O	626-630
tested	O	631-637
on	O	638-640
2	O	641-642
occasions	O	643-652
after	O	653-658
12	O	659-661
-	O	661-662
hour	O	662-666
abstinence	O	667-677
from	O	678-682
caffeine	O	683-691
in	O	692-694
each	O	695-699
of	O	700-702
2	O	703-704
protocols	O	705-714
;	O	714-715
this	O	716-720
required	O	721-729
a	O	730-731
total	O	732-737
of	O	738-740
4	O	741-742
laboratory	O	743-753
visits	O	754-760
.	O	760-761

Caffeine	O	762-770
-	O	770-771
induced	O	771-778
changes	O	779-786
in	O	787-789
diastolic	O	790-799
BP	O	800-802
were	O	803-807
2	O	808-809
to	O	810-812
3	O	813-814
times	O	815-820
larger	O	821-827
in	O	828-830
borderline	O	831-841
subjects	O	842-850
than	O	851-855
in	O	856-858
controls	O	859-867
(	O	868-869
+	O	869-870
8	O	870-871
.	O	871-872
4	O	872-873
vs	O	874-876
+	O	877-878
3	O	878-879
.	O	879-880
8	O	880-881
mm	O	882-884
Hg	O	885-887
,	O	887-888
p	O	889-890
<	O	891-892
0	O	893-894
.	O	894-895
0001	O	895-899
)	O	899-900
,	O	900-901
and	O	902-905
were	O	906-910
attributable	O	911-923
to	O	924-926
larger	O	927-933
changes	O	934-941
in	O	942-944
impedance	O	945-954
-	O	954-955
derived	O	955-962
measures	O	963-971
of	O	972-974
systemic	O	975-983
vascular	O	984-992
resistance	O	993-1003
(	O	1004-1005
+	O	1005-1006
135	O	1006-1009
vs	O	1010-1012
+	O	1013-1014
45	O	1014-1016
dynes	O	1017-1022
.	O	1022-1023
s	O	1021-1022
.	O	1022-1023
cm	O	1025-1027
-	O	1027-1028
5	O	1028-1029
,	O	1029-1030
p	O	1031-1032
<	O	1033-1034
0	O	1035-1036
.	O	1036-1037
004	O	1037-1040
)	O	1040-1041
.	O	1036-1037

These	O	1043-1048
findings	O	1049-1057
were	O	1058-1062
consistent	O	1063-1073
and	O	1074-1077
reached	O	1078-1085
significance	O	1086-1098
in	O	1099-1101
both	O	1102-1106
protocols	O	1107-1116
.	O	1116-1117

The	O	1118-1121
percentage	O	1122-1132
of	O	1133-1135
borderline	O	1136-1146
subjects	O	1147-1155
in	O	1156-1158
whom	O	1159-1163
diastolic	O	1164-1173
BP	O	1174-1176
changes	O	1177-1184
exceeded	O	1185-1193
the	O	1194-1197
median	O	1198-1204
control	O	1205-1212
response	O	1213-1221
was	O	1222-1225
96	O	1226-1228
%	O	1228-1229
.	O	1229-1230

Consequently	O	1231-1243
,	O	1243-1244
whereas	O	1245-1252
all	O	1253-1256
participants	O	1257-1269
exhibited	O	1270-1279
normotensive	O	1280-1292
levels	O	1293-1299
during	O	1300-1306
the	O	1307-1310
resting	O	1311-1318
predrug	O	1319-1326
baseline	O	1327-1335
,	O	1335-1336
33	O	1337-1339
%	O	1339-1340
of	O	1341-1343
borderline	O	1344-1354
subjects	O	1355-1363
achieved	O	1364-1372
hypertensive	B	1373-1385
BP	O	1386-1388
levels	O	1389-1395
after	O	1396-1401
caffeine	O	1402-1410
ingestion	O	1411-1420
.	O	1420-1421

Thus	O	1422-1426
,	O	1426-1427
in	O	1428-1430
borderline	O	1431-1441
hypertensive	B	1442-1454
men	O	1455-1458
,	O	1458-1459
exaggerated	O	1460-1471
responses	O	1472-1481
to	O	1482-1484
caffeine	O	1485-1493
were	O	1494-1498
:	O	1498-1499
selective	O	1500-1509
for	O	1510-1513
diastolic	O	1514-1523
BP	O	1524-1526
,	O	1526-1527
consistent	O	1528-1538
with	O	1539-1543
greater	O	1544-1551
vasoconstriction	O	1552-1568
,	O	1568-1569
replicated	O	1570-1580
in	O	1581-1583
2	O	1584-1585
protocols	O	1586-1595
,	O	1595-1596
and	O	1597-1600
representative	O	1601-1615
of	O	1616-1618
nearly	O	1619-1625
all	O	1626-1629
borderline	O	1630-1640
hypertensives	B	1641-1654
.	O	1654-1655

We	O	1656-1658
suspect	O	1659-1666
that	O	1667-1671
the	O	1672-1675
potential	O	1676-1685
for	O	1686-1689
caffeine	O	1690-1698
to	O	1699-1701
stabilize	O	1702-1711
high	O	1712-1716
resistance	O	1717-1727
states	O	1728-1734
in	O	1735-1737
susceptible	O	1738-1749
persons	O	1750-1757
suggests	O	1758-1766
that	O	1767-1771
its	O	1772-1775
use	O	1776-1779
may	O	1780-1783
facilitate	O	1784-1794
their	O	1795-1800
disease	O	1801-1808
progression	O	1809-1820
,	O	1820-1821
as	O	1822-1824
well	O	1825-1829
as	O	1830-1832
hinder	O	1833-1839
accurate	O	1840-1848
diagnosis	O	1849-1858
and	O	1859-1862
treatment	O	1863-1872
.	O	1872-1873

Hallucinations	B	0-14
and	O	15-18
ifosfamide	O	19-29
-	O	29-30
induced	O	30-37
neurotoxicity	B	38-51
.	O	51-52

BACKGROUND	O	53-63
:	O	63-64
Hallucinations	B	65-79
as	O	80-82
a	O	83-84
symptom	O	85-92
of	O	93-95
central	O	96-103
neurotoxicity	B	104-117
are	O	118-121
a	O	122-123
known	O	124-129
but	O	130-133
poorly	O	134-140
described	O	141-150
side	O	151-155
effect	O	156-162
of	O	163-165
ifosfamide	O	166-176
.	O	176-177

Most	O	178-182
cases	O	183-188
of	O	189-191
ifosfamide	O	192-202
-	O	202-203
induced	O	203-210
hallucinations	B	211-225
have	O	226-230
been	O	231-235
reported	O	236-244
with	O	245-249
other	O	250-255
mental	O	256-262
status	O	263-269
changes	O	270-277
.	O	277-278

METHODS	O	279-286
:	O	286-287
The	O	288-291
authors	O	292-299
interviewed	O	300-311
six	O	312-315
persons	O	316-323
with	O	324-328
ifosfamide	O	329-339
-	O	339-340
induced	O	340-347
hallucinations	B	348-362
in	O	363-365
the	O	366-369
presence	O	370-378
of	O	379-381
a	O	382-383
clear	O	384-389
sensorium	O	390-399
.	O	399-400

All	O	401-404
patients	O	405-413
were	O	414-418
receiving	O	419-428
high	O	429-433
-	O	433-434
dose	O	434-438
ifosfamide	O	439-449
as	O	450-452
part	O	453-457
of	O	458-460
their	O	461-466
bone	O	467-471
marrow	O	472-478
transplant	O	479-489
procedure	O	490-499
.	O	499-500

RESULTS	O	501-508
:	O	508-509
Hallucinations	B	510-524
occurred	O	525-533
only	O	534-538
when	O	539-543
the	O	544-547
patient	O	548-555
'	O	555-556
s	O	556-557
eyes	O	558-562
were	O	563-567
closed	O	568-574
and	O	575-578
,	O	578-579
in	O	580-582
all	O	583-586
but	O	587-590
one	O	591-594
case	O	595-599
,	O	599-600
were	O	601-605
reported	O	606-614
as	O	615-617
disturbing	O	618-628
or	O	629-631
frightening	O	632-643
.	O	643-644

Underreporting	O	645-659
of	O	660-662
these	O	663-668
hallucinations	B	669-683
by	O	684-686
patients	O	687-695
is	O	696-698
likely	O	699-705
.	O	705-706

CONCLUSIONS	O	707-718
:	O	718-719
Hallucinations	B	720-734
may	O	735-738
be	O	739-741
the	O	742-745
sole	O	746-750
or	O	751-753
first	O	754-759
manifestation	O	760-773
of	O	774-776
neurotoxicity	B	777-790
.	O	790-791

The	O	792-795
incidence	O	796-805
may	O	806-809
be	O	810-812
dose	O	813-817
and	O	818-821
infusion	O	822-830
-	O	830-831
time	O	831-835
related	O	836-843
.	O	843-844

The	O	845-848
clinician	O	849-858
should	O	859-865
be	O	866-868
alerted	O	869-876
for	O	877-880
possible	O	881-889
ifosfamide	O	890-900
-	O	900-901
induced	O	901-908
hallucinations	B	909-923
,	O	923-924
which	O	925-930
may	O	931-934
occur	O	935-940
without	O	941-948
other	O	949-954
signs	O	955-960
of	O	961-963
neurotoxicity	B	964-977
.	O	977-978

"	O	979-980
Eyes	O	980-984
-	O	984-985
closed	O	985-991
"	O	979-980
hallucinatory	B	993-1006
experiences	O	1007-1018
appear	O	1019-1025
to	O	1026-1028
be	O	1029-1031
an	O	1032-1034
unusual	O	1035-1042
feature	O	1043-1050
of	O	1051-1053
this	O	1054-1058
presentation	O	1059-1071
.	O	1071-1072

Patients	O	1073-1081
anxious	O	1082-1089
about	O	1090-1095
this	O	1096-1100
experience	O	1101-1111
respond	O	1112-1119
well	O	1120-1124
to	O	1125-1127
support	O	1128-1135
and	O	1136-1139
education	O	1140-1149
about	O	1150-1155
this	O	1156-1160
occurrence	O	1161-1171
.	O	1171-1172

Optimal	O	1173-1180
pharmacologic	O	1181-1194
management	O	1195-1205
of	O	1206-1208
disturbed	O	1209-1218
patients	O	1219-1227
is	O	1228-1230
unclear	O	1231-1238
.	O	1238-1239

If	O	1240-1242
agitation	B	1243-1252
becomes	O	1253-1260
marked	O	1261-1267
,	O	1267-1268
high	O	1269-1273
-	O	1273-1274
potency	O	1274-1281
neuroleptics	O	1282-1294
(	O	1295-1296
i	O	1296-1297
.	O	1297-1298
e	O	1298-1299
.	O	1297-1298
,	O	1300-1301
haloperidol	O	1302-1313
)	O	1313-1314
may	O	1315-1318
be	O	1319-1321
effective	O	1322-1331
.	O	1331-1332

Chlorpropamide	O	0-14
-	O	14-15
induced	O	15-22
optic	B	23-28
neuropathy	I	29-39
.	O	39-40

A	O	41-42
65	O	43-45
-	O	45-46
year	O	46-50
-	O	45-46
old	O	51-54
woman	O	55-60
with	O	61-65
adult	B	66-71
-	I	71-72
onset	I	72-77
diabetes	I	78-86
treated	O	87-94
with	O	95-99
chlorpropamide	O	100-114
(	O	115-116
Diabenese	O	116-125
)	O	125-126
had	O	127-130
a	O	131-132
toxic	B	133-138
optic	I	139-144
neuropathy	I	145-155
that	O	156-160
resolved	O	161-169
with	O	170-174
discontinuation	O	175-190
of	O	191-193
chlorpropamide	O	194-208
therapy	O	209-216
.	O	216-217

Visual	B	218-224
loss	I	225-229
occurs	O	230-236
in	O	237-239
diabetics	B	240-249
for	O	250-253
a	O	254-255
variety	O	256-263
of	O	264-266
reasons	O	267-274
,	O	274-275
and	O	276-279
accurate	O	280-288
diagnosis	O	289-298
is	O	299-301
necessary	O	302-311
to	O	312-314
institute	O	315-324
appropriate	O	325-336
therapy	O	337-344
.	O	344-345

The	O	346-349
possibility	O	350-361
of	O	362-364
a	O	365-366
drug	O	367-371
-	O	371-372
induced	O	372-379
optic	B	380-385
neuropathy	I	386-396
should	O	397-403
be	O	404-406
considered	O	407-417
in	O	418-420
the	O	421-424
differential	O	425-437
diagnosis	O	438-447
of	O	448-450
visual	B	451-457
loss	I	458-462
in	O	463-465
diabetics	B	466-475
.	O	475-476

Levodopa	O	0-8
-	O	8-9
induced	O	9-16
dyskinesia	B	17-27
and	O	28-31
thalamotomy	O	32-43
.	O	43-44

Levodopa	O	45-53
-	O	53-54
induced	O	54-61
dyskinesia	B	62-72
of	O	73-75
the	O	76-79
limbs	O	80-85
in	O	86-88
thirteen	O	89-97
cases	O	98-103
of	O	104-106
Parkinsonism	B	107-119
,	O	119-120
which	O	121-126
was	O	127-130
choreic	O	131-138
,	O	138-139
ballistic	O	140-149
or	O	150-152
dystonic	B	153-161
in	O	162-164
type	O	165-169
,	O	169-170
was	O	171-174
alleviated	O	175-185
almost	O	186-192
completely	O	193-203
by	O	204-206
stereotaxic	O	207-218
surgery	O	219-226
using	O	227-232
a	O	233-234
microelectrode	O	235-249
technique	O	250-259
for	O	260-263
the	O	264-267
ventralis	O	268-277
oralis	O	278-284
anterior	O	285-293
and	O	294-297
posterior	O	298-307
nuclei	O	308-314
of	O	315-317
the	O	318-321
thalamus	O	322-330
,	O	330-331
but	O	332-335
much	O	336-340
less	O	341-345
by	O	346-348
the	O	349-352
ventralis	O	353-362
intermedius	O	363-374
nucleus	O	375-382
.	O	382-383

Control	O	384-391
of	O	392-394
levodopa	O	395-403
-	O	403-404
induced	O	404-411
dyskinesias	B	412-423
by	O	424-426
thalamic	B	427-435
lesions	I	436-443
in	O	444-446
the	O	447-450
course	O	451-457
of	O	458-460
routine	O	461-468
treatment	O	469-478
of	O	479-481
Parkinsonism	B	482-494
is	O	495-497
discussed	O	498-507
.	O	507-508

Factors	O	0-7
associated	O	8-18
with	O	19-23
nephrotoxicity	B	24-38
and	O	39-42
clinical	O	43-51
outcome	O	52-59
in	O	60-62
patients	O	63-71
receiving	O	72-81
amikacin	O	82-90
.	O	90-91

Data	O	92-96
from	O	97-101
60	O	102-104
patients	O	105-113
treated	O	114-121
with	O	122-126
amikacin	O	127-135
were	O	136-140
analyzed	O	141-149
for	O	150-153
factors	O	154-161
associated	O	162-172
with	O	173-177
nephrotoxicity	B	178-192
.	O	192-193

In	O	194-196
42	O	197-199
of	O	200-202
these	O	203-208
patients	O	209-217
,	O	217-218
data	O	219-223
were	O	224-228
examined	O	229-237
for	O	238-241
factors	O	242-249
associated	O	250-260
with	O	261-265
clinical	O	266-274
outcome	O	275-282
.	O	282-283

Variables	O	284-293
evaluated	O	294-303
included	O	304-312
patient	O	313-320
weight	O	321-327
,	O	327-328
age	O	329-332
,	O	332-333
sex	O	334-337
,	O	337-338
serum	O	339-344
creatinine	O	345-355
level	O	356-361
,	O	361-362
creatinine	O	363-373
clearance	O	374-383
,	O	383-384
duration	O	385-393
of	O	394-396
therapy	O	397-404
,	O	404-405
total	O	406-411
dose	O	412-416
,	O	416-417
mean	O	418-422
daily	O	423-428
dose	O	429-433
,	O	433-434
organism	O	435-443
minimum	O	444-451
inhibitory	O	452-462
concentration	O	463-476
(	O	477-478
MIC	O	478-481
)	O	481-482
,	O	482-483
mean	O	484-488
peak	O	489-493
levels	O	494-500
,	O	500-501
mean	O	502-506
trough	O	507-513
levels	O	514-520
,	O	520-521
mean	O	522-526
area	O	527-531
under	O	532-537
the	O	538-541
serum	O	542-547
concentration	O	548-561
-	O	561-562
time	O	562-566
curve	O	567-572
(	O	573-574
AUC	O	574-577
)	O	577-578
,	O	578-579
total	O	580-585
AUC	O	586-589
,	O	589-590
mean	O	591-595
AUC	O	596-599
greater	O	600-607
than	O	608-612
MIC	O	613-616
,	O	616-617
total	O	618-623
AUC	O	624-627
greater	O	628-635
than	O	636-640
MIC	O	641-644
,	O	644-645
mean	O	646-650
Schumacher	O	651-661
'	O	661-662
s	O	662-663
intensity	O	664-673
factor	O	674-680
(	O	681-682
IF	O	682-684
)	O	684-685
,	O	685-686
total	O	687-692
IF	O	693-695
,	O	695-696
In	O	697-699
(	O	700-701
mean	O	701-705
maximum	O	706-713
concentration	O	714-727
[	O	728-729
Cmax	O	729-733
]	O	733-734
/	O	734-735
MIC	O	735-738
)	O	738-739
.	O	739-740

Model	O	741-746
-	O	746-747
dependent	O	747-756
pharmacokinetic	O	757-772
parameters	O	773-783
were	O	784-788
calculated	O	789-799
by	O	800-802
computer	O	803-811
based	O	812-817
on	O	818-820
a	O	821-822
one	O	823-826
-	O	826-827
compartment	O	827-838
model	O	839-844
.	O	844-845

When	O	846-850
the	O	851-854
parameters	O	855-865
were	O	866-870
examined	O	871-879
individually	O	880-892
,	O	892-893
duration	O	894-902
of	O	903-905
therapy	O	906-913
and	O	914-917
total	O	918-923
AUC	O	924-927
correlated	O	928-938
significantly	O	939-952
(	O	953-954
P	O	954-955
less	O	956-960
than	O	961-965
.	O	966-967
05	O	967-969
)	O	969-970

with	O	971-975
nephrotoxicity	B	976-990
.	O	990-991

In	O	992-994
contrast	O	995-1003
,	O	1003-1004
a	O	1005-1006
stepwise	O	1007-1015
discriminant	O	1016-1028
function	O	1029-1037
analysis	O	1038-1046
identified	O	1047-1057
only	O	1058-1062
duration	O	1063-1071
of	O	1072-1074
therapy	O	1075-1082
(	O	1083-1084
P	O	1084-1085
less	O	1086-1090
than	O	1091-1095
.	O	1096-1097
001	O	1097-1100
)	O	1100-1101

as	O	1102-1104
an	O	1105-1107
important	O	1108-1117
factor	O	1118-1124
.	O	1124-1125

Based	O	1126-1131
on	O	1132-1134
this	O	1135-1139
model	O	1140-1145
and	O	1146-1149
on	O	1150-1152
Bayes	O	1153-1158
'	O	1158-1159
theorem	O	1160-1167
,	O	1167-1168
the	O	1169-1172
predictive	O	1173-1183
accuracy	O	1184-1192
of	O	1193-1195
identifying	O	1196-1207
"	O	1208-1209
nephrotoxic	B	1209-1220
"	O	1208-1209
patients	O	1222-1230
increased	O	1231-1240
from	O	1241-1245
0	O	1246-1247
.	O	1247-1248
17	O	1248-1250
to	O	1251-1253
0	O	1254-1255
.	O	1255-1256
39	O	1256-1258
.	O	1255-1256

When	O	1260-1264
examined	O	1265-1273
individually	O	1274-1286
,	O	1286-1287
mean	O	1288-1292
IF	O	1293-1295
,	O	1295-1296
MIC	O	1297-1300
,	O	1300-1301
total	O	1302-1307
dose	O	1308-1312
,	O	1312-1313
mean	O	1314-1318
daily	O	1319-1324
dose	O	1325-1329
,	O	1329-1330
and	O	1331-1334
ln	O	1335-1337
(	O	1338-1339
mean	O	1339-1343
Cmax	O	1344-1348
/	O	1348-1349
MIC	O	1349-1352
)	O	1352-1353
correlated	O	1354-1364
significantly	O	1365-1378
(	O	1379-1380
P	O	1380-1381
less	O	1382-1386
than	O	1387-1391
.	O	1392-1393
05	O	1393-1395
)	O	1395-1396

with	O	1397-1401
cure	O	1402-1406
.	O	1406-1407

In	O	1408-1410
contrast	O	1411-1419
,	O	1419-1420
a	O	1421-1422
simultaneous	O	1423-1435
multivariable	O	1436-1449
analysis	O	1450-1458
identified	O	1459-1469
IF	O	1470-1472
,	O	1472-1473
MIC	O	1474-1477
,	O	1477-1478
and	O	1479-1482
total	O	1483-1488
dose	O	1489-1493
according	O	1494-1503
to	O	1504-1506
one	O	1507-1510
model	O	1511-1516
and	O	1517-1520
ln	O	1521-1523
(	O	1524-1525
mean	O	1525-1529
Cmax	O	1530-1534
/	O	1534-1535
MIC	O	1535-1538
)	O	1538-1539
according	O	1540-1549
to	O	1550-1552
a	O	1553-1554
second	O	1555-1561
statistical	O	1562-1573
model	O	1574-1579
of	O	1580-1582
parameters	O	1583-1593
selected	O	1594-1602
to	O	1603-1605
have	O	1606-1610
the	O	1611-1614
greatest	O	1615-1623
prospective	O	1624-1635
value	O	1636-1641
.	O	1641-1642

Based	O	1643-1648
on	O	1649-1651
Bayes	O	1652-1657
'	O	1657-1658
theorem	O	1659-1666
and	O	1667-1670
the	O	1671-1674
first	O	1675-1680
model	O	1681-1686
,	O	1686-1687
the	O	1688-1691
predictive	O	1692-1702
accuracy	O	1703-1711
of	O	1712-1714
identifying	O	1715-1726
patients	O	1727-1735
not	O	1736-1739
cured	O	1740-1745
increased	O	1746-1755
from	O	1756-1760
0	O	1761-1762
.	O	1762-1763
19	O	1763-1765
to	O	1766-1768
0	O	1769-1770
.	O	1770-1771
83	O	1771-1773
.	O	1770-1771

For	O	1775-1778
the	O	1779-1782
second	O	1783-1789
model	O	1790-1795
,	O	1795-1796
the	O	1797-1800
predictive	O	1801-1811
accuracy	O	1812-1820
increased	O	1821-1830
from	O	1831-1835
0	O	1836-1837
.	O	1837-1838
19	O	1838-1840
to	O	1841-1843
0	O	1844-1845
.	O	1845-1846
50	O	1846-1848
.	O	1845-1846
(	O	1849-1850
ABSTRACT	O	1850-1858

TRUNCATED	O	1859-1868
AT	O	1869-1871
250	O	1872-1875
WORDS	O	1876-1881
)	O	1881-1882

Cardiac	O	0-7
transplantation	O	8-23
:	O	23-24
improved	O	25-33
quality	O	34-41
of	O	42-44
survival	O	45-53
with	O	54-58
a	O	59-60
modified	O	61-69
immunosuppressive	O	70-87
protocol	O	88-96
.	O	96-97

The	O	98-101
effects	O	102-109
on	O	110-112
renal	O	113-118
function	O	119-127
on	O	128-130
two	O	131-134
different	O	135-144
immunosuppressive	O	145-162
protocols	O	163-172
were	O	173-177
evaluated	O	178-187
retrospectively	O	188-203
in	O	204-206
two	O	207-210
subsequent	O	211-221
groups	O	222-228
of	O	229-231
heart	O	232-237
transplant	O	238-248
recipients	O	249-259
.	O	259-260

In	O	261-263
group	O	264-269
I	O	270-271
,	O	271-272
cyclosporine	O	273-285
was	O	286-289
given	O	290-295
before	O	296-302
the	O	303-306
procedure	O	307-316
at	O	317-319
a	O	320-321
loading	O	322-329
dose	O	330-334
of	O	335-337
17	O	338-340
.	O	340-341
5	O	341-342
mg	O	343-345
/	O	345-346
kg	O	346-348
and	O	349-352
then	O	353-357
continued	O	358-367
after	O	368-373
the	O	374-377
procedure	O	378-387
to	O	388-390
keep	O	391-395
a	O	396-397
whole	O	398-403
blood	O	404-409
level	O	410-415
about	O	416-421
1000	O	422-426
ng	O	427-429
/	O	429-430
ml	O	430-432
.	O	432-433

In	O	434-436
group	O	437-442
II	O	443-445
,	O	445-446
cyclosporine	O	447-459
was	O	460-463
started	O	464-471
only	O	472-476
after	O	477-482
the	O	483-486
procedure	O	487-496
at	O	497-499
a	O	500-501
lower	O	502-507
dosage	O	508-514
and	O	515-518
was	O	519-522
complemented	O	523-535
by	O	536-538
azathioprine	O	539-551
,	O	551-552
which	O	553-558
was	O	559-562
used	O	563-567
for	O	568-571
the	O	572-575
first	O	576-581
postoperative	O	582-595
week	O	596-600
.	O	600-601

Group	O	602-607
II	O	608-610
showed	O	611-617
a	O	618-619
better	O	620-626
perioperative	O	627-640
renal	O	641-646
function	O	647-655
as	O	656-658
determined	O	659-669
by	O	670-672
serum	O	673-678
blood	O	679-684
urea	O	685-689
nitrogen	O	690-698
and	O	699-702
serum	O	703-708
creatinine	O	709-719
levels	O	720-726
.	O	726-727

Group	O	728-733
II	O	734-736
also	O	737-741
showed	O	742-748
a	O	749-750
significant	O	751-762
decrease	O	763-771
of	O	772-774
chronic	O	775-782
nephrotoxicity	B	783-797
secondary	O	798-807
to	O	808-810
long	O	811-815
-	O	815-816
term	O	816-820
therapy	O	821-828
with	O	829-833
cyclosporine	O	834-846
.	O	846-847

Despite	O	848-855
this	O	856-860
improvement	O	861-872
in	O	873-875
late	O	876-880
renal	O	881-886
function	O	887-895
,	O	895-896
group	O	897-902
II	O	903-905
still	O	906-911
shows	O	912-917
a	O	918-919
slow	O	920-924
rise	O	925-929
in	O	930-932
serum	O	933-938
creatinine	O	939-949
.	O	949-950

We	O	951-953
think	O	954-959
that	O	960-964
even	O	965-969
these	O	970-975
lower	O	976-981
dosages	O	982-989
of	O	990-992
cyclosporine	O	993-1005
can	O	1006-1009
cause	O	1010-1015
chronic	O	1016-1023
nephrotoxicity	B	1024-1038
and	O	1039-1042
that	O	1043-1047
further	O	1048-1055
modification	O	1056-1068
of	O	1069-1071
the	O	1072-1075
immunosuppressive	O	1076-1093
regimen	O	1094-1101
is	O	1102-1104
required	O	1105-1113
to	O	1114-1116
completely	O	1117-1127
abolish	O	1128-1135
this	O	1136-1140
toxic	O	1141-1146
side	O	1147-1151
effect	O	1152-1158
.	O	1158-1159

Reversible	O	0-10
cholestasis	B	11-22
with	O	23-27
bile	B	28-32
duct	I	33-37
injury	I	38-44
following	O	45-54
azathioprine	O	55-67
therapy	O	68-75
.	O	75-76

A	O	77-78
case	O	79-83
report	O	84-90
.	O	90-91

A	O	92-93
67	O	94-96
-	O	96-97
year	O	97-101
-	O	96-97
old	O	102-105
patient	O	106-113
,	O	113-114
with	O	115-119
primary	O	120-127
polymyositis	B	128-140
and	O	141-144
without	O	145-152
previous	O	153-161
evidence	O	162-170
of	O	171-173
liver	B	174-179
disease	I	180-187
,	O	187-188
developed	O	189-198
clinical	O	199-207
and	O	208-211
biochemical	O	212-223
features	O	224-232
of	O	233-235
severe	O	236-242
cholestasis	B	243-254
3	O	255-256
months	O	257-263
after	O	264-269
initiation	O	270-280
of	O	281-283
azathioprine	O	284-296
therapy	O	297-304
.	O	304-305

Liver	O	306-311
biopsy	O	312-318
showed	O	319-325
cholestasis	B	326-337
with	O	338-342
both	O	343-347
cytological	O	348-359
and	O	360-363
architectural	O	364-377
alterations	O	378-389
of	O	390-392
interlobular	O	393-405
bile	O	406-410
ducts	O	411-416
.	O	416-417

Azathioprine	O	418-430
withdrawal	O	431-441
resulted	O	442-450
after	O	451-456
7	O	457-458
weeks	O	459-464
in	O	465-467
the	O	468-471
resolution	O	472-482
of	O	483-485
clinical	O	486-494
and	O	495-498
biochemical	O	499-510
abnormalities	O	511-524
.	O	524-525

It	O	526-528
is	O	529-531
believed	O	532-540
that	O	541-545
this	O	546-550
is	O	551-553
the	O	554-557
first	O	558-563
reported	O	564-572
case	O	573-577
of	O	578-580
reversible	O	581-591
azathioprine	O	592-604
-	O	604-605
induced	O	605-612
cholestasis	B	613-624
associated	O	625-635
with	O	636-640
histological	O	641-653
evidence	O	654-662
of	O	663-665
bile	B	666-670
duct	I	671-675
injury	I	676-682
.	O	682-683

Renal	O	0-5
function	O	6-14
and	O	15-18
hemodynamics	O	19-31
during	O	32-38
prolonged	O	39-48
isoflurane	O	49-59
-	O	59-60
induced	O	60-67
hypotension	B	68-79
in	O	80-82
humans	O	83-89
.	O	89-90

The	O	91-94
effect	O	95-101
of	O	102-104
isoflurane	O	105-115
-	O	115-116
induced	O	116-123
hypotension	B	124-135
on	O	136-138
glomerular	O	139-149
function	O	150-158
and	O	159-162
renal	O	163-168
blood	O	169-174
flow	O	175-179
was	O	180-183
investigated	O	184-196
in	O	197-199
20	O	200-202
human	O	203-208
subjects	O	209-217
.	O	217-218

Glomerular	O	219-229
filtration	O	230-240
rate	O	241-245
(	O	246-247
GFR	O	247-250
)	O	250-251
and	O	252-255
effective	O	256-265
renal	O	266-271
plasma	O	272-278
flow	O	279-283
(	O	284-285
ERPF	O	285-289
)	O	289-290
were	O	291-295
measured	O	296-304
by	O	305-307
inulin	O	308-314
and	O	315-318
para	O	319-323
-	O	323-324
aminohippurate	O	324-338
(	O	339-340
PAH	O	340-343
)	O	343-344
clearance	O	345-354
,	O	354-355
respectively	O	356-368
.	O	368-369

Anesthesia	O	370-380
was	O	381-384
maintained	O	385-395
with	O	396-400
fentanyl	O	401-409
,	O	409-410
nitrous	O	411-418
oxide	O	419-424
,	O	424-425
oxygen	O	426-432
,	O	432-433
and	O	434-437
isoflurane	O	438-448
.	O	448-449

Hypotension	B	450-461
was	O	462-465
induced	O	466-473
for	O	474-477
236	O	478-481
.	O	481-482
9	O	482-483
+	O	484-485
/	O	485-486
-	O	486-487
15	O	488-490
.	O	490-491
1	O	488-489
min	O	493-496
by	O	497-499
increasing	O	500-510
the	O	511-514
isoflurane	O	515-525
inspired	O	526-534
concentration	O	535-548
to	O	549-551
maintain	O	552-560
a	O	561-562
mean	O	563-567
arterial	O	568-576
pressure	O	577-585
of	O	586-588
59	O	589-591
.	O	591-592
8	O	592-593
+	O	594-595
/	O	595-596
-	O	596-597
0	O	598-599
.	O	599-600
4	O	600-601
mmHg	O	602-606
.	O	606-607

GFR	O	608-611
and	O	612-615
ERPF	O	616-620
decreased	O	621-630
with	O	631-635
the	O	636-639
induction	O	640-649
of	O	650-652
anesthesia	O	653-663
but	O	664-667
not	O	668-671
significantly	O	672-685
more	O	686-690
during	O	691-697
hypotension	B	698-709
.	O	709-710

Postoperatively	O	711-726
,	O	726-727
ERPF	O	728-732
returned	O	733-741
to	O	742-744
preoperative	O	745-757
values	O	758-764
,	O	764-765
whereas	O	766-773
GFR	O	774-777
was	O	778-781
higher	O	782-788
than	O	789-793
preoperative	O	794-806
values	O	807-813
.	O	813-814

Renal	O	815-820
vascular	O	821-829
resistance	O	830-840
increased	O	841-850
during	O	851-857
anesthesia	O	858-868
but	O	869-872
decreased	O	873-882
when	O	883-887
hypotension	B	888-899
was	O	900-903
induced	O	904-911
,	O	911-912
allowing	O	913-921
the	O	922-925
maintenance	O	926-937
of	O	938-940
renal	O	941-946
blood	O	947-952
flow	O	953-957
.	O	957-958

We	O	959-961
conclude	O	962-970
that	O	971-975
renal	O	976-981
compensatory	O	982-994
mechanisms	O	995-1005
are	O	1006-1009
preserved	O	1010-1019
during	O	1020-1026
isoflurane	O	1027-1037
-	O	1037-1038
induced	O	1038-1045
hypotension	B	1046-1057
and	O	1058-1061
that	O	1062-1066
renal	O	1067-1072
function	O	1073-1081
and	O	1082-1085
hemodynamics	O	1086-1098
quickly	O	1099-1106
return	O	1107-1113
to	O	1114-1116
normal	O	1117-1123
when	O	1124-1128
normotension	O	1129-1141
is	O	1142-1144
resumed	O	1145-1152
.	O	1152-1153

Debrisoquine	O	0-12
phenotype	O	13-22
and	O	23-26
the	O	27-30
pharmacokinetics	O	31-47
and	O	48-51
beta	O	52-56
-	O	56-57
2	O	57-58
receptor	O	59-67
pharmacodynamics	O	68-84
of	O	85-87
metoprolol	O	88-98
and	O	99-102
its	O	103-106
enantiomers	O	107-118
.	O	118-119

The	O	120-123
metabolism	O	124-134
of	O	135-137
the	O	138-141
cardioselective	O	142-157
beta	O	158-162
-	O	162-163
blocker	O	163-170
metoprolol	O	171-181
is	O	182-184
under	O	185-190
genetic	O	191-198
control	O	199-206
of	O	207-209
the	O	210-213
debrisoquine	O	214-226
/	O	226-227
sparteine	O	227-236
type	O	237-241
.	O	241-242

The	O	243-246
two	O	247-250
metabolic	O	251-260
phenotypes	O	261-271
,	O	271-272
extensive	O	273-282
(	O	283-284
EM	O	284-286
)	O	286-287
and	O	288-291
poor	O	292-296
metabolizers	O	297-309
(	O	310-311
PM	O	311-313
)	O	313-314
,	O	314-315
show	O	316-320
different	O	321-330
stereoselective	O	331-346
metabolism	O	347-357
,	O	357-358
resulting	O	359-368
in	O	369-371
apparently	O	372-382
higher	O	383-389
beta	O	390-394
-	O	394-395
1	O	395-396
adrenoceptor	O	397-409
antagonistic	O	410-422
potency	O	423-430
of	O	431-433
racemic	O	434-441
metoprolol	O	442-452
in	O	453-455
EMs	O	456-459
.	O	459-460

We	O	461-463
investigated	O	464-476
if	O	477-479
the	O	480-483
latter	O	484-490
also	O	491-495
applies	O	496-503
to	O	504-506
the	O	507-510
beta	O	511-515
-	O	515-516
2	O	516-517
adrenoceptor	O	518-530
antagonism	O	531-541
by	O	542-544
metoprolol	O	545-555
.	O	555-556

The	O	557-560
drug	O	561-565
effect	O	566-572
studied	O	573-580
was	O	581-584
the	O	585-588
antagonism	O	589-599
by	O	600-602
metoprolol	O	603-613
of	O	614-616
terbutaline	O	617-628
-	O	628-629
induced	O	629-636
hypokalemia	B	637-648
.	O	648-649

By	O	650-652
using	O	653-658
pharmacokinetic	O	659-674
pharmacodynamic	O	675-690
modeling	O	691-699
the	O	700-703
pharmacodynamics	O	704-720
of	O	721-723
racemic	O	724-731
metoprolol	O	732-742
and	O	743-746
the	O	747-750
active	O	751-757
S	O	758-759
-	O	759-760
isomer	O	760-766
,	O	766-767
were	O	768-772
quantitated	O	773-784
in	O	785-787
EMs	O	788-791
and	O	792-795
PMs	O	796-799
in	O	800-802
terms	O	803-808
of	O	809-811
IC50	O	812-816
values	O	817-823
,	O	823-824
representing	O	825-837
metoprolol	O	838-848
plasma	O	849-855
concentrations	O	856-870
resulting	O	871-880
in	O	881-883
half	O	884-888
-	O	888-889
maximum	O	889-896
receptor	O	897-905
occupancy	O	906-915
.	O	915-916

Six	O	917-920
EMs	O	921-924
received	O	925-933
0	O	934-935
.	O	935-936
5	O	936-937
mg	O	938-940
of	O	941-943
terbutaline	O	944-955
s	O	956-957
.	O	957-958
c	O	958-959
.	O	957-958
on	O	961-963
two	O	964-967
different	O	968-977
occasions	O	978-987
:	O	987-988
1	O	989-990
)	O	990-991
1	O	992-993
hr	O	994-996
after	O	997-1002
administration	O	1003-1017
of	O	1018-1020
a	O	1021-1022
placebo	O	1023-1030
and	O	1031-1034
2	O	1035-1036
)	O	1036-1037
1	O	1038-1039
hr	O	1040-1042
after	O	1043-1048
150	O	1049-1052
mg	O	1053-1055
of	O	1056-1058
metoprolol	O	1059-1069
p	O	1070-1071
.	O	1071-1072
o	O	1072-1073
.	O	1071-1072
Five	O	1075-1079
PMs	O	1080-1083
were	O	1084-1088
studied	O	1089-1096
according	O	1097-1106
to	O	1107-1109
the	O	1110-1113
same	O	1114-1118
protocol	O	1119-1127
,	O	1127-1128
except	O	1129-1135
for	O	1136-1139
a	O	1140-1141
higher	O	1142-1148
terbutaline	O	1149-1160
dose	O	1161-1165
(	O	1166-1167
0	O	1167-1168
.	O	1168-1169
75	O	1169-1171
mg	O	1172-1174
)	O	1174-1175
on	O	1176-1178
day	O	1179-1182
2	O	1183-1184
.	O	1184-1185
Blood	O	1186-1191
samples	O	1192-1199
for	O	1200-1203
the	O	1204-1207
analysis	O	1208-1216
of	O	1217-1219
plasma	O	1220-1226
potassium	O	1227-1236
,	O	1236-1237
terbutaline	O	1238-1249
,	O	1249-1250
metoprolol	O	1251-1261
(	O	1262-1263
racemic	O	1263-1270
,	O	1270-1271
R	O	1272-1273
-	O	1273-1274
and	O	1275-1278
S	O	1279-1280
-	O	1280-1281
isomer	O	1281-1287
)	O	1287-1288
,	O	1288-1289
and	O	1290-1293
alpha	O	1294-1299
-	O	1299-1300
hydroxymetoprolol	O	1300-1317
concentrations	O	1318-1332
were	O	1333-1337
taken	O	1338-1343
at	O	1344-1346
regular	O	1347-1354
time	O	1355-1359
intervals	O	1360-1369
,	O	1369-1370
during	O	1371-1377
8	O	1378-1379
hr	O	1380-1382
after	O	1383-1388
metoprolol	O	1389-1399
.	O	1399-1400

In	O	1401-1403
PMs	O	1404-1407
,	O	1407-1408
metoprolol	O	1409-1419
increased	O	1420-1429
the	O	1430-1433
terbutaline	O	1434-1445
area	O	1446-1450
under	O	1451-1456
the	O	1457-1460
plasma	O	1461-1467
concentration	O	1468-1481
vs	O	1482-1484
.	O	1484-1485
time	O	1486-1490
curve	O	1491-1496
(	O	1497-1498
+	O	1498-1499
67	O	1499-1501
%	O	1501-1502
)	O	1502-1503
.	O	1503-1504

Higher	O	1505-1511
metoprolol	O	1512-1522
/	O	1522-1523
alpha	O	1523-1528
-	O	1528-1529
hydroxymetoprolol	O	1529-1546
ratios	O	1547-1553
in	O	1554-1556
PMs	O	1557-1560
were	O	1561-1565
predictive	O	1566-1576
for	O	1577-1580
higher	O	1581-1587
R	O	1588-1589
-	O	1589-1590
/	O	1590-1591
S	O	1591-1592
-	O	1589-1590
isomer	O	1593-1599
ratios	O	1600-1606
of	O	1607-1609
unchanged	O	1610-1619
drug	O	1620-1624
.	O	1624-1625

There	O	1626-1631
was	O	1632-1635
a	O	1636-1637
difference	O	1638-1648
in	O	1649-1651
metoprolol	O	1652-1662
potency	O	1663-1670
with	O	1671-1675
higher	O	1676-1682
racemic	O	1683-1690
metoprolol	O	1691-1701
IC50	O	1702-1706
values	O	1707-1713
in	O	1714-1716
PMs	O	1717-1720
(	O	1721-1722
72	O	1722-1724
+	O	1725-1726
/	O	1726-1727
-	O	1727-1728
7	O	1729-1730
ng	O	1731-1733
.	O	1733-1734
ml	O	1734-1736
-	O	1736-1737
1	O	1737-1738
)	O	1738-1739

than	O	1740-1744
EMs	O	1745-1748
(	O	1749-1750
42	O	1750-1752
+	O	1753-1754
/	O	1754-1755
-	O	1755-1756
8	O	1757-1758
ng	O	1759-1761
.	O	1761-1762
ml	O	1762-1764
-	O	1764-1765
1	O	1765-1766
,	O	1766-1767
P	O	1768-1769
less	O	1770-1774
than	O	1775-1779
.	O	1780-1781
001	O	1781-1784
)	O	1784-1785
.	O	1780-1781
(	O	1786-1787
ABSTRACT	O	1787-1795

TRUNCATED	O	1796-1805
AT	O	1806-1808
250	O	1809-1812
WORDS	O	1813-1818
)	O	1818-1819

Cefotetan	O	0-9
-	O	9-10
induced	O	10-17
immune	O	18-24
hemolytic	B	25-34
anemia	I	35-41
.	O	41-42

Immune	O	43-49
hemolytic	B	50-59
anemia	I	60-66
due	O	67-70
to	O	71-73
a	O	74-75
drug	O	76-80
-	O	80-81
adsorption	O	81-91
mechanism	O	92-101
has	O	102-105
been	O	106-110
described	O	111-120
primarily	O	121-130
in	O	131-133
patients	O	134-142
receiving	O	143-152
penicillins	O	153-164
and	O	165-168
first	O	169-174
-	O	174-175
generation	O	175-185
cephalosporins	O	186-200
.	O	200-201

We	O	202-204
describe	O	205-213
a	O	214-215
patient	O	216-223
who	O	224-227
developed	O	228-237
anemia	B	238-244
while	O	245-250
receiving	O	251-260
intravenous	O	261-272
cefotetan	O	273-282
.	O	282-283

Cefotetan	O	284-293
-	O	293-294
dependent	O	294-303
antibodies	O	304-314
were	O	315-319
detected	O	320-328
in	O	329-331
the	O	332-335
patient	O	336-343
'	O	343-344
s	O	344-345
serum	O	346-351
and	O	352-355
in	O	356-358
an	O	359-361
eluate	O	362-368
prepared	O	369-377
from	O	378-382
his	O	383-386
red	O	387-390
blood	O	391-396
cells	O	397-402
.	O	402-403

The	O	404-407
eluate	O	408-414
also	O	415-419
reacted	O	420-427
weakly	O	428-434
with	O	435-439
red	O	440-443
blood	O	444-449
cells	O	450-455
in	O	456-458
the	O	459-462
absence	O	463-470
of	O	471-473
cefotetan	O	474-483
,	O	483-484
suggesting	O	485-495
the	O	496-499
concomitant	O	500-511
formation	O	512-521
of	O	522-524
warm	O	525-529
-	O	529-530
reactive	O	530-538
autoantibodies	O	539-553
.	O	553-554

These	O	555-560
observations	O	561-573
,	O	573-574
in	O	575-577
conjunction	O	578-589
with	O	590-594
clinical	O	595-603
and	O	604-607
laboratory	O	608-618
evidence	O	619-627
of	O	628-630
extravascular	O	631-644
hemolysis	B	645-654
,	O	654-655
are	O	656-659
consistent	O	660-670
with	O	671-675
drug	O	676-680
-	O	680-681
induced	O	681-688
hemolytic	B	689-698
anemia	I	699-705
,	O	705-706
possibly	O	707-715
involving	O	716-725
both	O	726-730
drug	O	731-735
-	O	735-736
adsorption	O	736-746
and	O	747-750
autoantibody	O	751-763
formation	O	764-773
mechanisms	O	774-784
.	O	784-785

This	O	786-790
case	O	791-795
emphasizes	O	796-806
the	O	807-810
need	O	811-815
for	O	816-819
increased	O	820-829
awareness	O	830-839
of	O	840-842
hemolytic	O	843-852
reactions	O	853-862
to	O	863-865
all	O	866-869
cephalosporins	O	870-884
.	O	884-885

Acute	B	0-5
renal	I	6-11
failure	I	12-19
subsequent	O	20-30
to	O	31-33
the	O	34-37
administration	O	38-52
of	O	53-55
rifampicin	O	56-66
.	O	66-67

A	O	68-69
follow	O	70-76
-	O	76-77
up	O	77-79
study	O	80-85
of	O	86-88
cases	O	89-94
reported	O	95-103
earlier	O	104-111
.	O	111-112

A	O	113-114
clinical	O	115-123
presentation	O	124-136
is	O	137-139
made	O	140-144
of	O	145-147
a	O	148-149
2	O	150-151
-	O	151-152
3	O	152-153
year	O	154-158
follow	O	159-165
-	O	165-166
up	O	166-168
of	O	169-171
six	O	172-175
cases	O	176-181
of	O	182-184
acute	B	185-190
renal	I	191-196
failure	I	197-204
that	O	205-209
have	O	210-214
been	O	215-219
reported	O	220-228
earlier	O	229-236
.	O	236-237

The	O	238-241
patients	O	242-250
had	O	251-254
developed	O	255-264
transient	O	265-274
renal	B	275-280
failure	I	281-288
after	O	289-294
the	O	295-298
intermittent	O	299-311
administration	O	312-326
of	O	327-329
rifampicin	O	330-340
.	O	340-341

The	O	342-345
stage	O	346-351
of	O	352-354
olig	O	355-359
-	O	359-360
anuria	B	360-366
lasted	O	367-373
for	O	374-377
1	O	378-379
-	O	379-380
3	O	380-381
weeks	O	382-387
,	O	387-388
and	O	389-392
five	O	393-397
of	O	398-400
the	O	401-404
patients	O	405-413
were	O	414-418
treated	O	419-426
by	O	427-429
hemodialysis	O	430-442
.	O	442-443

Two	O	444-447
of	O	448-450
the	O	451-454
patients	O	455-463
died	O	464-468
due	O	469-472
to	O	473-475
unrelated	O	476-485
causes	O	486-492
during	O	493-499
the	O	500-503
follow	O	504-510
-	O	510-511
up	O	511-513
period	O	514-520
.	O	520-521

The	O	522-525
four	O	526-530
patients	O	531-539
re	O	540-542
-	O	542-543
examined	O	543-551
were	O	552-556
clinically	O	557-567
cured	O	568-573
.	O	573-574

Pathologic	O	575-585
findings	O	586-594
by	O	595-597
light	O	598-603
microscopy	O	604-614
and	O	615-618
immunofluorescence	O	619-637
at	O	638-640
biopsy	O	641-647
were	O	648-652
scarce	O	653-659
.	O	659-660

Nothing	O	661-668
abnormal	O	669-677
was	O	678-681
seen	O	682-686
by	O	687-689
electron	O	690-698
microscopy	O	699-709
in	O	710-712
two	O	713-716
of	O	717-719
the	O	720-723
cases	O	724-729
studied	O	730-737
.	O	737-738

Renal	O	739-744
function	O	745-753
was	O	754-757
normal	O	758-764
.	O	764-765

In	O	766-768
three	O	769-774
cases	O	775-780
the	O	781-784
excretion	O	785-794
at	O	795-797
131I	O	798-802
-	O	802-803
hippuran	O	803-811
renography	O	812-822
was	O	823-826
slightly	O	827-835
slowed	O	836-842
.	O	842-843

Although	O	844-852
in	O	853-855
the	O	856-859
acute	O	860-865
stage	O	866-871
the	O	872-875
renal	B	876-881
lesions	I	882-889
histologically	O	890-904
appeared	O	905-913
toxic	O	914-919
,	O	919-920
evidence	O	921-929
suggestive	O	930-940
of	O	941-943
an	O	944-946
immunological	O	947-960
mechanism	O	961-970
cannot	O	971-977
be	O	978-980
excluded	O	981-989
.	O	989-990

Type	B	0-4
B	I	5-6
hepatitis	I	7-16
after	O	17-22
needle	O	23-29
-	O	29-30
stick	O	30-35
exposure	O	36-44
:	O	44-45
prevention	O	46-56
with	O	57-61
hepatitis	B	62-71
B	I	72-73
immune	O	74-80
globulin	O	81-89
.	O	89-90

Final	O	91-96
report	O	97-103
of	O	104-106
the	O	107-110
Veterans	O	111-119
Administration	O	120-134
Cooperative	O	135-146
Study	O	147-152
.	O	152-153

Hepatitis	B	154-163
B	I	164-165
immune	O	166-172
globulin	O	173-181
(	O	182-183
HBIG	O	183-187
)	O	187-188
and	O	189-192
immune	O	193-199
serum	O	200-205
globulin	O	206-214
(	O	215-216
ISG	O	216-219
)	O	219-220
were	O	221-225
examined	O	226-234
in	O	235-237
a	O	238-239
randomized	O	240-250
,	O	250-251
double	O	252-258
-	O	258-259
blind	O	259-264
trial	O	265-270
to	O	271-273
assess	O	274-280
their	O	281-286
relative	O	287-295
efficacies	O	296-306
in	O	307-309
preventing	O	310-320
type	B	321-325
B	I	326-327
hepatitis	I	328-337
after	O	338-343
needle	O	344-350
-	O	350-351
stick	O	351-356
exposure	O	357-365
to	O	366-368
hepatitis	O	369-378
B	O	379-380
surface	O	381-388
antigen	O	389-396
(	O	397-398
HBsAG	O	398-403
)	O	403-404
-	O	404-405
positive	O	405-413
donors	O	414-420
.	O	420-421

Clinical	O	422-430
hepatitis	B	431-440
developed	O	441-450
in	O	451-453
1	O	454-455
.	O	455-456
4	O	456-457
%	O	457-458
of	O	459-461
HBIG	O	462-466
and	O	467-470
in	O	471-473
5	O	474-475
.	O	475-476
9	O	476-477
%	O	477-478
of	O	479-481
ISG	O	482-485
recipients	O	486-496
(	O	497-498
P	O	498-499
=	O	500-501
0	O	502-503
.	O	503-504
016	O	504-507
)	O	507-508
,	O	508-509
and	O	510-513
seroconversion	O	514-528
(	O	529-530
anti	O	530-534
-	O	534-535
HBs	O	535-538
)	O	538-539
occurred	O	540-548
in	O	549-551
5	O	552-553
.	O	553-554
6	O	554-555
%	O	555-556
and	O	557-560
20	O	561-563
.	O	563-564
7	O	564-565
%	O	565-566
of	O	567-569
them	O	570-574
respectively	O	575-587
(	O	588-589
P	O	589-590
less	O	591-595
than	O	596-600
0	O	601-602
.	O	602-603
001	O	603-606
)	O	606-607
.	O	602-603

Mild	O	609-613
and	O	614-617
transient	O	618-627
side	O	628-632
-	O	632-633
effects	O	633-640
were	O	641-645
noted	O	646-651
in	O	652-654
3	O	655-656
.	O	656-657
0	O	657-658
%	O	658-659
of	O	660-662
ISG	O	663-666
and	O	667-670
in	O	671-673
3	O	674-675
.	O	675-676
2	O	676-677
%	O	677-678
of	O	679-681
HBIG	O	682-686
recipients	O	687-697
.	O	697-698

Available	O	699-708
donor	O	709-714
sera	O	715-719
were	O	720-724
examined	O	725-733
for	O	734-737
DNA	O	738-741
polymerase	O	742-752
(	O	753-754
DNAP	O	754-758
)	O	758-759
and	O	760-763
e	O	764-765
antigen	O	766-773
and	O	774-777
antibody	O	778-786
(	O	787-788
HBeAg	O	788-793
;	O	793-794
anti	O	795-799
-	O	799-800
HBE	O	800-803
)	O	803-804
.	O	804-805

Both	O	806-810
DNAP	O	811-815
and	O	816-819
HBeAg	O	820-825
showed	O	826-832
a	O	833-834
highly	O	835-841
statistically	O	842-855
significant	O	856-867
correlation	O	868-879
with	O	880-884
the	O	885-888
infectivity	O	889-900
of	O	901-903
HBsAg	O	904-909
-	O	909-910
positive	O	910-918
donors	O	919-925
.	O	925-926

Hepatitis	B	927-936
B	I	937-938
immune	O	939-945
globulin	O	946-954
remained	O	955-963
significantly	O	964-977
superior	O	978-986
to	O	987-989
ISG	O	990-993
in	O	994-996
preventing	O	997-1007
type	B	1008-1012
B	I	1013-1014
hepatitis	I	1015-1024
even	O	1025-1029
when	O	1030-1034
the	O	1035-1038
analysis	O	1039-1047
was	O	1048-1051
confined	O	1052-1060
to	O	1061-1063
these	O	1064-1069
two	O	1070-1073
high	O	1074-1078
-	O	1078-1079
risk	O	1079-1083
subgroups	O	1084-1093
.	O	1093-1094

The	O	1095-1098
efficacy	O	1099-1107
of	O	1108-1110
ISG	O	1111-1114
in	O	1115-1117
preventing	O	1118-1128
type	B	1129-1133
B	I	1134-1135
hepatitis	I	1136-1145
cannot	O	1146-1152
be	O	1153-1155
ascertained	O	1156-1167
because	O	1168-1175
a	O	1176-1177
true	O	1178-1182
placebo	O	1183-1190
group	O	1191-1196
was	O	1197-1200
not	O	1201-1204
included	O	1205-1213
.	O	1213-1214

Serotonin	B	0-9
syndrome	I	10-18
from	O	19-23
venlafaxine	O	24-35
-	O	35-36
tranylcypromine	O	36-51
interaction	O	52-63
.	O	63-64

Excessive	O	65-74
stimulation	O	75-86
of	O	87-89
serotonin	O	90-99
5HT1A	O	100-105
receptors	O	106-115
causes	O	116-122
a	O	123-124
syndrome	O	125-133
of	O	134-136
serotonin	O	137-146
excess	O	147-153
that	O	154-158
consists	O	159-167
of	O	168-170
shivering	O	171-180
,	O	180-181
muscle	B	182-188
rigidity	I	189-197
,	O	197-198
salivation	B	199-209
,	O	209-210
confusion	B	211-220
,	O	220-221
agitation	B	222-231
and	O	232-235
hyperthermia	B	236-248
.	O	248-249

The	O	250-253
most	O	254-258
common	O	259-265
cause	O	266-271
of	O	272-274
this	O	275-279
syndrome	O	280-288
is	O	289-291
an	O	292-294
interaction	O	295-306
between	O	307-314
a	O	315-316
monoamine	O	317-326
oxidase	O	327-334
inhibitor	O	335-344
(	O	345-346
MAOI	O	346-350
)	O	350-351
and	O	352-355
a	O	356-357
specific	O	358-366
serotonin	O	367-376
reuptake	O	377-385
inhibitor	O	386-395
.	O	395-396

Venlafaxine	O	397-408
is	O	409-411
a	O	412-413
new	O	414-417
antidepressant	O	418-432
agent	O	433-438
that	O	439-443
inhibits	O	444-452
the	O	453-456
reuptake	O	457-465
of	O	466-468
serotonin	O	469-478
and	O	479-482
norepinephrine	O	483-497
.	O	497-498

We	O	499-501
report	O	502-508
a	O	509-510
venlafaxine	O	511-522
-	O	522-523
MAOI	O	523-527
interaction	O	528-539
that	O	540-544
resulted	O	545-553
in	O	554-556
the	O	557-560
serotonin	B	561-570
syndrome	I	571-579
in	O	580-582
a	O	583-584
23	O	585-587
-	O	587-588
y	O	588-589
-	O	587-588
old	O	590-593
male	O	594-598
who	O	599-602
was	O	603-606
taking	O	607-613
tranylcypromine	O	614-629
for	O	630-633
depression	B	634-644
.	O	644-645

He	O	646-648
had	O	649-652
been	O	653-657
well	O	658-662
until	O	663-668
the	O	669-672
morning	O	673-680
of	O	681-683
presentation	O	684-696
when	O	697-701
he	O	702-704
took	O	705-709
1	O	710-711
/	O	711-712
2	O	712-713
tab	O	714-717
of	O	718-720
venlafaxine	O	721-732
.	O	732-733

Within	O	734-740
2	O	741-742
h	O	743-744
he	O	745-747
became	O	748-754
confused	O	755-763
with	O	764-768
jerking	O	769-776
movements	O	777-786
of	O	787-789
his	O	790-793
extremities	O	794-805
,	O	805-806
tremors	B	807-814
and	O	815-818
rigidity	B	819-827
.	O	827-828

He	O	829-831
was	O	832-835
brought	O	836-843
directly	O	844-852
to	O	853-855
a	O	856-857
hospital	O	858-866
where	O	867-872
he	O	873-875
was	O	876-879
found	O	880-885
to	O	886-888
be	O	889-891
agitated	O	892-900
and	O	901-904
confused	O	905-913
with	O	914-918
shivering	O	919-928
,	O	928-929
myoclonic	B	930-939
jerks	I	940-945
,	O	945-946
rigidity	B	947-955
,	O	955-956
salivation	B	957-967
and	O	968-971
diaphoresis	O	972-983
.	O	983-984

His	O	985-988
pupils	O	989-995
were	O	996-1000
7	O	1001-1002
mm	O	1003-1005
and	O	1006-1009
sluggishly	O	1010-1020
reactive	O	1021-1029
to	O	1030-1032
light	O	1033-1038
.	O	1038-1039

Vital	O	1040-1045
signs	O	1046-1051
were	O	1052-1056
:	O	1056-1057
blood	O	1058-1063
pressure	O	1064-1072
120	O	1073-1076
/	O	1076-1077
67	O	1077-1079
mm	O	1080-1082
Hg	O	1083-1085
,	O	1085-1086
heart	O	1087-1092
rate	O	1093-1097
127	O	1098-1101
/	O	1101-1102
min	O	1102-1105
,	O	1105-1106
respiratory	O	1107-1118
rate	O	1119-1123
28	O	1124-1126
/	O	1126-1127
min	O	1127-1130
,	O	1130-1131
and	O	1132-1135
temperature	O	1136-1147
97	O	1148-1150
F	O	1151-1152
.	O	1152-1153
After	O	1154-1159
180	O	1160-1163
mg	O	1164-1166
of	O	1167-1169
diazepam	O	1170-1178
i	O	1179-1180
.	O	1180-1181
v	O	1181-1182
.	O	1180-1181
he	O	1184-1186
remained	O	1187-1195
tremulous	O	1196-1205
with	O	1206-1210
muscle	B	1211-1217
rigidity	I	1218-1226
and	O	1227-1230
clenched	O	1231-1239
jaws	O	1240-1244
.	O	1244-1245

He	O	1246-1248
was	O	1249-1252
intubated	O	1253-1262
for	O	1263-1266
airway	O	1267-1273
protection	O	1274-1284
and	O	1285-1288
because	O	1289-1296
of	O	1297-1299
hypoventilation	B	1300-1315
,	O	1315-1316
and	O	1317-1320
was	O	1321-1324
paralyzed	B	1325-1334
to	O	1335-1337
control	O	1338-1345
muscle	B	1346-1352
rigidity	I	1353-1361
.	O	1361-1362

His	O	1363-1366
subsequent	O	1367-1377
course	O	1378-1384
was	O	1385-1388
remarkable	O	1389-1399
for	O	1400-1403
non	O	1404-1407
-	O	1407-1408
immune	O	1408-1414
thrombocytopenia	B	1415-1431
which	O	1432-1437
resolved	O	1438-1446
.	O	1446-1447

The	O	1448-1451
patient	O	1452-1459
'	O	1459-1460
s	O	1460-1461
maximal	O	1462-1469
temperature	O	1470-1481
was	O	1482-1485
101	O	1486-1489
.	O	1489-1490
2	O	1490-1491
F	O	1492-1493
and	O	1494-1497
his	O	1498-1501
CPK	O	1502-1505
remained	O	1506-1514
<	O	1515-1516
500	O	1517-1520
units	O	1521-1526
/	O	1526-1527
L	O	1527-1528
with	O	1529-1533
no	O	1534-1536
other	O	1537-1542
evidence	O	1543-1551
of	O	1552-1554
rhabdomyolysis	B	1555-1569
.	O	1569-1570

His	O	1571-1574
mental	O	1575-1581
status	O	1582-1588
normalized	O	1589-1599
and	O	1600-1603
he	O	1604-1606
was	O	1607-1610
transferred	O	1611-1622
to	O	1623-1625
a	O	1626-1627
psychiatry	O	1628-1638
ward	O	1639-1643
.	O	1643-1644

This	O	1645-1649
patient	O	1650-1657
survived	O	1658-1666
without	O	1667-1674
sequelae	O	1675-1683
due	O	1684-1687
to	O	1688-1690
the	O	1691-1694
aggressive	O	1695-1705
sedation	O	1706-1714
and	O	1715-1718
neuromuscular	O	1719-1732
paralysis	B	1733-1742
.	O	1742-1743

Effect	O	0-6
of	O	7-9
nondopaminergic	O	10-25
drugs	O	26-31
on	O	32-34
L	O	35-36
-	O	36-37
dopa	O	37-41
-	O	36-37
induced	O	42-49
dyskinesias	B	50-61
in	O	62-64
MPTP	O	65-69
-	O	69-70
treated	O	70-77
monkeys	O	78-85
.	O	85-86

A	O	87-88
group	O	89-94
of	O	95-97
four	O	98-102
monkeys	O	103-110
was	O	111-114
rendered	O	115-123
parkinsonian	B	124-136
with	O	137-141
the	O	142-145
toxin	O	146-151
MPTP	O	152-156
.	O	156-157

They	O	158-162
were	O	163-167
then	O	168-172
treated	O	173-180
chronically	O	181-192
with	O	193-197
L	O	198-199
-	O	199-200
DOPA	O	200-204
/	O	204-205
benserazide	O	205-216
50	O	217-219
/	O	219-220
12	O	220-222
.	O	222-223
5	O	217-218
mg	O	225-227
/	O	227-228
kg	O	228-230
given	O	231-236
orally	O	237-243
daily	O	244-249
for	O	250-253
2	O	254-255
months	O	256-262
.	O	262-263

This	O	264-268
dose	O	269-273
produced	O	274-282
a	O	283-284
striking	O	285-293
antiparkinsonian	O	294-310
effect	O	311-317
,	O	317-318
but	O	319-322
all	O	323-326
animals	O	327-334
manifested	O	335-345
dyskinesia	B	346-356
.	O	356-357

A	O	358-359
series	O	360-366
of	O	367-369
agents	O	370-376
acting	O	377-383
primarily	O	384-393
on	O	394-396
neurotransmitters	O	397-414
other	O	415-420
than	O	421-425
dopamine	O	426-434
were	O	435-439
then	O	440-444
tested	O	445-451
in	O	452-454
combination	O	455-466
with	O	467-471
L	O	472-473
-	O	473-474
DOPA	O	474-478
to	O	479-481
see	O	482-485
if	O	486-488
the	O	489-492
dyskinetic	B	493-503
movements	O	504-513
would	O	514-519
be	O	520-522
modified	O	523-531
.	O	531-532

Several	O	533-540
drugs	O	541-546
,	O	546-547
including	O	548-557
clonidine	O	558-567
,	O	567-568
physostigmine	O	569-582
,	O	582-583
methysergide	O	584-596
,	O	596-597
5	O	598-599
-	O	599-600
MDOT	O	600-604
,	O	604-605
propranolol	O	606-617
,	O	617-618
and	O	619-622
MK	O	623-625
-	O	625-626
801	O	626-629
,	O	629-630
markedly	O	631-639
reduced	O	640-647
the	O	648-651
dyskinetic	B	652-662
movements	O	663-672
but	O	673-676
at	O	677-679
the	O	680-683
cost	O	684-688
of	O	689-691
a	O	692-693
return	O	694-700
of	O	701-703
parkinsonian	B	704-716
symptomatology	O	717-731
.	O	731-732

However	O	733-740
,	O	740-741
yohimbine	O	742-751
and	O	752-755
meperidine	O	756-766
reduced	O	767-774
predominantly	O	775-788
the	O	789-792
dyskinetic	B	793-803
movements	O	804-813
.	O	813-814

Baclofen	O	815-823
was	O	824-827
also	O	828-832
useful	O	833-839
in	O	840-842
one	O	843-846
monkey	O	847-853
against	O	854-861
a	O	862-863
more	O	864-868
dystonic	B	869-877
form	O	878-882
of	O	883-885
dyskinesia	B	886-896
.	O	896-897

Atropine	O	898-906
converted	O	907-916
the	O	917-920
dystonic	B	921-929
movements	O	930-939
into	O	940-944
chorea	B	945-951
.	O	951-952

CCNU	O	0-4
(	O	5-6
lomustine	O	6-15
)	O	15-16
toxicity	B	17-25
in	O	26-28
dogs	O	29-33
:	O	33-34
a	O	35-36
retrospective	O	37-50
study	O	51-56
(	O	57-58
2002	O	58-62
-	O	62-63
07	O	63-65
)	O	65-66
.	O	66-67

OBJECTIVE	O	68-77
:	O	77-78
To	O	79-81
describe	O	82-90
the	O	91-94
incidence	O	95-104
of	O	105-107
haematological	B	108-122
,	I	122-123
renal	I	124-129
,	I	129-130
hepatic	I	131-138
and	I	139-142
gastrointestinal	I	143-159
toxicities	I	160-170
in	O	171-173
tumour	O	174-180
-	O	180-181
bearing	O	181-188
dogs	O	189-193
receiving	O	194-203
1	O	204-205
-	O	205-206
(	O	206-207
2	O	207-208
-	O	205-206
chloroethyl	O	209-220
)	O	220-221
-	O	205-206
3	O	222-223
-	O	205-206
cyclohexyl	O	224-234
-	O	205-206
1	O	204-205
-	O	205-206
nitrosourea	O	237-248
(	O	249-250
CCNU	O	250-254
)	O	254-255
.	O	255-256

DESIGN	O	257-263
:	O	263-264
The	O	265-268
medical	O	269-276
records	O	277-284
of	O	285-287
206	O	288-291
dogs	O	292-296
that	O	297-301
were	O	302-306
treated	O	307-314
with	O	315-319
CCNU	O	320-324
at	O	325-327
the	O	328-331
Melbourne	O	332-341
Veterinary	O	342-352
Specialist	O	353-363
Centre	O	364-370
between	O	371-378
February	O	379-387
2002	O	388-392
and	O	393-396
December	O	397-405
2007	O	406-410
were	O	411-415
retrospectively	O	416-431
evaluated	O	432-441
.	O	441-442

RESULTS	O	443-450
:	O	450-451
Of	O	452-454
the	O	455-458
206	O	459-462
dogs	O	463-467
treated	O	468-475
with	O	476-480
CCNU	O	481-485
,	O	485-486
185	O	487-490
met	O	491-494
the	O	495-498
inclusion	O	499-508
criteria	O	509-517
for	O	518-521
at	O	522-524
least	O	525-530
one	O	531-534
class	O	535-540
of	O	541-543
toxicity	B	544-552
.	O	552-553

CCNU	O	554-558
was	O	559-562
used	O	563-567
most	O	568-572
commonly	O	573-581
in	O	582-584
the	O	585-588
treatment	O	589-598
of	O	599-601
lymphoma	B	602-610
,	O	610-611
mast	B	612-616
cell	I	617-621
tumour	I	622-628
,	O	628-629
brain	B	630-635
tumour	I	636-642
,	O	642-643
histiocytic	B	644-655
tumours	I	656-663
and	O	664-667
epitheliotropic	B	668-683
lymphoma	I	684-692
.	O	692-693

Throughout	O	694-704
treatment	O	705-714
,	O	714-715
56	O	716-718
.	O	718-719
9	O	719-720
%	O	720-721
of	O	722-724
dogs	O	725-729
experienced	O	730-741
neutropenia	B	742-753
,	O	753-754
34	O	755-757
.	O	757-758
2	O	758-759
%	O	759-760
experienced	O	761-772
anaemia	B	773-780
and	O	781-784
14	O	785-787
.	O	787-788
2	O	788-789
%	O	789-790
experienced	O	791-802
thrombocytopenia	B	803-819
.	O	819-820

Gastrointestinal	B	821-837
toxicosis	I	838-847
was	O	848-851
detected	O	852-860
in	O	861-863
37	O	864-866
.	O	866-867
8	O	867-868
%	O	868-869
of	O	870-872
dogs	O	873-877
,	O	877-878
the	O	879-882
most	O	883-887
common	O	888-894
sign	O	895-899
of	O	900-902
which	O	903-908
was	O	909-912
vomiting	B	913-921
(	O	922-923
24	O	923-925
.	O	925-926
3	O	926-927
%	O	927-928
)	O	928-929
.	O	925-926

Potential	O	931-940
renal	O	941-946
toxicity	B	947-955
and	O	956-959
elevated	O	960-968
alanine	O	969-976
transaminase	O	977-989
(	O	990-991
ALT	O	991-994
)	O	994-995
concentration	O	996-1009
were	O	1010-1014
reported	O	1015-1023
in	O	1024-1026
12	O	1027-1029
.	O	1029-1030
2	O	1028-1029
%	O	1031-1032
and	O	1033-1036
48	O	1037-1039
.	O	1039-1040
8	O	1038-1039
%	O	1041-1042
of	O	1043-1045
dogs	O	1046-1050
,	O	1050-1051
respectively	O	1052-1064
.	O	1064-1065

The	O	1066-1069
incidence	O	1070-1079
of	O	1080-1082
hepatic	B	1083-1090
failure	I	1091-1098
was	O	1099-1102
1	O	1103-1104
.	O	1104-1105
2	O	1105-1106
%	O	1106-1107
.	O	1104-1105

CONCLUSIONS	O	1109-1120
:	O	1120-1121
CCNU	O	1122-1126
-	O	1126-1127
associated	O	1127-1137
toxicity	B	1138-1146
in	O	1147-1149
dogs	O	1150-1154
is	O	1155-1157
common	O	1158-1164
,	O	1164-1165
but	O	1166-1169
is	O	1170-1172
usually	O	1173-1180
not	O	1181-1184
life	O	1185-1189
threatening	O	1190-1201
.	O	1201-1202

Neuroactive	O	0-11
steroids	O	12-20
protect	O	21-28
against	O	29-36
pilocarpine	O	37-48
-	O	48-49
and	O	50-53
kainic	O	54-60
acid	O	61-65
-	O	65-66
induced	O	66-73
limbic	O	74-80
seizures	B	81-89
and	O	90-93
status	B	94-100
epilepticus	I	101-112
in	O	113-115
mice	O	116-120
.	O	120-121

Several	O	122-129
structurally	O	130-142
related	O	143-150
metabolites	O	151-162
of	O	163-165
progesterone	O	166-178
(	O	179-180
3	O	180-181
alpha	O	182-187
-	O	187-188
hydroxy	O	188-195
pregnane	O	196-204
-	O	204-205
20	O	205-207
-	O	204-205
ones	O	208-212
)	O	212-213
and	O	214-217
deoxycorticosterone	O	218-237
(	O	238-239
3	O	239-240
alpha	O	241-246
-	O	246-247
hydroxy	O	247-254
pregnane	O	255-263
-	O	263-264
21	O	264-266
-	O	263-264
diol	O	267-271
-	O	263-264
20	O	272-274
-	O	263-264
ones	O	275-279
)	O	279-280
and	O	281-284
their	O	285-290
3	O	291-292
beta	O	293-297
-	O	297-298
epimers	O	298-305
were	O	306-310
evaluated	O	311-320
for	O	321-324
protective	O	325-335
activity	O	336-344
against	O	345-352
pilocarpine	O	353-364
-	O	364-365
,	O	365-366
kainic	O	367-373
acid	O	374-378
-	O	378-379
and	O	380-383
N	O	384-385
-	O	385-386
methyl	O	386-392
-	O	385-386
D	O	393-394
-	O	385-386
aspartate	O	395-404
(	O	405-406
NMDA	O	406-410
)	O	410-411
-	O	411-412
induced	O	412-419
seizures	B	420-428
in	O	429-431
mice	O	432-436
.	O	436-437

Steroids	O	438-446
with	O	447-451
the	O	452-455
3	O	456-457
-	O	457-458
hydroxy	O	458-465
group	O	466-471
in	O	472-474
the	O	475-478
alpha	O	479-484
-	O	484-485
position	O	485-493
and	O	494-497
5	O	498-499
-	O	499-500
H	O	500-501
in	O	502-504
the	O	505-508
alpha	O	509-514
-	O	514-515
or	O	516-518
beta	O	519-523
-	O	523-524
configurations	O	524-538
were	O	539-543
highly	O	544-550
effective	O	551-560
in	O	561-563
protecting	O	564-574
against	O	575-582
pilocarpine	O	583-594
(	O	595-596
416	O	596-599
mg	O	600-602
/	O	602-603
kg	O	603-605
,	O	605-606
s	O	607-608
.	O	608-609
c	O	609-610
.	O	608-609
)	O	611-612
-	O	612-613
induced	O	613-620
limbic	O	621-627
motor	O	628-633
seizures	B	634-642
and	O	643-646
status	B	647-653
epilepticus	I	654-665
(	O	666-667
ED50	O	667-671
values	O	672-678
,	O	678-679
7	O	680-681
.	O	681-682
0	O	682-683
-	O	683-684
18	O	684-686
.	O	681-682
7	O	680-681
mg	O	689-691
/	O	691-692
kg	O	692-694
,	O	694-695
i	O	696-697
.	O	697-698
p	O	698-699
.	O	697-698
)	O	700-701
.	O	697-698

The	O	703-706
corresponding	O	707-720
epimers	O	721-728
with	O	729-733
the	O	734-737
3	O	738-739
-	O	739-740
hydroxy	O	740-747
group	O	748-753
in	O	754-756
the	O	757-760
beta	O	761-765
-	O	765-766
position	O	766-774
were	O	775-779
also	O	780-784
effective	O	785-794
but	O	795-798
less	O	799-803
potent	O	804-810
(	O	811-812
ED50	O	812-816
values	O	817-823
,	O	823-824
33	O	825-827
.	O	827-828
8	O	828-829
-	O	829-830
63	O	830-832
.	O	827-828
5	O	833-834
,	O	834-835

i	O	836-837
.	O	837-838
p	O	838-839
.	O	837-838
)	O	840-841
.	O	837-838

Although	O	843-851
the	O	852-855
neuroactive	O	856-867
steroids	O	868-876
were	O	877-881
considerably	O	882-894
less	O	895-899
potent	O	900-906
than	O	907-911
the	O	912-915
benzodiazepine	O	916-930
clonazepam	O	931-941
in	O	942-944
protecting	O	945-955
against	O	956-963
pilocarpine	O	964-975
seizures	B	976-984
,	O	984-985
steroids	O	986-994
with	O	995-999
the	O	1000-1003
5	O	1004-1005
alpha	O	1006-1011
,	O	1011-1012
3	O	1012-1013
alpha	O	1014-1019
-	O	1019-1020
configuration	O	1020-1033
had	O	1034-1037
comparable	O	1038-1048
or	O	1049-1051
higher	O	1052-1058
protective	O	1059-1069
index	O	1070-1075
values	O	1076-1082
(	O	1083-1084
TD50	O	1084-1088
for	O	1089-1092
motor	O	1093-1098
impairment	O	1099-1109
divided	O	1110-1117
by	O	1118-1120
ED50	O	1121-1125
for	O	1126-1129
seizure	B	1130-1137
protection	O	1138-1148
)	O	1148-1149
than	O	1150-1154
clonazepam	O	1155-1165
,	O	1165-1166
indicating	O	1167-1177
that	O	1178-1182
some	O	1183-1187
neuroactive	O	1188-1199
steroids	O	1200-1208
may	O	1209-1212
have	O	1213-1217
lower	O	1218-1223
relative	O	1224-1232
toxicity	B	1233-1241
.	O	1241-1242

Steroids	O	1243-1251
with	O	1252-1256
the	O	1257-1260
5	O	1261-1262
alpha	O	1263-1268
,	O	1268-1269
3	O	1269-1270
alpha	O	1271-1276
-	O	1276-1277
or	O	1278-1280
5	O	1281-1282
beta	O	1283-1287
,	O	1287-1288
3	O	1288-1289
alpha	O	1290-1295
-	O	1295-1296
configurations	O	1296-1310
also	O	1311-1315
produced	O	1316-1324
a	O	1325-1326
dose	O	1327-1331
-	O	1331-1332
dependent	O	1332-1341
delay	O	1342-1347
in	O	1348-1350
the	O	1351-1354
onset	O	1355-1360
of	O	1361-1363
limbic	O	1364-1370
seizures	B	1371-1379
induced	O	1380-1387
by	O	1388-1390
kainic	O	1391-1397
acid	O	1398-1402
(	O	1403-1404
32	O	1404-1406
mg	O	1407-1409
/	O	1409-1410
kg	O	1410-1412
,	O	1412-1413
s	O	1414-1415
.	O	1415-1416
c	O	1416-1417
.	O	1415-1416
)	O	1418-1419
,	O	1419-1420
but	O	1421-1424
did	O	1425-1428
not	O	1429-1432
completely	O	1433-1443
protect	O	1444-1451
against	O	1452-1459
the	O	1460-1463
seizures	B	1464-1472
.	O	1472-1473

However	O	1474-1481
,	O	1481-1482
when	O	1483-1487
a	O	1488-1489
second	O	1490-1496
dose	O	1497-1501
of	O	1502-1504
the	O	1505-1508
steroid	O	1509-1516
was	O	1517-1520
administered	O	1521-1533
1	O	1534-1535
hr	O	1536-1538
after	O	1539-1544
the	O	1545-1548
first	O	1549-1554
dose	O	1555-1559
,	O	1559-1560
complete	O	1561-1569
protection	O	1570-1580
from	O	1581-1585
the	O	1586-1589
kainic	O	1590-1596
acid	O	1597-1601
-	O	1601-1602
induced	O	1602-1609
limbic	O	1610-1616
seizures	B	1617-1625
and	O	1626-1629
status	B	1630-1636
epilepticus	I	1637-1648
was	O	1649-1652
obtained	O	1653-1661
.	O	1661-1662

The	O	1663-1666
steroids	O	1667-1675
also	O	1676-1680
caused	O	1681-1687
a	O	1688-1689
dose	O	1690-1694
-	O	1694-1695
dependent	O	1695-1704
delay	O	1705-1710
in	O	1711-1713
NMDA	O	1714-1718
(	O	1719-1720
257	O	1720-1723
mg	O	1724-1726
/	O	1726-1727
kg	O	1727-1729
,	O	1729-1730
s	O	1731-1732
.	O	1732-1733
c	O	1733-1734
.	O	1732-1733
)	O	1735-1736
-	O	1736-1737
induced	O	1737-1744
lethality	O	1745-1754
,	O	1754-1755
but	O	1756-1759
did	O	1760-1763
not	O	1764-1767
completely	O	1768-1778
protect	O	1779-1786
against	O	1787-1794
NMDA	O	1795-1799
seizures	B	1800-1808
or	O	1809-1811
lethality	O	1812-1821
.	O	1821-1822

We	O	1823-1825
conclude	O	1826-1834
that	O	1835-1839
neuroactive	O	1840-1851
steroids	O	1852-1860
are	O	1861-1864
highly	O	1865-1871
effective	O	1872-1881
in	O	1882-1884
protecting	O	1885-1895
against	O	1896-1903
pilocarpine	O	1904-1915
-	O	1915-1916
and	O	1917-1920
kainic	O	1921-1927
acid	O	1928-1932
-	O	1932-1933
induced	O	1933-1940
seizures	B	1941-1949
and	O	1950-1953
status	B	1954-1960
epilepticus	I	1961-1972
in	O	1973-1975
mice	O	1976-1980
,	O	1980-1981
and	O	1982-1985
may	O	1986-1989
be	O	1990-1992
of	O	1993-1995
utility	O	1996-2003
in	O	2004-2006
the	O	2007-2010
treatment	O	2011-2020
of	O	2021-2023
some	O	2024-2028
forms	O	2029-2034
of	O	2035-2037
status	B	2038-2044
epilepticus	I	2045-2056
in	O	2057-2059
humans	O	2060-2066
.	O	2066-2067

The	O	0-3
safety	O	4-10
and	O	11-14
efficacy	O	15-23
of	O	24-26
combination	O	27-38
N	O	39-40
-	O	40-41
butyl	O	41-46
-	O	40-41
deoxynojirimycin	O	47-63
(	O	64-65
SC	O	65-67
-	O	67-68
48334	O	68-73
)	O	73-74
and	O	75-78
zidovudine	O	79-89
in	O	90-92
patients	O	93-101
with	O	102-106
HIV	B	107-110
-	I	110-111
1	I	111-112
infection	I	113-122
and	O	123-126
200	O	127-130
-	O	130-131
500	O	131-134
CD4	O	135-138
cells	O	139-144
/	O	144-145
mm3	O	145-148
.	O	148-149

We	O	150-152
conducted	O	153-162
a	O	163-164
double	O	165-171
-	O	171-172
blind	O	172-177
,	O	177-178
randomized	O	179-189
phase	O	190-195
II	O	196-198
study	O	199-204
to	O	205-207
evaluate	O	208-216
the	O	217-220
safety	O	221-227
and	O	228-231
activity	O	232-240
of	O	241-243
combination	O	244-255
therapy	O	256-263
with	O	264-268
N	O	269-270
-	O	270-271
butyl	O	271-276
-	O	270-271
deoxynojirimycin	O	277-293
(	O	294-295
SC	O	295-297
-	O	297-298
48334	O	298-303
)	O	303-304
(	O	305-306
an	O	306-308
alpha	O	309-314
-	O	314-315
glucosidase	O	315-326
I	O	327-328
inhibitor	O	329-338
)	O	338-339
and	O	340-343
zidovudine	O	344-354
versus	O	355-361
zidovudine	O	362-372
alone	O	373-378
.	O	378-379

Patients	O	380-388
with	O	389-393
200	O	394-397
to	O	398-400
500	O	401-404
CD4	O	405-408
cells	O	409-414
/	O	414-415
mm3	O	415-418
who	O	419-422
tolerated	O	423-432
<	O	433-434
or	O	435-437
=	O	438-439
12	O	440-442
weeks	O	443-448
of	O	449-451
prior	O	452-457
zidovudine	O	458-468
therapy	O	469-476
received	O	477-485
SC	O	486-488
-	O	488-489
48334	O	489-494
(	O	495-496
1000	O	496-500
mg	O	501-503
every	O	504-509
8	O	510-511
h	O	512-513
)	O	513-514
and	O	515-518
zidovudine	O	519-529
(	O	530-531
100	O	531-534
mg	O	535-537
every	O	538-543
8	O	544-545
h	O	546-547
)	O	547-548
or	O	549-551
zidovudine	O	552-562
and	O	563-566
placebo	O	567-574
.	O	574-575

Sixty	O	576-581
patients	O	582-590
received	O	591-599
combination	O	600-611
therapy	O	612-619
and	O	620-623
58	O	624-626
,	O	626-627
zidovudine	O	628-638
and	O	639-642
placebo	O	643-650
.	O	650-651

Twenty	O	652-658
-	O	658-659
three	O	659-664
patients	O	665-673
(	O	674-675
38	O	675-677
%	O	677-678
)	O	678-679
and	O	680-683
15	O	684-686
(	O	687-688
26	O	688-690
%	O	690-691
)	O	691-692
,	O	692-693
in	O	694-696
the	O	697-700
combination	O	701-712
and	O	713-716
zidovudine	O	717-727
groups	O	728-734
,	O	734-735
respectively	O	736-748
,	O	748-749
discontinued	O	750-762
therapy	O	763-770
(	O	771-772
p	O	772-773
=	O	774-775
0	O	776-777
.	O	777-778
15	O	778-780
)	O	780-781
.	O	777-778

The	O	783-786
mean	O	787-791
SC	O	792-794
-	O	794-795
48334	O	795-800
steady	O	801-807
-	O	807-808
state	O	808-813
trough	O	814-820
level	O	821-826
(	O	827-828
4	O	828-829
.	O	829-830
04	O	830-832
+	O	833-834
/	O	834-835
-	O	835-836
0	O	837-838
.	O	838-839
99	O	839-841
micrograms	O	842-852
/	O	852-853
ml	O	853-855
)	O	855-856
was	O	857-860
below	O	861-866
the	O	867-870
in	O	871-873
vitro	O	874-879
inhibitory	O	880-890
concentration	O	891-904
for	O	905-908
human	O	909-914
immunodeficiency	B	915-931
virus	O	932-937
(	O	938-939
HIV	O	939-942
)	O	942-943
.	O	943-944

The	O	945-948
mean	O	949-953
increase	O	954-962
in	O	963-965
CD4	O	966-969
cells	O	970-975
at	O	976-978
week	O	979-983
4	O	984-985
was	O	986-989
73	O	990-992
.	O	992-993
8	O	993-994
cells	O	995-1000
/	O	1000-1001
mm3	O	1001-1004
and	O	1005-1008
52	O	1009-1011
.	O	1011-1012
4	O	1012-1013
cells	O	1014-1019
/	O	1019-1020
mm3	O	1020-1023
for	O	1024-1027
the	O	1028-1031
combination	O	1032-1043
and	O	1044-1047
zidovudine	O	1048-1058
groups	O	1059-1065
,	O	1065-1066
respectively	O	1067-1079
(	O	1080-1081
p	O	1081-1082
>	O	1083-1084
0	O	1085-1086
.	O	1086-1087
36	O	1087-1089
)	O	1089-1090
.	O	1086-1087

For	O	1092-1095
patients	O	1096-1104
with	O	1105-1109
prior	O	1110-1115
zidovudine	O	1116-1126
therapy	O	1127-1134
,	O	1134-1135
the	O	1136-1139
mean	O	1140-1144
change	O	1145-1151
in	O	1152-1154
CD4	O	1155-1158
cells	O	1159-1164
in	O	1165-1167
the	O	1168-1171
combination	O	1172-1183
and	O	1184-1187
zidovudine	O	1188-1198
groups	O	1199-1205
was	O	1206-1209
63	O	1210-1212
.	O	1212-1213
7	O	1213-1214
cells	O	1215-1220
/	O	1220-1221
mm3	O	1221-1224
and	O	1225-1228
4	O	1229-1230
.	O	1230-1231
9	O	1231-1232
cells	O	1233-1238
/	O	1238-1239
mm3	O	1239-1242
at	O	1243-1245
week	O	1246-1250
8	O	1251-1252
and	O	1253-1256
6	O	1257-1258
.	O	1258-1259
8	O	1259-1260
cells	O	1261-1266
/	O	1266-1267
mm3	O	1267-1270
and	O	1271-1274
-	O	1275-1276
45	O	1276-1278
.	O	1278-1279
1	O	1279-1280
cells	O	1281-1286
/	O	1286-1287
mm3	O	1287-1290
at	O	1291-1293
week	O	1294-1298
16	O	1299-1301
,	O	1301-1302
respectively	O	1303-1315
.	O	1315-1316

The	O	1317-1320
number	O	1321-1327
of	O	1328-1330
patients	O	1331-1339
with	O	1340-1344
suppression	O	1345-1356
of	O	1357-1359
HIV	O	1360-1363
p24	O	1364-1367
antigenemia	O	1368-1379
in	O	1380-1382
the	O	1383-1386
combination	O	1387-1398
and	O	1399-1402
zidovudine	O	1403-1413
groups	O	1414-1420
was	O	1421-1424
six	O	1425-1428
(	O	1429-1430
40	O	1430-1432
%	O	1432-1433
)	O	1433-1434
and	O	1435-1438
two	O	1439-1442
(	O	1443-1444
11	O	1444-1446
%	O	1446-1447
)	O	1447-1448
at	O	1449-1451
week	O	1452-1456
4	O	1457-1458
(	O	1459-1460
p	O	1460-1461
=	O	1462-1463
0	O	1464-1465
.	O	1465-1466
10	O	1466-1468
)	O	1468-1469
and	O	1470-1473
five	O	1474-1478
(	O	1479-1480
45	O	1480-1482
%	O	1482-1483
)	O	1483-1484
and	O	1485-1488
two	O	1489-1492
(	O	1493-1494
14	O	1494-1496
%	O	1496-1497
)	O	1497-1498
at	O	1499-1501
week	O	1502-1506
24	O	1507-1509
(	O	1510-1511
p	O	1511-1512
=	O	1513-1514
0	O	1515-1516
.	O	1516-1517
08	O	1517-1519
)	O	1519-1520
,	O	1520-1521
respectively	O	1522-1534
.	O	1534-1535

Diarrhea	B	1536-1544
,	O	1544-1545
flatulence	B	1546-1556
,	O	1556-1557
abdominal	B	1558-1567
pain	I	1568-1572
,	O	1572-1573
and	O	1574-1577
weight	B	1578-1584
loss	I	1585-1589
were	O	1590-1594
common	O	1595-1601
for	O	1602-1605
combination	O	1606-1617
recipients	O	1618-1628
.	O	1628-1629
(	O	1629-1630
ABSTRACT	O	1630-1638

TRUNCATED	O	1639-1648
AT	O	1649-1651
250	O	1652-1655
WORDS	O	1656-1661
)	O	1661-1662

Recent	O	0-6
preclinical	O	7-18
and	O	19-22
clinical	O	23-31
studies	O	32-39
with	O	40-44
the	O	45-48
thymidylate	O	49-60
synthase	O	61-69
inhibitor	O	70-79
N10	O	80-83
-	O	83-84
propargyl	O	84-93
-	O	83-84
5	O	94-95
,	O	95-96
8	O	96-97
-	O	83-84
dideazafolic	O	98-110
acid	O	111-115
(	O	116-117
CB	O	117-119
3717	O	120-124
)	O	124-125
.	O	125-126

CB	O	127-129
3717	O	130-134
,	O	134-135
N10	O	136-139
-	O	139-140
propargyl	O	140-149
-	O	139-140
5	O	150-151
,	O	151-152
8	O	152-153
-	O	139-140
dideazafolic	O	154-166
acid	O	167-171
,	O	171-172
is	O	173-175
a	O	176-177
tight	O	178-183
-	O	183-184
binding	O	184-191
inhibitor	O	192-201
of	O	202-204
thymidylate	O	205-216
synthase	O	217-225
(	O	226-227
TS	O	227-229
)	O	229-230
whose	O	231-236
cytotoxicity	B	237-249
is	O	250-252
mediated	O	253-261
solely	O	262-268
through	O	269-276
the	O	277-280
inhibition	O	281-291
of	O	292-294
this	O	295-299
enzyme	O	300-306
.	O	306-307

Recent	O	308-314
preclinical	O	315-326
studies	O	327-334
have	O	335-339
focused	O	340-347
on	O	348-350
the	O	351-354
intracellular	O	355-368
formation	O	369-378
of	O	379-381
CB	O	382-384
3717	O	385-389
polyglutamates	O	390-404
.	O	404-405

Following	O	406-415
a	O	416-417
12	O	418-420
-	O	420-421
hour	O	421-425
exposure	O	426-434
of	O	435-437
L1210	O	438-443
cells	O	444-449
to	O	450-452
50	O	453-455
microM	O	456-462
[	O	463-464
3H	O	464-466
]	O	466-467
CB	O	467-469
3717	O	470-474
,	O	474-475
30	O	476-478
%	O	478-479
of	O	480-482
the	O	483-486
extractable	O	487-498
radioactivity	O	499-512
could	O	513-518
be	O	519-521
accounted	O	522-531
for	O	532-535
as	O	536-538
CB	O	539-541
3717	O	542-546
tetra	O	547-552
-	O	552-553
and	O	554-557
pentaglutamate	O	558-572
,	O	572-573
as	O	574-576
determined	O	577-587
by	O	588-590
high	O	591-595
-	O	595-596
pressure	O	596-604
liquid	O	605-611
chromatography	O	612-626
(	O	627-628
HPLC	O	628-632
)	O	632-633
analyses	O	634-642
.	O	642-643

As	O	644-646
inhibitors	O	647-657
of	O	658-660
isolated	O	661-669
L1210	O	670-675
TS	O	676-678
,	O	678-679
CB	O	680-682
3717	O	683-687
di	O	688-690
-	O	690-691
,	O	691-692
tri	O	693-696
-	O	696-697
,	O	697-698
tetra	O	699-704
-	O	704-705
and	O	706-709
pentaglutamate	O	710-724
are	O	725-728
26	O	729-731
-	O	731-732
,	O	732-733
87	O	734-736
-	O	736-737
,	O	737-738
119	O	739-742
-	O	742-743
and	O	744-747
114	O	748-751
-	O	751-752
fold	O	752-756
more	O	757-761
potent	O	762-768
than	O	769-773
CB	O	774-776
3717	O	777-781
,	O	781-782
respectively	O	783-795
,	O	795-796
and	O	797-800
their	O	801-806
formation	O	807-816
may	O	817-820
,	O	820-821
therefore	O	822-831
,	O	831-832
be	O	833-835
an	O	836-838
important	O	839-848
determinant	O	849-860
of	O	861-863
CB	O	864-866
3717	O	867-871
cytotoxicity	B	872-884
.	O	884-885

In	O	886-888
early	O	889-894
clinical	O	895-903
studies	O	904-911
with	O	912-916
CB	O	917-919
3717	O	920-924
,	O	924-925
activity	O	926-934
has	O	935-938
been	O	939-943
seen	O	944-948
in	O	949-951
breast	B	952-958
cancer	I	959-965
,	O	965-966
ovarian	B	967-974
cancer	I	975-981
,	O	981-982
hepatoma	B	983-991
,	O	991-992
and	O	993-996
mesothelioma	B	997-1009
.	O	1009-1010

Toxicities	B	1011-1021
included	O	1022-1030
hepatotoxicity	B	1031-1045
,	O	1045-1046
malaise	B	1047-1054
,	O	1054-1055
and	O	1056-1059
dose	O	1060-1064
-	O	1064-1065
limiting	O	1065-1073
nephrotoxicity	B	1074-1088
.	O	1088-1089

This	O	1090-1094
latter	O	1095-1101
effect	O	1102-1108
is	O	1109-1111
thought	O	1112-1119
to	O	1120-1122
be	O	1123-1125
due	O	1126-1129
to	O	1130-1132
drug	O	1133-1137
precipitation	O	1138-1151
within	O	1152-1158
the	O	1159-1162
renal	O	1163-1168
tubule	O	1169-1175
as	O	1176-1178
a	O	1179-1180
result	O	1181-1187
of	O	1188-1190
the	O	1191-1194
poor	O	1195-1199
solubility	O	1200-1210
of	O	1211-1213
CB	O	1214-1216
3717	O	1217-1221
under	O	1222-1227
acidic	O	1228-1234
conditions	O	1235-1245
.	O	1245-1246

In	O	1247-1249
an	O	1250-1252
attempt	O	1253-1260
to	O	1261-1263
overcome	O	1264-1272
this	O	1273-1277
problem	O	1278-1285
,	O	1285-1286
a	O	1287-1288
clinical	O	1289-1297
trial	O	1298-1303
of	O	1304-1306
CB	O	1307-1309
3717	O	1310-1314
administered	O	1315-1327
with	O	1328-1332
alkaline	O	1333-1341
diuresis	O	1342-1350
is	O	1351-1353
under	O	1354-1359
way	O	1360-1363
.	O	1363-1364

Preliminary	O	1365-1376
results	O	1377-1384
at	O	1385-1387
400	O	1388-1391
and	O	1392-1395
500	O	1396-1399
mg	O	1400-1402
/	O	1402-1403
m2	O	1403-1405
suggest	O	1406-1413
that	O	1414-1418
a	O	1419-1420
reduction	O	1421-1430
in	O	1431-1433
nephrotoxicity	B	1434-1448
may	O	1449-1452
have	O	1453-1457
been	O	1458-1462
achieved	O	1463-1471
with	O	1472-1476
only	O	1477-1481
1	O	1482-1483
instance	O	1484-1492
of	O	1493-1495
renal	B	1496-1501
toxicity	I	1502-1510
in	O	1511-1513
10	O	1514-1516
patients	O	1517-1525
.	O	1525-1526

Hepatotoxicity	B	1527-1541
and	O	1542-1545
malaise	B	1546-1553
are	O	1554-1557
again	O	1558-1563
the	O	1564-1567
most	O	1568-1572
frequent	O	1573-1581
side	O	1582-1586
effects	O	1587-1594
.	O	1594-1595

Evidence	O	1596-1604
of	O	1605-1607
antitumor	O	1608-1617
activity	O	1618-1626
has	O	1627-1630
been	O	1631-1635
seen	O	1636-1640
in	O	1641-1643
3	O	1644-1645
patients	O	1646-1654
.	O	1654-1655

Pharmacokinetic	O	1656-1671
investigations	O	1672-1686
have	O	1687-1691
shown	O	1692-1697
that	O	1698-1702
alkaline	O	1703-1711
diuresis	O	1712-1720
does	O	1721-1725
not	O	1726-1729
alter	O	1730-1735
CB	O	1736-1738
3717	O	1739-1743
plasma	O	1744-1750
levels	O	1751-1757
or	O	1758-1760
urinary	O	1761-1768
excretion	O	1769-1778
and	O	1779-1782
that	O	1783-1787
satisfactory	O	1788-1800
urinary	O	1801-1808
alkalinization	O	1809-1823
can	O	1824-1827
be	O	1828-1830
readily	O	1831-1838
achieved	O	1839-1847
.	O	1847-1848

Ethopropazine	O	0-13
and	O	14-17
benztropine	O	18-29
in	O	30-32
neuroleptic	O	33-44
-	O	44-45
induced	O	45-52
parkinsonism	B	53-65
.	O	65-66

In	O	67-69
a	O	70-71
12	O	72-74
-	O	74-75
week	O	75-79
controlled	O	80-90
study	O	91-96
ethopropazine	O	97-110
was	O	111-114
compared	O	115-123
to	O	124-126
benztropine	O	127-138
in	O	139-141
the	O	142-145
treatment	O	146-155
of	O	156-158
parkinsonism	B	159-171
induced	O	172-179
by	O	180-182
fluphenazine	O	183-195
enanthate	O	196-205
in	O	206-208
60	O	209-211
schizophrenic	B	212-225
outpatients	O	226-237
.	O	237-238

Ethopropazine	O	239-252
and	O	253-256
benztropine	O	257-268
were	O	269-273
found	O	274-279
to	O	280-282
be	O	283-285
equally	O	286-293
effective	O	294-303
in	O	304-306
controlling	O	307-318
parkinsonian	B	319-331
symptoms	I	332-340
and	O	341-344
were	O	345-349
as	O	350-352
efficacious	O	353-364
as	O	365-367
procyclidine	O	368-380
,	O	380-381
their	O	382-387
previous	O	388-396
antiparkinsonian	O	397-413
drug	O	414-418
.	O	418-419

However	O	420-427
,	O	427-428
benztropine	O	429-440
treated	O	441-448
patients	O	449-457
had	O	458-461
a	O	462-463
significant	O	464-475
increase	O	476-484
in	O	485-487
tardive	B	488-495
dyskinesia	I	496-506
compared	O	507-515
to	O	516-518
their	O	519-524
condition	O	525-534
during	O	535-541
procyclindine	O	542-555
treatment	O	556-565
,	O	565-566
and	O	567-570
significantly	O	571-584
more	O	585-589
anxiety	B	590-597
and	O	598-601
depression	B	602-612
than	O	613-617
ethopropazine	O	618-631
treated	O	632-639
patients	O	640-648
.	O	648-649

This	O	650-654
suggests	O	655-663
that	O	664-668
benztropine	O	669-680
is	O	681-683
not	O	684-687
the	O	688-691
anticholinergic	O	692-707
drug	O	708-712
of	O	713-715
choice	O	716-722
in	O	723-725
the	O	726-729
treatment	O	730-739
of	O	740-742
neuroleptic	O	743-754
-	O	754-755
induced	O	755-762
parkinsonian	B	763-775
symptoms	I	776-784
,	O	784-785
because	O	786-793
of	O	794-796
its	O	797-800
more	O	801-805
toxic	O	806-811
central	O	812-819
and	O	820-823
peripheral	O	824-834
atropinic	O	835-844
effect	O	845-851
.	O	851-852

Effect	O	0-6
of	O	7-9
alpha	O	10-15
-	O	15-16
tocopherol	O	16-26
and	O	27-30
deferoxamine	O	31-43
on	O	44-46
methamphetamine	O	47-62
-	O	62-63
induced	O	63-70
neurotoxicity	B	71-84
.	O	84-85

Methamphetamine	O	86-101
(	O	102-103
MA	O	103-105
)	O	105-106
-	O	106-107
induced	O	107-114
dopaminergic	O	115-127
neurotoxicity	B	128-141
is	O	142-144
believed	O	145-153
to	O	154-156
be	O	157-159
associated	O	160-170
with	O	171-175
the	O	176-179
increased	O	180-189
formation	O	190-199
of	O	200-202
free	O	203-207
radicals	O	208-216
.	O	216-217

This	O	218-222
study	O	223-228
examined	O	229-237
the	O	238-241
effect	O	242-248
of	O	249-251
alpha	O	252-257
-	O	257-258
tocopherol	O	258-268
(	O	269-270
alpha	O	270-275
-	O	275-276
TC	O	276-278
)	O	278-279
,	O	279-280
a	O	281-282
scavenger	O	283-292
of	O	293-295
reactive	O	296-304
oxygen	O	305-311
species	O	312-319
,	O	319-320
and	O	321-324
deferoxamine	O	325-337
(	O	338-339
DFO	O	339-342
)	O	342-343
,	O	343-344
an	O	345-347
iron	O	348-352
chelator	O	353-361
,	O	361-362
on	O	363-365
the	O	366-369
MA	O	370-372
-	O	372-373
induced	O	373-380
neurotoxicity	B	381-394
.	O	394-395

Male	O	396-400
rats	O	401-405
were	O	406-410
treated	O	411-418
with	O	419-423
MA	O	424-426
(	O	427-428
10	O	428-430
mg	O	431-433
/	O	433-434
kg	O	434-436
,	O	436-437
every	O	438-443
2	O	444-445
h	O	446-447
for	O	448-451
four	O	452-456
injections	O	457-467
)	O	467-468
.	O	468-469

The	O	470-473
rat	O	474-477
received	O	478-486
either	O	487-493
alpha	O	494-499
-	O	499-500
TC	O	500-502
(	O	503-504
20	O	504-506
mg	O	507-509
/	O	509-510
kg	O	510-512
)	O	512-513
intraperitoneally	O	514-531
for	O	532-535
3	O	536-537
days	O	538-542
and	O	543-546
30	O	547-549
min	O	550-553
prior	O	554-559
to	O	560-562
MA	O	563-565
administration	O	566-580
or	O	581-583
DFO	O	584-587
(	O	588-589
50	O	589-591
mg	O	592-594
/	O	594-595
kg	O	595-597
)	O	597-598
subcutaneously	O	599-613
30	O	614-616
min	O	617-620
before	O	621-627
MA	O	628-630
administration	O	631-645
.	O	645-646

The	O	647-650
concentrations	O	651-665
of	O	666-668
dopamine	O	669-677
(	O	678-679
DA	O	679-681
)	O	681-682
,	O	682-683
serotonin	O	684-693
and	O	694-697
their	O	698-703
metabolites	O	704-715
decreased	O	716-725
significantly	O	726-739
after	O	740-745
MA	O	746-748
administration	O	749-763
,	O	763-764
which	O	765-770
was	O	771-774
inhibited	O	775-784
by	O	785-787
the	O	788-791
alpha	O	792-797
-	O	797-798
TC	O	798-800
and	O	801-804
DFO	O	805-808
pretreatment	O	809-821
.	O	821-822

alpha	O	823-828
-	O	828-829
TC	O	829-831
and	O	832-835
DFO	O	836-839
attenuated	O	840-850
the	O	851-854
MA	O	855-857
-	O	857-858
induced	O	858-865
hyperthermia	B	866-878
as	O	879-881
well	O	882-886
as	O	887-889
the	O	890-893
alterations	O	894-905
in	O	906-908
the	O	909-912
locomotor	O	913-922
activity	O	923-931
.	O	931-932

The	O	933-936
level	O	937-942
of	O	943-945
lipid	O	946-951
peroxidation	O	952-964
was	O	965-968
higher	O	969-975
and	O	976-979
the	O	980-983
reduced	O	984-991
glutathione	O	992-1003
concentration	O	1004-1017
was	O	1018-1021
lower	O	1022-1027
in	O	1028-1030
the	O	1031-1034
MA	O	1035-1037
-	O	1037-1038
treated	O	1038-1045
rats	O	1046-1050
.	O	1050-1051

These	O	1052-1057
changes	O	1058-1065
were	O	1066-1070
significantly	O	1071-1084
attenuated	O	1085-1095
by	O	1096-1098
alpha	O	1099-1104
-	O	1104-1105
TC	O	1105-1107
and	O	1108-1111
DFO	O	1112-1115
.	O	1115-1116

This	O	1117-1121
suggests	O	1122-1130
that	O	1131-1135
alpha	O	1136-1141
-	O	1141-1142
TC	O	1142-1144
and	O	1145-1148
DFO	O	1149-1152
ameliorate	O	1153-1163
the	O	1164-1167
MA	O	1168-1170
-	O	1170-1171
induced	O	1171-1178
neuronal	B	1179-1187
damage	I	1188-1194
by	O	1195-1197
decreasing	O	1198-1208
the	O	1209-1212
level	O	1213-1218
of	O	1219-1221
oxidative	O	1222-1231
stress	O	1232-1238
.	O	1238-1239

Use	O	0-3
of	O	4-6
dexamethasone	O	7-20
with	O	21-25
mesna	O	26-31
for	O	32-35
the	O	36-39
prevention	O	40-50
of	O	51-53
ifosfamide	O	54-64
-	O	64-65
induced	O	65-72
hemorrhagic	B	73-84
cystitis	I	85-93
.	O	93-94

AIM	O	95-98
:	O	98-99
Hemorrhagic	B	100-111
cystitis	I	112-120
(	O	121-122
HC	B	122-124
)	O	124-125
is	O	126-128
a	O	129-130
limiting	O	131-139
side	O	140-144
-	O	144-145
effect	O	145-151
of	O	152-154
chemotherapy	O	155-167
with	O	168-172
ifosfamide	O	173-183
(	O	184-185
IFS	O	185-188
)	O	188-189
.	O	189-190

In	O	191-193
the	O	194-197
study	O	198-203
presented	O	204-213
here	O	214-218
,	O	218-219
we	O	220-222
investigated	O	223-235
the	O	236-239
use	O	240-243
of	O	244-246
dexamethasone	O	247-260
in	O	261-263
combination	O	264-275
with	O	276-280
mesna	O	281-286
for	O	287-290
the	O	291-294
prevention	O	295-305
of	O	306-308
IFS	O	309-312
-	O	312-313
induced	O	313-320
HC	B	321-323
.	O	323-324

METHODS	O	325-332
:	O	332-333
Male	O	334-338
Wistar	O	339-345
rats	O	346-350
(	O	351-352
150	O	352-355
-	O	355-356
200	O	356-359
g	O	360-361
;	O	361-362
6	O	363-364
rats	O	365-369
per	O	370-373
group	O	374-379
)	O	379-380
were	O	381-385
treated	O	386-393
with	O	394-398
saline	O	399-405
or	O	406-408
mesna	O	409-414
5	O	415-416
min	O	417-420
(	O	421-422
i	O	422-423
.	O	423-424
p	O	424-425
.	O	423-424
)	O	426-427
before	O	428-434
and	O	435-438
2	O	439-440
and	O	441-444
6	O	445-446
h	O	447-448
after	O	449-454
(	O	455-456
v	O	456-457
.	O	457-458
o	O	458-459
.	O	457-458
)	O	460-461
administration	O	462-476
of	O	477-479
IFS	O	480-483
.	O	483-484

One	O	485-488
,	O	488-489
two	O	490-493
or	O	494-496
three	O	497-502
doses	O	503-508
of	O	509-511
mesna	O	512-517
were	O	518-522
replaced	O	523-531
with	O	532-536
dexamethasone	O	537-550
alone	O	551-556
or	O	557-559
with	O	560-564
dexamethasone	O	565-578
plus	O	579-583
mesna	O	584-589
.	O	589-590

Cystitis	B	591-599
was	O	600-603
evaluated	O	604-613
24	O	614-616
h	O	617-618
after	O	619-624
its	O	625-628
induction	O	629-638
by	O	639-641
the	O	642-645
changes	O	646-653
in	O	654-656
bladder	O	657-664
wet	O	665-668
weight	O	669-675
and	O	676-679
by	O	680-682
macroscopic	O	683-694
and	O	695-698
microscopic	O	699-710
analysis	O	711-719
.	O	719-720

RESULTS	O	721-728
:	O	728-729
The	O	730-733
replacement	O	734-745
of	O	746-748
the	O	749-752
last	O	753-757
dose	O	758-762
or	O	763-765
the	O	766-769
last	O	770-774
two	O	775-778
doses	O	779-784
of	O	785-787
mesna	O	788-793
with	O	794-798
dexamethasone	O	799-812
reduced	O	813-820
the	O	821-824
increase	O	825-833
in	O	834-836
bladder	O	837-844
wet	O	845-848
weight	O	849-855
induced	O	856-863
by	O	864-866
IFS	O	867-870
by	O	871-873
84	O	874-876
.	O	876-877
79	O	877-879
%	O	879-880
and	O	881-884
89	O	885-887
.	O	887-888
13	O	888-890
%	O	890-891
,	O	891-892
respectively	O	893-905
.	O	905-906

In	O	907-909
addition	O	910-918
,	O	918-919
it	O	920-922
almost	O	923-929
abolished	O	930-939
the	O	940-943
macroscopic	O	944-955
and	O	956-959
microscopic	O	960-971
alterations	O	972-983
induced	O	984-991
by	O	992-994
IFS	O	995-998
.	O	998-999

Moreover	O	1000-1008
,	O	1008-1009
the	O	1010-1013
addition	O	1014-1022
of	O	1023-1025
dexamethasone	O	1026-1039
to	O	1040-1042
the	O	1043-1046
last	O	1047-1051
two	O	1052-1055
doses	O	1056-1061
of	O	1062-1064
mesna	O	1065-1070
was	O	1071-1074
more	O	1075-1079
efficient	O	1080-1089
than	O	1090-1094
three	O	1095-1100
doses	O	1101-1106
of	O	1107-1109
mesna	O	1110-1115
alone	O	1116-1121
when	O	1122-1126
evaluated	O	1127-1136
microscopically	O	1137-1152
.	O	1152-1153

CONCLUSION	O	1154-1164
:	O	1164-1165
Dexamethasone	O	1166-1179
in	O	1180-1182
combination	O	1183-1194
with	O	1195-1199
mesna	O	1200-1205
was	O	1206-1209
efficient	O	1210-1219
in	O	1220-1222
blocking	O	1223-1231
IFS	O	1232-1235
-	O	1235-1236
induced	O	1236-1243
HC	B	1244-1246
.	O	1246-1247

However	O	1248-1255
,	O	1255-1256
the	O	1257-1260
replacement	O	1261-1272
of	O	1273-1275
last	O	1276-1280
two	O	1281-1284
doses	O	1285-1290
of	O	1291-1293
mesna	O	1294-1299
with	O	1300-1304
saline	O	1305-1311
or	O	1312-1314
all	O	1315-1318
of	O	1319-1321
the	O	1322-1325
mesna	O	1326-1331
doses	O	1332-1337
with	O	1338-1342
dexamethasone	O	1343-1356
did	O	1357-1360
not	O	1361-1364
prevent	O	1365-1372
HC	B	1373-1375
.	O	1375-1376

Behavioral	O	0-10
effects	O	11-18
of	O	19-21
MK	O	22-24
-	O	24-25
801	O	25-28
on	O	29-31
reserpine	O	32-41
-	O	41-42
treated	O	42-49
mice	O	50-54
.	O	54-55

The	O	56-59
effects	O	60-67
of	O	68-70
dizocilpine	O	71-82
(	O	83-84
MK	O	84-86
-	O	86-87
801	O	87-90
)	O	90-91
,	O	91-92
a	O	93-94
noncompetitive	O	95-109
N	O	110-111
-	O	111-112
methyl	O	112-118
-	O	111-112
D	O	119-120
-	O	111-112
aspartate	O	121-130
(	O	131-132
NMDA	O	132-136
)	O	136-137
receptor	O	138-146
antagonist	O	147-157
,	O	157-158
were	O	159-163
studied	O	164-171
on	O	172-174
dopamine	O	175-183
-	O	183-184
related	O	184-191
behaviors	O	192-201
induced	O	202-209
by	O	210-212
reserpine	O	213-222
treatments	O	223-233
.	O	233-234

This	O	235-239
study	O	240-245
focuses	O	246-253
on	O	254-256
behavioral	O	257-267
syndromes	O	268-277
that	O	278-282
may	O	283-286
used	O	287-291
as	O	292-294
models	O	295-301
for	O	302-305
Parkinson	B	306-315
'	I	315-316
s	I	312-313
disease	I	318-325
,	O	325-326
or	O	327-329
tardive	B	330-337
dyskinesia	I	338-348
,	O	348-349
and	O	350-353
its	O	354-357
response	O	358-366
after	O	367-372
glutamatergic	O	373-386
blockage	O	387-395
.	O	395-396

Reserpine	O	397-406
(	O	407-408
1	O	408-409
mg	O	410-412
/	O	412-413
kg	O	413-415
)	O	415-416
,	O	416-417
administered	O	418-430
once	O	431-435
every	O	436-441
other	O	442-447
day	O	448-451
for	O	452-455
4	O	456-457
days	O	458-462
,	O	462-463
produced	O	464-472
increases	O	473-482
in	O	483-485
orofacial	B	486-495
dyskinesia	I	496-506
,	O	506-507
tongue	O	508-514
protrusion	O	515-525
and	O	526-529
vacuous	O	530-537
chewing	O	538-545
in	O	546-548
mice	O	549-553
,	O	553-554
which	O	555-560
are	O	561-564
signs	O	565-570
indicative	O	571-581
of	O	582-584
tardive	B	585-592
dyskinesia	I	593-603
.	O	603-604

Reserpine	O	605-614
also	O	615-619
produced	O	620-628
tremor	B	629-635
and	O	636-639
catalepsy	B	640-649
,	O	649-650
which	O	651-656
are	O	657-660
signs	O	661-666
suggestive	O	667-677
of	O	678-680
Parkinson	B	681-690
'	I	690-691
s	I	687-688
disease	I	693-700
.	O	700-701

MK	O	702-704
-	O	704-705
801	O	705-708
(	O	709-710
0	O	710-711
.	O	711-712
1	O	712-713
mg	O	714-716
/	O	716-717
kg	O	717-719
)	O	719-720
,	O	720-721
administered	O	722-734
30	O	735-737
min	O	738-741
before	O	742-748
the	O	749-752
observation	O	753-764
test	O	765-769
,	O	769-770
prevented	O	771-780
the	O	781-784
vacuous	O	785-792
chewing	O	793-800
movements	O	801-810
,	O	810-811
tongue	O	812-818
protrusions	O	819-830
and	O	831-834
catalepsy	B	835-844
induced	O	845-852
by	O	853-855
reserpine	O	856-865
.	O	865-866

However	O	867-874
,	O	874-875
MK	O	876-878
-	O	878-879
801	O	879-882
injection	O	883-892
produced	O	893-901
a	O	902-903
significant	O	904-915
increase	O	916-924
of	O	925-927
tremor	B	928-934
in	O	935-937
reserpine	O	938-947
-	O	947-948
treated	O	948-955
mice	O	956-960
.	O	960-961

Reserpine	O	962-971
(	O	972-973
1	O	973-974
mg	O	975-977
/	O	977-978
kg	O	978-980
)	O	980-981
,	O	981-982
administered	O	983-995
90	O	996-998
min	O	999-1002
before	O	1003-1009
the	O	1010-1013
test	O	1014-1018
and	O	1019-1022
followed	O	1023-1031
by	O	1032-1034
apomophine	O	1035-1045
injection	O	1046-1055
(	O	1056-1057
0	O	1057-1058
.	O	1058-1059
1	O	1059-1060
mg	O	1061-1063
/	O	1063-1064
kg	O	1064-1066
)	O	1066-1067
5	O	1068-1069
min	O	1070-1073
before	O	1074-1080
the	O	1081-1084
test	O	1085-1089
,	O	1089-1090
did	O	1091-1094
not	O	1095-1098
produce	O	1099-1106
oral	B	1107-1111
dyskinesia	I	1112-1122
in	O	1123-1125
mice	O	1126-1130
.	O	1130-1131

On	O	1132-1134
the	O	1135-1138
other	O	1139-1144
hand	O	1145-1149
,	O	1149-1150
reserpine	O	1151-1160
induced	O	1161-1168
increases	O	1169-1178
in	O	1179-1181
tremor	B	1182-1188
and	O	1189-1192
catalepsy	B	1193-1202
compared	O	1203-1211
to	O	1212-1214
control	O	1215-1222
mice	O	1223-1227
.	O	1227-1228

MK	O	1229-1231
-	O	1231-1232
801	O	1232-1235
(	O	1236-1237
0	O	1237-1238
.	O	1238-1239
1	O	1239-1240
mg	O	1241-1243
/	O	1243-1244
kg	O	1244-1246
)	O	1246-1247
administration	O	1248-1262
attenuated	O	1263-1273
the	O	1274-1277
catalepsy	B	1278-1287
and	O	1288-1291
tremor	B	1292-1298
induced	O	1299-1306
by	O	1307-1309
reserpine	O	1310-1319
.	O	1319-1320

Pretreatment	O	1321-1333
with	O	1334-1338
reserpine	O	1339-1348
(	O	1349-1350
1	O	1350-1351
mg	O	1352-1354
/	O	1354-1355
kg	O	1355-1357
)	O	1357-1358
24	O	1359-1361
h	O	1362-1363
before	O	1364-1370
the	O	1371-1374
observation	O	1375-1386
test	O	1387-1391
produced	O	1392-1400
increases	O	1401-1410
in	O	1411-1413
vacuous	O	1414-1421
chewing	O	1422-1429
movements	O	1430-1439
and	O	1440-1443
tongue	O	1444-1450
protrusion	O	1451-1461
,	O	1461-1462
as	O	1463-1465
well	O	1466-1470
as	O	1471-1473
increases	O	1474-1483
in	O	1484-1486
tremor	B	1487-1493
and	O	1494-1497
catalepsy	B	1498-1507
,	O	1507-1508
whereas	O	1509-1516
MK	O	1517-1519
-	O	1519-1520
801	O	1520-1523
(	O	1524-1525
0	O	1525-1526
.	O	1526-1527
1	O	1527-1528
mg	O	1529-1531
/	O	1531-1532
kg	O	1532-1534
)	O	1534-1535
injection	O	1536-1545
90	O	1546-1548
min	O	1549-1552
before	O	1553-1559
the	O	1560-1563
test	O	1564-1568
reversed	O	1569-1577
the	O	1578-1581
effects	O	1582-1589
of	O	1590-1592
reserpine	O	1593-1602
.	O	1602-1603

These	O	1604-1609
results	O	1610-1617
show	O	1618-1622
that	O	1623-1627
reserpine	O	1628-1637
produces	O	1638-1646
different	O	1647-1656
and	O	1657-1660
abnormal	B	1661-1669
movements	I	1670-1679
,	O	1679-1680
which	O	1681-1686
are	O	1687-1690
related	O	1691-1698
to	O	1699-1701
dose	O	1702-1706
and	O	1707-1710
schedule	O	1711-1719
employed	O	1720-1728
and	O	1729-1732
can	O	1733-1736
be	O	1737-1739
considered	O	1740-1750
as	O	1751-1753
parkinsonian	B	1754-1766
-	O	1766-1767
like	O	1767-1771
and	O	1772-1775
tardive	B	1776-1783
dsykinesia	I	1784-1794
signs	O	1795-1800
.	O	1800-1801

The	O	1802-1805
glutamatergic	O	1806-1819
blockage	O	1820-1828
produced	O	1829-1837
by	O	1838-1840
NMDA	O	1841-1845
can	O	1846-1849
restore	O	1850-1857
these	O	1858-1863
signs	O	1864-1869
,	O	1869-1870
such	O	1871-1875
as	O	1876-1878
vacuous	O	1879-1886
chewing	O	1887-1894
movements	O	1895-1904
,	O	1904-1905
tongue	O	1906-1912
protrusions	O	1913-1924
,	O	1924-1925
catalepsy	B	1926-1935
and	O	1936-1939
tremor	B	1940-1946
according	O	1947-1956
to	O	1957-1959
the	O	1960-1963
employed	O	1964-1972
model	O	1973-1978
.	O	1978-1979

Effect	O	0-6
of	O	7-9
glyceryl	O	10-18
trinitrate	O	19-29
on	O	30-32
the	O	33-36
sphincter	B	37-46
of	I	47-49
Oddi	I	50-54
spasm	I	55-60
evoked	O	61-67
by	O	68-70
prostigmine	O	71-82
-	O	82-83
morphine	O	83-91
administration	O	92-106
.	O	106-107

OBJECTIVE	O	108-117
:	O	117-118
In	O	119-121
this	O	122-126
study	O	127-132
the	O	133-136
effect	O	137-143
of	O	144-146
glyceryl	O	147-155
trinitrate	O	156-166
on	O	167-169
the	O	170-173
prostigmine	O	174-185
-	O	185-186
morphine	O	186-194
-	O	185-186
induced	O	195-202
sphincter	B	203-212
of	I	213-215
Oddi	I	216-220
spasm	I	221-226
was	O	227-230
evaluated	O	231-240
in	O	241-243
nine	O	244-248
female	O	249-255
patients	O	256-264
with	O	265-269
sphincter	B	270-279
of	I	280-282
Oddi	I	283-287
dyskinesia	I	288-298
.	O	298-299

METHOD	O	300-306
:	O	306-307
Sphincter	B	308-317
of	I	318-320
Oddi	I	321-325
spasm	I	326-331
was	O	332-335
induced	O	336-343
by	O	344-346
prostigmine	O	347-358
-	O	358-359
morphine	O	359-367
administration	O	368-382
(	O	383-384
0	O	384-385
.	O	385-386
5	O	386-387
mg	O	388-390
prostigmine	O	391-402
intramuscularly	O	403-418
and	O	419-422
10	O	423-425
mg	O	426-428
morphine	O	429-437
subcutaneously	O	438-452
)	O	452-453
and	O	454-457
visualized	O	458-468
by	O	469-471
quantitative	O	472-484
hepatobiliary	O	485-498
scintigraphy	O	499-511
.	O	511-512

The	O	513-516
entire	O	517-523
procedure	O	524-533
was	O	534-537
repeated	O	538-546
during	O	547-553
glyceryl	O	554-562
trinitrate	O	563-573
infusion	O	574-582
(	O	583-584
Nitrolingual	O	584-596
1	O	597-598
microg	O	599-605
/	O	605-606
kg	O	606-608
/	O	605-606
min	O	609-612
for	O	613-616
120	O	617-620
min	O	621-624
)	O	624-625
.	O	625-626

RESULTS	O	627-634
:	O	634-635
Prostigmine	O	636-647
-	O	647-648
morphine	O	648-656
provocation	O	657-668
caused	O	669-675
significant	O	676-687
increases	O	688-697
in	O	698-700
the	O	701-704
time	O	705-709
to	O	710-712
peak	O	713-717
activity	O	718-726
(	O	727-728
Tmax	O	728-732
)	O	732-733
over	O	734-738
the	O	739-742
hepatic	O	743-750
hilum	O	751-756
(	O	757-758
HH	O	758-760
:	O	760-761
34	O	762-764
.	O	764-765
33	O	765-767
+	O	768-769
/	O	769-770
-	O	770-771
5	O	772-773
.	O	773-774
05	O	774-776
vs	O	777-779
.	O	779-780
22	O	781-783
.	O	783-784
77	O	784-786
+	O	787-788
/	O	788-789
-	O	789-790
3	O	791-792
.	O	792-793
26	O	793-795
)	O	795-796
and	O	797-800
the	O	801-804
common	O	805-811
bile	O	812-816
duct	O	817-821
(	O	822-823
CBD	O	823-826
:	O	826-827
60	O	828-830
.	O	830-831
44	O	831-833
+	O	834-835
/	O	835-836
-	O	836-837
5	O	838-839
.	O	839-840
99	O	840-842
vs	O	843-845
.	O	845-846
40	O	847-849
.	O	849-850
0	O	848-849

+	O	852-853
/	O	853-854
-	O	854-855
2	O	856-857
.	O	857-858
88	O	858-860
)	O	860-861
and	O	862-865
in	O	866-868
the	O	869-872
half	O	873-877
-	O	877-878
time	O	878-882
of	O	883-885
excretion	O	886-895
(	O	896-897
T1	O	897-899
/	O	899-900
2	O	900-901
)	O	901-902
over	O	903-907
the	O	908-911
liver	O	912-917
parenchyma	O	918-928
(	O	929-930
LP	O	930-932
:	O	932-933
120	O	934-937
.	O	937-938
04	O	938-940
+	O	941-942
/	O	942-943
-	O	943-944
16	O	945-947
.	O	947-948
01	O	948-950
vs	O	951-953
.	O	953-954
27	O	955-957
.	O	957-958
37	O	958-960
+	O	961-962
/	O	962-963
-	O	963-964
2	O	965-966
.	O	966-967
19	O	967-969
)	O	969-970
,	O	970-971
HH	O	972-974
(	O	975-976
117	O	976-979
.	O	979-980
61	O	980-982
+	O	983-984
/	O	984-985
-	O	985-986
14	O	987-989
.	O	989-990
71	O	990-992
vs	O	993-995
.	O	995-996
31	O	997-999
.	O	999-1000
85	O	1000-1002

+	O	1003-1004
/	O	1004-1005
-	O	1005-1006
3	O	1007-1008
.	O	1008-1009
99	O	1009-1011
)	O	1011-1012
and	O	1013-1016
CBD	O	1017-1020
(	O	1021-1022
158	O	1022-1025
.	O	1025-1026
11	O	1026-1028

+	O	1029-1030
/	O	1030-1031
-	O	1031-1032
9	O	1033-1034
.	O	1034-1035
18	O	1035-1037
vs	O	1038-1040
.	O	1040-1041
40	O	1042-1044
.	O	1044-1045
1	O	1045-1046
+	O	1047-1048
/	O	1048-1049
-	O	1049-1050
6	O	1051-1052
.	O	1052-1053
24	O	1053-1055
)	O	1055-1056
,	O	1056-1057
indicating	O	1058-1068
a	O	1069-1070
complete	O	1071-1079
spasm	B	1080-1085
at	O	1086-1088
the	O	1089-1092
level	O	1093-1098
of	O	1099-1101
the	O	1102-1105
sphincter	O	1106-1115
of	O	1116-1118
Oddi	O	1119-1123
.	O	1123-1124

Glyceryl	O	1125-1133
trinitrate	O	1134-1144
infusion	O	1145-1153
completely	O	1154-1164
normalized	O	1165-1175
the	O	1176-1179
prostigmine	O	1180-1191
-	O	1191-1192
morphine	O	1192-1200
-	O	1191-1192
induced	O	1201-1208
alterations	O	1209-1220
in	O	1221-1223
these	O	1224-1229
quantitative	O	1230-1242
parameters	O	1243-1253
(	O	1254-1255
TmaX	O	1255-1259
over	O	1260-1264
the	O	1265-1268
LP	O	1269-1271
:	O	1271-1272
11	O	1273-1275
.	O	1275-1276
33	O	1276-1278
+	O	1279-1280
/	O	1280-1281
-	O	1281-1282
1	O	1283-1284
.	O	1284-1285
13	O	1285-1287
;	O	1287-1288
over	O	1289-1293
the	O	1294-1297
HH	O	1298-1300
:	O	1300-1301
18	O	1302-1304
.	O	1304-1305
88	O	1305-1307
+	O	1308-1309
/	O	1309-1310
-	O	1310-1311
1	O	1312-1313
.	O	1313-1314
48	O	1314-1316
;	O	1316-1317
and	O	1318-1321
over	O	1322-1326
the	O	1327-1330
CBD	O	1331-1334
:	O	1334-1335
36	O	1336-1338
.	O	1338-1339
22	O	1339-1341
+	O	1342-1343
/	O	1343-1344
-	O	1344-1345
1	O	1346-1347
.	O	1347-1348
92	O	1348-1350
;	O	1350-1351
and	O	1352-1355
T1	O	1356-1358
/	O	1358-1359
2	O	1359-1360
over	O	1361-1365
the	O	1366-1369
LP	O	1370-1372
:	O	1372-1373
28	O	1374-1376
.	O	1376-1377
21	O	1377-1379
+	O	1380-1381
/	O	1381-1382
-	O	1382-1383
1	O	1384-1385
.	O	1385-1386
83	O	1386-1388
;	O	1388-1389
over	O	1390-1394
the	O	1395-1398
HH	O	1399-1401
:	O	1401-1402
33	O	1403-1405
.	O	1405-1406
42	O	1406-1408
+	O	1409-1410
/	O	1410-1411
-	O	1411-1412
3	O	1413-1414
.	O	1414-1415
10	O	1415-1417
;	O	1417-1418
and	O	1419-1422
over	O	1423-1427
the	O	1428-1431
CBD	O	1432-1435
:	O	1435-1436
41	O	1437-1439
.	O	1439-1440
66	O	1440-1442
+	O	1443-1444
/	O	1444-1445
-	O	1445-1446
6	O	1447-1448
.	O	1448-1449
33	O	1449-1451
)	O	1451-1452
,	O	1452-1453
suggesting	O	1454-1464
an	O	1465-1467
effective	O	1468-1477
sphincter	O	1478-1487
-	O	1487-1488
relaxing	O	1488-1496
effect	O	1497-1503
of	O	1504-1506
glyceryl	O	1507-1515
trinitrate	O	1516-1526
.	O	1526-1527

CONCLUSION	O	1528-1538
:	O	1538-1539
These	O	1540-1545
results	O	1546-1553
provide	O	1554-1561
the	O	1562-1565
first	O	1566-1571
evidence	O	1572-1580
of	O	1581-1583
the	O	1584-1587
effectiveness	O	1588-1601
of	O	1602-1604
glyceryl	O	1605-1613
trinitrate	O	1614-1624
on	O	1625-1627
the	O	1628-1631
morphine	O	1632-1640
-	O	1640-1641
induced	O	1641-1648
sphincter	B	1649-1658
of	I	1659-1661
Oddi	I	1662-1666
spasm	I	1667-1672
in	O	1673-1675
humans	O	1676-1682
.	O	1682-1683

Since	O	1684-1689
glyceryl	O	1690-1698
trinitrate	O	1699-1709
is	O	1710-1712
able	O	1713-1717
to	O	1718-1720
overcome	O	1721-1729
even	O	1730-1734
the	O	1735-1738
drastic	O	1739-1746
effect	O	1747-1753
of	O	1754-1756
morphine	O	1757-1765
,	O	1765-1766
it	O	1767-1769
might	O	1770-1775
be	O	1776-1778
of	O	1779-1781
relevance	O	1782-1791
in	O	1792-1794
the	O	1795-1798
treatment	O	1799-1808
of	O	1809-1811
sphincter	B	1812-1821
of	I	1822-1824
Oddi	I	1825-1829
dyskinesia	I	1830-1840
.	O	1840-1841

Effects	O	0-7
of	O	8-10
acute	O	11-16
steroid	O	17-24
administration	O	25-39
on	O	40-42
ventilatory	O	43-54
and	O	55-58
peripheral	O	59-69
muscles	O	70-77
in	O	78-80
rats	O	81-85
.	O	85-86

Occasional	O	87-97
case	O	98-102
reports	O	103-110
have	O	111-115
shown	O	116-121
that	O	122-126
acute	O	127-132
myopathy	B	133-141
may	O	142-145
occur	O	146-151
in	O	152-154
patients	O	155-163
treated	O	164-171
with	O	172-176
massive	O	177-184
doses	O	185-190
of	O	191-193
corticosteroids	O	194-209
.	O	209-210

The	O	211-214
mechanism	O	215-224
of	O	225-227
this	O	228-232
myopathy	B	233-241
is	O	242-244
poorly	O	245-251
understood	O	252-262
.	O	262-263

Therefore	O	264-273
,	O	273-274
60	O	275-277
male	O	278-282
rats	O	283-287
were	O	288-292
randomly	O	293-301
assigned	O	302-310
to	O	311-313
receive	O	314-321
daily	O	322-327
injection	O	328-337
of	O	338-340
saline	O	341-347
(	O	348-349
C	O	349-350
)	O	350-351
,	O	351-352
methylprednisolone	O	353-371
(	O	372-373
M	O	373-374
)	O	374-375
,	O	375-376
or	O	377-379
triamcinolone	O	380-393
(	O	394-395
T	O	395-396
)	O	396-397
80	O	398-400
mg	O	401-403
/	O	403-404
kg	O	404-406
/	O	403-404
d	O	407-408
for	O	409-412
5	O	413-414
d	O	415-416
.	O	416-417

Nutritional	O	418-429
intake	O	430-436
,	O	436-437
measured	O	438-446
daily	O	447-452
in	O	453-455
15	O	456-458
animals	O	459-466
,	O	466-467
showed	O	468-474
a	O	475-476
significant	O	477-488
reduction	B	489-498
of	I	499-501
food	I	502-506
intake	I	507-513
in	O	514-516
the	O	517-520
steroid	O	521-528
-	O	528-529
treated	O	529-536
groups	O	537-543
(	O	544-545
-	O	545-546
50	O	546-548
and	O	549-552
-	O	553-554
79	O	554-556
%	O	556-557
in	O	558-560
M	O	561-562
and	O	563-566
T	O	567-568
,	O	568-569
respectively	O	570-582
)	O	582-583
.	O	583-584

This	O	585-589
was	O	590-593
associated	O	594-604
with	O	605-609
a	O	610-611
similar	O	612-619
loss	B	620-624
in	I	625-627
body	I	628-632
weight	I	633-639
.	O	639-640

In	O	641-643
the	O	644-647
45	O	648-650
remaining	O	651-660
animals	O	661-668
,	O	668-669
diaphragm	O	670-679
contractility	O	680-693
and	O	694-697
histopathologic	O	698-713
features	O	714-722
of	O	723-725
several	O	726-733
muscles	O	734-741
were	O	742-746
studied	O	747-754
.	O	754-755

Weights	O	756-763
of	O	764-766
respiratory	O	767-778
and	O	779-782
peripheral	O	783-793
muscles	O	794-801
were	O	802-806
similarly	O	807-816
decreased	O	817-826
after	O	827-832
steroid	O	833-840
treatment	O	841-850
.	O	850-851

Maximal	O	852-859
twitches	O	860-868
of	O	869-871
the	O	872-875
diaphragm	O	876-885
were	O	886-890
lower	O	891-896
in	O	897-899
the	O	900-903
C	O	904-905
group	O	906-911
(	O	912-913
653	O	913-916
+	O	917-918
/	O	918-919
-	O	919-920
174	O	921-924
g	O	925-926
/	O	926-927
cm	O	927-929
(	O	929-930
2	O	930-931
)	O	931-932
)	O	931-932
than	O	934-938
in	O	939-941
the	O	942-945
M	O	946-947
group	O	948-953
(	O	954-955
837	O	955-958
+	O	959-960
/	O	960-961
-	O	961-962
171	O	963-966
g	O	967-968
/	O	968-969
cm	O	969-971
(	O	971-972
2	O	972-973
)	O	973-974
;	O	974-975
p	O	976-977
<	O	978-979
0	O	980-981
.	O	981-982
05	O	982-984
)	O	984-985
and	O	986-989
the	O	990-993
T	O	994-995
group	O	996-1001
(	O	1002-1003
765	O	1003-1006
+	O	1007-1008
/	O	1008-1009
-	O	1009-1010
145	O	1011-1014
g	O	1015-1016
/	O	1016-1017
cm	O	1017-1019
(	O	1019-1020
2	O	1020-1021
)	O	1021-1022
,	O	1022-1023
NS	O	1024-1026
)	O	1026-1027
.	O	1027-1028

Half	O	1029-1033
-	O	1033-1034
relaxation	O	1034-1044
time	O	1045-1049
was	O	1050-1053
prolonged	O	1054-1063
in	O	1064-1066
both	O	1067-1071
steroid	O	1072-1079
groups	O	1080-1086
,	O	1086-1087
and	O	1088-1091
time	O	1092-1096
to	O	1097-1099
peak	O	1100-1104
tension	O	1105-1112
was	O	1113-1116
longer	O	1117-1123
with	O	1124-1128
M	O	1129-1130
,	O	1130-1131
whereas	O	1132-1139
tetanic	B	1140-1147
tensions	O	1148-1156
were	O	1157-1161
similar	O	1162-1169
.	O	1169-1170

Steroid	O	1171-1178
treatment	O	1179-1188
also	O	1189-1193
induced	O	1194-1201
a	O	1202-1203
leftward	O	1204-1212
shift	O	1213-1218
of	O	1219-1221
the	O	1222-1225
force	O	1226-1231
-	O	1231-1232
frequency	O	1232-1241
curve	O	1242-1247
at	O	1248-1250
25	O	1251-1253
and	O	1254-1257
50	O	1258-1260
Hz	O	1261-1263
when	O	1264-1268
compared	O	1269-1277
with	O	1278-1282
saline	O	1283-1289
treatment	O	1290-1299
(	O	1300-1301
p	O	1301-1302
<	O	1303-1304
0	O	1305-1306
.	O	1306-1307
05	O	1307-1309
)	O	1309-1310
.	O	1306-1307

ATPase	O	1312-1318
staining	O	1319-1327
of	O	1328-1330
the	O	1331-1334
diaphragm	O	1335-1344
,	O	1344-1345
scalenus	O	1346-1354
medius	O	1355-1361
,	O	1361-1362
and	O	1363-1366
gastrocnemius	O	1367-1380
showed	O	1381-1387
type	O	1388-1392
IIb	O	1393-1396
fiber	O	1397-1402
atrophy	B	1403-1410
in	O	1411-1413
the	O	1414-1417
steroid	O	1418-1425
groups	O	1426-1432
and	O	1433-1436
also	O	1437-1441
diaphragmatic	O	1442-1455
type	O	1456-1460
IIa	O	1461-1464
atrophy	B	1465-1472
with	O	1473-1477
T	O	1478-1479
,	O	1479-1480
whereas	O	1481-1488
histologic	O	1489-1499
examinations	O	1500-1512
revealed	O	1513-1521
a	O	1522-1523
normal	O	1524-1530
muscular	O	1531-1539
pattern	O	1540-1547
with	O	1548-1552
absence	O	1553-1560
of	O	1561-1563
necrosis	B	1564-1572
.	O	1572-1573

Finally	O	1574-1581
,	O	1581-1582
a	O	1583-1584
pair	O	1585-1589
-	O	1589-1590
fed	O	1590-1593
(	O	1594-1595
PF	O	1595-1597
)	O	1597-1598
study	O	1599-1604
,	O	1604-1605
performed	O	1606-1615
in	O	1616-1618
18	O	1619-1621
rats	O	1622-1626
(	O	1627-1628
C	O	1628-1629
,	O	1629-1630
T	O	1631-1632
,	O	1632-1633
and	O	1634-1637
PF	O	1638-1640
)	O	1640-1641
,	O	1641-1642
showed	O	1643-1649
that	O	1650-1654
muscle	B	1655-1661
atrophy	I	1662-1669
was	O	1670-1673
considerably	O	1674-1686
less	O	1687-1691
pronounced	O	1692-1702
in	O	1703-1705
PF	O	1706-1708
animals	O	1709-1716
than	O	1717-1721
in	O	1722-1724
T	O	1725-1726
-	O	1726-1727
treated	O	1727-1734
animals	O	1735-1742
.	O	1742-1743

We	O	1744-1746
conclude	O	1747-1755
that	O	1756-1760
(	O	1761-1762
1	O	1762-1763
)	O	1763-1764
short	O	1765-1770
-	O	1770-1771
term	O	1771-1775
treatment	O	1776-1785
with	O	1786-1790
massive	O	1791-1798
doses	O	1799-1804
of	O	1805-1807
steroids	O	1808-1816
induced	O	1817-1824
severe	O	1825-1831
respiratory	O	1832-1843
and	O	1844-1847
limb	O	1848-1852
muscle	O	1853-1859
wasting	O	1860-1867
;	O	1867-1868
(	O	1869-1870
2	O	1870-1871
)	O	1871-1872
both	O	1873-1877
types	O	1878-1883
of	O	1884-1886
steroids	O	1887-1895
induced	O	1896-1903
predominantly	O	1904-1917
type	O	1918-1922
IIb	O	1923-1926
atrophy	B	1927-1934
,	O	1934-1935
resulting	O	1936-1945
in	O	1946-1948
the	O	1949-1952
expected	O	1953-1961
alterations	O	1962-1973
in	O	1974-1976
diaphragm	O	1977-1986
contractile	O	1987-1998
properties	O	1999-2009
;	O	2009-2010
(	O	2011-2012
3	O	2012-2013
)	O	2013-2014
neither	O	2015-2022
steroid	O	2023-2030
caused	O	2031-2037
muscle	O	2038-2044
necrosis	B	2045-2053
;	O	2053-2054
(	O	2055-2056
4	O	2056-2057
)	O	2057-2058
type	O	2059-2063
IIb	O	2064-2067
atrophy	B	2068-2075
was	O	2076-2079
not	O	2080-2083
caused	O	2084-2090
by	O	2091-2093
acute	O	2094-2099
nutritional	O	2100-2111
deprivation	O	2112-2123
alone	O	2124-2129
.	O	2129-2130

Refractory	O	0-10
cardiogenic	B	11-22
shock	I	23-28
and	O	29-32
complete	O	33-41
heart	B	42-47
block	I	48-53
after	O	54-59
verapamil	O	60-69
SR	O	70-72
and	O	73-76
metoprolol	O	77-87
treatment	O	88-97
.	O	97-98

A	O	99-100
case	O	101-105
report	O	106-112
.	O	112-113

A	O	114-115
seventy	O	116-123
-	O	123-124
eight	O	124-129
-	O	123-124
year	O	130-134
-	O	123-124
old	O	135-138
woman	O	139-144
presented	O	145-154
with	O	155-159
complete	O	160-168
heart	B	169-174
block	I	175-180
and	O	181-184
refractory	O	185-195
hypotension	B	196-207
two	O	208-211
days	O	212-216
after	O	217-222
a	O	223-224
therapeutic	O	225-236
dose	O	237-241
of	O	242-244
sustained	O	245-254
-	O	254-255
release	O	255-262
verapamil	O	263-272
with	O	273-277
concomitant	O	278-289
use	O	290-293
of	O	294-296
metoprolol	O	297-307
.	O	307-308

The	O	309-312
patient	O	313-320
continued	O	321-330
to	O	331-333
remain	O	334-340
hypotensive	B	341-352
with	O	353-357
complete	O	358-366
heart	B	367-372
block	I	373-378
,	O	378-379
even	O	380-384
with	O	385-389
multiple	O	390-398
uses	O	399-403
of	O	404-406
intravenous	O	407-418
atropine	O	419-427
as	O	428-430
well	O	431-435
as	O	436-438
high	O	439-443
doses	O	444-449
of	O	450-452
pressor	O	453-460
agents	O	461-467
such	O	468-472
as	O	473-475
dopamine	O	476-484
and	O	485-488
dobutamine	O	489-499
.	O	499-500

However	O	501-508
,	O	508-509
shortly	O	510-517
after	O	518-523
the	O	524-527
use	O	528-531
of	O	532-534
intravenous	O	535-546
calcium	O	547-554
chloride	O	555-563
,	O	563-564
the	O	565-568
refractory	O	569-579
hypotension	B	580-591
and	O	592-595
complete	O	596-604
heart	B	605-610
block	I	611-616
resolved	O	617-625
.	O	625-626

A	O	0-1
phase	O	2-7
I	O	8-9
clinical	O	10-18
study	O	19-24
of	O	25-27
the	O	28-31
antipurine	O	32-42
antifolate	O	43-53
lometrexol	O	54-64
(	O	65-66
DDATHF	O	66-72
)	O	72-73
given	O	74-79
with	O	80-84
oral	O	85-89
folic	O	90-95
acid	O	96-100
.	O	100-101

Lometrexol	O	102-112
is	O	113-115
an	O	116-118
antifolate	O	119-129
which	O	130-135
inhibits	O	136-144
glycinamide	O	145-156
ribonucleotide	O	157-171
formyltransferase	O	172-189
(	O	190-191
GARFT	O	191-196
)	O	196-197
,	O	197-198
an	O	199-201
enzyme	O	202-208
essential	O	209-218
for	O	219-222
de	O	223-225
novo	O	226-230
purine	O	231-237
synthesis	O	238-247
.	O	247-248

Extensive	O	249-258
experimental	O	259-271
and	O	272-275
limited	O	276-283
clinical	O	284-292
data	O	293-297
have	O	298-302
shown	O	303-308
that	O	309-313
lometrexol	O	314-324
has	O	325-328
activity	O	329-337
against	O	338-345
tumours	B	346-353
which	O	354-359
are	O	360-363
refractory	O	364-374
to	O	375-377
other	O	378-383
drugs	O	384-389
,	O	389-390
notably	O	391-398
methotrexate	O	399-411
.	O	411-412

However	O	413-420
,	O	420-421
the	O	422-425
initial	O	426-433
clinical	O	434-442
development	O	443-454
of	O	455-457
lometrexol	O	458-468
was	O	469-472
curtailed	O	473-482
because	O	483-490
of	O	491-493
severe	O	494-500
and	O	501-504
cumulative	O	505-515
antiproliferative	O	516-533
toxicities	B	534-544
.	O	544-545

Preclinical	O	546-557
murine	O	558-564
studies	O	565-572
demonstrated	O	573-585
that	O	586-590
the	O	591-594
toxicity	B	595-603
of	O	604-606
lometrexol	O	607-617
can	O	618-621
be	O	622-624
prevented	O	625-634
by	O	635-637
low	O	638-641
dose	O	642-646
folic	O	647-652
acid	O	653-657
administration	O	658-672
,	O	672-673
i	O	674-675
.	O	675-676
e	O	676-677
.	O	675-676
for	O	679-682
7	O	683-684
days	O	685-689
prior	O	690-695
to	O	696-698
and	O	699-702
7	O	703-704
days	O	705-709
following	O	710-719
a	O	720-721
single	O	722-728
bolus	O	729-734
dose	O	735-739
.	O	739-740

This	O	741-745
observation	O	746-757
prompted	O	758-766
a	O	767-768
Phase	O	769-774
I	O	775-776
clinical	O	777-785
study	O	786-791
of	O	792-794
lometrexol	O	795-805
given	O	806-811
with	O	812-816
folic	O	817-822
acid	O	823-827
supplementation	O	828-843
which	O	844-849
has	O	850-853
confirmed	O	854-863
that	O	864-868
the	O	869-872
toxicity	B	873-881
of	O	882-884
lometrexol	O	885-895
can	O	896-899
be	O	900-902
markedly	O	903-911
reduced	O	912-919
by	O	920-922
folic	O	923-928
acid	O	929-933
supplementation	O	934-949
.	O	949-950

Thrombocytopenia	B	951-967
and	O	968-971
mucositis	B	972-981
were	O	982-986
the	O	987-990
major	O	991-996
toxicities	B	997-1007
.	O	1007-1008

There	O	1009-1014
was	O	1015-1018
no	O	1019-1021
clear	O	1022-1027
relationship	O	1028-1040
between	O	1041-1048
clinical	O	1049-1057
toxicity	B	1058-1066
and	O	1067-1070
the	O	1071-1074
extent	O	1075-1081
of	O	1082-1084
plasma	O	1085-1091
folate	O	1092-1098
elevation	O	1099-1108
.	O	1108-1109

Associated	O	1110-1120
studies	O	1121-1128
demonstrated	O	1129-1141
that	O	1142-1146
lometrexol	O	1147-1157
plasma	O	1158-1164
pharmacokinetics	O	1165-1181
were	O	1182-1186
not	O	1187-1190
altered	O	1191-1198
by	O	1199-1201
folic	O	1202-1207
acid	O	1208-1212
administration	O	1213-1227
indicating	O	1228-1238
that	O	1239-1243
supplementation	O	1244-1259
is	O	1260-1262
unlikely	O	1263-1271
to	O	1272-1274
reduce	O	1275-1281
toxicity	B	1282-1290
by	O	1291-1293
enhancing	O	1294-1303
lometrexol	O	1304-1314
plasma	O	1315-1321
clearance	O	1322-1331
.	O	1331-1332

The	O	1333-1336
work	O	1337-1341
described	O	1342-1351
in	O	1352-1354
this	O	1355-1359
report	O	1360-1366
has	O	1367-1370
identified	O	1371-1381
for	O	1382-1385
the	O	1386-1389
first	O	1390-1395
time	O	1396-1400
a	O	1401-1402
clinically	O	1403-1413
acceptable	O	1414-1424
schedule	O	1425-1433
for	O	1434-1437
the	O	1438-1441
administration	O	1442-1456
of	O	1457-1459
a	O	1460-1461
GARFT	O	1462-1467
inhibitor	O	1468-1477
.	O	1477-1478

This	O	1479-1483
information	O	1484-1495
will	O	1496-1500
facilitate	O	1501-1511
the	O	1512-1515
future	O	1516-1522
evaluation	O	1523-1533
of	O	1534-1536
this	O	1537-1541
class	O	1542-1547
of	O	1548-1550
compounds	O	1551-1560
in	O	1561-1563
cancer	B	1564-1570
therapy	O	1571-1578
.	O	1578-1579

Involvement	O	0-11
of	O	12-14
the	O	15-18
mu	O	19-21
-	O	21-22
opiate	O	22-28
receptor	O	29-37
in	O	38-40
peripheral	O	41-51
analgesia	B	52-61
.	O	61-62

The	O	63-66
intradermal	O	67-78
injection	O	79-88
of	O	89-91
mu	O	92-94
(	O	95-96
morphine	O	96-104
,	O	104-105
Tyr	O	106-109
-	O	109-110
D	O	110-111
-	O	109-110
Ala	O	112-115
-	O	109-110
Gly	O	116-119
-	O	109-110
NMe	O	120-123
-	O	109-110
Phe	O	124-127
-	O	109-110
Gly	O	116-119
-	O	109-110
ol	O	132-134
and	O	135-138
morphiceptin	O	139-151
)	O	151-152
,	O	152-153
kappa	O	154-159
(	O	160-161
trans	O	161-166
-	O	166-167
3	O	167-168
,	O	168-169
4	O	169-170
-	O	166-167
dichloro	O	171-179
-	O	166-167
N	O	180-181
-	O	166-167
methyl	O	182-188
-	O	166-167
N	O	180-181
[	O	190-191
2	O	191-192
-	O	166-167
(	O	160-161
1	O	194-195
-	O	166-167
pyrrolidinyl	O	196-208
)	O	208-209
cyclohexyl	O	210-220
]	O	220-221
benzeneactemide	O	221-236
)	O	236-237
and	O	238-241
delta	O	242-247
(	O	248-249
[	O	249-250
D	O	250-251
-	O	251-252
Pen2	O	252-256
.	O	256-257
5	O	257-258
]	O	258-259
-	O	251-252
enkephalin	O	260-270

and	O	271-274
[	O	275-276
D	O	276-277
-	O	277-278
Ser2	O	278-282
]	O	282-283
-	O	277-278
[	O	275-276
Leu	O	285-288
]	O	282-283
enkephalin	O	289-299
-	O	277-278
Thr	O	300-303
)	O	303-304
selective	O	305-314
opioid	O	315-321
-	O	321-322
agonists	O	322-330
,	O	330-331
by	O	332-334
themselves	O	335-345
,	O	345-346
did	O	347-350
not	O	351-354
significantly	O	355-368
affect	O	369-375
the	O	376-379
mechanical	O	380-390
nociceptive	O	391-402
threshold	O	403-412
in	O	413-415
the	O	416-419
hindpaw	O	420-427
of	O	428-430
the	O	431-434
rat	O	435-438
.	O	438-439

Intradermal	O	440-451
injection	O	452-461
of	O	462-464
mu	O	465-467
,	O	467-468
but	O	469-472
not	O	473-476
delta	O	477-482
or	O	483-485
kappa	O	486-491
opioid	O	492-498
-	O	498-499
agonists	O	499-507
,	O	507-508
however	O	509-516
,	O	516-517
produced	O	518-526
dose	O	527-531
-	O	531-532
dependent	O	532-541
inhibition	O	542-552
of	O	553-555
prostaglandin	O	556-569
E2	O	570-572
-	O	572-573
induced	O	573-580
hyperalgesia	B	581-593
.	O	593-594

The	O	595-598
analgesic	O	599-608
effect	O	609-615
of	O	616-618
the	O	619-622
mu	O	623-625
-	O	625-626
agonist	O	626-633
morphine	O	634-642
was	O	643-646
dose	O	647-651
-	O	651-652
dependently	O	652-663
antagonized	O	664-675
by	O	676-678
naloxone	O	679-687
and	O	688-691
prevented	O	692-701
by	O	702-704
co	O	705-707
-	O	707-708
injection	O	708-717
of	O	718-720
pertussis	O	721-730
toxin	O	731-736
.	O	736-737

Morphine	O	738-746
did	O	747-750
not	O	751-754
,	O	754-755
however	O	756-763
,	O	763-764
alter	O	765-770
the	O	771-774
hyperalgesia	B	775-787
induced	O	788-795
by	O	796-798
8	O	799-800
-	O	800-801
bromo	O	801-806
cyclic	O	807-813
adenosine	O	814-823
monophosphate	O	824-837
.	O	837-838

We	O	839-841
conclude	O	842-850
that	O	851-855
the	O	856-859
analgesic	O	860-869
action	O	870-876
of	O	877-879
opioids	O	880-887
on	O	888-890
the	O	891-894
peripheral	O	895-905
terminals	O	906-915
of	O	916-918
primary	O	919-926
afferents	O	927-936
is	O	937-939
via	O	940-943
a	O	944-945
binding	O	946-953
site	O	954-958
with	O	959-963
characteristics	O	964-979
of	O	980-982
the	O	983-986
mu	O	987-989
-	O	989-990
opioid	O	990-996
receptor	O	997-1005
and	O	1006-1009
that	O	1010-1014
this	O	1015-1019
action	O	1020-1026
is	O	1027-1029
mediated	O	1030-1038
by	O	1039-1041
inhibition	O	1042-1052
of	O	1053-1055
the	O	1056-1059
cyclic	O	1060-1066
adenosine	O	1067-1076
monophosphate	O	1077-1090
second	O	1091-1097
messenger	O	1098-1107
system	O	1108-1114
.	O	1114-1115

Adequate	O	0-8
timing	O	9-15
of	O	16-18
ribavirin	O	19-28
reduction	O	29-38
in	O	39-41
patients	O	42-50
with	O	51-55
hemolysis	B	56-65
during	O	66-72
combination	O	73-84
therapy	O	85-92
of	O	93-95
interferon	O	96-106
and	O	107-110
ribavirin	O	111-120
for	O	121-124
chronic	B	125-132
hepatitis	I	133-142
C	I	143-144
.	O	144-145
BACKGROUND	O	146-156
:	O	156-157
Hemolytic	B	158-167
anemia	I	168-174
is	O	175-177
one	O	178-181
of	O	182-184
the	O	185-188
major	O	189-194
adverse	O	195-202
events	O	203-209
of	O	210-212
the	O	213-216
combination	O	217-228
therapy	O	229-236
of	O	237-239
interferon	O	240-250
and	O	251-254
ribavirin	O	255-264
.	O	264-265

Because	O	266-273
of	O	274-276
ribavirin	O	277-286
-	O	286-287
related	O	287-294
hemolytic	B	295-304
anemia	I	305-311
,	O	311-312
dose	O	313-317
reduction	O	318-327
is	O	328-330
a	O	331-332
common	O	333-339
event	O	340-345
in	O	346-348
this	O	349-353
therapy	O	354-361
.	O	361-362

In	O	363-365
this	O	366-370
clinical	O	371-379
retrospective	O	380-393
cohort	O	394-400
study	O	401-406
we	O	407-409
have	O	410-414
examined	O	415-423
the	O	424-427
suitable	O	428-436
timing	O	437-443
of	O	444-446
ribavirin	O	447-456
reduction	O	457-466
in	O	467-469
patients	O	470-478
with	O	479-483
hemolysis	B	484-493
during	O	494-500
combination	O	501-512
therapy	O	513-520
.	O	520-521

METHODS	O	522-529
:	O	529-530
Thirty	O	531-537
-	O	537-538
seven	O	538-543
of	O	544-546
160	O	547-550
patients	O	551-559
who	O	560-563
had	O	564-567
HCV	O	568-571
-	O	571-572
genotype	O	572-580
1b	O	581-583
,	O	583-584
had	O	585-588
high	O	589-593
virus	O	594-599
load	O	600-604
,	O	604-605
and	O	606-609
received	O	610-618
24	O	619-621
-	O	621-622
week	O	622-626
combination	O	627-638
therapy	O	639-646
developed	O	647-656
anemia	B	657-663
with	O	664-668
hemoglobin	O	669-679
level	O	680-685
<	O	686-687
10	O	687-689
g	O	690-691
/	O	691-692
dl	O	692-694
or	O	695-697
anemia	B	698-704
-	O	704-705
related	O	705-712
signs	O	713-718
during	O	719-725
therapy	O	726-733
.	O	733-734

After	O	735-740
that	O	741-745
,	O	745-746
these	O	747-752
37	O	753-755
patients	O	756-764
were	O	765-769
reduced	O	770-777
one	O	778-781
tablet	O	782-788
of	O	789-791
ribavirin	O	792-801
(	O	802-803
200	O	803-806
mg	O	807-809
)	O	809-810
per	O	811-814
day	O	815-818
.	O	818-819

After	O	820-825
reduction	O	826-835
of	O	836-838
ribavirin	O	839-848
,	O	848-849
27	O	850-852
of	O	853-855
37	O	856-858
patients	O	859-867
could	O	868-873
continue	O	874-882
combination	O	883-894
therapy	O	895-902
for	O	903-906
a	O	907-908
total	O	909-914
of	O	915-917
24	O	918-920
weeks	O	921-926
(	O	927-928
group	O	928-933
A	O	934-935
)	O	935-936
.	O	936-937

However	O	938-945
,	O	945-946
10	O	947-949
of	O	950-952
37	O	953-955
patients	O	956-964
with	O	965-969
reduction	O	970-979
of	O	980-982
ribavirin	O	983-992
could	O	993-998
not	O	999-1002
continue	O	1003-1011
combination	O	1012-1023
therapy	O	1024-1031
because	O	1032-1039
their	O	1040-1045
<	O	1046-1047
8	O	1047-1048
.	O	1048-1049
5	O	1049-1050
g	O	1051-1052
/	O	1052-1053
dl	O	1053-1055
hemoglobin	O	1056-1066
values	O	1067-1073
decreased	O	1074-1083
to	O	1084-1086
or	O	1087-1089
anemia	B	1090-1096
-	O	1096-1097
related	O	1097-1104
severe	O	1105-1111
side	O	1112-1116
effects	O	1117-1124
occurred	O	1125-1133
(	O	1134-1135
group	O	1135-1140
B	O	1141-1142
)	O	1142-1143
.	O	1143-1144

We	O	1145-1147
assessed	O	1148-1156
the	O	1157-1160
final	O	1161-1166
efficacy	O	1167-1175
and	O	1176-1179
safety	O	1180-1186
after	O	1187-1192
reduction	O	1193-1202
of	O	1203-1205
ribavirin	O	1206-1215
in	O	1216-1218
groups	O	1219-1225
A	O	1226-1227
and	O	1228-1231
B	O	1232-1233
.	O	1233-1234
RESULTS	O	1235-1242
:	O	1242-1243
A	O	1244-1245
sustained	O	1246-1255
virological	O	1256-1267
response	O	1268-1276
(	O	1277-1278
SVR	O	1278-1281
)	O	1281-1282
was	O	1283-1286
29	O	1287-1289
.	O	1289-1290
6	O	1290-1291
%	O	1291-1292
(	O	1293-1294
8	O	1294-1295
/	O	1295-1296
27	O	1296-1298
)	O	1298-1299
in	O	1300-1302
group	O	1303-1308
A	O	1309-1310
and	O	1311-1314
10	O	1315-1317
%	O	1317-1318
(	O	1319-1320
1	O	1320-1321
/	O	1321-1322
10	O	1322-1324
)	O	1324-1325
in	O	1326-1328
group	O	1329-1334
B	O	1335-1336
,	O	1336-1337
respectively	O	1338-1350
.	O	1350-1351

A	O	1352-1353
34	O	1354-1356
.	O	1356-1357
4	O	1355-1356
%	O	1358-1359
(	O	1360-1361
12	O	1361-1363
/	O	1363-1364
27	O	1364-1366
)	O	1366-1367
of	O	1368-1370
SVR	O	1371-1374
+	O	1375-1376
biological	O	1377-1387
response	O	1388-1396
in	O	1397-1399
group	O	1400-1405
A	O	1406-1407
was	O	1408-1411
higher	O	1412-1418
than	O	1419-1423
10	O	1424-1426
%	O	1426-1427
(	O	1428-1429
1	O	1429-1430
/	O	1430-1431
10	O	1431-1433
)	O	1433-1434
in	O	1435-1437
group	O	1438-1443
B	O	1444-1445
(	O	1446-1447
P	O	1448-1449
=	O	1450-1451
0	O	1452-1453
.	O	1453-1454
051	O	1454-1457
)	O	1457-1458
,	O	1458-1459
with	O	1460-1464
slight	O	1465-1471
significance	O	1472-1484
.	O	1484-1485

With	O	1486-1490
respect	O	1491-1498
to	O	1499-1501
hemoglobin	O	1502-1512
level	O	1513-1518
at	O	1519-1521
the	O	1522-1525
time	O	1526-1530
of	O	1531-1533
ribavirin	O	1534-1543
reduction	O	1544-1553
,	O	1553-1554
a	O	1555-1556
rate	O	1557-1561
of	O	1562-1564
continuation	O	1565-1577
of	O	1578-1580
therapy	O	1581-1588
in	O	1589-1591
patients	O	1592-1600
with	O	1601-1605
>	O	1606-1607
or	O	1608-1610
=	O	1611-1612
10	O	1612-1614
g	O	1615-1616
/	O	1616-1617
dl	O	1617-1619
hemoglobin	O	1620-1630
was	O	1631-1634
higher	O	1635-1641
than	O	1642-1646
that	O	1647-1651
in	O	1652-1654
patients	O	1655-1663
with	O	1664-1668
<	O	1669-1670
10	O	1670-1672
g	O	1673-1674
/	O	1674-1675
dl	O	1675-1677
(	O	1678-1679
P	O	1680-1681
=	O	1682-1683
0	O	1684-1685
.	O	1685-1686
036	O	1686-1689
)	O	1689-1690
.	O	1685-1686

CONCLUSIONS	O	1692-1703
:	O	1703-1704
Reduction	O	1705-1714
of	O	1715-1717
ribavirin	O	1718-1727
at	O	1728-1730
hemoglobin	O	1731-1741
level	O	1742-1747
>	O	1748-1749
or	O	1750-1752
=	O	1753-1754
10	O	1754-1756
g	O	1757-1758
/	O	1758-1759
dl	O	1759-1761
is	O	1762-1764
suitable	O	1765-1773
in	O	1774-1776
terms	O	1777-1782
of	O	1783-1785
efficacy	O	1786-1794
and	O	1795-1798
side	O	1799-1803
effects	O	1804-1811
.	O	1811-1812

Increased	O	0-9
expression	O	10-20
and	O	21-24
apical	O	25-31
targeting	O	32-41
of	O	42-44
renal	O	45-50
ENaC	O	51-55
subunits	O	56-64
in	O	65-67
puromycin	O	68-77
aminonucleoside	O	78-93
-	O	93-94
induced	O	94-101
nephrotic	B	102-111
syndrome	I	112-120
in	O	121-123
rats	O	124-128
.	O	128-129

Nephrotic	B	130-139
syndrome	I	140-148
is	O	149-151
often	O	152-157
accompanied	O	158-169
by	O	170-172
sodium	O	173-179
retention	O	180-189
and	O	190-193
generalized	O	194-205
edema	B	206-211
.	O	211-212

However	O	213-220
,	O	220-221
the	O	222-225
molecular	O	226-235
basis	O	236-241
for	O	242-245
the	O	246-249
decreased	O	250-259
renal	O	260-265
sodium	O	266-272
excretion	O	273-282
remains	O	283-290
undefined	O	291-300
.	O	300-301

We	O	302-304
hypothesized	O	305-317
that	O	318-322
epithelial	O	323-333
Na	O	334-336
channel	O	337-344
(	O	345-346
ENaC	O	346-350
)	O	350-351
subunit	O	352-359
dysregulation	O	360-373
may	O	374-377
be	O	378-380
responsible	O	381-392
for	O	393-396
the	O	397-400
increased	O	401-410
sodium	O	411-417
retention	O	418-427
.	O	427-428

An	O	429-431
experimental	O	432-444
group	O	445-450
of	O	451-453
rats	O	454-458
was	O	459-462
treated	O	463-470
with	O	471-475
puromycin	O	476-485
aminonucleoside	O	486-501
(	O	502-503
PAN	O	503-506
;	O	506-507
180	O	508-511
mg	O	512-514
/	O	514-515
kg	O	515-517
iv	O	518-520
)	O	520-521
,	O	521-522
whereas	O	523-530
the	O	531-534
control	O	535-542
group	O	543-548
received	O	549-557
only	O	558-562
vehicle	O	563-570
.	O	570-571

After	O	572-577
7	O	578-579
days	O	580-584
,	O	584-585
PAN	O	586-589
treatment	O	590-599
induced	O	600-607
significant	O	608-619
proteinuria	B	620-631
,	O	631-632
hypoalbuminemia	B	633-648
,	O	648-649
decreased	O	650-659
urinary	O	660-667
sodium	O	668-674
excretion	O	675-684
,	O	684-685
and	O	686-689
extensive	O	690-699
ascites	B	700-707
.	O	707-708

The	O	709-712
protein	O	713-720
abundance	O	721-730
of	O	731-733
alpha	O	734-739
-	O	739-740
ENaC	O	740-744
and	O	745-748
beta	O	749-753
-	O	753-754
ENaC	O	754-758
was	O	759-762
increased	O	763-772
in	O	773-775
the	O	776-779
inner	O	780-785
stripe	O	786-792
of	O	793-795
the	O	796-799
outer	O	800-805
medulla	O	806-813
(	O	814-815
ISOM	O	815-819
)	O	819-820
and	O	821-824
in	O	825-827
the	O	828-831
inner	O	832-837
medulla	O	838-845
(	O	846-847
IM	O	847-849
)	O	849-850
but	O	851-854
was	O	855-858
not	O	859-862
altered	O	863-870
in	O	871-873
the	O	874-877
cortex	O	878-884
.	O	884-885

gamma	O	886-891
-	O	891-892
ENaC	O	892-896
abundance	O	897-906
was	O	907-910
increased	O	911-920
in	O	921-923
the	O	924-927
cortex	O	928-934
,	O	934-935
ISOM	O	936-940
,	O	940-941
and	O	942-945
IM	O	946-948
.	O	948-949

Immunoperoxidase	O	950-966
brightfield	O	967-978
-	O	978-979
and	O	980-983
laser	O	984-989
-	O	989-990
scanning	O	990-998
confocal	O	999-1007
fluorescence	O	1008-1020
microscopy	O	1021-1031
demonstrated	O	1032-1044
increased	O	1045-1054
targeting	O	1055-1064
of	O	1065-1067
alpha	O	1068-1073
-	O	1073-1074
ENaC	O	1074-1078
,	O	1078-1079
beta	O	1080-1084
-	O	1084-1085
ENaC	O	1085-1089
,	O	1089-1090
and	O	1091-1094
gamma	O	1095-1100
-	O	1100-1101
ENaC	O	1101-1105
subunits	O	1106-1114
to	O	1115-1117
the	O	1118-1121
apical	O	1122-1128
plasma	O	1129-1135
membrane	O	1136-1144
in	O	1145-1147
the	O	1148-1151
distal	O	1152-1158
convoluted	O	1159-1169
tubule	O	1170-1176
(	O	1177-1178
DCT2	O	1178-1182
)	O	1182-1183
,	O	1183-1184
connecting	O	1185-1195
tubule	O	1196-1202
,	O	1202-1203
and	O	1204-1207
cortical	O	1208-1216
and	O	1217-1220
medullary	O	1221-1230
collecting	O	1231-1241
duct	O	1242-1246
segments	O	1247-1255
.	O	1255-1256

Immunoelectron	O	1257-1271
microscopy	O	1272-1282
further	O	1283-1290
revealed	O	1291-1299
an	O	1300-1302
increased	O	1303-1312
labeling	O	1313-1321
of	O	1322-1324
alpha	O	1325-1330
-	O	1330-1331
ENaC	O	1331-1335
in	O	1336-1338
the	O	1339-1342
apical	O	1343-1349
plasma	O	1350-1356
membrane	O	1357-1365
of	O	1366-1368
cortical	O	1369-1377
collecting	O	1378-1388
duct	O	1389-1393
principal	O	1394-1403
cells	O	1404-1409
of	O	1410-1412
PAN	O	1413-1416
-	O	1416-1417
treated	O	1417-1424
rats	O	1425-1429
,	O	1429-1430
indicating	O	1431-1441
enhanced	O	1442-1450
apical	O	1451-1457
targeting	O	1458-1467
of	O	1468-1470
alpha	O	1471-1476
-	O	1476-1477
ENaC	O	1477-1481
subunits	O	1482-1490
.	O	1490-1491

In	O	1492-1494
contrast	O	1495-1503
,	O	1503-1504
the	O	1505-1508
protein	O	1509-1516
abundances	O	1517-1527
of	O	1528-1530
Na	O	1531-1533
(	O	1533-1534
+	O	1534-1535
)	O	1535-1536
/	O	1536-1537
H	O	1537-1538
(	O	1533-1534
+	O	1534-1535
)	O	1535-1536
exchanger	O	1542-1551
type	O	1552-1556
3	O	1557-1558
(	O	1559-1560
NHE3	O	1560-1564
)	O	1564-1565
,	O	1565-1566
Na	O	1567-1569
(	O	1569-1570
+	O	1570-1571
)	O	1571-1572
-	O	1572-1573
K	O	1573-1574
(	O	1569-1570
+	O	1570-1571
)	O	1571-1572
-	O	1572-1573
2Cl	O	1578-1581
(	O	1569-1570
-	O	1572-1573
)	O	1571-1572
cotransporter	O	1585-1598
(	O	1599-1600
BSC	O	1600-1603
-	O	1603-1604
1	O	1604-1605
)	O	1605-1606
,	O	1606-1607
and	O	1608-1611
thiazide	O	1612-1620
-	O	1620-1621
sensitive	O	1621-1630
Na	O	1631-1633
(	O	1633-1634
+	O	1634-1635
)	O	1635-1636
-	O	1636-1637
Cl	O	1637-1639
(	O	1633-1634
-	O	1636-1637
)	O	1635-1636
cotransporter	O	1643-1656
(	O	1657-1658
TSC	O	1658-1661
)	O	1661-1662
were	O	1663-1667
decreased	O	1668-1677
.	O	1677-1678

Moreover	O	1679-1687
,	O	1687-1688
the	O	1689-1692
abundance	O	1693-1702
of	O	1703-1705
the	O	1706-1709
alpha	O	1710-1715
(	O	1715-1716
1	O	1716-1717
)	O	1717-1718
-	O	1718-1719
subunit	O	1719-1726
of	O	1727-1729
the	O	1730-1733
Na	O	1734-1736
-	O	1736-1737
K	O	1737-1738
-	O	1736-1737
ATPase	O	1739-1745
was	O	1746-1749
decreased	O	1750-1759
in	O	1760-1762
the	O	1763-1766
cortex	O	1767-1773
and	O	1774-1777
ISOM	O	1778-1782
,	O	1782-1783
but	O	1784-1787
it	O	1788-1790
remained	O	1791-1799
unchanged	O	1800-1809
in	O	1810-1812
the	O	1813-1816
IM	O	1817-1819
.	O	1819-1820

In	O	1821-1823
conclusion	O	1824-1834
,	O	1834-1835
the	O	1836-1839
increased	O	1840-1849
or	O	1850-1852
sustained	O	1853-1862
expression	O	1863-1873
of	O	1874-1876
ENaC	O	1877-1881
subunits	O	1882-1890
combined	O	1891-1899
with	O	1900-1904
increased	O	1905-1914
apical	O	1915-1921
targeting	O	1922-1931
in	O	1932-1934
the	O	1935-1938
DCT2	O	1939-1943
,	O	1943-1944
connecting	O	1945-1955
tubule	O	1956-1962
,	O	1962-1963
and	O	1964-1967
collecting	O	1968-1978
duct	O	1979-1983
are	O	1984-1987
likely	O	1988-1994
to	O	1995-1997
play	O	1998-2002
a	O	2003-2004
role	O	2005-2009
in	O	2010-2012
the	O	2013-2016
sodium	O	2017-2023
retention	O	2024-2033
associated	O	2034-2044
with	O	2045-2049
PAN	O	2050-2053
-	O	2053-2054
induced	O	2054-2061
nephrotic	B	2062-2071
syndrome	I	2072-2080
.	O	2080-2081

The	O	2082-2085
decreased	O	2086-2095
abundance	O	2096-2105
of	O	2106-2108
NHE3	O	2109-2113
,	O	2113-2114
BSC	O	2115-2118
-	O	2118-2119
1	O	2119-2120
,	O	2120-2121
TSC	O	2122-2125
,	O	2125-2126
and	O	2127-2130
Na	O	2131-2133
-	O	2133-2134
K	O	2134-2135
-	O	2133-2134
ATPase	O	2136-2142
may	O	2143-2146
play	O	2147-2151
a	O	2152-2153
compensatory	O	2154-2166
role	O	2167-2171
to	O	2172-2174
promote	O	2175-2182
sodium	O	2183-2189
excretion	O	2190-2199
.	O	2199-2200

Does	O	0-4
hormone	O	5-12
therapy	O	13-20
for	O	21-24
the	O	25-28
treatment	O	29-38
of	O	39-41
breast	B	42-48
cancer	I	49-55
have	O	56-60
a	O	61-62
detrimental	B	63-74
effect	I	75-81
on	I	82-84
memory	I	85-91
and	I	92-95
cognition	I	96-105
?	O	105-106

A	O	107-108
pilot	O	109-114
study	O	115-120
.	O	120-121

This	O	122-126
pilot	O	127-132
study	O	133-138
examines	O	139-147
whether	O	148-155
hormone	O	156-163
therapy	O	164-171
for	O	172-175
breast	B	176-182
cancer	I	183-189
affects	O	190-197
cognition	O	198-207
.	O	207-208

Patients	O	209-217
participating	O	218-231
in	O	232-234
a	O	235-236
randomised	O	237-247
trial	O	248-253
of	O	254-256
anastrozole	O	257-268
,	O	268-269
tamoxifen	O	270-279
alone	O	280-285
or	O	286-288
combined	O	289-297
(	O	298-299
ATAC	O	299-303
)	O	303-304
(	O	305-306
n	O	306-307
=	O	307-308
94	O	308-310
)	O	310-311
and	O	312-315
a	O	316-317
group	O	318-323
of	O	324-326
women	O	327-332
without	O	333-340
breast	B	341-347
cancer	I	348-354
(	O	355-356
n	O	356-357
=	O	357-358
35	O	358-360
)	O	360-361
completed	O	362-371
a	O	372-373
battery	O	374-381
of	O	382-384
neuropsychological	O	385-403
measures	O	404-412
.	O	412-413

Compared	O	414-422
with	O	423-427
the	O	428-431
control	O	432-439
group	O	440-445
,	O	445-446
the	O	447-450
patients	O	451-459
were	O	460-464
impaired	O	465-473
on	O	474-476
a	O	477-478
processing	O	479-489
speed	O	490-495
task	O	496-500
(	O	501-502
p	O	502-503
=	O	503-504
0	O	504-505
.	O	505-506
032	O	506-509
)	O	509-510
and	O	511-514
on	O	515-517
a	O	518-519
measure	O	520-527
of	O	528-530
immediate	O	531-540
verbal	O	541-547
memory	O	548-554
(	O	555-556
p	O	556-557
=	O	557-558
0	O	558-559
.	O	559-560
026	O	560-563
)	O	563-564
after	O	565-570
controlling	O	571-582
for	O	583-586
the	O	587-590
use	O	591-594
of	O	595-597
hormone	O	598-605
replacement	O	606-617
therapy	O	618-625
in	O	626-628
both	O	629-633
groups	O	634-640
.	O	640-641

Patient	O	642-649
group	O	650-655
performance	O	656-667
was	O	668-671
not	O	672-675
significantly	O	676-689
related	O	690-697
to	O	698-700
length	O	701-707
of	O	708-710
treatment	O	711-720
or	O	721-723
measures	O	724-732
of	O	733-735
psychological	O	736-749
morbidity	O	750-759
.	O	759-760

The	O	761-764
results	O	765-772
showed	O	773-779
specific	O	780-788
impairments	O	789-800
in	O	801-803
processing	O	804-814
speed	O	815-820
and	O	821-824
verbal	O	825-831
memory	O	832-838
in	O	839-841
women	O	842-847
receiving	O	848-857
hormonal	O	858-866
therapy	O	867-874
for	O	875-878
the	O	879-882
treatment	O	883-892
of	O	893-895
breast	B	896-902
cancer	I	903-909
.	O	909-910

Verbal	O	911-917
memory	O	918-924
may	O	925-928
be	O	929-931
especially	O	932-942
sensitive	O	943-952
to	O	953-955
changes	O	956-963
in	O	964-966
oestrogen	O	967-976
levels	O	977-983
,	O	983-984
a	O	985-986
finding	O	987-994
commonly	O	995-1003
reported	O	1004-1012
in	O	1013-1015
studies	O	1016-1023
of	O	1024-1026
hormone	O	1027-1034
replacement	O	1035-1046
therapy	O	1047-1054
in	O	1055-1057
healthy	O	1058-1065
women	O	1066-1071
.	O	1071-1072

In	O	1073-1075
view	O	1076-1080
of	O	1081-1083
the	O	1084-1087
increased	O	1088-1097
use	O	1098-1101
of	O	1102-1104
hormone	O	1105-1112
therapies	O	1113-1122
in	O	1123-1125
an	O	1126-1128
adjuvant	O	1129-1137
and	O	1138-1141
preventative	O	1142-1154
setting	O	1155-1162
their	O	1163-1168
impact	O	1169-1175
on	O	1176-1178
cognitive	O	1179-1188
functioning	O	1189-1200
should	O	1201-1207
be	O	1208-1210
investigated	O	1211-1223
more	O	1224-1228
thoroughly	O	1229-1239
.	O	1239-1240

Association	O	0-11
of	O	12-14
nitric	O	15-21
oxide	O	22-27
production	O	28-38
and	O	39-42
apoptosis	O	43-52
in	O	53-55
a	O	56-57
model	O	58-63
of	O	64-66
experimental	O	67-79
nephropathy	B	80-91
.	O	91-92

BACKGROUND	O	93-103
:	O	103-104
In	O	105-107
recent	O	108-114
studies	O	115-122
increased	O	123-132
amounts	O	133-140
of	O	141-143
nitric	O	144-150
oxide	O	151-156
(	O	157-158
NO	O	158-160
)	O	160-161
and	O	162-165
apoptosis	O	166-175
have	O	176-180
been	O	181-185
implicated	O	186-196
in	O	197-199
various	O	200-207
pathological	O	208-220
conditions	O	221-231
in	O	232-234
the	O	235-238
kidney	O	239-245
.	O	245-246

We	O	247-249
have	O	250-254
studied	O	255-262
the	O	263-266
role	O	267-271
of	O	272-274
NO	O	275-277
and	O	278-281
its	O	282-285
association	O	286-297
with	O	298-302
apoptosis	O	303-312
in	O	313-315
an	O	316-318
experimental	O	319-331
model	O	332-337
of	O	338-340
nephrotic	B	341-350
syndrome	I	351-359
induced	O	360-367
by	O	368-370
a	O	371-372
single	O	373-379
injection	O	380-389
of	O	390-392
adriamycin	O	393-403
(	O	404-405
ADR	O	405-408
)	O	408-409
.	O	409-410

METHODS	O	411-418
:	O	418-419
The	O	420-423
alteration	O	424-434
in	O	435-437
the	O	438-441
NO	O	442-444
pathway	O	445-452
was	O	453-456
assessed	O	457-465
by	O	466-468
measuring	O	469-478
nitrite	O	479-486
levels	O	487-493
in	O	494-496
serum	O	497-502
/	O	502-503
urine	O	503-508
and	O	509-512
by	O	513-515
evaluating	O	516-526
the	O	527-530
changes	O	531-538
in	O	539-541
vascular	O	542-550
reactivity	O	551-561
of	O	562-564
the	O	565-568
isolated	O	569-577
perfused	O	578-586
rat	O	587-590
kidney	O	591-597
(	O	598-599
IPRK	O	599-603
)	O	603-604
system	O	605-611
.	O	611-612

Rats	O	613-617
were	O	618-622
stratified	O	623-633
into	O	634-638
control	O	639-646
groups	O	647-653
and	O	654-657
ADR	O	658-661
-	O	661-662
induced	O	662-669
nephropathy	B	670-681
groups	O	682-688
.	O	688-689

These	O	690-695
two	O	696-699
groups	O	700-706
were	O	707-711
then	O	712-716
divided	O	717-724
into	O	725-729
:	O	729-730
group	O	731-736
1	O	737-738
,	O	738-739
animals	O	740-747
receiving	O	748-757
saline	O	758-764
;	O	764-765
and	O	766-769
group	O	770-775
2	O	776-777
,	O	777-778
animals	O	779-786
receiving	O	787-796
aminoguanidine	O	797-811
(	O	812-813
AG	O	813-815
)	O	815-816
which	O	817-822
is	O	823-825
a	O	826-827
specific	O	828-836
inhibitor	O	837-846
of	O	847-849
inducible	O	850-859
-	O	859-860
NO	O	860-862
synthase	O	863-871
.	O	871-872

On	O	873-875
day	O	876-879
21	O	880-882
,	O	882-883
rats	O	884-888
were	O	889-893
sacrificed	O	894-904
after	O	905-910
obtaining	O	911-920
material	O	921-929
for	O	930-933
biochemical	O	934-945
analysis	O	946-954
.	O	954-955

RESULTS	O	956-963
:	O	963-964
Histopathological	O	965-982
examination	O	983-994
of	O	995-997
the	O	998-1001
kidneys	O	1002-1009
of	O	1010-1012
rats	O	1013-1017
treated	O	1018-1025
with	O	1026-1030
ADR	O	1031-1034
revealed	O	1035-1043
focal	O	1044-1049
areas	O	1050-1055
of	O	1056-1058
mesangial	B	1059-1068
proliferation	I	1069-1082
and	O	1083-1086
mild	O	1087-1091
tubulointerstitial	B	1092-1110
inflammation	I	1111-1123
.	O	1123-1124

They	O	1125-1129
also	O	1130-1134
had	O	1135-1138
significantly	O	1139-1152
higher	O	1153-1159
levels	O	1160-1166
of	O	1167-1169
proteinuria	B	1170-1181
compared	O	1182-1190
with	O	1191-1195
control	O	1196-1203
and	O	1204-1207
treatment	O	1208-1217
groups	O	1218-1224
(	O	1225-1226
P	O	1226-1227
<	O	1228-1229
0	O	1230-1231
.	O	1231-1232
05	O	1232-1234
)	O	1234-1235
.	O	1231-1232

Urine	O	1237-1242
nitrite	O	1243-1250
levels	O	1251-1257
were	O	1258-1262
significantly	O	1263-1276
increased	O	1277-1286
in	O	1287-1289
the	O	1290-1293
ADR	O	1294-1297
-	O	1297-1298
nephropathy	B	1298-1309
group	O	1310-1315
(	O	1316-1317
P	O	1317-1318
<	O	1319-1320
0	O	1321-1322
.	O	1322-1323
05	O	1323-1325
)	O	1325-1326
.	O	1322-1323

In	O	1328-1330
the	O	1331-1334
IPRK	O	1335-1339
phenylephrine	O	1340-1353
and	O	1354-1357
acetylcholine	O	1358-1371
related	O	1372-1379
responses	O	1380-1389
were	O	1390-1394
significantly	O	1395-1408
impaired	O	1409-1417
in	O	1418-1420
the	O	1421-1424
ADR	O	1425-1428
-	O	1428-1429
nephropathy	B	1429-1440
group	O	1441-1446
.	O	1446-1447

Apoptosis	O	1448-1457
was	O	1458-1461
not	O	1462-1465
detected	O	1466-1474
in	O	1475-1477
controls	O	1478-1486
.	O	1486-1487

However	O	1488-1495
,	O	1495-1496
in	O	1497-1499
the	O	1500-1503
ADR	O	1504-1507
-	O	1507-1508
nephropathy	B	1508-1519
group	O	1520-1525
,	O	1525-1526
numerous	O	1527-1535
apoptotic	O	1536-1545
cells	O	1546-1551
were	O	1552-1556
identified	O	1557-1567
in	O	1568-1570
the	O	1571-1574
tubulointerstitial	O	1575-1593
areas	O	1594-1599
.	O	1599-1600

Double	O	1601-1607
staining	O	1608-1616
revealed	O	1617-1625
numerous	O	1626-1634
interstitial	O	1635-1647
apoptotic	O	1648-1657
cells	O	1658-1663
to	O	1664-1666
stain	O	1667-1672
for	O	1673-1676
ED1	O	1677-1680
,	O	1680-1681
a	O	1682-1683
marker	O	1684-1690
for	O	1691-1694
monocytes	O	1695-1704
/	O	1704-1705
macrophages	O	1705-1716
.	O	1716-1717

Treatment	O	1718-1727
with	O	1728-1732
AG	O	1733-1735
prevented	O	1736-1745
the	O	1746-1749
impairment	O	1750-1760
of	O	1761-1763
renal	O	1764-1769
vascular	O	1770-1778
bed	O	1779-1782
responses	O	1783-1792
and	O	1793-1796
reduced	O	1797-1804
both	O	1805-1809
urine	O	1810-1815
nitrite	O	1816-1823
levels	O	1824-1830
and	O	1831-1834
apoptosis	O	1835-1844
to	O	1845-1847
control	O	1848-1855
levels	O	1856-1862
.	O	1862-1863

CONCLUSION	O	1864-1874
:	O	1874-1875
We	O	1876-1878
suggest	O	1879-1886
that	O	1887-1891
interactions	O	1892-1904
between	O	1905-1912
NO	O	1913-1915
and	O	1916-1919
apoptosis	O	1920-1929
are	O	1930-1933
important	O	1934-1943
in	O	1944-1946
the	O	1947-1950
pathogenesis	O	1951-1963
of	O	1964-1966
the	O	1967-1970
ADR	O	1971-1974
-	O	1974-1975
induced	O	1975-1982
nephrosis	B	1983-1992
.	O	1992-1993

The	O	0-3
attenuating	O	4-15
effect	O	16-22
of	O	23-25
carteolol	O	26-35
hydrochloride	O	36-49
,	O	49-50
a	O	51-52
beta	O	53-57
-	O	57-58
adrenoceptor	O	58-70
antagonist	O	71-81
,	O	81-82
on	O	83-85
neuroleptic	O	86-97
-	O	97-98
induced	O	98-105
catalepsy	B	106-115
in	O	116-118
rats	O	119-123
.	O	123-124

It	O	125-127
is	O	128-130
known	O	131-136
that	O	137-141
beta	O	142-146
-	O	146-147
adrenoceptor	O	147-159
antagonists	O	160-171
are	O	172-175
effective	O	176-185
in	O	186-188
the	O	189-192
treatment	O	193-202
of	O	203-205
akathisia	B	206-215
,	O	215-216
one	O	217-220
of	O	221-223
the	O	224-227
extrapyramidal	O	228-242
side	O	243-247
effects	O	248-255
that	O	256-260
occur	O	261-266
during	O	267-273
neuroleptic	O	274-285
treatment	O	286-295
.	O	295-296

Neuroleptic	O	297-308
-	O	308-309
induced	O	309-316
catalepsy	B	317-326
,	O	326-327
a	O	328-329
model	O	330-335
of	O	336-338
neuroleptic	O	339-350
-	O	350-351
induced	O	351-358
extrapyramidal	O	359-373
side	O	374-378
effects	O	379-386
,	O	386-387
was	O	388-391
considered	O	392-402
suitable	O	403-411
as	O	412-414
a	O	415-416
model	O	417-422
for	O	423-426
predicting	O	427-437
neuroleptic	O	438-449
-	O	449-450
induced	O	450-457
akathisia	B	458-467
in	O	468-470
humans	O	471-477
,	O	477-478
although	O	479-487
neuroleptic	O	488-499
-	O	499-500
induced	O	500-507
catalepsy	B	508-517
was	O	518-521
not	O	522-525
considered	O	526-536
a	O	537-538
specific	O	539-547
test	O	548-552
for	O	553-556
neuroleptic	O	557-568
-	O	568-569
induced	O	569-576
akathisia	B	577-586
.	O	586-587

Therefore	O	588-597
,	O	597-598
the	O	599-602
effects	O	603-610
of	O	611-613
carteolol	O	614-623
,	O	623-624
a	O	625-626
beta	O	627-631
-	O	631-632
adrenoceptor	O	632-644
antagonist	O	645-655
,	O	655-656
on	O	657-659
haloperidol	O	660-671
-	O	671-672
induced	O	672-679
catalepsy	B	680-689
in	O	690-692
rats	O	693-697
were	O	698-702
behaviorally	O	703-715
studied	O	716-723
and	O	724-727
compared	O	728-736
with	O	737-741
those	O	742-747
of	O	748-750
propranolol	O	751-762
and	O	763-766
biperiden	O	767-776
,	O	776-777
a	O	778-779
muscarinic	O	780-790
receptor	O	791-799
antagonist	O	800-810
.	O	810-811

Carteolol	O	812-821
,	O	821-822
as	O	823-825
well	O	826-830
as	O	831-833
propranolol	O	834-845
and	O	846-849
biperiden	O	850-859
,	O	859-860
inhibited	O	861-870
the	O	871-874
haloperidol	O	875-886
-	O	886-887
induced	O	887-894
catalepsy	B	895-904
.	O	904-905

The	O	906-909
inhibitory	O	910-920
effect	O	921-927
of	O	928-930
carteolol	O	931-940
was	O	941-944
almost	O	945-951
comparable	O	952-962
to	O	963-965
that	O	966-970
of	O	971-973
propranolol	O	974-985
,	O	985-986
but	O	987-990
was	O	991-994
weaker	O	995-1001
than	O	1002-1006
that	O	1007-1011
of	O	1012-1014
biperiden	O	1015-1024
.	O	1024-1025

Carteolol	O	1026-1035
did	O	1036-1039
not	O	1040-1043
evoke	O	1044-1049
postsynaptic	O	1050-1062
dopamine	O	1063-1071
receptor	O	1072-1080
-	O	1080-1081
stimulating	O	1081-1092
behavioral	O	1093-1103
signs	O	1104-1109
such	O	1110-1114
as	O	1115-1117
stereotypy	O	1118-1128
and	O	1129-1132
hyperlocomotion	B	1133-1148
in	O	1149-1151
rats	O	1152-1156
.	O	1156-1157

Carteolol	O	1158-1167
did	O	1168-1171
not	O	1172-1175
antagonize	O	1176-1186
the	O	1187-1190
inhibitory	O	1191-1201
effects	O	1202-1209
of	O	1210-1212
haloperidol	O	1213-1224
on	O	1225-1227
apomorphine	O	1228-1239
-	O	1239-1240
induced	O	1240-1247
stereotypy	O	1248-1258
and	O	1259-1262
locomotor	O	1263-1272
activity	O	1273-1281
in	O	1282-1284
rats	O	1285-1289
.	O	1289-1290

In	O	1291-1293
addition	O	1294-1302
,	O	1302-1303
carteolol	O	1304-1313
did	O	1314-1317
not	O	1318-1321
evoke	O	1322-1327
5	O	1328-1329
-	O	1329-1330
HT1A	O	1330-1334
receptor	O	1335-1343
-	O	1343-1344
stimulating	O	1344-1355
behavioral	O	1356-1366
signs	O	1367-1372
such	O	1373-1377
as	O	1378-1380
flat	O	1381-1385
body	O	1386-1390
posture	O	1391-1398
and	O	1399-1402
forepaw	O	1403-1410
treading	O	1411-1419
and	O	1420-1423
did	O	1424-1427
not	O	1428-1431
inhibit	O	1432-1439
5	O	1440-1441
-	O	1441-1442
hydroxytryptophan	O	1442-1459
-	O	1441-1442
induced	O	1460-1467
head	O	1468-1472
twitch	O	1473-1479
in	O	1480-1482
rats	O	1483-1487
.	O	1487-1488

Finally	O	1489-1496
,	O	1496-1497
carteolol	O	1498-1507
did	O	1508-1511
not	O	1512-1515
inhibit	O	1516-1523
physostigmine	O	1524-1537
-	O	1537-1538
induced	O	1538-1545
lethality	O	1546-1555
in	O	1556-1558
rats	O	1559-1563
.	O	1563-1564

These	O	1565-1570
results	O	1571-1578
strongly	O	1579-1587
suggest	O	1588-1595
that	O	1596-1600
carteolol	O	1601-1610
improves	O	1611-1619
haloperidol	O	1620-1631
-	O	1631-1632
induced	O	1632-1639
catalepsy	B	1640-1649
via	O	1650-1653
its	O	1654-1657
beta	O	1658-1662
-	O	1662-1663
adrenoceptor	O	1663-1675
antagonistic	O	1676-1688
activity	O	1689-1697
and	O	1698-1701
is	O	1702-1704
expected	O	1705-1713
to	O	1714-1716
be	O	1717-1719
effective	O	1720-1729
in	O	1730-1732
the	O	1733-1736
treatment	O	1737-1746
of	O	1747-1749
akathisia	B	1750-1759
without	O	1760-1767
attenuating	O	1768-1779
neuroleptic	O	1780-1791
-	O	1791-1792
induced	O	1792-1799
antipsychotic	O	1800-1813
effects	O	1814-1821
due	O	1822-1825
to	O	1826-1828
its	O	1829-1832
postsynaptic	O	1833-1845
dopamine	O	1846-1854
receptor	O	1855-1863
antagonistic	O	1864-1876
activity	O	1877-1885
.	O	1885-1886

Penicillamine	O	0-13
-	O	13-14
induced	O	14-21
rapidly	O	22-29
progressive	O	30-41
glomerulonephritis	B	42-60
in	O	61-63
a	O	64-65
patient	O	66-73
with	O	74-78
rheumatoid	B	79-89
arthritis	I	90-99
.	O	99-100

A	O	101-102
67	O	103-105
-	O	105-106
year	O	106-110
-	O	105-106
old	O	111-114
woman	O	115-120
with	O	121-125
rheumatoid	B	126-136
arthritis	I	137-146
presented	O	147-156
rapidly	O	157-164
progressive	O	165-176
glomerulonephritis	B	177-195
(	O	196-197
RPGN	B	197-201
)	O	201-202
after	O	203-208
5	O	209-210
months	O	211-217
of	O	218-220
D	O	221-222
-	O	222-223
penicillamine	O	223-236
(	O	237-238
250	O	238-241
mg	O	242-244
/	O	244-245
day	O	245-248
)	O	248-249
treatment	O	250-259
.	O	259-260

Light	O	261-266
microscopy	O	267-277
study	O	278-283
showed	O	284-290
severe	O	291-297
glomerulonephritis	B	298-316
with	O	317-321
crescent	O	322-330
formation	O	331-340
in	O	341-343
60	O	344-346
%	O	346-347
of	O	348-350
the	O	351-354
glomeruli	O	355-364
and	O	365-368
infiltration	O	369-381
of	O	382-384
inflammatory	O	385-397
cells	O	398-403
in	O	404-406
the	O	407-410
wall	O	411-415
of	O	416-418
an	O	419-421
arteriole	O	422-431
.	O	431-432

Immunofluorescence	O	433-451
revealed	O	452-460
scanty	O	461-467
granular	O	468-476
IgG	O	477-480
,	O	480-481
IgA	O	482-485
and	O	486-489
C3	O	490-492
deposits	O	493-501
along	O	502-507
the	O	508-511
capillary	O	512-521
walls	O	522-527
and	O	528-531
mesangium	O	532-541
.	O	541-542

The	O	543-546
patient	O	547-554
was	O	555-558
treated	O	559-566
with	O	567-571
steroid	O	572-579
pulse	O	580-585
,	O	585-586
plasmapheresis	O	587-601
,	O	601-602
cyclophosphamide	O	603-619
and	O	620-623
antiplatelet	O	624-636
agents	O	637-643
.	O	643-644

A	O	645-646
complete	O	647-655
recovery	O	656-664
of	O	665-667
renal	O	668-673
function	O	674-682
was	O	683-686
achieved	O	687-695
in	O	696-698
a	O	699-700
few	O	701-704
weeks	O	705-710
.	O	710-711

This	O	712-716
new	O	717-720
case	O	721-725
of	O	726-728
RPGN	B	729-733
in	O	734-736
the	O	737-740
course	O	741-747
of	O	748-750
D	O	751-752
-	O	752-753
penicillamine	O	753-766
treatment	O	767-776
emphasizes	O	777-787
the	O	788-791
need	O	792-796
for	O	797-800
frequent	O	801-809
monitoring	O	810-820
of	O	821-823
renal	O	824-829
function	O	830-838
and	O	839-842
evaluation	O	843-853
of	O	854-856
urinary	O	857-864
sediment	O	865-873
and	O	874-877
proteinuria	B	878-889
in	O	890-892
these	O	893-898
patients	O	899-907
.	O	907-908

The	O	909-912
prompt	O	913-919
discontinuation	O	920-935
of	O	936-938
D	O	939-940
-	O	940-941
penicillamine	O	941-954
and	O	955-958
vigorous	O	959-967
treatment	O	968-977
measures	O	978-986
could	O	987-992
allow	O	993-998
for	O	999-1002
a	O	1003-1004
good	O	1005-1009
prognosis	O	1010-1019
as	O	1020-1022
in	O	1023-1025
this	O	1026-1030
case	O	1031-1035
.	O	1035-1036

Nature	O	0-6
,	O	6-7
time	O	8-12
course	O	13-19
and	O	20-23
dose	O	24-28
dependence	O	29-39
of	O	40-42
zidovudine	O	43-53
-	O	53-54
related	O	54-61
side	O	62-66
effects	O	67-74
:	O	74-75
results	O	76-83
from	O	84-88
the	O	89-92
Multicenter	O	93-104
Canadian	O	105-113
Azidothymidine	O	114-128
Trial	O	129-134
.	O	134-135

To	O	136-138
characterize	O	139-151
the	O	152-155
nature	O	156-162
,	O	162-163
time	O	164-168
course	O	169-175
and	O	176-179
dose	O	180-184
dependency	O	185-195
of	O	196-198
zidovudine	O	199-209
-	O	209-210
related	O	210-217
side	O	218-222
effects	O	223-230
,	O	230-231
we	O	232-234
undertook	O	235-244
a	O	245-246
multicenter	O	247-258
,	O	258-259
prospective	O	260-271
,	O	271-272
dose	O	273-277
-	O	277-278
range	O	278-283
finding	O	284-291
study	O	292-297
.	O	297-298

Our	O	299-302
study	O	303-308
group	O	309-314
consisted	O	315-324
of	O	325-327
74	O	328-330
HIV	O	331-334
-	O	334-335
positive	O	335-343
homosexual	O	344-354
men	O	355-358
belonging	O	359-368
to	O	369-371
groups	O	372-378
II	O	379-381
B	O	382-383
,	O	383-384
III	O	385-388
and	O	389-392
IV	O	393-395
C2	O	396-398
from	O	399-403
the	O	404-407
Centers	O	408-415
for	O	416-419
Disease	O	420-427
Control	O	428-435
(	O	436-437
CDC	O	437-440
)	O	440-441
classification	O	442-456
of	O	457-459
HIV	B	460-463
disease	I	464-471
.	O	471-472

Following	O	473-482
a	O	483-484
3	O	485-486
-	O	486-487
week	O	487-491
observation	O	492-503
period	O	504-510
,	O	510-511
volunteers	O	512-522
were	O	523-527
treated	O	528-535
with	O	536-540
zidovudine	O	541-551
600	O	552-555
mg	O	556-558
/	O	558-559
day	O	559-562
for	O	563-566
18	O	567-569
weeks	O	570-575
,	O	575-576
900	O	577-580
mg	O	581-583
/	O	583-584
day	O	584-587
for	O	588-591
9	O	592-593
weeks	O	594-599
and	O	600-603
1200	O	604-608
mg	O	609-611
/	O	611-612
day	O	612-615
for	O	616-619
9	O	620-621
weeks	O	622-627
,	O	627-628
followed	O	629-637
by	O	638-640
a	O	641-642
washout	O	643-650
period	O	651-657
of	O	658-660
6	O	661-662
weeks	O	663-668
after	O	669-674
which	O	675-680
they	O	681-685
were	O	686-690
re	O	691-693
-	O	693-694
started	O	694-701
on	O	702-704
1200	O	705-709
mg	O	710-712
/	O	712-713
day	O	713-716
or	O	717-719
the	O	720-723
highest	O	724-731
tolerated	O	732-741
dose	O	742-746
at	O	747-749
8	O	750-751
-	O	751-752
hourly	O	752-758
intervals	O	759-768
.	O	768-769

Subjects	O	770-778
were	O	779-783
randomly	O	784-792
assigned	O	793-801
to	O	802-804
4	O	805-806
-	O	806-807
hourly	O	807-813
or	O	814-816
8	O	817-818
-	O	818-819
hourly	O	819-825
regimens	O	826-834
within	O	835-841
CDC	O	842-845
groups	O	846-852
while	O	853-858
taking	O	859-865
600	O	866-869
and	O	870-873
1200	O	874-878
mg	O	879-881
/	O	881-882
day	O	882-885
.	O	885-886

Clinical	O	887-895
and	O	896-899
laboratory	O	900-910
evaluations	O	911-922
were	O	923-927
performed	O	928-937
at	O	938-940
3	O	941-942
-	O	942-943
week	O	943-947
intervals	O	948-957
.	O	957-958

Symptomatic	O	959-970
adverse	O	971-978
effects	O	979-986
were	O	987-991
present	O	992-999
in	O	1000-1002
96	O	1003-1005
%	O	1005-1006
of	O	1007-1009
subjects	O	1010-1018
,	O	1018-1019
most	O	1020-1024
commonly	O	1025-1033
nausea	B	1034-1040
(	O	1041-1042
64	O	1042-1044
%	O	1044-1045
)	O	1045-1046
,	O	1046-1047
fatigue	B	1048-1055
(	O	1056-1057
55	O	1057-1059
%	O	1059-1060
)	O	1060-1061
and	O	1062-1065
headache	B	1066-1074
(	O	1075-1076
49	O	1076-1078
%	O	1078-1079
)	O	1079-1080
.	O	1080-1081

These	O	1082-1087
were	O	1088-1092
generally	O	1093-1102
self	O	1103-1107
-	O	1107-1108
limited	O	1108-1115
,	O	1115-1116
reappearing	O	1117-1128
briefly	O	1129-1136
at	O	1137-1139
each	O	1140-1144
dose	O	1145-1149
increment	O	1150-1159
.	O	1159-1160

A	O	1161-1162
decrease	O	1163-1171
in	O	1172-1174
hemoglobin	O	1175-1185
occurred	O	1186-1194
shortly	O	1195-1202
after	O	1203-1208
initiation	O	1209-1219
of	O	1220-1222
therapy	O	1223-1230
.	O	1230-1231

This	O	1232-1236
was	O	1237-1240
not	O	1241-1244
dose	O	1245-1249
dependent	O	1250-1259
and	O	1260-1263
reversed	O	1264-1272
rapidly	O	1273-1280
upon	O	1281-1285
discontinuation	O	1286-1301
of	O	1302-1304
treatment	O	1305-1314
.	O	1314-1315

A	O	1316-1317
red	O	1318-1321
blood	O	1322-1327
cell	O	1328-1332
count	O	1333-1338
decrease	O	1339-1347
,	O	1347-1348
a	O	1349-1350
mean	O	1351-1355
cell	O	1356-1360
volume	O	1361-1367
increase	O	1368-1376
and	O	1377-1380
a	O	1381-1382
granulocyte	O	1383-1394
count	O	1395-1400
decrease	O	1401-1409
developed	O	1410-1419
early	O	1420-1425
in	O	1426-1428
a	O	1429-1430
dose	O	1431-1435
-	O	1435-1436
independent	O	1436-1447
fashion	O	1448-1455
,	O	1455-1456
reverting	O	1457-1466
at	O	1467-1469
least	O	1470-1475
partially	O	1476-1485
during	O	1486-1492
the	O	1493-1496
washout	O	1497-1504
phase	O	1505-1510
.	O	1510-1511

The	O	1512-1515
decrease	O	1516-1524
in	O	1525-1527
reticulocyte	O	1528-1540
count	O	1541-1546
was	O	1547-1550
dose	O	1551-1555
related	O	1556-1563
between	O	1564-1571
600	O	1572-1575
and	O	1576-1579
900	O	1580-1583
mg	O	1584-1586
/	O	1586-1587
day	O	1587-1590
with	O	1591-1595
no	O	1596-1598
further	O	1599-1606
change	O	1607-1613
when	O	1614-1618
the	O	1619-1622
dose	O	1623-1627
was	O	1628-1631
escalated	O	1632-1641
to	O	1642-1644
1200	O	1645-1649
mg	O	1650-1652
/	O	1652-1653
day	O	1653-1656
.	O	1656-1657

Bone	O	1658-1662
marrow	O	1663-1669
changes	O	1670-1677
occurred	O	1678-1686
rapidly	O	1687-1694
as	O	1695-1697
demonstrated	O	1698-1710
by	O	1711-1713
megaloblastosis	B	1714-1729
in	O	1730-1732
95	O	1733-1735
%	O	1735-1736
of	O	1737-1739
65	O	1740-1742
specimens	O	1743-1752
at	O	1753-1755
week	O	1756-1760
18	O	1761-1763
.	O	1763-1764
(	O	1764-1765
ABSTRACT	O	1765-1773
TRUNCATED	O	1774-1783
AT	O	1784-1786
250	O	1787-1790
WORDS	O	1791-1796
)	O	1796-1797

Bilateral	B	0-9
optic	I	10-15
neuropathy	I	16-26
due	O	27-30
to	O	31-33
combined	O	34-42
ethambutol	O	43-53
and	O	54-57
isoniazid	O	58-67
treatment	O	68-77
.	O	77-78

The	O	79-82
case	O	83-87
of	O	88-90
a	O	91-92
40	O	93-95
-	O	95-96
year	O	96-100
-	O	95-96
old	O	101-104
patient	O	105-112
who	O	113-116
underwent	O	117-126
an	O	127-129
unsuccessful	O	130-142
cadaver	O	143-150
kidney	O	151-157
transplantation	O	158-173
and	O	174-177
was	O	178-181
treated	O	182-189
with	O	190-194
ethambutol	O	195-205
and	O	206-209
isoniazid	O	210-219
is	O	220-222
reported	O	223-231
.	O	231-232

A	O	233-234
bilateral	B	235-244
retrobulbar	I	245-256
neuropathy	I	257-267
with	O	268-272
an	O	273-275
unusual	O	276-283
central	O	284-291
bitemporal	O	292-302
hemianopic	O	303-313
scotoma	B	314-321
was	O	322-325
found	O	326-331
.	O	331-332

Ethambutol	O	333-343
was	O	344-347
stopped	O	348-355
and	O	356-359
only	O	360-364
small	O	365-370
improvement	O	371-382
of	O	383-385
the	O	386-389
visual	O	390-396
acuity	O	397-403
followed	O	404-412
.	O	412-413

Isoniazid	O	414-423
was	O	424-427
discontinued	O	428-440
later	O	441-446
,	O	446-447
followed	O	448-456
by	O	457-459
a	O	460-461
dramatic	O	462-470
improvement	O	471-482
in	O	483-485
the	O	486-489
visual	O	490-496
acuity	O	497-503
.	O	503-504

The	O	505-508
hazards	O	509-516
of	O	517-519
optic	O	520-525
nerve	O	526-531
toxicity	B	532-540
due	O	541-544
to	O	545-547
ethambutol	O	548-558
are	O	559-562
known	O	563-568
.	O	568-569

We	O	570-572
emphasize	O	573-582
the	O	583-586
potential	O	587-596
danger	O	597-603
in	O	604-606
the	O	607-610
use	O	611-614
of	O	615-617
ethambutol	O	618-628
and	O	629-632
isoniazid	O	633-642
.	O	642-643

Progestational	O	0-14
agents	O	15-21
and	O	22-25
blood	B	26-31
coagulation	I	32-43
.	O	43-44

VII	O	45-48
.	O	48-49

Thromboembolic	B	50-64
and	O	65-68
other	O	69-74
complications	O	75-88
of	O	89-91
oral	O	92-96
contraceptive	O	97-110
therapy	O	111-118
in	O	119-121
relationship	O	122-134
to	O	135-137
pretreatment	O	138-150
levels	O	151-157
of	O	158-160
blood	B	161-166
coagulation	I	167-178
factors	O	179-186
:	O	186-187
summary	O	188-195
report	O	196-202
of	O	203-205
a	O	206-207
ten	O	208-211
-	O	211-212
year	O	212-216
study	O	217-222
.	O	222-223

During	O	224-230
a	O	231-232
ten	O	233-236
-	O	236-237
year	O	237-241
period	O	242-248
,	O	248-249
348	O	250-253
women	O	254-259
were	O	260-264
studied	O	265-272
for	O	273-276
a	O	277-278
total	O	279-284
of	O	285-287
5	O	288-289
,	O	289-290
877	O	290-293
patient	O	294-301
months	O	302-308
in	O	309-311
four	O	312-316
separate	O	317-325
studies	O	326-333
relating	O	334-342
oral	O	343-347
contraceptives	O	348-362
to	O	363-365
changes	O	366-373
in	O	374-376
hematologic	O	377-388
parameters	O	389-399
.	O	399-400

Significant	O	401-412
increases	O	413-422
in	O	423-425
certain	O	426-433
factors	O	434-441
of	O	442-444
the	O	445-448
blood	B	449-454
coagulation	I	455-466
and	O	467-470
fibrinolysin	O	471-483
systems	O	484-491
(	O	492-493
factors	O	493-500
I	O	501-502
,	O	502-503
II	O	503-505
,	O	502-503
VII	O	506-509
,	O	502-503
VIII	O	510-514
,	O	502-503
IX	O	515-517
,	O	502-503
and	O	519-522
X	O	523-524
and	O	525-528
plasminogen	O	529-540
)	O	540-541
were	O	542-546
observed	O	547-555
in	O	556-558
the	O	559-562
treated	O	563-570
groups	O	571-577
.	O	577-578

Severe	O	579-585
complications	O	586-599
developed	O	600-609
in	O	610-612
four	O	613-617
patients	O	618-626
.	O	626-627

All	O	628-631
four	O	632-636
had	O	637-640
an	O	641-643
abnormal	O	644-652
blood	B	653-658
coagulation	I	659-670
profile	O	671-678
,	O	678-679
suggesting	O	680-690
"	O	691-692
hypercoagulability	B	692-710
"	O	691-692
before	O	712-718
initiation	O	719-729
of	O	730-732
therapy	O	733-740
.	O	740-741

Some	O	742-746
of	O	747-749
these	O	750-755
findings	O	756-764
represented	O	765-776
the	O	777-780
most	O	781-785
extreme	O	786-793
abnormalities	O	794-807
seen	O	808-812
in	O	813-815
the	O	816-819
entire	O	820-826
group	O	827-832
of	O	833-835
patients	O	836-844
;	O	844-845
some	O	846-850
increased	O	851-860
further	O	861-868
during	O	869-875
therapy	O	876-883
.	O	883-884

One	O	885-888
of	O	889-891
these	O	892-897
patients	O	898-906
developed	O	907-916
a	O	917-918
myocardial	B	919-929
infarction	I	930-940
before	O	941-947
receiving	O	948-957
any	O	958-961
medication	O	962-972
,	O	972-973
shortly	O	974-981
after	O	982-987
the	O	988-991
base	O	992-996
-	O	996-997
line	O	997-1001
values	O	1002-1008
were	O	1009-1013
obtained	O	1014-1022
.	O	1022-1023

One	O	1024-1027
patient	O	1028-1035
developed	O	1036-1045
retinopathy	B	1046-1057
19	O	1058-1060
months	O	1061-1067
after	O	1068-1073
she	O	1074-1077
began	O	1078-1083
therapy	O	1084-1091
,	O	1091-1092
and	O	1093-1096
another	O	1097-1104
developed	O	1105-1114
thrombophlebitis	B	1115-1131
after	O	1132-1137
27	O	1138-1140
months	O	1141-1147
of	O	1148-1150
therapy	O	1151-1158
.	O	1158-1159

The	O	1160-1163
fourth	O	1164-1170
patient	O	1171-1178
developed	O	1179-1188
thrombophlebitis	B	1189-1205
14	O	1206-1208
days	O	1209-1213
after	O	1214-1219
initiation	O	1220-1230
of	O	1231-1233
contraceptive	O	1234-1247
therapy	O	1248-1255
.	O	1255-1256

All	O	1257-1260
four	O	1261-1265
patients	O	1266-1274
were	O	1275-1279
of	O	1280-1282
the	O	1283-1286
A	O	1287-1288
or	O	1289-1291
AB	O	1292-1294
blood	O	1295-1300
group	O	1301-1306
.	O	1306-1307

Previous	O	1308-1316
studies	O	1317-1324
suggested	O	1325-1334
the	O	1335-1338
possiblility	O	1339-1351
of	O	1352-1354
increased	O	1355-1364
propensity	O	1365-1375
for	O	1376-1379
thromboembolic	B	1380-1394
episodes	I	1395-1403
in	O	1404-1406
patients	O	1407-1415
possessing	O	1416-1426
the	O	1427-1430
A	O	1431-1432
antigen	O	1433-1440
.	O	1440-1441

It	O	1442-1444
appears	O	1445-1452
from	O	1453-1457
these	O	1458-1463
data	O	1464-1468
that	O	1469-1473
hematologic	O	1474-1485
work	O	1486-1490
-	O	1490-1491
ups	O	1491-1494
may	O	1495-1498
be	O	1499-1501
useful	O	1502-1508
in	O	1509-1511
women	O	1512-1517
who	O	1518-1521
are	O	1522-1525
about	O	1526-1531
to	O	1532-1534
start	O	1535-1540
long	O	1541-1545
-	O	1545-1546
term	O	1546-1550
oral	O	1551-1555
contraceptive	O	1556-1569
therapy	O	1570-1577
.	O	1577-1578

Cardiac	B	0-7
arrest	I	8-14
in	O	15-17
a	O	18-19
child	O	20-25
with	O	26-30
cerebral	B	31-39
palsy	I	40-45
undergoing	O	46-56
sevoflurane	O	57-68
induction	O	69-78
of	O	79-81
anesthesia	O	82-92
after	O	93-98
preoperative	O	99-111
clonidine	O	112-121
.	O	121-122

Clonidine	O	123-132
is	O	133-135
a	O	136-137
frequently	O	138-148
administered	O	149-161
alpha2	O	162-168
-	O	168-169
adrenergic	O	169-179
agonist	O	180-187
which	O	188-193
can	O	194-197
decrease	O	198-206
heart	O	207-212
rate	O	213-217
and	O	218-221
blood	O	222-227
pressure	O	228-236
.	O	236-237

We	O	238-240
present	O	241-248
a	O	249-250
case	O	251-255
of	O	256-258
a	O	259-260
5	O	261-262
-	O	262-263
year	O	263-267
-	O	262-263
old	O	268-271
child	O	272-277
with	O	278-282
cerebral	B	283-291
palsy	I	292-297
and	O	298-301
seizure	B	302-309
disorder	I	310-318
,	O	318-319
receiving	O	320-329
clonidine	O	330-339
for	O	340-343
restlessness	B	344-356
,	O	356-357
who	O	358-361
presented	O	362-371
for	O	372-375
placement	O	376-385
of	O	386-388
a	O	389-390
baclofen	O	391-399
pump	O	400-404
.	O	404-405

Without	O	406-413
the	O	414-417
knowledge	O	418-427
of	O	428-430
the	O	431-434
medical	O	435-442
personnel	O	443-452
,	O	452-453
the	O	454-457
patient	O	458-465
'	O	465-466
s	O	466-467
mother	O	468-474
administered	O	475-487
three	O	488-493
doses	O	494-499
of	O	500-502
clonidine	O	503-512
during	O	513-519
the	O	520-523
evening	O	524-531
before	O	532-538
and	O	539-542
morning	O	543-550
of	O	551-553
surgery	O	554-561
to	O	562-564
reduce	O	565-571
anxiety	B	572-579
.	O	579-580

During	O	581-587
induction	O	588-597
of	O	598-600
anesthesia	O	601-611
,	O	611-612
the	O	613-616
patient	O	617-624
developed	O	625-634
bradycardia	B	635-646
and	O	647-650
hypotension	B	651-662
requiring	O	663-672
cardiac	O	673-680
resuscitation	O	681-694
.	O	694-695

There	O	696-701
are	O	702-705
no	O	706-708
previous	O	709-717
reports	O	718-725
of	O	726-728
clonidine	O	729-738
-	O	738-739
associated	O	739-749
cardiac	B	750-757
arrest	I	758-764
in	O	765-767
a	O	768-769
child	O	770-775
undergoing	O	776-786
induction	O	787-796
of	O	797-799
anesthesia	O	800-810
.	O	810-811

Effects	O	0-7
of	O	8-10
UMB24	O	11-16
and	O	17-20
(	O	21-22
+	O	22-23
/	O	23-24
-	O	24-25
)	O	25-26
-	O	24-25
SM	O	27-29
21	O	30-32
,	O	32-33
putative	O	34-42
sigma2	O	43-49
-	O	49-50
preferring	O	50-60
antagonists	O	61-72
,	O	72-73
on	O	74-76
behavioral	O	77-87
toxic	O	88-93
and	O	94-97
stimulant	O	98-107
effects	O	108-115
of	O	116-118
cocaine	O	119-126
in	O	127-129
mice	O	130-134
.	O	134-135

Earlier	O	136-143
studies	O	144-151
have	O	152-156
demonstrated	O	157-169
that	O	170-174
antagonism	O	175-185
of	O	186-188
sigma1	O	189-195
receptors	O	196-205
attenuates	O	206-216
the	O	217-220
convulsive	B	221-231
,	O	231-232
lethal	O	233-239
,	O	239-240
locomotor	O	241-250
stimulatory	O	251-262
and	O	263-266
rewarding	O	267-276
actions	O	277-284
of	O	285-287
cocaine	O	288-295
in	O	296-298
mice	O	299-303
.	O	303-304

In	O	305-307
contrast	O	308-316
,	O	316-317
the	O	318-321
contribution	O	322-334
of	O	335-337
sigma2	O	338-344
receptors	O	345-354
is	O	355-357
unclear	O	358-365
because	O	366-373
experimental	O	374-386
tools	O	387-392
to	O	393-395
selectively	O	396-407
target	O	408-414
this	O	415-419
subtype	O	420-427
are	O	428-431
unavailable	O	432-443
.	O	443-444

To	O	445-447
begin	O	448-453
addressing	O	454-464
this	O	465-469
need	O	470-474
,	O	474-475
we	O	476-478
characterized	O	479-492
UMB24	O	493-498
(	O	499-500
1	O	500-501
-	O	501-502
(	O	499-500
2	O	503-504
-	O	501-502
phenethyl	O	505-514
)	O	514-515
-	O	501-502
4	O	516-517
-	O	501-502
(	O	499-500
2	O	503-504
-	O	501-502
pyridyl	O	521-528
)	O	514-515
-	O	501-502
piperazine	O	530-540
)	O	514-515
and	O	542-545
(	O	546-547
+	O	547-548
/	O	548-549
-	O	549-550
)	O	550-551
-	O	549-550
SM	O	552-554
21	O	555-557
(	O	558-559
3alpha	O	559-565
-	O	565-566
tropanyl	O	566-574
-	O	565-566
2	O	575-576
-	O	565-566
(	O	558-559
4	O	578-579
-	O	565-566
chorophenoxy	O	580-592
)	O	592-593
butyrate	O	593-601
)	O	592-593
in	O	603-605
receptor	O	606-614
binding	O	615-622
and	O	623-626
behavioral	O	627-637
studies	O	638-645
.	O	645-646

Receptor	O	647-655
binding	O	656-663
studies	O	664-671
confirmed	O	672-681
that	O	682-686
UMB24	O	687-692
and	O	693-696
(	O	697-698
+	O	698-699
/	O	699-700
-	O	700-701
)	O	701-702
-	O	700-701
SM	O	703-705
21	O	706-708
display	O	709-716
preferential	O	717-729
affinity	O	730-738
for	O	739-742
sigma2	O	743-749
over	O	750-754
sigma1	O	755-761
receptors	O	762-771
.	O	771-772

In	O	773-775
behavioral	O	776-786
studies	O	787-794
,	O	794-795
pretreatment	O	796-808
of	O	809-811
Swiss	O	812-817
Webster	O	818-825
mice	O	826-830
with	O	831-835
UMB24	O	836-841
or	O	842-844
(	O	845-846
+	O	846-847
/	O	847-848
-	O	848-849
)	O	849-850
-	O	848-849
SM	O	851-853
21	O	854-856
significantly	O	857-870
attenuated	O	871-881
cocaine	O	882-889
-	O	889-890
induced	O	890-897
convulsions	B	898-909
and	O	910-913
locomotor	O	914-923
activity	O	924-932
,	O	932-933
but	O	934-937
not	O	938-941
lethality	O	942-951
.	O	951-952

When	O	953-957
administered	O	958-970
alone	O	971-976
,	O	976-977
(	O	978-979
+	O	979-980
/	O	980-981
-	O	981-982
)	O	982-983
-	O	981-982
SM	O	984-986
21	O	987-989
produced	O	990-998
no	O	999-1001
significant	O	1002-1013
effects	O	1014-1021
compared	O	1022-1030
to	O	1031-1033
control	O	1034-1041
injections	O	1042-1052
of	O	1053-1055
saline	O	1056-1062
,	O	1062-1063
but	O	1064-1067
UMB24	O	1068-1073
had	O	1074-1077
locomotor	O	1078-1087
depressant	O	1088-1098
actions	O	1099-1106
.	O	1106-1107

Together	O	1108-1116
,	O	1116-1117
the	O	1118-1121
data	O	1122-1126
suggest	O	1127-1134
that	O	1135-1139
sigma2	O	1140-1146
receptor	O	1147-1155
antagonists	O	1156-1167
have	O	1168-1172
the	O	1173-1176
potential	O	1177-1186
to	O	1187-1189
attenuate	O	1190-1199
some	O	1200-1204
of	O	1205-1207
the	O	1208-1211
behavioral	O	1212-1222
effects	O	1223-1230
of	O	1231-1233
cocaine	O	1234-1241
,	O	1241-1242
and	O	1243-1246
further	O	1247-1254
development	O	1255-1266
of	O	1267-1269
more	O	1270-1274
selective	O	1275-1284
,	O	1284-1285
high	O	1286-1290
affinity	O	1291-1299
ligands	O	1300-1307
are	O	1308-1311
warranted	O	1312-1321
.	O	1321-1322

Methimazole	O	0-11
-	O	11-12
induced	O	12-19
cholestatic	B	20-31
jaundice	I	32-40
.	O	40-41

Methimazole	O	42-53
is	O	54-56
a	O	57-58
widely	O	59-65
used	O	66-70
and	O	71-74
generally	O	75-84
well	O	85-89
-	O	89-90
tolerated	O	90-99
antithyroid	O	100-111
agent	O	112-117
.	O	117-118

A	O	119-120
43	O	121-123
-	O	123-124
year	O	124-128
-	O	123-124
old	O	129-132
woman	O	133-138
had	O	139-142
severe	O	143-149
jaundice	B	150-158
and	O	159-162
itching	B	163-170
1	O	171-172
month	O	173-178
after	O	179-184
receiving	O	185-194
methimazole	O	195-206
(	O	207-208
10	O	208-210
mg	O	211-213
tid	O	214-217
)	O	217-218
and	O	219-222
propranolol	O	223-234
(	O	235-236
20	O	236-238
mg	O	239-241
tid	O	242-245
)	O	245-246
for	O	247-250
treatment	O	251-260
of	O	261-263
hyperthyroidism	B	264-279
.	O	279-280

The	O	281-284
patient	O	285-292
continued	O	293-302
treatment	O	303-312
for	O	313-316
another	O	317-324
4	O	325-326
days	O	327-331
after	O	332-337
the	O	338-341
appearance	O	342-352
of	O	353-355
jaundice	B	356-364
until	O	365-370
she	O	371-374
finished	O	375-383
both	O	384-388
medications	O	389-400
.	O	400-401

When	O	402-406
seen	O	407-411
at	O	412-414
the	O	415-418
emergency	O	419-428
department	O	429-439
2	O	440-441
weeks	O	442-447
later	O	448-453
,	O	453-454
she	O	455-458
still	O	459-464
had	O	465-468
severe	O	469-475
icterus	B	476-483
,	O	483-484
pruritus	B	485-493
,	O	493-494
and	O	495-498
hyperbilirubinemia	B	499-517
,	O	517-518
formed	O	519-525
mainly	O	526-532
of	O	533-535
the	O	536-539
conjugated	O	540-550
fraction	O	551-559
.	O	559-560

Methimazole	O	561-572
-	O	572-573
induced	O	573-580
cholestasis	B	581-592
was	O	593-596
diagnosed	O	597-606
,	O	606-607
and	O	608-611
propranolol	O	612-623
therapy	O	624-631
was	O	632-635
resumed	O	636-643
.	O	643-644

Over	O	645-649
the	O	650-653
following	O	654-663
9	O	664-665
days	O	666-670
,	O	670-671
the	O	672-675
symptoms	O	676-684
improved	O	685-693
and	O	694-697
plasma	O	698-704
bilirubin	O	705-714
levels	O	715-721
were	O	722-726
normal	O	727-733
after	O	734-739
12	O	740-742
weeks	O	743-748
without	O	749-756
methimazole	O	757-768
.	O	768-769

In	O	770-772
rare	O	773-777
cases	O	778-783
within	O	784-790
the	O	791-794
first	O	795-800
few	O	801-804
weeks	O	805-810
of	O	811-813
therapy	O	814-821
,	O	821-822
this	O	823-827
drug	O	828-832
can	O	833-836
cause	O	837-842
severe	O	843-849
and	O	850-853
reversible	O	854-864
cholestatic	B	865-876
jaundice	I	877-885
.	O	885-886

Physicians	O	887-897
and	O	898-901
patients	O	902-910
should	O	911-917
be	O	918-920
aware	O	921-926
of	O	927-929
this	O	930-934
adverse	O	935-942
effect	O	943-949
so	O	950-952
that	O	953-957
,	O	957-958
upon	O	959-963
occurrence	O	964-974
,	O	974-975
they	O	976-980
can	O	981-984
discontinue	O	985-996
methimazole	O	997-1008
therapy	O	1009-1016
and	O	1017-1020
avoid	O	1021-1026
unnecessary	O	1027-1038
invasive	O	1039-1047
procedures	O	1048-1058
.	O	1058-1059

Ciprofloxacin	O	0-13
-	O	13-14
induced	O	14-21
acute	O	22-27
interstitial	B	28-40
nephritis	I	41-50
and	O	51-54
autoimmune	B	55-65
hemolytic	I	66-75
anemia	I	76-82
.	O	82-83

Ciprofloxacin	O	84-97
has	O	98-101
been	O	102-106
associated	O	107-117
with	O	118-122
several	O	123-130
side	O	131-135
effects	O	136-143
including	O	144-153
interstitial	B	154-166
nephritis	I	167-176
and	O	177-180
hemolytic	B	181-190
anemia	I	191-197
.	O	197-198

The	O	199-202
combination	O	203-214
of	O	215-217
both	O	218-222
side	O	223-227
effects	O	228-235
is	O	236-238
extremely	O	239-248
rare	O	249-253
.	O	253-254

In	O	255-257
this	O	258-262
report	O	263-269
,	O	269-270
we	O	271-273
describe	O	274-282
a	O	283-284
case	O	285-289
of	O	290-292
ciprofloxacin	O	293-306
-	O	306-307
induced	O	307-314
interstitial	B	315-327
nephritis	I	328-337
and	O	338-341
autoimmune	B	342-352
hemolytic	I	353-362
anemia	I	363-369
.	O	369-370

Hemolytic	B	371-380
anemia	I	381-387
improved	O	388-396
after	O	397-402
stopping	O	403-411
the	O	412-415
drug	O	416-420
and	O	421-424
initiation	O	425-435
of	O	436-438
steroid	O	439-446
therapy	O	447-454
.	O	454-455

Unfortunately	O	456-469
,	O	469-470
acute	O	471-476
interstitial	B	477-489
nephritis	I	490-499
was	O	500-503
irreversible	O	504-516
and	O	517-520
the	O	521-524
patient	O	525-532
developed	O	533-542
end	B	543-546
-	I	546-547
stage	I	547-552
renal	I	553-558
disease	I	559-566
.	O	566-567

Contribution	O	0-12
of	O	13-15
sodium	O	16-22
valproate	O	23-32
to	O	33-35
the	O	36-39
syndrome	B	40-48
of	I	49-51
inappropriate	I	52-65
secretion	I	66-75
of	I	76-78
antidiuretic	I	79-91
hormone	I	92-99
.	O	99-100

We	O	101-103
report	O	104-110
the	O	111-114
case	O	115-119
of	O	120-122
a	O	123-124
62	O	125-127
-	O	127-128
year	O	128-132
-	O	127-128
old	O	133-136
man	O	137-140
who	O	141-144
was	O	145-148
administered	O	149-161
sodium	O	162-168
valproate	O	169-178
(	O	179-180
VPA	O	180-183
)	O	183-184
and	O	185-188
who	O	189-192
subsequently	O	193-205
developed	O	206-215
the	O	216-219
syndrome	B	220-228
of	I	229-231
inappropriate	I	232-245
secretion	I	246-255
of	I	256-258
antidiuretic	I	259-271
hormone	I	272-279
(	O	280-281
SIADH	B	281-286
)	O	286-287
.	O	287-288

He	O	289-291
had	O	292-295
been	O	296-300
taking	O	301-307
VPA	O	308-311
for	O	312-315
treatment	O	316-325
of	O	326-328
idiopathic	O	329-339
generalized	O	340-351
tonic	B	352-357
-	I	357-358
clonic	I	358-364
convulsions	I	365-376
since	O	377-382
he	O	383-385
was	O	386-389
56	O	390-392
years	O	393-398
old	O	399-402
.	O	402-403

After	O	404-409
substituting	O	410-422
VPA	O	423-426
with	O	427-431
zonisamide	O	432-442
,	O	442-443
the	O	444-447
serum	O	448-453
sodium	O	454-460
level	O	461-466
returned	O	467-475
to	O	476-478
normal	O	479-485
.	O	485-486

We	O	487-489
consider	O	490-498
this	O	499-503
episode	O	504-511
of	O	512-514
SIADH	B	515-520
to	O	521-523
be	O	524-526
the	O	527-530
result	O	531-537
of	O	538-540
a	O	541-542
combination	O	543-554
of	O	555-557
factors	O	558-565
including	O	566-575
a	O	576-577
weakness	B	578-586
of	I	587-589
the	I	590-593
central	I	594-601
nervous	I	602-609
system	I	610-616
and	O	617-620
the	O	621-624
long	O	625-629
-	O	629-630
term	O	630-634
administration	O	635-649
of	O	650-652
VPA	O	653-656
.	O	656-657

Vasopressin	O	0-11
in	O	12-14
the	O	15-18
treatment	O	19-28
of	O	29-31
milrinone	O	32-41
-	O	41-42
induced	O	42-49
hypotension	B	50-61
in	O	62-64
severe	O	65-71
heart	B	72-77
failure	I	78-85
.	O	85-86

The	O	87-90
use	O	91-94
of	O	95-97
phosphodiesterase	O	98-115
inhibitors	O	116-126
such	O	127-131
as	O	132-134
milrinone	O	135-144
in	O	145-147
the	O	148-151
treatment	O	152-161
of	O	162-164
severe	O	165-171
heart	B	172-177
failure	I	178-185
is	O	186-188
frequently	O	189-199
restricted	O	200-210
because	O	211-218
they	O	219-223
cause	O	224-229
vasodilation	O	230-242
and	O	243-246
hypotension	B	247-258
.	O	258-259

In	O	260-262
patients	O	263-271
with	O	272-276
decompensated	O	277-290
heart	B	291-296
failure	I	297-304
with	O	305-309
hypotension	B	310-321
after	O	322-327
treatment	O	328-337
with	O	338-342
milrinone	O	343-352
,	O	352-353
low	O	354-357
doses	O	358-363
of	O	364-366
vasopressin	O	367-378
restored	O	379-387
blood	O	388-393
pressure	O	394-402
without	O	403-410
inhibiting	O	411-421
the	O	422-425
inotropic	O	426-435
effect	O	436-442
of	O	443-445
milrinone	O	446-455
.	O	455-456

Halogenated	O	0-11
anesthetics	O	12-23
form	O	24-28
liver	O	29-34
adducts	O	35-42
and	O	43-46
antigens	O	47-55
that	O	56-60
cross	O	61-66
-	O	66-67
react	O	67-72
with	O	73-77
halothane	O	78-87
-	O	87-88
induced	O	88-95
antibodies	O	96-106
.	O	106-107

Two	O	108-111
halogenated	O	112-123
anesthetics	O	124-135
,	O	135-136
enflurane	O	137-146
and	O	147-150
isoflurane	O	151-161
,	O	161-162
have	O	163-167
been	O	168-172
associated	O	173-183
with	O	184-188
an	O	189-191
allergic	O	192-200
-	O	200-201
type	O	201-205
hepatic	B	206-213
injury	I	214-220
both	O	221-225
alone	O	226-231
and	O	232-235
following	O	236-245
previous	O	246-254
exposure	O	255-263
to	O	264-266
halothane	O	267-276
.	O	276-277

Halothane	O	278-287
hepatitis	B	288-297
appears	O	298-305
to	O	306-308
involve	O	309-316
an	O	317-319
aberrant	O	320-328
immune	O	329-335
response	O	336-344
.	O	344-345

An	O	346-348
antibody	O	349-357
response	O	358-366
to	O	367-369
a	O	370-371
protein	O	372-379
-	O	379-380
bound	O	380-385
biotransformation	O	386-403
product	O	404-411
(	O	412-413
trifluoroacetyl	O	413-428
adduct	O	429-435
)	O	435-436
has	O	437-440
been	O	441-445
detected	O	446-454
on	O	455-457
halothane	O	458-467
hepatitis	B	468-477
patients	O	478-486
.	O	486-487

This	O	488-492
study	O	493-498
was	O	499-502
performed	O	503-512
to	O	513-515
determine	O	516-525
cross	O	526-531
-	O	531-532
reactivity	O	532-542
between	O	543-550
enflurane	O	551-560
and	O	561-564
isoflurane	O	565-575
with	O	576-580
the	O	581-584
hypersensitivity	B	585-601
induced	O	602-609
by	O	610-612
halothane	O	613-622
.	O	622-623

The	O	624-627
subcellular	O	628-639
and	O	640-643
lobular	O	644-651
production	O	652-662
of	O	663-665
hepatic	O	666-673
neoantigens	O	674-685
recognized	O	686-696
by	O	697-699
halothane	O	700-709
-	O	709-710
induced	O	710-717
antibodies	O	718-728
following	O	729-738
enflurane	O	739-748
and	O	749-752
isoflurane	O	753-763
,	O	763-764
and	O	765-768
the	O	769-772
biochemical	O	773-784
nature	O	785-791
of	O	792-794
these	O	795-800
neoantigens	O	801-812
was	O	813-816
investigated	O	817-829
in	O	830-832
two	O	833-836
animal	O	837-843
models	O	844-850
.	O	850-851

Enflurane	O	852-861
administration	O	862-876
resulted	O	877-885
in	O	886-888
neoantigens	O	889-900
detected	O	901-909
in	O	910-912
both	O	913-917
the	O	918-921
microsomal	O	922-932
and	O	933-936
cytosolic	O	937-946
fraction	O	947-955
of	O	956-958
liver	O	959-964
homogenates	O	965-976
and	O	977-980
in	O	981-983
the	O	984-987
centrilobular	O	988-1001
region	O	1002-1008
of	O	1009-1011
the	O	1012-1015
liver	O	1016-1021
.	O	1021-1022

In	O	1023-1025
the	O	1026-1029
same	O	1030-1034
liver	O	1035-1040
,	O	1040-1041
biochemical	O	1042-1053
analysis	O	1054-1062
detected	O	1063-1071
fluorinated	O	1072-1083
liver	O	1084-1089
adducts	O	1090-1097
that	O	1098-1102
were	O	1103-1107
up	O	1108-1110
to	O	1111-1113
20	O	1114-1116
-	O	1116-1117
fold	O	1117-1121
greater	O	1122-1129
in	O	1130-1132
guinea	O	1133-1139
pigs	O	1140-1144
than	O	1145-1149
in	O	1150-1152
rats	O	1153-1157
.	O	1157-1158

This	O	1159-1163
supports	O	1164-1172
and	O	1173-1176
extends	O	1177-1184
previous	O	1185-1193
evidence	O	1194-1202
for	O	1203-1206
a	O	1207-1208
mechanism	O	1209-1218
by	O	1219-1221
which	O	1222-1227
enflurane	O	1228-1237
and	O	1238-1241
/	O	1241-1242
or	O	1242-1244
isoflurane	O	1245-1255
could	O	1256-1261
produce	O	1262-1269
a	O	1270-1271
hypersensitivity	B	1272-1288
condition	O	1289-1298
similar	O	1299-1306
to	O	1307-1309
that	O	1310-1314
of	O	1315-1317
halothane	O	1318-1327
hepatitis	B	1328-1337
either	O	1338-1344
alone	O	1345-1350
or	O	1351-1353
subsequent	O	1354-1364
to	O	1365-1367
halothane	O	1368-1377
administration	O	1378-1392
.	O	1392-1393

The	O	1394-1397
guinea	O	1398-1404
pig	O	1405-1408
would	O	1409-1414
appear	O	1415-1421
to	O	1422-1424
be	O	1425-1427
a	O	1428-1429
useful	O	1430-1436
model	O	1437-1442
for	O	1443-1446
further	O	1447-1454
investigations	O	1455-1469
of	O	1470-1472
the	O	1473-1476
immunological	O	1477-1490
response	O	1491-1499
to	O	1500-1502
these	O	1503-1508
antigens	O	1509-1517
.	O	1517-1518

Induction	O	0-9
by	O	10-12
paracetamol	O	13-24
of	O	25-27
bladder	B	28-35
and	I	36-39
liver	I	40-45
tumours	I	46-53
in	O	54-56
the	O	57-60
rat	O	61-64
.	O	64-65

Effects	O	66-73
on	O	74-76
hepatocyte	O	77-87
fine	O	88-92
structure	O	93-102
.	O	102-103

Groups	O	104-110
of	O	111-113
male	O	114-118
and	O	119-122
female	O	123-129
inbred	O	130-136
Leeds	O	137-142
strain	O	143-149
rats	O	150-154
were	O	155-159
fed	O	160-163
diets	O	164-169
containing	O	170-180
either	O	181-187
0	O	188-189
.	O	189-190
5	O	190-191
%	O	191-192
or	O	193-195
1	O	196-197
.	O	197-198
0	O	198-199
%	O	199-200
paracetamol	O	201-212
by	O	213-215
weight	O	216-222
for	O	223-226
up	O	227-229
to	O	230-232
18	O	233-235
months	O	236-242
.	O	242-243

At	O	244-246
the	O	247-250
1	O	251-252
.	O	252-253
0	O	253-254
%	O	254-255
dosage	O	256-262
level	O	263-268
,	O	268-269
20	O	270-272
%	O	272-273
of	O	274-276
rats	O	277-281
of	O	282-284
both	O	285-289
sexes	O	290-295
developed	O	296-305
neoplastic	O	306-316
nodules	O	317-324
of	O	325-327
the	O	328-331
liver	O	332-337
,	O	337-338
a	O	339-340
statistically	O	341-354
significant	O	355-366
incidence	O	367-376
.	O	376-377

These	O	378-383
rats	O	384-388
also	O	389-393
showed	O	394-400
gross	O	401-406
enlargement	O	407-418
of	O	419-421
their	O	422-427
livers	O	428-434
and	O	435-438
an	O	439-441
increase	O	442-450
in	O	451-453
foci	O	454-458
of	O	459-461
cellular	O	462-470
alteration	O	471-481
,	O	481-482
the	O	483-486
latter	O	487-493
also	O	494-498
being	O	499-504
observed	O	505-513
in	O	514-516
the	O	517-520
low	O	521-524
dosage	O	525-531
male	O	532-536
rats	O	537-541
.	O	541-542

Papillomas	B	543-553
of	O	554-556
the	O	557-560
transitional	O	561-573
epithelium	O	574-584
of	O	585-587
the	O	588-591
bladder	O	592-599
developed	O	600-609
in	O	610-612
all	O	613-616
paracetamol	O	617-628
-	O	628-629
treated	O	629-636
groups	O	637-643
,	O	643-644
and	O	645-648
three	O	649-654
rats	O	655-659
bore	O	660-664
bladder	B	665-672
carcinomas	I	673-683
.	O	683-684

However	O	685-692
,	O	692-693
significant	O	694-705
yields	O	706-712
of	O	713-715
bladder	B	716-723
tumours	I	724-731
were	O	732-736
only	O	737-741
obtained	O	742-750
from	O	751-755
low	O	756-759
dosage	O	760-766
females	O	767-774
and	O	775-778
high	O	779-783
dosage	O	784-790
males	O	791-796
.	O	796-797

Additionally	O	798-810
,	O	810-811
20	O	812-814
to	O	815-817
25	O	818-820
%	O	820-821
of	O	822-824
paracetamol	O	825-836
-	O	836-837
treated	O	837-844
rats	O	845-849
developed	O	850-859
hyperplasia	B	860-871
of	O	872-874
the	O	875-878
bladder	O	879-886
epithelium	O	887-897
,	O	897-898
which	O	899-904
was	O	905-908
not	O	909-912
coincident	O	913-923
with	O	924-928
the	O	929-932
presence	O	933-941
of	O	942-944
bladder	B	945-952
calculi	I	953-960
.	O	960-961

A	O	962-963
low	O	964-967
yield	O	968-973
of	O	974-976
tumours	B	977-984
at	O	985-987
various	O	988-995
other	O	996-1001
sites	O	1002-1007
also	O	1008-1012
arose	O	1013-1018
following	O	1019-1028
paracetamol	O	1029-1040
feeding	O	1041-1048
.	O	1048-1049

An	O	1050-1052
electron	O	1053-1061
microscope	O	1062-1072
study	O	1073-1078
of	O	1079-1081
the	O	1082-1085
livers	O	1086-1092
of	O	1093-1095
paracetamol	O	1096-1107
-	O	1107-1108
treated	O	1108-1115
rats	O	1116-1120
revealed	O	1121-1129
ultrastructural	O	1130-1145
changes	O	1146-1153
in	O	1154-1156
the	O	1157-1160
hepatocytes	O	1161-1172
that	O	1173-1177
resemble	O	1178-1186
those	O	1187-1192
that	O	1193-1197
result	O	1198-1204
from	O	1205-1209
exposure	O	1210-1218
to	O	1219-1221
a	O	1222-1223
variety	O	1224-1231
of	O	1232-1234
known	O	1235-1240
hepatocarcinogens	B	1241-1258
.	O	1258-1259

Rat	O	0-3
extraocular	O	4-15
muscle	O	16-22
regeneration	O	23-35
.	O	35-36

Repair	O	37-43
of	O	44-46
local	O	47-52
anesthetic	O	53-63
-	O	63-64
induced	O	64-71
damage	O	72-78
.	O	78-79

Local	O	80-85
anesthetics	O	86-97
that	O	98-102
are	O	103-106
commonly	O	107-115
used	O	116-120
in	O	121-123
ophthalmic	O	124-134
surgery	O	135-142
(	O	143-144
0	O	144-145
.	O	145-146
75	O	146-148
%	O	148-149
bupivacaine	O	150-161
hydrochloride	O	162-175
,	O	175-176
2	O	177-178
.	O	178-179
0	O	179-180
%	O	180-181
mepivacaine	O	182-193
hydrochloride	O	194-207
,	O	207-208
and	O	209-212
2	O	213-214
.	O	214-215
0	O	215-216
%	O	216-217
lidocaine	O	218-227
hydrochloride	O	228-241
plus	O	242-246
1	O	247-248
:	O	248-249
100	O	249-252
,	O	252-253
000	O	253-256
epinephrine	O	257-268
)	O	268-269
were	O	270-274
injected	O	275-283
into	O	284-288
the	O	289-292
retrobulbar	O	293-304
area	O	305-309
of	O	310-312
rat	O	313-316
eyes	O	317-321
.	O	321-322

Controls	O	323-331
were	O	332-336
injected	O	337-345
with	O	346-350
physiological	O	351-364
saline	O	365-371
.	O	371-372

All	O	373-376
three	O	377-382
anesthetics	O	383-394
produced	O	395-403
massive	O	404-411
degeneration	O	412-424
of	O	425-427
the	O	428-431
extraocular	O	432-443
muscles	O	444-451
.	O	451-452

Muscle	B	453-459
degeneration	I	460-472
is	O	473-475
followed	O	476-484
by	O	485-487
regeneration	O	488-500
of	O	501-503
the	O	504-507
damaged	O	508-515
muscle	O	516-522
fibers	O	523-529
.	O	529-530

In	O	531-533
addition	O	534-542
to	O	543-545
muscle	B	546-552
damage	I	553-559
,	O	559-560
severe	O	561-567
damage	O	568-574
was	O	575-578
also	O	579-583
seen	O	584-588
in	O	589-591
harderian	O	592-601
glands	O	602-608
,	O	608-609
especially	O	610-620
after	O	621-626
exposure	O	627-635
to	O	636-638
mepivacaine	O	639-650
and	O	651-654
lidocaine	O	655-664
plus	O	665-669
epinephrine	O	670-681
.	O	681-682

With	O	683-687
these	O	688-693
findings	O	694-702
in	O	703-705
rats	O	706-710
,	O	710-711
it	O	712-714
is	O	715-717
hypothesized	O	718-730
that	O	731-735
the	O	736-739
temporary	O	740-749
diplopia	B	750-758
sometimes	O	759-768
seen	O	769-773
in	O	774-776
patients	O	777-785
after	O	786-791
ophthalmic	O	792-802
surgery	O	803-810
might	O	811-816
be	O	817-819
due	O	820-823
to	O	824-826
anesthetic	O	827-837
-	O	837-838
induced	O	838-845
damage	O	846-852
to	O	853-855
the	O	856-859
extraocular	O	860-871
muscles	O	872-879
.	O	879-880

Reversal	O	0-8
of	O	9-11
neuroleptic	O	12-23
-	O	23-24
induced	O	24-31
catalepsy	B	32-41
by	O	42-44
novel	O	45-50
aryl	O	51-55
-	O	55-56
piperazine	O	56-66
anxiolytic	O	67-77
drugs	O	78-83
.	O	83-84

The	O	85-88
novel	O	89-94
anxiolytic	O	95-105
drug	O	106-110
,	O	110-111
buspirone	O	112-121
,	O	121-122
reverses	O	123-131
catalepsy	B	132-141
induced	O	142-149
by	O	150-152
haloperidol	O	153-164
.	O	164-165

A	O	166-167
series	O	168-174
of	O	175-177
aryl	O	178-182
-	O	182-183
piperazine	O	183-193
analogues	O	194-203
of	O	204-206
buspirone	O	207-216
and	O	217-220
other	O	221-226
5	O	227-228
-	O	228-229
hydroxytryptaminergic	O	229-250
agonists	O	251-259
were	O	260-264
tested	O	265-271
for	O	272-275
their	O	276-281
ability	O	282-289
to	O	290-292
reverse	O	293-300
haloperidol	O	301-312
induced	O	313-320
catalepsy	B	321-330
.	O	330-331

Those	O	332-337
drugs	O	338-343
with	O	344-348
strong	O	349-355
affinity	O	356-364
for	O	365-368
5	O	369-370
-	O	370-371
hydroxytryptamine1a	O	371-390
receptors	O	391-400
were	O	401-405
able	O	406-410
to	O	411-413
reverse	O	414-421
catalepsy	B	422-431
.	O	431-432

Drugs	O	433-438
with	O	439-443
affinity	O	444-452
for	O	453-456
other	O	457-462
5	O	463-464
-	O	464-465
HT	O	465-467
receptors	O	468-477
or	O	478-480
weak	O	481-485
affinity	O	486-494
were	O	495-499
ineffective	O	500-511
.	O	511-512

However	O	513-520
,	O	520-521
inhibition	O	522-532
of	O	533-535
postsynaptic	O	536-548
5	O	549-550
-	O	550-551
HT	O	551-553
receptors	O	554-563
neither	O	564-571
inhibited	O	572-581
nor	O	582-585
potentiated	O	586-597
reversal	O	598-606
of	O	607-609
catalepsy	B	610-619
and	O	620-623
leaves	O	624-630
open	O	631-635
the	O	636-639
question	O	640-648
as	O	649-651
to	O	652-654
the	O	655-658
site	O	659-663
or	O	664-666
mechanism	O	667-676
for	O	677-680
this	O	681-685
effect	O	686-692
.	O	692-693

Diazepam	O	0-8
facilitates	O	9-20
reflex	O	21-27
bradycardia	B	28-39
in	O	40-42
conscious	O	43-52
rats	O	53-57
.	O	57-58

The	O	59-62
effects	O	63-70
of	O	71-73
diazepam	O	74-82
on	O	83-85
cardiovascular	O	86-100
function	O	101-109
were	O	110-114
assessed	O	115-123
in	O	124-126
conscious	O	127-136
rats	O	137-141
.	O	141-142

Intravenous	O	143-154
administration	O	155-169
of	O	170-172
diazepam	O	173-181
(	O	182-183
1	O	183-184
-	O	184-185
30	O	185-187
mg	O	188-190
kg	O	191-193
-	O	193-194
1	O	194-195
)	O	195-196
produced	O	197-205
a	O	206-207
dose	O	208-212
-	O	212-213
dependent	O	213-222
decrease	O	223-231
in	O	232-234
both	O	235-239
the	O	240-243
mean	O	244-248
arterial	O	249-257
pressure	O	258-266
and	O	267-270
the	O	271-274
heart	O	275-280
rate	O	281-285
.	O	285-286

Also	O	287-291
,	O	291-292
reflex	O	293-299
bradycardia	B	300-311
was	O	312-315
produced	O	316-324
in	O	325-327
rats	O	328-332
by	O	333-335
intravenous	O	336-347
infusion	O	348-356
of	O	357-359
adrenaline	O	360-370
(	O	371-372
1	O	372-373
.	O	373-374
25	O	374-376
-	O	376-377
2	O	374-375
.	O	373-374
5	O	375-376
micrograms	O	381-391
kg	O	392-394
-	O	394-395
1	O	395-396
)	O	396-397
.	O	397-398

Intravenous	O	399-410
pretreatment	O	411-423
of	O	424-426
the	O	427-430
rats	O	431-435
with	O	436-440
diazepam	O	441-449
,	O	449-450
although	O	451-459
causing	O	460-467
no	O	468-470
change	O	471-477
in	O	478-480
the	O	481-484
adrenaline	O	485-495
-	O	495-496
induced	O	496-503
pressor	O	504-511
effect	O	512-518
,	O	518-519
did	O	520-523
enhance	O	524-531
the	O	532-535
adrenaline	O	536-546
-	O	546-547
induced	O	547-554
reflex	O	555-561
bradycardia	B	562-573
.	O	573-574

However	O	575-582
,	O	582-583
the	O	584-587
diazepam	O	588-596
enhancement	O	597-608
of	O	609-611
adrenaline	O	612-622
-	O	622-623
induced	O	623-630
reflex	O	631-637
bradycardia	B	638-649
was	O	650-653
antagonized	O	654-665
by	O	666-668
pretreatment	O	669-681
of	O	682-684
rats	O	685-689
with	O	690-694
an	O	695-697
intravenous	O	698-709
dose	O	710-714
of	O	715-717
picrotoxin	O	718-728
(	O	729-730
an	O	730-732
agent	O	733-738
blocks	O	739-745
chloride	O	746-754
channels	O	755-763
by	O	764-766
binding	O	767-774
to	O	775-777
sites	O	778-783
associated	O	784-794
with	O	795-799
the	O	800-803
benzodiazepine	O	804-818
-	O	818-819
GABA	O	819-823
-	O	818-819
chloride	O	824-832
channel	O	833-840
macromolecular	O	841-855
complex	O	856-863
)	O	863-864
.	O	864-865

The	O	866-869
data	O	870-874
indicate	O	875-883
that	O	884-888
diazepam	O	889-897
acts	O	898-902
through	O	903-910
the	O	911-914
benzodiazepine	O	915-929
-	O	929-930
GABA	O	930-934
-	O	929-930
chloride	O	935-943
channel	O	944-951
macromolecular	O	952-966
complex	O	967-974
within	O	975-981
the	O	982-985
central	O	986-993
nervous	O	994-1001
system	O	1002-1008
to	O	1009-1011
facilitate	O	1012-1022
reflex	O	1023-1029
bradycardia	B	1030-1041
mediated	O	1042-1050
through	O	1051-1058
baroreceptor	O	1059-1071
reflexes	O	1072-1080
in	O	1081-1083
response	O	1084-1092
to	O	1093-1095
an	O	1096-1098
acute	O	1099-1104
increase	O	1105-1113
in	O	1114-1116
arterial	O	1117-1125
pressure	O	1126-1134
.	O	1134-1135

Chronic	O	0-7
carbamazepine	O	8-21
inhibits	O	22-30
the	O	31-34
development	O	35-46
of	O	47-49
local	O	50-55
anesthetic	O	56-66
seizures	B	67-75
kindled	O	76-83
by	O	84-86
cocaine	O	87-94
and	O	95-98
lidocaine	O	99-108
.	O	108-109

The	O	110-113
effects	O	114-121
of	O	122-124
carbamazepine	O	125-138
(	O	139-140
CBZ	O	140-143
)	O	143-144
treatment	O	145-154
on	O	155-157
local	O	158-163
anesthetic	O	164-174
-	O	174-175
kindled	O	175-182
seizures	B	183-191
and	O	192-195
lethality	O	196-205
were	O	206-210
evaluated	O	211-220
in	O	221-223
different	O	224-233
stages	O	234-240
of	O	241-243
the	O	244-247
kindling	O	248-256
process	O	257-264
and	O	265-268
under	O	269-274
different	O	275-284
methods	O	285-292
of	O	293-295
CBZ	O	296-299
administration	O	300-314
.	O	314-315

Chronic	O	316-323
oral	O	324-328
CBZ	O	329-332
inhibited	O	333-342
the	O	343-346
development	O	347-358
of	O	359-361
both	O	362-366
lidocaine	O	367-376
-	O	376-377
and	O	378-381
cocaine	O	382-389
-	O	389-390
induced	O	390-397
seizures	B	398-406
,	O	406-407
but	O	408-411
had	O	412-415
little	O	416-422
effect	O	423-429
on	O	430-432
the	O	433-436
fully	O	437-442
developed	O	443-452
local	O	453-458
anesthetic	O	459-469
seizures	B	470-478
.	O	478-479

Chronic	O	480-487
CBZ	O	488-491
also	O	492-496
decreased	O	497-506
the	O	507-510
incidence	O	511-520
of	O	521-523
seizure	B	524-531
-	O	531-532
related	O	532-539
mortality	O	540-549
in	O	550-552
the	O	553-556
cocaine	O	557-564
-	O	564-565
injected	O	565-573
rats	O	574-578
.	O	578-579

Acute	O	580-585
CBZ	O	586-589
over	O	590-594
a	O	595-596
range	O	597-602
of	O	603-605
doses	O	606-611
(	O	612-613
15	O	613-615
-	O	615-616
50	O	616-618
mg	O	619-621
/	O	621-622
kg	O	622-624
)	O	624-625
had	O	626-629
no	O	630-632
effect	O	633-639
on	O	640-642
completed	O	643-652
lidocaine	O	653-662
-	O	662-663
kindled	O	663-670
or	O	671-673
acute	O	674-679
cocaine	O	680-687
-	O	687-688
induced	O	688-695
seizures	B	696-704
.	O	704-705

Repeated	O	706-714
i	O	715-716
.	O	716-717
p	O	717-718
.	O	716-717
injection	O	720-729
of	O	730-732
CBZ	O	733-736
(	O	737-738
15	O	738-740
mg	O	741-743
/	O	743-744
kg	O	744-746
)	O	746-747
also	O	748-752
was	O	753-756
without	O	757-764
effect	O	765-771
on	O	772-774
the	O	775-778
development	O	779-790
of	O	791-793
lidocaine	O	794-803
-	O	803-804
or	O	805-807
cocaine	O	808-815
-	O	815-816
kindled	O	816-823
seizures	B	824-832
.	O	832-833

The	O	834-837
differential	O	838-850
effects	O	851-858
of	O	859-861
CBZ	O	862-865
depending	O	866-875
upon	O	876-880
stage	O	881-886
of	O	887-889
seizure	B	890-897
development	O	898-909
suggest	O	910-917
that	O	918-922
distinct	O	923-931
mechanisms	O	932-942
underlie	O	943-951
the	O	952-955
development	O	956-967
versus	O	968-974
maintenance	O	975-986
of	O	987-989
local	O	990-995
anesthetic	O	996-1006
-	O	1006-1007
kindled	O	1007-1014
seizures	B	1015-1023
.	O	1023-1024

The	O	1025-1028
effectiveness	O	1029-1042
of	O	1043-1045
chronic	O	1046-1053
but	O	1054-1057
not	O	1058-1061
repeated	O	1062-1070
,	O	1070-1071
intermittent	O	1072-1084
injections	O	1085-1095
of	O	1096-1098
CBZ	O	1099-1102
suggests	O	1103-1111
that	O	1112-1116
different	O	1117-1126
biochemical	O	1127-1138
consequences	O	1139-1151
result	O	1152-1158
from	O	1159-1163
the	O	1164-1167
different	O	1168-1177
treatment	O	1178-1187
regimens	O	1188-1196
.	O	1196-1197

The	O	1198-1201
possible	O	1202-1210
utility	O	1211-1218
of	O	1219-1221
chronic	O	1222-1229
CBZ	O	1230-1233
in	O	1234-1236
preventing	O	1237-1247
the	O	1248-1251
development	O	1252-1263
of	O	1264-1266
toxic	O	1267-1272
side	O	1273-1277
effects	O	1278-1285
in	O	1286-1288
human	O	1289-1294
cocaine	O	1295-1302
users	O	1303-1308
is	O	1309-1311
suggested	O	1312-1321
by	O	1322-1324
these	O	1325-1330
data	O	1331-1335
,	O	1335-1336
but	O	1337-1340
remains	O	1341-1348
to	O	1349-1351
be	O	1352-1354
directly	O	1355-1363
evaluated	O	1364-1373
.	O	1373-1374

D	O	0-1
-	O	1-2
penicillamine	O	2-15
in	O	16-18
the	O	19-22
treatment	O	23-32
of	O	33-35
localized	B	36-45
scleroderma	I	46-57
.	O	57-58

Localized	B	59-68
scleroderma	I	69-80
has	O	81-84
no	O	85-87
recognized	O	88-98
internal	O	99-107
organ	O	108-113
involvement	O	114-125
but	O	126-129
may	O	130-133
be	O	134-136
disfiguring	O	137-148
and	O	149-152
disabling	O	153-162
when	O	163-167
the	O	168-171
cutaneous	O	172-181
lesions	O	182-189
are	O	190-193
extensive	O	194-203
or	O	204-206
affect	O	207-213
children	O	214-222
.	O	222-223

There	O	224-229
is	O	230-232
no	O	233-235
accepted	O	236-244
or	O	245-247
proven	O	248-254
treatment	O	255-264
for	O	265-268
localized	B	269-278
scleroderma	I	279-290
.	O	290-291

Case	O	292-296
reports	O	297-304
of	O	305-307
11	O	308-310
patients	O	311-319
with	O	320-324
severe	O	325-331
,	O	331-332
extensive	O	333-342
localized	B	343-352
scleroderma	I	353-364
who	O	365-368
were	O	369-373
treated	O	374-381
with	O	382-386
D	O	387-388
-	O	388-389
penicillamine	O	389-402
are	O	403-406
summarized	O	407-417
in	O	418-420
this	O	421-425
article	O	426-433
.	O	433-434

This	O	435-439
drug	O	440-444
was	O	445-448
judged	O	449-455
to	O	456-458
have	O	459-463
a	O	464-465
favorable	O	466-475
effect	O	476-482
on	O	483-485
the	O	486-489
disease	O	490-497
course	O	498-504
in	O	505-507
7	O	508-509
(	O	510-511
64	O	511-513
%	O	513-514
)	O	514-515
of	O	516-518
11	O	519-521
patients	O	522-530
.	O	530-531

Improvement	O	532-543
began	O	544-549
within	O	550-556
3	O	557-558
to	O	559-561
6	O	562-563
months	O	564-570
and	O	571-574
consisted	O	575-584
of	O	585-587
cessation	O	588-597
of	O	598-600
active	O	601-607
cutaneous	O	608-617
lesions	O	618-625
in	O	626-628
all	O	629-632
7	O	633-634
patients	O	635-643
,	O	643-644
skin	O	645-649
softening	O	650-659
in	O	660-662
5	O	663-664
,	O	664-665
and	O	666-669
more	O	670-674
normal	O	675-681
growth	O	682-688
of	O	689-691
the	O	692-695
affected	O	696-704
limb	O	705-709
in	O	710-712
2	O	713-714
of	O	715-717
3	O	718-719
children	O	720-728
.	O	728-729

Joint	O	730-735
stiffness	O	736-745
and	O	746-749
contractures	B	750-762
also	O	763-767
improved	O	768-776
.	O	776-777

The	O	778-781
dose	O	782-786
of	O	787-789
D	O	790-791
-	O	791-792
penicillamine	O	792-805
associated	O	806-816
with	O	817-821
a	O	822-823
favorable	O	824-833
response	O	834-842
was	O	843-846
as	O	847-849
low	O	850-853
as	O	854-856
2	O	857-858
to	O	859-861
5	O	862-863
mg	O	864-866
/	O	866-867
kg	O	867-869
per	O	870-873
day	O	874-877
given	O	878-883
over	O	884-888
a	O	889-890
period	O	891-897
ranging	O	898-905
from	O	906-910
15	O	911-913
to	O	914-916
53	O	917-919
months	O	920-926
.	O	926-927

D	O	928-929
-	O	929-930
Penicillamine	O	930-943
caused	O	944-950
nephrotic	B	951-960
syndrome	I	961-969
in	O	970-972
1	O	973-974
patient	O	975-982
and	O	983-986
milder	O	987-993
reversible	O	994-1004
proteinuria	B	1005-1016
in	O	1017-1019
3	O	1020-1021
other	O	1022-1027
patients	O	1028-1036
;	O	1036-1037
none	O	1038-1042
developed	O	1043-1052
renal	B	1053-1058
insufficiency	I	1059-1072
.	O	1072-1073

These	O	1074-1079
data	O	1080-1084
suggest	O	1085-1092
that	O	1093-1097
D	O	1098-1099
-	O	1099-1100
penicillamine	O	1100-1113
may	O	1114-1117
be	O	1118-1120
effective	O	1121-1130
in	O	1131-1133
severe	O	1134-1140
cases	O	1141-1146
of	O	1147-1149
localized	B	1150-1159
scleroderma	I	1160-1171
.	O	1171-1172

Preservation	O	0-12
of	O	13-15
renal	O	16-21
blood	O	22-27
flow	O	28-32
during	O	33-39
hypotension	B	40-51
induced	O	52-59
with	O	60-64
fenoldopam	O	65-75
in	O	76-78
dogs	O	79-83
.	O	83-84

The	O	85-88
introduction	O	89-101
of	O	102-104
drugs	O	105-110
that	O	111-115
could	O	116-121
induce	O	122-128
hypotension	B	129-140
with	O	141-145
different	O	146-155
pharmacological	O	156-171
actions	O	172-179
would	O	180-185
be	O	186-188
advantageous	O	189-201
because	O	202-209
side	O	210-214
effects	O	215-222
unique	O	223-229
to	O	230-232
a	O	233-234
specific	O	235-243
drug	O	244-248
could	O	249-254
be	O	255-257
minimized	O	258-267
by	O	268-270
selecting	O	271-280
appropriate	O	281-292
therapy	O	293-300
.	O	300-301

Specific	O	302-310
dopamine	O	311-319
-	O	319-320
1	O	320-321
,	O	321-322
(	O	323-324
DA1	O	324-327
)	O	327-328
and	O	329-332
dopamine	O	333-341
-	O	341-342
2	O	342-343
(	O	344-345
DA2	O	345-348
)	O	348-349
receptor	O	350-358
agonists	O	359-367
are	O	368-371
now	O	372-375
under	O	376-381
clinical	O	382-390
investigation	O	391-404
.	O	404-405

Fenoldopam	O	406-416
mesylate	O	417-425
is	O	426-428
a	O	429-430
specific	O	431-439
DA1	O	440-443
receptor	O	444-452
agonist	O	453-460
that	O	461-465
lowers	O	466-472
blood	O	473-478
pressure	O	479-487
by	O	488-490
vasodilatation	O	491-505
.	O	505-506

The	O	507-510
hypothesis	O	511-521
that	O	522-526
fenoldopam	O	527-537
could	O	538-543
be	O	544-546
used	O	547-551
to	O	552-554
induce	O	555-561
hypotension	B	562-573
and	O	574-577
preserve	O	578-586
blood	O	587-592
flow	O	593-597
to	O	598-600
the	O	601-604
kidney	O	605-611
was	O	612-615
tested	O	616-622
.	O	622-623

Systemic	O	624-632
aortic	O	633-639
blood	O	640-645
pressure	O	646-654
and	O	655-658
renal	O	659-664
blood	O	665-670
flow	O	671-675
were	O	676-680
measured	O	681-689
continuously	O	690-702
with	O	703-707
a	O	708-709
carotid	O	710-717
arterial	O	718-726
catheter	O	727-735
and	O	736-739
an	O	740-742
electromagnetic	O	743-758
flow	O	759-763
probe	O	764-769
respectively	O	770-782
,	O	782-783
in	O	784-786
order	O	787-792
to	O	793-795
compare	O	796-803
the	O	804-807
cardiovascular	O	808-822
and	O	823-826
renal	O	827-832
vascular	O	833-841
effects	O	842-849
of	O	850-852
fenoldopam	O	853-863
and	O	864-867
sodium	O	868-874
nitroprusside	O	875-888
in	O	889-891
ten	O	892-895
dogs	O	896-900
under	O	901-906
halothane	O	907-916
general	O	917-924
anaesthesia	O	925-936
.	O	936-937

Mean	O	938-942
arterial	O	943-951
pressure	O	952-960
was	O	961-964
decreased	O	965-974
30	O	975-977
+	O	978-979
/	O	979-980
-	O	980-981
8	O	982-983
per	O	984-987
cent	O	988-992
from	O	993-997
control	O	998-1005
with	O	1006-1010
infusion	O	1011-1019
of	O	1020-1022
fenoldopam	O	1023-1033
(	O	1034-1035
3	O	1035-1036
.	O	1036-1037
4	O	1037-1038
+	O	1039-1040
/	O	1040-1041
-	O	1041-1042
2	O	1043-1044
.	O	1044-1045
0	O	1045-1046
micrograms	O	1047-1057
.	O	1057-1058
kg	O	1058-1060
-	O	1060-1061
1	O	1061-1062
.	O	1057-1058
min	O	1063-1066
-	O	1060-1061
1	O	1061-1062
)	O	1068-1069

and	O	1070-1073
34	O	1074-1076
+	O	1077-1078
/	O	1078-1079
-	O	1079-1080
4	O	1081-1082
per	O	1083-1086
cent	O	1087-1091
with	O	1092-1096
infusion	O	1097-1105
of	O	1106-1108
sodium	O	1109-1115
nitroprusside	O	1116-1129
(	O	1130-1131
5	O	1131-1132
.	O	1132-1133
9	O	1133-1134
micrograms	O	1135-1145
.	O	1145-1146
kg	O	1146-1148
-	O	1148-1149
1	O	1149-1150
.	O	1145-1146
min	O	1151-1154
-	O	1148-1149
1	O	1149-1150
)	O	1156-1157

(	O	1158-1159
NS	O	1159-1161
)	O	1161-1162
.	O	1162-1163

Renal	O	1164-1169
blood	O	1170-1175
flow	O	1176-1180
(	O	1181-1182
RBF	O	1182-1185
)	O	1185-1186
increased	O	1187-1196
during	O	1197-1203
fenoldopam	O	1204-1214
-	O	1214-1215
induced	O	1215-1222
hypotension	B	1223-1234
11	O	1235-1237
+	O	1238-1239
/	O	1239-1240
-	O	1240-1241
7	O	1242-1243
per	O	1244-1247
cent	O	1248-1252
and	O	1253-1256
decreased	O	1257-1266
21	O	1267-1269
+	O	1270-1271
/	O	1271-1272
-	O	1272-1273
8	O	1274-1275
per	O	1276-1279
cent	O	1280-1284
during	O	1285-1291
sodium	O	1292-1298
nitroprusside	O	1299-1312
-	O	1312-1313
induced	O	1313-1320
hypotension	B	1321-1332
(	O	1333-1334
P	O	1334-1335
less	O	1336-1340
than	O	1341-1345
0	O	1346-1347
.	O	1347-1348
01	O	1348-1350
)	O	1350-1351
.	O	1347-1348

Sodium	O	1353-1359
nitroprusside	O	1360-1373
is	O	1374-1376
a	O	1377-1378
non	O	1379-1382
-	O	1382-1383
selective	O	1383-1392
arteriolar	O	1393-1403
and	O	1404-1407
venous	O	1408-1414
vasodilator	O	1415-1426
that	O	1427-1431
can	O	1432-1435
produce	O	1436-1443
redistribution	O	1444-1458
of	O	1459-1461
blood	O	1462-1467
flow	O	1468-1472
away	O	1473-1477
from	O	1478-1482
the	O	1483-1486
kidney	O	1487-1493
during	O	1494-1500
induced	O	1501-1508
hypotension	B	1509-1520
.	O	1520-1521

Fenoldopam	O	1522-1532
is	O	1533-1535
a	O	1536-1537
selective	O	1538-1547
dopamine	O	1548-1556
-	O	1556-1557
1	O	1557-1558
(	O	1559-1560
DA1	O	1560-1563
)	O	1563-1564
receptor	O	1565-1573
agonist	O	1574-1581
that	O	1582-1586
causes	O	1587-1593
vasodilatation	O	1594-1608
to	O	1609-1611
the	O	1612-1615
kidney	O	1616-1622
and	O	1623-1626
other	O	1627-1632
organs	O	1633-1639
with	O	1640-1644
DA1	O	1645-1648
receptors	O	1649-1658
and	O	1659-1662
preserves	O	1663-1672
blood	O	1673-1678
flow	O	1679-1683
to	O	1684-1686
the	O	1687-1690
kidney	O	1691-1697
during	O	1698-1704
induced	O	1705-1712
hypotension	B	1713-1724
.	O	1724-1725

Antiarrhythmic	O	0-14
effects	O	15-22
of	O	23-25
optical	O	26-33
isomers	O	34-41
of	O	42-44
cibenzoline	O	45-56
on	O	57-59
canine	O	60-66
ventricular	B	67-78
arrhythmias	I	79-90
.	O	90-91

Antiarrhythmic	O	92-106
effects	O	107-114
of	O	115-117
(	O	118-119
+	O	119-120
)	O	120-121
-	O	121-122
cibenzoline	O	122-133
and	O	134-137
(	O	138-139
-	O	139-140
)	O	140-141
-	O	139-140
cibenzoline	O	142-153
were	O	154-158
examined	O	159-167
using	O	168-173
two	O	174-177
canine	O	178-184
ventricular	B	185-196
arrhythmia	I	197-207
models	O	208-214
.	O	214-215

Digitalis	O	216-225
arrhythmia	B	226-236
,	O	236-237
which	O	238-243
is	O	244-246
suppressed	O	247-257
by	O	258-260
Na	O	261-263
channel	O	264-271
blockers	O	272-280
,	O	280-281
was	O	282-285
induced	O	286-293
by	O	294-296
intermittent	O	297-309
intravenous	O	310-321
(	O	322-323
i	O	323-324
.	O	324-325
v	O	325-326
.	O	324-325
)	O	327-328
injection	O	329-338
of	O	339-341
ouabain	O	342-349
in	O	350-352
pentobarbital	O	353-366
-	O	366-367
anesthetized	O	367-379
dogs	O	380-384
.	O	384-385

Adrenaline	B	386-396
arrhythmia	I	397-407
,	O	407-408
which	O	409-414
is	O	415-417
suppressed	O	418-428
by	O	429-431
Ca	O	432-434
channel	O	435-442
blockers	O	443-451
,	O	451-452
was	O	453-456
induced	O	457-464
by	O	465-467
adrenaline	O	468-478
infusion	O	479-487
in	O	488-490
halothane	O	491-500
-	O	500-501
anesthetized	O	501-513
dogs	O	514-518
.	O	518-519

Ten	O	520-523
and	O	524-527
5	O	528-529
mg	O	530-532
/	O	532-533
kg	O	533-535
i	O	536-537
.	O	537-538
v	O	538-539
.	O	537-538

(	O	541-542
+	O	542-543
)	O	543-544
-	O	544-545
cibenzoline	O	545-556
suppressed	O	557-567
digitalis	O	568-577
-	O	577-578
and	O	579-582
adrenaline	O	583-593
-	O	593-594
induced	O	594-601
arrhythmias	B	602-613
,	O	613-614
respectively	O	615-627
.	O	627-628

The	O	629-632
minimum	O	633-640
effective	O	641-650
plasma	O	651-657
concentrations	O	658-672
of	O	673-675
(	O	676-677
+	O	677-678
)	O	678-679
-	O	679-680
cibenzoline	O	680-691
for	O	692-695
digitalis	O	696-705
-	O	705-706
and	O	707-710
adrenaline	O	711-721
-	O	721-722
induced	O	722-729
arrhythmias	B	730-741
were	O	742-746
1	O	747-748
.	O	748-749
4	O	749-750
+	O	751-752
/	O	752-753
-	O	753-754
0	O	755-756
.	O	756-757
4	O	757-758
and	O	759-762
2	O	763-764
.	O	764-765
0	O	765-766
+	O	767-768
/	O	768-769
-	O	769-770
0	O	771-772
.	O	772-773
6	O	773-774
micrograms	O	775-785
/	O	785-786
ml	O	786-788
,	O	788-789
respectively	O	790-802
(	O	803-804
mean	O	804-808
+	O	809-810
/	O	810-811
-	O	811-812
SD	O	813-815
,	O	815-816
n	O	817-818
=	O	819-820
6	O	821-822
)	O	822-823
.	O	823-824

A	O	825-826
lower	O	827-832
dose	O	833-837
of	O	838-840
1	O	841-842
mg	O	843-845
/	O	845-846
kg	O	846-848
i	O	849-850
.	O	850-851
v	O	851-852
.	O	850-851
of	O	854-856
(	O	857-858
-	O	858-859
)	O	859-860
-	O	858-859
cibenzoline	O	861-872
suppressed	O	873-883
the	O	884-887
digitalis	O	888-897
-	O	897-898
induced	O	898-905
arrhythmia	B	906-916
,	O	916-917
whereas	O	918-925
5	O	926-927
mg	O	928-930
/	O	930-931
kg	O	931-933
i	O	934-935
.	O	935-936
v	O	936-937
.	O	935-936
was	O	939-942
needed	O	943-949
to	O	950-952
suppress	O	953-961
adrenaline	O	962-972
-	O	972-973
induced	O	973-980
arrhythmias	B	981-992
.	O	992-993

The	O	994-997
minimum	O	998-1005
effective	O	1006-1015
plasma	O	1016-1022
concentrations	O	1023-1037
of	O	1038-1040
(	O	1041-1042
-	O	1042-1043
)	O	1043-1044
-	O	1042-1043
cibenzoline	O	1045-1056
for	O	1057-1060
digitalis	O	1061-1070
-	O	1070-1071
and	O	1072-1075
adrenaline	O	1076-1086
-	O	1086-1087
induced	O	1087-1094
arrhythmia	B	1095-1105
were	O	1106-1110
0	O	1111-1112
.	O	1112-1113
06	O	1113-1115
+	O	1116-1117
/	O	1117-1118
-	O	1118-1119
0	O	1120-1121
.	O	1121-1122
04	O	1122-1124
and	O	1125-1128
0	O	1129-1130
.	O	1130-1131
7	O	1131-1132
+	O	1133-1134
/	O	1134-1135
-	O	1135-1136
0	O	1137-1138
.	O	1138-1139
1	O	1139-1140
micrograms	O	1141-1151
/	O	1151-1152
ml	O	1152-1154
,	O	1154-1155
respectively	O	1156-1168
(	O	1169-1170
mean	O	1170-1174
+	O	1175-1176
/	O	1176-1177
-	O	1177-1178
SD	O	1179-1181
,	O	1181-1182
n	O	1183-1184
=	O	1185-1186
6	O	1187-1188
)	O	1188-1189
.	O	1189-1190

The	O	1191-1194
stronger	O	1195-1203
antiarrhythmic	O	1204-1218
effect	O	1219-1225
of	O	1226-1228
(	O	1229-1230
-	O	1230-1231
)	O	1231-1232
-	O	1230-1231
cibenzoline	O	1233-1244
indicates	O	1245-1254
that	O	1255-1259
(	O	1260-1261
-	O	1261-1262
)	O	1262-1263
-	O	1261-1262
isomer	O	1264-1270
may	O	1271-1274
have	O	1275-1279
an	O	1280-1282
effect	O	1283-1289
nearly	O	1290-1296
5	O	1297-1298
-	O	1298-1299
20	O	1299-1301
times	O	1302-1307
stronger	O	1308-1316
in	O	1317-1319
suppressing	O	1320-1331
Na	O	1332-1334
channels	O	1335-1343
,	O	1343-1344
but	O	1345-1348
effects	O	1349-1356
of	O	1357-1359
both	O	1360-1364
drugs	O	1365-1370
on	O	1371-1373
Ca	O	1374-1376
channels	O	1377-1385
may	O	1386-1389
be	O	1390-1392
almost	O	1393-1399
equipotent	O	1400-1410
.	O	1410-1411

Effect	O	0-6
of	O	7-9
Hibiscus	O	10-18
rosa	O	19-23
sinensis	O	24-32
on	O	33-35
reserpine	O	36-45
-	O	45-46
induced	O	46-53
neurobehavioral	O	54-69
and	O	70-73
biochemical	O	74-85
alterations	O	86-97
in	O	98-100
rats	O	101-105
.	O	105-106

Effect	O	107-113
of	O	114-116
methanolic	O	117-127
extract	O	128-135
of	O	136-138
Hibiscus	O	139-147
rosa	O	148-152
sinensis	O	153-161
(	O	162-163
100	O	163-166
-	O	166-167
300	O	167-170
mg	O	171-173
/	O	173-174
kg	O	174-176
)	O	176-177
was	O	178-181
studied	O	182-189
on	O	190-192
reserpine	O	193-202
-	O	202-203
induced	O	203-210
orofacial	O	211-220
dyskinesia	B	221-231
and	O	232-235
neurochemical	O	236-249
alterations	O	250-261
.	O	261-262

The	O	263-266
rats	O	267-271
were	O	272-276
treated	O	277-284
with	O	285-289
intraperitoneal	O	290-305
reserpine	O	306-315
(	O	316-317
1	O	317-318
mg	O	319-321
/	O	321-322
kg	O	322-324
,	O	324-325
ip	O	326-328
)	O	328-329
for	O	330-333
3	O	334-335
days	O	336-340
every	O	341-346
other	O	347-352
day	O	353-356
.	O	356-357

On	O	358-360
day	O	361-364
5	O	365-366
,	O	366-367
vacuous	O	368-375
chewing	O	376-383
movements	O	384-393
and	O	394-397
tongue	O	398-404
protrusions	O	405-416
were	O	417-421
counted	O	422-429
for	O	430-433
5	O	434-435
min	O	436-439
.	O	439-440

Reserpine	O	441-450
treated	O	451-458
rats	O	459-463
significantly	O	464-477
developed	O	478-487
vacuous	O	488-495
chewing	O	496-503
movements	O	504-513
and	O	514-517
tongue	O	518-524
protrusions	O	525-536
however	O	537-544
,	O	544-545
coadministration	O	546-562
of	O	563-565
Hibiscus	O	566-574
rosa	O	575-579
sinensis	O	580-588
roots	O	589-594
extract	O	595-602
(	O	603-604
100	O	604-607
,	O	607-608
200	O	609-612
and	O	613-616
300	O	617-620
mg	O	621-623
/	O	623-624
kg	O	624-626
,	O	626-627
per	O	628-631
orally	O	632-638
)	O	638-639
attenuated	O	640-650
the	O	651-654
effects	O	655-662
.	O	662-663

Biochemical	O	664-675
analysis	O	676-684
of	O	685-687
brain	O	688-693
revealed	O	694-702
that	O	703-707
the	O	708-711
reserpine	O	712-721
treatment	O	722-731
significantly	O	732-745
increased	O	746-755
lipid	O	756-761
peroxidation	O	762-774
and	O	775-778
decreased	O	779-788
levels	O	789-795
of	O	796-798
superoxide	O	799-809
dismutase	O	810-819
(	O	820-821
SOD	O	821-824
)	O	824-825
,	O	825-826
catalase	O	827-835
(	O	836-837
CAT	O	837-840
)	O	840-841
and	O	842-845
glutathione	O	846-857
reductase	O	858-867
(	O	868-869
GSH	O	869-872
)	O	872-873
,	O	873-874
an	O	875-877
index	O	878-883
of	O	884-886
oxidative	O	887-896
stress	O	897-903
process	O	904-911
.	O	911-912

Coadministration	O	913-929
of	O	930-932
extract	O	933-940
significantly	O	941-954
reduced	O	955-962
the	O	963-966
lipid	O	967-972
peroxidation	O	973-985
and	O	986-989
reversed	O	990-998
the	O	999-1002
decrease	O	1003-1011
in	O	1012-1014
brain	O	1015-1020
SOD	O	1021-1024
,	O	1024-1025
CAT	O	1026-1029
and	O	1030-1033
GSH	O	1034-1037
levels	O	1038-1044
.	O	1044-1045

The	O	1046-1049
results	O	1050-1057
of	O	1058-1060
the	O	1061-1064
present	O	1065-1072
study	O	1073-1078
suggested	O	1079-1088
that	O	1089-1093
Hibiscus	O	1094-1102
rosa	O	1103-1107
sinensis	O	1108-1116
had	O	1117-1120
a	O	1121-1122
protective	O	1123-1133
role	O	1134-1138
against	O	1139-1146
reserpine	O	1147-1156
-	O	1156-1157
induced	O	1157-1164
orofacial	O	1165-1174
dyskinesia	B	1175-1185
and	O	1186-1189
oxidative	O	1190-1199
stress	O	1200-1206
.	O	1206-1207

Comparison	O	0-10
of	O	11-13
aqueous	O	14-21
and	O	22-25
gellan	O	26-32
ophthalmic	O	33-43
timolol	O	44-51
with	O	52-56
placebo	O	57-64
on	O	65-67
the	O	68-71
24	O	72-74
-	O	74-75
hour	O	75-79
heart	O	80-85
rate	O	86-90
response	O	91-99
in	O	100-102
patients	O	103-111
on	O	112-114
treatment	O	115-124
for	O	125-128
glaucoma	B	129-137
.	O	137-138

PURPOSE	O	139-146
:	O	146-147
Topical	O	148-155
beta	O	156-160
-	O	160-161
blocker	O	161-168
treatment	O	169-178
is	O	179-181
routine	O	182-189
therapy	O	190-197
in	O	198-200
the	O	201-204
management	O	205-215
of	O	216-218
patients	O	219-227
with	O	228-232
glaucoma	B	233-241
.	O	241-242

Therapy	O	243-250
results	O	251-258
in	O	259-261
systemic	O	262-270
absorption	O	271-281
,	O	281-282
however	O	283-290
,	O	290-291
the	O	292-295
degree	O	296-302
of	O	303-305
reduction	O	306-315
of	O	316-318
resting	O	319-326
and	O	327-330
peak	O	331-335
heart	O	336-341
rate	O	342-346
has	O	347-350
not	O	351-354
been	O	355-359
quantified	O	360-370
.	O	370-371

DESIGN	O	372-378
:	O	378-379
This	O	380-384
trial	O	385-390
evaluated	O	391-400
the	O	401-404
effect	O	405-411
of	O	412-414
placebo	O	415-422
,	O	422-423
0	O	424-425
.	O	425-426
5	O	426-427
%	O	427-428
aqueous	O	429-436
timolol	O	437-444
(	O	445-446
timolol	O	446-453
solution	O	454-462
)	O	462-463
and	O	464-467
a	O	468-469
0	O	470-471
.	O	471-472
5	O	472-473
%	O	473-474
timolol	O	475-482
suspension	O	483-493
that	O	494-498
forms	O	499-504
a	O	505-506
gel	O	507-510
on	O	511-513
application	O	514-525
to	O	526-528
the	O	529-532
conjunctiva	O	533-544
(	O	545-546
timolol	O	546-553
gellan	O	554-560
)	O	560-561
on	O	562-564
the	O	565-568
24	O	569-571
-	O	571-572
hour	O	572-576
heart	O	577-582
rate	O	583-587
in	O	588-590
patients	O	591-599
currently	O	600-609
being	O	610-615
treated	O	616-623
for	O	624-627
glaucoma	B	628-636
to	O	637-639
quantify	O	640-648
the	O	649-652
reduction	O	653-662
in	O	663-665
mean	O	666-670
heart	O	671-676
rate	O	677-681
.	O	681-682

METHODS	O	683-690
:	O	690-691
Forty	O	692-697
-	O	697-698
three	O	698-703
Caucasian	O	704-713
patients	O	714-722
with	O	723-727
primary	O	728-735
open	B	736-740
-	I	740-741
angle	I	741-746
glaucoma	I	747-755
or	O	756-758
ocular	B	759-765
hypertension	I	766-778
with	O	779-783
a	O	784-785
mean	O	786-790
(	O	791-792
+	O	792-793
/	O	793-794
-	O	794-795
SD	O	795-797
)	O	797-798
age	O	799-802
of	O	803-805
63	O	806-808
(	O	809-810
+	O	810-811
/	O	811-812
-	O	812-813
8	O	813-814
)	O	814-815
years	O	816-821
were	O	822-826
randomized	O	827-837
and	O	838-841
crossed	O	842-849
over	O	850-854
in	O	855-857
a	O	858-859
double	O	860-866
-	O	866-867
masked	O	867-873
manner	O	874-880
to	O	881-883
14	O	884-886
days	O	887-891
of	O	892-894
treatment	O	895-904
with	O	905-909
placebo	O	910-917
(	O	918-919
morning	O	919-926
and	O	927-930
evening	O	931-938
in	O	939-941
both	O	942-946
eyes	O	947-951
)	O	951-952
,	O	952-953
timolol	O	954-961
solution	O	962-970
(	O	971-972
morning	O	972-979
and	O	980-983
evening	O	984-991
in	O	992-994
both	O	995-999
eyes	O	1000-1004
)	O	1004-1005
,	O	1005-1006
or	O	1007-1009
timolol	O	1010-1017
gellan	O	1018-1024
(	O	1025-1026
morning	O	1026-1033
in	O	1034-1036
both	O	1037-1041
eyes	O	1042-1046
with	O	1047-1051
placebo	O	1052-1059
in	O	1060-1062
the	O	1063-1066
evening	O	1067-1074
)	O	1074-1075
.	O	1075-1076

On	O	1077-1079
the	O	1080-1083
13th	O	1084-1088
day	O	1089-1092
of	O	1093-1095
each	O	1096-1100
period	O	1101-1107
,	O	1107-1108
heart	O	1109-1114
rate	O	1115-1119
was	O	1120-1123
recorded	O	1124-1132
continuously	O	1133-1145
during	O	1146-1152
a	O	1153-1154
typical	O	1155-1162
,	O	1162-1163
ambulant	O	1164-1172
24	O	1173-1175
-	O	1175-1176
hour	O	1176-1180
period	O	1181-1187
.	O	1187-1188

RESULTS	O	1189-1196
:	O	1196-1197
Both	O	1198-1202
timolol	O	1203-1210
solution	O	1211-1219
and	O	1220-1223
timolol	O	1224-1231
gellan	O	1232-1238
reduced	O	1239-1246
the	O	1247-1250
mean	O	1251-1255
24	O	1256-1258
-	O	1258-1259
hour	O	1259-1263
heart	O	1264-1269
rate	O	1270-1274
compared	O	1275-1283
with	O	1284-1288
placebo	O	1289-1296
(	O	1297-1298
P	O	1298-1299
<	O	1300-1301
or	O	1302-1304
=	O	1305-1306
.	O	1307-1308
001	O	1308-1311
)	O	1311-1312
,	O	1312-1313

and	O	1314-1317
this	O	1318-1322
reduction	O	1323-1332
was	O	1333-1336
most	O	1337-1341
pronounced	O	1342-1352
during	O	1353-1359
the	O	1360-1363
daytime	O	1364-1371
(	O	1372-1373
-	O	1373-1374
7	O	1374-1375
.	O	1375-1376
5	O	1376-1377
%	O	1377-1378
change	O	1379-1385
in	O	1386-1388
mean	O	1389-1393
heart	O	1394-1399
rate	O	1400-1404
,	O	1404-1405
-	O	1406-1407
5	O	1407-1408
.	O	1408-1409
7	O	1409-1410
beats	O	1411-1416
/	O	1416-1417
min	O	1417-1420
)	O	1420-1421
.	O	1421-1422

Timolol	O	1423-1430
gellan	O	1431-1437
showed	O	1438-1444
a	O	1445-1446
numerically	O	1447-1458
but	O	1459-1462
not	O	1463-1466
significantly	O	1467-1480
smaller	O	1481-1488
reduction	O	1489-1498
in	O	1499-1501
24	O	1502-1504
-	O	1504-1505
hour	O	1505-1509
heart	O	1510-1515
rate	O	1516-1520
,	O	1520-1521
compared	O	1522-1530
with	O	1531-1535
timolol	O	1536-1543
solution	O	1544-1552
.	O	1552-1553

During	O	1554-1560
the	O	1561-1564
night	O	1565-1570
,	O	1570-1571
the	O	1572-1575
mean	O	1576-1580
12	O	1581-1583
-	O	1583-1584
hour	O	1584-1588
heart	O	1589-1594
rate	O	1595-1599
on	O	1600-1602
placebo	O	1603-1610
and	O	1611-1614
timolol	O	1615-1622
gellan	O	1623-1629
were	O	1630-1634
both	O	1635-1639
significantly	O	1640-1653
less	O	1654-1658
than	O	1659-1663
on	O	1664-1666
timolol	O	1667-1674
solution	O	1675-1683
;	O	1683-1684
the	O	1685-1688
difference	O	1689-1699
between	O	1700-1707
solution	O	1708-1716
and	O	1717-1720
gellan	O	1721-1727
treatments	O	1728-1738
was	O	1739-1742
statistically	O	1743-1756
significant	O	1757-1768
(	O	1769-1770
P	O	1770-1771
=	O	1772-1773
.	O	1774-1775
01	O	1775-1777
)	O	1777-1778
.	O	1774-1775

CONCLUSIONS	O	1780-1791
:	O	1791-1792
Both	O	1793-1797
timolol	O	1798-1805
solution	O	1806-1814
and	O	1815-1818
timolol	O	1819-1826
gellan	O	1827-1833
decrease	O	1834-1842
the	O	1843-1846
mean	O	1847-1851
24	O	1852-1854
-	O	1854-1855
hour	O	1855-1859
heart	O	1860-1865
rate	O	1866-1870
compared	O	1871-1879
with	O	1880-1884
placebo	O	1885-1892
.	O	1892-1893

This	O	1894-1898
response	O	1899-1907
was	O	1908-1911
most	O	1912-1916
pronounced	O	1917-1927
during	O	1928-1934
the	O	1935-1938
active	O	1939-1945
daytime	O	1946-1953
period	O	1954-1960
.	O	1960-1961

These	O	1962-1967
data	O	1968-1972
quantify	O	1973-1981
the	O	1982-1985
modest	O	1986-1992
bradycardia	B	1993-2004
associated	O	2005-2015
with	O	2016-2020
ophthalmic	O	2021-2031
beta	O	2032-2036
-	O	2036-2037
blocker	O	2037-2044
therapy	O	2045-2052
in	O	2053-2055
a	O	2056-2057
typical	O	2058-2065
patient	O	2066-2073
population	O	2074-2084
on	O	2085-2087
therapy	O	2088-2095
for	O	2096-2099
glaucoma	B	2100-2108
.	O	2108-2109

Although	O	2110-2118
exercise	O	2119-2127
performance	O	2128-2139
was	O	2140-2143
not	O	2144-2147
assessed	O	2148-2156
in	O	2157-2159
this	O	2160-2164
trial	O	2165-2170
,	O	2170-2171
reductions	O	2172-2182
of	O	2183-2185
this	O	2186-2190
magnitude	O	2191-2200
should	O	2201-2207
not	O	2208-2211
have	O	2212-2216
substantial	O	2217-2228
clinical	O	2229-2237
consequences	O	2238-2250
.	O	2250-2251

5	O	0-1
flourouracil	O	2-14
-	O	14-15
induced	O	15-22
apical	B	23-29
ballooning	I	30-40
syndrome	I	41-49
:	O	49-50
a	O	51-52
case	O	53-57
report	O	58-64
.	O	64-65

The	O	66-69
apical	B	70-76
ballooning	I	77-87
syndrome	I	88-96
(	O	97-98
ABS	B	98-101
)	O	101-102
is	O	103-105
a	O	106-107
recently	O	108-116
described	O	117-126
stress	O	127-133
-	O	133-134
mediated	O	134-142
acute	B	143-148
cardiac	I	149-156
syndrome	I	157-165
characterized	O	166-179
by	O	180-182
transient	O	183-192
wall	O	193-197
-	O	197-198
motion	O	198-204
abnormalities	O	205-218
involving	O	219-228
the	O	229-232
apex	O	233-237
and	O	238-241
midventricle	O	242-254
with	O	255-259
hyperkinesis	B	260-272
of	O	273-275
the	O	276-279
basal	O	280-285
left	O	286-290
ventricular	O	291-302
(	O	303-304
LV	O	304-306
)	O	306-307
segments	O	308-316
without	O	317-324
obstructive	O	325-336
epicardial	B	337-347
coronary	I	348-356
disease	I	357-364
.	O	364-365

Cardiotoxicity	B	366-380
is	O	381-383
not	O	384-387
an	O	388-390
uncommon	O	391-399
adverse	O	400-407
effect	O	408-414
of	O	415-417
chemotherapeutic	O	418-434
agents	O	435-441
.	O	441-442

However	O	443-450
,	O	450-451
there	O	452-457
are	O	458-461
no	O	462-464
reports	O	465-472
of	O	473-475
ABS	B	476-479
secondary	O	480-489
to	O	490-492
chemotherapeutic	O	493-509
agents	O	510-516
.	O	516-517

We	O	518-520
describe	O	521-529
the	O	530-533
case	O	534-538
of	O	539-541
a	O	542-543
woman	O	544-549
who	O	550-553
developed	O	554-563
the	O	564-567
syndrome	O	568-576
after	O	577-582
chemotherapy	O	583-595
for	O	596-599
metastatic	O	600-610
cancer	B	611-617
.	O	617-618

A	O	619-620
79	O	621-623
-	O	623-624
year	O	624-628
-	O	623-624
old	O	629-632
woman	O	633-638
presented	O	639-648
with	O	649-653
typical	O	654-661
ischemic	B	662-670
chest	B	671-676
pain	I	677-681
,	O	681-682
elevated	O	683-691
cardiac	O	692-699
enzymes	O	700-707
with	O	708-712
significant	O	713-724
ST	O	725-727
-	O	727-728
segment	O	728-735
abnormalities	O	736-749
on	O	750-752
her	O	753-756
electrocardiogram	O	757-774
.	O	774-775

She	O	776-779
underwent	O	780-789
recent	O	790-796
chemotherapy	O	797-809
with	O	810-814
fluorouracil	O	815-827
for	O	828-831
metastatic	O	832-842
colorectal	B	843-853
cancer	I	854-860
.	O	860-861

Echocardiography	O	862-878
revealed	O	879-887
a	O	888-889
wall	O	890-894
-	O	894-895
motion	O	895-901
abnormality	O	902-913
involving	O	914-923
the	O	924-927
apical	O	928-934
and	O	935-938
periapical	O	939-949
segments	O	950-958
which	O	959-964
appeared	O	965-973
akinetic	B	974-982
.	O	982-983

Coronary	O	984-992
angiography	O	993-1004
revealed	O	1005-1013
no	O	1014-1016
obstructive	O	1017-1028
coronary	O	1029-1037
lesions	O	1038-1045
.	O	1045-1046

The	O	1047-1050
patient	O	1051-1058
was	O	1059-1062
stabilized	O	1063-1073
with	O	1074-1078
medical	O	1079-1086
therapy	O	1087-1094
.	O	1094-1095

Four	O	1096-1100
weeks	O	1101-1106
later	O	1107-1112
she	O	1113-1116
remained	O	1117-1125
completely	O	1126-1136
asymptomatic	O	1137-1149
.	O	1149-1150

Echocardiogram	O	1151-1165
revealed	O	1166-1174
a	O	1175-1176
normal	O	1177-1183
ejection	O	1184-1192
fraction	O	1193-1201
and	O	1202-1205
a	O	1206-1207
resolution	O	1208-1218
of	O	1219-1221
the	O	1222-1225
apical	O	1226-1232
akinesis	B	1233-1241
.	O	1241-1242

Pathogenetic	O	1243-1255
mechanisms	O	1256-1266
of	O	1267-1269
cardiac	B	1270-1277
complications	I	1278-1291
in	O	1292-1294
cancer	B	1295-1301
patients	O	1302-1310
undergoing	O	1311-1321
chemotherapy	O	1322-1334
include	O	1335-1342
coronary	B	1343-1351
vasospasm	I	1352-1361
,	O	1361-1362
endothelial	O	1363-1374
damage	O	1375-1381
and	O	1382-1385
consequent	O	1386-1396
thrombus	B	1397-1405
formation	O	1406-1415
.	O	1415-1416

In	O	1417-1419
our	O	1420-1423
patient	O	1424-1431
,	O	1431-1432
both	O	1433-1437
supraphysiologic	O	1438-1454
levels	O	1455-1461
of	O	1462-1464
plasma	O	1465-1471
catecholamines	O	1472-1486
and	O	1487-1490
stress	O	1491-1497
related	O	1498-1505
neuropeptides	O	1506-1519
caused	O	1520-1526
by	O	1527-1529
cancer	B	1530-1536
diagnosis	O	1537-1546
as	O	1547-1549
well	O	1550-1554
as	O	1555-1557
chemotherapy	O	1558-1570
may	O	1571-1574
have	O	1575-1579
contributed	O	1580-1591
the	O	1592-1595
development	O	1596-1607
of	O	1608-1610
ABS	B	1611-1614
.	O	1614-1615

Reduction	O	0-9
of	O	10-12
pain	B	13-17
during	O	18-24
induction	O	25-34
with	O	35-39
target	O	40-46
-	O	46-47
controlled	O	47-57
propofol	O	58-66
and	O	67-70
remifentanil	O	71-83
.	O	83-84

BACKGROUND	O	85-95
:	O	95-96
Pain	B	97-101
on	O	102-104
injection	O	105-114
of	O	115-117
propofol	O	118-126
is	O	127-129
unpleasant	O	130-140
.	O	140-141

We	O	142-144
hypothesized	O	145-157
that	O	158-162
propofol	O	163-171
infusion	O	172-180
pain	B	181-185
might	O	186-191
be	O	192-194
prevented	O	195-204
by	O	205-207
infusing	O	208-216
remifentanil	O	217-229
before	O	230-236
starting	O	237-245
the	O	246-249
propofol	O	250-258
infusion	O	259-267
in	O	268-270
a	O	271-272
clinical	O	273-281
setting	O	282-289
where	O	290-295
target	O	296-302
-	O	302-303
controlled	O	303-313
infusions	O	314-323
(	O	324-325
TCI	O	325-328
)	O	328-329
of	O	330-332
both	O	333-337
drugs	O	338-343
were	O	344-348
used	O	349-353
.	O	353-354

A	O	355-356
prospective	O	357-368
,	O	368-369
randomized	O	370-380
,	O	380-381
double	O	382-388
-	O	388-389
blind	O	389-394
,	O	394-395
placebo	O	396-403
-	O	403-404
controlled	O	404-414
trial	O	415-420
was	O	421-424
performed	O	425-434
to	O	435-437
determine	O	438-447
the	O	448-451
effect	O	452-458
-	O	458-459
site	O	459-463
concentration	O	464-477
(	O	478-479
Ce	O	479-481
)	O	481-482
of	O	483-485
remifentanil	O	486-498
to	O	499-501
prevent	O	502-509
the	O	510-513
pain	B	514-518
without	O	519-526
producing	O	527-536
complications	O	537-550
.	O	550-551

METHODS	O	552-559
:	O	559-560
A	O	561-562
total	O	563-568
of	O	569-571
128	O	572-575
patients	O	576-584
undergoing	O	585-595
general	O	596-603
surgery	O	604-611
were	O	612-616
randomly	O	617-625
allocated	O	626-635
to	O	636-638
receive	O	639-646
normal	O	647-653
saline	O	654-660
(	O	661-662
control	O	662-669
)	O	669-670
or	O	671-673
remifentanil	O	674-686
to	O	687-689
a	O	690-691
target	O	692-698
Ce	O	699-701
of	O	702-704
2	O	705-706
ng	O	707-709
ml	O	710-712
(	O	712-713
-	O	713-714
1	O	714-715
)	O	715-716
(	O	717-718
R2	O	718-720
)	O	720-721
,	O	721-722
4	O	723-724
ng	O	725-727
ml	O	728-730
(	O	730-731
-	O	731-732
1	O	732-733
)	O	733-734
(	O	735-736
R4	O	736-738
)	O	738-739
,	O	739-740
or	O	741-743
6	O	744-745
ng	O	746-748
ml	O	749-751
(	O	751-752
-	O	752-753
1	O	753-754
)	O	754-755
(	O	756-757
R6	O	757-759
)	O	759-760
administered	O	761-773
via	O	774-777
TCI	O	778-781
.	O	781-782

After	O	783-788
the	O	789-792
target	O	793-799
Ce	O	800-802
was	O	803-806
achieved	O	807-815
,	O	815-816
the	O	817-820
infusion	O	821-829
of	O	830-832
propofol	O	833-841
was	O	842-845
started	O	846-853
.	O	853-854

Remifentanil	O	855-867
-	O	867-868
related	O	868-875
complications	O	876-889
were	O	890-894
assessed	O	895-903
during	O	904-910
the	O	911-914
remifentanil	O	915-927
infusion	O	928-936
,	O	936-937
and	O	938-941
pain	B	942-946
caused	O	947-953
by	O	954-956
propofol	O	957-965
was	O	966-969
evaluated	O	970-979
using	O	980-985
a	O	986-987
four	O	988-992
-	O	992-993
point	O	993-998
scale	O	999-1004
during	O	1005-1011
the	O	1012-1015
propofol	O	1016-1024
infusion	O	1025-1033
.	O	1033-1034

RESULTS	O	1035-1042
:	O	1042-1043
The	O	1044-1047
incidence	O	1048-1057
of	O	1058-1060
pain	B	1061-1065
was	O	1066-1069
significantly	O	1070-1083
lower	O	1084-1089
in	O	1090-1092
Groups	O	1093-1099
R4	O	1100-1102
and	O	1103-1106
R6	O	1107-1109
than	O	1110-1114
in	O	1115-1117
the	O	1118-1121
control	O	1122-1129
and	O	1130-1133
R2	O	1134-1136
groups	O	1137-1143
(	O	1144-1145
12	O	1145-1147
/	O	1147-1148
32	O	1148-1150
and	O	1151-1154
6	O	1155-1156
/	O	1156-1157
31	O	1157-1159
vs	O	1160-1162
26	O	1163-1165
/	O	1165-1166
31	O	1166-1168
and	O	1169-1172
25	O	1173-1175
/	O	1175-1176
32	O	1176-1178
,	O	1178-1179
respectively	O	1180-1192
,	O	1192-1193
P	O	1194-1195
<	O	1195-1196
0	O	1196-1197
.	O	1197-1198
001	O	1198-1201
)	O	1201-1202
.	O	1197-1198

Pain	B	1204-1208
was	O	1209-1212
less	O	1213-1217
severe	O	1218-1224
in	O	1225-1227
Groups	O	1228-1234
R4	O	1235-1237
and	O	1238-1241
R6	O	1242-1244
than	O	1245-1249
in	O	1250-1252
the	O	1253-1256
control	O	1257-1264
and	O	1265-1268
R2	O	1269-1271
groups	O	1272-1278
(	O	1279-1280
P	O	1280-1281
<	O	1281-1282
0	O	1282-1283
.	O	1283-1284
001	O	1284-1287
)	O	1287-1288
.	O	1283-1284

However	O	1290-1297
,	O	1297-1298
both	O	1299-1303
incidence	O	1304-1313
and	O	1314-1317
severity	O	1318-1326
of	O	1327-1329
pain	B	1330-1334
were	O	1335-1339
not	O	1340-1343
different	O	1344-1353
between	O	1354-1361
Groups	O	1362-1368
R4	O	1369-1371
and	O	1372-1375
R6	O	1376-1378
.	O	1378-1379

No	O	1380-1382
significant	O	1383-1394
complications	O	1395-1408
were	O	1409-1413
observed	O	1414-1422
during	O	1423-1429
the	O	1430-1433
study	O	1434-1439
.	O	1439-1440

CONCLUSIONS	O	1441-1452
:	O	1452-1453
During	O	1454-1460
induction	O	1461-1470
of	O	1471-1473
anaesthesia	O	1474-1485
with	O	1486-1490
TCI	O	1491-1494
of	O	1495-1497
propofol	O	1498-1506
and	O	1507-1510
remifentanil	O	1511-1523
,	O	1523-1524
a	O	1525-1526
significant	O	1527-1538
reduction	O	1539-1548
in	O	1549-1551
propofol	O	1552-1560
infusion	O	1561-1569
pain	B	1570-1574
was	O	1575-1578
achieved	O	1579-1587
without	O	1588-1595
significant	O	1596-1607
complications	O	1608-1621
by	O	1622-1624
prior	O	1625-1630
administration	O	1631-1645
of	O	1646-1648
remifentanil	O	1649-1661
at	O	1662-1664
a	O	1665-1666
target	O	1667-1673
Ce	O	1674-1676
of	O	1677-1679
4	O	1680-1681
ng	O	1682-1684
ml	O	1685-1687
(	O	1687-1688
-	O	1688-1689
1	O	1689-1690
)	O	1690-1691
.	O	1691-1692

Prenatal	O	0-8
exposure	O	9-17
to	O	18-20
fluoxetine	O	21-31
induces	O	32-39
fetal	B	40-45
pulmonary	I	46-55
hypertension	I	56-68
in	O	69-71
the	O	72-75
rat	O	76-79
.	O	79-80

RATIONALE	O	81-90
:	O	90-91
Fluoxetine	O	92-102
is	O	103-105
a	O	106-107
selective	O	108-117
serotonin	O	118-127
reuptake	O	128-136
inhibitor	O	137-146
antidepressant	O	147-161
widely	O	162-168
used	O	169-173
by	O	174-176
pregnant	O	177-185
women	O	186-191
.	O	191-192

Epidemiological	O	193-208
data	O	209-213
suggest	O	214-221
that	O	222-226
fluoxetine	O	227-237
exposure	O	238-246
prenatally	O	247-257
increases	O	258-267
the	O	268-271
prevalence	O	272-282
of	O	283-285
persistent	O	286-296
pulmonary	B	297-306
hypertension	I	307-319
syndrome	I	320-328
of	O	329-331
the	O	332-335
newborn	O	336-343
.	O	343-344

The	O	345-348
mechanism	O	349-358
responsible	O	359-370
for	O	371-374
this	O	375-379
effect	O	380-386
is	O	387-389
unclear	O	390-397
and	O	398-401
paradoxical	O	402-413
,	O	413-414
considering	O	415-426
the	O	427-430
current	O	431-438
evidence	O	439-447
of	O	448-450
a	O	451-452
pulmonary	B	453-462
hypertension	I	463-475
protective	O	476-486
fluoxetine	O	487-497
effect	O	498-504
in	O	505-507
adult	O	508-513
rodents	O	514-521
.	O	521-522

OBJECTIVES	O	523-533
:	O	533-534
To	O	535-537
evaluate	O	538-546
the	O	547-550
fluoxetine	O	551-561
effect	O	562-568
on	O	569-571
fetal	O	572-577
rat	O	578-581
pulmonary	O	582-591
vascular	O	592-600
smooth	O	601-607
muscle	O	608-614
mechanical	O	615-625
properties	O	626-636
and	O	637-640
cell	O	641-645
proliferation	O	646-659
rate	O	660-664
.	O	664-665

METHODS	O	666-673
:	O	673-674
Pregnant	O	675-683
rats	O	684-688
were	O	689-693
treated	O	694-701
with	O	702-706
fluoxetine	O	707-717
(	O	718-719
10	O	719-721
mg	O	722-724
/	O	724-725
kg	O	725-727
)	O	727-728
from	O	729-733
Day	O	734-737
11	O	738-740
through	O	741-748
Day	O	749-752
21	O	753-755
of	O	756-758
gestation	O	759-768
.	O	768-769

MEASUREMENTS	O	770-782
AND	O	783-786
MAIN	O	787-791
RESULTS	O	792-799
:	O	799-800
Fetuses	O	801-808
were	O	809-813
delivered	O	814-823
by	O	824-826
cesarean	O	827-835
section	O	836-843
.	O	843-844

As	O	845-847
compared	O	848-856
with	O	857-861
controls	O	862-870
,	O	870-871
fluoxetine	O	872-882
exposure	O	883-891
resulted	O	892-900
in	O	901-903
fetal	B	904-909
pulmonary	I	910-919
hypertension	I	920-932
as	O	933-935
evidenced	O	936-945
by	O	946-948
an	O	949-951
increase	O	952-960
in	O	961-963
the	O	964-967
weight	O	968-974
ratio	O	975-980
of	O	981-983
the	O	984-987
right	O	988-993
ventricle	O	994-1003
to	O	1004-1006
the	O	1007-1010
left	O	1011-1015
ventricle	O	1016-1025
plus	O	1026-1030
septum	O	1031-1037
(	O	1038-1039
P	O	1039-1040
=	O	1041-1042
0	O	1043-1044
.	O	1044-1045
02	O	1045-1047
)	O	1047-1048
and	O	1049-1052
by	O	1053-1055
an	O	1056-1058
increase	O	1059-1067
in	O	1068-1070
pulmonary	O	1071-1080
arterial	O	1081-1089
medial	O	1090-1096
thickness	O	1097-1106
(	O	1107-1108
P	O	1108-1109
<	O	1110-1111
0	O	1112-1113
.	O	1113-1114
01	O	1114-1116
)	O	1116-1117
.	O	1113-1114

Postnatal	O	1119-1128
mortality	O	1129-1138
was	O	1139-1142
increased	O	1143-1152
among	O	1153-1158
experimental	O	1159-1171
animals	O	1172-1179
,	O	1179-1180
and	O	1181-1184
arterial	O	1185-1193
oxygen	O	1194-1200
saturation	O	1201-1211
was	O	1212-1215
96	O	1216-1218
+	O	1219-1220
/	O	1220-1221
-	O	1221-1222
1	O	1223-1224
%	O	1224-1225
in	O	1226-1228
1	O	1229-1230
-	O	1230-1231
day	O	1231-1234
-	O	1230-1231
old	O	1235-1238
control	O	1239-1246
animals	O	1247-1254
and	O	1255-1258
significantly	O	1259-1272
lower	O	1273-1278
(	O	1279-1280
P	O	1280-1281
<	O	1282-1283
0	O	1284-1285
.	O	1285-1286
01	O	1286-1288
)	O	1288-1289
in	O	1290-1292
fluoxetine	O	1293-1303
-	O	1303-1304
exposed	O	1304-1311
pups	O	1312-1316
(	O	1317-1318
79	O	1318-1320
+	O	1321-1322
/	O	1322-1323
-	O	1323-1324
2	O	1325-1326
%	O	1326-1327
)	O	1327-1328
.	O	1328-1329

In	O	1330-1332
vitro	O	1333-1338
,	O	1338-1339
fluoxetine	O	1340-1350
induced	O	1351-1358
pulmonary	O	1359-1368
arterial	O	1369-1377
muscle	O	1378-1384
contraction	O	1385-1396
in	O	1397-1399
fetal	O	1400-1405
,	O	1405-1406
but	O	1407-1410
not	O	1411-1414
adult	O	1415-1420
,	O	1420-1421
animals	O	1422-1429
(	O	1430-1431
P	O	1431-1432
<	O	1433-1434
0	O	1435-1436
.	O	1436-1437
01	O	1437-1439
)	O	1439-1440
and	O	1441-1444
reduced	O	1445-1452
serotonin	O	1453-1462
-	O	1462-1463
induced	O	1463-1470
contraction	O	1471-1482
at	O	1483-1485
both	O	1486-1490
ages	O	1491-1495
(	O	1496-1497
P	O	1497-1498
<	O	1499-1500
0	O	1501-1502
.	O	1502-1503
01	O	1503-1505
)	O	1505-1506
.	O	1502-1503

After	O	1508-1513
in	O	1514-1516
utero	O	1517-1522
exposure	O	1523-1531
to	O	1532-1534
a	O	1535-1536
low	O	1537-1540
fluoxetine	O	1541-1551
concentration	O	1552-1565
the	O	1566-1569
pulmonary	O	1570-1579
arterial	O	1580-1588
smooth	O	1589-1595
muscle	O	1596-1602
cell	O	1603-1607
proliferation	O	1608-1621
rate	O	1622-1626
was	O	1627-1630
significantly	O	1631-1644
increased	O	1645-1654
in	O	1655-1657
fetal	O	1658-1663
,	O	1663-1664
but	O	1665-1668
not	O	1669-1672
adult	O	1673-1678
,	O	1678-1679
cells	O	1680-1685
(	O	1686-1687
P	O	1687-1688
<	O	1689-1690
0	O	1691-1692
.	O	1692-1693
01	O	1693-1695
)	O	1695-1696
.	O	1692-1693

CONCLUSIONS	O	1698-1709
:	O	1709-1710
In	O	1711-1713
contrast	O	1714-1722
to	O	1723-1725
the	O	1726-1729
adult	O	1730-1735
,	O	1735-1736
fluoxetine	O	1737-1747
exposure	O	1748-1756
in	O	1757-1759
utero	O	1760-1765
induces	O	1766-1773
pulmonary	B	1774-1783
hypertension	I	1784-1796
in	O	1797-1799
the	O	1800-1803
fetal	O	1804-1809
rat	O	1810-1813
as	O	1814-1816
a	O	1817-1818
result	O	1819-1825
of	O	1826-1828
a	O	1829-1830
developmentally	O	1831-1846
regulated	O	1847-1856
increase	O	1857-1865
in	O	1866-1868
pulmonary	O	1869-1878
vascular	O	1879-1887
smooth	O	1888-1894
muscle	O	1895-1901
proliferation	O	1902-1915
.	O	1915-1916

Syncope	B	0-7
and	O	8-11
QT	B	12-14
prolongation	I	15-27
among	O	28-33
patients	O	34-42
treated	O	43-50
with	O	51-55
methadone	O	56-65
for	O	66-69
heroin	O	70-76
dependence	O	77-87
in	O	88-90
the	O	91-94
city	O	95-99
of	O	100-102
Copenhagen	O	103-113
.	O	113-114

BACKGROUND	O	115-125
:	O	125-126
Methadone	O	127-136
is	O	137-139
prescribed	O	140-150
to	O	151-153
heroin	O	154-160
addicts	O	161-168
to	O	169-171
decrease	O	172-180
illicit	O	181-188
opioid	O	189-195
use	O	196-199
.	O	199-200

Prolongation	O	201-213
of	O	214-216
the	O	217-220
QT	O	221-223
interval	O	224-232
in	O	233-235
the	O	236-239
ECG	O	240-243
of	O	244-246
patients	O	247-255
with	O	256-260
torsade	B	261-268
de	I	269-271
pointes	I	272-279
(	O	280-281
TdP	B	281-284
)	O	284-285
has	O	286-289
been	O	290-294
reported	O	295-303
in	O	304-306
methadone	O	307-316
users	O	317-322
.	O	322-323

As	O	324-326
heroin	O	327-333
addicts	O	334-341
sometimes	O	342-351
faint	O	352-357
while	O	358-363
using	O	364-369
illicit	O	370-377
drugs	O	378-383
,	O	383-384
doctors	O	385-392
might	O	393-398
attribute	O	399-408
too	O	409-412
many	O	413-417
episodes	O	418-426
of	O	427-429
syncope	B	430-437
to	O	438-440
illicit	O	441-448
drug	O	449-453
use	O	454-457
and	O	458-461
thereby	O	462-469
underestimate	O	470-483
the	O	484-487
incidence	O	488-497
of	O	498-500
TdP	B	501-504
in	O	505-507
this	O	508-512
special	O	513-520
population	O	521-531
,	O	531-532
and	O	533-536
the	O	537-540
high	O	541-545
mortality	O	546-555
in	O	556-558
this	O	559-563
population	O	564-574
may	O	575-578
,	O	578-579
in	O	580-582
part	O	583-587
,	O	587-588
be	O	589-591
caused	O	592-598
by	O	599-601
the	O	602-605
proarrhythmic	O	606-619
effect	O	620-626
of	O	627-629
methadone	O	630-639
.	O	639-640

METHODS	O	641-648
:	O	648-649
In	O	650-652
this	O	653-657
cross	O	658-663
-	O	663-664
sectional	O	664-673
study	O	674-679
interview	O	680-689
,	O	689-690
ECGs	O	691-695
and	O	696-699
blood	O	700-705
samples	O	706-713
were	O	714-718
collected	O	719-728
in	O	729-731
a	O	732-733
population	O	734-744
of	O	745-747
adult	O	748-753
heroin	O	754-760
addicts	O	761-768
treated	O	769-776
with	O	777-781
methadone	O	782-791
or	O	792-794
buprenorphine	O	795-808
on	O	809-811
a	O	812-813
daily	O	814-819
basis	O	820-825
.	O	825-826

Of	O	827-829
the	O	830-833
patients	O	834-842
at	O	843-845
the	O	846-849
Drug	O	850-854
Addiction	O	855-864
Service	O	865-872
in	O	873-875
the	O	876-879
municipal	O	880-889
of	O	890-892
Copenhagen	O	893-903
,	O	903-904
450	O	905-908
(	O	909-910
approximately	O	910-923
52	O	924-926
%	O	926-927
)	O	927-928
were	O	929-933
included	O	934-942
.	O	942-943

The	O	944-947
QT	O	948-950
interval	O	951-959
was	O	960-963
estimated	O	964-973
from	O	974-978
12	O	979-981
lead	O	982-986
ECGs	O	987-991
.	O	991-992

All	O	993-996
participants	O	997-1009
were	O	1010-1014
interviewed	O	1015-1026
about	O	1027-1032
any	O	1033-1036
experience	O	1037-1047
of	O	1048-1050
syncope	B	1051-1058
.	O	1058-1059

The	O	1060-1063
association	O	1064-1075
between	O	1076-1083
opioid	O	1084-1090
dose	O	1091-1095
and	O	1096-1099
QT	O	1100-1102
,	O	1102-1103
and	O	1104-1107
methadone	O	1108-1117
dose	O	1118-1122
and	O	1123-1126
reporting	O	1127-1136
of	O	1137-1139
syncope	B	1140-1147
was	O	1148-1151
assessed	O	1152-1160
using	O	1161-1166
multivariate	O	1167-1179
linear	O	1180-1186
regression	O	1187-1197
and	O	1198-1201
logistic	O	1202-1210
regression	O	1211-1221
,	O	1221-1222
respectively	O	1223-1235
.	O	1235-1236

RESULTS	O	1237-1244
:	O	1244-1245
Methadone	O	1246-1255
dose	O	1256-1260
was	O	1261-1264
associated	O	1265-1275
with	O	1276-1280
longer	O	1281-1287
QT	O	1288-1290
interval	O	1291-1299
of	O	1300-1302
0	O	1303-1304
.	O	1304-1305
140	O	1305-1308
ms	O	1309-1311
/	O	1311-1312
mg	O	1312-1314
(	O	1315-1316
p	O	1316-1317
=	O	1318-1319
0	O	1320-1321
.	O	1321-1322
002	O	1322-1325
)	O	1325-1326
.	O	1321-1322

No	O	1328-1330
association	O	1331-1342
between	O	1343-1350
buprenorphine	O	1351-1364
and	O	1365-1368
QTc	O	1369-1372
was	O	1373-1376
found	O	1377-1382
.	O	1382-1383

Among	O	1384-1389
the	O	1390-1393
subjects	O	1394-1402
treated	O	1403-1410
with	O	1411-1415
methadone	O	1416-1425
,	O	1425-1426
28	O	1427-1429
%	O	1429-1430
men	O	1431-1434
and	O	1435-1438
32	O	1439-1441
%	O	1441-1442
women	O	1443-1448
had	O	1449-1452
prolonged	B	1453-1462
QTc	I	1463-1466
interval	I	1467-1475
.	O	1475-1476

None	O	1477-1481
of	O	1482-1484
the	O	1485-1488
subjects	O	1489-1497
treated	O	1498-1505
with	O	1506-1510
buprenorphine	O	1511-1524
had	O	1525-1528
QTc	O	1529-1532
interval	O	1533-1541
>	O	1542-1543
0	O	1543-1544
.	O	1544-1545
440	O	1545-1548
s	O	1549-1550
(	O	1550-1551
(	O	1550-1551
1	O	1552-1553
/	O	1553-1554
2	O	1554-1555
)	O	1555-1556
)	O	1555-1556
.	O	1557-1558

A	O	1559-1560
50	O	1561-1563
mg	O	1564-1566
higher	O	1567-1573
methadone	O	1574-1583
dose	O	1584-1588
was	O	1589-1592
associated	O	1593-1603
with	O	1604-1608
a	O	1609-1610
1	O	1611-1612
.	O	1612-1613
2	O	1613-1614
(	O	1615-1616
95	O	1616-1618
%	O	1618-1619
CI	O	1620-1622
1	O	1623-1624
.	O	1624-1625
1	O	1623-1624
to	O	1627-1629
1	O	1630-1631
.	O	1631-1632
4	O	1632-1633
)	O	1633-1634
times	O	1635-1640
higher	O	1641-1647
odds	O	1648-1652
for	O	1653-1656
syncope	B	1657-1664
.	O	1664-1665

CONCLUSIONS	O	1666-1677
:	O	1677-1678
Methadone	O	1679-1688
is	O	1689-1691
associated	O	1692-1702
with	O	1703-1707
QT	B	1708-1710
prolongation	I	1711-1723
and	O	1724-1727
higher	O	1728-1734
reporting	O	1735-1744
of	O	1745-1747
syncope	B	1748-1755
in	O	1756-1758
a	O	1759-1760
population	O	1761-1771
of	O	1772-1774
heroin	O	1775-1781
addicts	O	1782-1789
.	O	1789-1790

Peripheral	B	0-10
neuropathy	I	11-21
caused	O	22-28
by	O	29-31
high	O	32-36
-	O	36-37
dose	O	37-41
cytosine	O	42-50
arabinoside	O	51-62
treatment	O	63-72
in	O	73-75
a	O	76-77
patient	O	78-85
with	O	86-90
acute	B	91-96
myeloid	I	97-104
leukemia	I	105-113
.	O	113-114

The	O	115-118
central	O	119-126
nervous	O	127-134
system	O	135-141
toxicity	B	142-150
of	O	151-153
high	O	154-158
-	O	158-159
dose	O	159-163
cytosine	O	164-172
arabinoside	O	173-184
is	O	185-187
well	O	188-192
recognized	O	193-203
,	O	203-204
but	O	205-208
the	O	209-212
toxicity	B	213-221
of	O	222-224
cytosine	O	225-233
arabinoside	O	234-245
in	O	246-248
the	O	249-252
peripheral	O	253-263
nervous	O	264-271
system	O	272-278
has	O	279-282
been	O	283-287
infrequently	O	288-300
reported	O	301-309
.	O	309-310

A	O	311-312
49	O	313-315
-	O	315-316
year	O	316-320
-	O	315-316
old	O	321-324
Japanese	O	325-333
man	O	334-337
was	O	338-341
diagnosed	O	342-351
with	O	352-356
acute	B	357-362
myeloid	I	363-370
leukemia	I	371-379
.	O	379-380

After	O	381-386
he	O	387-389
achieved	O	390-398
complete	O	399-407
remission	O	408-417
,	O	417-418
he	O	419-421
received	O	422-430
high	O	431-435
-	O	435-436
dose	O	436-440
cytosine	O	441-449
arabinoside	O	450-461
treatment	O	462-471
(	O	472-473
2	O	473-474
g	O	475-476
/	O	476-477
m2	O	477-479
twice	O	480-485
a	O	486-487
day	O	488-491
for	O	492-495
5	O	496-497
days	O	498-502
;	O	502-503
total	O	504-509
,	O	509-510
20	O	511-513
g	O	514-515
/	O	515-516
m2	O	516-518
)	O	518-519
as	O	520-522
consolidation	O	523-536
therapy	O	537-544
.	O	544-545

The	O	546-549
first	O	550-555
course	O	556-562
of	O	563-565
high	O	566-570
-	O	570-571
dose	O	571-575
cytosine	O	576-584
arabinoside	O	585-596
resulted	O	597-605
in	O	606-608
no	O	609-611
unusual	O	612-619
symptoms	O	620-628
,	O	628-629
but	O	630-633
on	O	634-636
day	O	637-640
21	O	641-643
of	O	644-646
the	O	647-650
second	O	651-657
course	O	658-664
of	O	665-667
treatment	O	668-677
,	O	677-678
the	O	679-682
patient	O	683-690
complained	O	691-701
of	O	702-704
numbness	B	705-713
in	O	714-716
his	O	717-720
right	O	721-726
foot	O	727-731
.	O	731-732

Electromyogram	O	733-747
and	O	748-751
nerve	O	752-757
-	O	757-758
conduction	O	758-768
studies	O	769-776
showed	O	777-783
peripheral	B	784-794
neuropathy	I	795-805
in	O	806-808
both	O	809-813
peroneal	O	814-822
nerves	O	823-829
.	O	829-830

This	O	831-835
neuropathy	B	836-846
was	O	847-850
gradually	O	851-860
resolving	O	861-870
;	O	870-871
however	O	872-879
,	O	879-880
after	O	881-886
the	O	887-890
patient	O	891-898
received	O	899-907
allogeneic	O	908-918
bone	O	919-923
marrow	O	924-930
transplantation	O	931-946
,	O	946-947
the	O	948-951
symptoms	O	952-960
worsened	O	961-969
,	O	969-970
with	O	971-975
the	O	976-979
development	O	980-991
of	O	992-994
graft	B	995-1000
-	I	1000-1001
versus	I	1001-1007
-	I	1000-1001
host	I	1008-1012
disease	I	1013-1020
,	O	1020-1021
and	O	1022-1025
the	O	1026-1029
symptoms	O	1030-1038
subsequently	O	1039-1051
responded	O	1052-1061
to	O	1062-1064
methylprednisolone	O	1065-1083
.	O	1083-1084

Although	O	1085-1093
the	O	1094-1097
mechanisms	O	1098-1108
of	O	1109-1111
peripheral	B	1112-1122
neuropathy	I	1123-1133
are	O	1134-1137
still	O	1138-1143
unclear	O	1144-1151
,	O	1151-1152
high	O	1153-1157
-	O	1157-1158
dose	O	1158-1162
cytosine	O	1163-1171
arabinoside	O	1172-1183
is	O	1184-1186
a	O	1187-1188
therapy	O	1189-1196
that	O	1197-1201
is	O	1202-1204
potentially	O	1205-1216
toxic	O	1217-1222
to	O	1223-1225
the	O	1226-1229
peripheral	O	1230-1240
nervous	O	1241-1248
system	O	1249-1255
,	O	1255-1256
and	O	1257-1260
auto	O	1261-1265
/	O	1265-1266
alloimmunity	O	1266-1278
may	O	1279-1282
play	O	1283-1287
an	O	1288-1290
important	O	1291-1300
role	O	1301-1305
in	O	1306-1308
these	O	1309-1314
mechanisms	O	1315-1325
.	O	1325-1326

Atorvastatin	O	0-12
prevented	O	13-22
and	O	23-26
reversed	O	27-35
dexamethasone	O	36-49
-	O	49-50
induced	O	50-57
hypertension	B	58-70
in	O	71-73
the	O	74-77
rat	O	78-81
.	O	81-82

To	O	83-85
assess	O	86-92
the	O	93-96
antioxidant	O	97-108
effects	O	109-116
of	O	117-119
atorvastatin	O	120-132
(	O	133-134
atorva	O	134-140
)	O	140-141
on	O	142-144
dexamethasone	O	145-158
(	O	159-160
dex	O	160-163
)	O	163-164
-	O	164-165
induced	O	165-172
hypertension	B	173-185
,	O	185-186
60	O	187-189
male	O	190-194
Sprague	O	195-202
-	O	202-203
Dawley	O	203-209
rats	O	210-214
were	O	215-219
treated	O	220-227
with	O	228-232
atorva	O	233-239
30	O	240-242
mg	O	243-245
/	O	245-246
kg	O	246-248
/	O	245-246
day	O	249-252
or	O	253-255
tap	O	256-259
water	O	260-265
for	O	266-269
15	O	270-272
days	O	273-277
.	O	277-278

Dex	O	279-282
increased	O	283-292
systolic	O	293-301
blood	O	302-307
pressure	O	308-316
(	O	317-318
SBP	O	318-321
)	O	321-322
from	O	323-327
109	O	328-331
+	O	332-333
/	O	333-334
-	O	334-335
1	O	336-337
.	O	337-338
8	O	338-339
to	O	340-342
135	O	343-346
+	O	347-348
/	O	348-349
-	O	349-350
0	O	351-352
.	O	352-353
6	O	353-354
mmHg	O	355-359
and	O	360-363
plasma	O	364-370
superoxide	O	371-381
(	O	382-383
5711	O	383-387
+	O	388-389
/	O	389-390
-	O	390-391
284	O	392-395
.	O	395-396
9	O	396-397
saline	O	398-404
,	O	404-405
7931	O	406-410
+	O	411-412
/	O	412-413
-	O	413-414
392	O	415-418
.	O	418-419
8	O	419-420
U	O	421-422
/	O	422-423
ml	O	423-425
dex	O	426-429
,	O	429-430
P	O	431-432
<	O	433-434
0	O	435-436
.	O	436-437
001	O	437-440
)	O	440-441
.	O	436-437

In	O	443-445
this	O	446-450
prevention	O	451-461
study	O	462-467
,	O	467-468
SBP	O	469-472
in	O	473-475
the	O	476-479
atorva	O	480-486
+	O	487-488
dex	O	489-492
group	O	493-498
was	O	499-502
increased	O	503-512
from	O	513-517
115	O	518-521
+	O	522-523
/	O	523-524
-	O	524-525
0	O	526-527
.	O	527-528
4	O	528-529
to	O	530-532
124	O	533-536
+	O	537-538
/	O	538-539
-	O	539-540
1	O	541-542
.	O	542-543
5	O	543-544
mmHg	O	545-549
,	O	549-550
but	O	551-554
this	O	555-559
was	O	560-563
significantly	O	564-577
lower	O	578-583
than	O	584-588
in	O	589-591
the	O	592-595
dex	O	596-599
-	O	599-600
only	O	600-604
group	O	605-610
(	O	611-612
P	O	612-613
'	O	613-614
<	O	615-616
0	O	617-618
.	O	618-619
05	O	619-621
)	O	621-622
.	O	618-619

Atorva	O	624-630
reversed	O	631-639
dex	O	640-643
-	O	643-644
induced	O	644-651
hypertension	B	652-664
(	O	665-666
129	O	666-669
+	O	670-671
/	O	671-672
-	O	672-673
0	O	674-675
.	O	675-676
6	O	676-677
mmHg	O	678-682
,	O	682-683
vs	O	684-686
.	O	686-687
135	O	688-691
+	O	692-693
/	O	693-694
-	O	694-695
0	O	696-697
.	O	697-698
6	O	698-699
mmHg	O	700-704
P	O	705-706
'	O	706-707
<	O	708-709
0	O	710-711
.	O	711-712
05	O	712-714
)	O	714-715
and	O	716-719
decreased	O	720-729
plasma	O	730-736
superoxide	O	737-747
(	O	748-749
7931	O	749-753
+	O	754-755
/	O	755-756
-	O	756-757
392	O	758-761
.	O	761-762
8	O	762-763
dex	O	764-767
,	O	767-768
1187	O	769-773
+	O	774-775
/	O	775-776
-	O	776-777
441	O	778-781
.	O	781-782
2	O	782-783
atorva	O	784-790
+	O	791-792
dex	O	793-796
,	O	796-797
P	O	798-799
<	O	800-801
0	O	802-803
.	O	803-804
0001	O	804-808
)	O	808-809
.	O	803-804

Plasma	O	811-817
nitrate	O	818-825
/	O	825-826
nitrite	O	826-833
(	O	834-835
NOx	O	835-838
)	O	838-839
was	O	840-843
decreased	O	844-853
in	O	854-856
dex	O	857-860
-	O	860-861
treated	O	861-868
rats	O	869-873
compared	O	874-882
to	O	883-885
saline	O	886-892
-	O	892-893
treated	O	893-900
rats	O	901-905
(	O	906-907
11	O	907-909
.	O	909-910
2	O	910-911
+	O	912-913
/	O	913-914
-	O	914-915
1	O	916-917
.	O	917-918
08	O	918-920
microm	O	921-927
,	O	927-928
15	O	929-931
.	O	931-932
3	O	932-933
+	O	934-935
/	O	935-936
-	O	936-937
1	O	938-939
.	O	939-940
17	O	940-942
microm	O	943-949
,	O	949-950
respectively	O	951-963
,	O	963-964
P	O	965-966
<	O	967-968
0	O	969-970
.	O	970-971
05	O	971-973
)	O	973-974
.	O	970-971

Atorva	O	976-982
affected	O	983-991
neither	O	992-999
plasma	O	1000-1006
NOx	O	1007-1010
nor	O	1011-1014
thymus	O	1015-1021
weight	O	1022-1028
.	O	1028-1029

Thus	O	1030-1034
,	O	1034-1035
atorvastatin	O	1036-1048
prevented	O	1049-1058
and	O	1059-1062
reversed	O	1063-1071
dexamethasone	O	1072-1085
-	O	1085-1086
induced	O	1086-1093
hypertension	B	1094-1106
in	O	1107-1109
the	O	1110-1113
rat	O	1114-1117
.	O	1117-1118

Two	O	0-3
prodrugs	O	4-12
of	O	13-15
potent	O	16-22
and	O	23-26
selective	O	27-36
GluR5	O	37-42
kainate	O	43-50
receptor	O	51-59
antagonists	O	60-71
actives	O	72-79
in	O	80-82
three	O	83-88
animal	O	89-95
models	O	96-102
of	O	103-105
pain	B	106-110
.	O	110-111

Amino	O	112-117
acids	O	118-123
5	O	124-125
and	O	126-129
7	O	130-131
,	O	131-132
two	O	133-136
potent	O	137-143
and	O	144-147
selective	O	148-157
competitive	O	158-169
GluR5	O	170-175
KA	O	176-178
receptor	O	179-187
antagonists	O	188-199
,	O	199-200
exhibited	O	201-210
high	O	211-215
GluR5	O	216-221
receptor	O	222-230
affinity	O	231-239
over	O	240-244
other	O	245-250
glutamate	O	251-260
receptors	O	261-270
.	O	270-271

Their	O	272-277
ester	O	278-283
prodrugs	O	284-292
6	O	293-294
and	O	295-298
8	O	299-300
were	O	301-305
orally	O	306-312
active	O	313-319
in	O	320-322
three	O	323-328
models	O	329-335
of	O	336-338
pain	B	339-343
:	O	343-344
reversal	O	345-353
of	O	354-356
formalin	O	357-365
-	O	365-366
induced	O	366-373
paw	O	374-377
licking	O	378-385
,	O	385-386
carrageenan	O	387-398
-	O	398-399
induced	O	399-406
thermal	B	407-414
hyperalgesia	I	415-427
,	O	427-428
and	O	429-432
capsaicin	O	433-442
-	O	442-443
induced	O	443-450
mechanical	B	451-461
hyperalgesia	I	462-474
.	O	474-475

Sirolimus	O	0-9
and	O	10-13
mycophenolate	O	14-27
mofetil	O	28-35
for	O	36-39
calcineurin	O	40-51
-	O	51-52
free	O	52-56
immunosuppression	O	57-74
in	O	75-77
renal	O	78-83
transplant	O	84-94
recipients	O	95-105
.	O	105-106

Calcineurin	O	107-118
inhibitors	O	119-129
,	O	129-130
such	O	131-135
as	O	136-138
cyclosporine	O	139-151
and	O	152-155
tacrolimus	O	156-166
,	O	166-167
have	O	168-172
been	O	173-177
available	O	178-187
for	O	188-191
almost	O	192-198
20	O	199-201
years	O	202-207
.	O	207-208

Although	O	209-217
these	O	218-223
drugs	O	224-229
are	O	230-233
highly	O	234-240
effective	O	241-250
and	O	251-254
represent	O	255-264
the	O	265-268
mainstay	O	269-277
of	O	278-280
transplant	O	281-291
immunosuppression	O	292-309
,	O	309-310
they	O	311-315
are	O	316-319
associated	O	320-330
with	O	331-335
acute	O	336-341
and	O	342-345
chronic	O	346-353
nephrotoxicity	B	354-368
.	O	368-369

Acute	O	370-375
nephrotoxicity	B	376-390
,	O	390-391
which	O	392-397
occurs	O	398-404
in	O	405-407
the	O	408-411
early	O	412-417
period	O	418-424
after	O	425-430
transplantation	O	431-446
,	O	446-447
leads	O	448-453
to	O	454-456
a	O	457-458
higher	O	459-465
rate	O	466-470
of	O	471-473
dialysis	O	474-482
,	O	482-483
and	O	484-487
chronic	O	488-495
nephrotoxicity	B	496-510
may	O	511-514
eventually	O	515-525
result	O	526-532
in	O	533-535
graft	O	536-541
loss	O	542-546
.	O	546-547

Acute	O	548-553
and	O	554-557
chronic	O	558-565
nephrotoxicity	B	566-580
is	O	581-583
becoming	O	584-592
more	O	593-597
common	O	598-604
as	O	605-607
the	O	608-611
use	O	612-615
of	O	616-618
marginal	O	619-627
kidneys	O	628-635
for	O	636-639
transplantation	O	640-655
increases	O	656-665
.	O	665-666

Two	O	667-670
recently	O	671-679
available	O	680-689
immunosuppressive	O	690-707
agents	O	708-714
,	O	714-715
mycophenolate	O	716-729
mofetil	O	730-737
and	O	738-741
sirolimus	O	742-751
(	O	752-753
rapamycin	O	753-762
)	O	762-763
,	O	763-764
have	O	765-769
no	O	770-772
nephrotoxicity	B	773-787
.	O	787-788

The	O	789-792
use	O	793-796
of	O	797-799
these	O	800-805
drugs	O	806-811
in	O	812-814
combination	O	815-826
with	O	827-831
other	O	832-837
agents	O	838-844
has	O	845-848
led	O	849-852
to	O	853-855
the	O	856-859
development	O	860-871
of	O	872-874
new	O	875-878
paradigms	O	879-888
of	O	889-891
immunosuppressive	O	892-909
therapy	O	910-917
.	O	917-918

This	O	919-923
paper	O	924-929
reviews	O	930-937
the	O	938-941
results	O	942-949
of	O	950-952
clinical	O	953-961
trials	O	962-968
that	O	969-973
have	O	974-978
investigated	O	979-991
these	O	992-997
new	O	998-1001
approaches	O	1002-1012
to	O	1013-1015
immunosuppression	O	1016-1033
in	O	1034-1036
renal	O	1037-1042
transplant	O	1043-1053
recipients	O	1054-1064
.	O	1064-1065

Erythropoietin	O	0-14
restores	O	15-23
the	O	24-27
anemia	B	28-34
-	O	34-35
induced	O	35-42
reduction	O	43-52
in	O	53-55
cyclophosphamide	O	56-72
cytotoxicity	B	73-85
in	O	86-88
rat	O	89-92
tumors	B	93-99
.	O	99-100

The	O	101-104
aim	O	105-108
of	O	109-111
this	O	112-116
study	O	117-122
was	O	123-126
to	O	127-129
examine	O	130-137
the	O	138-141
impact	O	142-148
of	O	149-151
anemia	B	152-158
prevention	O	159-169
by	O	170-172
recombinant	O	173-184
human	O	185-190
erythropoietin	O	191-205
(	O	206-207
rHuEPO	O	207-213
)	O	213-214
treatment	O	215-224
on	O	225-227
the	O	228-231
cytotoxicity	B	232-244
of	O	245-247
cyclophosphamide	O	248-264
in	O	265-267
solid	O	268-273
experimental	O	274-286
tumors	B	287-293
.	O	293-294

Anemia	B	295-301
was	O	302-305
induced	O	306-313
using	O	314-319
a	O	320-321
single	O	322-328
dose	O	329-333
of	O	334-336
carboplatin	O	337-348
(	O	349-350
50	O	350-352
mg	O	353-355
/	O	355-356
kg	O	356-358
i	O	359-360
.	O	360-361
v	O	361-362
.	O	360-361
)	O	363-364
resulting	O	365-374
in	O	375-377
a	O	378-379
long	O	380-384
-	O	384-385
lasting	O	385-392
reduction	O	393-402
(	O	403-404
30	O	404-406
%	O	406-407
)	O	407-408
of	O	409-411
the	O	412-415
hemoglobin	O	416-426
concentration	O	427-440
.	O	440-441

In	O	442-444
a	O	445-446
second	O	447-453
group	O	454-459
,	O	459-460
the	O	461-464
development	O	465-476
of	O	477-479
anemia	B	480-486
was	O	487-490
prevented	O	491-500
by	O	501-503
rHuEPO	O	504-510
(	O	511-512
1000	O	512-516
IU	O	517-519
/	O	519-520
kg	O	520-522
)	O	522-523
administered	O	524-536
s	O	537-538
.	O	538-539
c	O	539-540
.	O	538-539

three	O	542-547
times	O	548-553
/	O	553-554
week	O	554-558
starting	O	559-567
7	O	568-569
days	O	570-574
before	O	575-581
carboplatin	O	582-593
application	O	594-605
.	O	605-606

Four	O	607-611
days	O	612-616
after	O	617-622
carboplatin	O	623-634
treatment	O	635-644
,	O	644-645
tumors	B	646-652
(	O	653-654
DS	O	654-656
-	O	656-657
sarcoma	B	657-664
of	O	665-667
the	O	668-671
rat	O	672-675
)	O	675-676
were	O	677-681
implanted	O	682-691
s	O	692-693
.	O	693-694
c	O	694-695
.	O	693-694

onto	O	697-701
the	O	702-705
hind	O	706-710
food	O	711-715
dorsum	O	716-722
.	O	722-723

Neither	O	724-731
carboplatin	O	732-743
nor	O	744-747
rHuEPO	O	748-754
treatment	O	755-764
influenced	O	765-775
tumor	B	776-781
growth	O	782-788
rate	O	789-793
per	O	794-797
se	O	798-800
.	O	800-801

When	O	802-806
tumors	B	807-813
were	O	814-818
treated	O	819-826
with	O	827-831
a	O	832-833
single	O	834-840
dose	O	841-845
of	O	846-848
cyclophosphamide	O	849-865
(	O	866-867
60	O	867-869
mg	O	870-872
/	O	872-873
kg	O	873-875
i	O	876-877
.	O	877-878
p	O	878-879
.	O	877-878
)	O	880-881
5	O	882-883
days	O	884-888
after	O	889-894
implantation	O	895-907
,	O	907-908
a	O	909-910
growth	O	911-917
delay	O	918-923
with	O	924-928
a	O	929-930
subsequent	O	931-941
regrowth	O	942-950
of	O	951-953
the	O	954-957
tumors	B	958-964
was	O	965-968
observed	O	969-977
.	O	977-978

In	O	979-981
the	O	982-985
anemia	B	986-992
group	O	993-998
,	O	998-999
the	O	1000-1003
growth	O	1004-1010
delay	O	1011-1016
was	O	1017-1020
significantly	O	1021-1034
shorter	O	1035-1042
compared	O	1043-1051
with	O	1052-1056
nonanemic	O	1057-1066
controls	O	1067-1075
(	O	1076-1077
13	O	1077-1079
.	O	1079-1080
3	O	1078-1079
days	O	1082-1086
versus	O	1087-1093
8	O	1094-1095
.	O	1095-1096
6	O	1096-1097
days	O	1098-1102
)	O	1102-1103
.	O	1103-1104

In	O	1105-1107
the	O	1108-1111
group	O	1112-1117
where	O	1118-1123
anemia	B	1124-1130
was	O	1131-1134
prevented	O	1135-1144
by	O	1145-1147
rHuEPO	O	1148-1154
treatment	O	1155-1164
,	O	1164-1165
growth	O	1166-1172
delay	O	1173-1178
was	O	1179-1182
comparable	O	1183-1193
with	O	1194-1198
that	O	1199-1203
of	O	1204-1206
nonanemic	O	1207-1216
controls	O	1217-1225
(	O	1226-1227
13	O	1227-1229
.	O	1229-1230
3	O	1228-1229
days	O	1232-1236
)	O	1236-1237
.	O	1237-1238

These	O	1239-1244
results	O	1245-1252
suggest	O	1253-1260
that	O	1261-1265
chemotherapy	O	1266-1278
-	O	1278-1279
induced	O	1279-1286
anemia	B	1287-1293
reduces	O	1294-1301
cytotoxicity	B	1302-1314
of	O	1315-1317
cyclophosphamide	O	1318-1334
in	O	1335-1337
tumors	B	1338-1344
,	O	1344-1345
whereas	O	1346-1353
correction	O	1354-1364
of	O	1365-1367
anemia	B	1368-1374
by	O	1375-1377
rHuEPO	O	1378-1384
treatment	O	1385-1394
(	O	1395-1396
epoetin	O	1396-1403
alpha	O	1404-1409
)	O	1409-1410
increases	O	1411-1420
the	O	1421-1424
sensitivity	O	1425-1436
,	O	1436-1437
probably	O	1438-1446
as	O	1447-1449
a	O	1450-1451
result	O	1452-1458
of	O	1459-1461
an	O	1462-1464
improved	O	1465-1473
oxygen	O	1474-1480
supply	O	1481-1487
to	O	1488-1490
tumor	B	1491-1496
tissue	O	1497-1503
.	O	1503-1504

The	O	0-3
role	O	4-8
of	O	9-11
nitrergic	O	12-21
system	O	22-28
in	O	29-31
lidocaine	O	32-41
-	O	41-42
induced	O	42-49
convulsion	B	50-60
in	O	61-63
the	O	64-67
mouse	O	68-73
.	O	73-74

The	O	75-78
effects	O	79-86
of	O	87-89
N	O	90-91
-	O	91-92
nitro	O	92-97
-	O	91-92
L	O	98-99
-	O	91-92
arginine	O	100-108
-	O	91-92
methyl	O	109-115
ester	O	116-121
(	O	122-123
L	O	123-124
-	O	124-125
NAME	O	125-129
)	O	129-130
a	O	131-132
nitric	O	133-139
oxide	O	140-145
(	O	146-147
NO	O	147-149
)	O	149-150
synthase	O	151-159
inhibitor	O	160-169
and	O	170-173
L	O	174-175
-	O	175-176
arginine	O	176-184
,	O	184-185
a	O	186-187
NO	O	188-190
precursor	O	191-200
,	O	200-201
were	O	202-206
investigated	O	207-219
on	O	220-222
lidocaine	O	223-232
-	O	232-233
induced	O	233-240
convulsions	B	241-252
.	O	252-253

In	O	254-256
the	O	257-260
first	O	261-266
experiment	O	267-277
,	O	277-278
four	O	279-283
groups	O	284-290
of	O	291-293
mice	O	294-298
received	O	299-307
physiological	O	308-321
saline	O	322-328
(	O	329-330
0	O	330-331
.	O	331-332
9	O	332-333
%	O	333-334
)	O	334-335
,	O	335-336
L	O	337-338
-	O	338-339
arginine	O	339-347
(	O	348-349
300	O	349-352
mg	O	353-355
/	O	355-356
kg	O	356-358
,	O	358-359
i	O	360-361
.	O	361-362
p	O	362-363
.	O	361-362
)	O	364-365
,	O	365-366
L	O	367-368
-	O	368-369
NAME	O	369-373
(	O	374-375
100	O	375-378
mg	O	379-381
/	O	381-382
kg	O	382-384
,	O	384-385
i	O	386-387
.	O	387-388
p	O	388-389
.	O	387-388
)	O	390-391
and	O	392-395
diazepam	O	396-404
(	O	405-406
2	O	406-407
mg	O	408-410
/	O	410-411
kg	O	411-413
)	O	413-414
,	O	414-415
respectively	O	416-428
.	O	428-429

Thirty	O	430-436
minutes	O	437-444
after	O	445-450
these	O	451-456
injections	O	457-467
,	O	467-468
all	O	469-472
mice	O	473-477
received	O	478-486
lidocaine	O	487-496
(	O	497-498
50	O	498-500
mg	O	501-503
/	O	503-504
kg	O	504-506
,	O	506-507
i	O	508-509
.	O	509-510
p	O	510-511
.	O	509-510
)	O	512-513
.	O	509-510

In	O	515-517
the	O	518-521
second	O	522-528
experiment	O	529-539
,	O	539-540
four	O	541-545
groups	O	546-552
of	O	553-555
mice	O	556-560
received	O	561-569
similar	O	570-577
treatment	O	578-587
in	O	588-590
the	O	591-594
first	O	595-600
experiment	O	601-611
,	O	611-612
and	O	613-616
30	O	617-619
min	O	620-623
after	O	624-629
these	O	630-635
injections	O	636-646
,	O	646-647
all	O	648-651
mice	O	652-656
received	O	657-665
a	O	666-667
higher	O	668-674
dose	O	675-679
of	O	680-682
lidocaine	O	683-692
(	O	693-694
80	O	694-696
mg	O	697-699
/	O	699-700
kg	O	700-702
)	O	702-703
.	O	703-704

L	O	705-706
-	O	706-707
NAME	O	707-711
(	O	712-713
100	O	713-716
mg	O	717-719
/	O	719-720
kg	O	720-722
,	O	722-723
i	O	724-725
.	O	725-726
p	O	726-727
.	O	725-726
)	O	728-729
and	O	730-733
diazepam	O	734-742
(	O	743-744
2	O	744-745
mg	O	746-748
/	O	748-749
kg	O	749-751
)	O	751-752
significantly	O	753-766
decreased	O	767-776
the	O	777-780
incidence	O	781-790
of	O	791-793
lidocaine	O	794-803
(	O	804-805
50	O	805-807
mg	O	808-810
/	O	810-811
kg	O	811-813
)	O	813-814
-	O	814-815
induced	O	815-822
convulsions	B	823-834
.	O	834-835

In	O	836-838
contrast	O	839-847
,	O	847-848
the	O	849-852
L	O	853-854
-	O	854-855
arginine	O	855-863
treatment	O	864-873
increased	O	874-883
the	O	884-887
incidence	O	888-897
of	O	898-900
lidocaine	O	901-910
(	O	911-912
80	O	912-914
mg	O	915-917
/	O	917-918
kg	O	918-920
,	O	920-921
i	O	922-923
.	O	923-924
p	O	924-925
.	O	923-924
)	O	926-927
-	O	927-928
induced	O	928-935
convulsions	B	936-947
significantly	O	948-961
.	O	961-962

These	O	963-968
results	O	969-976
may	O	977-980
suggest	O	981-988
that	O	989-993
NO	O	994-996
is	O	997-999
a	O	1000-1001
proconvulsant	O	1002-1015
mediator	O	1016-1024
in	O	1025-1027
lidocaine	O	1028-1037
-	O	1037-1038
induced	O	1038-1045
convulsions	B	1046-1057
.	O	1057-1058

Effect	O	0-6
of	O	7-9
intravenous	O	10-21
metoprolol	O	22-32
or	O	33-35
intravenous	O	36-47
metoprolol	O	48-58
plus	O	59-63
glucagon	O	64-72
on	O	73-75
dobutamine	O	76-86
-	O	86-87
induced	O	87-94
myocardial	B	95-105
ischemia	I	106-114
.	O	114-115

STUDY	O	116-121
OBJECTIVE	O	122-131
:	O	131-132
To	O	133-135
determine	O	136-145
the	O	146-149
effect	O	150-156
of	O	157-159
metoprolol	O	160-170
on	O	171-173
dobutamine	O	174-184
stress	O	185-191
testing	O	192-199
with	O	200-204
technetium	O	205-215
-	O	215-216
99m	O	216-219
sestamibi	O	220-229
single	O	230-236
-	O	236-237
photon	O	237-243
emission	O	244-252
computed	O	253-261
tomography	O	262-272
imaging	O	273-280
and	O	281-284
ST	O	285-287
-	O	287-288
segment	O	288-295
monitoring	O	296-306
,	O	306-307
and	O	308-311
to	O	312-314
assess	O	315-321
the	O	322-325
impact	O	326-332
of	O	333-335
intravenous	O	336-347
glucagon	O	348-356
on	O	357-359
metoprolol	O	360-370
'	O	370-371
s	O	371-372
effects	O	373-380
.	O	380-381

DESIGN	O	382-388
:	O	388-389
Randomized	O	390-400
,	O	400-401
double	O	402-408
-	O	408-409
blind	O	409-414
,	O	414-415
placebo	O	416-423
-	O	423-424
controlled	O	424-434
trial	O	435-440
.	O	440-441

SETTING	O	442-449
:	O	449-450
Community	O	451-460
hospital	O	461-469
.	O	469-470

PATIENTS	O	471-479
:	O	479-480
Twenty	O	481-487
-	O	487-488
two	O	488-491
patients	O	492-500
with	O	501-505
known	O	506-511
reversible	O	512-522
perfusion	O	523-532
defects	O	533-540
.	O	540-541

INTERVENTION	O	542-554
:	O	554-555
Patients	O	556-564
underwent	O	565-574
dobutamine	O	575-585
stress	O	586-592
tests	O	593-598
per	O	599-602
standard	O	603-611
protocol	O	612-620
.	O	620-621

Before	O	622-628
dobutamine	O	629-639
was	O	640-643
begun	O	644-649
,	O	649-650
no	O	651-653
therapy	O	654-661
was	O	662-665
given	O	666-671
during	O	672-678
the	O	679-682
first	O	683-688
visit	O	689-694
,	O	694-695
and	O	696-699
patients	O	700-708
were	O	709-713
randomized	O	714-724
on	O	725-727
subsequent	O	728-738
visits	O	739-745
to	O	746-748
receive	O	749-756
metoprolol	O	757-767
or	O	768-770
metoprolol	O	771-781
plus	O	782-786
glucagon	O	787-795
1	O	796-797
mg	O	798-800
.	O	800-801

Metoprolol	O	802-812
was	O	813-816
dosed	O	817-822
to	O	823-825
achieve	O	826-833
a	O	834-835
resting	O	836-843
predobutamine	O	844-857
heart	O	858-863
rate	O	864-868
below	O	869-874
65	O	875-877
beats	O	878-883
/	O	883-884
minute	O	884-890
or	O	891-893
a	O	894-895
total	O	896-901
intravenous	O	902-913
dose	O	914-918
of	O	919-921
20	O	922-924
mg	O	925-927
.	O	927-928

MEASUREMENTS	O	929-941
AND	O	942-945
MAIN	O	946-950
RESULTS	O	951-958
:	O	958-959
Metoprolol	O	960-970
reduced	O	971-978
maximum	O	979-986
heart	O	987-992
rate	O	993-997
31	O	998-1000
%	O	1000-1001
,	O	1001-1002
summed	O	1003-1009
stress	O	1010-1016
scores	O	1017-1023
29	O	1024-1026
%	O	1026-1027
,	O	1027-1028
and	O	1029-1032
summed	O	1033-1039
difference	O	1040-1050
scores	O	1051-1057
43	O	1058-1060
%	O	1060-1061
versus	O	1062-1068
control	O	1069-1076
.	O	1076-1077

Metoprolol	O	1078-1088
plus	O	1089-1093
glucagon	O	1094-1102
also	O	1103-1107
reduced	O	1108-1115
the	O	1116-1119
maximum	O	1120-1127
heart	O	1128-1133
rate	O	1134-1138
29	O	1139-1141
%	O	1141-1142
versus	O	1143-1149
control	O	1150-1157
.	O	1157-1158

Summed	O	1159-1165
stress	O	1166-1172
and	O	1173-1176
summed	O	1177-1183
difference	O	1184-1194
scores	O	1195-1201
were	O	1202-1206
not	O	1207-1210
significantly	O	1211-1224
reduced	O	1225-1232
,	O	1232-1233
although	O	1234-1242
they	O	1243-1247
were	O	1248-1252
18	O	1253-1255
%	O	1255-1256
and	O	1257-1260
30	O	1261-1263
%	O	1263-1264
lower	O	1265-1270
,	O	1270-1271
respectively	O	1272-1284
,	O	1284-1285
than	O	1286-1290
control	O	1291-1298
.	O	1298-1299

No	O	1300-1302
significant	O	1303-1314
differences	O	1315-1326
were	O	1327-1331
found	O	1332-1337
in	O	1338-1340
any	O	1341-1344
parameter	O	1345-1354
between	O	1355-1362
metoprolol	O	1363-1373
and	O	1374-1377
metoprolol	O	1378-1388
-	O	1388-1389
glucagon	O	1389-1397
.	O	1397-1398

CONCLUSION	O	1399-1409
:	O	1409-1410
During	O	1411-1417
dobutamine	O	1418-1428
stress	O	1429-1435
testing	O	1436-1443
,	O	1443-1444
metoprolol	O	1445-1455
attenuates	O	1456-1466
or	O	1467-1469
eliminates	O	1470-1480
evidence	O	1481-1489
of	O	1490-1492
myocardial	B	1493-1503
ischemia	I	1504-1512
.	O	1512-1513

Glucagon	O	1514-1522
1	O	1523-1524
mg	O	1525-1527
,	O	1527-1528
although	O	1529-1537
somewhat	O	1538-1546
effective	O	1547-1556
,	O	1556-1557
does	O	1558-1562
not	O	1563-1566
correct	O	1567-1574
this	O	1575-1579
effect	O	1580-1586
to	O	1587-1589
the	O	1590-1593
extent	O	1594-1600
that	O	1601-1605
it	O	1606-1608
can	O	1609-1612
be	O	1613-1615
administered	O	1616-1628
clinically	O	1629-1639
.	O	1639-1640

Prednisolone	O	0-12
-	O	12-13
induced	O	13-20
muscle	B	21-27
dysfunction	I	28-39
is	O	40-42
caused	O	43-49
more	O	50-54
by	O	55-57
atrophy	B	58-65
than	O	66-70
by	O	71-73
altered	O	74-81
acetylcholine	O	82-95
receptor	O	96-104
expression	O	105-115
.	O	115-116

Large	O	117-122
doses	O	123-128
of	O	129-131
glucocorticoids	O	132-147
can	O	148-151
alter	O	152-157
muscle	O	158-164
physiology	O	165-175
and	O	176-179
susceptibility	O	180-194
to	O	195-197
neuromuscular	O	198-211
blocking	O	212-220
drugs	O	221-226
by	O	227-229
mechanisms	O	230-240
not	O	241-244
clearly	O	245-252
understood	O	253-263
.	O	263-264

We	O	265-267
investigated	O	268-280
the	O	281-284
effects	O	285-292
of	O	293-295
moderate	O	296-304
and	O	305-308
large	O	309-314
doses	O	315-320
of	O	321-323
prednisolone	O	324-336
on	O	337-339
muscle	O	340-346
function	O	347-355
and	O	356-359
pharmacology	O	360-372
,	O	372-373
and	O	374-377
their	O	378-383
relationship	O	384-396
to	O	397-399
changes	O	400-407
in	O	408-410
muscle	O	411-417
size	O	418-422
and	O	423-426
acetylcholine	O	427-440
receptor	O	441-449
(	O	450-451
AChR	O	451-455
)	O	455-456
expression	O	457-467
.	O	467-468

With	O	469-473
institutional	O	474-487
approval	O	488-496
,	O	496-497
35	O	498-500
Sprague	O	501-508
-	O	508-509
Dawley	O	509-515
rats	O	516-520
were	O	521-525
randomly	O	526-534
allocated	O	535-544
to	O	545-547
receive	O	548-555
daily	O	556-561
subcutaneous	O	562-574
doses	O	575-580
of	O	581-583
10	O	584-586
mg	O	587-589
/	O	589-590
kg	O	590-592
prednisolone	O	593-605
(	O	606-607
P10	O	607-610
group	O	611-616
)	O	616-617
,	O	617-618
100	O	619-622
mg	O	623-625
/	O	625-626
kg	O	626-628
prednisolone	O	629-641
(	O	642-643
P100	O	643-647
group	O	648-653
)	O	653-654
,	O	654-655
or	O	656-658
an	O	659-661
equal	O	662-667
volume	O	668-674
of	O	675-677
saline	O	678-684
(	O	685-686
S	O	686-687
group	O	688-693
)	O	693-694
for	O	695-698
7	O	699-700
days	O	701-705
.	O	705-706

A	O	707-708
fourth	O	709-715
group	O	716-721
of	O	722-724
rats	O	725-729
was	O	730-733
pair	O	734-738
fed	O	739-742
(	O	743-744
food	O	744-748
restricted	O	749-759
)	O	759-760
with	O	761-765
the	O	766-769
P100	O	770-774
rats	O	775-779
for	O	780-783
7	O	784-785
days	O	786-790
(	O	791-792
FR	O	792-794
group	O	795-800
)	O	800-801
.	O	801-802

On	O	803-805
Day	O	806-809
8	O	810-811
,	O	811-812
the	O	813-816
nerve	O	817-822
-	O	822-823
evoked	O	823-829
peak	O	830-834
twitch	O	835-841
tensions	O	842-850
,	O	850-851
tetanic	B	852-859
tensions	O	860-868
,	O	868-869
and	O	870-873
fatigability	O	874-886
,	O	886-887
and	O	888-891
the	O	892-895
dose	O	896-900
-	O	900-901
response	O	901-909
curves	O	910-916
of	O	917-919
d	O	920-921
-	O	921-922
tubocurarine	O	922-934
in	O	935-937
the	O	938-941
tibialis	O	942-950
cranialis	O	951-960
muscle	O	961-967
were	O	968-972
measured	O	973-981
in	O	982-984
vivo	O	985-989
and	O	990-993
related	O	994-1001
to	O	1002-1004
muscle	O	1005-1011
mass	O	1012-1016
or	O	1017-1019
expression	O	1020-1030
of	O	1031-1033
AChRs	O	1034-1039
.	O	1039-1040

Rate	O	1041-1045
of	O	1046-1048
body	O	1049-1053
weight	O	1054-1060
gain	O	1061-1065
was	O	1066-1069
depressed	O	1070-1079
in	O	1080-1082
the	O	1083-1086
P100	O	1087-1091
,	O	1091-1092
FR	O	1093-1095
,	O	1095-1096
and	O	1097-1100
P10	O	1101-1104
groups	O	1105-1111
compared	O	1112-1120
with	O	1121-1125
the	O	1126-1129
S	O	1130-1131
group	O	1132-1137
.	O	1137-1138

Tibialis	O	1139-1147
muscle	O	1148-1154
mass	O	1155-1159
was	O	1160-1163
smaller	O	1164-1171
in	O	1172-1174
the	O	1175-1178
P100	O	1179-1183
group	O	1184-1189
than	O	1190-1194
in	O	1195-1197
the	O	1198-1201
P10	O	1202-1205
or	O	1206-1208
S	O	1209-1210
groups	O	1211-1217
.	O	1217-1218

The	O	1219-1222
evoked	O	1223-1229
peak	O	1230-1234
twitch	O	1235-1241
and	O	1242-1245
tetanic	B	1246-1253
tensions	O	1254-1262
were	O	1263-1267
less	O	1268-1272
in	O	1273-1275
the	O	1276-1279
P100	O	1280-1284
group	O	1285-1290
than	O	1291-1295
in	O	1296-1298
the	O	1299-1302
P10	O	1303-1306
or	O	1307-1309
S	O	1310-1311
groups	O	1312-1318
,	O	1318-1319
however	O	1320-1327
,	O	1327-1328
tension	O	1329-1336
per	O	1337-1340
milligram	O	1341-1350
of	O	1351-1353
muscle	O	1354-1360
mass	O	1361-1365
was	O	1366-1369
greater	O	1370-1377
in	O	1378-1380
the	O	1381-1384
P100	O	1385-1389
group	O	1390-1395
than	O	1396-1400
in	O	1401-1403
the	O	1404-1407
S	O	1408-1409
group	O	1410-1415
.	O	1415-1416

The	O	1417-1420
50	O	1421-1423
%	O	1423-1424
effective	O	1425-1434
dose	O	1435-1439
of	O	1440-1442
d	O	1443-1444
-	O	1444-1445
tubocurarine	O	1445-1457
(	O	1458-1459
microg	O	1459-1465
/	O	1465-1466
kg	O	1466-1468
)	O	1468-1469
in	O	1470-1472
the	O	1473-1476
tibialis	O	1477-1485
muscle	O	1486-1492
was	O	1493-1496
smaller	O	1497-1504
in	O	1505-1507
the	O	1508-1511
P10	O	1512-1515
(	O	1516-1517
33	O	1517-1519
.	O	1519-1520
6	O	1520-1521
+	O	1522-1523
/	O	1523-1524
-	O	1524-1525
5	O	1526-1527
.	O	1527-1528
4	O	1528-1529
)	O	1529-1530
than	O	1531-1535
in	O	1536-1538
the	O	1539-1542
S	O	1543-1544
(	O	1545-1546
61	O	1546-1548
.	O	1548-1549
9	O	1549-1550
+	O	1551-1552
/	O	1552-1553
-	O	1553-1554
5	O	1555-1556
.	O	1556-1557
0	O	1557-1558
)	O	1558-1559
or	O	1560-1562
the	O	1563-1566
P100	O	1567-1571
(	O	1572-1573
71	O	1573-1575
.	O	1575-1576
3	O	1576-1577
+	O	1578-1579
/	O	1579-1580
-	O	1580-1581
9	O	1582-1583
.	O	1583-1584
6	O	1584-1585
)	O	1585-1586
groups	O	1587-1593
.	O	1593-1594

AChR	O	1595-1599
expression	O	1600-1610
was	O	1611-1614
less	O	1615-1619
in	O	1620-1622
the	O	1623-1626
P10	O	1627-1630
group	O	1631-1636
than	O	1637-1641
in	O	1642-1644
the	O	1645-1648
S	O	1649-1650
group	O	1651-1656
.	O	1656-1657

The	O	1658-1661
evoked	O	1662-1668
tensions	O	1669-1677
correlated	O	1678-1688
with	O	1689-1693
muscle	O	1694-1700
mass	O	1701-1705
(	O	1706-1707
r	O	1707-1708
(	O	1706-1707
2	O	1709-1710
)	O	1710-1711
=	O	1712-1713
0	O	1714-1715
.	O	1715-1716
32	O	1716-1718
,	O	1718-1719
P	O	1720-1721
<	O	1722-1723
0	O	1724-1725
.	O	1725-1726
001	O	1726-1729
)	O	1729-1730
,	O	1730-1731
however	O	1732-1739
,	O	1739-1740
not	O	1741-1744
with	O	1745-1749
expression	O	1750-1760
of	O	1761-1763
AChR	O	1764-1768
.	O	1768-1769

The	O	1770-1773
50	O	1774-1776
%	O	1776-1777
effective	O	1778-1787
dose	O	1788-1792
of	O	1793-1795
d	O	1796-1797
-	O	1797-1798
tubocurarine	O	1798-1810
did	O	1811-1814
not	O	1815-1818
correlate	O	1819-1828
with	O	1829-1833
muscle	O	1834-1840
mass	O	1841-1845
or	O	1846-1848
AChR	O	1849-1853
expression	O	1854-1864
.	O	1864-1865

Our	O	1866-1869
results	O	1870-1877
suggest	O	1878-1885
that	O	1886-1890
the	O	1891-1894
neuromuscular	B	1895-1908
dysfunction	I	1909-1920
after	O	1921-1926
prednisolone	O	1927-1939
is	O	1940-1942
dose	O	1943-1947
-	O	1947-1948
dependent	O	1948-1957
,	O	1957-1958
and	O	1959-1962
derives	O	1963-1970
primarily	O	1971-1980
from	O	1981-1985
muscle	B	1986-1992
atrophy	I	1993-2000
and	O	2001-2004
derives	O	2005-2012
less	O	2013-2017
so	O	2018-2020
from	O	2021-2025
changes	O	2026-2033
in	O	2034-2036
AChR	O	2037-2041
expression	O	2042-2052
.	O	2052-2053

IMPLICATIONS	O	2054-2066
:	O	2066-2067
The	O	2068-2071
mechanisms	O	2072-2082
by	O	2083-2085
which	O	2086-2091
chronic	O	2092-2099
glucocorticoid	O	2100-2114
therapy	O	2115-2122
alters	O	2123-2129
neuromuscular	O	2130-2143
physiology	O	2144-2154
and	O	2155-2158
pharmacology	O	2159-2171
are	O	2172-2175
unclear	O	2176-2183
.	O	2183-2184

We	O	2185-2187
suggest	O	2188-2195
that	O	2196-2200
the	O	2201-2204
observed	O	2205-2213
effects	O	2214-2221
are	O	2222-2225
dose	O	2226-2230
-	O	2230-2231
dependent	O	2231-2240
and	O	2241-2244
derive	O	2245-2251
primarily	O	2252-2261
from	O	2262-2266
muscle	B	2267-2273
atrophy	I	2274-2281
and	O	2282-2285
derive	O	2286-2292
less	O	2293-2297
from	O	2298-2302
changes	O	2303-2310
in	O	2311-2313
acetylcholine	O	2314-2327
receptor	O	2328-2336
expression	O	2337-2347
.	O	2347-2348

Rapid	O	0-5
reversal	O	6-14
of	O	15-17
life	O	18-22
-	O	22-23
threatening	O	23-34
diltiazem	O	35-44
-	O	44-45
induced	O	45-52
tetany	B	53-59
with	O	60-64
calcium	O	65-72
chloride	O	73-81
.	O	81-82

We	O	83-85
describe	O	86-94
a	O	95-96
patient	O	97-104
who	O	105-108
developed	O	109-118
tetany	B	119-125
with	O	126-130
sudden	O	131-137
respiratory	B	138-149
arrest	I	150-156
after	O	157-162
the	O	163-166
infusion	O	167-175
of	O	176-178
intravenous	O	179-190
diltiazem	O	191-200
.	O	200-201

The	O	202-205
administration	O	206-220
of	O	221-223
calcium	O	224-231
chloride	O	232-240
rapidly	O	241-248
resolved	O	249-257
the	O	258-261
patient	O	262-269
'	O	269-270
s	O	270-271
tetany	B	272-278
with	O	279-283
prompt	O	284-290
recovery	O	291-299
of	O	300-302
respiratory	O	303-314
function	O	315-323
,	O	323-324
averting	O	325-333
the	O	334-337
need	O	338-342
for	O	343-346
more	O	347-351
aggressive	O	352-362
airway	O	363-369
management	O	370-380
and	O	381-384
ventilatory	O	385-396
support	O	397-404
.	O	404-405

The	O	406-409
emergency	O	410-419
physician	O	420-429
should	O	430-436
be	O	437-439
aware	O	440-445
that	O	446-450
life	O	451-455
-	O	455-456
threatening	O	456-467
tetany	B	468-474
may	O	475-478
accompany	O	479-488
the	O	489-492
administration	O	493-507
of	O	508-510
intravenous	O	511-522
diltiazem	O	523-532
and	O	533-536
that	O	537-541
calcium	O	542-549
chloride	O	550-558
may	O	559-562
be	O	563-565
a	O	566-567
rapid	O	568-573
and	O	574-577
effective	O	578-587
remedy	O	588-594
.	O	594-595

Effects	O	0-7
of	O	8-10
nonsteroidal	O	11-23
anti	O	24-28
-	O	28-29
inflammatory	O	29-41
drugs	O	42-47
on	O	48-50
hemostasis	O	51-61
in	O	62-64
patients	O	65-73
with	O	74-78
aneurysmal	B	79-89
subarachnoid	I	90-102
hemorrhage	I	103-113
.	O	113-114

Platelet	O	115-123
function	O	124-132
is	O	133-135
impaired	O	136-144
by	O	145-147
nonsteroidal	O	148-160
anti	O	161-165
-	O	165-166
inflammatory	O	166-178
drugs	O	179-184
(	O	185-186
NSAIDs	O	186-192
)	O	192-193
with	O	194-198
prominent	O	199-208
anti	O	209-213
-	O	213-214
inflammatory	O	214-226
properties	O	227-237
.	O	237-238

Their	O	239-244
safety	O	245-251
in	O	252-254
patients	O	255-263
undergoing	O	264-274
intracranial	O	275-287
surgery	O	288-295
is	O	296-298
under	O	299-304
debate	O	305-311
.	O	311-312

Patients	O	313-321
with	O	322-326
aneurysmal	B	327-337
subarachnoid	I	338-350
hemorrhage	I	351-361
(	O	362-363
SAH	B	363-366
)	O	366-367
were	O	368-372
randomized	O	373-383
to	O	384-386
receive	O	387-394
either	O	395-401
ketoprofen	O	402-412
,	O	412-413
100	O	414-417
mg	O	418-420
,	O	420-421
three	O	422-427
times	O	428-433
a	O	434-435
day	O	436-439
(	O	440-441
ketoprofen	O	441-451
group	O	452-457
,	O	457-458
n	O	459-460
=	O	461-462
9	O	463-464
)	O	464-465
or	O	466-468
a	O	469-470
weak	O	471-475
NSAID	O	476-481
,	O	481-482
acetaminophen	O	483-496
,	O	496-497
1	O	498-499
g	O	500-501
,	O	501-502
three	O	503-508
times	O	509-514
a	O	515-516
day	O	517-520
(	O	521-522
acetaminophen	O	522-535
group	O	536-541
,	O	541-542
n	O	543-544
=	O	545-546
9	O	547-548
)	O	548-549
starting	O	550-558
immediately	O	559-570
after	O	571-576
the	O	577-580
diagnosis	O	581-590
of	O	591-593
aneurysmal	B	594-604
SAH	B	605-608
.	O	608-609

Treatment	O	610-619
was	O	620-623
continued	O	624-633
for	O	634-637
3	O	638-639
days	O	640-644
postoperatively	O	645-660
.	O	660-661

Test	O	662-666
blood	O	667-672
samples	O	673-680
were	O	681-685
taken	O	686-691
before	O	692-698
treatment	O	699-708
and	O	709-712
surgery	O	713-720
as	O	721-723
well	O	724-728
as	O	729-731
on	O	732-734
the	O	735-738
first	O	739-744
,	O	744-745
third	O	746-751
,	O	751-752
and	O	753-756
fifth	O	757-762
postoperative	O	763-776
mornings	O	777-785
.	O	785-786

Maximal	O	787-794
platelet	B	795-803
aggregation	I	804-815
induced	O	816-823
by	O	824-826
6	O	827-828
microM	O	829-835
of	O	836-838
adenosine	O	839-848
diphosphate	O	849-860
decreased	O	861-870
after	O	871-876
administration	O	877-891
of	O	892-894
ketoprofen	O	895-905
.	O	905-906

Aggregation	O	907-918
was	O	919-922
lower	O	923-928
(	O	929-930
P	O	930-931
<	O	932-933
.	O	934-935
05	O	935-937
)	O	937-938
in	O	939-941
the	O	942-945
ketoprofen	O	946-956
group	O	957-962
than	O	963-967
in	O	968-970
the	O	971-974
acetaminophen	O	975-988
group	O	989-994
just	O	995-999
before	O	1000-1006
surgery	O	1007-1014
and	O	1015-1018
on	O	1019-1021
the	O	1022-1025
third	O	1026-1031
postoperative	O	1032-1045
day	O	1046-1049
.	O	1049-1050

In	O	1051-1053
contrast	O	1054-1062
,	O	1062-1063
maximal	O	1064-1071
platelet	B	1072-1080
aggregation	I	1081-1092
increased	O	1093-1102
in	O	1103-1105
the	O	1106-1109
acetaminophen	O	1110-1123
group	O	1124-1129
on	O	1130-1132
the	O	1133-1136
third	O	1137-1142
postoperative	O	1143-1156
day	O	1157-1160
as	O	1161-1163
compared	O	1164-1172
with	O	1173-1177
the	O	1178-1181
pretreatment	O	1182-1194
platelet	B	1195-1203
aggregation	I	1204-1215
results	O	1216-1223
(	O	1224-1225
P	O	1225-1226
<	O	1227-1228
.	O	1229-1230
05	O	1230-1232
)	O	1232-1233
.	O	1229-1230

One	O	1235-1238
patient	O	1239-1246
in	O	1247-1249
the	O	1250-1253
ketoprofen	O	1254-1264
group	O	1265-1270
developed	O	1271-1280
a	O	1281-1282
postoperative	O	1283-1296
intracranial	O	1297-1309
hematoma	B	1310-1318
.	O	1318-1319

Coagulation	O	1320-1331
(	O	1332-1333
prothrombin	O	1333-1344
time	O	1345-1349
[	O	1350-1351
PT	O	1351-1353
]	O	1353-1354
,	O	1354-1355
activated	O	1356-1365
partial	O	1366-1373
thromboplastin	O	1374-1388
time	O	1389-1393
[	O	1394-1395
APPT	O	1395-1399
]	O	1399-1400
,	O	1400-1401
fibrinogen	O	1402-1412
concentration	O	1413-1426
,	O	1426-1427
and	O	1428-1431
antithrombin	O	1432-1444
III	O	1445-1448
[	O	1449-1450
AT	O	1450-1452
III	O	1453-1456
]	O	1456-1457
)	O	1457-1458
was	O	1459-1462
comparable	O	1463-1473
between	O	1474-1481
the	O	1482-1485
two	O	1486-1489
groups	O	1490-1496
.	O	1496-1497

Ketoprofen	O	1498-1508
but	O	1509-1512
not	O	1513-1516
acetaminophen	O	1517-1530
impaired	O	1531-1539
platelet	O	1540-1548
function	O	1549-1557
in	O	1558-1560
patients	O	1561-1569
with	O	1570-1574
SAH	B	1575-1578
.	O	1578-1579

If	O	1580-1582
ketoprofen	O	1583-1593
is	O	1594-1596
used	O	1597-1601
before	O	1602-1608
surgery	O	1609-1616
on	O	1617-1619
cerebral	O	1620-1628
artery	B	1629-1635
aneurysms	I	1636-1645
,	O	1645-1646
it	O	1647-1649
may	O	1650-1653
pose	O	1654-1658
an	O	1659-1661
additional	O	1662-1672
risk	O	1673-1677
factor	O	1678-1684
for	O	1685-1688
hemorrhage	B	1689-1699
.	O	1699-1700

Value	O	0-5
of	O	6-8
methylprednisolone	O	9-27
in	O	28-30
prevention	O	31-41
of	O	42-44
the	O	45-48
arthralgia	B	49-59
-	O	59-60
myalgia	B	60-67
syndrome	O	68-76
associated	O	77-87
with	O	88-92
the	O	93-96
total	O	97-102
dose	O	103-107
infusion	O	108-116
of	O	117-119
iron	O	120-124
dextran	O	125-132
:	O	132-133
a	O	134-135
double	O	136-142
blind	O	143-148
randomized	O	149-159
trial	O	160-165
.	O	165-166

The	O	167-170
safety	O	171-177
and	O	178-181
efficacy	O	182-190
of	O	191-193
total	O	194-199
dose	O	200-204
infusion	O	205-213
(	O	214-215
TDI	O	215-218
)	O	218-219
of	O	220-222
iron	O	223-227
dextran	O	228-235
has	O	236-239
been	O	240-244
well	O	245-249
documented	O	250-260
.	O	260-261

In	O	262-264
40	O	265-267
%	O	267-268
of	O	269-271
treated	O	272-279
patients	O	280-288
,	O	288-289
an	O	290-292
arthralgia	B	293-303
-	O	303-304
myalgia	B	304-311
syndrome	O	312-320
develops	O	321-329
.	O	329-330

The	O	331-334
purpose	O	335-342
of	O	343-345
this	O	346-350
randomized	O	351-361
,	O	361-362
double	O	363-369
-	O	369-370
blind	O	370-375
,	O	375-376
prospective	O	377-388
study	O	389-394
was	O	395-398
to	O	399-401
investigate	O	402-413
whether	O	414-421
intravenous	O	422-433
(	O	434-435
i	O	435-436
.	O	436-437
v	O	437-438
.	O	436-437
)	O	439-440
administration	O	441-455
of	O	456-458
methylprednisolone	O	459-477
(	O	478-479
MP	O	479-481
)	O	481-482
prevents	O	483-491
this	O	492-496
complication	O	497-509
.	O	509-510

Sixty	O	511-516
-	O	516-517
five	O	517-521
patients	O	522-530
,	O	530-531
34	O	532-534
women	O	535-540
and	O	541-544
31	O	545-547
men	O	548-551
,	O	551-552
ages	O	553-557
36	O	558-560
to	O	561-563
80	O	564-566
years	O	567-572
,	O	572-573
received	O	574-582
either	O	583-589
normal	O	590-596
saline	O	597-603
before	O	604-610
and	O	611-614
after	O	615-620
TDI	O	621-624
(	O	625-626
group	O	626-631
1	O	632-633
)	O	633-634
,	O	634-635
125	O	636-639
mg	O	640-642
i	O	643-644
.	O	644-645
v	O	645-646
.	O	644-645

MP	O	648-650
before	O	651-657
and	O	658-661
saline	O	662-668
after	O	669-674
TDI	O	675-678
(	O	679-680
group	O	680-685
2	O	686-687
)	O	687-688
,	O	688-689
or	O	690-692
125	O	693-696
mg	O	697-699
i	O	700-701
.	O	701-702
v	O	702-703
.	O	701-702

MP	O	705-707
before	O	708-714
and	O	715-718
after	O	719-724
TDI	O	725-728
(	O	729-730
group	O	730-735
3	O	736-737
)	O	737-738
.	O	738-739

Patients	O	740-748
were	O	749-753
observed	O	754-762
for	O	763-766
72	O	767-769
hours	O	770-775
and	O	776-779
reactions	O	780-789
were	O	790-794
recorded	O	795-803
and	O	804-807
graded	O	808-814
according	O	815-824
to	O	825-827
severity	O	828-836
.	O	836-837

Fifty	O	838-843
-	O	843-844
eight	O	844-849
percent	O	850-857
of	O	858-860
group	O	861-866
1	O	867-868
patients	O	869-877
,	O	877-878
33	O	879-881
%	O	881-882
of	O	883-885
group	O	886-891
2	O	892-893
,	O	893-894
and	O	895-898
26	O	899-901
%	O	901-902
of	O	903-905
group	O	906-911
3	O	912-913
had	O	914-917
reactions	O	918-927
to	O	928-930
TDI	O	931-934
.	O	934-935

The	O	936-939
severity	O	940-948
of	O	949-951
reactions	O	952-961
(	O	962-963
minimal	O	963-970
,	O	970-971
mild	O	972-976
,	O	976-977
and	O	978-981
moderate	O	982-990
,	O	990-991
respectively	O	992-1004
)	O	1004-1005
was	O	1006-1009
as	O	1010-1012
follows	O	1013-1020
:	O	1020-1021
group	O	1022-1027
1	O	1028-1029
-	O	1029-1030
-	O	1029-1030
6	O	1031-1032
,	O	1032-1033
6	O	1034-1035
,	O	1035-1036
and	O	1037-1040
2	O	1041-1042
;	O	1042-1043
group	O	1044-1049
2	O	1050-1051
-	O	1051-1052
-	O	1051-1052
1	O	1053-1054
,	O	1054-1055
5	O	1056-1057
,	O	1057-1058
and	O	1059-1062
0	O	1063-1064
;	O	1064-1065
group	O	1066-1071
3	O	1072-1073
-	O	1073-1074
-	O	1073-1074
5	O	1075-1076
,	O	1076-1077
1	O	1078-1079
,	O	1079-1080
and	O	1081-1084
0	O	1085-1086
.	O	1086-1087
Data	O	1088-1092
were	O	1093-1097
analyzed	O	1098-1106
by	O	1107-1109
the	O	1110-1113
two	O	1114-1117
-	O	1117-1118
sided	O	1118-1123
Fisher	O	1124-1130
'	O	1130-1131
s	O	1126-1127
exact	O	1133-1138
test	O	1139-1143
using	O	1144-1149
95	O	1150-1152
%	O	1152-1153
confidence	O	1154-1164
intervals	O	1165-1174
with	O	1175-1179
the	O	1180-1183
approximation	O	1184-1197
of	O	1198-1200
Woolf	O	1201-1206
.	O	1206-1207

These	O	1208-1213
data	O	1214-1218
demonstrate	O	1219-1230
that	O	1231-1235
administration	O	1236-1250
of	O	1251-1253
MP	O	1254-1256
before	O	1257-1263
and	O	1264-1267
after	O	1268-1273
TDI	O	1274-1277
reduces	O	1278-1285
the	O	1286-1289
frequency	O	1290-1299
and	O	1300-1303
severity	O	1304-1312
of	O	1313-1315
the	O	1316-1319
arthralgia	B	1320-1330
-	O	1330-1331
myalgia	B	1331-1338
syndrome	O	1339-1347
.	O	1347-1348

We	O	1349-1351
conclude	O	1352-1360
that	O	1361-1365
125	O	1366-1369
mg	O	1370-1372
i	O	1373-1374
.	O	1374-1375
v	O	1375-1376
.	O	1374-1375

MP	O	1378-1380
should	O	1381-1387
be	O	1388-1390
given	O	1391-1396
routinely	O	1397-1406
before	O	1407-1413
and	O	1414-1417
after	O	1418-1423
TDI	O	1424-1427
of	O	1428-1430
iron	O	1431-1435
dextran	O	1436-1443
.	O	1443-1444

Long	O	0-4
-	O	4-5
term	O	5-9
effects	O	10-17
of	O	18-20
vincristine	O	21-32
on	O	33-35
the	O	36-39
peripheral	O	40-50
nervous	O	51-58
system	O	59-65
.	O	65-66

Forty	O	67-72
patients	O	73-81
with	O	82-86
Non	B	87-90
-	I	90-91
Hodgkin	I	91-98
'	I	98-99
s	I	99-100
Lymphoma	I	101-109
treated	O	110-117
with	O	118-122
vincristine	O	123-134
between	O	135-142
1984	O	143-147
and	O	148-151
1990	O	152-156
(	O	157-158
cumulative	O	158-168
dose	O	169-173
12	O	174-176
mg	O	177-179
in	O	180-182
18	O	183-185
-	O	185-186
24	O	186-188
weeks	O	189-194
)	O	194-195
were	O	196-200
investigated	O	201-213
in	O	214-216
order	O	217-222
to	O	223-225
evaluate	O	226-234
the	O	235-238
long	O	239-243
term	O	244-248
effects	O	249-256
of	O	257-259
vincristine	O	260-271
on	O	272-274
the	O	275-278
peripheral	O	279-289
nervous	O	290-297
system	O	298-304
.	O	304-305

The	O	306-309
patients	O	310-318
were	O	319-323
interviewed	O	324-335
with	O	336-340
emphasis	O	341-349
on	O	350-352
neuropathic	B	353-364
symptoms	I	365-373
.	O	373-374

Physical	O	375-383
and	O	384-387
quantitative	O	388-400
sensory	O	401-408
examination	O	409-420
with	O	421-425
determination	O	426-439
of	O	440-442
vibratory	O	443-452
perception	O	453-463
and	O	464-467
thermal	O	468-475
discrimination	O	476-490
thresholds	O	491-501
were	O	502-506
performed	O	507-516
,	O	516-517
four	O	518-522
to	O	523-525
77	O	526-528
months	O	529-535
(	O	536-537
median	O	537-543
34	O	544-546
months	O	547-553
)	O	553-554
after	O	555-560
vincristine	O	561-572
treatment	O	573-582
.	O	582-583

Twenty	O	584-590
-	O	590-591
seven	O	591-596
patients	O	597-605
reported	O	606-614
neuropathic	B	615-626
symptoms	I	627-635
.	O	635-636

In	O	637-639
13	O	640-642
of	O	643-645
these	O	646-651
27	O	652-654
patients	O	655-663
symptoms	O	664-672
were	O	673-677
still	O	678-683
present	O	684-691
at	O	692-694
the	O	695-698
time	O	699-703
of	O	704-706
examination	O	707-718
.	O	718-719

In	O	720-722
these	O	723-728
patients	O	729-737
sensory	O	738-745
signs	O	746-751
and	O	752-755
symptoms	O	756-764
predominated	O	765-777
.	O	777-778

In	O	779-781
the	O	782-785
other	O	786-791
14	O	792-794
patients	O	795-803
symptoms	O	804-812
had	O	813-816
been	O	817-821
present	O	822-829
in	O	830-832
the	O	833-836
past	O	837-841
.	O	841-842

Symptoms	O	843-851
persisted	O	852-861
maximally	O	862-871
40	O	872-874
months	O	875-881
since	O	882-887
cessation	O	888-897
of	O	898-900
therapy	O	901-908
.	O	908-909

There	O	910-915
was	O	916-919
no	O	920-922
age	O	923-926
difference	O	927-937
between	O	938-945
patients	O	946-954
with	O	955-959
and	O	960-963
without	O	964-971
complaints	O	972-982
at	O	983-985
the	O	986-989
time	O	990-994
of	O	995-997
examination	O	998-1009
.	O	1009-1010

Normal	O	1011-1017
reflexes	O	1018-1026
were	O	1027-1031
found	O	1032-1037
in	O	1038-1040
two	O	1041-1044
third	O	1045-1050
of	O	1051-1053
patients	O	1054-1062
.	O	1062-1063

Neuropathic	O	1064-1075
complaints	O	1076-1086
were	O	1087-1091
not	O	1092-1095
very	O	1096-1100
troublesome	O	1101-1112
on	O	1113-1115
the	O	1116-1119
long	O	1120-1124
term	O	1125-1129
.	O	1129-1130

It	O	1131-1133
is	O	1134-1136
concluded	O	1137-1146
that	O	1147-1151
with	O	1152-1156
the	O	1157-1160
above	O	1161-1166
mentioned	O	1167-1176
vincristine	O	1177-1188
dose	O	1189-1193
schedule	O	1194-1202
signs	O	1203-1208
and	O	1209-1212
symptoms	O	1213-1221
of	O	1222-1224
vincristine	O	1225-1236
neuropathy	B	1237-1247
are	O	1248-1251
reversible	O	1252-1262
for	O	1263-1266
a	O	1267-1268
great	O	1269-1274
deal	O	1275-1279
and	O	1280-1283
prognosis	O	1284-1293
is	O	1294-1296
fairly	O	1297-1303
good	O	1304-1308
.	O	1308-1309

A	O	0-1
case	O	2-6
of	O	7-9
polymyositis	B	10-22
in	O	23-25
a	O	26-27
patient	O	28-35
with	O	36-40
primary	B	41-48
biliary	I	49-56
cirrhosis	I	57-66
treated	O	67-74
with	O	75-79
D	O	80-81
-	O	81-82
penicillamine	O	82-95
.	O	95-96

Although	O	97-105
D	O	106-107
-	O	107-108
penicillamine	O	108-121
has	O	122-125
been	O	126-130
used	O	131-135
for	O	136-139
many	O	140-144
rheumatologic	B	145-158
diseases	I	159-167
,	O	167-168
toxicity	B	169-177
limits	O	178-184
its	O	185-188
usefulness	O	189-199
in	O	200-202
many	O	203-207
patients	O	208-216
.	O	216-217

Polymyositis	B	218-230
/	O	230-231
dermatomyositis	B	231-246
can	O	247-250
develop	O	251-258
as	O	259-261
one	O	262-265
of	O	266-268
the	O	269-272
autoimmune	O	273-283
complications	O	284-297
of	O	298-300
D	O	301-302
-	O	302-303
penicillamine	O	303-316
treatment	O	317-326
,	O	326-327
but	O	328-331
its	O	332-335
exact	O	336-341
pathogenesis	O	342-354
remains	O	355-362
unclear	O	363-370
.	O	370-371

We	O	372-374
report	O	375-381
a	O	382-383
patient	O	384-391
with	O	392-396
primary	B	397-404
biliary	I	405-412
cirrhosis	I	413-422
,	O	422-423
who	O	424-427
developed	O	428-437
polymyositis	B	438-450
while	O	451-456
receiving	O	457-466
D	O	467-468
-	O	468-469
penicillamine	O	469-482
therapy	O	483-490
.	O	490-491

We	O	492-494
described	O	495-504
the	O	505-508
special	O	509-516
clinical	O	517-525
course	O	526-532
of	O	533-535
the	O	536-539
patient	O	540-547
.	O	547-548

Patients	O	549-557
receiving	O	558-567
D	O	568-569
-	O	569-570
penicillamine	O	570-583
therapy	O	584-591
should	O	592-598
be	O	599-601
followed	O	602-610
carefully	O	611-620
for	O	621-624
the	O	625-628
development	O	629-640
of	O	641-643
autoimmune	O	644-654
complications	O	655-668
like	O	669-673
polymyositis	B	674-686
/	O	686-687
dermatomyositis	B	687-702
.	O	702-703

Photodistributed	O	0-16
nifedipine	O	17-27
-	O	27-28
induced	O	28-35
facial	O	36-42
telangiectasia	B	43-57
.	O	57-58

Five	O	59-63
months	O	64-70
after	O	71-76
starting	O	77-85
nifedipine	O	86-96
(	O	97-98
Adalat	O	98-104
)	O	104-105
,	O	105-106
two	O	107-110
patients	O	111-119
developed	O	120-129
photodistributed	O	130-146
facial	O	147-153
telangiectasia	B	154-168
,	O	168-169
which	O	170-175
became	O	176-182
more	O	183-187
noticeable	O	188-198
with	O	199-203
time	O	204-208
.	O	208-209

Neither	O	210-217
patient	O	218-225
complained	O	226-236
of	O	237-239
photosensitivity	O	240-256
or	O	257-259
flushing	B	260-268
.	O	268-269

Both	O	270-274
patients	O	275-283
reported	O	284-292
a	O	293-294
significant	O	295-306
cosmetic	O	307-315
improvement	O	316-327
after	O	328-333
discontinuing	O	334-347
the	O	348-351
drug	O	352-356
.	O	356-357

One	O	358-361
commenced	O	362-371
the	O	372-375
closely	O	376-383
related	O	384-391
drug	O	392-396
amlodipine	O	397-407
3	O	408-409
years	O	410-415
later	O	416-421
,	O	421-422
with	O	423-427
recurrence	O	428-438
of	O	439-441
telangiectasia	B	442-456
.	O	456-457

The	O	458-461
photodistribution	O	462-479
of	O	480-482
the	O	483-486
telangiectasia	B	487-501
suggests	O	502-510
a	O	511-512
significant	O	513-524
drug	O	525-529
/	O	529-530
light	O	530-535
interaction	O	536-547
.	O	547-548

Nephrotoxicity	B	0-14
of	O	15-17
cyclosporin	O	18-29
A	O	30-31
and	O	32-35
FK506	O	36-41
:	O	41-42
inhibition	O	43-53
of	O	54-56
calcineurin	O	57-68
phosphatase	O	69-80
.	O	80-81

Cyclosporin	O	82-93
A	O	94-95
(	O	96-97
CsA	O	97-100
;	O	100-101
50	O	102-104
mg	O	105-107
/	O	107-108
kg	O	108-110
)	O	110-111
and	O	112-115
Fujimycine	O	116-126
(	O	127-128
FK506	O	128-133
;	O	133-134
5	O	135-136
mg	O	137-139
/	O	139-140
kg	O	140-142
)	O	142-143
,	O	143-144
but	O	145-148
not	O	149-152
the	O	153-156
related	O	157-164
macrolide	O	165-174
immunosuppressant	O	175-192
rapamycin	O	193-202
(	O	203-204
5	O	204-205
mg	O	206-208
/	O	208-209
kg	O	209-211
)	O	211-212
,	O	212-213
caused	O	214-220
a	O	221-222
reduction	O	223-232
of	O	233-235
glomerular	O	236-246
filtration	O	247-257
rate	O	258-262
,	O	262-263
degenerative	O	264-276
changes	O	277-284
of	O	285-287
proximal	O	288-296
tubular	O	297-304
epithelium	O	305-315
,	O	315-316
and	O	317-320
hypertrophy	B	321-332
of	O	333-335
the	O	336-339
juxtaglomerular	O	340-355
apparatus	O	356-365
in	O	366-368
male	O	369-373
Wistar	O	374-380
rats	O	381-385
when	O	386-390
given	O	391-396
for	O	397-400
10	O	401-403
days	O	404-408
.	O	408-409

The	O	410-413
molecular	O	414-423
mechanisms	O	424-434
of	O	435-437
CsA	O	438-441
and	O	442-445
FK506	O	446-451
toxicity	B	452-460
were	O	461-465
investigated	O	466-478
.	O	478-479

Cyclophilin	O	480-491
A	O	492-493
and	O	494-497
FK506	O	498-503
-	O	503-504
binding	O	504-511
protein	O	512-519
,	O	519-520
the	O	521-524
main	O	525-529
intracytoplasmic	O	530-546
receptors	O	547-556
for	O	557-560
CsA	O	561-564
and	O	565-568
FK506	O	569-574
,	O	574-575
respectively	O	576-588
,	O	588-589
were	O	590-594
each	O	595-599
detected	O	600-608
in	O	609-611
renal	O	612-617
tissue	O	618-624
extract	O	625-632
.	O	632-633

In	O	634-636
the	O	637-640
kidney	O	641-647
,	O	647-648
high	O	649-653
levels	O	654-660
of	O	661-663
immunoreactive	O	664-678
and	O	679-682
enzymatically	O	683-696
active	O	697-703
calcineurin	O	704-715
were	O	716-720
found	O	721-726
which	O	727-732
were	O	733-737
inhibited	O	738-747
by	O	748-750
the	O	751-754
immunosuppressants	O	755-773
CsA	O	774-777
and	O	778-781
FK506	O	782-787
,	O	787-788
but	O	789-792
not	O	793-796
by	O	797-799
rapamycin	O	800-809
.	O	809-810

Finally	O	811-818
,	O	818-819
specific	O	820-828
immunophilin	O	829-841
-	O	841-842
drug	O	842-846
-	O	841-842
calcineurin	O	847-858
complexes	O	859-868
formed	O	869-875
only	O	876-880
in	O	881-883
the	O	884-887
presence	O	888-896
of	O	897-899
CsA	O	900-903
and	O	904-907
FK506	O	908-913
,	O	913-914
but	O	915-918
not	O	919-922
rapamycin	O	923-932
.	O	932-933

These	O	934-939
results	O	940-947
suggest	O	948-955
that	O	956-960
the	O	961-964
nephrotoxic	B	965-976
effects	O	977-984
of	O	985-987
CsA	O	988-991
and	O	992-995
FK506	O	996-1001
is	O	1002-1004
likely	O	1005-1011
mediated	O	1012-1020
through	O	1021-1028
binding	O	1029-1036
to	O	1037-1039
renal	O	1040-1045
immunophilin	O	1046-1058
and	O	1059-1062
inhibiting	O	1063-1073
calcineurin	O	1074-1085
phosphatase	O	1086-1097
.	O	1097-1098

Massive	O	0-7
cerebral	B	8-16
edema	I	17-22
associated	O	23-33
with	O	34-38
fulminant	O	39-48
hepatic	B	49-56
failure	I	57-64
in	O	65-67
acetaminophen	O	68-81
overdose	B	82-90
:	O	90-91
possible	O	92-100
role	O	101-105
of	O	106-108
cranial	O	109-116
decompression	O	117-130
.	O	130-131

Cerebral	B	132-140
edema	I	141-146
may	O	147-150
complicate	O	151-161
the	O	162-165
course	O	166-172
of	O	173-175
fulminant	B	176-185
hepatic	I	186-193
failure	I	194-201
.	O	201-202

Response	O	203-211
to	O	212-214
conventional	O	215-227
therapy	O	228-235
has	O	236-239
been	O	240-244
disappointing	O	245-258
.	O	258-259

We	O	260-262
present	O	263-270
a	O	271-272
patient	O	273-280
with	O	281-285
fatal	O	286-291
acetaminophen	O	292-305
-	O	305-306
induced	O	306-313
fulminant	B	314-323
hepatic	I	324-331
failure	I	332-339
,	O	339-340
with	O	341-345
signs	O	346-351
and	O	352-355
symptoms	O	356-364
of	O	365-367
cerebral	B	368-376
edema	I	377-382
,	O	382-383
unresponsive	O	384-396
to	O	397-399
conventional	O	400-412
medical	O	413-420
therapy	O	421-428
.	O	428-429

Cranial	O	430-437
decompression	O	438-451
was	O	452-455
carried	O	456-463
out	O	464-467
.	O	467-468

A	O	469-470
justification	O	471-484
of	O	485-487
the	O	488-491
need	O	492-496
for	O	497-500
further	O	501-508
evaluation	O	509-519
of	O	520-522
cranial	O	523-530
decompression	O	531-544
in	O	545-547
such	O	548-552
patients	O	553-561
is	O	562-564
presented	O	565-574
.	O	574-575

Gentamicin	O	0-10
nephropathy	B	11-22
in	O	23-25
a	O	26-27
neonate	O	28-35
.	O	35-36

The	O	37-40
clinical	O	41-49
and	O	50-53
autopsy	O	54-61
findings	O	62-70
in	O	71-73
a	O	74-75
premature	O	76-85
baby	O	86-90
who	O	91-94
died	O	95-99
of	O	100-102
acute	B	103-108
renal	I	109-114
failure	I	115-122
after	O	123-128
therapy	O	129-136
with	O	137-141
gentamicin	O	142-152
(	O	153-154
5	O	154-155
mg	O	156-158
/	O	158-159
kg	O	159-161
/	O	158-159
day	O	162-165
)	O	165-166
and	O	167-170
penicillin	O	171-181
are	O	182-185
presented	O	186-195
.	O	195-196

The	O	197-200
serum	O	201-206
gentamicin	O	207-217
concentration	O	218-231
had	O	232-235
reached	O	236-243
toxic	O	244-249
levels	O	250-256
when	O	257-261
anuria	B	262-268
developed	O	269-278
.	O	278-279

Numerous	O	280-288
periodic	O	289-297
acid	O	298-302
Schiff	O	303-309
(	O	310-311
PAS	O	311-314
)	O	314-315
positive	O	316-324
,	O	324-325
diastase	O	326-334
resistant	O	335-344
cytoplasmic	O	345-356
inclusion	O	357-366
bodies	O	367-373
which	O	374-379
appeared	O	380-388
as	O	389-391
myelin	O	392-398
figures	O	399-406
in	O	407-409
cytosegresomes	O	410-424
under	O	425-430
the	O	431-434
electron	O	435-443
microscope	O	444-454
were	O	455-459
identified	O	460-470
in	O	471-473
the	O	474-477
proximal	O	478-486
convoluted	O	487-497
tubules	O	498-505
.	O	505-506

The	O	507-510
pathological	O	511-523
changes	O	524-531
induced	O	532-539
by	O	540-542
gentamicin	O	543-553
in	O	554-556
the	O	557-560
human	O	561-566
neonatal	O	567-575
kidneys	O	576-583
have	O	584-588
not	O	589-592
been	O	593-597
previously	O	598-608
reported	O	609-617
.	O	617-618

Anti	O	0-4
-	O	4-5
carcinogenic	B	5-17
action	O	18-24
of	O	25-27
phenobarbital	O	28-41
given	O	42-47
simultaneously	O	48-62
with	O	63-67
diethylnitrosamine	O	68-86
in	O	87-89
the	O	90-93
rat	O	94-97
.	O	97-98

The	O	99-102
present	O	103-110
work	O	111-115
has	O	116-119
been	O	120-124
planned	O	125-132
in	O	133-135
order	O	136-141
to	O	142-144
elucidate	O	145-154
the	O	155-158
effect	O	159-165
of	O	166-168
phenobarbital	O	169-182
(	O	183-184
PB	O	184-186
:	O	186-187
15	O	188-190
mg	O	191-193
per	O	194-197
rat	O	198-201
of	O	202-204
ingested	O	205-213
dose	O	214-218
)	O	218-219
on	O	220-222
carcinogenesis	B	223-237
when	O	238-242
it	O	243-245
is	O	246-248
administered	O	249-261
simultaneously	O	262-276
with	O	277-281
diethylnitrosamine	O	282-300
(	O	301-302
DEN	O	302-305
:	O	305-306
10	O	307-309
mg	O	310-312
/	O	312-313
kg	O	313-315
/	O	312-313
day	O	316-319
)	O	319-320
.	O	320-321

Wistar	O	322-328
rats	O	329-333
(	O	334-335
180	O	335-338
g	O	339-340
)	O	340-341
were	O	342-346
treated	O	347-354
by	O	355-357
DEN	O	358-361
alone	O	362-367
or	O	368-370
by	O	371-373
DEN	O	374-377
+	O	378-379
PB	O	380-382
during	O	383-389
2	O	390-391
,	O	391-392
4	O	393-394
and	O	395-398
6	O	399-400
weeks	O	401-406
according	O	407-416
to	O	417-419
our	O	420-423
schedule	O	424-432
for	O	433-436
hepatocarcinogenesis	B	437-457
.	O	457-458

After	O	459-464
the	O	465-468
end	O	469-472
of	O	473-475
the	O	476-479
treatment	O	480-489
,	O	489-490
the	O	491-494
number	O	495-501
and	O	502-505
the	O	506-509
size	O	510-514
of	O	515-517
induced	O	518-525
PAS	O	526-529
positive	O	530-538
preneoplastic	B	539-552
foci	I	553-557
was	O	558-561
significantly	O	562-575
reduced	O	576-583
when	O	584-588
PB	O	589-591
was	O	592-595
given	O	596-601
simultaneously	O	602-616
with	O	617-621
DEN	O	622-625
for	O	626-629
4	O	630-631
and	O	632-635
6	O	636-637
weeks	O	638-643
.	O	643-644

The	O	645-648
mitotic	O	649-656
inhibition	O	657-667
and	O	668-671
the	O	672-675
production	O	676-686
of	O	687-689
micronuclei	O	690-701
normally	O	702-710
observed	O	711-719
after	O	720-725
partial	O	726-733
hepatectomy	O	734-745
in	O	746-748
DEN	O	749-752
treated	O	753-760
rats	O	761-765
were	O	766-770
also	O	771-775
significantly	O	776-789
decreased	O	790-799
in	O	800-802
DEN	O	803-806
+	O	807-808
PB	O	809-811
treated	O	812-819
rats	O	820-824
.	O	824-825

When	O	826-830
the	O	831-834
treatment	O	835-844
last	O	845-849
only	O	850-854
2	O	855-856
weeks	O	857-862
,	O	862-863
the	O	864-867
presence	O	868-876
of	O	877-879
PB	O	880-882
did	O	883-886
not	O	887-890
change	O	891-897
significantly	O	898-911
the	O	912-915
last	O	916-920
parameters	O	921-931
.	O	931-932

In	O	933-935
DEN	O	936-939
+	O	940-941
PB	O	942-944
treated	O	945-952
rats	O	953-957
,	O	957-958
the	O	959-962
survival	O	963-971
was	O	972-975
prolonged	O	976-985
and	O	986-989
the	O	990-993
tumor	B	994-999
incidence	O	1000-1009
decreased	O	1010-1019
as	O	1020-1022
compared	O	1023-1031
with	O	1032-1036
the	O	1037-1040
results	O	1041-1048
obtained	O	1049-1057
by	O	1058-1060
DEN	O	1061-1064
alone	O	1065-1070
.	O	1070-1071

It	O	1072-1074
is	O	1075-1077
concluded	O	1078-1087
that	O	1088-1092
PB	O	1093-1095
,	O	1095-1096
which	O	1097-1102
promotes	O	1103-1111
carcinogenesis	B	1112-1126
when	O	1127-1131
administered	O	1132-1144
after	O	1145-1150
the	O	1151-1154
DEN	O	1155-1158
treatment	O	1159-1168
,	O	1168-1169
reduces	O	1170-1177
the	O	1178-1181
carcinogen	O	1182-1192
effect	O	1193-1199
when	O	1200-1204
given	O	1205-1210
simultaneously	O	1211-1225
with	O	1226-1230
DEN	O	1231-1234
.	O	1234-1235

This	O	1236-1240
'	O	1241-1242
anti	O	1242-1246
-	O	1246-1247
carcinogen	O	1247-1257
'	O	1241-1242
effect	O	1259-1265
acts	O	1266-1270
on	O	1271-1273
the	O	1274-1277
initiation	O	1278-1288
as	O	1289-1291
well	O	1292-1296
as	O	1297-1299
on	O	1300-1302
the	O	1303-1306
promotion	O	1307-1316
of	O	1317-1319
the	O	1320-1323
precancerous	B	1324-1336
lesions	I	1337-1344
.	O	1344-1345

Biochemical	O	1346-1357
investigations	O	1358-1372
are	O	1373-1376
in	O	1377-1379
progress	O	1380-1388
to	O	1389-1391
obtain	O	1392-1398
more	O	1399-1403
information	O	1404-1415
about	O	1416-1421
this	O	1422-1426
'	O	1427-1428
paradoxical	O	1428-1439
'	O	1427-1428
PB	O	1441-1443
effect	O	1444-1450
.	O	1450-1451

Post	O	0-4
-	O	4-5
operative	O	5-14
rigidity	B	15-23
after	O	24-29
fentanyl	O	30-38
administration	O	39-53
.	O	53-54

A	O	55-56
case	O	57-61
of	O	62-64
thoraco	O	65-72
-	O	72-73
abdominal	O	73-82
rigidity	B	83-91
leading	O	92-99
to	O	100-102
respiratory	B	103-114
failure	I	115-122
is	O	123-125
described	O	126-135
in	O	136-138
the	O	139-142
post	O	143-147
-	O	147-148
operative	O	148-157
period	O	158-164
in	O	165-167
an	O	168-170
elderly	O	171-178
patient	O	179-186
who	O	187-190
received	O	191-199
a	O	200-201
moderate	O	202-210
dose	O	211-215
of	O	216-218
fentanyl	O	219-227
.	O	227-228

This	O	229-233
was	O	234-237
successfully	O	238-250
reversed	O	251-259
by	O	260-262
naloxone	O	263-271
.	O	271-272

The	O	273-276
mechanisms	O	277-287
possibly	O	288-296
implicated	O	297-307
in	O	308-310
this	O	311-315
accident	O	316-324
are	O	325-328
discussed	O	329-338
.	O	338-339

Postpartum	O	0-10
psychosis	B	11-20
induced	O	21-28
by	O	29-31
bromocriptine	O	32-45
.	O	45-46

Two	O	47-50
multigravida	O	51-63
patients	O	64-72
with	O	73-77
no	O	78-80
prior	O	81-86
psychiatric	B	87-98
history	O	99-106
were	O	107-111
seen	O	112-116
with	O	117-121
postpartum	O	122-132
psychosis	B	133-142
,	O	142-143
having	O	144-150
received	O	151-159
bromocriptine	O	160-173
for	O	174-177
inhibition	B	178-188
of	I	189-191
lactation	I	192-201
.	O	201-202

Bromocriptine	O	203-216
given	O	217-222
in	O	223-225
high	O	226-230
doses	O	231-236
has	O	237-240
been	O	241-245
associated	O	246-256
with	O	257-261
psychosis	B	262-271
in	O	272-274
patients	O	275-283
receiving	O	284-293
the	O	294-297
drug	O	298-302
for	O	303-306
Parkinson	B	307-316
'	I	316-317
s	I	313-314
disease	I	319-326
.	O	326-327

These	O	328-333
cases	O	334-339
demonstrate	O	340-351
that	O	352-356
bromocriptine	O	357-370
may	O	371-374
cause	O	375-380
psychosis	B	381-390
even	O	391-395
when	O	396-400
given	O	401-406
in	O	407-409
low	O	410-413
doses	O	414-419
.	O	419-420

A	O	0-1
prospective	O	2-13
study	O	14-19
on	O	20-22
the	O	23-26
dose	O	27-31
dependency	O	32-42
of	O	43-45
cardiotoxicity	B	46-60
induced	O	61-68
by	O	69-71
mitomycin	O	72-81
C	O	82-83
.	O	83-84
Since	O	85-90
1975	O	91-95
mitomycin	O	96-105
C	O	106-107
(	O	108-109
MMC	O	109-112
)	O	112-113
has	O	114-117
been	O	118-122
suggested	O	123-132
to	O	133-135
be	O	136-138
cardiotoxic	B	139-150
,	O	150-151
especially	O	152-162
when	O	163-167
combined	O	168-176
with	O	177-181
or	O	182-184
given	O	185-190
following	O	191-200
doxorubicin	O	201-212
.	O	212-213

Data	O	214-218
on	O	219-221
dose	O	222-226
dependency	O	227-237
or	O	238-240
incidence	O	241-250
concerning	O	251-261
this	O	262-266
side	O	267-271
effect	O	272-278
were	O	279-283
not	O	284-287
known	O	288-293
.	O	293-294

We	O	295-297
have	O	298-302
initiated	O	303-312
a	O	313-314
prospective	O	315-326
study	O	327-332
to	O	333-335
obtain	O	336-342
some	O	343-347
more	O	348-352
data	O	353-357
on	O	358-360
these	O	361-366
subjects	O	367-375
.	O	375-376

Forty	O	377-382
-	O	382-383
four	O	383-387
MMC	O	388-391
-	O	391-392
treated	O	392-399
patients	O	400-408
were	O	409-413
studied	O	414-421
,	O	421-422
37	O	423-425
of	O	426-428
them	O	429-433
could	O	434-439
be	O	440-442
evaluated	O	443-452
.	O	452-453

All	O	454-457
patients	O	458-466
were	O	467-471
studied	O	472-479
by	O	480-482
repeated	O	483-491
physical	O	492-500
examinations	O	501-513
,	O	513-514
chest	O	515-520
X	O	521-522
-	O	522-523
rays	O	523-527
,	O	527-528
electro	O	529-536
-	O	536-537
and	O	538-541
echocardiography	O	542-558
and	O	559-562
radionuclide	O	563-575
left	O	576-580
ventricular	O	581-592
ejection	O	593-601
fraction	O	602-610
(	O	611-612
EF	O	612-614
)	O	614-615
determinations	O	616-630
.	O	630-631

The	O	632-635
results	O	636-643
were	O	644-648
evaluated	O	649-658
per	O	659-662
cumulative	O	663-673
dose	O	674-678
level	O	679-684
.	O	684-685

One	O	686-689
of	O	690-692
the	O	693-696
patients	O	697-705
developed	O	706-715
cardiac	B	716-723
failure	I	724-731
after	O	732-737
30	O	738-740
mg	O	741-743
m	O	744-745
-	O	745-746
2	O	746-747
MMC	O	748-751
and	O	752-755
only	O	756-760
150	O	761-764
mg	O	765-767
m	O	768-769
-	O	769-770
2	O	770-771
doxorubicin	O	772-783
.	O	783-784

The	O	785-788
cardiac	B	789-796
failure	I	797-804
was	O	805-808
predicted	O	809-818
by	O	819-821
a	O	822-823
drop	O	824-828
in	O	829-831
EF	O	832-834
determined	O	835-845
during	O	846-852
a	O	853-854
cold	O	855-859
pressor	O	860-867
test	O	868-872
.	O	872-873

None	O	874-878
of	O	879-881
the	O	882-885
other	O	886-891
patients	O	892-900
developed	O	901-910
clinical	O	911-919
cardiotoxicity	B	920-934
,	O	934-935
nor	O	936-939
did	O	940-943
the	O	944-947
studied	O	948-955
parameters	O	956-966
change	O	967-973
.	O	973-974

The	O	975-978
literature	O	979-989
on	O	990-992
this	O	993-997
subject	O	998-1005
was	O	1006-1009
also	O	1010-1014
reviewed	O	1015-1023
.	O	1023-1024

Based	O	1025-1030
on	O	1031-1033
the	O	1034-1037
combined	O	1038-1046
data	O	1047-1051
from	O	1052-1056
the	O	1057-1060
present	O	1061-1068
study	O	1069-1074
and	O	1075-1078
the	O	1079-1082
literature	O	1083-1093
,	O	1093-1094
we	O	1095-1097
suggest	O	1098-1105
that	O	1106-1110
MMC	O	1111-1114
-	O	1114-1115
related	O	1115-1122
cardiotoxicity	B	1123-1137
is	O	1138-1140
dose	O	1141-1145
dependent	O	1146-1155
,	O	1155-1156
occurring	O	1157-1166
at	O	1167-1169
cumulative	O	1170-1180
dose	O	1181-1185
levels	O	1186-1192
of	O	1193-1195
30	O	1196-1198
mg	O	1199-1201
m	O	1202-1203
-	O	1203-1204
2	O	1204-1205
or	O	1206-1208
more	O	1209-1213
,	O	1213-1214
mainly	O	1215-1221
in	O	1222-1224
patients	O	1225-1233
also	O	1234-1238
(	O	1239-1240
previously	O	1240-1250
or	O	1251-1253
simultaneously	O	1254-1268
)	O	1268-1269
treated	O	1270-1277
with	O	1278-1282
doxorubicin	O	1283-1294
.	O	1294-1295

The	O	1296-1299
incidence	O	1300-1309
is	O	1310-1312
likely	O	1313-1319
to	O	1320-1322
be	O	1323-1325
less	O	1326-1330
than	O	1331-1335
10	O	1336-1338
%	O	1338-1339
even	O	1340-1344
for	O	1345-1348
this	O	1349-1353
risk	O	1354-1358
group	O	1359-1364
.	O	1364-1365

Phlorizin	O	0-9
-	O	9-10
induced	O	10-17
glycosuria	B	18-28
does	O	29-33
not	O	34-37
prevent	O	38-45
gentamicin	O	46-56
nephrotoxicity	B	57-71
in	O	72-74
rats	O	75-79
.	O	79-80

Because	O	81-88
rats	O	89-93
with	O	94-98
streptozotocin	O	99-113
-	O	113-114
induced	O	114-121
diabetes	B	122-130
mellitus	I	131-139
(	O	140-141
DM	B	141-143
)	O	143-144
have	O	145-149
a	O	150-151
high	O	152-156
solute	O	157-163
diuresis	O	164-172
(	O	173-174
glycosuria	B	174-184
of	O	185-187
10	O	188-190
to	O	191-193
12	O	194-196
g	O	197-198
/	O	198-199
day	O	199-202
)	O	202-203
,	O	203-204
we	O	205-207
have	O	208-212
suggested	O	213-222
that	O	223-227
this	O	228-232
may	O	233-236
in	O	237-239
part	O	240-244
be	O	245-247
responsible	O	248-259
for	O	260-263
their	O	264-269
resistance	O	270-280
to	O	281-283
gentamicin	O	284-294
-	O	294-295
induced	O	295-302
acute	B	303-308
renal	I	309-314
failure	I	315-322
(	O	323-324
ARF	B	324-327
)	O	327-328
.	O	328-329

The	O	330-333
protection	O	334-344
from	O	345-349
gentamicin	O	350-360
nephrotoxicity	B	361-375
was	O	376-379
studied	O	380-387
in	O	388-390
non	O	391-394
-	O	394-395
diabetic	B	395-403
rats	O	404-408
with	O	409-413
chronic	O	414-421
solute	O	422-428
diuresis	O	429-437
induced	O	438-445
by	O	446-448
blockage	O	449-457
of	O	458-460
tubular	O	461-468
glucose	O	469-476
reabsorption	O	477-489
with	O	490-494
phlorizin	O	495-504
(	O	505-506
P	O	506-507
)	O	507-508
.	O	508-509

DM	B	510-512
rats	O	513-517
with	O	518-522
mild	O	523-527
glycosuria	B	528-538
(	O	539-540
similar	O	540-547
in	O	548-550
degree	O	551-557
to	O	558-560
that	O	561-565
of	O	566-568
the	O	569-572
P	O	573-574
treated	O	575-582
animals	O	583-590
)	O	590-591
were	O	592-596
also	O	597-601
studied	O	602-609
.	O	609-610

Unanesthetized	O	611-625
adult	O	626-631
female	O	632-638
,	O	638-639
Sprague	O	640-647
-	O	647-648
Dawley	O	648-654
rats	O	655-659
were	O	660-664
divided	O	665-672
in	O	673-675
four	O	676-680
groups	O	681-687
and	O	688-691
studied	O	692-699
for	O	700-703
15	O	704-706
days	O	707-711
.	O	711-712

Group	O	713-718
1	O	719-720
(	O	721-722
P	O	722-723
alone	O	724-729
)	O	729-730
received	O	731-739
P	O	740-741
,	O	741-742
360	O	743-746
mg	O	747-749
/	O	749-750
day	O	750-753
,	O	753-754
for	O	755-758
15	O	759-761
days	O	762-766
;	O	766-767
Group	O	768-773
II	O	774-776
(	O	777-778
P	O	778-779
+	O	780-781
gentamicin	O	782-792
)	O	792-793
;	O	793-794
Group	O	795-800
III	O	801-804
(	O	805-806
gentamicin	O	806-816
alone	O	817-822
)	O	822-823
and	O	824-827
Group	O	828-833
IV	O	834-836
(	O	837-838
mild	O	838-842
DM	B	843-845
+	O	846-847
gentamicin	O	848-858
)	O	858-859
.	O	859-860

Nephrotoxic	B	861-872
doses	O	873-878
(	O	879-880
40	O	880-882
mg	O	883-885
/	O	885-886
kg	O	886-888
body	O	889-893
wt	O	894-896
/	O	896-897
day	O	897-900
)	O	900-901
of	O	902-904
gentamicin	O	905-915
were	O	916-920
injected	O	921-929
during	O	930-936
the	O	937-940
last	O	941-945
nine	O	946-950
days	O	951-955
of	O	956-958
study	O	959-964
to	O	965-967
the	O	968-971
animals	O	972-979
of	O	980-982
groups	O	983-989
II	O	990-992
to	O	993-995
IV	O	996-998
.	O	998-999

In	O	1000-1002
Group	O	1003-1008
I	O	1009-1010
,	O	1010-1011
P	O	1012-1013
induced	O	1014-1021
a	O	1022-1023
moderate	O	1024-1032
and	O	1033-1036
stable	O	1037-1043
glycosuria	B	1044-1054
(	O	1055-1056
3	O	1056-1057
.	O	1057-1058
9	O	1058-1059
+	O	1060-1061
/	O	1061-1062
-	O	1062-1063
0	O	1064-1065
.	O	1065-1066
1	O	1066-1067
g	O	1068-1069
/	O	1069-1070
day	O	1070-1073
,	O	1073-1074
SE	O	1075-1077
)	O	1077-1078
,	O	1078-1079
and	O	1080-1083
no	O	1084-1086
functional	O	1087-1097
or	O	1098-1100
morphologic	O	1101-1112
evidence	O	1113-1121
of	O	1122-1124
renal	B	1125-1130
dysfunction	I	1131-1142
(	O	1143-1144
baseline	O	1144-1152
CCr	O	1153-1156
2	O	1157-1158
.	O	1158-1159
1	O	1159-1160
+	O	1161-1162
/	O	1162-1163
-	O	1163-1164
0	O	1165-1166
.	O	1166-1167
1	O	1167-1168
ml	O	1169-1171
/	O	1171-1172
min	O	1172-1175
,	O	1175-1176
undetectable	O	1177-1189
lysozymuria	O	1190-1201
)	O	1201-1202
or	O	1203-1205
damage	O	1206-1212
(	O	1213-1214
tubular	B	1214-1221
necrosis	I	1222-1230
score	O	1231-1236
[	O	1237-1238
maximum	O	1238-1245
4	O	1246-1247
]	O	1247-1248
,	O	1248-1249
zero	O	1250-1254
)	O	1254-1255
.	O	1255-1256

In	O	1257-1259
Group	O	1260-1265
II	O	1266-1268
,	O	1268-1269
P	O	1270-1271
did	O	1272-1275
not	O	1276-1279
prevent	O	1280-1287
gentamicin	O	1288-1298
-	O	1298-1299
ARF	B	1299-1302
(	O	1303-1304
maximal	O	1304-1311
decrease	O	1312-1320
in	O	1321-1323
CCr	O	1324-1327
at	O	1328-1330
day	O	1331-1334
9	O	1335-1336
.	O	1336-1337
89	O	1337-1339
%	O	1339-1340
,	O	1340-1341
P	O	1342-1343
less	O	1344-1348
than	O	1349-1353
0	O	1354-1355
.	O	1355-1356
001	O	1356-1359
;	O	1359-1360
peak	O	1361-1365
lysozymuria	O	1366-1377
,	O	1377-1378
1863	O	1379-1383
+	O	1384-1385
/	O	1385-1386
-	O	1386-1387
321	O	1388-1391
micrograms	O	1392-1402
/	O	1402-1403
day	O	1403-1406
;	O	1406-1407
and	O	1408-1411
tubular	B	1412-1419
necrosis	I	1420-1428
score	O	1429-1434
,	O	1434-1435
3	O	1436-1437
.	O	1437-1438
9	O	1438-1439
+	O	1440-1441
/	O	1441-1442
-	O	1442-1443
0	O	1444-1445
.	O	1445-1446
1	O	1446-1447
)	O	1447-1448
.	O	1445-1446

These	O	1450-1455
values	O	1456-1462
were	O	1463-1467
not	O	1468-1471
different	O	1472-1481
from	O	1482-1486
those	O	1487-1492
of	O	1493-1495
Group	O	1496-1501
III	O	1502-1505
:	O	1505-1506
maximal	O	1507-1514
decrease	O	1515-1523
in	O	1524-1526
CCr	O	1527-1530
73	O	1531-1533
%	O	1533-1534
(	O	1535-1536
P	O	1536-1537
less	O	1538-1542
than	O	1543-1547
0	O	1548-1549
.	O	1549-1550
001	O	1550-1553
)	O	1553-1554
;	O	1554-1555
lysozymuria	O	1556-1567
,	O	1567-1568
2147	O	1569-1573
+	O	1574-1575
/	O	1575-1576
-	O	1576-1577
701	O	1578-1581
micrograms	O	1582-1592
/	O	1592-1593
day	O	1593-1596
;	O	1596-1597
tubular	B	1598-1605
necrosis	I	1606-1614
score	O	1615-1620
,	O	1620-1621
3	O	1622-1623
.	O	1623-1624
8	O	1624-1625
+	O	1626-1627
/	O	1627-1628
-	O	1628-1629
0	O	1630-1631
.	O	1631-1632
1	O	1632-1633
.	O	1631-1632
(	O	1634-1635
ABSTRACT	O	1635-1643

TRUNCATED	O	1644-1653
AT	O	1654-1656
250	O	1657-1660
WORDS	O	1661-1666
)	O	1666-1667

Tiapride	O	0-8
in	O	9-11
levodopa	O	12-20
-	O	20-21
induced	O	21-28
involuntary	B	29-40
movements	I	41-50
.	O	50-51

Tiapride	O	52-60
,	O	60-61
a	O	62-63
substituted	O	64-75
benzamide	O	76-85
derivative	O	86-96
closely	O	97-104
related	O	105-112
to	O	113-115
metoclopramide	O	116-130
,	O	130-131
reduced	O	132-139
levodopa	O	140-148
-	O	148-149
induced	O	149-156
peak	O	157-161
dose	O	162-166
involuntary	B	167-178
movements	I	179-188
in	O	189-191
16	O	192-194
patients	O	195-203
with	O	204-208
idiopathic	B	209-219
Parkinson	I	220-229
'	I	229-230
s	I	226-227
disease	I	232-239
.	O	239-240

However	O	241-248
,	O	248-249
an	O	250-252
unacceptable	O	253-265
increase	O	266-274
in	O	275-277
disability	O	278-288
from	O	289-293
Parkinsonism	B	294-306
with	O	307-311
aggravation	O	312-323
of	O	324-326
end	O	327-330
-	O	330-331
of	O	331-333
-	O	330-331
dose	O	334-338
akinesia	B	339-347
led	O	348-351
to	O	352-354
its	O	355-358
cessation	O	359-368
in	O	369-371
14	O	372-374
patients	O	375-383
.	O	383-384

Tiapride	O	385-393
had	O	394-397
no	O	398-400
effect	O	401-407
on	O	408-410
levodopa	O	411-419
-	O	419-420
induced	O	420-427
early	O	428-433
morning	O	434-441
of	O	442-444
"	O	445-446
off	O	446-449
-	O	449-450
period	O	450-456
"	O	445-446
segmental	O	458-467
dystonia	B	468-476
.	O	476-477

These	O	478-483
results	O	484-491
fail	O	492-496
to	O	497-499
support	O	500-507
the	O	508-511
notion	O	512-518
that	O	519-523
levodopa	O	524-532
-	O	532-533
induced	O	533-540
dyskinesias	B	541-552
are	O	553-556
caused	O	557-563
by	O	564-566
overstimulation	O	567-582
of	O	583-585
a	O	586-587
separate	O	588-596
group	O	597-602
of	O	603-605
dopamine	O	606-614
receptors	O	615-624
.	O	624-625

Effects	O	0-7
of	O	8-10
the	O	11-14
hippocampal	O	15-26
deep	O	27-31
brain	O	32-37
stimulation	O	38-49
on	O	50-52
cortical	O	53-61
epileptic	B	62-71
discharges	O	72-82
in	O	83-85
penicillin	O	86-96
-	O	97-98
induced	O	99-106
epilepsy	B	107-115
model	O	116-121
in	O	122-124
rats	O	125-129
.	O	129-130

AIM	O	131-134
:	O	134-135
Experimental	O	136-148
and	O	149-152
clinical	O	153-161
studies	O	162-169
have	O	170-174
revealed	O	175-183
that	O	184-188
hippocampal	O	189-200
DBS	O	201-204
can	O	205-208
control	O	209-216
epileptic	B	217-226
activity	O	227-235
,	O	235-236
but	O	237-240
the	O	241-244
mechanism	O	245-254
of	O	255-257
action	O	258-264
is	O	265-267
obscure	O	268-275
and	O	276-279
optimal	O	280-287
stimulation	O	288-299
parameters	O	300-310
are	O	311-314
not	O	315-318
clearly	O	319-326
defined	O	327-334
.	O	334-335

The	O	336-339
aim	O	340-343
was	O	344-347
to	O	348-350
evaluate	O	351-359
the	O	360-363
effects	O	364-371
of	O	372-374
high	O	375-379
frequency	O	380-389
hippocampal	O	390-401
stimulation	O	402-413
on	O	414-416
cortical	O	417-425
epileptic	B	426-435
activity	O	436-444
in	O	445-447
penicillin	O	448-458
-	O	458-459
induced	O	459-466
epilepsy	B	467-475
model	O	476-481
.	O	481-482

MATERIAL	O	483-491
AND	O	492-495
METHODS	O	496-503
:	O	503-504
Twenty	O	505-511
-	O	511-512
five	O	512-516
Sprague	O	517-524
-	O	524-525
Dawley	O	525-531
rats	O	532-536
were	O	537-541
implanted	O	542-551
DBS	O	552-555
electrodes	O	556-566
.	O	566-567

In	O	568-570
group	O	571-576
-	O	576-577
1	O	577-578
(	O	579-580
n	O	580-581
=	O	581-582
10	O	582-584
)	O	584-585
hippocampal	O	586-597
DBS	O	598-601
was	O	602-605
off	O	606-609
and	O	610-613
in	O	614-616
the	O	617-620
group	O	621-626
-	O	626-627
2	O	627-628
(	O	629-630
n	O	630-631
=	O	631-632
10	O	632-634
)	O	634-635
hippocampal	O	636-647
DBS	O	648-651
was	O	652-655
on	O	656-658
(	O	659-660
185	O	660-663
Hz	O	664-666
,	O	666-667
0	O	668-669
.	O	669-670
5V	O	670-672
,	O	672-673
1V	O	674-676
,	O	676-677
2V	O	678-680
,	O	680-681
and	O	682-685
5V	O	686-688
for	O	689-692
60	O	693-695
sec	O	696-699
)	O	699-700
following	O	701-710
penicillin	O	711-721
G	O	722-723
injection	O	724-733
intracortically	O	734-749
.	O	749-750

In	O	751-753
the	O	754-757
control	O	758-765
group	O	766-771
hippocampal	O	772-783
DBS	O	784-787
was	O	788-791
on	O	792-794
following	O	795-804
8	O	805-806
l	O	808-809
saline	O	810-816
injection	O	817-826
intracortically	O	827-842
.	O	842-843

EEG	O	844-847
recordings	O	848-858
were	O	859-863
obtained	O	864-872
before	O	873-879
and	O	880-883
15	O	884-886
minutes	O	887-894
following	O	895-904
penicillin	O	905-915
-	O	915-916
G	O	916-917
injection	O	918-927
,	O	927-928
and	O	929-932
at	O	933-935
10th	O	936-940
minutes	O	941-948
following	O	949-958
each	O	959-963
stimulus	O	964-972
for	O	973-976
analysis	O	977-985
in	O	986-988
terms	O	989-994
of	O	995-997
frequency	O	998-1007
,	O	1007-1008
amplitude	O	1009-1018
,	O	1018-1019
and	O	1020-1023
power	O	1024-1029
spectrum	O	1030-1038
.	O	1038-1039

RESULTS	O	1040-1047
:	O	1047-1048
High	O	1049-1053
frequency	O	1054-1063
hippocampal	O	1064-1075
DBS	O	1076-1079
suppressed	O	1080-1090
the	O	1091-1094
acute	O	1095-1100
penicillin	O	1101-1111
-	O	1111-1112
induced	O	1112-1119
cortical	O	1120-1128
epileptic	B	1129-1138
activity	O	1139-1147
independent	O	1148-1159
from	O	1160-1164
stimulus	O	1165-1173
intensity	O	1174-1183
.	O	1183-1184

In	O	1185-1187
the	O	1188-1191
control	O	1192-1199
group	O	1200-1205
,	O	1205-1206
hippocampal	O	1207-1218
stimulation	O	1219-1230
alone	O	1231-1236
lead	O	1237-1241
only	O	1242-1246
to	O	1247-1249
diffuse	O	1250-1257
slowing	O	1258-1265
of	O	1266-1268
cerebral	O	1269-1277
bioelectrical	O	1278-1291
activity	O	1292-1300
at	O	1301-1303
5V	O	1304-1306
stimulation	O	1307-1318
.	O	1318-1319

CONCLUSION	O	1320-1330
:	O	1330-1331
Our	O	1332-1335
results	O	1336-1343
revealed	O	1344-1352
that	O	1353-1357
continuous	O	1358-1368
high	O	1369-1373
frequency	O	1374-1383
stimulation	O	1384-1395
of	O	1396-1398
the	O	1399-1402
hippocampus	O	1403-1414
suppressed	O	1415-1425
acute	O	1426-1431
cortical	O	1432-1440
epileptic	B	1441-1450
activity	O	1451-1459
effectively	O	1460-1471
without	O	1472-1479
causing	O	1480-1487
secondary	O	1488-1497
epileptic	B	1498-1507
discharges	O	1508-1518
.	O	1518-1519

These	O	1520-1525
results	O	1526-1533
are	O	1534-1537
important	O	1538-1547
in	O	1548-1550
terms	O	1551-1556
of	O	1557-1559
defining	O	1560-1568
the	O	1569-1572
optimal	O	1573-1580
parameters	O	1581-1591
of	O	1592-1594
hippocampal	O	1595-1606
DBS	O	1607-1610
in	O	1611-1613
patients	O	1614-1622
with	O	1623-1627
epilepsy	B	1628-1636
.	O	1636-1637

Neural	O	0-6
correlates	O	7-17
of	O	18-20
S	O	21-22
-	O	22-23
ketamine	O	23-31
induced	O	32-39
psychosis	B	40-49
during	O	50-56
overt	O	57-62
continuous	O	63-73
verbal	O	74-80
fluency	O	81-88
.	O	88-89

The	O	90-93
glutamatergic	O	94-107
N	O	108-109
-	O	109-110
methyl	O	110-116
-	O	109-110
D	O	117-118
-	O	109-110
aspartate	O	119-128
(	O	129-130
NMDA	O	130-134
)	O	134-135
receptor	O	136-144
has	O	145-148
been	O	149-153
implicated	O	154-164
in	O	165-167
the	O	168-171
pathophysiology	O	172-187
of	O	188-190
schizophrenia	B	191-204
.	O	204-205

Administered	O	206-218
to	O	219-221
healthy	O	222-229
volunteers	O	230-240
,	O	240-241
a	O	242-243
subanesthetic	O	244-257
dose	O	258-262
of	O	263-265
the	O	266-269
non	O	270-273
-	O	273-274
competitive	O	274-285
NMDA	O	286-290
receptor	O	291-299
antagonist	O	300-310
ketamine	O	311-319
leads	O	320-325
to	O	326-328
psychopathological	O	329-347
symptoms	O	348-356
similar	O	357-364
to	O	365-367
those	O	368-373
observed	O	374-382
in	O	383-385
schizophrenia	B	386-399
.	O	399-400

In	O	401-403
patients	O	404-412
with	O	413-417
schizophrenia	B	418-431
,	O	431-432
ketamine	O	433-441
exacerbates	O	442-453
the	O	454-457
core	O	458-462
symptoms	O	463-471
of	O	472-474
illness	O	475-482
,	O	482-483
supporting	O	484-494
the	O	495-498
hypothesis	O	499-509
of	O	510-512
a	O	513-514
glutamatergic	B	515-528
dysfunction	I	529-540
.	O	540-541

In	O	542-544
a	O	545-546
counterbalanced	O	547-562
,	O	562-563
placebo	O	564-571
-	O	571-572
controlled	O	572-582
,	O	582-583
double	O	584-590
-	O	590-591
blind	O	591-596
study	O	597-602
design	O	603-609
,	O	609-610
healthy	O	611-618
subjects	O	619-627
were	O	628-632
administered	O	633-645
a	O	646-647
continuous	O	648-658
subanesthetic	O	659-672
S	O	673-674
-	O	674-675
ketamine	O	675-683
infusion	O	684-692
while	O	693-698
differences	O	699-710
in	O	711-713
BOLD	O	714-718
responses	O	719-728
measured	O	729-737
with	O	738-742
fMRI	O	743-747
were	O	748-752
detected	O	753-761
.	O	761-762

During	O	763-769
the	O	770-773
scanning	O	774-782
period	O	783-789
,	O	789-790
subjects	O	791-799
performed	O	800-809
continuous	O	810-820
overt	O	821-826
verbal	O	827-833
fluency	O	834-841
tasks	O	842-847
(	O	848-849
phonological	O	849-861
,	O	861-862
lexical	O	863-870
and	O	871-874
semantic	O	875-883
)	O	883-884
.	O	884-885

Ketamine	O	886-894
-	O	894-895
induced	O	895-902
psychopathological	O	903-921
symptoms	O	922-930
were	O	931-935
assessed	O	936-944
with	O	945-949
the	O	950-953
Positive	O	954-962
and	O	963-966
Negative	O	967-975
Syndrome	O	976-984
Scale	O	985-990
(	O	991-992
PANSS	O	992-997
)	O	997-998
.	O	998-999

Ketamine	O	1000-1008
elicited	O	1009-1017
psychosis	B	1018-1027
like	O	1028-1032
psychopathology	O	1033-1048
.	O	1048-1049

Post	O	1050-1054
-	O	1054-1055
hoc	O	1055-1058
t	O	1059-1060
-	O	1060-1061
tests	O	1061-1066
revealed	O	1067-1075
significant	O	1076-1087
differences	O	1088-1099
between	O	1100-1107
placebo	O	1108-1115
and	O	1116-1119
ketamine	O	1120-1128
for	O	1129-1132
the	O	1133-1136
amounts	O	1137-1144
of	O	1145-1147
words	O	1148-1153
generated	O	1154-1163
during	O	1164-1170
lexical	O	1171-1178
and	O	1179-1182
semantic	O	1183-1191
verbal	O	1192-1198
fluency	O	1199-1206
,	O	1206-1207
while	O	1208-1213
the	O	1214-1217
phonological	O	1218-1230
domain	O	1231-1237
remained	O	1238-1246
unaffected	O	1247-1257
.	O	1257-1258

Ketamine	O	1259-1267
led	O	1268-1271
to	O	1272-1274
enhanced	O	1275-1283
cortical	O	1284-1292
activations	O	1293-1304
in	O	1305-1307
supramarginal	O	1308-1321
and	O	1322-1325
frontal	O	1326-1333
brain	O	1334-1339
regions	O	1340-1347
for	O	1348-1351
phonological	O	1352-1364
and	O	1365-1368
lexical	O	1369-1376
verbal	O	1377-1383
fluency	O	1384-1391
,	O	1391-1392
but	O	1393-1396
not	O	1397-1400
for	O	1401-1404
semantic	O	1405-1413
verbal	O	1414-1420
fluency	O	1421-1428
.	O	1428-1429

Ketamine	O	1430-1438
induces	O	1439-1446
activation	O	1447-1457
changes	O	1458-1465
in	O	1466-1468
healthy	O	1469-1476
subjects	O	1477-1485
similar	O	1486-1493
to	O	1494-1496
those	O	1497-1502
observed	O	1503-1511
in	O	1512-1514
patients	O	1515-1523
with	O	1524-1528
schizophrenia	B	1529-1542
,	O	1542-1543
particularly	O	1544-1556
in	O	1557-1559
frontal	O	1560-1567
and	O	1568-1571
temporal	O	1572-1580
brain	O	1581-1586
regions	O	1587-1594
.	O	1594-1595

Our	O	1596-1599
results	O	1600-1607
provide	O	1608-1615
further	O	1616-1623
support	O	1624-1631
for	O	1632-1635
the	O	1636-1639
hypothesis	O	1640-1650
of	O	1651-1653
an	O	1654-1656
NMDA	O	1657-1661
receptor	O	1662-1670
dysfunction	O	1671-1682
in	O	1683-1685
the	O	1686-1689
pathophysiology	O	1690-1705
of	O	1706-1708
schizophrenia	B	1709-1722
.	O	1722-1723

Dopamine	O	0-8
is	O	9-11
not	O	12-15
essential	O	16-25
for	O	26-29
the	O	30-33
development	O	34-45
of	O	46-48
methamphetamine	O	49-64
-	O	64-65
induced	O	65-72
neurotoxicity	B	73-86
.	O	86-87

It	O	88-90
is	O	91-93
widely	O	94-100
believed	O	101-109
that	O	110-114
dopamine	O	115-123
(	O	124-125
DA	O	125-127
)	O	127-128
mediates	O	129-137
methamphetamine	O	138-153
(	O	154-155
METH	O	155-159
)	O	159-160
-	O	160-161
induced	O	161-168
toxicity	B	169-177
to	O	178-180
brain	O	181-186
dopaminergic	O	187-199
neurons	O	200-207
,	O	207-208
because	O	209-216
drugs	O	217-222
that	O	223-227
interfere	O	228-237
with	O	238-242
DA	O	243-245
neurotransmission	O	246-263
decrease	O	264-272
toxicity	B	273-281
,	O	281-282
whereas	O	283-290
drugs	O	291-296
that	O	297-301
increase	O	302-310
DA	O	311-313
neurotransmission	O	314-331
enhance	O	332-339
toxicity	B	340-348
.	O	348-349

However	O	350-357
,	O	357-358
temperature	O	359-370
effects	O	371-378
of	O	379-381
drugs	O	382-387
that	O	388-392
have	O	393-397
been	O	398-402
used	O	403-407
to	O	408-410
manipulate	O	411-421
brain	O	422-427
DA	O	428-430
neurotransmission	O	431-448
confound	O	449-457
interpretation	O	458-472
of	O	473-475
the	O	476-479
data	O	480-484
.	O	484-485

Here	O	486-490
we	O	491-493
show	O	494-498
that	O	499-503
the	O	504-507
recently	O	508-516
reported	O	517-525
ability	O	526-533
of	O	534-536
L	O	537-538
-	O	538-539
dihydroxyphenylalanine	O	539-561
to	O	562-564
reverse	O	565-572
the	O	573-576
protective	O	577-587
effect	O	588-594
of	O	595-597
alpha	O	598-603
-	O	603-604
methyl	O	604-610
-	O	603-604
para	O	611-615
-	O	603-604
tyrosine	O	616-624
on	O	625-627
METH	O	628-632
-	O	632-633
induced	O	633-640
DA	O	641-643
neurotoxicity	B	644-657
is	O	658-660
also	O	661-665
confounded	O	666-676
by	O	677-679
drug	O	680-684
effects	O	685-692
on	O	693-695
body	O	696-700
temperature	O	701-712
.	O	712-713

Further	O	714-721
,	O	721-722
we	O	723-725
show	O	726-730
that	O	731-735
mice	O	736-740
genetically	O	741-752
engineered	O	753-763
to	O	764-766
be	O	767-769
deficient	O	770-779
in	O	780-782
brain	O	783-788
DA	O	789-791
develop	O	792-799
METH	O	800-804
neurotoxicity	B	805-818
,	O	818-819
as	O	820-822
long	O	823-827
as	O	828-830
the	O	831-834
thermic	O	835-842
effects	O	843-850
of	O	851-853
METH	O	854-858
are	O	859-862
preserved	O	863-872
.	O	872-873

In	O	874-876
addition	O	877-885
,	O	885-886
we	O	887-889
demonstrate	O	890-901
that	O	902-906
mice	O	907-911
genetically	O	912-923
engineered	O	924-934
to	O	935-937
have	O	938-942
unilateral	O	943-953
brain	O	954-959
DA	O	960-962
deficits	O	963-971
develop	O	972-979
METH	O	980-984
-	O	984-985
induced	O	985-992
dopaminergic	B	993-1005
deficits	I	1006-1014
that	O	1015-1019
are	O	1020-1023
of	O	1024-1026
comparable	O	1027-1037
magnitude	O	1038-1047
on	O	1048-1050
both	O	1051-1055
sides	O	1056-1061
of	O	1062-1064
the	O	1065-1068
brain	O	1069-1074
.	O	1074-1075

Taken	O	1076-1081
together	O	1082-1090
,	O	1090-1091
these	O	1092-1097
findings	O	1098-1106
demonstrate	O	1107-1118
that	O	1119-1123
DA	O	1124-1126
is	O	1127-1129
not	O	1130-1133
essential	O	1134-1143
for	O	1144-1147
the	O	1148-1151
development	O	1152-1163
of	O	1164-1166
METH	O	1167-1171
-	O	1171-1172
induced	O	1172-1179
dopaminergic	O	1180-1192
neurotoxicity	B	1193-1206
and	O	1207-1210
suggest	O	1211-1218
that	O	1219-1223
mechanisms	O	1224-1234
independent	O	1235-1246
of	O	1247-1249
DA	O	1250-1252
warrant	O	1253-1260
more	O	1261-1265
intense	O	1266-1273
investigation	O	1274-1287
.	O	1287-1288

Brainstem	B	0-9
dysgenesis	I	10-20
in	O	21-23
an	O	24-26
infant	O	27-33
prenatally	O	34-44
exposed	O	45-52
to	O	53-55
cocaine	O	56-63
.	O	63-64

Many	O	65-69
authors	O	70-77
described	O	78-87
the	O	88-91
effects	O	92-99
on	O	100-102
the	O	103-106
fetus	O	107-112
of	O	113-115
maternal	O	116-124
cocaine	B	125-132
abuse	I	133-138
during	O	139-145
pregnancy	O	146-155
.	O	155-156

Vasoconstriction	O	157-173
appears	O	174-181
to	O	182-184
be	O	185-187
the	O	188-191
common	O	192-198
mechanism	O	199-208
of	O	209-211
action	O	212-218
leading	O	219-226
to	O	227-229
a	O	230-231
wide	O	232-236
range	O	237-242
of	O	243-245
fetal	B	246-251
anomalies	I	252-261
.	O	261-262

We	O	263-265
report	O	266-272
on	O	273-275
an	O	276-278
infant	O	279-285
with	O	286-290
multiple	B	291-299
cranial	I	300-307
-	I	307-308
nerve	I	308-313
involvement	I	314-325
attributable	O	326-338
to	O	339-341
brainstem	B	342-351
dysgenesis	I	352-362
,	O	362-363
born	O	364-368
to	O	369-371
a	O	372-373
cocaine	B	374-381
-	I	381-382
addicted	I	382-390
mother	O	391-397
.	O	397-398

The	O	0-3
protective	O	4-14
role	O	15-19
of	O	20-22
Nrf2	O	23-27
in	O	28-30
streptozotocin	O	31-45
-	O	45-46
induced	O	46-53
diabetic	B	54-62
nephropathy	I	63-74
.	O	74-75

OBJECTIVE	O	76-85
:	O	85-86
Diabetic	B	87-95
nephropathy	I	96-107
is	O	108-110
one	O	111-114
of	O	115-117
the	O	118-121
major	O	122-127
causes	O	128-134
of	O	135-137
renal	B	138-143
failure	I	144-151
,	O	151-152
which	O	153-158
is	O	159-161
accompanied	O	162-173
by	O	174-176
the	O	177-180
production	O	181-191
of	O	192-194
reactive	O	195-203
oxygen	O	204-210
species	O	211-218
(	O	219-220
ROS	O	220-223
)	O	223-224
.	O	224-225

Nrf2	O	226-230
is	O	231-233
the	O	234-237
primary	O	238-245
transcription	O	246-259
factor	O	260-266
that	O	267-271
controls	O	272-280
the	O	281-284
antioxidant	O	285-296
response	O	297-305
essential	O	306-315
for	O	316-319
maintaining	O	320-331
cellular	O	332-340
redox	O	341-346
homeostasis	O	347-358
.	O	358-359

Here	O	360-364
,	O	364-365
we	O	366-368
report	O	369-375
our	O	376-379
findings	O	380-388
demonstrating	O	389-402
a	O	403-404
protective	O	405-415
role	O	416-420
of	O	421-423
Nrf2	O	424-428
against	O	429-436
diabetic	B	437-445
nephropathy	I	446-457
.	O	457-458

RESEARCH	O	459-467
DESIGN	O	468-474
AND	O	475-478
METHODS	O	479-486
:	O	486-487
We	O	488-490
explore	O	491-498
the	O	499-502
protective	O	503-513
role	O	514-518
of	O	519-521
Nrf2	O	522-526
against	O	527-534
diabetic	B	535-543
nephropathy	I	544-555
using	O	556-561
human	O	562-567
kidney	O	568-574
biopsy	O	575-581
tissues	O	582-589
from	O	590-594
diabetic	B	595-603
nephropathy	I	604-615
patients	O	616-624
,	O	624-625
a	O	626-627
streptozotocin	O	628-642
-	O	642-643
induced	O	643-650
diabetic	B	651-659
nephropathy	I	660-671
model	O	672-677
in	O	678-680
Nrf2	O	681-685
(	O	685-686
-	O	686-687
/	O	687-688
-	O	686-687
)	O	689-690
mice	O	691-695
,	O	695-696
and	O	697-700
cultured	O	701-709
human	O	710-715
mesangial	O	716-725
cells	O	726-731
.	O	731-732

RESULTS	O	733-740
:	O	740-741
The	O	742-745
glomeruli	O	746-755
of	O	756-758
human	O	759-764
diabetic	B	765-773
nephropathy	I	774-785
patients	O	786-794
were	O	795-799
under	O	800-805
oxidative	O	806-815
stress	O	816-822
and	O	823-826
had	O	827-830
elevated	O	831-839
Nrf2	O	840-844
levels	O	845-851
.	O	851-852

In	O	853-855
the	O	856-859
animal	O	860-866
study	O	867-872
,	O	872-873
Nrf2	O	874-878
was	O	879-882
demonstrated	O	883-895
to	O	896-898
be	O	899-901
crucial	O	902-909
in	O	910-912
ameliorating	O	913-925
streptozotocin	O	926-940
-	O	940-941
induced	O	941-948
renal	B	949-954
damage	I	955-961
.	O	961-962

This	O	963-967
is	O	968-970
evident	O	971-978
by	O	979-981
Nrf2	O	982-986
(	O	986-987
-	O	987-988
/	O	988-989
-	O	987-988
)	O	990-991
mice	O	992-996
having	O	997-1003
higher	O	1004-1010
ROS	O	1011-1014
production	O	1015-1025
and	O	1026-1029
suffering	O	1030-1039
from	O	1040-1044
greater	O	1045-1052
oxidative	O	1053-1062
DNA	O	1063-1066
damage	O	1067-1073
and	O	1074-1077
renal	B	1078-1083
injury	I	1084-1090
compared	O	1091-1099
with	O	1100-1104
Nrf2	O	1105-1109
(	O	1109-1110
+	O	1110-1111
/	O	1111-1112
+	O	1110-1111
)	O	1113-1114
mice	O	1115-1119
.	O	1119-1120

Mechanistic	O	1121-1132
studies	O	1133-1140
in	O	1141-1143
both	O	1144-1148
in	O	1149-1151
vivo	O	1152-1156
and	O	1157-1160
in	O	1161-1163
vitro	O	1164-1169
systems	O	1170-1177
showed	O	1178-1184
that	O	1185-1189
the	O	1190-1193
Nrf2	O	1194-1198
-	O	1198-1199
mediated	O	1199-1207
protection	O	1208-1218
against	O	1219-1226
diabetic	B	1227-1235
nephropathy	I	1236-1247
is	O	1248-1250
,	O	1250-1251
at	O	1252-1254
least	O	1255-1260
,	O	1260-1261
partially	O	1262-1271
through	O	1272-1279
inhibition	O	1280-1290
of	O	1291-1293
transforming	O	1294-1306
growth	O	1307-1313
factor	O	1314-1320
-	O	1320-1321
beta1	O	1321-1326
(	O	1327-1328
TGF	O	1328-1331
-	O	1331-1332
beta1	O	1332-1337
)	O	1337-1338
and	O	1339-1342
reduction	O	1343-1352
of	O	1353-1355
extracellular	O	1356-1369
matrix	O	1370-1376
production	O	1377-1387
.	O	1387-1388

In	O	1389-1391
human	O	1392-1397
renal	O	1398-1403
mesangial	O	1404-1413
cells	O	1414-1419
,	O	1419-1420
high	O	1421-1425
glucose	O	1426-1433
induced	O	1434-1441
ROS	O	1442-1445
production	O	1446-1456
and	O	1457-1460
activated	O	1461-1470
expression	O	1471-1481
of	O	1482-1484
Nrf2	O	1485-1489
and	O	1490-1493
its	O	1494-1497
downstream	O	1498-1508
genes	O	1509-1514
.	O	1514-1515

Furthermore	O	1516-1527
,	O	1527-1528
activation	O	1529-1539
or	O	1540-1542
overexpression	O	1543-1557
of	O	1558-1560
Nrf2	O	1561-1565
inhibited	O	1566-1575
the	O	1576-1579
promoter	O	1580-1588
activity	O	1589-1597
of	O	1598-1600
TGF	O	1601-1604
-	O	1604-1605
beta1	O	1605-1610
in	O	1611-1613
a	O	1614-1615
dose	O	1616-1620
-	O	1620-1621
dependent	O	1621-1630
manner	O	1631-1637
,	O	1637-1638
whereas	O	1639-1646
knockdown	O	1647-1656
of	O	1657-1659
Nrf2	O	1660-1664
by	O	1665-1667
siRNA	O	1668-1673
enhanced	O	1674-1682
TGF	O	1683-1686
-	O	1686-1687
beta1	O	1687-1692
transcription	O	1693-1706
and	O	1707-1710
fibronectin	O	1711-1722
production	O	1723-1733
.	O	1733-1734

CONCLUSIONS	O	1735-1746
:	O	1746-1747
This	O	1748-1752
work	O	1753-1757
clearly	O	1758-1765
indicates	O	1766-1775
a	O	1776-1777
protective	O	1778-1788
role	O	1789-1793
of	O	1794-1796
Nrf2	O	1797-1801
in	O	1802-1804
diabetic	B	1805-1813
nephropathy	I	1814-1825
,	O	1825-1826
suggesting	O	1827-1837
that	O	1838-1842
dietary	O	1843-1850
or	O	1851-1853
therapeutic	O	1854-1865
activation	O	1866-1876
of	O	1877-1879
Nrf2	O	1880-1884
could	O	1885-1890
be	O	1891-1893
used	O	1894-1898
as	O	1899-1901
a	O	1902-1903
strategy	O	1904-1912
to	O	1913-1915
prevent	O	1916-1923
or	O	1924-1926
slow	O	1927-1931
down	O	1932-1936
the	O	1937-1940
progression	O	1941-1952
of	O	1953-1955
diabetic	B	1956-1964
nephropathy	I	1965-1976
.	O	1976-1977

High	O	0-4
-	O	4-5
dose	O	5-9
tranexamic	O	10-20
Acid	O	21-25
is	O	26-28
associated	O	29-39
with	O	40-44
nonischemic	O	45-56
clinical	O	57-65
seizures	B	66-74
in	O	75-77
cardiac	O	78-85
surgical	O	86-94
patients	O	95-103
.	O	103-104

BACKGROUND	O	105-115
:	O	115-116
In	O	117-119
2	O	120-121
separate	O	122-130
centers	O	131-138
,	O	138-139
we	O	140-142
observed	O	143-151
a	O	152-153
notable	O	154-161
increase	O	162-170
in	O	171-173
the	O	174-177
incidence	O	178-187
of	O	188-190
postoperative	O	191-204
convulsive	B	205-215
seizures	B	216-224
from	O	225-229
1	O	230-231
.	O	231-232
3	O	232-233
%	O	233-234
to	O	235-237
3	O	238-239
.	O	239-240
8	O	240-241
%	O	241-242
in	O	243-245
patients	O	246-254
having	O	255-261
undergone	O	262-271
major	O	272-277
cardiac	O	278-285
surgical	O	286-294
procedures	O	295-305
.	O	305-306

These	O	307-312
events	O	313-319
were	O	320-324
temporally	O	325-335
coincident	O	336-346
with	O	347-351
the	O	352-355
initial	O	356-363
use	O	364-367
of	O	368-370
high	O	371-375
-	O	375-376
dose	O	376-380
tranexamic	O	381-391
acid	O	392-396
(	O	397-398
TXA	O	398-401
)	O	401-402
therapy	O	403-410
after	O	411-416
withdrawal	O	417-427
of	O	428-430
aprotinin	O	431-440
from	O	441-445
general	O	446-453
clinical	O	454-462
usage	O	463-468
.	O	468-469

The	O	470-473
purpose	O	474-481
of	O	482-484
this	O	485-489
review	O	490-496
was	O	497-500
to	O	501-503
perform	O	504-511
a	O	512-513
retrospective	O	514-527
analysis	O	528-536
to	O	537-539
examine	O	540-547
whether	O	548-555
there	O	556-561
was	O	562-565
a	O	566-567
relation	O	568-576
between	O	577-584
TXA	O	585-588
usage	O	589-594
and	O	595-598
seizures	B	599-607
after	O	608-613
cardiac	O	614-621
surgery	O	622-629
.	O	629-630

METHODS	O	631-638
:	O	638-639
An	O	640-642
in	O	643-645
-	O	645-646
depth	O	646-651
chart	O	652-657
review	O	658-664
was	O	665-668
undertaken	O	669-679
in	O	680-682
all	O	683-686
24	O	687-689
patients	O	690-698
who	O	699-702
developed	O	703-712
perioperative	O	713-726
seizures	B	727-735
.	O	735-736

Electroencephalographic	O	737-760
activity	O	761-769
was	O	770-773
recorded	O	774-782
in	O	783-785
11	O	786-788
of	O	789-791
these	O	792-797
patients	O	798-806
,	O	806-807
and	O	808-811
all	O	812-815
patients	O	816-824
had	O	825-828
a	O	829-830
formal	O	831-837
neurological	O	838-850
evaluation	O	851-861
and	O	862-865
brain	O	866-871
imaging	O	872-879
studies	O	880-887
.	O	887-888

RESULTS	O	889-896
:	O	896-897
Twenty	O	898-904
-	O	904-905
one	O	905-908
of	O	909-911
the	O	912-915
24	O	916-918
patients	O	919-927
did	O	928-931
not	O	932-935
have	O	936-940
evidence	O	941-949
of	O	950-952
new	O	953-956
cerebral	B	957-965
ischemic	I	966-974
injury	I	975-981
,	O	981-982
but	O	983-986
seizures	B	987-995
were	O	996-1000
likely	O	1001-1007
due	O	1008-1011
to	O	1012-1014
ischemic	B	1015-1023
brain	I	1024-1029
injury	I	1030-1036
in	O	1037-1039
3	O	1040-1041
patients	O	1042-1050
.	O	1050-1051

All	O	1052-1055
patients	O	1056-1064
with	O	1065-1069
seizures	B	1070-1078
did	O	1079-1082
not	O	1083-1086
have	O	1087-1091
permanent	O	1092-1101
neurological	B	1102-1114
abnormalities	I	1115-1128
.	O	1128-1129

All	O	1130-1133
24	O	1134-1136
patients	O	1137-1145
with	O	1146-1150
seizures	B	1151-1159
received	O	1160-1168
high	O	1169-1173
doses	O	1174-1179
of	O	1180-1182
TXA	O	1183-1186
intraoperatively	O	1187-1203
ranging	O	1204-1211
from	O	1212-1216
61	O	1217-1219
to	O	1220-1222
259	O	1223-1226
mg	O	1227-1229
/	O	1229-1230
kg	O	1230-1232
,	O	1232-1233
had	O	1234-1237
a	O	1238-1239
mean	O	1240-1244
age	O	1245-1248
of	O	1249-1251
69	O	1252-1254
.	O	1254-1255
9	O	1253-1254
years	O	1257-1262
,	O	1262-1263
and	O	1264-1267
21	O	1268-1270
of	O	1271-1273
24	O	1274-1276
had	O	1277-1280
undergone	O	1281-1290
open	O	1291-1295
chamber	O	1296-1303
rather	O	1304-1310
than	O	1311-1315
coronary	O	1316-1324
bypass	O	1325-1331
procedures	O	1332-1342
.	O	1342-1343

All	O	1344-1347
but	O	1348-1351
one	O	1352-1355
patient	O	1356-1363
were	O	1364-1368
managed	O	1369-1376
using	O	1377-1382
cardiopulmonary	O	1383-1398
bypass	O	1399-1405
.	O	1405-1406

No	O	1407-1409
evidence	O	1410-1418
of	O	1419-1421
brain	B	1422-1427
ischemic	I	1428-1436
,	O	1436-1437
metabolic	O	1438-1447
,	O	1447-1448
or	O	1449-1451
hyperthermia	B	1452-1464
-	O	1464-1465
induced	O	1465-1472
causes	O	1473-1479
for	O	1480-1483
their	O	1484-1489
seizures	B	1490-1498
was	O	1499-1502
apparent	O	1503-1511
.	O	1511-1512

CONCLUSION	O	1513-1523
:	O	1523-1524
Our	O	1525-1528
results	O	1529-1536
suggest	O	1537-1544
that	O	1545-1549
use	O	1550-1553
of	O	1554-1556
high	O	1557-1561
-	O	1561-1562
dose	O	1562-1566
TXA	O	1567-1570
in	O	1571-1573
older	O	1574-1579
patients	O	1580-1588
in	O	1589-1591
conjunction	O	1592-1603
with	O	1604-1608
cardiopulmonary	O	1609-1624
bypass	O	1625-1631
and	O	1632-1635
open	O	1636-1640
-	O	1640-1641
chamber	O	1641-1648
cardiac	O	1649-1656
surgery	O	1657-1664
is	O	1665-1667
associated	O	1668-1678
with	O	1679-1683
clinical	O	1684-1692
seizures	B	1693-1701
in	O	1702-1704
susceptible	O	1705-1716
patients	O	1717-1725
.	O	1725-1726

Recurrent	O	0-9
dysosmia	B	10-18
induced	O	19-26
by	O	27-29
pyrazinamide	O	30-42
.	O	42-43

Pyrazinamide	O	44-56
can	O	57-60
have	O	61-65
adverse	O	66-73
effects	O	74-81
such	O	82-86
as	O	87-89
hepatic	B	90-97
toxicity	I	98-106
,	O	106-107
hyperuricemia	B	108-121
or	O	122-124
digestive	O	125-134
disorders	O	135-144
.	O	144-145

In	O	146-148
rare	O	149-153
cases	O	154-159
,	O	159-160
alterations	O	161-172
in	O	173-175
taste	O	176-181
and	O	182-185
smell	O	186-191
function	O	192-200
have	O	201-205
been	O	206-210
reported	O	211-219
for	O	220-223
pyrazinamide	O	224-236
when	O	237-241
combined	O	242-250
with	O	251-255
other	O	256-261
drugs	O	262-267
.	O	267-268

We	O	269-271
report	O	272-278
a	O	279-280
case	O	281-285
of	O	286-288
reversible	O	289-299
olfactory	B	300-309
disorder	I	310-318
related	O	319-326
to	O	327-329
pyrazinamide	O	330-342
in	O	343-345
a	O	346-347
woman	O	348-353
,	O	353-354
with	O	355-359
a	O	360-361
positive	O	362-370
rechallenge	O	371-382
.	O	382-383

The	O	384-387
patient	O	388-395
presented	O	396-405
every	O	406-411
day	O	412-415
a	O	416-417
sensation	O	418-427
of	O	428-430
smelling	O	431-439
something	O	440-449
burning	O	450-457
15	O	458-460
min	O	461-464
after	O	465-470
drug	O	471-475
intake	O	476-482
.	O	482-483

Dysosmia	B	484-492
disappeared	O	493-504
completely	O	505-515
after	O	516-521
pyrazinamide	O	522-534
withdrawal	O	535-545
and	O	546-549
recurred	O	550-558
after	O	559-564
its	O	565-568
rechallenge	O	569-580
.	O	580-581

The	O	582-585
case	O	586-590
was	O	591-594
reported	O	595-603
to	O	604-606
the	O	607-610
Tunisian	O	611-619
Centre	O	620-626
of	O	627-629
Pharmacovigilance	O	630-647
.	O	647-648

Longitudinal	O	0-12
assessment	O	13-23
of	O	24-26
air	O	27-30
conduction	O	31-41
audiograms	O	42-52
in	O	53-55
a	O	56-57
phase	O	58-63
III	O	64-67
clinical	O	68-76
trial	O	77-82
of	O	83-85
difluoromethylornithine	O	86-109
and	O	110-113
sulindac	O	114-122
for	O	123-126
prevention	O	127-137
of	O	138-140
sporadic	O	141-149
colorectal	B	150-160
adenomas	I	161-169
.	O	169-170

A	O	171-172
phase	O	173-178
III	O	179-182
clinical	O	183-191
trial	O	192-197
assessed	O	198-206
the	O	207-210
recurrence	O	211-221
of	O	222-224
adenomatous	B	225-236
polyps	I	237-243
after	O	244-249
treatment	O	250-259
for	O	260-263
36	O	264-266
months	O	267-273
with	O	274-278
difluoromethylornithine	O	279-302
(	O	303-304
DFMO	O	304-308
)	O	308-309
plus	O	310-314
sulindac	O	315-323
or	O	324-326
matched	O	327-334
placebos	O	335-343
.	O	343-344

Temporary	O	345-354
hearing	B	355-362
loss	I	363-367
is	O	368-370
a	O	371-372
known	O	373-378
toxicity	B	379-387
of	O	388-390
treatment	O	391-400
with	O	401-405
DFMO	O	406-410
,	O	410-411
thus	O	412-416
a	O	417-418
comprehensive	O	419-432
approach	O	433-441
was	O	442-445
developed	O	446-455
to	O	456-458
analyze	O	459-466
serial	O	467-473
air	O	474-477
conduction	O	478-488
audiograms	O	489-499
.	O	499-500

The	O	501-504
generalized	O	505-516
estimating	O	517-527
equation	O	528-536
method	O	537-543
estimated	O	544-553
the	O	554-557
mean	O	558-562
difference	O	563-573
between	O	574-581
treatment	O	582-591
arms	O	592-596
with	O	597-601
regard	O	602-608
to	O	609-611
change	O	612-618
in	O	619-621
air	O	622-625
conduction	O	626-636
pure	O	637-641
tone	O	642-646
thresholds	O	647-657
while	O	658-663
accounting	O	664-674
for	O	675-678
within	O	679-685
-	O	685-686
subject	O	686-693
correlation	O	694-705
due	O	706-709
to	O	710-712
repeated	O	713-721
measurements	O	722-734
at	O	735-737
frequencies	O	738-749
.	O	749-750

Based	O	751-756
on	O	757-759
290	O	760-763
subjects	O	764-772
,	O	772-773
there	O	774-779
was	O	780-783
an	O	784-786
average	O	787-794
difference	O	795-805
of	O	806-808
0	O	809-810
.	O	810-811
50	O	811-813
dB	O	814-816
between	O	817-824
subjects	O	825-833
treated	O	834-841
with	O	842-846
DFMO	O	847-851
plus	O	852-856
sulindac	O	857-865
compared	O	866-874
with	O	875-879
those	O	880-885
treated	O	886-893
with	O	894-898
placebo	O	899-906
(	O	907-908
95	O	908-910
%	O	910-911
confidence	O	912-922
interval	O	923-931
,	O	931-932
-	O	933-934
0	O	934-935
.	O	935-936
64	O	936-938
to	O	939-941
1	O	942-943
.	O	943-944
63	O	944-946
dB	O	947-949
;	O	949-950
P	O	951-952
=	O	953-954
0	O	955-956
.	O	956-957
39	O	957-959
)	O	959-960
,	O	960-961
adjusted	O	962-970
for	O	971-974
baseline	O	975-983
values	O	984-990
,	O	990-991
age	O	992-995
,	O	995-996
and	O	997-1000
frequencies	O	1001-1012
.	O	1012-1013

In	O	1014-1016
the	O	1017-1020
normal	O	1021-1027
speech	O	1028-1034
range	O	1035-1040
of	O	1041-1043
500	O	1044-1047
to	O	1048-1050
3	O	1051-1052
,	O	1052-1053
000	O	1053-1056
Hz	O	1057-1059
,	O	1059-1060
an	O	1061-1063
estimated	O	1064-1073
difference	O	1074-1084
of	O	1085-1087
0	O	1088-1089
.	O	1089-1090
99	O	1090-1092
dB	O	1093-1095
(	O	1096-1097
-	O	1097-1098
0	O	1098-1099
.	O	1099-1100
17	O	1100-1102
to	O	1103-1105
2	O	1106-1107
.	O	1107-1108
14	O	1108-1110
dB	O	1111-1113
;	O	1113-1114
P	O	1115-1116
=	O	1117-1118
0	O	1119-1120
.	O	1120-1121
09	O	1121-1123
)	O	1123-1124
was	O	1125-1128
detected	O	1129-1137
.	O	1137-1138

Dose	O	1139-1143
intensity	O	1144-1153
did	O	1154-1157
not	O	1158-1161
add	O	1162-1165
information	O	1166-1177
to	O	1178-1180
models	O	1181-1187
.	O	1187-1188

There	O	1189-1194
were	O	1195-1199
14	O	1200-1202
of	O	1203-1205
151	O	1206-1209
(	O	1210-1211
9	O	1211-1212
.	O	1212-1213
3	O	1213-1214
%	O	1214-1215
)	O	1215-1216
in	O	1217-1219
the	O	1220-1223
DFMO	O	1224-1228
plus	O	1229-1233
sulindac	O	1234-1242
group	O	1243-1248
and	O	1249-1252
4	O	1253-1254
of	O	1255-1257
139	O	1258-1261
(	O	1262-1263
2	O	1263-1264
.	O	1264-1265
9	O	1265-1266
%	O	1266-1267
)	O	1267-1268
in	O	1269-1271
the	O	1272-1275
placebo	O	1276-1283
group	O	1284-1289
who	O	1290-1293
experienced	O	1294-1305
at	O	1306-1308
least	O	1309-1314
15	O	1315-1317
dB	O	1318-1320
hearing	O	1321-1328
reduction	O	1329-1338
from	O	1339-1343
baseline	O	1344-1352
in	O	1353-1355
2	O	1356-1357
or	O	1358-1360
more	O	1361-1365
consecutive	O	1366-1377
frequencies	O	1378-1389
across	O	1390-1396
the	O	1397-1400
entire	O	1401-1407
range	O	1408-1413
tested	O	1414-1420
(	O	1421-1422
P	O	1422-1423
=	O	1424-1425
0	O	1426-1427
.	O	1427-1428
02	O	1428-1430
)	O	1430-1431
.	O	1427-1428

Follow	O	1433-1439
-	O	1439-1440
up	O	1440-1442
air	O	1443-1446
conduction	O	1447-1457
done	O	1458-1462
at	O	1463-1465
least	O	1466-1471
6	O	1472-1473
months	O	1474-1480
after	O	1481-1486
end	O	1487-1490
of	O	1491-1493
treatment	O	1494-1503
showed	O	1504-1510
an	O	1511-1513
adjusted	O	1514-1522
mean	O	1523-1527
difference	O	1528-1538
in	O	1539-1541
hearing	O	1542-1549
thresholds	O	1550-1560
of	O	1561-1563
1	O	1564-1565
.	O	1565-1566
08	O	1566-1568
dB	O	1569-1571
(	O	1572-1573
-	O	1573-1574
0	O	1574-1575
.	O	1575-1576
81	O	1576-1578
to	O	1579-1581
2	O	1582-1583
.	O	1583-1584
96	O	1584-1586
dB	O	1587-1589
;	O	1589-1590
P	O	1591-1592
=	O	1593-1594
0	O	1595-1596
.	O	1596-1597
26	O	1597-1599
)	O	1599-1600
between	O	1601-1608
treatment	O	1609-1618
arms	O	1619-1623
.	O	1623-1624

There	O	1625-1630
was	O	1631-1634
no	O	1635-1637
significant	O	1638-1649
difference	O	1650-1660
in	O	1661-1663
the	O	1664-1667
proportion	O	1668-1678
of	O	1679-1681
subjects	O	1682-1690
in	O	1691-1693
the	O	1694-1697
DFMO	O	1698-1702
plus	O	1703-1707
sulindac	O	1708-1716
group	O	1717-1722
who	O	1723-1726
experienced	O	1727-1738
clinically	O	1739-1749
significant	O	1750-1761
hearing	B	1762-1769
loss	I	1770-1774
compared	O	1775-1783
with	O	1784-1788
the	O	1789-1792
placebo	O	1793-1800
group	O	1801-1806
.	O	1806-1807

The	O	1808-1811
estimated	O	1812-1821
attributable	O	1822-1834
risk	O	1835-1839
of	O	1840-1842
ototoxicity	B	1843-1854
from	O	1855-1859
exposure	O	1860-1868
to	O	1869-1871
the	O	1872-1875
drug	O	1876-1880
is	O	1881-1883
8	O	1884-1885
.	O	1885-1886
4	O	1886-1887
%	O	1887-1888
(	O	1889-1890
95	O	1890-1892
%	O	1892-1893
confidence	O	1894-1904
interval	O	1905-1913
,	O	1913-1914
-	O	1915-1916
2	O	1916-1917
.	O	1917-1918
0	O	1918-1919
%	O	1919-1920
to	O	1921-1923
18	O	1924-1926
.	O	1926-1927
8	O	1925-1926
%	O	1928-1929
;	O	1929-1930
P	O	1931-1932
=	O	1933-1934
0	O	1935-1936
.	O	1936-1937
12	O	1937-1939
)	O	1939-1940
.	O	1936-1937

There	O	1942-1947
is	O	1948-1950
a	O	1951-1952
<	O	1953-1954
2	O	1954-1955
dB	O	1956-1958
difference	O	1959-1969
in	O	1970-1972
mean	O	1973-1977
threshold	O	1978-1987
for	O	1988-1991
patients	O	1992-2000
treated	O	2001-2008
with	O	2009-2013
DFMO	O	2014-2018
plus	O	2019-2023
sulindac	O	2024-2032
compared	O	2033-2041
with	O	2042-2046
those	O	2047-2052
treated	O	2053-2060
with	O	2061-2065
placebo	O	2066-2073
.	O	2073-2074

Increased	O	0-9
mental	B	10-16
slowing	I	17-24
associated	O	25-35
with	O	36-40
the	O	41-44
APOE	O	45-49
epsilon4	O	50-58
allele	O	59-65
after	O	66-71
trihexyphenidyl	O	72-87
oral	O	88-92
anticholinergic	O	93-108
challenge	O	109-118
in	O	119-121
healthy	O	122-129
elderly	O	130-137
.	O	137-138

OBJECTIVES	O	139-149
:	O	149-150
The	O	151-154
objectives	O	155-165
of	O	166-168
this	O	169-173
study	O	174-179
were	O	180-184
to	O	185-187
examine	O	188-195
the	O	196-199
relationship	O	200-212
between	O	213-220
APOE	O	221-225
epsilon4	O	226-234
and	O	235-238
subjective	O	239-249
effects	O	250-257
of	O	258-260
trihexyphenidyl	O	261-276
on	O	277-279
measures	O	280-288
reflecting	O	289-299
sedation	O	300-308
and	O	309-312
confusion	B	313-322
and	O	323-326
to	O	327-329
investigate	O	330-341
the	O	342-345
relationship	O	346-358
between	O	359-366
trihexyphenidyl	O	367-382
-	O	382-383
induced	O	383-390
subjective	O	391-401
effects	O	402-409
and	O	410-413
objective	O	414-423
memory	O	424-430
performance	O	431-442
.	O	442-443

METHODS	O	444-451
:	O	451-452
This	O	453-457
study	O	458-463
comprised	O	464-473
24	O	474-476
cognitively	O	477-488
intact	O	489-495
,	O	495-496
health	O	497-503
elderly	O	504-511
adults	O	512-518
(	O	519-520
12	O	520-522
APOE	O	523-527
epsilon4	O	528-536
carriers	O	537-545
)	O	545-546
at	O	547-549
an	O	550-552
outpatient	O	553-563
geriatric	O	564-573
psychiatry	O	574-584
research	O	585-593
clinic	O	594-600
.	O	600-601

This	O	602-606
was	O	607-610
a	O	611-612
randomized	O	613-623
,	O	623-624
double	O	625-631
blind	O	632-637
,	O	637-638
placebo	O	639-646
-	O	646-647
controlled	O	647-657
,	O	657-658
three	O	659-664
-	O	664-665
way	O	665-668
,	O	668-669
crossover	O	670-679
experimental	O	680-692
design	O	693-699
.	O	699-700

All	O	701-704
participants	O	705-717
received	O	718-726
1	O	727-728
.	O	728-729
0	O	729-730
mg	O	731-733
or	O	734-736
2	O	737-738
.	O	738-739
0	O	739-740
mg	O	741-743
trihexyphenidyl	O	744-759
or	O	760-762
placebo	O	763-770
administered	O	771-783
in	O	784-786
counterbalanced	O	787-802
sequences	O	803-812
over	O	813-817
a	O	818-819
period	O	820-826
of	O	827-829
three	O	830-835
consecutive	O	836-847
weeks	O	848-853
.	O	853-854

Bond	O	855-859
and	O	860-863
Lader	O	864-869
'	O	869-870
s	O	870-871
visual	O	872-878
analog	O	879-885
scales	O	886-892
and	O	893-896
alternate	O	897-906
versions	O	907-915
of	O	916-918
the	O	919-922
Buschke	O	923-930
Selective	O	931-940
Reminding	O	941-950
Test	O	951-955
were	O	956-960
administered	O	961-973
in	O	974-976
a	O	977-978
repeated	O	979-987
measures	O	988-996
design	O	997-1003
at	O	1004-1006
baseline	O	1007-1015
,	O	1015-1016
1	O	1017-1018
,	O	1018-1019
2	O	1020-1021
.	O	1021-1022
5	O	1022-1023
,	O	1023-1024
and	O	1025-1028
5	O	1029-1030
hours	O	1031-1036
postdrug	O	1037-1045
administration	O	1046-1060
.	O	1060-1061

RESULTS	O	1062-1069
:	O	1069-1070
A	O	1071-1072
2	O	1073-1074
.	O	1074-1075
0	O	1075-1076
-	O	1076-1077
mg	O	1077-1079
oral	O	1080-1084
dose	O	1085-1089
of	O	1090-1092
trihexyphenidyl	O	1093-1108
resulted	O	1109-1117
in	O	1118-1120
increased	O	1121-1130
subjective	O	1131-1141
ratings	O	1142-1149
of	O	1150-1152
mental	B	1153-1159
slowness	I	1160-1168
in	O	1169-1171
carriers	O	1172-1180
of	O	1181-1183
the	O	1184-1187
APOE	O	1188-1192
epsilon4	O	1193-1201
allele	O	1202-1208
only	O	1209-1213
.	O	1213-1214

Drug	O	1215-1219
effects	O	1220-1227
as	O	1228-1230
determined	O	1231-1241
by	O	1242-1244
difference	O	1245-1255
scores	O	1256-1262
between	O	1263-1270
2	O	1271-1272
.	O	1272-1273
0	O	1273-1274
mg	O	1275-1277
trihexyphenidyl	O	1278-1293
and	O	1294-1297
placebo	O	1298-1305
on	O	1306-1308
ratings	O	1309-1316
of	O	1317-1319
mental	B	1320-1326
slowness	I	1327-1335
significantly	O	1336-1349
correlated	O	1350-1360
with	O	1361-1365
total	O	1366-1371
and	O	1372-1375
delayed	O	1376-1383
recall	O	1384-1390
on	O	1391-1393
the	O	1394-1397
Buschke	O	1398-1405
Selective	O	1406-1415
Reminding	O	1416-1425
Test	O	1426-1430
in	O	1431-1433
carriers	O	1434-1442
of	O	1443-1445
the	O	1446-1449
APOE	O	1450-1454
epsilon4	O	1455-1463
allele	O	1464-1470
only	O	1471-1475
.	O	1475-1476

However	O	1477-1484
,	O	1484-1485
no	O	1486-1488
significant	O	1489-1500
effects	O	1501-1508
were	O	1509-1513
found	O	1514-1519
with	O	1520-1524
other	O	1525-1530
visual	O	1531-1537
analog	O	1538-1544
scales	O	1545-1551
reflecting	O	1552-1562
subjective	O	1563-1573
sedation	O	1574-1582
and	O	1583-1586
clear	O	1587-1592
-	O	1592-1593
headedness	O	1593-1603
.	O	1603-1604

CONCLUSION	O	1605-1615
:	O	1615-1616
The	O	1617-1620
epsilon4	O	1621-1629
allele	O	1630-1636
in	O	1637-1639
healthy	O	1640-1647
elderly	O	1648-1655
was	O	1656-1659
associated	O	1660-1670
with	O	1671-1675
increased	O	1676-1685
subjective	O	1686-1696
mental	B	1697-1703
slowing	I	1704-1711
after	O	1712-1717
trihexyphenidyl	O	1718-1733
anticholinergic	O	1734-1749
challenge	O	1750-1759
.	O	1759-1760

Behavioral	O	0-10
effects	O	11-18
of	O	19-21
pubertal	O	22-30
anabolic	O	31-39
androgenic	O	40-50
steroid	O	51-58
exposure	O	59-67
in	O	68-70
male	O	71-75
rats	O	76-80
with	O	81-85
low	O	86-89
serotonin	O	90-99
.	O	99-100

The	O	101-104
goal	O	105-109
of	O	110-112
this	O	113-117
study	O	118-123
was	O	124-127
to	O	128-130
assess	O	131-137
the	O	138-141
interactive	O	142-153
effects	O	154-161
of	O	162-164
chronic	O	165-172
anabolic	O	173-181
androgenic	O	182-192
steroid	O	193-200
(	O	201-202
AAS	O	202-205
)	O	205-206
exposure	O	207-215
and	O	216-219
brain	O	220-225
serotonin	O	226-235
(	O	236-237
5	O	237-238
-	O	238-239
hydroxytryptamine	O	239-256
,	O	256-257
5	O	258-259
-	O	259-260
HT	O	260-262
)	O	262-263
depletion	O	264-273
on	O	274-276
behavior	O	277-285
of	O	286-288
pubertal	O	289-297
male	O	298-302
rats	O	303-307
.	O	307-308

Serotonin	O	309-318
was	O	319-322
depleted	O	323-331
beginning	O	332-341
on	O	342-344
postnatal	O	345-354
day	O	355-358
26	O	359-361
with	O	362-366
parachlorophenylalanine	O	367-390
(	O	391-392
PCPA	O	392-396
100	O	397-400
mg	O	401-403
/	O	403-404
kg	O	404-406
,	O	406-407
every	O	408-413
other	O	414-419
day	O	420-423
)	O	423-424
;	O	424-425
controls	O	426-434
received	O	435-443
saline	O	444-450
.	O	450-451

At	O	452-454
puberty	O	455-462
(	O	463-464
P40	O	464-467
)	O	467-468
,	O	468-469
half	O	470-474
the	O	475-478
PCPA	O	479-483
-	O	483-484
treated	O	484-491
rats	O	492-496
and	O	497-500
half	O	501-505
the	O	506-509
saline	O	510-516
-	O	516-517
treated	O	517-524
rats	O	525-529
began	O	530-535
treatment	O	536-545
with	O	546-550
testosterone	O	551-563
(	O	564-565
T	O	565-566
,	O	566-567
5	O	568-569
mg	O	570-572
/	O	572-573
kg	O	573-575
,	O	575-576
5	O	577-578
days	O	579-583
/	O	583-584
week	O	584-588
)	O	588-589
.	O	589-590

Behavioral	O	591-601
measures	O	602-610
included	O	611-619
locomotion	O	620-630
,	O	630-631
irritability	B	632-644
,	O	644-645
copulation	O	646-656
,	O	656-657
partner	O	658-665
preference	O	666-676
,	O	676-677
and	O	678-681
aggression	B	682-692
.	O	692-693

Animals	O	694-701
were	O	702-706
tested	O	707-713
for	O	714-717
aggression	B	718-728
in	O	729-731
their	O	732-737
home	O	738-742
cage	O	743-747
,	O	747-748
both	O	749-753
with	O	754-758
and	O	759-762
without	O	763-770
physical	O	771-779
provocation	O	780-791
(	O	792-793
mild	O	793-797
tail	O	798-802
pinch	O	803-808
)	O	808-809
.	O	809-810

Brain	O	811-816
levels	O	817-823
of	O	824-826
5	O	827-828
-	O	828-829
HT	O	829-831
and	O	832-835
its	O	836-839
metabolite	O	840-850
,	O	850-851
5	O	852-853
-	O	853-854
hydroxyindoleacetic	O	854-873
acid	O	874-878
(	O	879-880
5	O	880-881
-	O	881-882
HIAA	O	882-886
)	O	886-887
,	O	887-888
were	O	889-893
determined	O	894-904
using	O	905-910
HPLC	O	911-915
.	O	915-916

PCPA	O	917-921
significantly	O	922-935
and	O	936-939
substantially	O	940-953
depleted	O	954-962
5	O	963-964
-	O	964-965
HT	O	965-967
and	O	968-971
5	O	972-973
-	O	973-974
HIAA	O	974-978
in	O	979-981
all	O	982-985
brain	O	986-991
regions	O	992-999
examined	O	1000-1008
.	O	1008-1009

Chronic	O	1010-1017
T	O	1018-1019
treatment	O	1020-1029
significantly	O	1030-1043
decreased	O	1044-1053
5	O	1054-1055
-	O	1055-1056
HT	O	1056-1058
and	O	1059-1062
5	O	1063-1064
-	O	1064-1065
HIAA	O	1065-1069
in	O	1070-1072
certain	O	1073-1080
brain	O	1081-1086
areas	O	1087-1092
,	O	1092-1093
but	O	1094-1097
to	O	1098-1100
a	O	1101-1102
much	O	1103-1107
lesser	O	1108-1114
extent	O	1115-1121
than	O	1122-1126
PCPA	O	1127-1131
.	O	1131-1132

Chronic	O	1133-1140
exposure	O	1141-1149
to	O	1150-1152
PCPA	O	1153-1157
alone	O	1158-1163
significantly	O	1164-1177
decreased	O	1178-1187
locomotor	O	1188-1197
activity	O	1198-1206
and	O	1207-1210
increased	O	1211-1220
irritability	B	1221-1233
but	O	1234-1237
had	O	1238-1241
no	O	1242-1244
effect	O	1245-1251
on	O	1252-1254
sexual	O	1255-1261
behavior	O	1262-1270
,	O	1270-1271
partner	O	1272-1279
preference	O	1280-1290
,	O	1290-1291
or	O	1292-1294
aggression	B	1295-1305
.	O	1305-1306

T	O	1307-1308
alone	O	1309-1314
had	O	1315-1318
no	O	1319-1321
effect	O	1322-1328
on	O	1329-1331
locomotion	O	1332-1342
,	O	1342-1343
irritability	B	1344-1356
,	O	1356-1357
or	O	1358-1360
sexual	O	1361-1367
behavior	O	1368-1376
but	O	1377-1380
increased	O	1381-1390
partner	O	1391-1398
preference	O	1399-1409
and	O	1410-1413
aggression	B	1414-1424
.	O	1424-1425

The	O	1426-1429
most	O	1430-1434
striking	O	1435-1443
effect	O	1444-1450
of	O	1451-1453
combining	O	1454-1463
T	O	1464-1465
+	O	1465-1466
PCPA	O	1466-1470
was	O	1471-1474
a	O	1475-1476
significant	O	1477-1488
increase	O	1489-1497
in	O	1498-1500
attack	O	1501-1507
frequency	O	1508-1517
as	O	1518-1520
well	O	1521-1525
as	O	1526-1528
a	O	1529-1530
significant	O	1531-1542
decrease	O	1543-1551
in	O	1552-1554
the	O	1555-1558
latency	O	1559-1566
to	O	1567-1569
attack	O	1570-1576
,	O	1576-1577
particularly	O	1578-1590
following	O	1591-1600
physical	O	1601-1609
provocation	O	1610-1621
.	O	1621-1622

Based	O	1623-1628
on	O	1629-1631
these	O	1632-1637
data	O	1638-1642
,	O	1642-1643
it	O	1644-1646
can	O	1647-1650
be	O	1651-1653
speculated	O	1654-1664
that	O	1665-1669
pubertal	O	1670-1678
AAS	O	1679-1682
users	O	1683-1688
with	O	1689-1693
low	O	1694-1697
central	O	1698-1705
5	O	1706-1707
-	O	1707-1708
HT	O	1708-1710
may	O	1711-1714
be	O	1715-1717
especially	O	1718-1728
prone	O	1729-1734
to	O	1735-1737
exhibit	O	1738-1745
aggressive	B	1746-1756
behavior	I	1757-1765
.	O	1765-1766

Intracavitary	O	0-13
chemotherapy	O	14-26
(	O	27-28
paclitaxel	O	28-38
/	O	38-39
carboplatin	O	39-50
liquid	O	51-57
crystalline	O	58-69
cubic	O	70-75
phases	O	76-82
)	O	82-83
for	O	84-87
recurrent	O	88-97
glioblastoma	B	98-110
-	O	111-112
-	O	111-112
clinical	O	114-122
observations	O	123-135
.	O	135-136

Human	O	137-142
malignant	O	143-152
brain	B	153-158
tumors	I	159-165
have	O	166-170
a	O	171-172
poor	O	173-177
prognosis	O	178-187
in	O	188-190
spite	O	191-196
of	O	197-199
surgery	O	200-207
and	O	208-211
radiation	O	212-221
therapy	O	222-229
.	O	229-230

Cubic	O	231-236
phases	O	237-243
consist	O	244-251
of	O	252-254
curved	O	255-261
biocontinuous	O	262-275
lipid	O	276-281
bilayers	O	282-290
,	O	290-291
separating	O	292-302
two	O	303-306
congruent	O	307-316
networks	O	317-325
of	O	326-328
water	O	329-334
channels	O	335-343
.	O	343-344

Used	O	345-349
as	O	350-352
a	O	353-354
host	O	355-359
for	O	360-363
cytotoxic	O	364-373
drugs	O	374-379
,	O	379-380
the	O	381-384
gel	O	385-388
-	O	388-389
like	O	389-393
matrix	O	394-400
can	O	401-404
easily	O	405-411
be	O	412-414
applied	O	415-422
to	O	423-425
the	O	426-429
walls	O	430-435
of	O	436-438
a	O	439-440
surgical	O	441-449
resection	O	450-459
cavity	O	460-466
.	O	466-467

For	O	468-471
human	O	472-477
glioblastoma	B	478-490
recurrences	O	491-502
,	O	502-503
the	O	504-507
feasibility	O	508-519
,	O	519-520
safety	O	521-527
,	O	527-528
and	O	529-532
short	O	533-538
-	O	538-539
term	O	539-543
effects	O	544-551
of	O	552-554
a	O	555-556
surgical	O	557-565
intracavitary	O	566-579
application	O	580-591
of	O	592-594
paclitaxel	O	595-605
and	O	606-609
carboplatin	O	610-621
encapsulated	O	622-634
by	O	635-637
liquid	O	638-644
crystalline	O	645-656
cubic	O	657-662
phases	O	663-669
are	O	670-673
examined	O	674-682
in	O	683-685
a	O	686-687
pilot	O	688-693
study	O	694-699
.	O	699-700

A	O	701-702
total	O	703-708
of	O	709-711
12	O	712-714
patients	O	715-723
with	O	724-728
a	O	729-730
recurrence	O	731-741
of	O	742-744
a	O	745-746
glioblastoma	B	747-759
multiforme	O	760-770
underwent	O	771-780
re	O	781-783
-	O	783-784
resection	O	784-793
and	O	794-797
received	O	798-806
an	O	807-809
intracavitary	O	810-823
application	O	824-835
of	O	836-838
paclitaxel	O	839-849
and	O	850-853
carboplatin	O	854-865
cubic	O	866-871
phases	O	872-878
in	O	879-881
different	O	882-891
dosages	O	892-899
.	O	899-900

Six	O	901-904
of	O	905-907
the	O	908-911
patients	O	912-920
received	O	921-929
more	O	930-934
than	O	935-939
15	O	940-942
mg	O	943-945
paclitaxel	O	946-956
and	O	957-960
suffered	O	961-969
from	O	970-974
moderate	O	975-983
to	O	984-986
severe	O	987-993
brain	B	994-999
edema	I	1000-1005
,	O	1005-1006
while	O	1007-1012
the	O	1013-1016
remaining	O	1017-1026
patients	O	1027-1035
received	O	1036-1044
only	O	1045-1049
a	O	1050-1051
total	O	1052-1057
of	O	1058-1060
15	O	1061-1063
mg	O	1064-1066
paclitaxel	O	1067-1077
.	O	1077-1078

In	O	1079-1081
the	O	1082-1085
latter	O	1086-1092
group	O	1093-1098
,	O	1098-1099
brain	B	1100-1105
edema	I	1106-1111
was	O	1112-1115
markedly	O	1116-1124
reduced	O	1125-1132
and	O	1133-1136
dealt	O	1137-1142
medically	O	1143-1152
.	O	1152-1153

Intracavitary	O	1154-1167
chemotherapy	O	1168-1180
in	O	1181-1183
recurrent	O	1184-1193
glioblastoma	B	1194-1206
using	O	1207-1212
cubic	O	1213-1218
phases	O	1219-1225
is	O	1226-1228
feasible	O	1229-1237
and	O	1238-1241
safe	O	1242-1246
,	O	1246-1247
yet	O	1248-1251
the	O	1252-1255
clinical	O	1256-1264
benefit	O	1265-1272
remains	O	1273-1280
to	O	1281-1283
be	O	1284-1286
examined	O	1287-1295
in	O	1296-1298
a	O	1299-1300
clinical	O	1301-1309
phase	O	1310-1315
II	O	1316-1318
study	O	1319-1324
.	O	1324-1325

Methylphenidate	O	0-15
-	O	15-16
induced	O	16-23
obsessive	B	24-33
-	I	33-34
compulsive	I	34-44
symptoms	I	45-53
in	O	54-56
an	O	57-59
elderly	O	60-67
man	O	68-71
.	O	71-72

An	O	73-75
82	O	76-78
-	O	78-79
year	O	79-83
-	O	78-79
old	O	84-87
man	O	88-91
with	O	92-96
treatment	B	97-106
-	I	106-107
resistant	I	107-116
depression	I	117-127
and	O	128-131
early	O	132-137
Alzheimer	B	138-147
'	I	147-148
s	I	148-149
disease	I	150-157
was	O	158-161
started	O	162-169
on	O	170-172
methylphenidate	O	173-188
.	O	188-189

Significant	O	190-201
obsessive	B	202-211
-	I	211-212
compulsive	I	212-222
behavior	I	223-231
ensued	O	232-238
but	O	239-242
diminished	O	243-253
over	O	254-258
several	O	259-266
weeks	O	267-272
when	O	273-277
methylphenidate	O	278-293
was	O	294-297
replaced	O	298-306
by	O	307-309
fluvoxamine	O	310-321
.	O	321-322

The	O	323-326
patient	O	327-334
had	O	335-338
no	O	339-341
prior	O	342-347
psychiatric	B	348-359
history	O	360-367
,	O	367-368
but	O	369-372
he	O	373-375
had	O	376-379
a	O	380-381
sister	O	382-388
with	O	389-393
obsessive	B	394-403
-	I	403-404
compulsive	I	404-414
disorder	I	415-423
.	O	423-424

It	O	425-427
appears	O	428-435
that	O	436-440
methylphenidate	O	441-456
precipitated	O	457-469
the	O	470-473
patient	O	474-481
'	O	481-482
s	O	482-483
pathological	O	484-496
behavior	O	497-505
.	O	505-506

Cardiac	B	0-7
arrest	I	8-14
after	O	15-20
intravenous	O	21-32
metoclopramide	O	33-47
-	O	48-49
a	O	50-51
case	O	52-56
of	O	57-59
five	O	60-64
repeated	O	65-73
injections	O	74-84
of	O	85-87
metoclopramide	O	88-102
causing	O	103-110
five	O	111-115
episodes	O	116-124
of	O	125-127
cardiac	B	128-135
arrest	I	136-142
.	O	142-143

We	O	144-146
describe	O	147-155
a	O	156-157
patient	O	158-165
where	O	166-171
intravenous	O	172-183
injection	O	184-193
of	O	194-196
metoclopramide	O	197-211
was	O	212-215
immediately	O	216-227
followed	O	228-236
by	O	237-239
asystole	B	240-248
repeatedly	O	249-259
.	O	259-260

The	O	261-264
patient	O	265-272
received	O	273-281
metoclopramide	O	282-296
10	O	297-299
mg	O	300-302
i	O	303-304
.	O	304-305
v	O	305-306
.	O	304-305

five	O	308-312
times	O	313-318
during	O	319-325
48	O	326-328
h	O	329-330
.	O	330-331

After	O	332-337
interviewing	O	338-350
the	O	351-354
attending	O	355-364
nurses	O	365-371
and	O	372-375
reviewing	O	376-385
the	O	386-389
written	O	390-397
documentation	O	398-411
,	O	411-412
it	O	413-415
is	O	416-418
clear	O	419-424
that	O	425-429
every	O	430-435
administration	O	436-450
of	O	451-453
metoclopramide	O	454-468
was	O	469-472
immediately	O	473-484
(	O	485-486
within	O	486-492
s	O	493-494
)	O	494-495
followed	O	496-504
by	O	505-507
asystole	B	508-516
.	O	516-517

The	O	518-521
asystole	B	522-530
lasted	O	531-537
15	O	538-540
-	O	540-541
30	O	541-543
s	O	544-545
on	O	546-548
four	O	549-553
occasions	O	554-563
,	O	563-564
on	O	565-567
one	O	568-571
occasion	O	572-580
it	O	581-583
lasted	O	584-590
2	O	591-592
min	O	593-596
.	O	596-597

The	O	598-601
patient	O	602-609
received	O	610-618
atropine	O	619-627
0	O	628-629
.	O	629-630
5	O	630-631
-	O	631-632
1	O	632-633
mg	O	634-636
and	O	637-640
chest	O	641-646
compressions	O	647-659
,	O	659-660
before	O	661-667
sinus	O	668-673
rhythm	O	674-680
again	O	681-686
took	O	687-691
over	O	692-696
.	O	696-697

We	O	698-700
interpret	O	701-710
this	O	711-715
as	O	716-718
episodes	O	719-727
of	O	728-730
cardiac	B	731-738
arrest	I	739-745
caused	O	746-752
by	O	753-755
metoclopramide	O	756-770
.	O	770-771

The	O	772-775
rapid	O	776-781
injection	O	782-791
via	O	792-795
the	O	796-799
central	O	800-807
venous	O	808-814
route	O	815-820
and	O	821-824
the	O	825-828
concomitant	O	829-840
tapering	O	841-849
of	O	850-852
dopamine	O	853-861
infusion	O	862-870
might	O	871-876
have	O	877-881
contributed	O	882-893
in	O	894-896
precipitating	O	897-910
the	O	911-914
adverse	O	915-922
drug	O	923-927
reaction	O	928-936
.	O	936-937

Severe	O	0-6
immune	O	7-13
hemolytic	B	14-23
anemia	I	24-30
associated	O	31-41
with	O	42-46
prophylactic	O	47-59
use	O	60-63
of	O	64-66
cefotetan	O	67-76
in	O	77-79
obstetric	O	80-89
and	O	90-93
gynecologic	O	94-105
procedures	O	106-116
.	O	116-117

Second	O	118-124
-	O	124-125
and	O	126-129
third	O	130-135
-	O	135-136
generation	O	136-146
cephalosporins	O	147-161
,	O	161-162
especially	O	163-173
cefotetan	O	174-183
,	O	183-184
are	O	185-188
increasingly	O	189-201
associated	O	202-212
with	O	213-217
severe	O	218-224
,	O	224-225
sometimes	O	226-235
fatal	O	236-241
immune	O	242-248
hemolytic	B	249-258
anemia	I	259-265
.	O	265-266

We	O	267-269
noticed	O	270-277
that	O	278-282
10	O	283-285
of	O	286-288
our	O	289-292
35	O	293-295
cases	O	296-301
of	O	302-304
cefotetan	O	305-314
-	O	314-315
induced	O	315-322
hemolytic	B	323-332
anemias	I	333-340
were	O	341-345
in	O	346-348
patients	O	349-357
who	O	358-361
had	O	362-365
received	O	366-374
cefotetan	O	375-384
prophylactically	O	385-401
for	O	402-405
obstetric	O	406-415
and	O	416-419
gynecologic	O	420-431
procedures	O	432-442
.	O	442-443

Eight	O	444-449
of	O	450-452
these	O	453-458
cases	O	459-464
of	O	465-467
severe	O	468-474
immune	O	475-481
hemolytic	B	482-491
anemia	I	492-498
are	O	499-502
described	O	503-512
.	O	512-513

Cauda	B	0-5
equina	I	6-12
syndrome	I	13-21
after	O	22-27
spinal	O	28-34
anaesthesia	O	35-46
with	O	47-51
hyperbaric	O	52-62
5	O	63-64
%	O	64-65
lignocaine	O	66-76
:	O	76-77
a	O	78-79
review	O	80-86
of	O	87-89
six	O	90-93
cases	O	94-99
of	O	100-102
cauda	B	103-108
equina	I	109-115
syndrome	I	116-124
reported	O	125-133
to	O	134-136
the	O	137-140
Swedish	O	141-148
Pharmaceutical	O	149-163
Insurance	O	164-173
1993	O	174-178
-	O	178-179
1997	O	179-183
.	O	183-184

Six	O	185-188
cases	O	189-194
of	O	195-197
cauda	B	198-203
equina	I	204-210
syndrome	I	211-219
with	O	220-224
varying	O	225-232
severity	O	233-241
were	O	242-246
reported	O	247-255
to	O	256-258
the	O	259-262
Swedish	O	263-270
Pharmaceutical	O	271-285
Insurance	O	286-295
during	O	296-302
the	O	303-306
period	O	307-313
1993	O	314-318
-	O	318-319
1997	O	319-323
.	O	323-324

All	O	325-328
were	O	329-333
associated	O	334-344
with	O	345-349
spinal	O	350-356
anaesthesia	O	357-368
using	O	369-374
hyperbaric	O	375-385
5	O	386-387
%	O	387-388
lignocaine	O	389-399
.	O	399-400

Five	O	401-405
cases	O	406-411
had	O	412-415
single	O	416-422
-	O	422-423
shot	O	423-427
spinal	O	428-434
anaesthesia	O	435-446
and	O	447-450
one	O	451-454
had	O	455-458
a	O	459-460
repeat	O	461-467
spinal	O	468-474
anaesthetic	O	475-486
due	O	487-490
to	O	491-493
inadequate	O	494-504
block	O	505-510
.	O	510-511

The	O	512-515
dose	O	516-520
of	O	521-523
hyperbaric	O	524-534
5	O	535-536
%	O	536-537
lignocaine	O	538-548
administered	O	549-561
ranged	O	562-568
from	O	569-573
60	O	574-576
to	O	577-579
120	O	580-583
mg	O	584-586
.	O	586-587

Three	O	588-593
of	O	594-596
the	O	597-600
cases	O	601-606
were	O	607-611
most	O	612-616
likely	O	617-623
caused	O	624-630
by	O	631-633
direct	O	634-640
neurotoxicity	B	641-654
of	O	655-657
hyperbaric	O	658-668
5	O	669-670
%	O	670-671
lignocaine	O	672-682
.	O	682-683

In	O	684-686
the	O	687-690
other	O	691-696
3	O	697-698
cases	O	699-704
,	O	704-705
direct	O	706-712
neurotoxicity	B	713-726
was	O	727-730
also	O	731-735
probable	O	736-744
,	O	744-745
but	O	746-749
unfortunately	O	750-763
radiological	O	764-776
investigations	O	777-791
were	O	792-796
not	O	797-800
done	O	801-805
to	O	806-808
definitely	O	809-819
exclude	O	820-827
a	O	828-829
compressive	O	830-841
aetiology	O	842-851
.	O	851-852

All	O	853-856
cases	O	857-862
sustained	O	863-872
permanent	O	873-882
neurological	B	883-895
deficits	I	896-904
.	O	904-905

We	O	906-908
recommend	O	909-918
that	O	919-923
hyperbaric	O	924-934
lignocaine	O	935-945
should	O	946-952
be	O	953-955
administered	O	956-968
in	O	969-971
concentrations	O	972-986
not	O	987-990
greater	O	991-998
than	O	999-1003
2	O	1004-1005
%	O	1005-1006
and	O	1007-1010
at	O	1011-1013
a	O	1014-1015
total	O	1016-1021
dose	O	1022-1026
preferably	O	1027-1037
not	O	1038-1041
exceeding	O	1042-1051
60	O	1052-1054
mg	O	1055-1057
.	O	1057-1058

Cortical	O	0-8
motor	O	9-14
overactivation	O	15-29
in	O	30-32
parkinsonian	B	33-45
patients	O	46-54
with	O	55-59
L	O	60-61
-	O	61-62
dopa	O	62-66
-	O	61-62
induced	O	67-74
peak	O	75-79
-	O	79-80
dose	O	80-84
dyskinesia	B	85-95
.	O	95-96

We	O	97-99
have	O	100-104
studied	O	105-112
the	O	113-116
regional	O	117-125
cerebral	O	126-134
blood	O	135-140
flow	O	141-145
(	O	146-147
rCBF	O	147-151
)	O	151-152
changes	O	153-160
induced	O	161-168
by	O	169-171
the	O	172-175
execution	O	176-185
of	O	186-188
a	O	189-190
finger	O	191-197
-	O	197-198
to	O	198-200
-	O	197-198
thumb	O	201-206
opposition	O	207-217
motor	O	218-223
task	O	224-228
in	O	229-231
the	O	232-235
supplementary	O	236-249
and	O	250-253
primary	O	254-261
motor	O	262-267
cortex	O	268-274
of	O	275-277
two	O	278-281
groups	O	282-288
of	O	289-291
parkinsonian	B	292-304
patients	O	305-313
on	O	314-316
L	O	317-318
-	O	318-319
dopa	O	319-323
medication	O	324-334
,	O	334-335
the	O	336-339
first	O	340-345
one	O	346-349
without	O	350-357
L	O	358-359
-	O	359-360
dopa	O	360-364
induced	O	365-372
dyskinesia	B	373-383
(	O	384-385
n	O	385-386
=	O	387-388
23	O	389-391
)	O	391-392
and	O	393-396
the	O	397-400
other	O	401-406
with	O	407-411
moderate	O	412-420
peak	O	421-425
-	O	425-426
dose	O	426-430
dyskinesia	B	431-441
(	O	442-443
n	O	443-444
=	O	445-446
15	O	447-449
)	O	449-450
,	O	450-451
and	O	452-455
of	O	456-458
a	O	459-460
group	O	461-466
of	O	467-469
14	O	470-472
normal	O	473-479
subjects	O	480-488
.	O	488-489

Single	O	490-496
photon	O	497-503
emission	O	504-512
tomography	O	513-523
with	O	524-528
i	O	529-530
.	O	530-531
v	O	531-532
.	O	530-531

133Xe	O	534-539
was	O	540-543
used	O	544-548
to	O	549-551
measure	O	552-559
the	O	560-563
rCBF	O	564-568
changes	O	569-576
.	O	576-577

The	O	578-581
dyskinetic	B	582-592
parkinsonian	B	593-605
patients	O	606-614
exhibited	O	615-624
a	O	625-626
pattern	O	627-634
of	O	635-637
response	O	638-646
which	O	647-652
was	O	653-656
markedly	O	657-665
different	O	666-675
from	O	676-680
those	O	681-686
of	O	687-689
the	O	690-693
normal	O	694-700
subjects	O	701-709
and	O	710-713
non	O	714-717
-	O	717-718
dyskinetic	B	718-728
parkinsonian	B	729-741
patients	O	742-750
,	O	750-751
with	O	752-756
a	O	757-758
significant	O	759-770
overactivation	O	771-785
in	O	786-788
the	O	789-792
supplementary	O	793-806
motor	O	807-812
area	O	813-817
and	O	818-821
the	O	822-825
ipsi	O	826-830
-	O	830-831
and	O	832-835
contralateral	O	836-849
primary	O	850-857
motor	O	858-863
areas	O	864-869
.	O	869-870

These	O	871-876
results	O	877-884
are	O	885-888
compatible	O	889-899
with	O	900-904
the	O	905-908
hypothesis	O	909-919
that	O	920-924
an	O	925-927
hyperkinetic	B	928-940
abnormal	B	941-949
involuntary	I	950-961
movement	I	962-970
,	O	970-971
like	O	972-976
L	O	977-978
-	O	978-979
dopa	O	979-983
-	O	978-979
induced	O	984-991
peak	O	992-996
dose	O	997-1001
dyskinesia	B	1002-1012
,	O	1012-1013
is	O	1014-1016
due	O	1017-1020
to	O	1021-1023
a	O	1024-1025
disinhibition	O	1026-1039
of	O	1040-1042
the	O	1043-1046
primary	O	1047-1054
and	O	1055-1058
associated	O	1059-1069
motor	O	1070-1075
cortex	O	1076-1082
secondary	O	1083-1092
to	O	1093-1095
an	O	1096-1098
excessive	O	1099-1108
outflow	O	1109-1116
of	O	1117-1119
the	O	1120-1123
pallidothalamocortical	O	1124-1146
motor	O	1147-1152
loop	O	1153-1157
.	O	1157-1158

Dexamethasone	O	0-13
-	O	13-14
induced	O	14-21
ocular	B	22-28
hypertension	I	29-41
in	O	42-44
perfusion	O	45-54
-	O	54-55
cultured	O	55-63
human	O	64-69
eyes	O	70-74
.	O	74-75

PURPOSE	O	76-83
:	O	83-84
Glucocorticoid	O	85-99
administration	O	100-114
can	O	115-118
lead	O	119-123
to	O	124-126
the	O	127-130
development	O	131-142
of	O	143-145
ocular	B	146-152
hypertension	I	153-165
and	O	166-169
corticosteroid	B	170-184
glaucoma	I	185-193
in	O	194-196
a	O	197-198
subset	O	199-205
of	O	206-208
the	O	209-212
population	O	213-223
through	O	224-231
a	O	232-233
decrease	O	234-242
in	O	243-245
the	O	246-249
aqueous	O	250-257
humor	O	258-263
outflow	O	264-271
facility	O	272-280
.	O	280-281

The	O	282-285
purpose	O	286-293
of	O	294-296
this	O	297-301
study	O	302-307
was	O	308-311
to	O	312-314
determine	O	315-324
whether	O	325-332
glucocorticoid	O	333-347
treatment	O	348-357
can	O	358-361
directly	O	362-370
affect	O	371-377
the	O	378-381
outflow	O	382-389
facility	O	390-398
of	O	399-401
isolated	O	402-410
,	O	410-411
perfusion	O	412-421
-	O	421-422
cultured	O	422-430
human	O	431-436
eyes	O	437-441
.	O	441-442

METHODS	O	443-450
:	O	450-451
The	O	452-455
anterior	O	456-464
segments	O	465-473
of	O	474-476
human	O	477-482
donor	O	483-488
eyes	O	489-493
from	O	494-498
regional	O	499-507
eye	O	508-511
banks	O	512-517
were	O	518-522
placed	O	523-529
in	O	530-532
a	O	533-534
constant	O	535-543
flow	O	544-548
,	O	548-549
variable	O	550-558
pressure	O	559-567
perfusion	O	568-577
culture	O	578-585
system	O	586-592
.	O	592-593

Paired	O	594-600
eyes	O	601-605
were	O	606-610
perfused	O	611-619
in	O	620-622
serum	O	623-628
-	O	628-629
free	O	629-633
media	O	634-639
with	O	640-644
or	O	645-647
without	O	648-655
10	O	656-658
(	O	658-659
-	O	659-660
7	O	660-661
)	O	661-662
M	O	663-664
dexamethasone	O	665-678
for	O	679-682
12	O	683-685
days	O	686-690
.	O	690-691

Intraocular	O	692-703
pressure	O	704-712
was	O	713-716
monitored	O	717-726
daily	O	727-732
.	O	732-733

After	O	734-739
incubation	O	740-750
,	O	750-751
the	O	752-755
eyes	O	756-760
were	O	761-765
morphologically	O	766-781
characterized	O	782-795
by	O	796-798
light	O	799-804
microscopy	O	805-815
,	O	815-816
transmission	O	817-829
and	O	830-833
scanning	O	834-842
electron	O	843-851
microscopy	O	852-862
,	O	862-863
and	O	864-867
scanning	O	868-876
laser	O	877-882
confocal	O	883-891
microscopy	O	892-902
.	O	902-903

RESULTS	O	904-911
:	O	911-912
A	O	913-914
significant	O	915-926
increase	O	927-935
in	O	936-938
intraocular	O	939-950
pressure	O	951-959
developed	O	960-969
in	O	970-972
13	O	973-975
of	O	976-978
the	O	979-982
44	O	983-985
pairs	O	986-991
of	O	992-994
eyes	O	995-999
perfused	O	1000-1008
with	O	1009-1013
dexamethasone	O	1014-1027
with	O	1028-1032
an	O	1033-1035
average	O	1036-1043
pressure	O	1044-1052
rise	O	1053-1057
of	O	1058-1060
17	O	1061-1063
.	O	1063-1064
5	O	1064-1065
+	O	1066-1067
/	O	1067-1068
-	O	1068-1069
3	O	1070-1071
.	O	1071-1072
8	O	1072-1073
mm	O	1074-1076
Hg	O	1077-1079
after	O	1080-1085
12	O	1086-1088
days	O	1089-1093
of	O	1094-1096
dexamethasone	O	1097-1110
exposure	O	1111-1119
.	O	1119-1120

The	O	1121-1124
contralateral	O	1125-1138
control	O	1139-1146
eyes	O	1147-1151
,	O	1151-1152
which	O	1153-1158
did	O	1159-1162
not	O	1163-1166
receive	O	1167-1174
dexamethasone	O	1175-1188
,	O	1188-1189
maintained	O	1190-1200
a	O	1201-1202
stable	O	1203-1209
intraocular	O	1210-1221
pressure	O	1222-1230
during	O	1231-1237
the	O	1238-1241
same	O	1242-1246
period	O	1247-1253
.	O	1253-1254

The	O	1255-1258
outflow	O	1259-1266
pathway	O	1267-1274
of	O	1275-1277
the	O	1278-1281
untreated	O	1282-1291
eyes	O	1292-1296
appeared	O	1297-1305
morphologically	O	1306-1321
normal	O	1322-1328
.	O	1328-1329

In	O	1330-1332
contrast	O	1333-1341
,	O	1341-1342
the	O	1343-1346
dexamethasone	O	1347-1360
-	O	1360-1361
treated	O	1361-1368
hypertensive	B	1369-1381
eyes	I	1382-1386
had	O	1387-1390
thickened	O	1391-1400
trabecular	O	1401-1411
beams	O	1412-1417
,	O	1417-1418
decreased	O	1419-1428
intertrabecular	O	1429-1444
spaces	O	1445-1451
,	O	1451-1452
thickened	O	1453-1462
juxtacanalicular	O	1463-1479
tissue	O	1480-1486
,	O	1486-1487
activated	O	1488-1497
trabecular	O	1498-1508
meshwork	O	1509-1517
cells	O	1518-1523
,	O	1523-1524
and	O	1525-1528
increased	O	1529-1538
amounts	O	1539-1546
of	O	1547-1549
amorphogranular	O	1550-1565
extracellular	O	1566-1579
material	O	1580-1588
,	O	1588-1589
especially	O	1590-1600
in	O	1601-1603
the	O	1604-1607
juxtacanalicular	O	1608-1624
tissue	O	1625-1631
and	O	1632-1635
beneath	O	1636-1643
the	O	1644-1647
endothelial	O	1648-1659
lining	O	1660-1666
of	O	1667-1669
the	O	1670-1673
canal	O	1674-1679
of	O	1680-1682
Schlemm	O	1683-1690
.	O	1690-1691

The	O	1692-1695
dexamethasone	O	1696-1709
-	O	1709-1710
treated	O	1710-1717
nonresponder	O	1718-1730
eyes	O	1731-1735
appeared	O	1736-1744
to	O	1745-1747
be	O	1748-1750
morphologically	O	1751-1766
similar	O	1767-1774
to	O	1775-1777
the	O	1778-1781
untreated	O	1782-1791
eyes	O	1792-1796
,	O	1796-1797
although	O	1798-1806
several	O	1807-1814
subtle	O	1815-1821
dexamethasone	O	1822-1835
-	O	1835-1836
induced	O	1836-1843
morphologic	O	1844-1855
changes	O	1856-1863
were	O	1864-1868
evident	O	1869-1876
.	O	1876-1877

CONCLUSION	O	1878-1888
:	O	1888-1889
Dexamethasone	O	1890-1903
treatment	O	1904-1913
of	O	1914-1916
isolated	O	1917-1925
,	O	1925-1926
perfusion	O	1927-1936
-	O	1936-1937
cultured	O	1937-1945
human	O	1946-1951
eyes	O	1952-1956
led	O	1957-1960
to	O	1961-1963
the	O	1964-1967
generation	O	1968-1978
of	O	1979-1981
ocular	B	1982-1988
hypertension	I	1989-2001
in	O	2002-2004
approximately	O	2005-2018
30	O	2019-2021
%	O	2021-2022
of	O	2023-2025
the	O	2026-2029
dexamethasone	O	2030-2043
-	O	2043-2044
treated	O	2044-2051
eyes	O	2052-2056
.	O	2056-2057

Steroid	O	2058-2065
treatment	O	2066-2075
resulted	O	2076-2084
in	O	2085-2087
morphologic	O	2088-2099
changes	O	2100-2107
in	O	2108-2110
the	O	2111-2114
trabecular	O	2115-2125
meshwork	O	2126-2134
similar	O	2135-2142
to	O	2143-2145
those	O	2146-2151
reported	O	2152-2160
for	O	2161-2164
corticosteroid	B	2165-2179
glaucoma	I	2180-2188
and	O	2189-2192
open	B	2193-2197
angle	I	2198-2203
glaucoma	I	2204-2212
.	O	2212-2213

This	O	2214-2218
system	O	2219-2225
may	O	2226-2229
provide	O	2230-2237
an	O	2238-2240
acute	O	2241-2246
model	O	2247-2252
in	O	2253-2255
which	O	2256-2261
to	O	2262-2264
study	O	2265-2270
the	O	2271-2274
pathogenic	O	2275-2285
mechanisms	O	2286-2296
involved	O	2297-2305
in	O	2306-2308
steroid	B	2309-2316
glaucoma	I	2317-2325
and	O	2326-2329
primary	B	2330-2337
open	I	2338-2342
angle	I	2343-2348
glaucoma	I	2349-2357
.	O	2357-2358

Cognitive	B	0-9
deterioration	I	10-23
from	O	24-28
long	O	29-33
-	O	33-34
term	O	34-38
abuse	O	39-44
of	O	45-47
dextromethorphan	O	48-64
:	O	64-65
a	O	66-67
case	O	68-72
report	O	73-79
.	O	79-80

Dextromethorphan	O	81-97
(	O	98-99
DM	O	99-101
)	O	101-102
,	O	102-103
the	O	104-107
dextrorotatory	O	108-122
isomer	O	123-129
of	O	130-132
3	O	133-134
-	O	134-135
hydroxy	O	135-142
-	O	134-135
N	O	143-144
-	O	134-135
methylmorphinan	O	145-160
,	O	160-161
is	O	162-164
the	O	165-168
main	O	169-173
ingredient	O	174-184
in	O	185-187
a	O	188-189
number	O	190-196
of	O	197-199
widely	O	200-206
available	O	207-216
,	O	216-217
over	O	218-222
-	O	222-223
the	O	223-226
-	O	222-223
counter	O	227-234
antitussives	O	235-247
.	O	247-248

Initial	O	249-256
studies	O	257-264
(	O	265-266
Bornstein	O	266-275
1968	O	276-280
)	O	280-281
showed	O	282-288
that	O	289-293
it	O	294-296
possessed	O	297-306
no	O	307-309
respiratory	O	310-321
suppressant	O	322-333
effects	O	334-341
and	O	342-345
no	O	346-348
addiction	O	349-358
liability	O	359-368
.	O	368-369

Subsequently	O	370-382
,	O	382-383
however	O	384-391
,	O	391-392
several	O	393-400
articles	O	401-409
reporting	O	410-419
abuse	O	420-425
of	O	426-428
this	O	429-433
drug	O	434-438
have	O	439-443
appeared	O	444-452
in	O	453-455
the	O	456-459
literature	O	460-470
.	O	470-471

The	O	472-475
drug	O	476-480
is	O	481-483
known	O	484-489
to	O	490-492
cause	O	493-498
a	O	499-500
variety	O	501-508
of	O	509-511
acute	O	512-517
toxic	O	518-523
effects	O	524-531
,	O	531-532
ranging	O	533-540
from	O	541-545
nausea	B	546-552
,	O	552-553
restlessness	B	554-566
,	O	566-567
insomnia	B	568-576
,	O	576-577
ataxia	B	578-584
,	O	584-585
slurred	O	586-593
speech	O	594-600
and	O	601-604
nystagmus	B	605-614
to	O	615-617
mood	O	618-622
changes	O	623-630
,	O	630-631
perceptual	O	632-642
alterations	O	643-654
,	O	654-655
inattention	O	656-667
,	O	667-668
disorientation	O	669-683
and	O	684-687
aggressive	B	688-698
behavior	I	699-707
(	O	708-709
Rammer	O	709-715
et	O	716-718
al	O	719-721
1988	O	722-726
;	O	726-727
Katona	O	728-734
and	O	735-738
Watson	O	739-745
1986	O	746-750
;	O	750-751
Isbell	O	752-758
and	O	759-762
Fraser	O	763-769
1953	O	770-774
;	O	774-775
Devlin	O	776-782
et	O	783-785
al	O	786-788
1985	O	789-793
;	O	793-794
McCarthy	O	795-803
1971	O	804-808
;	O	808-809
Dodds	O	810-815
and	O	816-819
Revai	O	820-825
1967	O	826-830
;	O	830-831
Degkwitz	O	832-840
1964	O	841-845
;	O	845-846
Hildebrand	O	847-857
et	O	858-860
al	O	861-863
1989	O	864-868
)	O	868-869
.	O	869-870

There	O	871-876
have	O	877-881
also	O	882-886
been	O	887-891
two	O	892-895
reported	O	896-904
fatalities	O	905-915
from	O	916-920
DM	O	921-923
overdoses	O	924-933
(	O	934-935
Fleming	O	935-942
1986	O	943-947
)	O	947-948
.	O	948-949

However	O	950-957
,	O	957-958
there	O	959-964
are	O	965-968
no	O	969-971
reports	O	972-979
describing	O	980-990
the	O	991-994
effects	O	995-1002
of	O	1003-1005
chronic	O	1006-1013
abuse	O	1014-1019
.	O	1019-1020

This	O	1021-1025
report	O	1026-1032
describes	O	1033-1042
a	O	1043-1044
case	O	1045-1049
of	O	1050-1052
cognitive	B	1053-1062
deterioration	I	1063-1076
resulting	O	1077-1086
from	O	1087-1091
prolonged	O	1092-1101
use	O	1102-1105
of	O	1106-1108
DM	O	1109-1111
.	O	1111-1112

Long	O	0-4
-	O	4-5
term	O	5-9
lithium	O	10-17
treatment	O	18-27
and	O	28-31
the	O	32-35
kidney	O	36-42
.	O	42-43

Interim	O	44-51
report	O	52-58
on	O	59-61
fifty	O	62-67
patients	O	68-76
.	O	76-77

This	O	78-82
is	O	83-85
a	O	86-87
report	O	88-94
on	O	95-97
the	O	98-101
first	O	102-107
part	O	108-112
of	O	113-115
our	O	116-119
study	O	120-125
of	O	126-128
the	O	129-132
effects	O	133-140
of	O	141-143
long	O	144-148
-	O	148-149
term	O	149-153
lithium	O	154-161
treatment	O	162-171
on	O	172-174
the	O	175-178
kidney	O	179-185
.	O	185-186

Creatinine	O	187-197
clearance	O	198-207
,	O	207-208
maximum	O	209-216
urinary	O	217-224
osmolality	O	225-235
and	O	236-239
24	O	240-242
hour	O	243-247
urine	O	248-253
volume	O	254-260
have	O	261-265
been	O	266-270
tested	O	271-277
in	O	278-280
50	O	281-283
affectively	O	284-295
ill	O	296-299
patients	O	300-308
who	O	309-312
have	O	313-317
been	O	318-322
on	O	323-325
long	O	326-330
-	O	330-331
term	O	331-335
lithium	O	336-343
for	O	344-347
more	O	348-352
than	O	353-357
one	O	358-361
year	O	362-366
.	O	366-367

These	O	368-373
findings	O	374-382
have	O	383-387
been	O	388-392
compared	O	393-401
with	O	402-406
norms	O	407-412
and	O	413-416
with	O	417-421
values	O	422-428
of	O	429-431
the	O	432-435
same	O	436-440
tests	O	441-446
from	O	447-451
screening	O	452-461
prior	O	462-467
to	O	468-470
lithium	O	471-478
,	O	478-479
available	O	480-489
for	O	490-493
most	O	494-498
of	O	499-501
our	O	502-505
patients	O	506-514
.	O	514-515

No	O	516-518
evidence	O	519-527
was	O	528-531
found	O	532-537
for	O	538-541
any	O	542-545
reduction	O	546-555
of	O	556-558
glomerular	O	559-569
filtration	O	570-580
during	O	581-587
lithium	O	588-595
treatment	O	596-605
.	O	605-606

Low	O	607-610
clearance	O	611-620
values	O	621-627
found	O	628-633
in	O	634-636
several	O	637-644
patients	O	645-653
could	O	654-659
be	O	660-662
accounted	O	663-672
for	O	673-676
by	O	677-679
their	O	680-685
age	O	686-689
and	O	690-693
their	O	694-699
pre	O	700-703
-	O	703-704
lithium	O	704-711
values	O	712-718
.	O	718-719

Urinary	O	720-727
concentration	O	728-741
defect	O	742-748
appeared	O	749-757
frequent	O	758-766
but	O	767-770
the	O	771-774
extent	O	775-781
of	O	782-784
the	O	785-788
impairment	O	789-799
is	O	800-802
difficult	O	803-812
to	O	813-815
assess	O	816-822
because	O	823-830
of	O	831-833
the	O	834-837
uncertainty	O	838-849
about	O	850-855
the	O	856-859
norms	O	860-865
applicable	O	866-876
to	O	877-879
this	O	880-884
group	O	885-890
of	O	891-893
patients	O	894-902
.	O	902-903

The	O	904-907
concentration	O	908-921
defect	O	922-928
appeared	O	929-937
reversible	O	938-948
,	O	948-949
at	O	950-952
least	O	953-958
in	O	959-961
part	O	962-966
.	O	966-967

Polyuria	B	968-976
above	O	977-982
3	O	983-984
litres	O	985-991
/	O	991-992
24	O	992-994
hours	O	995-1000
was	O	1001-1004
found	O	1005-1010
in	O	1011-1013
10	O	1014-1016
%	O	1016-1017
of	O	1018-1020
patients	O	1021-1029
.	O	1029-1030

An	O	1031-1033
attempt	O	1034-1041
is	O	1042-1044
made	O	1045-1049
to	O	1050-1052
draw	O	1053-1057
practical	O	1058-1067
conclusions	O	1068-1079
from	O	1080-1084
the	O	1085-1088
preliminary	O	1089-1100
findings	O	1101-1109
.	O	1109-1110

Complete	O	0-8
heart	B	9-14
block	I	15-20
following	O	21-30
a	O	31-32
single	O	33-39
dose	O	40-44
of	O	45-47
trazodone	O	48-57
.	O	57-58

Forty	O	59-64
minutes	O	65-72
after	O	73-78
receiving	O	79-88
a	O	89-90
single	O	91-97
starting	O	98-106
dose	O	107-111
of	O	112-114
trazodone	O	115-124
,	O	124-125
a	O	126-127
patient	O	128-135
developed	O	136-145
complete	O	146-154
heart	B	155-160
block	I	161-166
.	O	166-167

The	O	168-171
case	O	172-176
illustrates	O	177-188
that	O	189-193
,	O	193-194
despite	O	195-202
the	O	203-206
results	O	207-214
of	O	215-217
earlier	O	218-225
studies	O	226-233
,	O	233-234
trazodone	O	235-244
'	O	244-245
s	O	245-246
effect	O	247-253
on	O	254-256
cardiac	O	257-264
conduction	O	265-275
may	O	276-279
be	O	280-282
severe	O	283-289
in	O	290-292
individuals	O	293-304
at	O	305-307
risk	O	308-312
for	O	313-316
conduction	O	317-327
delay	O	328-333
.	O	333-334

Quinidine	O	0-9
phenylethylbarbiturate	O	10-32
-	O	32-33
induced	O	33-40
fulminant	O	41-50
hepatitis	B	51-60
in	O	61-63
a	O	64-65
pregnant	O	66-74
woman	O	75-80
.	O	80-81

A	O	82-83
case	O	84-88
report	O	89-95
.	O	95-96

We	O	97-99
report	O	100-106
the	O	107-110
case	O	111-115
of	O	116-118
a	O	119-120
19	O	121-123
-	O	123-124
year	O	124-128
-	O	123-124
old	O	129-132
Laotian	O	133-140
patient	O	141-148
affected	O	149-157
by	O	158-160
fulminant	O	161-170
hepatitis	B	171-180
during	O	181-187
the	O	188-191
third	O	192-197
trimester	O	198-207
of	O	208-210
her	O	211-214
pregnancy	O	215-224
after	O	225-230
a	O	231-232
1	O	233-234
-	O	234-235
month	O	235-240
administration	O	241-255
of	O	256-258
quinidine	O	259-268
phenylethylbarbiturate	O	269-291
.	O	291-292

After	O	293-298
delivery	O	299-307
,	O	307-308
the	O	309-312
patient	O	313-320
underwent	O	321-330
orthotopic	O	331-341
liver	O	342-347
transplantation	O	348-363
.	O	363-364

The	O	365-368
patient	O	369-376
was	O	377-380
in	O	381-383
good	O	384-388
condition	O	389-398
16	O	399-401
months	O	402-408
after	O	409-414
liver	O	415-420
transplantation	O	421-436
.	O	436-437

Quinidine	O	438-447
itself	O	448-454
or	O	455-457
phenylethylbarbiturate	O	458-480
may	O	481-484
be	O	485-487
responsible	O	488-499
for	O	500-503
fulminant	O	504-513
hepatitis	B	514-523
in	O	524-526
this	O	527-531
patient	O	532-539
.	O	539-540

The	O	0-3
epidemiology	O	4-16
of	O	17-19
the	O	20-23
acute	O	24-29
flank	B	30-35
pain	I	36-40
syndrome	O	41-49
from	O	50-54
suprofen	O	55-63
.	O	63-64

Suprofen	O	65-73
,	O	73-74
a	O	75-76
new	O	77-80
nonsteroidal	O	81-93
anti	O	94-98
-	O	98-99
inflammatory	O	99-111
drug	O	112-116
,	O	116-117
was	O	118-121
marketed	O	122-130
in	O	131-133
early	O	134-139
1986	O	140-144
as	O	145-147
an	O	148-150
analgesic	O	151-160
agent	O	161-166
.	O	166-167

Until	O	168-173
physicians	O	174-184
began	O	185-190
reporting	O	191-200
an	O	201-203
unusual	O	204-211
acute	O	212-217
flank	B	218-223
pain	I	224-228
syndrome	O	229-237
to	O	238-240
the	O	241-244
spontaneous	O	245-256
reporting	O	257-266
system	O	267-273
,	O	273-274
700	O	275-278
,	O	278-279
000	O	279-282
persons	O	283-290
used	O	291-295
the	O	296-299
drug	O	300-304
in	O	305-307
the	O	308-311
United	O	312-318
States	O	319-325
.	O	325-326

Through	O	327-334
August	O	335-341
1986	O	342-346
,	O	346-347
a	O	348-349
total	O	350-355
of	O	356-358
163	O	359-362
cases	O	363-368
of	O	369-371
this	O	372-376
syndrome	O	377-385
were	O	386-390
reported	O	391-399
.	O	399-400

To	O	401-403
elucidate	O	404-413
the	O	414-417
epidemiology	O	418-430
of	O	431-433
the	O	434-437
syndrome	O	438-446
,	O	446-447
a	O	448-449
case	O	450-454
-	O	454-455
control	O	455-462
study	O	463-468
was	O	469-472
performed	O	473-482
,	O	482-483
comparing	O	484-493
62	O	494-496
of	O	497-499
the	O	500-503
case	O	504-508
patients	O	509-517
who	O	518-521
had	O	522-525
been	O	526-530
reported	O	531-539
to	O	540-542
the	O	543-546
spontaneous	O	547-558
reporting	O	559-568
system	O	569-575
to	O	576-578
185	O	579-582
suprofen	O	583-591
-	O	591-592
exposed	O	592-599
control	O	600-607
subjects	O	608-616
who	O	617-620
did	O	621-624
not	O	625-628
have	O	629-633
the	O	634-637
syndrome	O	638-646
.	O	646-647

Case	O	648-652
patients	O	653-661
were	O	662-666
more	O	667-671
likely	O	672-678
to	O	679-681
be	O	682-684
men	O	685-688
(	O	689-690
odds	O	690-694
ratio	O	695-700
,	O	700-701
3	O	702-703
.	O	703-704
8	O	704-705
;	O	705-706
95	O	707-709
%	O	709-710
confidence	O	711-721
interval	O	722-730
,	O	730-731
1	O	732-733
.	O	733-734
2	O	734-735
-	O	735-736
12	O	736-738
.	O	733-734
1	O	732-733
)	O	740-741
,	O	741-742

suffer	O	743-749
from	O	750-754
hay	B	755-758
fever	I	759-764
and	O	765-768
asthma	B	769-775
(	O	776-777
odds	O	777-781
ratio	O	782-787
,	O	787-788
3	O	789-790
.	O	790-791
4	O	791-792
;	O	792-793
95	O	794-796
%	O	796-797
confidence	O	798-808
interval	O	809-817
,	O	817-818
1	O	819-820
.	O	820-821
0	O	821-822
-	O	822-823
11	O	823-825
.	O	820-821
9	O	826-827
)	O	827-828
;	O	828-829

to	O	830-832
participate	O	833-844
in	O	845-847
regular	O	848-855
exercise	O	856-864
(	O	865-866
odds	O	866-870
ratio	O	871-876
,	O	876-877
5	O	878-879
.	O	879-880
9	O	880-881
;	O	881-882
95	O	883-885
%	O	885-886
confidence	O	887-897
interval	O	898-906
,	O	906-907
1	O	908-909
.	O	909-910
1	O	908-909
-	O	911-912
30	O	912-914
.	O	909-910
7	O	915-916
)	O	916-917
,	O	917-918

especially	O	919-929
in	O	930-932
the	O	933-936
use	O	937-940
of	O	941-943
Nautilus	O	944-952
equipment	O	953-962
(	O	963-964
p	O	964-965
=	O	966-967
0	O	968-969
.	O	969-970
02	O	970-972
)	O	972-973
;	O	973-974
and	O	975-978
to	O	979-981
use	O	982-985
alcohol	O	986-993
(	O	994-995
odds	O	995-999
ratio	O	1000-1005
,	O	1005-1006
4	O	1007-1008
.	O	1008-1009
4	O	1007-1008
;	O	1010-1011
95	O	1012-1014
%	O	1014-1015
confidence	O	1016-1026
interval	O	1027-1035
,	O	1035-1036
1	O	1037-1038
.	O	1038-1039
1	O	1037-1038
-	O	1040-1041
17	O	1041-1043
.	O	1038-1039
5	O	1044-1045
)	O	1045-1046
.	O	1038-1039

Possible	O	1048-1056
risk	O	1057-1061
factors	O	1062-1069
included	O	1070-1078
young	O	1079-1084
age	O	1085-1088
,	O	1088-1089
concurrent	O	1090-1100
use	O	1101-1104
of	O	1105-1107
other	O	1108-1113
analgesic	O	1114-1123
agents	O	1124-1130
(	O	1131-1132
especially	O	1132-1142
ibuprofen	O	1143-1152
)	O	1152-1153
,	O	1153-1154
preexisting	O	1155-1166
renal	B	1167-1172
disease	I	1173-1180
,	O	1180-1181
a	O	1182-1183
history	O	1184-1191
of	O	1192-1194
kidney	B	1195-1201
stones	I	1202-1208
,	O	1208-1209
a	O	1210-1211
history	O	1212-1219
of	O	1220-1222
gout	B	1223-1227
,	O	1227-1228
a	O	1229-1230
recent	O	1231-1237
increase	O	1238-1246
in	O	1247-1249
activity	O	1250-1258
,	O	1258-1259
a	O	1260-1261
recent	O	1262-1268
increase	O	1269-1277
in	O	1278-1280
sun	O	1281-1284
exposure	O	1285-1293
,	O	1293-1294
and	O	1295-1298
residence	O	1299-1308
in	O	1309-1311
the	O	1312-1315
Sunbelt	O	1316-1323
.	O	1323-1324

These	O	1325-1330
were	O	1331-1335
findings	O	1336-1344
that	O	1345-1349
were	O	1350-1354
suggestive	O	1355-1365
but	O	1366-1369
did	O	1370-1373
not	O	1374-1377
reach	O	1378-1383
conventional	O	1384-1396
statistical	O	1397-1408
significance	O	1409-1421
.	O	1421-1422

These	O	1423-1428
findings	O	1429-1437
are	O	1438-1441
consistent	O	1442-1452
with	O	1453-1457
the	O	1458-1461
postulated	O	1462-1472
mechanism	O	1473-1482
for	O	1483-1486
this	O	1487-1491
unusual	O	1492-1499
syndrome	O	1500-1508
:	O	1508-1509
acute	O	1510-1515
diffuse	O	1516-1523
crystallization	O	1524-1539
of	O	1540-1542
uric	O	1543-1547
acid	O	1548-1552
in	O	1553-1555
renal	O	1556-1561
tubules	O	1562-1569
.	O	1569-1570

Hemolytic	B	0-9
-	I	9-10
uremic	I	10-16
syndrome	I	17-25
associated	O	26-36
with	O	37-41
ingestion	O	42-51
of	O	52-54
quinine	O	55-62
.	O	62-63

Hemolytic	B	64-73
-	I	73-74
uremic	I	74-80
syndrome	I	81-89
following	O	90-99
quinine	O	100-107
ingestion	O	108-117
is	O	118-120
a	O	121-122
newly	O	123-128
described	O	129-138
phenomenon	O	139-149
,	O	149-150
with	O	151-155
just	O	156-160
two	O	161-164
previous	O	165-173
descriptions	O	174-186
of	O	187-189
4	O	190-191
cases	O	192-197
in	O	198-200
the	O	201-204
literature	O	205-215
.	O	215-216

We	O	217-219
describe	O	220-228
a	O	229-230
5th	O	231-234
case	O	235-239
.	O	239-240

The	O	241-244
reaction	O	245-253
may	O	254-257
be	O	258-260
mediated	O	261-269
by	O	270-272
the	O	273-276
presence	O	277-285
of	O	286-288
antibodies	O	289-299
reactive	O	300-308
against	O	309-316
platelets	O	317-326
in	O	327-329
the	O	330-333
presence	O	334-342
of	O	343-345
quinine	O	346-353
.	O	353-354

Treatment	O	355-364
has	O	365-368
included	O	369-377
use	O	378-381
of	O	382-384
plasma	O	385-391
exchange	O	392-400
,	O	400-401
prednisone	O	402-412
,	O	412-413
aspirin	O	414-421
,	O	421-422
and	O	423-426
dipyridamole	O	427-439
.	O	439-440

The	O	441-444
patients	O	445-453
have	O	454-458
all	O	459-462
regained	O	463-471
some	O	472-476
degree	O	477-483
of	O	484-486
renal	O	487-492
function	O	493-501
.	O	501-502

However	O	503-510
,	O	510-511
it	O	512-514
is	O	515-517
unclear	O	518-525
whether	O	526-533
pharmacological	O	534-549
treatment	O	550-559
or	O	560-562
spontaneous	O	563-574
resolution	O	575-585
is	O	586-588
responsible	O	589-600
for	O	601-604
the	O	605-608
improvement	O	609-620
.	O	620-621

Quinine	O	622-629
-	O	629-630
associated	O	630-640
hemolytic	B	641-650
-	I	650-651
uremic	I	651-657
syndrome	I	658-666
probably	O	667-675
occurs	O	676-682
more	O	683-687
often	O	688-693
than	O	694-698
is	O	699-701
recognized	O	702-712
.	O	712-713

It	O	714-716
is	O	717-719
important	O	720-729
to	O	730-732
recognize	O	733-742
this	O	743-747
reaction	O	748-756
when	O	757-761
it	O	762-764
occurs	O	765-771
and	O	772-775
to	O	776-778
avoid	O	779-784
further	O	785-792
quinine	O	793-800
exposure	O	801-809
,	O	809-810
since	O	811-816
the	O	817-820
reaction	O	821-829
seems	O	830-835
to	O	836-838
be	O	839-841
recurrent	O	842-851
.	O	851-852

Pyeloureteral	O	0-13
filling	O	14-21
defects	O	22-29
associated	O	30-40
with	O	41-45
systemic	O	46-54
anticoagulation	O	55-70
:	O	70-71
a	O	72-73
case	O	74-78
report	O	79-85
.	O	85-86

The	O	87-90
etiology	O	91-99
of	O	100-102
pyeloureteritis	B	103-118
cystica	I	119-126
has	O	127-130
long	O	131-135
been	O	136-140
attributed	O	141-151
to	O	152-154
chronic	O	155-162
infection	B	163-172
and	O	173-176
inflammation	B	177-189
.	O	189-190

A	O	191-192
case	O	193-197
is	O	198-200
presented	O	201-210
that	O	211-215
is	O	216-218
unique	O	219-225
in	O	226-228
that	O	229-233
the	O	234-237
acute	O	238-243
onset	O	244-249
and	O	250-253
the	O	254-257
rapid	O	258-263
resolution	O	264-274
of	O	275-277
pyeloureteral	O	278-291
filling	O	292-299
defects	O	300-307
in	O	308-310
this	O	311-315
patient	O	316-323
were	O	324-328
documented	O	329-339
by	O	340-342
radiography	O	343-354
.	O	354-355

There	O	356-361
is	O	362-364
no	O	365-367
evidence	O	368-376
of	O	377-379
antecedent	O	380-390
or	O	391-393
concurrent	O	394-404
infection	B	405-414
in	O	415-417
this	O	418-422
patient	O	423-430
.	O	430-431

The	O	432-435
disease	O	436-443
occurred	O	444-452
subsequent	O	453-463
to	O	464-466
the	O	467-470
initiation	O	471-481
of	O	482-484
heparin	O	485-492
therapy	O	493-500
for	O	501-504
suspected	O	505-514
pelvic	O	515-521
thrombophlebitis	B	522-538
and	O	539-542
cleared	O	543-550
rapidly	O	551-558
subsequent	O	559-569
to	O	570-572
its	O	573-576
discontinuation	O	577-592
.	O	592-593

The	O	594-597
rate	O	598-602
of	O	603-605
resolution	O	606-616
of	O	617-619
the	O	620-623
radiographic	O	624-636
findings	O	637-645
may	O	646-649
be	O	650-652
helpful	O	653-660
in	O	661-663
distinguishing	O	664-678
between	O	679-686
true	O	687-691
pyeloureteritis	B	692-707
cystica	I	708-715
and	O	716-719
submucosal	B	720-730
hemorrhage	I	731-741
.	O	741-742

Changes	O	0-7
in	O	8-10
peroxisomes	O	11-22
in	O	23-25
preneoplastic	O	26-39
liver	O	40-45
and	O	46-49
hepatoma	B	50-58
of	O	59-61
mice	O	62-66
induced	O	67-74
by	O	75-77
alpha	O	78-83
-	O	83-84
benzene	O	84-91
hexachloride	O	92-104
.	O	104-105

Peroxisomes	O	106-117
in	O	118-120
hepatomas	B	121-130
and	O	131-134
hyperplastic	O	135-147
preneoplastic	O	148-161
liver	B	162-167
lesions	I	168-175
induced	O	176-183
in	O	184-186
mice	O	187-191
by	O	192-194
500	O	195-198
ppm	O	199-202
alpha	O	203-208
-	O	208-209
benzene	O	209-216
hexachloride	O	217-229
were	O	230-234
examined	O	235-243
histochemically	O	244-259
and	O	260-263
electron	O	264-272
microscopically	O	273-288
.	O	288-289

Although	O	290-298
most	O	299-303
of	O	304-306
the	O	307-310
hepatomas	B	311-320
were	O	321-325
well	O	326-330
-	O	330-331
differentiated	O	331-345
tumors	B	346-352
and	O	353-356
contained	O	357-366
a	O	367-368
considerable	O	369-381
number	O	382-388
of	O	389-391
peroxisomes	O	392-403
,	O	403-404
the	O	405-408
tumor	B	409-414
cells	O	415-420
did	O	421-424
not	O	425-428
respond	O	429-436
to	O	437-439
ethyl	O	440-445
-	O	445-446
alpha	O	446-451
-	O	445-446
p	O	448-449
-	O	445-446
chlorophenoxyisobutyrate	O	454-478
with	O	479-483
proliferation	O	484-497
of	O	498-500
peroxisomes	O	501-512
.	O	512-513

At	O	514-516
the	O	517-520
16th	O	521-525
week	O	526-530
of	O	531-533
carcinogen	O	534-544
feeding	O	545-552
,	O	552-553
hyperplastic	O	554-566
nodules	O	567-574
appeared	O	575-583
and	O	584-587
advanced	O	588-596
to	O	597-599
further	O	600-607
stages	O	608-614
.	O	614-615

A	O	616-617
majority	O	618-626
of	O	627-629
the	O	630-633
nodules	O	634-641
showed	O	642-648
a	O	649-650
considerable	O	651-663
number	O	664-670
of	O	671-673
peroxisomes	O	674-685
and	O	686-689
the	O	690-693
inductive	O	694-703
proliferation	O	704-717
of	O	718-720
peroxisomes	O	721-732
.	O	732-733

Within	O	734-740
the	O	741-744
nodules	O	745-752
,	O	752-753
foci	O	754-758
of	O	759-761
proliferation	O	762-775
of	O	776-778
the	O	779-782
cells	O	783-788
that	O	789-793
showed	O	794-800
no	O	801-803
inducibility	O	804-816
of	O	817-819
proliferation	O	820-833
of	O	834-836
peroxisomes	O	837-848
appeared	O	849-857
.	O	857-858

These	O	859-864
cells	O	865-870
proliferated	O	871-883
further	O	884-891
,	O	891-892
replacing	O	893-902
the	O	903-906
most	O	907-911
part	O	912-916
of	O	917-919
the	O	920-923
nodules	O	924-931
,	O	931-932
and	O	933-936
with	O	937-941
this	O	942-946
process	O	947-954
hepatomas	B	955-964
appeared	O	965-973
to	O	974-976
have	O	977-981
been	O	982-986
formed	O	987-993
.	O	993-994

No	O	995-997
abnormal	O	998-1006
matrical	O	1007-1015
inclusions	O	1016-1026
of	O	1027-1029
peroxisomes	O	1030-1041
were	O	1042-1046
formed	O	1047-1053
in	O	1054-1056
the	O	1057-1060
cells	O	1061-1066
of	O	1067-1069
hyperplastic	O	1070-1082
nodules	O	1083-1090
by	O	1091-1093
ethyl	O	1094-1099
-	O	1099-1100
alpha	O	1100-1105
-	O	1099-1100
p	O	1102-1103
-	O	1099-1100
chlorophenoxyisobutyrate	O	1108-1132
unlike	O	1133-1139
in	O	1140-1142
the	O	1143-1146
case	O	1147-1151
of	O	1152-1154
rats	O	1155-1159
.	O	1159-1160

Quinidine	O	0-9
hepatitis	B	10-19
.	O	19-20

Long	O	21-25
-	O	25-26
term	O	26-30
administration	O	31-45
of	O	46-48
quinidine	O	49-58
was	O	59-62
associated	O	63-73
with	O	74-78
persistent	O	79-89
elevation	O	90-99
of	O	100-102
serum	O	103-108
concentrations	O	109-123
of	O	124-126
SGOT	O	127-131
,	O	131-132
lactic	O	133-139
acid	O	140-144
dehydrogenase	O	145-158
,	O	158-159
and	O	160-163
alkaline	O	164-172
phosphatase	O	173-184
.	O	184-185

Liver	O	186-191
biopsy	O	192-198
showed	O	199-205
active	O	206-212
hepatitis	B	213-222
.	O	222-223

Discontinuance	O	224-238
of	O	239-241
quinidine	O	242-251
therapy	O	252-259
led	O	260-263
to	O	264-266
normalization	O	267-280
of	O	281-283
liver	O	284-289
function	O	290-298
tests	O	299-304
.	O	304-305

A	O	306-307
challenge	O	308-317
dose	O	318-322
of	O	323-325
quinidine	O	326-335
caused	O	336-342
clinical	O	343-351
symptoms	O	352-360
and	O	361-364
abrupt	O	365-371
elevation	O	372-381
of	O	382-384
SGOT	O	385-389
,	O	389-390
alkaline	O	391-399
phosphatase	O	400-411
,	O	411-412
and	O	413-416
lactic	O	417-423
acid	O	424-428
dehydrogenase	O	429-442
values	O	443-449
.	O	449-450

We	O	451-453
concluded	O	454-463
that	O	464-468
this	O	469-473
patient	O	474-481
had	O	482-485
quinidine	O	486-495
hepatotoxicity	B	496-510
and	O	511-514
believe	O	515-522
that	O	523-527
this	O	528-532
is	O	533-535
the	O	536-539
first	O	540-545
case	O	546-550
reported	O	551-559
with	O	560-564
liver	O	565-570
biopsy	O	571-577
documentation	O	578-591
.	O	591-592

This	O	593-597
report	O	598-604
also	O	605-609
suggests	O	610-618
that	O	619-623
,	O	623-624
even	O	625-629
after	O	630-635
long	O	636-640
-	O	640-641
term	O	641-645
administration	O	646-660
,	O	660-661
the	O	662-665
hepatic	B	666-673
toxicity	I	674-682
is	O	683-685
reversible	O	686-696
.	O	696-697

Cholesteryl	O	0-11
hemisuccinate	O	12-25
treatment	O	26-35
protects	O	36-44
rodents	O	45-52
from	O	53-57
the	O	58-61
toxic	O	62-67
effects	O	68-75
of	O	76-78
acetaminophen	O	79-92
,	O	92-93
adriamycin	O	94-104
,	O	104-105
carbon	O	106-112
tetrachloride	O	113-126
,	O	126-127
chloroform	O	128-138
and	O	139-142
galactosamine	O	143-156
.	O	156-157

In	O	158-160
addition	O	161-169
to	O	170-172
its	O	173-176
use	O	177-180
as	O	181-183
a	O	184-185
stabilizer	O	186-196
/	O	196-197
rigidifier	O	197-207
of	O	208-210
membranes	O	211-220
,	O	220-221
cholesteryl	O	222-233
hemisuccinate	O	234-247
,	O	247-248
tris	O	249-253
salt	O	254-258
(	O	259-260
CS	O	260-262
)	O	262-263
administration	O	264-278
has	O	279-282
also	O	283-287
been	O	288-292
shown	O	293-298
to	O	299-301
protect	O	302-309
rats	O	310-314
from	O	315-319
the	O	320-323
hepatotoxic	B	324-335
effects	O	336-343
of	O	344-346
carbon	O	347-353
tetrachloride	O	354-367
(	O	368-369
CCl4	O	369-373
)	O	373-374
.	O	374-375

To	O	376-378
further	O	379-386
our	O	387-390
understanding	O	391-404
of	O	405-407
the	O	408-411
mechanism	O	412-421
of	O	422-424
CS	O	425-427
cytoprotection	O	428-442
,	O	442-443
we	O	444-446
examined	O	447-455
in	O	456-458
rats	O	459-463
and	O	464-467
mice	O	468-472
the	O	473-476
protective	O	477-487
abilities	O	488-497
of	O	498-500
CS	O	501-503
and	O	504-507
the	O	508-511
non	O	512-515
-	O	515-516
hydrolyzable	O	516-528
ether	O	529-534
form	O	535-539
of	O	540-542
CS	O	543-545
,	O	545-546
gamma	O	547-552
-	O	552-553
cholesteryloxybutyric	O	553-574
acid	O	575-579
,	O	579-580
tris	O	581-585
salt	O	586-590
(	O	591-592
CSE	O	592-595
)	O	595-596
against	O	597-604
acetaminophen	O	605-618
-	O	618-619
,	O	619-620
adriamycin	O	621-631
-	O	631-632
,	O	632-633
carbon	O	634-640
tetrachloride	O	641-654
-	O	654-655
,	O	655-656
chloroform	O	657-667
-	O	667-668
and	O	669-672
galactosamine	O	673-686
-	O	686-687
induced	O	687-694
toxicity	B	695-703
.	O	703-704

The	O	705-708
results	O	709-716
of	O	717-719
these	O	720-725
studies	O	726-733
demonstrated	O	734-746
that	O	747-751
CS	O	752-754
-	O	754-755
mediated	O	755-763
protection	O	764-774
is	O	775-777
not	O	778-781
selective	O	782-791
for	O	792-795
a	O	796-797
particular	O	798-808
species	O	809-816
,	O	816-817
organ	O	818-823
system	O	824-830
or	O	831-833
toxic	O	834-839
chemical	O	840-848
.	O	848-849

A	O	850-851
24	O	852-854
-	O	854-855
h	O	855-856
pretreatment	O	857-869
of	O	870-872
both	O	873-877
rats	O	878-882
and	O	883-886
mice	O	887-891
with	O	892-896
a	O	897-898
single	O	899-905
dose	O	906-910
of	O	911-913
CS	O	914-916
(	O	917-918
100mg	O	918-923
/	O	923-924
kg	O	924-926
,	O	926-927
i	O	928-929
.	O	929-930
p	O	930-931
.	O	929-930
)	O	932-933
,	O	933-934
resulted	O	935-943
in	O	944-946
significant	O	947-958
protection	O	959-969
against	O	970-977
the	O	978-981
hepatotoxic	B	982-993
effects	O	994-1001
of	O	1002-1004
CCl4	O	1005-1009
,	O	1009-1010
CHCl3	O	1011-1016
,	O	1016-1017
acetaminophen	O	1018-1031
and	O	1032-1035
galactosamine	O	1036-1049
and	O	1050-1053
against	O	1054-1061
the	O	1062-1065
lethal	O	1066-1072
(	O	1073-1074
and	O	1074-1077
presumably	O	1078-1088
cardiotoxic	B	1089-1100
)	O	1100-1101
effect	O	1102-1108
of	O	1109-1111
adriamycin	O	1112-1122
administration	O	1123-1137
.	O	1137-1138

Maximal	O	1139-1146
CS	O	1147-1149
-	O	1149-1150
mediated	O	1150-1158
protection	O	1159-1169
was	O	1170-1173
observed	O	1174-1182
in	O	1183-1185
experimental	O	1186-1198
animals	O	1199-1206
pretreated	O	1207-1217
24	O	1218-1220
h	O	1221-1222
prior	O	1223-1228
to	O	1229-1231
the	O	1232-1235
toxic	O	1236-1241
insult	O	1242-1248
.	O	1248-1249

These	O	1250-1255
data	O	1256-1260
suggest	O	1261-1268
that	O	1269-1273
CS	O	1274-1276
intervenes	O	1277-1287
in	O	1288-1290
a	O	1291-1292
critical	O	1293-1301
cellular	O	1302-1310
event	O	1311-1316
that	O	1317-1321
is	O	1322-1324
an	O	1325-1327
important	O	1328-1337
common	O	1338-1344
pathway	O	1345-1352
to	O	1353-1355
toxic	O	1356-1361
cell	O	1362-1366
death	O	1367-1372
.	O	1372-1373

The	O	1374-1377
mechanism	O	1378-1387
of	O	1388-1390
CS	O	1391-1393
protection	O	1394-1404
does	O	1405-1409
not	O	1410-1413
appear	O	1414-1420
to	O	1421-1423
be	O	1424-1426
dependent	O	1427-1436
on	O	1437-1439
the	O	1440-1443
inhibition	O	1444-1454
of	O	1455-1457
chemical	O	1458-1466
bioactivation	O	1467-1480
to	O	1481-1483
a	O	1484-1485
toxic	O	1486-1491
reactive	O	1492-1500
intermediate	O	1501-1513
(	O	1514-1515
in	O	1515-1517
light	O	1518-1523
of	O	1524-1526
the	O	1527-1530
protection	O	1531-1541
observed	O	1542-1550
against	O	1551-1558
galactosamine	O	1559-1572
hepatotoxicity	B	1573-1587
)	O	1587-1588
.	O	1588-1589

However	O	1590-1597
,	O	1597-1598
based	O	1599-1604
on	O	1605-1607
the	O	1608-1611
data	O	1612-1616
presented	O	1617-1626
,	O	1626-1627
we	O	1628-1630
can	O	1631-1634
not	O	1635-1638
exclude	O	1639-1646
the	O	1647-1650
possibility	O	1651-1662
that	O	1663-1667
CS	O	1668-1670
administration	O	1671-1685
inhibits	O	1686-1694
chemical	O	1695-1703
bioactivation	O	1704-1717
.	O	1717-1718

Our	O	1719-1722
findings	O	1723-1731
do	O	1732-1734
suggest	O	1735-1742
that	O	1743-1747
CS	O	1748-1750
-	O	1750-1751
mediated	O	1751-1759
protection	O	1760-1770
is	O	1771-1773
dependent	O	1774-1783
on	O	1784-1786
the	O	1787-1790
action	O	1791-1797
of	O	1798-1800
the	O	1801-1804
intact	O	1805-1811
anionic	O	1812-1819
CS	O	1820-1822
molecule	O	1823-1831
(	O	1832-1833
non	O	1833-1836
-	O	1836-1837
hydrolyzable	O	1837-1849
CSE	O	1850-1853
was	O	1854-1857
as	O	1858-1860
protective	O	1861-1871
as	O	1872-1874
CS	O	1875-1877
)	O	1877-1878
,	O	1878-1879
whose	O	1880-1885
mechanism	O	1886-1895
has	O	1896-1899
yet	O	1900-1903
to	O	1904-1906
be	O	1907-1909
defined	O	1910-1917
.	O	1917-1918

DSMM	O	0-4
XI	O	5-7
study	O	8-13
:	O	13-14
dose	O	15-19
definition	O	20-30
for	O	31-34
intravenous	O	35-46
cyclophosphamide	O	47-63
in	O	64-66
combination	O	67-78
with	O	79-83
bortezomib	O	84-94
/	O	94-95
dexamethasone	O	95-108
for	O	109-112
remission	O	113-122
induction	O	123-132
in	O	133-135
patients	O	136-144
with	O	145-149
newly	O	150-155
diagnosed	O	156-165
myeloma	B	166-173
.	O	173-174

A	O	175-176
clinical	O	177-185
trial	O	186-191
was	O	192-195
initiated	O	196-205
to	O	206-208
evaluate	O	209-217
the	O	218-221
recommended	O	222-233
dose	O	234-238
of	O	239-241
cyclophosphamide	O	242-258
in	O	259-261
combination	O	262-273
with	O	274-278
bortezomib	O	279-289
and	O	290-293
dexamethasone	O	294-307
as	O	308-310
induction	O	311-320
treatment	O	321-330
before	O	331-337
stem	O	338-342
cell	O	343-347
transplantation	O	348-363
for	O	364-367
younger	O	368-375
patients	O	376-384
with	O	385-389
newly	O	390-395
diagnosed	O	396-405
multiple	B	406-414
myeloma	I	415-422
(	O	423-424
MM	B	424-426
)	O	426-427
.	O	427-428

Thirty	O	429-435
patients	O	436-444
were	O	445-449
treated	O	450-457
with	O	458-462
three	O	463-468
21	O	469-471
-	O	471-472
day	O	472-475
cycles	O	476-482
of	O	483-485
bortezomib	O	486-496
1	O	497-498
.	O	498-499
3	O	499-500
mg	O	501-503
/	O	503-504
m	O	501-502
(	O	505-506
2	O	506-507
)	O	507-508
on	O	509-511
days	O	512-516
1	O	517-518
,	O	518-519
4	O	520-521
,	O	521-522
8	O	523-524
,	O	524-525
and	O	526-529
11	O	530-532
plus	O	533-537
dexamethasone	O	538-551
40	O	552-554
mg	O	555-557
on	O	558-560
the	O	561-564
day	O	565-568
of	O	569-571
bortezomib	O	572-582
injection	O	583-592
and	O	593-596
the	O	597-600
day	O	601-604
after	O	605-610
plus	O	611-615
cyclophosphamide	O	616-632
at	O	633-635
900	O	636-639
,	O	639-640
1	O	641-642
,	O	642-643
200	O	643-646
,	O	642-643
or	O	648-650
1	O	651-652
,	O	652-653
500	O	653-656
mg	O	657-659
/	O	659-660
m	O	657-658
(	O	661-662
2	O	662-663
)	O	663-664
on	O	665-667
day	O	668-671
1	O	672-673
.	O	673-674

The	O	675-678
maximum	O	679-686
tolerated	O	687-696
dose	O	697-701
of	O	702-704
cyclophosphamide	O	705-721
was	O	722-725
defined	O	726-733
as	O	734-736
900	O	737-740
mg	O	741-743
/	O	743-744
m	O	741-742
(	O	745-746
2	O	746-747
)	O	747-748
.	O	748-749

At	O	750-752
this	O	753-757
dose	O	758-762
level	O	763-768
,	O	768-769
92	O	770-772
%	O	772-773
of	O	774-776
patients	O	777-785
achieved	O	786-794
at	O	795-797
least	O	798-803
a	O	804-805
partial	O	806-813
response	O	814-822
.	O	822-823

The	O	824-827
overall	O	828-835
response	O	836-844
rate	O	845-849
[	O	850-851
complete	O	851-859
response	O	860-868
(	O	869-870
CR	O	870-872
)	O	872-873
plus	O	874-878
partial	O	879-886
response	O	887-895
(	O	896-897
PR	O	897-899
)	O	899-900
]	O	900-901
across	O	902-908
all	O	909-912
dose	O	913-917
levels	O	918-924
was	O	925-928
77	O	929-931
%	O	931-932
,	O	932-933
with	O	934-938
a	O	939-940
10	O	941-943
%	O	943-944
CR	O	945-947
rate	O	948-952
.	O	952-953

No	O	954-956
patient	O	957-964
experienced	O	965-976
progressive	O	977-988
disease	O	989-996
.	O	996-997

The	O	998-1001
most	O	1002-1006
frequent	O	1007-1015
adverse	O	1016-1023
events	O	1024-1030
were	O	1031-1035
hematological	B	1036-1049
and	I	1050-1053
gastrointestinal	I	1054-1070
toxicities	I	1071-1081
as	O	1082-1084
well	O	1085-1089
as	O	1090-1092
neuropathy	B	1093-1103
.	O	1103-1104

The	O	1105-1108
results	O	1109-1116
suggest	O	1117-1124
that	O	1125-1129
bortezomib	O	1130-1140
in	O	1141-1143
combination	O	1144-1155
with	O	1156-1160
cyclophosphamide	O	1161-1177
at	O	1178-1180
900	O	1181-1184
mg	O	1185-1187
/	O	1187-1188
m	O	1185-1186
(	O	1189-1190
2	O	1190-1191
)	O	1191-1192
and	O	1193-1196
dexamethasone	O	1197-1210
is	O	1211-1213
an	O	1214-1216
effective	O	1217-1226
induction	O	1227-1236
treatment	O	1237-1246
for	O	1247-1250
patients	O	1251-1259
with	O	1260-1264
newly	O	1265-1270
diagnosed	O	1271-1280
MM	B	1281-1283
that	O	1284-1288
warrants	O	1289-1297
further	O	1298-1305
investigation	O	1306-1319
.	O	1319-1320

Results	O	0-7
of	O	8-10
a	O	11-12
comparative	O	13-24
,	O	24-25
phase	O	26-31
III	O	32-35
,	O	35-36
12	O	37-39
-	O	39-40
week	O	40-44
,	O	44-45
multicenter	O	46-57
,	O	57-58
prospective	O	59-70
,	O	70-71
randomized	O	72-82
,	O	82-83
double	O	84-90
-	O	90-91
blind	O	91-96
assessment	O	97-107
of	O	108-110
the	O	111-114
efficacy	O	115-123
and	O	124-127
tolerability	O	128-140
of	O	141-143
a	O	144-145
fixed	O	146-151
-	O	151-152
dose	O	152-156
combination	O	157-168
of	O	169-171
telmisartan	O	172-183
and	O	184-187
amlodipine	O	188-198
versus	O	199-205
amlodipine	O	206-216
monotherapy	O	217-228
in	O	229-231
Indian	O	232-238
adults	O	239-245
with	O	246-250
stage	O	251-256
II	O	257-259
hypertension	B	260-272
.	O	272-273

OBJECTIVE	O	274-283
:	O	283-284
The	O	285-288
aim	O	289-292
of	O	293-295
this	O	296-300
study	O	301-306
was	O	307-310
to	O	311-313
evaluate	O	314-322
the	O	323-326
efficacy	O	327-335
and	O	336-339
tolerability	O	340-352
of	O	353-355
a	O	356-357
new	O	358-361
fixed	O	362-367
-	O	367-368
dose	O	368-372
combination	O	373-384
(	O	385-386
FDC	O	386-389
)	O	389-390
of	O	391-393
telmisartan	O	394-405
40	O	406-408
mg	O	409-411
+	O	412-413
amlodipine	O	414-424
5	O	425-426
mg	O	427-429
(	O	430-431
T	O	431-432
+	O	432-433
A	O	433-434
)	O	434-435
compared	O	436-444
with	O	445-449
amlodipine	O	450-460
5	O	461-462
-	O	462-463
mg	O	463-465
monotherapy	O	466-477
(	O	478-479
A	O	479-480
)	O	480-481
in	O	482-484
adult	O	485-490
Indian	O	491-497
patients	O	498-506
with	O	507-511
stage	O	512-517
II	O	518-520
hypertension	B	521-533
.	O	533-534

METHODS	O	535-542
:	O	542-543
This	O	544-548
comparative	O	549-560
,	O	560-561
Phase	O	562-567
III	O	568-571
,	O	571-572
12	O	573-575
-	O	575-576
week	O	576-580
,	O	580-581
multicenter	O	582-593
,	O	593-594
prospective	O	595-606
,	O	606-607
randomized	O	608-618
,	O	618-619
double	O	620-626
-	O	626-627
blind	O	627-632
study	O	633-638
was	O	639-642
conducted	O	643-652
in	O	653-655
Indian	O	656-662
patients	O	663-671
aged	O	672-676
18	O	677-679
to	O	680-682
65	O	683-685
years	O	686-691
with	O	692-696
established	O	697-708
stage	O	709-714
II	O	715-717
hypertension	B	718-730
.	O	730-731

Patients	O	732-740
were	O	741-745
treated	O	746-753
with	O	754-758
oral	O	759-763
FDC	O	764-767
of	O	768-770
T	O	771-772
+	O	772-773
A	O	773-774
or	O	775-777
A	O	778-779
QD	O	780-782
before	O	783-789
breakfast	O	790-799
for	O	800-803
12	O	804-806
weeks	O	807-812
;	O	812-813
blood	O	814-819
pressure	O	820-828
(	O	829-830
BP	O	830-832
)	O	832-833
and	O	834-837
heart	O	838-843
rate	O	844-848
were	O	849-853
measured	O	854-862
in	O	863-865
the	O	866-869
sitting	O	870-877
position	O	878-886
.	O	886-887

Primary	O	888-895
efficacy	O	896-904
end	O	905-908
points	O	909-915
were	O	916-920
reduction	O	921-930
in	O	931-933
clinical	O	934-942
systolic	O	943-951
BP	O	952-954
(	O	955-956
SBP	O	956-959
)	O	959-960
/	O	960-961
diastolic	O	962-971
BP	O	972-974
(	O	975-976
DBP	O	976-979
)	O	979-980
from	O	981-985
baseline	O	986-994
to	O	995-997
study	O	998-1003
end	O	1004-1007
and	O	1008-1011
number	O	1012-1018
of	O	1019-1021
responders	O	1022-1032
(	O	1033-1034
ie	O	1034-1036
,	O	1036-1037
patients	O	1038-1046
who	O	1047-1050
achieved	O	1051-1059
target	O	1060-1066
SBP	O	1067-1070
/	O	1070-1071
DBP	O	1072-1075
<	O	1076-1077
130	O	1077-1080
/	O	1080-1081
<	O	1076-1077
80	O	1082-1084
mm	O	1085-1087
Hg	O	1088-1090
)	O	1090-1091
at	O	1092-1094
end	O	1095-1098
of	O	1099-1101
study	O	1102-1107
.	O	1107-1108

Tolerability	O	1109-1121
was	O	1122-1125
assessed	O	1126-1134
by	O	1135-1137
treatment	O	1138-1147
-	O	1147-1148
emergent	O	1148-1156
adverse	O	1157-1164
events	O	1165-1171
,	O	1171-1172
identified	O	1173-1183
using	O	1184-1189
physical	O	1190-1198
examination	O	1199-1210
,	O	1210-1211
laboratory	O	1212-1222
analysis	O	1223-1231
,	O	1231-1232
and	O	1233-1236
electrocardiography	O	1237-1256
.	O	1256-1257

RESULTS	O	1258-1265
:	O	1265-1266
A	O	1267-1268
total	O	1269-1274
of	O	1275-1277
210	O	1278-1281
patients	O	1282-1290
were	O	1291-1295
enrolled	O	1296-1304
in	O	1305-1307
the	O	1308-1311
study	O	1312-1317
;	O	1317-1318
203	O	1319-1322
patients	O	1323-1331
(	O	1332-1333
143	O	1333-1336
men	O	1337-1340
,	O	1340-1341
60	O	1342-1344
women	O	1345-1350
)	O	1350-1351
completed	O	1352-1361
the	O	1362-1365
study	O	1366-1371
while	O	1372-1377
7	O	1378-1379
were	O	1380-1384
lost	O	1385-1389
to	O	1390-1392
follow	O	1393-1399
-	O	1399-1400
up	O	1400-1402
(	O	1403-1404
4	O	1404-1405
patients	O	1406-1414
in	O	1415-1417
the	O	1418-1421
T	O	1422-1423
+	O	1423-1424
A	O	1424-1425
group	O	1426-1431
and	O	1432-1435
3	O	1436-1437
in	O	1438-1440
the	O	1441-1444
A	O	1445-1446
group	O	1447-1452
)	O	1452-1453
and	O	1454-1457
considered	O	1458-1468
with	O	1469-1473
-	O	1473-1474
drawn	O	1474-1479
.	O	1479-1480

At	O	1481-1483
study	O	1484-1489
end	O	1490-1493
,	O	1493-1494
statistically	O	1495-1508
significant	O	1509-1520
percentage	O	1521-1531
reductions	O	1532-1542
from	O	1543-1547
baseline	O	1548-1556
within	O	1557-1563
groups	O	1564-1570
and	O	1571-1574
between	O	1575-1582
groups	O	1583-1589
were	O	1590-1594
observed	O	1595-1603
in	O	1604-1606
SBP	O	1607-1610
(	O	1611-1612
T	O	1612-1613
+	O	1613-1614
A	O	1614-1615
[	O	1616-1617
-	O	1617-1618
27	O	1618-1620
.	O	1620-1621
4	O	1621-1622
%	O	1622-1623
]	O	1623-1624
;	O	1624-1625

A	O	1626-1627
[	O	1628-1629
-	O	1629-1630
16	O	1630-1632
.	O	1632-1633
6	O	1631-1632
%	O	1634-1635
]	O	1635-1636
)	O	1636-1637
and	O	1638-1641
DBP	O	1642-1645
(	O	1646-1647
T	O	1647-1648
+	O	1648-1649
A	O	1649-1650
[	O	1651-1652
-	O	1652-1653
20	O	1653-1655
.	O	1655-1656
1	O	1656-1657
%	O	1657-1658
]	O	1658-1659
;	O	1659-1660

A	O	1661-1662
[	O	1663-1664
-	O	1664-1665
13	O	1665-1667
.	O	1667-1668
3	O	1666-1667
%	O	1669-1670
]	O	1670-1671
)	O	1671-1672
(	O	1673-1674
all	O	1674-1677
,	O	1677-1678
P	O	1679-1680
<	O	1681-1682
0	O	1683-1684
.	O	1684-1685
05	O	1685-1687
)	O	1687-1688
.	O	1684-1685

Response	O	1690-1698
rates	O	1699-1704
were	O	1705-1709
87	O	1710-1712
.	O	1712-1713
3	O	1713-1714
%	O	1714-1715
(	O	1716-1717
89	O	1717-1719
/	O	1719-1720
102	O	1720-1723
)	O	1723-1724
in	O	1725-1727
the	O	1728-1731
T	O	1732-1733
+	O	1733-1734
A	O	1734-1735
group	O	1736-1741
and	O	1742-1745
69	O	1746-1748
.	O	1748-1749
3	O	1749-1750
%	O	1750-1751
(	O	1752-1753
70	O	1753-1755
/	O	1755-1756
101	O	1756-1759
)	O	1759-1760
in	O	1761-1763
the	O	1764-1767
A	O	1768-1769
group	O	1770-1775
(	O	1776-1777
P	O	1777-1778
<	O	1779-1780
0	O	1781-1782
.	O	1782-1783
05	O	1783-1785
)	O	1785-1786
.	O	1782-1783

The	O	1788-1791
prevalences	O	1792-1803
of	O	1804-1806
adverse	O	1807-1814
events	O	1815-1821
were	O	1822-1826
not	O	1827-1830
significantly	O	1831-1844
different	O	1845-1854
between	O	1855-1862
the	O	1863-1866
2	O	1867-1868
treatment	O	1869-1878
groups	O	1879-1885
(	O	1886-1887
T	O	1887-1888
+	O	1888-1889
A	O	1889-1890
,	O	1890-1891
16	O	1892-1894
.	O	1894-1895
0	O	1895-1896
%	O	1896-1897
[	O	1898-1899
17	O	1899-1901
/	O	1901-1902
106	O	1902-1905
]	O	1905-1906
;	O	1906-1907
A	O	1908-1909
,	O	1909-1910
15	O	1911-1913
.	O	1913-1914
4	O	1914-1915
%	O	1915-1916
[	O	1917-1918
16	O	1918-1920
/	O	1920-1921
104	O	1921-1924
]	O	1924-1925
)	O	1925-1926
.	O	1926-1927

Peripheral	O	1928-1938
edema	B	1939-1944
was	O	1945-1948
reported	O	1949-1957
in	O	1958-1960
8	O	1961-1962
.	O	1962-1963
5	O	1963-1964
%	O	1964-1965
patients	O	1966-1974
(	O	1975-1976
9	O	1976-1977
/	O	1977-1978
106	O	1978-1981
)	O	1981-1982
in	O	1983-1985
the	O	1986-1989
T	O	1990-1991
+	O	1991-1992
A	O	1992-1993
group	O	1994-1999
compared	O	2000-2008
with	O	2009-2013
13	O	2014-2016
.	O	2016-2017
5	O	2017-2018
%	O	2018-2019
(	O	2020-2021
14	O	2021-2023
/	O	2023-2024
104	O	2024-2027
)	O	2027-2028
in	O	2029-2031
the	O	2032-2035
A	O	2036-2037
group	O	2038-2043
,	O	2043-2044
and	O	2045-2048
cough	B	2049-2054
was	O	2055-2058
reported	O	2059-2067
in	O	2068-2070
3	O	2071-2072
.	O	2072-2073
8	O	2073-2074
%	O	2074-2075
patients	O	2076-2084
(	O	2085-2086
4	O	2086-2087
/	O	2087-2088
106	O	2088-2091
)	O	2091-2092
in	O	2093-2095
the	O	2096-2099
T	O	2100-2101
+	O	2101-2102
A	O	2102-2103
group	O	2104-2109
and	O	2110-2113
1	O	2114-2115
.	O	2115-2116
0	O	2116-2117
%	O	2117-2118
(	O	2119-2120
1	O	2120-2121
/	O	2121-2122
104	O	2122-2125
)	O	2125-2126
patients	O	2127-2135
in	O	2136-2138
the	O	2139-2142
A	O	2143-2144
group	O	2145-2150
;	O	2150-2151
these	O	2152-2157
differences	O	2158-2169
did	O	2170-2173
not	O	2174-2177
reach	O	2178-2183
statistical	O	2184-2195
significance	O	2196-2208
.	O	2208-2209

The	O	2210-2213
incidences	O	2214-2224
of	O	2225-2227
headache	B	2228-2236
,	O	2236-2237
dizziness	B	2238-2247
,	O	2247-2248
and	O	2249-2252
diarrhea	B	2253-2261
were	O	2262-2266
similar	O	2267-2274
between	O	2275-2282
the	O	2283-2286
2	O	2287-2288
groups	O	2289-2295
.	O	2295-2296

CONCLUSIONS	O	2297-2308
:	O	2308-2309
Among	O	2310-2315
these	O	2316-2321
Indian	O	2322-2328
patients	O	2329-2337
with	O	2338-2342
stage	O	2343-2348
II	O	2349-2351
hypertension	B	2352-2364
,	O	2364-2365
the	O	2366-2369
FDC	O	2370-2373
of	O	2374-2376
T	O	2377-2378
+	O	2378-2379
A	O	2379-2380
was	O	2381-2384
found	O	2385-2390
to	O	2391-2393
be	O	2394-2396
significantly	O	2397-2410
more	O	2411-2415
effective	O	2416-2425
,	O	2425-2426
with	O	2427-2431
regard	O	2432-2438
to	O	2439-2441
BP	O	2442-2444
reductions	O	2445-2455
,	O	2455-2456
than	O	2457-2461
A	O	2462-2463
,	O	2463-2464
and	O	2465-2468
both	O	2469-2473
treatments	O	2474-2484
were	O	2485-2489
well	O	2490-2494
tolerated	O	2495-2504
.	O	2504-2505

Cutaneous	B	0-9
leucocytoclastic	I	10-26
vasculitis	I	27-37
associated	O	38-48
with	O	49-53
oxacillin	O	54-63
.	O	63-64

A	O	65-66
67	O	67-69
-	O	69-70
year	O	70-74
-	O	69-70
old	O	75-78
man	O	79-82
who	O	83-86
was	O	87-90
treated	O	91-98
with	O	99-103
oxacillin	O	104-113
for	O	114-117
one	O	118-121
week	O	122-126
because	O	127-134
of	O	135-137
Staphylococcus	B	138-152
aureus	I	153-159
bacteremia	I	160-170
,	O	170-171
developed	O	172-181
renal	B	182-187
failure	I	188-195
and	O	196-199
diffuse	O	200-207
,	O	207-208
symmetric	O	209-218
,	O	218-219
palpable	O	220-228
purpuric	B	229-237
lesions	I	238-245
on	O	246-248
his	O	249-252
feet	O	253-257
.	O	257-258

Necrotic	B	259-267
blisters	I	268-276
were	O	277-281
noted	O	282-287
on	O	288-290
his	O	291-294
fingers	O	295-302
.	O	302-303

Skin	O	304-308
biopsies	O	309-317
showed	O	318-324
findings	O	325-333
diagnostic	O	334-344
of	O	345-347
leucocytoclastic	B	348-364
vasculitis	I	365-375
.	O	375-376

Oxacillin	O	377-386
was	O	387-390
discontinued	O	391-403
and	O	404-407
patient	O	408-415
was	O	416-419
treated	O	420-427
with	O	428-432
corticosteroids	O	433-448
.	O	448-449

The	O	450-453
rash	B	454-458
disappeared	O	459-470
after	O	471-476
three	O	477-482
weeks	O	483-488
and	O	489-492
renal	O	493-498
function	O	499-507
returned	O	508-516
to	O	517-519
normal	O	520-526
.	O	526-527

Leucocytoclastic	B	528-544
vasculitis	I	545-555
presents	O	556-564
as	O	565-567
palpable	O	568-576
purpura	B	577-584
of	O	585-587
the	O	588-591
lower	O	592-597
extremities	O	598-609
often	O	610-615
accompanied	O	616-627
by	O	628-630
abdominal	B	631-640
pain	I	641-645
,	O	645-646
arthralgia	B	647-657
,	O	657-658
and	O	659-662
renal	B	663-668
involvement	I	669-680
.	O	680-681

Etiologic	O	682-691
factors	O	692-699
or	O	700-702
associated	O	703-713
disorders	O	714-723
include	O	724-731
infections	B	732-742
,	O	742-743
medications	O	744-755
,	O	755-756
collagen	B	757-765
vascular	I	766-774
disease	I	775-782
and	O	783-786
neoplasia	B	787-796
.	O	796-797

However	O	798-805
,	O	805-806
in	O	807-809
half	O	810-814
of	O	815-817
the	O	818-821
cases	O	822-827
no	O	828-830
etiologic	O	831-840
factor	O	841-847
is	O	848-850
identified	O	851-861
.	O	861-862

Usually	O	863-870
it	O	871-873
is	O	874-876
a	O	877-878
self	O	879-883
-	O	883-884
limited	O	884-891
disorder	O	892-900
,	O	900-901
but	O	902-905
corticosteroid	O	906-920
therapy	O	921-928
may	O	929-932
be	O	933-935
needed	O	936-942
in	O	943-945
life	O	946-950
-	O	950-951
threatening	O	951-962
cases	O	963-968
since	O	969-974
early	O	975-980
treatment	O	981-990
with	O	991-995
corticosteroids	O	996-1011
in	O	1012-1014
severe	O	1015-1021
cases	O	1022-1027
can	O	1028-1031
prevent	O	1032-1039
complications	O	1040-1053
.	O	1053-1054

Oxacillin	O	1055-1064
should	O	1065-1071
be	O	1072-1074
included	O	1075-1083
among	O	1084-1089
the	O	1090-1093
drugs	O	1094-1099
that	O	1100-1104
can	O	1105-1108
cause	O	1109-1114
leucocytoclastic	B	1115-1131
vasculitis	I	1132-1142
.	O	1142-1143

Naloxazone	O	0-10
pretreatment	O	11-23
modifies	O	24-32
cardiorespiratory	O	33-50
,	O	50-51
temperature	O	52-63
,	O	63-64
and	O	65-68
behavioral	O	69-79
effects	O	80-87
of	O	88-90
morphine	O	91-99
.	O	99-100

Behavioral	O	101-111
and	O	112-115
cardiorespiratory	O	116-133
responses	O	134-143
to	O	144-146
a	O	147-148
lethal	O	149-155
dose	O	156-160
of	O	161-163
morphine	O	164-172
were	O	173-177
evaluated	O	178-187
in	O	188-190
rats	O	191-195
pretreated	O	196-206
with	O	207-211
saline	O	212-218
or	O	219-221
naloxazone	O	222-232
,	O	232-233
an	O	234-236
antagonist	O	237-247
of	O	248-250
high	O	251-255
-	O	255-256
affinity	O	256-264
mu	O	265-267
1	O	268-269
opioid	O	270-276
receptors	O	277-286
.	O	286-287

Pretreatment	O	288-300
with	O	301-305
naloxazone	O	306-316
significantly	O	317-330
blocked	O	331-338
morphine	O	339-347
analgesia	B	348-357
,	O	357-358
catalepsy	B	359-368
and	O	369-372
hypothermia	B	373-384
at	O	385-387
a	O	388-389
dose	O	390-394
which	O	395-400
completely	O	401-411
eliminated	O	412-422
high	O	423-427
-	O	427-428
affinity	O	428-436
binding	O	437-444
in	O	445-447
brain	O	448-453
membranes	O	454-463
.	O	463-464

Moreover	O	465-473
,	O	473-474
naloxazone	O	475-485
significantly	O	486-499
attenuated	O	500-510
the	O	511-514
morphine	O	515-523
-	O	523-524
induced	O	524-531
hypotension	B	532-543
and	O	544-547
respiratory	B	548-559
depression	I	560-570
,	O	570-571
whereas	O	572-579
morphine	O	580-588
-	O	588-589
induced	O	589-596
bradycardia	B	597-608
was	O	609-612
less	O	613-617
affected	O	618-626
.	O	626-627

Results	O	628-635
indicate	O	636-644
that	O	645-649
subpopulations	O	650-664
of	O	665-667
mu	O	668-670
receptors	O	671-680
may	O	681-684
mediate	O	685-692
selective	O	693-702
behavioral	O	703-713
and	O	714-717
cardiorespiratory	O	718-735
responses	O	736-745
to	O	746-748
morphine	O	749-757
.	O	757-758

Dexrazoxane	O	0-11
protects	O	12-20
against	O	21-28
myelosuppression	B	29-45
from	O	46-50
the	O	51-54
DNA	O	55-58
cleavage	O	59-67
-	O	67-68
enhancing	O	68-77
drugs	O	78-83
etoposide	O	84-93
and	O	94-97
daunorubicin	O	98-110
but	O	111-114
not	O	115-118
doxorubicin	O	119-130
.	O	130-131

PURPOSE	O	132-139
:	O	139-140
The	O	141-144
anthracyclines	O	145-159
daunorubicin	O	160-172
and	O	173-176
doxorubicin	O	177-188
and	O	189-192
the	O	193-196
epipodophyllotoxin	O	197-215
etoposide	O	216-225
are	O	226-229
potent	O	230-236
DNA	O	237-240
cleavage	O	241-249
-	O	249-250
enhancing	O	250-259
drugs	O	260-265
that	O	266-270
are	O	271-274
widely	O	275-281
used	O	282-286
in	O	287-289
clinical	O	290-298
oncology	O	299-307
;	O	307-308
however	O	309-316
,	O	316-317
myelosuppression	B	318-334
and	O	335-338
cardiac	B	339-346
toxicity	I	347-355
limit	O	356-361
their	O	362-367
use	O	368-371
.	O	371-372

Dexrazoxane	O	373-384
(	O	385-386
ICRF	O	386-390
-	O	390-391
187	O	391-394
)	O	394-395
is	O	396-398
recommended	O	399-410
for	O	411-414
protection	O	415-425
against	O	426-433
anthracycline	O	434-447
-	O	447-448
induced	O	448-455
cardiotoxicity	B	456-470
.	O	470-471

EXPERIMENTAL	O	472-484
DESIGN	O	485-491
:	O	491-492
Because	O	493-500
of	O	501-503
their	O	504-509
widespread	O	510-520
use	O	521-524
,	O	524-525
the	O	526-529
hematologic	B	530-541
toxicity	I	542-550
following	O	551-560
coadministration	O	561-577
of	O	578-580
dexrazoxane	O	581-592
and	O	593-596
these	O	597-602
three	O	603-608
structurally	O	609-621
different	O	622-631
DNA	O	632-635
cleavage	O	636-644
enhancers	O	645-654
was	O	655-658
investigated	O	659-671
:	O	671-672
Sensitivity	O	673-684
of	O	685-687
human	O	688-693
and	O	694-697
murine	O	698-704
blood	O	705-710
progenitor	O	711-721
cells	O	722-727
to	O	728-730
etoposide	O	731-740
,	O	740-741
daunorubicin	O	742-754
,	O	754-755
and	O	756-759
doxorubicin	O	760-771
+	O	772-773
/	O	773-774
-	O	774-775
dexrazoxane	O	776-787
was	O	788-791
determined	O	792-802
in	O	803-805
granulocyte	O	806-817
-	O	817-818
macrophage	O	818-828
colony	O	829-835
forming	O	836-843
assays	O	844-850
.	O	850-851

Likewise	O	852-860
,	O	860-861
in	O	862-864
vivo	O	865-869
,	O	869-870
B6D2F1	O	871-877
mice	O	878-882
were	O	883-887
treated	O	888-895
with	O	896-900
etoposide	O	901-910
,	O	910-911
daunorubicin	O	912-924
,	O	924-925
and	O	926-929
doxorubicin	O	930-941
,	O	941-942
with	O	943-947
or	O	948-950
without	O	951-958
dexrazoxane	O	959-970
over	O	971-975
a	O	976-977
wide	O	978-982
range	O	983-988
of	O	989-991
doses	O	992-997
:	O	997-998
posttreatment	O	999-1012
,	O	1012-1013
a	O	1014-1015
full	O	1016-1020
hematologic	O	1021-1032
evaluation	O	1033-1043
was	O	1044-1047
done	O	1048-1052
.	O	1052-1053

RESULTS	O	1054-1061
:	O	1061-1062
Nontoxic	O	1063-1071
doses	O	1072-1077
of	O	1078-1080
dexrazoxane	O	1081-1092
reduced	O	1093-1100
myelosuppression	B	1101-1117
and	O	1118-1121
weight	B	1122-1128
loss	I	1129-1133
from	O	1134-1138
daunorubicin	O	1139-1151
and	O	1152-1155
etoposide	O	1156-1165
in	O	1166-1168
mice	O	1169-1173
and	O	1174-1177
antagonized	O	1178-1189
their	O	1190-1195
antiproliferative	O	1196-1213
effects	O	1214-1221
in	O	1222-1224
the	O	1225-1228
colony	O	1229-1235
assay	O	1236-1241
;	O	1241-1242
however	O	1243-1250
,	O	1250-1251
dexrazoxane	O	1252-1263
neither	O	1264-1271
reduced	O	1272-1279
myelosuppression	B	1280-1296
,	O	1296-1297
weight	B	1298-1304
loss	I	1305-1309
,	O	1309-1310
nor	O	1311-1314
the	O	1315-1318
in	O	1319-1321
vitro	O	1322-1327
cytotoxicity	B	1328-1340
from	O	1341-1345
doxorubicin	O	1346-1357
.	O	1357-1358

CONCLUSION	O	1359-1369
:	O	1369-1370
Although	O	1371-1379
our	O	1380-1383
findings	O	1384-1392
support	O	1393-1400
the	O	1401-1404
observation	O	1405-1416
that	O	1417-1421
dexrazoxane	O	1422-1433
reduces	O	1434-1441
neither	O	1442-1449
hematologic	O	1450-1461
activity	O	1462-1470
nor	O	1471-1474
antitumor	O	1475-1484
activity	O	1485-1493
from	O	1494-1498
doxorubicin	O	1499-1510
clinically	O	1511-1521
,	O	1521-1522
the	O	1523-1526
potent	O	1527-1533
antagonism	O	1534-1544
of	O	1545-1547
daunorubicin	O	1548-1560
activity	O	1561-1569
raises	O	1570-1576
concern	O	1577-1584
;	O	1584-1585
a	O	1586-1587
possible	O	1588-1596
interference	O	1597-1609
with	O	1610-1614
anticancer	O	1615-1625
efficacy	O	1626-1634
certainly	O	1635-1644
would	O	1645-1650
call	O	1651-1655
for	O	1656-1659
renewed	O	1660-1667
attention	O	1668-1677
.	O	1677-1678

Our	O	1679-1682
data	O	1683-1687
also	O	1688-1692
suggest	O	1693-1700
that	O	1701-1705
significant	O	1706-1717
etoposide	O	1718-1727
dose	O	1728-1732
escalation	O	1733-1743
is	O	1744-1746
perhaps	O	1747-1754
possible	O	1755-1763
by	O	1764-1766
the	O	1767-1770
use	O	1771-1774
of	O	1775-1777
dexrazoxane	O	1778-1789
.	O	1789-1790

Clinical	O	1791-1799
trials	O	1800-1806
in	O	1807-1809
patients	O	1810-1818
with	O	1819-1823
brain	O	1824-1829
metastases	B	1830-1840
combining	O	1841-1850
dexrazoxane	O	1851-1862
and	O	1863-1866
high	O	1867-1871
doses	O	1872-1877
of	O	1878-1880
etoposide	O	1881-1890
is	O	1891-1893
ongoing	O	1894-1901
with	O	1902-1906
the	O	1907-1910
aim	O	1911-1914
of	O	1915-1917
improving	O	1918-1927
efficacy	O	1928-1936
without	O	1937-1944
aggravating	O	1945-1956
hematologic	B	1957-1968
toxicity	I	1969-1977
.	O	1977-1978

If	O	1979-1981
successful	O	1982-1992
,	O	1992-1993
this	O	1994-1998
represents	O	1999-2009
an	O	2010-2012
exciting	O	2013-2021
mechanism	O	2022-2031
for	O	2032-2035
pharmacologic	O	2036-2049
regulation	O	2050-2060
of	O	2061-2063
side	O	2064-2068
effects	O	2069-2076
from	O	2077-2081
cytotoxic	O	2082-2091
chemotherapy	O	2092-2104
.	O	2104-2105

Effects	O	0-7
of	O	8-10
the	O	11-14
novel	O	15-20
compound	O	21-29
aniracetam	O	30-40
(	O	41-42
Ro	O	42-44
13	O	45-47
-	O	47-48
5057	O	48-52
)	O	52-53
upon	O	54-58
impaired	B	59-67
learning	I	68-76
and	I	77-80
memory	I	81-87
in	O	88-90
rodents	O	91-98
.	O	98-99

The	O	100-103
effect	O	104-110
of	O	111-113
aniracetam	O	114-124
(	O	125-126
Ro	O	126-128
13	O	129-131
-	O	131-132
5057	O	132-136
,	O	136-137
1	O	138-139
-	O	139-140
anisoyl	O	140-147
-	O	139-140
2	O	148-149
-	O	139-140
pyrrolidinone	O	150-163
)	O	163-164
was	O	165-168
studied	O	169-176
on	O	177-179
various	O	180-187
forms	O	188-193
of	O	194-196
experimentally	O	197-211
impaired	B	212-220
cognitive	I	221-230
functions	I	231-240
(	O	241-242
learning	O	242-250
and	O	251-254
memory	O	255-261
)	O	261-262
in	O	263-265
rodents	O	266-273
and	O	274-277
produced	O	278-286
the	O	287-290
following	O	291-300
effects	O	301-308
:	O	308-309
(	O	310-311
1	O	311-312
)	O	312-313
almost	O	314-320
complete	O	321-329
prevention	O	330-340
of	O	341-343
the	O	344-347
incapacity	O	348-358
to	O	359-361
learn	O	362-367
a	O	368-369
discrete	O	370-378
escape	O	379-385
response	O	386-394
in	O	395-397
rats	O	398-402
exposed	O	403-410
to	O	411-413
sublethal	O	414-423
hypercapnia	B	424-435
immediately	O	436-447
before	O	448-454
the	O	455-458
acquisition	O	459-470
session	O	471-478
;	O	478-479
(	O	480-481
2	O	481-482
)	O	482-483
partial	O	484-491
(	O	492-493
rats	O	493-497
)	O	497-498
or	O	499-501
complete	O	502-510
(	O	511-512
mice	O	512-516
)	O	516-517
prevention	O	518-528
of	O	529-531
the	O	532-535
scopolamine	O	536-547
-	O	547-548
induced	O	548-555
short	O	556-561
-	O	561-562
term	O	562-566
amnesia	B	567-574
for	O	575-578
a	O	579-580
passive	O	581-588
avoidance	O	589-598
task	O	599-603
;	O	603-604
(	O	605-606
3	O	606-607
)	O	607-608
complete	O	609-617
protection	O	618-628
against	O	629-636
amnesia	B	637-644
for	O	645-648
a	O	649-650
passive	O	651-658
avoidance	O	659-668
task	O	669-673
in	O	674-676
rats	O	677-681
submitted	O	682-691
to	O	692-694
electroconvulsive	O	695-712
shock	O	713-718
immediately	O	719-730
after	O	731-736
avoidance	O	737-746
acquisition	O	747-758
;	O	758-759
(	O	760-761
4	O	761-762
)	O	762-763
prevention	O	764-774
of	O	775-777
the	O	778-781
long	O	782-786
-	O	786-787
term	O	787-791
retention	O	792-801
-	O	801-802
or	O	803-805
retrieval	O	806-815
-	O	815-816
deficit	O	816-823
for	O	824-827
a	O	828-829
passive	O	830-837
avoidance	O	838-847
task	O	848-852
induced	O	853-860
in	O	861-863
rats	O	864-868
and	O	869-872
mice	O	873-877
by	O	878-880
chloramphenicol	O	881-896
or	O	897-899
cycloheximide	O	900-913
administered	O	914-926
immediately	O	927-938
after	O	939-944
acquisition	O	945-956
;	O	956-957
(	O	958-959
5	O	959-960
)	O	960-961
reversal	O	962-970
,	O	970-971
when	O	972-976
administered	O	977-989
as	O	990-992
late	O	993-997
as	O	998-1000
1	O	1001-1002
h	O	1003-1004
before	O	1005-1011
the	O	1012-1015
retention	O	1016-1025
test	O	1026-1030
,	O	1030-1031
of	O	1032-1034
the	O	1035-1038
deficit	O	1039-1046
in	O	1047-1049
retention	O	1050-1059
or	O	1060-1062
retrieval	O	1063-1072
of	O	1073-1075
a	O	1076-1077
passive	O	1078-1085
avoidance	O	1086-1095
task	O	1096-1100
induced	O	1101-1108
by	O	1109-1111
cycloheximide	O	1112-1125
injected	O	1126-1134
2	O	1135-1136
days	O	1137-1141
previously	O	1142-1152
;	O	1152-1153
(	O	1154-1155
6	O	1155-1156
)	O	1156-1157
prevention	O	1158-1168
of	O	1169-1171
the	O	1172-1175
deficit	O	1176-1183
in	O	1184-1186
the	O	1187-1190
retrieval	O	1191-1200
of	O	1201-1203
an	O	1204-1206
active	O	1207-1213
avoidance	O	1214-1223
task	O	1224-1228
induced	O	1229-1236
in	O	1237-1239
mice	O	1240-1244
by	O	1245-1247
subconvulsant	O	1248-1261
electroshock	O	1262-1274
or	O	1275-1277
hypercapnia	B	1278-1289
applied	O	1290-1297
immediately	O	1298-1309
before	O	1310-1316
retrieval	O	1317-1326
testing	O	1327-1334
(	O	1335-1336
24	O	1336-1338
h	O	1339-1340
after	O	1341-1346
acquisition	O	1347-1358
)	O	1358-1359
.	O	1359-1360

These	O	1361-1366
improvements	O	1367-1379
or	O	1380-1382
normalizations	O	1383-1397
of	O	1398-1400
impaired	B	1401-1409
cognitive	I	1410-1419
functions	I	1420-1429
were	O	1430-1434
seen	O	1435-1439
at	O	1440-1442
oral	O	1443-1447
aniracetam	O	1448-1458
doses	O	1459-1464
of	O	1465-1467
10	O	1468-1470
-	O	1470-1471
100	O	1471-1474
mg	O	1475-1477
/	O	1477-1478
kg	O	1478-1480
.	O	1480-1481

Generally	O	1482-1491
,	O	1491-1492
the	O	1493-1496
dose	O	1497-1501
-	O	1501-1502
response	O	1502-1510
curves	O	1511-1517
were	O	1518-1522
bell	O	1523-1527
-	O	1527-1528
shaped	O	1528-1534
.	O	1534-1535

The	O	1536-1539
mechanisms	O	1540-1550
underlying	O	1551-1561
the	O	1562-1565
activity	O	1566-1574
of	O	1575-1577
aniracetam	O	1578-1588
and	O	1589-1592
its	O	1593-1596
'	O	1597-1598
therapeutic	O	1598-1609
window	O	1610-1616
'	O	1616-1617
are	O	1618-1621
unknown	O	1622-1629
.	O	1629-1630

Piracetam	O	1631-1640
,	O	1640-1641
another	O	1642-1649
pyrrolidinone	O	1650-1663
derivative	O	1664-1674
was	O	1675-1678
used	O	1679-1683
for	O	1684-1687
comparison	O	1688-1698
.	O	1698-1699

It	O	1700-1702
was	O	1703-1706
active	O	1707-1713
only	O	1714-1718
in	O	1719-1721
six	O	1722-1725
of	O	1726-1728
nine	O	1729-1733
tests	O	1734-1739
and	O	1740-1743
had	O	1744-1747
about	O	1748-1753
one	O	1754-1757
-	O	1757-1758
tenth	O	1758-1763
the	O	1764-1767
potency	O	1768-1775
of	O	1776-1778
aniracetam	O	1779-1789
.	O	1789-1790

The	O	1791-1794
results	O	1795-1802
indicate	O	1803-1811
that	O	1812-1816
aniracetam	O	1817-1827
improves	O	1828-1836
cognitive	O	1837-1846
functions	O	1847-1856
which	O	1857-1862
are	O	1863-1866
impaired	O	1867-1875
by	O	1876-1878
different	O	1879-1888
procedure	O	1889-1898
and	O	1899-1902
in	O	1903-1905
different	O	1906-1915
phases	O	1916-1922
of	O	1923-1925
the	O	1926-1929
learning	O	1930-1938
and	O	1939-1942
memory	O	1943-1949
process	O	1950-1957
.	O	1957-1958

Nicotine	O	0-8
potentiation	O	9-21
of	O	22-24
morphine	O	25-33
-	O	33-34
induced	O	34-41
catalepsy	B	42-51
in	O	52-54
mice	O	55-59
.	O	59-60

In	O	61-63
the	O	64-67
present	O	68-75
study	O	76-81
,	O	81-82
effects	O	83-90
of	O	91-93
nicotine	O	94-102
on	O	103-105
catalepsy	B	106-115
induced	O	116-123
by	O	124-126
morphine	O	127-135
in	O	136-138
mice	O	139-143
have	O	144-148
been	O	149-153
investigated	O	154-166
.	O	166-167

Morphine	O	168-176
but	O	177-180
not	O	181-184
nicotine	O	185-193
induced	O	194-201
a	O	202-203
dose	O	204-208
-	O	208-209
dependent	O	209-218
catalepsy	B	219-228
.	O	228-229

The	O	230-233
response	O	234-242
of	O	243-245
morphine	O	246-254
was	O	255-258
potentiated	O	259-270
by	O	271-273
nicotine	O	274-282
.	O	282-283

Intraperitoneal	O	284-299
administration	O	300-314
of	O	315-317
atropine	O	318-326
,	O	326-327
naloxone	O	328-336
,	O	336-337
mecamylamine	O	338-350
,	O	350-351
and	O	352-355
hexamethonium	O	356-369
to	O	370-372
mice	O	373-377
reduced	O	378-385
catalepsy	B	386-395
induced	O	396-403
by	O	404-406
a	O	407-408
combination	O	409-420
of	O	421-423
morphine	O	424-432
with	O	433-437
nicotine	O	438-446
.	O	446-447

Intracerebroventricular	O	448-471
injection	O	472-481
of	O	482-484
atropine	O	485-493
,	O	493-494
hexamethonium	O	495-508
,	O	508-509
and	O	510-513
naloxone	O	514-522
also	O	523-527
decreased	O	528-537
catalepsy	B	538-547
induced	O	548-555
by	O	556-558
morphine	O	559-567
plus	O	568-572
nicotine	O	573-581
.	O	581-582

Intraperitoneal	O	583-598
administration	O	599-613
of	O	614-616
atropine	O	617-625
,	O	625-626
but	O	627-630
not	O	631-634
intraperitoneal	O	635-650
or	O	651-653
intracerebroventricular	O	654-677
injection	O	678-687
of	O	688-690
hexamethonium	O	691-704
,	O	704-705
decreased	O	706-715
the	O	716-719
effect	O	720-726
of	O	727-729
a	O	730-731
single	O	732-738
dose	O	739-743
of	O	744-746
morphine	O	747-755
.	O	755-756

It	O	757-759
was	O	760-763
concluded	O	764-773
that	O	774-778
morphine	O	779-787
catalepsy	B	788-797
can	O	798-801
be	O	802-804
elicited	O	805-813
by	O	814-816
opioid	O	817-823
and	O	824-827
cholinergic	O	828-839
receptors	O	840-849
,	O	849-850
and	O	851-854
the	O	855-858
potentiation	O	859-871
of	O	872-874
morphine	O	875-883
induced	O	884-891
by	O	892-894
nicotine	O	895-903
may	O	904-907
also	O	908-912
be	O	913-915
mediated	O	916-924
through	O	925-932
cholinergic	O	933-944
receptor	O	945-953
mechanisms	O	954-964
.	O	964-965

Reduced	O	0-7
cardiotoxicity	B	8-22
and	O	23-26
preserved	O	27-36
antitumor	O	37-46
efficacy	O	47-55
of	O	56-58
liposome	O	59-67
-	O	67-68
encapsulated	O	68-80
doxorubicin	O	81-92
and	O	93-96
cyclophosphamide	O	97-113
compared	O	114-122
with	O	123-127
conventional	O	128-140
doxorubicin	O	141-152
and	O	153-156
cyclophosphamide	O	157-173
in	O	174-176
a	O	177-178
randomized	O	179-189
,	O	189-190
multicenter	O	191-202
trial	O	203-208
of	O	209-211
metastatic	O	212-222
breast	B	223-229
cancer	I	230-236
.	O	236-237

PURPOSE	O	238-245
:	O	245-246
To	O	247-249
determine	O	250-259
whether	O	260-267
Myocet	O	268-274
(	O	275-276
liposome	O	276-284
-	O	284-285
encapsulated	O	285-297
doxorubicin	O	298-309
;	O	309-310
The	O	311-314
Liposome	O	315-323
Company	O	324-331
,	O	331-332
Elan	O	333-337
Corporation	O	338-349
,	O	349-350
Princeton	O	351-360
,	O	360-361
NJ	O	362-364
)	O	364-365
in	O	366-368
combination	O	369-380
with	O	381-385
cyclophosphamide	O	386-402
significantly	O	403-416
reduces	O	417-424
doxorubicin	O	425-436
cardiotoxicity	B	437-451
while	O	452-457
providing	O	458-467
comparable	O	468-478
antitumor	O	479-488
efficacy	O	489-497
in	O	498-500
first	O	501-506
-	O	506-507
line	O	507-511
treatment	O	512-521
of	O	522-524
metastatic	O	525-535
breast	B	536-542
cancer	I	543-549
(	O	550-551
MBC	B	551-554
)	O	554-555
.	O	555-556

PATIENTS	O	557-565
AND	O	566-569
METHODS	O	570-577
:	O	577-578
Two	O	579-582
hundred	O	583-590
ninety	O	591-597
-	O	597-598
seven	O	598-603
patients	O	604-612
with	O	613-617
MBC	B	618-621
and	O	622-625
no	O	626-628
prior	O	629-634
chemotherapy	O	635-647
for	O	648-651
metastatic	O	652-662
disease	O	663-670
were	O	671-675
randomized	O	676-686
to	O	687-689
receive	O	690-697
either	O	698-704
60	O	705-707
mg	O	708-710
/	O	710-711
m	O	708-709
(	O	712-713
2	O	713-714
)	O	714-715
of	O	716-718
Myocet	O	719-725
(	O	726-727
M	O	727-728
)	O	728-729
or	O	730-732
conventional	O	733-745
doxorubicin	O	746-757
(	O	758-759
A	O	759-760
)	O	760-761
,	O	761-762
in	O	763-765
combination	O	766-777
with	O	778-782
600	O	783-786
mg	O	787-789
/	O	789-790
m	O	787-788
(	O	791-792
2	O	792-793
)	O	793-794
of	O	795-797
cyclophosphamide	O	798-814
(	O	815-816
C	O	816-817
)	O	817-818
,	O	818-819
every	O	820-825
3	O	826-827
weeks	O	828-833
until	O	834-839
disease	O	840-847
progression	O	848-859
or	O	860-862
unacceptable	O	863-875
toxicity	B	876-884
.	O	884-885

Cardiotoxicity	B	886-900
was	O	901-904
defined	O	905-912
by	O	913-915
reductions	O	916-926
in	O	927-929
left	O	930-934
-	O	934-935
ventricular	O	935-946
ejection	O	947-955
fraction	O	956-964
,	O	964-965
assessed	O	966-974
by	O	975-977
serial	O	978-984
multigated	O	985-995
radionuclide	O	996-1008
angiography	O	1009-1020
scans	O	1021-1026
,	O	1026-1027
or	O	1028-1030
congestive	B	1031-1041
heart	I	1042-1047
failure	I	1048-1055
(	O	1056-1057
CHF	B	1057-1060
)	O	1060-1061
.	O	1061-1062

Antitumor	O	1063-1072
efficacy	O	1073-1081
was	O	1082-1085
assessed	O	1086-1094
by	O	1095-1097
objective	O	1098-1107
tumor	B	1108-1113
response	O	1114-1122
rates	O	1123-1128
(	O	1129-1130
World	O	1130-1135
Health	O	1136-1142
Organization	O	1143-1155
criteria	O	1156-1164
)	O	1164-1165
,	O	1165-1166
time	O	1167-1171
to	O	1172-1174
progression	O	1175-1186
,	O	1186-1187
and	O	1188-1191
survival	O	1192-1200
.	O	1200-1201

RESULTS	O	1202-1209
:	O	1209-1210
Six	O	1211-1214
percent	O	1215-1222
of	O	1223-1225
MC	O	1226-1228
patients	O	1229-1237
versus	O	1238-1244
21	O	1245-1247
%	O	1247-1248
(	O	1249-1250
including	O	1250-1259
five	O	1260-1264
cases	O	1265-1270
of	O	1271-1273
CHF	B	1274-1277
)	O	1277-1278
of	O	1279-1281
AC	O	1282-1284
patients	O	1285-1293
developed	O	1294-1303
cardiotoxicity	B	1304-1318
(	O	1319-1320
P	O	1320-1321
=	O	1322-1323
.	O	1323-1324
0002	O	1324-1328
)	O	1328-1329
.	O	1323-1324

Median	O	1331-1337
cumulative	O	1338-1348
doxorubicin	O	1349-1360
dose	O	1361-1365
at	O	1366-1368
onset	O	1369-1374
was	O	1375-1378
more	O	1379-1383
than	O	1384-1388
2	O	1389-1390
,	O	1390-1391
220	O	1391-1394
mg	O	1395-1397
/	O	1397-1398
m	O	1395-1396
(	O	1399-1400
2	O	1400-1401
)	O	1401-1402
for	O	1403-1406
MC	O	1407-1409
versus	O	1410-1416
480	O	1417-1420
mg	O	1421-1423
/	O	1423-1424
m	O	1421-1422
(	O	1425-1426
2	O	1426-1427
)	O	1427-1428
for	O	1429-1432
AC	O	1433-1435
(	O	1436-1437
P	O	1437-1438
=	O	1439-1440
.	O	1440-1441
0001	O	1441-1445
,	O	1445-1446
hazard	O	1447-1453
ratio	O	1454-1459
,	O	1459-1460
5	O	1461-1462
.	O	1462-1463
04	O	1463-1465
)	O	1465-1466
.	O	1462-1463

MC	O	1468-1470
patients	O	1471-1479
also	O	1480-1484
experienced	O	1485-1496
less	O	1497-1501
grade	O	1502-1507
4	O	1508-1509
neutropenia	B	1510-1521
.	O	1521-1522

Antitumor	O	1523-1532
efficacy	O	1533-1541
of	O	1542-1544
MC	O	1545-1547
versus	O	1548-1554
AC	O	1555-1557
was	O	1558-1561
comparable	O	1562-1572
:	O	1572-1573
objective	O	1574-1583
response	O	1584-1592
rates	O	1593-1598
,	O	1598-1599
43	O	1600-1602
%	O	1602-1603
versus	O	1604-1610
43	O	1611-1613
%	O	1613-1614
;	O	1614-1615
median	O	1616-1622
time	O	1623-1627
to	O	1628-1630
progression	O	1631-1642
,	O	1642-1643
5	O	1644-1645
.	O	1645-1646
1	O	1646-1647
%	O	1647-1648
versus	O	1649-1655
5	O	1656-1657
.	O	1657-1658
5	O	1656-1657
months	O	1660-1666
;	O	1666-1667
median	O	1668-1674
time	O	1675-1679
to	O	1680-1682
treatment	O	1683-1692
failure	O	1693-1700
,	O	1700-1701
4	O	1702-1703
.	O	1703-1704
6	O	1704-1705
versus	O	1706-1712
4	O	1713-1714
.	O	1714-1715
4	O	1713-1714
months	O	1717-1723
;	O	1723-1724
and	O	1725-1728
median	O	1729-1735
survival	O	1736-1744
,	O	1744-1745
19	O	1746-1748
versus	O	1749-1755
16	O	1756-1758
months	O	1759-1765
.	O	1765-1766

CONCLUSION	O	1767-1777
:	O	1777-1778
Myocet	O	1779-1785
improves	O	1786-1794
the	O	1795-1798
therapeutic	O	1799-1810
index	O	1811-1816
of	O	1817-1819
doxorubicin	O	1820-1831
by	O	1832-1834
significantly	O	1835-1848
reducing	O	1849-1857
cardiotoxicity	B	1858-1872
and	O	1873-1876
grade	O	1877-1882
4	O	1883-1884
neutropenia	B	1885-1896
and	O	1897-1900
provides	O	1901-1909
comparable	O	1910-1920
antitumor	O	1921-1930
efficacy	O	1931-1939
,	O	1939-1940
when	O	1941-1945
used	O	1946-1950
in	O	1951-1953
combination	O	1954-1965
with	O	1966-1970
cyclophosphamide	O	1971-1987
as	O	1988-1990
first	O	1991-1996
-	O	1996-1997
line	O	1997-2001
therapy	O	2002-2009
for	O	2010-2013
MBC	B	2014-2017
.	O	2017-2018

Protective	O	0-10
effect	O	11-17
of	O	18-20
a	O	21-22
specific	O	23-31
platelet	O	32-40
-	O	40-41
activating	O	41-51
factor	O	52-58
antagonist	O	59-69
,	O	69-70
BN	O	71-73
52021	O	74-79
,	O	79-80
on	O	81-83
bupivacaine	O	84-95
-	O	95-96
induced	O	96-103
cardiovascular	B	104-118
impairments	I	119-130
in	O	131-133
rats	O	134-138
.	O	138-139

Administration	O	140-154
of	O	155-157
the	O	158-161
local	O	162-167
anaesthetic	O	168-179
bupivacaine	O	180-191
(	O	192-193
1	O	193-194
.	O	194-195
5	O	195-196
or	O	197-199
2	O	200-201
mg	O	202-204
/	O	204-205
kg	O	205-207
,	O	207-208
i	O	209-210
.	O	210-211
v	O	211-212
.	O	210-211
)	O	213-214
to	O	215-217
rats	O	218-222
elicited	O	223-231
a	O	232-233
marked	O	234-240
decrease	B	241-249
of	I	250-252
mean	I	253-257
arterial	I	258-266
blood	I	267-272
pressure	I	273-281
(	I	282-283
MBP	I	283-286
)	I	286-287
and	I	288-291
heart	I	292-297
rate	I	298-302
(	I	303-304
HR	I	304-306
)	I	306-307
leading	O	308-315
to	O	316-318
death	O	319-324
(	O	325-326
in	O	326-328
67	O	329-331
%	O	331-332
or	O	333-335
90	O	336-338
%	O	338-339
of	O	340-342
animals	O	343-350
respectively	O	351-363
)	O	363-364
.	O	364-365

Intravenous	O	366-377
injection	O	378-387
of	O	388-390
the	O	391-394
specific	O	395-403
platelet	O	404-412
-	O	412-413
activating	O	413-423
factor	O	424-430
(	O	431-432
PAF	O	432-435
)	O	435-436
antagonist	O	437-447
BN	O	448-450
52021	O	451-456
(	O	457-458
10	O	458-460
mg	O	461-463
/	O	463-464
kg	O	464-466
)	O	466-467
,	O	467-468
30	O	469-471
min	O	472-475
before	O	476-482
bupivacaine	O	483-494
administration	O	495-509
(	O	510-511
2	O	511-512
mg	O	513-515
/	O	515-516
kg	O	516-518
i	O	519-520
.	O	520-521
v	O	521-522
.	O	520-521
)	O	523-524
suppressed	O	525-535
both	O	536-540
the	O	541-544
decrease	B	545-553
of	I	554-556
MBP	I	557-560
and	I	561-564
HR	I	565-567
.	O	567-568

In	O	569-571
contrast	O	572-580
,	O	580-581
doses	O	582-587
of	O	588-590
1	O	591-592
mg	O	593-595
/	O	595-596
kg	O	596-598
BN	O	599-601
52021	O	602-607
given	O	608-613
30	O	614-616
min	O	617-620
before	O	621-627
or	O	628-630
10	O	631-633
mg	O	634-636
/	O	636-637
kg	O	637-639
administered	O	640-652
5	O	653-654
min	O	655-658
before	O	659-665
i	O	666-667
.	O	667-668
v	O	668-669
.	O	667-668

injection	O	671-680
of	O	681-683
bupivacaine	O	684-695
were	O	696-700
ineffective	O	701-712
.	O	712-713

When	O	714-718
BN	O	719-721
52021	O	722-727
(	O	728-729
20	O	729-731
mg	O	732-734
/	O	734-735
kg	O	735-737
i	O	738-739
.	O	739-740
v	O	740-741
.	O	739-740
)	O	742-743
was	O	744-747
injected	O	748-756
immediately	O	757-768
after	O	769-774
bupivacaine	O	775-786
(	O	787-788
2	O	788-789
mg	O	790-792
/	O	792-793
kg	O	793-795
)	O	795-796
,	O	796-797
a	O	798-799
partial	O	800-807
reversion	O	808-817
of	O	818-820
the	O	821-824
decrease	B	825-833
of	I	834-836
MBP	I	837-840
and	I	841-844
HR	I	845-847
was	O	848-851
observed	O	852-860
,	O	860-861
whereas	O	862-869
the	O	870-873
dose	O	874-878
of	O	879-881
10	O	882-884
mg	O	885-887
/	O	887-888
kg	O	888-890
was	O	891-894
ineffective	O	895-906
.	O	906-907

A	O	908-909
partial	O	910-917
recovery	O	918-926
of	O	927-929
bupivacaine	O	930-941
-	O	941-942
induced	O	942-949
ECG	O	950-953
alterations	O	954-965
was	O	966-969
observed	O	970-978
after	O	979-984
pretreatment	O	985-997
of	O	998-1000
the	O	1001-1004
rats	O	1005-1009
with	O	1010-1014
BN	O	1015-1017
52021	O	1018-1023
.	O	1023-1024

Since	O	1025-1030
the	O	1031-1034
administration	O	1035-1049
of	O	1050-1052
BN	O	1053-1055
52021	O	1056-1061
,	O	1061-1062
at	O	1063-1065
all	O	1066-1069
doses	O	1070-1075
studied	O	1076-1083
,	O	1083-1084
did	O	1085-1088
not	O	1089-1092
alter	O	1093-1098
MBP	O	1099-1102
and	O	1103-1106
HR	O	1107-1109
at	O	1110-1112
the	O	1113-1116
doses	O	1117-1122
used	O	1123-1127
,	O	1127-1128
the	O	1129-1132
bulk	O	1133-1137
of	O	1138-1140
these	O	1141-1146
results	O	1147-1154
clearly	O	1155-1162
demonstrate	O	1163-1174
a	O	1175-1176
protective	O	1177-1187
action	O	1188-1194
of	O	1195-1197
BN	O	1198-1200
52021	O	1201-1206
,	O	1206-1207
a	O	1208-1209
specific	O	1210-1218
antagonist	O	1219-1229
of	O	1230-1232
PAF	O	1233-1236
,	O	1236-1237
against	O	1238-1245
bupivacaine	O	1246-1257
-	O	1257-1258
induced	O	1258-1265
cardiovascular	B	1266-1280
toxicity	I	1281-1289
.	O	1289-1290

Thus	O	1291-1295
,	O	1295-1296
consistent	O	1297-1307
with	O	1308-1312
its	O	1313-1316
direct	O	1317-1323
effect	O	1324-1330
on	O	1331-1333
heart	O	1334-1339
,	O	1339-1340
PAF	O	1341-1344
appears	O	1345-1352
to	O	1353-1355
be	O	1356-1358
implicated	O	1359-1369
in	O	1370-1372
bupivacaine	O	1373-1384
-	O	1384-1385
induced	O	1385-1392
cardiovascular	B	1393-1407
alterations	I	1408-1419
.	O	1419-1420

Benzylacyclouridine	O	0-19
reverses	O	20-28
azidothymidine	O	29-43
-	O	43-44
induced	O	44-51
marrow	B	52-58
suppression	I	59-70
without	O	71-78
impairment	O	79-89
of	O	90-92
anti	O	93-97
-	O	97-98
human	O	98-103
immunodeficiency	B	104-120
virus	O	121-126
activity	O	127-135
.	O	135-136

Increased	O	137-146
extracellular	O	147-160
concentrations	O	161-175
of	O	176-178
uridine	O	179-186
(	O	187-188
Urd	O	188-191
)	O	191-192
have	O	193-197
been	O	198-202
reported	O	203-211
to	O	212-214
reduce	O	215-221
,	O	221-222
in	O	223-225
vitro	O	226-231
,	O	231-232
azidothymidine	O	233-247
(	O	248-249
AZT	O	249-252
)	O	252-253
-	O	253-254
induced	O	254-261
inhibition	O	262-272
of	O	273-275
human	O	276-281
granulocyte	O	282-293
-	O	293-294
macrophage	O	294-304
progenitor	O	305-315
cells	O	316-321
without	O	322-329
impairment	O	330-340
of	O	341-343
its	O	344-347
antihuman	O	348-357
immunodeficiency	B	358-374
virus	O	375-380
(	O	381-382
HIV	O	382-385
)	O	385-386
activity	O	387-395
.	O	395-396

Because	O	397-404
of	O	405-407
the	O	408-411
clinical	O	412-420
toxicities	B	421-431
associated	O	432-442
with	O	443-447
chronic	O	448-455
Urd	O	456-459
administration	O	460-474
,	O	474-475
the	O	476-479
ability	O	480-487
of	O	488-490
benzylacyclouridine	O	491-510
(	O	511-512
BAU	O	512-515
)	O	515-516
to	O	517-519
effect	O	520-526
,	O	526-527
in	O	528-530
vivo	O	531-535
,	O	535-536
AZT	O	537-540
-	O	540-541
induced	O	541-548
anemia	B	549-555
and	O	556-559
leukopenia	B	560-570
was	O	571-574
assessed	O	575-583
.	O	583-584

This	O	585-589
agent	O	590-595
inhibits	O	596-604
Urd	O	605-608
catabolism	O	609-619
and	O	620-623
,	O	623-624
in	O	625-627
vivo	O	628-632
,	O	632-633
increases	O	634-643
the	O	644-647
plasma	O	648-654
concentration	O	655-668
of	O	669-671
Urd	O	672-675
in	O	676-678
a	O	679-680
dose	O	681-685
-	O	685-686
dependent	O	686-695
manner	O	696-702
,	O	702-703
without	O	704-711
Urd	O	712-715
-	O	715-716
related	O	716-723
toxicity	B	724-732
.	O	732-733

In	O	734-736
mice	O	737-741
rendered	O	742-750
anemic	B	751-757
and	O	758-761
leukopenic	B	762-772
by	O	773-775
the	O	776-779
administration	O	780-794
of	O	795-797
AZT	O	798-801
for	O	802-805
28	O	806-808
days	O	809-813
in	O	814-816
drinking	O	817-825
water	O	826-831
(	O	832-833
1	O	833-834
.	O	834-835
5	O	835-836
mg	O	837-839
/	O	839-840
mL	O	840-842
)	O	842-843
,	O	843-844
the	O	845-848
continued	O	849-858
administration	O	859-873
of	O	874-876
AZT	O	877-880
plus	O	881-885
daily	O	886-891
BAU	O	892-895
(	O	896-897
300	O	897-900
mg	O	901-903
/	O	903-904
kg	O	904-906
,	O	906-907
orally	O	908-914
)	O	914-915
partially	O	916-925
reversed	O	926-934
AZT	O	935-938
-	O	938-939
induced	O	939-946
anemia	B	947-953
and	O	954-957
leukopenia	B	958-968
(	O	969-970
P	O	970-971
less	O	972-976
than	O	977-981
.	O	982-983
05	O	983-985
)	O	985-986
,	O	986-987

increased	O	988-997
peripheral	O	998-1008
reticulocytes	O	1009-1022
(	O	1023-1024
to	O	1024-1026
4	O	1027-1028
.	O	1028-1029
9	O	1029-1030
%	O	1030-1031
,	O	1031-1032
P	O	1033-1034
less	O	1035-1039
than	O	1040-1044
.	O	1045-1046
01	O	1046-1048
)	O	1048-1049
,	O	1049-1050

increased	O	1051-1060
cellularity	O	1061-1072
in	O	1073-1075
the	O	1076-1079
marrow	O	1080-1086
,	O	1086-1087
and	O	1088-1091
improved	O	1092-1100
megaloblastosis	B	1101-1116
.	O	1116-1117

When	O	1118-1122
coadministered	O	1123-1137
with	O	1138-1142
AZT	O	1143-1146
from	O	1147-1151
the	O	1152-1155
onset	O	1156-1161
of	O	1162-1164
drug	O	1165-1169
administration	O	1170-1184
,	O	1184-1185
BAU	O	1186-1189
reduced	O	1190-1197
AZT	O	1198-1201
-	O	1201-1202
induced	O	1202-1209
marrow	B	1210-1216
toxicity	I	1217-1225
.	O	1225-1226

In	O	1227-1229
vitro	O	1230-1235
,	O	1235-1236
at	O	1237-1239
a	O	1240-1241
concentration	O	1242-1255
of	O	1256-1258
100	O	1259-1262
mumol	O	1263-1268
/	O	1268-1269
L	O	1269-1270
,	O	1270-1271
BAU	O	1272-1275
possesses	O	1276-1285
minimal	O	1286-1293
anti	O	1294-1298
-	O	1298-1299
HIV	O	1299-1302
activity	O	1303-1311
and	O	1312-1315
has	O	1316-1319
no	O	1320-1322
effect	O	1323-1329
on	O	1330-1332
the	O	1333-1336
ability	O	1337-1344
of	O	1345-1347
AZT	O	1348-1351
to	O	1352-1354
reverse	O	1355-1362
the	O	1363-1366
HIV	O	1367-1370
-	O	1370-1371
induced	O	1371-1378
cytopathic	O	1379-1389
effect	O	1390-1396
in	O	1397-1399
MT4	O	1400-1403
cells	O	1404-1409
.	O	1409-1410

The	O	1411-1414
clinical	O	1415-1423
and	O	1424-1427
biochemical	O	1428-1439
implications	O	1440-1452
of	O	1453-1455
these	O	1456-1461
findings	O	1462-1470
are	O	1471-1474
discussed	O	1475-1484
.	O	1484-1485

Cyclophosphamide	O	0-16
-	O	16-17
induced	O	17-24
cystitis	B	25-33
in	O	34-36
freely	O	37-43
-	O	43-44
moving	O	44-50
conscious	O	51-60
rats	O	61-65
:	O	65-66
behavioral	O	67-77
approach	O	78-86
to	O	87-89
a	O	90-91
new	O	92-95
model	O	96-101
of	O	102-104
visceral	B	105-113
pain	I	114-118
.	O	118-119

PURPOSE	O	120-127
:	O	127-128
To	O	129-131
develop	O	132-139
a	O	140-141
model	O	142-147
of	O	148-150
visceral	B	151-159
pain	I	160-164
in	O	165-167
rats	O	168-172
using	O	173-178
a	O	179-180
behavioral	O	181-191
approach	O	192-200
.	O	200-201

Cyclophosphamide	O	202-218
(	O	219-220
CP	O	220-222
)	O	222-223
,	O	223-224
an	O	225-227
antitumoral	O	228-239
agent	O	240-245
known	O	246-251
to	O	252-254
produce	O	255-262
toxic	O	263-268
effects	O	269-276
on	O	277-279
the	O	280-283
bladder	O	284-291
wall	O	292-296
through	O	297-304
its	O	305-308
main	O	309-313
toxic	O	314-319
metabolite	O	320-330
acrolein	O	331-339
,	O	339-340
was	O	341-344
used	O	345-349
to	O	350-352
induce	O	353-359
cystitis	B	360-368
.	O	368-369

MATERIALS	O	370-379
AND	O	380-383
METHODS	O	384-391
:	O	391-392
CP	O	393-395
was	O	396-399
administered	O	400-412
at	O	413-415
doses	O	416-421
of	O	422-424
50	O	425-427
,	O	427-428
100	O	429-432
and	O	433-436
200	O	437-440
mg	O	441-443
.	O	443-444
/	O	444-445
kg	O	445-447
.	O	443-444

i	O	449-450
.	O	450-451
p	O	451-452
.	O	450-451
to	O	454-456
male	O	457-461
rats	O	462-466
,	O	466-467
and	O	468-471
their	O	472-477
behavior	O	478-486
observed	O	487-495
and	O	496-499
scored	O	500-506
.	O	506-507

The	O	508-511
effects	O	512-519
of	O	520-522
morphine	O	523-531
(	O	532-533
0	O	533-534
.	O	534-535
5	O	535-536
to	O	537-539
4	O	540-541
mg	O	542-544
.	O	544-545
/	O	545-546
kg	O	546-548
.	O	544-545

i	O	550-551
.	O	551-552
v	O	552-553
.	O	551-552
)	O	554-555
on	O	556-558
CP	O	559-561
-	O	561-562
induced	O	562-569
behavioral	O	570-580
modifications	O	581-594
were	O	595-599
tested	O	600-606
administered	O	607-619
alone	O	620-625
and	O	626-629
after	O	630-635
naloxone	O	636-644
(	O	645-646
1	O	646-647
mg	O	648-650
.	O	650-651
/	O	651-652
kg	O	652-654
.	O	650-651

s	O	656-657
.	O	657-658
c	O	658-659
.	O	657-658
)	O	660-661
.	O	657-658

In	O	663-665
addition	O	666-674
,	O	674-675
90	O	676-678
minutes	O	679-686
after	O	687-692
CP	O	693-695
injection	O	696-705
,	O	705-706
that	O	707-711
is	O	712-714
,	O	714-715
at	O	716-718
the	O	719-722
time	O	723-727
of	O	728-730
administration	O	731-745
of	O	746-748
morphine	O	749-757
,	O	757-758
the	O	759-762
bladder	O	763-770
was	O	771-774
removed	O	775-782
in	O	783-785
some	O	786-790
rats	O	791-795
for	O	796-799
histological	O	800-812
examination	O	813-824
.	O	824-825

Finally	O	826-833
,	O	833-834
to	O	835-837
show	O	838-842
that	O	843-847
the	O	848-851
bladder	O	852-859
is	O	860-862
essential	O	863-872
for	O	873-876
the	O	877-880
CP	O	881-883
-	O	883-884
induced	O	884-891
behavioral	O	892-902
modifications	O	903-916
,	O	916-917
female	O	918-924
rats	O	925-929
also	O	930-934
received	O	935-943
CP	O	944-946
at	O	947-949
doses	O	950-955
of	O	956-958
200	O	959-962
mg	O	963-965
.	O	965-966
/	O	966-967
kg	O	967-969
.	O	965-966

i	O	971-972
.	O	972-973
p	O	973-974
.	O	972-973
and	O	976-979
of	O	980-982
20	O	983-985
mg	O	986-988
.	O	988-989
by	O	990-992
the	O	993-996
intravesical	O	997-1009
route	O	1010-1015
,	O	1015-1016
and	O	1017-1020
acrolein	O	1021-1029
at	O	1030-1032
doses	O	1033-1038
of	O	1039-1041
0	O	1042-1043
.	O	1043-1044
5	O	1044-1045
mg	O	1046-1048
.	O	1048-1049
by	O	1050-1052
the	O	1053-1056
intravesical	O	1057-1069
route	O	1070-1075
and	O	1076-1079
of	O	1080-1082
5	O	1083-1084
mg	O	1085-1087
.	O	1087-1088
/	O	1088-1089
kg	O	1089-1091
.	O	1087-1088

i	O	1093-1094
.	O	1094-1095
v	O	1095-1096
.	O	1094-1095

RESULTS	O	1098-1105
:	O	1105-1106
CP	O	1107-1109
dose	O	1110-1114
-	O	1114-1115
relatedly	O	1115-1124
induced	O	1125-1132
marked	O	1133-1139
behavioral	O	1140-1150
modifications	O	1151-1164
in	O	1165-1167
male	O	1168-1172
rats	O	1173-1177
:	O	1177-1178
breathing	O	1179-1188
rate	O	1189-1193
decrease	O	1194-1202
,	O	1202-1203
closing	O	1204-1211
of	O	1212-1214
the	O	1215-1218
eyes	O	1219-1223
and	O	1224-1227
occurrence	O	1228-1238
of	O	1239-1241
specific	O	1242-1250
postures	O	1251-1259
.	O	1259-1260

Morphine	O	1261-1269
dose	O	1270-1274
-	O	1274-1275
dependently	O	1275-1286
reversed	O	1287-1295
these	O	1296-1301
behavioral	B	1302-1312
disorders	I	1313-1322
.	O	1322-1323

A	O	1324-1325
dose	O	1326-1330
of	O	1331-1333
0	O	1334-1335
.	O	1335-1336
5	O	1336-1337
mg	O	1338-1340
.	O	1340-1341
/	O	1341-1342
kg	O	1342-1344
.	O	1340-1341

produced	O	1346-1354
a	O	1355-1356
reduction	O	1357-1366
of	O	1367-1369
almost	O	1370-1376
50	O	1377-1379
%	O	1379-1380
of	O	1381-1383
the	O	1384-1387
behavioral	O	1388-1398
score	O	1399-1404
induced	O	1405-1412
by	O	1413-1415
CP	O	1416-1418
200	O	1419-1422
mg	O	1423-1425
.	O	1425-1426
/	O	1426-1427
kg	O	1427-1429
.	O	1425-1426

This	O	1431-1435
effect	O	1436-1442
was	O	1443-1446
completely	O	1447-1457
prevented	O	1458-1467
by	O	1468-1470
pretreatment	O	1471-1483
with	O	1484-1488
naloxone	O	1489-1497
.	O	1497-1498

At	O	1499-1501
the	O	1502-1505
time	O	1506-1510
of	O	1511-1513
administration	O	1514-1528
of	O	1529-1531
morphine	O	1532-1540
,	O	1540-1541
histological	O	1542-1554
modifications	O	1555-1568
of	O	1569-1571
the	O	1572-1575
bladder	O	1576-1583
wall	O	1584-1588
,	O	1588-1589
such	O	1590-1594
as	O	1595-1597
chorionic	O	1598-1607
and	O	1608-1611
muscle	O	1612-1618
layer	O	1619-1624
edema	B	1625-1630
,	O	1630-1631
were	O	1632-1636
observed	O	1637-1645
.	O	1645-1646

In	O	1647-1649
female	O	1650-1656
rats	O	1657-1661
,	O	1661-1662
CP	O	1663-1665
200	O	1666-1669
mg	O	1670-1672
.	O	1672-1673
/	O	1673-1674
kg	O	1674-1676
.	O	1672-1673

i	O	1678-1679
.	O	1679-1680
p	O	1680-1681
.	O	1679-1680
produced	O	1683-1691
the	O	1692-1695
same	O	1696-1700
marked	O	1701-1707
behavioral	O	1708-1718
modifications	O	1719-1732
as	O	1733-1735
those	O	1736-1741
observed	O	1742-1750
in	O	1751-1753
male	O	1754-1758
rats	O	1759-1763
.	O	1763-1764

Administered	O	1765-1777
at	O	1778-1780
the	O	1781-1784
dose	O	1785-1789
of	O	1790-1792
20	O	1793-1795
mg	O	1796-1798
.	O	1798-1799

intravesically	O	1800-1814
,	O	1814-1815
CP	O	1816-1818
did	O	1819-1822
not	O	1823-1826
produce	O	1827-1834
any	O	1835-1838
behavioral	O	1839-1849
effects	O	1850-1857
,	O	1857-1858
whereas	O	1859-1866
acrolein	O	1867-1875
at	O	1876-1878
0	O	1879-1880
.	O	1880-1881
5	O	1881-1882
mg	O	1883-1885
.	O	1885-1886

intravesically	O	1887-1901
induced	O	1902-1909
behavioral	O	1910-1920
modifications	O	1921-1934
identical	O	1935-1944
to	O	1945-1947
those	O	1948-1953
under	O	1954-1959
CP	O	1960-1962
200	O	1963-1966
mg	O	1967-1969
.	O	1969-1970
/	O	1970-1971
kg	O	1971-1973
.	O	1969-1970

i	O	1975-1976
.	O	1976-1977
p	O	1977-1978
.	O	1976-1977
,	O	1979-1980
with	O	1981-1985
the	O	1986-1989
same	O	1990-1994
maximal	O	1995-2002
levels	O	2003-2009
.	O	2009-2010

Conversely	O	2011-2021
,	O	2021-2022
acrolein	O	2023-2031
5	O	2032-2033
mg	O	2034-2036
.	O	2036-2037
/	O	2037-2038
kg	O	2038-2040
.	O	2036-2037

i	O	2042-2043
.	O	2043-2044
v	O	2044-2045
.	O	2043-2044
did	O	2047-2050
not	O	2051-2054
produce	O	2055-2062
any	O	2063-2066
behavioral	O	2067-2077
effects	O	2078-2085
at	O	2086-2088
all	O	2089-2092
.	O	2092-2093

CONCLUSIONS	O	2094-2105
:	O	2105-2106
Overall	O	2107-2114
,	O	2114-2115
these	O	2116-2121
results	O	2122-2129
indicate	O	2130-2138
that	O	2139-2143
this	O	2144-2148
experimental	O	2149-2161
model	O	2162-2167
of	O	2168-2170
CP	O	2171-2173
-	O	2173-2174
induced	O	2174-2181
cystitis	B	2182-2190
may	O	2191-2194
be	O	2195-2197
an	O	2198-2200
interesting	O	2201-2212
new	O	2213-2216
behavioral	O	2217-2227
model	O	2228-2233
of	O	2234-2236
inflammatory	O	2237-2249
visceral	B	2250-2258
pain	I	2259-2263
,	O	2263-2264
allowing	O	2265-2273
a	O	2274-2275
better	O	2276-2282
understanding	O	2283-2296
of	O	2297-2299
these	O	2300-2305
painful	B	2306-2313
syndromes	I	2314-2323
and	O	2324-2327
thus	O	2328-2332
a	O	2333-2334
better	O	2335-2341
therapeutic	O	2342-2353
approach	O	2354-2362
to	O	2363-2365
them	O	2366-2370
.	O	2370-2371

Hyperalgesia	B	0-12
and	O	13-16
myoclonus	B	17-26
in	O	27-29
terminal	O	30-38
cancer	B	39-45
patients	O	46-54
treated	O	55-62
with	O	63-67
continuous	O	68-78
intravenous	O	79-90
morphine	O	91-99
.	O	99-100

Eight	O	101-106
cancer	B	107-113
patients	O	114-122
in	O	123-125
the	O	126-129
terminal	O	130-138
stages	O	139-145
of	O	146-148
the	O	149-152
disease	O	153-160
treated	O	161-168
with	O	169-173
high	O	174-178
doses	O	179-184
of	O	185-187
intravenous	O	188-199
morphine	O	200-208
developed	O	209-218
hyperalgesia	B	219-231
.	O	231-232

All	O	233-236
cases	O	237-242
were	O	243-247
retrospectively	O	248-263
sampled	O	264-271
from	O	272-276
three	O	277-282
different	O	283-292
hospitals	O	293-302
in	O	303-305
Copenhagen	O	306-316
.	O	316-317

Five	O	318-322
patients	O	323-331
developed	O	332-341
universal	O	342-351
hyperalgesia	B	352-364
and	O	365-368
hyperesthesia	B	369-382
which	O	383-388
in	O	389-391
2	O	392-393
cases	O	394-399
were	O	400-404
accompanied	O	405-416
by	O	417-419
myoclonus	B	420-429
.	O	429-430

In	O	431-433
3	O	434-435
patients	O	436-444
a	O	445-446
pre	O	447-450
-	O	450-451
existing	O	451-459
neuralgia	B	460-469
increased	O	470-479
to	O	480-482
excruciating	O	483-495
intensity	O	496-505
and	O	506-509
in	O	510-512
2	O	513-514
of	O	515-517
these	O	518-523
cases	O	524-529
myoclonus	B	530-539
occurred	O	540-548
simultaneously	O	549-563
.	O	563-564

Although	O	565-573
only	O	574-578
few	O	579-582
clinical	O	583-591
descriptions	O	592-604
of	O	605-607
the	O	608-611
relationship	O	612-624
between	O	625-632
hyperalgesia	B	633-645
/	O	645-646
myoclonus	B	646-655
and	O	656-659
high	O	660-664
doses	O	665-670
of	O	671-673
morphine	O	674-682
are	O	683-686
available	O	687-696
,	O	696-697
experimental	O	698-710
support	O	711-718
from	O	719-723
animal	O	724-730
studies	O	731-738
indicates	O	739-748
that	O	749-753
morphine	O	754-762
,	O	762-763
or	O	764-766
its	O	767-770
metabolites	O	771-782
,	O	782-783
plays	O	784-789
a	O	790-791
causative	O	792-801
role	O	802-806
for	O	807-810
the	O	811-814
observed	O	815-823
behavioural	O	824-835
syndrome	O	836-844
.	O	844-845

The	O	846-849
possible	O	850-858
mechanisms	O	859-869
are	O	870-873
discussed	O	874-883
and	O	884-887
treatment	O	888-897
proposals	O	898-907
given	O	908-913
suggesting	O	914-924
the	O	925-928
use	O	929-932
of	O	933-935
more	O	936-940
efficacious	O	941-952
opioids	O	953-960
with	O	961-965
less	O	966-970
excitatory	O	971-981
potency	O	982-989
in	O	990-992
these	O	993-998
situations	O	999-1009
.	O	1009-1010

A	O	0-1
prospective	O	2-13
study	O	14-19
of	O	20-22
adverse	O	23-30
reactions	O	31-40
associated	O	41-51
with	O	52-56
vancomycin	O	57-67
therapy	O	68-75
.	O	75-76

A	O	77-78
prospective	O	79-90
evaluation	O	91-101
of	O	102-104
the	O	105-108
efficacy	O	109-117
and	O	118-121
safety	O	122-128
of	O	129-131
vancomycin	O	132-142
was	O	143-146
conducted	O	147-156
in	O	157-159
54	O	160-162
consecutive	O	163-174
patients	O	175-183
over	O	184-188
a	O	189-190
16	O	191-193
-	O	193-194
month	O	194-199
period	O	200-206
.	O	206-207

Vancomycin	O	208-218
was	O	219-222
curative	O	223-231
in	O	232-234
95	O	235-237
%	O	237-238
of	O	239-241
43	O	242-244
patients	O	245-253
with	O	254-258
proven	O	259-265
infection	B	266-275
.	O	275-276

Drugs	O	277-282
were	O	283-287
ceased	O	288-294
in	O	295-297
six	O	298-301
patients	O	302-310
because	O	311-318
of	O	319-321
adverse	O	322-329
reactions	O	330-339
;	O	339-340
in	O	341-343
three	O	344-349
of	O	350-352
these	O	353-358
vancomycin	O	359-369
was	O	370-373
considered	O	374-384
the	O	385-388
likely	O	389-395
cause	O	396-401
.	O	401-402

Reactions	O	403-412
included	O	413-421
thrombophlebitis	B	422-438
(	O	439-440
20	O	440-442
of	O	443-445
54	O	446-448
patients	O	449-457
)	O	457-458
,	O	458-459
rash	B	460-464
(	O	465-466
4	O	466-467
of	O	468-470
54	O	471-473
)	O	473-474
,	O	474-475
nephrotoxicity	B	476-490
(	O	491-492
4	O	492-493
of	O	494-496
50	O	497-499
)	O	499-500
,	O	500-501
proteinuria	B	502-513
(	O	514-515
1	O	515-516
of	O	517-519
50	O	520-522
)	O	522-523
and	O	524-527
ototoxicity	B	528-539
(	O	540-541
1	O	541-542
of	O	543-545
11	O	546-548
patients	O	549-557
tested	O	558-564
by	O	565-567
audiometry	O	568-578
)	O	578-579
.	O	579-580

Thrombophlebitis	B	581-597
occurred	O	598-606
only	O	607-611
with	O	612-616
infusion	O	617-625
through	O	626-633
peripheral	O	634-644
cannulae	O	645-653
;	O	653-654
nephrotoxicity	B	655-669
and	O	670-673
ototoxicity	B	674-685
were	O	686-690
confined	O	691-699
to	O	700-702
patients	O	703-711
receiving	O	712-721
an	O	722-724
aminoglycoside	O	725-739
plus	O	740-744
vancomycin	O	745-755
.	O	755-756

We	O	757-759
conclude	O	760-768
that	O	769-773
vancomycin	O	774-784
,	O	784-785
administered	O	786-798
appropriately	O	799-812
,	O	812-813
constitutes	O	814-825
safe	O	826-830
,	O	830-831
effective	O	832-841
therapy	O	842-849
for	O	850-853
infections	B	854-864
caused	O	865-871
by	O	872-874
susceptible	O	875-886
bacteria	O	887-895
.	O	895-896

Blockade	O	0-8
of	O	9-11
both	O	12-16
D	O	17-18
-	O	18-19
1	O	19-20
and	O	21-24
D	O	25-26
-	O	26-27
2	O	27-28
dopamine	O	29-37
receptors	O	38-47
may	O	48-51
induce	O	52-58
catalepsy	B	59-68
in	O	69-71
mice	O	72-76
.	O	76-77
1	O	78-79
.	O	79-80

The	O	81-84
catalepsy	B	85-94
induced	O	95-102
by	O	103-105
dopamine	O	106-114
antagonists	O	115-126
has	O	127-130
been	O	131-135
tested	O	136-142
and	O	143-146
the	O	147-150
possible	O	151-159
dopamine	O	160-168
subtypes	O	169-177
involved	O	178-186
in	O	187-189
catalepsy	B	190-199
was	O	200-203
determined	O	204-214
.	O	214-215

2	O	216-217
.	O	217-218
Dopamine	O	219-227
antagonist	O	228-238
fluphenazine	O	239-251
,	O	251-252
D	O	253-254
-	O	254-255
1	O	255-256
antagonist	O	257-267
SCH	O	268-271
23390	O	272-277
or	O	278-280
D	O	281-282
-	O	282-283
2	O	283-284
antagonist	O	285-295
sulpiride	O	296-305
induced	O	306-313
catalepsy	B	314-323
.	O	323-324

The	O	325-328
effect	O	329-335
of	O	336-338
fluphenazine	O	339-351
and	O	352-355
sulpiride	O	356-365
was	O	366-369
dose	O	370-374
-	O	374-375
dependent	O	375-384
.	O	384-385

Combination	O	386-397
of	O	398-400
SCH	O	401-404
23390	O	405-410
with	O	411-415
sulpiride	O	416-425
did	O	426-429
not	O	430-433
induce	O	434-440
catalepsy	B	441-450
potentiation	O	451-463
.	O	463-464

3	O	465-466
.	O	466-467
D	O	468-469
-	O	469-470
1	O	470-471
agonist	O	472-479
SKF	O	480-483
38393	O	484-489
or	O	490-492
D	O	493-494
-	O	494-495
2	O	495-496
agonist	O	497-504
quinpirole	O	505-515
decreased	O	516-525
the	O	526-529
catalepsy	B	530-539
induced	O	540-547
by	O	548-550
fluphenazine	O	551-563
,	O	563-564
SCH	O	565-568
23390	O	569-574
or	O	575-577
sulpiride	O	578-587
.	O	587-588

4	O	589-590
.	O	590-591
Combination	O	592-603
of	O	604-606
SKF	O	607-610
38393	O	611-616
with	O	617-621
quinpirole	O	622-632
did	O	633-636
not	O	637-640
cause	O	641-646
potentiated	O	647-658
inhibitory	O	659-669
effect	O	670-676
on	O	677-679
catalepsy	B	680-689
induced	O	690-697
by	O	698-700
dopamine	O	701-709
antagonists	O	710-721
.	O	721-722

5	O	723-724
.	O	724-725

The	O	726-729
data	O	730-734
may	O	735-738
indicate	O	739-747
that	O	748-752
although	O	753-761
D	O	762-763
-	O	763-764
2	O	764-765
receptor	O	766-774
blockade	O	775-783
is	O	784-786
involved	O	787-795
in	O	796-798
catalepsy	B	799-808
,	O	808-809
the	O	810-813
D	O	814-815
-	O	815-816
1	O	816-817
receptor	O	818-826
may	O	827-830
plan	O	831-835
a	O	836-837
role	O	838-842
.	O	842-843

Dextran	O	0-7
-	O	7-8
etodolac	O	8-16
conjugates	O	17-27
:	O	27-28
synthesis	O	29-38
,	O	38-39
in	O	40-42
vitro	O	43-48
and	O	49-52
in	O	53-55
vivo	O	56-60
evaluation	O	61-71
.	O	71-72

Etodolac	O	73-81
(	O	82-83
E	O	83-84
)	O	84-85
,	O	85-86
is	O	87-89
a	O	90-91
non	O	92-95
-	O	95-96
narcotic	O	96-104
analgesic	O	105-114
and	O	115-118
antiinflammatory	O	119-135
drug	O	136-140
.	O	140-141

A	O	142-143
biodegradable	O	144-157
polymer	O	158-165
dextran	O	166-173
has	O	174-177
been	O	178-182
utilized	O	183-191
as	O	192-194
a	O	195-196
carrier	O	197-204
for	O	205-208
synthesis	O	209-218
of	O	219-221
etodolac	O	222-230
-	O	230-231
dextran	O	231-238
conjugates	O	239-249
(	O	250-251
ED	O	251-253
)	O	253-254
to	O	255-257
improve	O	258-265
its	O	266-269
aqueous	O	270-277
solubility	O	278-288
and	O	289-292
reduce	O	293-299
gastrointestinal	O	300-316
side	O	317-321
effects	O	322-329
.	O	329-330

An	O	331-333
activated	O	334-343
moiety	O	344-350
,	O	350-351
i	O	352-353
.	O	353-354
e	O	354-355
.	O	353-354

N	O	357-358
-	O	358-359
acylimidazole	O	359-372
derivative	O	373-383
of	O	384-386
etodolac	O	387-395
(	O	396-397
EAI	O	397-400
)	O	400-401
,	O	401-402
was	O	403-406
condensed	O	407-416
with	O	417-421
the	O	422-425
polysaccharide	O	426-440
polymer	O	441-448
dextran	O	449-456
of	O	457-459
different	O	460-469
molecular	O	470-479
weights	O	480-487
(	O	488-489
40000	O	489-494
,	O	494-495
60000	O	496-501
,	O	501-502
110000	O	503-509
and	O	510-513
200000	O	514-520
)	O	520-521
.	O	521-522

IR	O	523-525
spectral	O	526-534
data	O	535-539
confirmed	O	540-549
formation	O	550-559
of	O	560-562
ester	O	563-568
bonding	O	569-576
in	O	577-579
the	O	580-583
conjugates	O	584-594
.	O	594-595

Etodolac	O	596-604
contents	O	605-613
were	O	614-618
evaluated	O	619-628
by	O	629-631
UV	O	632-634
-	O	634-635
spectrophotometric	O	635-653
analysis	O	654-662
.	O	662-663

The	O	664-667
molecular	O	668-677
weights	O	678-685
were	O	686-690
determined	O	691-701
by	O	702-704
measuring	O	705-714
viscosity	O	715-724
using	O	725-730
the	O	731-734
Mark	O	735-739
-	O	739-740
Howink	O	740-746
-	O	739-740
Sakurada	O	747-755
equation	O	756-764
.	O	764-765

In	O	766-768
vitro	O	769-774
hydrolysis	O	775-785
of	O	786-788
ED	O	789-791
was	O	792-795
done	O	796-800
in	O	801-803
aqueous	O	804-811
buffers	O	812-819
(	O	820-821
pH	O	821-823
1	O	824-825
.	O	825-826
2	O	826-827
,	O	827-828
7	O	829-830
.	O	830-831
4	O	831-832
,	O	832-833
9	O	834-835
)	O	835-836
and	O	837-840
in	O	841-843
80	O	844-846
%	O	846-847
(	O	848-849
v	O	849-850
/	O	850-851
v	O	849-850
)	O	852-853
human	O	854-859
plasma	O	860-866
(	O	867-868
pH	O	868-870
7	O	871-872
.	O	872-873
4	O	873-874
)	O	874-875
.	O	872-873

At	O	877-879
pH	O	880-882
9	O	883-884
,	O	884-885
a	O	886-887
higher	O	888-894
rate	O	895-899
of	O	900-902
etodolac	O	903-911
release	O	912-919
from	O	920-924
ED	O	925-927
was	O	928-931
observed	O	932-940
as	O	941-943
compared	O	944-952
to	O	953-955
aqueous	O	956-963
buffer	O	964-970
of	O	971-973
pH	O	974-976
7	O	977-978
.	O	978-979
4	O	979-980
and	O	981-984
80	O	985-987
%	O	987-988
human	O	989-994
plasma	O	995-1001
(	O	1002-1003
pH	O	1003-1005
7	O	1006-1007
.	O	1007-1008
4	O	1008-1009
)	O	1009-1010
,	O	1010-1011
following	O	1012-1021
first	O	1022-1027
-	O	1027-1028
order	O	1028-1033
kinetics	O	1034-1042
.	O	1042-1043

In	O	1044-1046
vivo	O	1047-1051
investigations	O	1052-1066
were	O	1067-1071
performed	O	1072-1081
in	O	1082-1084
animals	O	1085-1092
.	O	1092-1093

Acute	O	1094-1099
analgesic	O	1100-1109
and	O	1110-1113
antiinflammatory	O	1114-1130
activities	O	1131-1141
were	O	1142-1146
ascertained	O	1147-1158
using	O	1159-1164
acetic	O	1165-1171
acid	O	1172-1176
induced	O	1177-1184
writhing	B	1185-1193
model	O	1194-1199
(	O	1200-1201
mice	O	1201-1205
)	O	1205-1206
and	O	1207-1210
carrageenan	O	1211-1222
-	O	1222-1223
induced	O	1223-1230
rat	O	1231-1234
paw	O	1235-1238
edema	B	1239-1244
model	O	1245-1250
,	O	1250-1251
respectively	O	1252-1264
.	O	1264-1265

In	O	1266-1268
comparison	O	1269-1279
to	O	1280-1282
control	O	1283-1290
,	O	1290-1291
E	O	1292-1293
and	O	1294-1297
ED1	O	1298-1301
-	O	1301-1302
ED4	O	1302-1305
showed	O	1306-1312
highly	O	1313-1319
significant	O	1320-1331
analgesic	O	1332-1341
and	O	1342-1345
antiinflammatory	O	1346-1362
activities	O	1363-1373
(	O	1374-1375
p	O	1375-1376
<	O	1377-1378
0	O	1378-1379
.	O	1379-1380
001	O	1380-1383
)	O	1383-1384
.	O	1379-1380

Biological	O	1386-1396
evaluation	O	1397-1407
suggested	O	1408-1417
that	O	1418-1422
conjugates	O	1423-1433
(	O	1434-1435
ED1	O	1435-1438
-	O	1438-1439
ED4	O	1439-1442
)	O	1442-1443
retained	O	1444-1452
comparable	O	1453-1463
analgesic	O	1464-1473
and	O	1474-1477
antiinflammatory	O	1478-1494
activities	O	1495-1505
with	O	1506-1510
remarkably	O	1511-1521
reduced	O	1522-1529
ulcerogenicity	O	1530-1544
as	O	1545-1547
compared	O	1548-1556
to	O	1557-1559
their	O	1560-1565
parent	O	1566-1572
drug	O	1573-1577
-	O	1577-1578
-	O	1577-1578
etodolac	O	1579-1587
.	O	1587-1588

Hypersensitivity	B	0-16
myocarditis	B	17-28
complicating	O	29-41
hypertrophic	B	42-54
cardiomyopathy	I	55-69
heart	O	70-75
.	O	75-76

The	O	77-80
present	O	81-88
report	O	89-95
describes	O	96-105
a	O	106-107
case	O	108-112
of	O	113-115
eosinophilic	B	116-128
myocarditis	I	129-140
complicating	O	141-153
hypertrophic	B	154-166
cardiomyopathy	I	167-181
.	O	181-182

The	O	183-186
47	O	187-189
-	O	189-190
year	O	190-194
-	O	189-190
old	O	195-198
female	O	199-205
patient	O	206-213
,	O	213-214
known	O	215-220
to	O	221-223
have	O	224-228
hypertrophic	B	229-241
cardiomyopathy	I	242-256
,	O	256-257
was	O	258-261
admitted	O	262-270
with	O	271-275
biventricular	B	276-289
failure	I	290-297
and	O	298-301
managed	O	302-309
aggressively	O	310-322
with	O	323-327
dobutamine	O	328-338
infusion	O	339-347
and	O	348-351
other	O	352-357
drugs	O	358-363
while	O	364-369
being	O	370-375
assessed	O	376-384
for	O	385-388
heart	O	389-394
transplantation	O	395-410
.	O	410-411

On	O	412-414
transthoracic	O	415-428
echocardiogram	O	429-443
,	O	443-444
she	O	445-448
had	O	449-452
moderate	O	453-461
left	B	462-466
ventricular	I	467-478
dysfunction	I	479-490
with	O	491-495
regional	O	496-504
variability	O	505-516
and	O	517-520
moderate	O	521-529
mitral	B	530-536
regurgitation	I	537-550
.	O	550-551

The	O	552-555
recipient	O	556-565
'	O	565-566
s	O	566-567
heart	O	568-573
showed	O	574-580
the	O	581-584
features	O	585-593
of	O	594-596
apical	O	597-603
hypertrophic	B	604-616
cardiomyopathy	I	617-631
and	O	632-635
myocarditis	B	636-647
with	O	648-652
abundant	O	653-661
eosinophils	O	662-673
.	O	673-674

Myocarditis	B	675-686
is	O	687-689
rare	O	690-694
and	O	695-698
eosinophilic	B	699-711
myocarditis	I	712-723
is	O	724-726
rarer	O	727-732
.	O	732-733

It	O	734-736
is	O	737-739
likely	O	740-746
that	O	747-751
the	O	752-755
hypersensitivity	B	756-772
(	O	773-774
eosinophilic	B	774-786
)	O	786-787
myocarditis	B	788-799
was	O	800-803
related	O	804-811
to	O	812-814
dobutamine	O	815-825
infusion	O	826-834
therapy	O	835-842
.	O	842-843

Eosinophilic	B	844-856
myocarditis	I	857-868
has	O	869-872
been	O	873-877
reported	O	878-886
with	O	887-891
an	O	892-894
incidence	O	895-904
of	O	905-907
2	O	908-909
.	O	909-910
4	O	910-911
%	O	911-912
to	O	913-915
7	O	916-917
.	O	917-918
2	O	918-919
%	O	919-920
in	O	921-923
explanted	O	924-933
hearts	O	934-940
and	O	941-944
may	O	945-948
be	O	949-951
related	O	952-959
to	O	960-962
multidrug	O	963-972
therapy	O	973-980
.	O	980-981

All	O	0-3
-	O	3-4
trans	O	5-10
-	O	10-11
retinoic	O	11-19
acid	O	20-24
-	O	24-25
induced	O	25-32
erythema	B	33-41
nodosum	I	42-49
in	O	50-52
patients	O	53-61
with	O	62-66
acute	B	67-72
promyelocytic	I	73-86
leukemia	I	87-95
.	O	95-96

Erythema	B	97-105
nodosum	I	106-113
associated	O	114-124
with	O	125-129
all	O	130-133
-	O	133-134
trans	O	135-140
-	O	140-141
retinoic	O	141-149
acid	O	150-154
(	O	155-156
ATRA	O	156-160
)	O	160-161
for	O	162-165
acute	B	166-171
promyelocytic	I	172-185
leukemia	I	186-194
(	O	195-196
APL	B	196-199
)	O	199-200
is	O	201-203
very	O	204-208
rare	O	209-213
.	O	213-214

We	O	215-217
describe	O	218-226
four	O	227-231
patients	O	232-240
with	O	241-245
classic	O	246-253
APL	B	254-257
who	O	258-261
developed	O	262-271
erythema	B	272-280
nodosum	I	281-288
during	O	289-295
ATRA	O	296-300
therapy	O	301-308
.	O	308-309

Fever	B	310-315
and	O	316-319
subsequent	O	320-330
multiple	O	331-339
painful	B	340-347
erythematous	B	348-360
nodules	I	361-368
over	O	369-373
extremities	O	374-385
developed	O	386-395
on	O	396-398
D11	O	399-402
,	O	402-403
D16	O	404-407
,	O	407-408
D17	O	409-412
,	O	412-413
and	O	414-417
D19	O	418-421
,	O	421-422
respectively	O	423-435
,	O	435-436
after	O	437-442
ATRA	O	443-447
therapy	O	448-455
.	O	455-456

The	O	457-460
skin	O	461-465
biopsy	O	466-472
taken	O	473-478
from	O	479-483
each	O	484-488
patient	O	489-496
was	O	497-500
consistent	O	501-511
with	O	512-516
erythema	B	517-525
nodosum	I	526-533
.	O	533-534

All	O	535-538
patients	O	539-547
received	O	548-556
short	O	557-562
course	O	563-569
of	O	570-572
steroids	O	573-581
.	O	581-582

Fever	B	583-588
subsided	O	589-597
rapidly	O	598-605
and	O	606-609
the	O	610-613
skin	O	614-618
lesions	O	619-626
regressed	O	627-636
completely	O	637-647
.	O	647-648

All	O	649-652
patients	O	653-661
achieved	O	662-670
complete	O	671-679
remission	O	680-689
without	O	690-697
withdrawal	O	698-708
of	O	709-711
ATRA	O	712-716
.	O	716-717

ATRA	O	718-722
seemed	O	723-729
to	O	730-732
be	O	733-735
the	O	736-739
most	O	740-744
possible	O	745-753
etiology	O	754-762
of	O	763-765
erythema	B	766-774
nodosum	I	775-782
in	O	783-785
our	O	786-789
patients	O	790-798
.	O	798-799

Short	O	800-805
-	O	805-806
term	O	806-810
use	O	811-814
of	O	815-817
steroid	O	818-825
is	O	826-828
very	O	829-833
effective	O	834-843
in	O	844-846
ATRA	O	847-851
-	O	851-852
induced	O	852-859
erythema	B	860-868
nodosum	I	869-876
.	O	876-877

Delayed	O	0-7
-	O	7-8
onset	O	8-13
heparin	O	14-21
-	O	21-22
induced	O	22-29
thrombocytopenia	B	30-46
.	O	46-47

BACKGROUND	O	48-58
:	O	58-59
Heparin	O	60-67
-	O	67-68
induced	O	68-75
thrombocytopenia	B	76-92
presents	O	93-101
5	O	102-103
to	O	104-106
12	O	107-109
days	O	110-114
after	O	115-120
heparin	O	121-128
exposure	O	129-137
,	O	137-138
with	O	139-143
or	O	144-146
without	O	147-154
arterial	B	155-163
or	I	164-166
venous	I	167-173
thromboemboli	I	174-187
.	O	187-188

Delayed	O	189-196
recognition	O	197-208
and	O	209-212
treatment	O	213-222
of	O	223-225
heparin	O	226-233
-	O	233-234
induced	O	234-241
thrombocytopenia	B	242-258
contribute	O	259-269
to	O	270-272
poor	O	273-277
patient	O	278-285
outcomes	O	286-294
.	O	294-295

OBJECTIVE	O	296-305
:	O	305-306
To	O	307-309
describe	O	310-318
and	O	319-322
increase	O	323-331
awareness	O	332-341
of	O	342-344
a	O	345-346
clinical	O	347-355
scenario	O	356-364
in	O	365-367
which	O	368-373
the	O	374-377
onset	O	378-383
or	O	384-386
manifestations	O	387-401
of	O	402-404
heparin	O	405-412
-	O	412-413
induced	O	413-420
thrombocytopenia	B	421-437
are	O	438-441
delayed	O	442-449
.	O	449-450

DESIGN	O	451-457
:	O	457-458
Retrospective	O	459-472
case	O	473-477
series	O	478-484
.	O	484-485

SETTING	O	486-493
:	O	493-494
Three	O	495-500
large	O	501-506
urban	O	507-512
hospitals	O	513-522
(	O	523-524
with	O	524-528
active	O	529-535
cardiovascular	O	536-550
surgery	O	551-558
programs	O	559-567
)	O	567-568
.	O	568-569

PATIENTS	O	570-578
:	O	578-579
14	O	580-582
patients	O	583-591
seen	O	592-596
over	O	597-601
a	O	602-603
3	O	604-605
-	O	605-606
year	O	606-610
period	O	611-617
in	O	618-620
whom	O	621-625
heparin	O	626-633
-	O	633-634
induced	O	634-641
thrombocytopenia	B	642-658
became	O	659-665
apparent	O	666-674
on	O	675-677
delayed	O	678-685
presentation	O	686-698
with	O	699-703
thromboembolic	B	704-718
complications	O	719-732
.	O	732-733

MEASUREMENTS	O	734-746
:	O	746-747
Platelet	O	748-756
counts	O	757-763
,	O	763-764
onset	O	765-770
of	O	771-773
objectively	O	774-785
determined	O	786-796
thromboembolism	B	797-812
,	O	812-813
results	O	814-821
of	O	822-824
heparin	O	825-832
-	O	832-833
induced	O	833-840
platelet	O	841-849
factor	O	850-856
4	O	857-858
antibody	O	859-867
tests	O	868-873
,	O	873-874
and	O	875-878
outcomes	O	879-887
.	O	887-888

RESULTS	O	889-896
:	O	896-897
Patients	O	898-906
went	O	907-911
home	O	912-916
after	O	917-922
hospitalizations	O	923-939
that	O	940-944
had	O	945-948
included	O	949-957
heparin	O	958-965
exposure	O	966-974
-	O	974-975
-	O	974-975
in	O	976-978
most	O	979-983
cases	O	984-989
,	O	989-990
with	O	991-995
no	O	996-998
thrombocytopenia	B	999-1015
recognized	O	1016-1026
-	O	1026-1027
-	O	1026-1027
only	O	1028-1032
to	O	1033-1035
return	O	1036-1042
to	O	1043-1045
the	O	1046-1049
hospital	O	1050-1058
(	O	1059-1060
median	O	1060-1066
,	O	1066-1067
day	O	1068-1071
14	O	1072-1074
)	O	1074-1075
with	O	1076-1080
thromboembolic	B	1081-1095
complications	O	1096-1109
.	O	1109-1110

Thromboemboli	B	1111-1124
were	O	1125-1129
venous	O	1130-1136
(	O	1137-1138
12	O	1138-1140
patients	O	1141-1149
,	O	1149-1150
7	O	1151-1152
with	O	1153-1157
pulmonary	B	1158-1167
emboli	I	1168-1174
)	O	1174-1175
or	O	1176-1178
arterial	O	1179-1187
(	O	1188-1189
4	O	1189-1190
patients	O	1191-1199
)	O	1199-1200
or	O	1201-1203
both	O	1204-1208
.	O	1208-1209

Platelet	O	1210-1218
counts	O	1219-1225
were	O	1226-1230
mildly	O	1231-1237
decreased	O	1238-1247
in	O	1248-1250
all	O	1251-1254
but	O	1255-1258
2	O	1259-1260
patients	O	1261-1269
on	O	1270-1272
second	O	1273-1279
presentation	O	1280-1292
.	O	1292-1293

On	O	1294-1296
readmission	O	1297-1308
,	O	1308-1309
11	O	1310-1312
patients	O	1313-1321
received	O	1322-1330
therapeutic	O	1331-1342
heparin	O	1343-1350
,	O	1350-1351
which	O	1352-1357
worsened	O	1358-1366
the	O	1367-1370
patients	O	1371-1379
'	O	1379-1380
clinical	O	1381-1389
condition	O	1390-1399
and	O	1400-1403
,	O	1403-1404
in	O	1405-1407
all	O	1408-1411
11	O	1412-1414
cases	O	1415-1420
,	O	1420-1421
decreased	O	1422-1431
the	O	1432-1435
platelet	O	1436-1444
count	O	1445-1450
(	O	1451-1452
mean	O	1452-1456
at	O	1457-1459
readmission	O	1460-1471
,	O	1471-1472
143	O	1473-1476
x	O	1477-1478
10	O	1479-1481
(	O	1481-1482
9	O	1482-1483
)	O	1483-1484
cells	O	1485-1490
/	O	1490-1491
L	O	1491-1492
;	O	1492-1493
mean	O	1494-1498
nadir	O	1499-1504
after	O	1505-1510
heparin	O	1511-1518
re	O	1519-1521
-	O	1521-1522
exposure	O	1522-1530
,	O	1530-1531
39	O	1532-1534
x	O	1535-1536
10	O	1537-1539
(	O	1539-1540
9	O	1540-1541
)	O	1541-1542
cells	O	1543-1548
/	O	1548-1549
L	O	1549-1550
)	O	1550-1551
.	O	1551-1552

Results	O	1553-1560
of	O	1561-1563
serologic	O	1564-1573
tests	O	1574-1579
for	O	1580-1583
heparin	O	1584-1591
-	O	1591-1592
induced	O	1592-1599
antibodies	O	1600-1610
were	O	1611-1615
positive	O	1616-1624
in	O	1625-1627
all	O	1628-1631
patients	O	1632-1640
.	O	1640-1641

Subsequent	O	1642-1652
treatments	O	1653-1663
included	O	1664-1672
alternative	O	1673-1684
anticoagulants	O	1685-1699
(	O	1700-1701
11	O	1701-1703
patients	O	1704-1712
)	O	1712-1713
,	O	1713-1714
thrombolytic	O	1715-1727
drugs	O	1728-1733
(	O	1734-1735
3	O	1735-1736
patients	O	1737-1745
)	O	1745-1746
,	O	1746-1747
inferior	O	1748-1756
vena	O	1757-1761
cava	O	1762-1766
filters	O	1767-1774
(	O	1775-1776
3	O	1776-1777
patients	O	1778-1786
)	O	1786-1787
and	O	1788-1791
,	O	1791-1792
eventually	O	1793-1803
,	O	1803-1804
warfarin	O	1805-1813
(	O	1814-1815
11	O	1815-1817
patients	O	1818-1826
)	O	1826-1827
.	O	1827-1828

Three	O	1829-1834
patients	O	1835-1843
died	O	1844-1848
.	O	1848-1849

CONCLUSIONS	O	1850-1861
:	O	1861-1862
Delayed	O	1863-1870
-	O	1870-1871
onset	O	1871-1876
heparin	O	1877-1884
-	O	1884-1885
induced	O	1885-1892
thrombocytopenia	B	1893-1909
is	O	1910-1912
increasingly	O	1913-1925
being	O	1926-1931
recognized	O	1932-1942
.	O	1942-1943

To	O	1944-1946
avoid	O	1947-1952
disastrous	O	1953-1963
outcomes	O	1964-1972
,	O	1972-1973
physicians	O	1974-1984
must	O	1985-1989
consider	O	1990-1998
heparin	O	1999-2006
-	O	2006-2007
induced	O	2007-2014
thrombocytopenia	B	2015-2031
whenever	O	2032-2040
a	O	2041-2042
recently	O	2043-2051
hospitalized	O	2052-2064
patient	O	2065-2072
returns	O	2073-2080
with	O	2081-2085
thromboembolism	B	2086-2101
;	O	2101-2102
therapy	O	2103-2110
with	O	2111-2115
alternative	O	2116-2127
anticoagulants	O	2128-2142
,	O	2142-2143
not	O	2144-2147
heparin	O	2148-2155
,	O	2155-2156
should	O	2157-2163
be	O	2164-2166
initiated	O	2167-2176
.	O	2176-2177

Valsartan	O	0-9
,	O	9-10
a	O	11-12
new	O	13-16
angiotensin	O	17-28
II	O	29-31
antagonist	O	32-42
for	O	43-46
the	O	47-50
treatment	O	51-60
of	O	61-63
essential	O	64-73
hypertension	B	74-86
:	O	86-87
a	O	88-89
comparative	O	90-101
study	O	102-107
of	O	108-110
the	O	111-114
efficacy	O	115-123
and	O	124-127
safety	O	128-134
against	O	135-142
amlodipine	O	143-153
.	O	153-154

OBJECTIVE	O	155-164
:	O	164-165
To	O	166-168
compare	O	169-176
the	O	177-180
antihypertensive	O	181-197
efficacy	O	198-206
of	O	207-209
a	O	210-211
new	O	212-215
angiotensin	O	216-227
II	O	228-230
antagonist	O	231-241
,	O	241-242
valsartan	O	243-252
,	O	252-253
with	O	254-258
a	O	259-260
reference	O	261-270
therapy	O	271-278
,	O	278-279
amlodipine	O	280-290
.	O	290-291

METHODS	O	292-299
:	O	299-300
One	O	301-304
hundred	O	305-312
sixty	O	313-318
-	O	318-319
eight	O	319-324
adult	O	325-330
outpatients	O	331-342
with	O	343-347
mild	O	348-352
to	O	353-355
moderate	O	356-364
hypertension	B	365-377
were	O	378-382
randomly	O	383-391
allocated	O	392-401
in	O	402-404
double	O	405-411
-	O	411-412
blind	O	412-417
fashion	O	418-425
and	O	426-429
equal	O	430-435
number	O	436-442
to	O	443-445
receive	O	446-453
80	O	454-456
mg	O	457-459
valsartan	O	460-469
or	O	470-472
5	O	473-474
mg	O	475-477
amlodipine	O	478-488
for	O	489-492
12	O	493-495
weeks	O	496-501
.	O	501-502

After	O	503-508
8	O	509-510
weeks	O	511-516
of	O	517-519
therapy	O	520-527
,	O	527-528
in	O	529-531
patients	O	532-540
whose	O	541-546
blood	O	547-552
pressure	O	553-561
remained	O	562-570
uncontrolled	O	571-583
,	O	583-584
5	O	585-586
mg	O	587-589
amlodipine	O	590-600
was	O	601-604
added	O	605-610
to	O	611-613
the	O	614-617
initial	O	618-625
therapy	O	626-633
.	O	633-634

Patients	O	635-643
were	O	644-648
assessed	O	649-657
at	O	658-660
4	O	661-662
,	O	662-663
8	O	664-665
,	O	665-666
and	O	667-670
12	O	671-673
weeks	O	674-679
.	O	679-680

The	O	681-684
primary	O	685-692
efficacy	O	693-701
variable	O	702-710
was	O	711-714
change	O	715-721
from	O	722-726
baseline	O	727-735
in	O	736-738
mean	O	739-743
sitting	O	744-751
diastolic	O	752-761
blood	O	762-767
pressure	O	768-776
at	O	777-779
8	O	780-781
weeks	O	782-787
.	O	787-788

Secondary	O	789-798
variables	O	799-808
included	O	809-817
change	O	818-824
in	O	825-827
sitting	O	828-835
systolic	O	836-844
blood	O	845-850
pressure	O	851-859
and	O	860-863
responder	O	864-873
rates	O	874-879
.	O	879-880

RESULTS	O	881-888
:	O	888-889
Both	O	890-894
valsartan	O	895-904
and	O	905-908
amlodipine	O	909-919
were	O	920-924
effective	O	925-934
at	O	935-937
lowering	O	938-946
blood	O	947-952
pressure	O	953-961
at	O	962-964
4	O	965-966
,	O	966-967
8	O	968-969
,	O	969-970
and	O	971-974
12	O	975-977
weeks	O	978-983
.	O	983-984

Similar	O	985-992
decreases	O	993-1002
were	O	1003-1007
observed	O	1008-1016
in	O	1017-1019
both	O	1020-1024
groups	O	1025-1031
,	O	1031-1032
with	O	1033-1037
no	O	1038-1040
statistically	O	1041-1054
significant	O	1055-1066
differences	O	1067-1078
between	O	1079-1086
the	O	1087-1090
groups	O	1091-1097
for	O	1098-1101
any	O	1102-1105
variable	O	1106-1114
analyzed	O	1115-1123
.	O	1123-1124

For	O	1125-1128
the	O	1129-1132
primary	O	1133-1140
variable	O	1141-1149
the	O	1150-1153
difference	O	1154-1164
was	O	1165-1168
0	O	1169-1170
.	O	1170-1171
5	O	1171-1172
mm	O	1173-1175
Hg	O	1176-1178
in	O	1179-1181
favor	O	1182-1187
of	O	1188-1190
valsartan	O	1191-1200
(	O	1201-1202
p	O	1202-1203
=	O	1204-1205
0	O	1206-1207
.	O	1207-1208
68	O	1208-1210
;	O	1210-1211
95	O	1212-1214
%	O	1214-1215
confidence	O	1216-1226
interval	O	1227-1235
,	O	1235-1236
-	O	1237-1238
2	O	1238-1239
.	O	1239-1240
7	O	1240-1241
to	O	1242-1244
1	O	1245-1246
.	O	1246-1247
7	O	1247-1248
)	O	1248-1249
.	O	1246-1247

Responder	O	1251-1260
rates	O	1261-1266
at	O	1267-1269
8	O	1270-1271
weeks	O	1272-1277
were	O	1278-1282
66	O	1283-1285
.	O	1285-1286
7	O	1286-1287
%	O	1287-1288
for	O	1289-1292
valsartan	O	1293-1302
and	O	1303-1306
60	O	1307-1309
.	O	1309-1310
2	O	1310-1311
%	O	1311-1312
for	O	1313-1316
amlodipine	O	1317-1327
(	O	1328-1329
p	O	1329-1330
=	O	1331-1332
0	O	1333-1334
.	O	1334-1335
39	O	1335-1337
)	O	1337-1338
.	O	1334-1335

Both	O	1340-1344
treatments	O	1345-1355
were	O	1356-1360
well	O	1361-1365
tolerated	O	1366-1375
.	O	1375-1376

The	O	1377-1380
incidence	O	1381-1390
of	O	1391-1393
drug	O	1394-1398
-	O	1398-1399
related	O	1399-1406
dependent	O	1407-1416
edema	B	1417-1422
was	O	1423-1426
somewhat	O	1427-1435
higher	O	1436-1442
in	O	1443-1445
the	O	1446-1449
amlodipine	O	1450-1460
group	O	1461-1466
,	O	1466-1467
particularly	O	1468-1480
at	O	1481-1483
a	O	1484-1485
dose	O	1486-1490
of	O	1491-1493
10	O	1494-1496
mg	O	1497-1499
per	O	1500-1503
day	O	1504-1507
(	O	1508-1509
2	O	1509-1510
.	O	1510-1511
4	O	1511-1512
%	O	1512-1513
for	O	1514-1517
80	O	1518-1520
mg	O	1521-1523
valsartan	O	1524-1533
;	O	1533-1534
3	O	1535-1536
.	O	1536-1537
6	O	1537-1538
%	O	1538-1539
for	O	1540-1543
5	O	1544-1545
mg	O	1546-1548
amlodipine	O	1549-1559
;	O	1559-1560
0	O	1561-1562
%	O	1562-1563
for	O	1564-1567
valsartan	O	1568-1577
plus	O	1578-1582
5	O	1583-1584
mg	O	1585-1587
amlodipine	O	1588-1598
;	O	1598-1599
14	O	1600-1602
.	O	1602-1603
3	O	1603-1604
%	O	1604-1605
for	O	1606-1609
10	O	1610-1612
mg	O	1613-1615
amlodipine	O	1616-1626
)	O	1626-1627
.	O	1627-1628

CONCLUSIONS	O	1629-1640
:	O	1640-1641
The	O	1642-1645
data	O	1646-1650
show	O	1651-1655
that	O	1656-1660
valsartan	O	1661-1670
is	O	1671-1673
at	O	1674-1676
least	O	1677-1682
as	O	1683-1685
effective	O	1686-1695
as	O	1696-1698
amlodipine	O	1699-1709
in	O	1710-1712
the	O	1713-1716
treatment	O	1717-1726
of	O	1727-1729
mild	O	1730-1734
to	O	1735-1737
moderate	O	1738-1746
hypertension	B	1747-1759
.	O	1759-1760

The	O	1761-1764
results	O	1765-1772
also	O	1773-1777
show	O	1778-1782
valsartan	O	1783-1792
to	O	1793-1795
be	O	1796-1798
well	O	1799-1803
tolerated	O	1804-1813
and	O	1814-1817
suggest	O	1818-1825
that	O	1826-1830
it	O	1831-1833
is	O	1834-1836
not	O	1837-1840
associated	O	1841-1851
with	O	1852-1856
side	O	1857-1861
effects	O	1862-1869
characteristic	O	1870-1884
of	O	1885-1887
this	O	1888-1892
comparator	O	1893-1903
class	O	1904-1909
,	O	1909-1910
dihydropyridine	O	1911-1926
calcium	O	1927-1934
antagonists	O	1935-1946
.	O	1946-1947

KF17837	O	0-7
:	O	7-8
a	O	9-10
novel	O	11-16
selective	O	17-26
adenosine	O	27-36
A2A	O	37-40
receptor	O	41-49
antagonist	O	50-60
with	O	61-65
anticataleptic	O	66-80
activity	O	81-89
.	O	89-90

KF17837	O	91-98
is	O	99-101
a	O	102-103
novel	O	104-109
selective	O	110-119
adenosine	O	120-129
A2A	O	130-133
receptor	O	134-142
antagonist	O	143-153
.	O	153-154

Oral	O	155-159
administration	O	160-174
of	O	175-177
KF17837	O	178-185
(	O	186-187
2	O	187-188
.	O	188-189
5	O	189-190
,	O	190-191
10	O	192-194
.	O	194-195
0	O	193-194
and	O	197-200
30	O	201-203
.	O	203-204
0	O	202-203
mg	O	206-208
/	O	208-209
kg	O	209-211
)	O	211-212
significantly	O	213-226
ameliorated	O	227-238
the	O	239-242
cataleptic	B	243-253
responses	O	254-263
induced	O	264-271
by	O	272-274
intracerebroventricular	O	275-298
administration	O	299-313
of	O	314-316
an	O	317-319
adenosine	O	320-329
A2A	O	330-333
receptor	O	334-342
agonist	O	343-350
,	O	350-351
CGS	O	352-355
21680	O	356-361
(	O	362-363
10	O	363-365
micrograms	O	366-376
)	O	376-377
,	O	377-378
in	O	379-381
a	O	382-383
dose	O	384-388
-	O	388-389
dependent	O	389-398
manner	O	399-405
.	O	405-406

KF17837	O	407-414
also	O	415-419
reduced	O	420-427
the	O	428-431
catalepsy	B	432-441
induced	O	442-449
by	O	450-452
haloperidol	O	453-464
(	O	465-466
1	O	466-467
mg	O	468-470
/	O	470-471
kg	O	471-473
i	O	474-475
.	O	475-476
p	O	476-477
.	O	475-476
)	O	478-479
and	O	480-483
by	O	484-486
reserpine	O	487-496
(	O	497-498
5	O	498-499
mg	O	500-502
/	O	502-503
kg	O	503-505
i	O	506-507
.	O	507-508
p	O	508-509
.	O	507-508
)	O	510-511
.	O	507-508

These	O	513-518
anticataleptic	O	519-533
effects	O	534-541
were	O	542-546
exhibited	O	547-556
dose	O	557-561
dependently	O	562-573
at	O	574-576
doses	O	577-582
from	O	583-587
0	O	588-589
.	O	589-590
625	O	590-593
and	O	594-597
2	O	598-599
.	O	599-600
5	O	600-601
mg	O	602-604
/	O	604-605
kg	O	605-607
p	O	608-609
.	O	609-610
o	O	610-611
.	O	609-610
,	O	612-613
respectively	O	614-626
.	O	626-627

Moreover	O	628-636
,	O	636-637
KF17837	O	638-645
(	O	646-647
0	O	647-648
.	O	648-649
625	O	649-652
mg	O	653-655
/	O	655-656
kg	O	656-658
p	O	659-660
.	O	660-661
o	O	661-662
.	O	660-661
)	O	663-664
potentiated	O	665-676
the	O	677-680
anticataleptic	O	681-695
effects	O	696-703
of	O	704-706
a	O	707-708
subthreshold	O	709-721
dose	O	722-726
of	O	727-729
L	O	730-731
-	O	731-732
3	O	732-733
,	O	733-734
4	O	734-735
-	O	731-732
dihydroxyphenylalanine	O	736-758
(	O	759-760
L	O	760-761
-	O	761-762
DOPA	O	762-766
;	O	766-767
25	O	768-770
mg	O	771-773
/	O	773-774
kg	O	774-776
i	O	777-778
.	O	778-779
p	O	779-780
.	O	778-779
)	O	781-782
plus	O	783-787
benserazide	O	788-799
(	O	800-801
6	O	801-802
.	O	802-803
25	O	803-805
mg	O	806-808
/	O	808-809
kg	O	809-811
i	O	812-813
.	O	813-814
p	O	814-815
.	O	813-814
)	O	816-817
.	O	813-814

These	O	819-824
results	O	825-832
suggested	O	833-842
that	O	843-847
KF17837	O	848-855
is	O	856-858
a	O	859-860
centrally	O	861-870
active	O	871-877
adenosine	O	878-887
A2A	O	888-891
receptor	O	892-900
antagonist	O	901-911
and	O	912-915
that	O	916-920
the	O	921-924
dopaminergic	O	925-937
function	O	938-946
of	O	947-949
the	O	950-953
nigrostriatal	O	954-967
pathway	O	968-975
is	O	976-978
potentiated	O	979-990
by	O	991-993
adenosine	O	994-1003
A2A	O	1004-1007
receptor	O	1008-1016
antagonists	O	1017-1028
.	O	1028-1029

Furthermore	O	1030-1041
,	O	1041-1042
KF17837	O	1043-1050
may	O	1051-1054
be	O	1055-1057
a	O	1058-1059
useful	O	1060-1066
drug	O	1067-1071
in	O	1072-1074
the	O	1075-1078
treatment	O	1079-1088
of	O	1089-1091
parkinsonism	B	1092-1104
.	O	1104-1105

Some	O	0-4
central	O	5-12
effects	O	13-20
of	O	21-23
repeated	O	24-32
treatment	O	33-42
with	O	43-47
fluvoxamine	O	48-59
.	O	59-60

We	O	61-63
investigated	O	64-76
the	O	77-80
effect	O	81-87
of	O	88-90
repeated	O	91-99
treatment	O	100-109
with	O	110-114
fluvoxamine	O	115-126
,	O	126-127
a	O	128-129
selective	O	130-139
serotonin	O	140-149
uptake	O	150-156
inhibitor	O	157-166
,	O	166-167
on	O	168-170
behavioral	O	171-181
effects	O	182-189
of	O	190-192
dopaminomimetics	O	193-209
and	O	210-213
methoxamine	O	214-225
and	O	226-229
on	O	230-232
the	O	233-236
animal	O	237-243
behavior	O	244-252
in	O	253-255
the	O	256-259
"	O	260-261
behavioral	O	261-271
despair	O	272-279
"	O	279-280
test	O	281-285
.	O	285-286

A	O	287-288
repeated	O	289-297
treatment	O	298-307
with	O	308-312
fluvoxamine	O	313-324
(	O	325-326
twice	O	326-331
daily	O	332-337
for	O	338-341
14	O	342-344
days	O	345-349
)	O	349-350
potentiated	O	351-362
in	O	363-365
mice	O	366-370
and	O	371-374
in	O	375-377
rats	O	378-382
(	O	383-384
weaker	O	384-390
)	O	390-391
the	O	392-395
amphetamine	O	396-407
-	O	407-408
induced	O	408-415
hyperactivity	B	416-429
.	O	429-430

The	O	431-434
hyperactivity	B	435-448
induced	O	449-456
by	O	457-459
nomifensine	O	460-471
in	O	472-474
mice	O	475-479
remained	O	480-488
unaffected	O	489-499
by	O	500-502
fluvoxamine	O	503-514
.	O	514-515

The	O	516-519
stimulation	O	520-531
of	O	532-534
locomotor	O	535-544
activity	O	545-553
by	O	554-556
intracerebroventricularly	O	557-582
administered	O	583-595
methoxamine	O	596-607
was	O	608-611
not	O	612-615
affected	O	616-624
by	O	625-627
repeated	O	628-636
treatment	O	637-646
with	O	647-651
fluvoxamine	O	652-663
.	O	663-664

Given	O	665-670
three	O	671-676
times	O	677-682
fluvoxamine	O	683-694
had	O	695-698
no	O	699-701
effect	O	702-708
on	O	709-711
the	O	712-715
immobilization	O	716-730
time	O	731-735
in	O	736-738
the	O	739-742
"	O	743-744
behavioral	O	744-754
despair	O	755-762
"	O	762-763
test	O	764-768
in	O	769-771
rats	O	772-776
.	O	776-777

The	O	778-781
results	O	782-789
indicate	O	790-798
that	O	799-803
fluvoxamine	O	804-815
given	O	816-821
repeatedly	O	822-832
acts	O	833-837
differently	O	838-849
than	O	850-854
citalopram	O	855-865
,	O	865-866
another	O	867-874
selective	O	875-884
serotonin	O	885-894
uptake	O	895-901
inhibitor	O	902-911
,	O	911-912
and	O	913-916
differs	O	917-924
also	O	925-929
from	O	930-934
other	O	935-940
antidepressant	O	941-955
drugs	O	956-961
.	O	961-962

Severe	O	0-6
congestive	B	7-17
heart	I	18-23
failure	I	24-31
patient	O	32-39
on	O	40-42
amiodarone	O	43-53
presenting	O	54-64
with	O	65-69
myxedemic	B	70-79
coma	I	80-84
:	O	84-85
a	O	86-87
case	O	88-92
report	O	93-99
.	O	99-100

This	O	101-105
is	O	106-108
a	O	109-110
case	O	111-115
report	O	116-122
of	O	123-125
myxedema	B	126-134
coma	I	135-139
secondary	O	140-149
to	O	150-152
amiodarone	O	153-163
-	O	163-164
induced	O	164-171
hypothyroidism	B	172-186
in	O	187-189
a	O	190-191
patient	O	192-199
with	O	200-204
severe	O	205-211
congestive	B	212-222
heart	I	223-228
failure	I	229-236
(	O	237-238
CHF	B	238-241
)	O	241-242
.	O	242-243

To	O	244-246
our	O	247-250
knowledge	O	251-260
and	O	261-264
after	O	265-270
reviewing	O	271-280
the	O	281-284
literature	O	285-295
there	O	296-301
is	O	302-304
one	O	305-308
case	O	309-313
report	O	314-320
of	O	321-323
myxedema	B	324-332
coma	I	333-337
during	O	338-344
long	O	345-349
term	O	350-354
amiodarone	O	355-365
therapy	O	366-373
.	O	373-374

Myxedema	B	375-383
coma	I	384-388
is	O	389-391
a	O	392-393
life	O	394-398
threatening	O	399-410
condition	O	411-420
that	O	421-425
carries	O	426-433
a	O	434-435
mortality	O	436-445
reaching	O	446-454
as	O	455-457
high	O	458-462
as	O	463-465
20	O	466-468
%	O	468-469
with	O	470-474
treatment	O	475-484
.	O	484-485

The	O	486-489
condition	O	490-499
is	O	500-502
treated	O	503-510
with	O	511-515
intravenous	O	516-527
thyroxine	O	528-537
(	O	538-539
T4	O	539-541
)	O	541-542
or	O	543-545
intravenous	O	546-557
tri	O	558-561
-	O	561-562
iodo	O	562-566
-	O	561-562
thyronine	O	567-576
(	O	577-578
T3	O	578-580
)	O	580-581
.	O	581-582

Patients	O	583-591
with	O	592-596
CHF	B	597-600
on	O	601-603
amiodarone	O	604-614
may	O	615-618
suffer	O	619-625
serious	O	626-633
morbidity	O	634-643
and	O	644-647
mortality	O	648-657
from	O	658-662
hypothyroidism	B	663-677
,	O	677-678
and	O	679-682
thus	O	683-687
may	O	688-691
deserve	O	692-699
closer	O	700-706
follow	O	707-713
up	O	714-716
for	O	717-720
thyroid	O	721-728
stimulating	O	729-740
hormone	O	741-748
(	O	749-750
TSH	O	750-753
)	O	753-754
levels	O	755-761
.	O	761-762

This	O	763-767
case	O	768-772
report	O	773-779
carries	O	780-787
an	O	788-790
important	O	791-800
clinical	O	801-809
application	O	810-821
given	O	822-827
the	O	828-831
frequent	O	832-840
usage	O	841-846
of	O	847-849
amiodarone	O	850-860
among	O	861-866
CHF	B	867-870
patients	O	871-879
.	O	879-880

The	O	881-884
myriad	O	885-891
clinical	O	892-900
presentation	O	901-913
of	O	914-916
myxedema	B	917-925
coma	I	926-930
and	O	931-934
its	O	935-938
serious	O	939-946
morbidity	O	947-956
and	O	957-960
mortality	O	961-970
stresses	O	971-979
the	O	980-983
need	O	984-988
to	O	989-991
suspect	O	992-999
this	O	1000-1004
clinical	O	1005-1013
syndrome	O	1014-1022
among	O	1023-1028
CHF	B	1029-1032
patients	O	1033-1041
presenting	O	1042-1052
with	O	1053-1057
hypotension	B	1058-1069
,	O	1069-1070
weakness	B	1071-1079
or	O	1080-1082
other	O	1083-1088
unexplained	O	1089-1100
symptoms	O	1101-1109
.	O	1109-1110

Fear	O	0-4
-	O	4-5
potentiated	O	5-16
startle	B	17-24
,	O	24-25
but	O	26-29
not	O	30-33
light	O	34-39
-	O	39-40
enhanced	O	40-48
startle	B	49-56
,	O	56-57
is	O	58-60
enhanced	O	61-69
by	O	70-72
anxiogenic	O	73-83
drugs	O	84-89
.	O	89-90

RATIONALE	O	91-100
AND	O	101-104
OBJECTIVES	O	105-115
:	O	115-116
The	O	117-120
light	O	121-126
-	O	126-127
enhanced	O	127-135
startle	B	136-143
paradigm	O	144-152
(	O	153-154
LES	O	154-157
)	O	157-158
is	O	159-161
suggested	O	162-171
to	O	172-174
model	O	175-180
anxiety	B	181-188
,	O	188-189
because	O	190-197
of	O	198-200
the	O	201-204
non	O	205-208
-	O	208-209
specific	O	209-217
cue	O	218-221
and	O	222-225
the	O	226-229
long	O	230-234
-	O	234-235
term	O	235-239
effect	O	240-246
.	O	246-247

In	O	248-250
contrast	O	251-259
,	O	259-260
the	O	261-264
fear	O	265-269
-	O	269-270
potentiated	O	270-281
startle	B	282-289
(	O	290-291
FPS	O	291-294
)	O	294-295
is	O	296-298
suggested	O	299-308
to	O	309-311
model	O	312-317
conditioned	O	318-329
fear	O	330-334
.	O	334-335

However	O	336-343
,	O	343-344
the	O	345-348
pharmacological	O	349-364
profiles	O	365-373
of	O	374-376
these	O	377-382
two	O	383-386
paradigms	O	387-396
are	O	397-400
very	O	401-405
similar	O	406-413
.	O	413-414

The	O	415-418
present	O	419-426
study	O	427-432
investigated	O	433-445
the	O	446-449
effects	O	450-457
of	O	458-460
putative	O	461-469
anxiogenic	O	470-480
drugs	O	481-486
on	O	487-489
LES	O	490-493
and	O	494-497
FPS	O	498-501
and	O	502-505
aimed	O	506-511
at	O	512-514
determining	O	515-526
the	O	527-530
sensitivity	O	531-542
of	O	543-545
LES	O	546-549
for	O	550-553
anxiogenic	O	554-564
drugs	O	565-570
and	O	571-574
to	O	575-577
potentially	O	578-589
showing	O	590-597
a	O	598-599
pharmacological	O	600-615
differentiation	O	616-631
between	O	632-639
these	O	640-645
two	O	646-649
paradigms	O	650-659
.	O	659-660

METHODS	O	661-668
:	O	668-669
Male	O	670-674
Wistar	O	675-681
rats	O	682-686
received	O	687-695
each	O	696-700
dose	O	701-705
of	O	706-708
the	O	709-712
alpha	O	713-718
(	O	718-719
2	O	719-720
)	O	720-721
-	O	721-722
adrenoceptor	O	722-734
antagonist	O	735-745
yohimbine	O	746-755
(	O	756-757
0	O	757-758
.	O	758-759
25	O	759-761
-	O	761-762
1	O	762-763
.	O	758-759
0mg	O	764-767
/	O	767-768
kg	O	768-770
)	O	770-771
,	O	771-772
the	O	773-776
5	O	777-778
-	O	778-779
HT	O	779-781
(	O	781-782
2C	O	782-784
)	O	784-785
receptor	O	786-794
agonist	O	795-802
m	O	803-804
-	O	804-805
chlorophenylpiperazine	O	805-827
(	O	828-829
mCPP	O	829-833
,	O	833-834
0	O	835-836
.	O	836-837
5	O	837-838
-	O	838-839
2	O	839-840
.	O	836-837
0mg	O	841-844
/	O	844-845
kg	O	845-847
)	O	847-848

or	O	849-851
the	O	852-855
GABA	O	856-860
(	O	860-861
A	O	857-858
)	O	862-863
inverse	O	864-871
receptor	O	872-880
agonist	O	881-888
pentylenetetrazole	O	889-907
(	O	908-909
PTZ	O	909-912
,	O	912-913
3	O	914-915
-	O	915-916
30mg	O	916-920
/	O	920-921
kg	O	921-923
)	O	923-924
and	O	925-928
were	O	929-933
subsequently	O	934-946
tested	O	947-953
in	O	954-956
either	O	957-963
LES	O	964-967
or	O	968-970
FPS	O	971-974
.	O	974-975

RESULTS	O	976-983
:	O	983-984
None	O	985-989
of	O	990-992
the	O	993-996
drugs	O	997-1002
enhanced	O	1003-1011
LES	O	1012-1015
,	O	1015-1016
whereas	O	1017-1024
mCPP	O	1025-1029
increased	O	1030-1039
percentage	O	1040-1050
FPS	O	1051-1054
and	O	1055-1058
yohimbine	O	1059-1068
increased	O	1069-1078
absolute	O	1079-1087
FPS	O	1088-1091
values	O	1092-1098
.	O	1098-1099

Furthermore	O	1100-1111
,	O	1111-1112
yohimbine	O	1113-1122
increased	O	1123-1132
baseline	O	1133-1141
startle	B	1142-1149
amplitude	O	1150-1159
in	O	1160-1162
the	O	1163-1166
LES	O	1167-1170
,	O	1170-1171
while	O	1172-1177
mCPP	O	1178-1182
suppressed	O	1183-1193
baseline	O	1194-1202
startle	B	1203-1210
in	O	1211-1213
both	O	1214-1218
the	O	1219-1222
LES	O	1223-1226
and	O	1227-1230
FPS	O	1231-1234
and	O	1235-1238
PTZ	O	1239-1242
suppressed	O	1243-1253
baseline	O	1254-1262
startle	B	1263-1270
in	O	1271-1273
the	O	1274-1277
FPS	O	1278-1281
.	O	1281-1282

CONCLUSIONS	O	1283-1294
:	O	1294-1295
In	O	1296-1298
contrast	O	1299-1307
to	O	1308-1310
findings	O	1311-1319
in	O	1320-1322
the	O	1323-1326
FPS	O	1327-1330
paradigm	O	1331-1339
,	O	1339-1340
none	O	1341-1345
of	O	1346-1348
the	O	1349-1352
drugs	O	1353-1358
were	O	1359-1363
able	O	1364-1368
to	O	1369-1371
exacerbate	O	1372-1382
the	O	1383-1386
LES	O	1387-1390
response	O	1391-1399
.	O	1399-1400

Thus	O	1401-1405
,	O	1405-1406
a	O	1407-1408
clear	O	1409-1414
pharmacological	O	1415-1430
differentiation	O	1431-1446
was	O	1447-1450
found	O	1451-1456
between	O	1457-1464
LES	O	1465-1468
and	O	1469-1472
FPS	O	1473-1476
.	O	1476-1477

Proteinase	O	0-10
3	O	11-12
-	O	12-13
antineutrophil	O	13-27
cytoplasmic	O	28-39
antibody	O	40-48
-	O	48-49
(	O	49-50
PR3	O	50-53
-	O	48-49
ANCA	O	54-58
)	O	58-59
positive	O	60-68
necrotizing	O	69-80
glomerulonephritis	B	81-99
after	O	100-105
restarting	O	106-116
sulphasalazine	O	117-131
treatment	O	132-141
.	O	141-142

A	O	143-144
59	O	145-147
-	O	147-148
year	O	148-152
-	O	147-148
old	O	153-156
woman	O	157-162
with	O	163-167
ulcerative	B	168-178
colitis	I	179-186
developed	O	187-196
red	B	197-200
eyes	I	201-205
,	O	205-206
pleural	B	207-214
effusion	I	215-223
,	O	223-224
eosinophilia	B	225-237
and	O	238-241
urinary	B	242-249
abnormalities	I	250-263
after	O	264-269
restarting	O	270-280
of	O	281-283
sulphasalazine	O	284-298
treatment	O	299-308
.	O	308-309

Light	O	310-315
microscopy	O	316-326
of	O	327-329
a	O	330-331
kidney	O	332-338
biopsy	O	339-345
revealed	O	346-354
segmental	B	355-364
necrotizing	I	365-376
glomerulonephritis	I	377-395
without	O	396-403
deposition	O	404-414
of	O	415-417
immunoglobulin	O	418-432
or	O	433-435
complement	O	436-446
.	O	446-447

Proteinase	O	448-458
3	O	459-460
-	O	460-461
antineutrophil	O	461-475
cytoplasmic	O	476-487
antibody	O	488-496
(	O	497-498
PR3	O	498-501
-	O	501-502
ANCA	O	502-506
)	O	506-507
titer	O	508-513
was	O	514-517
elevated	O	518-526
at	O	527-529
183	O	530-533
ELISA	O	534-539
units	O	540-545
(	O	546-547
EU	O	547-549
)	O	549-550
in	O	551-553
sera	O	554-558
(	O	559-560
normal	O	560-566
range	O	567-572
less	O	573-577
than	O	578-582
10	O	583-585
EU	O	586-588
)	O	588-589
,	O	589-590
myeloperoxidase	O	591-606
-	O	606-607
ANCA	O	607-611
was	O	612-615
negative	O	616-624
.	O	624-625

PR3	O	626-629
-	O	629-630
ANCA	O	630-634
titer	O	635-640
was	O	641-644
250	O	645-648
and	O	649-652
1	O	653-654
,	O	654-655
070	O	655-658
EU	O	659-661
in	O	662-664
pleural	B	665-672
effusions	I	673-682
on	O	683-685
right	O	686-691
and	O	692-695
left	O	696-700
side	O	701-705
,	O	705-706
respectively	O	707-719
.	O	719-720

Although	O	721-729
cessation	O	730-739
of	O	740-742
sulphasalazine	O	743-757
treatment	O	758-767
resulted	O	768-776
in	O	777-779
improvements	O	780-792
in	O	793-795
fever	B	796-801
,	O	801-802
red	B	803-806
eyes	I	807-811
,	O	811-812
chest	B	813-818
pain	I	819-823
,	O	823-824
titer	O	825-830
of	O	831-833
C	O	834-835
-	O	835-836
reactive	O	836-844
protein	O	845-852
and	O	853-856
volume	O	857-863
of	O	864-866
the	O	867-870
pleural	B	871-878
effusions	I	879-888
,	O	888-889
we	O	890-892
initiated	O	893-902
steroid	O	903-910
therapy	O	911-918
,	O	918-919
because	O	920-927
PR3	O	928-931
-	O	931-932
ANCA	O	932-936
titer	O	937-942
rose	O	943-947
to	O	948-950
320	O	951-954
EU	O	955-957
,	O	957-958
eosinophil	O	959-969
count	O	970-975
increased	O	976-985
to	O	986-988
1	O	989-990
,	O	990-991
100	O	991-994
cells	O	995-1000
/	O	1000-1001
microl	O	1001-1007
,	O	1007-1008
and	O	1009-1012
the	O	1013-1016
pleural	B	1017-1024
effusion	I	1025-1033
remained	O	1034-1042
.	O	1042-1043

One	O	1044-1047
month	O	1048-1053
after	O	1054-1059
steroid	O	1060-1067
therapy	O	1068-1075
,	O	1075-1076
the	O	1077-1080
pleural	B	1081-1088
effusion	I	1089-1097
disappeared	O	1098-1109
,	O	1109-1110
and	O	1111-1114
PR3	O	1115-1118
-	O	1118-1119
ANCA	O	1119-1123
titer	O	1124-1129
normalized	O	1130-1140
3	O	1141-1142
months	O	1143-1149
later	O	1150-1155
.	O	1155-1156

This	O	1157-1161
case	O	1162-1166
suggests	O	1167-1175
that	O	1176-1180
sulphasalazine	O	1181-1195
can	O	1196-1199
induce	O	1200-1206
PR3	O	1207-1210
-	O	1210-1211
ANCA	O	1211-1215
-	O	1210-1211
positive	O	1216-1224
necrotizing	O	1225-1236
glomerulonephritis	B	1237-1255
.	O	1255-1256

Is	O	0-2
phenytoin	O	3-12
administration	O	13-27
safe	O	28-32
in	O	33-35
a	O	36-37
hypothermic	B	38-49
child	O	50-55
?	O	55-56

A	O	57-58
male	O	59-63
neonate	O	64-71
with	O	72-76
a	O	77-78
Chiari	B	79-85
malformation	I	86-98
and	O	99-102
a	O	103-104
leaking	O	105-112
myelomeningocoele	O	113-130
underwent	O	131-140
ventriculoperitoneal	O	141-161
shunt	O	162-167
insertion	O	168-177
followed	O	178-186
by	O	187-189
repair	O	190-196
of	O	197-199
myelomeningocoele	O	200-217
.	O	217-218

During	O	219-225
anaesthesia	O	226-237
and	O	238-241
surgery	O	242-249
,	O	249-250
he	O	251-253
inadvertently	O	254-267
became	O	268-274
moderately	O	275-285
hypothermic	B	286-297
.	O	297-298

Intravenous	O	299-310
phenytoin	O	311-320
was	O	321-324
administered	O	325-337
during	O	338-344
the	O	345-348
later	O	349-354
part	O	355-359
of	O	360-362
the	O	363-366
surgery	O	367-374
for	O	375-378
seizure	B	379-386
prophylaxis	O	387-398
.	O	398-399

Following	O	400-409
phenytoin	O	410-419
administration	O	420-434
,	O	434-435
the	O	436-439
patient	O	440-447
developed	O	448-457
acute	O	458-463
severe	O	464-470
bradycardia	B	471-482
,	O	482-483
refractory	O	484-494
to	O	495-497
atropine	O	498-506
and	O	507-510
adrenaline	O	511-521
.	O	521-522

The	O	523-526
cardiac	O	527-534
depressant	O	535-545
actions	O	546-553
of	O	554-556
phenytoin	O	557-566
and	O	567-570
hypothermia	B	571-582
can	O	583-586
be	O	587-589
additive	O	590-598
.	O	598-599

Administration	O	600-614
of	O	615-617
phenytoin	O	618-627
in	O	628-630
the	O	631-634
presence	O	635-643
of	O	644-646
hypothermia	B	647-658
may	O	659-662
lead	O	663-667
to	O	668-670
an	O	671-673
adverse	O	674-681
cardiac	O	682-689
event	O	690-695
in	O	696-698
children	O	699-707
.	O	707-708

As	O	709-711
phenytoin	O	712-721
is	O	722-724
a	O	725-726
commonly	O	727-735
used	O	736-740
drug	O	741-745
,	O	745-746
clinicians	O	747-757
need	O	758-762
to	O	763-765
be	O	766-768
aware	O	769-774
of	O	775-777
this	O	778-782
interaction	O	783-794
.	O	794-795

Amisulpride	O	0-11
related	O	12-19
tic	B	20-23
-	I	23-24
like	I	24-28
symptoms	I	29-37
in	O	38-40
an	O	41-43
adolescent	O	44-54
schizophrenic	B	55-68
.	O	68-69

Tic	B	70-73
disorders	I	74-83
can	O	84-87
be	O	88-90
effectively	O	91-102
treated	O	103-110
by	O	111-113
atypical	O	114-122
antipsychotics	O	123-137
such	O	138-142
as	O	143-145
risperidone	O	146-157
,	O	157-158
olanzapine	O	159-169
and	O	170-173
ziprasidone	O	174-185
.	O	185-186

However	O	187-194
,	O	194-195
there	O	196-201
are	O	202-205
two	O	206-209
case	O	210-214
reports	O	215-222
that	O	223-227
show	O	228-232
tic	B	233-236
-	I	236-237
like	I	237-241
symptoms	I	242-250
,	O	250-251
including	O	252-261
motor	O	262-267
and	O	268-271
phonic	O	272-278
variants	O	279-287
,	O	287-288
occurring	O	289-298
during	O	299-305
treatment	O	306-315
with	O	316-320
quetiapine	O	321-331
or	O	332-334
clozapine	O	335-344
.	O	344-345

We	O	346-348
present	O	349-356
a	O	357-358
15	O	359-361
-	O	361-362
year	O	362-366
-	O	361-362
old	O	367-370
girl	O	371-375
schizophrenic	B	376-389
who	O	390-393
developed	O	394-403
frequent	O	404-412
involuntary	B	413-424
eye	I	425-428
-	I	428-429
blinking	I	429-437
movements	I	438-447
after	O	448-453
5	O	454-455
months	O	456-462
of	O	463-465
amisulpride	O	466-477
treatment	O	478-487
(	O	488-489
1000	O	489-493
mg	O	494-496
per	O	497-500
day	O	501-504
)	O	504-505
.	O	505-506

The	O	507-510
tic	B	511-514
-	I	514-515
like	I	515-519
symptoms	I	520-528
resolved	O	529-537
completely	O	538-548
after	O	549-554
we	O	555-557
reduced	O	558-565
the	O	566-569
dose	O	570-574
of	O	575-577
amisulpride	O	578-589
down	O	590-594
to	O	595-597
800	O	598-601
mg	O	602-604
per	O	605-608
day	O	609-612
.	O	612-613

However	O	614-621
,	O	621-622
her	O	623-626
psychosis	B	627-636
recurred	O	637-645
after	O	646-651
the	O	652-655
dose	O	656-660
reduction	O	661-670
.	O	670-671

We	O	672-674
then	O	675-679
placed	O	680-686
her	O	687-690
on	O	691-693
an	O	694-696
additional	O	697-707
100	O	708-711
mg	O	712-714
per	O	715-718
day	O	719-722
of	O	723-725
quetiapine	O	726-736
.	O	736-737

She	O	738-741
has	O	742-745
been	O	746-750
in	O	751-753
complete	O	754-762
remission	O	763-772
under	O	773-778
the	O	779-782
combined	O	783-791
medications	O	792-803
for	O	804-807
more	O	808-812
than	O	813-817
one	O	818-821
year	O	822-826
and	O	827-830
maintains	O	831-840
a	O	841-842
fair	O	843-847
role	O	848-852
function	O	853-861
.	O	861-862

No	O	863-865
more	O	866-870
tic	B	871-874
-	I	874-875
like	I	875-879
symptoms	I	880-888
or	O	889-891
other	O	892-897
side	O	898-902
effects	O	903-910
have	O	911-915
been	O	916-920
reported	O	921-929
.	O	929-930

Together	O	931-939
with	O	940-944
previously	O	945-955
reported	O	956-964
cases	O	965-970
,	O	970-971
our	O	972-975
patient	O	976-983
suggests	O	984-992
that	O	993-997
tic	B	998-1001
-	I	1001-1002
like	I	1002-1006
symptoms	I	1007-1015
might	O	1016-1021
occur	O	1022-1027
in	O	1028-1030
certain	O	1031-1038
vulnerable	O	1039-1049
individuals	O	1050-1061
during	O	1062-1068
treatment	O	1069-1078
with	O	1079-1083
atypical	O	1084-1092
antipsychotics	O	1093-1107
such	O	1108-1112
as	O	1113-1115
quetiapine	O	1116-1126
,	O	1126-1127
clozapine	O	1128-1137
,	O	1137-1138
or	O	1139-1141
amisulpride	O	1142-1153
.	O	1153-1154

Comparison	O	0-10
of	O	11-13
developmental	O	14-27
toxicology	O	28-38
of	O	39-41
aspirin	O	42-49
(	O	50-51
acetylsalicylic	O	51-66
acid	O	67-71
)	O	71-72
in	O	73-75
rats	O	76-80
using	O	81-86
selected	O	87-95
dosing	O	96-102
paradigms	O	103-112
.	O	112-113

BACKGROUND	O	114-124
:	O	124-125
Analysis	O	126-134
of	O	135-137
the	O	138-141
literature	O	142-152
for	O	153-156
nonsteroidal	O	157-169
anti	O	170-174
-	O	174-175
inflammatory	O	175-187
drugs	O	188-193
(	O	194-195
NSAIDs	O	195-201
)	O	201-202
suggests	O	203-211
that	O	212-216
a	O	217-218
low	O	219-222
incidence	O	223-232
of	O	233-235
developmental	B	236-249
anomalies	I	250-259
occurs	O	260-266
in	O	267-269
rats	O	270-274
given	O	275-280
NSAIDs	O	281-287
on	O	288-290
specific	O	291-299
days	O	300-304
during	O	305-311
organogenesis	O	312-325
.	O	325-326

Aspirin	O	327-334
(	O	335-336
acetylsalicylic	O	336-351
acid	O	352-356
[	O	357-358
ASA	O	358-361
]	O	361-362
)	O	362-363
,	O	363-364
an	O	365-367
irreversible	O	368-380
cyclooxygenase	O	381-395
1	O	396-397
and	O	398-401
2	O	402-403
inhibitor	O	404-413
,	O	413-414
induces	O	415-422
developmental	B	423-436
anomalies	I	437-446
when	O	447-451
administered	O	452-464
to	O	465-467
Wistar	O	468-474
rats	O	475-479
on	O	480-482
gestational	O	483-494
day	O	495-498
(	O	499-500
GD	O	500-502
)	O	502-503
9	O	504-505
,	O	505-506
10	O	507-509
,	O	509-510
or	O	511-513
11	O	514-516
(	O	517-518
Kimmel	O	518-524
CA	O	525-527
,	O	527-528
Wilson	O	529-535
JG	O	536-538
,	O	538-539
Schumacher	O	540-550
HJ	O	551-553
.	O	553-554

Teratology	O	555-565
4	O	566-567
:	O	567-568
15	O	568-570
-	O	570-571
24	O	571-573
,	O	573-574
1971	O	575-579
)	O	579-580
.	O	580-581

There	O	582-587
are	O	588-591
no	O	592-594
published	O	595-604
ASA	O	605-608
studies	O	609-616
using	O	617-622
the	O	623-626
multiple	O	627-635
dosing	O	636-642
paradigm	O	643-651
of	O	652-654
GDs	O	655-658
6	O	659-660
to	O	661-663
17	O	664-666
.	O	666-667
Objectives	O	668-678
of	O	679-681
the	O	682-685
current	O	686-693
study	O	694-699
were	O	700-704
to	O	705-707
compare	O	708-715
results	O	716-723
between	O	724-731
Sprague	O	732-739
-	O	739-740
Dawley	O	740-746
(	O	747-748
SD	O	748-750
)	O	750-751
and	O	752-755
Wistar	O	756-762
strains	O	763-770
when	O	771-775
ASA	O	776-779
is	O	780-782
administered	O	783-795
on	O	796-798
GD	O	799-801
9	O	802-803
,	O	803-804
10	O	805-807
,	O	807-808
or	O	809-811
11	O	812-814
;	O	814-815
to	O	816-818
compare	O	819-826
the	O	827-830
malformation	O	831-843
patterns	O	844-852
following	O	853-862
single	O	863-869
and	O	870-873
multiple	O	874-882
dosings	O	883-890
during	O	891-897
organogenesis	O	898-911
in	O	912-914
SD	O	915-917
rats	O	918-922
;	O	922-923
and	O	924-927
to	O	928-930
test	O	931-935
the	O	936-939
hypothesis	O	940-950
that	O	951-955
maternal	O	956-964
gastrointestinal	B	965-981
toxicity	I	982-990
confounds	O	991-1000
the	O	1001-1004
detection	O	1005-1014
of	O	1015-1017
low	O	1018-1021
incidence	O	1022-1031
malformations	B	1032-1045
with	O	1046-1050
ASA	O	1051-1054
when	O	1055-1059
a	O	1060-1061
multiple	O	1062-1070
dosing	O	1071-1077
paradigm	O	1078-1086
is	O	1087-1089
used	O	1090-1094
.	O	1094-1095

METHODS	O	1096-1103
:	O	1103-1104
ASA	O	1105-1108
was	O	1109-1112
administered	O	1113-1125
as	O	1126-1128
a	O	1129-1130
single	O	1131-1137
dose	O	1138-1142
on	O	1143-1145
GD	O	1146-1148
9	O	1149-1150
(	O	1151-1152
0	O	1152-1153
,	O	1153-1154
250	O	1155-1158
,	O	1158-1159
500	O	1160-1163
,	O	1163-1164
or	O	1165-1167
625	O	1168-1171
mg	O	1172-1174
/	O	1174-1175
kg	O	1175-1177
)	O	1177-1178
,	O	1178-1179
10	O	1180-1182
(	O	1183-1184
0	O	1184-1185
,	O	1185-1186
500	O	1187-1190
,	O	1190-1191
625	O	1192-1195
,	O	1195-1196
or	O	1197-1199
750	O	1200-1203
mg	O	1204-1206
/	O	1206-1207
kg	O	1207-1209
)	O	1209-1210
,	O	1210-1211
or	O	1212-1214
11	O	1215-1217
(	O	1218-1219
0	O	1219-1220
,	O	1220-1221
500	O	1222-1225
,	O	1225-1226
750	O	1227-1230
,	O	1230-1231
or	O	1232-1234
1000	O	1235-1239
mg	O	1240-1242
/	O	1242-1243
kg	O	1243-1245
)	O	1245-1246
and	O	1247-1250
from	O	1251-1255
GD	O	1256-1258
6	O	1259-1260
to	O	1261-1263
GD	O	1264-1266
17	O	1267-1269
(	O	1270-1271
0	O	1271-1272
,	O	1272-1273
50	O	1274-1276
,	O	1276-1277
125	O	1278-1281
,	O	1281-1282
or	O	1283-1285
250	O	1286-1289
mg	O	1290-1292
/	O	1292-1293
kg	O	1293-1295
a	O	1296-1297
day	O	1298-1301
)	O	1301-1302
in	O	1303-1305
the	O	1306-1309
multiple	O	1310-1318
dose	O	1319-1323
study	O	1324-1329
to	O	1330-1332
SD	O	1333-1335
rats	O	1336-1340
.	O	1340-1341

Animals	O	1342-1349
were	O	1350-1354
killed	O	1355-1361
on	O	1362-1364
GD	O	1365-1367
21	O	1368-1370
,	O	1370-1371
and	O	1372-1375
fetuses	O	1376-1383
were	O	1384-1388
examined	O	1389-1397
viscerally	O	1398-1408
.	O	1408-1409

RESULTS	O	1410-1417
:	O	1417-1418
The	O	1419-1422
literature	O	1423-1433
evaluation	O	1434-1444
suggested	O	1445-1454
that	O	1455-1459
NSAIDs	O	1460-1466
induce	O	1467-1473
ventricular	B	1474-1485
septal	I	1486-1492
defects	I	1493-1500
(	O	1501-1502
VSDs	B	1502-1506
)	O	1506-1507
and	O	1508-1511
midline	B	1512-1519
defects	I	1520-1527
(	O	1528-1529
MDs	B	1529-1532
)	O	1532-1533
in	O	1534-1536
rats	O	1537-1541
and	O	1542-1545
diaphragmatic	B	1546-1559
hernia	I	1560-1566
(	O	1567-1568
DH	B	1568-1570
)	O	1570-1571
,	O	1571-1572
MDs	B	1573-1576
,	O	1576-1577
and	O	1578-1581
VSDs	B	1582-1586
in	O	1587-1589
rabbits	O	1590-1597
(	O	1598-1599
Cook	O	1599-1603
JC	O	1604-1606
et	O	1607-1609
al	O	1610-1612
.	O	1612-1613
,	O	1613-1614
2003	O	1615-1619
)	O	1619-1620
;	O	1620-1621
hence	O	1622-1627
,	O	1627-1628
the	O	1629-1632
present	O	1633-1640
study	O	1641-1646
focused	O	1647-1654
on	O	1655-1657
these	O	1658-1663
malformations	B	1664-1677
,	O	1677-1678
even	O	1679-1683
though	O	1684-1690
ASA	O	1691-1694
induces	O	1695-1702
several	O	1703-1710
other	O	1711-1716
low	O	1717-1720
-	O	1720-1721
incidence	O	1721-1730
malformations	B	1731-1744
.	O	1744-1745

In	O	1746-1748
single	O	1749-1755
dose	O	1756-1760
studies	O	1761-1768
,	O	1768-1769
DH	B	1770-1772
,	O	1772-1773
MD	B	1774-1776
,	O	1776-1777
and	O	1778-1781
VSD	B	1782-1785
were	O	1786-1790
induced	O	1791-1798
on	O	1799-1801
GDs	O	1802-1805
9	O	1806-1807
and	O	1808-1811
10	O	1812-1814
.	O	1814-1815

VSD	B	1816-1819
also	O	1820-1824
was	O	1825-1828
noted	O	1829-1834
following	O	1835-1844
treatment	O	1845-1854
on	O	1855-1857
GD	O	1858-1860
11	O	1861-1863
.	O	1863-1864

In	O	1865-1867
contrast	O	1868-1876
,	O	1876-1877
DH	B	1878-1880
and	O	1881-1884
MD	B	1885-1887
were	O	1888-1892
noted	O	1893-1898
in	O	1899-1901
the	O	1902-1905
multiple	O	1906-1914
dose	O	1915-1919
study	O	1920-1925
design	O	1926-1932
only	O	1933-1937
in	O	1938-1940
the	O	1941-1944
high	O	1945-1949
-	O	1949-1950
dose	O	1950-1954
group	O	1955-1960
,	O	1960-1961
and	O	1962-1965
VSD	B	1966-1969
was	O	1970-1973
noted	O	1974-1979
across	O	1980-1986
all	O	1987-1990
dose	O	1991-1995
groups	O	1996-2002
.	O	2002-2003

CONCLUSIONS	O	2004-2015
:	O	2015-2016
High	O	2017-2021
concordance	O	2022-2033
in	O	2034-2036
major	O	2037-2042
developmental	B	2043-2056
anomalies	I	2057-2066
between	O	2067-2074
Wistar	O	2075-2081
and	O	2082-2085
SD	O	2086-2088
rats	O	2089-2093
were	O	2094-2098
noted	O	2099-2104
with	O	2105-2109
the	O	2110-2113
exception	O	2114-2123
of	O	2124-2126
VSD	B	2127-2130
in	O	2131-2133
the	O	2134-2137
SD	O	2138-2140
rats	O	2141-2145
and	O	2146-2149
hydrocephalus	B	2150-2163
in	O	2164-2166
the	O	2167-2170
Wistar	O	2171-2177
rats	O	2178-2182
.	O	2182-2183

Variations	O	2184-2194
and	O	2195-2198
malformations	B	2199-2212
were	O	2213-2217
similar	O	2218-2225
when	O	2226-2230
ASA	O	2231-2234
was	O	2235-2238
administered	O	2239-2251
as	O	2252-2254
a	O	2255-2256
single	O	2257-2263
dose	O	2264-2268
or	O	2269-2271
during	O	2272-2278
the	O	2279-2282
period	O	2283-2289
of	O	2290-2292
organogenesis	O	2293-2306
(	O	2307-2308
GDs	O	2308-2311
6	O	2312-2313
to	O	2314-2316
17	O	2317-2319
)	O	2319-2320
.	O	2320-2321

It	O	2322-2324
was	O	2325-2328
also	O	2329-2333
evident	O	2334-2341
that	O	2342-2346
,	O	2346-2347
by	O	2348-2350
titrating	O	2351-2360
the	O	2361-2364
dose	O	2365-2369
to	O	2370-2372
achieve	O	2373-2380
a	O	2381-2382
maximum	O	2383-2390
tolerated	O	2391-2400
dose	O	2401-2405
,	O	2405-2406
malformations	B	2407-2420
that	O	2421-2425
normally	O	2426-2434
occur	O	2435-2440
at	O	2441-2443
low	O	2444-2447
incidence	O	2448-2457
,	O	2457-2458
as	O	2459-2461
reported	O	2462-2470
from	O	2471-2475
previous	O	2476-2484
single	O	2485-2491
dose	O	2492-2496
studies	O	2497-2504
,	O	2504-2505
could	O	2506-2511
also	O	2512-2516
be	O	2517-2519
induced	O	2520-2527
with	O	2528-2532
ASA	O	2533-2536
given	O	2537-2542
at	O	2543-2545
multiple	O	2546-2554
doses	O	2555-2560
.	O	2560-2561

Torsade	B	0-7
de	I	8-10
pointes	I	11-18
induced	O	19-26
by	O	27-29
metoclopramide	O	30-44
in	O	45-47
an	O	48-50
elderly	O	51-58
woman	O	59-64
with	O	65-69
preexisting	O	70-81
complete	O	82-90
left	B	91-95
bundle	I	96-102
branch	I	103-109
block	I	110-115
.	O	115-116

There	O	117-122
is	O	123-125
a	O	126-127
growing	O	128-135
list	O	136-140
of	O	141-143
drugs	O	144-149
implicated	O	150-160
in	O	161-163
acquired	O	164-172
long	B	173-177
QT	I	178-180
syndrome	I	181-189
and	O	190-193
torsade	B	194-201
de	I	202-204
pointes	I	205-212
.	O	212-213

However	O	214-221
,	O	221-222
the	O	223-226
torsadogenic	O	227-239
potential	O	240-249
of	O	250-252
metoclopramide	O	253-267
,	O	267-268
a	O	269-270
commonly	O	271-279
used	O	280-284
antiemetic	O	285-295
and	O	296-299
prokinetic	O	300-310
drug	O	311-315
,	O	315-316
has	O	317-320
not	O	321-324
been	O	325-329
reported	O	330-338
in	O	339-341
the	O	342-345
literature	O	346-356
,	O	356-357
despite	O	358-365
its	O	366-369
chemical	O	370-378
similarity	O	379-389
to	O	390-392
procainamide	O	393-405
.	O	405-406

We	O	407-409
report	O	410-416
on	O	417-419
a	O	420-421
92	O	422-424
-	O	424-425
year	O	425-429
-	O	424-425
old	O	430-433
woman	O	434-439
with	O	440-444
preexisting	O	445-456
complete	O	457-465
left	B	466-470
bundle	I	471-477
branch	I	478-484
block	I	485-490
who	O	491-494
developed	O	495-504
torsade	B	505-512
de	I	513-515
pointes	I	516-523
after	O	524-529
intravenous	O	530-541
and	O	542-545
oral	O	546-550
administration	O	551-565
of	O	566-568
metoclopramide	O	569-583
.	O	583-584

This	O	585-589
patient	O	590-597
also	O	598-602
developed	O	603-612
torsade	B	613-620
de	I	621-623
pointes	I	624-631
when	O	632-636
cisapride	O	637-646
and	O	647-650
erythromycin	O	651-663
were	O	664-668
given	O	669-674
simultaneously	O	675-689
.	O	689-690

These	O	691-696
two	O	697-700
episodes	O	701-709
were	O	710-714
suppressed	O	715-725
successfully	O	726-738
after	O	739-744
discontinuing	O	745-758
the	O	759-762
offending	O	763-772
drugs	O	773-778
and	O	779-782
administering	O	783-796
class	O	797-802
IB	O	803-805
drugs	O	806-811
.	O	811-812

This	O	813-817
is	O	818-820
the	O	821-824
first	O	825-830
documentation	O	831-844
that	O	845-849
metoclopramide	O	850-864
provokes	O	865-873
torsade	B	874-881
de	I	882-884
pointes	I	885-892
clinically	O	893-903
.	O	903-904

Metoclopramide	O	905-919
should	O	920-926
be	O	927-929
used	O	930-934
cautiously	O	935-945
in	O	946-948
patients	O	949-957
with	O	958-962
a	O	963-964
risk	O	965-969
of	O	970-972
torsade	B	973-980
de	I	981-983
pointes	I	984-991
.	O	991-992

Apomorphine	O	0-11
:	O	11-12
an	O	13-15
underutilized	O	16-29
therapy	O	30-37
for	O	38-41
Parkinson	B	42-51
'	I	51-52
s	I	48-49
disease	I	54-61
.	O	61-62

Apomorphine	O	63-74
was	O	75-78
the	O	79-82
first	O	83-88
dopaminergic	O	89-101
drug	O	102-106
ever	O	107-111
used	O	112-116
to	O	117-119
treat	O	120-125
symptoms	O	126-134
of	O	135-137
Parkinson	B	138-147
'	I	147-148
s	I	144-145
disease	I	150-157
.	O	157-158

While	O	159-164
powerful	O	165-173
antiparkinsonian	O	174-190
effects	O	191-198
had	O	199-202
been	O	203-207
observed	O	208-216
as	O	217-219
early	O	220-225
as	O	226-228
1951	O	229-233
,	O	233-234
the	O	235-238
potential	O	239-248
of	O	249-251
treating	O	252-260
fluctuating	O	261-272
Parkinson	B	273-282
'	I	282-283
s	I	279-280
disease	I	285-292
by	O	293-295
subcutaneous	O	296-308
administration	O	309-323
of	O	324-326
apomorphine	O	327-338
has	O	339-342
only	O	343-347
recently	O	348-356
become	O	357-363
the	O	364-367
subject	O	368-375
of	O	376-378
systematic	O	379-389
study	O	390-395
.	O	395-396

A	O	397-398
number	O	399-405
of	O	406-408
small	O	409-414
scale	O	415-420
clinical	O	421-429
trials	O	430-436
have	O	437-441
unequivocally	O	442-455
shown	O	456-461
that	O	462-466
intermittent	O	467-479
subcutaneous	O	480-492
apomorphine	O	493-504
injections	O	505-515
produce	O	516-523
antiparkinsonian	O	524-540
benefit	O	541-548
close	O	549-554
if	O	555-557
not	O	558-561
identical	O	562-571
to	O	572-574
that	O	575-579
seen	O	580-584
with	O	585-589
levodopa	O	590-598
and	O	599-602
that	O	603-607
apomorphine	O	608-619
rescue	O	620-626
injections	O	627-637
can	O	638-641
reliably	O	642-650
revert	O	651-657
off	O	658-661
-	O	661-662
periods	O	662-669
even	O	670-674
in	O	675-677
patients	O	678-686
with	O	687-691
complex	O	692-699
on	O	700-702
-	O	702-703
off	O	703-706
motor	O	707-712
swings	O	713-719
.	O	719-720

Continuous	O	721-731
subcutaneous	O	732-744
apomorphine	O	745-756
infusions	O	757-766
can	O	767-770
reduce	O	771-777
daily	O	778-783
off	O	784-787
-	O	787-788
time	O	788-792
by	O	793-795
more	O	796-800
than	O	801-805
50	O	806-808
%	O	808-809
in	O	810-812
this	O	813-817
group	O	818-823
of	O	824-826
patients	O	827-835
,	O	835-836
which	O	837-842
appears	O	843-850
to	O	851-853
be	O	854-856
a	O	857-858
stronger	O	859-867
effect	O	868-874
than	O	875-879
that	O	880-884
generally	O	885-894
seen	O	895-899
with	O	900-904
add	O	905-908
-	O	908-909
on	O	909-911
therapy	O	912-919
with	O	920-924
oral	O	925-929
dopamine	O	930-938
agonists	O	939-947
or	O	948-950
COMT	O	951-955
inhibitors	O	956-966
.	O	966-967

Extended	O	968-976
follow	O	977-983
-	O	983-984
up	O	984-986
studies	O	987-994
of	O	995-997
up	O	998-1000
to	O	1001-1003
8	O	1004-1005
years	O	1006-1011
have	O	1012-1016
demonstrated	O	1017-1029
long	O	1030-1034
-	O	1034-1035
term	O	1035-1039
persistence	O	1040-1051
of	O	1052-1054
apomorphine	O	1055-1066
efficacy	O	1067-1075
.	O	1075-1076

In	O	1077-1079
addition	O	1080-1088
,	O	1088-1089
there	O	1090-1095
is	O	1096-1098
convincing	O	1099-1109
clinical	O	1110-1118
evidence	O	1119-1127
that	O	1128-1132
monotherapy	O	1133-1144
with	O	1145-1149
continuous	O	1150-1160
subcutaneous	O	1161-1173
apomorphine	O	1174-1185
infusions	O	1186-1195
is	O	1196-1198
associated	O	1199-1209
with	O	1210-1214
marked	O	1215-1221
reductions	O	1222-1232
of	O	1233-1235
preexisting	O	1236-1247
levodopa	O	1248-1256
-	O	1256-1257
induced	O	1257-1264
dyskinesias	B	1265-1276
.	O	1276-1277

The	O	1278-1281
main	O	1282-1286
side	O	1287-1291
effects	O	1292-1299
of	O	1300-1302
subcutaneous	O	1303-1315
apomorphine	O	1316-1327
treatment	O	1328-1337
are	O	1338-1341
related	O	1342-1349
to	O	1350-1352
cutaneous	O	1353-1362
tolerability	O	1363-1375
problems	O	1376-1384
,	O	1384-1385
whereas	O	1386-1393
sedation	O	1394-1402
and	O	1403-1406
psychiatric	B	1407-1418
complications	O	1419-1432
play	O	1433-1437
a	O	1438-1439
lesser	O	1440-1446
role	O	1447-1451
.	O	1451-1452

Given	O	1453-1458
the	O	1459-1462
marked	O	1463-1469
degree	O	1470-1476
of	O	1477-1479
efficacy	O	1480-1488
of	O	1489-1491
subcutaneous	O	1492-1504
apomorphine	O	1505-1516
treatment	O	1517-1526
in	O	1527-1529
fluctuating	O	1530-1541
Parkinson	B	1542-1551
'	I	1551-1552
s	I	1548-1549
disease	I	1554-1561
,	O	1561-1562
this	O	1563-1567
approach	O	1568-1576
seems	O	1577-1582
to	O	1583-1585
deserve	O	1586-1593
more	O	1594-1598
widespread	O	1599-1609
clinical	O	1610-1618
use	O	1619-1622
.	O	1622-1623

Fatal	O	0-5
excited	O	6-13
delirium	B	14-22
following	O	23-32
cocaine	O	33-40
use	O	41-44
:	O	44-45
epidemiologic	O	46-59
findings	O	60-68
provide	O	69-76
new	O	77-80
evidence	O	81-89
for	O	90-93
mechanisms	O	94-104
of	O	105-107
cocaine	O	108-115
toxicity	B	116-124
.	O	124-125

We	O	126-128
describe	O	129-137
an	O	138-140
outbreak	O	141-149
of	O	150-152
deaths	O	153-159
from	O	160-164
cocaine	O	165-172
-	O	172-173
induced	O	173-180
excited	O	181-188
delirium	B	189-197
(	O	198-199
EDDs	B	199-203
)	O	203-204
in	O	205-207
Dade	O	208-212
County	O	213-219
,	O	219-220
Florida	O	221-228
between	O	229-236
1979	O	237-241
and	O	242-245
1990	O	246-250
.	O	250-251

From	O	252-256
a	O	257-258
registry	O	259-267
of	O	268-270
all	O	271-274
cocaine	O	275-282
-	O	282-283
related	O	283-290
deaths	O	291-297
in	O	298-300
Dade	O	301-305
County	O	306-312
,	O	312-313
Florida	O	314-321
,	O	321-322
from	O	323-327
1969	O	328-332
-	O	332-333
1990	O	333-337
,	O	337-338
58	O	339-341
EDDs	B	342-346
were	O	347-351
compared	O	352-360
with	O	361-365
125	O	366-369
victims	O	370-377
of	O	378-380
accidental	O	381-391
cocaine	O	392-399
overdose	B	400-408
without	O	409-416
excited	O	417-424
delirium	B	425-433
.	O	433-434

Compared	O	435-443
with	O	444-448
controls	O	449-457
,	O	457-458
EDDs	B	459-463
were	O	464-468
more	O	469-473
frequently	O	474-484
black	O	485-490
,	O	490-491
male	O	492-496
,	O	496-497
and	O	498-501
younger	O	502-509
.	O	509-510

They	O	511-515
were	O	516-520
less	O	521-525
likely	O	526-532
to	O	533-535
have	O	536-540
a	O	541-542
low	O	543-546
body	O	547-551
mass	O	552-556
index	O	557-562
,	O	562-563
and	O	564-567
more	O	568-572
likely	O	573-579
to	O	580-582
have	O	583-587
died	O	588-592
in	O	593-595
police	O	596-602
custody	O	603-610
,	O	610-611
to	O	612-614
have	O	615-619
received	O	620-628
medical	O	629-636
treatment	O	637-646
immediately	O	647-658
before	O	659-665
death	O	666-671
,	O	671-672
to	O	673-675
have	O	676-680
survived	O	681-689
for	O	690-693
a	O	694-695
longer	O	696-702
period	O	703-709
,	O	709-710
to	O	711-713
have	O	714-718
developed	O	719-728
hyperthermia	B	729-741
,	O	741-742
and	O	743-746
to	O	747-749
have	O	750-754
died	O	755-759
in	O	760-762
summer	O	763-769
months	O	770-776
.	O	776-777

EDDs	B	778-782
had	O	783-786
concentrations	O	787-801
of	O	802-804
cocaine	O	805-812
and	O	813-816
benzoylecgonine	O	817-832
in	O	833-835
autopsy	O	836-843
blood	O	844-849
that	O	850-854
were	O	855-859
similar	O	860-867
to	O	868-870
those	O	871-876
for	O	877-880
controls	O	881-889
.	O	889-890

The	O	891-894
epidemiologic	O	895-908
findings	O	909-917
are	O	918-921
most	O	922-926
consistent	O	927-937
with	O	938-942
the	O	943-946
hypothesis	O	947-957
that	O	958-962
chronic	O	963-970
cocaine	O	971-978
use	O	979-982
disrupts	O	983-991
dopaminergic	O	992-1004
function	O	1005-1013
and	O	1014-1017
,	O	1017-1018
when	O	1019-1023
coupled	O	1024-1031
with	O	1032-1036
recent	O	1037-1043
cocaine	O	1044-1051
use	O	1052-1055
,	O	1055-1056
may	O	1057-1060
precipitate	O	1061-1072
agitation	B	1073-1082
,	O	1082-1083
delirium	B	1084-1092
,	O	1092-1093
aberrant	O	1094-1102
thermoregulation	O	1103-1119
,	O	1119-1120
rhabdomyolysis	B	1121-1135
,	O	1135-1136
and	O	1137-1140
sudden	B	1141-1147
death	I	1148-1153
.	O	1153-1154

Heparin	O	0-7
-	O	7-8
induced	O	8-15
thrombocytopenia	B	16-32
,	O	32-33
thrombosis	B	34-44
,	O	44-45
and	O	46-49
hemorrhage	B	50-60
.	O	60-61

Sixty	O	62-67
-	O	67-68
two	O	68-71
patients	O	72-80
with	O	81-85
a	O	86-87
heparin	O	88-95
-	O	95-96
induced	O	96-103
thrombocytopenia	B	104-120
are	O	121-124
reported	O	125-133
.	O	133-134

Clinical	O	135-143
manifestations	O	144-158
of	O	159-161
this	O	162-166
disorder	O	167-175
include	O	176-183
hemorrhage	B	184-194
or	O	195-197
,	O	197-198
more	O	199-203
frequently	O	204-214
,	O	214-215
thromboembolic	B	216-230
events	O	231-237
in	O	238-240
patients	O	241-249
receiving	O	250-259
heparin	O	260-267
.	O	267-268

Laboratory	O	269-279
testing	O	280-287
has	O	288-291
revealed	O	292-300
a	B	301-302
falling	I	303-310
platelet	I	311-319
count	I	320-325
,	O	325-326
increased	O	327-336
resistance	O	337-347
to	O	348-350
heparin	O	351-358
,	O	358-359
and	O	360-363
aggregation	O	364-375
of	O	376-378
platelets	O	379-388
by	O	389-391
the	O	392-395
patient	O	396-403
'	O	403-404
s	O	404-405
plasma	O	406-412
when	O	413-417
heparin	O	418-425
is	O	426-428
added	O	429-434
.	O	434-435

Immunologic	O	436-447
testing	O	448-455
has	O	456-459
demonstrated	O	460-472
the	O	473-476
presence	O	477-485
of	O	486-488
a	O	489-490
heparin	O	491-498
-	O	498-499
dependent	O	499-508
platelet	O	509-517
membrane	O	518-526
antibody	O	527-535
.	O	535-536

The	O	537-540
20	O	541-543
deaths	O	544-550
,	O	550-551
52	O	552-554
hemorrhagic	B	555-566
and	I	567-570
thromboembolic	I	571-585
complications	I	586-599
,	O	599-600
and	O	601-604
21	O	605-607
surgical	O	608-616
procedures	O	617-627
to	O	628-630
manage	O	631-637
the	O	638-641
complications	O	642-655
confirm	O	656-663
the	O	664-667
seriousness	O	668-679
of	O	680-682
the	O	683-686
disorder	O	687-695
.	O	695-696

Specific	O	697-705
risk	O	706-710
factors	O	711-718
have	O	719-723
not	O	724-727
been	O	728-732
identified	O	733-743
;	O	743-744
therefore	O	745-754
,	O	754-755
all	O	756-759
patients	O	760-768
receiving	O	769-778
heparin	O	779-786
should	O	787-793
be	O	794-796
monitored	O	797-806
.	O	806-807

If	O	808-810
the	O	811-814
platelet	O	815-823
count	O	824-829
falls	O	830-835
to	O	836-838
less	O	839-843
than	O	844-848
100	O	849-852
,	O	852-853
000	O	853-856
/	O	856-857
mm3	O	857-860
,	O	852-853
while	O	862-867
the	O	868-871
patient	O	872-879
is	O	880-882
receiving	O	883-892
heparin	O	893-900
,	O	900-901
platelet	B	902-910
aggregation	I	911-922
testing	O	923-930
,	O	930-931
using	O	932-937
the	O	938-941
patient	O	942-949
'	O	949-950
s	O	950-951
plasma	O	952-958
,	O	958-959
is	O	960-962
indicated	O	963-972
.	O	972-973

Management	O	974-984
consists	O	985-993
of	O	994-996
cessation	O	997-1006
of	O	1007-1009
heparin	O	1010-1017
,	O	1017-1018
platelet	O	1019-1027
anti	O	1028-1032
-	O	1032-1033
aggregating	O	1033-1044
agents	O	1045-1051
,	O	1051-1052
and	O	1053-1056
alternate	O	1057-1066
forms	O	1067-1072
of	O	1073-1075
anticoagulation	O	1076-1091
when	O	1092-1096
indicated	O	1097-1106
.	O	1106-1107

Cardiac	B	0-7
toxicity	I	8-16
of	O	17-19
5	O	20-21
-	O	21-22
fluorouracil	O	22-34
.	O	34-35

Report	O	36-42
of	O	43-45
a	O	46-47
case	O	48-52
of	O	53-55
spontaneous	O	56-67
angina	B	68-74
.	O	74-75

We	O	76-78
report	O	79-85
a	O	86-87
case	O	88-92
of	O	93-95
a	O	96-97
patient	O	98-105
with	O	106-110
colon	B	111-116
carcinoma	I	117-126
and	O	127-130
liver	O	131-136
metastasis	B	137-147
who	O	148-151
presented	O	152-161
chest	B	162-167
pain	I	168-172
after	O	173-178
5	O	179-180
-	O	180-181
fluorouracil	O	181-193
(	O	194-195
5	O	195-196
-	O	196-197
FU	O	197-199
)	O	199-200
administration	O	201-215
.	O	215-216

Clinical	O	217-225
electrocardiographic	O	226-246
evolution	O	247-256
was	O	257-260
similar	O	261-268
to	O	269-271
that	O	272-276
observed	O	277-285
in	O	286-288
Prinzmetal	B	289-299
'	I	299-300
s	I	300-301
angina	I	302-308
,	O	308-309
and	O	310-313
chest	B	314-319
pain	I	320-324
promptly	O	325-333
resolved	O	334-342
with	O	343-347
nifedipine	O	348-358
.	O	358-359

These	O	360-365
data	O	366-370
suggest	O	371-378
that	O	379-383
coronary	B	384-392
spasm	I	393-398
may	O	399-402
be	O	403-405
the	O	406-409
cause	O	410-415
of	O	416-418
cardiotoxicity	B	419-433
due	O	434-437
to	O	438-440
5	O	441-442
-	O	442-443
FU	O	443-445
,	O	445-446
and	O	447-450
that	O	451-455
calcium	O	456-463
antagonists	O	464-475
may	O	476-479
probably	O	480-488
be	O	489-491
used	O	492-496
in	O	497-499
the	O	500-503
prevention	O	504-514
or	O	515-517
treatment	O	518-527
of	O	528-530
5	O	531-532
-	O	532-533
FU	O	533-535
cardiotoxicity	B	536-550
.	O	550-551

Toxicity	B	0-8
due	O	9-12
to	O	13-15
remission	O	16-25
inducing	O	26-34
drugs	O	35-40
in	O	41-43
rheumatoid	B	44-54
arthritis	I	55-64
.	O	64-65

Association	O	66-77
with	O	78-82
HLA	O	83-86
-	O	86-87
B35	O	87-90
and	O	91-94
Cw4	O	95-98
antigens	O	99-107
.	O	107-108

Twenty	O	109-115
-	O	115-116
five	O	116-120
patients	O	121-129
with	O	130-134
rheumatoid	B	135-145
arthritis	I	146-155
(	O	156-157
RA	B	157-159
)	O	159-160
who	O	161-164
developed	O	165-174
toxicity	B	175-183
while	O	184-189
taking	O	190-196
remission	O	197-206
inducing	O	207-215
drugs	O	216-221
and	O	222-225
30	O	226-228
without	O	229-236
toxicity	B	237-245
were	O	246-250
studied	O	251-258
for	O	259-262
possible	O	263-271
associations	O	272-284
with	O	285-289
class	O	290-295
I	O	296-297
and	O	298-301
II	O	302-304
HLA	O	305-308
antigens	O	309-317
.	O	317-318

A	O	319-320
strong	O	321-327
association	O	328-339
has	O	340-343
been	O	344-348
found	O	349-354
between	O	355-362
nephritis	B	363-372
and	O	373-376
dermatitis	B	377-387
due	O	388-391
to	O	392-394
Tiopronin	O	395-404
(	O	405-406
a	O	406-407
D	O	408-409
-	O	409-410
Penicillamine	O	410-423
like	O	424-428
compound	O	429-437
)	O	437-438
and	O	439-442
class	O	443-448
I	O	449-450
antigens	O	451-459
B35	O	460-463
-	O	463-464
Cw4	O	464-467
,	O	467-468
and	O	469-472
between	O	473-480
dermatitis	B	481-491
due	O	492-495
to	O	496-498
gold	O	499-503
thiosulphate	O	504-516
and	O	517-520
B35	O	521-524
.	O	524-525

Compared	O	526-534
to	O	535-537
healthy	O	538-545
controls	O	546-554
a	O	555-556
lower	O	557-562
DR5	O	563-566
frequency	O	567-576
was	O	577-580
observed	O	581-589
in	O	590-592
patients	O	593-601
with	O	602-606
RA	B	607-609
except	O	610-616
for	O	617-620
the	O	621-624
Tiopronin	O	625-634
related	O	635-642
nephritis	B	643-652
group	O	653-658
.	O	658-659

Transient	O	0-9
hemiparesis	B	10-21
:	O	21-22
a	O	23-24
rare	O	25-29
manifestation	O	30-43
of	O	44-46
diphenylhydantoin	O	47-64
toxicity	B	65-73
.	O	73-74

Report	O	75-81
of	O	82-84
two	O	85-88
cases	O	89-94
.	O	94-95

Among	O	96-101
the	O	102-105
common	O	106-112
side	O	113-117
effects	O	118-125
of	O	126-128
diphenylhydantoin	O	129-146
(	O	147-148
DPH	O	148-151
)	O	151-152
overdose	B	153-161
,	O	161-162
the	O	163-166
most	O	167-171
frequently	O	172-182
encountered	O	183-194
neurological	O	195-207
signs	O	208-213
are	O	214-217
those	O	218-223
of	O	224-226
cerebellar	B	227-237
dysfunction	I	238-249
.	O	249-250

Very	O	251-255
rarely	O	256-262
,	O	262-263
the	O	264-267
toxic	O	268-273
neurological	O	274-286
manifestations	O	287-301
of	O	302-304
this	O	305-309
drug	O	310-314
are	O	315-318
of	O	319-321
cerebral	O	322-330
origin	O	331-337
.	O	337-338

Two	O	339-342
patients	O	343-351
are	O	352-355
presented	O	356-365
who	O	366-369
suffered	O	370-378
progressive	O	379-390
hemiparesis	B	391-402
due	O	403-406
to	O	407-409
DPH	O	410-413
overdose	B	414-422
.	O	422-423

Both	O	424-428
had	O	429-432
brain	O	433-438
surgery	O	439-446
before	O	447-453
DPH	O	454-457
treatment	O	458-467
.	O	467-468

It	O	469-471
is	O	472-474
assumed	O	475-482
that	O	483-487
patients	O	488-496
with	O	497-501
some	O	502-506
cerebral	B	507-515
damage	I	516-522
are	O	523-526
liable	O	527-533
to	O	534-536
manifest	O	537-545
DPH	O	546-549
toxicity	B	550-558
as	O	559-561
focal	O	562-567
neurological	O	568-580
signs	O	581-586
.	O	586-587

Nerve	O	0-5
growth	O	6-12
factor	O	13-19
and	O	20-23
prostaglandins	O	24-38
in	O	39-41
the	O	42-45
urine	O	46-51
of	O	52-54
female	O	55-61
patients	O	62-70
with	O	71-75
overactive	B	76-86
bladder	I	87-94
.	O	94-95

PURPOSE	O	96-103
:	O	103-104
NGF	O	105-108
and	O	109-112
PGs	O	113-116
in	O	117-119
the	O	120-123
bladder	O	124-131
can	O	132-135
be	O	136-138
affected	O	139-147
by	O	148-150
pathological	O	151-163
changes	O	164-171
in	O	172-174
the	O	175-178
bladder	O	179-186
and	O	187-190
these	O	191-196
changes	O	197-204
can	O	205-208
be	O	209-211
detected	O	212-220
in	O	221-223
urine	O	224-229
.	O	229-230

We	O	231-233
investigated	O	234-246
changes	O	247-254
in	O	255-257
urinary	O	258-265
NGF	O	266-269
and	O	270-273
PGs	O	274-277
in	O	278-280
women	O	281-286
with	O	287-291
OAB	B	292-295
.	O	295-296

MATERIALS	O	297-306
AND	O	307-310
METHODS	O	311-318
:	O	318-319
The	O	320-323
study	O	324-329
groups	O	330-336
included	O	337-345
65	O	346-348
women	O	349-354
with	O	355-359
OAB	B	360-363
and	O	364-367
20	O	368-370
without	O	371-378
bladder	O	379-386
symptoms	O	387-395
who	O	396-399
served	O	400-406
as	O	407-409
controls	O	410-418
.	O	418-419

Evaluation	O	420-430
included	O	431-439
patient	O	440-447
history	O	448-455
,	O	455-456
urinalysis	O	457-467
,	O	467-468
a	O	469-470
voiding	O	471-478
diary	O	479-484
and	O	485-488
urodynamic	O	489-499
studies	O	500-507
.	O	507-508

Urine	O	509-514
samples	O	515-522
were	O	523-527
collected	O	528-537
.	O	537-538

NGF	O	539-542
,	O	542-543
PGE2	O	544-548
,	O	548-549
PGF2alpha	O	550-559
and	O	560-563
PGI2	O	564-568
were	O	569-573
measured	O	574-582
using	O	583-588
enzyme	O	589-595
-	O	595-596
linked	O	596-602
immunosorbent	O	603-616
assay	O	617-622
and	O	623-626
compared	O	627-635
between	O	636-643
the	O	644-647
groups	O	648-654
.	O	654-655

In	O	656-658
addition	O	659-667
,	O	667-668
correlations	O	669-681
between	O	682-689
urinary	O	690-697
NGF	O	698-701
and	O	702-705
PG	O	706-708
,	O	708-709
and	O	710-713
urodynamic	O	714-724
parameters	O	725-735
in	O	736-738
patients	O	739-747
with	O	748-752
OAB	B	753-756
were	O	757-761
examined	O	762-770
.	O	770-771

RESULTS	O	772-779
:	O	779-780
Urinary	O	781-788
NGF	O	789-792
,	O	792-793
PGE2	O	794-798
and	O	799-802
PGF2alpha	O	803-812
were	O	813-817
significantly	O	818-831
increased	O	832-841
in	O	842-844
patients	O	845-853
with	O	854-858
OAB	B	859-862
compared	O	863-871
with	O	872-876
controls	O	877-885
(	O	886-887
p	O	887-888
<	O	889-890
0	O	890-891
.	O	891-892
05	O	892-894
)	O	894-895
.	O	891-892

However	O	897-904
,	O	904-905
urinary	O	906-913
PGI2	O	914-918
was	O	919-922
not	O	923-926
different	O	927-936
between	O	937-944
controls	O	945-953
and	O	954-957
patients	O	958-966
with	O	967-971
OAB	B	972-975
.	O	975-976

In	O	977-979
patients	O	980-988
with	O	989-993
OAB	B	994-997
urinary	O	998-1005
PGE2	O	1006-1010
positively	O	1011-1021
correlated	O	1022-1032
with	O	1033-1037
volume	O	1038-1044
at	O	1045-1047
first	O	1048-1053
desire	O	1054-1060
to	O	1061-1063
void	O	1064-1068
and	O	1069-1072
maximum	O	1073-1080
cystometric	O	1081-1092
capacity	O	1093-1101
(	O	1102-1103
p	O	1103-1104
<	O	1105-1106
0	O	1106-1107
.	O	1107-1108
05	O	1108-1110
)	O	1110-1111
.	O	1107-1108

Urinary	O	1113-1120
NGF	O	1121-1124
,	O	1124-1125
PGF2alpha	O	1126-1135
and	O	1136-1139
PGI2	O	1140-1144
did	O	1145-1148
not	O	1149-1152
correlate	O	1153-1162
with	O	1163-1167
urodynamic	O	1168-1178
parameters	O	1179-1189
in	O	1190-1192
patients	O	1193-1201
with	O	1202-1206
OAB	B	1207-1210
.	O	1210-1211

CONCLUSIONS	O	1212-1223
:	O	1223-1224
NGF	O	1225-1228
and	O	1229-1232
PGs	O	1233-1236
have	O	1237-1241
important	O	1242-1251
roles	O	1252-1257
in	O	1258-1260
the	O	1261-1264
development	O	1265-1276
of	O	1277-1279
OAB	B	1280-1283
symptoms	O	1284-1292
in	O	1293-1295
female	O	1296-1302
patients	O	1303-1311
.	O	1311-1312

Urinary	O	1313-1320
levels	O	1321-1327
of	O	1328-1330
these	O	1331-1336
factors	O	1337-1344
may	O	1345-1348
be	O	1349-1351
used	O	1352-1356
as	O	1357-1359
markers	O	1360-1367
to	O	1368-1370
evaluate	O	1371-1379
OAB	B	1380-1383
symptoms	O	1384-1392
.	O	1392-1393

Acute	O	0-5
low	B	6-9
back	I	10-14
pain	I	15-19
during	O	20-26
intravenous	O	27-38
administration	O	39-53
of	O	54-56
amiodarone	O	57-67
:	O	67-68
a	O	69-70
report	O	71-77
of	O	78-80
two	O	81-84
cases	O	85-90
.	O	90-91

Amiodarone	O	92-102
represents	O	103-113
an	O	114-116
effective	O	117-126
antiarrhythmic	O	127-141
drug	O	142-146
for	O	147-150
cardioversion	O	151-164
of	O	165-167
recent	O	168-174
-	O	174-175
onset	O	175-180
atrial	B	181-187
fibrillation	I	188-200
(	O	201-202
AF	B	202-204
)	O	204-205
and	O	206-209
maintenance	O	210-221
of	O	222-224
sinus	O	225-230
rhythm	O	231-237
.	O	237-238

We	O	239-241
briefly	O	242-249
describe	O	250-258
two	O	259-262
patients	O	263-271
suffering	O	272-281
from	O	282-286
recent	O	287-293
-	O	293-294
onset	O	294-299
atrial	B	300-306
fibrillation	I	307-319
,	O	319-320
who	O	321-324
experienced	O	325-336
an	O	337-339
acute	O	340-345
devastating	O	346-357
low	B	358-361
back	I	362-366
pain	I	367-371
a	O	372-373
few	O	374-377
minutes	O	378-385
after	O	386-391
initiation	O	392-402
of	O	403-405
intravenous	O	406-417
amiodarone	O	418-428
loading	O	429-436
.	O	436-437

Notably	O	438-445
,	O	445-446
this	O	447-451
side	O	452-456
effect	O	457-463
has	O	464-467
not	O	468-471
been	O	472-476
ever	O	477-481
reported	O	482-490
in	O	491-493
the	O	494-497
medical	O	498-505
literature	O	506-516
.	O	516-517

Clinicians	O	518-528
should	O	529-535
be	O	536-538
aware	O	539-544
of	O	545-547
this	O	548-552
reaction	O	553-561
since	O	562-567
prompt	O	568-574
termination	O	575-586
of	O	587-589
parenteral	O	590-600
administration	O	601-615
leads	O	616-621
to	O	622-624
complete	O	625-633
resolution	O	634-644
.	O	644-645

Postoperative	B	0-13
myalgia	I	14-21
after	O	22-27
succinylcholine	O	28-43
:	O	43-44
no	O	45-47
evidence	O	48-56
for	O	57-60
an	O	61-63
inflammatory	O	64-76
origin	O	77-83
.	O	83-84

A	O	85-86
common	O	87-93
side	O	94-98
effect	O	99-105
associated	O	106-116
with	O	117-121
succinylcholine	O	122-137
is	O	138-140
postoperative	B	141-154
myalgia	I	155-162
.	O	162-163

The	O	164-167
pathogenesis	O	168-180
of	O	181-183
this	O	184-188
myalgia	B	189-196
is	O	197-199
still	O	200-205
unclear	O	206-213
;	O	213-214
inflammation	B	215-227
has	O	228-231
been	O	232-236
suggested	O	237-246
but	O	247-250
without	O	251-258
convincing	O	259-269
evidence	O	270-278
.	O	278-279

We	O	280-282
designed	O	283-291
the	O	292-295
present	O	296-303
study	O	304-309
to	O	310-312
investigate	O	313-324
whether	O	325-332
an	O	333-335
inflammatory	O	336-348
reaction	O	349-357
contributes	O	358-369
to	O	370-372
this	O	373-377
myalgia	B	378-385
.	O	385-386

The	O	387-390
incidence	O	391-400
and	O	401-404
severity	O	405-413
of	O	414-416
succinylcholine	O	417-432
-	O	432-433
associated	O	433-443
myalgia	B	444-451
was	O	452-455
determined	O	456-466
in	O	467-469
64	O	470-472
patients	O	473-481
pretreated	O	482-492
with	O	493-497
saline	O	498-504
or	O	505-507
dexamethasone	O	508-521
before	O	522-528
succinylcholine	O	529-544
(	O	545-546
n	O	546-547
=	O	548-549
32	O	550-552
for	O	553-556
each	O	557-561
)	O	561-562
.	O	562-563

Incidence	O	564-573
and	O	574-577
severity	O	578-586
of	O	587-589
myalgia	B	590-597
did	O	598-601
not	O	602-605
differ	O	606-612
significantly	O	613-626
between	O	627-634
the	O	635-638
two	O	639-642
groups	O	643-649
:	O	649-650
15	O	651-653
patients	O	654-662
in	O	663-665
the	O	666-669
dexamethasone	O	670-683
group	O	684-689
complained	O	690-700
of	O	701-703
myalgia	B	704-711
compared	O	712-720
with	O	721-725
18	O	726-728
patients	O	729-737
in	O	738-740
the	O	741-744
saline	O	745-751
group	O	752-757
,	O	757-758
and	O	759-762
severe	O	763-769
myalgia	B	770-777
was	O	778-781
reported	O	782-790
by	O	791-793
five	O	794-798
patients	O	799-807
and	O	808-811
three	O	812-817
patients	O	818-826
,	O	826-827
respectively	O	828-840
(	O	841-842
not	O	842-845
significant	O	846-857
)	O	857-858
.	O	858-859

At	O	860-862
48	O	863-865
h	O	866-867
after	O	868-873
surgery	O	874-881
,	O	881-882
12	O	883-885
patients	O	886-894
in	O	895-897
both	O	898-902
groups	O	903-909
still	O	910-915
suffered	O	916-924
from	O	925-929
myalgia	B	930-937
(	O	938-939
not	O	939-942
significant	O	943-954
)	O	954-955
.	O	955-956

In	O	957-959
addition	O	960-968
,	O	968-969
interleukin	O	970-981
-	O	981-982
6	O	982-983
(	O	984-985
IL	O	985-987
-	O	987-988
6	O	988-989
)	O	989-990
as	O	991-993
an	O	994-996
early	O	997-1002
marker	O	1003-1009
of	O	1010-1012
inflammation	B	1013-1025
was	O	1026-1029
assessed	O	1030-1038
in	O	1039-1041
a	O	1042-1043
subgroup	O	1044-1052
of	O	1053-1055
10	O	1056-1058
patients	O	1059-1067
pretreated	O	1068-1078
with	O	1079-1083
saline	O	1084-1090
.	O	1090-1091

We	O	1092-1094
found	O	1095-1100
an	O	1101-1103
increase	O	1104-1112
of	O	1113-1115
IL	O	1116-1118
-	O	1118-1119
6	O	1119-1120
for	O	1121-1124
only	O	1125-1129
three	O	1130-1135
patients	O	1136-1144
,	O	1144-1145
but	O	1146-1149
only	O	1150-1154
one	O	1155-1158
patient	O	1159-1166
reported	O	1167-1175
myalgia	B	1176-1183
;	O	1183-1184
no	O	1185-1187
relationship	O	1188-1200
between	O	1201-1208
myalgia	B	1209-1216
and	O	1217-1220
the	O	1221-1224
increase	O	1225-1233
of	O	1234-1236
IL	O	1237-1239
-	O	1239-1240
6	O	1240-1241
was	O	1242-1245
found	O	1246-1251
.	O	1251-1252

In	O	1253-1255
conclusion	O	1256-1266
,	O	1266-1267
there	O	1268-1273
is	O	1274-1276
no	O	1277-1279
evidence	O	1280-1288
for	O	1289-1292
an	O	1293-1295
inflammatory	O	1296-1308
origin	O	1309-1315
of	O	1316-1318
succinylcholine	O	1319-1334
-	O	1334-1335
associated	O	1335-1345
myalgia	B	1346-1353
.	O	1353-1354

IMPLICATIONS	O	1355-1367
:	O	1367-1368
Administration	O	1369-1383
of	O	1384-1386
dexamethasone	O	1387-1400
before	O	1401-1407
succinylcholine	O	1408-1423
was	O	1424-1427
not	O	1428-1431
effective	O	1432-1441
in	O	1442-1444
decreasing	O	1445-1455
the	O	1456-1459
incidence	O	1460-1469
or	O	1470-1472
the	O	1473-1476
severity	O	1477-1485
of	O	1486-1488
succinylcholine	O	1489-1504
-	O	1504-1505
induced	O	1505-1512
postoperative	B	1513-1526
myalgia	I	1527-1534
.	O	1534-1535

Furthermore	O	1536-1547
,	O	1547-1548
there	O	1549-1554
was	O	1555-1558
no	O	1559-1561
significant	O	1562-1573
relationship	O	1574-1586
between	O	1587-1594
postoperative	B	1595-1608
myalgia	I	1609-1616
and	O	1617-1620
time	O	1621-1625
course	O	1626-1632
of	O	1633-1635
interleukin	O	1636-1647
-	O	1647-1648
6	O	1648-1649
concentrations	O	1650-1664
,	O	1664-1665
a	O	1666-1667
marker	O	1668-1674
of	O	1675-1677
inflammation	B	1678-1690
.	O	1690-1691

Pretreatment	O	1692-1704
with	O	1705-1709
dexamethasone	O	1710-1723
is	O	1724-1726
not	O	1727-1730
justified	O	1731-1740
to	O	1741-1743
prevent	O	1744-1751
postoperative	B	1752-1765
myalgia	I	1766-1773
after	O	1774-1779
succinylcholine	O	1780-1795
.	O	1795-1796

Levodopa	O	0-8
-	O	8-9
induced	O	9-16
oromandibular	O	17-30
dystonia	B	31-39
in	O	40-42
progressive	B	43-54
supranuclear	I	55-67
palsy	I	68-73
.	O	73-74

Levodopa	O	75-83
-	O	83-84
induced	O	84-91
dyskinesias	B	92-103
have	O	104-108
been	O	109-113
reported	O	114-122
in	O	123-125
Parkinson	B	126-135
'	I	135-136
s	I	132-133
disease	I	138-145
and	O	146-149
multiple	B	150-158
system	I	159-165
atrophy	I	166-173
.	O	173-174

Cranial	O	175-182
dystonias	B	183-192
are	O	193-196
rare	O	197-201
in	O	202-204
patients	O	205-213
with	O	214-218
progressive	B	219-230
supranuclear	I	231-243
palsy	I	244-249
(	O	250-251
PSP	B	251-254
)	O	254-255
.	O	255-256

In	O	257-259
this	O	260-264
report	O	265-271
we	O	272-274
describe	O	275-283
an	O	284-286
unusual	O	287-294
case	O	295-299
of	O	300-302
reversible	O	303-313
levodopa	O	314-322
-	O	322-323
induced	O	323-330
Oromandibular	B	331-344
dystonia	I	345-353
(	O	354-355
OMD	B	355-358
)	O	358-359
in	O	360-362
a	O	363-364
PSP	B	365-368
patient	O	369-376
to	O	377-379
highlight	O	380-389
the	O	390-393
importance	O	394-404
of	O	405-407
recognizing	O	408-419
this	O	420-424
drug	O	425-429
related	O	430-437
complication	O	438-450
in	O	451-453
the	O	454-457
management	O	458-468
of	O	469-471
PSP	B	472-475
,	O	475-476
and	O	477-480
discuss	O	481-488
the	O	489-492
possible	O	493-501
underlying	O	502-512
pathophysiology	O	513-528
.	O	528-529

Protective	O	0-10
effect	O	11-17
of	O	18-20
edaravone	O	21-30
against	O	31-38
streptomycin	O	39-51
-	O	51-52
induced	O	52-59
vestibulotoxicity	B	60-77
in	O	78-80
the	O	81-84
guinea	O	85-91
pig	O	92-95
.	O	95-96

This	O	97-101
study	O	102-107
investigated	O	108-120
alleviation	O	121-132
of	O	133-135
streptomycin	O	136-148
-	O	148-149
induced	O	149-156
vestibulotoxicity	B	157-174
by	O	175-177
edaravone	O	178-187
in	O	188-190
guinea	O	191-197
pigs	O	198-202
.	O	202-203

Edaravone	O	204-213
,	O	213-214
a	O	215-216
free	O	217-221
radical	O	222-229
scavenger	O	230-239
,	O	239-240
has	O	241-244
potent	O	245-251
free	O	252-256
radical	O	257-264
quenching	O	265-274
action	O	275-281
and	O	282-285
is	O	286-288
used	O	289-293
in	O	294-296
clinical	O	297-305
practice	O	306-314
to	O	315-317
treat	O	318-323
cerebral	B	324-332
infarction	I	333-343
.	O	343-344

Streptomycin	O	345-357
was	O	358-361
administered	O	362-374
to	O	375-377
the	O	378-381
inner	O	382-387
ear	O	388-391
by	O	392-394
osmotic	O	395-402
pump	O	403-407
for	O	408-411
24	O	412-414
h	O	415-416
,	O	416-417
and	O	418-421
edaravone	O	422-431
(	O	432-433
n	O	433-434
=	O	434-435
8	O	435-436
)	O	436-437
or	O	438-440
saline	O	441-447
(	O	448-449
n	O	449-450
=	O	450-451
6	O	451-452
)	O	452-453
was	O	454-457
intraperitoneally	O	458-475
injected	O	476-484
once	O	485-489
a	O	490-491
day	O	492-495
for	O	496-499
7	O	500-501
days	O	502-506
.	O	506-507

We	O	508-510
observed	O	511-519
horizontal	O	520-530
vestibulo	O	531-540
-	O	540-541
ocular	O	541-547
reflex	O	548-554
as	O	555-557
a	O	558-559
marker	O	560-566
of	O	567-569
postoperative	O	570-583
vestibular	O	584-594
function	O	595-603
.	O	603-604

Animals	O	605-612
injected	O	613-621
with	O	622-626
saline	O	627-633
showed	O	634-640
statistically	O	641-654
smaller	O	655-662
gains	O	663-668
than	O	669-673
those	O	674-679
injected	O	680-688
with	O	689-693
edaravone	O	694-703
.	O	703-704

These	O	705-710
results	O	711-718
suggest	O	719-726
that	O	727-731
edaravone	O	732-741
suppresses	O	742-752
streptomycin	O	753-765
-	O	765-766
induced	O	766-773
vestibulotoxicity	B	774-791
.	O	791-792

Ketamine	O	0-8
in	O	9-11
war	O	12-15
/	O	15-16
tropical	O	16-24
surgery	O	25-32
(	O	33-34
a	O	34-35
final	O	36-41
tribute	O	42-49
to	O	50-52
the	O	53-56
racemic	O	57-64
mixture	O	65-72
)	O	72-73
.	O	73-74

A	O	75-76
technique	O	77-86
of	O	87-89
continuous	O	90-100
intravenous	O	101-112
anaesthesia	O	113-124
with	O	125-129
ketamine	O	130-138
was	O	139-142
used	O	143-147
successfully	O	148-160
during	O	161-167
the	O	168-171
Somalia	O	172-179
civil	O	180-185
war	O	186-189
in	O	190-192
1994	O	193-197
and	O	198-201
in	O	202-204
north	O	205-210
Uganda	O	211-217
in	O	218-220
1999	O	221-225
for	O	226-229
64	O	230-232
operations	O	233-243
in	O	244-246
62	O	247-249
patients	O	250-258
,	O	258-259
aged	O	260-264
from	O	265-269
6	O	270-271
weeks	O	272-277
to	O	278-280
70	O	281-283
years	O	284-289
,	O	289-290
undergoing	O	291-301
limb	O	302-306
and	O	307-310
abdominal	O	311-320
surgery	O	321-328
including	O	329-338
caesarian	O	339-348
sections	O	349-357
and	O	358-361
interventions	O	362-375
in	O	376-378
neonates	O	379-387
.	O	387-388

Operations	O	389-399
lasting	O	400-407
up	O	408-410
to	O	411-413
2h	O	414-416
could	O	417-422
be	O	423-425
performed	O	426-435
in	O	436-438
the	O	439-442
absence	O	443-450
of	O	451-453
sophisticated	O	454-467
equipment	O	468-477
such	O	478-482
as	O	483-485
pulse	O	486-491
oximeters	O	492-501
or	O	502-504
ventilators	O	505-516
in	O	517-519
patients	O	520-528
on	O	529-531
spontaneous	O	532-543
ventilation	O	544-555
breathing	O	556-565
air	O	566-569
/	O	569-570
oxygen	O	570-576
only	O	577-581
.	O	581-582

After	O	583-588
premedication	O	589-602
with	O	603-607
diazepam	O	608-616
,	O	616-617
glycopyrrolate	O	618-632
and	O	633-636
local	O	637-642
anaesthesia	O	643-654
,	O	654-655
and	O	656-659
induction	O	660-669
with	O	670-674
standard	O	675-683
doses	O	684-689
of	O	690-692
ketamine	O	693-701
,	O	701-702
a	O	703-704
maintenance	O	705-716
dose	O	717-721
of	O	722-724
10	O	725-727
-	O	727-728
20	O	728-730
microg	O	731-737
/	O	737-738
kg	O	738-740
/	O	737-738
min	O	741-744
of	O	745-747
ketamine	O	748-756
proved	O	757-763
safe	O	764-768
and	O	769-772
effective	O	773-782
.	O	782-783

Emphasis	O	784-792
was	O	793-796
placed	O	797-803
on	O	804-806
bedside	O	807-814
clinical	O	815-823
monitoring	O	824-834
,	O	834-835
relying	O	836-843
heavily	O	844-851
on	O	852-854
the	O	855-858
heart	O	859-864
rate	O	865-869
.	O	869-870

Diazepam	O	871-879
,	O	879-880
unless	O	881-887
contraindicated	O	888-903
or	O	904-906
risky	O	907-912
,	O	912-913
remains	O	914-921
the	O	922-925
only	O	926-930
necessary	O	931-940
complementary	O	941-954
drug	O	955-959
to	O	960-962
ketamine	O	963-971
as	O	972-974
it	O	975-977
buffers	O	978-985
its	O	986-989
cardiovascular	O	990-1004
response	O	1005-1013
and	O	1014-1017
decreases	O	1018-1027
the	O	1028-1031
duration	O	1032-1040
and	O	1041-1044
intensity	O	1045-1054
of	O	1055-1057
operative	O	1058-1067
and	O	1068-1071
postoperative	O	1072-1085
hallucinations	B	1086-1100
.	O	1100-1101

Local	O	1102-1107
anaesthetic	O	1108-1119
blocks	O	1120-1126
were	O	1127-1131
useful	O	1132-1138
in	O	1139-1141
decreasing	O	1142-1152
the	O	1153-1156
requirement	O	1157-1168
for	O	1169-1172
postoperative	O	1173-1186
analgesia	B	1187-1196
.	O	1196-1197

An	O	1198-1200
antisialogue	O	1201-1213
was	O	1214-1217
usually	O	1218-1225
unnecessary	O	1226-1237
in	O	1238-1240
operations	O	1241-1251
lasting	O	1252-1259
up	O	1260-1262
to	O	1263-1265
2	O	1266-1267
h	O	1268-1269
,	O	1269-1270
glycopyrrolate	O	1271-1285
being	O	1286-1291
the	O	1292-1295
best	O	1296-1300
choice	O	1301-1307
for	O	1308-1311
its	O	1312-1315
lowest	O	1316-1322
psychotropic	O	1323-1335
and	O	1336-1339
chronotropic	O	1340-1352
effects	O	1353-1360
,	O	1360-1361
especially	O	1362-1372
in	O	1373-1375
a	O	1376-1377
hot	O	1378-1381
climate	O	1382-1389
.	O	1389-1390

Experience	O	1391-1401
in	O	1402-1404
war	O	1405-1408
/	O	1408-1409
tropical	O	1409-1417
settings	O	1418-1426
suggests	O	1427-1435
this	O	1436-1440
technique	O	1441-1450
could	O	1451-1456
be	O	1457-1459
useful	O	1460-1466
in	O	1467-1469
civilian	O	1470-1478
contexts	O	1479-1487
such	O	1488-1492
as	O	1493-1495
outdoor	O	1496-1503
life	O	1504-1508
-	O	1508-1509
saving	O	1509-1515
emergency	O	1516-1525
surgery	O	1526-1533
or	O	1534-1536
in	O	1537-1539
mass	O	1540-1544
casualties	O	1545-1555
where	O	1556-1561
,	O	1561-1562
e	O	1563-1564
.	O	1564-1565
g	O	1565-1566
.	O	1564-1565

amputation	O	1568-1578
and	O	1579-1582
rapid	O	1583-1588
extrication	O	1589-1600
were	O	1601-1605
required	O	1606-1614
.	O	1614-1615

Steroid	O	0-7
structure	O	8-17
and	O	18-21
pharmacological	O	22-37
properties	O	38-48
determine	O	49-58
the	O	59-62
anti	O	63-67
-	O	67-68
amnesic	B	68-75
effects	O	76-83
of	O	84-86
pregnenolone	O	87-99
sulphate	O	100-108
in	O	109-111
the	O	112-115
passive	O	116-123
avoidance	O	124-133
task	O	134-138
in	O	139-141
rats	O	142-146
.	O	146-147

Pregnenolone	O	148-160
sulphate	O	161-169
(	O	170-171
PREGS	O	171-176
)	O	176-177
has	O	178-181
generated	O	182-191
interest	O	192-200
as	O	201-203
one	O	204-207
of	O	208-210
the	O	211-214
most	O	215-219
potent	O	220-226
memory	O	227-233
-	O	233-234
enhancing	O	234-243
neurosteroids	O	244-257
to	O	258-260
be	O	261-263
examined	O	264-272
in	O	273-275
rodent	O	276-282
learning	O	283-291
studies	O	292-299
,	O	299-300
with	O	301-305
particular	O	306-316
importance	O	317-327
in	O	328-330
the	O	331-334
ageing	O	335-341
process	O	342-349
.	O	349-350

The	O	351-354
mechanism	O	355-364
by	O	365-367
which	O	368-373
this	O	374-378
endogenous	O	379-389
steroid	O	390-397
enhances	O	398-406
memory	O	407-413
formation	O	414-423
is	O	424-426
hypothesized	O	427-439
to	O	440-442
involve	O	443-450
actions	O	451-458
on	O	459-461
glutamatergic	O	462-475
and	O	476-479
GABAergic	O	480-489
systems	O	490-497
.	O	497-498

This	O	499-503
hypothesis	O	504-514
stems	O	515-520
from	O	521-525
findings	O	526-534
that	O	535-539
PREGS	O	540-545
is	O	546-548
a	O	549-550
potent	O	551-557
positive	O	558-566
modulator	O	567-576
of	O	577-579
N	O	580-581
-	O	581-582
methyl	O	582-588
-	O	581-582
d	O	589-590
-	O	581-582
aspartate	O	591-600
receptors	O	601-610
(	O	611-612
NMDARs	O	612-618
)	O	618-619
and	O	620-623
a	O	624-625
negative	O	626-634
modulator	O	635-644
of	O	645-647
gamma	O	648-653
-	O	653-654
aminobutyric	O	654-666
acid	O	667-671
(	O	671-672
A	O	672-673
)	O	673-674
receptors	O	675-684
(	O	685-686
GABA	O	686-690
(	O	685-686
A	O	687-688
)	O	692-693
Rs	O	693-695
)	O	692-693
.	O	696-697

Moreover	O	698-706
,	O	706-707
PREGS	O	708-713
is	O	714-716
able	O	717-721
to	O	722-724
reverse	O	725-732
the	O	733-736
amnesic	B	737-744
-	O	744-745
like	O	745-749
effects	O	750-757
of	O	758-760
NMDAR	O	761-766
and	O	767-770
GABA	O	771-775
(	O	775-776
A	O	772-773
)	O	777-778
R	O	778-779
ligands	O	780-787
.	O	787-788

To	O	789-791
investigate	O	792-803
this	O	804-808
hypothesis	O	809-819
,	O	819-820
the	O	821-824
present	O	825-832
study	O	833-838
in	O	839-841
rats	O	842-846
examined	O	847-855
the	O	856-859
memory	O	860-866
-	O	866-867
altering	O	867-875
abilities	O	876-885
of	O	886-888
structural	O	889-899
analogs	O	900-907
of	O	908-910
PREGS	O	911-916
,	O	916-917
which	O	918-923
differ	O	924-930
in	O	931-933
their	O	934-939
modulation	O	940-950
of	O	951-953
NMDAR	O	954-959
and	O	960-963
/	O	963-964
or	O	964-966
GABA	O	967-971
(	O	971-972
A	O	968-969
)	O	973-974
R	O	974-975
function	O	976-984
.	O	984-985

The	O	986-989
analogs	O	990-997
tested	O	998-1004
were	O	1005-1009
:	O	1009-1010
11	O	1011-1013
-	O	1013-1014
ketopregnenolone	O	1014-1030
sulphate	O	1031-1039
(	O	1040-1041
an	O	1041-1043
agent	O	1044-1049
that	O	1050-1054
is	O	1055-1057
inactive	O	1058-1066
at	O	1067-1069
GABA	O	1070-1074
(	O	1074-1075
A	O	1071-1072
)	O	1076-1077
Rs	O	1077-1079
and	O	1080-1083
NMDARs	O	1084-1090
)	O	1090-1091
,	O	1091-1092
epipregnanolone	O	1093-1108
(	O	1109-1110
[	O	1110-1111
3beta	O	1111-1116
-	O	1116-1117
hydroxy	O	1117-1124
-	O	1116-1117
5beta	O	1125-1130
-	O	1116-1117
pregnan	O	1131-1138
-	O	1116-1117
20	O	1139-1141
-	O	1116-1117
one	O	1142-1145
]	O	1145-1146
sulphate	O	1147-1155
,	O	1155-1156
an	O	1157-1159
inhibitor	O	1160-1169
of	O	1170-1172
both	O	1173-1177
GABA	O	1178-1182
(	O	1182-1183
A	O	1179-1180
)	O	1184-1185
Rs	O	1185-1187
and	O	1188-1191
NMDARs	O	1192-1198
)	O	1198-1199
,	O	1199-1200
and	O	1201-1204
a	O	1205-1206
newly	O	1207-1212
synthesized	O	1213-1224
(	O	1225-1226
-	O	1226-1227
)	O	1227-1228
PREGS	O	1229-1234
enantiomer	O	1235-1245
(	O	1246-1247
which	O	1247-1252
is	O	1253-1255
identical	O	1256-1265
to	O	1266-1268
PREGS	O	1269-1274
in	O	1275-1277
effects	O	1278-1285
on	O	1286-1288
GABA	O	1289-1293
(	O	1293-1294
A	O	1290-1291
)	O	1295-1296
Rs	O	1296-1298
and	O	1299-1302
NMDARs	O	1303-1309
)	O	1309-1310
.	O	1310-1311

The	O	1312-1315
memory	O	1316-1322
-	O	1322-1323
enhancing	O	1323-1332
effects	O	1333-1340
of	O	1341-1343
PREGS	O	1344-1349
and	O	1350-1353
its	O	1354-1357
analogs	O	1358-1365
were	O	1366-1370
tested	O	1371-1377
in	O	1378-1380
the	O	1381-1384
passive	O	1385-1392
avoidance	O	1393-1402
task	O	1403-1407
using	O	1408-1413
the	O	1414-1417
model	O	1418-1423
of	O	1424-1426
scopolamine	O	1427-1438
-	O	1438-1439
induced	O	1439-1446
amnesia	B	1447-1454
.	O	1454-1455

Both	O	1456-1460
PREGS	O	1461-1466
and	O	1467-1470
its	O	1471-1474
(	O	1475-1476
-	O	1476-1477
)	O	1477-1478
enantiomer	O	1479-1489
blocked	O	1490-1497
the	O	1498-1501
effects	O	1502-1509
of	O	1510-1512
scopolamine	O	1513-1524
.	O	1524-1525

The	O	1526-1529
results	O	1530-1537
show	O	1538-1542
that	O	1543-1547
,	O	1547-1548
unlike	O	1549-1555
PREGS	O	1556-1561
,	O	1561-1562
11	O	1563-1565
-	O	1565-1566
ketopregnenolone	O	1566-1582
sulphate	O	1583-1591
and	O	1592-1595
epipregnanolone	O	1596-1611
sulphate	O	1612-1620
failed	O	1621-1627
to	O	1628-1630
block	O	1631-1636
the	O	1637-1640
effect	O	1641-1647
of	O	1648-1650
scopolamine	O	1651-1662
,	O	1662-1663
suggesting	O	1664-1674
that	O	1675-1679
altering	O	1680-1688
the	O	1689-1692
modulation	O	1693-1703
of	O	1704-1706
NMDA	O	1707-1711
receptors	O	1712-1721
diminishes	O	1722-1732
the	O	1733-1736
memory	O	1737-1743
-	O	1743-1744
enhancing	O	1744-1753
effects	O	1754-1761
of	O	1762-1764
PREGS	O	1765-1770
.	O	1770-1771

Moreover	O	1772-1780
,	O	1780-1781
enantioselectivity	O	1782-1800
was	O	1801-1804
demonstrated	O	1805-1817
by	O	1818-1820
the	O	1821-1824
ability	O	1825-1832
of	O	1833-1835
natural	O	1836-1843
PREGS	O	1844-1849
to	O	1850-1852
be	O	1853-1855
an	O	1856-1858
order	O	1859-1864
of	O	1865-1867
magnitude	O	1868-1877
more	O	1878-1882
effective	O	1883-1892
than	O	1893-1897
its	O	1898-1901
synthetic	O	1902-1911
enantiomer	O	1912-1922
in	O	1923-1925
reversing	O	1926-1935
scopolamine	O	1936-1947
-	O	1947-1948
induced	O	1948-1955
amnesia	B	1956-1963
.	O	1963-1964

These	O	1965-1970
results	O	1971-1978
identify	O	1979-1987
a	O	1988-1989
novel	O	1990-1995
neuropharmacological	O	1996-2016
site	O	2017-2021
for	O	2022-2025
the	O	2026-2029
modulation	O	2030-2040
of	O	2041-2043
memory	O	2044-2050
processes	O	2051-2060
by	O	2061-2063
neuroactive	O	2064-2075
steroids	O	2076-2084
.	O	2084-2085

Preliminary	O	0-11
efficacy	O	12-20
assessment	O	21-31
of	O	32-34
intrathecal	O	35-46
injection	O	47-56
of	O	57-59
an	O	60-62
American	O	63-71
formulation	O	72-83
of	O	84-86
adenosine	O	87-96
in	O	97-99
humans	O	100-106
.	O	106-107

BACKGROUND	O	108-118
:	O	118-119
Preclinical	O	120-131
studies	O	132-139
of	O	140-142
intrathecal	O	143-154
adenosine	O	155-164
suggest	O	165-172
it	O	173-175
may	O	176-179
be	O	180-182
effective	O	183-192
in	O	193-195
the	O	196-199
treatment	O	200-209
of	O	210-212
acute	B	213-218
and	I	219-222
chronic	I	223-230
pain	I	231-235
in	O	236-238
humans	O	239-245
,	O	245-246
and	O	247-250
preliminary	O	251-262
studies	O	263-270
in	O	271-273
volunteers	O	274-284
and	O	285-288
patients	O	289-297
with	O	298-302
a	O	303-304
Swedish	O	305-312
formulation	O	313-324
of	O	325-327
adenosine	O	328-337
suggests	O	338-346
it	O	347-349
may	O	350-353
be	O	354-356
effective	O	357-366
in	O	367-369
hypersensitivity	B	370-386
states	O	387-393
but	O	394-397
not	O	398-401
with	O	402-406
acute	O	407-412
noxious	O	413-420
stimulation	O	421-432
.	O	432-433

The	O	434-437
purpose	O	438-445
of	O	446-448
this	O	449-453
study	O	454-459
was	O	460-463
to	O	464-466
screen	O	467-473
for	O	474-477
efficacy	O	478-486
of	O	487-489
a	O	490-491
different	O	492-501
formulation	O	502-513
of	O	514-516
adenosine	O	517-526
marketed	O	527-535
in	O	536-538
the	O	539-542
US	O	543-545
,	O	545-546
using	O	547-552
both	O	553-557
acute	O	558-563
noxious	O	564-571
stimulation	O	572-583
and	O	584-587
capsaicin	O	588-597
-	O	597-598
evoked	O	598-604
mechanical	O	605-615
hypersensitivity	B	616-632
.	O	632-633

METHODS	O	634-641
:	O	641-642
Following	O	643-652
Food	O	653-657
and	O	658-661
Drug	O	662-666
Administration	O	667-681
and	O	682-685
institutional	O	686-699
review	O	700-706
board	O	707-712
approval	O	713-721
and	O	722-725
written	O	726-733
informed	O	734-742
consent	O	743-750
,	O	750-751
65	O	752-754
volunteers	O	755-765
were	O	766-770
studied	O	771-778
in	O	779-781
two	O	782-785
trials	O	786-792
:	O	792-793
an	O	794-796
open	O	797-801
-	O	801-802
label	O	802-807
,	O	807-808
dose	O	809-813
-	O	813-814
escalating	O	814-824
trial	O	825-830
with	O	831-835
intrathecal	O	836-847
adenosine	O	848-857
doses	O	858-863
of	O	864-866
0	O	867-868
.	O	868-869
25	O	869-871
-	O	871-872
2	O	869-870
.	O	868-869
0	O	867-868

mg	O	876-878
and	O	879-882
a	O	883-884
double	O	885-891
-	O	891-892
blind	O	892-897
,	O	897-898
placebo	O	899-906
-	O	906-907
controlled	O	907-917
trial	O	918-923
of	O	924-926
adenosine	O	927-936
,	O	936-937
2	O	938-939
mg	O	940-942
.	O	942-943

Cerebrospinal	O	944-957
fluid	O	958-963
was	O	964-967
obtained	O	968-976
for	O	977-980
pharmacokinetic	O	981-996
analysis	O	997-1005
,	O	1005-1006
and	O	1007-1010
pain	B	1011-1015
ratings	O	1016-1023
in	O	1024-1026
response	O	1027-1035
to	O	1036-1038
acute	O	1039-1044
heat	O	1045-1049
stimuli	O	1050-1057
and	O	1058-1061
areas	O	1062-1067
of	O	1068-1070
mechanical	B	1071-1081
hyperalgesia	I	1082-1094
and	O	1095-1098
allodynia	B	1099-1108
after	O	1109-1114
intradermal	O	1115-1126
capsaicin	O	1127-1136
injection	O	1137-1146
were	O	1147-1151
determined	O	1152-1162
.	O	1162-1163

RESULTS	O	1164-1171
:	O	1171-1172
Adenosine	O	1173-1182
produced	O	1183-1191
no	O	1192-1194
effect	O	1195-1201
on	O	1202-1204
pain	B	1205-1209
report	O	1210-1216
to	O	1217-1219
acute	O	1220-1225
noxious	O	1226-1233
thermal	O	1234-1241
or	O	1242-1244
chemical	O	1245-1253
stimulation	O	1254-1265
but	O	1266-1269
reduced	O	1270-1277
mechanical	B	1278-1288
hyperalgesia	I	1289-1301
and	O	1302-1305
allodynia	B	1306-1315
from	O	1316-1320
intradermal	O	1321-1332
capsaicin	O	1333-1342
injection	O	1343-1352
for	O	1353-1356
at	O	1357-1359
least	O	1360-1365
24	O	1366-1368
h	O	1369-1370
.	O	1370-1371

In	O	1372-1374
contrast	O	1375-1383
,	O	1383-1384
residence	O	1385-1394
time	O	1395-1399
of	O	1400-1402
adenosine	O	1403-1412
in	O	1413-1415
cerebrospinal	O	1416-1429
fluid	O	1430-1435
was	O	1436-1439
short	O	1440-1445
(	O	1446-1447
<	O	1447-1448
4	O	1449-1450
h	O	1451-1452
)	O	1452-1453
.	O	1453-1454

CONCLUSIONS	O	1455-1466
:	O	1466-1467
These	O	1468-1473
results	O	1474-1481
show	O	1482-1486
selective	O	1487-1496
inhibition	O	1497-1507
by	O	1508-1510
intrathecal	O	1511-1522
adenosine	O	1523-1532
of	O	1533-1535
hypersensitivity	B	1536-1552
,	O	1552-1553
presumed	O	1554-1562
to	O	1563-1565
reflect	O	1566-1573
central	O	1574-1581
sensitization	O	1582-1595
in	O	1596-1598
humans	O	1599-1605
after	O	1606-1611
peripheral	O	1612-1622
capsaicin	O	1623-1632
injection	O	1633-1642
.	O	1642-1643

The	O	1644-1647
long	O	1648-1652
-	O	1652-1653
lasting	O	1653-1660
effect	O	1661-1667
is	O	1668-1670
consistent	O	1671-1681
with	O	1682-1686
that	O	1687-1691
observed	O	1692-1700
in	O	1701-1703
preliminary	O	1704-1715
reports	O	1716-1723
of	O	1724-1726
patients	O	1727-1735
with	O	1736-1740
chronic	O	1741-1748
neuropathic	B	1749-1760
pain	I	1761-1765
and	O	1766-1769
is	O	1770-1772
not	O	1773-1776
due	O	1777-1780
to	O	1781-1783
prolonged	O	1784-1793
residence	O	1794-1803
of	O	1804-1806
adenosine	O	1807-1816
in	O	1817-1819
cerebrospinal	O	1820-1833
fluid	O	1834-1839
.	O	1839-1840

Effect	O	0-6
of	O	7-9
lithium	O	10-17
maintenance	O	18-29
therapy	O	30-37
on	O	38-40
thyroid	O	41-48
and	O	49-52
parathyroid	O	53-64
function	O	65-73
.	O	73-74

OBJECTIVES	O	75-85
:	O	85-86
To	O	87-89
assess	O	90-96
changes	O	97-104
induced	O	105-112
by	O	113-115
lithium	O	116-123
maintenance	O	124-135
therapy	O	136-143
on	O	144-146
the	O	147-150
incidence	O	151-160
of	O	161-163
thyroid	O	164-171
,	O	171-172
parathyroid	O	173-184
and	O	185-188
ion	O	189-192
alterations	O	193-204
.	O	204-205

These	O	206-211
were	O	212-216
evaluated	O	217-226
with	O	227-231
respect	O	232-239
to	O	240-242
the	O	243-246
duration	O	247-255
of	O	256-258
lithium	O	259-266
therapy	O	267-274
,	O	274-275
age	O	276-279
,	O	279-280
sex	O	281-284
,	O	284-285
and	O	286-289
family	O	290-296
history	O	297-304
(	O	305-306
whether	O	306-313
or	O	314-316
not	O	317-320
the	O	321-324
patient	O	325-332
had	O	333-336
a	O	337-338
first	O	339-344
-	O	344-345
degree	O	345-351
relative	O	352-360
with	O	361-365
thyroid	B	366-373
disease	I	374-381
)	O	381-382
.	O	382-383

DESIGN	O	384-390
:	O	390-391
Prospective	O	392-403
study	O	404-409
.	O	409-410

SETTING	O	411-418
:	O	418-419
Affective	O	420-429
Disorders	O	430-439
Clinic	O	440-446
at	O	447-449
St	O	450-452
.	O	452-453
Mary	O	454-458
'	O	458-459
s	O	459-460
Hospital	O	461-469
,	O	469-470
Montreal	O	471-479
.	O	479-480

PATIENTS	O	481-489
:	O	489-490
One	O	491-494
hundred	O	495-502
and	O	503-506
one	O	507-510
patients	O	511-519
(	O	520-521
28	O	521-523
men	O	524-527
and	O	528-531
73	O	532-534
women	O	535-540
)	O	540-541
with	O	542-546
bipolar	B	547-554
disorder	I	555-563
receiving	O	564-573
lithium	O	574-581
maintenance	O	582-593
therapy	O	594-601
ranging	O	602-609
from	O	610-614
1	O	615-616
year	O	617-621
'	O	621-622
s	O	622-623
to	O	624-626
32	O	627-629
years	O	630-635
'	O	635-636
duration	O	637-645
.	O	645-646

The	O	647-650
control	O	651-658
group	O	659-664
consisted	O	665-674
of	O	675-677
82	O	678-680
patients	O	681-689
with	O	690-694
no	O	695-697
psychiatric	B	698-709
or	O	710-712
endocrinological	O	713-729
diagnoses	O	730-739
from	O	740-744
the	O	745-748
hospital	O	749-757
'	O	757-758
s	O	751-752
out	O	760-763
-	O	763-764
patient	O	764-771
clinics	O	772-779
.	O	779-780

OUTCOME	O	781-788
MEASURES	O	789-797
:	O	797-798
Laboratory	O	799-809
analyses	O	810-818
of	O	819-821
calcium	O	822-829
,	O	829-830
magnesium	O	831-840
and	O	841-844
thyroid	O	845-852
-	O	852-853
stimulating	O	853-864
hormone	O	865-872
levels	O	873-879
performed	O	880-889
before	O	890-896
beginning	O	897-906
lithium	O	907-914
therapy	O	915-922
and	O	923-926
at	O	927-929
biannual	O	930-938
follow	O	939-945
-	O	945-946
up	O	946-948
.	O	948-949

RESULTS	O	950-957
:	O	957-958
Hypothyroidism	B	959-973
developed	O	974-983
in	O	984-986
40	O	987-989
patients	O	990-998
,	O	998-999
excluding	O	1000-1009
8	O	1010-1011
patients	O	1012-1020
who	O	1021-1024
were	O	1025-1029
hypothyroid	B	1030-1041
at	O	1042-1044
baseline	O	1045-1053
.	O	1053-1054

All	O	1055-1058
patients	O	1059-1067
having	O	1068-1074
first	O	1075-1080
-	O	1080-1081
degree	O	1081-1087
relatives	O	1088-1097
affected	O	1098-1106
by	O	1107-1109
thyroid	B	1110-1117
illness	I	1118-1125
had	O	1126-1129
accelerated	O	1130-1141
onset	O	1142-1147
of	O	1148-1150
hypothyroidism	B	1151-1165
(	O	1166-1167
3	O	1167-1168
.	O	1168-1169
7	O	1169-1170
years	O	1171-1176
after	O	1177-1182
onset	O	1183-1188
of	O	1189-1191
lithium	O	1192-1199
therapy	O	1200-1207
)	O	1207-1208
compared	O	1209-1217
with	O	1218-1222
patients	O	1223-1231
without	O	1232-1239
a	O	1240-1241
family	O	1242-1248
history	O	1249-1256
(	O	1257-1258
8	O	1258-1259
.	O	1259-1260
6	O	1260-1261
years	O	1262-1267
after	O	1268-1273
onset	O	1274-1279
of	O	1280-1282
lithium	O	1283-1290
therapy	O	1291-1298
)	O	1298-1299
.	O	1299-1300

Women	O	1301-1306
over	O	1307-1311
60	O	1312-1314
years	O	1315-1320
of	O	1321-1323
age	O	1324-1327
were	O	1328-1332
more	O	1333-1337
often	O	1338-1343
affected	O	1344-1352
by	O	1353-1355
hypothyroidism	B	1356-1370
than	O	1371-1375
women	O	1376-1381
under	O	1382-1387
60	O	1388-1390
years	O	1391-1396
of	O	1397-1399
age	O	1400-1403
(	O	1404-1405
34	O	1405-1407
.	O	1407-1408
6	O	1408-1409
%	O	1409-1410
versus	O	1411-1417
31	O	1418-1420
.	O	1420-1421
9	O	1421-1422
%	O	1422-1423
)	O	1423-1424
.	O	1420-1421

Magnesium	O	1426-1435
levels	O	1436-1442
in	O	1443-1445
patients	O	1446-1454
on	O	1455-1457
lithium	O	1458-1465
treatment	O	1466-1475
were	O	1476-1480
unchanged	O	1481-1490
from	O	1491-1495
baseline	O	1496-1504
levels	O	1505-1511
.	O	1511-1512

After	O	1513-1518
lithium	O	1519-1526
treatment	O	1527-1536
,	O	1536-1537
calcium	O	1538-1545
levels	O	1546-1552
were	O	1553-1557
higher	O	1558-1564
than	O	1565-1569
either	O	1570-1576
baseline	O	1577-1585
levels	O	1586-1592
or	O	1593-1595
control	O	1596-1603
levels	O	1604-1610
.	O	1610-1611

Thus	O	1612-1616
,	O	1616-1617
lithium	O	1618-1625
treatment	O	1626-1635
counteracted	O	1636-1648
the	O	1649-1652
decrease	O	1653-1661
in	O	1662-1664
plasma	O	1665-1671
calcium	O	1672-1679
levels	O	1680-1686
associated	O	1687-1697
with	O	1698-1702
aging	O	1703-1708
.	O	1708-1709

CONCLUSIONS	O	1710-1721
:	O	1721-1722
Familial	O	1723-1731
thyroid	B	1732-1739
illness	I	1740-1747
is	O	1748-1750
a	O	1751-1752
risk	O	1753-1757
factor	O	1758-1764
for	O	1765-1768
hypothyroidism	B	1769-1783
and	O	1784-1787
hypercalcemia	B	1788-1801
during	O	1802-1808
lithium	O	1809-1816
therapy	O	1817-1824
.	O	1824-1825

Systemic	O	0-8
toxicity	B	9-17
following	O	18-27
administration	O	28-42
of	O	43-45
sirolimus	O	46-55
(	O	56-57
formerly	O	57-65
rapamycin	O	66-75
)	O	75-76
for	O	77-80
psoriasis	B	81-90
:	O	90-91
association	O	92-103
of	O	104-106
capillary	B	107-116
leak	I	117-121
syndrome	I	122-130
with	O	131-135
apoptosis	O	136-145
of	O	146-148
lesional	O	149-157
lymphocytes	O	158-169
.	O	169-170

BACKGROUND	O	171-181
:	O	181-182
Sirolimus	O	183-192
(	O	193-194
formerly	O	194-202
rapamycin	O	203-212
)	O	212-213
is	O	214-216
an	O	217-219
immunosuppressive	O	220-237
agent	O	238-243
that	O	244-248
interferes	O	249-259
with	O	260-264
T	O	265-266
-	O	266-267
cell	O	267-271
activation	O	272-282
.	O	282-283

After	O	284-289
2	O	290-291
individuals	O	292-303
with	O	304-308
psoriasis	B	309-318
developed	O	319-328
a	O	329-330
capillary	B	331-340
leak	I	341-345
syndrome	I	346-354
following	O	355-364
treatment	O	365-374
with	O	375-379
oral	O	380-384
sirolimus	O	385-394
lesional	O	395-403
skin	O	404-408
cells	O	409-414
and	O	415-418
activated	O	419-428
peripheral	O	429-439
blood	O	440-445
cells	O	446-451
were	O	452-456
analyzed	O	457-465
for	O	466-469
induction	O	470-479
of	O	480-482
apoptosis	O	483-492
.	O	492-493

OBSERVATIONS	O	494-506
:	O	506-507
A	O	508-509
keratome	O	510-518
skin	O	519-523
specimen	O	524-532
from	O	533-537
1	O	538-539
patient	O	540-547
with	O	548-552
sirolimus	O	553-562
-	O	562-563
induced	O	563-570
capillary	B	571-580
leak	I	581-585
syndrome	I	586-594
had	O	595-598
a	O	599-600
2	O	601-602
.	O	602-603
3	O	603-604
-	O	604-605
fold	O	605-609
increase	O	610-618
in	O	619-621
percentage	O	622-632
of	O	633-635
apoptotic	O	636-645
cells	O	646-651
(	O	652-653
to	O	653-655
48	O	656-658
%	O	658-659
)	O	659-660
compared	O	661-669
with	O	670-674
an	O	675-677
unaffected	O	678-688
sirolimus	O	689-698
-	O	698-699
treated	O	699-706
patient	O	707-714
with	O	715-719
psoriasis	B	720-729
(	O	730-731
21	O	731-733
%	O	733-734
)	O	734-735
.	O	735-736

Activated	O	737-746
peripheral	O	747-757
blood	O	758-763
T	O	764-765
cells	O	766-771
from	O	772-776
patients	O	777-785
with	O	786-790
psoriasis	B	791-800
tended	O	801-807
to	O	808-810
exhibit	O	811-818
greater	O	819-826
spontaneous	O	827-838
or	O	839-841
dexamethasone	O	842-855
-	O	855-856
induced	O	856-863
apoptosis	O	864-873
than	O	874-878
did	O	879-882
normal	O	883-889
T	O	890-891
cells	O	892-897
,	O	897-898
particularly	O	899-911
in	O	912-914
the	O	915-918
presence	O	919-927
of	O	928-930
sirolimus	O	931-940
.	O	940-941

CONCLUSIONS	O	942-953
:	O	953-954
Severe	O	955-961
adverse	O	962-969
effects	O	970-977
of	O	978-980
sirolimus	O	981-990
include	O	991-998
fever	B	999-1004
,	O	1004-1005
anemia	B	1006-1012
,	O	1012-1013
and	O	1014-1017
capillary	B	1018-1027
leak	I	1028-1032
syndrome	I	1033-1041
.	O	1041-1042

These	O	1043-1048
symptoms	O	1049-1057
may	O	1058-1061
be	O	1062-1064
the	O	1065-1068
result	O	1069-1075
of	O	1076-1078
drug	O	1079-1083
-	O	1083-1084
induced	O	1084-1091
apoptosis	O	1092-1101
of	O	1102-1104
lesional	O	1105-1113
leukocytes	O	1114-1124
,	O	1124-1125
especially	O	1126-1136
activated	O	1137-1146
T	O	1147-1148
lymphocytes	O	1149-1160
,	O	1160-1161
and	O	1162-1165
possibly	O	1166-1174
release	O	1175-1182
of	O	1183-1185
inflammatory	O	1186-1198
mediators	O	1199-1208
.	O	1208-1209

Because	O	1210-1217
patients	O	1218-1226
with	O	1227-1231
severe	O	1232-1238
psoriasis	B	1239-1248
may	O	1249-1252
develop	O	1253-1260
capillary	B	1261-1270
leak	I	1271-1275
from	O	1276-1280
various	O	1281-1288
systemic	O	1289-1297
therapies	O	1298-1307
,	O	1307-1308
clinical	O	1309-1317
monitoring	O	1318-1328
is	O	1329-1331
advisable	O	1332-1341
for	O	1342-1345
patients	O	1346-1354
with	O	1355-1359
inflammatory	B	1360-1372
diseases	I	1373-1381
who	O	1382-1385
are	O	1386-1389
treated	O	1390-1397
with	O	1398-1402
immune	O	1403-1409
modulators	O	1410-1420
.	O	1420-1421

Contribution	O	0-12
of	O	13-15
the	O	16-19
glycine	O	20-27
site	O	28-32
of	O	33-35
NMDA	O	36-40
receptors	O	41-50
in	O	51-53
rostral	O	54-61
and	O	62-65
intermediate	O	66-78
-	O	78-79
caudal	O	79-85
parts	O	86-91
of	O	92-94
the	O	95-98
striatum	O	99-107
to	O	108-110
the	O	111-114
regulation	O	115-125
of	O	126-128
muscle	O	129-135
tone	O	136-140
in	O	141-143
rats	O	144-148
.	O	148-149

The	O	150-153
aim	O	154-157
of	O	158-160
the	O	161-164
present	O	165-172
study	O	173-178
was	O	179-182
to	O	183-185
assess	O	186-192
the	O	193-196
contribution	O	197-209
of	O	210-212
the	O	213-216
glycine	O	217-224
site	O	225-229
of	O	230-232
NMDA	O	233-237
receptors	O	238-247
in	O	248-250
the	O	251-254
striatum	O	255-263
to	O	264-266
the	O	267-270
regulation	O	271-281
of	O	282-284
muscle	O	285-291
tone	O	292-296
.	O	296-297

Muscle	O	298-304
tone	O	305-309
was	O	310-313
examined	O	314-322
using	O	323-328
a	O	329-330
combined	O	331-339
mechanoand	O	340-350
electromyographic	O	351-368
method	O	369-375
,	O	375-376
which	O	377-382
measured	O	383-391
simultaneously	O	392-406
the	O	407-410
muscle	O	411-417
resistance	O	418-428
(	O	429-430
MMG	O	430-433
)	O	433-434
of	O	435-437
the	O	438-441
rat	O	442-445
'	O	445-446
s	O	446-447
hind	O	448-452
foot	O	453-457
to	O	458-460
passive	O	461-468
extension	O	469-478
and	O	479-482
flexion	O	483-490
in	O	491-493
the	O	494-497
ankle	O	498-503
joint	O	504-509
and	O	510-513
the	O	514-517
electromyographic	O	518-535
activity	O	536-544
(	O	545-546
EMG	O	546-549
)	O	549-550
of	O	551-553
the	O	554-557
antagonistic	O	558-570
muscles	O	571-578
of	O	579-581
that	O	582-586
joint	O	587-592
:	O	592-593
gastrocnemius	O	594-607
and	O	608-611
tibialis	O	612-620
anterior	O	621-629
.	O	629-630

Muscle	B	631-637
rigidity	I	638-646
was	O	647-650
induced	O	651-658
by	O	659-661
haloperidol	O	662-673
(	O	674-675
2	O	675-676
.	O	676-677
5	O	677-678
mg	O	679-681
/	O	681-682
kg	O	682-684
i	O	685-686
.	O	686-687
p	O	687-688
.	O	686-687
)	O	689-690
.	O	686-687

5	O	692-693
,	O	693-694
7	O	694-695
-	O	695-696
dichlorokynurenic	O	696-713
acid	O	714-718
(	O	719-720
5	O	720-721
,	O	721-722
7	O	722-723
-	O	723-724
DCKA	O	724-728
)	O	728-729
,	O	721-722
a	O	731-732
selective	O	733-742
glycine	O	743-750
site	O	751-755
antagonist	O	756-766
,	O	766-767
injected	O	768-776
in	O	777-779
doses	O	780-785
of	O	786-788
2	O	789-790
.	O	790-791
5	O	791-792
and	O	793-796
4	O	797-798
.	O	798-799
5	O	799-800
microg	O	801-807
/	O	807-808
0	O	808-809
.	O	809-810
5	O	810-811

microl	O	812-818
bilaterally	O	819-830
,	O	830-831
into	O	832-836
the	O	837-840
rostral	O	841-848
region	O	849-855
of	O	856-858
the	O	859-862
striatum	O	863-871
,	O	871-872
decreased	O	873-882
both	O	883-887
the	O	888-891
haloperidol	O	892-903
-	O	903-904
induced	O	904-911
muscle	B	912-918
rigidity	I	919-927
(	O	928-929
MMG	O	929-932
)	O	932-933
and	O	934-937
the	O	938-941
enhanced	O	942-950
electromyographic	O	951-968
activity	O	969-977
(	O	978-979
EMG	O	979-982
)	O	982-983
.	O	983-984

5	O	985-986
,	O	986-987
7	O	987-988
-	O	988-989
DCKA	O	989-993
injected	O	994-1002
bilaterally	O	1003-1014
in	O	1015-1017
a	O	1018-1019
dose	O	1020-1024
of	O	1025-1027
4	O	1028-1029
.	O	1029-1030
5	O	1030-1031
microg	O	1032-1038
/	O	1038-1039
0	O	1039-1040
.	O	1040-1041
5	O	1041-1042

microl	O	1043-1049
into	O	1050-1054
the	O	1055-1058
intermediate	O	1059-1071
-	O	1071-1072
caudal	O	1072-1078
region	O	1079-1085
of	O	1086-1088
the	O	1089-1092
striatum	O	1093-1101
of	O	1102-1104
rats	O	1105-1109
not	O	1110-1113
pretreated	O	1114-1124
with	O	1125-1129
haloperidol	O	1130-1141
had	O	1142-1145
no	O	1146-1148
effect	O	1149-1155
on	O	1156-1158
the	O	1159-1162
muscle	O	1163-1169
tone	O	1170-1174
.	O	1174-1175

The	O	1176-1179
present	O	1180-1187
results	O	1188-1195
suggest	O	1196-1203
that	O	1204-1208
blockade	O	1209-1217
of	O	1218-1220
the	O	1221-1224
glycine	O	1225-1232
site	O	1233-1237
of	O	1238-1240
NMDA	O	1241-1245
receptors	O	1246-1255
in	O	1256-1258
the	O	1259-1262
rostral	O	1263-1270
part	O	1271-1275
of	O	1276-1278
the	O	1279-1282
striatum	O	1283-1291
may	O	1292-1295
be	O	1296-1298
mainly	O	1299-1305
responsible	O	1306-1317
for	O	1318-1321
the	O	1322-1325
antiparkinsonian	O	1326-1342
action	O	1343-1349
of	O	1350-1352
this	O	1353-1357
drug	O	1358-1362
.	O	1362-1363

Efficacy	O	0-8
and	O	9-12
tolerability	O	13-25
of	O	26-28
lovastatin	O	29-39
in	O	40-42
3390	O	43-47
women	O	48-53
with	O	54-58
moderate	O	59-67
hypercholesterolemia	B	68-88
.	O	88-89
OBJECTIVE	O	90-99
:	O	99-100
To	O	101-103
evaluate	O	104-112
the	O	113-116
efficacy	O	117-125
and	O	126-129
safety	O	130-136
of	O	137-139
lovastatin	O	140-150
in	O	151-153
women	O	154-159
with	O	160-164
moderate	O	165-173
hypercholesterolemia	B	174-194
.	O	194-195
DESIGN	O	196-202
:	O	202-203
The	O	204-207
Expanded	O	208-216
Clinical	O	217-225
Evaluation	O	226-236
of	O	237-239
Lovastatin	O	240-250
(	O	251-252
EXCEL	O	252-257
)	O	257-258
Study	O	259-264
,	O	264-265
a	O	266-267
multicenter	O	268-279
,	O	279-280
double	O	281-287
-	O	287-288
blind	O	288-293
,	O	293-294
diet	O	295-299
-	O	299-300
and	O	301-304
placebo	O	305-312
-	O	312-313
controlled	O	313-323
trial	O	324-329
,	O	329-330
in	O	331-333
which	O	334-339
participants	O	340-352
were	O	353-357
randomly	O	358-366
assigned	O	367-375
to	O	376-378
receive	O	379-386
placebo	O	387-394
or	O	395-397
lovastatin	O	398-408
at	O	409-411
doses	O	412-417
of	O	418-420
20	O	421-423
or	O	424-426
40	O	427-429
mg	O	430-432
once	O	433-437
daily	O	438-443
,	O	443-444
or	O	445-447
20	O	448-450
or	O	451-453
40	O	454-456
mg	O	457-459
twice	O	460-465
daily	O	466-471
for	O	472-475
48	O	476-478
weeks	O	479-484
.	O	484-485

SETTING	O	486-493
:	O	493-494
Ambulatory	O	495-505
patients	O	506-514
recruited	O	515-524
by	O	525-527
362	O	528-531
participating	O	532-545
centers	O	546-553
throughout	O	554-564
the	O	565-568
United	O	569-575
States	O	576-582
.	O	582-583

PATIENTS	O	584-592
:	O	592-593
Women	O	594-599
(	O	600-601
n	O	601-602
=	O	603-604
3390	O	605-609
)	O	609-610
from	O	611-615
the	O	616-619
total	O	620-625
cohort	O	626-632
of	O	633-635
8245	O	636-640
volunteers	O	641-651
.	O	651-652

MEASUREMENTS	O	653-665
:	O	665-666
Plasma	O	667-673
total	O	674-679
,	O	679-680
low	O	681-684
-	O	684-685
density	O	685-692
lipoprotein	O	693-704
(	O	705-706
LDL	O	706-709
)	O	709-710
,	O	710-711
and	O	712-715
high	O	716-720
-	O	720-721
density	O	721-728
lipoprotein	O	729-740
(	O	741-742
HDL	O	742-745
)	O	745-746
cholesterol	O	747-758
,	O	758-759
and	O	760-763
triglycerides	O	764-777
;	O	777-778
and	O	779-782
laboratory	O	783-793
and	O	794-797
clinical	O	798-806
evidence	O	807-815
of	O	816-818
adverse	O	819-826
events	O	827-833
monitored	O	834-843
periodically	O	844-856
throughout	O	857-867
the	O	868-871
study	O	872-877
.	O	877-878

RESULTS	O	879-886
:	O	886-887
Among	O	888-893
women	O	894-899
,	O	899-900
lovastatin	O	901-911
(	O	912-913
20	O	913-915
to	O	916-918
80	O	919-921
mg	O	922-924
/	O	924-925
d	O	925-926
)	O	926-927
produced	O	928-936
sustained	O	937-946
(	O	947-948
12	O	948-950
-	O	950-951
to	O	952-954
48	O	955-957
-	O	957-958
week	O	958-962
)	O	962-963
,	O	963-964
dose	O	965-969
-	O	969-970
related	O	970-977
changes	O	978-985
(	O	986-987
P	O	987-988
<	O	989-990
0	O	991-992
.	O	992-993
001	O	993-996
)	O	996-997
:	O	997-998
decreases	O	999-1008
in	O	1009-1011
LDL	O	1012-1015
cholesterol	O	1016-1027
(	O	1028-1029
24	O	1029-1031
%	O	1031-1032
to	O	1033-1035
40	O	1036-1038
%	O	1038-1039
)	O	1039-1040
and	O	1041-1044
triglycerides	O	1045-1058
(	O	1059-1060
9	O	1060-1061
%	O	1061-1062
to	O	1063-1065
18	O	1066-1068
%	O	1068-1069
)	O	1069-1070
,	O	1070-1071
and	O	1072-1075
increases	O	1076-1085
in	O	1086-1088
HDL	O	1089-1092
cholesterol	O	1093-1104
(	O	1105-1106
6	O	1106-1107
.	O	1107-1108
7	O	1108-1109
%	O	1109-1110
to	O	1111-1113
8	O	1114-1115
.	O	1115-1116
6	O	1116-1117
%	O	1117-1118
)	O	1118-1119
.	O	1115-1116

Depending	O	1121-1130
on	O	1131-1133
the	O	1134-1137
dose	O	1138-1142
,	O	1142-1143
from	O	1144-1148
82	O	1149-1151
%	O	1151-1152
to	O	1153-1155
95	O	1156-1158
%	O	1158-1159
of	O	1160-1162
lovastatin	O	1163-1173
-	O	1173-1174
treated	O	1174-1181
women	O	1182-1187
achieved	O	1188-1196
the	O	1197-1200
National	O	1201-1209
Cholesterol	O	1210-1221
Education	O	1222-1231
Program	O	1232-1239
goal	O	1240-1244
of	O	1245-1247
LDL	O	1248-1251
cholesterol	O	1252-1263
levels	O	1264-1270
less	O	1271-1275
than	O	1276-1280
4	O	1281-1282
.	O	1282-1283
14	O	1283-1285
mmol	O	1286-1290
/	O	1290-1291
L	O	1291-1292
(	O	1293-1294
160	O	1294-1297
mg	O	1298-1300
/	O	1300-1301
dL	O	1301-1303
)	O	1303-1304
,	O	1304-1305
and	O	1306-1309
40	O	1310-1312
%	O	1312-1313
to	O	1314-1316
87	O	1317-1319
%	O	1319-1320
achieved	O	1321-1329
the	O	1330-1333
goal	O	1334-1338
of	O	1339-1341
3	O	1342-1343
.	O	1343-1344
36	O	1344-1346
mmol	O	1347-1351
/	O	1351-1352
L	O	1352-1353
(	O	1354-1355
130	O	1355-1358
mg	O	1359-1361
/	O	1361-1362
dL	O	1362-1364
)	O	1364-1365
.	O	1365-1366

Successive	O	1367-1377
transaminase	O	1378-1390
elevations	O	1391-1401
greater	O	1402-1409
than	O	1410-1414
three	O	1415-1420
times	O	1421-1426
the	O	1427-1430
upper	O	1431-1436
limit	O	1437-1442
of	O	1443-1445
normal	O	1446-1452
occurred	O	1453-1461
in	O	1462-1464
0	O	1465-1466
.	O	1466-1467
1	O	1467-1468
%	O	1468-1469
of	O	1470-1472
women	O	1473-1478
and	O	1479-1482
were	O	1483-1487
dose	O	1488-1492
dependent	O	1493-1502
above	O	1503-1508
the	O	1509-1512
20	O	1513-1515
-	O	1515-1516
mg	O	1516-1518
dose	O	1519-1523
.	O	1523-1524

Myopathy	B	1525-1533
,	O	1533-1534
defined	O	1535-1542
as	O	1543-1545
muscle	O	1546-1552
symptoms	O	1553-1561
with	O	1562-1566
creatine	O	1567-1575
kinase	O	1576-1582
elevations	O	1583-1593
greater	O	1594-1601
than	O	1602-1606
10	O	1607-1609
times	O	1610-1615
the	O	1616-1619
upper	O	1620-1625
limit	O	1626-1631
of	O	1632-1634
normal	O	1635-1641
,	O	1641-1642
was	O	1643-1646
rare	O	1647-1651
and	O	1652-1655
associated	O	1656-1666
with	O	1667-1671
the	O	1672-1675
highest	O	1676-1683
recommended	O	1684-1695
daily	O	1696-1701
dose	O	1702-1706
of	O	1707-1709
lovastatin	O	1710-1720
(	O	1721-1722
80	O	1722-1724
mg	O	1725-1727
)	O	1727-1728
.	O	1728-1729

Estrogen	O	1730-1738
-	O	1738-1739
replacement	O	1739-1750
therapy	O	1751-1758
appeared	O	1759-1767
to	O	1768-1770
have	O	1771-1775
no	O	1776-1778
effect	O	1779-1785
on	O	1786-1788
either	O	1789-1795
the	O	1796-1799
efficacy	O	1800-1808
or	O	1809-1811
safety	O	1812-1818
profile	O	1819-1826
of	O	1827-1829
lovastatin	O	1830-1840
.	O	1840-1841

CONCLUSION	O	1842-1852
:	O	1852-1853
Lovastatin	O	1854-1864
is	O	1865-1867
highly	O	1868-1874
effective	O	1875-1884
and	O	1885-1888
generally	O	1889-1898
well	O	1899-1903
tolerated	O	1904-1913
as	O	1914-1916
therapy	O	1917-1924
for	O	1925-1928
primary	O	1929-1936
hypercholesterolemia	B	1937-1957
in	O	1958-1960
women	O	1961-1966
.	O	1966-1967

REM	B	0-3
sleep	I	4-9
deprivation	I	10-21
changes	O	22-29
behavioral	O	30-40
response	O	41-49
to	O	50-52
catecholaminergic	O	53-70
and	O	71-74
serotonergic	O	75-87
receptor	O	88-96
activation	O	97-107
in	O	108-110
rats	O	111-115
.	O	115-116

The	O	117-120
effects	O	121-128
of	O	129-131
REM	B	132-135
sleep	I	136-141
deprivation	I	142-153
(	O	154-155
REMD	B	155-159
)	O	159-160
on	O	161-163
apomorphine	O	164-175
-	O	175-176
induced	O	176-183
aggressiveness	B	184-198
and	O	199-202
quipazine	O	203-212
-	O	212-213
induced	O	213-220
head	B	221-225
twitches	I	226-234
in	O	235-237
rats	O	238-242
were	O	243-247
determined	O	248-258
.	O	258-259

Forty	O	260-265
-	O	265-266
eight	O	266-271
hr	O	272-274
of	O	275-277
REMD	B	278-282
increased	O	283-292
apomorphine	O	293-304
-	O	304-305
induced	O	305-312
aggressiveness	B	313-327
,	O	327-328
and	O	329-332
reduced	O	333-340
(	O	341-342
immediately	O	342-353
after	O	354-359
completing	O	360-370
of	O	371-373
REMD	B	374-378
)	O	378-379
or	O	380-382
increased	O	383-392
(	O	393-394
96	O	394-396
hr	O	397-399
after	O	400-405
completing	O	406-416
of	O	417-419
REMD	B	420-424
)	O	424-425
quipazine	O	426-435
-	O	435-436
induced	O	436-443
head	B	444-448
twitches	I	449-457
.	O	457-458

Results	O	459-466
are	O	467-470
discussed	O	471-480
in	O	481-483
terms	O	484-489
of	O	490-492
similarity	O	493-503
to	O	504-506
pharmacological	O	507-522
effects	O	523-530
of	O	531-533
other	O	534-539
antidepressive	O	540-554
treatments	O	555-565
.	O	565-566

Extrapyramidal	O	0-14
side	O	15-19
effects	O	20-27
and	O	28-31
oral	O	32-36
haloperidol	O	37-48
:	O	48-49
an	O	50-52
analysis	O	53-61
of	O	62-64
explanatory	O	65-76
patient	O	77-84
and	O	85-88
treatment	O	89-98
characteristics	O	99-114
.	O	114-115

The	O	116-119
incidence	O	120-129
of	O	130-132
extrapyramidal	O	133-147
side	O	148-152
effects	O	153-160
(	O	161-162
EPS	O	162-165
)	O	165-166
was	O	167-170
evaluated	O	171-180
in	O	181-183
98	O	184-186
patients	O	187-195
treated	O	196-203
with	O	204-208
haloperidol	O	209-220
.	O	220-221

The	O	222-225
incidence	O	226-235
of	O	236-238
parkinsonism	B	239-251
was	O	252-255
higher	O	256-262
at	O	263-265
higher	O	266-272
doses	O	273-278
of	O	279-281
haloperidol	O	282-293
and	O	294-297
in	O	298-300
younger	O	301-308
patients	O	309-317
.	O	317-318

Prophylactic	O	319-331
antiparkinsonian	O	332-348
medication	O	349-359
was	O	360-363
effective	O	364-373
in	O	374-376
younger	O	377-384
but	O	385-388
not	O	389-392
in	O	393-395
older	O	396-401
patients	O	402-410
.	O	410-411

However	O	412-419
,	O	419-420
these	O	421-426
medications	O	427-438
were	O	439-443
more	O	444-448
effective	O	449-458
in	O	459-461
both	O	462-466
young	O	467-472
and	O	473-476
old	O	477-480
patients	O	481-489
when	O	490-494
given	O	495-500
after	O	501-506
parkinsonism	B	507-519
developed	O	520-529
.	O	529-530

Akathisia	B	531-540
was	O	541-544
controlled	O	545-555
by	O	556-558
the	O	559-562
benzodiazepine	O	563-577
lorazepam	O	578-587
in	O	588-590
14	O	591-593
out	O	594-597
of	O	598-600
16	O	601-603
patients	O	604-612
,	O	612-613
while	O	614-619
prophylactic	O	620-632
antiparkinsonians	O	633-650
were	O	651-655
ineffective	O	656-667
.	O	667-668

The	O	669-672
present	O	673-680
study	O	681-686
points	O	687-693
to	O	694-696
patient	O	697-704
characteristics	O	705-720
that	O	721-725
may	O	726-729
be	O	730-732
of	O	733-735
significance	O	736-748
in	O	749-751
the	O	752-755
development	O	756-767
of	O	768-770
EPS	O	771-774
due	O	775-778
to	O	779-781
haloperidol	O	782-793
.	O	793-794

Hepatic	B	0-7
veno	I	8-12
-	I	12-13
occlusive	I	13-22
disease	I	23-30
caused	O	31-37
by	O	38-40
6	O	41-42
-	O	42-43
thioguanine	O	43-54
.	O	54-55

Clinically	O	56-66
reversible	O	67-77
veno	B	78-82
-	I	82-83
occlusive	I	83-92
disease	I	93-100
of	I	101-103
the	I	104-107
liver	I	108-113
developed	O	114-123
in	O	124-126
a	O	127-128
23	O	129-131
-	O	131-132
year	O	132-136
-	O	131-132
old	O	137-140
man	O	141-144
with	O	145-149
acute	B	150-155
lymphocytic	I	156-167
leukemia	I	168-176
after	O	177-182
10	O	183-185
months	O	186-192
of	O	193-195
maintenance	O	196-207
therapy	O	208-215
with	O	216-220
6	O	221-222
-	O	222-223
thioguanine	O	223-234
.	O	234-235

Serial	O	236-242
liver	O	243-248
biopsies	O	249-257
showed	O	258-264
the	O	265-268
development	O	269-280
and	O	281-284
resolution	O	285-295
of	O	296-298
intense	O	299-306
sinusoidal	O	307-317
engorgement	O	318-329
.	O	329-330

Although	O	331-339
this	O	340-344
disease	O	345-352
was	O	353-356
clinically	O	357-367
reversible	O	368-378
,	O	378-379
some	O	380-384
subintimal	O	385-395
fibrosis	B	396-404
about	O	405-410
the	O	411-414
terminal	O	415-423
hepatic	O	424-431
veins	O	432-437
persisted	O	438-447
.	O	447-448

This	O	449-453
case	O	454-458
presented	O	459-468
a	O	469-470
unique	O	471-477
opportunity	O	478-489
to	O	490-492
observe	O	493-500
the	O	501-504
histologic	O	505-515
features	O	516-524
of	O	525-527
clinically	O	528-538
reversible	O	539-549
hepatic	B	550-557
veno	I	558-562
-	I	562-563
occlusive	I	563-572
disease	I	573-580
over	O	581-585
time	O	586-590
,	O	590-591
and	O	592-595
may	O	596-599
be	O	600-602
the	O	603-606
first	O	607-612
case	O	613-617
of	O	618-620
veno	O	621-625
-	O	625-626
occlusive	O	626-635
related	O	636-643
solely	O	644-650
to	O	651-653
6	O	654-655
-	O	655-656
thioguanine	O	656-667
.	O	667-668

Treatment	O	0-9
of	O	10-12
ifosfamide	O	13-23
-	O	23-24
induced	O	24-31
urothelial	B	32-42
toxicity	I	43-51
by	O	52-54
oral	O	55-59
administration	O	60-74
of	O	75-77
sodium	O	78-84
2	O	85-86
-	O	86-87
mercaptoethane	O	87-101
sulphonate	O	102-112
(	O	113-114
MESNA	O	114-119
)	O	119-120
to	O	121-123
patients	O	124-132
with	O	133-137
inoperable	O	138-148
lung	B	149-153
cancer	I	154-160
.	O	160-161

The	O	162-165
protective	O	166-176
effect	O	177-183
of	O	184-186
oral	O	187-191
administration	O	192-206
of	O	207-209
the	O	210-213
thiol	O	214-219
compound	O	220-228
sodium	O	229-235
2	O	236-237
-	O	237-238
mercaptoethane	O	238-252
sulphonate	O	253-263
(	O	264-265
MESNA	O	265-270
)	O	270-271
against	O	272-279
urothelial	B	280-290
toxicity	I	291-299
induced	O	300-307
by	O	308-310
ifosfamide	O	311-321
(	O	322-323
IF	O	323-325
)	O	325-326
was	O	327-330
tested	O	331-337
in	O	338-340
a	O	341-342
group	O	343-348
of	O	349-351
45	O	352-354
patients	O	355-363
with	O	364-368
inoperable	O	369-379
lung	B	380-384
cancer	I	385-391
under	O	392-397
treatment	O	398-407
with	O	408-412
IF	O	413-415
(	O	416-417
2250	O	417-421
mg	O	422-424
/	O	424-425
m2	O	425-427
on	O	428-430
days	O	431-435
2	O	436-437
-	O	437-438
5	O	438-439
)	O	439-440
as	O	441-443
part	O	444-448
of	O	449-451
a	O	452-453
polychemotherapy	O	454-470
regimen	O	471-478
repeated	O	479-487
in	O	488-490
a	O	491-492
4	O	493-494
-	O	494-495
week	O	495-499
cycle	O	500-505
.	O	505-506

MESNA	O	507-512
was	O	513-516
given	O	517-522
orally	O	523-529
on	O	530-532
the	O	533-536
days	O	537-541
of	O	542-544
treatment	O	545-554
with	O	555-559
IF	O	560-562
in	O	563-565
3	O	566-567
doses	O	568-573
of	O	574-576
840	O	577-580
mg	O	581-583
/	O	583-584
m2	O	584-586
,	O	586-587
each	O	588-592
administered	O	593-605
at	O	606-608
0	O	609-610
hr	O	611-613
(	O	614-615
=	O	615-616
injection	O	617-626
of	O	627-629
IF	O	630-632
)	O	632-633
,	O	633-634
4	O	635-636
hr	O	637-639
and	O	640-643
8	O	644-645
hr	O	646-648
p	O	649-650
.	O	650-651
i	O	651-652
.	O	650-651
Out	O	654-657
of	O	658-660
a	O	661-662
total	O	663-668
of	O	669-671
88	O	672-674
courses	O	675-682
of	O	683-685
this	O	686-690
treatment	O	691-700
we	O	701-703
observed	O	704-712
10	O	713-715
episodes	O	716-724
of	O	725-727
asymptomatic	O	728-740
microscopic	O	741-752
haematuria	B	753-763
and	O	764-767
no	O	768-770
episodes	O	771-779
of	O	780-782
gross	O	783-788
haematuria	B	789-799
.	O	799-800

In	O	801-803
this	O	804-808
group	O	809-814
of	O	815-817
45	O	818-820
patients	O	821-829
under	O	830-835
protection	O	836-846
with	O	847-851
MESNA	O	852-857
there	O	858-863
were	O	864-868
5	O	869-870
complete	O	871-879
remissions	O	880-890
and	O	891-894
9	O	895-896
partial	O	897-904
remissions	O	905-915
(	O	916-917
total	O	917-922
31	O	923-925
%	O	925-926
)	O	926-927
.	O	927-928

A	O	929-930
further	O	931-938
group	O	939-944
of	O	945-947
25	O	948-950
patients	O	951-959
under	O	960-965
polychemotherapy	O	966-982
with	O	983-987
IF	O	988-990
were	O	991-995
treated	O	996-1003
by	O	1004-1006
conventional	O	1007-1019
prophylactic	O	1020-1032
measures	O	1033-1041
(	O	1042-1043
raised	O	1043-1049
fluid	O	1050-1055
intake	O	1056-1062
and	O	1063-1066
forced	O	1067-1073
diuresis	O	1074-1082
)	O	1082-1083
.	O	1083-1084

In	O	1085-1087
this	O	1088-1092
group	O	1093-1098
there	O	1099-1104
were	O	1105-1109
1	O	1110-1111
complete	O	1112-1120
and	O	1121-1124
5	O	1125-1126
partial	O	1127-1134
remissions	O	1135-1145
(	O	1146-1147
total	O	1147-1152
24	O	1153-1155
%	O	1155-1156
)	O	1156-1157
,	O	1157-1158
but	O	1159-1162
nearly	O	1163-1169
all	O	1170-1173
patients	O	1174-1182
developed	O	1183-1192
either	O	1193-1199
gross	O	1200-1205
haematuria	B	1206-1216
and	O	1217-1220
/	O	1220-1221
or	O	1221-1223
symptoms	O	1224-1232
of	O	1233-1235
bladder	B	1236-1243
irritation	I	1244-1254
(	O	1255-1256
cystitis	B	1256-1264
and	O	1265-1268
pollakisuria	B	1269-1281
)	O	1281-1282
.	O	1282-1283

There	O	1284-1289
were	O	1290-1294
no	O	1295-1297
appreciable	O	1298-1309
differences	O	1310-1321
between	O	1322-1329
the	O	1330-1333
MESNA	O	1334-1339
series	O	1340-1346
and	O	1347-1350
the	O	1351-1354
conventional	O	1355-1367
prophylaxis	O	1368-1379
series	O	1380-1386
with	O	1387-1391
respect	O	1392-1399
to	O	1400-1402
either	O	1403-1409
haematological	O	1410-1424
or	O	1425-1427
systemic	O	1428-1436
toxicity	B	1437-1445
of	O	1446-1448
the	O	1449-1452
cytostatic	O	1453-1463
treatment	O	1464-1473
.	O	1473-1474

Our	O	1475-1478
results	O	1479-1486
support	O	1487-1494
the	O	1495-1498
view	O	1499-1503
that	O	1504-1508
MESNA	O	1509-1514
,	O	1514-1515
given	O	1516-1521
orally	O	1522-1528
in	O	1529-1531
conjunction	O	1532-1543
with	O	1544-1548
combined	O	1549-1557
cytostatic	O	1558-1568
regimens	O	1569-1577
which	O	1578-1583
include	O	1584-1591
IF	O	1592-1594
,	O	1594-1595
simplifies	O	1596-1606
the	O	1607-1610
treatment	O	1611-1620
and	O	1621-1624
provides	O	1625-1633
optimum	O	1634-1641
protection	O	1642-1652
for	O	1653-1656
the	O	1657-1660
urinary	O	1661-1668
epithelium	O	1669-1679
.	O	1679-1680

Protection	O	1681-1691
with	O	1692-1696
oral	O	1697-1701
MESNA	O	1702-1707
is	O	1708-1710
particularly	O	1711-1723
suitable	O	1724-1732
for	O	1733-1736
outpatients	O	1737-1748
.	O	1748-1749

Time	O	0-4
course	O	5-11
alterations	O	12-23
of	O	24-26
QTC	O	27-30
interval	O	31-39
due	O	40-43
to	O	44-46
hypaque	O	47-54
76	O	55-57
.	O	57-58

Sequential	O	59-69
measurement	O	70-81
of	O	82-84
QT	O	85-87
interval	O	88-96
during	O	97-103
left	O	104-108
ventricular	O	109-120
angiography	O	121-132
was	O	133-136
made	O	137-141
30	O	142-144
seconds	O	145-152
and	O	153-156
one	O	157-160
,	O	160-161
three	O	162-167
,	O	167-168
five	O	169-173
and	O	174-177
ten	O	178-181
minutes	O	182-189
after	O	190-195
injection	O	196-205
of	O	206-208
hypaque	O	209-216
76	O	217-219
.	O	219-220

The	O	221-224
subjects	O	225-233
were	O	234-238
ten	O	239-242
patients	O	243-251
found	O	252-257
to	O	258-260
have	O	261-265
normal	O	266-272
left	O	273-277
ventricles	O	278-288
and	O	289-292
coronary	O	293-301
arteries	O	302-310
.	O	310-311

Significant	O	312-323
QTC	B	324-327
prolongation	I	328-340
occurred	O	341-349
in	O	350-352
30	O	353-355
seconds	O	356-363
to	O	364-366
one	O	367-370
minute	O	371-377
in	O	378-380
association	O	381-392
with	O	393-397
marked	O	398-404
hypotension	B	405-416
and	O	417-420
elevation	O	421-430
of	O	431-433
cardiac	O	434-441
output	O	442-448
.	O	448-449

Production	O	0-10
of	O	11-13
autochthonous	O	14-27
prostate	B	28-36
cancer	I	37-43
in	O	44-46
Lobund	O	47-53
-	O	53-54
Wistar	O	54-60
rats	O	61-65
by	O	66-68
treatments	O	69-79
with	O	80-84
N	O	85-86
-	O	86-87
nitroso	O	87-94
-	O	86-87
N	O	85-86
-	O	86-87
methylurea	O	97-107
and	O	108-111
testosterone	O	112-124
.	O	124-125

More	O	126-130
than	O	131-135
50	O	136-138
%	O	138-139
of	O	140-142
Lobund	O	143-149
-	O	149-150
Wistar	O	150-156
(	O	157-158
L	O	158-159
-	O	159-160
W	O	160-161
)	O	161-162
strain	O	163-169
rats	O	170-174
developed	O	175-184
large	O	185-190
,	O	190-191
palpable	O	192-200
prostate	B	201-209
adenocarcinomas	I	210-225
(	O	226-227
PAs	B	227-230
)	O	230-231
following	O	232-241
treatments	O	242-252
with	O	253-257
N	O	258-259
-	O	259-260
nitroso	O	260-267
-	O	259-260
N	O	258-259
-	O	259-260
methylurea	O	270-280
(	O	281-282
CAS	O	282-285
:	O	285-286
684	O	287-290
-	O	290-291
93	O	291-293
-	O	290-291
5	O	294-295
)	O	295-296
and	O	297-300
testosterone	O	301-313
propionate	O	314-324
[	O	325-326
(	O	326-327
TP	O	327-329
)	O	329-330
CAS	O	331-334
:	O	334-335
57	O	336-338
-	O	338-339
85	O	339-341
-	O	338-339
2	O	342-343
]	O	343-344
,	O	344-345
and	O	346-349
most	O	350-354
of	O	355-357
the	O	358-361
tumor	B	362-367
-	O	367-368
bearing	O	368-375
rats	O	376-380
manifested	O	381-391
metastatic	O	392-402
lesions	O	403-410
.	O	410-411

The	O	412-415
incubation	O	416-426
periods	O	427-434
averaged	O	435-443
10	O	444-446
.	O	446-447
6	O	447-448
months	O	449-455
.	O	455-456

Within	O	457-463
the	O	464-467
same	O	468-472
timeframe	O	473-482
,	O	482-483
no	O	484-486
L	O	487-488
-	O	488-489
W	O	489-490
rat	O	491-494
developed	O	495-504
a	O	505-506
similar	O	507-514
palpable	O	515-523
PA	B	524-526
when	O	527-531
treated	O	532-539
only	O	540-544
with	O	545-549
TP	O	550-552
.	O	552-553

In	O	554-556
L	O	557-558
-	O	558-559
W	O	559-560
rats	O	561-565
,	O	565-566
TP	O	567-569
acted	O	570-575
as	O	576-578
a	O	579-580
tumor	B	581-586
enhancement	O	587-598
agent	O	599-604
,	O	604-605
with	O	606-610
primary	O	611-618
emphasis	O	619-627
on	O	628-630
the	O	631-634
development	O	635-646
of	O	647-649
prostate	B	650-658
cancer	I	659-665
.	O	665-666

A	O	0-1
dystonia	B	2-10
-	O	10-11
like	O	11-15
syndrome	O	16-24
after	O	25-30
neuropeptide	O	31-43
(	O	44-45
MSH	O	45-48
/	O	48-49
ACTH	O	49-53
)	O	53-54
stimulation	O	55-66
of	O	67-69
the	O	70-73
rat	O	74-77
locus	O	78-83
ceruleus	O	84-92
.	O	92-93

The	O	94-97
movement	B	98-106
disorder	I	107-115
investigated	O	116-128
in	O	129-131
these	O	132-137
studies	O	138-145
has	O	146-149
some	O	150-154
features	O	155-163
in	O	164-166
common	O	167-173
with	O	174-178
human	O	179-184
idiopathic	O	185-195
dystonia	B	196-204
,	O	204-205
and	O	206-209
information	O	210-221
obtained	O	222-230
in	O	231-233
these	O	234-239
studies	O	240-247
may	O	248-251
be	O	252-254
of	O	255-257
potential	O	258-267
clinical	O	268-276
benefit	O	277-284
.	O	284-285

The	O	286-289
present	O	290-297
experimental	O	298-310
results	O	311-318
indicated	O	319-328
that	O	329-333
peptidergic	O	334-345
stimulation	O	346-357
of	O	358-360
the	O	361-364
LC	O	365-367
resulted	O	368-376
in	O	377-379
a	O	380-381
NE	O	382-384
-	O	384-385
mediated	O	385-393
inhibition	O	394-404
of	O	405-407
cerebellar	O	408-418
Purkinje	O	419-427
cells	O	428-433
located	O	434-441
at	O	442-444
terminals	O	445-454
of	O	455-457
the	O	458-461
ceruleo	O	462-469
-	O	469-470
cerebellar	O	470-480
pathway	O	481-488
.	O	488-489

However	O	490-497
,	O	497-498
it	O	499-501
is	O	502-504
not	O	505-508
certain	O	509-516
as	O	517-519
to	O	520-522
the	O	523-526
following	O	527-536
:	O	536-537
(	O	538-539
a	O	539-540
)	O	540-541
what	O	542-546
receptors	O	547-556
were	O	557-561
stimulated	O	562-572
by	O	573-575
the	O	576-579
ACTH	O	580-584
N	O	585-586
-	O	586-587
terminal	O	587-595
fragments	O	596-605
at	O	606-608
the	O	609-612
LC	O	613-615
that	O	616-620
resulted	O	621-629
in	O	630-632
this	O	633-637
disorder	O	638-646
;	O	646-647
(	O	648-649
b	O	649-650
)	O	650-651
whether	O	652-659
NE	O	660-662
,	O	662-663
released	O	664-672
onto	O	673-677
Purkinje	O	678-686
cell	O	687-691
synapses	O	692-700
located	O	701-708
at	O	709-711
terminals	O	712-721
of	O	722-724
the	O	725-728
ceruleo	O	729-736
-	O	736-737
cerebellar	O	737-747
pathway	O	748-755
,	O	755-756
did	O	757-760
indeed	O	761-767
cause	O	768-773
the	O	774-777
long	O	778-782
-	O	782-783
term	O	783-787
depression	B	788-798
at	O	799-801
Purkinje	O	802-810
cell	O	811-815
synapses	O	816-824
(	O	825-826
previously	O	826-836
described	O	837-846
by	O	847-849
others	O	850-856
)	O	856-857
that	O	858-862
resulted	O	863-871
in	O	872-874
the	O	875-878
long	O	879-883
duration	O	884-892
of	O	893-895
the	O	896-899
movement	B	900-908
disorder	I	909-917
;	O	917-918
(	O	919-920
c	O	920-921
)	O	921-922
whether	O	923-930
the	O	931-934
inhibition	O	935-945
of	O	946-948
inhibitory	O	949-959
Purkinje	O	960-968
cells	O	969-974
resulted	O	975-983
in	O	984-986
disinhibition	O	987-1000
or	O	1001-1003
increased	O	1004-1013
excitability	O	1014-1026
of	O	1027-1029
the	O	1030-1033
unilateral	O	1034-1044
cerebellar	O	1045-1055
fastigial	O	1056-1065
or	O	1066-1068
interpositus	O	1069-1081
nuclei	O	1082-1088
,	O	1088-1089
the	O	1090-1093
output	O	1094-1100
targets	O	1101-1108
of	O	1109-1111
the	O	1112-1115
Purkinje	O	1116-1124
cell	O	1125-1129
axons	O	1130-1135
,	O	1135-1136
that	O	1137-1141
may	O	1142-1145
have	O	1146-1150
been	O	1151-1155
an	O	1156-1158
important	O	1159-1168
contributing	O	1169-1181
factor	O	1182-1188
to	O	1189-1191
this	O	1192-1196
disorder	O	1197-1205
.	O	1205-1206

These	O	1207-1212
questions	O	1213-1222
are	O	1223-1226
currently	O	1227-1236
being	O	1237-1242
investigated	O	1243-1255
.	O	1255-1256

Dexmedetomidine	O	0-15
,	O	15-16
acting	O	17-23
through	O	24-31
central	O	32-39
alpha	O	40-45
-	O	45-46
2	O	46-47
adrenoceptors	O	48-61
,	O	61-62
prevents	O	63-71
opiate	O	72-78
-	O	78-79
induced	O	79-86
muscle	B	87-93
rigidity	I	94-102
in	O	103-105
the	O	106-109
rat	O	110-113
.	O	113-114

The	O	115-118
highly	O	119-125
-	O	125-126
selective	O	126-135
alpha	O	136-141
-	O	141-142
2	O	142-143
adrenergic	O	144-154
agonist	O	155-162
dexmedetomidine	O	163-178
(	O	179-180
D	O	180-181
-	O	181-182
MED	O	182-185
)	O	185-186
is	O	187-189
capable	O	190-197
of	O	198-200
inducing	O	201-209
muscle	B	210-216
flaccidity	I	217-227
and	O	228-231
anesthesia	O	232-242
in	O	243-245
rats	O	246-250
and	O	251-254
dogs	O	255-259
.	O	259-260

Intense	O	261-268
generalized	O	269-280
muscle	B	281-287
rigidity	I	288-296
is	O	297-299
an	O	300-302
undesirable	O	303-314
side	O	315-319
effect	O	320-326
of	O	327-329
potent	O	330-336
opiate	O	337-343
agonists	O	344-352
.	O	352-353

Although	O	354-362
the	O	363-366
neurochemistry	O	367-381
of	O	382-384
opiate	O	385-391
-	O	391-392
induced	O	392-399
rigidity	B	400-408
has	O	409-412
yet	O	413-416
to	O	417-419
be	O	420-422
fully	O	423-428
elucidated	O	429-439
,	O	439-440
recent	O	441-447
work	O	448-452
suggests	O	453-461
a	O	462-463
role	O	464-468
for	O	469-472
a	O	473-474
central	O	475-482
adrenergic	O	483-493
mechanism	O	494-503
.	O	503-504

In	O	505-507
the	O	508-511
present	O	512-519
study	O	520-525
,	O	525-526
the	O	527-530
authors	O	531-538
determined	O	539-549
if	O	550-552
treatment	O	553-562
with	O	563-567
D	O	568-569
-	O	569-570
MED	O	570-573
prevents	O	574-582
the	O	583-586
muscle	B	587-593
rigidity	I	594-602
caused	O	603-609
by	O	610-612
high	O	613-617
-	O	617-618
dose	O	618-622
alfentanil	O	623-633
anesthesia	O	634-644
in	O	645-647
the	O	648-651
rat	O	652-655
.	O	655-656

Animals	O	657-664
(	O	665-666
n	O	666-667
=	O	668-669
42	O	670-672
)	O	672-673
were	O	674-678
treated	O	679-686
intraperitoneally	O	687-704
with	O	705-709
one	O	710-713
of	O	714-716
the	O	717-720
following	O	721-730
six	O	731-734
regimens	O	735-743
:	O	743-744
1	O	745-746
)	O	746-747
L	O	748-749
-	O	749-750
MED	O	750-753
(	O	754-755
the	O	755-758
inactive	O	759-767
L	O	768-769
-	O	769-770
isomer	O	770-776
of	O	777-779
medetomidine	O	780-792
)	O	792-793
,	O	793-794
30	O	795-797
micrograms	O	798-808
/	O	808-809
kg	O	809-811
;	O	811-812
2	O	813-814
)	O	814-815
D	O	816-817
-	O	817-818
MED	O	818-821
,	O	821-822
10	O	823-825
micrograms	O	826-836
/	O	836-837
kg	O	837-839
;	O	839-840
3	O	841-842
)	O	842-843
D	O	844-845
-	O	845-846
MED	O	846-849
,	O	849-850
30	O	851-853
micrograms	O	854-864
/	O	864-865
kg	O	865-867
;	O	867-868
4	O	869-870
)	O	870-871
D	O	872-873
-	O	873-874
MED	O	874-877
[	O	878-879
30	O	879-881
micrograms	O	882-892
/	O	892-893
kg	O	893-895
]	O	895-896
and	O	897-900
the	O	901-904
central	O	905-912
-	O	912-913
acting	O	913-919
alpha	O	920-925
-	O	925-926
2	O	926-927
antagonist	O	928-938
,	O	938-939
idazoxan	O	940-948
[	O	949-950
10	O	950-952
mg	O	953-955
/	O	955-956
kg	O	956-958
]	O	958-959
;	O	959-960
5	O	961-962
)	O	962-963
D	O	964-965
-	O	965-966
MED	O	966-969
[	O	970-971
30	O	971-973
micrograms	O	974-984
/	O	984-985
kg	O	985-987
]	O	987-988
and	O	989-992
the	O	993-996
peripheral	O	997-1007
-	O	1007-1008
acting	O	1008-1014
alpha	O	1015-1020
-	O	1020-1021
2	O	1021-1022
antagonist	O	1023-1033
DG	O	1034-1036
-	O	1036-1037
5128	O	1037-1041
[	O	1042-1043
10	O	1043-1045
mg	O	1046-1048
/	O	1048-1049
kg	O	1049-1051
]	O	1051-1052
,	O	1052-1053
or	O	1054-1056
;	O	1056-1057
6	O	1058-1059
)	O	1059-1060
saline	O	1061-1067
.	O	1067-1068

Baseline	O	1069-1077
electromyographic	O	1078-1095
activity	O	1096-1104
was	O	1105-1108
recorded	O	1109-1117
from	O	1118-1122
the	O	1123-1126
gastrocnemius	O	1127-1140
muscle	O	1141-1147
before	O	1148-1154
and	O	1155-1158
after	O	1159-1164
drug	O	1165-1169
treatment	O	1170-1179
.	O	1179-1180

Each	O	1181-1185
rat	O	1186-1189
was	O	1190-1193
then	O	1194-1198
injected	O	1199-1207
with	O	1208-1212
alfentanil	O	1213-1223
(	O	1224-1225
ALF	O	1225-1228
,	O	1228-1229
0	O	1230-1231
.	O	1231-1232
5	O	1232-1233
mg	O	1234-1236
/	O	1236-1237
kg	O	1237-1239
sc	O	1240-1242
)	O	1242-1243
.	O	1243-1244

ALF	O	1245-1248
injection	O	1249-1258
resulted	O	1259-1267
in	O	1268-1270
a	O	1271-1272
marked	O	1273-1279
increase	O	1280-1288
in	O	1289-1291
hindlimb	O	1292-1300
EMG	O	1301-1304
activity	O	1305-1313
in	O	1314-1316
the	O	1317-1320
L	O	1321-1322
-	O	1322-1323
MED	O	1323-1326
treatment	O	1327-1336
group	O	1337-1342
which	O	1343-1348
was	O	1349-1352
indistinguishable	O	1353-1370
from	O	1371-1375
that	O	1376-1380
seen	O	1381-1385
in	O	1386-1388
animals	O	1389-1396
treated	O	1397-1404
with	O	1405-1409
saline	O	1410-1416
.	O	1416-1417

In	O	1418-1420
contrast	O	1421-1429
,	O	1429-1430
D	O	1431-1432
-	O	1432-1433
MED	O	1433-1436
prevented	O	1437-1446
alfentanil	O	1447-1457
-	O	1457-1458
induced	O	1458-1465
muscle	B	1466-1472
rigidity	I	1473-1481
in	O	1482-1484
a	O	1485-1486
dose	O	1487-1491
-	O	1491-1492
dependent	O	1492-1501
fashion	O	1502-1509
.	O	1509-1510

The	O	1511-1514
small	O	1515-1520
EMG	O	1521-1524
values	O	1525-1531
obtained	O	1532-1540
in	O	1541-1543
the	O	1544-1547
high	O	1548-1552
-	O	1552-1553
dose	O	1553-1557
D	O	1558-1559
-	O	1559-1560
MED	O	1560-1563
group	O	1564-1569
were	O	1570-1574
comparable	O	1575-1585
with	O	1586-1590
those	O	1591-1596
recorded	O	1597-1605
in	O	1606-1608
earlier	O	1609-1616
studies	O	1617-1624
from	O	1625-1629
control	O	1630-1637
animals	O	1638-1645
not	O	1646-1649
given	O	1650-1655
any	O	1656-1659
opiate	O	1660-1666
.	O	1666-1667

The	O	1668-1671
high	O	1672-1676
-	O	1676-1677
dose	O	1677-1681
D	O	1682-1683
-	O	1683-1684
MED	O	1684-1687
animals	O	1688-1695
were	O	1696-1700
flaccid	O	1701-1708
,	O	1708-1709
akinetic	B	1710-1718
,	O	1718-1719
and	O	1720-1723
lacked	O	1724-1730
a	O	1731-1732
startle	B	1733-1740
response	O	1741-1749
during	O	1750-1756
the	O	1757-1760
entire	O	1761-1767
experimental	O	1768-1780
period	O	1781-1787
.	O	1787-1788
(	O	1788-1789
ABSTRACT	O	1789-1797

TRUNCATED	O	1798-1807
AT	O	1808-1810
250	O	1811-1814
WORDS	O	1815-1820
)	O	1820-1821

Seizure	B	0-7
activity	O	8-16
with	O	17-21
imipenem	O	22-30
therapy	O	31-38
:	O	38-39
incidence	O	40-49
and	O	50-53
risk	O	54-58
factors	O	59-66
.	O	66-67

Two	O	68-71
elderly	O	72-79
patients	O	80-88
with	O	89-93
a	O	94-95
history	O	96-103
of	O	104-106
either	O	107-113
cerebral	B	114-122
vascular	I	123-131
accident	I	132-140
(	O	141-142
CVA	B	142-145
)	O	145-146
or	O	147-149
head	B	150-154
trauma	I	155-161
and	O	162-165
no	O	166-168
evidence	O	169-177
of	O	178-180
renal	B	181-186
disease	I	187-194
developed	O	195-204
seizures	B	205-213
while	O	214-219
receiving	O	220-229
maximum	O	230-237
doses	O	238-243
of	O	244-246
imipenem	O	247-255
/	O	255-256
cilastatin	O	256-266
.	O	266-267

Neither	O	268-275
patient	O	276-283
had	O	284-287
reported	O	288-296
previous	O	297-305
seizures	B	306-314
or	O	315-317
seizure	B	318-325
-	O	325-326
like	O	326-330
activity	O	331-339
nor	O	340-343
was	O	344-347
receiving	O	348-357
anticonvulsant	O	358-372
agents	O	373-379
.	O	379-380

All	O	381-384
seizures	B	385-393
were	O	394-398
controlled	O	399-409
with	O	410-414
therapeutic	O	415-426
doses	O	427-432
of	O	433-435
phenytoin	O	436-445
.	O	445-446

Both	O	447-451
patients	O	452-460
had	O	461-464
received	O	465-473
maximum	O	474-481
doses	O	482-487
of	O	488-490
other	O	491-496
beta	O	497-501
-	O	501-502
lactam	O	502-508
antibiotics	O	509-520
without	O	521-528
evidence	O	529-537
of	O	538-540
seizure	B	541-548
activity	O	549-557
.	O	557-558

The	O	0-3
ability	O	4-11
of	O	12-14
insulin	O	15-22
treatment	O	23-32
to	O	33-35
reverse	O	36-43
or	O	44-46
prevent	O	47-54
the	O	55-58
changes	O	59-66
in	O	67-69
urinary	O	70-77
bladder	O	78-85
function	O	86-94
caused	O	95-101
by	O	102-104
streptozotocin	O	105-119
-	O	119-120
induced	O	120-127
diabetes	B	128-136
mellitus	I	137-145
.	O	145-146

1	O	147-148
.	O	148-149

The	O	150-153
effects	O	154-161
of	O	162-164
insulin	O	165-172
treatment	O	173-182
on	O	183-185
in	O	186-188
vivo	O	189-193
and	O	194-197
in	O	198-200
vitro	O	201-206
urinary	O	207-214
bladder	O	215-222
function	O	223-231
in	O	232-234
streptozotocin	O	235-249
-	O	249-250
diabetic	B	250-258
rats	O	259-263
were	O	264-268
investigated	O	269-281
.	O	281-282

2	O	283-284
.	O	284-285
Diabetes	B	286-294
of	O	295-297
2	O	298-299
months	O	300-306
duration	O	307-315
resulted	O	316-324
in	O	325-327
decreases	O	328-337
in	O	338-340
body	O	341-345
weight	O	346-352
and	O	353-356
increases	O	357-366
in	O	367-369
fluid	O	370-375
consumption	O	376-387
,	O	387-388
urine	O	389-394
volume	O	395-401
,	O	401-402
frequency	O	403-412
of	O	413-415
micturition	O	416-427
,	O	427-428
and	O	429-432
average	O	433-440
volume	O	441-447
per	O	448-451
micturition	O	452-463
;	O	463-464
effects	O	465-472
which	O	473-478
were	O	479-483
prevented	O	484-493
by	O	494-496
insulin	O	497-504
treatment	O	505-514
.	O	514-515

3	O	516-517
.	O	517-518
Insulin	O	519-526
treatment	O	527-536
also	O	537-541
prevented	O	542-551
the	O	552-555
increases	O	556-565
in	O	566-568
contractile	O	569-580
responses	O	581-590
of	O	591-593
bladder	O	594-601
body	O	602-606
strips	O	607-613
from	O	614-618
diabetic	B	619-627
rats	O	628-632
to	O	633-635
nerve	O	636-641
stimulation	O	642-653
,	O	653-654
ATP	O	655-658
,	O	658-659
and	O	660-663
bethanechol	O	664-675
.	O	675-676

4	O	677-678
.	O	678-679
Diabetes	B	680-688
of	O	689-691
4	O	692-693
months	O	694-700
duration	O	701-709
also	O	710-714
resulted	O	715-723
in	O	724-726
decreases	O	727-736
in	O	737-739
body	O	740-744
weight	O	745-751
,	O	751-752
and	O	753-756
increases	O	757-766
in	O	767-769
fluid	O	770-775
consumption	O	776-787
,	O	787-788
urine	O	789-794
volume	O	795-801
,	O	801-802
frequency	O	803-812
of	O	813-815
micturition	O	816-827
,	O	827-828
and	O	829-832
average	O	833-840
volume	O	841-847
per	O	848-851
micturition	O	852-863
,	O	863-864
effects	O	865-872
which	O	873-878
were	O	879-883
reversed	O	884-892
by	O	893-895
insulin	O	896-903
treatment	O	904-913
for	O	914-917
the	O	918-921
final	O	922-927
2	O	928-929
months	O	930-936
of	O	937-939
the	O	940-943
study	O	944-949
.	O	949-950

5	O	951-952
.	O	952-953
Insulin	O	954-961
treatment	O	962-971
reversed	O	972-980
the	O	981-984
increases	O	985-994
in	O	995-997
contractile	O	998-1009
responses	O	1010-1019
of	O	1020-1022
bladder	O	1023-1030
body	O	1031-1035
strips	O	1036-1042
from	O	1043-1047
diabetic	B	1048-1056
rats	O	1057-1061
to	O	1062-1064
nerve	O	1065-1070
stimulation	O	1071-1082
,	O	1082-1083
ATP	O	1084-1087
,	O	1087-1088
and	O	1089-1092
bethanechol	O	1093-1104
.	O	1104-1105

6	O	1106-1107
.	O	1107-1108

The	O	1109-1112
data	O	1113-1117
indicate	O	1118-1126
that	O	1127-1131
the	O	1132-1135
effects	O	1136-1143
of	O	1144-1146
streptozotocin	O	1147-1161
-	O	1161-1162
induced	O	1162-1169
diabetes	B	1170-1178
on	O	1179-1181
urinary	O	1182-1189
bladder	O	1190-1197
function	O	1198-1206
are	O	1207-1210
both	O	1211-1215
prevented	O	1216-1225
and	O	1226-1229
reversed	O	1230-1238
by	O	1239-1241
insulin	O	1242-1249
treatment	O	1250-1259
.	O	1259-1260

Delayed	O	0-7
institution	O	8-19
of	O	20-22
hypertension	B	23-35
during	O	36-42
focal	O	43-48
cerebral	B	49-57
ischemia	I	58-66
:	O	66-67
effect	O	68-74
on	O	75-77
brain	B	78-83
edema	I	84-89
.	O	89-90

The	O	91-94
effect	O	95-101
of	O	102-104
induced	O	105-112
hypertension	B	113-125
instituted	O	126-136
after	O	137-142
a	O	143-144
2	O	145-146
-	O	146-147
h	O	147-148
delay	O	149-154
following	O	155-164
middle	B	165-171
cerebral	I	172-180
artery	I	181-187
occlusion	I	188-197
(	O	198-199
MCAO	B	199-203
)	O	203-204
on	O	205-207
brain	B	208-213
edema	I	214-219
formation	O	220-229
and	O	230-233
histochemical	O	234-247
injury	O	248-254
was	O	255-258
studied	O	259-266
.	O	266-267

Under	O	268-273
isoflurane	O	274-284
anesthesia	O	285-295
,	O	295-296
the	O	297-300
MCA	O	301-304
of	O	305-307
14	O	308-310
spontaneously	O	311-324
hypertensive	B	325-337
rats	O	338-342
was	O	343-346
occluded	O	347-355
.	O	355-356

In	O	357-359
the	O	360-363
control	O	364-371
group	O	372-377
(	O	378-379
n	O	379-380
=	O	381-382
7	O	383-384
)	O	384-385
,	O	385-386
the	O	387-390
mean	O	391-395
arterial	O	396-404
pressure	O	405-413
(	O	414-415
MAP	O	415-418
)	O	418-419
was	O	420-423
not	O	424-427
manipulated	O	428-439
.	O	439-440

In	O	441-443
the	O	444-447
hypertensive	B	448-460
group	O	461-466
(	O	467-468
n	O	468-469
=	O	470-471
7	O	472-473
)	O	473-474
,	O	474-475
the	O	476-479
MAP	O	480-483
was	O	484-487
elevated	O	488-496
by	O	497-499
25	O	500-502
-	O	502-503
30	O	503-505
mm	O	506-508
Hg	O	509-511
beginning	O	512-521
2	O	522-523
h	O	524-525
after	O	526-531
MCAO	B	532-536
.	O	536-537

Four	O	538-542
hours	O	543-548
after	O	549-554
MCAO	B	555-559
,	O	559-560
the	O	561-564
rats	O	565-569
were	O	570-574
killed	O	575-581
and	O	582-585
the	O	586-589
brains	O	590-596
harvested	O	597-606
.	O	606-607

The	O	608-611
brains	O	612-618
were	O	619-623
sectioned	O	624-633
along	O	634-639
coronal	O	640-647
planes	O	648-654
spanning	O	655-663
the	O	664-667
distribution	O	668-680
of	O	681-683
ischemia	B	684-692
produced	O	693-701
by	O	702-704
MCAO	B	705-709
.	O	709-710

Specific	O	711-719
gravity	O	720-727
(	O	728-729
SG	O	729-731
)	O	731-732
was	O	733-736
determined	O	737-747
in	O	748-750
the	O	751-754
subcortex	O	755-764
and	O	765-768
in	O	769-771
two	O	772-775
sites	O	776-781
in	O	782-784
the	O	785-788
cortex	O	789-795
(	O	796-797
core	O	797-801
and	O	802-805
periphery	O	806-815
of	O	816-818
the	O	819-822
ischemic	B	823-831
territory	O	832-841
)	O	841-842
.	O	842-843

The	O	844-847
extent	O	848-854
of	O	855-857
neuronal	B	858-866
injury	I	867-873
was	O	874-877
determined	O	878-888
by	O	889-891
2	O	892-893
,	O	893-894
3	O	894-895
,	O	893-894
5	O	896-897
-	O	897-898
triphenyltetrazolium	O	898-918
staining	O	919-927
.	O	927-928

In	O	929-931
the	O	932-935
ischemic	B	936-944
core	O	945-949
,	O	949-950
there	O	951-956
was	O	957-960
no	O	961-963
difference	O	964-974
in	O	975-977
SG	O	978-980
in	O	981-983
the	O	984-987
subcortex	O	988-997
and	O	998-1001
cortex	O	1002-1008
in	O	1009-1011
the	O	1012-1015
two	O	1016-1019
groups	O	1020-1026
.	O	1026-1027

In	O	1028-1030
the	O	1031-1034
periphery	O	1035-1044
of	O	1045-1047
the	O	1048-1051
ischemic	B	1052-1060
territory	O	1061-1070
,	O	1070-1071
SG	O	1072-1074
in	O	1075-1077
the	O	1078-1081
cortex	O	1082-1088
was	O	1089-1092
greater	O	1093-1100
(	O	1101-1102
less	O	1102-1106
edema	B	1107-1112
accumulation	O	1113-1125
)	O	1125-1126
in	O	1127-1129
the	O	1130-1133
hypertensive	B	1134-1146
group	O	1147-1152
(	O	1153-1154
1	O	1154-1155
.	O	1155-1156
041	O	1156-1159
+	O	1160-1161
/	O	1161-1162
-	O	1162-1163
0	O	1164-1165
.	O	1165-1166
001	O	1166-1169
vs	O	1170-1172
1	O	1173-1174
.	O	1174-1175
039	O	1175-1178
+	O	1179-1180
/	O	1180-1181
-	O	1181-1182
0	O	1183-1184
.	O	1184-1185
001	O	1185-1188
,	O	1188-1189
P	O	1190-1191
less	O	1192-1196
than	O	1197-1201
0	O	1202-1203
.	O	1203-1204
05	O	1204-1206
)	O	1206-1207
.	O	1203-1204

The	O	1209-1212
area	O	1213-1217
of	O	1218-1220
histochemical	O	1221-1234
injury	O	1235-1241
(	O	1242-1243
as	O	1243-1245
a	O	1246-1247
percent	O	1248-1255
of	O	1256-1258
the	O	1259-1262
cross	O	1263-1268
-	O	1268-1269
sectional	O	1269-1278
area	O	1279-1283
of	O	1284-1286
the	O	1287-1290
hemisphere	O	1291-1301
)	O	1301-1302
was	O	1303-1306
less	O	1307-1311
in	O	1312-1314
the	O	1315-1318
hypertensive	B	1319-1331
group	O	1332-1337
(	O	1338-1339
33	O	1339-1341
+	O	1342-1343
/	O	1343-1344
-	O	1344-1345
3	O	1346-1347
%	O	1347-1348
vs	O	1349-1351
21	O	1352-1354
+	O	1355-1356
/	O	1356-1357
-	O	1357-1358
2	O	1359-1360
%	O	1360-1361
,	O	1361-1362
P	O	1363-1364
less	O	1365-1369
than	O	1370-1374
0	O	1375-1376
.	O	1376-1377
05	O	1377-1379
)	O	1379-1380
.	O	1376-1377

The	O	1382-1385
data	O	1386-1390
indicate	O	1391-1399
that	O	1400-1404
phenylephrine	O	1405-1418
-	O	1418-1419
induced	O	1419-1426
hypertension	B	1427-1439
instituted	O	1440-1450
2	O	1451-1452
h	O	1453-1454
after	O	1455-1460
MCAO	B	1461-1465
does	O	1466-1470
not	O	1471-1474
aggravate	O	1475-1484
edema	B	1485-1490
in	O	1491-1493
the	O	1494-1497
ischemic	B	1498-1506
core	O	1507-1511
,	O	1511-1512
that	O	1513-1517
it	O	1518-1520
improves	O	1521-1529
edema	B	1530-1535
in	O	1536-1538
the	O	1539-1542
periphery	O	1543-1552
of	O	1553-1555
the	O	1556-1559
ischemic	B	1560-1568
territory	O	1569-1578
,	O	1578-1579
and	O	1580-1583
that	O	1584-1588
it	O	1589-1591
reduces	O	1592-1599
the	O	1600-1603
area	O	1604-1608
of	O	1609-1611
histochemical	O	1612-1625
neuronal	B	1626-1634
dysfunction	I	1635-1646
.	O	1646-1647

Amiodarone	O	0-10
pulmonary	B	11-20
toxicity	I	21-29
.	O	29-30

Amiodarone	O	31-41
is	O	42-44
an	O	45-47
effective	O	48-57
antiarrhythmic	O	58-72
agent	O	73-78
whose	O	79-84
utility	O	85-92
is	O	93-95
limited	O	96-103
by	O	104-106
many	O	107-111
side	O	112-116
-	O	116-117
effects	O	117-124
,	O	124-125
the	O	126-129
most	O	130-134
problematic	O	135-146
being	O	147-152
pneumonitis	B	153-164
.	O	164-165

The	O	166-169
pulmonary	B	170-179
toxicity	I	180-188
of	O	189-191
amiodarone	O	192-202
is	O	203-205
thought	O	206-213
to	O	214-216
result	O	217-223
from	O	224-228
direct	O	229-235
injury	O	236-242
related	O	243-250
to	O	251-253
the	O	254-257
intracellular	O	258-271
accumulation	O	272-284
of	O	285-287
phospholipid	O	288-300
and	O	301-304
T	O	305-306
cell	O	307-311
-	O	311-312
mediated	O	312-320
hypersensitivity	B	321-337
pneumonitis	I	338-349
.	O	349-350

The	O	351-354
clinical	O	355-363
and	O	364-367
radiographic	O	368-380
features	O	381-389
of	O	390-392
amiodarone	O	393-403
-	O	403-404
induced	O	404-411
pulmonary	B	412-421
toxicity	I	422-430
are	O	431-434
characteristic	O	435-449
but	O	450-453
nonspecific	O	454-465
.	O	465-466

The	O	467-470
diagnosis	O	471-480
depends	O	481-488
on	O	489-491
exclusion	O	492-501
of	O	502-504
other	O	505-510
entities	O	511-519
,	O	519-520
such	O	521-525
as	O	526-528
heart	B	529-534
failure	I	535-542
,	O	542-543
infection	B	544-553
,	O	553-554
and	O	555-558
malignancy	B	559-569
.	O	569-570

While	O	571-576
withdrawal	O	577-587
of	O	588-590
amiodarone	O	591-601
leads	O	602-607
to	O	608-610
clinical	O	611-619
improvement	O	620-631
in	O	632-634
majority	O	635-643
of	O	644-646
cases	O	647-652
,	O	652-653
this	O	654-658
is	O	659-661
not	O	662-665
always	O	666-672
possible	O	673-681
or	O	682-684
advisable	O	685-694
.	O	694-695

Dose	O	696-700
reduction	O	701-710
or	O	711-713
concomitant	O	714-725
steroid	O	726-733
therapy	O	734-741
may	O	742-745
have	O	746-750
a	O	751-752
role	O	753-757
in	O	758-760
selected	O	761-769
patients	O	770-778
.	O	778-779

Light	O	0-5
chain	O	6-11
proteinuria	B	12-23
and	O	24-27
cellular	O	28-36
mediated	O	37-45
immunity	O	46-54
in	O	55-57
rifampin	O	58-66
treated	O	67-74
patients	O	75-83
with	O	84-88
tuberculosis	B	89-101
.	O	101-102

Light	O	103-108
chain	O	109-114
proteinuria	B	115-126
was	O	127-130
found	O	131-136
in	O	137-139
9	O	140-141
of	O	142-144
17	O	145-147
tuberculosis	B	148-160
patients	O	161-169
treated	O	170-177
with	O	178-182
rifampin	O	183-191
.	O	191-192

Concomitant	O	193-204
assay	O	205-210
of	O	211-213
cellular	O	214-222
mediated	O	223-231
immunity	O	232-240
in	O	241-243
these	O	244-249
patients	O	250-258
using	O	259-264
skin	O	265-269
test	O	270-274
antigen	O	275-282
and	O	283-286
a	O	287-288
lymphokine	O	289-299
in	O	300-302
vitro	O	303-308
test	O	309-313
provided	O	314-322
results	O	323-330
that	O	331-335
were	O	336-340
different	O	341-350
.	O	350-351

Response	O	352-360
to	O	361-363
Varidase	O	364-372
skin	O	373-377
test	O	378-382
antigen	O	383-390
was	O	391-394
negative	O	395-403
for	O	404-407
all	O	408-411
eight	O	412-417
tuberculosis	B	418-430
patients	O	431-439
tested	O	440-446
,	O	446-447
but	O	448-451
there	O	452-457
occurred	O	458-466
a	O	467-468
hyper	O	469-474
-	O	474-475
responsiveness	O	475-489
of	O	490-492
the	O	493-496
lymphocytes	O	497-508
of	O	509-511
these	O	512-517
eight	O	518-523
patients	O	524-532
to	O	533-535
phytomitogen	O	536-548
(	O	549-550
PHA	O	550-553
-	O	553-554
P	O	550-551
)	O	555-556
.	O	556-557

as	O	558-560
well	O	561-565
as	O	566-568
of	O	569-571
those	O	572-577
of	O	578-580
seven	O	581-586
other	O	587-592
tuberculous	B	593-604
patients	O	605-613
.	O	613-614

This	O	615-619
last	O	620-624
finding	O	625-632
may	O	633-636
be	O	637-639
related	O	640-647
to	O	648-650
time	O	651-655
of	O	656-658
testing	O	659-666
and	O	667-670
/	O	670-671
or	O	671-673
endogenous	O	674-684
serum	O	685-690
binding	O	691-698
of	O	699-701
rifampin	O	702-710
which	O	711-716
could	O	717-722
have	O	723-727
inhibited	O	728-737
mitogen	O	738-745
activity	O	746-754
for	O	755-758
the	O	759-762
lymphocyte	O	763-773
.	O	773-774

Initial	O	0-7
potassium	O	8-17
loss	O	18-22
and	O	23-26
hypokalaemia	B	27-39
during	O	40-46
chlorthalidone	O	47-61
administration	O	62-76
in	O	77-79
patients	O	80-88
with	O	89-93
essential	O	94-103
hypertension	B	104-116
:	O	116-117
the	O	118-121
influence	O	122-131
of	O	132-134
dietary	O	135-142
sodium	O	143-149
restriction	O	150-161
.	O	161-162

To	O	163-165
investigate	O	166-177
the	O	178-181
initial	O	182-189
potassium	O	190-199
loss	O	200-204
and	O	205-208
development	O	209-220
of	O	221-223
hypokalaemia	B	224-236
during	O	237-243
the	O	244-247
administration	O	248-262
of	O	263-265
an	O	266-268
oral	O	269-273
diuretic	O	274-282
,	O	282-283
metabolic	O	284-293
balance	O	294-301
studies	O	302-309
were	O	310-314
performed	O	315-324
in	O	325-327
ten	O	328-331
patients	O	332-340
with	O	341-345
essential	O	346-355
hypertension	B	356-368
who	O	369-372
had	O	373-376
shown	O	377-382
hypokalaemia	B	383-395
under	O	396-401
prior	O	402-407
oral	O	408-412
diuretic	O	413-421
treatment	O	422-431
.	O	431-432

Chlorthalidone	O	433-447
(	O	448-449
50	O	449-451
mg	O	452-454
daily	O	455-460
)	O	460-461
was	O	462-465
given	O	466-471
for	O	472-475
14	O	476-478
days	O	479-483
.	O	483-484

Six	O	485-488
patients	O	489-497
received	O	498-506
a	O	507-508
normal	O	509-515
-	O	515-516
sodium	O	516-522
diet	O	523-527
and	O	528-531
four	O	532-536
a	O	537-538
low	O	539-542
-	O	542-543
sodium	O	543-549
(	O	550-551
17	O	551-553
mmol	O	554-558
/	O	558-559
day	O	559-562
)	O	562-563
diet	O	564-568
.	O	568-569

All	O	570-573
patients	O	574-582
had	O	583-586
a	O	587-588
normal	O	589-595
initial	O	596-603
total	O	604-609
body	O	610-614
potassium	O	615-624
(	O	625-626
40K	O	626-629
)	O	629-630
.	O	630-631

The	O	632-635
electrolyte	O	636-647
balances	O	648-656
,	O	656-657
weight	O	658-664
,	O	664-665
bromide	O	666-673
space	O	674-679
,	O	679-680
plasma	O	681-687
renin	O	688-693
activity	O	694-702
,	O	702-703
and	O	704-707
aldosterone	O	708-719
secretion	O	720-729
rate	O	730-734
were	O	735-739
measured	O	740-748
.	O	748-749

In	O	750-752
both	O	753-757
groups	O	758-764
a	O	765-766
potassium	O	767-776
deficit	O	777-784
developed	O	785-794
,	O	794-795
with	O	796-800
proportionally	O	801-815
larger	O	816-822
losses	O	823-829
from	O	830-834
the	O	835-838
extracellular	O	839-852
than	O	853-857
from	O	858-862
the	O	863-866
intracellular	O	867-880
compartment	O	881-892
.	O	892-893

In	O	894-896
the	O	897-900
normal	O	901-907
-	O	907-908
sodium	O	908-914
group	O	915-920
the	O	921-924
highest	O	925-932
mean	O	933-937
potassium	O	938-947
deficit	O	948-955
was	O	956-959
176	O	960-963
mmol	O	964-968
on	O	969-971
day	O	972-975
9	O	976-977
,	O	977-978
after	O	979-984
which	O	985-990
some	O	991-995
potassium	O	996-1005
was	O	1006-1009
regained	O	1010-1018
;	O	1018-1019
in	O	1020-1022
the	O	1023-1026
low	O	1027-1030
-	O	1030-1031
sodium	O	1031-1037
group	O	1038-1043
the	O	1044-1047
highest	O	1048-1055
deficit	O	1056-1063
was	O	1064-1067
276	O	1068-1071
mmol	O	1072-1076
on	O	1077-1079
day	O	1080-1083
13	O	1084-1086
.	O	1086-1087

The	O	1088-1091
normal	O	1092-1098
-	O	1098-1099
sodium	O	1099-1105
group	O	1106-1111
showed	O	1112-1118
an	O	1119-1121
immediate	O	1122-1131
but	O	1132-1135
temporary	O	1136-1145
rise	O	1146-1150
of	O	1151-1153
the	O	1154-1157
renin	O	1158-1163
and	O	1164-1167
aldosterone	O	1168-1179
levels	O	1180-1186
;	O	1186-1187
in	O	1188-1190
the	O	1191-1194
low	O	1195-1198
-	O	1198-1199
sodium	O	1199-1205
group	O	1206-1211
renin	O	1212-1217
and	O	1218-1221
aldosterone	O	1222-1233
increased	O	1234-1243
more	O	1244-1248
slowly	O	1249-1255
but	O	1256-1259
remained	O	1260-1268
elevated	O	1269-1277
.	O	1277-1278

It	O	1279-1281
is	O	1282-1284
concluded	O	1285-1294
that	O	1295-1299
dietary	O	1300-1307
sodium	O	1308-1314
restriction	O	1315-1326
increases	O	1327-1336
diuretic	O	1337-1345
-	O	1345-1346
induced	O	1346-1353
potassium	O	1354-1363
loss	O	1364-1368
,	O	1368-1369
presumably	O	1370-1380
by	O	1381-1383
an	O	1384-1386
increased	O	1387-1396
activity	O	1397-1405
of	O	1406-1408
the	O	1409-1412
renin	O	1413-1418
-	O	1418-1419
angiotensin	O	1419-1430
-	O	1418-1419
aldosterone	O	1431-1442
system	O	1443-1449
,	O	1449-1450
while	O	1451-1456
sodium	O	1457-1463
delivery	O	1464-1472
to	O	1473-1475
the	O	1476-1479
distal	O	1480-1486
renal	O	1487-1492
tubules	O	1493-1500
remains	O	1501-1508
sufficiently	O	1509-1521
high	O	1522-1526
to	O	1527-1529
allow	O	1530-1535
increased	O	1536-1545
potassium	O	1546-1555
secretion	O	1556-1565
.	O	1565-1566

Dynamic	O	0-7
response	O	8-16
of	O	17-19
blood	O	20-25
vessel	O	26-32
in	O	33-35
acute	B	36-41
renal	I	42-47
failure	I	48-55
.	O	55-56

In	O	57-59
this	O	60-64
study	O	65-70
we	O	71-73
postulated	O	74-84
that	O	85-89
during	O	90-96
acute	B	97-102
renal	I	103-108
failure	I	109-116
induced	O	117-124
by	O	125-127
gentamicin	O	128-138
the	O	139-142
transient	O	143-152
or	O	153-155
dynamic	O	156-163
response	O	164-172
of	O	173-175
blood	O	176-181
vessels	O	182-189
could	O	190-195
be	O	196-198
affected	O	199-207
,	O	207-208
and	O	209-212
that	O	213-217
antioxidants	O	218-230
can	O	231-234
prevent	O	235-242
the	O	243-246
changes	O	247-254
in	O	255-257
dynamic	O	258-265
responses	O	266-275
of	O	276-278
blood	O	279-284
vessels	O	285-292
.	O	292-293

The	O	294-297
new	O	298-301
approach	O	302-310
to	O	311-313
ex	O	314-316
vivo	O	317-321
blood	O	322-327
vessel	O	328-334
experiments	O	335-346
in	O	347-349
which	O	350-355
not	O	356-359
only	O	360-364
the	O	365-368
end	O	369-372
points	O	373-379
of	O	380-382
vessels	O	383-390
response	O	391-399
within	O	400-406
the	O	407-410
time	O	411-415
interval	O	416-424
is	O	425-427
considered	O	428-438
,	O	438-439
but	O	440-443
also	O	444-448
dynamics	O	449-457
of	O	458-460
this	O	461-465
response	O	466-474
,	O	474-475
was	O	476-479
used	O	480-484
in	O	485-487
this	O	488-492
paper	O	493-498
.	O	498-499

Our	O	500-503
results	O	504-511
confirm	O	512-519
the	O	520-523
alteration	O	524-534
in	O	535-537
dynamic	O	538-545
response	O	546-554
of	O	555-557
blood	O	558-563
vessels	O	564-571
during	O	572-578
the	O	579-582
change	O	583-589
of	O	590-592
pressure	O	593-601
in	O	602-604
gentamicin	O	605-615
-	O	615-616
treated	O	616-623
animals	O	624-631
.	O	631-632

The	O	633-636
beneficial	O	637-647
effects	O	648-655
of	O	656-658
vitamin	O	659-666
C	O	667-668
administration	O	669-683
to	O	684-686
gentamicin	O	687-697
-	O	697-698
treated	O	698-705
animals	O	706-713
are	O	714-717
also	O	718-722
confirmed	O	723-732
through	O	733-740
:	O	740-741
lower	O	742-747
level	O	748-753
of	O	754-756
blood	O	757-762
urea	O	763-767
and	O	768-771
creatinine	O	772-782
and	O	783-786
higher	O	787-793
level	O	794-799
of	O	800-802
potassium	O	803-812
.	O	812-813

The	O	814-817
pressure	O	818-826
dynamic	O	827-834
responses	O	835-844
of	O	845-847
isolated	O	848-856
blood	O	857-862
vessels	O	863-870
show	O	871-875
a	O	876-877
faster	O	878-884
pressure	O	885-893
change	O	894-900
in	O	901-903
gentamicin	O	904-914
-	O	914-915
treated	O	915-922
animals	O	923-930
(	O	931-932
8	O	932-933
.	O	933-934
07	O	934-936
+	O	937-938
/	O	938-939
-	O	939-940
1	O	941-942
.	O	942-943
7	O	943-944
s	O	945-946
vs	O	947-949
.	O	949-950
5	O	951-952
.	O	952-953
64	O	953-955
+	O	956-957
/	O	957-958
-	O	958-959
0	O	960-961
.	O	961-962
18	O	962-964
s	O	965-966
)	O	966-967
.	O	967-968

Vitamin	O	969-976
C	O	977-978
administration	O	979-993
induced	O	994-1001
slowdown	O	1002-1010
of	O	1011-1013
pressure	O	1014-1022
change	O	1023-1029
back	O	1030-1034
to	O	1035-1037
the	O	1038-1041
control	O	1042-1049
values	O	1050-1056
.	O	1056-1057

The	O	1058-1061
pressure	O	1062-1070
dynamic	O	1071-1078
properties	O	1079-1089
,	O	1089-1090
quantitatively	O	1091-1105
defined	O	1106-1113
by	O	1114-1116
comparative	O	1117-1128
pressure	O	1129-1137
dynamic	O	1138-1145
and	O	1146-1149
total	O	1150-1155
pressure	O	1156-1164
dynamic	O	1165-1172
,	O	1172-1173
confirm	O	1174-1181
the	O	1182-1185
alteration	O	1186-1196
in	O	1197-1199
dynamic	O	1200-1207
response	O	1208-1216
of	O	1217-1219
blood	O	1220-1225
vessels	O	1226-1233
during	O	1234-1240
the	O	1241-1244
change	O	1245-1251
of	O	1252-1254
pressure	O	1255-1263
in	O	1264-1266
gentamicin	O	1267-1277
-	O	1277-1278
treated	O	1278-1285
animals	O	1286-1293
and	O	1294-1297
beneficial	O	1298-1308
effects	O	1309-1316
of	O	1317-1319
vitamin	O	1320-1327
C	O	1328-1329
administration	O	1330-1344
.	O	1344-1345

The	O	0-3
hemodynamics	O	4-16
of	O	17-19
oxytocin	O	20-28
and	O	29-32
other	O	33-38
vasoactive	O	39-49
agents	O	50-56
during	O	57-63
neuraxial	O	64-73
anesthesia	O	74-84
for	O	85-88
cesarean	O	89-97
delivery	O	98-106
:	O	106-107
findings	O	108-116
in	O	117-119
six	O	120-123
cases	O	124-129
.	O	129-130

Oxytocin	O	131-139
is	O	140-142
a	O	143-144
commonly	O	145-153
used	O	154-158
uterotonic	O	159-169
that	O	170-174
can	O	175-178
cause	O	179-184
significant	O	185-196
and	O	197-200
even	O	201-205
fatal	O	206-211
hypotension	B	212-223
,	O	223-224
particularly	O	225-237
when	O	238-242
given	O	243-248
as	O	249-251
a	O	252-253
bolus	O	254-259
.	O	259-260

The	O	261-264
resulting	O	265-274
hypotension	B	275-286
can	O	287-290
be	O	291-293
produced	O	294-302
by	O	303-305
a	O	306-307
decrease	O	308-316
in	O	317-319
systemic	O	320-328
vascular	O	329-337
resistance	O	338-348
or	O	349-351
cardiac	O	352-359
output	O	360-366
through	O	367-374
a	O	375-376
decrease	O	377-385
in	O	386-388
venous	O	389-395
return	O	396-402
.	O	402-403

Parturients	O	404-415
with	O	416-420
normal	O	421-427
volume	O	428-434
status	O	435-441
,	O	441-442
heart	O	443-448
valves	O	449-455
and	O	456-459
pulmonary	O	460-469
vasculature	O	470-481
most	O	482-486
often	O	487-492
respond	O	493-500
to	O	501-503
this	O	504-508
hypotension	B	509-520
with	O	521-525
a	O	526-527
compensatory	O	528-540
increase	O	541-549
in	O	550-552
heart	O	553-558
rate	O	559-563
and	O	564-567
stroke	B	568-574
volume	O	575-581
.	O	581-582

Oxytocin	O	583-591
-	O	591-592
induced	O	592-599
hypotension	B	600-611
at	O	612-614
cesarean	O	615-623
delivery	O	624-632
may	O	633-636
be	O	637-639
incorrectly	O	640-651
attributed	O	652-662
to	O	663-665
blood	B	666-671
loss	I	672-676
.	O	676-677

Pulse	O	678-683
power	O	684-689
analysis	O	690-698
(	O	699-700
also	O	700-704
called	O	705-711
"	O	712-713
pulse	O	713-718
contour	O	719-726
analysis	O	727-735
"	O	735-736
)	O	736-737
of	O	738-740
an	O	741-743
arterial	O	744-752
pressure	O	753-761
wave	O	762-766
form	O	767-771
allows	O	772-778
continuous	O	779-789
evaluation	O	790-800
of	O	801-803
systemic	O	804-812
vascular	O	813-821
resistance	O	822-832
and	O	833-836
cardiac	O	837-844
output	O	845-851
in	O	852-854
real	O	855-859
time	O	860-864
,	O	864-865
thereby	O	866-873
elucidating	O	874-885
the	O	886-889
causative	O	890-899
factors	O	900-907
behind	O	908-914
changes	O	915-922
in	O	923-925
blood	O	926-931
pressure	O	932-940
.	O	940-941

Pulse	O	942-947
power	O	948-953
analysis	O	954-962
was	O	963-966
conducted	O	967-976
in	O	977-979
six	O	980-983
cases	O	984-989
of	O	990-992
cesarean	O	993-1001
delivery	O	1002-1010
performed	O	1011-1020
under	O	1021-1026
neuraxial	O	1027-1036
anesthesia	O	1037-1047
.	O	1047-1048

Hypotension	B	1049-1060
in	O	1061-1063
response	O	1064-1072
to	O	1073-1075
oxytocin	O	1076-1084
was	O	1085-1088
associated	O	1089-1099
with	O	1100-1104
a	O	1105-1106
decrease	O	1107-1115
in	O	1116-1118
systemic	O	1119-1127
vascular	O	1128-1136
resistance	O	1137-1147
and	O	1148-1151
a	O	1152-1153
compensatory	O	1154-1166
increase	O	1167-1175
in	O	1176-1178
stroke	B	1179-1185
volume	O	1186-1192
,	O	1192-1193
heart	O	1194-1199
rate	O	1200-1204
and	O	1205-1208
cardiac	O	1209-1216
output	O	1217-1223
.	O	1223-1224

Pulse	O	1225-1230
power	O	1231-1236
analysis	O	1237-1245
may	O	1246-1249
be	O	1250-1252
helpful	O	1253-1260
in	O	1261-1263
determining	O	1264-1275
the	O	1276-1279
etiology	O	1280-1288
of	O	1289-1291
and	O	1292-1295
treating	O	1296-1304
hypotension	B	1305-1316
during	O	1317-1323
cesarean	O	1324-1332
delivery	O	1333-1341
under	O	1342-1347
neuraxial	O	1348-1357
anesthesia	O	1358-1368
.	O	1368-1369

Exaggerated	O	0-11
expression	O	12-22
of	O	23-25
inflammatory	O	26-38
mediators	O	39-48
in	O	49-51
vasoactive	O	52-62
intestinal	O	63-73
polypeptide	O	74-85
knockout	O	86-94
(	O	95-96
VIP	O	96-99
-	O	99-100
/	O	100-101
-	O	99-100
)	O	102-103
mice	O	104-108
with	O	109-113
cyclophosphamide	O	114-130
(	O	131-132
CYP	O	132-135
)	O	135-136
-	O	136-137
induced	O	137-144
cystitis	B	145-153
.	O	153-154

Vasoactive	O	155-165
intestinal	O	166-176
polypeptide	O	177-188
(	O	189-190
VIP	O	190-193
)	O	193-194
is	O	195-197
an	O	198-200
immunomodulatory	O	201-217
neuropeptide	O	218-230
distributed	O	231-242
in	O	243-245
micturition	O	246-257
pathways	O	258-266
.	O	266-267

VIP	O	268-271
(	O	271-272
-	O	272-273
/	O	273-274
-	O	272-273
)	O	275-276
mice	O	277-281
exhibit	O	282-289
altered	O	290-297
bladder	O	298-305
function	O	306-314
and	O	315-318
neurochemical	O	319-332
properties	O	333-343
in	O	344-346
micturition	O	347-358
pathways	O	359-367
after	O	368-373
cyclophosphamide	O	374-390
(	O	391-392
CYP	O	392-395
)	O	395-396
-	O	396-397
induced	O	397-404
cystitis	B	405-413
.	O	413-414

Given	O	415-420
VIP	O	421-424
'	O	424-425
s	O	425-426
role	O	427-431
as	O	432-434
an	O	435-437
anti	O	438-442
-	O	442-443
inflammatory	O	443-455
mediator	O	456-464
,	O	464-465
we	O	466-468
hypothesized	O	469-481
that	O	482-486
VIP	O	487-490
(	O	490-491
-	O	491-492
/	O	492-493
-	O	491-492
)	O	494-495
mice	O	496-500
would	O	501-506
exhibit	O	507-514
enhanced	O	515-523
inflammatory	O	524-536
mediator	O	537-545
expression	O	546-556
after	O	557-562
cystitis	B	563-571
.	O	571-572

A	O	573-574
mouse	O	575-580
inflammatory	O	581-593
cytokine	O	594-602
and	O	603-606
receptor	O	607-615
RT2	O	616-619
profiler	O	620-628
array	O	629-634
was	O	635-638
used	O	639-643
to	O	644-646
determine	O	647-656
regulated	O	657-666
transcripts	O	667-678
in	O	679-681
the	O	682-685
urinary	O	686-693
bladder	O	694-701
of	O	702-704
wild	O	705-709
type	O	710-714
(	O	715-716
WT	O	716-718
)	O	718-719
and	O	720-723
VIP	O	724-727
(	O	727-728
-	O	728-729
/	O	729-730
-	O	728-729
)	O	731-732
mice	O	733-737
with	O	738-742
or	O	743-745
without	O	746-753
CYP	O	754-757
-	O	757-758
induced	O	758-765
cystitis	B	766-774
(	O	775-776
150	O	776-779
mg	O	780-782
/	O	782-783
kg	O	783-785
;	O	785-786
i	O	787-788
.	O	788-789
p	O	789-790
.	O	788-789
;	O	791-792
48	O	793-795
h	O	796-797
)	O	797-798
.	O	798-799

Four	O	800-804
binary	O	805-811
comparisons	O	812-823
were	O	824-828
made	O	829-833
:	O	833-834
WT	O	835-837
control	O	838-845
versus	O	846-852
CYP	O	853-856
treatment	O	857-866
(	O	867-868
48	O	868-870
h	O	871-872
)	O	872-873
,	O	873-874
VIP	O	875-878
(	O	878-879
-	O	879-880
/	O	880-881
-	O	879-880
)	O	882-883
control	O	884-891
versus	O	892-898
CYP	O	899-902
treatment	O	903-912
(	O	913-914
48	O	914-916
h	O	917-918
)	O	918-919
,	O	919-920
WT	O	921-923
control	O	924-931
versus	O	932-938
VIP	O	939-942
(	O	942-943
-	O	943-944
/	O	944-945
-	O	943-944
)	O	946-947
control	O	948-955
,	O	955-956
and	O	957-960
WT	O	961-963
with	O	964-968
CYP	O	969-972
treatment	O	973-982
(	O	983-984
48	O	984-986
h	O	987-988
)	O	988-989
versus	O	990-996
VIP	O	997-1000
(	O	1000-1001
-	O	1001-1002
/	O	1002-1003
-	O	1001-1002
)	O	1004-1005
with	O	1006-1010
CYP	O	1011-1014
treatment	O	1015-1024
(	O	1025-1026
48	O	1026-1028
h	O	1029-1030
)	O	1030-1031
.	O	1031-1032

The	O	1033-1036
genes	O	1037-1042
presented	O	1043-1052
represent	O	1053-1062
(	O	1063-1064
1	O	1064-1065
)	O	1065-1066
greater	O	1067-1074
than	O	1075-1079
1	O	1080-1081
.	O	1081-1082
5	O	1082-1083
-	O	1083-1084
fold	O	1084-1088
change	O	1089-1095
in	O	1096-1098
either	O	1099-1105
direction	O	1106-1115
and	O	1116-1119
(	O	1120-1121
2	O	1121-1122
)	O	1122-1123
the	O	1124-1127
p	O	1128-1129
value	O	1130-1135
is	O	1136-1138
less	O	1139-1143
than	O	1144-1148
0	O	1149-1150
.	O	1150-1151
05	O	1151-1153
for	O	1154-1157
the	O	1158-1161
comparison	O	1162-1172
being	O	1173-1178
made	O	1179-1183
.	O	1183-1184

Several	O	1185-1192
regulated	O	1193-1202
genes	O	1203-1208
were	O	1209-1213
validated	O	1214-1223
using	O	1224-1229
enzyme	O	1230-1236
-	O	1236-1237
linked	O	1237-1243
immunoassays	O	1244-1256
including	O	1257-1266
IL	O	1267-1269
-	O	1269-1270
1beta	O	1270-1275
and	O	1276-1279
CXCL1	O	1280-1285
.	O	1285-1286

CYP	O	1287-1290
treatment	O	1291-1300
significantly	O	1301-1314
(	O	1315-1316
p	O	1316-1317
<	O	1318-1319
or	O	1320-1322
=	O	1323-1324
0	O	1325-1326
.	O	1326-1327
001	O	1327-1330
)	O	1330-1331
increased	O	1332-1341
expression	O	1342-1352
of	O	1353-1355
CXCL1	O	1356-1361
and	O	1362-1365
IL	O	1366-1368
-	O	1368-1369
1beta	O	1369-1374
in	O	1375-1377
the	O	1378-1381
urinary	O	1382-1389
bladder	O	1390-1397
of	O	1398-1400
WT	O	1401-1403
and	O	1404-1407
VIP	O	1408-1411
(	O	1411-1412
-	O	1412-1413
/	O	1413-1414
-	O	1412-1413
)	O	1415-1416
mice	O	1417-1421
,	O	1421-1422
but	O	1423-1426
expression	O	1427-1437
in	O	1438-1440
VIP	O	1441-1444
(	O	1444-1445
-	O	1445-1446
/	O	1446-1447
-	O	1445-1446
)	O	1448-1449
mice	O	1450-1454
with	O	1455-1459
CYP	O	1460-1463
treatment	O	1464-1473
was	O	1474-1477
significantly	O	1478-1491
(	O	1492-1493
p	O	1493-1494
<	O	1495-1496
or	O	1497-1499
=	O	1500-1501
0	O	1502-1503
.	O	1503-1504
001	O	1504-1507
)	O	1507-1508
greater	O	1509-1516
(	O	1517-1518
4	O	1518-1519
.	O	1519-1520
2	O	1520-1521
-	O	1521-1522
to	O	1523-1525
13	O	1526-1528
-	O	1528-1529
fold	O	1529-1533
increase	O	1534-1542
)	O	1542-1543
than	O	1544-1548
that	O	1549-1553
observed	O	1554-1562
in	O	1563-1565
WT	O	1566-1568
urinary	O	1569-1576
bladder	O	1577-1584
(	O	1585-1586
3	O	1586-1587
.	O	1587-1588
6	O	1588-1589
-	O	1589-1590
to	O	1591-1593
5	O	1594-1595
-	O	1595-1596
fold	O	1596-1600
increase	O	1601-1609
)	O	1609-1610
.	O	1610-1611

The	O	1612-1615
data	O	1616-1620
suggest	O	1621-1628
that	O	1629-1633
in	O	1634-1636
VIP	O	1637-1640
(	O	1640-1641
-	O	1641-1642
/	O	1642-1643
-	O	1641-1642
)	O	1644-1645
mice	O	1646-1650
with	O	1651-1655
bladder	B	1656-1663
inflammation	I	1664-1676
,	O	1676-1677
inflammatory	O	1678-1690
mediators	O	1691-1700
are	O	1701-1704
increased	O	1705-1714
above	O	1715-1720
that	O	1721-1725
observed	O	1726-1734
in	O	1735-1737
WT	O	1738-1740
with	O	1741-1745
CYP	O	1746-1749
.	O	1749-1750

This	O	1751-1755
shift	O	1756-1761
in	O	1762-1764
balance	O	1765-1772
may	O	1773-1776
contribute	O	1777-1787
to	O	1788-1790
increased	O	1791-1800
bladder	B	1801-1808
dysfunction	I	1809-1820
in	O	1821-1823
VIP	O	1824-1827
(	O	1827-1828
-	O	1828-1829
/	O	1829-1830
-	O	1828-1829
)	O	1831-1832
mice	O	1833-1837
with	O	1838-1842
bladder	B	1843-1850
inflammation	I	1851-1863
and	O	1864-1867
altered	O	1868-1875
neurochemical	O	1876-1889
expression	O	1890-1900
in	O	1901-1903
micturition	O	1904-1915
pathways	O	1916-1924
.	O	1924-1925

Intraocular	O	0-11
pressure	O	12-20
in	O	21-23
patients	O	24-32
with	O	33-37
uveitis	B	38-45
treated	O	46-53
with	O	54-58
fluocinolone	O	59-71
acetonide	O	72-81
implants	O	82-90
.	O	90-91

OBJECTIVE	O	92-101
:	O	101-102
To	O	103-105
report	O	106-112
the	O	113-116
incidence	O	117-126
and	O	127-130
management	O	131-141
of	O	142-144
elevated	B	145-153
intraocular	I	154-165
pressure	I	166-174
(	O	175-176
IOP	O	176-179
)	O	179-180
in	O	181-183
patients	O	184-192
with	O	193-197
uveitis	B	198-205
treated	O	206-213
with	O	214-218
the	O	219-222
fluocinolone	O	223-235
acetonide	O	236-245
(	O	246-247
FA	O	247-249
)	O	249-250
intravitreal	O	251-263
implant	O	264-271
.	O	271-272

DESIGN	O	273-279
:	O	279-280
Pooled	O	281-287
data	O	288-292
from	O	293-297
3	O	298-299
multicenter	O	300-311
,	O	311-312
double	O	313-319
-	O	319-320
masked	O	320-326
,	O	326-327
randomized	O	328-338
,	O	338-339
controlled	O	340-350
,	O	350-351
phase	O	352-357
2b	O	358-360
/	O	360-361
3	O	361-362
clinical	O	363-371
trials	O	372-378
evaluating	O	379-389
the	O	390-393
safety	O	394-400
and	O	401-404
efficacy	O	405-413
of	O	414-416
the	O	417-420
0	O	421-422
.	O	422-423
59	O	423-425
-	O	425-426
mg	O	426-428
or	O	429-431
2	O	432-433
.	O	433-434
1	O	434-435
-	O	435-436
mg	O	436-438
FA	O	439-441
intravitreal	O	442-454
implant	O	455-462
or	O	463-465
standard	O	466-474
therapy	O	475-482
were	O	483-487
analyzed	O	488-496
.	O	496-497

RESULTS	O	498-505
:	O	505-506
During	O	507-513
the	O	514-517
3	O	518-519
-	O	519-520
year	O	520-524
follow	O	525-531
-	O	531-532
up	O	532-534
,	O	534-535
71	O	536-538
.	O	538-539
0	O	539-540
%	O	540-541
of	O	542-544
implanted	O	545-554
eyes	O	555-559
had	O	560-563
an	O	564-566
IOP	O	567-570
increase	O	571-579
of	O	580-582
10	O	583-585
mm	O	586-588
Hg	O	589-591
or	O	592-594
more	O	595-599
than	O	600-604
baseline	O	605-613
and	O	614-617
55	O	618-620
.	O	620-621
1	O	621-622
%	O	622-623
,	O	623-624
24	O	625-627
.	O	627-628
7	O	628-629
%	O	629-630
,	O	630-631
and	O	632-635
6	O	636-637
.	O	637-638
2	O	638-639
%	O	639-640
of	O	641-643
eyes	O	644-648
reached	O	649-656
an	O	657-659
IOP	O	660-663
of	O	664-666
30	O	667-669
mm	O	670-672
Hg	O	673-675
or	O	676-678
more	O	679-683
,	O	683-684
40	O	685-687
mm	O	688-690
Hg	O	691-693
or	O	694-696
more	O	697-701
,	O	701-702
and	O	703-706
50	O	707-709
mm	O	710-712
Hg	O	713-715
or	O	716-718
more	O	719-723
,	O	723-724
respectively	O	725-737
.	O	737-738

Topical	O	739-746
IOP	O	747-750
-	O	750-751
lowering	O	751-759
medication	O	760-770
was	O	771-774
administered	O	775-787
in	O	788-790
74	O	791-793
.	O	793-794
8	O	794-795
%	O	795-796
of	O	797-799
implanted	O	800-809
eyes	O	810-814
,	O	814-815
and	O	816-819
IOP	O	820-823
-	O	823-824
lowering	O	824-832
surgeries	O	833-842
,	O	842-843
most	O	844-848
of	O	849-851
which	O	852-857
were	O	858-862
trabeculectomies	O	863-879
(	O	880-881
76	O	881-883
.	O	883-884
2	O	884-885
%	O	885-886
)	O	886-887
,	O	887-888
were	O	889-893
performed	O	894-903
on	O	904-906
36	O	907-909
.	O	909-910
6	O	908-909
%	O	911-912
of	O	913-915
implanted	O	916-925
eyes	O	926-930
.	O	930-931

Intraocular	O	932-943
pressure	O	944-952
-	O	952-953
lowering	O	953-961
surgeries	O	962-971
were	O	972-976
considered	O	977-987
a	O	988-989
success	O	990-997
(	O	998-999
postoperative	O	999-1012
IOP	O	1013-1016
of	O	1017-1019
6	O	1020-1021
-	O	1021-1022
21	O	1022-1024
mm	O	1025-1027
Hg	O	1028-1030
with	O	1031-1035
or	O	1036-1038
without	O	1039-1046
additional	O	1047-1057
IOP	O	1058-1061
-	O	1061-1062
lowering	O	1062-1070
medication	O	1071-1081
)	O	1081-1082
in	O	1083-1085
85	O	1086-1088
.	O	1088-1089
1	O	1089-1090
%	O	1090-1091
of	O	1092-1094
eyes	O	1095-1099
at	O	1100-1102
1	O	1103-1104
year	O	1105-1109
.	O	1109-1110

The	O	1111-1114
rate	O	1115-1119
of	O	1120-1122
hypotony	B	1123-1131
(	O	1132-1133
IOP	O	1133-1136
<	O	1137-1138
/	O	1138-1139
=	O	1139-1140
5	O	1141-1142
mm	O	1143-1145
Hg	O	1146-1148
)	O	1148-1149
following	O	1150-1159
IOP	O	1160-1163
-	O	1163-1164
lowering	O	1164-1172
surgery	O	1173-1180
(	O	1181-1182
42	O	1182-1184
.	O	1184-1185
5	O	1185-1186
%	O	1186-1187
)	O	1187-1188
was	O	1189-1192
not	O	1193-1196
different	O	1197-1206
from	O	1207-1211
that	O	1212-1216
of	O	1217-1219
implanted	O	1220-1229
eyes	O	1230-1234
not	O	1235-1238
subjected	O	1239-1248
to	O	1249-1251
surgery	O	1252-1259
(	O	1260-1261
35	O	1261-1263
.	O	1263-1264
4	O	1264-1265
%	O	1265-1266
)	O	1266-1267
(	O	1268-1269
P	O	1269-1270
=	O	1271-1272
.	O	1273-1274
09	O	1274-1276
)	O	1276-1277
.	O	1273-1274

CONCLUSION	O	1279-1289
:	O	1289-1290
Elevated	O	1291-1299
IOP	O	1300-1303
is	O	1304-1306
a	O	1307-1308
significant	O	1309-1320
complication	O	1321-1333
with	O	1334-1338
the	O	1339-1342
FA	O	1343-1345
intravitreal	O	1346-1358
implant	O	1359-1366
but	O	1367-1370
may	O	1371-1374
be	O	1375-1377
controlled	O	1378-1388
with	O	1389-1393
medication	O	1394-1404
and	O	1405-1408
surgery	O	1409-1416
.	O	1416-1417

Pallidal	O	0-8
stimulation	O	9-20
:	O	20-21
an	O	22-24
alternative	O	25-36
to	O	37-39
pallidotomy	O	40-51
?	O	51-52

A	O	53-54
resurgence	O	55-65
of	O	66-68
interest	O	69-77
in	O	78-80
the	O	81-84
surgical	O	85-93
treatment	O	94-103
of	O	104-106
Parkinson	B	107-116
'	I	116-117
s	I	113-114
disease	I	119-126
(	O	127-128
PD	B	128-130
)	O	130-131
came	O	132-136
with	O	137-141
the	O	142-145
rediscovery	O	146-157
of	O	158-160
posteroventral	O	161-175
pallidotomy	O	176-187
by	O	188-190
Laitinen	O	191-199
in	O	200-202
1985	O	203-207
.	O	207-208

Laitinen	O	209-217
'	O	217-218
s	O	218-219
procedure	O	220-229
improved	O	230-238
most	O	239-243
symptoms	O	244-252
in	O	253-255
drug	O	256-260
-	O	260-261
resistant	O	261-270
PD	B	271-273
,	O	273-274
which	O	275-280
engendered	O	281-291
wide	O	292-296
interest	O	297-305
in	O	306-308
the	O	309-312
neurosurgical	O	313-326
community	O	327-336
.	O	336-337

Another	O	338-345
lesioning	O	346-355
procedure	O	356-365
,	O	365-366
ventrolateral	O	367-380
thalamotomy	O	381-392
,	O	392-393
has	O	394-397
become	O	398-404
a	O	405-406
powerful	O	407-415
alternative	O	416-427
to	O	428-430
stimulate	O	431-440
the	O	441-444
nucleus	O	445-452
ventralis	O	453-462
intermedius	O	463-474
,	O	474-475
producing	O	476-485
high	O	486-490
long	O	491-495
-	O	495-496
term	O	496-500
success	O	501-508
rates	O	509-514
and	O	515-518
low	O	519-522
morbidity	O	523-532
rates	O	533-538
.	O	538-539

Pallidal	O	540-548
stimulation	O	549-560
has	O	561-564
not	O	565-568
met	O	569-572
with	O	573-577
the	O	578-581
same	O	582-586
success	O	587-594
.	O	594-595

According	O	596-605
to	O	606-608
the	O	609-612
literature	O	613-623
pallidotomy	O	624-635
improves	O	636-644
the	O	645-648
"	O	649-650
on	O	650-652
"	O	649-650
symptoms	O	654-662
of	O	663-665
PD	B	666-668
,	O	668-669
such	O	670-674
as	O	675-677
dyskinesias	B	678-689
,	O	689-690
as	O	691-693
well	O	694-698
as	O	699-701
the	O	702-705
"	O	706-707
off	O	707-710
"	O	706-707
symptoms	O	712-720
,	O	720-721
such	O	722-726
as	O	727-729
rigidity	B	730-738
,	O	738-739
bradykinesia	B	740-752
,	O	752-753
and	O	754-757
on	O	758-760
-	O	760-761
off	O	761-764
fluctuations	O	765-777
.	O	777-778

Pallidal	O	779-787
stimulation	O	788-799
improves	O	800-808
bradykinesia	B	809-821
and	O	822-825
rigidity	B	826-834
to	O	835-837
a	O	838-839
minor	O	840-845
extent	O	846-852
;	O	852-853
however	O	854-861
,	O	861-862
its	O	863-866
strength	O	867-875
seems	O	876-881
to	O	882-884
be	O	885-887
in	O	888-890
improving	O	891-900
levodopa	O	901-909
-	O	909-910
induced	O	910-917
dyskinesias	B	918-929
.	O	929-930

Stimulation	O	931-942
often	O	943-948
produces	O	949-957
an	O	958-960
improvement	O	961-972
in	O	973-975
the	O	976-979
hyper	B	980-985
-	I	985-986
or	I	987-989
dyskinetic	I	990-1000
upper	O	1001-1006
limbs	O	1007-1012
,	O	1012-1013
but	O	1014-1017
increases	O	1018-1027
the	O	1028-1031
"	O	1032-1033
freezing	O	1033-1041
"	O	1032-1033
phenomenon	O	1043-1053
in	O	1054-1056
the	O	1057-1060
lower	O	1061-1066
limbs	O	1067-1072
at	O	1073-1075
the	O	1076-1079
same	O	1080-1084
time	O	1085-1089
.	O	1089-1090

Considering	O	1091-1102
the	O	1103-1106
small	O	1107-1112
increase	O	1113-1121
in	O	1122-1124
the	O	1125-1128
patient	O	1129-1136
'	O	1136-1137
s	O	1137-1138
independence	O	1139-1151
,	O	1151-1152
the	O	1153-1156
high	O	1157-1161
costs	O	1162-1167
of	O	1168-1170
bilateral	O	1171-1180
implants	O	1181-1189
,	O	1189-1190
and	O	1191-1194
the	O	1195-1198
difficulty	O	1199-1209
most	O	1210-1214
patients	O	1215-1223
experience	O	1224-1234
in	O	1235-1237
handling	O	1238-1246
the	O	1247-1250
devices	O	1251-1258
,	O	1258-1259
the	O	1260-1263
question	O	1264-1272
arises	O	1273-1279
as	O	1280-1282
to	O	1283-1285
whether	O	1286-1293
bilateral	O	1294-1303
pallidal	O	1304-1312
stimulation	O	1313-1324
is	O	1325-1327
a	O	1328-1329
real	O	1330-1334
alternative	O	1335-1346
to	O	1347-1349
pallidotomy	O	1350-1361
.	O	1361-1362

Case	O	0-4
report	O	5-11
:	O	11-12
Dexatrim	O	13-21
(	O	22-23
Phenylpropanolamine	O	23-42
)	O	42-43
as	O	44-46
a	O	47-48
cause	O	49-54
of	O	55-57
myocardial	B	58-68
infarction	I	69-79
.	O	79-80

Phenylpropanolamine	O	81-100
(	O	101-102
PPA	O	102-105
)	O	105-106
is	O	107-109
a	O	110-111
sympathetic	O	112-123
amine	O	124-129
used	O	130-134
in	O	135-137
over	O	138-142
-	O	142-143
the	O	143-146
-	O	142-143
counter	O	147-154
cold	O	155-159
remedies	O	160-168
and	O	169-172
weight	O	173-179
-	O	179-180
control	O	180-187
preparations	O	188-200
worldwide	O	201-210
.	O	210-211

Its	O	212-215
use	O	216-219
has	O	220-223
been	O	224-228
associated	O	229-239
with	O	240-244
hypertensive	B	245-257
episodes	O	258-266
and	O	267-270
hemorrhagic	B	271-282
strokes	I	283-290
in	O	291-293
younger	O	294-301
women	O	302-307
.	O	307-308

Several	O	309-316
reports	O	317-324
have	O	325-329
linked	O	330-336
the	O	337-340
abuse	O	341-346
of	O	347-349
PPA	O	350-353
with	O	354-358
myocardial	B	359-369
injury	I	370-376
,	O	376-377
especially	O	378-388
when	O	389-393
overdose	B	394-402
is	O	403-405
involved	O	406-414
.	O	414-415

We	O	416-418
report	O	419-425
here	O	426-430
the	O	431-434
first	O	435-440
case	O	441-445
of	O	446-448
Dexatrim	O	449-457
(	O	458-459
PPA	O	459-462
)	O	462-463
-	O	463-464
induced	O	464-471
myocardial	B	472-482
injury	I	483-489
in	O	490-492
a	O	493-494
young	O	495-500
woman	O	501-506
who	O	507-510
was	O	511-514
using	O	515-520
it	O	521-523
at	O	524-526
recommended	O	527-538
doses	O	539-544
for	O	545-548
weight	O	549-555
control	O	556-563
.	O	563-564

In	O	565-567
addition	O	568-576
,	O	576-577
we	O	578-580
review	O	581-587
the	O	588-591
7	O	592-593
other	O	594-599
cases	O	600-605
of	O	606-608
PPA	O	609-612
related	O	613-620
myocardial	B	621-631
injury	I	632-638
that	O	639-643
have	O	644-648
been	O	649-653
reported	O	654-662
so	O	663-665
far	O	666-669
.	O	669-670

Physicians	O	671-681
and	O	682-685
patients	O	686-694
should	O	695-701
be	O	702-704
alert	O	705-710
to	O	711-713
the	O	714-717
potential	O	718-727
cardiac	O	728-735
risk	O	736-740
associated	O	741-751
with	O	752-756
the	O	757-760
use	O	761-764
of	O	765-767
PPA	O	768-771
,	O	771-772
even	O	773-777
at	O	778-780
doses	O	781-786
generally	O	787-796
considered	O	797-807
to	O	808-810
be	O	811-813
safe	O	814-818
.	O	818-819

Risperidone	O	0-11
-	O	11-12
associated	O	12-22
,	O	22-23
benign	O	24-30
transient	O	31-40
visual	B	41-47
disturbances	I	48-60
in	O	61-63
schizophrenic	B	64-77
patients	O	78-86
with	O	87-91
a	O	92-93
past	O	94-98
history	O	99-106
of	O	107-109
LSD	O	110-113
abuse	O	114-119
.	O	119-120

Two	O	121-124
schizophrenic	B	125-138
patients	O	139-147
,	O	147-148
who	O	149-152
had	O	153-156
a	O	157-158
prior	O	159-164
history	O	165-172
of	O	173-175
LSD	O	176-179
abuse	O	180-185
and	O	186-189
who	O	190-193
had	O	194-197
previously	O	198-208
developed	O	209-218
EPS	B	219-222
with	O	223-227
classic	O	228-235
antipsychotics	O	236-250
,	O	250-251
were	O	252-256
successfully	O	257-269
treated	O	270-277
with	O	278-282
risperidone	O	283-294
.	O	294-295

They	O	296-300
both	O	301-305
reported	O	306-314
short	O	315-320
episodes	O	321-329
of	O	330-332
transient	O	333-342
visual	B	343-349
disturbances	I	350-362
,	O	362-363
which	O	364-369
appeared	O	370-378
immediately	O	379-390
after	O	391-396
starting	O	397-405
treatment	O	406-415
with	O	416-420
risperidone	O	421-432
.	O	432-433

This	O	434-438
imagery	O	439-446
resembled	O	447-456
visual	B	457-463
disturbances	I	464-476
previously	O	477-487
experienced	O	488-499
as	O	500-502
"	O	503-504
flashbacks	O	504-514
"	O	503-504
related	O	516-523
to	O	524-526
prior	O	527-532
LSD	O	533-536
consumption	O	537-548
.	O	548-549

Risperidone	O	550-561
administration	O	562-576
was	O	577-580
continued	O	581-590
and	O	591-594
the	O	595-598
visual	B	599-605
disturbances	I	606-618
gradually	O	619-628
wore	O	629-633
off	O	634-637
.	O	637-638

During	O	639-645
a	O	646-647
six	O	648-651
-	O	651-652
month	O	652-657
follow	O	658-664
-	O	664-665
up	O	665-667
period	O	668-674
,	O	674-675
there	O	676-681
was	O	682-685
no	O	686-688
recurrence	O	689-699
of	O	700-702
visual	B	703-709
disturbances	I	710-722
.	O	722-723

This	O	724-728
phenomenon	O	729-739
may	O	740-743
be	O	744-746
interpreted	O	747-758
as	O	759-761
a	O	762-763
benign	O	764-770
,	O	770-771
short	O	772-777
-	O	777-778
term	O	778-782
and	O	783-786
self	O	787-791
-	O	791-792
limiting	O	792-800
side	O	801-805
effect	O	806-812
which	O	813-818
does	O	819-823
not	O	824-827
contraindicate	O	828-842
the	O	843-846
use	O	847-850
of	O	851-853
risperidone	O	854-865
or	O	866-868
interfere	O	869-878
with	O	879-883
treatment	O	884-893
.	O	893-894

Conclusions	O	895-906
based	O	907-912
on	O	913-915
two	O	916-919
case	O	920-924
reports	O	925-932
should	O	933-939
be	O	940-942
taken	O	943-948
with	O	949-953
appropriate	O	954-965
caution	O	966-973
.	O	973-974

Activation	O	0-10
of	O	11-13
poly	O	14-18
(	O	18-19
ADP	O	19-22
-	O	22-23
ribose	O	23-29
)	O	29-30
polymerase	O	31-41
contributes	O	42-53
to	O	54-56
development	O	57-68
of	O	69-71
doxorubicin	O	72-83
-	O	83-84
induced	O	84-91
heart	B	92-97
failure	I	98-105
.	O	105-106

Activation	O	107-117
of	O	118-120
the	O	121-124
nuclear	O	125-132
enzyme	O	133-139
poly	O	140-144
(	O	144-145
ADP	O	145-148
-	O	148-149
ribose	O	149-155
)	O	155-156
polymerase	O	157-167
(	O	168-169
PARP	O	169-173
)	O	173-174
by	O	175-177
oxidant	O	178-185
-	O	185-186
mediated	O	186-194
DNA	O	195-198
damage	O	199-205
is	O	206-208
an	O	209-211
important	O	212-221
pathway	O	222-229
of	O	230-232
cell	O	233-237
dysfunction	O	238-249
and	O	250-253
tissue	O	254-260
injury	O	261-267
in	O	268-270
conditions	O	271-281
associated	O	282-292
with	O	293-297
oxidative	O	298-307
stress	O	308-314
.	O	314-315

Increased	O	316-325
oxidative	O	326-335
stress	O	336-342
is	O	343-345
a	O	346-347
major	O	348-353
factor	O	354-360
implicated	O	361-371
in	O	372-374
the	O	375-378
cardiotoxicity	B	379-393
of	O	394-396
doxorubicin	O	397-408
(	O	409-410
DOX	O	410-413
)	O	413-414
,	O	414-415
a	O	416-417
widely	O	418-424
used	O	425-429
antitumor	O	430-439
anthracycline	O	440-453
antibiotic	O	454-464
.	O	464-465

Thus	O	466-470
,	O	470-471
we	O	472-474
hypothesized	O	475-487
that	O	488-492
the	O	493-496
activation	O	497-507
of	O	508-510
PARP	O	511-515
may	O	516-519
contribute	O	520-530
to	O	531-533
the	O	534-537
DOX	O	538-541
-	O	541-542
induced	O	542-549
cardiotoxicity	B	550-564
.	O	564-565

Using	O	566-571
a	O	572-573
dual	O	574-578
approach	O	579-587
of	O	588-590
PARP	O	591-595
-	O	595-596
1	O	596-597
suppression	O	598-609
,	O	609-610
by	O	611-613
genetic	O	614-621
deletion	O	622-630
or	O	631-633
pharmacological	O	634-649
inhibition	O	650-660
with	O	661-665
the	O	666-669
phenanthridinone	O	670-686
PARP	O	687-691
inhibitor	O	692-701
PJ34	O	702-706
,	O	706-707
we	O	708-710
now	O	711-714
demonstrate	O	715-726
the	O	727-730
role	O	731-735
of	O	736-738
PARP	O	739-743
in	O	744-746
the	O	747-750
development	O	751-762
of	O	763-765
cardiac	B	766-773
dysfunction	I	774-785
induced	O	786-793
by	O	794-796
DOX	O	797-800
.	O	800-801

PARP	O	802-806
-	O	806-807
1	O	807-808
+	O	808-809
/	O	809-810
+	O	808-809
and	O	812-815
PARP	O	816-820
-	O	820-821
1	O	821-822
-	O	820-821
/	O	823-824
-	O	820-821
mice	O	826-830
received	O	831-839
a	O	840-841
single	O	842-848
injection	O	849-858
of	O	859-861
DOX	O	862-865
(	O	866-867
25	O	867-869
mg	O	870-872
/	O	872-873
kg	O	873-875
i	O	876-877
.	O	877-878
p	O	878-879
)	O	879-880
.	O	877-878

Five	O	882-886
days	O	887-891
after	O	892-897
DOX	O	898-901
administration	O	902-916
,	O	916-917
left	O	918-922
ventricular	O	923-934
performance	O	935-946
was	O	947-950
significantly	O	951-964
depressed	O	965-974
in	O	975-977
PARP	O	978-982
-	O	982-983
1	O	983-984
+	O	984-985
/	O	985-986
+	O	984-985
mice	O	988-992
,	O	992-993
but	O	994-997
only	O	998-1002
to	O	1003-1005
a	O	1006-1007
smaller	O	1008-1015
extent	O	1016-1022
in	O	1023-1025
PARP	O	1026-1030
-	O	1030-1031
1	O	1031-1032
-	O	1030-1031
/	O	1033-1034
-	O	1030-1031
ones	O	1036-1040
.	O	1040-1041

Similar	O	1042-1049
experiments	O	1050-1061
were	O	1062-1066
conducted	O	1067-1076
in	O	1077-1079
BALB	O	1080-1084
/	O	1084-1085
c	O	1085-1086
mice	O	1087-1091
treated	O	1092-1099
with	O	1100-1104
PJ34	O	1105-1109
or	O	1110-1112
vehicle	O	1113-1120
.	O	1120-1121

Treatment	O	1122-1131
with	O	1132-1136
a	O	1137-1138
PJ34	O	1139-1143
significantly	O	1144-1157
improved	O	1158-1166
cardiac	B	1167-1174
dysfunction	I	1175-1186
and	O	1187-1190
increased	O	1191-1200
the	O	1201-1204
survival	O	1205-1213
of	O	1214-1216
the	O	1217-1220
animals	O	1221-1228
.	O	1228-1229

In	O	1230-1232
addition	O	1233-1241
PJ34	O	1242-1246
significantly	O	1247-1260
reduced	O	1261-1268
the	O	1269-1272
DOX	O	1273-1276
-	O	1276-1277
induced	O	1277-1284
increase	O	1285-1293
in	O	1294-1296
the	O	1297-1300
serum	O	1301-1306
lactate	O	1307-1314
dehydrogenase	O	1315-1328
and	O	1329-1332
creatine	O	1333-1341
kinase	O	1342-1348
activities	O	1349-1359
but	O	1360-1363
not	O	1364-1367
metalloproteinase	O	1368-1385
activation	O	1386-1396
in	O	1397-1399
the	O	1400-1403
heart	O	1404-1409
.	O	1409-1410

Thus	O	1411-1415
,	O	1415-1416
PARP	O	1417-1421
activation	O	1422-1432
contributes	O	1433-1444
to	O	1445-1447
the	O	1448-1451
cardiotoxicity	B	1452-1466
of	O	1467-1469
DOX	O	1470-1473
.	O	1473-1474

PARP	O	1475-1479
inhibitors	O	1480-1490
may	O	1491-1494
exert	O	1495-1500
protective	O	1501-1511
effects	O	1512-1519
against	O	1520-1527
the	O	1528-1531
development	O	1532-1543
of	O	1544-1546
severe	O	1547-1553
cardiac	B	1554-1561
complications	I	1562-1575
associated	O	1576-1586
with	O	1587-1591
the	O	1592-1595
DOX	O	1596-1599
treatment	O	1600-1609
.	O	1609-1610

Fluconazole	O	0-11
-	O	11-12
induced	O	12-19
torsade	B	20-27
de	I	28-30
pointes	I	31-38
.	O	38-39

OBJECTIVE	O	40-49
:	O	49-50
To	O	51-53
present	O	54-61
a	O	62-63
case	O	64-68
of	O	69-71
fluconazole	O	72-83
-	O	83-84
associated	O	84-94
torsade	B	95-102
de	I	103-105
pointes	I	106-113
(	O	114-115
TDP	B	115-118
)	O	118-119
and	O	120-123
discuss	O	124-131
fluconazole	O	132-143
'	O	143-144
s	O	144-145
role	O	146-150
in	O	151-153
causing	O	154-161
TDP	B	162-165
.	O	165-166

CASE	O	167-171
SUMMARY	O	172-179
:	O	179-180
A	O	181-182
68	O	183-185
-	O	185-186
year	O	186-190
-	O	185-186
old	O	191-194
white	O	195-200
woman	O	201-206
with	O	207-211
Candida	O	212-219
glabrata	O	220-228
isolated	O	229-237
from	O	238-242
a	O	243-244
presacral	O	245-254
abscess	O	255-262
developed	O	263-272
TDP	B	273-276
eight	O	277-282
days	O	283-287
after	O	288-293
commencing	O	294-304
oral	O	305-309
fluconazole	O	310-321
The	O	322-325
patient	O	326-333
had	O	334-337
no	O	338-340
other	O	341-346
risk	O	347-351
factors	O	352-359
for	O	360-363
TDP	B	364-367
,	O	367-368
including	O	369-378
coronary	B	379-387
artery	I	388-394
disease	I	395-402
,	O	402-403
cardiomyopathy	B	404-418
,	O	418-419
congestive	B	420-430
heart	I	431-436
failure	I	437-444
,	O	444-445
and	O	446-449
electrolyte	O	450-461
abnormalities	O	462-475
There	O	476-481
was	O	482-485
a	O	486-487
temporal	O	488-496
association	O	497-508
between	O	509-516
the	O	517-520
initiation	O	521-531
of	O	532-534
fluconazole	O	535-546
and	O	547-550
TDP	B	551-554
.	O	554-555

The	O	556-559
TDP	B	560-563
resolved	O	564-572
when	O	573-577
fluconazole	O	578-589
was	O	590-593
discontinued	O	594-606
;	O	606-607
however	O	608-615
,	O	615-616
the	O	617-620
patient	O	621-628
continued	O	629-638
to	O	639-641
have	O	642-646
premature	B	647-656
ventricular	I	657-668
contractions	I	669-681
and	O	682-685
nonsustained	O	686-698
ventricular	B	699-710
tachycardia	I	711-722
(	O	723-724
NSVT	B	724-728
)	O	728-729
until	O	730-735
six	O	736-739
days	O	740-744
after	O	745-750
drug	O	751-755
cessation	O	756-765
DISCUSSION	O	766-776
:	O	776-777
Use	O	778-781
of	O	782-784
the	O	785-788
Naranjo	O	789-796
probability	O	797-808
scale	O	809-814
indicates	O	815-824
a	O	825-826
probable	O	827-835
relationship	O	836-848
between	O	849-856
the	O	857-860
use	O	861-864
of	O	865-867
fluconazole	O	868-879
and	O	880-883
the	O	884-887
development	O	888-899
of	O	900-902
TDP	B	903-906
.	O	906-907

The	O	908-911
possible	O	912-920
mechanism	O	921-930
is	O	931-933
depression	B	934-944
of	O	945-947
rapidly	O	948-955
activating	O	956-966
delayed	O	967-974
rectifier	O	975-984
potassium	O	985-994
currents	O	995-1003
.	O	1003-1004

In	O	1005-1007
our	O	1008-1011
patient	O	1012-1019
,	O	1019-1020
there	O	1021-1026
was	O	1027-1030
no	O	1031-1033
other	O	1034-1039
etiology	O	1040-1048
identified	O	1049-1059
that	O	1060-1064
could	O	1065-1070
explain	O	1071-1078
QT	B	1079-1081
prolongation	I	1082-1094
or	O	1095-1097
TDP	B	1098-1101
The	O	1102-1105
complete	O	1106-1114
disappearance	O	1115-1128
of	O	1129-1131
NSVT	B	1132-1136
and	O	1137-1140
premature	B	1141-1150
ventricular	I	1151-1162
contractions	I	1163-1175
followed	O	1176-1184
by	O	1185-1187
normalization	O	1188-1201
of	O	1202-1204
QT	O	1205-1207
interval	O	1208-1216
after	O	1217-1222
the	O	1223-1226
drug	O	1227-1231
was	O	1232-1235
stopped	O	1236-1243
strongly	O	1244-1252
suggests	O	1253-1261
fluconazole	O	1262-1273
as	O	1274-1276
the	O	1277-1280
etiology	O	1281-1289
.	O	1289-1290

CONCLUSIONS	O	1291-1302
:	O	1302-1303
Clinicians	O	1304-1314
should	O	1315-1321
be	O	1322-1324
aware	O	1325-1330
that	O	1331-1335
fluconazole	O	1336-1347
,	O	1347-1348
even	O	1349-1353
at	O	1354-1356
low	O	1357-1360
doses	O	1361-1366
,	O	1366-1367
may	O	1368-1371
cause	O	1372-1377
prolongation	B	1378-1390
of	I	1391-1393
the	I	1394-1397
QT	I	1398-1400
interval	I	1401-1409
,	O	1409-1410
leading	O	1411-1418
to	O	1419-1421
TDP	B	1422-1425
.	O	1425-1426

Serial	O	1427-1433
electrocardiographic	O	1434-1454
monitoring	O	1455-1465
may	O	1466-1469
be	O	1470-1472
considered	O	1473-1483
when	O	1484-1488
fluconazole	O	1489-1500
is	O	1501-1503
administered	O	1504-1516
in	O	1517-1519
patients	O	1520-1528
who	O	1529-1532
are	O	1533-1536
at	O	1537-1539
risk	O	1540-1544
for	O	1545-1548
ventricular	B	1549-1560
arrhythmias	I	1561-1572
.	O	1572-1573

High	O	0-4
-	O	4-5
dose	O	5-9
methylprednisolone	O	10-28
may	O	29-32
do	O	33-35
more	O	36-40
harm	O	41-45
for	O	46-49
spinal	B	50-56
cord	I	57-61
injury	I	62-68
.	O	68-69

Because	O	70-77
of	O	78-80
the	O	81-84
National	O	85-93
Acute	O	94-99
Spinal	B	100-106
Cord	I	107-111
Injury	I	112-118
Studies	O	119-126
(	O	127-128
NASCIS	O	128-134
)	O	134-135
,	O	135-136
high	O	137-141
-	O	141-142
dose	O	142-146
methylprednisolone	O	147-165
became	O	166-172
the	O	173-176
standard	O	177-185
of	O	186-188
care	O	189-193
for	O	194-197
the	O	198-201
acute	O	202-207
spinal	B	208-214
cord	I	215-219
injury	I	220-226
.	O	226-227

In	O	228-230
the	O	231-234
NASCIS	O	235-241
,	O	241-242
there	O	243-248
was	O	249-252
no	O	253-255
mention	O	256-263
regarding	O	264-273
the	O	274-277
possibility	O	278-289
of	O	290-292
acute	O	293-298
corticosteroid	O	299-313
myopathy	B	314-322
that	O	323-327
high	O	328-332
-	O	332-333
dose	O	333-337
methylprednisolone	O	338-356
may	O	357-360
cause	O	361-366
.	O	366-367

The	O	368-371
dosage	O	372-378
of	O	379-381
methylprednisolone	O	382-400
recommended	O	401-412
by	O	413-415
the	O	416-419
NASCIS	O	420-426
3	O	427-428
is	O	429-431
the	O	432-435
highest	O	436-443
dose	O	444-448
of	O	449-451
steroids	O	452-460
ever	O	461-465
being	O	466-471
used	O	472-476
during	O	477-483
a	O	484-485
2	O	486-487
-	O	487-488
day	O	488-491
period	O	492-498
for	O	499-502
any	O	503-506
clinical	O	507-515
condition	O	516-525
.	O	525-526

We	O	527-529
hypothesize	O	530-541
that	O	542-546
it	O	547-549
may	O	550-553
cause	O	554-559
some	O	560-564
damage	B	565-571
to	I	572-574
the	I	575-578
muscle	I	579-585
of	O	586-588
spinal	B	589-595
cord	I	596-600
injury	I	601-607
patients	O	608-616
.	O	616-617

Further	O	618-625
,	O	625-626
steroid	O	627-634
myopathy	B	635-643
recovers	O	644-652
naturally	O	653-662
and	O	663-666
the	O	667-670
neurological	O	671-683
improvement	O	684-695
shown	O	696-701
in	O	702-704
the	O	705-708
NASCIS	O	709-715
may	O	716-719
be	O	720-722
just	O	723-727
a	O	728-729
recording	O	730-739
of	O	740-742
this	O	743-747
natural	O	748-755
motor	O	756-761
recovery	O	762-770
from	O	771-775
the	O	776-779
steroid	O	780-787
myopathy	B	788-796
,	O	796-797
instead	O	798-805
of	O	806-808
any	O	809-812
protection	O	813-823
that	O	824-828
methylprednisolone	O	829-847
offers	O	848-854
to	O	855-857
the	O	858-861
spinal	B	862-868
cord	I	869-873
injury	I	874-880
.	O	880-881

To	O	882-884
our	O	885-888
knowledge	O	889-898
,	O	898-899
this	O	900-904
is	O	905-907
the	O	908-911
first	O	912-917
discussion	O	918-928
considering	O	929-940
the	O	941-944
possibility	O	945-956
that	O	957-961
the	O	962-965
methylprednisolone	O	966-984
recommended	O	985-996
by	O	997-999
NASCIS	O	1000-1006
may	O	1007-1010
cause	O	1011-1016
acute	O	1017-1022
corticosteroid	O	1023-1037
myopathy	B	1038-1046
.	O	1046-1047

Probing	O	0-7
peripheral	O	8-18
and	O	19-22
central	O	23-30
cholinergic	O	31-42
system	O	43-49
responses	O	50-59
.	O	59-60

OBJECTIVE	O	61-70
:	O	70-71
The	O	72-75
pharmacological	O	76-91
response	O	92-100
to	O	101-103
drugs	O	104-109
that	O	110-114
act	O	115-118
on	O	119-121
the	O	122-125
cholinergic	O	126-137
system	O	138-144
of	O	145-147
the	O	148-151
iris	O	152-156
has	O	157-160
been	O	161-165
used	O	166-170
to	O	171-173
predict	O	174-181
deficits	O	182-190
in	O	191-193
central	O	194-201
cholinergic	O	202-213
functioning	O	214-225
due	O	226-229
to	O	230-232
diseases	O	233-241
such	O	242-246
as	O	247-249
Alzheimer	B	250-259
'	I	259-260
s	I	260-261
disease	I	262-269
,	O	269-270
yet	O	271-274
correlations	O	275-287
between	O	288-295
central	O	296-303
and	O	304-307
peripheral	O	308-318
responses	O	319-328
have	O	329-333
not	O	334-337
been	O	338-342
properly	O	343-351
studied	O	352-359
.	O	359-360

This	O	361-365
study	O	366-371
assessed	O	372-380
the	O	381-384
effect	O	385-391
of	O	392-394
normal	O	395-401
aging	O	402-407
on	O	408-410
(	O	411-412
1	O	412-413
)	O	413-414
the	O	415-418
tropicamide	O	419-430
-	O	430-431
induced	O	431-438
increase	O	439-447
in	O	448-450
pupil	O	451-456
diameter	O	457-465
,	O	465-466
and	O	467-470
(	O	471-472
2	O	472-473
)	O	473-474
the	O	475-478
reversal	O	479-487
of	O	488-490
this	O	491-495
effect	O	496-502
with	O	503-507
pilocarpine	O	508-519
.	O	519-520

Scopolamine	O	521-532
was	O	533-536
used	O	537-541
as	O	542-544
a	O	545-546
positive	O	547-555
control	O	556-563
to	O	564-566
detect	O	567-573
age	O	574-577
-	O	577-578
dependent	O	578-587
changes	O	588-595
in	O	596-598
central	O	599-606
cholinergic	O	607-618
functioning	O	619-630
in	O	631-633
the	O	634-637
elderly	O	638-645
.	O	645-646

DESIGN	O	647-653
:	O	653-654
Randomized	O	655-665
double	O	666-672
-	O	672-673
blind	O	673-678
controlled	O	679-689
trial	O	690-695
.	O	695-696

PARTICIPANTS	O	697-709
:	O	709-710
Ten	O	711-714
healthy	O	715-722
elderly	O	723-730
(	O	731-732
mean	O	732-736
age	O	737-740
70	O	741-743
)	O	743-744
and	O	745-748
9	O	749-750
young	O	751-756
(	O	757-758
mean	O	758-762
age	O	763-766
33	O	767-769
)	O	769-770
volunteers	O	771-781
.	O	781-782

INTERVENTIONS	O	783-796
:	O	796-797
Pupil	O	798-803
diameter	O	804-812
was	O	813-816
monitored	O	817-826
using	O	827-832
a	O	833-834
computerized	O	835-847
infrared	O	848-856
pupillometer	O	857-869
over	O	870-874
4	O	875-876
hours	O	877-882
.	O	882-883

The	O	884-887
study	O	888-893
involved	O	894-902
4	O	903-904
sessions	O	905-913
.	O	913-914

In	O	915-917
1	O	918-919
session	O	920-927
,	O	927-928
tropicamide	O	929-940
(	O	941-942
20	O	942-944
microL	O	945-951
,	O	951-952
0	O	953-954
.	O	954-955
01	O	955-957
%	O	957-958
)	O	958-959
was	O	960-963
administered	O	964-976
to	O	977-979
one	O	980-983
eye	O	984-987
and	O	988-991
placebo	O	992-999
to	O	1000-1002
the	O	1003-1006
other	O	1007-1012
.	O	1012-1013

In	O	1014-1016
another	O	1017-1024
session	O	1025-1032
,	O	1032-1033
tropicamide	O	1034-1045
(	O	1046-1047
20	O	1047-1049
microL	O	1050-1056
,	O	1056-1057
0	O	1058-1059
.	O	1059-1060
01	O	1060-1062
%	O	1062-1063
)	O	1063-1064
was	O	1065-1068
administered	O	1069-1081
to	O	1082-1084
both	O	1085-1089
eyes	O	1090-1094
,	O	1094-1095
followed	O	1096-1104
23	O	1105-1107
minutes	O	1108-1115
later	O	1116-1121
by	O	1122-1124
the	O	1125-1128
application	O	1129-1140
of	O	1141-1143
pilocarpine	O	1144-1155
(	O	1156-1157
20	O	1157-1159
microL	O	1160-1166
,	O	1166-1167
0	O	1168-1169
.	O	1169-1170
1	O	1170-1171
%	O	1171-1172
)	O	1172-1173
to	O	1174-1176
one	O	1177-1180
eye	O	1181-1184
and	O	1185-1188
placebo	O	1189-1196
to	O	1197-1199
the	O	1200-1203
other	O	1204-1209
.	O	1209-1210

All	O	1211-1214
eye	O	1215-1218
drops	O	1219-1224
were	O	1225-1229
given	O	1230-1235
in	O	1236-1238
a	O	1239-1240
randomized	O	1241-1251
order	O	1252-1257
.	O	1257-1258

In	O	1259-1261
2	O	1262-1263
separate	O	1264-1272
sessions	O	1273-1281
,	O	1281-1282
a	O	1283-1284
single	O	1285-1291
dose	O	1292-1296
of	O	1297-1299
scopolamine	O	1300-1311
(	O	1312-1313
0	O	1313-1314
.	O	1314-1315
5	O	1315-1316
mg	O	1317-1319
,	O	1319-1320
intravenously	O	1321-1334
)	O	1334-1335
or	O	1336-1338
placebo	O	1339-1346
was	O	1347-1350
administered	O	1351-1363
,	O	1363-1364
and	O	1365-1368
the	O	1369-1372
effects	O	1373-1380
on	O	1381-1383
word	O	1384-1388
recall	O	1389-1395
were	O	1396-1400
measured	O	1401-1409
using	O	1410-1415
the	O	1416-1419
Buschke	O	1420-1427
Selective	O	1428-1437
Reminding	O	1438-1447
Test	O	1448-1452
over	O	1453-1457
2	O	1458-1459
hours	O	1460-1465
.	O	1465-1466

OUTCOME	O	1467-1474
MEASURES	O	1475-1483
:	O	1483-1484
Pupil	O	1485-1490
size	O	1491-1495
at	O	1496-1498
time	O	1499-1503
points	O	1504-1510
after	O	1511-1516
administration	O	1517-1531
of	O	1532-1534
tropicamide	O	1535-1546
and	O	1547-1550
pilocarpine	O	1551-1562
;	O	1562-1563
scopolamine	O	1564-1575
-	O	1575-1576
induced	O	1576-1583
impairment	B	1584-1594
in	I	1595-1597
word	I	1598-1602
recall	I	1603-1609
.	O	1609-1610

RESULTS	O	1611-1618
:	O	1618-1619
There	O	1620-1625
was	O	1626-1629
no	O	1630-1632
significant	O	1633-1644
difference	O	1645-1655
between	O	1656-1663
elderly	O	1664-1671
and	O	1672-1675
young	O	1676-1681
volunteers	O	1682-1692
in	O	1693-1695
pupillary	O	1696-1705
response	O	1706-1714
to	O	1715-1717
tropicamide	O	1718-1729
at	O	1730-1732
any	O	1733-1736
time	O	1737-1741
point	O	1742-1747
(	O	1748-1749
p	O	1749-1750
>	O	1751-1752
0	O	1753-1754
.	O	1754-1755
05	O	1755-1757
)	O	1757-1758
.	O	1754-1755

The	O	1760-1763
elderly	O	1764-1771
group	O	1772-1777
had	O	1778-1781
a	O	1782-1783
significantly	O	1784-1797
greater	O	1798-1805
pilocarpine	O	1806-1817
-	O	1817-1818
induced	O	1818-1825
net	O	1826-1829
decrease	O	1830-1838
in	O	1839-1841
pupil	O	1842-1847
size	O	1848-1852
85	O	1853-1855
,	O	1855-1856
125	O	1857-1860
,	O	1860-1861
165	O	1862-1865
and	O	1866-1869
215	O	1870-1873
minutes	O	1874-1881
after	O	1882-1887
administration	O	1888-1902
,	O	1902-1903
compared	O	1904-1912
with	O	1913-1917
the	O	1918-1921
young	O	1922-1927
group	O	1928-1933
(	O	1934-1935
p	O	1935-1936
<	O	1937-1938
0	O	1939-1940
.	O	1940-1941
05	O	1941-1943
)	O	1943-1944
.	O	1940-1941

Compared	O	1946-1954
with	O	1955-1959
the	O	1960-1963
young	O	1964-1969
group	O	1970-1975
,	O	1975-1976
the	O	1977-1980
elderly	O	1981-1988
group	O	1989-1994
had	O	1995-1998
greater	O	1999-2006
scopolamine	O	2007-2018
-	O	2018-2019
induced	O	2019-2026
impairment	B	2027-2037
in	I	2038-2040
word	I	2041-2045
recall	I	2046-2052
60	O	2053-2055
,	O	2055-2056
90	O	2057-2059
and	O	2060-2063
120	O	2064-2067
minutes	O	2068-2075
after	O	2076-2081
administration	O	2082-2096
(	O	2097-2098
p	O	2098-2099
<	O	2100-2101
0	O	2102-2103
.	O	2103-2104
05	O	2104-2106
)	O	2106-2107
.	O	2103-2104

CONCLUSION	O	2109-2119
:	O	2119-2120
There	O	2121-2126
is	O	2127-2129
an	O	2130-2132
age	O	2133-2136
-	O	2136-2137
related	O	2137-2144
pupillary	O	2145-2154
response	O	2155-2163
to	O	2164-2166
pilocarpine	O	2167-2178
that	O	2179-2183
is	O	2184-2186
not	O	2187-2190
found	O	2191-2196
with	O	2197-2201
tropicamide	O	2202-2213
.	O	2213-2214

Thus	O	2215-2219
,	O	2219-2220
pilocarpine	O	2221-2232
may	O	2233-2236
be	O	2237-2239
useful	O	2240-2246
to	O	2247-2249
assess	O	2250-2256
variations	O	2257-2267
in	O	2268-2270
central	O	2271-2278
cholinergic	O	2279-2290
function	O	2291-2299
in	O	2300-2302
elderly	O	2303-2310
patients	O	2311-2319
.	O	2319-2320

Acetazolamide	O	0-13
-	O	13-14
induced	O	14-21
Gerstmann	B	22-31
syndrome	I	32-40
.	O	40-41

Acute	O	42-47
confusion	B	48-57
induced	O	58-65
by	O	66-68
acetazolamide	O	69-82
is	O	83-85
a	O	86-87
well	O	88-92
known	O	93-98
adverse	O	99-106
drug	O	107-111
reaction	O	112-120
in	O	121-123
patients	O	124-132
with	O	133-137
renal	B	138-143
impairment	I	144-154
.	O	154-155

We	O	156-158
report	O	159-165
a	O	166-167
case	O	168-172
of	O	173-175
acetazolamide	O	176-189
-	O	189-190
induced	O	190-197
Gerstmann	B	198-207
syndrome	I	208-216
in	O	217-219
a	O	220-221
patient	O	222-229
with	O	230-234
normal	O	235-241
renal	O	242-247
function	O	248-256
,	O	256-257
to	O	258-260
highlight	O	261-270
predisposing	O	271-283
factors	O	284-291
that	O	292-296
are	O	297-300
frequently	O	301-311
overlooked	O	312-322
.	O	322-323

Hypomania	B	0-9
-	O	9-10
like	O	10-14
syndrome	O	15-23
induced	O	24-31
by	O	32-34
olanzapine	O	35-45
.	O	45-46

We	O	47-49
report	O	50-56
a	O	57-58
female	O	59-65
patient	O	66-73
with	O	74-78
a	O	79-80
diagnosis	O	81-90
of	O	91-93
a	O	94-95
not	O	96-99
otherwise	O	100-109
specified	O	110-119
psychotic	B	120-129
disorder	I	130-138
(	O	139-140
DSM	O	140-143
-	O	143-144
IV	O	144-146
)	O	146-147
who	O	148-151
developed	O	152-161
hypomania	B	162-171
shortly	O	172-179
after	O	180-185
the	O	186-189
introduction	O	190-202
of	O	203-205
olanzapine	O	206-216
treatment	O	217-226
.	O	226-227

Neutrophil	O	0-10
superoxide	O	11-21
and	O	22-25
hydrogen	O	26-34
peroxide	O	35-43
production	O	44-54
in	O	55-57
patients	O	58-66
with	O	67-71
acute	B	72-77
liver	I	78-83
failure	I	84-91
.	O	91-92

Defects	O	93-100
in	O	101-103
superoxide	O	104-114
and	O	115-118
hydrogen	O	119-127
peroxide	O	128-136
production	O	137-147
may	O	148-151
be	O	152-154
implicated	O	155-165
in	O	166-168
the	O	169-172
high	O	173-177
incidence	O	178-187
of	O	188-190
bacterial	B	191-200
infections	I	201-211
in	O	212-214
patients	O	215-223
with	O	224-228
acute	B	229-234
liver	I	235-240
failure	I	241-248
(	O	249-250
ALF	B	250-253
)	O	253-254
.	O	254-255

In	O	256-258
the	O	259-262
present	O	263-270
study	O	271-276
,	O	276-277
oxygen	O	278-284
radical	O	285-292
production	O	293-303
in	O	304-306
patients	O	307-315
with	O	316-320
ALF	B	321-324
due	O	325-328
to	O	329-331
paracetamol	O	332-343
overdose	B	344-352
was	O	353-356
compared	O	357-365
with	O	366-370
that	O	371-375
of	O	376-378
healthy	O	379-386
volunteers	O	387-397
.	O	397-398

Neutrophils	O	399-410
from	O	411-415
14	O	416-418
ALF	B	419-422
patients	O	423-431
were	O	432-436
stimulated	O	437-447
via	O	448-451
the	O	452-455
complement	O	456-466
receptors	O	467-476
using	O	477-482
zymosan	O	483-490
opsonized	O	491-500
with	O	501-505
ALF	B	506-509
or	O	510-512
control	O	513-520
serum	O	521-526
.	O	526-527

Superoxide	O	528-538
and	O	539-542
hydrogen	O	543-551
peroxide	O	552-560
production	O	561-571
by	O	572-574
ALF	B	575-578
neutrophils	O	579-590
stimulated	O	591-601
with	O	602-606
zymosan	O	607-614
opsonized	O	615-624
with	O	625-629
ALF	B	630-633
serum	O	634-639
was	O	640-643
significantly	O	644-657
reduced	O	658-665
compared	O	666-674
with	O	675-679
the	O	680-683
control	O	684-691
subjects	O	692-700
(	O	701-702
P	O	702-703
<	O	704-705
0	O	706-707
.	O	707-708
01	O	708-710
)	O	710-711
.	O	707-708

This	O	713-717
defect	O	718-724
persisted	O	725-734
when	O	735-739
zymosan	O	740-747
opsonized	O	748-757
by	O	758-760
control	O	761-768
serum	O	769-774
was	O	775-778
used	O	779-783
(	O	784-785
P	O	785-786
<	O	787-788
0	O	789-790
.	O	790-791
05	O	791-793
)	O	793-794
.	O	790-791

Superoxide	O	796-806
and	O	807-810
hydrogen	O	811-819
peroxide	O	820-828
production	O	829-839
in	O	840-842
neutrophils	O	843-854
stimulated	O	855-865
with	O	866-870
formyl	O	871-877
-	O	877-878
methionyl	O	878-887
-	O	877-878
leucyl	O	888-894
-	O	877-878
phenylalanine	O	895-908
(	O	909-910
fMLP	O	910-914
)	O	914-915
from	O	916-920
a	O	921-922
further	O	923-930
18	O	931-933
ALF	B	934-937
patients	O	938-946
was	O	947-950
unaffected	O	951-961
compared	O	962-970
with	O	971-975
control	O	976-983
neutrophils	O	984-995
.	O	995-996

Serum	O	997-1002
C3	O	1003-1005
complement	O	1006-1016
levels	O	1017-1023
were	O	1024-1028
significantly	O	1029-1042
reduced	O	1043-1050
in	O	1051-1053
ALF	B	1054-1057
patients	O	1058-1066
compared	O	1067-1075
with	O	1076-1080
control	O	1081-1088
subjects	O	1089-1097
(	O	1098-1099
P	O	1099-1100
<	O	1101-1102
0	O	1103-1104
.	O	1104-1105
0005	O	1105-1109
)	O	1109-1110
.	O	1104-1105

These	O	1112-1117
results	O	1118-1125
demonstrate	O	1126-1137
a	O	1138-1139
neutrophil	O	1140-1150
defect	O	1151-1157
in	O	1158-1160
ALF	B	1161-1164
due	O	1165-1168
to	O	1169-1171
paracetamol	O	1172-1183
overdose	B	1184-1192
,	O	1192-1193
that	O	1194-1198
is	O	1199-1201
complement	O	1202-1212
dependent	O	1213-1222
but	O	1223-1226
independent	O	1227-1238
of	O	1239-1241
serum	O	1242-1247
complement	O	1248-1258
,	O	1258-1259
possibly	O	1260-1268
connected	O	1269-1278
to	O	1279-1281
the	O	1282-1285
complement	O	1286-1296
receptor	O	1297-1305
.	O	1305-1306

Absence	O	0-7
of	O	8-10
effect	O	11-17
of	O	18-20
sertraline	O	21-31
on	O	32-34
time	O	35-39
-	O	39-40
based	O	40-45
sensitization	O	46-59
of	O	60-62
cognitive	B	63-72
impairment	I	73-83
with	O	84-88
haloperidol	O	89-100
.	O	100-101

This	O	102-106
double	O	107-113
-	O	113-114
blind	O	114-119
,	O	119-120
randomized	O	121-131
,	O	131-132
placebo	O	133-140
-	O	140-141
controlled	O	141-151
study	O	152-157
evaluated	O	158-167
the	O	168-171
effects	O	172-179
of	O	180-182
haloperidol	O	183-194
alone	O	195-200
and	O	201-204
haloperidol	O	205-216
plus	O	217-221
sertraline	O	222-232
on	O	233-235
cognitive	O	236-245
and	O	246-249
psychomotor	O	250-261
function	O	262-270
in	O	271-273
24	O	274-276
healthy	O	277-284
male	O	285-289
subjects	O	290-298
.	O	298-299

METHOD	O	300-306
:	O	306-307
All	O	308-311
subjects	O	312-320
received	O	321-329
placebo	O	330-337
on	O	338-340
Day	O	341-344
1	O	345-346
and	O	347-350
haloperidol	O	351-362
2	O	363-364
mg	O	365-367
on	O	368-370
Days	O	371-375
2	O	376-377
and	O	378-381
25	O	382-384
.	O	384-385

From	O	386-390
Days	O	391-395
9	O	396-397
to	O	398-400
25	O	401-403
,	O	403-404
subjects	O	405-413
were	O	414-418
randomly	O	419-427
assigned	O	428-436
to	O	437-439
either	O	440-446
sertraline	O	447-457
(	O	458-459
12	O	459-461
subjects	O	462-470
)	O	470-471
or	O	472-474
placebo	O	475-482
(	O	483-484
12	O	484-486
subjects	O	487-495
)	O	495-496
;	O	496-497
the	O	498-501
sertraline	O	502-512
dose	O	513-517
was	O	518-521
titrated	O	522-530
from	O	531-535
50	O	536-538
to	O	539-541
200	O	542-545
mg	O	546-548
/	O	548-549
day	O	549-552
from	O	553-557
Days	O	558-562
9	O	563-564
to	O	565-567
16	O	568-570
,	O	570-571
and	O	572-575
remained	O	576-584
at	O	585-587
200	O	588-591
mg	O	592-594
/	O	594-595
day	O	595-598
for	O	599-602
the	O	603-606
final	O	607-612
10	O	613-615
days	O	616-620
of	O	621-623
the	O	624-627
drug	O	628-632
administration	O	633-647
period	O	648-654
.	O	654-655

Cognitive	O	656-665
function	O	666-674
testing	O	675-682
was	O	683-686
performed	O	687-696
before	O	697-703
dosing	O	704-710
and	O	711-714
over	O	715-719
a	O	720-721
24	O	722-724
-	O	724-725
hour	O	725-729
period	O	730-736
after	O	737-742
dosing	O	743-749
on	O	750-752
Days	O	753-757
1	O	758-759
,	O	759-760
2	O	761-762
,	O	762-763
and	O	764-767
25	O	768-770
.	O	770-771

RESULTS	O	772-779
:	O	779-780
Impairment	B	781-791
of	I	792-794
cognitive	I	795-804
function	I	805-813
was	O	814-817
observed	O	818-826
6	O	827-828
to	O	829-831
8	O	832-833
hours	O	834-839
after	O	840-845
administration	O	846-860
of	O	861-863
haloperidol	O	864-875
on	O	876-878
Day	O	879-882
2	O	883-884
but	O	885-888
was	O	889-892
not	O	893-896
evident	O	897-904
23	O	905-907
hours	O	908-913
after	O	914-919
dosing	O	920-926
.	O	926-927

When	O	928-932
single	O	933-939
-	O	939-940
dose	O	940-944
haloperidol	O	945-956
was	O	957-960
given	O	961-966
again	O	967-972
25	O	973-975
days	O	976-980
later	O	981-986
,	O	986-987
greater	O	988-995
impairment	O	996-1006
with	O	1007-1011
earlier	O	1012-1019
onset	O	1020-1025
was	O	1026-1029
noted	O	1030-1035
in	O	1036-1038
several	O	1039-1046
tests	O	1047-1052
in	O	1053-1055
both	O	1056-1060
treatment	O	1061-1070
groups	O	1071-1077
,	O	1077-1078
suggesting	O	1079-1089
enhancement	O	1090-1101
of	O	1102-1104
this	O	1105-1109
effect	O	1110-1116
.	O	1116-1117

There	O	1118-1123
was	O	1124-1127
no	O	1128-1130
indication	O	1131-1141
that	O	1142-1146
sertraline	O	1147-1157
exacerbated	O	1158-1169
the	O	1170-1173
impairment	O	1174-1184
produced	O	1185-1193
by	O	1194-1196
haloperidol	O	1197-1208
since	O	1209-1214
an	O	1215-1217
equivalent	O	1218-1228
effect	O	1229-1235
also	O	1236-1240
occurred	O	1241-1249
in	O	1250-1252
the	O	1253-1256
placebo	O	1257-1264
group	O	1265-1270
.	O	1270-1271

Three	O	1272-1277
subjects	O	1278-1286
(	O	1287-1288
2	O	1288-1289
on	O	1290-1292
sertraline	O	1293-1303
and	O	1304-1307
1	O	1308-1309
on	O	1310-1312
placebo	O	1313-1320
)	O	1320-1321
withdrew	O	1322-1330
from	O	1331-1335
the	O	1336-1339
study	O	1340-1345
because	O	1346-1353
of	O	1354-1356
side	O	1357-1361
effects	O	1362-1369
.	O	1369-1370

Ten	O	1371-1374
subjects	O	1375-1383
in	O	1384-1386
each	O	1387-1391
group	O	1392-1397
reported	O	1398-1406
side	O	1407-1411
effects	O	1412-1419
related	O	1420-1427
to	O	1428-1430
treatment	O	1431-1440
.	O	1440-1441

The	O	1442-1445
side	O	1446-1450
effect	O	1451-1457
profiles	O	1458-1466
of	O	1467-1469
sertraline	O	1470-1480
and	O	1481-1484
of	O	1485-1487
placebo	O	1488-1495
were	O	1496-1500
similar	O	1501-1508
.	O	1508-1509

CONCLUSION	O	1510-1520
:	O	1520-1521
Haloperidol	O	1522-1533
produced	O	1534-1542
a	O	1543-1544
clear	O	1545-1550
profile	O	1551-1558
of	O	1559-1561
cognitive	B	1562-1571
impairment	I	1572-1582
that	O	1583-1587
was	O	1588-1591
not	O	1592-1595
worsened	O	1596-1604
by	O	1605-1607
concomitant	O	1608-1619
sertraline	O	1620-1630
administration	O	1631-1645
.	O	1645-1646

Ciprofloxacin	O	0-13
-	O	13-14
induced	O	14-21
nephrotoxicity	B	22-36
in	O	37-39
patients	O	40-48
with	O	49-53
cancer	B	54-60
.	O	60-61

Nephrotoxicity	B	62-76
associated	O	77-87
with	O	88-92
ciprofloxacin	O	93-106
is	O	107-109
uncommon	O	110-118
.	O	118-119

Five	O	120-124
patients	O	125-133
with	O	134-138
cancer	B	139-145
who	O	146-149
developed	O	150-159
acute	B	160-165
renal	I	166-171
failure	I	172-179
that	O	180-184
followed	O	185-193
treatment	O	194-203
with	O	204-208
ciprofloxacin	O	209-222
are	O	223-226
described	O	227-236
and	O	237-240
an	O	241-243
additional	O	244-254
15	O	255-257
cases	O	258-263
reported	O	264-272
in	O	273-275
the	O	276-279
literature	O	280-290
are	O	291-294
reviewed	O	295-303
.	O	303-304

Other	O	305-310
than	O	311-315
elevation	O	316-325
of	O	326-328
serum	O	329-334
creatinine	O	335-345
levels	O	346-352
,	O	352-353
characteristic	O	354-368
clinical	O	369-377
manifestations	O	378-392
and	O	393-396
abnormal	O	397-405
laboratory	O	406-416
findings	O	417-425
are	O	426-429
not	O	430-433
frequently	O	434-444
present	O	445-452
.	O	452-453

Allergic	O	454-462
interstitial	B	463-475
nephritis	I	476-485
is	O	486-488
believed	O	489-497
to	O	498-500
be	O	501-503
the	O	504-507
underlying	O	508-518
pathological	O	519-531
-	O	531-532
process	O	532-539
.	O	539-540
Definitive	O	541-551
diagnosis	O	552-561
requires	O	562-570
performance	O	571-582
of	O	583-585
renal	O	586-591
biopsy	O	592-598
,	O	598-599
although	O	600-608
this	O	609-613
is	O	614-616
not	O	617-620
always	O	621-627
feasible	O	628-636
.	O	636-637

An	O	638-640
improvement	O	641-652
in	O	653-655
renal	O	656-661
function	O	662-670
that	O	671-675
followed	O	676-684
the	O	685-688
discontinuation	O	689-704
of	O	705-707
the	O	708-711
offending	O	712-721
antibiotic	O	722-732
supports	O	733-741
the	O	742-745
presumptive	O	746-757
diagnosis	O	758-767
of	O	768-770
ciprofloxacin	O	771-784
-	O	784-785
induced	O	785-792
acute	B	793-798
renal	I	799-804
failure	I	805-812
.	O	812-813

Case	O	0-4
report	O	5-11
:	O	11-12
pentamidine	O	13-24
and	O	25-28
polymorphic	O	29-40
ventricular	B	41-52
tachycardia	I	53-64
revisited	O	65-74
.	O	74-75

Pentamidine	O	76-87
isethionate	O	88-99
has	O	100-103
been	O	104-108
associated	O	109-119
with	O	120-124
ventricular	B	125-136
tachyarrhythmias	I	137-153
,	O	153-154
including	O	155-164
torsade	B	165-172
de	I	173-175
pointes	I	176-183
.	O	183-184

This	O	185-189
article	O	190-197
reports	O	198-205
two	O	206-209
cases	O	210-215
of	O	216-218
this	O	219-223
complication	O	224-236
and	O	237-240
reviews	O	241-248
all	O	249-252
reported	O	253-261
cases	O	262-267
to	O	268-270
date	O	271-275
.	O	275-276

Pentamidine	O	277-288
-	O	288-289
induced	O	289-296
torsade	B	297-304
de	I	305-307
pointes	I	308-315
may	O	316-319
be	O	320-322
related	O	323-330
to	O	331-333
serum	O	334-339
magnesium	O	340-349
levels	O	350-356
and	O	357-360
hypomagnesemia	B	361-375
may	O	376-379
synergistically	O	380-395
induce	O	396-402
torsade	O	403-410
.	O	410-411

Torsade	B	412-419
de	I	420-422
pointes	I	423-430
occurred	O	431-439
after	O	440-445
an	O	446-448
average	O	449-456
of	O	457-459
10	O	460-462
days	O	463-467
of	O	468-470
treatment	O	471-480
with	O	481-485
pentamidine	O	486-497
.	O	497-498

In	O	499-501
these	O	502-507
patients	O	508-516
,	O	516-517
no	O	518-520
other	O	521-526
acute	O	527-532
side	O	533-537
effects	O	538-545
of	O	546-548
pentamidine	O	549-560
were	O	561-565
observed	O	566-574
.	O	574-575

Torsade	B	576-583
de	I	584-586
pointes	I	587-594
can	O	595-598
be	O	599-601
treated	O	602-609
when	O	610-614
recognized	O	615-625
early	O	626-631
,	O	631-632
possibly	O	633-641
without	O	642-649
discontinuation	O	650-665
of	O	666-668
pentamidine	O	669-680
.	O	680-681

When	O	682-686
QTc	B	687-690
interval	I	691-699
prolongation	I	700-712
is	O	713-715
observed	O	716-724
,	O	724-725
early	O	726-731
magnesium	O	732-741
supplementation	O	742-757
is	O	758-760
advocated	O	761-770
.	O	770-771

Time	O	0-4
dependence	O	5-15
of	O	16-18
plasma	O	19-25
malondialdehyde	O	26-41
,	O	41-42
oxypurines	O	43-53
,	O	53-54
and	O	55-58
nucleosides	O	59-70
during	O	71-77
incomplete	O	78-88
cerebral	B	89-97
ischemia	I	98-106
in	O	107-109
the	O	110-113
rat	O	114-117
.	O	117-118

Incomplete	O	119-129
cerebral	B	130-138
ischemia	I	139-147
(	O	148-149
30	O	149-151
min	O	152-155
)	O	155-156
was	O	157-160
induced	O	161-168
in	O	169-171
the	O	172-175
rat	O	176-179
by	O	180-182
bilaterally	O	183-194
clamping	O	195-203
the	O	204-207
common	O	208-214
carotid	O	215-222
arteries	O	223-231
.	O	231-232

Peripheral	O	233-243
venous	O	244-250
blood	O	251-256
samples	O	257-264
were	O	265-269
withdrawn	O	270-279
from	O	280-284
the	O	285-288
femoral	O	289-296
vein	O	297-301
four	O	302-306
times	O	307-312
(	O	313-314
once	O	314-318
every	O	319-324
5	O	325-326
min	O	327-330
)	O	330-331
before	O	332-338
ischemia	B	339-347
(	O	348-349
0	O	349-350
time	O	351-355
)	O	355-356
and	O	357-360
5	O	361-362
,	O	362-363
15	O	364-366
,	O	366-367
and	O	368-371
30	O	372-374
min	O	375-378
after	O	379-384
ischemia	B	385-393
.	O	393-394

Plasma	O	395-401
extracts	O	402-410
were	O	411-415
analyzed	O	416-424
by	O	425-427
a	O	428-429
highly	O	430-436
sensitive	O	437-446
high	O	447-451
-	O	451-452
performance	O	452-463
liquid	O	464-470
chromatographic	O	471-486
method	O	487-493
for	O	494-497
the	O	498-501
direct	O	502-508
determination	O	509-522
of	O	523-525
malondialdehyde	O	526-541
,	O	541-542
oxypurines	O	543-553
,	O	553-554
and	O	555-558
nucleosides	O	559-570
.	O	570-571

During	O	572-578
ischemia	B	579-587
,	O	587-588
a	O	589-590
time	O	591-595
-	O	595-596
dependent	O	596-605
increase	O	606-614
of	O	615-617
plasma	O	618-624
oxypurines	O	625-635
and	O	636-639
nucleosides	O	640-651
was	O	652-655
observed	O	656-664
.	O	664-665

Plasma	O	666-672
malondialdehyde	O	673-688
,	O	688-689
which	O	690-695
was	O	696-699
present	O	700-707
in	O	708-710
minimal	O	711-718
amount	O	719-725
at	O	726-728
zero	O	729-733
time	O	734-738
(	O	739-740
0	O	740-741
.	O	741-742
058	O	742-745
mumol	O	746-751
/	O	751-752
liter	O	752-757
plasma	O	758-764
;	O	764-765
SD	O	766-768
0	O	769-770
.	O	770-771
015	O	771-774
)	O	774-775
,	O	775-776
increased	O	777-786
after	O	787-792
5	O	793-794
min	O	795-798
of	O	799-801
ischemia	B	802-810
,	O	810-811
resulting	O	812-821
in	O	822-824
a	O	825-826
fivefold	O	827-835
increase	O	836-844
after	O	845-850
30	O	851-853
min	O	854-857
of	O	858-860
carotid	O	861-868
occlusion	O	869-878
(	O	879-880
0	O	880-881
.	O	881-882
298	O	882-885
mumol	O	886-891
/	O	891-892
liter	O	892-897
plasma	O	898-904
;	O	904-905
SD	O	906-908
0	O	909-910
.	O	910-911
078	O	911-914
)	O	914-915
.	O	910-911

Increased	O	917-926
plasma	O	927-933
malondialdehyde	O	934-949
was	O	950-953
also	O	954-958
recorded	O	959-967
in	O	968-970
two	O	971-974
other	O	975-980
groups	O	981-987
of	O	988-990
animals	O	991-998
subjected	O	999-1008
to	O	1009-1011
the	O	1012-1015
same	O	1016-1020
experimental	O	1021-1033
model	O	1034-1039
,	O	1039-1040
one	O	1041-1044
receiving	O	1045-1054
20	O	1055-1057
mg	O	1058-1060
/	O	1060-1061
kg	O	1061-1063
b	O	1064-1065
.	O	1065-1066
w	O	1066-1067
.	O	1065-1066
of	O	1069-1071
the	O	1072-1075
cyclooxygenase	O	1076-1090
inhibitor	O	1091-1100
acetylsalicylate	O	1101-1117
intravenously	O	1118-1131
immediately	O	1132-1143
before	O	1144-1150
ischemia	B	1151-1159
,	O	1159-1160
the	O	1161-1164
other	O	1165-1170
receiving	O	1171-1180
650	O	1181-1184
micrograms	O	1185-1195
/	O	1195-1196
kg	O	1196-1198
b	O	1199-1200
.	O	1200-1201
w	O	1201-1202
.	O	1200-1201
of	O	1204-1206
the	O	1207-1210
hypotensive	B	1211-1222
drug	O	1223-1227
nitroprusside	O	1228-1241
at	O	1242-1244
a	O	1245-1246
flow	O	1247-1251
rate	O	1252-1256
of	O	1257-1259
103	O	1260-1263
microliters	O	1264-1275
/	O	1275-1276
min	O	1276-1279
intravenously	O	1280-1293
during	O	1294-1300
ischemia	B	1301-1309
,	O	1309-1310
although	O	1311-1319
in	O	1320-1322
this	O	1323-1327
latter	O	1328-1334
group	O	1335-1340
malondialdehyde	O	1341-1356
was	O	1357-1360
significantly	O	1361-1374
higher	O	1375-1381
.	O	1381-1382

The	O	1383-1386
present	O	1387-1394
data	O	1395-1399
indicate	O	1400-1408
that	O	1409-1413
the	O	1414-1417
determination	O	1418-1431
of	O	1432-1434
malondialdehyde	O	1435-1450
,	O	1450-1451
oxypurines	O	1452-1462
,	O	1462-1463
and	O	1464-1467
nucleosides	O	1468-1479
in	O	1480-1482
peripheral	O	1483-1493
blood	O	1494-1499
,	O	1499-1500
may	O	1501-1504
be	O	1505-1507
used	O	1508-1512
to	O	1513-1515
monitor	O	1516-1523
the	O	1524-1527
metabolic	O	1528-1537
alterations	O	1538-1549
of	O	1550-1552
tissues	O	1553-1560
occurring	O	1561-1570
during	O	1571-1577
ischemic	B	1578-1586
phenomena	O	1587-1596
.	O	1596-1597
(	O	1597-1598
ABSTRACT	O	1598-1606

TRUNCATED	O	1607-1616
AT	O	1617-1619
250	O	1620-1623
WORDS	O	1624-1629
)	O	1629-1630

Cholinergic	O	0-11
toxicity	B	12-20
resulting	O	21-30
from	O	31-35
ocular	O	36-42
instillation	O	43-55
of	O	56-58
echothiophate	O	59-72
iodide	O	73-79
eye	O	80-83
drops	O	84-89
.	O	89-90

A	O	91-92
patient	O	93-100
developed	O	101-110
a	O	111-112
severe	O	113-119
cholinergic	O	120-131
syndrome	O	132-140
from	O	141-145
the	O	146-149
use	O	150-153
of	O	154-156
echothiophate	O	157-170
iodide	O	171-177
ophthalmic	O	178-188
drops	O	189-194
,	O	194-195
presented	O	196-205
with	O	206-210
profound	O	211-219
muscle	B	220-226
weakness	I	227-235
and	O	236-239
was	O	240-243
initially	O	244-253
given	O	254-259
the	O	260-263
diagnosis	O	264-273
of	O	274-276
myasthenia	B	277-287
gravis	I	288-294
.	O	294-295

Red	O	296-299
blood	O	300-305
cell	O	306-310
and	O	311-314
serum	O	315-320
cholinesterase	O	321-335
levels	O	336-342
were	O	343-347
severely	O	348-356
depressed	O	357-366
and	O	367-370
symptoms	O	371-379
resolved	O	380-388
spontaneously	O	389-402
following	O	403-412
discontinuation	O	413-428
of	O	429-431
the	O	432-435
eye	O	436-439
drops	O	440-445
.	O	445-446

Acute	B	0-5
renal	I	6-11
failure	I	12-19
in	O	20-22
high	O	23-27
dose	O	28-32
carboplatin	O	33-44
chemotherapy	O	45-57
.	O	57-58

Carboplatin	O	59-70
has	O	71-74
been	O	75-79
reported	O	80-88
to	O	89-91
cause	O	92-97
acute	B	98-103
renal	I	104-109
failure	I	110-117
when	O	118-122
administered	O	123-135
in	O	136-138
high	O	139-143
doses	O	144-149
to	O	150-152
adult	O	153-158
patients	O	159-167
.	O	167-168

We	O	169-171
report	O	172-178
a	O	179-180
4	O	181-182
1	O	183-184
/	O	184-185
2	O	185-186
-	O	186-187
year	O	187-191
-	O	186-187
old	O	192-195
girl	O	196-200
who	O	201-204
was	O	205-208
treated	O	209-216
with	O	217-221
high	O	222-226
-	O	226-227
dose	O	227-231
carboplatin	O	232-243
for	O	244-247
metastatic	O	248-258
parameningeal	O	259-272
embryonal	B	273-282
rhabdomyosarcoma	I	283-299
.	O	299-300

Acute	B	301-306
renal	I	307-312
failure	I	313-320
developed	O	321-330
followed	O	331-339
by	O	340-342
a	O	343-344
slow	O	345-349
partial	O	350-357
recovery	O	358-366
of	O	367-369
renal	O	370-375
function	O	376-384
.	O	384-385

Possible	O	386-394
contributing	O	395-407
factors	O	408-415
are	O	416-419
discussed	O	420-429
.	O	429-430

Endometrial	B	0-11
carcinoma	I	12-21
after	O	22-27
Hodgkin	B	28-35
disease	I	36-43
in	O	44-46
childhood	O	47-56
.	O	56-57

A	O	58-59
34	O	60-62
-	O	62-63
year	O	63-67
-	O	62-63
old	O	68-71
patient	O	72-79
developed	O	80-89
metastic	O	90-98
endometrial	B	99-110
carcinoma	I	111-120
after	O	121-126
Hodgkin	B	127-134
disease	I	135-142
in	O	143-145
childhood	O	146-155
.	O	155-156

She	O	157-160
had	O	161-164
ovarian	B	165-172
failure	I	173-180
after	O	181-186
abdominal	O	187-196
irradiation	O	197-208
and	O	209-212
chemotherapy	O	213-225
for	O	226-229
Hodgkin	B	230-237
disease	I	238-245
,	O	245-246
and	O	247-250
received	O	251-259
exogenous	O	260-269
estrogens	O	270-279
,	O	279-280
a	O	281-282
treatment	O	283-292
implicated	O	293-303
in	O	304-306
the	O	307-310
development	O	311-322
of	O	323-325
endometrial	B	326-337
cancer	I	338-344
in	O	345-347
menopausal	O	348-358
women	O	359-364
.	O	364-365

Young	O	366-371
women	O	372-377
on	O	378-380
replacement	O	381-392
estrogens	O	393-402
for	O	403-406
ovarian	B	407-414
failure	I	415-422
after	O	423-428
cancer	B	429-435
therapy	O	436-443
may	O	444-447
also	O	448-452
have	O	453-457
increased	O	458-467
risk	O	468-472
of	O	473-475
endometrial	B	476-487
carcinoma	I	488-497
and	O	498-501
should	O	502-508
be	O	509-511
examined	O	512-520
periodically	O	521-533
.	O	533-534

Induction	O	0-9
of	O	10-12
the	O	13-16
obstructive	B	17-28
sleep	I	29-34
apnea	I	35-40
syndrome	I	41-49
in	O	50-52
a	O	53-54
woman	O	55-60
by	O	61-63
exogenous	O	64-73
androgen	O	74-82
administration	O	83-97
.	O	97-98

We	O	99-101
documented	O	102-112
airway	O	113-119
occlusion	O	120-129
during	O	130-136
sleep	O	137-142
and	O	143-146
an	O	147-149
abnormally	O	150-160
high	O	161-165
supraglottic	O	166-178
resistance	O	179-189
while	O	190-195
awake	O	196-201
in	O	202-204
a	O	205-206
54	O	207-209
-	O	209-210
yr	O	210-212
-	O	209-210
old	O	213-216
woman	O	217-222
who	O	223-226
had	O	227-230
developed	O	231-240
physical	O	241-249
changes	O	250-257
and	O	258-261
the	O	262-265
syndrome	B	266-274
of	I	275-277
obstructive	I	278-289
sleep	I	290-295
apnea	I	296-301
while	O	302-307
being	O	308-313
administered	O	314-326
exogenous	O	327-336
androgens	O	337-346
.	O	346-347

When	O	348-352
the	O	353-356
androgens	O	357-366
were	O	367-371
withdrawn	O	372-381
,	O	381-382
the	O	383-386
patient	O	387-394
'	O	394-395
s	O	395-396
physical	O	397-405
changes	O	406-413
,	O	413-414
symptoms	O	415-423
,	O	423-424
sleep	O	425-430
study	O	431-436
,	O	436-437
and	O	438-441
supraglottic	O	442-454
resistance	O	455-465
all	O	466-469
returned	O	470-478
to	O	479-481
normal	O	482-488
.	O	488-489

A	O	490-491
rechallenge	O	492-503
with	O	504-508
androgen	O	509-517
produced	O	518-526
symptoms	O	527-535
of	O	536-538
obstructive	B	539-550
sleep	I	551-556
apnea	I	557-562
that	O	563-567
abated	O	568-574
upon	O	575-579
withdrawal	O	580-590
of	O	591-593
the	O	594-597
hormone	O	598-605
.	O	605-606

Previous	O	607-615
reports	O	616-623
have	O	624-628
favored	O	629-636
a	O	637-638
role	O	639-643
of	O	644-646
androgens	O	647-656
in	O	657-659
the	O	660-663
pathogenesis	O	664-676
of	O	677-679
sleep	B	680-685
apnea	I	686-691
.	O	691-692

Our	O	693-696
report	O	697-703
provides	O	704-712
direct	O	713-719
evidence	O	720-728
for	O	729-732
this	O	733-737
role	O	738-742
.	O	742-743

Structural	O	744-754
and	O	755-758
functional	O	759-769
measurements	O	770-782
indicate	O	783-791
that	O	792-796
androgens	O	797-806
exert	O	807-812
a	O	813-814
permissive	O	815-825
or	O	826-828
necessary	O	829-838
action	O	839-845
on	O	846-848
the	O	849-852
structural	O	853-863
configuration	O	864-877
of	O	878-880
the	O	881-884
oropharynx	O	885-895
that	O	896-900
predisposes	O	901-912
to	O	913-915
obstruction	O	916-927
during	O	928-934
sleep	O	935-940
.	O	940-941

Development	O	942-953
of	O	954-956
the	O	957-960
obstructive	B	961-972
sleep	I	973-978
apnea	I	979-984
syndrome	I	985-993
must	O	994-998
be	O	999-1001
considered	O	1002-1012
a	O	1013-1014
possible	O	1015-1023
side	O	1024-1028
effect	O	1029-1035
of	O	1036-1038
androgen	O	1039-1047
therapy	O	1048-1055
.	O	1055-1056

Effect	O	0-6
of	O	7-9
captopril	O	10-19
on	O	20-22
pre	O	23-26
-	O	26-27
existing	O	27-35
and	O	36-39
aminonucleoside	O	40-55
-	O	55-56
induced	O	56-63
proteinuria	B	64-75
in	O	76-78
spontaneously	O	79-92
hypertensive	B	93-105
rats	O	106-110
.	O	110-111

Proteinuria	B	112-123
is	O	124-126
a	O	127-128
side	O	129-133
effect	O	134-140
of	O	141-143
captopril	O	144-153
treatment	O	154-163
in	O	164-166
hypertensive	B	167-179
patients	O	180-188
.	O	188-189

The	O	190-193
possibility	O	194-205
of	O	206-208
reproducing	O	209-220
the	O	221-224
same	O	225-229
renal	B	230-235
abnormality	I	236-247
with	O	248-252
captopril	O	253-262
was	O	263-266
examined	O	267-275
in	O	276-278
SHR	O	279-282
.	O	282-283

Oral	O	284-288
administration	O	289-303
of	O	304-306
captopril	O	307-316
at	O	317-319
100	O	320-323
mg	O	324-326
/	O	326-327
kg	O	327-329
for	O	330-333
14	O	334-336
days	O	337-341
failed	O	342-348
to	O	349-351
aggravate	O	352-361
proteinuria	B	362-373
pre	O	374-377
-	O	377-378
existing	O	378-386
in	O	387-389
SHR	O	390-393
.	O	393-394

Also	O	395-399
,	O	399-400
captopril	O	401-410
treatment	O	411-420
failed	O	421-427
to	O	428-430
potentiate	O	431-441
or	O	442-444
facilitate	O	445-455
development	O	456-467
of	O	468-470
massive	O	471-478
proteinuria	B	479-490
invoked	O	491-498
by	O	499-501
puromycin	O	502-511
aminonucleoside	O	512-527
in	O	528-530
SHR	O	531-534
.	O	534-535

Captopril	O	536-545
had	O	546-549
little	O	550-556
or	O	557-559
no	O	560-562
demonstrable	O	563-575
effects	O	576-583
on	O	584-586
serum	O	587-592
electrolyte	O	593-604
concentrations	O	605-619
,	O	619-620
excretion	O	621-630
of	O	631-633
urine	O	634-639
,	O	639-640
sodium	O	641-647
and	O	648-651
potassium	O	652-661
,	O	661-662
endogenous	O	663-673
creatinine	O	674-684
clearance	O	685-694
,	O	694-695
body	O	696-700
weight	O	701-707
,	O	707-708
and	O	709-712
food	O	713-717
and	O	718-721
water	O	722-727
consumption	O	728-739
.	O	739-740

However	O	741-748
,	O	748-749
ketone	O	750-756
bodies	O	757-763
were	O	764-768
consistently	O	769-781
present	O	782-789
in	O	790-792
urine	O	793-798
and	O	799-802
several	O	803-810
lethalities	O	811-822
occurred	O	823-831
during	O	832-838
multiple	O	839-847
dosing	O	848-854
of	O	855-857
captopril	O	858-867
in	O	868-870
SHR	O	871-874
.	O	874-875

Epileptogenic	O	0-13
properties	O	14-24
of	O	25-27
enflurane	O	28-37
and	O	38-41
their	O	42-47
clinical	O	48-56
interpretation	O	57-71
.	O	71-72

Three	O	73-78
cases	O	79-84
of	O	85-87
EEG	O	88-91
changes	O	92-99
induced	O	100-107
by	O	108-110
single	O	111-117
exposure	O	118-126
to	O	127-129
enflurane	O	130-139
anesthesia	O	140-150
are	O	151-154
reported	O	155-163
.	O	163-164

In	O	165-167
one	O	168-171
patient	O	172-179
,	O	179-180
enflurane	O	181-190
administered	O	191-203
during	O	204-210
a	O	211-212
donor	O	213-218
nephrectomy	O	219-230
resulted	O	231-239
in	O	240-242
unexpected	O	243-253
partial	O	254-261
motor	O	262-267
seizures	B	268-276
.	O	276-277

Until	O	278-283
the	O	284-287
cause	O	288-293
of	O	294-296
the	O	297-300
seizures	B	301-309
was	O	310-313
correctly	O	314-323
identified	O	324-334
,	O	334-335
the	O	336-339
patient	O	340-347
was	O	348-351
inappropriately	O	352-367
treated	O	368-375
with	O	376-380
anticonvulsants	O	381-396
.	O	396-397

Two	O	398-401
other	O	402-407
patients	O	408-416
suffered	O	417-425
from	O	426-430
partial	O	431-438
,	O	438-439
complex	O	440-447
and	O	448-451
generalized	O	452-463
seizures	B	464-472
uncontrolled	O	473-485
by	O	486-488
medication	O	489-499
.	O	499-500

Epileptic	B	501-510
foci	O	511-515
delineated	O	516-526
and	O	527-530
activated	O	531-540
by	O	541-543
enflurane	O	544-553
were	O	554-558
surgically	O	559-569
ablated	O	570-577
and	O	578-581
the	O	582-585
patients	O	586-594
are	O	595-598
now	O	599-602
seizure	B	603-610
-	O	610-611
free	O	611-615
.	O	615-616

Previous	O	617-625
exposures	O	626-635
to	O	636-638
enflurane	O	639-648
have	O	649-653
to	O	654-656
be	O	657-659
disclosed	O	660-669
to	O	670-672
avoid	O	673-678
mistakes	O	679-687
in	O	688-690
clinical	O	691-699
interpretation	O	700-714
of	O	715-717
the	O	718-721
EEG	O	722-725
.	O	725-726

On	O	727-729
the	O	730-733
other	O	734-739
hand	O	740-744
,	O	744-745
enflurane	O	746-755
may	O	756-759
prove	O	760-765
to	O	766-768
be	O	769-771
a	O	772-773
safe	O	774-778
fast	O	779-783
acting	O	784-790
activator	O	791-800
of	O	801-803
epileptic	B	804-813
foci	O	814-818
during	O	819-825
corticography	O	826-839
or	O	840-842
depth	O	843-848
electrode	O	849-858
intraoperative	O	859-873
recordings	O	874-884
.	O	884-885

Reversible	O	0-10
cerebral	B	11-19
lesions	I	20-27
associated	O	28-38
with	O	39-43
tiazofurin	O	44-54
usage	O	55-60
:	O	60-61
MR	O	62-64
demonstration	O	65-78
.	O	78-79

Tiazofurin	O	80-90
is	O	91-93
an	O	94-96
experimental	O	97-109
chemotherapeutic	O	110-126
agent	O	127-132
currently	O	133-142
undergoing	O	143-153
clinical	O	154-162
evaluation	O	163-173
.	O	173-174

We	O	175-177
report	O	178-184
our	O	185-188
results	O	189-196
with	O	197-201
magnetic	O	202-210
resonance	O	211-220
(	O	221-222
MR	O	222-224
)	O	224-225
in	O	226-228
demonstrating	O	229-242
reversible	O	243-253
cerebral	B	254-262
abnormalities	I	263-276
concurrent	O	277-287
with	O	288-292
the	O	293-296
use	O	297-300
of	O	301-303
this	O	304-308
drug	O	309-313
.	O	313-314

The	O	315-318
abnormalities	O	319-332
on	O	333-335
MR	O	336-338
were	O	339-343
correlated	O	344-354
with	O	355-359
findings	O	360-368
on	O	369-371
CT	O	372-374
as	O	375-377
well	O	378-382
as	O	383-385
with	O	386-390
cerebral	O	391-399
angiography	O	400-411
.	O	411-412

The	O	413-416
utility	O	417-424
of	O	425-427
MR	O	428-430
in	O	431-433
the	O	434-437
evaluation	O	438-448
of	O	449-451
patients	O	452-460
receiving	O	461-470
this	O	471-475
new	O	476-479
agent	O	480-485
is	O	486-488
illustrated	O	489-500
.	O	500-501

Antagonism	O	0-10
of	O	11-13
diazepam	O	14-22
-	O	22-23
induced	O	23-30
sedative	O	31-39
effects	O	40-47
by	O	48-50
Ro15	O	51-55
-	O	55-56
1788	O	56-60
in	O	61-63
patients	O	64-72
after	O	73-78
surgery	O	79-86
under	O	87-92
lumbar	O	93-99
epidural	O	100-108
block	O	109-114
.	O	114-115

A	O	116-117
double	O	118-124
-	O	124-125
blind	O	125-130
placebo	O	131-138
-	O	138-139
controlled	O	139-149
investigation	O	150-163
of	O	164-166
efficacy	O	167-175
and	O	176-179
safety	O	180-186
.	O	186-187

The	O	188-191
aim	O	192-195
of	O	196-198
this	O	199-203
study	O	204-209
was	O	210-213
to	O	214-216
assess	O	217-223
the	O	224-227
efficacy	O	228-236
of	O	237-239
Ro15	O	240-244
-	O	244-245
1788	O	245-249
and	O	250-253
a	O	254-255
placebo	O	256-263
in	O	264-266
reversing	O	267-276
diazepam	O	277-285
-	O	285-286
induced	O	286-293
effects	O	294-301
after	O	302-307
surgery	O	308-315
under	O	316-321
epidural	O	322-330
block	O	331-336
,	O	336-337
and	O	338-341
to	O	342-344
evaluate	O	345-353
the	O	354-357
local	O	358-363
tolerance	O	364-373
and	O	374-377
general	O	378-385
safety	O	386-392
of	O	393-395
Ro15	O	396-400
-	O	400-401
1788	O	401-405
.	O	405-406

Fifty	O	407-412
-	O	412-413
seven	O	413-418
patients	O	419-427
were	O	428-432
sedated	O	433-440
with	O	441-445
diazepam	O	446-454
for	O	455-458
surgery	O	459-466
under	O	467-472
epidural	O	473-481
anaesthesia	O	482-493
.	O	493-494

Antagonism	O	495-505
of	O	506-508
diazepam	O	509-517
-	O	517-518
induced	O	518-525
effects	O	526-533
by	O	534-536
Ro15	O	537-541
-	O	541-542
1788	O	542-546
was	O	547-550
investigated	O	551-563
postoperatively	O	564-579
in	O	580-582
a	O	583-584
double	O	585-591
-	O	591-592
blind	O	592-597
placebo	O	598-605
-	O	605-606
controlled	O	606-616
trial	O	617-622
.	O	622-623

The	O	624-627
patient	O	628-635
'	O	635-636
s	O	636-637
subjective	O	638-648
assessment	O	649-659
of	O	660-662
mood	O	663-667
rating	O	668-674
,	O	674-675
an	O	676-678
objective	O	679-688
test	O	689-693
of	O	694-696
performance	O	697-708
,	O	708-709
a	O	710-711
test	O	712-716
for	O	717-720
amnesia	B	721-728
,	O	728-729
and	O	730-733
vital	O	734-739
signs	O	740-745
were	O	746-750
recorded	O	751-759
for	O	760-763
up	O	764-766
to	O	767-769
300	O	770-773
min	O	774-777
after	O	778-783
administration	O	784-798
of	O	799-801
the	O	802-805
trial	O	806-811
drug	O	812-816
.	O	816-817

No	O	818-820
significant	O	821-832
differences	O	833-844
between	O	845-852
the	O	853-856
two	O	857-860
groups	O	861-867
were	O	868-872
observed	O	873-881
for	O	882-885
mood	O	886-890
rating	O	891-897
,	O	897-898
amnesia	B	899-906
,	O	906-907
or	O	908-910
vital	O	911-916
signs	O	917-922
.	O	922-923

The	O	924-927
Ro15	O	928-932
-	O	932-933
1788	O	933-937
group	O	938-943
showed	O	944-950
a	O	951-952
significant	O	953-964
improvement	O	965-976
in	O	977-979
the	O	980-983
performance	O	984-995
test	O	996-1000
up	O	1001-1003
to	O	1004-1006
120	O	1007-1010
min	O	1011-1014
after	O	1015-1020
administration	O	1021-1035
of	O	1036-1038
the	O	1039-1042
drug	O	1043-1047
.	O	1047-1048

There	O	1049-1054
was	O	1055-1058
no	O	1059-1061
evidence	O	1062-1070
of	O	1071-1073
reaction	O	1074-1082
at	O	1083-1085
the	O	1086-1089
injection	O	1090-1099
site	O	1100-1104
.	O	1104-1105

Enhanced	O	0-8
stimulus	O	9-17
-	O	17-18
induced	O	18-25
neurotransmitter	O	26-42
overflow	O	43-51
in	O	52-54
epinephrine	O	55-66
-	O	66-67
induced	O	67-74
hypertensive	B	75-87
rats	O	88-92
is	O	93-95
not	O	96-99
mediated	O	100-108
by	O	109-111
prejunctional	O	112-125
beta	O	126-130
-	O	130-131
adrenoceptor	O	131-143
activation	O	144-154
.	O	154-155

The	O	156-159
present	O	160-167
study	O	168-173
examines	O	174-182
the	O	183-186
effect	O	187-193
of	O	194-196
6	O	197-198
-	O	198-199
day	O	199-202
epinephrine	O	203-214
treatment	O	215-224
(	O	225-226
100	O	226-229
micrograms	O	230-240
/	O	240-241
kg	O	241-243
per	O	244-247
h	O	248-249
,	O	249-250
s	O	251-252
.	O	252-253
c	O	253-254
.	O	252-253
)	O	255-256
on	O	257-259
stimulus	O	260-268
-	O	268-269
induced	O	269-276
(	O	277-278
1	O	278-279
Hz	O	280-282
)	O	282-283
endogenous	O	284-294
neurotransmitter	O	295-311
overflow	O	312-320
from	O	321-325
the	O	326-329
isolated	O	330-338
perfused	O	339-347
kidney	O	348-354
of	O	355-357
vehicle	O	358-365
-	O	365-366
and	O	367-370
epinephrine	O	371-382
-	O	382-383
treated	O	383-390
rats	O	391-395
.	O	395-396

Renal	O	397-402
catecholamine	O	403-416
stores	O	417-423
and	O	424-427
stimulus	O	428-436
-	O	436-437
induced	O	437-444
overflow	O	445-453
in	O	454-456
the	O	457-460
vehicle	O	461-468
-	O	468-469
treated	O	469-476
group	O	477-482
consisted	O	483-492
of	O	493-495
norepinephrine	O	496-510
only	O	511-515
.	O	515-516

However	O	517-524
,	O	524-525
epinephrine	O	526-537
treatment	O	538-547
resulted	O	548-556
in	O	557-559
the	O	560-563
incorporation	O	564-577
of	O	578-580
epinephrine	O	581-592
into	O	593-597
renal	O	598-603
catecholamine	O	604-617
stores	O	618-624
such	O	625-629
that	O	630-634
approximately	O	635-648
40	O	649-651
%	O	651-652
of	O	653-655
the	O	656-659
catecholamine	O	660-673
present	O	674-681
was	O	682-685
epinephrine	O	686-697
while	O	698-703
the	O	704-707
norepinephrine	O	708-722
content	O	723-730
was	O	731-734
reduced	O	735-742
by	O	743-745
a	O	746-747
similar	O	748-755
degree	O	756-762
.	O	762-763

Total	O	764-769
tissue	O	770-776
catecholamine	O	777-790
content	O	791-798
of	O	799-801
the	O	802-805
kidney	O	806-812
on	O	813-815
a	O	816-817
molar	O	818-823
basis	O	824-829
was	O	830-833
unchanged	O	834-843
.	O	843-844

Stimulus	O	845-853
-	O	853-854
induced	O	854-861
fractional	O	862-872
overflow	O	873-881
of	O	882-884
neurotransmitter	O	885-901
from	O	902-906
the	O	907-910
epinephrine	O	911-922
-	O	922-923
treated	O	923-930
kidneys	O	931-938
was	O	939-942
approximately	O	943-956
twice	O	957-962
normal	O	963-969
and	O	970-973
consisted	O	974-983
of	O	984-986
both	O	987-991
norepinephrine	O	992-1006
and	O	1007-1010
epinephrine	O	1011-1022
in	O	1023-1025
proportions	O	1026-1037
similar	O	1038-1045
to	O	1046-1048
those	O	1049-1054
found	O	1055-1060
in	O	1061-1063
the	O	1064-1067
kidney	O	1068-1074
.	O	1074-1075

This	O	1076-1080
difference	O	1081-1091
in	O	1092-1094
fractional	O	1095-1105
overflow	O	1106-1114
between	O	1115-1122
groups	O	1123-1129
was	O	1130-1133
not	O	1134-1137
affected	O	1138-1146
by	O	1147-1149
neuronal	O	1150-1158
and	O	1159-1162
extraneuronal	O	1163-1176
uptake	O	1177-1183
blockade	O	1184-1192
.	O	1192-1193

Propranolol	O	1194-1205
had	O	1206-1209
no	O	1210-1212
effect	O	1213-1219
on	O	1220-1222
stimulus	O	1223-1231
-	O	1231-1232
induced	O	1232-1239
overflow	O	1240-1248
in	O	1249-1251
either	O	1252-1258
group	O	1259-1264
.	O	1264-1265

Phentolamine	O	1266-1278
increased	O	1279-1288
stimulus	O	1289-1297
-	O	1297-1298
induced	O	1298-1305
overflow	O	1306-1314
in	O	1315-1317
both	O	1318-1322
groups	O	1323-1329
although	O	1330-1338
the	O	1339-1342
increment	O	1343-1352
in	O	1353-1355
overflow	O	1356-1364
was	O	1365-1368
greater	O	1369-1376
in	O	1377-1379
the	O	1380-1383
epinephrine	O	1384-1395
-	O	1395-1396
treated	O	1396-1403
group	O	1404-1409
.	O	1409-1410

In	O	1411-1413
conclusion	O	1414-1424
,	O	1424-1425
chronic	O	1426-1433
epinephrine	O	1434-1445
treatment	O	1446-1455
results	O	1456-1463
in	O	1464-1466
enhanced	O	1467-1475
fractional	O	1476-1486
neurotransmitter	O	1487-1503
overflow	O	1504-1512
.	O	1512-1513

However	O	1514-1521
,	O	1521-1522
neither	O	1523-1530
alterations	O	1531-1542
in	O	1543-1545
prejunctional	O	1546-1559
beta	O	1560-1564
-	O	1564-1565
adrenoceptor	O	1565-1577
influences	O	1578-1588
nor	O	1589-1592
alterations	O	1593-1604
in	O	1605-1607
neuronal	O	1608-1616
and	O	1617-1620
extraneuronal	O	1621-1634
uptake	O	1635-1641
mechanisms	O	1642-1652
appear	O	1653-1659
to	O	1660-1662
be	O	1663-1665
responsible	O	1666-1677
for	O	1678-1681
this	O	1682-1686
alteration	O	1687-1697
.	O	1697-1698

Furthermore	O	1699-1710
,	O	1710-1711
data	O	1712-1716
obtained	O	1717-1725
with	O	1726-1730
phentolamine	O	1731-1743
alone	O	1744-1749
do	O	1750-1752
not	O	1753-1756
suggest	O	1757-1764
alpha	O	1765-1770
-	O	1770-1771
adrenoceptor	O	1771-1783
desensitization	O	1784-1799
as	O	1800-1802
the	O	1803-1806
cause	O	1807-1812
of	O	1813-1815
the	O	1816-1819
enhanced	O	1820-1828
neurotransmitter	O	1829-1845
overflow	O	1846-1854
after	O	1855-1860
epinephrine	O	1861-1872
treatment	O	1873-1882
.	O	1882-1883

Ocular	O	0-6
manifestations	O	7-21
of	O	22-24
juvenile	B	25-33
rheumatoid	I	34-44
arthritis	I	45-54
.	O	54-55

We	O	56-58
followed	O	59-67
210	O	68-71
cases	O	72-77
of	O	78-80
juvenile	B	81-89
rheumatoid	I	90-100
arthritis	I	101-110
closely	O	111-118
for	O	119-122
eleven	O	123-129
years	O	130-135
.	O	135-136

Thirty	O	137-143
-	O	143-144
six	O	144-147
of	O	148-150
the	O	151-154
210	O	155-158
patients	O	159-167
(	O	168-169
17	O	169-171
.	O	171-172
2	O	172-173
%	O	173-174
)	O	174-175
developed	O	176-185
iridocyclitis	B	186-199
.	O	199-200

Iridocyclitis	B	201-214
was	O	215-218
seen	O	219-223
most	O	224-228
frequently	O	229-239
in	O	240-242
young	O	243-248
female	O	249-255
patients	O	256-264
(	O	265-266
0	O	266-267
to	O	268-270
4	O	271-272
years	O	273-278
)	O	278-279
with	O	280-284
the	O	285-288
monoarticular	O	289-302
or	O	303-305
pauciatricular	O	306-320
form	O	321-325
of	O	326-328
the	O	329-332
arthritis	B	333-342
.	O	342-343

However	O	344-351
,	O	351-352
30	O	353-355
%	O	355-356
of	O	357-359
the	O	360-363
patients	O	364-372
developed	O	373-382
uveitis	B	383-390
after	O	391-396
16	O	397-399
years	O	400-405
of	O	406-408
age	O	409-412
.	O	412-413

Although	O	414-422
61	O	423-425
%	O	425-426
of	O	427-429
patients	O	430-438
had	O	439-442
a	O	443-444
noncontributory	O	445-460
ocular	O	461-467
history	O	468-475
on	O	476-478
entry	O	479-484
,	O	484-485
42	O	486-488
%	O	488-489
had	O	490-493
active	O	494-500
uveitis	B	501-508
on	O	509-511
entry	O	512-517
.	O	517-518

Our	O	519-522
approach	O	523-531
was	O	532-535
effective	O	536-545
in	O	546-548
detecting	O	549-558
uveitis	B	559-566
in	O	567-569
new	O	570-573
cases	O	574-579
and	O	580-583
exacerbations	O	584-597
of	O	598-600
uveitis	B	601-608
in	O	609-611
established	O	612-623
cases	O	624-629
.	O	629-630

Forty	O	631-636
-	O	636-637
four	O	637-641
percent	O	642-649
of	O	650-652
patients	O	653-661
with	O	662-666
uveitis	B	667-674
had	O	675-678
one	O	679-682
or	O	683-685
more	O	686-690
identifiable	O	691-703
signs	O	704-709
or	O	710-712
symptoms	O	713-721
,	O	721-722
such	O	723-727
as	O	728-730
red	O	731-734
eye	O	735-738
,	O	738-739
ocular	B	740-746
pain	I	747-751
,	O	751-752
decreased	B	753-762
visual	I	763-769
acuity	I	770-776
,	O	776-777
or	O	778-780
photophobia	B	781-792
,	O	792-793
in	O	794-796
order	O	797-802
of	O	803-805
decreasing	O	806-816
frequency	O	817-826
.	O	826-827

Even	O	828-832
after	O	833-838
early	O	839-844
detection	O	845-854
and	O	855-858
prompt	O	859-865
treatment	O	866-875
,	O	875-876
41	O	877-879
%	O	879-880
of	O	881-883
cases	O	884-889
of	O	890-892
uveitis	B	893-900
did	O	901-904
not	O	905-908
respond	O	909-916
to	O	917-919
more	O	920-924
than	O	925-929
six	O	930-933
months	O	934-940
of	O	941-943
intensive	O	944-953
topical	O	954-961
treatment	O	962-971
with	O	972-976
corticosteroids	O	977-992
and	O	993-996
mydriatics	O	997-1007
.	O	1007-1008

Despite	O	1009-1016
this	O	1017-1021
,	O	1021-1022
there	O	1023-1028
was	O	1029-1032
a	O	1033-1034
dramatic	O	1035-1043
decrease	O	1044-1052
in	O	1053-1055
the	O	1056-1059
50	O	1060-1062
%	O	1062-1063
incidence	O	1064-1073
of	O	1074-1076
blinding	O	1077-1085
complications	O	1086-1099
of	O	1100-1102
uveitis	B	1103-1110
cited	O	1111-1116
in	O	1117-1119
earlier	O	1120-1127
studies	O	1128-1135
.	O	1135-1136

Cataract	B	1137-1145
and	O	1146-1149
band	B	1150-1154
keratopathy	I	1155-1166
occurred	O	1167-1175
in	O	1176-1178
only	O	1179-1183
22	O	1184-1186
and	O	1187-1190
13	O	1191-1193
%	O	1193-1194
of	O	1195-1197
our	O	1198-1201
group	O	1202-1207
,	O	1207-1208
respectively	O	1209-1221
.	O	1221-1222

We	O	1223-1225
used	O	1226-1230
chloroquine	O	1231-1242
or	O	1243-1245
hydroxychloroquine	O	1246-1264
in	O	1265-1267
173	O	1268-1271
of	O	1272-1274
210	O	1275-1278
cases	O	1279-1284
and	O	1285-1288
found	O	1289-1294
only	O	1295-1299
one	O	1300-1303
case	O	1304-1308
of	O	1309-1311
chorioretinopathy	B	1312-1329
attributable	O	1330-1342
to	O	1343-1345
these	O	1346-1351
drugs	O	1352-1357
.	O	1357-1358

Systemically	O	1359-1371
administered	O	1372-1384
corticosteroids	O	1385-1400
were	O	1401-1405
used	O	1406-1410
in	O	1411-1413
75	O	1414-1416
of	O	1417-1419
210	O	1420-1423
cases	O	1424-1429
;	O	1429-1430
a	O	1431-1432
significant	O	1433-1444
number	O	1445-1451
of	O	1452-1454
posterior	O	1455-1464
subcapsular	O	1465-1476
cataracts	B	1477-1486
was	O	1487-1490
found	O	1491-1496
.	O	1496-1497

Typical	O	1498-1505
keratoconjunctivitis	B	1506-1526
sicca	O	1527-1532
developed	O	1533-1542
in	O	1543-1545
three	O	1546-1551
of	O	1552-1554
the	O	1555-1558
uveitis	B	1559-1566
cases	O	1567-1572
.	O	1572-1573

This	O	1574-1578
association	O	1579-1590
with	O	1591-1595
uveitis	B	1596-1603
and	O	1604-1607
JRA	O	1608-1611
was	O	1612-1615
not	O	1616-1619
noted	O	1620-1625
previously	O	1626-1636
.	O	1636-1637

Surgical	O	1638-1646
treatment	O	1647-1656
of	O	1657-1659
cataracts	B	1660-1669
,	O	1669-1670
band	B	1671-1675
keratopathy	I	1676-1687
,	O	1687-1688
and	O	1689-1692
glaucoma	B	1693-1701
achieved	O	1702-1710
uniformly	O	1711-1720
discouraging	O	1721-1733
results	O	1734-1741
.	O	1741-1742

Water	B	0-5
intoxication	I	6-18
associated	O	19-29
with	O	30-34
oxytocin	O	35-43
administration	O	44-58
during	O	59-65
saline	O	66-72
-	O	72-73
induced	O	73-80
abortion	B	81-89
.	O	89-90

Four	O	91-95
cases	O	96-101
of	O	102-104
water	B	105-110
intoxication	I	111-123
in	O	124-126
connection	O	127-137
with	O	138-142
oxytocin	O	143-151
administration	O	152-166
during	O	167-173
saline	O	174-180
-	O	180-181
induced	O	181-188
abortions	B	189-198
are	O	199-202
described	O	203-212
.	O	212-213

The	O	214-217
mechanism	O	218-227
of	O	228-230
water	B	231-236
intoxication	I	237-249
is	O	250-252
discussed	O	253-262
in	O	263-265
regard	O	266-272
to	O	273-275
these	O	276-281
cases	O	282-287
.	O	287-288

Oxytocin	O	289-297
administration	O	298-312
during	O	313-319
midtrimester	O	320-332
-	O	332-333
induced	O	333-340
abortions	B	341-350
is	O	351-353
advocated	O	354-363
only	O	364-368
if	O	369-371
it	O	372-374
can	O	375-378
be	O	379-381
carried	O	382-389
out	O	390-393
under	O	394-399
careful	O	400-407
observations	O	408-420
of	O	421-423
an	O	424-426
alert	O	427-432
nursing	O	433-440
staff	O	441-446
,	O	446-447
aware	O	448-453
of	O	454-456
the	O	457-460
symptoms	O	461-469
of	O	470-472
water	B	473-478
intoxication	I	479-491
and	O	492-495
instructed	O	496-506
to	O	507-509
watch	O	510-515
the	O	516-519
diuresis	O	520-528
and	O	529-532
report	O	533-539
such	O	540-544
early	O	545-550
signs	O	551-556
of	O	557-559
the	O	560-563
syndrome	O	564-572
as	O	573-575
asthenia	B	576-584
,	O	584-585
muscular	O	586-594
irritability	B	595-607
,	O	607-608
or	O	609-611
headaches	B	612-621
.	O	621-622

The	O	623-626
oxytocin	O	627-635
should	O	636-642
be	O	643-645
given	O	646-651
only	O	652-656
in	O	657-659
Ringers	O	660-667
lactate	O	668-675
or	O	676-678
,	O	678-679
alternately	O	680-691
,	O	691-692
in	O	693-695
Ringers	O	696-703
lactate	O	704-711
and	O	712-715
a	O	716-717
5	O	718-719
per	O	720-723
cent	O	724-728
dextrose	O	729-737
and	O	738-741
water	O	742-747
solutions	O	748-757
.	O	757-758

The	O	759-762
urinary	O	763-770
output	O	771-777
should	O	778-784
be	O	785-787
monitored	O	788-797
and	O	798-801
the	O	802-805
oxytocin	O	806-814
administration	O	815-829
discontinued	O	830-842
and	O	843-846
the	O	847-850
serum	O	851-856
electrolytes	O	857-869
checked	O	870-877
if	O	878-880
the	O	881-884
urinary	O	885-892
output	O	893-899
decreases	O	900-909
.	O	909-910

The	O	911-914
oxytocin	O	915-923
should	O	924-930
not	O	931-934
be	O	935-937
administered	O	938-950
in	O	951-953
excess	O	954-960
of	O	961-963
36	O	964-966
hours	O	967-972
.	O	972-973

If	O	974-976
the	O	977-980
patient	O	981-988
has	O	989-992
not	O	993-996
aborted	O	997-1004
by	O	1005-1007
then	O	1008-1012
the	O	1013-1016
oxytocin	O	1017-1025
should	O	1026-1032
be	O	1033-1035
discontinued	O	1036-1048
for	O	1049-1052
10	O	1053-1055
to	O	1056-1058
12	O	1059-1061
hours	O	1062-1067
in	O	1068-1070
order	O	1071-1076
to	O	1077-1079
perform	O	1080-1087
electrolyte	O	1088-1099
determinations	O	1100-1114
and	O	1115-1118
correct	O	1119-1126
any	O	1127-1130
electrolyte	O	1131-1142
imbalance	O	1143-1152
.	O	1152-1153

